<SEC-DOCUMENT>0001193125-24-040745.txt : 20240221
<SEC-HEADER>0001193125-24-040745.hdr.sgml : 20240221
<ACCEPTANCE-DATETIME>20240221080111
ACCESSION NUMBER:		0001193125-24-040745
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		194
CONFORMED PERIOD OF REPORT:	20231130
FILED AS OF DATE:		20240221
DATE AS OF CHANGE:		20240221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		24656431

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d680117d20f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:thtx="http://www.theratech.com/20231130" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>20-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="max-width: auto"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P12_01_2022To11_30_2023" id="ixv-43393">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P12_01_2022To11_30_2023" id="ixv-43394">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P12_01_2022To11_30_2023" id="ixv-43395">0001512717</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P12_01_2022To11_30_2023" id="ixv-43396">--11-30</ix:nonNumeric><ix:footnote id="FN_350225" xml:lang="en-US">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</ix:footnote><ix:footnote id="FN_350223" xml:lang="en-US">See note 1 for share consolidation.</ix:footnote><ix:footnote id="FN_350226" xml:lang="en-US">On February 17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its right-of-use assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. The gain is presented in finance costs (Note 5)</ix:footnote><ix:footnote id="FN_350227" xml:lang="en-US">On March 1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a right-of-use asset and a lease liability of $326.</ix:footnote></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="thtx-20231130.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn11_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2018To10_04_2018"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-04</xbrli:startDate> <xbrli:endDate>2018-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2023To02_17_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-17</xbrli:startDate> <xbrli:endDate>2023-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2023To03_01_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-01</xbrli:startDate> <xbrli:endDate>2023-03-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2023To11_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-21</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_03_2022To10_03_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-03</xbrli:startDate> <xbrli:endDate>2022-10-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_03_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_28_2023To07_28_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-28</xbrli:startDate> <xbrli:endDate>2023-07-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_29_2023To10_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-29</xbrli:startDate> <xbrli:endDate>2023-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_TrogarzoMemberTHTXCommitmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:TrogarzoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashbondAndMoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_EURsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_BottomOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_USsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:MultidosePassInjectorDevelopedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_KatanaMemberifrsfullBusinessCombinationsAxis_LicenseAgreementTransferPlusLPMemberTHTXTypeOfArrangementsAxis_MilestonePhaseTwoLiveDemonstrationMemberTHTXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestonePhaseTwoLiveDemonstrationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:LicenseAgreementTransferPlusLPMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CAifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_IEifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_USifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_IEsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LoanFacilityTranche3LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche3LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_TrogarzoMemberTHTXCommitmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:TrogarzoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashbondAndMoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_EURsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyNineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyNineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFourMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFiveMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySixMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySevenMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentySevenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyEightMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyEightMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_USsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_MilestoneSixMemberTHTXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_MilestoneFiveMemberTHTXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:MultidosePassInjectorDevelopedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BusinessCombinationAdjustmentToPurchaseConsiderationAxis">thtx:BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentOneMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BusinessCombinationAdjustmentToPurchaseConsiderationAxis">thtx:BusinessCombinationAdjustmentToConsiderationInstallmentOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_USifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CAifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IEifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:RevenueMultipleMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_TopOfRangeMemberifrsfullRangeAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:RevenueMultipleMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LoanFacilityTranche3And4LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche3And4LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:AverageOptionLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:ExercisePriceToAcquireOneCommonShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:SharePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IEsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AllOtherSegmentsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_RxCrossRoadsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_EURsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_USsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_USifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CAifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To11_30_2022_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:LocationInIncomeStatementAxis">thtx:CostOfGoodsSoldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ThtxCommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:ThtxCommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_OtherAssetsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AllOtherSegmentsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_RxCrossRoadsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_EURsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_USsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:AgreementAxis">thtx:FifthAmendmentOfTheLoanFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_USifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CAifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_FirstFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:FeesPeriodAxis">thtx:FirstFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:NatureOfFeesAxis">thtx:RoyaltyRelatedLicensePeptidesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AfterFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:FeesPeriodAxis">thtx:AfterFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:NatureOfFeesAxis">thtx:RoyaltyRelatedLicensePeptidesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:NetSalesBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:NetSalesBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:RoyaltyRevenueSublicenseBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:RoyaltyRevenueSublicenseBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_SellingAndMarketingExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_GeneralAndAdministrativeExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_SeveranceAndOtherExpensesMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:SeveranceAndOtherExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_ResearchAndDevelopmentExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:LocationInIncomeStatementAxis">thtx:CostOfGoodsSoldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To11_30_2023_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1And2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_AllOtherSegmentsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_RxCrossRoadsMemberifrsfullSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_StockAppreciationRightsMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_USifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_CAifrsfullGeographicalAreasAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-03-06</xbrli:startDate> <xbrli:endDate>2017-03-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-03-06</xbrli:startDate> <xbrli:endDate>2017-03-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2016_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_01_2017_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-12-01</xbrli:startDate> <xbrli:endDate>2016-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To11_30_2017_EuropeMemberifrsfullGeographicalAreasAxis_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2017-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022_TrogarzoMemberifrsfullProductsAndServicesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-12-01</xbrli:startDate> <xbrli:endDate>2019-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueWithOneYearMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2018_DueInNextFourToFiveYearsMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueInNextFourToFiveYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueWithOneYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_23_2021To07_23_2021_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-23</xbrli:startDate> <xbrli:endDate>2021-07-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AtmProgramMemberTHTXProgramNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_DevelopmentMilestonePhaseThreeClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseThreeClinicalTrialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_DevelopmentMilestonePhaseTwoClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseTwoClinicalTrialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseOneClinicalTrialMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_15_2018_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_15_2018_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_20_2022_LoanFacilityTranche4LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche4LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis_SecuredOvernightFinancingRateMemberifrsfullTypesOfInterestRatesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1And2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-20</xbrli:startDate> <xbrli:endDate>2022-07-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-27</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_19_2021To01_19_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-19</xbrli:startDate> <xbrli:endDate>2021-01-19</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2023To10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-31</xbrli:startDate> <xbrli:endDate>2023-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2023To10_31_2023_BottomOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-31</xbrli:startDate> <xbrli:endDate>2023-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2023To10_31_2023_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-31</xbrli:startDate> <xbrli:endDate>2023-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:OverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:NonVotingSubscriptionReceiptsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:OverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2023-11-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2023-11-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:NonVotingSubscriptionReceiptsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2023-11-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2023-11-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">thtx:TaiMedBiologicsInc.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-01</xbrli:startDate> <xbrli:endDate>2023-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-30</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_10_2023To07_21_2023_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-10</xbrli:startDate> <xbrli:endDate>2023-07-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_10_2023To07_21_2023_BottomOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-10</xbrli:startDate> <xbrli:endDate>2023-07-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_22_2023To07_28_2023_BottomOfRangeMemberifrsfullRangeAxis_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-22</xbrli:startDate> <xbrli:endDate>2023-07-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_22_2023To07_28_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis_TopOfRangeMemberifrsfullRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-22</xbrli:startDate> <xbrli:endDate>2023-07-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_13_2023To10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-13</xbrli:startDate> <xbrli:endDate>2023-10-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:AgreementAxis">thtx:FifthAmendmentOfTheLoanFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-27</xbrli:startDate> <xbrli:endDate>2023-02-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:AverageOptionLifeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:ExercisePriceToAcquireOneCommonShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:SharePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2023To06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-21</xbrli:startDate> <xbrli:endDate>2023-06-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTrancheTwoLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-21</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2023To11_30_2023_MarathonWarrantsMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-21</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2023To11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-21</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2022To07_27_2022_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-27</xbrli:startDate> <xbrli:endDate>2022-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_USsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001512717</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD"> <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR"> <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_CAD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Y"> <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_101085289" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085290" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085727" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085731" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085733" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085737" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085739" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085746" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085748" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085752" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101085989" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086103" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086122" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086174" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086181" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086182" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086183" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086184" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086251" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086281" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086282" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086287" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086288" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086292" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086296" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086333" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086334" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086714" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086715" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086720" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086762" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086766" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086768" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086772" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086774" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086777" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086781" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086784" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101086792" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086796" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086804" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086805" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086808" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101086852" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101087140" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101087431" toRefs="FN_350226"></ix:relationship><ix:relationship fromRefs="Fact_101087432" toRefs="FN_350227"></ix:relationship><ix:relationship fromRefs="Fact_101087538" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087540" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087543" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087547" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087549" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087614" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087616" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087740" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101087741" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101087742" toRefs="FN_350223"></ix:relationship><ix:relationship fromRefs="Fact_101087746" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087749" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087860" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087865" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087866" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087870" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087871" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087873" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087877" toRefs="FN_350225"></ix:relationship><ix:relationship fromRefs="Fact_101087880" toRefs="FN_350225"></ix:relationship></ix:resources></ix:header></div><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">WASHINGTON, D.C. 20549 </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FORM&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P12_01_2022To11_30_2023" id="ixv-47757">20-F</ix:nonNumeric></div></div> </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47758">&#9744;</ix:nonNumeric></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-true" id="ixv-47759">&#9746;</ix:nonNumeric></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P12_01_2022To11_30_2023" format="ixt:date-monthname-day-year-en" id="ixv-47760">November 30, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P12_01_2022To11_30_2023" id="ixv-47761">2023</ix:nonNumeric></ix:nonNumeric> </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47762">&#9744;</ix:nonNumeric></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47763">&#9744;</ix:nonNumeric></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Date of event requiring this shell company report <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;</div> </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;</div> to<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;</div> </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission file number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P12_01_2022To11_30_2023" id="ixv-47764">001-35203</ix:nonNumeric></div></div> </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P12_01_2022To11_30_2023" id="ixv-47765">THERATECHNOLOGIES INC.</ix:nonNumeric></div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of Registrant as specified in its charter) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Translation of Registrant&#8217;s name into English) </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:edgarprovcountryen" id="ixv-47766">Quebec</ix:nonNumeric></div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Jurisdiction of incorporation or organization) </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P12_01_2022To11_30_2023" id="ixv-47767">2015 Peel Street</ix:nonNumeric></div>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P12_01_2022To11_30_2023" id="ixv-47768">11th Floor</ix:nonNumeric>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P12_01_2022To11_30_2023" id="ixv-47769">Montreal</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:stateprovnameen" id="ixv-47770">Quebec</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:countrynameen" id="ixv-47771">Canada</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P12_01_2022To11_30_2023" id="ixv-47772">H3A 1T8</ix:nonNumeric></div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices) </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47773">Jocelyn Lafond</ix:nonNumeric></div>, Tel.: (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47774">438</ix:nonNumeric></div>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47775">315-6607</ix:nonNumeric></div>,</div> Fax: <ix:nonNumeric name="dei:ContactPersonnelFaxNumber" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47776">(514) 331-9691</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47777">2015 Peel Street</ix:nonNumeric></div>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47778">11th Floor</ix:nonNumeric>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47779">Montreal</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:stateprovnameen" id="ixv-47780">Quebec</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:countrynameen" id="ixv-47781">Canada</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47782">H3A 1T8</ix:nonNumeric></div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, Telephone, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-mail</div> and/or Facsimile number and Address of Company Contact Person) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act. </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Symbol(s)</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">on which registered</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P12_01_2022To11_30_2023" id="ixv-47783">Common Shares, no par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P12_01_2022To11_30_2023" id="ixv-47784">THTX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:exchnameen" id="ixv-47785">NASDAQ</ix:nonNumeric> Capital Market</td> </tr> </table> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act. </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Title of Class) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Title of Class) </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act. </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Common Shares </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Title of Class) </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn11_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47786">45,980,019</ix:nonFraction></div> Common Shares </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#8195;Yes&#8194;&#9744;&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P12_01_2022To11_30_2023" id="ixv-47787">No</ix:nonNumeric></div>&#8194;&#9746; </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.&#8195;Yes&#8194;&#9744;&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P12_01_2022To11_30_2023" id="ixv-47788">No</ix:nonNumeric></div>&#8194;&#9746; </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P12_01_2022To11_30_2023" id="ixv-47789">Yes</ix:nonNumeric></div>&#8194;&#9746;&#8195;No&#8194;&#9744; </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P12_01_2022To11_30_2023" id="ixv-47790">Yes</ix:nonNumeric></div>&#8194;&#9746;&#8195;No&#8194;&#9744; </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#9744;&#8194;Large accelerated filer&#8195;&#9744;&#8194;Accelerated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">filer&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#8194;<ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:entityfilercategoryen" id="ixv-47791">Non-accelerated filer</ix:nonNumeric>&#8195;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-true" id="ixv-47792">&#9746;</ix:nonNumeric></div>&#8194;Emerging&#160;Growth&#160;Company</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47793">&#9744;</ix:nonNumeric></div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b) by the registered public accounting firm that prepared or issued its audit report.&#8194;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47794">&#9744;</ix:nonNumeric></div> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:33%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:34%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#8195;Auditor Name: <ix:nonNumeric name="dei:AuditorName" contextRef="P12_01_2022To11_30_2023" id="ixv-47795">KPMG LLP</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Auditor&#160;Location:&#160;<ix:nonNumeric name="dei:AuditorLocation" contextRef="P12_01_2022To11_30_2023" id="ixv-47796">Montreal, Quebec, Canada</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right;">Auditor Firm ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="P12_01_2022To11_30_2023" id="ixv-47797">85</ix:nonNumeric>&#8195;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#8194;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47798">&#9744;</ix:nonNumeric></div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.10D-1(b).&#8194;&#9744;</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark which basis of accounting the registrant has used to prepare the statements included in this filing: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:19%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:61%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">U.S.&#160;GAAP&#8194;&#9744;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#8195;&#8195;<ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="P12_01_2022To11_30_2023" id="ixv-47799">International Financial Reporting Standards</ix:nonNumeric> as issued</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right;">Other&#8194;&#9744;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#8195;&#8195;by the International Accounting Standards Board</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. &#8195;Item&#160;17&#8194;&#9744;&#8195; Item&#160;18&#8194;&#9746; </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#8195;Yes&#8194;&#9744;&#8195; No&#8194;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="P12_01_2022To11_30_2023" format="ixt:fixed-false" id="ixv-47800">&#9746;</ix:nonNumeric></div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROC<div style="letter-spacing: 0px; top: 0px;;display:inline;">E</div>EDINGS DURING THE PAST FIVE YEARS) </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.&#8195;&#9744;&#8194;Yes&#8195;&#9744;&#8194;No </div> <div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&#160;</p> <p style="margin-top:1pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:83%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap">Page&#8196;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><a href="#tx680117_1">INTRODUCTION</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">4</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt" colspan="5"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><a href="#tx680117_2">PART I</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;1.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_3">Identity of Directors, Senior Management and Advisors </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_4">Directors and Senior Management</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_5">Advisors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_6">Auditors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">8</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;2.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_7">Offer Statistics and Expected Timetable </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_8">Offer Statistics</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_9">Method and Expected Timetable</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;3.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_10">Key Information </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_11">[Reserved]</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_12">Capitalization and Indebtedness</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_13">Reasons for the Offer and Use of Proceeds</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_14">Risk Factors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">9</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;4.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_15">Information on the Company </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_16">History and Development of the Company</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">33</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_17">Business Overview</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">36</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_18">Organizational Structure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">51</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_19">Property, Plants and Equipment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">52</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;4A.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_20">Unresolved Staff Comments </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">52</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;5.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_21">Operating and Financial Review and Prospects </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_22">Operating Results</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">52</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_23">Liquidity and Capital Resources</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">56</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_24">Research and Development, Patents and Licenses, etc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">61</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_25">Trend Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">61</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">E.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_26">Critical Accounting Estimates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">62</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;6.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_27">Directors, Senior Management and Employees </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_28">Directors and Senior Management</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">63</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_29">Compensation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">75</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_30">Board Practices</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">101</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_31">Employees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">102</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">E.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_32">Share Ownership</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">103</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">F.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_33">Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">103</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;7.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_34">Major Shareholders and Related Party Transactions </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_35">Major Shareholders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">104</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_36">Related Party Transactions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">104</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_37">Interests of Experts and Counsel</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">104</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;8.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_38">Financial Information </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_39">Consolidated Statements and Other Financial Information </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">104</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;9.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_40">The Offer and Listings </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_41">Offer and Listing Details</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_42">Plan of Distribution</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_43">Markets</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_44">Selling Shareholders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">E.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_45">Dilution</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">F.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_46">Expenses of the Issue</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:83%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap">Page&#8196;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;10.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_47">Additional Information </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_48">Share Capital</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_49">Memorandum and Articles of Association</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">105</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_50">Material Contracts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">119</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_51">Exchange Controls</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">122</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">E.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_52">Taxation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">122</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">F.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_53">Dividends and Paying Agents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">129</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">G.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_54">Statement by Experts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">129</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">H.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_55">Documents on Display</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">129</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">I.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_56">Subsidiary Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">129</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">J.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_57">Annual Report to Security Holders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">129</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;11.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_58">Quantitative and Qualitative Disclosures about Market Risks</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">130</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;12.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_59">Description of Securities Other than Equity Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">A.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_60">Debt Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">130</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">B.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_61">Warrants and Rights</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">130</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">C.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_62">Other Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">130</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">D.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#tx680117_63">American Depositary Shares</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">130</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt" colspan="5"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><a href="#tx680117_64">PART II </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">131</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;13.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_65">Defaults, Dividend Arrearages and Delinquencies</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">131</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;14.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_66">Material Modification to the Rights of Security Holders and Use of Proceeds</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">131</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;15.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_67">Controls and Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">131</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_68">[Reserved]</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">133</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16A.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_69">Audit Committee Financial Expert</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">133</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16B.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_70">Code of Ethics</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">133</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16C.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_71">Principal Accountant Fees and Services</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">133</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_72">Exemptions from the Listing Standards for Audit Committees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16E.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_73">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16F.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_74">Change in Registrant&#8217;s Certifying Accountant</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16G.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_75">Corporate Governance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16H.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_76">Mine Safety Disclosure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16I.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_77">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">134</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16J.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_78">Insider Trading Policies</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">135</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;16K.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_79">Cybersecurity</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">135</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt" colspan="5"/>
<td style="height:14.25pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><a href="#tx680117_80">PART III </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">136</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;17.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_81">Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">136</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;18.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_82">Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">136</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;19.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><a href="#tx680117_83">Exhibits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">137</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt" colspan="5"/>
<td style="height:7.5pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><a href="#tx680117_84">SIGNATURES </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">140</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx680117_1">INTRODUCTION </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">BASIS OF PRESENTATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;text-align:justify">In this Annual Report on Form <span style="white-space:nowrap">20-F</span> (&#8220;Annual Report&#8221;): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">References to &#8220;Theratechnologies&#8221;, the &#8220;Company&#8221;, the &#8220;Corporation&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; or similar terms refer to Theratechnologies Inc. and its subsidiaries on a consolidated basis, unless otherwise indicated or unless the context requires otherwise. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify"><span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> (tesamorelin for injection) refers to tesamorelin indicated for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy. <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> is our registered trademark in the United States and this mark is used in the United States to commercialize tesamorelin for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ibalizumab-uiyk) refers to a recombinant humanized monoclonal antibody. Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, in combination with other antiretroviral(s) (&#8220;ARV&#8221;), is indicated for the treatment of human immunodeficiency virus type 1 <span style="white-space:nowrap">(&#8220;HIV-1&#8221;)</span> infection in heavily treatment-experienced adults with multidrug-resistant (&#8220;MDR&#8221;) <span style="white-space:nowrap">HIV-1</span> infection failing their current ARV regimen. Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is a registered trademark of TaiMed Biologics, Inc. (&#8220;TaiMed&#8221;) and is under licence to us for use in the United States and Canada. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify"><span style="font-style:italic">THERA Patient Support</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> is our registered trademark in the United States and it refers to our patients and physicians service desk providing support to these people in connection with our commercialized products. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify"><span style="font-style:italic">SORT1+ Technology</span> is our trademark and refers to our licensed platform to develop peptide-drug conjugates (&#8220;PDC&#8221;). </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Except as otherwise indicated, the financial information contained in this Annual Report and in our financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The Company&#8217;s functional and presentation currency is the United States dollar. Except as otherwise indicated, all monetary amounts set forth in this Annual Report are expressed in United States dollar. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">References to &#8220;$&#8221; and &#8220;US$&#8221; are to U.S. dollars and references to &#8220;CA$&#8221; or &#8220;CAD&#8221; are to Canadian dollars. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Any references in this Annual Report to the number of common shares (&#8220;Common Shares&#8221;) (including earnings per share), Marathon Warrants (as defined below), share options and the exercise price of the Marathon Warrants, share options and other equity-linked securities issued by the Corporation have been retrospectively adjusted and restated to reflect the effect of the Consolidation (as defined below), on a retrospective basis. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">All information is provided as of November&#160;30, 2023, except where otherwise stated. </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:14pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This Annual Report and the documents contained herein by reference contain forward-looking statements and forward-looking information within the meaning of applicable securities laws that are based on our management&#8217;s belief and assumptions and on information currently available to our management (collectively, &#8220;Forward-Looking Statements&#8221;). In some cases, you can identify Forward-Looking Statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;predict&#8221;, &#8220;intend&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; and similar expressions intended to identify Forward-Looking Statements. Although we believe that the expectations reflected in these Forward-Looking Statements are reasonable, these statements relate to future events or our future performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these Forward-Looking Statements. Forward-Looking Statements include, but are not limited to, statements about: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our expectations regarding the commercialization of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, despite new market entrants; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability and capacity to grow the sales of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> successfully in the United States; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to meet supply and demand for our products; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our revenue and Adjusted EBITDA (as defined below) guidance, which are based on our assumption that our revenues continue to grow in Fiscal 2024 and that we continue our close monitoring and management of expenses; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to continue generating a positive Adjusted EBITDA; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the market acceptance of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>in the United States; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the continuation of our collaborations and other significant agreements with our existing commercial partners and third-party suppliers and our ability to establish and maintain additional collaboration agreements; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our success in continuing to seek and in maintaining reimbursement for <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> by third-party payors in the United States; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the pricing and reimbursement conditions of other competing drugs or therapies that are or may become available; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to protect and maintain our intellectual property rights in tesamorelin and our other peptide-drug conjugates; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to enroll patients and complete our Phase 1 clinical trial studying sudocetaxel zendusortide; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to develop other peptide-drug conjugates generated through our SORT1+Technology<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to successfully address the questions raised by the FDA in its complete response letter (&#8220;CRL&#8221;) regarding the F8 formulation of tesamorelin (&#8220;F8 Formulation&#8221;) and to resubmit the F8 Formulation for approval to the United States Food and Drug Administration (&#8220;FDA&#8221;); </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the approval of the F8 Formulation by the FDA; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to successfully complete the human factors validation study (&#8220;HFS&#8221;) results for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and to resubmit a Changes Being Effected (&#8220;CBE&#8221;) supplement with the FDA for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> on or before September&#160;15, 2024, or any other prescribed deadline we may be able to negotiate with the FDA; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to meet the undertakings, covenants and obligations contained in the credit agreement dated July&#160;20, 2022, as amended from time to time (&#8220;Marathon Credit Agreement&#8221;), entered into with Marathon&#8217;s affiliates (collectively &#8220;Marathon&#8221;) and not be in default thereof; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to find a partner to conduct a Phase 2b/3 clinical trial using tesamorelin for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) in the general population; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to find a partner to pursue the development of sudocetaxel zendusortide once the Phase 1 clinical trial is completed; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our capacity to acquire, <span style="white-space:nowrap">in-license,</span> or copromote new commercialized drug products; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our expectations regarding our financial performance, including revenues, expenses, gross margins, profitability, liquidity, capital expenditures and income taxes; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our estimates regarding our capital requirements; and </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our ability to meet the timelines set forth herein. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Such statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed in or implied by the Forward-Looking Statements. Certain assumptions made in preparing the Forward-Looking Statements include that: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">sales of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States will increase over time; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our expenses will remain under control; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our commercial practices in the United States will not be found to be in violation of applicable laws; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the long-term use of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> will not change their respective current safety profile; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">no recall or market withdrawal of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> will occur; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">no laws, regulation, order, decree or judgment will be passed or issued by a governmental body negatively affecting the marketing, promotion or sale of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">continuous supply of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>will be available to meet market demand on a timely basis; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our relations with third-party suppliers of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> will be conflict-free; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the level of product returns and the value of chargebacks and rebates will not exceed our estimates in relation thereto; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">no biosimilar version of tesamorelin will be approved by the FDA; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">we will be able to satisfactorily answer all of the questions asked by the FDA in the CRL related to the F8 Formulation and to resubmit our file to the FDA seeking the approval of the F8 Formulation; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the FDA will approve the F8 Formulation; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">no vaccine or cure will be found for the prevention or eradication of HIV; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the HFS for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> will be successfully completed and we will resubmit a CBE supplement with the FDA for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> within the prescribed timelines; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the FDA will approve the CBE supplement for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the FDA will approve the intramuscular (&#8220;IM&#8221;) method of administration for the maintenance dose of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">we will not default under the terms and conditions of the Marathon Credit Agreement, including meeting the minimum liquidity and Marathon Adjusted EBITDA (as defined below) target covenants therein; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the interest rate on the amount borrowed from Marathon under the Marathon Credit Agreement will not materially vary upwards; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the Corporation will continue as a going concern; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">we will find a partner to conduct a Phase 2b/3 clinical trial studying tesamorelin for the treatment of NASH in the general population; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">we will be able to recruit patients for our Phase 1 clinical trial studying sudocetaxel zendusortide and will be able to see signs of efficacy without observing material adverse effects; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">we will find a partner to pursue the development of sudocetaxel zendusortide once the Phase 1 clinical trial has been completed; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our research and development activities will yield positive results; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the data obtained from our market research on the potential market for <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and on the potential market for Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States are accurate; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the timelines set forth herein will not be materially adversely impacted by unforeseen events that could arise subsequent to the date of this Annual Report; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">our business plan will not be substantially modified; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">no international event, such as a pandemic or worldwide war, will occur and adversely affect global trade. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Forward-Looking Statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, the Forward-Looking Statements and circumstances discussed in this Annual Report may not occur, and you should not place undue reliance on these Forward-Looking Statements. We discuss many of our risks in greater detail under &#8220;Item 3D &#8211; Risk Factors&#8221; (below) but additional risks and uncertainties, including those that we do not know about or that we currently believe are immaterial, may also adversely affect the Forward-Looking Statements, our business, financial condition and prospects. Also, these Forward-Looking Statements represent our estimates and assumptions only as of the date of this Annual Report. We undertake no obligation and do not intend to update or revise these Forward-Looking Statements, unless required by law. We qualify all of the information presented in this Annual Report, and particularly our Forward-Looking Statements, with these cautionary statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">STATUS AS AN EMERGING GROWTH COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are an &#8220;emerging growth company&#8221; as defined in Section&#160;3(a) of the United States Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;) by the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We will continue to qualify as an &#8220;emerging growth company&#8221; until the earliest to occur of: (a)&#160;the last day of the fiscal year during which we had total annual gross revenues of $1,235,000,000 (as such amount is indexed for inflation every 5 years by the United States Securities and Exchange Commission (&#8220;SEC&#8221;)) or more; (b)&#160;the last day of our fiscal year following the fifth anniversary of the date of the first sale of equity securities pursuant to an effective registration statement under the United States Securities Act of 1933, as amended (&#8220;Securities Act&#8221;); (c) the date on which we have, during the previous <span style="white-space:nowrap">3-year</span> period, issued more than $1,000,000,000 in <span style="white-space:nowrap">non-convertible</span> debt; or (d)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221;, as defined in Exchange Act Rule <span style="white-space:nowrap">12b-2.</span> We expect to continue to be an emerging growth company for the immediate future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Generally, a registrant that registers any class of its securities under Section&#160;12 of the Exchange Act is required to include in the second and all subsequent annual reports filed by it under the Exchange Act a management report on internal control over financial reporting and, subject to an exemption available to registrants that are neither an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer&#8221; (as those terms are defined in Exchange Act Rule <span style="white-space:nowrap">12b-2),</span> an auditor attestation report on management&#8217;s assessment of internal control over financial reporting. However, for so long as we continue to qualify as an emerging growth company, we will be exempt from the requirement to include an auditor attestation report on management&#8217;s assessment of internal controls over financial reporting in its annual reports filed under the Exchange Act, even if we were to qualify as an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOREIGN PRIVATE ISSUER FILINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are considered a &#8220;foreign private issuer&#8221; pursuant to Rule 405 promulgated under the Securities Act. In our capacity as a foreign private issuer, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&#160;14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section&#160;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our shares. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. For as long as we are a &#8220;foreign private issuer&#8221; we intend to file our annual financial statements on Form <span style="white-space:nowrap">20-F</span> and furnish our quarterly financial statements on Form <span style="white-space:nowrap">6-K</span> to the SEC for so long as we are subject to the reporting requirements of Section&#160;13(g) or 15(d) of the Exchange Act. However, the information we file or furnish may not be the same as the information that is required in annual and quarterly reports on Form <span style="white-space:nowrap">10-K</span> or Form <span style="white-space:nowrap">10-Q</span> for United States domestic issuers. Accordingly, there may be less information publicly available concerning us than there is for a company that files as a domestic issuer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We are required to determine our status as a foreign private issuer on an annual basis at the end of our second fiscal quarter. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by United States residents and any of the following three circumstances applies: (1)&#160;the majority of our executive officers or directors are United States citizens or residents; (2)&#160;more than 50% of our assets are located in the United States; or (3)&#160;our business is administered principally in the United States. If we lose our &#8220;foreign private issuer status&#8221; we would be required to comply with Exchange Act reporting and other requirements applicable to United States domestic issuers, which are more detailed and extensive than the requirement for foreign private issuers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">NON-IFRS</span> AND <span style="white-space:nowrap">NON-U.S.</span> GAAP MEASURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The information presented in this Annual Report includes a measure that is not determined in accordance with IFRS or U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), being the term &#8220;Adjusted EBITDA&#8221;. &#8220;Adjusted EBITDA&#8221; is used by the Corporation as an indicator of financial performance and is obtained by adding to net profit or loss, finance income and costs, depreciation and amortization, income taxes, share-based compensation from stock options, certain restructuring costs and certain write-downs (or related reversals) of inventories. &#8220;Adjusted EBITDA&#8221; excludes the effects of items that primarily reflect the impact of long-term investment and financing decisions rather than the results of <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations. The Corporation believes that this measure can be a useful indicator of its operational performance from one period to another. The Corporation uses this <span style="white-space:nowrap">non-IFRS</span> measure to make financial, strategic and operating decisions. &#8220;Adjusted EBITDA&#8221; is not a standardized financial measure under the financial reporting framework used to prepare the financial statements of the Corporation to which the measure relates and might not be comparable to similar financial measures disclosed by other issuers. A quantitative reconciliation of Adjusted EBITDA is presented under &#8220;Item 5 &#8211; Operating and Financial Review and Prospects &#8211; Reconciliation of Adjusted EBITDA&#8221; of this Annual Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The calculation of the &#8220;Adjusted EBITDA&#8221; in this Annual Report is different from the calculation of the adjusted EBITDA (&#8220;Marathon Adjusted EBITDA&#8221;) under the Marathon Credit Agreement for the purpose of complying with the covenants therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx680117_2">PART I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_3">Item&#8201;1. Identity of Directors, Senior Management and Advisers </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_4"><span style="font-weight:bold">A.</span>&#8195;<span style="font-weight:bold"><span style="font-style:italic">&#8195;&#8195;Directors and senior management.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_5"><span style="font-weight:bold">B.</span>&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">&#8195;Advisers.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_6"><span style="font-weight:bold">C.</span>&#8195;<span style="font-weight:bold"><span style="font-style:italic">&#8195;&#8195;Auditors.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_7">Item&#8201;2. Offer Statistics and Expected Timetable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_8"><span style="font-weight:bold">A.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Offer Statistics</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_9"><span style="font-weight:bold">B.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Method and Expected Timetable</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_10">Item&#8201;3. Key Information </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_11"><span style="font-weight:bold">A.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">(Reserved)</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_12"><span style="font-weight:bold">B.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Capitalization and indebtedness</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_13"><span style="font-weight:bold">C.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Reasons for the offer and use of proceeds</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_14"><span style="font-weight:bold">D.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Risks factors</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Before you invest in our securities, you should understand the high degree of risk involved and consider carefully the risks and uncertainties described below. The following risks may adversely impact our business, financial condition, operating results and prospects. Additional risks and uncertainties, including those that we do not know about or that we currently believe are immaterial, may also develop as our operations evolve and, therefore, may adversely affect our business, financial condition, operating results or prospects. As a result, the trading price of our securities, including our common shares, could decline and you could lose all or part of your investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This Annual Report also contains Forward-Looking Statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these Forward-Looking Statements as a result of certain factors, including the risks described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to the Corporation&#8217;s Cash Position</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The Corporation&#8217;s report of independent registered public accounting firm (&#8220;Auditors Report&#8221;) to shareholders and the Board of Directors of the Corporation, as well as note 1 to the audited consolidated financial statements of the Corporation for the fiscal year ended November&#160;30, 2023 contains a going concern note about the Corporation&#8217;s ability to continue as a going concern and its capacity to honor its obligations as they fall due during a period of at least, but not limited to, 12 months from November&#160;30, 2023. The going concern note casts substantial doubt about the capacity of the Corporation to meet its monetary obligations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation&#8217;s Auditors Report to the shareholders and Board of Directors, as well as note 1 to the audited annual consolidated financial statements of the Corporation for the fiscal year ended November&#160;30, 2023, contains a going concern note about the Corporation&#8217;s ability to continue as a going concern and the capacity of the Corporation to realize its assets and discharge its liabilities and commitments in the normal course of business. The going concern note casts substantial doubt about the capacity of the Corporation to honor its obligations as they fall due during a period of at least 12 months from November&#160;30, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A breach of a financial covenant under the Marathon Credit Agreement would entitle the lender to demand immediate repayment of the Corporation&#8217;s debt. As at November&#160;30, 2023, the Corporation&#8217;s cash, bonds and money market funds amounted to $40.4&#160;million whereas the principal of the loan to be reimbursed would amount to $60.6&#160;million. Therefore, the Corporation could be unable to reimburse its debt unless it is able to find additional external financing by way of an equity offering. Absent such additional source of financing, the Corporation may have to resort to insolvency laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">In the event there occurs an event of default under the Marathon Credit Agreement, the interest rate payable on the loaned amount increases by 300 basis points and Marathon has the right to declare all amounts outstanding under the loan immediately due and payable. If Marathon was to declare all loaned amounts due and payable under the Marathon Credit Agreement, the Corporation would not currently be able to repay such amount unless it secures additional financings. Therefore, the Corporation would have to issue additional equity or secure access to alternative funding enabling it to repay in full the loaned amounts under the Marathon Credit Agreement. The issuance of additional equity would dilute current shareholders and such dilution could be substantial depending on the amount of money the Corporation would have to raise and the price at which such equity offering would be made. In the event the Corporation is unable to implement measures allowing it to secure the repayment of its debt, the Corporation could also have to sell or liquidate its assets or resort to insolvency laws. A recourse to any of these alternatives would have a material adverse effect on the Corporation and its shareholders. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Marathon Credit Agreement contains various covenants, undertakings and obligations, any breach of which could trigger an event of default under the Marathon Credit Agreement resulting in the interest rate payable on any outstanding loaned amount to be increased by 300 basis points and would allow Marathon to declare such principal amount and interest thereon immediately due and payable. Marathon would have the option to foreclose on all of the assets of the Corporation pursuant to the liens registered against all of the assets of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">An event of default under the Marathon Credit Agreement resulting in Marathon declaring all principal amount and interest thereon immediately due and payable would require the Corporation to seek and find alternative sources of financing if liquidities readily available to the Corporation were below the amount of the debt to be repaid. As at November&#160;30, 2023, the Corporation had approximatively $40.4&#160;million in cash, bonds and money market funds while the principal of the debt amounted to $60.6&#160;million. Alternative sources of financing could include the issuance of equity, subject to then prevailing market conditions. The issuance of equity security would dilute shareholders and such dilution could be substantial depending on the price at which the equity offering would be made and the amount to be raised. If the Corporation was unable to secure additional financing to repay any of its outstanding loaned amount, the Corporation could have to sell or liquidate its assets or resort to insolvency laws. A recourse to any of these alternatives would have a material adverse effect on the Corporation and its shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the past, the Corporation has breached certain terms and conditions of the Marathon Credit Agreement. While we have been successful in negotiating waivers of default and amendments to the Marathon Credit Agreement, there can be no assurance that, going forward, Marathon will agree to additional waivers or amendments to the Marathon Credit Agreement if the Corporation breaches any of the covenants, undertakings or obligations under such agreement. Furthermore, any additional waivers or amendments to the Marathon Credit Agreement could be costly to the Corporation. The failure to amend the Marathon Credit Agreement or to obtain a waiver from Marathon in the future in the event we are in default under the Marathon Credit Agreement could have a material adverse effect on the Corporation and its business prospects in the event Marathon declares all principal amounts and interest thereon immediately due and payable and the Corporation is unable to repay the loaned amounts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We did not generate a profit from our operations in the fiscal year ended November&#160;30, 2023. There can be no guarantee that we will ever achieve profitability. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have a history of net losses, including a net loss of $24&#160;million for the fiscal year ended November&#160;30, 2023. In the future, our profitability will mainly depend on our capacity to successfully maintain the commercialization of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States through a <span style="white-space:nowrap">low-cost</span> and effective distribution network, compliance with applicable laws, the recruitment and retention of talented personnel, the deployment of effective marketing campaigns and through continued reimbursement coverage for <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> under U.S. Medicare and Medicaid programs and under private-health insurers programs in the United States. Our long-term profitability will also depend on our ability and capacity to acquire or <span style="white-space:nowrap">in-license</span> additional commercialized drug products immediately accretive to our business, and to control our operating expenses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There is no guarantee that we will continue succeeding in growing sales of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States or that we will be successful in acquiring or <span style="white-space:nowrap">in-licensing</span> additional commercialized drug products. The acquisition or <span style="white-space:nowrap">in-licensing</span> of additional commercialized drug products will depend on our ability to identify such products, our capacity to enter into agreements on terms satisfactory to us and to obtain all approvals, if any are required. If revenues grow more slowly than we anticipate or if our operating expenses exceed our expectations, our business, financial condition and operating results could be materially adversely affected, and we may never obtain or sustain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We may not be able to generate sufficient cash from our operating activities to service our debt obligations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Future financial and operating performance remain subject to prevailing economic and competitive conditions and to certain financial, business and other factors beyond our control. We may be unable to generate a level of positive cash flows from operating activities sufficient to pay the principal and interest on the loan provided by Marathon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the three months ended November 30, 2023, and for the fiscal year ended November&#160;30, 2023, the Corporation had negative operating cash flows of $4.1 million and $5.7&#160;million, respectively. If the cash flow we generate and our capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay expenditures and capital additions, seek additional capital or restructure or refinance our debt. These measures may not be successful and may not permit us to meet our scheduled debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and we could have to resort to insolvency laws to seek protection from our creditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Interest rate fluctuations may have a material adverse effect on our capacity to reimburse the loaned amounts under the Marathon Credit Agreement and on our capacity to execute on our business plan. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The interest rate we have to pay Marathon under the Marathon Credit Agreement is based on the Secured Overnight Financing Rate (&#8220;SOFR&#8221;), plus 9.5%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">SOFR is a broad measure of the cost of borrowing cash overnight collateralized by U.S. Treasury securities. SOFR has a limited history, and the future performance of SOFR cannot be predicted based on its limited historical performance. The level of SOFR may bear little or no relation to historical, actual or indicative data. Prior observed patterns, if any, in the behavior of market variables and their relation to SOFR, such as correlations, may change in the future. While some <span style="white-space:nowrap">pre-publication</span> historical data have been released by the Federal Reserve Bank of New York, such analysis inherently involves assumptions, estimates and approximations, and hypothetical or historical performance data are not indicative of, and have no bearing on, the potential performance of SOFR. The future performance of SOFR is therefore impossible to predict, and no future performance of SOFR may be inferred from any of the historical, actual or indicative data. Changes in the levels of SOFR will affect the interest rate we have to pay to Marathon under the Marathon Credit Agreement during the term of the loan and may adversely affect the amount of cash we will have to allocate to the repayment of the loan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Interest rates are highly sensitive to many factors, including governmental monetary policies, domestic and international economic and political conditions, and other factors beyond our control. If SOFR increases as a result of events over which we have no control, this could have a material adverse effect on our financial condition and results of operations. If SOFR increases, our debt service obligations would increase even if the amount borrowed remained the same, and our net loss will increase and cash flows from operating activities, including cash available for servicing our indebtedness, will correspondingly decrease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The Marathon Credit Agreement includes significant operating and financial restrictions on the Corporation, any of which could prevent us from capitalizing on business opportunities. In addition, our failure to comply with such restrictions could trigger an event of default which would increase by 300 basis points the interest payable on any loaned amounts under the Marathon Credit Agreement and would allow Marathon to declare the outstanding loaned amounts immediately due and payable in addition to providing Marathon with the right to foreclose on all of the assets of the Corporation pursuant to the liens registered against all of the assets of the Corporation. If we are unable to cure an event of default or obtain a waiver from Marathon in relation to such event of default, and if we do not have the financial capacity to repay any amount loaned becoming due and payable, we may have to cease our operations and to resort to insolvency laws. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Marathon Credit Agreement governing our outstanding $60.6&#160;million loan imposes significant operating and financial restrictions on the Corporation. These restrictions limit our ability and the ability of our subsidiaries to, among other things: (i)&#160;incur or guarantee additional debt or issue disqualified stock or preferred stock; (ii)&#160;pay dividends and make other distributions on, or redeem or repurchase, capital stock; (iii)&#160;make certain investments; (iv)&#160;incur additional liens; (v)&#160;enter into transactions related to the acquisition, disposition, <span style="white-space:nowrap">in-licensing</span> or <span style="white-space:nowrap">out-licensing</span> of assets; and (vi)&#160;merge or consolidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, the Marathon Credit Agreement imposes that we maintain a minimum level of liquidity of between $15&#160;million and $20&#160;million in cash, cash equivalent and eligible investments at all times based on the Marathon Adjusted EBITDA thresholds over the most recently ended four fiscal quarters. The minimum liquidity covenant restricts the management of the Corporation&#8217;s liquidity and could increase the likelihood that the Corporation may not be able to meet its obligations as they become due. The Marathon Credit Agreement also imposes a minimum Marathon Adjusted EBITDA covenant on a quarterly basis that began with the quarter ending November&#160;30, 2023. The Marathon Credit Agreement further imposes reporting requirements on our business activities on a quarterly basis. These reporting requirements extend beyond those that we have to comply with under securities regulations and add a layer of complexity to our reporting obligations. The minimum liquidity covenant restricts the management of the Corporation&#8217;s liquidity and increases the likelihood that the Corporation may not be able to meet its obligations as they become due. As a result of the restrictions and obligations described above, we will be limited as to how we conduct our business and we may be unable to enter into transactions that may be accretive to our business to compete effectively or to take advantage of new business opportunities unless we are able to negotiate waivers or amendments to the Marathon Credit Agreement. Debt financing opportunities will also be limited in the event that we are unable to raise capital through the issuance of equity. There can be no assurances that we will be able to maintain compliance with these requirements and covenants in the future and, if we fail to do so, that we will be able to obtain waivers from Marathon and/or amend the covenants contained in the Marathon Credit Agreement to remove those obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our failure to comply with the covenants described above as well as other terms of our indebtedness will result in an event of default under the Marathon Credit Agreement which, if not cured or waived, will result in an increase of 300 basis point on the interest payable on the outstanding loaned amount. An event of default under the Marathon Credit Agreement would also allow Marathon to declare all loaned amounts immediately due and payable and entitle Marathon to execute on its first ranking security interest on all of our assets and foreclose on our assets. In the event there occurs an event of default under the Marathon Credit Agreement and we are unable to cure such event of default or obtain a waiver from Marathon in relation thereto, and if we do not have the financial capacity to repay any amount loaned becoming due and payable, we may have to cease our operations and to resort to insolvency laws. Any of those circumstances will have a material adverse effect on shareholders as they will lose the entire value of their investment in the capital of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to the Commercialization of Our Products</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our commercial success and revenue growth depend on the commercialization of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States; unsatisfactory future sales levels of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States will have a material adverse effect on us. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our ability to generate revenue and sustain growth is currently concentrated solely on the commercialization of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States. Our success in generating sales revenue from <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States will depend on our capacity: (a)&#160;to pursue the deployment of a commercialization strategy that will be accepted by patients, healthcare professionals and third-party payors; (b)&#160;to maintain reimbursement coverage for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> by third-party payors; (c)&#160;to maintain the registration of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> on U.S. governmental forms as drugs available for purchase in the United States; (d)&#160;to ensure that adequate supplies of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> are available; (e)&#160;to maintain conflict-free relationships with our principal third-party suppliers of services, namely our manufacturers (TaiMed, Bachem Americas Inc. (&#8220;Bachem&#8221;), and Jubilant HollisterStier, General Partnership (&#8220;Jubilant&#8221;)), our distributor in the United States Mckesson Specialty Care Distribution, LLC (&#8220;McKesson&#8221;), as well as other specialized third parties; and (f)&#160;remain compliant with applicable laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our success in commercializing our products in the United States will also depend on our capacity to retain qualified, motivated and talented sales representatives and other key individuals instrumental in the commercialization of our products and the capacity of our third-party suppliers to comply with all laws and regulations applicable to the conduct of their respective businesses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There can be no assurance that sales of our products<span style="font-style:italic"> </span>to customers in the United States will increase in the future or that we<sup style="font-size:75%; vertical-align:top"> </sup>will generate sales at a profitable level. If sales of our products decrease, our revenue would be adversely affected which, in turn, could materially adversely affect our business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Because we expect to be dependent on revenues solely from <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> for the foreseeable future, any negative developments relating to these products, such as safety or efficacy issues, manufacturing issues, the introduction or greater acceptance of competing products, or adverse regulatory or legislative developments, or our inability to successfully manage any of the abovementioned factors, will have a material adverse effect on our business and our future business prospects and could also result in a default to meet the Marathon Adjusted EBITDA covenant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">McKesson is our only client in the United States in connection with the sale of EGRIFTA&#160;SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>and we are currently negotiating the terms and conditions of a new agreement with McKesson. Any default or a dispute under our current agreement, or its termination, or the failure to enter into a new agreement, would materially adversely affect our revenues, business and operating results. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">More than 95% of our revenues are derived from the sale of our products to McKesson that acts as our exclusive distributor in the United States. Our current agreement with McKesson is subject to automatic renewal in April of each year unless a party provides the other with a 120-day written notice of its intent not to renew the agreement or there is no agreement on the fees to be paid annually to McKesson if there is a material change in the industry that causes a financial hardship to McKesson to continue providing its services pursuant to the then agreed upon pricing. In the latter circumstances, McKesson could be entitled to terminate its agreement with us upon a 90-day prior written notice. Both parties also have termination rights in certain other circumstances such as a breach of the agreement. If our agreement with McKesson is terminated, or we are unable to agree on the terms of a new agreement and we are unable to find another distributor prior to its term, or if we are in default or engaged in a dispute with McKesson, our sales may be materially adversely impacted and our revenues could decrease substantially. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, under the terms of our agreement with McKesson, we agreed to reimburse McKesson for chargebacks and other discounts that McKesson may offer to its clients. If McKesson&#8217;s clients omit to timely claim from McKesson any discount they are entitled to, or if they make a mistake in assessing the types of discounts they are entitled to claim and they claim those discounts later in a year, we will have to refund McKesson for such discounts to which McKesson&#8217;s clients are entitled to and this may materially adversely affect our level of revenues and operating results for the year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We rely on third parties for the manufacture, distribution and commercialization of our products and such reliance may adversely affect our revenues, business and future business prospects if the third parties are unable or unwilling to fulfill their obligations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have a single third-party service provider for some of our core business activities pertaining to the commercialization of our products, namely their manufacturing and distribution. Any material issues such third-party service providers may encounter that relate to the provision of services to us would have a material adverse effect on our revenues, business and future business prospects since these third-party service providers may not be easily or rapidly replaced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We do not own or operate manufacturing facilities for the production of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top"> </sup></span></span>and tesamorelin, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on Bachem and Jubilant to manufacture and supply all of our required raw materials, drug substance and drug product for sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>. We will also rely on a single third-party supplier, Lyophilization Services of New England (&#8220;LSNE&#8221;) for the manufacture of the F8 Formulation. We have not qualified alternative manufacturers to date and no assurance can be given that such manufacturers will be qualified in the future or receive necessary regulatory approvals. There are a limited number of third-party suppliers that are compliant with current good manufacturing practice, (&#8220;GMP&#8221;), and that also have the necessary expertise and capacity to manufacture our drug substance and drug product. The replacement of a third-party manufacturer is time-consuming and costly due to the required validation of their capabilities. The validation process includes an assessment of the capacity of such third-party manufacturer to produce the quantities that we may request from time to time, the manufacturing process and its compliance with GMP regulations. In addition, the third-party manufacturer would have to familiarize itself with our technology. Validation of an additional third-party manufacturer takes at least twenty-four (24)&#160;months and could take as long as <span style="white-space:nowrap">thirty-six</span> (36)&#160;months or more. The delays associated with the validation of a third-party manufacturer could negatively affect our ability to commercialize our products in a timely manner and on budget. Given the long lead times to change manufacturers, existing manufacturers may utilize this as leverage in negotiations with us in a manner that is adverse to our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">TaiMed is our sole supplier of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. TaiMed does not currently own or operate any manufacturing facilities for the production of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>and must rely on its suppliers, WuXi Apptec Biologics, Inc., (&#8220;WuXi&#8221;) and Samsung Biologics Laboratories in South Korea (&#8220;Samsung&#8221;). We are not in a contractual relationship with WuXi and Samsung for Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and, therefore, we may not be able to interact with any of them in the event they encounter issues which could adversely affect the supply of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. In such circumstances, we will need to rely on TaiMed to address any of those issues. We have no control over the time and efforts that TaiMed will devote in finding solutions to supply issues if such were to occur, or any say on the solution itself. Any delay in addressing manufacturing issues or any solution to address a manufacturing problem that is not to our liking could have a material adverse effect on the supply and sale of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and, accordingly, materially adversely affect our revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We do not have state licensure in the United States to distribute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> or any other product we may acquire or <span style="white-space:nowrap">in-license</span> and we have not made any application to obtain the licenses required in order to distribute a drug product in the United States. Our supply chain model is based upon that fact and the distribution of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States is done through McKesson which currently holds all state licensure required to distribute a drug product in every American state. Although potential alternative third-party service providers have been identified to replace McKesson in the event that it becomes unable to distribute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, we have not entered into any agreements with them and no assurance can be given that such providers would enter into any agreement with us on terms satisfactory to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Syneos Health, Inc. (&#8220;Syneos&#8221;)<span style="font-weight:bold"> </span>continues to provide us with support for the commercialization of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States through the provision of personnel as part of the managed market and reimbursement teams. Although we are aware that there exist other third-party service providers that could provide the same services as Syneos, we have not entered into any agreements with them nor conducted any audit on them. If we need to find another third-party service provider for some or all of the services provided by Syneos, it will be time-consuming and will be disruptive to our business. In addition, there can be no assurance that we will be able to find such third-party service provider if we are unable to agree on the terms and conditions of an agreement with them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Finally, we may retain contract research organizations (&#8220;CROs&#8221;) to support us with the conduct of clinical trials from time to time. These CROs will be tasked with the recruitment of patients, negotiations of clinical study agreements with various clinics and the monitoring of those clinics in connection with our clinical trials. If these CROs default on their covenants or are found, for instance, to be in violation of applicable laws, our clinical trials could be delayed, and any timelines set forth in our public communications could be wrong. In addition, if these CROs are found to be in violation of applicable laws, any data generated in the course of our clinical trials could be questioned by regulatory agencies and this could lead to a rejection of any data submitted to those regulatory agencies at the time of submitting a supplemental Biologics License Application (&#8220;sBLA&#8221;) or New Drug Application (&#8220; NDA&#8221;) seeking the approval of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our reliance on single third-party service providers for some of our core business activities exposes us to a number of risks. For instance, we may be subject to delays in, or suspension of, the manufacturing of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> if a third-party manufacturer: (a)&#160;becomes unavailable to us, or to TaiMed, for any reason, including as a result of the failure to comply with GMP regulations; (b)&#160;experiences manufacturing problems or other operational failures, such as labour disputes, equipment failures or unplanned facility shutdowns required to comply with GMP, or damage from any event, including fire, flood, earthquake, business restructuring, labour disputes, epidemics including global health concerns, or insolvency; (c)&#160;fails to perform its contractual obligations under our agreement, such as failing to deliver the quantities requested on a timely basis or not meeting product specifications; (d)&#160;makes errors in manufacturing raw materials, components or products that could negatively affect the efficacy or safety of our products or cause delays in the shipment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We may also be subject to distribution disruption and interrupted sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States if: (a)&#160;we are unable to negotiate the terms of a new agreement to include serialization services (b)&#160;McKesson becomes unavailable to us for any reason, including as a result of its failure to meet applicable laws; (c)&#160;McKesson experiences warehousing problems or other operational failure, such as unplanned facility shutdown or damage from any event, including fire, flood, earthquake, epidemics including global health concerns, business restructuring or insolvency; or (d)&#160;McKesson fails to perform its contractual obligations under our agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We may be subject to a decrease in sales of our products in the United States or we may face reimbursement challenges if Syneos (a)&#160;becomes unavailable to us for any reason, including as a result of its incapacity to motivate and retain the employees working on the commercialization of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and/or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>; (b)&#160;experiences compliance issues with the FDA; or (c)&#160;fails to perform its contractual obligations under our agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We no longer have a long-term supply agreement for the supply of sterile water for injection (&#8220;SWI&#8221;) which is provided to patients with other ancillary devices contained in the administration box in connection with EGRIFTA&#160;SV<sup style="font-size:75%; vertical-align:top">&#174;</sup>. As a result, we may run into supply issues because there exists no commitment to supply us with such product and we must order the SWI on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis. If we are unable to purchase SWI, we may have to change our offering to patients, and this could be perceived negatively and could adversely affect the sales, revenues, and operating results of the Corporation. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We no longer have a long-term supply agreement with a supplier of SWI. The Corporation provides SWI to patients in the medication box along with other ancillary devices including alcohol swabs, syringes and needles in connection with <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>As a result, we may run into supply issues because there exists no commitment to supply us with SWI and we must order the SWI on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis. If we are unable to purchase SWI, we may have to change our offering to patients, and this could be perceived negatively and could adversely affect the sales, revenues, and operating results of the Corporation<span style="font-weight:bold"><span style="font-style:italic">.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We do not currently have plans to enter into a long-term supply agreement for SWI. The Corporation intends to pursue the approval of the F8 Formulation and plans to withdraw <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> from the market if and when the F8 Formulation is approved by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Significant safety problems may arise with respect to EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> which could result in restrictions in EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8217;s or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8217;s label, product recall or withdrawal of any of our products from the market, any of which could materially adversely impact our business and our future business prospects. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">New safety issues may arise as <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> are used over longer periods of time by a wider group of patients, some of whom may be taking numerous other medicines, or may suffer from additional underlying health problems. Such safety issues could include an increase in the severity or frequency of known problems or the discovery of previously unknown problems and may result in a variety of adverse regulatory actions. Under U.S. laws, the FDA has broad authority over drug manufacturers to compel any number of actions if safety problems arise, including, but not limited to: (i)&#160;requiring manufacturers to conduct post-approval clinical studies to assess known risks or signals of serious risks, or to identify unexpected serious risks; (ii)&#160;mandating labeling changes to a product based on new safety information; or (iii)&#160;requiring manufacturers to implement a risk evaluation mitigation strategy where necessary to assure safe use of the drug. Similar laws and regulations exist in countries outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Previously unknown safety problems could also result in product recalls, or withdrawal of the products from the territory(ies) where they are approved for commercialization. If new safety issues are discovered, sales of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and/or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> may decrease and result in a material adverse effect on our business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our levels of revenues are highly dependent on obtaining and maintaining patient reimbursement for EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Market acceptance and sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> substantially depend on the availability of reimbursement from third-party payors such as governmental authorities, including U.S. Medicare and Medicaid, managed care providers, and private insurance plans and may be affected by healthcare reform measures in the United States. Third-party payors decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors are attempting to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors have been challenging the prices charged for products. Third-party payors may decrease the level of reimbursement of a product or cease such reimbursement and the occurrence of any of these events could materially adversely affect the sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> to patients benefitting from U.S. Government funded reimbursement programs represent a significant part of our sales. Denial of coverage for any of those products under any of the current programs would materially adversely affect our revenues. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Even though EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> are approved for sale in the United States, revenue that we generate from their sales may be limited. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> will continue to depend upon the acceptance of such products by the medical community, including physicians, patients and third-party payors. The degree of market acceptance of these products will depend on a number of factors, including: (a)&#160;demonstrated product safety, including the prevalence and severity of side effects, and effectiveness as a treatment that addresses a significant unmet medical need; (b)&#160;storage requirements, dosing regimen and ease of administration; (c)&#160;the availability of competitive alternatives; (d)&#160;our ability to obtain and maintain sufficient third-party coverage for reimbursement from government health care programs, including U.S. Medicare and Medicaid, private health insurers and other third-party payors; (e)&#160;the willingness and ability of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> for medications; (f)&#160;the product price; and (g)&#160;the effectiveness of sales and marketing efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If our products are not accepted by the marketplace, the revenue generated therefrom will be limited and our capacity to grow our revenue and become profitable will be hampered. Our failure to grow our revenue and to become profitable will adversely impact the value of the Corporation, including the market price of our shares. If we fail to achieve adequate sales, we may not generate sufficient revenue in order to become profitable and to service the repayment of our debt under the Marathon Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We face competition and the development of new products by other companies could materially adversely affect our business and operating results. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The biopharmaceutical and pharmaceutical industries are highly competitive and we must compete with pharmaceutical companies, biotechnology companies, academic and research institutions as well as governmental agencies for the development and commercialization of products, most of which have substantially greater financial, technical and personnel resources than us. We believe there are currently few approved drug products competing directly with our approved products. However, with respect to Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, we face competition from Fostemsavir and Lenacapavir in the United States. In addition, we are aware of other agents, including dolutegravir and darunavir, that are either indicated or commonly used in combination in regimens to treat heavily-treatment experienced patients with MDR <span style="white-space:nowrap">HIV-1.</span> With respect to <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>, we face competition from companies selling human growth hormone, testosterone, insulin sensitizing agents, <span style="white-space:nowrap">GLP-1</span> receptor agonists and sermorelin as those products may be prescribed by physicians. In addition, other approaches to reduce visceral adipose tissue in the abdominal area include coping mechanisms such as lifestyle modification (diet and exercise), switching ARTs or liposuction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The development of a vaccine against HIV or of any cure against HIV would have a material adverse effect on our business, operating results and financial conditions. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Although there exists no known vaccine and cure for HIV, we are aware that there are research and development activities carried out in order to eradicate this disease. We are also aware that a very low number of patients were cured from HIV. If a vaccine or a cure was found to prevent or cure HIV, sales of our products would be materially adversely impacted and our revenue growth would be hampered. The discovery of any vaccine or cure against HIV would have a material adverse effect on our business, operating results and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Research and Development Activities</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The conduct of research and development activities is costly, risky and results obtained therefrom may not be those anticipated. Therefore, there can be no assurance that any research and development plan on a product candidate, a new formulation or a new method or route of administration will result in an approved drug, new formulation or new method or route of administration. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The development of new therapies is highly costly, risky and the results obtained therefrom may not yield any of the anticipated benefits. The development of a product candidate into a new drug requires capital or access thereto, as well as the conduct of many tests on animals and humans, all of which must comply with stringent regulation and require substantial investments. There can be no assurance that any research and development program designed to develop a new drug, a new formulation, a new method or route of administration or provide a new treatment, such as the conduct of our Phase 1 clinical trial using sudocetaxel zendusortide for the potential treatment of ovarian cancer, the development of our peptide-drug conjugates resulting from our SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform, and the potential development of tesamorelin for the treatment of NASH in the general population, will end up generating positive results leading to an approved drug, label expansion, new formulation, or a new method or route of administration by a regulatory authority. The failure to develop a new drug, a new formulation or a new method or route of administration could hamper the long-term growth of our business and have long-term adverse effects on our potential revenues and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The development of sudocetaxel zendusortide for the potential treatment of various types of sortilin-expressing cancers is still uncertain given that the Corporation&#8217;s primary goal is to grow its Adjusted EBITDA and, to the extent it is successful in achieving such positive Adjusted EBITDA, the Corporation stated that upon completion of Part 3 of the Phase 1 clinical trial, the Corporation has decided that all future research in oncology would be made through partnership deals. There can be no assurance that the development of sudocetaxel zendusortide will be completed, including the Phase 1 clinical trial, if the revenues generated from the sale of the Corporation&#8217;s products and its operating expenses do not result in the achievement of a positive Adjusted EBITDA. Even if the Phase 1 clinical trial is completed, there can be no assurance that the further development of sudocetaxel zendusortide will be pursued if the Corporation is unable to find a partner or if the terms and conditions of any agreement with a partner are not satisfactory to the Corporation. As a result of any of the foregoing, the Corporation may have to cancel the development of sudocetaxel zendusortide, including its Phase 1 clinical trial, and the development of its SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform. Any such cancellation will materially adversely affect its pipeline of drug candidates, all of which would materially adversely affect its long-term growth and prospects. The cancellation of the research and development program in oncology could also have a material adverse effect on the price of our Common Share. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On January&#160;4, 2023, we announced that the development of sudocetaxel zendusortide would be stage-gated and that all decisions related to its development would be carefully taken in the context of the Corporation&#8217;s goal to generate a positive Adjusted EBITDA in 2023 and beyond. Over the course of the fiscal year 2023, we have reiterated this message and have implemented a reorganization in July and October 2023 mostly impacting research and development positions within the organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Despite the Corporation&#8217;s goal of achieving a positive Adjusted EBITDA in 2023 and beyond, on June&#160;2, 2023, the Corporation announced FDA&#8217;s acceptance of the Corporation&#8217;s amended protocol for the Phase 1 clinical trial using sudocetaxel zendusortide and the Corporation resumed the conduct of such Phase 1 clinical trial.<span style="font-weight:bold"><span style="font-style:italic"> </span></span>The amended protocol was designed to improve the therapeutic window of sudocetaxel zendusortide and extend its duration of therapy. The frequency of administration was changed to weekly dosing and the patient population was narrowed to focus on those with high grade serous ovarian cancer, including high-grade peritoneal or fallopian tube cancer, or high-grade endometrioid cancer. Patient selection was also refined to focus on those who are less heavily pretreated, with no more than one taxane failure and a maximum of eight prior cancer treatment regimens. The Corporation has committed to delivering on Part 3 of the Phase 1 clinical trial in advanced ovarian cancers. However, this commitment remains subject to the Corporation becoming cash-flow positive and on growing its Adjusted EBITDA. The ability of the Corporation to generate a positive Adjusted EBITDA will depend on the Corporation&#8217;s revenues generated from the sale of its products and on its operating expenses. There can be no assurance that<span style="font-weight:bold"><span style="font-style:italic"> </span></span>the development of sudocetaxel zendusortide will be completed, including the Phase 1 clinical trial, if the revenues generated from the sale of the Corporation&#8217;s products and its operating expenses do not result in the growth of its Adjusted EBITDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Additionally, to the extent the Phase 1 clinical trial using sudocetaxel zendusortide is not halted or cancelled prior to the finalization of the Phase 1 clinical trial, the Corporation has decided that, upon completion of the Phase 1 clinical trial, all future research in oncology, including the pursuit of the development of sudocetaxel zendusortide, will be made through partnership deals. There can be no assurance that a partner will be found or that a partnership agreement will be entered into on terms satisfactory to the Corporation. If a partner is not found, the Corporation may have to halt or cancel this program. The halt or the cancellation of the development of sudocetaxel zendusortide as well as any other research and development activities in oncology will materially adversely affect its pipeline of drug candidates, all of which would materially adversely affect the Corporation&#8217;s long-term growth and prospects. The cancellation of the research and development program in oncology could also have a material adverse effect on the price of our Common Share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Despite the resumption of the Phase 1 clinical trial, the conduct of clinical trials is risky and results may adversely vary from those that are expected. If any data collected from the Phase 1 clinical trial were to demonstrate safety or efficacy issues, the Corporation could halt or cancel the development of its SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform, including sudocetaxel zendusortide, all of which would materially adversely affect its long-term growth and prospects. Furthermore, the value associated to the SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform asset would be depreciated, thereby adversely impacting the market value of the Corporation, including the price of its Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The Corporation has filed a sBLA seeking the approval of the F8 Formulation. On January&#160;24, 2024, the Corporation announced that the FDA had issued a CRL to the Corporation with questions largely related to chemistry, manufacturing and controls (&#8220;CMC&#8221;) concerning the microbiology, assays, impurities and stability for both the lyophilized product and the final reconstituted drug product. The FDA also requested additional information to understand the potential impact of the proposed formulation on immunogenicity risk. Responding to the questions asked by the FDA in the CRL will result in additional expenses to be incurred by the Corporation. There can be no assurance that the Corporation will be able to satisfactorily respond to the questions raised by the FDA in its CRL, nor that the FDA will approve the F8 Formulation when a sBLA is resubmitted. If the F8 Formulation is not approved and commercialized, our revenues and operating results could be adversely affected and the introduction of a biosimilar version of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States market could be facilitated since EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> is not patent protected. The entry of a biosimilar version of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States market could materially adversely affect the revenues and operating results of the Corporation. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has conducted studies to assess the bioequivalence of the F8 Formulation against the original 1 mg/vial formulation of <span style="font-style:italic">EGRIFTA</span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span></span>. In September 2023, the Corporation filed a sBLA with the FDA seeking the approval of the F8 Formulation for commercial use and, in January 2024, the Corporation received a CRL from the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation plans on addressing the questions raised by the FDA in its CRL. To adequately address these questions, the Corporation may have to incur additional expenses. Even if the Corporation addresses all of the questions raised by the FDA and resubmits a sBLA, the FDA could determine that the answers provided are not to its satisfaction and issue another CRL.<span style="font-weight:bold"><span style="font-style:italic"> </span></span>If the FDA<span style="font-weight:bold"><span style="font-style:italic"> </span></span>does not approve the F8 Formulation, the Corporation could have to conduct additional testing using the F8 Formulation which would delay the time by which the Corporation could commercialize the F8 Formulation and which would require the Corporation to incur additional expenses and potential inventory write-downs, all of which could adversely affect the Corporation&#8217;s revenues, operating results and its potential profitability. Finally, the <span style="white-space:nowrap">non-approval</span> of the F8 Formulation would expose the Corporation to the entry of biosimilar versions of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top"> </sup></span></span>given that the patent protection for this product expired in August 2023. Since the F8 Formulation is patent protected until 2033 in the United States, the commercialization of tesamorelin for the treatment of lipodystrophy using the F8 Formulation could protect the entry of biosimilar versions until the expiry of this patent in 2033. The entry of a biosimilar version of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>could materially adversely affect the revenues and operating results of the Corporation<span style="font-style:italic">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">On March&#160;26, 2021, the Corporation submitted to the FDA a CBE supplement to the Instructions For Use (&#8220;IFU&#8221;) included in the EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> product labeling. The FDA responded to our CBE supplement with a CRL on March&#160;15, 2022, asking us to carry out a HFS to ensure that patients reconstitute the product in the proper manner. The Corporation subsequently filed two requests for an extension to file the HFS results. The FDA granted each request, and the Corporation has until September&#160;15, 2024, to file the HFS results. If the Corporation is unable to complete and file the HFS results by that date, or if it is unable to obtain from the FDA an additional extension of time to file the HFS results, the Corporation will be in default under applicable laws. Even if the Corporation files the HFS results by the prescribed deadline set by the FDA, the FDA may not approve the HFS results and may issue an additional CRL. A default by the Corporation to comply with applicable laws could result in sanctions such as the imposition of fines or penalties, all of which could have a material adverse effect on the Corporation&#8217;s operating results as well as its reputation. Moreover, the failure to submit the HFS results within the timelines prescribed by the FDA, or the issuance of a CRL based on the rejection by the FDA of the HFS results, could ultimately result in the FDA prohibiting the sale of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States due to the difficulty by patients to administer the right dose of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup>. If we were unable to commercialize EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States, absent the commercialization of the F8 Formulation, our revenues and operating results would be materially affected and would result in a default under the Marathon Credit Agreement. </span></p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Per the FDA request, the Corporation is required to complete a HFS for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> by September&#160;15, 2024.&#160;To date, the Corporation has completed the first part of the study, the formative study.&#160;The validation study remains to be conducted and the results thereof remain to be filed and accepted by the FDA.&#160;If the F8 Formulation had been approved, the Corporation expected to withdraw the CBE and be relieved from the obligation to complete the HFS for <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> given that the F8 Formulation would have replaced the current formulation of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> before the deadline to file the results of the HFS for <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>.&#160;With the F8 Formulation having been subject to a CRL, if the Corporation is unable to complete and resubmit the results of the HFS of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> by September&#160;15, 2024, or if the Corporation does not obtain from the FDA an additional extension of time to complete and file the results of such HFS before any prescribed deadline, the Corporation would be in violation of applicable laws which could result in sanctions such as the imposition of fines or penalties. If the results of the HFS are filed in due time but the FDA does not approve the HFS results, the FDA could issue an additional CRL. The failure to complete and submit the HFS results within prescribed timelines, or the issuance of a CRL based on the rejection by the FDA of the HFS results, could ultimately result in the prohibition to sell <span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup></span> in the United States due to the difficulty by patients to administer the right dose of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>. Any order issued by the FDA prohibiting the sale of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States would have a material adverse effect on the revenues and results of operations of the Corporation and, absent any material additional revenue-generating products commercialized by the Corporation, would result in a breach of the Marathon Credit Agreement.&#160;Any breach of the Marathon Credit Agreement under such circumstances would potentially lead to Marathon foreclosing on all of the assets of the Corporation or the Corporation resorting to insolvency laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The conduct of the second part of the study, the validation study, is expected to be costly, the result of which will be to adversely impact the operating expenses of the Corporation and its potential capacity to grow its Adjusted EBITDA as well as becoming profitable. In addition, there can be no assurance that the Corporation will be able to complete the HFS within any timelines prescribed by the FDA since the enrollment of patients in the first part of the HFS proved to be difficult and longer than expected. Furthermore, there can be no assurance that the FDA would grant any additional extension of time to the Corporation to complete and file the results of the HFS for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>. If the Corporation in unable to complete the HFS, the Corporation could be in violation of applicable laws and, in addition to the measures described above, the FDA could also impose additional requirements on the Corporation in order to continue its commercialization of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States (to the extent <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> is not withdrawn from the market). These additional measures could result in additional expenses to the Corporation and could potentially adversely affect its operating results and its capacity to generate a positive Adjusted EBITDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The Corporation has decided to seek a partner to conduct a Phase 2b/3 clinical trial evaluating tesamorelin for the treatment of NASH in the general population. Although the Corporation has begun the search for a potential partner and preliminary discussions are ongoing, there can be no assurance that a partner will be found or that a partnership agreement will be entered into on terms satisfactory to the Corporation. If a partner is not found, the Corporation may have to cancel this program unless it has access to substantial financial resources to pursue such development program and there can be no guarantee that the Corporation will secure such substantial resources in an amount sufficient to initiate or complete the Phase 2b/3 clinical trial. Moreover, the FDA has issued comments and asked questions on the revised protocol filed by the Corporation in February 2022 and the Corporation has voluntarily decided not to reply to those comments and questions until it can find a partner. In addition, the Corporation&#8217;s decision to design its Phase 2b/3 clinical trial to meet the FDA&#8217;s primary endpoints may prevent the Corporation from seeking approval of tesamorelin for the treatment of NASH in the general population from the European Medicines Agency (&#8220;EMA&#8221;) since the primary endpoint for this agency is different from that of the FDA. If the Corporation is unable to find a partner to develop tesamorelin for the treatment of NASH in the general population or to secure substantial financial resources to do it on its own, the Corporation may cancel this program and the development of tesamorelin for the treatment of NASH may never occur. Even if the Corporation finds a partner, the conduct of the Phase 2b/3 clinical trial may be delayed or never begun if the Corporation is unable to properly address the comments and questions raised by the FDA based on the Corporation&#8217;s amended protocol. Finally, if the Corporation is unable to meet the endpoints of its Phase 2b/3 clinical trial, it will not receive approval for tesamorelin for the treatment of NASH in the general population. Even if the Corporation meets the endpoints of the clinical trial, the FDA could issue a conditional approval letter such that if the Corporation is unable to meet the conditions contained in such letter, the Corporation could lose such approval. If the conduct of the clinical trial is cancelled, or if the Corporation does not receive approval for tesamorelin for the treatment of NASH in the general population, its potential long-term revenues, growth and prospects will be materially adversely affected. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In July 2021, we announced that the final Phase 3 clinical trial design would result in higher costs than what we had expected and, as a result, we decided to seek a potential partner to undertake this clinical trial. To date, we are still continuing to seek a partner and discussions are still ongoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In February 2022, in order to <span style="white-space:nowrap">de-risk</span> the Phase 3 trial, the Corporation submitted an amended protocol to the FDA resulting in the FDA providing us with a list of questions and comments on this amended protocol. We have voluntarily decided not to respond to those questions and comments in order to address them with any potential partner we may find to optimize the design, if deemed relevant. The amended protocol includes a Phase 2b/3 seamless study design where the first 350 or so patients&#8217; data will be analyzed by a data monitoring committee to assess the efficacy of tesamorelin on a smaller subset of patients. The amended protocol would allow us to generate hard endpoint data on NAS score and fibrosis. A decision would then be made whether to continue the study until the full number of patients (1,094) have completed 18 months of treatment. These amendments would not change the total number of patients required to seek accelerated approval of tesamorelin for the treatment of NASH, but it would inform the continuation of enrollment while providing an indication of benefit to patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There can be no guarantee that tesamorelin will be studied for the treatment of NASH in the general population if the Corporation is unable to find a partner to conduct the development program on its own. Even if the Corporation finds a partner, the terms and conditions pursuant to which such partner may be interested in assisting the Corporation may not be satisfactory to the Corporation or may be unfavorable. Under such circumstances, the Corporation may decide to forego the development of tesamorelin for the treatment of NASH in the general population or turn to alternative sources of financing. If the Corporation is unable to, or does not proceed with, the development of tesamorelin for the treatment of NASH in the general population, it could have a material adverse effect on its potential long-term revenues, growth and business prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Even if the Corporation finds a partner to initiate a Phase 2b/3 clinical trial, there can be no guarantee that the FDA will be satisfied with the responses to the questions and comments asked in connection with the amendments to the protocol filed in February 2022 and allow the initiation of such trial. Even if the FDA or any other regulatory agency approves the study of tesamorelin for the treatment of NASH in the general population, there can be no guarantee that the results will meet the endpoints of the study and that tesamorelin will be approved for such treatment. Even if the Corporation meets the FDA&#8217;s primary endpoints and approval is received from the FDA, such approval may be conditioned on conducting additional studies which, if not conducted or if the results therefrom are not positive on certain clinical outcomes, could result in the FDA withdrawing its approval for the use of tesamorelin for the treatment of NASH in the general population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has decided to design its Phase 2b/3 clinical trial based on the FDA guidelines requiring it to demonstrate &#8220;NASH resolution and no worsening of fibrosis&#8221; as primary endpoints. This trial design does not follow the current EMA guidelines which require a sponsor to demonstrate both (i)&#160;NASH resolution and no worsening of fibrosis and (ii)&#160;improvement of fibrosis by one stage without worsening of NASH as primary endpoints. Therefore, even if the Corporation meets the primary endpoints for FDA purposes, the EMA may not approve tesamorelin for the treatment of NASH in this territory since the trial was not designed to demonstrate both endpoints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If the Corporation is unable to obtain approval of tesamorelin for the treatment of NASH in the United States, this would have material adverse effects on its revenues, financial results and long-term growth and prospects. In addition, even if the FDA approves tesamorelin for the treatment of NASH, the lack of an approval in Europe will limit the Corporation&#8217;s ability to maximize its revenue growth potential, therefore potentially hampering its long-term growth and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The conduct of clinical trials is subject to a variety of risks, many of which can be beyond the control of the Corporation forcing it to delay the initiation or conduct of clinical trials or forego same. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The beginning or completion of clinical trials may be delayed or prevented for several reasons, including, among others: (a)&#160;negative results from the Corporation&#8217;s clinical trial resulting in a failure to meet the endpoints of its clinical trial; (b)&#160;delays in reaching or failing to reach agreement on acceptable terms with clinical study sites, the terms of which can be subject to considerable negotiation and may vary significantly among different study sites; (c)&#160;any breach of the terms of any CRO agreement by us or by our third-party suppliers that have responsibility to assist us with the conduct of our clinical trials; (d)&#160;inadequate quantity or quality of the active pharmaceutical ingredient or other materials necessary to conduct clinical trials; (e)&#160;challenges in recruiting and enrolling patients to participate in clinical trials, such as the proximity of patients to study sites, eligibility criteria to be included in a clinical trial, the nature of a clinical trial and the competition from other clinical study programs for the treatment of similar diseases as those the Corporation may seek to treat; (f)&#160;severe or unexpected adverse drug effects experienced by patients; (g)&#160;regulatory agencies requiring a sponsor to conduct additional clinical studies prior to approving a new drug application, a sBLA, or the equivalent thereof in other jurisdictions after review of Phase 3 clinical trial results; (h)&#160;regulatory agencies may disagree with a sponsor &#8217;s interpretation of data resulting from its Phase 3 clinical trials, or may change the requirements for approval even after they have approved the sponsor&#8217;s Phase&#160;3 clinical trial design; and (i)&#160;difficulties in retaining patients who have enrolled in a sponsor&#8217;s Phase&#160;3 clinical trial but who may be prone to withdraw due to rigours of the clinical trial, lack of efficacy, side effects, personal issues or loss of interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. A sponsor may decide to suspend or terminate its clinical trial, or regulatory agencies could order a sponsor to do so for several reasons, including, among others, failure to conduct the clinical trial in accordance with the regulatory requirements of a sponsor&#8217;s study protocol and inspections of the clinical study operations or study sites by regulatory agencies that would reveal deficiencies or violations requiring a sponsor to undertake corrective actions (to the extent any are available). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If the Corporation incurs any delay in the conduct of a clinical trial or decides to suspend or terminate such trial, this could materially adversely affect the business prospects of the Corporation and its potential long-term revenues derived from the potential sale of its drug candidates. Any delay or suspension of a clinical trial may also adversely impact the duration of the protection afforded by the issuance of patents covering the drug candidate subject to such clinical trial and lead to earlier entries of competitors in the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Regulatory Risks</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The pharmaceutical industry is highly regulated and pharmaceutical companies are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute and the federal False Claims Act. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. The laws that may affect our ability to operate include: (a)&#160;the federal healthcare program&#8217;s anti-kickback law, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; (b)&#160;federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; (c)&#160;the federal Health Insurance Portability and Accountability Act of 1996, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; (d)&#160;the <span style="font-style:italic">Federal Food, Drug and Cosmetic Act</span>, as amended, of the United States (&#8220;FFDCA&#8221;) and similar laws regulating advertisement and labeling; and (e)&#160;U.S. States&#8217; law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the United States, the federal anti-kickback law has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers or formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce or reward prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Most American states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which apply to items and services covered by Medicaid and other state programs, or, in several states, apply regardless of the payor. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. Further, the Health Care Reform Law, among other things, amends the intent requirement of the U.S. federal anti-kickback and criminal healthcare fraud statutes. A person or entity can now be found guilty under the federal anti-kickback law without actual knowledge of the statute or specific intent to violate it. In addition, the Health Care Reform Law provides that the U.S. government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion from Medicare and Medicaid programs and forfeiture of amounts collected in violation of such prohibitions. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">To enforce compliance with the federal laws, the U.S. Department of Justice (&#8220;DOJ&#8221;) scrutinizes interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be time and resource consuming and can divert management&#8217;s attention from the business. Additionally, if a healthcare provider settles an investigation with the DOJ or other law enforcement agencies, we may be forced to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips or items and gifts of value to prescribers, &#8220;sham&#8221; consulting fees and grants and other monetary benefits to prescribers; reporting inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <span style="white-space:nowrap">off-label</span> promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, there has been a recent trend of increased federal and state regulation on payments made to physicians for marketing. Some states, such as California, Massachusetts and Vermont, mandate implementation of commercial compliance programs, along with the tracking and reporting of gifts, compensation and other remuneration to certain healthcare professionals. The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may run afoul of one or more of the requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If our activities are found to be in violation of these laws or any other federal and state fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our activities with regard to the commercialization of our products in the United States, which could harm the commercial sales of our products and materially affect our business, financial condition and results of operations. We cannot guarantee that we will be able to mitigate all operational risks. In addition, we cannot guarantee that we, our employees, our consultants or our contractors are or will be in compliance with all potentially applicable U.S. federal and state regulations and/or laws. Because of the <span style="white-space:nowrap">far-reaching</span> nature of these laws, we may be required to alter or discontinue one or more of our business practices to be in compliance with these laws. If we fail to adequately mitigate our operational risks or if we or our agents fail to comply with any of those regulations, laws and/or requirements, a range of actions could result, including, but not limited to, the termination of clinical trials, the failure to approve a product candidate, restrictions on <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">, </span>Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> or their respective manufacturing processes, withdrawal of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation. Such occurrences could have a material adverse effect on our product sales, business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. U.S. federal or state regulatory authorities might challenge our current or future activities under these laws. Any such challenge could have a material adverse effect on our reputation, business, results of operations and financial condition. Any state or federal regulatory review of us or the third parties with whom we contract, regardless of the outcome, would be costly and time-consuming. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We may be subject to enforcement action if we engage in the <span style="white-space:nowrap">off-label</span> promotion of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our promotional materials and training methods must comply with the FFDCA, as well as with other applicable laws and regulations, including restraints and prohibitions on the promotion of <span style="white-space:nowrap">off-label,</span> or unapproved, use. Physicians may prescribe our products for <span style="white-space:nowrap">off-label</span> use without regard to these prohibitions, as the FFDCA does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. However, if the FDA determines that our promotional materials or training of company employees or agents constitutes promotion of an <span style="white-space:nowrap">off-label</span> use, it could request that we modify our training or promotional materials, issue corrective action, or subject us to regulatory or enforcement actions, including but not limited to the issuance of an untitled letter or warning letter, and a judicial action seeking injunction, product seizure and civil or criminal penalties. It is also possible that other federal, state or <span style="white-space:nowrap">non-U.S.</span> enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Our reputation would also be damaged. Although our policy is to refrain from written or oral statements that could be considered <span style="white-space:nowrap">off-label</span> promotion of our products, the FDA could disagree and conclude that we have engaged in <span style="white-space:nowrap">off-label</span> promotion. In addition, the <span style="white-space:nowrap">off-label</span> use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us and harm our reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are not allowed to conduct promotional activities related to <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Canada and in Europe since none of those products have been approved in this territory. Promotional activities may begin once a drug is approved by the heath authority of a country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The research, development, manufacture and marketing of pharmaceutical products are governed by various governmental authorities throughout the world to ensure the efficacy and safety of such products. If we fail to comply with the applicable requirements at any time during the product development process, approval process or commercialization process, we may be subject to administrative or judicial sanctions. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Governmental authorities in the United States, Canada, and other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products, such as <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and any other compound that we may develop. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. If we fail to comply with the applicable requirements at any time during the product development process, approval process or commercialization process, we may be subject to administrative or judicial sanctions. Sanctions could include, but are not limited to, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters or other enforcement letters, product recalls, import/export delays, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, and government reimbursement, restitution, disgorgement or civil or criminal penalties. Any sanctions could result in a material adverse effect on our reputation, business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to our Intellectual Property</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our patent protection related to the use of tesamorelin for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy expired in August 2023. Until we can commercialize tesamorelin using the F8 Formulation, the <span style="white-space:nowrap">FDA-approved</span> use of tesamorelin for the treatment of lipodystrophy is no longer patent protected and we may face direct competition from biosimilar versions of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup>. If we face competition from biosimilar products, our revenues are likely to be reduced thus adversely affecting our revenue growth and results of operations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The use of tesamorelin for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy is no longer patent protected in the United States. Tesamorelin, the active ingredient of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>, is no longer patent protected and the formulation of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> is not patent protected. If, and when approved, the Corporation will rely on the use of the F8 Formulation to benefit from patent protection until 2033 in the United States in connection with the sale of tesamorelin for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Although we are not aware that a company has filed any biosimilar version of tesamorelin with the FDA, nothing prevents a company from filing with the FDA a biosimilar version of tesamorelin using the same formulation as that of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and to seek the same indication as that of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If such a filing was made and the FDA were to approve a biosimilar version of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>, we would expect the price of that biosimilar to be lower than that of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and we could have to lower our price in order to be able to compete with such biosimilar. A lower price of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> would reduce our revenue and would have an adverse effect on our operating results. Even if we were to introduce the F8 Formulation, such biosimilar version could still be a direct competitor to us, albeit with an older formulation of tesamorelin. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our failure to protect our intellectual property may have a material adverse effect on our ability to develop and commercialize our products. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our intellectual property rights are covered and protected by valid and enforceable patents, trademarks and copyrights or are effectively maintained as trade secrets. We try to protect our intellectual property position by, among other things, filing patent applications and trademark applications related to our proprietary technologies, inventions, improvements and tradenames that are important to the development of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Because the patent and trademark position of pharmaceutical companies involves complex legal and factual questions, the issuance, scope, validity, and enforceability of patents and trademarks cannot be predicted with certainty. Patents and trademarks, if issued, may be challenged, invalidated or circumvented. For example, if our patents are invalidated or found to be unenforceable, we would lose the ability to exclude others from making, using or selling the inventions claimed. Moreover, an issued patent does not guarantee us the right to use the patented technology or commercialize a product using that technology. Third parties may have blocking patents that could be used to prevent us from developing our compounds, selling our products or commercializing our patented technology. Thus, patents that we own may not allow us to exploit the rights conferred by our intellectual property protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our pending patent applications may not be issued or granted as patents. Even if issued, they may not be issued with claims of sufficient breadth to protect our product candidates and technologies or may not provide us with a competitive advantage against competitors with similar products or technologies. Furthermore, others may independently develop products or technologies similar to those that we have developed or may reverse engineer or discover our trade secrets through proper means. In addition, the laws of many countries do not protect intellectual property rights to the same extent as the laws of Canada, the United States and the European Patent Convention, and those countries may also lack adequate rules and procedures for defending intellectual property rights effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We also rely on trade secrets, <span style="white-space:nowrap">know-how</span> and technology, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality agreements with parties who have access to such confidential information, such as our current and prospective suppliers, distributors, manufacturers, commercial partners, employees and consultants. Any of these parties may breach the agreements and disclose confidential information to our competitors. It is possible that a competitor will make use of such information, and that our competitive position could be disadvantaged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Enforcing a claim that a third party infringes on, has illegally obtained or is using an intellectual property right, including a trade secret or <span style="white-space:nowrap">know-how,</span> is expensive and time-consuming and the outcome is unpredictable. In addition, enforcing such a claim could divert management&#8217;s attention from our business. If any intellectual property right were to be infringed, disclosed to, or independently developed by, a competitor, our competitive position could be harmed. Any adverse outcome of such litigation or settlement of such a dispute could subject us to significant liabilities, could put one or more of our pending patent applications at risk of being invalidated or interpreted narrowly, could put one or more of our patents at risk of not issuing, or could facilitate the entry of generic products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. For example, confidential information may be disclosed, inadvertently or as ordered by the court, in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. This disclosure would provide our competitors with access to our proprietary information and may harm our competitive position. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our commercial success depends, in part, on our ability not to infringe on third party patents and other intellectual property rights. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our capacity to commercialize <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> or any other drug product we may acquire or <span style="white-space:nowrap">in-license</span> will depend, in part, upon our ability to avoid infringing third party patents and other third-party intellectual property rights. The biopharmaceutical and pharmaceutical industries have produced a multitude of patents and it is not always easy for participants, including us, to determine which patents cover various types of products, processes of manufacture or methods of use. The scope and breadth of patents is subject to interpretation by the courts and such interpretation may vary depending on the jurisdiction where the claim is filed and the court where such claim is litigated. For instance, the fact that an entity owns or has rights to use patents pertaining to a subject matter in a country does not guarantee that it is not infringing one or more third-party patents in such country. Therefore, there can be no guarantee that any patent that we own of have rights to will not infringe or violate third-party patents and other third-party intellectual property rights in the country where such patent has been issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Patent analysis for <span style="white-space:nowrap">non-infringement</span> is based in part on a review of publicly available databases. Although we review from time to time certain databases to conduct patent searches, we do not have access to all databases. It is also possible that we will not have reviewed some of the information contained in the databases or we found it to be irrelevant at the time we conducted the searches. In addition, because patents take years to issue, there may be currently pending applications that have not yet been published or that we are unaware of, which may issue later as patents. As a result, there can be no guarantee that we will not violate third-party patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Because of the difficulty in analyzing and interpreting patents, there can be no guarantee that a third party will not assert that we infringe such third-party&#8217;s patents or any of its other intellectual property rights. Under such circumstances, there is no guarantee that we would not become involved in litigation. Litigation with any third party, even if the allegations are without merit, is expensive, time-consuming and would divert management&#8217;s attention from the daily execution of our business plan. Litigation implies that a portion of our financial assets would be used to sustain the costs of litigation instead of being allocated to further the development of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If we are involved in patent infringement litigation, we would need to prevail in demonstrating that our products do not infringe the asserted patent claims of the relevant patent, that the patent claims are invalid or that the patent is unenforceable. If we are found to infringe a third-party patent or other intellectual property right, we could be required to enter into royalty or licensing agreements on terms and conditions that may not be favorable to us, and/or pay damages, including up to treble damages in the United States (for example, if found liable of willful infringement) and/or cease the development and commercialization of our product candidates. Even if we were able to obtain a license, the rights may be <span style="white-space:nowrap">non-exclusive,</span> which could result in our competitors gaining access to the same intellectual property and to compete with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There may be issued patents that we are unaware of that our products may infringe, or patents that we believe we do not infringe but ultimately could be found to infringe. If we were to challenge the validity of a competitor&#8217;s issued United States patent in a United States court, we would need to overcome a statutory presumption of validity that attaches to every United States patent. This means that, in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. We cannot guarantee that a court would find in our favour on questions of infringement and validity. Any finding that we infringe or violate a third-party patent or other intellectual property right could materially adversely affect our business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Litigation Risks</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">If we fail to comply with our contractual obligations, undertakings and covenants under our agreements with our commercial partners and third-party service providers, we may be exposed to claims for damages and/or termination of these agreements. Furthermore, if we fail to comply with securities laws and applicable pharmaceutical regulations in connection with the commercialization of our products, we may be exposed to claims for damages, fines, penalties, and other sanctions. Any claims for damages, and/or termination of our material contracts, the imposition of fines or penalties could materially adversely affect the commercialization of EGRIFTA&#160;SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, our capacity to generate revenues and management&#8217;s attention to the development of our business. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We rely on third-party service providers for distribution and manufacturing activities related to <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>in the United States. Under our agreements with our third-party service providers, we have assumed certain obligations, undertakings and covenants which, if breached by us and not remedied within the agreed upon periods, could expose us to claims for damages and/or termination of these agreements. If we are unable to meet our obligations under any of our agreements with such third-party service providers which results in termination of such agreements, this will materially adversely affect our business, financial condition and operating results since we rely on single third-party service providers, each of whom performing key services for the success of our business plan. Additionally, if such third-party service providers do not meet their obligations under agreements and we decide to litigate any breach or dispute any amount owed under our agreements, this might materially adversely affect our relationship with such third-party services providers which, in turn, could adversely affect our capacity and ability to deliver on our business plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As a publicly traded pharmaceutical company we have to comply with securities laws and various laws related to the commercialization of drug products, any violation of which could result in claims for damages and/or the imposition of fines, penalties and other sanctions. If we are subject to claims for damages and/or the imposition of fines, penalties, or other sanctions this could have the effect of diverting management&#8217;s attention from the operation of the business, limit the financial resources available to the Corporation to execute its business plan and adversely affect the Corporation&#8217;s reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">If product liability lawsuits are brought against us, they could result in costly and time-consuming litigation and significant liabilities. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Despite all reasonable efforts to ensure the safety of our products we may be commercializing, it is possible that we or our commercial partners will sell products which are defective, to which patients react in an unexpected manner, or which are alleged to have side effects. The development, manufacture and sale of such products may expose us to potential liability, and the pharmaceutical industry has been subject to significant product liability litigation. Any claims, with or without merit, could result in costly litigation, reduced sales, significant liabilities and diversion of our management&#8217;s time and attention and could have a material adverse effect on our financial condition, business and operating results. A product liability claim could also tarnish our reputation, whether or not such claims are with or without merit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim and, if the claim is successful, damage awards may be substantial and/or may not be covered, in whole or in part, by our insurance. We may not have sufficient capital resources to pay the damages resulting from a judgment, in which case our creditors could levy against our assets. We may also be obligated to indemnify our commercial partners and third-party service providers as well as make payments to other parties with respect to product liability damages and claims. Defending any product liability claims, or indemnifying others against those claims, could require us to expend significant financial and managerial resources and would have a material adverse effect on our reputation and our financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline"><span style="white-space:nowrap">Geo-Political</span> Risks</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">A variety of risks associated with our international business relationships could materially adversely affect our business. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">International business relationships in the United States, Europe, Ukraine, the Middle East, China, Taiwan and elsewhere subject us to additional risks, including: (a)&#160;disruptions of important government services; (b)&#160;differing regulatory requirements for drug approvals in foreign countries; (c)&#160;potentially reduced protection for intellectual property rights, including unexpected changes in the rules governing patents and their enforcement; (d)&#160;potential third-party patent rights in foreign countries; (e)&#160;the potential for <span style="white-space:nowrap">so-called</span> parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market, with low or lower prices, rather than buying them locally; (f)&#160;unexpected changes in tariffs, trade barriers and regulatory requirements; (g)&#160;economic weakness, including inflation, or political instability, particularly in foreign economies and markets; (h)&#160;compliance with tax, employment, immigration and labor laws for employees traveling abroad and for new talents we may desire to recruit; (i)&#160;foreign taxes; (j)&#160;foreign exchange contracts and foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; (k)&#160;workforce uncertainty in countries where labor unrest is more common than in the United States and Canada; (l)&#160;production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and (m)&#160;business interruptions resulting from <span style="white-space:nowrap">geo-political</span> actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires, or epidemic such as the one related to the coronavirus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">These and other risks of international business relationships may have a material adverse effect on our business, financial condition and operating results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Cybersecurity and Data Privacy Risks</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We rely extensively on the information technology systems of third-party service providers to store data, such as personal identifiable information, regarding our commercial activities for EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Security breaches and other disruptions to those information technology systems could cause a violation of privacy laws, exposing us to liability which could cause our business and reputation to suffer. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the ordinary course of business, we rely upon information technology and networks, most of which are managed by third parties, to process, transmit and store electronic information to manage and support our business decisions and strategy. We have no control and access over the information technology systems of third-party service providers where most of this information is stored and we are unable to assess whether appropriate measures have been implemented to prevent or limit a security breach of their information technology systems. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We also use our information technology systems to collect and store proprietary data, such as those related to our intellectual property, customers, employees and suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In connection with our presence in Canada and Europe, we must comply with privacy laws and regulations of Qu&#233;bec and Europe. Both of those laws and regulations introduced data protection requirements relating to the consent of individuals to whom the personnel data relates, the information provided to the individuals, the security we must retain, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. These laws have increased the responsibility of all parties collecting personal data. We have reviewed and are currently complementing our <span style="white-space:nowrap">in-house</span> policies and related procedures to ensure compliance with those laws. In the United States, there exists no federal laws regarding the protection of personal information and all such laws are State-regulated. With the addition of a sales and medical team <span style="white-space:nowrap">in-house,</span> we are in the process of assessing compliance with the privacy laws in each of the States where the bulk of our activities is conducted. However, there can be no guarantee that the Corporation will not be found to violate some of those laws as a result of the combination of our business activities in various jurisdictions and the complexity of those laws and their interpretations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The secure and uninterrupted operation of third-party information technology systems and of ours is material to our business operations and strategy. More and more businesses are subject to information technology system intrusion for which cyber-terrorists often use ransomware to demand payment of a ransom to allow those businesses to regain access to its data. Despite the measures that we have implemented against unwanted intrusion by third parties, there can be no guarantee that our systems could resist to a cyber-attack. Unauthorized access to data files held in our information technology systems or those of third parties could result in inappropriate use, change or disclosure of sensitive and/or personal data of our customers, employees, suppliers and patients. Any such access, disclosure or other loss of information could subject us to litigation, regulatory fines, penalties or reputational damages, any of which could have a material adverse effect on our competitive position, reputation, business, financial condition and operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Other Risks Related to Our Business</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We may require additional funding and may not be able to raise the capital necessary to fund all or part of our capital requirements. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We may need financing in order to fund all or part of our capital requirements to sustain our growth, to develop our marketing and commercial capabilities, and to <span style="white-space:nowrap">in-license</span> or acquire approved products. Our business performance may prevent us from generating enough cash-flow to achieve our business plan and the market conditions may also prevent us from having access to the public market in the future at the times or in the amounts necessary. Therefore, there can be no guarantee that we will be able to continue to raise additional capital by way of public or private offerings in the future. In addition, the conditions precedent to have access to the third and fourth tranches under the Marathon Credit Agreement based on its current terms are not met, and therefore, unless an amendment to the Marathon Credit Agreement is entered into with Marathon, there is no ability to access these tranches. In such a case, we would have to use other means of financing, such as entering into private financing or, with the consent of Marathon, incur additional debt, the terms and conditions of which may not be favorable to us. We currently have no arranged sources of financing available to us. The issuance and sale of substantial amounts of equity, or other securities, or the perception that such issuances and sales may occur could adversely affect the market price of our Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We depend on our current personnel to pursue our business plan and the loss of our key employees and the inability to attract and hire highly qualified individuals to replace the loss of our current key employees could have a material adverse effect on our business and growth potential. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Because of the specialized nature of our business, our success depends to a significant extent on the continued service of our key employees and on our ability to be able to attract, retain and motivate qualified commercial, medical, regulatory and scientific personnel. We have entered into employment agreements with our executive officers and provided them, as well as to other key employees, with long-term incentives as a retention mechanism, but such agreements and incentives do not guarantee that our executive officers and other key employees will remain employed by us for any significant period of time, or at all. In addition, we have a limited workforce to pursue our business plan and the loss of any of our key employees could materially adversely affect our business. The loss of key account managers and medical science liaison personnel and our inability to attract and retain them could have a material adverse effect on our commercial and medical activities related to <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and, accordingly, on our business, financial condition and operating results. In addition, it could adversely affect the market price of our Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There is intense competition for qualified personnel in the areas of our activities, and we and our third-party service providers may not be able to continue to attract and retain the qualified personnel necessary for the growth of our business. Our failure and the failure of our third-party service providers to attract and retain such personnel could impose significant limits on our business operations and hinder our ability to successfully and efficiently realize our business plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We may not achieve our publicly announced financial, milestones or our commercial objectives on time. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In January 2023, we announced revenue guidance for the fiscal year ended November&#160;30, 2023, in the range of $90&#160;million to $95&#160;million. In July 2023, we revised such revenue guidance to be in the range of $82&#160;million to $87&#160;million. In September 2023, such revenue guidance was tightened to be in the range of $82&#160;million to $85&#160;million. From time to time, we publicly announce the timing of certain events to occur or the attainment of certain commercial objectives. These statements are forward-looking and are based on the best estimate of management at the time, relating to the achievement of such guidance or to the occurrence of such events. However, the actual timing of such events or our ability to achieve these objectives may differ from what has been publicly disclosed. Events such as beginning of commercialization of a product, levels of sales, revenues and other financial metrics may vary from what is publicly disclosed. These variations may occur as a result of a series of events, including problems with a supplier or a commercial partner, change in the procurement policy of a commercial partner or any other event having the effect of delaying the publicly announced timeline or reducing the publicly announced commercial objective. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law. Any variation in the timing of certain events having the effect of postponing such events or any variation in the occurrence of certain events having the effect of altering publicly announced commercial objectives could have a material adverse effect on our business, financial condition and operating results. In addition, it could adversely affect the market price of our Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">In connection with the reporting of our financial results, we are required to make estimates and assumptions, which involve uncertainties and any significant differences between our estimates and actual results could have an adverse impact on our reported financial position, operating results and cash flows. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The preparation of our consolidated financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, our management evaluates our critical and other significant estimates and assumptions, including among others, those associated with revenue and sales allowances and chargebacks, realizable value of inventories, estimation of accruals for clinical trial expenses, measurement and recoverability of intangible assets, the measurement of derivative financial assets, and the measurement of share-based arrangements. Any significant differences between our actual results and our estimates and assumptions could negatively impact our reported financial position, operating results and cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">If actual future payments for allowances for discounts, returns, rebates and chargebacks exceed the estimates the Corporation made at the time of the sale of its products, its financial position, results of operations, and cash flows may be negatively impacted. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Pursuant to the Corporation&#8217;s accounts and revenue recognition policies, the product revenue recognized quarter over quarter by the Corporation is net of estimated allowances for discounts, returns, rebates and chargebacks, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiations. Such estimates require subjective and complex judgment due to the need to make estimates about matters that are inherently uncertain. Based on industry practice, pharmaceutical companies, including the Corporation, have liberal return policies, sometimes making it difficult to estimate the timing and amount of expected revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A&#160;chargeback&#160;is the difference between the price the wholesaler pays the Corporation (wholesale acquisition cost) and the price that the wholesaler&#8217;s customer pays for the Corporation&#8217;s product (contracted customer). The Corporation&#8217;s products were subject to certain programs with federal government qualified entities whereby pricing on products is discounted to such entities and results in a&#160;chargeback&#160;claim to the Corporation, or for the Corporation to bill certain qualifying Public Health Service <span style="white-space:nowrap">end-users</span> at government-mandated pricing. To the extent that the Corporation&#8217;s sales to discount purchasers, such as federal government qualified entities, increases,&#160;chargeback&#160;claims will also increase. There may be significant lag time between the Corporation&#8217;s original sale to the wholesaler and the Corporation&#8217;s receipt of the corresponding government&#160;chargeback&#160;claims from the Corporation&#8217;s wholesalers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation&#8217;s products are subject to state government-managed&#160;Medicaid&#160;programs, whereby rebates for purchases are issued to participating state governments. These rebates arise when the patient treated with the Corporation&#8217;s products is covered under&#160;Medicaid. The Corporation&#8217;s calculations require the Corporation to estimate <span style="white-space:nowrap">end-user</span> and patient mix to determine which of its sales will likely be subject to these rebates. There is a significant time lag in the Corporation receiving these&#160;rebate&#160;notices (generally several months after its sale is made). The Corporation&#8217;s estimates are based on its historical claims from participating state governments, as supplemented by management&#8217;s judgment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Although the Corporation believes that it has sufficient allowances, actual results may differ significantly from its estimated allowances for discounts, returns, rebates and chargebacks. Changes in estimates and assumptions based upon actual results may have a material impact on its financial condition, results of operations and cash flows. Such changes to estimates will be made to the financial statements in the period in which the estimate is changed. In addition, the Corporation&#8217;s financial position, results of operations and cash flows may be negatively impacted if actual future payments for allowances, discounts, returns, rebates and chargebacks exceed the estimates the Corporation made at the time of the sale of its products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We have identified a material weakness in our internal controls over financial reporting for the fiscal year ended November&#160;30, 2022, in connection with the documentation of the analysis and relating to the monitoring of certain conditions and covenants included in the Marathon Credit Agreement. For the fiscal year ended November&#160;30, 2023, we have remediated such material weakness but there can be no assurance that we will not identify other material weakness in our internal controls over financial reporting for the fiscal year ended November&#160;30, 2024, and beyond. A material weakness may hamper our ability to meet our reporting obligations and could result in a material misstatement in the Corporation&#8217;s financial statements. As a result, the trading price of our Common Shares could be negatively affected. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Accordingly, a material weakness increases the risk that we are unable to comply with our reporting obligations and/or that the financial information we report contains material errors. Any of those events could materially adversely affect the trading price of our Common Shares. A failure to comply with our reporting requirements could also subject us to sanctions and/or investigations by securities regulatory authorities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have identified a material weakness in our internal controls over financial reporting for the fiscal year ended November&#160;30, 2022, in connection with the documentation of the analysis and relating to the monitoring of certain conditions and covenants included in the Marathon Credit Agreement. This control failure caused ineffective controls over the assessment of going concern uncertainty, including the underlying financial data and assumptions supporting the forecasted financial information utilized to prepare projected cash flows and liquidity requirements to comply with some of the covenants in the Marathon Credit Agreement. The Corporation&#8217;s management team has implemented remediation measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented and operating efficiently. While the Corporation succeeded in implementing remediation measures in the fiscal year ended November&#160;30, 2023, there can be no assurance that we will not identify other material weakness in our internal controls over financial reporting for the fiscal year ended November&#160;30, 2024, and beyond. If the Corporation fails to maintain effective internal controls in the future, it could result in a material misstatement of the Corporation&#8217;s financial statements, which could cause investors to lose confidence in the Corporation&#8217;s financial statements and cause the trading price of its Common Shares to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We regularly review and update our internal controls, disclosure controls and procedures, and corporate governance policies. In addition, we are required under securities laws to report annually on our internal control over financial reporting. We are not currently required, and do not, obtain an audit of our internal controls over financial reporting. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to our Common Shares</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our share price has been volatile, and an investment in our Common Shares could suffer a decline in value. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation&#8217;s Common Shares are listed on the Toronto Stock Exchange (&#8220;TSX&#8221;) and on the U.S. Nasdaq Capital market (&#8220;Nasdaq&#8221;). The market price of the Common Shares on the Nasdaq and the TSX has fluctuated significantly in the past and the Corporation expects the market prices to continue to fluctuate in the future, and such prices may decline. For example, since the Corporation&#8217;s listing of its Common Shares on Nasdaq to December&#160;31, 2023, the Corporation&#8217;s closing share price on Nasdaq has ranged from a low of $0.89<span style="font-weight:bold"> </span>to a high of $16.28. Consequently, you may not be able to sell your Common Shares at prices equal to or greater than the price paid by you. In addition, the market price of the Common Shares may be influenced by many factors, some of which are or may be beyond the Corporation&#8217;s control, including: actual or anticipated variations in the Corporation&#8217;s operating results and/or research and development activities; announcements by the Corporation or the Corporation&#8217;s competitors of significant contracts or acquisitions; additions or departures of key personnel; announcement or expectation of additional financing efforts; impairment of assets; changes in accounting principles; changes in the general market and economic conditions; future sales of the Common Shares; the failure of financial analysts to initiate or maintain coverage of the Common Shares, changes in financial estimates by financial analysts, or any failure by the Corporation to meet or exceed any of these estimates, or changes in the recommendations of any financial analysts that elect to follow the Common Shares or the shares of the Corporation&#8217;s competitors; and investor perceptions of the Corporation and the industry in which the Corporation operates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, stock markets, in general, have experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of particular companies affected. These broad market and industry factors may materially harm the market price of the Common Shares, regardless of the Corporation&#8217;s operating performance. Dual listing of the Common Shares on the Nasdaq and the TSX may increase share price volatility on both exchanges because trading is in the two markets, which may result in less liquidity on both exchanges. In addition, different liquidity levels, volumes of trading, currencies and market conditions on the two exchanges may result in different prevailing trading prices. In the past, following periods of volatility in the market price of certain companies&#8217; securities, securities class action litigation has sometimes been instituted against these companies. This litigation, if instituted against the Corporation, could adversely affect the financial condition or results of operations of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">The liquidity of our Common Shares is uneven and oftentimes scarce and shareholders desiring to purchase or sell Common Shares could be unable to, if the liquidity in our Common Shares is low. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The volume of Common Shares traded on the TSX and the Nasdaq has been uneven over time and is often low. Therefore, any investor who desires to purchase or sell Common Shares of the Corporation over the TSX or the Nasdaq may be unable to rapidly execute its order and, if the liquidity is low, the price at which such investor may purchase or sell Common Shares may be adversely affected by the lack of trading volume. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our Common Shares may be delisted from the Nasdaq stock market if the minimum bid price of our Common Shares remains below US$1.00 per share for 30 consecutive trading days. The delisting of our Common Shares could reduce the liquidity in our Common Shares and could trigger a <span style="white-space:nowrap">sell-off</span> from U.S. shareholders. Any reduction in the liquidity of our Common Shares or a <span style="white-space:nowrap">sell-off</span> of our Common Shares could result in a decline in the price of our Common Shares. Being delisted from the Nasdaq stock market could also adversely affect analysts coverage of our business and prevent us from retaining U.S. investment bankers to raise capital in public offerings. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the Nasdaq minimum bid price requirement, the minimum bid price of our Common Shares may not remain below $1.00 per share for 30 consecutive trading days. If such event occurs, the Corporation will receive a deficiency notice providing the Corporation with a <span style="white-space:nowrap">180-calendar</span> day cure period from the date of the notice during which the minimum bid price of the Common Shares will have to be $1.00 or more per share for ten consecutive business days in order to avoid delisting. If, at the expiry of the <span style="white-space:nowrap">180-calendar</span> day cure period, the Corporation has not regained compliance with the minimum bid price requirement, the Corporation could be afforded an additional <span style="white-space:nowrap">180-calendar</span> day cure period, provided that it meets certain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If the Common Shares of the Corporation are delisted from the Nasdaq stock market, the liquidity in our Common Shares could decrease and investors may have difficulties in buying or selling our Common Shares. In addition, a delisting of our Common Shares on the Nasdaq stock market could trigger a <span style="white-space:nowrap">sell-off</span> from current <span style="white-space:nowrap">U.S-based</span> shareholders whose internal policies could prevent them from holding securities of companies that are not traded on a U.S. stock market. Any <span style="white-space:nowrap">sell-off</span> by these shareholders could result in a material decline in the price of our Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Finally, if the minimum bid price of the Common Shares were to be below $1.00 per share for <span style="white-space:nowrap">30-consecutive</span> trading days, there can be no assurance that the cure period provided by Nasdaq rules to regain compliance with the minimum bid price requirement would result in the Corporation regaining compliance with such rules in order to avoid a delisting of the Common Shares. Even if the Corporation was to proceed with a reverse-split of its Common Shares, as performed on July&#160;31, 2023, there can be no assurance that the long term bid price of the Common Shares post reverse-split would meet the minimum bid price requirement of the Nasdaq stock market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our revenues and expenses may fluctuate significantly and any failure to meet financial expectations and/or our own financial guidance, if any, may disappoint securities analysts or investors and result in a decline in the price of our Common Shares. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our revenues and expenses have fluctuated in the past and are likely to do so in the future. These fluctuations could cause our share price to decline. Some of the factors that could cause revenues and expenses to fluctuate include the following: (a)&#160;the level of sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>in the United States; (b)&#160;the level of sales of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States; (c)&#160;supply issues with <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>; (d)&#160;default under the terms of the Marathon Credit Agreement; (e)&#160;the inability to adequately manage our liquidity; (f)&#160;the outcome of any litigation; (g)&#160;payment of fines or penalties for violations of laws; (h)&#160;foreign currency and/or interest rate fluctuations; (i)&#160;the timing of achievement and the receipt of milestone or royalty payments from future third parties; and (j)&#160;failure to enter into new or the expiration or termination of current agreements with third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, or if we need to reduce our financial guidance, if any, the price of our Common Shares could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, the price of our Common Shares and trading volume may decline. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The trading market for our Common Shares will rely in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our Common Shares, the lack of research coverage may adversely affect the market price of our Common Shares. Furthermore, if one or more of the analysts who do cover us downgrade the target price of our Common Shares or if those analysts issue other unfavorable commentary about us or our business, the price of our Common Shares would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our Common Shares could decrease, which in turn could cause our share price or trading volume to decline and may also impair our ability to expand our business with existing customers and attract new customers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We do not intend to pay dividends on our Common Shares and, consequently, the ability of investors to achieve a return on their investment will depend on appreciation in the price of our Common Shares. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have never declared or paid any cash dividend on our Common Shares and we do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. Therefore, the success of an investment in our Common Shares will depend upon any future appreciation in their value. There is no guarantee that our Common Shares will appreciate in value or even maintain the price at which our shareholders have purchased their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Our shareholder rights plan and certain Canadian laws could delay or deter a change of control. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our shareholder rights plan (&#8220;Rights Plan&#8221;) entitles a rights holder, other than a person or group holding 20% or more of our Common Shares, to subscribe for our Common Shares at a discount of 50% to the market price at that time, subject to certain exceptions. See &#8220;Item 10B &#8211; Memorandum and Articles of Association <span style="font-weight:bold"><span style="font-style:italic">&#8211;</span></span> Shareholder Rights Plan&#8221; for information on our Rights Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The <span style="font-style:italic">Investment Canada Act</span> (Canada) subjects an acquisition of control of a company by a <span style="white-space:nowrap">non-Canadian</span> to government review if the value of the assets as calculated pursuant to the legislation exceeds a threshold amount. A reviewable acquisition may not proceed unless the relevant minister is satisfied that the investment is likely to be a net benefit to Canada. See &#8220;Item 10B &#8211; Memorandum and Articles of Association <span style="font-weight:bold"><span style="font-style:italic">&#8211;</span></span> Limitations on Rights to Own Securities&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Any of the foregoing could prevent or delay a change of control and may deprive or limit strategic opportunities for our shareholders to sell their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">We are governed by the corporate and securities laws of Canada, which in some cases have a different effect on shareholders than the corporate laws of Delaware, U.S. and U.S. securities laws. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are governed by the <span style="font-style:italic">Business Corporations Act</span> (Qu&#233;bec) (&#8220;QBCA&#8221;) and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our charter documents, have the effect of delaying, deferring or discouraging another party from acquiring control of the Corporation by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the QBCA and Delaware General Corporation Law (&#8220;DGCL&#8221;) that may have the greatest such effect include, but are not limited to, the following: (i)&#160;for material corporate transactions (such as mergers and amalgamations, other extraordinary corporate transactions or amendments to the our articles) the QBCA generally requires a <span style="white-space:nowrap">two-thirds</span> majority vote by shareholders, whereas DGCL generally requires only a majority vote; and (ii)&#160;under the QBCA, holders of 10% or more of our shares that carry the right to vote at a meeting of shareholders can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL. See &#8220;Item 10B &#8211; Memorandum and Articles of Association <span style="font-weight:bold"><span style="font-style:italic">&#8211;</span></span> Differences in Corporate Law&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The economic effects of a pandemic, epidemic or outbreak of an infectious disease could adversely affect our operations or the market price of our Common Shares. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Public health crises such as pandemics, epidemics or similar outbreaks, including coronavirus known as <span style="white-space:nowrap">&#8220;COVID-19&#8221;,</span> could adversely impact our operations or the market price of our Common Shares. The extent to which a pandemic, epidemic or outbreak would affect our operations, or the market price of our Common Shares would depend on future developments, including the duration of any such pandemic, epidemic or outbreak and actions to contain or treat any such pandemic, epidemic or outbreak, among others. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_15">Item&#8201;4. Information on the Company </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_16"><span style="font-weight:bold">A.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">History and development of the Company.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Name, Address and Incorporation</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our legal name and commercial name is Theratechnologies Inc. Our head office and principal place of business is located at 2015 Peel Street, 11<sup style="font-size:75%; vertical-align:top">th</sup> Floor, Montreal, Qu&#233;bec, Canada H3A 1T8. Our telephone number is <span style="white-space:nowrap">(514)&#160;336-7800.</span> Our website is www.theratech.com.&#160;Our agent for service in the United States is CT Corporation System, 28 Liberty Street, New York, NY 10005 <span style="white-space:nowrap">(212)&#160;894-8940.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We were incorporated under Part IA of the <span style="font-style:italic">Companies Act</span> (Qu&#233;bec) (&#8220;CAQ&#8221;), on October&#160;19,&#160;1993, under the name Theratechnologies Inc. We amended our articles on October&#160;20, 1993, by repealing the restrictions applicable to private companies. On December&#160;6, 1993, we again amended our articles to increase the number of directors and to modify our share capital. On March&#160;26, 1997, we further modified our share capital to consist of an unlimited number of common shares and an unlimited number of preferred shares. Finally, on June&#160;21, 2011, we amended our articles to give the power to our directors to appoint a number of additional directors equal to 33.33% of the number of directors elected at the last shareholders meeting preceding any appointment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On February&#160;14, 2011, the CAQ was abrogated and replaced by the <span style="font-style:italic">QBCA</span>, and companies governed by Part IA of the CAQ such as us became business corporations governed by the QBCA. Accordingly, we did not have to file articles of continuation or amend our existing corporate articles. The QBCA was applicable immediately without having to complete any formalities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Authorized Share Capital</span>: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are authorized to issue an unlimited number of Common Shares, without nominal value and an unlimited number of preferred shares, without nominal value, issuable in one or more series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Subject to the priority rights of holders of preferred shares, holders of Common Shares are entitled to any dividend declared by the Board of Directors, to one vote per share at meetings of our shareholders and, in the event of our liquidation or dissolution, to participate in the distribution of the assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Preferred shares carry no voting rights. Preferred shares may be issued at any time in one or more series. Our articles of incorporation give our Board of Directors the power to fix the number of preferred shares and the consideration per share, as well as to determine the provisions attached to the preferred shares of each series (including dividends, redemption and conversion rights, if any). The shares of every series of preferred shares will have priority over all our other shares, including common shares, with respect to the payment of dividends and return of capital in the event of our liquidation or dissolution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Common Shares issued represent the total voting rights pertaining to our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">Our Common Shares are listed on the TSX under the symbol &#8220;TH&#8221;, and on the U.S. Nasdaq under the symbol &#8220;THTX&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Dividend Policy</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have never declared or paid cash dividends on our Common Shares and do not anticipate paying any cash dividends on our Common Shares in the foreseeable future. We presently intend to retain future earnings, if any, to finance the expansion and growth of our business. Any future determination to pay dividends will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirements and other factors the Board of Directors deems relevant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Recent Developments</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Marathon Credit Agreement and Amendments Thereto </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;20, 2022, we entered into the Marathon Credit Agreement with Marathon providing for a credit facility of up to $100&#160;million available in four tranches of $40&#160;million, $20&#160;million, $15&#160;million and $25&#160;million, respectively. The availability of each tranche is subject to meeting certain conditions. To date, the Corporation has drawn $60&#160;million down from the Marathon Credit Agreement and the Corporation does not meet the conditions precedent to drawdown additional amounts under the Marathon Credit Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the last fiscal year ended November&#160;30, 2023, we entered into various agreements with Marathon to amend some of the terms and conditions of the Marathon Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On February&#160;27, 2023, we entered into amendments to the Marathon Credit Agreement providing for, among other things: the removal of the condition related to the submission to the FDA of the Corporation&#8217;s HFS results related to <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in order to be able to draw down on the $20,000,000 second tranche under the Marathon Credit Agreement. The amendment was entered into in consideration of the issuance of 5,000,000 common share purchase warrants (&#8220;Marathon Warrants&#8221;) to Marathon. Each Marathon Warrant then entitled the holder thereof to purchase one Common Share of the Corporation at a price of $5.80 per share (&#8220;Exercise Price&#8221;) until February&#160;27, 2030. On June&#160;21, 2023, the Corporation drew down on the second tranche of $20,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On May&#160;15, 2023, we entered into an additional amendment to the Marathon Credit Agreement to lower the minimum net revenue target the Corporation was required to meet in its second quarter of the fiscal year 2023 as part of its obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;10, 2023, we entered into an additional amendment to the Marathon Credit Agreement to reduce the amount of liquidity the Corporation had to maintain from $20,000,000 to $14,000,000 from July&#160;10, 2023, to July&#160;21, 2023, and then to $16,000,000 until July&#160;28, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;28, 2023, we entered into further amendments to the Marathon Credit Agreement providing for, among other things, (i)&#160;the delivery to Marathon until October&#160;31, 2023, of weekly reports about the Corporation&#8217;s liquidity position; and (ii)&#160;the amount of liquidity the Corporation had to maintain between various periods of time ranging from July&#160;10, 2023, up to and until October&#160;31, 2023. Beginning on November&#160;1, 2023, the prescribed level of liquidity was set at $20,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On September&#160;21, 2023, we entered into an amended and restated fourth amendment to the Marathon Credit Agreement which reiterated the amendments agreed to on July&#160;28, 2023, but contained a waiver from Marathon of any default or event of default that may have occurred as a result of the Corporation&#8217;s failure to meet the minimum liquidity covenant between July&#160;3, 2023, up to and including July&#160;9, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On October&#160;13, 2023, we entered into additional amendments to the Marathon Credit Agreement providing for, among other things,: (i) revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between $15,000,000 and $20,000,000, based on the Marathon Adjusted EBITDA thresholds over the most recently ended four fiscal quarters; (ii)&#160;revising the minimum revenue requirements to be based on quarterly Marathon Adjusted EBITDA-based targets instead of quarterly revenue-based targets, beginning with the quarter ending November&#160;30, 2023; and (iii)&#160;deleting the prohibition against the Corporation having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Corporation that accompanies the Corporation&#8217;s annual report. In consideration of these amendments, the Corporation has agreed to (i)&#160;pay an amount equal to $600,000, or 100 basis points calculated on the funded debt as of that day ($60,000,000), over the term of the loan and added to the outstanding principal amount of the funded debt as payment in kind; and (ii)&#160;reprice the Exercise Price of the Marathon Warrants to $2.30 from $5.80. Following the Consolidation completed on July&#160;31, 2023, the exercise of four Marathon Warrants and the payment of $2.30 are required to purchase one Common Share of the Corporation, for up to a maximum issuance of 1,250,000 Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Reimbursement of 5.75% Convertible Unsecured Senior Notes </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On June&#160;19, 2018, the Corporation issued by way of prospectus an aggregate principal amount of $57.5&#160;million of 5.75% convertible unsecured senior notes maturing on June&#160;30, 2023 (&#8220;Convertible Notes&#8221;). In July 2022, the Corporation bought back and cancelled $30&#160;million principal amount of Convertible Notes through private agreements with certain U.S. Convertible Note holders. On June&#160;30, 2023, the Corporation reimbursed all of the outstanding principal amount of $27.5&#160;million of Convertible Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Share Consolidation </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;31, 2023, we announced that we had completed the consolidation of the issued and outstanding Common Shares of the Corporation&#8217;s share capital on the basis of one (1)&#160;post-consolidation share for each four <span style="white-space:nowrap">(4)&#160;pre-consolidation</span> shares issued and outstanding (&#8220;Consolidation&#8221;). The Corporation&#8217;s Common Shares began trading on the TSX and the Nasdaq on a consolidated basis on that date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Reorganization of Research&#160;&amp; Development Activities </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As a result of the weakness in the Company&#8217;s net revenues in the first half of Fiscal 2023, the Corporation initiated a reorganization in July 2023, mainly focused on its research and development activities, which is expected to result in annualized savings of at least $5,500,000 for the fiscal year ended November 30, 2024 and beyond. Most of these costs will be associated with headcount reduction and a decrease in the number and scope of research and development projects. As such, the Corporation recorded a charge of $719,000 in the third quarter of Fiscal 2023 to cover severance and other costs. On October 24, 2023, the Corporation announced further changes to its operations that would result in a tapering of research and development activities, which necessitated a reduction of approximately 25 positions. The Corporation expects to realize further recurring yearly savings of approximately $3,500,000 resulting from this reorganization and has recorded an additional restructuring charge of approximately $1,244,000 in the fourth quarter of Fiscal 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Public Offering and Concurrent Private Placement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On October&#160;31, 2023, the Corporation announced the closing of a financing for gross proceeds of $25,000,000. The financing was done by way of prospectus (&#8220;2023 Public Offering&#8221;) resulting in the issuance of 12,500,000 Common Shares at $1.00 per Common Share (&#8220;Offering Price&#8221;) and by way of a private placement (&#8220;Concurrent Private Placement&#8221;) resulting in the issuance of 9,118,184 Common Shares at the Offering Price and of 3,381,816 fully-funded, <span style="white-space:nowrap">non-voting</span> subscription receipts exchangeable into Common Shares on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis (&#8220;Exchangeable Subscription Receipts&#8221;). As part of the Concurrent Private Placement, the Company paid to the subscriber, Investissement Qu&#233;bec, a commitment fee of 1.5%. In connection with the 2023 Public Offering, the Company also granted the underwriter a <span style="white-space:nowrap">30-day</span> option to purchase up to 1,875,000 Common Shares at the Offering Price. This option was partially exercised resulting in gross proceeds of $160,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Exchangeable Subscription Receipts<span style="font-weight:bold"> </span>were issued pursuant to and are governed by the Exchangeable Receipt Agreement, dated October 31, 2023 between the Corporation and Investissement Qu&#233;bec (the &#8220;Exchangeable Receipt Agreement&#8221;). The component of the Concurrent Private Placement in the form of Exchangeable Subscription Receipts is designed to ensure that, following completion of the 2023 Public Offering and the Concurrent Private Placement, Investissement Qu&#233;bec does not have beneficial ownership or control over more than 19.9% of the issued and outstanding Common Shares and, therefore, is not a &#8220;control person&#8221; within applicable Canadian securities laws (&#8220;Exchangeable Condition&#8221;). Pursuant to the Exchangeable Receipt Agreement, the Exchange Condition is subject to a number of exceptions, including (i)&#160;in the context of a take-over bid, arrangement, merger or similar transaction for the purpose of allowing the holder to participate to such transaction equally and rateably with the shareholders of the Corporation, (ii)&#160;in the context of a concurrent sale of Common Shares issued upon the exchange of the Exchangeable Subscription Receipts, or (iii)&#160;with the prior approval of the shareholders of the Corporation or TSX. The Exchangeable Subscription Receipts entitle their holder to receive a payment equivalent to any dividend declared on the Common Shares and participate in any rights offering that the Corporation may undertake. In addition, to the extent that the Corporation undertakes certain transactions affecting its Common Shares, such as a stock split, a reverse stock split, a share reclassification or the payment of dividend in shares, requisite adjustments will be made to the Exchangeable Subscription Receipts so that the holder may receive upon exchange thereof the same number of Common Shares that it would have been entitled to receive under the transaction if the Exchangeable Subscription Receipts had been exchanged into Common Shares immediately prior to such transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As part of the Concurrent Private Placement, the Corporation has also entered into an investor rights agreement with Investissement Qu&#233;bec (&#8220;Investor Rights Agreement&#8221;) pursuant to which Investissement Qu&#233;bec is entitled to nominate one director to the Company&#8217;s board of directors and to designate one individual acting as an observer at each meeting of the Company&#8217;s Board of Directors for as long as it holds 50% of the Common Shares purchased under the Concurrent Private Placement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In its prospectus supplement dated October&#160;25, 2023, filed as part of the 2023 Public Offering, the Corporation indicated that it intended to use the net proceeds of the 2023 Public Offering and the Concurrent Private Placement for general corporate purposes, which may include working capital, general and administrative expenses, commercialization expenses, repayment of outstanding debt under the Marathon Credit Agreement, and potential acquisitions <span style="white-space:nowrap">or&#160;in-licensing&#160;of</span> commercial products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A portion of the Corporation&#8217;s working capital will be used to maintain the minimum amount of liquidities, ranging between $15&#160;million and $20&#160;million, that the Corporation is required to maintain at all times under the Marathon Credit Agreement based on the Marathon Adjusted EBITDA thresholds set forth in the Marathon Credit Agreement over the most recently ended four fiscal quarters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The prepayment of the outstanding principal amount of $40&#160;million loaned to the Corporation under the Marathon Credit Agreement is subject to certain restrictions until July&#160;27, 2024, and no such prepayment is expected to be made by the Corporation before then. Thereafter, any prepayment will be evaluated on prevailing circumstances, including the Corporation&#8217;s financial position and opportunities available to the Corporation. Use of proceeds for the purpose of potential acquisitions or <span style="white-space:nowrap">in-licensing</span> of commercial products will depend on available opportunities as they may arise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Capital Expenditure and Divestitures</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Since the beginning of the Corporation&#8217;s last three financial years,<span style="font-style:italic"> </span>the Corporation has not made any material capital expenditures. However, in its fiscal year ended November&#160;30, 2022, the Corporation incurred capital divestiture amounting to $6.4&#160;million as a result of the acceleration and amortization of its intangible asset relating to rights to commercialize Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe following its decision to return all commercialization rights to this product to TaiMed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Public Takeover Offer</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During the last and current financial year, we have not been subject to any public takeover offer by third parties in respect of the Company&#8217;s Common Shares and the Company has not made any public offer to any company to purchase such company&#8217;s shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_17"><span style="font-weight:bold">B.</span>&#8195;<span style="font-weight:bold"><span style="font-style:italic">&#8195;&#8195;Business Overview.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Principal Products and Activities</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our business strategy is to grow revenues and Adjusted EBITDA from the sale of our existing and potential future assets in North America and to develop a portfolio of complementary products, compatible with our expertise in drug development and our commercialization <span style="white-space:nowrap">know-how.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We currently commercialize two approved products for people living with HIV, namely: <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. In addition to the sale of our products, we are conducting research and development activities and we have a pipeline of investigational medicines in the areas of oncology and NASH. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Our Products and Pipeline</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;text-align:justify">Tesamorelin is the active peptide comprising <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span> Tesamorelin is a stabilized 44 amino acid human growth hormone-releasing factor analogue (&#8220;GRF&#8221;), which was synthesized in our laboratories in 1995 using our long-acting peptide method. Although natural peptides have significant therapeutic potential, they are subject to enzymatic degradation which severely limits their effectiveness in clinical use. Our long-acting peptide method is a peptide stabilization process which increases the target protein&#8217;s resistance to enzymatic degradation, while maintaining its natural specificity. This usually results in a more stable and efficient compound, which can thus prolong its duration of action. Tesamorelin induces growth hormone secretion in a natural and pulsatile way. The clinical results obtained to date using tesamorelin suggest a therapeutic potential in both anabolic and lipolytic indications. Tesamorelin for injection induces the release of growth hormone which causes a reduction in excess visceral abdominal fat (lipohypertrophy) in <span style="white-space:nowrap">HIV-infected</span> adult patients without reducing or interfering with subcutaneous fat, and, as such, has no clinically significant effect on undesired loss of subcutaneous fat (lipoatrophy). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> (tesamorelin for injection) is a new formulation of <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> which was originally approved by the FDA in November 2010 and was launched in the United States in January 2011. <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> was approved by the FDA in November 2018, was launched in 2019 and has now replaced <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in such country.<span style="font-style:italic"> EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> can be kept at room temperature, comes in a single vial and has a higher concentration resulting in a smaller volume of administration.<span style="font-style:italic"> EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> is currently the only approved therapy in the United States for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy. We have been commercializing this product in the United States since May 1<sup style="font-size:75%; vertical-align:top">st</sup>, 2014. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Lipodystrophy </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Lipodystrophy is characterized by abnormalities in the production and storage of fat. It has two components: lipohypertrophy, and excessive abdominal fat accumulation, and lipoatrophy, the noticeable, localized loss of fat tissue under the skin. In patients with lipohypertrophy, fat accumulation occurs mostly around the waist and may also occur in other regions, including breast tissue and in dorsocervical tissues in the neck, resulting in a &#8220;buffalo hump&#8221;. Excess fat also appears as lipomas, or benign tumors composed of fat cells. In patients with lipoatrophy, the loss of fat tissue generally occurs in the limbs and facial area. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In <span style="white-space:nowrap">HIV-infected</span> patients, lipodystrophy may be caused by the viral infection itself, the use of ARV therapy (not class-specific), presence of hormonal imbalance (growth hormone) and/or microbiome alteration and chronic inflammation. Different pathophysiological mechanisms are involved in the development of lipohypertrophy and lipoatrophy. The most common statistically significant independent risk factors identified for lipohypertrophy are duration of ARV therapy and markers of disease severity, including higher <span style="white-space:nowrap">pre-ARV</span> treatment viral load. Other factors include age, genetics, and gender. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Mechanism of Action </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. GRF is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone, which is both anabolic and lipolytic. Growth hormone exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by insulin-like growth factor one, <span style="white-space:nowrap">IGF-1,</span> produced in the liver and in peripheral tissues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The effects of recombinant human growth hormone (&#8220;rhGH&#8221;) and tesamorelin have been the subject of several clinical trials in the area of <span style="white-space:nowrap">HIV-associated</span> lipodystrophy. Based on these clinical trials, the safety profiles of rhGH and tesamorelin appear to be very different. The natural synthesis of growth hormone is regulated by a feedback mechanism preventing its overproduction. Tesamorelin induces optimal activity of the somatotrope function and retains the natural rhythm (pulsatility) of the physiological secretion of growth hormone without interfering with the feedback mechanism mentioned above. With the exogenous administration of rhGH, the feedback mechanisms are short-circuited, which gives rise to higher levels of growth hormone. The side effects associated with rhGH include nerve, muscle or joint pain, swelling due to fluid retention (edema), carpal tunnel syndrome, numbness and tingling of skin and increased risk of diabetes. These side effects are particularly frequent among older people. In addition, rhGH can cause hyperglycemia which makes it contraindicated for patients with diabetes or <span style="white-space:nowrap">pre-diabetic</span> conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ibalizumab-uiyk) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ibalizumab-uiyk) is a <span style="white-space:nowrap">CD-4</span> directed post-attachment <span style="white-space:nowrap">HIV-1</span> inhibitor. Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was approved by the FDA on March&#160;6,&#160;2018, and was made commercially available in the United States on April&#160;30,&#160;2018. In the United States, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is indicated for the treatment of <span style="white-space:nowrap">HIV-1</span> infection in heavily treatment-experienced adults with MDR <span style="white-space:nowrap">HIV-1</span> infection failing their current ARV regimen.<span style="font-weight:bold"> </span>Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was the first HIV treatment approved with a new mechanism of action in more than 10 years. The treatment is administered every two weeks. It is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs.<span style="font-weight:bold"> </span>Since its approval, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was included in the treatment guidelines issued by the International Antiviral Society-United States and the treatment guidelines issued by the U.S. Department of Health and Human Services.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was also approved by the EMA in September&#160;2019 and is no longer under licence to us in Europe further to our decision to terminate and return to TaiMed our commercialization rights to this product in April 2022. The EMA has since withdrawn the marketing approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe. See &#8220;Item 4B &#8211; Business Overview - Markets &#8211; Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221; of this Annual Report for more information on the return of commercialization rights to TaiMed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was developed by TaiMed and pursuant to an amended and restated distribution agreement entered into on March&#160;6, 2017 (as further amended) (&#8220;TaiMed Agreement&#8221;) we have an exclusive license to commercialize this product in the United States and Canada. See &#8220;Item 10C - Material Contracts &#8211; TaiMed Agreement&#8221; of this Annual Report and refer to Notes 3 and 13 of the Audited Financial Statements for information on the TaiMed Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;text-align:justify">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is administered by intravenous infusion as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every two weeks after dilution in 250 mL of 0.9% Sodium Chloride Injection, USP. The Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> loading dose can also be administered as an undiluted intravenous (&#8220;IV&#8221;) push over 90 seconds, and the maintenance dose can be administered as an undiluted IV push over 30 seconds. See &#8220;Item 4B &#8211; Business Overview &#8211; Our Products and Pipeline &#8211; Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> &#8211; Life Cyle&#8221; of this Annual Report for information on the life cycle of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Mechanism of Action </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Unlike other ARV agents, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> binds primarily to the second extracellular domain of the CD4 receptor, away from major histocompatibility complex II molecule binding sites. It potentially prevents the HIV virus from infecting CD4+ immune cells while preserving normal immunological function. Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is active across all major HIV clades and irrespective of tropism. No drug-drug interactions and no cross-resistance with other ART were noted during the clinical trials nor are expected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Life Cycle </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On October&#160;3, 2022, the FDA approved the <span style="white-space:nowrap">30-second</span> IV Push method of administration for the maintenance dose of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and on December&#160;13, 2023, the FDA approved the IV Push administration of the loading dose of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. IV Push is a method by which the undiluted medication is &#8220;pushed&#8221; by syringe for faster administration into the body&#8217;s circulation and is designed to make Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> administration easier and more convenient for people with HIV and their health care providers. As a result, we expect that more clinics will be able to initiate new patients to the product and provide ongoing treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On October&#160;13, 2023, the Company announced results from a study evaluating the intramuscular (&#8220;IM&#8221;) method of administration of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. This study <span style="white-space:nowrap">(&#8220;TMB-302&#8217;),</span> conducted in partnership with TaiMed, enrolled 21 subjects (7 <span style="white-space:nowrap">HIV-positive</span> and 14 <span style="white-space:nowrap">HIV-negative)</span> to assess the pharmacokinetics, efficacy, and safety of the IM administration of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;as compared to the IV infusion. Mean Trogarzo<span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;trough concentrations were greater than 15 &#181;g/mL, suggesting that IM injection was sufficient at maintaining the drug trough concentration above the therapeutic level of 0.3 &#181;g/mL. The mean trough concentrations were comparable between IV infusion and IM injection in <span style="white-space:nowrap">HIV-positive</span> subjects. However, the primary endpoint measuring a 90% confidence interval of the ratio of IM injection to IV infusion (0.69, 1.08) did not meet the equivalence limits (0.8, 1.25). Viral suppression, a key secondary clinical endpoint, was maintained in all <span style="white-space:nowrap">HIV-positive</span> subjects throughout the IM phase and the overall study. Each study subject received IM maintenance doses for eight weeks of treatment and a total of 152 IM injections were administered, which were well tolerated. One subject reported injection-site pruritus (itching) at a single time point, and no subjects reported injection-site pain when Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;was administered intramuscularly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has now completed the study of the use of the IM method of administration of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and on January&#160;2, 2024, we announced the filing of a sBLA with the FDA seeking approval of the IM method of administration for maintenance doses of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. We are currently awaiting a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Research and Development Activities</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition to the sale of our products, we are conducting research and development activities. We have established a promising pipeline of investigational medicines in areas of high unmet need, including oncology and NASH. In previous years, we have also worked on extending the lifecycle of tesamorelin and ibalizumab-uiyk. With respect to the latter, we improved the method of administration of both the loading dose and the maintenance dose by obtaining approval of an IV Push method of administration and we have filed a sBLA with the FDA seeking the approval of an IM method of administration of the maintenance dose. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Lifecyle Management of Tesamorelin in Lipodystrophy</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">F8 Formulation </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On September&#160;25, 2023, the Company announced the filing of a sBLA with the FDA seeking the approval of the F8 Formulation. On January&#160;23, 2024, the Company received a CRL from the FDA. The questions outlined in the CRL are largely related to chemistry, manufacturing and controls concerning the microbiology, assays, impurities and stability for both the lyophilized product and the final reconstituted drug product. In addition, the FDA requested further information to understand the potential impact of the proposed formulation on immunogenicity risk. The Company will address the FDA&#8217;s questions and intends to pursue the approval of the F8 Formulation. To that end, the Company has requested a Type A meeting with the FDA to ensure that its approach is aligned with the FDA expectations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The F8 Formulation is eight times more concentrated than <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and two times more concentrated than the current F4 formulation sold under the trade name <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>. The Company plans to withdraw <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>from the market if and when the F8 Formulation is approved by the FDA. The F8 Formulation can be kept at room temperature, comes in a single vial and has a higher concentration resulting in a smaller volume of administration than <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>. The F8 Formulation has the distinct advantage of requiring a single reconstitution per seven days of daily therapy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Once approved, the F8 Formulation could be used in our proposed Phase 2b/3 clinical trial studying tesamorelin for the treatment of NASH in the general population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Following the launch of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> in the United States in 2019, the Company received a number of complaints from patients relating to the reconstitution of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>. In March 2021, the Company proactively decided to submit to the FDA a CBE supplement to the IFU included in the <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> product labeling and, per the timelines set forth in the regulation. The Company implemented these changes, which included an amended IFU. We also provided patients with detailed training through our call center, THERA Patient Support<sup style="font-size:75%; vertical-align:top">&#174;</sup>, related to the changes. The FDA responded to our CBE supplement with a CRL asking us to carry out a HFS to ensure that patients reconstitute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top"> </sup></span>in the proper manner. To date, the Company has completed the first part of the HFS, the formative study.&#160;The validation study remains to be conducted and the results thereof remain to be filed and accepted by the FDA. The Company has until September&#160;15, 2024 to submit the HFS results to the FDA. The Company intends to apply for an extension of this deadline.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Multi -Dose Pen Injector </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the fiscal year 2021, we began developing a device in the form of a pen for the administration of tesamorelin. This pen was intended to be used in conjunction with the F8 Formulation. To date, its development is not completed, and we have halted all activities in relation to the development of this device. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Tesamorelin for NASH in the General Population</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:0%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On September&#160;10, 2020, we announced our intent to study tesamorelin for the potential treatment of NASH in the general population using the F8 Formulation. In November 2020, we filed an Investigational New Drug Application (&#8220;IND&#8221;) with the FDA for a Phase 3 clinical trial evaluating tesamorelin for the treatment of NASH and we received a &#8220;Study May Proceed&#8221; letter for such Phase 3 clinical trial from the FDA in December 2020. The letter contained a recommendation that the Company requests a meeting to discuss the questions and comments contained in such letter to address certain aspects of the proposed trial design to ensure alignment with the agency&#8217;s expectations with NASH trials. The Company followed up on the FDA&#8217;s recommendation and requested a meeting with the agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:0%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The finalized trial design is planned for a multicenter, randomized, double-blind, placebo-controlled <span style="white-space:nowrap">two-part</span> study designed to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis. Part 1 of the study will include a total of approximately 1,100 patients (1:1, tesamorelin:placebo), including approximately 75 to 100 people living with HIV. A second liver biopsy will be performed after the first approximately 1,100 participants have completed 18 months of treatment. This should form the basis for filing a sBLA with the FDA. The clinical trial will also include a futility analysis that would be conducted after the first approximately 400 patients have completed 18 months of treatment and have received a second liver biopsy. The futility analysis will provide a perfunctory review indicating if an early treatment effect with tesamorelin has been observed and will determine if the study should proceed as planned. Following a potential sBLA approval, Part 2 of the trial will continue to enroll an additional approximately 1,800 patients (3:1, tesamorelin:placebo) to continue to measure clinical outcomes over a period of five years. A total of approximately 2,900 patients are expected to be enrolled. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:0%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In July 2021, after completion of our discussions with both the FDA and EMA with respect to this trial, we announced that the final Phase 3 clinical trial design would result in higher costs than what we had expected and, as a result, we were assessing our options to best execute this program, including seeking a potential partner. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:0%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In order to <span style="white-space:nowrap">de-risk</span> the Phase 3 trial, in February 2022, the Company submitted an amended protocol to the FDA resulting in the FDA providing us with a list of questions and comments on this amended protocol. We have voluntarily decided not to respond to those questions and comments in order to address these with any potential partner we may find to optimize the design, if deemed relevant. The amended protocol includes a Phase 2b/3 seamless study design where the first 350 or so patients&#8217; data will be analyzed by a data monitoring committee to assess the efficacy of tesamorelin on a smaller subset of patients. The amended protocol would allow us to generate hard endpoint data on NAS score and fibrosis. A decision would then be made whether to continue the study until the full number of patients (1,094) have completed 18 months of treatment. These amendments would not change the total number of patients required to seek accelerated approval of tesamorelin for the treatment of NASH, but it would inform the continuation of enrollment while providing an indication of benefit to patients. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:0%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Currently, we continue to pursue potential NASH partners in the marketplace. We continue to maintain that the further development of tesamorelin allows the Company to keep its positioning as one of the few options for drug developers to immediately partner with a company in order to launch a Phase 2b/3 NASH clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Oncology </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM </sup>Platform </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> is the name we gave our platform that provides for the development of new proprietary peptides for cancer drug development targeting SORT1 receptors. SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development. Expression has been demonstrated in, but not limited to, ovarian, triple-negative breast, endometrial, skin, small cell and <span style="white-space:nowrap">non-small</span> cell lung, colorectal and pancreatic cancers. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. Preliminary assessments have demonstrated that the SORT1 receptor is expressed in 40% to 90% of cases of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation&#8217;s PDC generated through the SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> demonstrate distinct pharmacodynamic and pharmacokinetic properties that differentiate them from traditional chemotherapy. In contrast to traditional chemotherapy, our proprietary PDCs are designed to enable selective delivery of certain anti-cancer drugs within the tumor microenvironment, and more importantly, directly inside SORT1 cancer cells. Commercially available anticancer drugs, like docetaxel, doxorubicin, SN38 or tyrosine kinase inhibitors are conjugated to our peptide to specifically target SORT1 receptors. This could potentially improve the efficacy and safety of those agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In preclinical data, the Corporation&#8217;s lead investigational PDC, sudocetaxel zendusortide, derived from our SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup>, has shown to improve anti-tumor activity and reduce neutropenia and systemic toxicity compared to traditional chemotherapy. Additionally, in preclinical models, sudocetaxel zendusortide has shown to bypass the multidrug resistance protein 1 (MDR1; also known as <span style="white-space:nowrap">P-glycoprotein)</span> and inhibit the formation of vasculogenic mimicry - two key resistance mechanisms to chemotherapy treatment. Sudocetaxel zendusortide combines our proprietary peptide and the cytotoxic drug, docetaxel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We acquired the SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform following the acquisition of all of the issued and outstanding shares of Katana BioPharma Inc. (&#8220;Katana&#8221;) on February&#160;25, 2019 (&#8220;Katana Agreement&#8221;). Katana had the exclusive worldwide rights, through a royalty-bearing licence agreement entered into with Transfert Plus, LP (&#8220;Transfert Plus&#8221;), to a technology platform using peptides as a vehicle to specifically deliver cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells (&#8220;Transfert Plus License Agreement&#8221;). Katana has since been wound up into Theratechnologies and we became a party to the Transfer Plus License Agreement. See &#8220;Item 10C &#8211; Material Contracts &#8211; Katana Agreement&#8221; of this Annual Report and Note&#160;13 of the Audited Financial Statements for information regarding the Katana Agreement and &#8220;Item 10C &#8211; Material Contracts &#8211; Transfert Plus License Agreement&#8221; of this Annual Report and Note&#160;13 of the Audited Financial Statements for information regarding the Transfert Plus License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are no longer conducting research and development work on TH1904, one of our other investigational PDCs. However, we continue the conduct of research and development activities on other PDCs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Sudocetaxel Zendusortide Phase 1 Clinical Trial </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In March 2021, we initiated a Phase 1 clinical trial evaluating sudocetaxel zendusortide for the treatment of cancers where the sortilin receptor is expressed. The Phase 1 clinical trial design included a Part A dose escalation study to evaluate the safety, pharmacokinetics, maximum tolerated dose (&#8220;MTD&#8221;) and preliminary anti-tumor activity of sudocetaxel zendusortide administered once every three weeks in patients with advanced solid tumors refractory to available anti- cancer therapies. Part B of the Phase 1 clinical trial, also known as the &#8220;basket trial&#8221; initially consisted in recruiting a total of approximately 70 patients to study the safety and tolerability of sudocetaxel zendusortide in the following various solid tumor types, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. As per the study protocol, the MTD is established once a significant adverse event is observed in two or more patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Part A of the Phase 1 clinical trial was completed in the summer of 2022. We then reported that a total of 18 heavily <span style="white-space:nowrap">pre-treated</span> patients, who received an average of eight prior cancer treatments, were enrolled in the dose escalation portion of the study. Following the safety observations at 420 mg/m2 including grade 3 neuropathy, grade 4 neutropenia, grade 3 ocular changes (visual acuity, keratitis and ocular surface dryness) and grade 2 skin toxicities (rash, pruritis and inflammation), the dose of sudocetaxel zendusortide was decreased to 300 mg/m2 for the next dose level and was expanded to a total of six patients. No dose limiting toxicity (&#8220;DLT&#8221;) were observed during the first cycle, therefore, the dose of 300 mg/m2 was selected for continuation of the basket trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, we reported that 300 mg/m<sup style="font-size:75%; vertical-align:top">2</sup> appeared to be a well-tolerated dose level. We further reported the observation of signs of efficacy in three heavily pretreated patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Part 2 of the Phase&#160;1 clinical trial (basket expansion), the 300mg/m2 dose (given every 3 weeks) was further explored and we enrolled an additional 18 patients. In December 2022, after consulting with our investigators, we decided to voluntarily pause the enrollment of patients and revisit the study design of our clinical trial studying sudocetaxel zendusortide in various types of cancer. The efficacy results observed were not convincing enough to pursue the further enrollment of patients at this dose level and did not outweigh the adverse events seen in some patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Following the voluntary pause, the Company formed a Scientific Advisory Committee to help determine the best developmental path forward for sudocetaxel zendusortide which led to the filing of an amended protocol with the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On June&#160;2, 2023, we announced the FDA&#8217;s agreement to our amended Phase 1 trial protocol for sudocetaxel zendusortide following the submission of such amended protocol. The amended protocol is designed to improve the therapeutic window of sudocetaxel zendusortide and extend its duration of therapy. The amended protocol includes a change in the frequency of administration to weekly dosing and a narrowing of the patient population to focus on those with high-grade serous ovarian cancer, including high-grade peritoneal or fallopian tube cancer, or high-grade endometrioid cancer - a population in which preliminary efficacy has been observed thus far and has known high SORT1 expression. Patient selection has also been refined to focus on those who are less heavily pretreated, with no more than one taxane failure and a maximum of eight prior cancer treatment regimens. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amended protocol is a modified 6+6 design with two different dosing regimens that are within the efficacious range for sudocetaxel zendusortide: 1.75 mg/kg on days 1, 8, and 15 of a <span style="white-space:nowrap">28-day</span> cycle (similar to 210 mg/m<sup style="font-size:75%; vertical-align:top">2</sup> every 3 weeks) and 2.5 mg/kg on the same schedule (similar to 300 mg/m<sup style="font-size:75%; vertical-align:top">2</sup> every 3 weeks). A minimum of six patients will be enrolled at the 1.75 mg/kg dose followed by an observational period of three months to assess DLT. If deemed safe (0 or 1 DLT), the trial will enroll an additional six patients at the 2.5 mg/kg dose. Following a second three-month observational period, four more patients will be enrolled at the higher dose, for a total of 16 patients in Part 3 of the trial. The amended protocol also includes an option for a basket expansion stage that will comprise patients with selected, <span style="white-space:nowrap"><span style="white-space:nowrap">difficult-to-treat</span></span> tumor types in which sudocetaxel zendusortide has shown activity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">To date, all six patients forming part of the first cohort of patients to receive sudocetaxel zendusortide have been enrolled. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consistent with the Company&#8217;s objective of generating positive Adjusted EBITDA, the Company has announced that any new investments in the research and development activities pertaining to its SORT1+ Technology<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, including the conduct of its Phase 1 clinical trial would be stage-gated and the Company has allocated a budget of approximately $4.8&#160;million to carry out research and development activities in the field of oncology for the fiscal year 2024. In addition, Theratechnologies is currently reaching out to pharmaceutical companies to pursue the development of sudocetaxel zendusortide once the Phase 1 clinical trial will have been completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Since announcing our decision to voluntarily pause the enrollment of patients in our Phase 1 clinical trial studying sudocetaxel zendusortide in various types of cancer, partnership discussions in Greater China regarding the development and commercialization of sudocetaxel zendusortide have been paused as well. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Markets </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><sup style="font-size:75%; vertical-align:top"> </sup>is solely commercialized in the United States and almost all of the Company&#8217;s revenues are generated from one customer, McKesson (as defined below). Total revenues generated by the Company for the sale of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States amounted to $53.7&#160;million, $50.4&#160;million and $43.0&#160;million for each of the fiscal years ended November&#160;30, 2023, 2022, and 2021, respectively. Prior to November 2019, the date on which <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> became commercially available in the United States, <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> was also commercialized in the United States and Canada. However, <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> is no longer offered for sale in the United States since being replaced by <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>in the 2020 fiscal year. We also discontinued the sale of <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in Canada in October 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In November 2022, we entered into an agreement with foreign distributors providing them with the exclusive right to distribute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> under named patient programs only in various countries based in the regions of Latin America, Middle East, North Africa and Turkey and Central and Eastern Europe. This agreement has a five-year term. The exclusive distributors have no minimum purchase obligations but have to buy and pay <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> in U.S. denominated dollars at a discount to the current list price in the United States or at a discount to the price at which they are entitled to sell it in a country under the named patient program of such country. This agreement contains restrictive covenants regarding the sale of competitive products to <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">. </span>In July 2023, we also entered into an agreement with a foreign distributor providing it with the exclusive right to distribute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> under named patient programs in various countries based in Western Europe, Nordic Region and the United Kingdom. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Since the last fiscal year, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is solely commercialized in the United States. For the fiscal years ended on November&#160;30, 2022 and 2021, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was also commercialized in certain European countries. Total revenues generated by the Company from the sale of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States amounted to $28.0&#160;million, $29.6&#160;million and $26.8&#160;million for each of the fiscal years ended November&#160;30, 2023, 2022 and 2021, respectively. Revenues generated from the sale of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in certain European countries for the fiscal years ended November&#160;30, 2022 and 2021 amounted to $1.3&#160;million and $1.5&#160;million, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Canada, we are responsible, but under no obligation, to seek the approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> from Health Canada. No filing seeking the approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> has been made in Canada and to date, it is unlikely that a filing seeking the approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Canada will be made. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Prior to December&#160;15, 2022, the TaiMed Agreement provided us with the exclusive rights to commercialize Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the European Union countries and in certain additional European countries (&#8220;European Territory&#8221;). Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> was then commercially available in the European Territory through our European subsidiary, Theratechnologies Europe Limited, until December&#160;15, 2022, the effective date on which all of our commercialization rights to Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> were returned to TaiMed under the TaiMed Agreement. Since our decision to return to TaiMed our commercial rights to Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the European Territory, we have ceased all activities related to the commercialization of this product in the various European countries in which such activities were ongoing. The EMA has since withdrawn the marketing approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Seasonality</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As a specialized biopharmaceutical company, the Company views none of its commercial and research and development activities as subject to seasonal variations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Manufacturing</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Today, we are not aware of material sourcing issues or pricing volatility of raw materials, however, we no longer have a long-term supply agreement for SWI for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">. </span>See &#8220;Item 3D&#160;&#8211;&#160;Risk Factors &#8211; Risks Related to the Commercialization of Our&#160;Products&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We do not own or operate manufacturing facilities for the production of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and tesamorelin, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party service providers, i.e. Bachem and Jubilant to manufacture and supply all of our required raw materials, drug substance and drug product for sales of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>. We will rely on LSNE for the manufacture of the F8 Formulation if and when approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Active Pharmaceutical Ingredient</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July 31<sup style="font-size:75%; vertical-align:top">st</sup>, 2023, we signed a manufacturing and supply agreement with Bachem (&#8220;Bachem Agreement&#8221;) relating to the manufacture and supply of the active pharmaceutical ingredient of tesamorelin (&#8220;API&#8221;) for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span> Bachem is our only approved manufacturer for the API to date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Finished Product</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have an agreement with Jubilant providing for the manufacture and supply of the finished form of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>for commercial sale in the United States and for tesamorelin in connection with clinical trials (&#8220;Jubilant Agreement&#8221;). Under the Jubilant Agreement, Jubilant <span style="font-style:italic"></span><span style="font-style:italic"></span>must fill vials with tesamorelin, lyophilize it, label and package those vials and deliver them to locations in accordance with our instructions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have an agreement with LSNE, providing for the manufacturing and commercial supply of the F8 Formulation with an effective date of May&#160;11, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation also provides patients with the administration boxes which include the necessary supplies to administer the product. These administration boxes are comprised of alcohol swabs, syringes, needles and water for injection. The packaging of these administration boxes for EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> is done through Sharp Packaging Services, LLC (&#8220;Sharp&#8221;) and will be done through Almac Pharma Services LLC (&#8220;Almac&#8221;) for the F8 Formulation if and when approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">TaiMed is our sole supplier of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. TaiMed does not currently own or operate any manufacturing facilities for the production of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and has subcontracted the manufacture of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>to WuXi in China, and to Samsung, in South Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Sudocetaxel Zendusortide </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Active Pharmaceutical Ingredient</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We do not own or operate manufacturing facilities for the production of sudocetaxel zendusortide nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently have an agreement with STA Pharmaceutical Hong Kong Limited (&#8220;STA&#8221;) providing for the manufacture of our peptide (TH19P01) and to produce sudocetaxel zendusortide. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Finished Product</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We rely on Piramal Pharma Solutions, Inc. (&#8220;Piramal&#8221;) to manufacture the finished form of sudocetaxel zendusortide as vials of sterile solution for injection. The vials are then shipped to Sharp Clinical Services, LLC, with whom we have an agreement for the labelling and packaging of the vials for clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Distribution Channels</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> <span style="text-decoration:underline"></span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In connection with the commercialization of our products in the United States, we have entered into various agreements with third-party service providers to distribute our products to patients. The distribution of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> is tightly controlled and is only available through certain selected pharmacies. Below is a summary of our agreements entered into with our third-party service providers forming part of the supply chain of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Logistics Service Provider and Distributor</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On November&#160;1, 2017, we entered into an amended and restated master services agreement with RxC Acquisition Company, LLC, doing business as RxCrossroads by McKesson and subsequently assigned to McKesson Specialty Care Distribution LLC (&#8220;McKesson&#8221;) along with two amended and restated statements of work (collectively, &#8220;McKesson Agreement&#8221;). Under the terms of the McKesson Agreement, McKesson acts as our exclusive third-party logistics service provider for all of our products in the United States and as such, provides us with warehousing and logistical support services, including inventory control, account management, customers support, product return management and fulfillment of orders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the McKesson Agreement, McKesson also acts as our exclusive third-party distributor of our products in the United States. In such role, McKesson purchases products from us and takes title thereto. McKesson&#8217;s purchases of our products are triggered by its expectations of market demand over a certain period of time. McKesson fulfills orders received from authorized wholesalers and certain authorized specialty pharmacies and, with respect to <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>, delivers it directly to that authorized wholesaler&#8217;s client, namely a specialty pharmacy forming part of our network of specialty pharmacies, or directly to those authorized specialty pharmacies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Wholesalers</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our supply chain of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States is comprised of a limited number of wholesalers through which specialty pharmacies we have contracted with can order <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span> These wholesalers accept purchase orders from those specialty pharmacies, purchase <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> from McKesson, and resell this product to these specialty pharmacies. Our wholesalers do not handle the physical delivery of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic">.</span> The shipping and delivery of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> to those specialty pharmacies is handled by McKesson. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Specialty Pharmacies</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have entered into agreements with various specialty pharmacies across the United States providing them with the right to order <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> from our authorized wholesalers and distribute <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> to patients in the United States through their networks of local pharmacies. In addition, a limited number of those specialty pharmacies are authorized to purchase <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>directly from McKesson for their own retail specialty pharmacy stores. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Logistics Service Provider and Distributor</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">McKesson also acts as our exclusive third-party logistics service provider and exclusive third-party distributor for Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States under the McKesson Agreements. Orders for Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> are made directly by a limited number of specialty pharmacies and specialty distributors and delivery of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is made directly to those specialty pharmacies and specialty distributors by McKesson. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Specialty Pharmacies and Distributors</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have entered into agreements with specialty pharmacies, specialty distributors, and infusion therapy providers that have a large U.S. network capable of handling drug products whose administration is made intravenously. These specialty pharmacies and specialty distributors have the capacity to deliver Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> to patients, physicians or infusion centers. Each of those specialty pharmacies and specialty distributors purchase Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>from McKesson and deliver it to infusion centers, physicians or patients for home-infusion. Specialty pharmacies and specialty distributors may not purchase Trogarzo from our wholesalers. Patients are administered Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> at infusion centers, at physicians&#8217; offices or at home with the assistance of nurses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Marketing</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our marketing and sales activities in the United States for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> are conducted from our head office in Montreal, Qu&#233;bec, Canada. We have also retained the services of Syneos Health (&#8220;Syneos&#8221;), a third party service provider, to assist us with market access and reimbursement activities in the United States. The market access and reimbursement teams provided by Syneos are solely dedicated to our products. Syneos is a recognized provider of services around the globe. We have renewed our agreement with Syneos and we entered into an amendment to our amended and restated master service agreement in this respect effective as of December&#160;1, 2021 (&#8220;Syneos Agreement&#8221;) pursuant to which Syneos will continue providing us with certain services in connection with the commercialization of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States until November&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have contracted with Asembia, LLC (&#8220;Asembia&#8221;) for the provision of services related, amongst other things, to a call center. The call center, THERA Patient Support<sup style="font-size:75%; vertical-align:top">&#174;</sup>, guides physicians and patients through the process of initiating treatment under reimbursement. This process, which can be complex and time-consuming, begins with a referral and concludes with the final reimbursement decision. THERA Patient Support<sup style="font-size:75%; vertical-align:top">&#174;</sup> also helps patients adhering to their treatment and answering questions about our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Intellectual Property</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We recognize the significance of safeguarding our business through the protection of patents and trade secrets. Our prosperity is contingent, in part, on our capacity to secure robust patents, maintain the confidentiality of trade secrets, and operate without violating the proprietary rights of others. The success of products integrating our technologies may hinge, to some extent, on our ability to secure effective patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our intellectual property practice is to keep all information relating to proprietary compounds, inventions, improvements, trade secrets, <span style="white-space:nowrap">know-how</span> and continuing technological innovation confidential and, where practicable, file patent and trademark applications. In particular, as part of our intellectual property protection practice, we: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">where practicable, file patent applications for any new and patentable invention, development or improvement in the United States and in other countries where we deem patent protection to be of value; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">prosecute all pending patent applications in conformity with applicable patent laws and in a manner that efficiently covers our activities; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">file trademark applications in countries of interest for our trademarks; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">register domain names whose addresses include our trademark names; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">maintain our intellectual property rights by paying government fees as may be necessary to ensure such rights remain in force. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company relies on multiple patents related to tesamorelin, the active ingredient of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> in the United States and in other countries. For instance, the F8 Formulation is patent protected in the United States until 2033. We also have additional patents in the United States covering tesamorelin for the treatment of NASH scheduled to expire in 2040. Moreover, our PDCs stemming from our licensed SORT1+ Technology<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform are also patent protected in the United States and other countries and patent applications are pending in various countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Moreover, the Company depends on trade secrets and <span style="white-space:nowrap">know-how</span> to sustain our competitive standing. The management of the disclosure and utilization of our <span style="white-space:nowrap">know-how</span> and confidential information is governed by agreements with the relevant parties. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Apart from the patents and trade secrets, the Company relies on specific licensing agreements which are essential to maintain our commercial and R&amp;D activities, namely: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The distribution and marketing agreement with TaiMed granting the Company the exclusive right to market Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Canada and in the United States. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The licensing agreement with Katana granting the Company a worldwide exclusive license to use and develop the SORT1+ Technology<sup style="font-size:75%; vertical-align:top">&#8482;</sup> Platform. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The licensing agreement with the Massachusetts General Hospital (&#8220;MGH&#8221;) for the development of tesamorelin for the potential treatment of NASH in the general population. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Competition </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are not aware of other GRF products indicated for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> patients with lipodystrophy being commercialized. However, we are aware that we face indirect competition for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> from other drugs, such as human growth-hormone, testosterone, insulin sensitizing agents, <span style="white-space:nowrap">GLP-1</span> receptor agonists and sermorelin that may be prescribed by physicians. To our knowledge, the use of these other drugs for the reduction of excess abdominal fat in <span style="white-space:nowrap">HIV-infected</span> adult patients with lipodystrophy has not been proven nor approved by the FDA. Other approaches to reduce excess abdominal fat include coping mechanisms such as lifestyle modification (diet and exercise), switching ARV therapy, or liposuction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Fostemsavir and Lenacapavir are direct competitors to Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Contrary to Fostemsavir which is administered orally twice per day, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> is a long-acting ARV that only needs to be administered intravenously every two weeks. Like Fostemsavir, Lenacapavir&#8217;s indication for use targets the same patient population as that of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Lenacapavir is administrated subcutaneously once every six months. In addition, we are aware of other agents including, but not limited to, dolutegravir and darunavir, that are either indicated or commonly used in combination in regimens for the treatment of heavily treatment-experienced patients with MDR <span style="white-space:nowrap">HIV-1.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Tesamorelin for the Treatment of NASH in the General Population </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There exists no approved medicine for the treatment of NASH. However, there are various compounds currently being studied for the treatment of this disease, some of which are already in Phase 3 clinical trials. These compounds have different mechanisms of action to treat different aspect of the disease, either fat accumulation or inflammation. Tesamorelin has a unique mechanism of action targeting liver fat. However, it has been shown that tesamorelin also improved inflammatory markers. Tesamorelin also benefits from a good safety profile based on more than ten (10)&#160;years of use. The development of tesamorelin for the treatment of NASH, if successful, may compete with many potential other drugs for this patient population and we expect strong competition among those companies that will have succeeded in developing and commercializing a medicine for this disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> Platform in Oncology </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The development of novel treatments in oncology is competitive. Many companies are investing in the development of innovative cancer treatments or in finding a cure for cancer. Most of those companies have significant means and scientific experience. Some of those companies are at more advanced development stage of their drugs than us. In addition, there exists many drug candidates, such as antibody drug conjugates aimed at a variety of potential targets: some treatment will aim at focusing on one particular cancer type whereas others, like our PDCs, could be used in various types of cancers. Our Phase 1 clinical trial studying sudocetaxel zendusortide in various types of cancer was voluntarily paused and was resumed in June 2023 for the potential treatment of ovarian cancer. Even if successful, by the time we enter the market, there may be approved medicines that would directly compete with sudocetaxel zendusortide or any other PDCs we may develop. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Government Regulations</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The text below explains some of the most important features of government regulations that we must follow in connection with the commercialization of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Sales and Marketing Regulation - United States </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are subject to various United States requirements relating to the sales and marketing of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States. The FDA regulates all advertising and promotional activities for prescription drug products under its jurisdiction both prior to and after approval. <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> may be promoted only for their approved indications and in accordance with the provisions of their approved label. Any promotional claims regarding an approved drug must be accurate, not misleading and contain a fair balance of risk and benefit information. The FDA, as well as other government authorities, actively enforces the laws and regulations prohibiting the promotion of inaccurate, misleading or inadequately balanced product claims and the promotion of product for unapproved (i.e., <span style="white-space:nowrap">off-label)</span> uses. If we are found to have improperly promoted a prescription drug, we may be subject to significant sanctions. Failure to comply with applicable FDA requirements may subject us to adverse publicity, enforcement action by the FDA, corrective advertising, and the full range of civil and criminal penalties available to the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The FDA does not regulate the practice of medicine by physicians in their choice of treatment and prescribing decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The marketing of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> within the United States may also be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including but not limited to the federal Anti-kickback Statute, Civil Monetary Penalties Law, and False Claims Act and analogous state laws. The federal Anti-kickback Statute prohibits a person from knowingly and willfully offering, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce referring or recommending an individual to another person to receive items or services or to purchase, lease, order, or arrange for any good, facility, item or service payable in whole or in part under a Federal health care program. The Civil Monetary Penalties Law prohibits, among other things, a person from offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of Medicare or Medicaid payable items or services. Sanctions under these laws include civil monetary penalties, imposition of a corporate integrity agreement, exclusion from U.S. federal and state healthcare programs (i.e., those programs will not provide reimbursement or payment coverage for <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and/or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>), and criminal penalties, including imprisonment; further, an alleged violation of the Anti-kickback Statute could be used as a basis for a federal or state false claims law challenge. The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program, knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Generally, claims for drugs prescribed for <span style="white-space:nowrap">off-label</span> uses may be considered to be &#8220;false claims.&#8221; Sanctions under false claims laws include significant civil monetary penalties. In addition, there is ability for private individuals to bring similar actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, several states require that companies implement compliance programs or comply with industry ethics codes, adopt marketing spending limits, and report to state governments any gifts, compensation, and other remuneration provided to certain healthcare professionals. Also, the federal Physician Payments Sunshine Act, also known as the Open Payments Act, requires certain manufacturers of drugs, medical devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or Children&#8217;s Health Insurance Program to record and disclose to the federal government certain transfers of value to physicians and teaching hospitals and ownership and investment interests held by physicians and their immediate family members. Any activities relating to the sale and marketing of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> may be subject to scrutiny under these laws. Failure to make these required reports or comply with these laws can result in civil monetary penalties and/or other sanctions. If the government were to allege or convict us of violating these laws, our business could be harmed. There are a number of states that have similar reporting and disclosure requirements, and failure to comply with these laws could have adverse consequences. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Privacy </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Qu&#233;bec, Canada, privacy is governed by an Act Respecting the Protection of Personal Information in the Private Sector (&#8220;Qu&#233;bec Privacy Law&#8221;). The Qu&#233;bec Privacy Law was enacted in September 2021 and takes effect over a three (3) year period between 2021 and 2024. The Qu&#233;bec Privacy Law modernized the obligations of <span style="white-space:nowrap">Qu&#233;bec-based</span> companies in dealing with the protection of personal information with respect, among other things, to the collection, holding, use and communication of personal information to third parties. The Qu&#233;bec Privacy Law requires <span style="white-space:nowrap">Qu&#233;bec-based</span> companies to appoint a privacy officer, the individual responsible to ensure compliance with the Qu&#233;bec Privacy Law, to establish and implement policies on various aspects covered by the Qu&#233;bec Privacy Law and imposes substantial fines and penalties on companies violating the Qu&#233;bec Privacy Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In 2023, privacy law continued to evolve in the U.S., mainly at the state level. The California Privacy Rights Act (&#8220;CPRA&#8221;) amended the California Consumer Privacy Act (&#8220;CCPA&#8221;) in California, while similar comprehensive consumer privacy laws took effect in four other states&#8212;Virginia, Colorado, Connecticut, and Utah. An additional seven states enacted omnibus privacy laws that will take effect at various points over the next few years. Some of these state laws require <span style="white-space:nowrap">opt-in</span> consent to process sensitive personal data, including health data. In addition, three states&#8212;Washington, Nevada, and Connecticut&#8212;passed laws specifically regulating consumer health data, with the intention of regulating data that is not otherwise regulated by the Health Insurance Portability Act of 1996 (&#8220;HIPAA&#8221;). The Federal Trade Commission also ramped up its enforcement of the Health Breach Notification Rule (&#8220;HBNR&#8221;), asserting that unauthorized disclosures of personal health information for advertising purposes violate the HBNR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On the security side, new Security and Exchange Commission (&#8220;SEC&#8221;) regulations took effect requiring publicly traded companies to report material cybersecurity incidents within 4 days of determining the incident was material, and on annual reports. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Good Manufacturing Practices </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Drug products must be manufactured and packaged in accordance, among other things, with GMP and both Bachem and Jubilant, the contract manufacturers of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>, as well as WuXi and Samsung, the manufacturer of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, must adhere to GMPs in connection with the manufacture, labeling, packaging, and any other quality-related functions for these products. If a company wants to make certain changes in its manufacturing equipment, location or process, FDA regulatory review and approval may be required. The FDA often conducts audits of manufacturing sites to ensure that manufacturers comply with quality-related requirements and GMPs. If, as a result of these inspections, it is determined that a manufacturer&#8217;s equipment, facilities or processes do not comply with the regulations and conditions of product approval, the FDA may issue an <span style="white-space:nowrap">FDA-483</span> list of observations or seek civil, criminal or administrative sanctions and/or remedies against the manufacturer, including seeking corrective action, or requiring suspension of manufacturing operations, which would delay the product and sale of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Good Clinical Practices </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The FDA promulgates regulations and standards, commonly referred to as good clinical practices, (&#8220;GCPs&#8217;), for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the trial participants are adequately protected. Our research and development activities are subject to GCPs. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If study sites fail to comply with applicable GCPs or other applicable requirements, such as informed consent or Institutional Review Board oversight, the clinical data generated in clinical trials may be deemed unreliable and the FDA may require a sponsor to redo its studies or even stop a study. Where patient safety is at risk, the FDA could impose a clinical hold. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">FDA Authorization of State Importation Program </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">FDA authorized its first section 804 importation program, a program allowing Florida to import certain prescription products from Canada. Section&#160;804 (21 U.S.C. &#167; 384) of the FFDCA provides a pathway for states and Indian tribes to allow importation of certain prescription drugs from Canada. Programs under this pathway must significantly reduce the cost of these drugs to the American consumer, without imposing additional risk to public health and safety. As the first program of its kind, we have yet to see how it will be implemented and what specific products will be imported. There is much opposition from industry regarding this program, but if Florida can execute it as planned, it may signal a trend in the US. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Industry is still waiting to understand the practical implications of this program, and what implications this may have on state pharmaceutical industries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Pharmaceutical Pricing and Reimbursement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the United States and in other countries, sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> will depend in large part on the availability of reimbursement from third-party payors. These payors include both government (such as Federal Medicare and State Medicaid, AIDS Drug Assistance Programs and special needs plans in the United States) and privately managed care organizations as well as pharmacy benefit managers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and/or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> may not be considered cost- effective. It is time consuming and expensive for us, and our commercial partners, to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us, or our commercial partners, to sell <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and/or Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> on a competitive and profitable basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">United States </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The U.S. Congress, state legislatures, and federal and state agencies from time to time propose and adopt initiatives aimed at cost containment, which could impact our ability to sell our drug products profitably. For example, in March 2010, the Patient Protection and Affordable Care Act, and the associated reconciliation bill, which we refer to collectively as the Health Care Reform Law was enacted, and was a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements (inclusive of price increases) for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Effective October&#160;1, 2010, the Health Care Reform Law revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of all Medicaid drug rebates. On January 21, 2016, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), finalized a rule detailing reforms to the rebate and reimbursement systems for Medicaid prescription drugs. This final rule was intended to save taxpayers billions and ultimately improve beneficiary access to prescription drugs. The final rule allowed manufacturers to recalculate the baseline &#8220;average manufacturer price&#8221; and includes U.S. territories in the calculation of &#8220;average manufacturer price&#8221; and &#8220;best price&#8221; effective April 1, 2017. Further, the new law imposed a significant annual fee on companies that manufacture or import certain branded prescription drug products and biologic agents. On December 31, 2020, CMS issued a final rule to support state flexibility to enter into value-based purchasing arrangements (&#8220;VBPs&#8221;), with manufacturers for prescription drugs and to provide manufacturers with regulatory support to enter into VBPs with payers, including Medicaid. This final rule is intended in part to further value-based payment arrangements. Implementation of certain aspects of this final rule were delayed until July 1, 2022. Substantial new provisions affecting compliance also have been enacted, which may require us to modify our business practices with healthcare practitioners, and also may increase our regulatory burdens and operating costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The U.S. Medicare program provides payment for many pharmaceuticals under the Medicare Part D program. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both standalone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under Part D, government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while Part D applies only to drug benefits for Medicare beneficiaries, state Medicaid programs and private payors may follow Medicare coverage policy limitations in setting their own payment rates. Any reduction in payment that results under Part D may influence decision-making and negotiations for payments from <span style="white-space:nowrap">non-governmental</span> payors. Payors are, however, forbidden to negotiate both commercial and Part D agreements together. Negotiations must be kept separate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The cost of pharmaceuticals continues to generate substantial governmental and third-party private payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, particularly towards specialty pharmacy, the increasing influence of managed care organizations, and additional legislative proposals. For example, CMS issued an interim final rule on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in spending for Medicare Part B drugs without adversely affecting quality of care. This followed an Executive Order issued in September 2020 that directed the Secretary of the U.S. Department of Health and Human Services (&#8220;DHHS&#8221;) to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221; and high drug prices in the United States. Implementation of this interim final rule was blocked by a temporary restraining order and preliminary injunctions through various court actions, and on December 29, 2021, CMS formally rescinded the interim final rule, effective February 28, 2022. Nonetheless, we expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Health Care Reform Law. The Health Care Reform Law may be modified, amended or repealed at any time and may or may not be replaced with a different law or health care payment system. We are unable to predict the full impact of any such potential modification, amendment or repeal of the Health Care Reform Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The passage of the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) further affects Medicare reimbursement. The IRA has three key elements reforming Medicare drug pricing policy. However, the implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific implications for pharmaceutical pricing and reimbursement are yet to be determined. Likewise, we are unable to predict potential modification, amendment, or repeal of the IRA, though some predict that challenges may be made to the IRA as different provisions are enacted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As the first key element, the IRA created a Medicare drug price negotiation program enabling the Secretary of DHHS to negotiate the prices of certain costly, single-source drugs or biologics within the Medicare program. Certain drugs are excluded from this negotiation process, such as drugs that are less than 9 years, or biologics less than 13 years, from their <span style="white-space:nowrap">FDA-approval</span> or licensure date, and drugs with an orphan designation as their only <span style="white-space:nowrap">FDA-approved</span> indication. The first set of these negotiated prices will not take effect until 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Second, the IRA requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program. This inflation rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect in 2022 as the starting point for measuring drug price increases, with rebate payments required as of the beginning of 2023. DHHS will start to send rebate invoices to drug manufacturers in 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Third, the IRA restructures the Medicare Part D benefit to limit patients&#8217; <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs and rebalance the bearing of risk for Part D plans and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs for covered drugs once they reach the catastrophic coverage level (when the policyholder&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> spending reaches $7,400). Other aspects of this provision will take effect in 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The industry is still waiting to understand the full implications of these changes and the practical impact on pharmaceutical pricing and reimbursement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Also, the bipartisan Drug-Price Transparency for Consumers Act was introduced to Senate on April&#160;20, 2023, and the House of Representatives on October&#160;13, 2023 (S.1250 and H.R.5958, respectively) (&#8220;Act&#8221;). The Act is currently in committee. This Act would require that <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertisements for drugs and biologicals include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable under Medicare or Medicaid and for which <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertisements are required to include information relating to side effects, contraindications, and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, the Act would amend the Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition cost (&#8220;WAC&#8221;) cost for a <span style="white-space:nowrap">30-day</span> supply or typical course of treatment and clearly and conspicuously present such price information. If enacted, the Act contemplates that implementing regulations would include the visual and audio components required to communicate the WAC appropriately for the medium of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the way the manufacturer may include a statement explaining that certain consumers may pay a different amount depending on their insurance coverage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_18"><span style="font-weight:bold">C.&#8195;&#8195;&#8195;</span><span style="font-weight:bold"><span style="font-style:italic">Organizational Structure</span></span><span style="font-weight:bold"></span><span style="font-style:italic"> </span><span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As of November&#160;30, 2023, Theratechnologies had the following five wholly owned subsidiaries with Theratechnologies U.S. Inc. being the only material subsidiary among Theratechnologies&#8217; affiliates: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Theratechnologies U.S., Inc., a company governed by the DGCL. Theratechnologies U.S., Inc. assists Theratechnologies Inc. with its commercial activities in the United States; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Theratechnologies Europe Limited, a company governed by the <span style="font-style:italic">Companies Act 2014</span> (Ireland). Theratechnologies Europe Limited assists Theratechnologies Inc. with its commercial activities in the United States; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Theratechnologies Intercontinental Inc., a company governed by the QBCA. Theratechnologies Intercontinental Inc., formerly Theratechnologies ME Inc., used to control the worldwide rights to commercialize <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup>, except in the United States, Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian countries, and Canada. Theratechnologies Intercontinental Inc. is no longer an active subsidiary; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Theratechnologies Europe Inc., a company governed by the QBCA. Theratechnologies Europe Inc., formerly 9176-5057 Qu&#233;bec Inc., used to control the rights to commercialize <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian countries. Theratechnologies Europe Inc. is no longer an active subsidiary; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Pharma-G Inc., a company governed by the QBCA. <span style="white-space:nowrap">Pharma-G</span> Inc. is no longer an active subsidiary. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following chart illustrates our current corporate structure. </p> <p style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117dsp18.jpg" alt="LOGO"/>
 </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">These are no longer active subsidiaries. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_19"><span style="font-weight:bold">D.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Property, plants and equipment</span></span><span style="font-style:italic"> </span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our head office and principal place of business is located at 2015 Peel Street, 11<sup style="font-size:75%; vertical-align:top">th</sup> Floor, Montreal, Qu&#233;bec, Canada H3A 1T8. We lease the entire 10<sup style="font-size:75%; vertical-align:top">th</sup> and 11<sup style="font-size:75%; vertical-align:top">th</sup> floors of the building for a total of 14,992 square feet. We lease additional office and R&amp;D space as set forth in the table below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:17%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:middle">Location</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">Use of Space</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">Square Footage</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap">Type of Interest</td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">7210 Frederick-Banting Suite 100, <span style="white-space:nowrap">St-Laurent,</span> Qu&#233;bec, Canada H4S 2A1</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Occupied for R&amp;D</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">9,394</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Leasehold</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">2101 Jeanne-Mance, Montr&#233;al, Qu&#233;bec, Canada H2X 2J6.</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Occupied for R&amp;D</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2,461</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Leasehold</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">1<sup style="font-size:75%; vertical-align:top">st</sup> Floor, 12 Duke Lane Upper, Royal Hibernian Way, Dublin 2 Ireland D02 DX07.</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Occupied for administration&#8194;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">1,652</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Leasehold</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">101 Hudson Street, 21<sup style="font-size:75%; vertical-align:top">st</sup> Floor, Jersey City, New Jersey 07302</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Occupied for administration&#8194;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">119</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Leasehold</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_20">Item&#8201;4A. Unresolved Staff Comments </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_21">Item&#8201;5. Operating and Financial Review and Prospects </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following section is intended to help the reader understand the factors that have affected the Company&#8217;s financial condition and results of operations for the historical period covered by the financial statements and management&#8217;s assessment of factors and trends which are anticipated to have a material effect on the Company&#8217;s financial condition and results in future periods. This section should be read in conjunction with, our audited annual consolidated financial statements and the notes thereto as at November 30, 2023 (&#8220;Audited Financial Statements&#8217;) and the other financial information contained elsewhere in this document. See &#8220;Item 18 &#8211; Financial Statements&#8221;. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_22"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Operating results.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Fourth-Quarter and Fiscal 2023 Revenue Highlights </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">(in 000s of US$)</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three-month<br/>periods&#160;ended</span><br/><span style="font-weight:bold">November 30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br/>November 30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span>&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold"><span style="text-decoration:underline">2023</span></span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span><span style="text-decoration:underline"></span>&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span>&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold"><span style="text-decoration:underline">2022</span></span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span><span style="text-decoration:underline"></span>&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span>&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold"><span style="text-decoration:underline">2023</span></span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span><span style="text-decoration:underline"></span>&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span>&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="center"><span style="font-weight:bold"><span style="text-decoration:underline">2022</span></span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline"></span>&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales<span style="font-style:italic"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic"></span><span style="font-weight:bold">16,958</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>14,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">53,705</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>50,454</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,494</span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>6,963</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(6.7</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,059</span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>29,603</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(5.2</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Revenue</span><span style="font-weight:bold"></span></p></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-weight:bold"></span><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">23,452</span></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>$</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>21,421</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top" align="right"><span style="font-weight:bold">9.5</span></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-weight:bold">%</span>&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">81,764</span></td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>$</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>80,057</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">2.1</td>
<td style="BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Fiscal Year 2023 Financial Results compared to Fiscal Year 2022 Financial Results</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated revenue for the fiscal year ended November 30, 2023 (&#8220;Fiscal 2023&#8221;) was $81,764,000 compared to $80,057,000 for the same period last year, representing an increase of 2.1%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For Fiscal 2023, sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> reached $53,705,000 compared to $50,454,000 for the same period last year representing growth of 6.4%. The increase in net sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> was mostly the result of a higher number of units sold compared to the previous year, as well as a higher net selling price. Overall growth of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top"> </sup></span>net sales was hampered in 2023 by draw downs in inventory at one of our large specialty pharmacies during the second quarter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2023, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales were $28,059,000 compared to $29,603,000 in the prior year, a decrease of 5.2%. Net sales of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> were negatively affected in the second quarter of 2023 by two factors: (a)&#160;drawdowns in inventory at one of our large specialty pharmacies resulting from larger than necessary purchases in the latter part of calendar year 2022; and (b)&#160;further inventory drawdowns at another specialty pharmacy with which we renegotiated contract terms resulting in a lowering of their overall inventory levels. Net sales of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> were also impacted by greater than anticipated rebates to government payers. The Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales decrease is also attributable to a lesser degree to our decision to stop commercializing the product in Europe in the fiscal year ending November 30, 2022 (&#8220;Fiscal 2022&#8221;), resulting in a $975,000 decrease in Fiscal 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Cost of Sales </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For Fiscal 2023, cost of sales was $19,635,000 compared to $26,279,000 in the comparable period of Fiscal 2022. Cost of sales included cost of goods sold that amounted to $19,635,000 in Fiscal 2023 compared to $23,838,000 in Fiscal 2022. The decrease in cost of goods sold was mainly due to a number of factors occurring in Fiscal 2022 that did not reoccur in Fiscal 2023, namely: (1)&#160;a charge arising from the <span style="white-space:nowrap">non-production</span> of scheduled batches of <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> that were cancelled due to the planned transition to the F8 Formulation in the amount of $1,788,000; and (2)&#160;a provision of $1,477,000 related to the write down of F8 Formulation for <span style="white-space:nowrap">pre-commercial</span> material which could expire prior to the launch of the F8 Formulation, if approved. Cost of goods sold for Fiscal 2023 also included other provisions totalling $220,000, related to the pending approval of the F8 Formulation (See Note 9 of the Audited Financial Statements). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2022, cost of sales included an amortization charge of $2,441,000 in connection with the settlement of the future royalty obligation which has been accounted as &#8220;Other asset&#8221; on the consolidated statement of the financial position. The Other asset was fully amortized during the first half of Fiscal 2022, and thus this charge was Nil in Fiscal 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">R&amp;D Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">R&amp;D expenses were $30,370,000 for Fiscal 2023 compared to $36,939,000 for Fiscal 2022, a decrease of 17.8%, mostly due to lower spending on our various programs. R&amp;D expenses in the first and second quarters of Fiscal 2023 were also negatively impacted by expenses of $3,730,000 related to sudocetaxel zendusortide material and expenses of $536,000 related to the production of bacteriostatic water for injection (&#8220;BWFI&#8221;). Excluding these expenses, R&amp;D expenses are down significantly in Fiscal 2023 compared to last year, mostly as a result of lower spending on our oncology program. R&amp;D expenses also included $1,384,000 in severance and other expenses related to the reorganization announced in July 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Selling Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Selling expenses for Fiscal 2023 were $26,769,000 compared to $39,391,000 for Fiscal 2022. The decrease in selling expenses is mainly related to higher expenses incurred in Fiscal 2022 related to the setting up of our internal field force in the United States as well as severance costs incurred following our decision in 2022 to exit the European market for the commercialization of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. The decrease is also due in large part to a charge of $6,356,000 related to the accelerated amortization, in the second quarter of Fiscal 2022, of the Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> commercialization rights for the European Territory. Selling expenses in Fiscal 2023 included $220,000 in severance and other expenses related to the reorganization announced in July 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amortization of the intangible asset value for the <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> commercialization rights is also included under selling expenses. As such, we recorded amortization expenses of $2,513,000 for Fiscal 2023, compared to $9,211,000 in Fiscal 2022 (which included the charge related to accelerated amortization of the Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> commercialization rights for the European territory). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">General and administrative expenses for Fiscal 2023 were $15,617,000 compared to $17,356,000 for the same period in Fiscal 2022. The decrease in general and administrative expenses is largely due to our decision to terminate the commercialization activities of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe during the second quarter of Fiscal 2022.&#160;General and administrative expenses for Fiscal 2023 also included $359,000 in severance and other expenses related to the reorganization announced in July 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Finance Costs </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Net finance costs for Fiscal 2023 were $12,909,000 compared to $6,886,000 in Fiscal 2022. The increase in net finance costs in Fiscal 2023 versus Fiscal 2022 was mostly due to the higher interest expense on the Company&#8217;s Loan Facility ($3,906,000), as well as expenses of $3,540,000 related to the amendments to the Marathon Credit Agreement. Other expenses in Fiscal 2023 include the <span style="white-space:nowrap">write-off</span> deferred financing costs ($954,000). These higher costs are offset by gain on the change of fair value of the Marathon Warrants and a lower foreign exchange loss. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Adjusted EBITDA </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Adjusted EBITDA was $(2,907,000) for Fiscal 2023 compared to $(22,088,000) for Fiscal 2022. Adjusted EBITDA in the first and second quarters of Fiscal 2023 was negatively affected by expenses of $3,749,000 related to sudocetaxel zendusortide material and expenses of $536,000 related to the production of BWFI. No such expenses were recorded in the third and fourth quarters of Fiscal 2023. See <span style="white-space:nowrap">&#8220;Non-IFRS</span> and <span style="white-space:nowrap"><span style="white-space:nowrap">Non-US-GAAP</span></span> Measure&#8221; above and see &#8220;Reconciliation of Adjusted EBITDA&#8221; below for a reconciliation to Net Loss for the relevant periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Loss </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Taking into account the revenue and expense variations described above, we recorded a net loss of $23,957,000, or $0.91 per share, in Fiscal 2023 compared to $47,237,000, or $1.98 per share, in Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Fourth-Quarter Fiscal 2023 Financial Results</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated revenue for the three months ended November&#160;30, 2023, amounted to $23,452,000 compared to $21,421,000 for the same period last year, representing an increase of 9.5%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the fourth quarter of Fiscal 2023, sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> reached $16,958,000 compared to $14,458,000 in the fourth quarter of the prior year, representing an increase of 17.3%. Strong sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> were mostly the result of increased unit sales, and somewhat offset by higher rebates to government payers than in Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the fourth quarter of Fiscal 2023, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> sales amounted to $6,494,000 compared to $6,963,000 for the same quarter of Fiscal 2022, representing a decrease of 6.7%. The decrease was mainly due to lower unit sales in the quarter as compared to last year. Lower unit sales in the fourth quarter of Fiscal 2023, were also a result of higher inventory buildup in Fiscal 2022, a situation which has resolved itself in Fiscal 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Cost of Sales </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the three-month period ended November&#160;30, 2023, cost of sales was $5,066,000 compared to $5,909,000 in the comparable period of Fiscal 2022. Lower cost of sales for the fourth quarter of Fiscal 2023 is explained by a provision in cost of goods sold for the fourth quarter of Fiscal 2022 which included a provision of $1,477,000 related to the write down of F8 Formulation for <span style="white-space:nowrap">pre-commercial</span> material which could expire prior to the launch of the F8 Formulation. This decrease was partially offset by an increase from higher sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup> </span>and various production-related costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">R&amp;D Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">R&amp;D expenses in the three-month period ended November&#160;30, 2023, amounted to $5,229,000 compared to $9,455,000 in the comparable period of Fiscal 2022. The decrease during the fourth quarter of Fiscal 2023 was largely due to lower spending across all areas, including the Phase 1 clinical trial for sudocetaxel zendusortide, the HFS for the F8 Formulation, as well as the development of the IM method of administration of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. These last projects were mostly completed in the fourth quarter of Fiscal 2023. R&amp;D expenses also included $876,000 in severance and other expenses related to the reorganization announced in July 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Selling Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Selling expenses in the three-month period ended November&#160;30, 2023, amounted to $6,748,000 compared to $7,809,000 in the comparable period of Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The decrease in selling expenses is largely associated to the careful management of expenses to achieve our stated goal of achieving a positive Adjusted EBITDA towards the end of Fiscal 2023. Selling expenses also included $79,000 in severance and other expenses related to the reorganization announced in July 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">General and administrative expenses in the fourth quarter of Fiscal 2023 amounted to $3,739,000, compared to $3,956,000 reported in the same period of Fiscal 2022. General and administrative expenses include $289,000 in severance and other expenses related to the reorganization announced in July 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Finance Costs </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Net finance costs for the three-month period ended November&#160;30, 2023, were $5,352,000 compared to $2,078,000 in the same period last year. The increase in net finance costs is due to the higher balance outstanding under the Marathon Credit Agreement, which carries a higher interest than the Convertible Notes then outstanding in Fiscal 2022. Net finance costs in the fourth quarter of Fiscal 2022 included interest on the Convertible Notes, whereas this amount was nil in the fourth quarter of Fiscal 2023. The higher interest is also a function of higher interest rates in Fiscal 2023 versus Fiscal 2022. Other increases in the fourth quarter of Fiscal 2023 are related to the costs associated with the amendment to the Loan Facility ($890,000), the <span style="white-space:nowrap">write-off</span> of deferred financing costs ($954,000), and the change in fair value of the Marathon Warrants ($825,000). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Adjusted EBITDA </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Adjusted EBITDA, a <span style="white-space:nowrap">non-GAAP</span> measure, was $4,965,000 for the fourth quarter of Fiscal 2023, compared to $(2,439,000) for the same period of Fiscal 2022. See <span style="white-space:nowrap">&#8220;Non-IFRS</span> and <span style="white-space:nowrap"><span style="white-space:nowrap">Non-US-GAAP</span></span> Measure&#8221; above and see &#8220;Reconciliation of Adjusted EBITDA&#8221; below for a reconciliation to Net Loss for the relevant periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Loss </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Taking into account the revenue and expense variations described above, we recorded a net loss of $2,755,000, or $0.08 per share, in the fourth quarter of Fiscal 2023 compared to a net loss of $7,929,000, or $0.09 per share, in the fourth quarter of Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Fiscal Year 2022 Financial Results compared to Fiscal Year 2021 Financial Results</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Revenue for Fiscal 2022 was $80,057,000 compared to $69,823,000 in Fiscal 2021, representing an increase of 14.7%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For Fiscal 2022, net sales of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> reached $50,454,000 compared to $43,009,000 for Fiscal 2021 representing growth of 17.3%. Strong net sales of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> were mostly the result of a higher number of units sold compared to the previous year, as well as higher net selling price. In addition, COVID-19 had a lesser impact on new prescriptions in Fiscal 2022 compared to Fiscal 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2022, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales were $29,603,000 compared to $26,814,000 in Fiscal 2021, an increase of 10.4%. Higher sales were a result of higher unit sales and a higher net selling price in the United States but were offset by slightly lower revenue in Europe. During Fiscal 2021, Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> net sales in Europe were impacted by a provision taken in the fourth quarter related to greater than anticipated clawbacks on units sold in France prior to finalization of reimbursement terms, pursuant to temporary use authorizations (&#8220;ATU&#8221; and &#8220;AAP&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Cost of Sales </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For Fiscal 2022, cost of sales was $26,279,000 compared to $23,260,000 in Fiscal 2021. Cost of sales included cost of goods sold that amounted to $23,838,000 in Fiscal 2022 compared to $18,378,000 in Fiscal 2021. The increase in cost of goods sold was mainly due to (1) higher product sales, (2), to a charge arising from the non-production of scheduled batches of EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> that were cancelled due to the planned transition to the F8 Formulation in the amount of $1,788,000, and (3) a provision of $1,477,000 related to the write down of F8 Formulation for pre-commercial material which could expire prior to the launch of the F8 Formulation. Cost of goods sold for Fiscal 2022 also included other write downs totalling $660,000 (See Note 9 of the Audited Financial Statements). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2021, cost of sales included an amortization charge of $4,882,000 in connection with the settlement of the future royalty obligation which has been accounted as &#8220;Other asset&#8221; on the consolidated statement of the financial position. The Other asset was fully amortized during the first half of Fiscal 2022, and thus this charge was lower in Fiscal 2022, in the amount of $2,441,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">R&amp;D Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">R&amp;D expenses were $36,939,000 for Fiscal 2022 compared to $28,274,000 for Fiscal 2021. The increase in R&amp;D expenses was largely due to the development of our oncology platform, including the Phase 1 clinical trial, the IM method of administration clinical trial, spending on the development of the multi-dose pen injector for the F8 Formulation, and spending on the HFS for EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Fiscal 2022 spending also included costs associated to the VAMOS and Promise studies in the United States, as well as increased salaries related to the higher level of activity. These costs were offset by lower spending on the preparation of the NASH clinical trial and a decreased level of activity in Europe. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Selling Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Selling expenses for Fiscal 2022 were $39,391,000 compared to $28,909,000 in Fiscal 2021. The increase is mainly due to the addition of personnel and an increase in promotional activities related to our commercial products in the United States and was offset by lower levels of activity in Europe. The increase is also related to the accelerated amortization of the Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> commercialization rights for the European territory in the amount of $6,356,000 following our decision to cease commercialization activities in that territory in the second quarter of Fiscal 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">General and administrative expenses for Fiscal 2022 were $17,356,000 compared to $14,616,000 in Fiscal 2021. The increase in general and administrative expenses was mainly associated with an overall increase in business activities following the on-boarding of our field force in the United States, as well as higher share-based compensation expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Finance Costs </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Net finance costs for Fiscal 2022 were $6,886,000 compared to $6,426,000 in Fiscal 2021. The increase in net finance costs in Fiscal 2022 versus Fiscal 2021 was mostly due to higher interest expense on the Company&#8217;s Loan Facility in the third quarter of Fiscal 2022 and Convertible Notes and were offset by higher interest income and a gain on the repurchase of Convertible Notes in July 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Adjusted EBITDA </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Adjusted EBITDA was $(22,088,000) for Fiscal 2022 compared to $(14,586,000) for Fiscal 2021. Adjusted EBITDA in Fiscal 2022 was affected by higher overall spending, as detailed above. The increase in expenses was offset by higher net sales and gross margins. See &#8220;Non-IFRS and Non-US-GAAP Measure&#8221; above and see &#8220;Reconciliation of Adjusted EBITDA&#8221; below for a reconciliation to Net Loss for the relevant periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Net Loss </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Taking into account the revenue and expense variations described above, we recorded a net loss of $47,237,000, or $1.98 per share, in Fiscal 2022 compared to $31,725,000, or $1.37 per share, in Fiscal 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Quarterly Financial Information</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table is a summary of our unaudited consolidated operating results for the last 8 quarters of Fiscal 2023 and Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands of dollars, except per share amounts) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">2022</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Q4</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q3</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q2</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q1</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q4</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q3</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q2</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-weight:bold">Q1</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><span style="font-weight:bold">Revenue</span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">23,452</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>20,855</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Cost of goods sold</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">5,066</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>4,967</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Amortization of other asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">-</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>-</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">5,229</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>5,396</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Selling </p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">6,748</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>6,728</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">3,739</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>3,710</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,716</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">20,857</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>20,801</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Net finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">(5,005</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">)</span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(674</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,078</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,879</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Income taxes </p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">(73</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">)</span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(126</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(96</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(122</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman;font-weight:bold">Net&#160;loss </p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">(2,755</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">)</span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(746</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,443</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,549</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><span style="font-weight:bold">Basic and diluted loss per share</span><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(1)</sup></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">(0.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">)</span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.96</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Amounts from Q1-2022 to Q2-2023 have been restated to reflect the 1 for 4 share consolidation completed on July 31, 2023 </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Factors Affecting the Variability of Financial Results</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">There are quarter-over-quarter variations in net sales revenue, principally due to changes in distributor inventory levels with some additional impact from time to time related to average net selling price, which is affected by changes in the mix of private payors versus government drug reimbursement plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Higher expenses in Fiscal 2022 were associated with the development of our product pipeline and our decision to stop commercialization activities for Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the European Territory. Lower R&amp;D expenses in the second half of Fiscal 2023 are the result of lower overall activities due to the completion of lifecycle management programs for EGRIFTA SV<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and the absence of charges and provisions taken in the first and second quarters of Fiscal 2023 related to production and inventory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The variability of Net finance costs is mostly due to the costs associated with the amendments to the Loan Facility, the write-off of deferred financing costs, and the change in fair value of the Marathon Warrants, which are reevaluated on a quarterly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Selected Annual Information</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands of dollars, except per share amounts) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:85%;border:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Years ended November 30</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2022</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2021</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">81,764</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>80,057</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,823</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,635</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>26,279</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,260</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">30,370</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>36,939</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,274</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling expenses</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">26,769</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>39,391</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,909</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,617</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>17,356</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,616</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(23,957</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)</span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(47,237</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31,725</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share: Basic and diluted</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(0.91</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)</span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>(1.98</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.37</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, bonds and money market funds</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">40,387</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>33,070</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,354</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">77,769</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>93,260</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,212</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan Facility (including current portion)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57,974</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>37,894</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities (including current portion)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">994</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1,922</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,518</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible unsecured senior notes</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">-</span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>26,895</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">54,227</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_23"><span style="font-weight:bold">B.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Liquidity and capital resources.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Going Concern Uncertainty</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As part of the preparation of the Audited Financial Statements, management is responsible for identifying any event or situation that may cast doubt on the Company&#8217;s ability to continue as a going concern. Substantial doubt regarding the Company&#8217;s ability to continue as a going concern exists if events or conditions, considered collectively, indicate that the Company may be unable to honor its obligations as they fall due during a period of at least, but not limited to, 12 months from November&#160;30, 2023. If the Company concludes that events or conditions cast substantial doubt on its ability to continue as a going concern, it must assess whether the plans developed to mitigate these events or conditions will remove any possible substantial doubt. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the year ended November&#160;30, 2023, the Company incurred a net loss of $23,957,000 (2022-$47,237,000; 2021-$31,725,000) and had negative cash flows from operating activities of $5,678,000 (2022- $14,692,000; 2021- $17,501,000). As at November&#160;30, 2023, cash amounted to $34,097,000 and bonds and money market funds amounted to $6,290,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Marathon Credit Agreement contains various covenants, including minimum liquidity covenants whereby the Company needs to maintain significant cash, cash equivalent and eligible short-term investments balances in specified accounts, which restricts the management of the Company&#8217;s liquidity (refer to Notes 17 of the Audited Financial Statements). A liquidity breach provides the lender with the ability to demand immediate repayment of the Loan Facility and makes available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements. It may trigger an increase of 300 basis points of the interest rate on the outstanding loan balance. On July&#160;3, 2023, the Company incurred a liquidity breach resulting in the lender having the ability to demand immediate repayment of the debt, which breach was waived on September&#160;21, 2023. During Fiscal 2023, the Company entered into several amendments to the Marathon Credit Agreement to amend certain of the terms and conditions therein (see note 17 of the Audited Financial Statements). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amendments to the Marathon Credit Agreement covenants resulted in: (i)&#160;revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between $15,000,000 and $20,000,000, based on the Marathon Adjusted EBITDA thresholds over the most recently ended four fiscal quarters; (ii)&#160;revising the minimum revenue requirements to be based on Marathon Adjusted EBITDA targets instead of quarterly revenue-based targets, beginning with the quarter ending November&#160;30, 2023; and (iii)&#160;deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies the Company&#8217;s annual report. Notwithstanding the latest amendments, there is no assurance that the lender will agree to amend or to waive any future potential covenant breaches, if any. The Company does not meet the conditions precedent to drawdown additional amounts under the Marathon Credit Agreement and does not currently have other committed sources of financing available to it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s ability to continue as a going concern for a period of at least, but not limited to, 12 months from November&#160;30, 2023, involves significant judgement and is dependent on the adherence to the conditions of Marathon Credit Agreement or to obtain the support of the lender (including possible waivers and amendments), increase its revenues and the management of its expenses (including the reorganization mainly focused on its R&amp;D <span style="white-space:nowrap">activities-see</span> Note 16(a) of the Audited Financial Statements) in order to generate sufficient positive operating cash flows. Some elements of management&#8217;s plans are outside of management&#8217;s control and the outcome cannot be predicted at this time. Should management&#8217;s plans not materialize, the Company may be in default under the Marathon Credit Agreement, be forced to reduce or delay expenditures and capital additions and seek additional alternative financing, or sell or liquidate its assets. As a result, there is material uncertainty related to events or conditions that cast substantial doubt about the Company&#8217;s ability to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Audited Financial Statements have been prepared assuming the Company will continue as a going concern, which assumes the Company will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Audited Financial Statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that might result from the outcome of this uncertainty and that may be necessary if the going concern basis was not appropriate for the Audited Financial Statements. If the Company was unable to continue as a going concern, material impairment of the carrying values of the Company&#8217;s assets, including intangible assets, could be required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Analysis of cash flows</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As at November&#160;30,&#160;2023, cash, bonds and money market funds amounted to $40,387,000 compared to $33,070,000 at November&#160;30,&#160;2022. Available cash is invested in highly liquid fixed income instruments including governmental, municipal and paragovernmental organizations, high-grade corporate bonds and money market funds. The Company currently is required to maintain $20,000,000 in cash, bonds and money market funds to respect its minimum liquidity covenant (&#8220;Liquidity Covenant&#8221;). The Liquidity Covenant can decrease to $17,500,000 and again to $15,000,000 should the Company achieve the predetermined Marathon Adjusted EBITDA thresholds (as set forth in the Marathon Credit Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company voluntarily changed its accounting policy in Fiscal 2022 to classify interest paid and received as part of operating activities, which were previously classified as cash flow from financing activities and interest received as cash flows from investing activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During Fiscal 2023, cash flows used in operating activities were $5,678,000, compared to $14,692,000 in Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2023, changes in operating assets and liabilities had a positive impact on cash flow from operations of $8,133,000 (2022-positive impact of $13,017,000). These changes included positive impacts from a decrease in inventories ($10,327,000), lower prepaid expenses and deposits ($4,511,000) and higher provisions ($1,920,000). Decreased accounts payable ($7,508,000) had a negative impact on cash flow, as did higher trade and other receivables ($902,000). The decrease in inventories was mainly due to a planned reduction of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> inventory levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During the fourth quarter of Fiscal 2023, cash flows used in operating activities were $5,606,000. Changes in operating assets and liabilities had a negative impact on cash flow from operations of $6,910,000. These changes included negative impacts from an increase in trade and other receivables ($4,339,000) and prepaid expenses and deposits ($1,366,000) as well as a decrease in accounts payable and accrued liabilities ($2,108,000). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During Fiscal 2023, the Company received net proceeds of $19,300,000 from the draw-down of the second tranche under the Marathon Credit Agreement. On June&#160;30, 2023, we redeemed the remaining $27,452,000 of Convertible Notes. As at November&#160;30, 2023, no Convertible Notes remained outstanding. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During the fourth quarter of Fiscal 2023, the Company realized net proceeds of $23,575,000 from the issuance of Common Shares, and Exchangeable Subscription Receipts from the 2023 Public Offering and Concurrent Private Placement. This amount includes the proceeds from the exercise of the over-allotment option, resulting in the issuance of 160,000 Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company does not meet the conditions precedent to draw-down the third ($15,000,000) and fourth ($25,000,000) tranches of the Loan Facility. These will cease to be available to the Company after March&#160;31, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As stated above, the amendments to the Marathon Credit Agreement covenants resulted in: (i)&#160;revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between $15,000,000 and $20,000,000, based on Marathon Adjusted EBITDA thresholds over the most recently ended four fiscal quarters (or shorter period set forth in the Marathon Credit Agreement); and (ii) revising the minimum revenue requirements to be based on Marathon Adjusted EBITDA targets instead of quarterly revenue-based targets, beginning with the quarter ending November&#160;30, 2023. While the Company&#8217;s current cash, bonds and money market funds amounted to $40,387,000, we continue to monitor these balances in order to continuously meet the minimum liquidity requirements as set out in the Marathon Credit Agreement. We currently also meet the Marathon Adjusted EBITDA, and our current operating plan projects that we will continue to meet these targets for the foreseeable future. We plan to ensure continued compliance through close management of expenses and will adapt spending in the event of weakness in our revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Commitments</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Off Balance Sheet Arrangements </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company has no <span style="white-space:nowrap">off-balance</span> sheet arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Contractual obligations</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table lists as of November&#160;30, 2023, information with respect to the Company&#8217;s contractual obligations. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:93%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;Contractual Obligations</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">Total</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Less&#160;than</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 Year</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1&#160;to&#160;3</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Years</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3&#160;to&#160;5</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Years</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">More</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">than&#160;5</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">years</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">1,108,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">487,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">516,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">105,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="4"/>
<td style="height:7.5pt" colspan="4"/>
<td style="height:7.5pt" colspan="4"/>
<td style="height:7.5pt" colspan="4"/>
<td style="height:7.5pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, including interest <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">80,141,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">17,416,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">50,348,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="white-space:nowrap;vertical-align:middle" align="right">12,377,000</td>
<td style="white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:middle"/>
<td style="vertical-align:middle"/>
<td style="vertical-align:middle"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/>
<td style="height:12pt" colspan="4"/>
<td style="height:12pt" colspan="4"/>
<td style="height:12pt" colspan="4"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase Obligations <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="right">&#8195;&#8194;15,489,000</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="right">10,989,000</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="right">2,250,000</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="right">2,250,000</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="right">&#8212;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">96,738,000</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;28,892,000</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;53,114,000</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,732,000</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;&#8195;&#8194;&#8212;</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Based on SOFR forward rates. The maturities above reflect the fact that the Loan Facility has been amended in the subsequent event period and as such, the contractual maturities are used. </p></td>
<td style="width:1%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The Corporation has long-term procurement agreements with third party suppliers in connection with the commercialization of <span style="font-style:italic">EGRIFTA SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>. As at November&#160;30, 2023, the Corporation had outstanding purchase orders and minimum payments under these agreements amounting to $14,682,000 for the manufacture of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup>, <span style="font-style:italic">EGRIFTA</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;SV</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and for various services. The Corporation also had research commitments and outstanding clinical material purchase orders amounting to $807,000 in connection with its oncology platform. </p></td>
<td style="width:1%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">License agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On February&#160;3, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (&#8220;MGH&#8221;), as amended on April&#160;15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of NASH in the general population. Under the terms of the amended agreement, the MGH, through Dr.&#160;Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including <span style="white-space:nowrap">Non-Alcoholic</span> Fatty Liver Disease or NASH in the general population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Financial Risk Management</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This section provides disclosures relating to the nature and extent of the Company&#8217;s exposure to risks arising from financial instruments, including credit risk, liquidity risk, currency risk and interest rate risk, and how the Company manages those risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Credit Risk </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Credit risk refers to the risk of a loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s exposure to credit risk currently relates to accounts receivable with one major customer (refer to Note&#160;27 to the Audited Financial Statements), other receivable and derivative financial assets which it manages by dealing only with highly rated Canadian financial institutions. Included in the consolidated statements of financial position are trade receivables of $12,798,000 (2022&#160;&#8211; $10,659,000), all of which were aged under 60 days or received after year end. There was no amount recorded as bad debt expense for Fiscal 2023 and Fiscal 2022. Financial instruments other than cash and trade and other receivables that potentially subject the Company to significant credit risk consists principally of bonds and money market funds. The Company invests its available cash in highly liquid fixed income instruments from governmental, paragovernmental, municipal and <span style="white-space:nowrap">high-grade</span> corporate bodies and money market funds (2023&#160;&#8211; $6,290,000; 2022&#160;&#8211; $9,214,000). As at November&#160;30, 2023, the Company believes it was not exposed to any significant credit risk. The Company&#8217;s maximum credit exposure corresponded to the carrying amount of these financial assets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Liquidity Risk </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Liquidity risk refers to the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in Note 24 to the Audited Financial Statements, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company&#8217;s operating and capital budgets, as well as any material transactions out of the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company has adopted an investment policy in respect of the safety and preservation of its capital designed to ensure that the Company&#8217;s liquidity needs are met. The instruments are selected with regards to the expected timing of expenditures and prevailing interest rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Pursuant to the Marathon Credit Agreement, the Company is required to maintain cash, cash equivalents and eligible short-term investments overtime between $15,000,000 to $20,000,000 based on the last twelve months adjusted EBITDA-based targets, which restricts the management of the Company&#8217;s liquidity. Refer to notes 1 and 17 of the Audited Financial Statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Currency Risk </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company is exposed to financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company&#8217;s business transactions denominated in currencies other than US$, primarily cash, sale of goods and expenses incurred in CA$ and euros. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Exchange rate fluctuations for foreign currency transactions can cause cash flows, as well as amounts recorded in the consolidated statements of net loss, to vary from period to period and not necessarily correspond to those forecasted in operating budgets and projections. Additional earnings variability arises from the translation of monetary assets and liabilities denominated in currencies other than the US$ at the rates of exchange at each consolidated statement of financial position date, the impact of which is reported as foreign exchange gain or loss in the consolidated statements of net loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table presents the significant items in the original currencies exposed to currency risk as at November&#160;30, 2023 and 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:2.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:2.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:2.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:2.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:2.00pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2022</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:top;white-space:nowrap" align="right"><span style="font-weight:bold">CA$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">EURO</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:top;white-space:nowrap" align="right"><span style="font-weight:bold">CA$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">EURO</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:14.25pt"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/>
<td style="height:14.25pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">358</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,547</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonds and money market funds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8195;&#8195;&#8195;&#8195;8,543</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8195;&#8195;&#8195;&#8195;12,387</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">296</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">733</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;2,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits and grants receivable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">497</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">66</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payables and accrued liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(5,395</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(224</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(10,784</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(5,849</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(925</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(288</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">(1,362</td>
<td style="white-space:nowrap;vertical-align:top">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/>
<td style="height:3pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top" align="right">(326</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;(3,192</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top" align="right">-</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(3,486</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total exposure</p></td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top" align="right">3,048</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(3,434</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top" align="right">2,587</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(7,592</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following exchange rates are those applicable as at November&#160;30, 2023 and 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-TOP:2.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-TOP:2.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Average</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">rate</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Reporting<br/>date&#160;rate</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Average<br/>rate</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Reporting<br/>date rate</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CA$ &#8211; US$</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">&#8195;&#8195;&#8195;&#8195;0,7404</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">&#8195;&#8195;&#8195;&#8195;0,7363</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">&#8195;&#8195;&#8195;&#8195;0,7722</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">&#8195;&#8195;&#8195;&#8195;0,7439</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Euro &#8211; US$</p></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap">1,0792</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap">1,0903</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap">1,0600</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="right" style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom;white-space:nowrap">1,0406</td></tr>
</table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Based on the Company&#8217;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the CA$ or the euro would have an impact on net earnings for CA$ and in the accumulated other comprehensive loss for euro as follows, assuming that all other variables remained constant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:53%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="padding-bottom:6pt ;BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="padding-bottom:6pt ;BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2022</span></td>
<td style=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="BORDER-TOP:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">CA$</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="BORDER-TOP:0.75pt solid #000000;vertical-align:top;white-space:nowrap"><span style="font-weight:bold">Euro</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="BORDER-TOP:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">CA$</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="right" style="BORDER-TOP:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Euro</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:18pt"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/>
<td style="height:18pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Positive (negative) impact</p></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;152</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top" align="right">&#8195;&#8199;&#8195;&#8195;&#8195;(172)</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;129</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;(380)</td>
<td style="padding-bottom:3pt ;BORDER-BOTTOM:1.50pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">An assumed 5% weakening of the CA$ or of the euro would have had an equal but opposite effect on the above currencies in the amounts shown above, assuming that all other variables remained constant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Interest Rate Risk </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Interest rate risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Short-term</span> bonds held by the Company are invested at fixed interest rates and/or mature in the short term. <span style="white-space:nowrap">Long-term</span> bonds are also instruments that bear interest at fixed rates. The risk that the Company will realize a loss as a result of a decline in the fair value of its bonds is limited because these investments, although they are classified as fair value through OCI, are generally held until close to maturity. The unrealized gains or losses on bonds are recorded in accumulated other comprehensive income (loss). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Based on the value of the Company&#8217;s <span style="white-space:nowrap">short-</span> and <span style="white-space:nowrap">long-term</span> bonds as at November&#160;30, 2023, an assumed 0.5% decrease in market interest rates would have increased the fair value of these bonds and the accumulated other comprehensive income (loss) by approximately $42,000 (2022&#160;&#8211; $79,000); an assumed increase in market interest rates of 0.5% would have an equal but opposite effect, assuming that all other variables remained constant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Cash and money market funds bear interest at variable rates. Trade and other receivables, accounts payable and accrued liabilities and provisions bear no interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Based on the average value of variable <span style="white-space:nowrap">interest-bearing</span> cash and money market funds during the year ended November&#160;30, 2023 of $20,231,000 (2022&#160;&#8211; $23,505,000), an assumed 0.5% increase in interest rates during such year would have increased future cash flows and net profit by approximately $101,000 (2022&#160;&#8211; $118,000); an assumed decrease of 0.5% would have had an equal but opposite effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Based on the value of the Company&#8217;s long-term loan as at November&#160;30, 2023, an assumed 0.5% increase in SOFR rate during such year would have decreased future cash flows and net profit by approximately $300,000 and an assumed increase of 0.5% would have had an equal but opposite effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Determination of Fair Values</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Financial assets and financial liabilities measured at fair value </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">Level&#8201;1:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Defined as observable inputs such as quoted prices in active markets. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">Level&#8201;2:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">Level&#8201;3:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Other financial assets and financial liabilities </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company has determined that the carrying values of its <span style="white-space:nowrap">short-term</span> financial assets and financial liabilities, including cash, trade and other receivables, and accounts payable and accrued liabilities approximate their fair value because of their relatively short period to maturity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Bonds and money market funds and derivative financial assets and financial liabilities are stated at fair value, determined by inputs that are primarily based on broker quotes at the reporting date (Level&#160;2). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company has determined that the carrying value of its Loan Facility approximates its fair value because the terms were&#160;modified near the end of the 2023 fiscal <span style="white-space:nowrap">year-end.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Share-based</span> payment transactions </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The fair value of the employee stock options is measured based on the <span style="white-space:nowrap">Black-Scholes</span> valuation model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the <span style="white-space:nowrap">risk-free</span> interest rate (based on government bonds). Service and <span style="white-space:nowrap">non-market</span> performance conditions attached to the transactions, if any, are not taken into account in determining fair value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The fair value of the DSUs is determined using the quoted price of the Common Shares of the&#160;Company and considered Level&#160;2 in the fair value hierarchy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. A reasonably possible changes at the reporting date to one of the significant unobservable inputs, holding other inputs consistent, would have the following effects: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands of U.S. dollars) </span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:2.00pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="8" style="BORDER-TOP:2.00pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:2.00pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Net profit (loss)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">&#8195;&#8195;&#8195;Increase</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">&#8195;&#8195;&#8195;&#8195;Decrease</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">&#8195;&#8195;&#8195;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.60em; font-size:10pt; font-family:Times New Roman">Expected volatility (10% movement) (100bps))</p></td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8194;(100)&#8195;&#8194;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">$&#8195;125&#8195;&#8195;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:2.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:2.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Related party transactions</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Refer to Note 28 of the Audited Financial Statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Reconciliation of Adjusted EBITDA</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">(in thousands of U.S. dollars) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Three-month&#160;periods&#160;ended</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">November&#160;30</p></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Years&#160;ended<br/>November&#160;30</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000;height:6pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">2022</td>
<td style=" BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">2022</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">2021</td>
<td style=" BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;&#8194;&#8195;(2,755</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;(7,929)</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;&#8195;&#8195;(23,957)</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;(47,237)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;(31,725)</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add :</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization<sup style="font-size:75%; vertical-align:top">1</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;&#8194;&#8195;&#8199;&#8195;576</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8199;&#8194;&#8201;&#8195;&#8195;940</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8195;&#8195;&#8201;&#8199;&#8199;&#8195;3,315</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8194;&#8195;12,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;8,748</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="right" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:right">Net Finance costs<sup style="font-size:75%; vertical-align:top">2</sup>&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,352</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,078</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,909</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,426</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">73</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">143</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">421</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">63</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">418</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">852</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,215</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,872</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,932</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory provision (reversal)<sup style="font-size:75%; vertical-align:top">3</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">50</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,477</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">220</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(30</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td style="height:3.75pt" colspan="4"/>
<td style="height:3.75pt" colspan="4"/>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs<sup style="font-size:75%; vertical-align:top">4</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,244</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,963</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:1.00pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:1.00pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Adjusted EBITDA</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,958</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(2,439</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,914</span></td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(22,088</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:1.00pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">(14,586</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:1.00pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><sup style="font-size:75%; vertical-align:top">1</sup> Includes depreciation of property and equipment, amortization of intangible, other assets and <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><sup style="font-size:75%; vertical-align:top">2</sup> Includes all finance income and finance costs consisting of: Foreign exchange, interest income, accretion expense and amortization of deferred financing costs, interest expense, bank charges, gain or loss on financial instruments carried at fair value and loss on debt modification and gain on lease termination. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><sup style="font-size:75%; vertical-align:top">3</sup> Inventory provision pending marketing approval of the F8 Formulation. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><sup style="font-size:75%; vertical-align:top">4</sup> Restructuring costs include severance and other expenses associated with termination of employment related to the reorganization announced in July 2023 and completed in October 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_24"><span style="font-weight:bold">C.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Research and development, patents and licenses. </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For a description of our Research and Development activities for the last three years, see &#8220;Item 4B &#8211; Business Overview &#8211; Research and Development Activities&#8221;, as well as &#8220;Item 5A &#8211; Operating Results&#8221;. Over the past three years, our research and development activities have mainly focused on the following: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">A Phase 1 clinical trial of sudocetaxel zendusortide; </p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The development of our SORT1+ technology platform, including the development of new PDCs; </p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Life-cycle management programs for tesamorelin, including the development and regulatory filing of the F8 Formulation; </p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">Life-cycle management programs for ibalizumab, including the development of new modes of administration, namely intravenous push and intra-muscular modes of administration. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_25"><span style="font-weight:bold">D.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Trend information.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Other than as disclosed below and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on our net revenue, income from continuing operations, profitability, liquidity, or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_26"><span style="font-weight:bold">E.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Critical Accounting Estimates.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Use of estimates and judgments</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The preparation of the Company&#8217;s consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Judgments in applying accounting policies </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Information about critical judgments in applying accounting policies and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Milestones payments </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The purchase consideration for the oncology platform (Note 13 to the Audited Financial Statements) includes additional milestone payments based on the attainment of commercial milestones that will be settled through the issuance of the Company&#8217;s common shares, which represent a transaction in the scope of IFRS 2. Accordingly, the fair value of the oncology platform at the date of acquisition incorporates management&#8217;s judgement as to the probability of attaining the share-based milestones as well as the expected timing of the attainment of the milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Management uses judgement in determining whether milestone payments are performance-related development milestones which are capitalized as an intangible asset or are milestones related to the activity or usage of an asset which are expensed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Key sources of estimation uncertainty </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Sales allowances </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Management uses judgment in estimating provisions for sale allowances such as cash discounts, returns, rebates and chargebacks, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation. The product revenue recognized quarter over quarter is net of these estimated allowances. Such estimates require the need to make estimates about matters that are inherently uncertain. These estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends such as competitive pricing and new product introductions, estimated inventory levels, and the shelf life of products. If actual future results vary, these estimates need to be adjusted, with an effect on sales and earnings in the period of the adjustment. (see Notes 2 (Revenue recognition) and 3 to the Audited Financial Statements for additional information). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Recoverability of inventories </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company regularly reviews inventory to determine whether the inventory cost exceeds its net realizable value. The determination of the net realizable value requires management to make estimates and use judgement in considering shelf life of a product, the effects of technological changes and new product introductions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Other </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Other areas of judgment and uncertainty are related to the estimation of accruals for clinical trial expenses, the recoverability of intangible assets, the measurement of derivative financial assets, the measurement of share based arrangements, the Marathon Warrants and gain or loss on amendments to the Marathon Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company is subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. Management regularly evaluates estimates and assumptions using historical experience and expectations about the future. Management adjusts estimates and assumptions when facts and circumstances indicate the need for change. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Recent Changes in Accounting Standards</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">New Accounting Standard Adopted </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Onerous contracts &#8211; Cost of Fulfilling a Contract (Amendments to IAS 37) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#8217;s annual reporting periods beginning on December 1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Standards issued but not yet effective </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A number of new standards are effective for annual periods beginning after December 1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing the Audited Financial Statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Classification of Liabilities as Current or Non-current (Amendments to IAS 1) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the purposes of non-current classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or non-current. Covenants with which a company must comply after the reporting date do not affect a liability&#8217;s classification at that date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#8217;s own equity instruments to the counterparty; and when classifying liabilities as current or non-current a company can ignore only those conversion options that are recognized as equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amendments will be effective for the Company&#8217;s annual reporting period beginning on December 1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_27">Item&#8201;6. Directors, Senior Management and Employees </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_28"><span style="font-weight:bold">A.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Directors and senior management.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Our Directors </span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below sets forth the following information about our directors as at November&#160;30, 2023: his/her name, age, province/state of residence, principal occupation, the year each director first became a director of the Corporation, his/her status as an independent director, his/her biography, his/her areas of expertise, his/her memberships on the committees of the Board of Directors, whether he/she acts as director for other public companies, and the number of Common Shares, DSUs and options beneficially held or controlled. </p> <p style="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w01.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Joseph P. Arena</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 69</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Norristown, Pennsylvania,<br/>USA</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;13, 2021</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Regulatory Affairs</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Drug Development</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Medical Education</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Management</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company<br/>Directorship:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">None</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Joseph Arena was elected to the Board of Directors of Theratechnologies in May 2021.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Joseph Arena was Vice President, Oncology Products, Global Regulatory Affairs at Pfizer, Inc. (&#8220;Pfizer&#8221;) between 2018 and 2021. In such a role, he managed a team that provided strategic global leadership to Medicine Teams for Pfizer&#8217;s portfolio in oncology. The group was responsible for regulatory strategy and registration of products globally. His tasks included providing guidance on the worldwide regulatory requirements for registration of new chemical entities and new claims, identification of pharmaceutical, toxicological and clinical developmental issues and problem resolution, overseeing the preparation of high quality, effective regulatory submissions, providing oversight and input for all communications agencies and leading scientific teams in direct negotiations with agencies on all issues of product development, product registration and labeling (including post-marketing surveillance).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Prior to acting as Vice President, Oncology Products, Global Regulatory Affairs, he acted as Vice President, Cardiovascular and Metabolic Products, between 2016 and 2018 when he joined the Pfizer Worldwide Safety and Regulatory organization. In such a role, he managed a team that provided strategic global leadership to Medicine Teams for Pfizer&#8217;s portfolio in Cardiovascular and Metabolic Diseases. The group was responsible for regulatory strategy and registration of products globally.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Prior to joining Pfizer, he was at Merck and Co. Inc. (&#8220;Merck&#8221;) where he held the role of Vice President, Therapeutic Area Lead Oncology, Immunology and in vitro Diagnostics from 2015 to 2016. His team provided global leadership to development teams for oncology and immunology products and in vitro diagnostics across the portfolio. The group was responsible for regulatory strategy and registration of Merck&#8217;s products globally with a focus on the United States, European Union, China and Japan.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Arena began his career as a research scientist in 1989 at Merck Research Laboratories in Rahway, New Jersey. In 1996, he moved to a position in Regulatory Affairs International focusing primarily on Merck&#8217;s cardiovascular products. He eventually assumed management and leadership roles with Regulatory Affairs International, including management of therapeutic areas in Diabetes, Neuroscience, Atherosclerosis and Cardiovascular.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Arena received his B.S. in Pharmacy from St. John&#8217;s University in Queens, New York. After four (4)&#160;years in community and hospital settings, he attended the University of Medicine and Dentistry of New Jersey and received a Ph.D. in Pharmacology, followed by a post-doctoral fellowship in the Physiology Department at the University of Rochester in New York.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">13,750</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">8,977</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of the Compensation Committee</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w02.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Frank A. Holler</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 67</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summerland, B.C.,<br/>Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">June&#160;23, 2021</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Corporate Finance</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">- &#8201;Life Sciences</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Management</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company<br/>Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sernova Corp.; and<br/>Harvest One Cannabis Inc.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">President and CEO, Ponderosa Capital Inc.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Frank A. Holler was appointed to the Board of Directors in June 2021.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He is currently the President&#160;&amp; CEO of Ponderosa Capital Inc. He previously served as Chairman&#160;&amp; CEO of BC Advantage Funds (VCC) Ltd., a venture capital firm investing in emerging technology companies in British Columbia.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He also served as President and CEO of Xenon Pharmaceuticals Inc. from 1999 to 2003 after having been President and CEO of ID Biomedical Corporation from 1991 to 1998. In addition, he was a founding director of Angiotech Pharmaceuticals.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Prior to working in biotechnology and healthcare, Mr.&#160;Holler was a Vice-President of Investment Banking with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Holler is a member of the board of directors of two additional public companies: Sernova Corp. in Ontario, Canada, and Harvest One Cannabis Inc. in British Columbia, Canada.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Holler holds an MBA and BA (Economics) from the University of British Columbia.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">59,750</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">1,325</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">8,977</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Member of Audit Committee</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chair of Financing Committee<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:30pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">The Financing Committee was created on August&#160;15, 2023, and dissolved on December&#160;15, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w03.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">G&#233;rald A. Lacoste</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 80</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Ste-Ad&#232;le,</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qu&#233;bec, Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&#160;8,&#160;2006</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">- &#8201;Securities and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Market Regulations</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Corporate Governance</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">- &#8201;Mergers &amp;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Acquisitions</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company<br/>Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director&#8195;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">G&#233;rald A. Lacoste is a retired lawyer with extensive experience in the fields of securities regulation, financing and corporate governance. He was previously Chairman of the Qu&#233;bec Securities Commission (now known as the Autorit&#233; des march&#233;s financiers) and was also President and Chief Executive Officer of the Montreal Exchange. During his career, Mr.&#160;Lacoste acted as legal counsel to the Canadian Standing Senate Committee on Banking, Trade and Commerce, he chaired the Qu&#233;bec Advisory Committee on Financial Institutions, and was a member of the task force on the capitalization of life insurance companies in Qu&#233;bec. Mr.&#160;Lacoste has been a member of the North American Free Trade Agreement arbitration panel and is currently a corporate director.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">27,499</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">5,484</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">26,478</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chair of Nominating and Corporate Governance Committee<br/>Member of Audit Committee</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of Financing Committee<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:7pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">The Financing Committee was created on August&#160;15, 2023, and dissolved on December&#160;15, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w04.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Paul L&#233;vesque</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 60</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westmount, Qu&#233;bec,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-independent</span></p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&#160;6, 2020</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&#8194;&#8202;Pharmaceutical Industry</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- &#8201;Sales and Marketing</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Management</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Human Resources</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">President and Chief Executive Officer of the Corporation&#8195;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Paul L&#233;vesque has built an enviable reputation in the pharmaceutical industry both here and abroad. He is recognized for his track record at delivering growth.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Paul has worked in the research-based pharmaceutical industry since 1985. He started with Upjohn Canada and then joined Pfizer Canada in 1992. He went on to occupy increasingly senior positions within the organization including as Vice President of Marketing in Canada and in France, Country Manager for Canada, Chief Marketing Officer for the U.S. in Primary Care and as Regional President in Asia-Pacific for the innovative division of Pfizer.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He also assumed the role of Global President and General Manager for the Rare Disease Unit until he joined Theratechnologies on April&#160;6, 2020.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Paul carries a passion for bringing to patients therapies in areas of unmet medical needs and will put to contribution his learnings from his 35 years in the pharmaceutical industry.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Paul holds a BSc in biochemistry from Laval University and a Diploma in Management from McGill University.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">72,800</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">533,682</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">N.A.</p> <p style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:10pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w05.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dale Weil</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 68</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baie d&#8217;Urf&#233;,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qu&#233;bec, Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;16, 2017</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Healthcare Industry</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&#8194;&#8202;Commercialization of products</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-&#8201; Management</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- &#8201;Strategic Planning</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company Directorship:</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Ms.&#160;Dale MacCandlish Weil has more than 35 years of experience in the commercialization, marketing, sale of consumer products and B2B services. From May 2018 to January 2020, Ms.&#160;Weil has been Managing Director of the Montreal Institute for Palliative Care (a branch of the Teresa Dellar Palliative Care Residence) and, in January 2020, she became Executive Director of the Teresa Dellar Palliative Care Residence and of the Montreal Institute for Palliative Care. She spent the prior 18&#160;years of her career in management positions related to health care services such as distribution, pharmaceutical and retail pharmacy services. She worked with McKesson Canada Corporation, or McKesson, since August 1999 where she occupied the position of Vice President and Senior Vice President for various divisions of McKesson. She acted in an advisory role to the President from May&#160;2015 to February&#160;2018. Prior to May&#160;2015, she acted as Senior Vice President Retail Management Services with McKesson from July&#160;2014 to May&#160;2015 and, from November&#160;2011 to June&#160;2014, she acted as Senior Vice President, Integrated Health Care Solutions, Strategy and Business Development with McKesson. Ms.&#160;Weil is a member of the board of directors of Tetra <span style="white-space:nowrap">Bio-Pharma</span> Inc. in Ontario. Ms.&#160;Weil holds a Master&#8217;s in business administration from McGill University and has obtained her certification as a certified director after successfully completing the ICD Directors Education Program.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">44,160</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">1,383</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">22,728</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chair of Compensation Committee</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of Nominating and Corporate Governance Committee</p> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:20pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w06.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Andrew Molson</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 56</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westmount, Qu&#233;bec,<br/>Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">October&#160;15, 2020</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">- &#8201;Communications</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Governance</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company<br/>Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Molson Coors Beverage<br/>Company;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dundee Corporation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director&#8195;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Andrew Molson serves as chairman of AVENIR GLOBAL, an organization uniting seven strategic communications firms across Canada, the U.S., Europe and the Middle East. He is also chairman of Molson Coors Beverage Company and a member of the board of directors of Groupe Desch&#234;nes Inc., Dundee Corporation and the CH Group Limited Partnership, owner of Evenko and the Montreal Canadiens.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He previously served as a director of The Group Jean Coutu PJC Inc. from 2014 to 2018, as Chair of Molson Coors from May 2011 to May 2013 and as its Vice Chair from May 2009 to May 2011. Mr.&#160;Molson serves on several <span style="white-space:nowrap">non-profit</span> boards, including the Institute for Governance of Private and Public Organizations, Concordia University Foundation, the Qu&#233;bec Blue Cross, the Evenko foundation for emerging talent, the Montreal General Hospital Foundation and the Molson Foundation, a family foundation dedicated to the betterment of Canadian society.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Molson holds a Bachelor of Laws from Laval University (Quebec City). He also holds a Bachelor of Arts from Princeton University and a Master of Science in corporate governance and ethics from University of London (Birkbeck College).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">137,500</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">2,531</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">12,292</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Member of Compensation Committee</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of Nominating and Corporate Governance Committee</p> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:10pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w07.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dawn Svoronos</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 70</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hudson,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qu&#233;bec, Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&#160;8, 2013</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&#8194;&#8202;Pharmaceutical Industry</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&#8194;&#8202;Commercialization of Drug Products</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Xenon Pharmaceuticals Inc.; </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverum Biotechnologies, Inc; and Acelyrin, Inc.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director &#8211; Chair of the Board of the Corporation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Ms.&#160;Dawn Svoronos worked in the commercial side of the business for the multinational pharmaceutical company Merck&#160;&amp; Co. Inc., for 23&#160;years, retiring in 2011. From 2009 to 2011, Ms.&#160;Svoronos was President of the Europe/Canada region for Merck and from 2006 to 2009 was President of Merck in Canada. Previously held positions with Merck include Vice-President of Asia Pacific and Vice-President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms.&#160;Svoronos is a member of the board of directors of three other public companies: Xenon Pharmaceuticals Inc. in British Columbia, Canada; Adverum Biotechnologies, Inc. in Redwood City, California; and Acelyrin, Inc. in Agoura Hills, California.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">110,900</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">214</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">26,478</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of Nominating and Corporate Governance Committee</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Member of Financing Committee<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:60pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">The Financing Committee was created on August&#160;15, 2023, and dissolved on December&#160;15, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom"/>
<td style="width:23%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w08.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Alain Trudeau</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 64</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montr&#233;al, Qu&#233;bec,<br/>Canada</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Independent</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director since:</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">October&#160;15, 2020</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Areas of Expertise:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Accounting</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">- &#8201;Finance</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">- &#8201;Governance</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Public Company<br/>Directorship:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8195;&#8194;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Corporate Director&#8195;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">A fellow of the Quebec Chartered Professional Accountant Order, Alain Trudeau has had a distinguished career at Ernst&#160;&amp; Young from 1982 to 2019 where he held the position of Managing Partner, Assurance Services, for EY offices in the Province of Quebec from 2008 to 2019. He was also responsible for the audit of many publicly-traded companies.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He currently serves on the board of directors of <span style="white-space:nowrap">Loto-Qu&#233;bec,</span> the&#160;Institut de m&#233;diation et d&#8217;arbitrage du Qu&#233;bec&#160;(IMAQ) and Blue Bridge Trust Company Inc.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">From 2008 to 2019, Mr.&#160;Trudeau was a lecturer at the Coll&#232;ge des administrateurs de soci&#233;t&#233;s de l&#8217;Universit&#233; Laval in Quebec City.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Trudeau holds a Bachelor of Arts in Accounting from HEC Montr&#233;al.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">4,825</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">8,434&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">12,292</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold">Committees of the Board of Directors</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chair of Audit Committee<br/>Member of Financing Committee<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="font-size:60pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:left">The Financing Committee was created on August&#160;15, 2023, and dissolved on December&#160;15, 2023. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None of our directors have a family relationship with each other and with each of our executive officers. To our knowledge, none of our directors have arrangements with our major shareholders, customers and suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Our Senior Management </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below sets forth the following information about our senior management (&#8220;Executive Officers&#8221;) as at November&#160;30, 2023: his/her name, age, province/state of residence, his/her principal occupation, the year each Executive Officer joined the Corporation, his/her biography, and the number of Common Shares, DSUs and options beneficially held or controlled. The information about Mr.&#160;Paul L&#233;vesque, the President and Chief Executive Officer of the Corporation, is found in the table above regarding information about our directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w09.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Marie-No&#235;l</span><br/>Colussi</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 55</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;9, 2002</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laval, Qu&#233;bec,</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Canada</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8194;&#8195;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Vice President, Finance</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Ms.&#160;Marie-No&#235;l</span> Colussi is a graduate of the <span style="font-style:italic">Universit&#233; du Qu&#233;bec &#224; Montr&#233;al</span> in business administration and is a member of the Quebec Chartered Professional Accountant Order. Prior to joining us, Ms.&#160;Colussi worked for eight years with KPMG, an international accounting firm. Ms.&#160;Colussi has experience in accounting, auditing, control and taxation, particularly in research and development. She joined us in 1997, and prior to her appointment as Vice President, Finance, she held the position of Director, Accounting and Internal Control and Controller.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8194;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8194;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">2,769</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">796&#8195;&#8194;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">104,523</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g50w10.jpg" alt="LOGO"/>
</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Philippe Dubuc</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 57</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&#160;24, 2016</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montreal, Qu&#233;bec,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="right" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;background-color:#d6d7d6">&#8195;&#8194;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Senior Vice President and Chief Financial Officer</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Dubuc brings more than 25&#160;years of experience in investment banking in the healthcare sector and in management. He started his career as a management consultant at Groupe Secor, a well-known Quebec-based consulting firm which is now part of KPMG. He then served as Managing Director, Investment Banking at National Bank Financial. In this role, he headed the healthcare group and was involved in numerous financing and M&amp;A transactions. He later founded a manufacturing company which he sold after seven years of successful operations. Mr.&#160;Dubuc holds a M.B.A. from McGill University and a B.Comm. from Concordia University.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8194;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8194;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">15,750</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil&#8195;&#8194;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">214,604</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:25%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w11.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Andr&#233; Dupras</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 60</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;31, 2021</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mont-Tremblant,<br/>Qu&#233;bec, Canada</p> <p style="font-size:10pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8195;&#8194;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Vice President, Human Resources</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Andr&#233; Dupras joined Theratechnologies as Vice President, Human Resources in May 2021.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Dupras brings more than 25 years of experience in Human Resources. Most recently, Mr.&#160;Dupras was Vice President, Human Resources at Clementia Pharmaceuticals. Previously, he spent close to 15 years at Pfizer Canada in various leadership roles in Human Resources and Commercialization. He also worked at Bombardier Aerospace as Director of Human Resources and Director of Global Compensation, at Aon Hewitt as a consultant in Compensation and Organizational Effectiveness and at <span style="white-space:nowrap">R&#233;no-D&#233;p&#244;t</span> as Director of Human Resources.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Dupras holds a Master&#8217;s Degree in Management Science (Human Resources) and a Bachelor&#8217;s Degree in Administration (Marketing and Human Resources). He is a member of the Order of Certified Human Resources Professionals (CHRP, CHRA).</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">85,351</p></td></tr>
</table> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:25%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w12.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jocelyn Lafond</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 56</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&#160;16, 2007</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montreal, Qu&#233;bec,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada</p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8195;&#8194;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">General Counsel and Corporate Secretary</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Lafond has over 20&#160;years of experience in the fields of corporate and securities law. Mr.&#160;Lafond holds a law degree from the <span style="font-style:italic">Universit&#233; Laval</span> and a Masters Degree in Law from the University of Toronto. He has been a member of the <span style="font-style:italic">Barreau du Qu&#233;bec</span> since 1992. Prior to joining us in 2007, Mr.&#160;Lafond was a partner with the international law firm of Fasken Martineau DuMoulin LLP.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">4,500</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">1,250&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:75pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">146,214</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:25%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w13.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">John Leasure</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 59</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;29, 2021</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underhill,<br/>Vermont,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8195;&#8194;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Global Commercial Officer</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">John Leasure was hired as Global Commercial Officer in March 2021. He brings extensive experience in Sales, Marketing, Operations and General Management both in the U.S and internationally. He has expertise managing brands across multiple stages of the product life cycle and has launched numerous products in a variety of therapeutic areas.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Prior to joining Theratechnologies, John spent 30 years at Pfizer where he led teams in Anti-infectives, Inflammation, Immunology and Oncology. Most recently, John led the Oncology business in Canada where, under his leadership, the business experienced unprecedented growth and launched over 10 new products.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">He holds a B.A., Business from Gettysburg College in Pennsylvania.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:15pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">51,250</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:15pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nil&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:15pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">101,212</p></td></tr>
</table> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:25%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="5" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g680117g40w14.jpg" alt="LOGO"/>
</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Christian<br/>Marsolais</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 61</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive since:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;7, 2007</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Town of Mount</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royal, Qu&#233;bec,</p> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Canada</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Principal Occupation</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d6d7d6"><span style="font-weight:bold">&#8195;&#8194;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Senior Vice President and Chief Medical Officer</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Dr.&#160;Christian Marsolais has over 25 years of experience in the research, development and commercialization of new drugs. He started his career in international pharmaceutical companies, including Sandoz, Biochem and Pfizer, where he held different positions from medical advisor to director clinical research and medical affairs. He was also appointed to the global oncology team at Pfizer, which managed the global oncology portfolio. Dr.&#160;Marsolais joined Theratechnologies in 2007 and leads the medical team which was central to the approval of <span style="font-style:italic">EGRIFTA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> by the FDA. He was also instrumental in the efforts that led to the US and European acquisition of the commercial rights to Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> and the approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> by the FDA. More recently, he also led the team to pursue the approval of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Europe. Dr.&#160;Marsolais holds a Ph.D. in biochemistry from the Universit&#233; de Montr&#233;al.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td colspan="7" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Securities Held or Controlled</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Shares</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DSU&#8195;&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;background-color:#d9d9d9">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;background-color:#d9d9d9"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:60pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">14,824</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;&#160;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:60pt ;BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">1,578&#8195;&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:60pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">245,093</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None of our Executive Officers have a family relationship with each other and with our directors and, to our knowledge, none of our Executive Officers have arrangements with our major shareholders, customers and suppliers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Cease Trade Orders, Bankruptcies, Penalties or Sanctions</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">To the knowledge of the Corporation, except with respect to Mr.&#160;Frank Holler and Mrs.&#160;Dale Weil, none of our directors and Executive Officers (a)&#160;is, as at the date of this Annual Report, or has been within the ten (10)&#160;years before the date of this Annual Report, a director or executive officer of any company (including the Corporation) that, while that person was acting in that capacity, (i)&#160;was the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than thirty&#160;consecutive days; (ii)&#160;was subject to an event that resulted, after the director or executive officer ceased to be a director or executive officer, in the company being the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than thirty&#160;consecutive days; or (iii)&#160;within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or (b)&#160;has, within the ten (10)&#160;years before the date of this Annual Report, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold his assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Frank Holler was a director of Contech Enterprises Inc. (&#8220;Contech&#8221;), one of the privately held emerging technology companies forming part of the BC Advantage Funds (&#8220;BCAF&#8221;) portfolio. Mr. Holler acted as Chair and Chief Executive Officer of BCAF. On December&#160;23, 2013, Contech made a proposal to its creditors under the <span style="font-style:italic">Bankruptcy and Insolvency Act</span> (Canada) and a reorganization of its share structure was approved by the Supreme Court of British Columbia on January&#160;26, 2015. The proposal was intended to facilitate a financing by a new lender and a debt restructuring that, taken together, would enable Contech to carry on its business for the foreseeable future. On March&#160;6, 2015, the Court of Appeal of British Columbia overturned the approval of the proposal by the Supreme Court and placed Contech into bankruptcy. Mr.&#160;Holler ceased acting as a director of Contech effective March&#160;6, 2015. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Mrs.&#160;Dale Weil was a director of <span style="white-space:nowrap">Tetra-Bio</span> Pharma Inc. (&#8220;Tetra&#8221;), a cannabinoid-derided drug and development company. On August&#160;1, 2023. Tetra announced that it made a voluntary assignment into bankruptcy under the Bankruptcy and Insolvency Act (Canada) and a trustee was then appointed. On September&#160;8, 2023, Tetra was delisted from the TSX. Mrs.&#160;Weil ceased acting as a director of Tetra on July&#160;28, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Directors&#8217; Mandatory Retirement Policy</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Board has adopted a formal retirement policy in the context of its succession planning process. Under this policy, directors who are not employees of the Corporation who reach the age of 75 or who have been acting as directors for fifteen (15)&#160;consecutive years may not be nominees for <span style="white-space:nowrap">re-election</span> at the subsequent annual meeting of shareholders. Mr.&#160;G&#233;rald&#160;A. Lacoste is grandfathered from this policy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Board Gender Diversity</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In February&#160;2017, the Board approved an amendment to the Charter of the Nominating and Corporate Governance Committee to embed in such Charter an obligation by the Nominating and Corporate Governance Committee to take into consideration gender diversity when the Committee recruits candidates for directorship. Gender diversity is now one of the criteria that the Committee will consider in recruiting a candidate to act as a director of the Corporation. The Board did not implement a formal policy setting forth a target for gender diversity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As at November&#160;30,&#160;2023, two (2)&#160;women, one of whom acting as Chair, comprised the Board of Directors. As at that date, women represented 29% of all independent Board members and 25% of all Board members. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below illustrates the composition and diversity of the Board of Directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:97%;border:0;margin-left:auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Country of Principal Executive Offices</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td>
<td colspan="13" align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Canada</span></td>
<td style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Private Issuer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td>
<td colspan="13" align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Yes</span></td>
<td style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Disclosure Prohibited under Home Country Law</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td>
<td colspan="13" align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">No</span></td>
<td style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Number of Directors</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td>
<td colspan="13" align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">8</span></td>
<td style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part I: Gender Identity</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center"><span style="font-weight:bold">&#8195;Female&#8195;</span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center"><span style="font-weight:bold">&#8195;Male&#8195;</span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center"><span style="font-weight:bold"><span style="white-space:nowrap">&#8194;Non-Binary&#8194;</span></span></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"></p></td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center"><span style="font-weight:bold">&#8195;Did&#160;Not&#8195;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Disclose</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Gender</p></td>
<td style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:middle"><span style="font-weight:bold">&#160;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center">2</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center">6</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part II: Demographic Background</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or American Indian</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center">2</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle" align="center">6</td>
<td style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="16" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td colspan="13" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle">&#160;</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Directors and Executive Officers Shareholding Policy</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In December&#160;2010, the Board adopted a shareholding policy for its directors and Executive Officers (&#8220;Shareholding Policy&#8221;) and the DSU Plan (as defined below). The Shareholding Policy was suspended in April&#160;2013. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the 2017 fiscal year, the Board reinstated a revised DSU Plan for its directors and Executive Officers and a revised Shareholding Policy for its directors who are not employed on a full-time basis by the Corporation. The revised Shareholding Policy requires that each newly appointed or elected director who is not an employee of the Corporation owns a number of Common Shares or deferred share units (&#8220;DSUs&#8221;) having a value representing at least twice the value of his/her annual retainer to act as a Board member (three times for the Chair of the Board). Each director has four years to comply with the Shareholding Policy. Each director must acquire at least 25% of that value over each of those four years. The four year-period begins running from the fiscal year following the fiscal year during which an individual is newly appointed or elected as a director. The value is determined as at November&#160;30 of each calendar year and is equal to the higher of the acquisition cost of a Common Share or DSUs and the fair market value of those Common Shares and DSUs as at November&#160;30 of each year of such four-year period. Common Share value fluctuations do not require directors to purchase additional Common Shares or DSUs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify" id="tx680117_29"><span style="font-weight:bold">B.</span>&#8195;&#8195;&#8195;<span style="font-weight:bold"><span style="font-style:italic">Compensation</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The compensation of the directors and the Executive Officers of the Corporation is reviewed by the compensation committee (&#8220;Compensation Committee&#8221;). For the fiscal year ended November&#160;30, 2023, the Compensation Committee was initially comprised of three (3)&#160;independent directors, namely Gary Littlejohn (Chair), Dawn Svoronos and Alain Trudeau. Effective March&#160;1, 2023, members of the Compensation Committee were replaced by the following three (3)&#160;independent directors: Dale Weil (Chair), Andrew Molson and Joseph Arena. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Compensation Discussion and Analysis of Directors</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has a compensation policy for its directors who are not employed on a full-time basis by the Corporation. The goal of the compensation policy is to attract and retain qualified directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the policy, directors are paid an annual retainer fee only. Annual retainer fees are paid quarterly on the first day of each calendar quarter. In addition, the Corporation&#8217;s compensation policy provides for the reimbursement of all reasonable expenses incurred by each director who are not employed on a full-time basis by the Corporation to attend meetings of the Board and meetings of the committees of the Board. Directors who are not employed on a full-time basis by the Corporation are also entitled to be granted options under the Option Plan (as defined below) as part of their annual compensation. The Compensation Committee reviews the compensation of the Board and its committees annually at the same time that it reviews the compensation of the Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">At its meeting of the Board of Directors in November 2022, the Board of Directors determined that the compensation to be paid to directors who are not employed on a full-time basis by the Corporation for the fiscal year ended November&#160;30, 2023, was as set forth in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:66%;border:0;margin:0 auto">


<tr>

<td style="width:92%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="6" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position at Board Level or<br/>Committee Level</p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="5" align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top"><span style="font-weight:bold">Compensation&#160;for&#160;Fiscal&#160;Year&#160;2023&#8194;</span></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Annual&#8195;&#8194;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">&#8194;Retainer<sup style="font-size:75%; vertical-align:top">(1)</sup>&#8195;&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Value&#160;in</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Stock&#160;Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:12pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Retainer to Chair of the Board</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$122,166</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$25,914</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Retainer to Board Members</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$44,179</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$25,914</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Chair of the Audit Committee</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$11,846</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Chair of the Compensation Committee</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$8,884</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Chair of the Nominating and Corporate Governance Committee</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$7,722</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Audit Committee Members</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$7,404</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Compensation Committee Members</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$2,962</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">Annual Retainer to Nominating and Corporate Governance Committee Members</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">$2,962</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">N.A.</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">These amounts were paid in CAD and were converted into U.S. dollars using the average exchange rate for the year ended November&#160;30, 2023, where CAD1.00 = $0.7404 </p></td>
<td style="width:20%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Compensation of Directors </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details all components of the compensation provided to the directors of the Corporation for the fiscal year ended November&#160;30,&#160;2023, and the value thereof. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fees</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8194;earned&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">&#8194;Share-based&#8194;</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">awards<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option-<br/>based<br/>awards<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-equity</span><br/>incentive<br/>plan<br/>&#8201;compensation&#8201;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pension&#8194;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">value&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All&#160;other<br/>&#8194;compensation&#8194;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">&#8194;Total&#8194;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(#)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">($)</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Joseph Arena<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">46,522</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">72,436</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Frank Holler</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">50,347</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">76,261</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">G&#233;rald A. Lacoste</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">57,751</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">83,665</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Paul L&#233;vesque<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Gary Littlejohn<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">42,203</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">68,117</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Andrew Molson</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">48,866</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">74,780</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Dawn Svoronos</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">126,608</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">152,522</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Alain Trudeau</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">57,751</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">83,665</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Dale Weil</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">51,828</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">25,914</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap">77,742</td></tr>
</table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Share-based awards are composed of DSUs. DSUs are issued under the deferred share unit plan (&#8220;DSU Plan&#8221;). No DSU was issued in the last fiscal year. See &#8220;Deferred Share Unit Plan&#8221; below for a description of the DSU Plan. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Each director who was not employed on a full-time basis by the Corporation on December&#160;1, 2022, received 21,739 options (5,435 on a post-consolidation basis) having an aggregate value of approximately $25,914. Options are issued under the share option plan (&#8220;Option Plan&#8221;). See &#8220;Option Plan&#8221; below for a description of the Option Plan. These options were issued on February&#160;28, 2023, but the number of stock options to be issued was determined using the Black-Scholes models as at November&#160;21, 2022, which was CAD 1.61. This column indicates the value as at that date and not as at the date of grant. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="margin-top:2pt; margin-bottom:0pt; margin-left:11%; margin-right:4%; font-size:9pt; font-family:Times New Roman;text-align:justify">Each option will expire on February&#160;28, 2033, and entitles the holder thereof to purchase one common share of the Corporation at an exercise price of CAD1.29 (CAD5.16 on a post-consolidation basis). The exercise price of the option was based on the closing price of the common shares on the TSX on February&#160;28, 2023. Per the terms of the Option Plan, the exercise price of Joe Arena&#8217;s options was based on the closing price of the common shares on the Nasdaq since Mr.&#160;Arena is a U.S. resident and such exercise price was set at US$0.95 (US$3.80 on a post-consolidation basis). Each option vested on the date of grant. </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">All cash-based compensation related to Mr.&#160;Arena&#8217;s directorship is paid to JP Arena Regulatory Consulting, LLC, a company controlled by Mr.&#160;Arena, under the terms of a consulting agreement entered into between the Corporation and this entity with an effective date of May&#160;13, 2021. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">No compensation was paid to Mr.&#160;L&#233;vesque for acting as a director of the Corporation given his position as President and Chief Executive Officer of the Corporation. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Littlejohn resigned from the Board and all committees of the Board in July 2023. </p></td>
<td style="width:4%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Outstanding Option-Based Awards and Share-Based Awards </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details all outstanding option-based awards and outstanding share-based awards as at November&#160;30,&#160;2023 for each of the directors who was not employed on a full-time basis by the Corporation as at that date. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="11" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option-Based Awards</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="5" align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">Share-Based Awards</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">securities</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">underlying</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">unexercised</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">options</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option&#8194;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">exercise&#8194;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">price&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option&#8194;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">expiration&#8194;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">date&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">unexercised&#160;in-</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">the-money</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">options<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number&#160;of&#160;shares&#8194;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">or units&#160;of&#8194;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">shares&#160;that&#160;have&#8194;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">not&#160;vested&#8194;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Market&#160;or</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">payout&#160;value</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">of&#160;share-based</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">awards&#160;that</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">have&#160;not</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">vested</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Market&#160;or</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">payout&#160;value&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">vested&#160;share-<br/>based&#160;awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">not&#160;paid&#160;out&#160;or</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">distributed<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(#)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(CAD)&#8194;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(#)&#8194;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">($)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">($)</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td rowspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Joseph Arena</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">13.20<sup style="font-size:75%; vertical-align:top">(3)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">3.80</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Frank Holler</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">3,877</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td rowspan="2" style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">G&#233;rald A. Lacoste</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">9.80</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2026.07.12</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">8,730</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,749</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">26.92</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2027.05.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,812</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">38.24</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2028.04.06</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,225</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">35.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2029.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,650</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,315</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,543</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Andrew Molson</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,315</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">4,029</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,543</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td rowspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dawn Svoronos</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,750</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">9.80</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2026.07.12</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">341</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,749</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">26.92</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2027.05.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">1,812</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">38.24</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2028.04.06</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,225</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">35.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2029.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,650</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,315</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,543</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Alain Trudeau</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,315</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">13,426</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,543</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td rowspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dale Weil</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,749</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">26.92</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2027.05.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2,202</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">1,812</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">38.24</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2028.04.06</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,225</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">35.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2029.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">2,650</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,315</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">3,543</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">--</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:right">5,434</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman">&#160;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value of unexercised <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> options at fiscal <span style="white-space:nowrap">year-end</span> is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15), and the respective exercise price of the options. These amounts were calculated in CAD and were converted into U.S. dollars using the average exchange rate for the year ended November 30, 2023, where CAD1.00 = $0.7404. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Share-based awards are comprised of DSUs issued under the DSU Plan. The market or payout value of share-based awards that have vested as at November&#160;30, 2023, is determined by multiplying the closing price of the Common Shares on the TSX as at November&#160;30, 2023 (CAD 2.15) by the number of share-based awards held as at November&#160;30, 2023. The actual payout value will vary based on the date on which the DSUs will be redeemed. The market value was calculated in CAD and was converted into U.S. dollars using the average exchange rate for the year ended November 30, 2023, where CAD1.00 = $0.7404. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:8%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The exercise price of Joseph Arena&#8217;s stock options is denominated in U.S. dollars as Mr.&#160;Arena is a U.S. resident and the exercise price of his stock options is based on the closing price of the Corporation&#8217;s Common Shares on the Nasdaq. </p></td>
<td style="width:6%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Incentive Plan Awards &#8211; Value Vested or Earned During the Year </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details the value vested or earned during the fiscal year ended November&#160;30,&#160;2023, under each incentive plan for each of the directors who was not employed on a full-time basis by the Corporation as at that date. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:23%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option-based&#160;awards&#160;&#8211;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;vested&#160;during&#160;the&#160;year<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Share-based&#160;awards&#160;&#8211;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;vested&#160;during&#160;the</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">year<sup style="font-size:75%; vertical-align:top">(2)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-equity&#160;incentive</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">plan&#160;compensation&#160;&#8211;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;earned&#160;during</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">the year</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Arena</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Holler</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10,693</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&#233;rald A. Lacoste</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Molson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">22,586</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dawn Svoronos</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Trudeau</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">45,689</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td style="height:3pt" colspan="2"/>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dale Weil</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">--</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">All options granted to directors vest as at the date of grant and the exercise price of these options was the closing price of the Common Shares on February&#160;28, 2023, on the TSX (CAD 5.16). On February&#160;28, 2023, the date of grant of the options, the closing price of the Common Shares on the TSX was CAD 5.16. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Share-based awards are comprised of DSUs issued under the DSU Plan. No DSU was issued in the last fiscal year. The value of share-based awards is determined by multiplying the closing price of the Common Shares on the TSX on the date(s) of grant by the number of share-based awards held as at such date since DSUs vest as at the date of grant. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Compensation Discussions and Analysis of Executive Officers</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Objectives of the Compensation Program </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The objectives of the compensation program (&#8220;Compensation Program&#8221;) for the Executive Officers of the Corporation aim at attracting, retaining, engaging and rewarding executive officers. The Corporation is committed to an overall compensation policy that is competitive and drives business performance while taking into consideration shareholders&#8217; interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">What the Compensation Program is Designed to Reward </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Compensation Program is designed to reward Executive Officers for (i)&#160;implementing strategies, both in the short and the long term, to realize the business plan of the Corporation, (ii)&#160;meeting the annual objectives of the Corporation and those of each Executive Officer, and (iii)&#160;enhancing shareholder value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Compensation Program provides reasonable and competitive total executive compensation. Remuneration and incentive components are established to compete with remuneration practices of similar companies that are involved in the biopharmaceutical and pharmaceutical industries, as well as certain other companies involved in other industries where the skills and knowledge of an executive officer may be used. The Corporation tries to provide its Executive Officers with total compensation at the median level of these other companies. To that end, from time to time, the Compensation Committee retains independent compensation consultants to benchmark the Compensation Program made available to its directors and Executive Officers. See &#8220;Item 6B &#8211; Compensation &#8211; Compensation Discussions and Analysis of Executive Officers &#8211; Compensation Consultant&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In designing the Compensation Program of Executive Officers, the Compensation Committee assesses the short-term and long-term risks associated with such program. The Compensation Program tries to strike a balance between the attainment of short-term and long-term goals by providing Executive Officers with short-term incentive awards and long-term incentive awards. Recommendations made by the Compensation Committee with respect to the Compensation Program are reviewed by the Board to ensure a fair balance between the short-term and long-term compensation components. For the fiscal year ended November&#160;30,&#160;2023, the Board did not identify any risk arising from the Corporation&#8217;s Compensation Program, its policies and practices in determining compensation that are reasonably likely to have a material adverse effect on the Corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">When and How Is Compensation Determined </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Compensation is determined at the end or at the beginning of each fiscal year, usually in November or December. The Compensation Committee meets to determine the base salary of Executive Officers for such fiscal year. During this meeting, the Compensation Committee also reviews the performance of the Corporation and the performance of each of its Executive Officers for the last completed fiscal year to determine whether an Executive Officer is entitled to the payment of a bonus. At such meeting, the Compensation Committee also assesses whether stock options should be granted to each Executive Officer and the number, if any. The determination by the Compensation Committee of (i)&#160;the annual base salary for the ensuing fiscal year; (ii)&#160;the payment of a bonus for the last completed fiscal year; and (iii)&#160;the grant (and number) of stock options for each Executive Officer is reviewed by the Board that has discretion to approve, disapprove or change the determination made by the Compensation Committee for each Executive Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Elements of Compensation Program </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The major elements of the Compensation Program are base salary, short-term performance reward program that takes the form of cash bonuses, and long-term incentive awards that take the form of stock option grants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Annual Base Salary </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Base salaries for each of the Executive Officers are based on the experience, expertise and competencies of each Executive Officer, as well as on a review from time to time of annual salaries paid to persons holding the position and/or playing roles in other organizations similar to those played by the Executive Officers of the Corporation. Base salaries may also be based on reports from compensation consultants retained by the Corporation from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Performance Reward Program </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The short-term performance reward program is designed to recognize the contribution of each Executive Officer in helping the Corporation achieve its corporate objectives and to increase its value. Usually, bonuses are paid based on the achievement of the Corporation&#8217;s annual corporate objectives and the achievement of an Executive Officer&#8217;s personal objectives. The Compensation Committee has discretion in recommending the payment of bonuses to an Executive Officer based on his/her overall performance. Corporate objectives are usually set by the Board early in the fiscal year. Although corporate objectives are determined early in the fiscal year, the Board has discretion to take into consideration certain events that can occur during such year leading to a change in priorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Long-Term Incentive Programs </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The long-term incentive program of the Corporation for its Executive Officers is comprised of the Option Plan and the DSU Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Option Plan </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan was originally adopted in December&#160;1993, and was subsequently amended from time to time to attract, retain and engage employees in key positions and align their interests with those of the Corporation&#8217;s shareholders by allowing optionees to participate in the increased value of the Common Shares. See &#8220;Item&#160;6B &#8211; Compensation &#8211; Description of the Option Plan&#8221; below for a description of the Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The number of options granted under the Option Plan is determined by various factors, including: (i)&#160;the position held by each Executive Officer; (ii)&#160;the potential contribution of an Executive Officer in achieving the Corporation&#8217;s objectives; (iii)&#160;the financial value of the options at the time of assessing a grant of options as part of the total compensation paid to an Executive Officer; (iv) the available pool of options remaining available for grants; and (v) comparator benchmarking. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Compensation Consultant </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the fiscal year ended November&#160;30, 2023, the Compensation Committee retained the services of Gallagher (&#8220;Gallagher&#8221;) (formerly, PCI Compensation Consulting), an independent third-party consulting firm, to update the executive compensation market positioning analysis conducted in the Fall of 2022 (&#8220;2022 Gallagher Report&#8221;), to review the market long-term incentive plan practices and to benchmark the Executive Officers&#8217; Compensation with reference market practices. The objective of the analysis was to determine if the base salary adjustments and the increased number of options granted in February&#160;2023 bridged the gap to market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Peer Groups </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Gallagher collected market data on the total compensation paid to executive officers of both publicly traded Canadian and U.S. companies, with a strong focus on those with a Canadian domicile. All the publicly traded companies used as a reference point were selected after taking into consideration the following criteria: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">-&#8201;biotechnology activities, some oncology-related while others in different activities; </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">-&#8201;market capitalization between $100&#160;million to $3&#160;billion; </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">-&#8201;revenue, pipeline status, research and development expenses, number of employees, cash and cash equivalent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following Canadian companies were used as the main reference market (&#8220;Reference Market&#8221;): </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:61%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8194;&#8195;- Knight Therapeutics Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Repare Therapeutics Inc.;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8194;&#8195;&#8195;- HLS Therapeutics;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Essa Pharma;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8194;&#8195;&#8195;- Zymeworks Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Aurinia Pharmaceuticals Inc.;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8194;&#8195;- Bellus Health Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Aptose BioScience;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8194;&#8195;&#8195;- Xenon Pharmaceuticals Inc.;</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8194;&#8195;- Oncolytics Biotech Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Milestone Pharmaceuticals Inc.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following U.S. companies, not part of the Reference Market, were used for complementary information only: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:61%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8195;&#8194;- Urogen Pharma Ltd.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- ORIC Pharmaceuticals, Inc.;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8194;&#8195;- Olema Pharmaceuticals Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Pyxis Oncology, Inc.;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8194;&#8195;- Verastem Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Cardiff Oncology, Inc.;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8195;&#8194;- BioAtla, Inc.;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Oncternal Therapeutics, Inc;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8195;&#8194;- G1 Therapeutics;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Rubius Therapeutics, Inc;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt"/>
<td style="height:3pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8195;&#8194;- Silverback Therapeutics, Inc;</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8195;&#8195;&#8194;- Kura Oncology Inc;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.73em; font-size:11pt; font-family:Times New Roman;text-align:justify">- Athenex Inc.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The review conducted by Gallagher in the fiscal year ended November 30, 2023, and their report (&#8220;2023 Gallagher Report&#8221;) provided to the Compensation Committee led the Compensation Committee to recommend to the Board to substantially increase the long-term incentive compensation paid to Executive Officers. The report concluded that the number and value of stock options granted to Executive Officers of the Corporation was still substantially below the number and value of stock options granted to executive officers of companies forming part of the Reference Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Except for compensation services provided to the Corporation, Gallagher has not provided other services to the Corporation and, to the knowledge of the Corporation, to any of its directors and Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">All services provided to the Corporation by compensation consultants must be approved by the Compensation Committee or the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details the aggregate fees billed to the Corporation for the two most recently completed fiscal years by the compensation consultant retained during these periods to assist in the determination of the compensation paid to any of the Corporation&#8217;s directors and/or Executive Officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:29%"/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:20%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Fees</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fiscal&#160;year&#160;ended</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;November&#160;30,&#160;2023<sup style="font-size:75%; vertical-align:top">(1)</sup>&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fiscal&#160;year&#160;ended</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;November&#160;30,&#160;2022<sup style="font-size:75%; vertical-align:top">(2)</sup>&#8195;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify">Gallagher</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Executive Compensation &#8211; Related Fees</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">$17,311</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">$75,228</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All Other Fees</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">$2,369</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">$10,280</p></td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The fees were paid in CAD and were converted into U.S. dollars using the average exchange rate for the year ended November&#160;30, 2023, where CAD1.00 = $0.7404. </p></td>
<td style="width:4%">&#160;</td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The fees were paid in CAD and were converted into U.S. dollars using the average exchange rate for the year ended November&#160;30, 2022, where CAD1.00 = $0.7722. </p></td>
<td style="width:4%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Determination of Total Compensation Paid to Executive Officers in the Fiscal Year Ended November&#160;30, 2023</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Annual Base Salary </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The annual base salary of each Executive Officer for the fiscal year ended November&#160;30, 2023, was determined at the November 2022 Compensation Committee and Board meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The adjustments to the Executive Officers&#8217; annual base salaries were based on the executive market positioning analysis contained in the 2023 Gallagher Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Performance Reward Program </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the fiscal year ended November&#160;30, 2023, the Compensation Committee recommended to the Board, which agreed with the recommendation, that the payment to Executive Officers of bonuses based on financial metrics be paid after approval by the Board of Directors of the annual audited consolidated financial statements of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the fiscal year ended November&#160;30, 2023, except for the President and Chief Executive Officer, the payment of bonuses for Executive Officers was based as to 30% on the achievement of corporate objectives and as to 40% on the achievement of individual objectives. The achievement of financial targets and corporate milestones each accounted for 30% of the total bonus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Financial targets were based as to 15% on the attainment of <span style="white-space:nowrap">pre-determined</span> consolidated revenues and as to 15% on the attainment of Adjusted EBITDA targets. The Adjusted EBITDA targets are not disclosed since the Corporation did not provide any specific Adjusted EBITDA targets as part of its financial guidance in the last fiscal year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details the bonus payout percentage based on the attainment of the consolidated revenue targets and the Adjusted EBITDA targets for all Executive Officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:86%;border:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:23%"/></tr>
<tr style="font-size:1pt">
<td colspan="7" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="7" align="center" style="padding-bottom:3pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt; padding-right:2pt;vertical-align:middle"><span style="font-weight:bold">Bonus Payout</span></td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" align="center" style="padding-bottom:3pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"><span style="font-weight:bold">Pre-Determined Consolidated Revenue Target</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" align="center" style="padding-bottom:3pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Pre-Determined Adjusted EBITDA Target</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"><span style="font-weight:bold">Achievement ($ in Million)</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Payment (%)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Achievement (%)</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">Payment (%)</span></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">96.0+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">110</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">&gt;100</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">110</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">91.0-96.0</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">100</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">50-100</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">100</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">86.5-91.0</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">95</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(100)-50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">95</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">81.5-86.5</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">90</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(150)-(100)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">90</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">76.5-81.5</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">85</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(200)-(150)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">85</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(233)-(200)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">80</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(267)-(233)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">75</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">(300)-(267)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">70</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Below is a description of the 2023 corporate milestones for the fiscal year ended November 30, 2023, for all Executive Officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:86%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" style="BORDER:0.75pt solid #000000; padding-left:8pt; padding-right:2pt;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">2023 Corporate Milestones</span></p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Strategic Imperatives</span></p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Area of Focus</span></p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Commercial Excellence</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leverage the Corporation&#8217;s commercial infrastructure to grow the top line and ensure profitability of the in-line business.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Pipeline Development</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Continue to successfully deliver life-cycle initiatives while advancing pipeline activities for future growth.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Financing and Business Development</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secure capital to ensure continued solvency and to allow pursuing key company objectives related to growth and pipeline.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Human Capital Strategy</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:middle"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drive an effective and committed organization through company culture and continuous improvement.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:11pt; font-family:Times New Roman;text-align:justify">The achievement of the individual objectives of each Executive Officer was left at the discretion of the Compensation Committee based on an initial assessment made by the President and Chief Executive Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the President and Chief Executive Officer, the objectives were weighed differently than for the Executive Officers, namely: (i) 20% was related to the delivery of pre-determined consolidated revenue targets; (ii) 30% was related to the delivery of Adjusted EBITDA targets; (iii) 20% was related to capital market activities, including equity financing; (iv) 10% was related to business development activities; (v) 10% was related to pipeline development activities; and (vi) 10% was related to human resources activities, including talent retention. The Compensation Committee determines the President and Chief Executive Officer&#8217;s achievement of the non-financial objectives. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Both the Board and Compensation Committee believe that discretion is a valid component in their assessment of the achievement of the Corporation&#8217;s corporate objectives and in the achievement of an individual&#8217;s objectives, especially when unplanned events occur during a fiscal year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Discretion allows the Board and the Compensation Committee to review the achievement of all objectives set forth at the beginning of a fiscal year and to assess such objectives against all other activities carried out during the year to meet such objectives. In addition, discretion is afforded to the President and Chief Executive Officer to assess the capacity of each Executive Officer to adapt, react, respond and act in the best interests of the Corporation when unplanned events occur. However, to avoid too large a discretion to the President and Chief Executive Officer and limit potential bias in the determination of the performance of an executive officer&#8217;s overall performance, all recommendations made by the President and Chief Executive Officer are reviewed by the Compensation Committee, and may be modified before any recommendation is made to the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In December 2023 and in February 2024, both the Compensation Committee and the Board reviewed the achievement of the Corporation&#8217; objectives and determined that the overall corporate result score was set at 63.8% of target. For Executive Officers (excluding the President and Chief Executive Officer), combined with the achievements of each individual objectives, the percentage of bonus to be paid varied from 67% to 75%. Based on the abovementioned objectives for the President and Chief Executive Officer and due to a higher importance attributed to financial performance and capital market activities, the Board determined that his overall result score was set at 82% of target. Consistent with its decision to wait for the approval by the Board of Directors of the annual audited consolidated financial statements of the Corporation before making any payment, none of the proposed bonuses to Executive Officers, including the President and Chief Executive Officer, have been paid. The annual audited consolidated financial statements of the Corporation were approved by the Board on February&#160;20, 2024, and the bonuses are expected to be paid shortly. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details for each of the President and Chief Executive Officer, the Senior Vice President and Chief Financial Officer and the three most highly compensated Executive Officers of the Corporation (&#8220;Named Executive Officers&#8221;), the percentage of their annual base salary which may be paid as bonus, the targeted bonus that each of them may receive, the actual bonus earned during the fiscal year ended November&#160;30, 2023 and to be paid in 2024 and the percentage of the target bonus to be paid in 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:85%;border:0;margin:0 auto">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Percentage&#160;of</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Annual Base</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Salary&#160;Payable</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Bonus</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Target</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Bonus</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Bonus</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Paid<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Percentage&#8195;&#8194;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Target&#8195;&#8194;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Bonus&#160;Paid&#8195;&#8194;</p></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#8201;Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center"><span style="font-weight:bold">(%)</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:middle;white-space:nowrap" align="center"><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center"><span style="font-weight:bold">(%)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#8201;Paul L&#233;vesque, <br/>&#8201;President and Chief Executive Officer</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">75</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">494,576</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">405,553</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">82</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#8201;Philippe Dubuc, <br/>&#8201;Senior Vice President and Chief Financial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">40</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">133,289</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">100,067</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">75</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#8201;Christian Marsolais, <br/>&#8201;Senior Vice&#160;President and Chief Medical Officer</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">40</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">135,937</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">95,537</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">70</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#8201;John Leasure, <br/>&#8201;Global Commercial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">40</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">133,647</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">89,651</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">67</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/>
<td style="height:7.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8201;Jocelyn Lafond</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8201;General Counsel and Corporate Secretary</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">33</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">84,049</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">62,376</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">74</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">These amounts will be paid in CAD in February 2024 and have been converted into U.S. dollars for illustrative purposes only using the average exchange rate for the year ended November&#160;30, 2023, where CAD&#160;1.00 = $ 0.7404. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below details all components of the compensation paid to the Named Executive Officers for the fiscal years ended November 30, 2023, November 30, 2022, and November 30, 2021. Except as described in the notes below, these amounts were paid in Canadian dollars and were converted into U.S. dollars using the average exchange rate for the fiscal year ended November 30, 2023 (CAD&#160;1.00 = $0.7404), November 30, 2022 (CAD&#160;1.00 = $0.7722), and November&#160;30, 2021 (CAD&#160;1.00 = $0.7979). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For the fiscal year ended November 30, 2023, the Corporation changed the method to report the value of option-based awards indicated under the column &#8220;Option-based awards&#8221; in the table below to align with market practices.&#160;In the past, the Corporation reported the value of option-based awards on the date those were reserved for future issuances if the Corporation was unable to grant those option-based awards because of black-out periods.&#160;The fair value of the option-based awards on the date of grant was reported in a footnote to the table.&#160;Typically, option-based awards were reserved in the fiscal year for which the report on compensation was included, while the grant date occurred in the subsequent fiscal year. To align with market practices, the Corporation has decided to report the value of option-based awards when grants actually occur and to use the same hypotheses as those contained in the Audited Financial Statements. As a result, option-based awards reported in this document for the fiscal year ended November&#160;30, 2023, are those granted on February 28, 2023 (rather than those reserved in November&#160;2023 for grant in the fiscal year 2024), and option-based awards reserved in November of 2023 will only be reported with respect to the fiscal year ending November&#160;30, 2024, if granted during such fiscal year. Moreover, corresponding adjustments to use the value on the date of grant have been made in the table below with respect to option-base awards for the fiscal years ended November&#160;30,&#160;2022, and 2021. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td rowspan="2" style="padding-bottom:8pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">&#8201;Name and principal</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">&#8201;position</p></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Year&#8194;</span><br/></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Salary<br/>($)</span></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Share-&#8194;<br/>based&#8194;<br/>awards&#8194;<br/>($)&#8194;</span></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="white-space:nowrap">Option-based&#8194;</span><br/>awards<sup style="font-size:75%; vertical-align:top">(1)</sup><sup style="font-size:75%; vertical-align:top">(2)</sup><sup style="font-size:75%; vertical-align:top">(3)</sup>&#8194;</span> <p style="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8194; </p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="white-space:nowrap">Non-equity&#160;incentive</span></span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">plan&#160;compensation&#160;($)</p></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Pension&#8194;<br/>value<sup style="font-size:75%; vertical-align:top">(4)</sup>&#8194;<br/>($)&#8194;</span></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">All other&#8194;<br/>compensation<sup style="font-size:75%; vertical-align:top">(5)</sup>&#8194;<br/>($)&#8194;</span></td>
<td rowspan="2" style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td rowspan="2" align="center" style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Total&#8194;<br/>compensation&#8194;<br/>($)&#8194;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Annual&#8194;<br/>Incentive&#8194;<br/>plans&#8194; </p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Long-term&#8194;</span><br/>Incentive&#8194;<br/>plans&#8194; </p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Paul L&#233;vesque</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">President and Chief Executive Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2023&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">658,524</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">695,976<sup style="font-size:75%; vertical-align:top">(6)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">405,553</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">117,572<sup style="font-size:75%; vertical-align:top">(7)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">22,790</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">1,900,415</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">656,885</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">917,188<sup style="font-size:75%; vertical-align:top">(8)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">535,526</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">117,572</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">22,556</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2,249,727</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2021&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">638,778</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">543,579<sup style="font-size:75%; vertical-align:top">(9)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">480,059</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">117,572</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">22,337</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">1,802,325</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Philippe Dubuc</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2023&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">332,246</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">208,793<sup style="font-size:75%; vertical-align:top">(10)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">100,067</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">13,394</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">654,500&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">311,016</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">358,466<sup style="font-size:75%; vertical-align:top">(11)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">138,743</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,301</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">819,526&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2021&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">279,003</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">163,609<sup style="font-size:75%; vertical-align:top">(12)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">112,946</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,169</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">566,727&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Christian Marsolais</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Senior Vice President and Chief Medical Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2023&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">339,068</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">208,793<sup style="font-size:75%; vertical-align:top">(13)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">95,537</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">13,394</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">656,792&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">328,185</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">358,466<sup style="font-size:75%; vertical-align:top">(14)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">138,625</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,301</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">836,577&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2021&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">271,995</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">212,670<sup style="font-size:75%; vertical-align:top">(15)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">110,110</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,169</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">605,944&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td rowspan="3" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">John Leasure<sup style="font-size:75%; vertical-align:top">(16)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Global Commercial Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2023&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">331,258</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">170,000<sup style="font-size:75%; vertical-align:top">(17)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">89,651</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">13,394</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">604,303&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">313,911<sup style="font-size:75%; vertical-align:top">(18)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">310,664<sup style="font-size:75%; vertical-align:top">(19)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">148,574</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">7,808</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">51,463<sup style="font-size:75%; vertical-align:top">(20)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">832,420</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2021&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">207,635<sup style="font-size:75%; vertical-align:top">(21)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">52,069<sup style="font-size:75%; vertical-align:top">(22)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">85,545</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">345,249</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td rowspan="3" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Jocelyn Lafond</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">General Counsel and Corporate Secretary</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2023&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">253,918</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">139,195<sup style="font-size:75%; vertical-align:top">(23)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">62,376</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">13,394</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">468,883&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">239,307</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">252,917<sup style="font-size:75%; vertical-align:top">(24)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">86,554</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,301</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">590,079&#8194;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2021&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">241,005</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">141,330<sup style="font-size:75%; vertical-align:top">(25)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">79,693</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11,169</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">473,197&#8194;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold">Fiscal Year 202</span><span style="font-weight:bold">3</span>: A total of 512,500 options were granted to the Named Executive Officers on February 28, 2023 as part of the long-term incentive compensation program of the Corporation. The value of the options set forth in this column represents the value of the options on the date of grant based on the Black Scholes model using the following assumptions, except with respect to the 62,500 options granted to Mr. Leasure: </p></td>
<td style="width:2%">&#160;</td></tr></table>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:78%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.33%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8201;&#8194;&#8201;&#8195;&#8201;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">64.3%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">9.5&#160;years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;5.16</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;5.16</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD 3.76</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; margin-right:2%; font-size:9pt; font-family:Times New Roman;text-align:justify">The 62,500 options granted to Mr. Leasure on February 28, 2023, were issued with an exercise price denominated in U.S. dollars and the value of those options as at that date was determined using the Black-Scholes model with the following assumptions: </p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:79%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">3.92%</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8201;&#8194;&#8201;&#8195;&#8201;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">62.0%</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9.5&#160;years</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">--</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$3.80</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$3.80</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$2.72</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold">Fiscal Year 202</span><span style="font-weight:bold">2</span>: A total of 241,132 options were granted to the Named Executive Officers on December 1, 2021 as part of the long-term incentive compensation program of the Corporation. The value of the options set forth in this column represents the value of the options on the date of grant based on the Black Scholes model using the following assumptions, except with respect to the 33,333 options granted to Mr. Leasure: </p></td>
<td style="width:2%">&#160;</td></tr></table>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:77%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">1.57%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8201;&#8194;&#8201;&#8195;&#8201;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">65.87%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">9&#160;years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;16.84</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;16.84</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;11.76</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; margin-right:2%; font-size:9pt; font-family:Times New Roman;text-align:justify">The 33,333 options granted to Mr. Leasure on December 1, 2021, were issued with an exercise price denominated in U.S. dollars and the value of those options as at that date was determined using the Black-Scholes model with the following assumptions: </p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:81%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">1.44%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">67.23%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8194;&#8201;&#8201;&#8201;&#8195;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">9&#160;years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$13.20</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$13.20</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8201;&#8201;(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$9.32</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold">Fiscal Year 2021</span>: A total of 118,748 options were granted to the Named Executive Officers on February 26, 2021, as part of the long-term incentive compensation program of the Corporation. No option was granted to Mr. Leasure on that date since he was not an employee of the Corporation. The value of the options set forth in this column represents the value of the options on the date of grant based on the Black Scholes model using the following assumptions: </p></td>
<td style="width:2%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:77%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">1.36%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">70.51%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8194;&#8201;&#8201;&#8201;&#8201;&#8201;&#8195;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">8.5&#160;years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD&#160;15.72</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD 15.72</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">CAD 11.20</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; margin-right:2%; font-size:9pt; font-family:Times New Roman;text-align:justify">A total of 5,379 options were granted to Mr. John Leasure on July 27, 2021. These options were issued with an exercise price denominated in U.S. dollars and the value of those options as at that date was determined using the Black-Scholes model with the following assumptions: </p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:40%;border:0">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:79%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(i)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Risk-free interest rate:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">1.24%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(ii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected volatility:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">67.95%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">&#8195;&#8194;&#8201;&#8201;&#8201;&#8201;&#8201;&#8195;&#8195;&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(iii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Average option life in years:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">8.5&#160;years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(iv)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Expected dividends:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(v)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date share price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$13.92</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(vi)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Option exercise price:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$13.92</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">(vii)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Grant date fair value:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">$9.68</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Pension value consists of the amount of the contribution made by the Corporation to a Named Executive Officer&#8217;s registered retirement savings plan. The Corporation has a group-RRSP for all of its employees under which the Corporation matches every dollar invested by an employee in such group-RRSP but up to three percent (3%)&#160;of the annual base salary of each employee, except with respect to (i) Executive Officers where the Corporation&#8217;s contribution is not subject to such three percent (3%) limit and (ii) Mr. Paul L&#233;vesque. Under the terms of Mr.&#160;L&#233;vesque&#8217;s employment agreement, the Corporation agreed to contribute on an annual basis to Mr.&#160;L&#233;vesque&#8217;s RRSP to the fullest amount permissible under Canadian laws. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">All other compensation includes perquisites and other form of compensation (such as retention or signing bonuses) not described in the other columns. Except with respect to Mr. Leasure (see note 20 below), perquisites for each Named Executive Officer have not been included since they do not meet the prescribed threshold of the lesser of CAD 50,000 and 10% of each of the respective Named Executive Officer&#8217;s salary in the last fiscal year. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 250,000 options granted on February 28, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">On December 21, 2020, the Corporation and Paul L&#233;vesque entered into a retention bonus agreement (&#8220;Retention Agreement&#8221;) pursuant to which the Corporation agreed to pay Mr. Paul L&#233;vesque the amount of $352,716 in three&#160;(3) equal installments of $117,572 over a three (3) year period on each anniversary date of his employment date (April&#160;6, 2020) with the Corporation. The entire payment of $117,572 was made as at the date of this Annual Report. The Retention Agreement was entered into, among other things, as a result of the role Mr. L&#233;vesque was asked to take on with the departure of the chief commercial officer of the Corporation when Mr. L&#233;vesque joined the Corporation. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 101,000 options granted on December 1, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of the 60,827 options granted on February 26, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 75,000 options granted on February 28, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 39,474 options on December 1, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 18,308 options granted on February 26, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 75,000 options reserved for issuance on February 28, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 39,474 options granted on December 1, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 23,798 options granted on February 26, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr. Leasure joined the Corporation&#8217;s wholly-owned subsidiary, Theratechnologies U.S., Inc., as Global Commercial Officer, on March 29, 2021. Effective April 11, 2022, Mr. Leasure ceased being employed by this wholly-owned subsidiary and he became an employee of the Corporation as Global Commercial Officer. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 62,500 options granted on February 28, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr. Leasure&#8217;s annual base salary was set at CAD 402,062. This salary was paid by Theratechnologies U.S., Inc. from December 1, 2021, until April 11, 2022 ($98,969) and by the Corporation ($214,942) beginning on April 11, 2022. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(19)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 33,333 options granted on December 1, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(20)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">As a U.S. resident, Mr. Leasure&#8217;s employment agreement with the Corporation provides for tax equalization payments with respect to his annual base salary and bonus to the extent the tax rate in his home State is lower than the combined federal and provincial tax rate in Canada. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(21)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr. Leasure&#8217;s annual base salary was set at $305,000. The amount was prorated and represents his annual base salary earned between March 29, 2021, and November 30, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(22)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 5,379 options granted on July 27, 2021, as inducement to enter into his employment agreement. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(23)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 50,000 options granted on February 28, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(24)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 27,851 options granted on December 1, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(25)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents the value of 15,815 options granted on February 26, 2021. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Description of Option Plan</span> </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan is designed to attract, retain, motivate and reward the services of key personnel. The persons eligible to receive options under the Option Plan are the directors, senior executives and key employees of the Corporation and its subsidiaries, as well as consultants who work on behalf of the Corporation. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Board administers the Option Plan, provided that the Board may, from time to time, solicit and/or accept recommendations regarding the Option Plan made by the Compensation Committee. The Board has discretion to designate the optionees and determine the number of Common Shares underlying these options, the vesting period, the exercise price and the expiry date of each option, as well as all other related matters, the whole in compliance with the terms of the Option Plan and applicable legislative provisions established by securities regulatory authorities. The Board is not bound by the recommendations made by the Compensation Committee with respect to the abovementioned matters. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan currently provides that the number of Common Shares authorized to be issued thereunder, together with all other security-based compensation arrangements of the Corporation, may not exceed 17% of the issued and outstanding Common Shares, on a <span style="white-space:nowrap">non-diluted</span> basis, as calculated on the date of grant. Because options exercised or cancelled become available again for future grant, the Option Plan is considered an &#8220;evergreen&#8221; plan and, under the TSX requirements, the TSX requires that the Option Plan be submitted to shareholders of the Corporation for ratification every three (3)&#160;years. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan provides that the number of Common Shares set aside for the exercise of options by one individual may not represent more than 5% of the issued and outstanding Common Shares. Further, the number of Common Shares issuable to insiders, at any time, under all security-based compensation arrangements of the Corporation, cannot exceed 17% of the issued and outstanding Common Shares, and the number of Common Shares issued to Insiders, within any <span style="white-space:nowrap">one-year</span> period, under all security-based compensation arrangements, cannot exceed 17% of the issued and outstanding Common Shares. The Option Plan also provides that the total number of Common Shares set aside for the exercise of options to each <span style="white-space:nowrap">non-employee</span> director within any <span style="white-space:nowrap">one-year</span> period cannot exceed a value of CAD 100,000, calculated on the date of grant, and an aggregate value of CAD 150,000 under all security-based compensation arrangements, including the Option Plan. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan provides that the exercise price at which the Common Shares may be purchased is determined by the Board on the date of grant, but such exercise price cannot be less than the &#8220;market price&#8221; of the Common Shares. Generally, under the Option Plan, the term &#8220;market price&#8221; means for options granted to (i)&#160;Canadian and <span style="white-space:nowrap">non-US</span> resident optionees, the closing price of the Common Shares on the TSX on the last trading day immediately preceding the date of grant; and <span style="white-space:nowrap">(ii)&#160;US-resident</span> optionees, the closing price of the Common Shares on the U.S. Nasdaq stock market on the last trading day immediately preceding the date of grant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation does not provide any financial assistance to optionees. However, optionees may elect to undertake a &#8220;cashless exercise&#8221; of their options with the assistance of a broker, whereby the broker may sell on the open market a number of Common Shares issued as a result of an optionee&#8217;s exercise of its options, as is necessary to fund and pay the Corporation an amount equal to the aggregate subscription price of the underlying Common Shares. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Unless otherwise determined by the Board, options vest as to 33 1/3% on each of the first, second and third anniversary date of the date of grant, starting twelve (12)&#160;months after the date of grant. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Unless otherwise determined by the Board, the options granted pursuant to the Option Plan may be exercised within a maximum period of ten (10)&#160;years following the date of grant, subject to applicable optionee termination provisions. The Option Plan provides that if the expiry date of an option falls during, or within ten (10)&#160;business days after the end of, a period imposed by the Corporation prohibiting the trading of securities of the Corporation, the term of the option is automatically extended to the end of the day on the tenth (10th) consecutive business day after the end of such restriction period. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan provides that options can be exercised, with the Corporation&#8217;s prior approval, by an optionee&#8217;s retirement savings trust, registered retirement savings plans or registered retirement income fund, if the optionee is and remains the annuitant. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan provides that, with respect to options granted before May&#160;10, 2022: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if an optionee&#8217;s employment is terminated, other than for death, prior to the expiry date of his or her options, the optionee may exercise any or all unexercised vested options at any time until the earlier of (i)&#160;twelve (12) months following the date of termination of employment of the optionee, and (ii)&#160;the expiry date of such options; and </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if an optionee that is a <span style="white-space:nowrap">non-employee</span> director ceases to act as a director of the Corporation, other than for death, the optionee may exercise any or all unexercised vested options at any time until the earlier of (i)&#160;twelve (12) months following the public disclosure of the quarterly financial statements of the Corporation made after the date such director ceased to act as such, and (ii)&#160;the expiry date of such options. </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan further provides that, with respect to options granted on or after May&#160;10, 2022: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if, prior to the expiry date of his or her options, an optionee other than a <span style="white-space:nowrap">non-employee</span> director ceases to be an employee or consultant other than for Cause (as defined in the Option Plan) or death, such optionee&#8217;s unexercised vested options as at the Date of Termination of Employment (as defined in the Option Plan) be exercisable at any time until the earlier of (i)&#160;twelve (12) months following the Date of Termination of Employment, and (ii)&#160;the expiry date of such options; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if, prior to the expiry date of his or her options, an optionee that is a <span style="white-space:nowrap">non-employee</span> director ceases to be a director of the Corporation, other than for Cause (as defined in the Option Plan) or death, such optionee&#8217;s unexercised vested options as at the date on which such optionee ceased to act as director be exercisable at any time until the earlier of (i)&#160;twelve (12) months following the date such director ceased to hold office, and (ii)&#160;the expiry date of such options; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if, prior to the expiry date of his or her options, an optionee ceases to be a director, employee or consultant for Cause (as defined in the Option Plan), (i) all unexercised options of such optionee, whether vested or unvested, be forfeited, cancelled and terminated as at the Date of Termination (as defined in the Option Plan), or, in the case of a director, the date on which he or she ceased to hold office, unless otherwise determined by the Board, and (ii)&#160;such optionee forfeit and repay the Corporation any compensation, gain or other value realized on the vesting, exercise or settlement of options or the sale of Common Shares acquired in respect of such options, since the date of first occurrence of the events, actions or facts that gave rise to the termination for Cause. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Whether options are granted before, on, or after May&#160;10, 2022, if, prior to the expiry date of his or her options, an optionee ceases to act as an employee, director or consultant to the Corporation as a result of his or her death, such optionee&#8217;s legal personal representative(s) may exercise any or all vested unexercised options on the date of death of the optionee at any time until the earlier of (i)&#160;twelve (12) months following the death of an optionee and (ii)&#160;the expiry date of such options. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The options granted in accordance with the Option Plan cannot be transferred, assigned or subject to any form of alienation, sale, pledge, hypothec or other encumbrance, except by will or other means in the event of the death of an optionee. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan contains &#8220;clawback&#8221; provisions for options granted on or after May&#160;10, 2022. The Option Plan provides that the Board may: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">cancel options granted to an optionee if such optionee, without the consent of the Corporation, (i)&#160;has engaged in or engages in activity that is in conflict with or adverse to the interests of the Corporation or its subsidiaries, including fraud or conduct having contributed to financial restatements or irregularities, or (ii)&#160;violates a <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disparagement</span> or <span style="white-space:nowrap">non-disclosure</span> covenant with the Corporation or its subsidiaries, or if an optionee is terminated for Cause (as defined in the Option Plan); and </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">determine that such optionee must forfeit any compensation, gain or other value realized on the vesting, exercise or settlement or transfer of options or Common Shares acquired in respect of such options, and repay such amounts to the Corporation. </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Subject to the terms and conditions of the Option Plan and in compliance with the rules set forth by regulatory authorities, the Board can amend, suspend or terminate the Option Plan, or any outstanding option or portion of the Option Plan or of an option, without shareholder approval. Without limiting the generality of the foregoing, the Board may make the following types of amendments without seeking shareholder approval: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">amendments of a &#8220;housekeeping&#8221; or ministerial nature including, without limiting the generality of the foregoing, any amendment for the purpose of curing any ambiguity, error or omission in the Plan or to correct or supplement any provision of the Option Plan that is inconsistent with any other provision of the Option Plan; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">amendments necessary to comply with the provisions of applicable law (including, without limitation, the rules, regulations and policies of the TSX and/or Nasdaq); </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">amendments necessary in order for options to qualify for favorable treatment under applicable taxation laws; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">amendments respecting administration of the Option Plan; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any amendment to the vesting provisions of the Option Plan or any option, it being understood that in the event of the amendment to the vesting provisions of an option, the Board shall not be under any obligation to amend the vesting provisions of any other option; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any amendment which reduces the exercise price or purchase price of an option held by an optionee who is not an Insider of the Corporation; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any amendment to the early termination provisions of the Option Plan or any option, whether or not such option is held by an Insider, provided such amendment does not entail an extension beyond the original expiry date; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the addition or modification of a cashless exercise feature, payable in cash or Common Shares; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">amendments necessary to suspend or terminate the Option Plan; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(j)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any other amendment, whether fundamental or otherwise, not requiring shareholder approval under applicable law or the Option Plan. </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following amendments require the approval of a majority of the voting shareholders of the Corporation present at a duly called shareholder meeting: </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any increase to the maximum number of Common Shares that may be issued under the Option Plan, including an increase to a fixed maximum percentage of Common Shares or a change from a fixed maximum percentage of Common Shares to a fixed maximum number; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the reduction of the exercise price of options held by Insiders; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the cancellation and reissue of options to the same individual; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the extension of the period of time pursuant to which options may be exercised; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any transfer and assignment of options other than in accordance with the Option Plan; </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the removal or increase of limits to the number of options that may be granted to Insiders; and </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(g)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the removal or increase of limits to the number of options that may be granted to <span style="white-space:nowrap">non-employee</span> directors; and </p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(h)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">any amendment to the amending provisions of the Option Plan. </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Option Plan contains language which aligns with best governance and market practices with respect to circumstances in which the vote of Insiders shall not be included when amendments to the Option Plan require shareholder approval. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During the fiscal year ended November&#160;30,&#160;2023, 996,128 options were granted under the Option Plan and, as at November&#160;30, 2023, 2,053,928 options were issued and outstanding. As at February&#160;20, 2024, there were 2,053,231 issued and outstanding options under the Option Plan which, if all exercised, would result in the issuance of 2,053,231 Common Shares, or 4.46% of all the issued and outstanding Common Shares as at that date. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table sets forth the information regarding the equity compensation plan of the Corporation as at November&#160;30,&#160;2023. As at November&#160;30, 2023, the number of Common Shares issued and outstanding amounted to 45,980,019. </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Plan Category</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of&#160;Securities&#8194;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">to be Issued upon&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exercise&#160;of&#160;Outstanding&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options&#160;(%&#160;of&#160;Issued&#160;and&#8194;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding&#160;Share&#160;Capital)&#8194;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="white-space:nowrap">Weighted-Average&#8194;</span></span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exercise Price of&#8194;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding&#160;Options&#8194;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of&#160;Securities&#8194;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Remaining Available&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">for Future Issuance&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">under&#160;Equity&#160;Compensation&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Plan&#8194;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(% of Issued&#160;&amp; Outstanding&#8194;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Share Capital)&#8194;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle">Equity Compensation Plan Approved by Shareholders</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold"></span>2,053,928<br/>(4.46%)<span style="font-weight:bold"></span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">$8.14</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">5,762,675<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(12.54%)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle">Equity Compensation Plans Not Approved by Shareholders</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">--</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">--</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td align="center" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:middle"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">2,053,928<br/>(4.46%)</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">$8.14</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:middle;white-space:nowrap"><span style="font-weight:bold">5,762,675</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(12.54%)</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table sets forth the information regarding the burn rate of the Option Plan for the fiscal years ended November&#160;30,&#160;2023, 2022 and 2021, respectively. The burn rate reflects the potential dilutive effect of equity grants on the Corporation&#8217;s outstanding equity over a certain period of time. The calculation below was made pursuant to Section&#160;613(p) of the TSX Company Manual. </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:74%;border:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap"><span style="font-weight:bold">2023&#8194;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap"><span style="font-weight:bold">2022&#8194;</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap"><span style="font-weight:bold">2021&#8194;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Burn Rate</span><sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">3.78%&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2.71%&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">1.26%&#8194;</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Total options granted under the Option Plan during the applicable fiscal year / weighted average number of Common Shares during this applicable fiscal year. </p></td>
<td style="width:14%">&#160;</td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">DSU Plan</span> </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On December&#160;10, 2010, the Board adopted the DSU Plan for the benefit of its directors and Executive Officers (&#8220;Beneficiaries&#8221;). </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The goal of the DSU Plan is to increase the Corporation&#8217;s ability to attract and retain high-quality individuals to act as directors or Executive Officers and better align the interests of the directors and Executive Officers with those of the shareholders of the Corporation in the creation of long-term value. The DSU Plan was also adopted to promote equity-based ownership in the Corporation. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the terms of the DSU Plan, Beneficiaries who are directors (including the Chair) are entitled to elect to receive all or part of their annual retainer as Board member in DSUs. The election is done on a quarterly basis. Beneficiaries who act as Executive Officers are entitled to elect to receive all or part of their annual cash bonus, if any, in DSUs. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The value of a DSU (&#8220;DSU Value&#8221;) is equal to the average closing price of the Common Shares on the TSX on the date on which a Beneficiary determines that he desires to purchase or redeem DSUs and during the four previous trading days. Beneficiaries who act as directors have to elect to receive DSUs as complete or partial consideration of their annual retainer to act as Board members prior to each calendar quarter. Beneficiaries who act as Executive Officers are required to elect to purchase DSUs within 48 hours after having been notified of their annual cash bonus, if any. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">DSUs may only be redeemed when a Beneficiary ceases to act as a director or an Executive Officer of the Corporation. On the date a Beneficiary ceases to act as a director or Executive Officer (&#8220;Redemption Date&#8221;), the Beneficiary is entitled to send a notice to the Corporation (&#8220;Redemption Notice&#8221;) specifying the date on which the DSUs will be redeemed (&#8220;Payment Date&#8221;). The Payment Date must be no earlier than five (5)&#160;business days after the date on which the Corporation receives the Redemption Notice and no later than November&#160;30 of the year following the Redemption Date. If a Beneficiary does not send a Redemption Notice prior to November&#160;15 in the year following the Redemption Date, the DSU Plan provides that a Beneficiary will be deemed to have sent, and the Corporation received, a Redemption Notice on November&#160;15 of that year. On the Payment Date, the Corporation must provide a Beneficiary with an amount in cash equal to the DSU Value as at the Payment Date. No Common Share is issued under the DSU Plan. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Beneficiaries may not sell, transfer or otherwise assign their DSUs or any rights associated therewith other than by will or in accordance with legislation regarding the vesting and partition of successions. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Board administers the DSU Plan and the DSU Plan provides that the Board may delegate all or part of its obligations to the Compensation Committee or to any other committee of the Board. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">To protect against fluctuations in DSU Value, the Corporation enters into cash settled forward contracts with an independent third party such that, upon a Payment Date, the Corporation is not exposed to the appreciation of the price of its Common Shares. The execution of such contracts requires the signature of two of the following Executive Officers: the President and Chief Executive Officer, the Vice President, Finance, and the General Counsel and Corporate Secretary. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman;text-align:justify">As at November&#160;30, 2023, and as at the date of this Annual Report, 24,878 DSUs were issued and outstanding. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Incentive Plan Awards</span> </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Outstanding Option-Based Awards and Share-Based Awards </span></p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">During the fiscal year ended November&#160;30,&#160;2023, no DSUs were issued to the Named Executive Officers and 512,500 (2,050,000 pre-Consolidation) options to purchase Common Shares were granted to the Named Executive Officers. The table below details the outstanding option-based awards held by each of the Named Executive Officers as at November&#160;30, 2023 and the value thereof as at that date, if any. Unless otherwise indicated, all amounts expressing a value in the table below were calculated in CAD and were converted into U.S. dollars using the exchange rate as at November&#160;30, 2023 where CAD 1.00 = $0.7404. </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:98%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom"/>
<td/></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:3.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td>
<td colspan="6" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="2" style="padding-bottom:4pt ;BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option-Based Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" align="center" style="padding-bottom:4pt ;BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">Share-Based Awards<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">securities</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">underlying</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">unexercised</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">options</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">exercise</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">price</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(CAD)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">expiration</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">date</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Value&#160;of</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">unexercised</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap"><span style="white-space:nowrap">in-the-</span></span></p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">money</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">options<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">shares&#160;or</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">units&#160;of</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">shares&#160;that</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">have&#160;not</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">vested</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Market&#160;or</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">payout&#160;value</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">of&#160;share-</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">based</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">awards&#160;that</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">have&#160;not</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">vested</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:4pt ;BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Market&#160;or</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">payout&#160;value</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">of&#160;vested</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">share-based</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">awards&#160;not</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">paid&#160;out&#160;or</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">distributed<sup style="font-size:75%; vertical-align:top">(4)</sup></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Paul L&#233;vesque President and Chief Executive Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">121,855<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">60,827<sup style="font-size:75%; vertical-align:top">(5)</sup></p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">101,000<sup style="font-size:75%; vertical-align:top">(6)</sup></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">250,000<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">11.48<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">15.72</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">16.84</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">5.16</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2030.04.15<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2031.02.26</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2031.12.01</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2033.02.28</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="8" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Philippe Dubuc Senior Vice President and Chief Financial Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">43,750</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">8.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2026.04.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">10,000</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">23.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2027.04.07</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">7,247</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">38.24</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2028.04.06</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">8,325</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">35.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2029.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">12,500</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">18,308<sup style="font-size:75%; vertical-align:top">(8)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">39,474<sup style="font-size:75%; vertical-align:top">(9)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">75,000<sup style="font-size:75%; vertical-align:top">(10) </sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td rowspan="10" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Christian Marsolais Senior Vice President and Chief Medical Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">31,249</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">1.52</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2022.12.20<sup style="font-size:75%; vertical-align:top">(11)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">14,577</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2,512<sup style="font-size:75%; vertical-align:top">(12)</sup></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,500</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">8.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2026.04.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">10,000</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">23.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2027.04.07</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">7,247</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">38.24</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2028.04.06</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">8,325</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">35.04</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2029.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,500</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">25,000</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">12.88</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2030.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">23,798<sup style="font-size:75%; vertical-align:top">(13)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">15.72</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2031.02.26</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">39,474<sup style="font-size:75%; vertical-align:top">(14)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">16.84</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">75,000<sup style="font-size:75%; vertical-align:top">(15)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">5.16</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td rowspan="3" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">John Leasure Global Commercial Officer</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">5,379<sup style="font-size:75%; vertical-align:top">(16)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">13.92</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.07.27</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">33,333<sup style="font-size:75%; vertical-align:top">(17)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">9.32</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2031.12.01</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">62,500<sup style="font-size:75%; vertical-align:top">(18)</sup></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">3.80</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2033.02.28</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jocelyn Lafond General Counsel and Corporate Secretary</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">33,750<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">7,500</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">3,750</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">3,623</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">4,450</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">6,975</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">15,815<sup style="font-size:75%; vertical-align:top">(21)</sup></p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">27,851<sup style="font-size:75%; vertical-align:top">(22)</sup></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">50,000<sup style="font-size:75%; vertical-align:top">(23)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">1.52<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">8.04</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">23.84</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">38.24</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">35.04</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">12.88</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">15.72</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">16.84</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">5.16</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">2022.12.20<sup style="font-size:75%; vertical-align:top">(19)</sup><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2026.04.04</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2027.04.07</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2028.04.06</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2029.02.26</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2030.02.26</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2031.02.26</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2031.12.01</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">2033.02.28</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">12,244<br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">--</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">--</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">1,990<sup style="font-size:75%; vertical-align:top">(20)</sup></td></tr>
</table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Share-based awards are comprised of DSUs issued under the DSU Plan. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The exercise price of the options granted to John Leasure is expressed in U.S. dollars. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value of unexercised <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> options is determined by multiplying the difference between the exercise price of the options and the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD2.15), and, in the case of Mr.&#160;Leasure, the Nasdaq ($1.58), by the number of options held and vested as at November&#160;30, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The market or payout value of share-based awards that have vested as at November&#160;30, 2023 is determined by multiplying the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD2.15) by the number of share-based awards held as at November&#160;30, 2023. DSUs may only be redeemed when a Beneficiary leaves his/her position with the Corporation. </p></td>
<td style="width:2%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">20,275 options vested on February&#160;26, 2022, and 20,276 options vested on February&#160;26, 2023. 20,276 options will vest on February&#160;26, 2024. Therefore, as at November&#160;30, 2023, 20,276 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">33,666 options vested on December&#160;1, 2022. 33,667 options will vest on December&#160;1, 2023, and on December&#160;1, 2024, respectively. Therefore, as at November&#160;30, 2023, 67,334 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">83,333 options will vest on February&#160;28, 2024, and on February&#160;28, 2025, respectively, and 83,334 options will vest on February&#160;28, 2026. Therefore, as at November&#160;30, 2023, none of these options could be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">6,102 options vested on February&#160;26, 2022, and 6,103 options vested on February&#160;26, 2023. 6,103 options will vest on February&#160;26, 2024. Therefore, as at November&#160;30, 2023, 6,103 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">13,158 options vested on December&#160;1, 2022, and an equal number of options will vest on December&#160;1, 2023, and on December&#160;1, 2024, respectively. Therefore, as at November&#160;30, 2023, 26,316 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">25,000 options will vest on each of February&#160;28, 2024, February&#160;28, 2025, and February&#160;28, 2026. Therefore, as at November&#160;30, 2023, none of these options could be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Pursuant to the Option Plan, since these options were scheduled to expire during a <span style="white-space:nowrap">black-out</span> period, the term of these options was extended to end on the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) consecutive business day following the expiry of a <span style="white-space:nowrap">black-out</span> period. Since December&#160;20, 2022, no ten (10)&#160;consecutive business day period elapsed during which the Corporation was not in a <span style="white-space:nowrap">black-out</span> period. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents 1,578 DSUs granted on December&#160;15, 2010. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">7,932 options vested on February&#160;26, 2022, and 7,933 options vested on February&#160;26, 2023. 7,933 options will vest on February&#160;26, 2024. Therefore, as at November&#160;30, 2023, 7,933 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">13,158 options vested on December&#160;1, 2022. 13,158 options will vest on December&#160;1, 2023, and December&#160;1, 2024, respectively. Therefore, as at November&#160;30, 2023, 26,316 options could not be exercised as at November&#160;30, 2023. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">25,000 options will vest on each of February&#160;28, 2024, February&#160;28, 2025, and February&#160;28, 2026. Therefore, as at November&#160;30, 2023, none of these options could be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">1,793 options vested on each of July&#160;27, 2022, and July&#160;27, 2023. 1,793 options will vest on July&#160;27, 2024. Therefore, as at November&#160;30, 2023, 1,793 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">11,111 options vested on December&#160;1, 2022, and 11,111 options will vest on each of December&#160;1, 2023, and December&#160;1, 2024. Therefore, as at November&#160;30, 2023, 22,222 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">20,833 options will vest on each of February&#160;28, 2024, and February&#160;28, 2025. 20,834 options will vest on February&#160;28, 2026. Therefore, as at November&#160;30, 2023, none of these options could be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(19)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">See note 11 above. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(20)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Represents 1,250 DSUs granted on December&#160;15, 2010. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(21)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">5,271 options vested on February&#160;26, 2022, and 5,272 options vested on February&#160;26, 2023. 5,272 options will vest on February&#160;26, 2024. Therefore, as at November&#160;30, 2023, 5,272 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(22)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">9,283 options vested on December&#160;1, 2022. 9,284 options will vest on each of December&#160;1, 2023, and December&#160;1, 2024, respectively. Therefore, as at November&#160;30, 2023, 18,568 options could not be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(23)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">16,666 options will vest on February&#160;28, 2024, and 16,667 options will vest on each of February&#160;28, 2025, and February&#160;28, 2026, respectively. Therefore, as at November&#160;30, 2023, none of these options could be exercised. </p></td>
<td style="width:2%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Incentive Plan Awards &#8211; Value vested or earned during the year </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The table below shows the value vested or earned during the fiscal year ended November&#160;30,&#160;2023, under each incentive plan for each of the Named Executive Officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option-based&#160;awards-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value vested during&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">the year <sup style="font-size:75%; vertical-align:top">(1)</sup>&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Share-based&#160;awards-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value vested&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">during the year&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-equity&#160;incentive&#8195;</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">plan compensation-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value earned&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">during the year <sup style="font-size:75%; vertical-align:top">(2)</sup>&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul L&#233;vesque</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">405,553&#8195;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dubuc</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">100,067&#8195;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Marsolais</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Medical Officer</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">95,537&#8195;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Leasure</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Global Commercial Officer</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Nil&#8195;</td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">89,651&#8195;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option-based&#160;awards-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value vested during&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">the year <sup style="font-size:75%; vertical-align:top">(1)</sup>&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Share-based&#160;awards-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value vested&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">during the year&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-equity&#160;incentive&#8195;</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">plan compensation-&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value earned&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">during the year <sup style="font-size:75%; vertical-align:top">(2)</sup>&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)&#8195;</p></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jocelyn Lafond</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel and Corporate Secretary</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:6pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">Nil&#8195;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:6pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">Nil&#8195;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="padding-bottom:6pt ;BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">62,376&#8195;</td></tr>
</table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value is determined by assuming that the options that vested during the financial year ended November&#160;30, 2023, would have been exercised on their vesting date if they were <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> on that date. The value corresponds to the difference between the closing price of the Common Shares on the TSX, or the Nasdaq, as the case may be, on the vesting date and the exercise price of the options that vested on that date. The closing price of the Common Shares on the TSX and Nasdaq was lower than the exercise price of the options that vested during the financial year ended November&#160;30, 2023, and, accordingly, no value was recorded. </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Except as detailed in the note below, the value was calculated in Canadian dollars and converted into U.S. dollars using the average exchange rate for the fiscal year ended November&#160;30, 2023, where CAD&#160;1.00 = $0.7404. </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Summary of Employment Agreements - Termination and Change of Control Provisions</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Below is a summary of the employment agreements of each of the Named Executive Officers together with a table detailing the value of the severance payment that would be payable by the Corporation to each of them pursuant to his employment agreement if one of the events described in the table had occurred on November&#160;30,&#160;2023. Except with respect to Mr.&#160;John Leasure and except as disclosed in the notes to the tables below, the amounts set forth in the tables below under &#8220;Severance&#8221; and under &#8220;Value of Stock Options&#8221; and &#8220;Value of Share-Based Awards&#8221; were calculated in CAD and were converted into U.S. dollars using the average exchange rate for the fiscal year ended November&#160;30, 2023, where CAD&#160;1.00 = $0.7404. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Paul L&#233;vesque </span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Paul L&#233;vesque on March&#160;1, 2020. Mr.&#160;L&#233;vesque&#8217;s employment agreement provides for the payment of an annual base salary subject to review on an annual basis by the Board, and the payment of an annual bonus of 75% of his annual base salary conditional upon his attainment of annual objectives set by the Board. In addition, Mr.&#160;L&#233;vesque&#8217;s employment agreement provides that he is entitled to participate in incentive programs developed by the Board or any committee thereof and, as such, is entitled to receive up to 100% of the value of his annual base salary in the form of options granted under the Option Plan. The terms of Mr.&#160;L&#233;vesque&#8217;s employment agreement contain <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disclosure</span> and assignment of intellectual property provisions in favour of the Corporation. The Corporation agreed to provide a limited annual stipend to Mr.&#160;L&#233;vesque with respect to tax advice, medical expenses which would not be covered under the Corporation&#8217;s group benefit plan, or any other ancillary matter. The Corporation also agreed to fund Mr.&#160;L&#233;vesque&#8217;s Canadian registered retirement savings plan up to the full amount prescribed under applicable laws. Mr.&#160;L&#233;vesque can terminate his employment agreement at any time upon four (4)&#160;weeks prior written notice to the Corporation. The Corporation can terminate Mr.&#160;L&#233;vesque&#8217;s employment agreement with cause at any time. The termination of Mr.&#160;L&#233;vesque&#8217;s employment agreement by the Corporation without just and sufficient cause will entitle Mr.&#160;L&#233;vesque to receive an amount equal to eighteen (18)&#160;months of his then annual base salary plus an amount equal to 150% of his annual bonus target, calculated at a rate of 75% on his then annual base salary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event of a &#8220;Change of Control&#8221; of the Corporation resulting in the termination of Mr.&#160;L&#233;vesque&#8217;s employment without just and sufficient cause occurring within twenty-four (24)&#160;months of such &#8220;Change of Control&#8221;, Mr.&#160;L&#233;vesque will be entitled to receive (i) 200% of his then annual base salary, (ii) 200% of his annual bonus target calculated at a rate of 75% on his then annual base salary, and (iii)&#160;the cash value of his benefits calculated over a twenty-four-month period preceding the date of his termination. All of his unvested options will also become vested. Mr.&#160;L&#233;vesque is entitled to terminate his employment agreement at his sole discretion within twelve (12)&#160;months following the occurrence of a &#8220;Change of Control&#8221; of the Corporation. In such circumstance, Mr.&#160;L&#233;vesque will be entitled to receive (i) 100% of his then annual base salary, (ii) 100% of his annual bonus target calculated on his then annual base salary, and (iii)&#160;the cash value of his benefits calculated over a twelve-month period preceding the date of his termination. All of his unvested options will also become vested. In Mr.&#160;L&#233;vesque&#8217;s employment agreement, a &#8220;Change of Control&#8221; is defined as the acquisition by a third party, acting alone or in concert with one or more persons, by way of takeover, merger, amalgamation, arrangement or other similar transactions, of (i)&#160;more than forty percent (40%) of the Common Shares of the Corporation or (ii)&#160;more than forty percent (40%) of the economic value of the Corporation. A &#8220;Change of Control&#8221; is also defined as a change in the majority of the individuals composing the Board of Directors at the date of execution of Mr.&#160;L&#233;vesque&#8217;s employment agreement (&#8220;Incumbent Board&#8221;); provided, however, that any individual becoming a member of the Board of Directors subsequent to the date of execution of Mr.&#160;L&#233;vesque&#8217;s employment agreement whose election or nomination for election was approved by a vote of at least a majority of the directors then comprising the Board of Directors will be considered as though such member were part of the Incumbent Board and will not constitute a &#8220;Change of Control&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Events</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Severance&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of&#160;Stock<br/>Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of&#160;share-</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">based&#160;awards&#160;<sup style="font-size:75%; vertical-align:top">(2)</sup><br/>($)</p></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1,728,626</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2,377,709</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1,188,855</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value assumes that upon the occurrence of any event set forth in this table, all <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> vested options (except in the case of a termination resulting from a Change of Control where all of his options become vested) would be exercised. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each vested option as at that date. As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr.&#160;L&#233;vesque does not hold any share-based awards. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Under the Option Plan, the termination of a person&#8217;s employment with the Corporation entitles him to exercise his vested options over a <span style="white-space:nowrap">one-year</span> period after the termination date. As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">In the event of a Change of Control, all of Mr.&#160;L&#233;vesque&#8217;s options become vested. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each option he holds as at that date. As at November&#160;30, 2023, none of the options held by Mr.&#160;L&#233;vesque had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Philippe Dubuc </span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Senior Vice President and Chief Financial Officer </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Philippe Dubuc on February&#160;24,&#160;2016. Mr.&#160;Dubuc&#8217;s employment agreement provides for the payment of an annual base salary subject to review on an annual basis by the Board, and the payment of an annual bonus of up to 40% of his annual base salary conditional upon his attainment of annual objectives set by the President and Chief Executive Officer. In addition, Mr.&#160;Dubuc is entitled to participate in incentive programs developed by the Board or any committee thereof. The terms of Mr.&#160;Dubuc&#8217;s employment agreement contain <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disclosure</span> and assignment of intellectual property provisions in favour of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2023, Mr.&#160;Dubuc&#8217;s employment agreement was amended to provide new termination terms. Under the new terms, if the Corporation terminates Mr.&#160;Dubuc&#8217;s employment without just and sufficient cause or further to an internal reorganization (but excluding after a &#8220;Change of Control&#8221;), Mr.&#160;Dubuc will be entitled to receive an amount equal to (i) 18 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for an <span style="white-space:nowrap">18-month</span> period if Mr.&#160;Dubuc has less than 10 years of service upon termination of his employment agreement; or 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period if Mr.&#160;Dubuc has 10 years or more of service upon termination of his employment agreement. Mr.&#160;Dubuc will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event of a &#8220;Change of Control&#8221; of the Corporation resulting in the termination of Mr.&#160;Dubuc&#8217;s employment without just and sufficient cause occurring within twenty-four (24)&#160;months of such &#8220;Change of Control&#8221;, or if Mr.&#160;Dubuc decides to terminate his employment agreement at his sole discretion 24 four months following the occurrence of a &#8220;Change of Control&#8221; of the Corporation, Mr.&#160;Dubuc will be entitled to receive an amount equal to (i) 18 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for an <span style="white-space:nowrap">18-month</span> period if Mr.&#160;Dubuc has less than 10 years of service upon termination of his employment agreement; or (ii) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period if Mr.&#160;Dubuc has 10 years or more of service upon termination of his employment agreement. All of his unvested options will also become vested. Mr.&#160;Dubuc will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. In Mr.&#160;Dubuc&#8217;s agreement, a &#8220;Change of Control is defined as (i)&#160;the acquisition by a third party, acting alone or in concert with one or more persons, regardless of its structure, of 40% or more of the outstanding voting securities of the Corporation, or (ii)&#160;a transaction resulting in (x)&#160;the shareholders of the Corporation no longer holding more than 60% of the outstanding voting securities of the Corporation post-transaction, or (y)&#160;post-transaction, the board of directors of the company resulting from this transaction no longer being comprised of a majority of the directors who were then acting as directors prior to the transaction; or (iii)&#160;a change in the composition of the board of directors of the Corporation occurring, without the approval by a majority vote of the directors comprising the board of directors of the Corporation prior to such change, during a shareholders&#8217; meeting or pursuant to a resolution passed by the shareholders of the Corporation, and which results in the board of directors of the Corporation no longer being comprised of a majority of the directors of the Corporation who sat as directors immediately prior to such meeting or resolution; or (iv)&#160;a sale or the grant of an exclusive license related to all or substantially all of the assets of the Corporation which represents more than 75% of the assets disposed of calculated as at the date of the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing</span> or more than 75% of the revenues generated by the Corporation during the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Events</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Severance&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of&#160;Stock<br/>Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of&#160;share-</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">based&#160;awards&#160;<sup style="font-size:75%; vertical-align:top">(2)</sup><br/>($)</p></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">697,717</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">697,717</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">697,717</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
</table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value assumes that upon the occurrence of an event set forth in this table, all <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> vested options would be exercised. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each vested option as at that date. As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Dubuc does not hold any share-based awards. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Under the Option Plan, the termination of a person&#8217;s employment with the Corporation entitles him to exercise his vested options over a <span style="white-space:nowrap">one-year</span> period after the termination date. As at November&#160;30, 2023, As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">In the event of a Change of Control, all of Mr.&#160;Dubuc&#8217;s options become vested. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each option he holds as at that date. As at November&#160;30, 2023, none of the options held by Mr.&#160;Dubuc had an exercise price inferior to the closing price of the Common Shares on the TSX. </p></td>
<td style="width:6%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Christian Marsolais </span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Senior Vice&#160;President and Chief Medical Officer </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Christian&#160;Marsolais on April&#160;13,&#160;2007. His agreement was subsequently amended on May&#160;23,&#160;2012, and July&#160;17,&#160;2012. An amended and restated employment agreement was entered into on December&#160;21,&#160;2012, between Mr.&#160;Marsolais and the Corporation. The amended and restated employment agreement was entered into to reflect Mr.&#160;Marsolais&#8217; new position as Senior Vice President, Medical Affairs, to set its targeted bonus rate at 40%, to revise and add new restrictive covenants in favour of the Corporation and to amend his severance payment conditions in the event the Corporation terminates his employment without just and sufficient cause. Mr.&#160;Marsolais&#8217; employment agreement provides for the payment of an annual base salary subject to review on an annual basis by the Compensation Committee, and the payment of an annual bonus of up to 40% of his annual base salary conditional upon his attainment of annual objectives set by the President and Chief Executive Officer. In addition, Mr.&#160;Marsolais is entitled to participate in incentive programs developed by the Board or any committee thereof. The terms of Mr.&#160;Marsolais&#8217; employment agreement contain <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disclosure</span> and assignment of intellectual property provisions in favour of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;28, 2023, Mr.&#160;Marsolais&#8217; employment agreement was further amended to provide new termination terms. Under the new terms, if the Corporation terminates Mr.&#160;Marsolais&#8217; employment without just and sufficient cause or further to an internal reorganization (but excluding after a &#8220;Change of Control&#8221;), Mr.&#160;Marsolais will be entitled to receive an amount equal to (i) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period. Mr.&#160;Marsolais will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event of a &#8220;Change of Control&#8221; of the Corporation resulting in the termination of Mr.&#160;Marsolais&#8217; employment without just and sufficient cause occurring within 24 months of such &#8220;Change of Control&#8221;, or if Mr.&#160;Marsolais decides to terminate his employment agreement at his sole discretion 24 four months following the occurrence of a &#8220;Change of Control&#8221; of the Corporation, Mr.&#160;Marsolais will be entitled to receive an amount equal to (i) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period. All of his unvested options will also become vested. Mr.&#160;Marsolais will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. In Mr.&#160;Marsolais&#8217; agreement, a &#8220;Change of Control is defined as (i)&#160;the acquisition by a third party, acting alone or in concert with one or more persons, regardless of its structure, of 40% or more of the outstanding voting securities of the Corporation, or (ii)&#160;a transaction resulting in (x)&#160;the shareholders of the Corporation no longer holding more than 60% of the outstanding voting securities of the Corporation post-transaction, or (y)&#160;post-transaction, the board of directors of the company resulting from this transaction no longer being comprised of a majority of the directors who were then acting as directors prior to the transaction; or (iii)&#160;a change in the composition of the board of directors of the Corporation occurring, without the approval by a majority vote of the directors comprising the board of directors of the Corporation prior to such change, during a shareholders&#8217; meeting or pursuant to a resolution passed by the shareholders of the Corporation, and which results in the board of directors of the Corporation no longer being comprised of a majority of the directors of the Corporation who sat as directors immediately prior to such meeting or resolution; or (iv)&#160;a sale or the grant of an exclusive license related to all or substantially all of the assets of the Corporation which represents more than 75% of the assets disposed of calculated as at the date of the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing</span> or more than 75% of the revenues generated by the Corporation during the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:10%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-size:9pt"><span style="font-weight:bold">Events</span></span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">&#8201;Severance&#8201;<br/>($)</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value&#160;of&#160;Stock<br/>Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Value&#160;of&#160;share-<br/>based&#160;awards<sup style="font-size:75%; vertical-align:top">(2)</sup><br/>($)</span></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15,577</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">2,512</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">949,390</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15,577</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">2,512</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">949,390</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15,577</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">2,512</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">949,390</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15,577</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">2,512</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">15,577</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">2,512</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value assumes that upon the occurrence of an event set forth in this table, all <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> vested options would be exercised. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each vested option as at that date. As at November&#160;30, 2023, 31,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value of the share-based awards assumes that upon the occurrence of an event, all DSUs are redeemed. The value of share-based awards is determined by multiplying the number of DSUs held as at November&#160;30, 2023 (1,578) by the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15). </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Under the Option Plan, the termination of a person&#8217;s employment with the Corporation entitles him to exercise his vested options over a <span style="white-space:nowrap">one-year</span> period after the termination date. As at November&#160;30, 2023, 31,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:7%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">In the event of a Change of Control, all of Mr.&#160;Marsolais&#8217; options become vested. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each option he holds as at that date. As at November&#160;30, 2023, 31,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">John Leasure </span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Global Commercial Officer </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation, through its wholly-owned subsidiary Theratechnologies U.S., Inc. (&#8220;Thera US&#8221;), entered into an employment agreement with Mr.&#160;John Leasure on March&#160;23, 2021, for an indeterminate term. Effective April&#160;11, 2022, the Corporation entered into a new employment agreement (&#8220;2022 Agreement&#8221;) with Mr.&#160;Leasure for an indeterminate term. Under the terms of the 2022 Agreement, Mr.&#160;Leasure acts as Global Commercial Officer of the Corporation and of all of the Corporation&#8217;s subsidiaries. Mr.&#160;Leasure is entitled to receive an annual base salary subject to review on an annual basis by the Compensation Committee, and the payment of an annual bonus set at 40% of his annual base salary conditional upon his attainment of annual objectives set by the President and Chief Executive Officer. The payment of an annual bonus is subject to clawback provisions requiring Mr.&#160;Leasure to repay to the Corporation the last bonus received in the event of violations of certain U.S. Food and Drug Administration rules or other laws applicable to the commercialization of pharmaceutical products in the United States. Under the terms of the 2022 Agreement, Mr.&#160;Leasure is also entitled to participate in equity-based incentive plans that the Corporation may implement from time to time. The 2022 Agreement provides that he is entitled to receive a number of stock options of the Corporation, if and when granted by the Board of the Corporation under the Option Plan, representing a target value between 20% to 45% of his annual base salary. The Corporation agreed to match on a <span style="white-space:nowrap"><span style="white-space:nowrap">dollar-for-dollar</span></span> basis the funding by Mr.&#160;Leasure&#8217;s Canadian registered retirement savings plan up to an amount equal to 50% of the maximum annual contribution allowed under Canadian applicable laws. Mr.&#160;Leasure is entitled to participate in Thera US&#8217; social benefits comprised of disability and <span style="white-space:nowrap"><span style="white-space:nowrap">death-in-service</span></span> benefits and health insurance. The 2022 Agreement contains <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disclosure</span> and assignment of intellectual property provisions in favour of the Corporation. Mr.&#160;Leasure is entitled to terminate the 2022 Agreement at will upon thirty (30)&#160;days prior written notice to the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;31, 2023, the 2022 Agreement was amended to provide new termination terms. Under the new terms, if the Corporation terminates Mr.&#160;Leasure&#8217;s employment without just and sufficient cause or further to an internal reorganization (but excluding after a &#8220;Change of Control&#8221;), Mr.&#160;Leasure will be entitled to receive an amount equal to (i) 12 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">12-month</span> period if Mr.&#160;Leasure has less than 5 years of service upon termination of his employment agreement (ii) 18 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for an <span style="white-space:nowrap">18-month</span> period if Mr.&#160;Leasure has less more than 5 years but less than 10 years of service upon termination of his employment agreement; or (ii) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period if Mr.&#160;Leasure has 10 years or more of service upon termination of his employment agreement. Mr.&#160;Leasure will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event of a &#8220;Change of Control&#8221; of the Corporation resulting in the termination of Mr.&#160;Leasure&#8217;s employment without just and sufficient cause occurring within twenty-four (24)&#160;months of such &#8220;Change of Control&#8221;, or if Mr.&#160;Leasure decides to terminate his employment agreement at his sole discretion 24 four months following the occurrence of a &#8220;Change of Control&#8221; of the Corporation, Mr.&#160;Leasure will be entitled to receive an amount equal to (i) 12 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">12-month</span> period if Mr.&#160;Leasure has less than 5 years of service upon termination of his employment agreement, (ii) 18 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for an <span style="white-space:nowrap">18-month</span> period if Mr.&#160;Leasure has more than 5 years but less than 10 years of service upon termination of his employment agreement; or (iii) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period if Mr.&#160;Leasure has 10 years or more of service upon termination of his employment agreement. All of his unvested options will also become vested. Mr.&#160;Leasure will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Mr.&#160;Leasure&#8217;s agreement, a &#8220;Change of Control is defined as (i)&#160;the acquisition by a third party, acting alone or in concert with one or more persons, regardless of its structure, of 40% or more of the outstanding voting securities of the Corporation, or (ii)&#160;a transaction resulting in (x)&#160;the shareholders of the Corporation no longer holding more than 60% of the outstanding voting securities of the Corporation post-transaction, or (y)&#160;post-transaction, the board of directors of the company resulting from this transaction no longer being comprised of a majority of the directors who were then acting as directors prior to the transaction; or (iii)&#160;a change in the composition of the board of directors of the Corporation occurring, without the approval by a majority vote of the directors comprising the board of directors of the Corporation prior to such change, during a shareholders&#8217; meeting or pursuant to a resolution passed by the shareholders of the Corporation, and which results in the board of directors of the Corporation no longer being comprised of a majority of the directors of the Corporation who sat as directors immediately prior to such meeting or resolution; or (iv)&#160;a sale or the grant of an exclusive license related to all or substantially all of the assets of the Corporation which represents more than 75% of the assets disposed of calculated as at the date of the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing</span> or more than 75% of the revenues generated by the Corporation during the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:16%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Events</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Severance&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Value&#160;of&#160;Stock&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">&#8194;Value&#160;of&#160;share-<br/>&#8194;based&#160;awards</span><sup style="font-size:75%; vertical-align:top"></sup><span style="font-size:6.5pt"><sup style="font-size:75%; vertical-align:top">(2)<span style="font-weight:bold">&#160;</span></sup><span style="font-weight:bold">($)</span></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-size:12pt">Nil</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">463,761</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Termination of Employment without Just Cause in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">463,761</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">463,761</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">Nil</td></tr>
</table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value assumes that upon the occurrence of an event, all <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> vested options would be exercised. The value is the difference between the closing price of the Common Shares on November&#160;30, 2023, on the Nasdaq ($1.58) and the exercise price of each vested option as at November&#160;30, 2023. As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the Nasdaq. </p></td>
<td style="width:8%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Mr.&#160;Leasure does not hold any share-based awards. </p></td>
<td style="width:8%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Under the Option Plan, the termination of a person&#8217;s employment with the Corporation entitles him to exercise his vested options over a <span style="white-space:nowrap">one-year</span> period after the termination date. As at November&#160;30, 2023, none of the options that were vested had an exercise price inferior to the closing price of the Common Shares on the Nasdaq. </p></td>
<td style="width:8%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">In the event of a Change of Control, all of Mr.&#160;Leasure&#8217;s options become vested. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023, on the Nasdaq ($1.58) and the exercise price of each option he holds as at that date. As at November&#160;30, 2023, none of the options held by Mr.&#160;Leasure had an exercise price inferior to the closing price of the Common Shares on the Nasdaq. </p></td>
<td style="width:8%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">Jocelyn Lafond </span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">General Counsel and Corporate Secretary </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Lafond on March&#160;29, 2007, and an amendment was subsequently entered into on July&#160;5, 2012, to change some of the termination terms. Additional amendments were then entered into on July 2027, 2023, and December&#160;15, 2023, to further amend the termination terms of Mr.&#160;Lafond&#8217;s employment and to increase his annual bonus target rate to 40% from 33.33% beginning in the 2024 fiscal year of the Corporation. Mr.&#160;Lafond&#8217;s employment agreement provides for the payment of an annual base salary subject to review on an annual basis by the Compensation Committee, and the payment of an annual bonus of up to 40% (33.33% in the 2023 fiscal) of his annual base salary conditional upon his attainment of annual objectives set by the President and Chief Executive Officer. In addition, Mr.&#160;Lafond is entitled to participate in incentive programs developed by the Board or any committee thereof. The terms of Mr.&#160;Lafond&#8217;s employment agreement contain <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">non-disclosure</span> and assignment of intellectual property provisions in favour of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2023, an amendment to the termination terms of Mr.&#160;Lafond&#8217;s employment agreement was entered into. Under the new terms, if the Corporation terminates Mr.&#160;Lafond&#8217; employment without just and sufficient cause or further to an internal reorganization (but excluding after a &#8220;Change of Control&#8221;), Mr.&#160;Lafond will be entitled to receive an amount equal to (i) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period. Mr.&#160;Lafond will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event of a &#8220;Change of Control&#8221; of the Corporation resulting in the termination of Mr.&#160;Lafond&#8217;s employment without just and sufficient cause occurring within 24 months of such &#8220;Change of Control&#8221;, or if Mr.&#160;Lafond decides to terminate his employment agreement at his sole discretion 24 four months following the occurrence of a &#8220;Change of Control&#8221; of the Corporation, Mr.&#160;Lafond will be entitled to receive an amount equal to (i) 24 months of his annual base salary plus an amount equal to 100% of his annual bonus target, calculated at a rate of 40% on his then annual base salary for a <span style="white-space:nowrap">24-month</span> period. All of his unvested options will also become vested. Mr.&#160;Lafond will not be entitled to receive any payment related to the value of any security-based compensation and social benefits received while employed with the Corporation. In Mr.&#160;Lafond&#8217;s agreement, a &#8220;Change of Control is defined as (i)&#160;the acquisition by a third party, acting alone or in concert with one or more persons, regardless of its structure, of 40% or more of the outstanding voting securities of the Corporation, or (ii)&#160;a transaction resulting in (x)&#160;the shareholders of the Corporation no longer holding more than 60% of the outstanding voting securities of the Corporation post-transaction, or (y)&#160;post-transaction, the board of directors of the company resulting from this transaction no longer being comprised of a majority of the directors who were then acting as directors prior to the transaction; or (iii)&#160;a change in the composition of the board of directors of the Corporation occurring, without the approval by a majority vote of the directors comprising the board of directors of the Corporation prior to such change, during a shareholders&#8217; meeting or pursuant to a resolution passed by the shareholders of the Corporation, and which results in the board of directors of the Corporation no longer being comprised of a majority of the directors of the Corporation who sat as directors immediately prior to such meeting or resolution; or (iv)&#160;a sale or the grant of an exclusive license related to all or substantially all of the assets of the Corporation which represents more than 75% of the assets disposed of calculated as at the date of the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing</span> or more than 75% of the revenues generated by the Corporation during the last financial year preceding such sale or <span style="white-space:nowrap">out-licensing.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Events</span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Severance&#8195;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;Value&#160;of&#160;Stock&#8195;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options<sup style="font-size:75%; vertical-align:top">(1)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8194;Value&#160;of&#160;share-&#8194;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">based&#160;awards<sup style="font-size:75%; vertical-align:top">(2)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,244</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">1,990</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">677,098</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,244</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">1,990</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Employment without Just Cause in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">677,098</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,244</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">1,990</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation in the event of a Change of Control<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">677,098</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,244</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">1,990</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="2" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voluntary Resignation<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">Nil</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">12,244</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">1,990</td></tr>
</table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value assumes that upon the occurrence of an event, all <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> vested options would be exercised. The value is the difference between the closing price of the Common Shares on November&#160;30, 2023 on the TSX (CAD 2.15) and the exercise price of each vested option as at November&#160;30, 2023. As at November&#160;30, 2023, 26,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The value of the share-based awards assumes that upon the occurrence of an event, all DSUs are redeemed. The value of share-based awards is determined by multiplying the number of DSUs held as at November&#160;30, 2023 (1,250) by the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15). </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Under the Option Plan, the termination of a person&#8217;s employment with the Corporation entitles him to exercise his vested options over a <span style="white-space:nowrap">one-year</span> period after the termination date. As at November&#160;30, 2023, 26,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:7%">&#160;</td></tr></table> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">In the event of a Change of Control, all of Mr.&#160;Lafond&#8217;s options become vested. The value is the difference between the closing price of the Common Shares on the TSX on November&#160;30, 2023 (CAD 2.15) and the exercise price of each option he holds as at that date. As at November&#160;30, 2023, 26,250 options with an exercise price of CAD 1.52 were vested. </p></td>
<td style="width:7%">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_30"><span style="font-weight:bold">C.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Board Practices. </span></span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">See &#8220;Item 6A &#8211; Directors and Senior Management&#8221; of this Annual Report for information regarding the term of office of our directors and Executive Officers and the period during which each of them has served in that office. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In the event any of our directors resign from the Board or is not reelected, they are not entitled to receive any benefit, other than the right to redeem their DSUs under the DSU Plan and to exercise their options under the Option Plan. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change of Control Provisions&#8221; for a summary of our Executive Officers Employment&#160;Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We have entered into a consulting agreement with JP Arena Regulatory Consulting, LLC (&#8220;JP Arena Agreement&#8221;), a company wholly owned by Joseph Arena. Under the JP Arena Agreement, JP Arena Regulatory Consulting, LLC provides the services of Joseph Arena to act as a director of the Company. The annual retainer fee payable in cash to Joseph Arena is made to JP Arena Regulatory Consulting, LLC. All DSUs or options granted pursuant to the DSU Plan or the Option Plan are issued to Joseph Arena, personally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Committees of the Board of Directors</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our Board of Directors currently has three (3)&#160;committees: an audit committee (&#8220;Audit Committee&#8221;), the Compensation Committee, and a nominating and corporate governance committee (&#8220;Corporate Governance Committee&#8221;). Each of these committees has adopted charters describing their mandates, roles and functions. These charters are available on our website at <span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.theratech.com</span></span><span style="font-family:Times New Roman"> and have been attached as exhibits to this Annual Report. All of the members of these committees are independent directors, are appointed annually by our Board of Directors and carry out their mandate until the next annual meeting of shareholders or until they resign. In August 2023, a financing committee (&#8220;Financing Committee&#8221;) was created to assist management with, and to review, financing alternatives available to the Company in relation to the Marathon Credit Agreement. The Financing Committee was comprised of four (4)&#160;independent directors and was dissolved on December&#160;15, 2023. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Audit Committee is currently composed of three independent directors, namely, Mr.&#160;Alain Trudeau, who acts as the Chair, G&#233;rald A. Lacoste and Frank Holler. All of our Audit Committee&#8217;s members are financially literate. The Board of Directors has determined that Mr.&#160;Alain Trudeau meets the &#8220;Audit Committee financial expert&#8221; criteria prescribed by the SEC. The Audit Committee members are scheduled to meet without Executive Officers being present on a regular basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Audit Committee is responsible for assisting our Board of Directors to oversee the followings: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the integrity of the Corporation&#8217;s financial statements and information related thereto; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the Corporation&#8217;s internal control system; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the appointment and performance assessment of our external auditors; and </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the Corporation&#8217;s risk management matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Audit Committee reviews our annual and quarterly consolidated financial statements, as well as our annual and quarterly MD&amp;A, approves our quarterly consolidated financial statements and MD&amp;A related thereto, reviews and discusses with our Executive Officers and external auditors major issues regarding accounting principles and financial statement presentations as well as major issues relating to the adequacy of our internal controls systems. The Audit Committee is also responsible to supervise the performance of our external auditors, recommend to the Board of Directors the compensation to be paid to our external auditors, to approve all services which are <span style="white-space:nowrap">non-audit</span> services, together with the costs therefor, and to oversee the most important risks faced by the Corporation and make recommendations to the Board of Directors with respect thereto as well as on measures that could be implemented to reduce those risks. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Compensation Committee is currently composed of three independent directors, namely Mrs.&#160;Dale Weil who acts as Chair, Mr.&#160;Andrew Molson and Mr.&#160;Joseph Arena. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Compensation Committee is responsible for assisting the Board of Directors to oversee the followings: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the compensation of the Executive Officers; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the assessment of the Executive Officers; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the compensation of directors and members of committees; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;stock option grants; and </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;overall increase in total compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Compensation Committee is responsible to develop a compensation system that allows the Corporation to retain and attract skilled individuals. The Compensation Committee reviews and establishes the total compensation to be paid to Executive Officers and to the directors, oversees the terms and conditions of the Executive Officers&#8217; employment agreements and any amendment thereto, oversees short and long-term compensation programs for Executive Officers and directors and assess the performance of the President and Chief Executive Officer as well as the performance of Executive Officers in collaboration with the President and Chief Executive Officer. The Compensation Committee also oversees on an annual basis the increase in overall compensation to all of our employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Corporate Governance Committee </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporate Governance Committee is currently composed of four independent directors, namely Mr.&#160;G&#233;rald A. Lacoste, who acts as the Chair, Mr.&#160;Andrew Molson, Mrs.&#160;Dawn Svoronos and Mrs.&#160;Dale Weil. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporate Governance Committee is responsible for assisting the Board of Directors to oversee the followings: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;recruiting candidates for the Board; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;reviewing the size, composition and function of the Board; </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;the orientation and education of directors; and </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:11%; text-indent:-4%; font-size:11pt; font-family:Times New Roman;text-align:justify">&#8211; &#8195;governance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporate Governance Committee&#8217;s role consists in assessing the effectiveness of the Board of Directors by examining its size, the areas of expertise of each director and ensuring that governance principles are followed. The Corporate Governance Committee is responsible for the recruitment of candidates when need be and for the development of orientation and continuing education policy for directors. The Corporate Governance Committee reviews the corporate governance rules and guidelines published from time to time by regulatory agencies and by shareholders groups and reports to the Board of Directors. Guidelines are adopted if they are suitable for the Corporation given its size and level of activities. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_31"><span style="font-weight:bold">D.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Employees </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As at November&#160;30, 2023, we had a total of 58 employees in Canada, 42 employees in the United States and 3 employees in Ireland. All of our employees are engaged in the following activities: (i) 31 in administration, (ii) 20 in regulatory and medical, (iii) 39 in commercialization, including marketing, and (iv) 13 in research and development functions. None of our employees are unionized. We believe the relations with our employees are good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Through Syneos, as a November&#160;30, 2023, we had an additional 6 full-time and 5 part-time persons dedicated to the commercialization of <span style="font-style:italic">EGRIFTA SV</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;12, 2023 and October&#160;24, 2023, the Corporation announced a reduction of positions. The cumulative number of positions reduced was 42. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_32"><span style="font-weight:bold">E.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Share ownership </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">See &#8220;Item 6A &#8211; Directors and Senior Management&#8221; of this Annual Report for additional information on the share ownership and details on the number of options and DSUs held by our directors and Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As of the date of this Annual Report, the total number of Common Shares held by our directors and Executive Officers amounted to 560,277, which represented 1.22% of our issued and outstanding Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">See &#8220;Item 6B &#8211; Compensation&#8221; of this Annual Report for a description of the Option Plan and DSU Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_33"><span style="font-weight:bold">F.</span><span style="font-weight:bold"><span style="font-style:italic"></span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify"><span style="font-style:italic">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">On November&#160;30, 2023, the Board of Directors of the Corporation adopted a compensation recovery policy (&#8220;Clawback Policy&#8221;) in compliance with Nasdaq Rule 5608. The Clawback Policy is effective for &#8220;Incentive Compensation&#8221; paid to Executive Officers on and after October&#160;2, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">The Clawback Policy is administered by the Compensation Committee which has authority to interpret, issue and revoke rules and construe the Clawback Policy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">The Clawback Policy is binding and enforceable against all Executive Officers and provides that the Corporation will recover, recoup, cancel or forfeit reasonably promptly from Executive Officers the amount of &#8220;Erroneously Awarded Compensation&#8221; in the event the Corporation is required to prepare a &#8220;Restatement&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">The Compensation Committee has discretion in determining the manner and method for recovering Erroneously Awarded Compensation, including (i)&#160;seeking recovery or reimbursement of any cash (including bonus or retention awards) and equity-based award made to the Executive Officer, (ii)&#160;cancelling or offsetting against any contractually required or planned future cash (including bonus or retention awards) or equity-based awards made to the Executive Officer, (iii)&#160;requiring the forfeiture of or cancelling of any previously-granted or awarded cash (including bonus or retention awards) or equity-based awards made to the Executive Officer, or (iv)&#160;offsetting, requiring the forfeiture of or cancelling amounts paid or to be paid in severance to the Executive Officer pursuant to any severance or similar policy of the Corporation. The Clawback Policy provides for limited exceptions under which the Compensation Committee may omit to recover Erroneously Awarded Compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">Under the Clawback Policy, the term &#8220;Incentive Compensation&#8221; means any compensation, cash or equity, that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure, such as a measure based on or derived from the financial statement of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">Under the Clawback Policy, the term &#8220;Erroneously Awarded Compensation&#8221; means the amount of Incentive Compensation received by an Executive Officer that exceeds the amount of Incentive Compensation that otherwise would have been received by the Executive Officer had it been determined based on the restated performance metrics and/or restated financial statements or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">Under the Clawback Policy, the term &#8220;Restatement&#8221; means, among other things, an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">The adoption of the Clawback Policy is in addition to, and not in substitution for, the clawback provision contained in the Option Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_34">Item&#8201;7. Major Shareholders and Related Party Transactions </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_35"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Major shareholders.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Based on information publicly available as of February&#160;15, 2024, on EDGAR (<span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.sec.gov/edgar</span></span><span style="font-family:Times New Roman">), the following table provides information on the major shareholders of the Company that are the beneficial owners of, or have control over, 5% or more of the Common Shares. No major shareholder has different voting rights. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Names&#160;of&#160;shareholders</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of&#160;Common<br/>Shares<sup style="font-size:75%; vertical-align:top">&#160;</sup></span></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Percentage&#160;of<br/>Common&#160;Shares</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investissement Qu&#233;bec</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">9,118,184</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">19.8%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soleus Capital Master Fund, L.P.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">4,801,376</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">10.4%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AIGH Capital Management, LLC</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">3,719,302</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">8.1%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Management, LLC</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2,682,228</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;white-space:nowrap">5.8%</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Soleus Capital Master Fund, L.P. (&#8220;Soleus&#8221;) reported holding 2,199,781 Common Shares on February&#160;14, 2023, or approximately 9.03% of the then issued and outstanding Common Shares. Soleus reported holding 2,031,477 Common Shares on November&#160;14, 2023, or approximately 8.3% of the then issued and outstanding Common Shares. Soleus reported holding 1,923,021 Common Shares on February&#160;10, 2022, or approximately 7.9% of the then issued and outstanding Common Shares. Soleus reported holding 1,468,846 Common Shares on February 23, 2021, or approximately 6.03% of the then issued and outstanding Common Shares. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following table indicates as of December&#160;31, 2023, the total number of Common Shares issued and outstanding, the approximate total number of holders of record of Common Shares, the number of holders of record of Common Shares with U.S. addresses, the portion of the outstanding Common Shares held by U.S. holders of record and the percentage of Common Shares held by U.S. holders of record. This table does not indicate beneficial ownership of Common Shares. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" style="BORDER:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Total&#160;number&#160;of&#8195;</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">holders&#160;of&#160;record<sup style="font-size:75%; vertical-align:top">(1)</sup>&#8195;</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Total&#160;number&#160;of&#8195;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common&#160;Shares&#160;issued&#8195;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">and outstanding&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of&#160;U.S&#8195;&#8195;</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">holders&#160;of&#160;record&#8195;&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number&#160;of&#160;Common&#8195;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Shares&#160;held&#160;by&#160;U.S.&#8195;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">holders&#160;of&#160;record<sup style="font-size:75%; vertical-align:top">&#160;(2)</sup>&#8195;</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Percentage&#160;of&#8195;</span><br/> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common&#160;Shares&#160;held&#8195;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">by U.S. holders of&#8195;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">record&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">45,980,019</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">2</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">13,918,352</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td align="center" style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">30.27%</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">A holder of record is a shareholder whose Common Shares are registered in his name in the Corporation&#8217;s share register. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">The computation of the number of Common Shares held in the U.S. is based upon the number of registered holders of record with U.S. addresses. U.S. residents may beneficially own Common Shares owned of record by <span style="white-space:nowrap">non-U.S.</span> residents. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation is not owned or controlled, directly or indirectly, by any other corporation or by any foreign government. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">To our knowledge, there is no arrangement, the operation of which may at a subsequent date result in a change in control of the Corporation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_36"><span style="font-weight:bold">B.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Related party transactions.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">No material related party transactions have occurred since the beginning of our last fiscal year or as at February&#160;20, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None of our directors and Executive Officers or persons who held such positions during the fiscal year ended November&#160;30, 2023 is indebted to us or any of our subsidiaries or was indebted to us or any of our subsidiaries at any time during the fiscal year ended November&#160;30, 2023 or as at February&#160;20, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_37"><span style="font-weight:bold">C.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Interests of experts and counsel.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_38">Item&#8201;8. Financial Information </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_39"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Consolidated Statements and Other Financial Information.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">See &#8220;Item 18 &#8211; Financial Statements&#8221; of this Annual Report for certain other information required by this Item. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_40">Item&#8201;9. The Offer and Listings </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_41"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Offer and listing details</span></span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable, except for Item 9A(4). Our Common Shares are listed and posted for trading on the TSX and on the Nasdaq under the symbol &#8220;TH&#8221; and &#8220;THTX&#8221;, respectively. See &#8220;Item 10B &#8211; Memorandum and Articles of Association &#8211; Rights, Preference and Restrictions&#8221; of this Annual Report for a description of the rights attached to our Common Shares. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_42"><span style="font-weight:bold">B.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Plan of distribution.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:1%; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_43"><span style="font-weight:bold">C.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Markets.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our Common Shares are listed and posted for trading on the TSX and on the Nasdaq under the symbol &#8220;TH&#8221; and &#8220;THTX&#8221;, respectively. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_44"><span style="font-weight:bold">D.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Selling shareholders.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_45"><span style="font-weight:bold">E.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Dilution.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_46"><span style="font-weight:bold">F.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Expenses of the issue.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_47">Item&#8201;10. Additional Information </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_48"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Share capital.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_49"><span style="font-weight:bold">B.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Memorandum and Articles of Association.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Incorporation</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are governed by our articles of incorporation (&#8220;Articles&#8221;), under the QBCA, and by our general <span style="white-space:nowrap">by-laws</span> <span style="white-space:nowrap">(&#8220;By-laws&#8221;).</span> Our Articles and <span style="white-space:nowrap">By-laws</span> can be found on our website (<span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.theratech.com</span></span><span style="font-family:Times New Roman">) under the tab &#8220;Investors -Corporate Governance &#8211; Documents&#160;&amp; Charters&#8221; and under the heading &#8220;Corporate Documents&#8221;. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Objects and Purposes</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our Articles and <span style="white-space:nowrap">By-laws</span> do not define any of the Corporation&#8217;s objects and purposes. In that respect, the Corporation has no limit on the type of business it can carry out. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Directors</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our Articles do not contain any provision regarding: (a)&#160;a director&#8217;s power to vote on a proposal, arrangement or contract in which the director is materially interested; (b)&#160;a director&#8217;s power in the absence of an independent quorum, to vote compensation to itself or any members of the committees of the Board of Directors; (c)&#160;borrowing powers exercisable by the directors and how such powers can be varied; (d)&#160;retirement or <span style="white-space:nowrap">non-retirement</span> of directors under an age limit requirement; and (e)&#160;number of shares, if any, required for a director&#8217;s qualification. However, our <span style="white-space:nowrap">By-laws</span> provide that a director shall avoid placing himself/herself in a situation where his/her personal interest would conflict with his/her obligations as a director of the Corporation. If such is the case, our <span style="white-space:nowrap">By-laws</span> provide that he/she must declare to the Corporation any interest he/she has in an enterprise or other entity that may place him/her in a situation of conflict of interest. Our <span style="white-space:nowrap">By-laws</span> do not prohibit a director from acquiring rights in the Corporation&#8217;s property or from entering into contracts with the Corporation on the condition that he/she immediately informs the Corporation of such fact by indicating any interest he/she has in an enterprise or other entity that may place him/her in a situation of conflict of interest. A director who is interested in an acquisition of property from the Corporation or a contract with the Corporation must abstain, unless required, from the discussion and voting on the question. However, the foregoing does not apply to questions regarding the remuneration or directorship of a director. Furthermore, the <span style="white-space:nowrap">By-laws</span> state that an interested director must leave the meeting while the Board of Directors discusses and votes on such acquisition or contract if requested by the Chair of the Board of Directors or any director. The same rule is applicable to any director who has an interest in an offeror making an offer to purchase the Common Shares of the Corporation by way of a take-over bid while the Board of Directors discusses and votes on such offer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The quorum at every meeting of the Board of Directors has been set to the majority of the directors in office, with a minimum of three (3). Our <span style="white-space:nowrap">By-laws</span> require that a quorum be present for the entire duration of the meeting. As a result of the foregoing, in the absence of a quorum, a director has no power to make any decision regarding, among other things, compensation to himself/herself or to any member of the committees of the Board of Directors. Our <span style="white-space:nowrap">By-laws</span> provide that the directors may borrow money upon the credit of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> do not contain any requirements with respect to a mandatory retirement age for our directors and the number of shares required for directors&#8217; qualifications. However, in December 2010, the Board adopted the Shareholding Policy for its directors and Executive Officers. See &#8220;Item 6A &#8211; Directors and senior management &#8211; Directors and Executive Officers Shareholding Policy&#8221; of this Annual Report for a description of the Shareholding Policy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Board has adopted a formal retirement policy in the context of its succession planning process. Under this policy, directors who are not employees of the Corporation who reach the age of 75 or who have been acting as directors for fifteen (15)&#160;consecutive years may not be nominees for <span style="white-space:nowrap">re-election</span> at the subsequent annual meeting of shareholders. Mr.&#160;G&#233;rald&#160;A. Lacoste is grandfathered from this policy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> contain a framework in relation to the nomination of directors of the Corporation (&#8220;Advance Notice <span style="white-space:nowrap">By-Law&#8221;).</span> The Advance Notice <span style="white-space:nowrap">By-law</span> fixes a deadline by which director nominations must be submitted by a shareholder to the Corporation prior to any annual or special meeting of shareholders and specifies the information that a shareholder must include in the notice. Pursuant to the Advance Notice <span style="white-space:nowrap">By-law,</span> notices must be made, not less than thirty days (30)&#160;prior to the date of the annual meeting of shareholders; provided, however, that in the event that the annual meeting of shareholders is to be held on a date that is less than fifty (50)&#160;days after the date (&#8220;Notice Date&#8221;) on which the first public announcement of the date of the meeting was made, notice by the nominating shareholder may be made not later than the close of business on the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day following the Notice Date. In the case of a special meeting (which is not also an annual meeting) of shareholders called for the purpose of electing directors (whether or not called for other purposes), notice by the nominating shareholders must be made not later than the close of business on the fifteenth (15<sup style="font-size:75%; vertical-align:top">th</sup>) day following the date on which the first public announcement of the date of the meeting was made. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Description of Capital</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are authorized to issue an unlimited number of Common Shares and an unlimited number of preferred shares issuable in series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Rights, Preference and Restrictions</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Subject to the priority rights of holders of preferred shares, holders of Common Shares are entitled to any dividend declared by the Board of Directors, to one vote per share at meetings of our shareholders and, in the event of our liquidation or dissolution, to participate in the distribution of the assets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Preferred shares carry no voting rights. Preferred shares may be issued at any time in one or more series. Our articles of incorporation give our Board of Directors the power to fix the number of preferred shares and the consideration per share, as well as to determine the provisions attached to the preferred shares of each series (including dividends, redemption and conversion rights, if any). The shares of every series of preferred shares will have priority over all our other shares, including Common Shares, with respect to the payment of dividends and return of capital in the event of our liquidation or dissolution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Common Shares issued represent the total voting rights pertaining to our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our shareholders are not liable to capital calls by the Corporation and there exists no provision discriminating against any existing or prospective holder of our Common Shares as a result of a shareholder owning a substantial number of our Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In order to change the rights attached to our Common Shares and, if issued, the rights attached to our preferred shares, the vote of at least 66 2/3% of the holders of Common Shares or holders of preferred shares, as the case may be, must be cast at a shareholders meeting called for amending the rights attached to our Common Shares or preferred shares, as the case may be. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Shareholder Meetings</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> provide that the annual meeting of shareholders of the Corporation must be held on a yearly basis on such date and on such time as may be fixed by the Board of Directors. However, under the rules and regulations of the TSX, annual general meetings must be held within six (6)&#160;months of the fiscal <span style="white-space:nowrap">year-end</span> of a listed issuer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> provide that special meetings of shareholders may be called at any time as determined by the Board of Directors, the Chair of the Board of Directors or the President and Chief Executive Officer of the Corporation. Our shareholders are entitled to call special general meetings of shareholders provided that they hold at least 10% of the issued and outstanding classes of shares entitled to vote at the meeting so called. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> provide that notice of each annual and special meeting of shareholders must be sent to the shareholders entitled to attend such meetings at least <span style="white-space:nowrap">twenty-one</span> (21)&#160;days prior to the date fixed for such meeting. The only persons entitled to assist to a meeting of shareholders are the shareholders themselves, unless this requirement is waived by the Chair of the meeting at the beginning of each meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> provide that one or more persons present in person or duly represented and holding not less than 10% of the shares giving the right to vote at a meeting constitute the quorum. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Limitations on Rights to Own Securities</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Neither Canadian law nor our Articles or <span style="white-space:nowrap">By-laws</span> limit the right of a <span style="white-space:nowrap">non-resident</span> to hold or vote our Common Shares, other than as provided in the <span style="font-style:italic">Investment</span> <span style="font-style:italic">Canada Act </span>(&#8220;Investment Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Investment Act requires any person that is a <span style="white-space:nowrap">&#8220;non-Canadian&#8221;</span> (as defined in the Investment Act) who acquires &#8220;control&#8221; (as defined in the Investment Act) of an existing Canadian business to file either a <span style="white-space:nowrap">pre-closing</span> application for review or a post-closing notification with Innovation, Science and Economic Development Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As of the date hereof, the threshold for review of a direct acquisition of control of a <span style="white-space:nowrap">non-cultural</span> Canadian business by a World Trade Organization member country investor that is not a state-owned enterprise is an enterprise value of assets that exceeds CA$1.326&#160;billion. For &#8220;trade agreement investors&#8221; that are not state-owned enterprises (as defined in the Investment Act), the threshold for review of a direct acquisition of control of a <span style="white-space:nowrap">non-cultural</span> Canadian business is an enterprise value of assets that exceeds CA$1.989&#160;billion. The enterprise value review thresholds for both World Trade Organization member countries and trade agreement investors are indexed to annual GDP growth and are adjusted accordingly each year. For purposes of a publicly traded company, the &#8220;enterprise value&#8221; of the assets of the Canadian business is equal to the market capitalization of the entity, plus its liabilities (excluding its operating liabilities), minus its cash and cash equivalents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">As such, under the Investment Act, the acquisition of control of us (either through the acquisition of our Common Shares or all or substantially all our assets) by a <span style="white-space:nowrap">non-Canadian</span> who is a World Trade Organization member country investor or a trade agreement investor, including a U.S. investor, would be reviewable only if the enterprise value of our assets exceeds the specified threshold for review. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Where the acquisition of control is a reviewable transaction, the Investment Act generally prohibits the implementation of the reviewable transaction unless, after review, the relevant Minister is satisfied or deemed to be satisfied that the acquisition is likely to be of net benefit to Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The acquisition of a majority of the voting interests of an entity is deemed to be acquisition of &#8220;control&#8221; of that entity. The acquisition of less than a majority but <span style="white-space:nowrap">one-third</span> or more of the total number of votes attached to all of the voting shares of a corporation or of an equivalent undivided ownership interest in the total number of votes attached to all of the voting shares of the corporation is presumed to be an acquisition of control of that corporation unless it can be established that, on the acquisition, the corporation is not controlled in fact by the acquiror through the ownership of voting shares. The acquisition of less than <span style="white-space:nowrap">one-third</span> of the total number of votes attached to all of the voting shares of a corporation is deemed not to be acquisition of control of that corporation subject to certain discretionary rights relative to investments involving state-owned enterprises. Other than in connection with a &#8220;national security&#8221; review, discussed below, certain transactions in relation to our Common Shares would be exempt from the Investment Act including: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the acquisition of our Common Shares by a person in the ordinary course of that person&#8217;s business as a trader or dealer in securities; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the acquisition or control of us in connection with the realization of security granted for a loan or other financial assistance and not for any purpose related to the provisions of the Investment Act, if the acquisition is subject to approval under the Bank Act, the Cooperative Credit Associations Act, the Insurance Companies Act or the Trust and Loan Companies Act; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the acquisition or control of us by reason of an amalgamation, merger, consolidation or corporate reorganization following which the ultimate direct or indirect control in fact of us, through the ownership of our voting interests, remains unchanged. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the national security regime in the Investment Act, review on a discretionary basis may also be undertaken by the federal government in respect of a much broader range of investments by a <span style="white-space:nowrap">non-Canadian</span> to &#8220;acquire, in whole or in part, or to establish an entity carrying on all or any part of its operations in Canada&#8221;. The relevant test is whether such an investment by a <span style="white-space:nowrap">non-Canadian</span> could be &#8220;injurious to national security&#8221;. The Minister of Innovation, Science and Economic Development has broad discretion to determine whether an investor is a <span style="white-space:nowrap">non-Canadian</span> and therefore may be subject to national security review. Review on national security grounds is at the discretion of the federal government and may occur on a <span style="white-space:nowrap">pre-</span> or post-closing basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Change in Control</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our <span style="white-space:nowrap">By-laws</span> do not contain any provision that would have the effect of delaying, deferring or preventing a change in control of the Corporation. However, the Corporation has a shareholder rights plan in place which could act as a deterrent to acquire the control of the Corporation. See &#8216;Item 10B -Memorandum of Articles of Association - Shareholder Rights Plan&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Shareholder Rights Plan</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On March&#160;3, 2022, the Board approved the amendment and renewal of the Corporation&#8217;s Shareholder Rights Plan and, on April&#160;6, 2022, the Corporation and Computershare Trust Services of Canada entered into an amended and restated shareholder rights plan agreement (&#8220;Rights Plan&#8221;) which was subsequently ratified by the shareholders on May&#160;9, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The original Shareholder Rights Plan was adopted by the Board on February&#160;10, 2010 and ratified by the shareholders on March&#160;25, 2010. It was first renewed on February&#160;21, 2013 and ratified by the shareholders on May&#160;24, 2013 and subsequently renewed on April&#160;15, 2016 and April&#160;10, 2019 and ratified by shareholders on May&#160;17, 2016 and May&#160;15, 2019. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Purpose of the Rights Plan </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The purpose of the Rights Plan is to ensure equal treatment of shareholders and to give adequate time for shareholders to properly assess the merits of a bid without undue pressure, and to allow competing bids to emerge. The Rights Plan is designed to give the Board time to consider alternatives, allowing shareholders to receive full and fair value for their shares. The Rights Plan was not renewed by the Board in response to any acquisition proposal and is not designed to secure the continuance in office of the current management or the directors of the Corporation. The renewal of the Rights Plan does not in any way lessen the duties of the directors to fully and fairly examine all bids which may be made to acquire the Common Shares of the Corporation and to exercise such duties with a view to the best interest of the shareholders and the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under Canadian securities legislation, a takeover bid generally means an offer to acquire voting or equity voting shares of a corporation that, together with shares already owned by the bidder and certain parties related thereto, amount to 20% or more of the outstanding shares of that class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the legislative framework for takeover bids in Canada, as amended on May&#160;9, 2016, shareholders may not be treated equally if an important number of Common Shares is acquired pursuant to a private agreement in which a small group of shareholders or a shareholder dispose of their Common Shares at a premium to market price, which premium is not shared with the other shareholders of the Corporation. In addition, a person may gradually accumulate Common Shares through stock exchange acquisitions which results in an acquisition of control of the Corporation, without payment of fair value for control or a fair sharing of a control premium amongst all shareholders. The Rights Plan addresses these concerns by applying to all acquisitions of 20% or more of the Common Shares of the Corporation, ensuring that shareholders receive equal treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Rights Plan also addresses the use of &#8220;hard&#8221; <span style="white-space:nowrap">lock-up</span> agreements, whereby shareholders commit to tender their Common Shares to a takeover bid in <span style="white-space:nowrap">lock-up</span> agreements which are either irrevocable or revocable but subject to restrictive termination conditions. Such agreements could have the effect of deterring other potential bidders from bringing forward competing bids, particularly where the number of <span style="white-space:nowrap">lock-up</span> shares would make it difficult or unlikely for a competing bidder&#8217;s bid to achieve the 50% minimum tender requirement imposed by the takeover bid rules. The Rights Plan is designed to prevent these <span style="white-space:nowrap">lock-up</span> agreements that are not in the best interest of the Corporation and its shareholders and to encourage bidders to structure <span style="white-space:nowrap">lock-up</span> agreements so as to provide the <span style="white-space:nowrap">locked-up</span> shareholders reasonable flexibility to terminate such agreements to deposit their shares to a higher value bid or support another transaction offering greater value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The issue of rights (&#8220;Rights&#8221;) will not in any way adversely alter the financial condition of the Corporation and will not change the way in which shareholders trade their Common Shares. However, by permitting holders of Rights other than an &#8220;Acquiring Person&#8221; (as defined below) to acquire additional Common Shares of the Corporation at a discount to market value, the Rights may cause substantial dilution to a person or group that acquires 20% or more of the outstanding Common Shares other than by way of a &#8220;Permitted Bid&#8221; (as defined below). A potential bidder can avoid the dilutive features of the Rights Plan by making a bid that conforms to the requirements of a Permitted Bid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has reviewed the Rights Plan for conformity with current practices of Canadian companies with respect to shareholder protection rights plans and believe that the Rights Plan preserves the fair treatment of shareholders, is consistent with best Canadian corporate practices and addresses institutional investor guidelines. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Terms of the Rights Plan </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following is a summary of the principal terms of the Rights Plan and is provided subject to the terms and conditions thereof. A complete copy of the Rights Plan has been filed and is available on SEDAR+ at <span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.sedarplus.ca</span></span><span style="font-family:Times New Roman"> and on EDGAR at www.sec.gov/edgar. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Issue of Rights </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In order to implement the rights plan in 2010, the Board authorized the Corporation to issue one right in respect of each Common Share outstanding as of 6:00 p.m. (Montreal time) on March&#160;25, 2010 (&#8220;Record Time&#8221;). One Right was also issued with each Common Share issued after March&#160;25, 2010, and one Right will also continue to be issued and attached to each subsequently issued Common Share if the Rights Plan is approved by shareholders at the Meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Rights-Exercise Privilege </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Rights will be separate from the Common Shares to which they are attached and will become exercisable at the time (&#8220;Separation Time&#8221;) that is ten (10)&#160;business days after the earlier of: (i)&#160;the first date of public announcement that an &#8220;Acquiring Person&#8221; (as defined below) has become such; (ii)&#160;the date of commencement of, or first public announcement in respect of, a takeover bid which will permit an offeror to hold 20% or more of the Common Shares, other than by an acquisition pursuant to a takeover bid permitted by the Rights Plan (&#8220;Permitted Bid&#8221; as defined below); (iii) the date upon which a Permitted Bid ceases to be a Permitted Bid; or (iv)&#160;such other date as may be determined in good faith by the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The acquisition permitting a person (&#8220;Acquiring Person&#8221;), including others acting jointly or in concert with such person, to hold 20% or more of the outstanding Common Shares, other than by way of a Permitted Bid, is referred to as a <span style="white-space:nowrap">&#8220;Flip-in</span> Event.&#8221; Any Rights held by an Acquiring Person on or after the earlier of the Separation Time or the first date of a public announcement (&#8220;Common Share Acquisition Date&#8221;) by the Corporation or an Acquiring Person that an Acquiring Person has become such will become null and void upon the occurrence of a <span style="white-space:nowrap">Flip-in</span> Event. Ten (10)&#160;trading days (or such longer period as may be required to satisfy the requirements of applicable securities laws) after the occurrence of the Common Share Acquisition Date, each Right (other than those held by the Acquiring Person) will permit the holder to purchase for the exercise price that number of Common Shares determined as follows: a value of twice the exercise price divided by the &#8220;Market Price&#8221; (defined under the Rights Plan as being the average weighted trading price per Common Share for the 20 consecutive trading days through and including the trading day immediately preceding the relevant date) on the Common Share Acquisition Date. The exercise price under the Rights Plan has been set to three (3)&#160;times the Market Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Upon the occurrence of a <span style="white-space:nowrap">Flip-in</span> Event and the separation of the Rights from the Common Shares, reported earnings per share on a fully diluted or <span style="white-space:nowrap">non-diluted</span> basis may be affected. Holders of Rights who do not exercise their Rights upon the occurrence of a <span style="white-space:nowrap">Flip-in</span> Event may suffer substantial dilution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Permitted <span style="white-space:nowrap">Lock-Up</span> Agreements </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A bidder may enter into <span style="white-space:nowrap">lock-up</span> agreements with the shareholders of the Corporation whereby such shareholders agree to tender their Common Shares to the takeover bid <span style="white-space:nowrap">(&#8220;Lock-up</span> Bid&#8221;) without a <span style="white-space:nowrap">Flip-in</span> Event occurring. Any such agreement must be made available to the public and must permit or must have the effect to permit the shareholder to withdraw the Common Shares to tender to another takeover bid or to support another transaction that exceeds the value of the <span style="white-space:nowrap">Lock-up</span> Bid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Certificates and Transferability </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Prior to the Separation Time, the Rights will be evidenced by a legend imprinted on certificates for Common Shares issued after the Record Time (or, if issued in book entry form, by the book entry form registration for the associated Common Shares). Rights are also attached to Common Shares outstanding on the Record Time, although share certificates will not bear such a legend. Prior to the Separation Time, Rights will not be transferable separately from the Common Shares. From and after the Separation Time, the Rights will be evidenced by Rights certificates (or separate book entry registration), which will be transferable and traded separately from the Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">&#8220;Permitted Bid&#8221; Requirements </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A &#8220;Permitted Bid&#8221; is a takeover bid that does not trigger the exercise of Rights. A &#8220;Permitted Bid&#8221; is a bid that aims to acquire shares which, together with the other securities beneficially owned by the bidder, represent not less than 20% of the outstanding Common Shares and satisfies the following requirements: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the bid is made by means of a takeover bid circular; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the bid must be made to all holders of Common Shares; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the bid must be outstanding for a minimum period of 105 days or such shorter period that a take-over bid must remain open for deposits of securities, in the applicable circumstances, pursuant to Canadian securities laws; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">Common Shares and/or Convertible Securities tendered pursuant to the bid may not be taken up prior to the expiry of the period referred to in paragraph (iii)&#160;above and only if at such time more than 50% of the Common Shares and/or Convertible Securities held by the shareholders other than the bidder, its associates and affiliates, and persons acting jointly or in concert with such persons (&#8220;Independent Shareholders&#8221;), have been tendered pursuant to the bid and not withdrawn; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:6%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">if more than 50% of the Common Shares and/or Convertible Securities held by Independent Shareholders are tendered to the bid within the <span style="white-space:nowrap">105-day</span> period, the bidder must make a public announcement of that fact and the bid must remain open for deposits of shares for an additional ten (10)&#160;business days from the date of such public announcement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Rights Plan allows for a competing Permitted Bid (&#8220;Competing Permitted Bid&#8221;) to be made while a Permitted Bid is in existence. A Competing Permitted Bid must satisfy all the requirements of a Permitted Bid except that, as proposed to be amended, it must be outstanding for a minimum number of days as required under Canadian securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Waiver and Redemptions </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Board acting in good faith may, prior to a <span style="white-space:nowrap">Flip-in</span> Event, waive the dilutive effects of the Rights Plan in respect of a particular <span style="white-space:nowrap">Flip-in</span> Event that would result from a takeover bid made by way of takeover bid circular to all holders of Common Shares, in which event such waiver would be deemed also to be a waiver in respect of any other <span style="white-space:nowrap">Flip-in</span> Event. The Board may also waive the Rights Plan in respect of a particular <span style="white-space:nowrap">Flip-in</span> Event that has occurred through inadvertence, provided that the Acquiring Person that inadvertently triggered such <span style="white-space:nowrap">Flip-in</span> Event reduces its beneficial holdings to less than 20% of the outstanding Common Shares within 14 days or any other period that may be specified by the Board. At any time prior to the occurrence of a <span style="white-space:nowrap">Flip-in</span> Event, the Board may, subject to the prior approval of the holders of Common Shares, elect to redeem all, but not less than all, of the outstanding Rights at a price of $0.0001 per right. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Exemption for Investment Managers </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Investment managers (for client accounts), trust companies and pension funds (acting in their capacity as trustees and administrators) acquiring shares permitting them to hold 20% or more of the Common Shares are exempt from triggering a <span style="white-space:nowrap">Flip-in</span> Event, provided that they are not making, or are not part of a group making, a takeover bid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Supplements and Amendments </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation is authorized to make amendments to the Rights Plan to correct any clerical or typographical error or to maintain the validity of the Rights Plan as a result of changes in laws or regulations. Material amendments or supplements to the Rights Plan will require, subject to the regulatory authorities, the prior approval of the shareholders or, after the Separation Time, holders of Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman"><span style="text-decoration:underline">Differences in Corporate Law</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are governed by the QBCA which is generally similar to laws applicable to United States corporations. Below are significant differences between the QBCA and the DGCL, which governs companies incorporated in the State of Delaware. The DGCL was selected as a comparable against the QBCA given that many U.S. companies are incorporated under the DGCL. This summary is not an exhaustive review of the two statutes, and reference should be made to the full text of both statutes for particulars of the differences. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Quebec</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Number and Election of Directors</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, the board of directors must consist of at least one member. The number of directors shall be fixed by the bylaws of the corporation, unless the certificate of incorporation fixes the number of directors, in which case a change in the number of directors shall only be made by an amendment of the certificate of incorporation. Under the DGCL, directors are elected at annual stockholder meetings by plurality vote of the stockholders, unless a shareholder-adopted bylaw prescribes a different required vote.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, the board of directors of a corporation must consist of at least three members, at least two of whom must not be officers or employees of the corporation or an affiliate of the corporation, so long as the corporation remains a &#8220;reporting issuer&#8221; for purposes of the QBCA, which includes a corporation that has made a distribution of securities to the public. Under the QBCA, directors are elected by the shareholders, in the manner and for the term, not exceeding three years, set out in the corporation&#8217;s bylaws. Our By laws provide that our directors are elected at each annual meeting of shareholders and our articles of incorporation provide that directors may appoint one or more directors between such meetings until the close of the next annual meeting of the shareholders, so long as the total number of directors appointed does not exceed thirty-three and <span style="white-space:nowrap">one-third</span> percent (33 1/3%) of the number of directors elected at the previous annual meeting of shareholders.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Removal of Directors</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, any or all directors may be removed with or without cause by the holders of a majority of shares entitled to vote at an election of directors unless the corporation has a classified board (and the certificate of incorporation does not say otherwise), then such removal can only be for cause, or in certain other circumstances if the corporation has cumulative voting.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, unless the articles of a corporation provide for cumulative voting (which is not the case for us), shareholders of the corporation may, by resolution passed by a majority of the vote cast thereon at a special meeting of shareholders, remove any or all directors from office and may elect any qualified person to fill the resulting vacancy.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Vacancies on the Board of Directors</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, vacancies and newly created directorships resulting from an increase in the authorized number of directors elected by all the stockholders having the right to vote as a single class, may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, vacancies that exist on the board of directors may generally be filled by the board if the remaining directors constitute a quorum. In the absence of a quorum, the remaining directors shall call a meeting of shareholders to fill the vacancy.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Board of Directors Quorum and Vote Requirements</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, a majority of the total number of directors shall constitute a quorum for the transaction of business unless the certificate or bylaws require a greater number. The bylaws may lower the number required for a quorum to <span style="white-space:nowrap">one-third</span> the number of directors, but no less.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, subject to the corporation&#8217;s bylaws, a majority of the directors in office constitutes a quorum at any meeting of the board. Our By laws also provide that a majority of the directors in office, although no less than three, constitutes a quorum at any meeting of the board.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, the board of directors may take action by the majority vote of the directors present at a meeting at which a quorum is present unless the certificate of incorporation or bylaws require a greater vote.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, a quorum of directors may exercise all the powers of the directors despite any vacancy on the board.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transactions with Directors and Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">The DGCL generally provides that no transaction between a corporation and one or more of its directors or officers, or between a corporation and any other corporation or other organization in which one or more of its directors or officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes the transaction, or solely because any such director&#8217;s or officer&#8217;s votes are counted for such purpose, if (i)&#160;the material facts as to the director&#8217;s or officer&#8217;s interest and as to the transaction are known to the board of directors or the committee, and the board or committee in good faith authorizes the transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum (ii)&#160;the material facts as to the director&#8217;s or officer&#8217;s interest and as to the transaction are disclosed or are known to the stockholders entitled to vote thereon, and the transaction is specifically approved in good faith by vote of the stockholders; or (iii)&#160;the transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the board of directors, a committee or the stockholders.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, every director or officer of a corporation must disclose the nature and value of any interest he or she has in a contract or transaction to which the corporation is a party. For the purposes of this rule, &#8220;interest&#8221; means any financial stake in a contract or transaction that may reasonably be considered likely to influence decision-making. Furthermore, a proposed contract or a proposed transaction, including related negotiations, is considered a contract or transaction. In addition, a director or an officer must disclose any contract or transaction to which the corporation and any of the following are a party: (i)&#160;an associate of the director or officer; (ii)&#160;a group of which the director or officer is a director or officer; or (iii)&#160;a group in which the director or officer or an associate of the director or officer has an interest. Such disclosure is required even for a contract or transaction that does not require approval by the board of directors. If a director is required to disclose his or her interest in a contract or transaction, such director is not allowed to vote on any resolution to approve, amend or terminate the contract or transaction or be present during deliberations concerning the approval, amendment or termination of such contract or transaction, unless the contract or transaction (i)&#160;relates primarily to the remuneration of the director or an associate of the director as a director or an affiliate of the corporation, or, if the corporation is not a reporting issuer, as an officer, employee or mandatory of the corporation or an affiliate of the corporation, (ii)&#160;is for indemnity or liability insurance under the QBCA, or (iii)&#160;is with an affiliate of the corporation, and the sole interest of the director is as a director or officer of the affiliate. If a director or officer does not disclose his or her interest in accordance with the QBCA, or (in the case of a director) votes in respect of a resolution on a contract or transaction in which he or she is interested contrary to the QBCA, the corporation or a shareholder may ask the court to declare the contract or transaction null and to require the director or officer to account to the corporation for any profit or gain realized on it by the director or officer or the associates of the director or officer, and to remit the profit or gain to the corporation, according to the conditions the court considers appropriate. However, the contract or transaction may not be declared null if it was approved by the board of directors and the contract or transaction was in the interest of the corporation when it was approved, nor may the director or officer concerned, in such a case, be required to account for any profit or gain realized or to remit the profit or gain to the corporation. In addition, the contract or transaction may not be declared null if it was approved by ordinary resolution by the shareholders entitled to vote who do not have an interest in the contract or transaction, the required disclosure was made to the shareholders before the transaction was approved and the contract or transaction was in the best interests of the corporation when it was approved, and if the director or officer acted honestly and in good faith, he or she may not be required to account for the profit or gain realized and to remit the profit or gain to the corporation.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Limitation on Liability of Directors</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">The DGCL permits indemnification for derivative suits only for expenses (including legal fees) and only if the person is not found liable, unless a court determines the person is fairly and reasonably entitled to the indemnification.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the QBCA, a corporation must indemnify a director or officer, a former director or officer, a mandatory or any other person who acts or acted at the corporation&#8217;s request as a director or officer, or an individual acting in a similar capacity of another group (who is referred to in this document as an indemnifiable person) against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the indemnifiable person on the exercise of the person&#8217;s functions or arising from any investigative or other proceeding in which the person is involved if (i)&#160;the person acted with honestly and loyalty in the interest of the corporation or other group, and (ii)&#160;in the case of a proceeding enforceable by a monetary penalty, the person had reasonable grounds for believing the person&#8217;s conduct was lawful.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">An indemnifiable person may not be indemnified by the corporation if the court determines that the person has committed an intentional or gross fault. In the case of a derivative action, indemnity may be made only with court approval.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Call and Notice of Stockholder Meetings</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, an annual stockholder meeting is held on such date and at such time as designated by or in the manner provided in the bylaws and any stockholders meeting may be held at such place as may be designated by or in the manner provided in the certificate of incorporation or bylaws, or if not so designated, as determined by the board of directors. Special stockholder meetings may be called by the board of directors or any other person authorized to call such meeting under the corporation&#8217;s certificate of incorporation or bylaws. If an annual meeting for election of directors is not held on the date designated or an action by written consent to elect directors in lieu of an annual meeting has not been taken within 30 days after the date designated for the annual meeting, or if no date has been designated, for a period of 13 months after the later of the last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting, the Delaware Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, an annual meeting of shareholders must be held no later than fifteen months after holding the last preceding annual meeting. Under the QBCA, the directors of a corporation may call a special meeting at any time. In addition, holders of not less than 10&#160;percent of the issued shares of a corporation that carry the right to vote at a meeting sought to be held may requisition the directors to call a meeting of shareholders.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Stockholder Action by Written Consent</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, stockholders may act by written consent without a meeting if they hold outstanding stock that has at least the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on the action were present and voted, unless such action is prohibited by the corporation&#8217;s certificate of incorporation.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, a written resolution signed by all the shareholders of a corporation who would have been entitled to vote on the resolution at a meeting is effective to approve the resolution.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholder Nominations and Proposals</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Not applicable.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the QBCA, a shareholder entitled to vote at a shareholders&#8217; meeting may submit a shareholder proposal relating to matters which the shareholder wishes to propose and discuss at an annual shareholders&#8217; meeting and, subject to such shareholder&#8217;s compliance with the prescribed time periods and other requirements of the QBCA pertaining to shareholder proposals, the corporation is required to include such proposal in the information circular pertaining to any annual meeting at which it solicits proxies, subject to certain exceptions. Notice of such a proposal must be provided to the corporation at least 90 days before the one year anniversary date of the notice of meeting for the last annual shareholders&#8217; meeting.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In addition, the QBCA requires that any shareholder proposal that includes nominations for the election of directors must be signed by one or more holders of shares representing in the aggregate not less than five per cent of the shares or five per cent of the shares of a class of shares of the corporation entitled to vote at the meeting to which the proposal is to be presented.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholder Quorum and Vote Requirements</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, a quorum for a stock corporation is a majority of the shares entitled to vote at the meeting unless the certificate of incorporation or bylaws specify a different quorum, but in no event may a quorum be less than <span style="white-space:nowrap">one-third</span> of the shares entitled to vote, except where a separate vote by a class(es) or series is required, in which case a quorum will consist of no less than <span style="white-space:nowrap">one-third</span> of the shares of such class(es) or series. Unless the DGCL, certificate of incorporation or bylaws provide for a greater vote, generally the required vote under the DGCL is a majority of the shares present in person or represented by proxy, except for the election of directors which requires a plurality of the votes of the shares present in person or represented by proxy.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the QBCA, unless the bylaws otherwise provide, the holders of a majority of the shares of a corporation entitled to vote at a meeting of shareholders, whether present in person or represented by proxy, constitute a quorum.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Amendment of Governing Instrument</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Amendment of Certificate of Incorporation. Generally, under the DGCL, the affirmative vote of the holders of a majority of the outstanding stock, and a majority of the outstanding stock of each class, entitled to vote on such matter, is required to approve a proposed amendment to the certificate of incorporation, following the adoption of the amendment by the board of directors of the corporation, provided that the certificate of incorporation may provide for a greater vote. Under the DGCL, holders of the outstanding shares of a class are entitled to vote as a class on the proposed amendment (whether or not entitled to vote on such matter by the certificate of incorporation), if the amendment would have certain consequences that adversely affect the rights and preferences of such class. If the adverse consequences of the amendment would impact one or more series of any class, but not the entire class, then only the shares of the series being affected by the amendment will be considered a separate class when voting on the proposed amendment.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Amendment of Bylaws. Under the DGCL, after a corporation has received any payment for any of its stock, the power to adopt, amend or repeal bylaws shall be vested in the stockholders entitled to vote; provided, however, that any corporation may, in its certificate of incorporation, provide that bylaws may be adopted, amended or repealed by the board of directors. The fact that such power has been conferred upon the board of directors shall not divest the stockholders of the power nor limit their power to adopt, amend or repeal the bylaws.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Amendment of Articles. Under the QBCA, amendments to the articles of incorporation generally require the approval of not less than two thirds of the votes cast by shareholders entitled to vote on the resolution. Specified amendments may also require the approval of other classes of shares. If the amendment is of a nature affecting a particular class or series in a manner requiring a separate class or series vote, that class or series is entitled to vote on the amendment whether or not it otherwise carries the right to vote.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Amendment of Bylaws. Under the QBCA, the directors may, by resolution, make, amend or repeal any bylaws that regulates the business or affairs of the corporation. Where the directors make, amend or repeal a bylaw, they are required under the QBCA to submit that action to the shareholders at the next meeting of shareholders and the shareholders may confirm, reject or amend that action by simple majority, or ordinary resolution. If the action is rejected by shareholders, or the directors of a corporation do not submit the action to the shareholders at the next meeting of shareholders, the action will cease to be effective, and no subsequent resolution of the directors to make, amend or repeal a bylaw having substantially the same purpose or effect will he effective until it is confirmed.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Votes on Mergers, Consolidations and Sales of Assets</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">The DGCL provides that the adoption of a merger agreement requires the approval of a majority of the outstanding stock of the corporation entitled to vote thereon.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the QBCA, certain extraordinary corporate actions, such as amalgamations (other than with certain affiliated corporations), continuances and sales, leases or exchanges of the property of a corporation if as a result of such alienation the corporation would be unable to retain a significant part of its business activities, and other extraordinary corporate actions such as liquidations, dissolutions and (if ordered by a court) arrangements, are required to be approved by &#8220;special resolution.&#8221;</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">A &#8220;special resolution&#8221; is a resolution passed by not less than <span style="white-space:nowrap">two-thirds</span> of the votes cast at a shareholders meeting by the shareholders entitled to vote on the resolution or signed by all shareholders entitled to vote on the resolution. In specified cases, a special resolution to approve the extraordinary corporate action is also required to be approved separately by the holders of a class or series of shares, including in certain cases a class or series of shares not otherwise carrying voting rights.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Dissenter&#8217;s Rights of Appraisal</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, a stockholder of a Delaware corporation generally has the right to dissent to a merger or consolidation in which the Delaware corporation is participating, subject to specified procedural requirements, including that such dissenting stockholder does not vote in favor of the merger or consolidation. However, the DGCL does not confer appraisal rights, in certain circumstances, including if the dissenting stockholder owns shares traded on a national securities exchange and will receive publicly traded shares in the merger or consolidation. Under the DGCL, a stockholder asserting appraisal rights does not receive any payment for his or her shares until the court determines the fair value or the parties otherwise agree to a value. The costs of the proceeding may be determined by the court and assessed against the parties as the court deems equitable under the circumstances.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The QBCA provides that shareholders of a corporation are entitled to exercise dissent rights (called &#8220;the right to demand the repurchase of shares&#8221;) and to be paid the fair value of their shares in connection with specified matters, including: (i) any amalgamation with another corporation (other than with certain affiliated corporations); (ii) an amendment to the corporation&#8217;s articles to add, change or remove any provisions restricting or constraining the transfer of shares; (iii)&#160;an amendment to the corporation&#8217;s articles to add. change or remove any restriction upon the businesses or businesses that the corporation may carry on; (iv) a continuance under the laws of another jurisdiction; (v) a sale, lease or exchange of the property of the corporation or of its subsidiaries if, as a result of such alienation, the corporation is unable to retain a significant part of its business activity; (vi)&#160;a court order permitting a shareholder to exercise his right to demand the repurchase of his shares in connection with an application to the court for an order approving an arrangement proposed by the corporation; (vii) the carrying out of a going-private transaction; and (viii)&#160;certain amendments to the articles of a corporation which require a separate class or series vote by a holder of shares of any class or series.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">However, a shareholder is not entitled to dissent if an amendment to the articles is effected by a court order approving reorganization or by a court order made in connection with an action for an oppression remedy.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Oppression Remedy</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The DGCL does not provide for a similar remedy.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The QBCA provides an oppression remedy (called &#8220;rectification of abuse of power or iniquity&#8221;) that enables a court to make any order, whether interim or final, to rectify matters that are oppressive or unfairly prejudicial to the interests of any securityholder, director or officer of the corporation if an application is made to a court by an &#8220;applicant&#8221;. An &#8220;applicant&#8221; with respect to a corporation means any of the following: (i)&#160;a present or former registered holder or beneficiary of securities of the corporation or any of its affiliates; (ii)&#160;a present or former officer or director of the corporation or any of its affiliates and (iii)&#160;any other person who in the discretion of the court has the interest to make the application.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The oppression remedy provides the court with very broad and flexible powers to intervene in corporate affairs to protect shareholders and other complainants. While conduct that is in breach of fiduciary duties of directors or that is contrary to the legal right of a complainant will normally trigger the court&#8217;s jurisdiction under the oppression remedy, the exercise of that jurisdiction does not depend on a finding of a breach of those legal and equitable rights. Furthermore, the court may order a corporation to pay the interim expenses of an applicant seeking an oppression remedy, but the applicant may be held accountable for interim costs on final disposition of the complaint (as in the case of a derivative action as described in &#8220;Shareholder Derivative Actions&#8221; below).</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Shareholder Derivative Actions</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Under the DGCL, stockholders may bring derivative actions on behalf of, and for the benefit of the corporation. The plaintiff in a derivative action on behalf of the corporation either must be or have been a stockholder of the corporation at the time of the transaction or must be a stockholder who became a stockholder by operation of law in the transaction regarding which the stockholder complains. A stockholder may not sue derivatively on behalf of the corporation unless the stockholder first makes demand on the corporation that it bring suit and the demand is refused, unless it is shown that making the demand would have been a futile act.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the QBCA, an applicant, as described directly above, may apply to a Quebec court for leave to bring an action in the name of, and on behalf of, the corporation or any subsidiary, or to intervene in an existing action to which the corporation or any of its subsidiaries is a party, for the purpose of prosecuting, defending or discontinuing an action on behalf of the corporation or its subsidiary. Under the QBCA, no action may be brought and no intervention in an action may be made unless a court is satisfied that: (i)&#160;the shareholder has given the required <span style="white-space:nowrap">14-day</span> notice to the directors of the corporation or the subsidiary of the shareholder&#8217;s intention to apply to the court if the directors do not bring, diligently prosecute or defend or discontinue the action; (ii)&#160;the shareholder is acting in good faith; and (iii)&#160;it appears to be in the interests of the corporation or the relevant subsidiary that the action be brought. prosecuted, defended or discontinued.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the QBCA, the court in a derivative action may make any order it thinks fit. In addition, under the QBCA, a court may order the corporation or its relevant subsidiary to pay the shareholder&#8217;s interim costs, including reasonable legal fees and disbursements. Although the shareholder may be held accountable for the interim costs on final disposition of the complaint, the shareholder is not required to give security for costs in a derivative action.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Anti-Takeover and Ownership Provisions</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Unless an issuer opts out of the provisions of Section&#160;203 of the DGCL, Section&#160;203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with a holder of 15% or more of the corporation&#8217;s outstanding voting stock (as defined in Section&#160;203), referred to as an interested stockholder, for a period of three years after the time that such stockholder became an interested stockholder, except as otherwise provided in Section&#160;203. For these purposes, the term &#8220;business combination&#8221; includes mergers, assets sales and other similar transactions with an interested stockholder.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">While the QBCA does not contain specific anti- takeover provisions with respect to &#8220;business combinations&#8221;, rules and policies of certain Canadian securities regulatory authorities, including Multilateral Instrument <span style="white-space:nowrap">61-101&#8212;Protection</span> of Minority Security Holders in Special Transactions, or Multilateral Instrument <span style="white-space:nowrap">61-101,</span> contain requirements in connection with, among other things, &#8220;related party transactions&#8221; and &#8220;business combinations&#8221;, including, among other things, any transaction by which an issuer directly or indirectly engages in the following with a related party: acquires, sells, leases or transfers an asset, acquires the related party, acquires or issues treasury securities, amends the terms of a security if the security is owned by the related party or assumes or becomes subject to a liability or takes certain other actions with respect to debt.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The term &#8220;related party&#8221; includes (i)&#160;a control person of the corporation, including a person of which the corporation is a control person, (ii)&#160;directors and senior officers and (iii)&#160;holders of more than 10% of the voting rights attached to all outstanding voting securities of the issuer or holders of a sufficient number of any securities of the issuer to materially affect control of the issuer.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Multilateral Instrument <span style="white-space:nowrap">61-101</span> requires, subject to certain exceptions, the preparation of a formal valuation relating to certain aspects of the transaction and more detailed disclosure in the proxy material sent to security holders in connection with a related party transaction including related to the valuation. Multilateral Instrument <span style="white-space:nowrap">61-101</span> also requires, subject to certain exceptions, that an issuer not engage in a related party transaction unless the shareholders of the issuer, other than the related parties, approve the transaction by a simple majority of the votes cast.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_50"><span style="font-weight:bold">C.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Material contracts.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Other than contracts entered into in the ordinary course of business, the following contracts summarized below are the material contracts that the Company has been a party to for the two years preceding the publication of this Annual Report: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Marathon Credit Agreement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On July&#160;13, 2022, we announced that we had entered into a binding commitment with affiliated funds of Marathon Asset Management providing for a <span style="white-space:nowrap">non-dilutive</span> term loan of up to $100&#160;million and, on July&#160;20, 2022, the Company executed the Marathon Credit Agreement. The Marathon Credit Agreement provides for the disbursement of $100&#160;million in four various tranches. As guarantee for the repayment of the loan, the Corporation and each of its subsidiaries have granted a first ranking security interest on all of their assets subject to certain credit card arrangements restrictions. Refer to Note 17 to the Audited Financial Statements and &#8220;Item 4A &#8211; History and development of the Company &#8211; Recent Developments&#8221; for further information on the Marathon Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">TaiMed Agreement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On March&#160;18, 2016, we entered into a distribution and marketing agreement with TaiMed granting the Company the exclusive right to market and distribute Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in Canada and the United States. On March&#160;6, 2017, we amended and restated the distribution and marketing agreement granting the Company the exclusive rights to commercialize Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the United States and Canada (&#8220;North American Territory&#8221;), as well as in the European Territory. TaiMed is responsible for the manufacture and supply of Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> under the TaiMed Agreement. TaiMed kept all rights related to the further development of ibalizumab. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On April&#160;27, 2022, we notified TaiMed pursuant to the terms of the TaiMed Agreement that we were terminating our rights to commercialize Trogarzo<sup style="font-size:75%; vertical-align:top">&#174;</sup> in the European Territory. Such notice of termination became effective on December&#160;15, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Refer to Notes 3 and 13 of the Audited Financial Statements for more information on the TaiMed Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">MGH License Agreement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On February&#160;3, 2020, we entered into the MGH License Agreement, granting us an exclusive, worldwide, royalty-bearing license under the MGH&#8217;s rights to all data, inventions and patents rights, or Proprietary Rights, resulting from the study conducted by the MGH regarding &#8220;<span style="font-style:italic">Tesamorelin effects on liver fat and histology in HIV</span>&#8221;. The MGH License Agreement is scheduled to expire on the latest of (i)&#160;the date on which all issued patents, if any, and filed patent applications have expired or been abandoned, and (ii)&#160;one year after the last sale for which a royalty is due under the MGH License Agreement, unless earlier terminated pursuant to certain customary termination provisions. Refer to Note&#160;26 of the Audited Financial Statements for more information on the MGH License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Katana Agreement </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We acquired the SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> platform following the acquisition of all of the issued and outstanding shares of Katana on February&#160;25, 2019. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">See &#8220;Item 4B &#8211; Business Overview &#8211; Research and Development Activities &#8211; Oncology &#8211; SORT1+ Technology<sup style="font-size:75%; vertical-align:top">&#8482;</sup> Platform&#8221; and refer to Note 13 of the Audited Financial Statements for more information on the Katana Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Transfert Plus License Agreement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Under the Transfert Plus License Agreement, we obtained the exclusive worldwide rights to develop, make, have made, use, sell, offer to sell, distribute, commercialize and import the technology related to the technology platform that uses peptides as a vehicle to deliver existing cytotoxic agents to sortilin receptors which are overexpressed on cancer cells. See &#8220;Item&#160;4B &#8211; Business Overview &#8211; Research and Development Activities &#8211; Oncology &#8211; SORT1+ Technology<sup style="font-size:75%; vertical-align:top">TM</sup> Platform&#8221; and refer to Note&#160;13 of the Audited Financial Statements for further information on the Transfert Plus License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Investor Rights Agreement</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">On October&#160;31, 2023, in connection with the Concurrent Private Placement, the Corporation entered into the Investor Rights Agreement with Investissement Qu&#233;bec. See &#8220;Item 4A &#8211; History and Development of the Company &#8211; Recent Developments &#8211; Public Offering and Concurrent Private Placement&#8221; and Note&#160;20 of the Audited Financial Statements for more information on the Investor Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Employment Agreements</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Paul L&#233;vesque on March&#160;1, 2020. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change Control Provisions &#8211; Paul L&#233;vesque&#8221; of this Annual Report for a summary of Mr.&#160;Paul L&#233;vesque&#8217;s employment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Philippe Dubuc on February&#160;24,&#160;2016, as was further amended. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change Control Provisions &#8211; Philippe Dubuc&#8221; of this Annual Report for a summary of Mr.&#160;Philippe Dubuc&#8217;s employment agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Christian&#160;Marsolais on April&#160;13,&#160;2007, as was further amended. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change Control Provisions &#8211; Christian Marsolais&#8221; of this Annual Report for a summary of Mr.&#160;Christian Marsolais&#8217; employment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation, through Thera US, entered into an employment agreement with Mr.&#160;John Leasure on March&#160;23, 2021, for an indeterminate term. Effective April&#160;11, 2022, the Corporation entered into the 2022 Agreement, as was further amended, with Mr.&#160;Leasure for an inderminate term. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change Control Provisions &#8211; John Leasure&#8221; of this Annual Report for a summary of Mr.&#160;John Leasure&#8217;s employment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation entered into an employment agreement for an indeterminate term with Mr.&#160;Lafond on March&#160;29, 2007, as was further amended. See &#8220;Item 6B &#8211; Compensation &#8211; Summary of Employment Agreements &#8211; Termination and Change Control Provisions &#8211; Jocelyn Lafond&#8221; of this Annual Report for a summary of Mr.&#160;Jocelyn Lafond&#8217;s employment agreement. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_51"><span style="font-weight:bold">D.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Exchange controls.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman;text-align:justify">Canada has no system of currency exchange controls. There are no governmental laws, decrees or regulations in Canada that restrict the export or import of capital, including but not limited to, foreign exchange controls, or that affect the remittance of dividends, interest or other payments to <span style="white-space:nowrap">non-resident</span> holders of the Company&#8217;s securities. However, if dividends are paid to U.S. holders, they will be subject to Canadian withholding tax. See &#8220;Item 10 E - Taxation - Canadian Federal Income Tax Considerations - Dividends&#8221; for more detail. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_52"><span style="font-weight:bold">E.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Taxation.</span></span> </p></td></tr></table> <p style="margin-top:14pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Canadian Federal Income Tax Considerations</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following is, as of the date hereof, a summary of certain Canadian federal income tax considerations generally applicable to a holder of Common Shares who, at all relevant times, (A)&#160;is a resident of the United States for purposes of the <span style="font-style:italic">Canada-United States Income Tax Convention (1980)</span> (&#8220;Treaty&#8221;), is fully entitled to the benefits of the Treaty, and did not, does not and will not have a fixed base or permanent establishment in Canada within the meaning of the Treaty, and (B)&#160;for purposes of the <span style="font-style:italic">Income Tax Act </span>(Canada) (&#8220;Tax Act&#8221;), (i) is not a resident, or deemed to be a resident, of Canada; (ii)&#160;holds the Common Shares as capital property and as beneficial owner; (iii)&#160;deals at arm&#8217;s length with the Corporation and is not affiliated with the Corporation; (iv)&#160;does not use or hold, and is not deemed to use or hold, such Common Shares in the course of carrying on a business in Canada; (v)&#160;did not acquire the Common Shares by virtue of employment, and (vi)&#160;is not a financial institution, specified financial institution, registered <span style="white-space:nowrap">non-resident</span> insurer, authorized foreign bank, exempt entity, partnership or trust (each as defined in the Tax Act) (a &#8220;U.S. Holder&#8221;). Generally, the Common Shares will be considered to be capital property to a U.S. Holder unless the U.S. Holder holds such securities in the course of carrying on a business or has acquired them in one or more transactions considered to be an adventure or concern in the nature of trade. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This summary is based upon the current provisions of the Tax Act in force as of the date hereof and our understanding of the current published administrative policies and assessing practices of the Canada Revenue Agency (&#8220;CRA&#8221;). This summary takes into account all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (&#8220;Tax Proposals&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. This summary does not otherwise take into account any changes in law or in the administrative policies or assessing practices of the CRA, whether by legislative, governmental or judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular U.S. Holder. This summary is not exhaustive of all Canadian federal income tax considerations. U.S. Holders should consult their own tax advisors with respect to their particular circumstances. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Currency Conversion </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of Common Shares (including dividends, adjusted cost base and proceeds of disposition) must be expressed in Canadian dollars based on the rate as quoted by the Bank of Canada for the applicable day or such other rate of exchange that is acceptable to the CRA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Amounts paid or credited or deemed to be paid or credited as, on account or in lieu of payment of, or in satisfaction of, dividends on Common Shares to a U.S. Holder will be subject to Canadian withholding tax. Under the Treaty, the rate of withholding tax on dividends paid or credited by the Corporation to a U.S. Holder that beneficially owns such dividends and qualifies for the full benefits of the Treaty is generally limited to 15% of the gross amount of the dividend. This rate is further reduced to 5% in the case of a U.S. Holder that is a company for purposes of the Treaty that owns at least 10% of the Corporation&#8217;s voting shares at the time the dividend is paid or deemed to be paid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Dispositions of Common Shares </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A U.S. Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, nor will capital losses arising therefrom be recognized under the Tax Act, unless the Common Share constitutes &#8220;taxable Canadian property&#8221; to the U.S. Holder for purposes of the Tax Act, and the gain is not exempt from tax pursuant to the terms of the Treaty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes the TSX), at the time of disposition, such shares generally will not constitute taxable Canadian property of a U.S. Holder at that time, unless at any time during the <span style="white-space:nowrap">60-month</span> period immediately preceding the disposition of the Common Shares, the following two conditions are met concurrently: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">the U.S. Holder, persons with whom the U.S. Holder did not deal at arm&#8217;s length, partnerships in which the U.S. Holder or such <span style="white-space:nowrap">non-arm&#8217;s</span> length person holds a membership interest (either directly or indirectly through one or more partnerships), or the U.S. Holder together with all such persons, owned 25% or more of the issued shares of any class or series of the capital stock of the Corporation; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">more than 50% of the fair market value of the Common Shares was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), &#8220;timber resource properties&#8221; (as defined in the Tax Act) or an option, an interest or right in such property, whether or not such property exists. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a U.S. Holder for purposes of the Tax Act in certain circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">U.S. Holders who may hold Common Shares that are, or may be, taxable Canadian property should consult their own tax advisors with respect to the application of Canadian capital gains taxation, any potential relief under the Treaty, and compliance procedures under the Tax Act, none of which is described in this summary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Material U.S. Federal Income Tax Considerations</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following is a summary of material U.S. federal income tax consequences of the acquisition, ownership and disposition of the Common Shares by U.S. Holders, as defined below. This discussion is not a complete analysis or listing of all of the possible tax consequences to U.S. Holders and does not address all tax considerations that might be relevant to particular U.S. Holders of the Common Shares in light of their individual circumstances or to persons that are subject to special tax rules, such as: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">banks, insurance companies and certain other financial institutions; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">regulated investment companies; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">real estate investment trusts; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">brokers, dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">tax exempt entities, qualified retirement plans, individual retirement accounts, other <span style="white-space:nowrap">tax-deferred</span> accounts or government organizations; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">persons that do not hold Common Shares as capital assets, within the meaning of Section&#160;1221 of the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;); </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">persons holding the Common Shares as part of an integrated or conversion transaction or a constructive sale or a straddle; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">persons that own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power of our outstanding Common Shares; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">U.S. expatriates; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">S corporations, partnerships, or other entities or arrangements classified as partnerships or otherwise treated as pass-through entities for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">persons holding the Common Shares in connection with a trade or business, permanent establishment, or fixed base outside the United States; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">dealers or traders in securities; or </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">U.S. Holders whose functional currency is not the U.S. dollar. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This summary does not address any alternative minimum tax rules, U.S. federal estate and gift tax consequences or tax consequences under any state, local or <span style="white-space:nowrap">non-U.S.</span> laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of Common Shares that is: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">an individual citizen or resident alien of the United States for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">a trust (A)&#160;if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have authority to control all substantial decisions of the trust, or (B)&#160;that has a valid election in effect under applicable tax regulations (&#8220;Treasury Regulations&#8221;) issued by the United States Internal Revenue Service (&#8220;IRS&#8221;), a bureau of the U.S. Treasury Department (&#8220;U.S. Treasury&#8221;) to be treated as a U.S. person. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If a partnership or other pass through entity is a beneficial owner of Common Shares, the U.S. federal income tax consequences to the partners (or other owners) will generally depend upon the status of the partners (or other owners) and the activities of the entity. Partners (or other owners) of a partnership or other pass through entity that acquires Common Shares should consult with their tax advisors regarding the tax consequences of acquiring, owning and disposing of Common Shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following discussion is based upon the Code, existing and proposed Treasury Regulations, judicial decisions, and administrative pronouncements, all as in effect as of the date hereof and all of which are subject to change, possibly with retroactive effect. Any such change could result in U.S. federal income tax consequences different from those discussed below. In particular, this summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation; legislation that, if enacted, could be applied on a retroactive or prospective basis, and that could cause the tax consequences to be different than discussed in this summary. We have not requested, and do not intend to request, a ruling or other guidance from the IRS with respect to any of the U.S. federal income tax consequences described below, and there can be no assurance that the IRS will not disagree with or challenge any of the conclusions described herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following discussion is for general information only and is not intended to be, nor should it be construed to be, legal or tax advice to any beneficial owner or prospective beneficial owner of Common Shares and no opinion or representation with respect to the U.S. federal income tax consequences to any such beneficial owner or prospective beneficial owner is given. Prospective purchasers are urged to consult their tax advisors as to the particular consequences to them under U.S. federal, state and local, and any applicable <span style="white-space:nowrap">non-U.S.,</span> tax laws of the acquisition, ownership and disposition of Common Shares. Holders of Common Shares are also urged to carefully review the discussion contained herein under &#8220;<span style="font-style:italic">Canadian Federal Income Tax Considerations</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Ownership of Common Shares </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The following discussion is subject in its entirety to the rules described below under the heading &#8220;<span style="font-style:italic">Passive Foreign Investment Company Rules</span>&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Distributions on Common Shares </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Distributions (including the amount of Canadian taxes withheld, if any) paid on Common Shares generally will be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) and will be includible in income by U.S. Holders when received. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <span style="white-space:nowrap">tax-free</span> return of capital up to the U.S. Holder&#8217;s tax basis in Common Shares. Any remaining excess distribution generally will be treated as capital gain recognized on a sale or exchange of Common Shares on the day actually or constructively received by the U.S. Holder (as described below under the heading, &#8220;<span style="font-style:italic">Sale or Other Taxable Disposition of Common Shares</span>&#8221;). However, the Corporation may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder should assume that any distribution with respect to Common Shares will constitute ordinary dividend income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Provided that we are eligible for the benefits of the <span style="white-space:nowrap">Canada-U.S.</span> Tax Convention or that the Common Shares are &#8220;readily tradable&#8221; on a U.S. securities market, dividends paid by us to <span style="white-space:nowrap">non-corporate</span> U.S. Holders generally will be eligible for the preferential tax rates applicable to qualified dividend income, in each case provided certain holding periods and other conditions are satisfied, including that we will not be classified as a PFIC (as defined below) in the tax year of distribution or in the preceding tax year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Foreign Tax Credit </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In general, any Canadian withholding tax imposed on dividend payments in respect of Common Shares will be treated as a foreign income tax eligible for credit against a U.S. Holder&#8217;s U.S. federal income tax liability (or, at a U.S. Holder&#8217;s election, may, in certain circumstances, be deducted in computing taxable income). Dividends paid on Common Shares will be treated as foreign-source income, and generally treated as &#8220;passive category income&#8221; for U.S. foreign tax credit purposes. The Code applies complex limitations on the amount of foreign taxes that may be claimed as a credit by U.S. taxpayers. U.S. Holders are urged to consult their own tax advisors with respect to the amount of foreign taxes that can be claimed as a credit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Sale or Other Taxable Disposition of Common Shares </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A U.S. Holder will generally recognize capital gain or loss upon the sale or other taxable disposition of Common Shares in an amount equal to the difference between the U.S. Holder&#8217;s tax basis in the Common Shares disposed of and the amount realized on the disposition. Gain or loss realized by a U.S. Holder on the sale or other taxable disposition of Common Shares will be capital gain or loss for U.S. federal income tax purposes, and will be long term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Shares is more than one year. In the case of a <span style="white-space:nowrap">non-corporate</span> U.S. Holder, long term capital gains will be subject to reduced rates of taxation. The deductibility of capital losses is subject to limitations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Passive Foreign Investment Company Rules </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If we are classified as a passive foreign investment company (&#8220;PFIC&#8221;) in any taxable year, a U.S. Holder will be subject to special rules&#160;generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a <span style="white-space:nowrap">non-U.S.</span> corporation that does not distribute all of its earnings on a current basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A <span style="white-space:nowrap">non-U.S.</span> corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules, either: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">at least 75% of its gross income is passive income (such as interest income); or </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for the production of passive income. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For purposes of the gross income and gross asset tests, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation, the equity of which we own, directly or indirectly, 25% or more (by value). Pursuant to proposed Treasury Regulations, we will also be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any partnership, the equity of which we own, directly or indirectly, 25% or more (by value). In addition, if we own, directly or indirectly, less than 25% (by value) of the equity of a partnership, our proportionate share of the income of the partnership will be treated as passive income, and the partnership interest will be treated as a passive asset. The proposed Treasury Regulations would apply to tax years of U.S. persons that are shareholders in certain foreign corporations beginning on or after the date of publication of the U.S. Treasury decision adopting the proposed Treasury Regulations as final regulations in the Federal Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman">The determination of PFIC status is inherently factual, is subject to a number of uncertainties, and can be determined only annually after the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. The Corporation does not believe that it was a PFIC for its taxable year ended November&#160;30, 2023. There can be no assurance, however, that (i)&#160;the IRS could not successfully challenge the Corporation&#8217;s PFIC status for any prior tax year; or (ii)&#160;the Corporation will not be classified as a PFIC for the current tax year or any prior or future tax year. No opinion of legal counsel or ruling from the IRS concerning the status of the Corporation as a PFIC has been obtained or will be requested. U.S. Holders should consult their own tax advisors regarding the PFIC status of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If we are classified as a PFIC in any year that a U.S. Holder owns any Common Shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns any Common Shares, regardless of whether we continue to meet the tests described above unless (i)&#160;we cease to be a PFIC and the U.S. Holder has made a &#8220;deemed sale&#8221; election under the PFIC rules,&#160;or (ii)&#160;the U.S. Holder makes an available Qualified Electing Fund Election (a &#8220;QEF Election&#8221;) for all taxable years during such U.S. Holder&#8217;s holding period in which we are a PFIC. If the &#8220;deemed sale&#8221; election is made, a U.S. Holder will be deemed to have sold such U.S. Holder&#8217;s Common Shares at their fair market value and any gain from such deemed sale would be subject to the &#8220;excess distribution&#8221; rules&#160;described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. Holder&#8217;s Common Shares with respect to which such election was made will not be treated as shares in a PFIC and the U.S. Holder will not be subject to the rules&#160;described below with respect to any &#8220;excess distribution&#8221; the U.S. Holder receives from us or any gain from an actual sale or other disposition of the Common Shares. U.S. Holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if we cease to be a PFIC and such election becomes available. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">For each taxable year we are treated as a PFIC, a U.S. Holder will be subject to special tax rules&#160;for any &#8220;excess distribution&#8221; such U.S. Holder receives and any gain such U.S. Holder recognizes from a sale or other disposition (pursuant to proposed Treasury Regulations, including, under certain circumstances, a pledge) of Common Shares, unless (i)&#160;such U.S. Holder makes an available QEF Election, or (ii)&#160;in the case of a U.S. Holder holding our Common Shares, our Common Shares constitute &#8220;marketable&#8221; securities, and such U.S. Holder makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election as discussed below. Absent the making of a QEF Election or an available <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election, distributions a U.S. Holder receives in a taxable year that are greater than 125% of the average annual distributions a U.S. Holder received during the shorter of the three preceding taxable years or the U.S. Holder&#8217;s holding period for the Common Shares will be treated as an excess distribution. Under these special tax rules:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the excess distribution or gain will be allocated rateably over a U.S. Holder&#8217;s holding period for the Common Shares; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#9679;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The tax liability for amounts allocated to years prior to the year of disposition or excess distribution cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the Common Shares cannot be treated as capital, even if a U.S. Holder holds the Common Shares as capital assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In addition, if we are a PFIC, a U.S. Holder will generally be subject to similar rules&#160;with respect to distributions <span style="font-style:italic">we</span> receive from, and <span style="font-style:italic">our</span> dispositions of the stock of, any of our direct or indirect subsidiaries that also are PFICs, as if such distributions were indirectly received by, and/or dispositions were indirectly carried out by, such U.S. Holder. U.S. Holders should consult their tax advisors regarding the application of the PFIC rules&#160;to our subsidiaries and to their ownership of the Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">If a U.S. Holder makes an effective QEF Election, the U.S. Holder will be required to include in gross income each year, whether or not we make distributions, as capital gains, such U.S. Holder&#8217;s pro rata share of our net capital gains and, as ordinary income, such U.S. Holder&#8217;s pro rata share of our earnings in excess of our net capital gains. A U.S. Holder that makes a QEF Election generally (a)&#160;may receive a <span style="white-space:nowrap">tax-free</span> distribution from the Corporation to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Corporation that were previously included in income by the U.S. Holder because of such QEF Election and (b)&#160;will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a <span style="white-space:nowrap">tax-free</span> distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares. Currently, we do not expect that we would provide the information necessary for U.S. Holders to make a QEF Election if we determine that we are a PFIC. Thus, prospective investors should assume that a QEF Election will not be available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">U.S. Holders also can avoid the PFIC interest charge on excess distributions or gain relating to the Common Shares by making a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election with respect to the Common Shares, provided that the Common Shares are &#8220;marketable.&#8221; Common Shares will be marketable if they are &#8220;regularly traded&#8221; on certain U.S. stock exchanges or on a foreign stock exchange that meets certain conditions. For these purposes, the Common Shares will be considered regularly traded in any calendar year during which they are traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Any trades, the principal purpose of which is to meet this requirement, will be disregarded. The Common Shares are listed on the Nasdaq, which is a qualified exchange for these purposes. Consequently, if the Common Shares remain listed on the Nasdaq<span style="font-weight:bold"> </span>and are regularly traded, we expect the <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election would be available to U.S. Holders if we are a PFIC. Each U.S. Holder should consult its own tax advisor as to whether a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election is available or advisable with respect to the Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A U.S. Holder that makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election must include in ordinary income for each year the Corporation is a PFIC an amount equal to the excess, if any, of the fair market value of the Common Shares at the close of the taxable year over the U.S. Holder&#8217;s adjusted tax basis in the Common Shares. An electing U.S. Holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder&#8217;s adjusted basis in the Common Shares over the fair market value of the Common Shares at the close of the taxable year, but this deduction is allowable only to the extent of any net <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> gains for prior years. Gains from an actual sale or other disposition of the Common Shares will be treated as ordinary income, and any losses incurred on a sale or other disposition of the shares will be treated as an ordinary loss to the extent of any net <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> gains for prior years. Any loss in excess thereof will be taxed as a capital loss, and capital losses are subject to significant limitations under the Code. Once made, the election cannot be revoked without the consent of the IRS unless the Common Shares cease to be marketable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">However, a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#8220;marketable.&#8221; As a result, even if a U.S. Holder validly makes a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> election with respect to the Common Shares, the U.S. Holder may continue to be subject to the PFIC rules&#160;(described above) with respect to the U.S. Holder&#8217;s indirect interest in any of our investments that are treated as an equity interest in a PFIC. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the tax consequences of the alternative treatments would be in their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Additional Considerations Applicable to Common Shares </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Receipt of Foreign Currency</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The amount of any distributions on or proceeds on the sale, exchange or other taxable disposition of Common Shares paid to a U.S. Holder in foreign currency, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt, regardless of whether such foreign currency is converted into U.S. dollars at that time. A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Medicare Tax</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">An additional 3.8% Medicare tax is imposed on the &#8220;net investment income&#8221; of certain U.S. Holders who are individuals, estates or trusts. Among other items, &#8220;net investment income&#8221; generally includes gross income from dividends, and certain net gains from sales or other taxable dispositions of Common Shares. Special rules apply to PFICs. U.S. Holders are urged to consult their tax advisors with respect to the Medicare tax and its applicability in their particular circumstances to income and gains in respect of an investment in the Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic"><span style="text-decoration:underline">Backup Withholding and Information Reporting</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In general, information reporting will apply to payments made through a U.S. paying the Agent or U.S. intermediary to a U.S. Holder other than certain exempt recipients, such as corporations. In the event that a U.S. Holder fails to file any such required form, the U.S. Holder could be subject to significant penalties. In general, payments to U.S. Holders may be subject to backup withholding, currently at a rate of 24%, if the U.S. Holder fails to provide its taxpayer identification number (generally by providing us with a IRS <span style="white-space:nowrap">Form&#160;W-9)</span> or otherwise comply with the backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld from payments to a U.S. Holder under the backup withholding rules will be allowed as a credit against such U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such U.S. Holder to a refund, provided the required information is furnished to the IRS. Each U.S. Holder is urged to consult its own tax advisor regarding the information reporting and backup withholding tax rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Owners of &#8220;specified foreign financial assets&#8221; with an aggregate value in excess of $50,000 (and in some circumstances, a higher threshold), may be required to file an information report (usually on IRS Form&#160;8938) with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221; generally include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained by financial institutions: (i)&#160;stocks and securities issued by <span style="white-space:nowrap">non-U.S.</span> persons, (ii)&#160;financial instruments and contracts held for investment that have <span style="white-space:nowrap">non-U.S.</span> issuers or counterparties and (iii)&#160;interests in foreign entities. U.S. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">
Holders are urged to consult their own tax advisors regarding IRS Form 8938 and any other information reporting that may be required in connection with their ownership of Common Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_53"><span style="font-weight:bold">F.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Dividends and paying agents.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_54"><span style="font-weight:bold">G</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Statements by experts.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_55"><span style="font-weight:bold">H</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Documents on display.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We &#8220;incorporate by reference&#8221; information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Annual Report and more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Annual Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are required to file reports and other information with the securities commissions in all provinces of Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from SEDAR+ (<span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.sedarplus.ca</span></span><span style="font-family:Times New Roman">), the Canadian equivalent of the SEC&#8217;s electronic document gathering and retrieval system EDGAR. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">We are required to file reports and other information with the SEC under the <span style="font-style:italic">Securities Exchange Act of 1934</span>, as amended, or Exchange Act. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders. Under the Exchange Act, as a foreign private issuer, we are also not required to publish financial statements as frequently or as promptly as United States companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">You may read and copy any of our reports and information, including this Annual Report and its Exhibits at, and obtain copies upon payments of prescribed fees from, The Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C., 20549. In addition, the SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC on EDGAR (www.sec.gov/edgar). The public may obtain information on the operation of the Public Reference Room by calling the SEC at <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">1-800-SEC-0330.</span></span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Additional information relating to the Corporation may be found on SEDAR+ (<span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.sedarplus.ca</span></span><span style="font-family:Times New Roman">) and on EDGAR (www.sec.gov/edgar)), as well as on our website (</span><span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.theratech.com</span></span><span style="font-family:Times New Roman">). </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_56"><span style="font-weight:bold">I</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Subsidiary information.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Information about our subsidiaries is detailed under &#8220;Item 4C - Organizational Structure&#8221; of this Annual Report. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_57"><span style="font-weight:bold">J.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">Annual Report to Security Holders.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_58">Item&#8201;11. Quantitative and Qualitative Disclosures about Market Risks </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Information relating to quantitative and qualitative disclosures about market risks is detailed in our Audited Financial Statements. Refer to Note 23 of the Audited Financial Statements and &#8220;Item 5 - Operating and Financial Review and Prospects&#8221; of this Annual Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_59">Item&#8201;12. Description of Securities Other than Equity Securities </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_60"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Debt Securities.</span></span><span style="font-weight:bold"> </span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_61"><span style="font-weight:bold">B</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Warrants and Rights.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_62"><span style="font-weight:bold">C</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Other Securities.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%;vertical-align:top" align="left" id="tx680117_63"><span style="font-weight:bold">D.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-weight:bold"><span style="font-style:italic">American Depositary Shares.</span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx680117_64">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_65">Item&#8201;13. Defaults, Dividend Arrearages and Delinquencies </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_66">Item&#8201;14. Material Modification to the Rights of Security Holders and Use of Proceeds </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">None </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_67">Item&#8201;15. Controls and Procedures </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the annual filings, interim filings or other reports filed under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation and include controls and procedures designed to ensure that information required to be disclosed is accumulated and communicated to management, including our President and Chief Executive Officer, and our Senior Vice President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, have evaluated, or caused the evaluation of, under their direct supervision, the design and operating effectiveness of the Company&#8217;s disclosure controls and procedures, as defined under National Instrument <span style="white-space:nowrap">52-109</span> &#8211; Certification of Disclosure and Rule <span style="white-space:nowrap">13a-15(e)</span> and <span style="white-space:nowrap">15d-15(e)</span> under the Securities and Exchange Act of 1934 within the U.S. in Issuer&#8217;s Annual and Interim Filings as at November&#160;30, 2023. Based upon that evaluation, our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, have concluded that, as of November&#160;30, 2023, our disclosure controls and procedures were designed and operating effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under National Instrument <span style="white-space:nowrap">52-109</span> &#8211; Certification of Disclosure in Issuer&#8217;s Annual and Interim Filings and Rule <span style="white-space:nowrap">13a-15(f)</span> and <span style="white-space:nowrap">15d-15(f)</span> under the Securities Exchange Act of 1934 within the U.S. Our internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS, as issued by the IASB. Internal controls over financial reporting include those policies and procedures that: (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, as issued by the IASB, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements on a timely basis. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to consolidated financial statements preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, concluded that a material weakness existed as described below, and due to this material weakness, the Company&#8217;s internal control over financial reporting was not effective as of November 30, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In connection with the Company&#8217;s Fiscal 2022 evaluation of internal controls over financial reporting, the follow control deficiency was considered to be a material weakness as of November&#160;30, 2022; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify">The process level controls were ineffective relating to the documentation of the analysis and relating to the monitoring of certain conditions and covenants included in a financing arrangement. This control failure caused ineffective controls over the assessment of going concern uncertainty, including the underlying financial data and assumptions supporting the forecasted financial information utilized to prepare projected cash flows and liquidity requirements to comply with some of the covenants in such financing arrangement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">In Fiscal 2023, the Company&#8217;s management team remediated the ineffective controls related to the above-described material weakness. The material weaknesses can now be considered fully remediated at November 30, 2023 as management has concluded, through testing, that these controls are operating effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, assessed the design and operating effectiveness of our internal controls over financial reporting as of November 30, 2023 based on the criteria established in the &#8220;<span style="font-style:italic">Internal Control - Integrated Framework</span>&#8221; (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Management&#8217;s assessment included an evaluation of the design of our internal controls over financial reporting and testing of the operating effectiveness of our internal control over financial reporting. Based on that assessment, our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, concluded that as of November&#160;30,&#160;2023, our internal controls over financial reporting were appropriately designed and operating effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">This Annual Report does not include an attestation report of the Company&#8217;s registered public accounting firm relating to the Company&#8217;s internal control over financial reporting due to a transition period established by rules of the SEC for emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Other than the remediation of the material weakness described above, there were no changes in our internal controls over financial reporting that occurred during the period from September 1<sup style="font-size:75%; vertical-align:top">st</sup>, 2023 to November&#160;30, 2023 and the period from December 1, 2022 to November 30, 2023 that materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_68">Item&#8201;16. [Reserved] </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_69">Item&#8201;16A. Audit Committee Financial Expert. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has an Audit Committee comprised of three independent directors, namely: Alain Trudeau, its Chair, G&#233;rald A. Lacoste, and Frank Holler. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">All three members of the Audit Committee are independent and financially literate. The board of directors has determined that Mr.&#160;Alain Trudeau is the financial expert of the Audit Committee. The SEC has indicated that the designation or identification of Mr.&#160;Trudeau as an audit committee financial expert does not deem him an &#8220;expert&#8221; for any purpose, impose any duties, obligations or liability on Mr.&#160;Trudeau that are greater than those imposed on members of the Audit Committee and board of directors who do not carry this designation or identification, or affect the duties, obligations or liability of any other member of the Audit Committee or board of directors. See &#8220;Item 6.A &#8211; Directors and Senior Management&#8221; of this Annual Report for the biography of each of the Audit Committee members. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Each member of the Audit Committee has acquired <span style="white-space:nowrap">in-depth</span> financial expertise giving each the ability to read and understand a set of financial statements which presents the breadth and level of complexity of accounting issues that are generally comparable to those that can reasonably be expected to be raised in the Corporation&#8217;s financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_70">Item&#8201;16B. Code of Ethics </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation has adopted a code of ethics for all of its directors, officers and employees (&#8220;Code of Ethics&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">No waiver from a provision of the Code of Ethics was issued by the Corporation during the Corporation&#8217;s most recently completed fiscal year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Code of Ethics has been posted on the Corporation&#8217;s website and is available at <span style="font-family:Times New Roman; font-size:11pt;color:#0000ff"><span style="text-decoration:underline">www.theratech.com</span></span><span style="font-family:Times New Roman">. The Corporation undertakes to provide to any person without charge, upon request, a copy of the Code of Ethics. In order to obtain such document, a written request must be made to the Corporate Secretary of the Corporation at the following address: 2015 Peel Street, Suite 1100, Montreal, Qu&#233;bec, Canada, H3A 1T8. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_71">Item&#8201;16C. Principal Accountant Fees and Services </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">KPMG LLP have been acting as our auditors since 1993. In addition to performing the audit of our consolidated financial statements, KPMG LLP provided other services to us and they billed us the following fees in respect of each of our fiscal years ended November&#160;30, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fees</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;<br/><br/></span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">Fiscal&#160;year&#160;ended<br/>November&#160;30,&#160;2023<br/>CAD</span></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><br/><br/>&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;<br/></span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"></p></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">Fiscal&#160;year&#160;ended<br/>November&#160;30,&#160;2022</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">CAD</p></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><br/>&#160;</span><br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">599,200&#8194;&#8201;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">750,615</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,251&#8194;&#8201;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,865</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173,564&#8194;&#8201;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115,293</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other Fees</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">Nil</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right">Nil</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td>
<td colspan="4" style="BORDER-RIGHT:0.75pt solid #000000;height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.20em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total:</p></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">824,015&#8194;&#8201;</span></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">919,773</span></td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
</table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Refers to the aggregate fees billed by our external auditors for audit services, including interim reviews and work performed in connection with securities filings. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Refers to the aggregate fees billed for professional services rendered by our external auditors for translation. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:justify">Refers to the aggregate fees billed for professional services rendered by our external auditors for tax compliance, tax advice and tax planning, including transfer pricing. </p></td>
<td style="width:6%">&#160;</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="text-decoration:underline">Audit Committee&#8217;s <span style="white-space:nowrap">Pre-Approval</span> Policies and Procedures</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:justify">The Audit Committee charter sets out responsibilities regarding the provision of <span style="white-space:nowrap">non-audit</span> services by the Corporation&#8217;s external auditors and requires the Audit Committee to <span style="white-space:nowrap">pre-approve</span> all permitted <span style="white-space:nowrap">non-audit</span> services to be provided by the Corporation&#8217;s external auditors, which <span style="white-space:nowrap">pre-approval</span> may be delegated to any member of the Audit Committee. The Corporation also requires <span style="white-space:nowrap">pre-approval</span> of all audit services to be provided by its external auditors. All audit and <span style="white-space:nowrap">non-audit</span> services performed by the Corporation&#8217;s external auditors for the fiscal year ended November&#160;30, 2023, were <span style="white-space:nowrap">pre-approved</span> by the Audit Committee and none were approved on the basis of the <span style="font-style:italic">de minimis</span> exemption set forth in Rule <span style="white-space:nowrap">2-01(c)(7)(i)(C)</span> of Regulation <span style="white-space:nowrap">S-X.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_72">Item&#8201;16D. Exemptions from the Listing Standards for Audit Committees </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_73">Item&#8201;16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_74">Item&#8201;16F. Change in Registrant&#8217;s Certifying Accountant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_75">Item&#8201;16G. Corporate Governance </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule <span style="white-space:nowrap">3b-4</span> under the Exchange Act and the Common Shares are listed on Nasdaq. Rule 5615(a)(3) of The Nasdaq Stock Market Rules permits foreign private issuers to follow home country practices in lieu of certain provisions of The Nasdaq Stock Market Rules. A foreign private issuer that follows home country practices in lieu of certain provisions of Nasdaq Stock Market Rules must disclose ways in which its corporate governance practices differ from those followed by domestic companies either on its website or in the annual report that it distributes to shareholders in the United States. A description of the ways in which the Company&#8217;s governance practices differ from those followed by domestic companies pursuant to Nasdaq standards are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify"><span style="font-style:italic">Shareholder Meeting Quorum Requirement</span>: Nasdaq Stock Market Rule 5620(c) (&#8220;Rule 5620(c)&#8221;) requires that the minimum quorum requirement for a meeting of shareholders be 33 1/3&#160;% of the outstanding Common Shares. In addition, Rule 5620(c) requires that an issuer listed on Nasdaq state its quorum requirement in its <span style="white-space:nowrap">by-laws.</span> In lieu of following Rule 5620(c), the Company has elected to follow Canadian practices consistent with the requirements of the TSX and the QBCA. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-family:SYMBOL; font-size:9pt;color:#000000">&#183;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt;text-align:justify"><span style="font-style:italic">Shareholder Approval Requirement</span>: Nasdaq Stock Market Rule 5635(d) (&#8220;Rule 5635(d)&#8221;) requires shareholder approval prior to a transaction involving the sale or issuance of a company&#8217;s common stock (or securities convertible into or exercisable for its common stock): (i) at a price below the greater of book value or market value; and (ii)&#160;which together with sales by officers, directors, or substantial stockholders, is equal to 20% or more of the company&#8217;s outstanding shares of common stock or 20% or more of the voting power prior to issuance. In lieu of following Rule 5635(d), the Company has elected to follow Canadian practices consistent with the requirements of the TSX and the QBCA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_76">Item&#8201;16H. Mine Safety Disclosure </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_77">Item&#8201;16I. Disclosure Regarding Foreign Jurisdiction that Prevents Inspection </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_78">Item&#8201;16J. Insider Trading Policies </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Corporation&#8217;s insider trading policy (&#8220;Insider Policy&#8221;) prohibits anyone in possession of material undisclosed information from trading in the securities of the Corporation as well as from disclosing to a third party such material undisclosed information (<span style="font-style:italic">tipping</span>). The Insider Policy also contains restrictions on all directors and Executive Officers from trading in the Corporation&#8217;s securities during certain periods of the year <span style="white-space:nowrap">(&#8220;Black-Out</span> Periods&#8221;). Regularly-scheduled <span style="white-space:nowrap">Black-Out</span> Periods usually begins on the day immediately following the end of a fiscal quarter and ends on and includes the first trading day following the date of disclosure of the financial results for that quarter. Notwithstanding the foregoing, the <span style="white-space:nowrap">Black-Out</span> Periods should not prevent the Corporation from (i)&#160;granting stock options and other equity awards to the Corporation&#8217;s personnel as part of the yearly operational and planning and budget approval processes, as approved by the Board in accordance with applicable laws and regulations; (ii)&#160;automatic purchases or dispositions in accordance with applicable laws and regulations pursuant to any written automatic plan established by the Corporation prior to the relevant periods; and (iii)&#160;issuing DSUs to the Corporation&#8217;s <span style="white-space:nowrap">non-employee</span> directors in accordance with the DSU Plan, as may be amended and/or restated from time to time, and the compensation policies of the Board which may then be in effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Insider Policy contains anti-hedging measures that prohibit directors, Executive Officers and certain other members of the Corporation&#8217;s personnel designated from time to time by the Corporation from engaging in (i)&#160;short-sales in the Corporation&#8217;s securities; (ii)&#160;derivative transactions in respect of the Corporation&#8217;s securities, including put and call options; or (iii)&#160;any other hedging or equity monetization transaction in which an individual&#8217;s economic interest and risk exposure in the Corporation&#8217;s securities is changed, including collars and forward sales contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Finally, the Insider Policy prohibits directors, Executive Officers and certain other members of the Corporation&#8217;s personnel designated from time to time by the Corporation from engaging in speculative trading in short-term price fluctuations in the value of the Corporation&#8217;s securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_79">Item&#8201;16K. Cybersecurity </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx680117_80">PART III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_81">Item&#8201;17. Financial Statements </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">See</span> <span style="font-style:italic">Item 18 &#8211; Financial Statements</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_82">Item&#8201;18. Financial Statements </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The Consolidated Financial Statements and schedules appear on pages 1 through 82 of this Annual Report and are incorporated herein by reference. Our audited financial statements as prepared by our management and approved by the Board include: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Consolidated Financial Statements for the Years Ended November&#160;30, 2023, 2022 and 2021 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Report of Independent Registered Public Accounting Firm (KPMG LLP, Montreal, Quebec, Canada, Auditor Firm ID: 85) </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated Statements of Financial Position </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated Statements of Net Loss and Comprehensive Loss </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated Statements of Changes in Equity </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Consolidated Statements of Cash Flows </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">Notes to Consolidated Financial Statements </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" id="hidden101085993" contextRef="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">Lower of lease term and economic life</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P12_01_2022To11_30_2023" id="ixv-47804">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P12_01_2022To11_30_2023" id="ixv-47805">0001512717</ix:nonNumeric><ix:nonFraction name="ifrs-full:NoncurrentAssets" id="hidden101085991" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3">14472000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="thtx-20231130.xsd"/></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 12%; font-family: arial; font-size: 11pt; margin-top: 160pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements </div></div><div style="text-indent: 12%; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars) </div></div><div style="text-indent: 12%; font-family: Calibri; font-size: 18pt; margin-top: 40pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">THERATECHNOLOGIES INC. </div></div></div><div style="text-indent: 12%; font-family: arial; font-size: 11pt; margin-top: 40pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">November&#160;30, 2023, 2022 and 2021 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Calibri; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">THERATECHNOLOGIES INC. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Table of Contents </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars) </div></div><div style="font-size: 30pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 30pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 95%; font-family: arial; font-size: 11pt; margin-left: auto; border-collapse: collapse;">
<tr>
<td style="width: 95%; font-family: Calibri;"/>
<td style="width: 1%; vertical-align: bottom; font-family: Calibri;"/>
<td style="font-family: Calibri;"/>
<td style="font-family: Calibri;"/>
<td style="font-family: Calibri;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt; font-family: Calibri;"/>
<td colspan="4" style="height: 26.25pt; font-family: Calibri;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin680117_1">Consolidated Statements of Financial Position</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; font-family: arial;"/>
<td colspan="4" style="height: 7.5pt; font-family: arial;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin680117_2">Consolidated Statements of Net Loss and Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; font-family: arial;"/>
<td colspan="4" style="height: 7.5pt; font-family: arial;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin680117_3">Consolidated Statements of Changes in Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; font-family: arial;"/>
<td colspan="4" style="height: 7.5pt; font-family: arial;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin680117_4">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; font-family: arial;"/>
<td colspan="4" style="height: 7.5pt; font-family: arial;"/></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin680117_5">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6-82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: ARIAL; font-size: 10pt; margin-top: 50pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm</div> </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and Board of Directors </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Theratechnologies Inc.: </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Consolidated Financial Statements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:arial">We have audited the accompanying consolidated statements of financial position of Theratechnologies Inc. (the Company) as of November 30, 2023, and 2022, the related consolidated statements of net loss and comprehensive loss, changes in equity, and cash flows for each of the years in the three-year period ended November 30, 2023 and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of November&#160;30, 2023 and 2022, and its financial performance and its cash flows for each of the years in the three-year period ended November&#160;30, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </div><div style="font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming the <div style="display:inline;">Company </div>will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred net losses and negative cash flows from operating activities. The Company&#8217;s Loan Facility contains various covenants, including minimum liquidity covenants. There is material uncertainty related to events or conditions that cast substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regards to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks <div style="display:inline;">of</div> material misstatement of <div style="display:inline;">the</div> consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial">/s/ KPMG LLP </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial">We have served as the Company&#8217;s auditor since 1993. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Montr&#233;al, Canada </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">February 20, 2024 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin680117_1" style="font-family: Calibri; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">THERATECHNOLOGIES INC. </div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 2pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Financial Position </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars) </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As at November 30, 2023 and 2022 </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 7.5pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 73%; line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 5.5pt;;display:inline;">&#160;</div></div></td>
<td style="width: 6%; vertical-align: bottom; line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="width: 6%; vertical-align: bottom; line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: bottom; line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 5.5pt; font-size: 5.5pt;"><div style="font-size:5.5pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Note</div></div></div></div><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">November&#160;30,</div></div></div></div><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">November&#160;30,</div></div></div></div><div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47809">34,097</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47810">23,856</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds and money market funds</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47811">6,290</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47812">9,214</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade and other receivables</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47813">13,023</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47814">12,045</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credits and grants receivable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47815">524</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47816">299</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes receivable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncomeTaxReceivableCurrent" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47817">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncomeTaxReceivableCurrent" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47818">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47819">29</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47820">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47821">6,066</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47822">19,688</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and deposits</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47823">3,154</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47824">7,665</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative financial assets</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(e)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47825">110</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentDerivativeFinancialAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47826">603</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47827">63,297</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47828">73,370</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-current assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47829">1,206</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47830">1,494</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use-assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47831">770</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47832">1,595</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47833">12,496</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47834">15,009</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="thtx:DeferredFinancingCosts" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47835">-</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:DeferredFinancingCosts" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47836">1,792</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total non-current assets</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-hidden:hidden101085991;display:inline;">14,<div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">472</div></div></div><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;"></div></div><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;"></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47837">19,890</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total assets</div></div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47838">77,769</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Assets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47839">93,260</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Liabilities</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47840">28,471</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47841">41,065</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47842">9,603</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47843">7,517</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47844">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47845">26,895</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:arial">Current portion of Loan Facility</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LoanFacilityCurrent" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47846">7,286</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LoanFacilityCurrent" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47847">37,894</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47848">421</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47849">476</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Marathon Warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(c)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:WarrantsCurrent" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47850">1,475</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:WarrantsCurrent" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47851">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47852">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47853">394</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47854">38</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47855">38</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47856">47,294</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47857">114,279</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-current liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loan Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LoanFacilityNoncurrent" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47858">50,688</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LoanFacilityNoncurrent" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47859">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47860">573</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47861">1,446</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47862">84</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherNoncurrentLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47863">106</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total non-current liabilities</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47864">51,345</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47865">1,552</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47866">98,639</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47867">115,831</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share capital, warrants and subscription receipts</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47868">363,927</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47869">338,751</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity component of convertible unsecured senior notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47870">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47871">2,132</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed surplus</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdditionalPaidinCapital" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47872">23,178</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdditionalPaidinCapital" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47873">18,810</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deficit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47874">408,659</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47875">382,649</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income </div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">j</div></div></div>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47876">684</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47877">385</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47878">20,870</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47879">22,571</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;">&#160;</td>
<td colspan="4" style="height: 3.75pt;">&#160;</td>
<td colspan="4" style="height: 3.75pt;">&#160;</td>
<td colspan="4" style="height: 3.75pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 4pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total liabilities and equity</div></div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47880">77,769</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47881">93,260</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part <div style="display:inline;">of </div>these consolidated financial statements. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 20%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 30%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 20%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 27%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td colspan="7" style="vertical-align: top;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Approved by the Board of Directors</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(signed)&#8194;&#160;Alain&#160;Trudeau&#8194;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(signed)&#8194;&#160;G&#233;rald&#160;Lacoste&#8194;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: arial; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin680117_2" style="font-family: Calibri; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">THERATECHNOLOGIES INC. </div></div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 2pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Net Loss and Comprehensive Loss </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, except per share amounts) </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 7.5pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 62%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47882">81,764</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47883">80,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47884">69,823</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of goods sold</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47885">19,635</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47886">23,838</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CostOfSales" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47887">18,378</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of other asset</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AmortizationOfOtherAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47888">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AmortizationOfOtherAssets" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47889">2,441</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AmortizationOfOtherAssets" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47890">4,882</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses, net of tax credits of $&#160;<ix:nonFraction name="thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47891">539</ix:nonFraction> (2022 - $ <ix:nonFraction name="thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47892">316</ix:nonFraction>; 2021&#160;&#8211; $ <ix:nonFraction name="thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47893">277</ix:nonFraction>)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47894">30,370</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47895">36,939</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47896">28,274</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47897">26,769</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47898">39,391</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:SellingExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47899">28,909</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47900">15,617</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47901">17,356</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47902">14,616</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47903">92,391</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47904">119,965</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47905">95,059</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss from operating activities</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47906">10,627</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47907">39,908</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47908">25,236</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47909">2,147</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47910">673</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47911">195</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance costs</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47912">15,056</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47913">7,559</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47914">6,621</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47915">12,909</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47916">6,886</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47917">6,426</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss before income taxes</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47918">23,536</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47919">46,794</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47920">31,662</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income tax expense</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47921">421</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47922">443</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47923">63</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47924">23,957</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47925">47,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47926">31,725</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other comprehensive income (loss), net of tax</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Items that may be reclassified to net profit (loss) in the future</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in fair value of financial assets at fair value through other comprehensive income (&#8220;FVOCI&#8221;)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47927">299</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47928">360</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47929">197</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences on translation of foreign operations</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47930">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47931">789</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47932">634</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47933">299</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47934">429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47935">437</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total comprehensive loss</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47936">23,658</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47937">46,808</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47938">31,288</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss per share</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;">&#160;</td>
<td colspan="4" style="height: 1.5pt;">&#160;</td>
<td colspan="4" style="height: 1.5pt;">&#160;</td>
<td colspan="4" style="height: 1.5pt;">&#160;</td>
<td colspan="4" style="height: 1.5pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted (1)</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(i)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101087740"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101087140">0,91</ix:nonFraction></ix:nonFraction>)</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101087741"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101086714">1,98</ix:nonFraction></ix:nonFraction>)</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101087742"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_101086715">1,37</ix:nonFraction></ix:nonFraction>)</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 8pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 1 for share consolidation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div> </div> </div> <div></div> </div> <div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin680117_3" style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Changes in Equity </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, except for share amounts) </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 7.5pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 38%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;capital</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription&#160;receipts&#160;and</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering&#160;Warrants</div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">component</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;convertible</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">unsecured</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">senior</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">notes</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">other<br/>comprehensive</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">income&#160;(loss)</div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Note</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;shares&#160;(1)</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Contributed</div></div></div></div> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">surplus</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deficit</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 9.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr>
<td style="width: 38%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as at November 30, 2020</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086103">19,253,360</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47946">287,312</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47947">4,457</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47948">12,065</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47949">300,129</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47950">481</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47951">3,224</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total comprehensive loss</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47952">31,725</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47953">31,725</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net change in fair value of FVOCI financial assets </div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47954">197</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47955">197</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="padding-bottom: 4pt; vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences on translation of foreign&#160;operations</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47956">634</ix:nonFraction></div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47957">634</ix:nonFraction></div></td>
<td style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive loss</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47958">31,725</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47959">437</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47960">31,288</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transactions with owners, recorded directly in equity</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Public issue of common shares and&#160;warrants</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(a)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086808">4,181,975</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47962">46,002</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47963">46,002</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47964">3,394</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47965">3,394</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of warrants</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(a)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086720">58,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47967">742</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47968">742</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue &#8211; Oncology</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(b)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086805">120,482</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringPeriodValueAcquisitions" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47970">668</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:StockIssuedDuringPeriodValueAcquisitions" contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47971">668</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation plan:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation for stock option&#160;plan</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(h)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47972">1,879</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47973">1,879</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of Options:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Monetary consideration</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086333">166,250</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsValue" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47975">595</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsValue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47976">595</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Attributed value</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExerciseOfStockOptionsAttributedValue" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47977">433</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ExerciseOfStockOptionsAttributedValue" contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47978">433</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total contributions by owners</div></div> </td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086182">4,527,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47980">48,440</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47981">778</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47982">3,394</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47983">45,824</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as at November 30,</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086183">23,780,417</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47985">335,752</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47986">4,457</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47987">12,843</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47988">335,248</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47989">44</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47990">17,760</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total comprehensive loss</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47991">47,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47992">47,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net change in fair value of FVOCI financial assets, net of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>tax</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47993">360</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47994">360</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange differences on translation of foreign&#160;operations</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47995">789</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47996">789</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive loss</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47997">47,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47998">429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47999">46,808</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transactions with owners, recorded directly in equity</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue - ATM program</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(d)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:NumberOfSharesIssuedThroughAtmProgram" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086804">400,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48001">2,960</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48002">2,960</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48003">164</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48004">164</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of convertible unsecured senior notes</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48005">2,325</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48006">2,125</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48007">200</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation plan:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation for stock option&#160;plan</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(h)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48008">3,860</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48009">3,860</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of Options:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Monetary consideration</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(h)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086334">21,165</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsValue" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48011">21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughExerciseOfOptionsValue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48012">21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1.5em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Attributed value</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExerciseOfStockOptionsAttributedValue" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48013">18</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ExerciseOfStockOptionsAttributedValue" contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48014">18</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%; border-bottom: 0.75pt solid rgb(0, 0, 0);"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total contributions by owners</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086181">421,165</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48016">2,999</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48017">2,325</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48018">5,967</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48019">164</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48020">6,477</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="text-indent: -1em; font-family: arial; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as at November 30,&#160;2022</div></div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086184">24,201,582</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48022">338,751</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48023">2,132</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48024">18,810</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8201;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48025">382,649</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48026">385</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$&#8199;(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48027">22,571</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 1.5pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 8pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 1 for share consolidation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 2pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Changes in Equity (continued) </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, except for share amounts) </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 6.5pt; border-collapse: collapse; text-indent: 0px;">
<tr>
<td style="width: 38%;">&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 3%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="8" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 12pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 7.5pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: right; font-family: Calibri; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Note</div></div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share&#160;capital,&#160;Subscription</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">receipts&#160;and&#160;Public&#160;Offering</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">component</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;of&#160;convertible</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">notes</div></div></div> <div style="text-align: left; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">other</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;comprehensive</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">income</div></div></div> <div style="text-align: left; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 7.5pt; break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;of&#160;shares<div style="font-size: 75%; vertical-align: top;;display:inline;">(1)</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;Amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;Contributed</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">surplus</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Deficit</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as at November&#160;30,&#160;2022</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086174">24,201,582</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48029">338,751</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48030">2,132</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48031">18,810</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48032">382,649</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48033">385</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48034">22,571</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total comprehensive loss for the period</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48035">23,957</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48036">23,957</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in fair value of FVOCI financial assets, net of tax</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48037">299</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48038">299</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive loss for the period</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48039">23,957</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48040">299</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48041">23,658</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transactions with owners, recorded directly in&#160;equity</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td>
<td colspan="4" style="height: 24pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Public issue of common shares</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodSharesNewIssues" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086792">21,778,184</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodValueNewIssues" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48043">25,160</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodValueNewIssues" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48044">25,160</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue costs</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48045">2,053</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:ShareIssueCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48046">2,053</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of convertible unsecured senior notes</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086796">253</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48048">16</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48049">1</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48050">15</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of convertible unsecured senior notes</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48051">2,131</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48052">2,131</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48053">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation for stock option&#160;plan</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(h)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48054">2,237</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48055">2,237</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total contributions by owners</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101085989">21,778,437</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48057">25,176</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48058">2,132</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48059">4,368</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48060">2,053</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48061">25,359</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-size: 6.5pt; break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"> <div style="text-indent: -1em; font-size: 6.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as at November&#160;30,&#160;2023</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_101086852">45,980,019</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48063">363,927</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48064">-</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48065">23,178</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48066">408,659</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48067">684</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:Equity" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48068">20,870</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 8pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">See note for share consolidation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></div> </div> </div> <div></div> </div> <div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin680117_4" style="font-family: Calibri; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">THERATECHNOLOGIES INC. </div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars) </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 8pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 7pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 66%; line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom; line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: bottom; line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td>
<td style="line-height: 3.5pt; font-size: 3.5pt;"><div style="font-size:3.5pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 3pt; border-top-color: rgb(0, 0, 0); border-top-width: 1.5pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Calibri; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-align: right; font-family: Calibri; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;Note</div></div></div></div><div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-align: right; font-family: Calibri; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></div><div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-align: right; font-family: Calibri; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></div><div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;;text-align:right;"><div style="text-align: right; font-family: Calibri; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div><div style="text-align: right; font-family: Calibri; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(recast<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.8px">1</div>)</div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash flows from (used in)</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Net loss</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48069">23,957</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48070">47,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101086251">31,725</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Adjustments for</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation of property and equipment</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48072">450</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48073">390</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086296">237</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangible assets and other asset</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,&#160;14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48075">2,513</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48076">11,652</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086292">8,062</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of right-of-use assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAmortizationOfRightofuseAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48078">352</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAmortizationOfRightofuseAssets" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48079">429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAmortizationOfRightofuseAssets" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085733">449</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation for stock option plan and stock appreciation rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48081">2,215</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48082">3,872</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087549">1,932</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on lease termination</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48084">121</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_101086777">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative financial assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(e)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48086">492</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48087">217</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087547">212</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of liability related to deferred stock&#160;unit&#160;plan</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(e)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48089">224</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48090">221</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087543">209</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on convertible unsecured senior notes and Loan Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48092">8,263</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48093">4,357</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087540">3,306</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest paid on convertible unsecured senior notes and Loan Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48095">8,812</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48096">4,634</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086768">3,306</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48098">769</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48099">316</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForInterestIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085731">195</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest received</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48101">865</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48102">456</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086772">282</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48104">421</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48105">443</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncomeTaxExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086762">63</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes paid</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48107">848</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48108">109</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086766">19</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48110">282</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48111">1,209</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085290">890</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on repurchase of convertible unsecured senior notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48113">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48114">357</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense and amortization of deferred financing costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48115">2,098</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48116">2,140</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087538">2,358</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of Marathon Warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48118">1,525</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on Loan Facility modifications</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:GainLossOnLoanFacilityModifications" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48119">3,540</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Write off of deferred financing costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,&#160;20(d)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48120">954</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 9.75pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48121">13,811</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48122">27,709</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101085289">17,669</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Change in operating assets and liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade and other receivables</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48124">902</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48125">1,669</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087880">1,852</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credits and grants receivable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:AdjustmentsForTaxCreditsAndGrantsReceivable" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48127">215</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForTaxCreditsAndGrantsReceivable" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48128">126</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdjustmentsForTaxCreditsAndGrantsReceivable" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085737">323</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48130">10,327</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48131">8,991</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087877">4,217</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and deposits</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48133">4,511</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48134">3,058</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087873">5,569</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48136">7,508</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48137">1,100</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087871">5,549</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48139">1,920</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48140">3,627</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086288">2,226</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48142">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48143">16</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085727">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInWorkingCapital" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48145">8,133</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInWorkingCapital" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48146">13,017</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInWorkingCapital" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101086287">168</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash used in operating activities</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48148">5,678</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48149">14,692</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101086282">17,501</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing activities</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Repurchase of convertible unsecured senior notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48151">27,452</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48152">28,746</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Costs related to repurchase of convertible unsecured senior notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48153">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48154">73</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Proceeds from issuance of Loan Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48155">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48156">40,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Costs related to issuance of Loan Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsForDebtIssueCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48157">700</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsForDebtIssueCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48158">2,285</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Repayment of other obligations</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:RepaymentOfOtherObligations" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48159">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:RepaymentOfOtherObligations" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48160">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:RepaymentOfOtherObligations" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086774">5,000</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Proceeds from exercise of Options</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48162">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48163">21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086281">595</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Proceeds from exercise of warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48165">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48166">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086784">742</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Proceeds from issue of common shares, Public Offering Warrants and subscription receipts</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(a)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ProceedsFromIssuingSharesAndWarrants" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48168">25,160</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ProceedsFromIssuingSharesAndWarrants" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48169">2,960</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ProceedsFromIssuingSharesAndWarrants" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101086781">46,002</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Costs related to issuance of common shares, Public Offering Warrants and subscription receipts</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20(a)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48171">1,585</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48172">89</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087746">3,394</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Deferred financing costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:AdjustmentsForDeferredFinancingCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48174">196</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:AdjustmentsForDeferredFinancingCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48175">1,527</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:AdjustmentsForDeferredFinancingCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087749">447</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Payment of lease liability</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48177">452</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48178">605</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085739">635</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash from financing activities</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48180">14,775</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48181">9,656</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087616">37,863</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investing activities</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Acquisition of intangible assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48183">1,500</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48184">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087614">39</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Acquisition of property and equipment</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48186">318</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48187">985</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085752">127</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Proceeds from sale of bonds and money market funds</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48189">3,030</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48190">9,906</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085748">640</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Acquisition of bonds and money market funds</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48192">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48193">239</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101085746">13,210</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8201;Acquisition of derivative financial assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:PaymentsToAcquireDerivativeFinancialAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48195">104</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="height: 7.5pt; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash from (used in) investing activities</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48196">1,108</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48197">8,682</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101086122">12,736</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td>
<td colspan="4" style="height: 7.5pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net change in cash</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48199">10,205</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48200">3,646</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087870">7,626</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash, beginning of year</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48202">23,856</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48203">20,399</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087866">12,737</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of foreign exchange on cash</div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48205">36</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48206">189</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087865">36</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="text-indent: -1em; font-family: arial; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash, end of year</div></div></div></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48208">34,097</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48209">23,856</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087860">20,399</ix:nonFraction></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: arial; font-size: 7pt; margin-top: 8pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:5.8px">1</div> The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to Note 22 for supplemental cash flow disclosures. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin680117_5" style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated) </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Theratechnologies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements (&#8220;Financial Statements&#8221;) include the accounts of Theratechnologies Inc. and its wholly- owned subsidiaries (together referred to as the &#8220;Company&#8221; and individually as the &#8220;subsidiaries of the Company&#8221;). </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one material wholly-owned subsidiary: </div></div></div> <div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Theratechnologies U.S., Inc., a company governed by the <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Delaware General Corporation Law</div></div></div> (Delaware). Theratechnologies U.S., Inc. provides the services of personnel to Theratechnologies Inc. for its activities in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Theratechnologies Inc. is governed by the <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Corporations Act</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> (Qu&#233;bec) and is domiciled in Qu&#233;bec, Canada. The Company is located at 2015 Peel Street, Suite 1100, Montr&#233;al, Qu&#233;bec, H3A 1T8, Canada.</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086273" id="ixv-24687"><div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Basis of preparation </div></div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Share consolidation </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;19, 2023, the Board of Directors approved a consolidation of the issued and outstanding common shares (the &#8220;Common Shares&#8221;) on the basis of one for four <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(1-for-4)</div></div> common shares (the &#8220;Consolidation&#8221;) effective July&#160;31, 2023. All references in these Financial Statements to the number of common shares, Public Offering Warrants (as defined in Note 20(a)), Marathon Warrants (as defined in Note 20(c)), Options (as defined in Note 20(h)), weighted average number of common shares, basic and diluted loss per share and the exercise prices of the Public Offering Warrants, Marathon Warrants and Options have been retrospectively adjusted and restated to reflect the effect of the Consolidation for all periods presented. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement of compliance </div></div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</div></div></div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">6 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Basis of preparation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of compliance</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> (continued) </div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <ix:continuation id="TextSelection_101086273" continuedAt="TextSelectionAppend_101086273_1"> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These Financial Statements were authorized for issue by the Board of Directors on February&#160;20,&#160;2024. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Going concern uncertainty </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the preparation of these Financial Statements, management is responsible for identifying any event or situation that may cast doubt on the Company&#8217;s ability to continue as a going concern. Substantial doubt regarding the Company&#8217;s ability to continue as a going concern exists if events or conditions, considered collectively, indicate that the Company may be unable to honor its obligations as they fall due during a period of at least, but not limited to, 12 months from November&#160;30, 2023. If the Company concludes that events or conditions cast substantial doubt on its ability to continue as a going concern, it must assess whether the plans developed to mitigate these events or conditions will remove any possible substantial doubt. </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">For the year ended November&#160;30, 2023, the Company incurred a net loss of $<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48211">23,957</ix:nonFraction> (2022-$<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48212">47,237</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">; 2021-$<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48213">31,725</ix:nonFraction></div>) and had negative cash <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">flows</div> from operating activities of $<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48214">5,678</ix:nonFraction> (2022- <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48215">14,692</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">; 2021- $<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48216">17,501</ix:nonFraction></div>). As at November&#160;30, 2023, cash amounted to $<ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48217">34,097</ix:nonFraction> and bonds and money market funds amounted to $<ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48218">6,290</ix:nonFraction>.</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Loan Facility contains various covenants, including minimum liquidity covenants whereby the Company needs to maintain significant cash, cash equivalent and eligible short-term investments balances in specified accounts, which restricts the management of the Company&#8217;s liquidity (refer to Note 17). A breach of the liquidity covenant (a &#8220;Liquidity Breach&#8221;) provides the lender with the ability to demand immediate repayment of the Loan Facility and makes available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements, and may trigger an increase of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="ifrs-full:BorrowingsInterestRateBasis" contextRef="P12_01_2022To11_30_2023" id="ixv-48219">300 basis points</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the interest rate on the outstanding loan balance. On July 3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt, which breach was waived on September 21, 2023. During fiscal 2023, the Company entered into several amendments to the Marathon Credit Agreement to amend certain of the terms and conditions therein (see note 17).</div></div></div></div></div> </ix:continuation> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">7 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Basis of preparation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Going concern uncertainty</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> (continued) </div></div></div><ix:continuation id="TextSelectionAppend_101086273_1" continuedAt="TextSelectionAppend_101086273_2"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The amendments to the Marathon Credit Agreement resulted in: (i)&#160;revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between</div></div> $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:MinimumLiquidityRequirementAmount" contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48220">15,000</ix:nonFraction></div> and $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:MinimumLiquidityRequirementAmount" contextRef="P12_01_2022To11_30_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48221">20,000</ix:nonFraction></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div></div><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">ased on the Marathon adjusted EBITDA (as defined in the Marathon Credit Agreement, the &#8220;Marathon Adjusted EBITDA&#8221;) targets over the most recently ended four fiscal quarters; (ii)&#160;deleting the quarterly minimum revenue targets and replacing them with Marathon Adjusted EBITDA targets, beginning with the quarter ending November&#160;30, 2023; and (iii)&#160;deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies the Company&#8217;s annual report. Notwithstanding these amendments, there is no assurance that the lender will agree to amend or to waive any future potential covenant breaches, if any. The Company does not meet the condition precedents to drawdown additional amounts under the Marathon Credit Agreement and does not currently have other committed sources of financing available to i</div><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">t.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s ability to continue as a going concern for a period of at least, but not limited to, 12 months from November&#160;30, 2023, involves significant judgement and is dependent on the adherence to the conditions of the Marathon Credit Agreement or to obtain the support of the lender (including possible waivers and amendments, if necessary), increase its revenues and the management of its expenses (including the reorganization mainly focused on its R&amp;D activities-see Note 16(a)) in order to meet or exceed the Marathon Adjusted EBITDA target and generate sufficient positive operating cash flows. Some elements of management&#8217;s plans are outside of management&#8217;s control and the outcome cannot be predicted at this time. Should management&#8217;s plans not materialize, the Company may be in default under the Marathon Credit Agreement, be forced to reduce or delay expenditures and capital additions and seek additional alternative financing, or sell or liquidate its assets. As a result, there is material uncertainty related to events or conditions that cast substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 16pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These Financial Statements have been prepared assuming the Company will continue as a going concern, which assumes the Company will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. These Financial Statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that might result from the outcome of this uncertainty and that may be necessary if the going concern basis was not appropriate for these Financial Statements. If the Company was unable to continue as a going concern, material impairment of the carrying values of the Company&#8217;s assets, including intangible assets, could be required. </div></div></div></ix:continuation> <div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">8 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Basis of preparation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of measurement</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> (continued) </div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:continuation id="TextSelectionAppend_101086273_2" continuedAt="TextSelectionAppend_101086273_3"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Financial Statements have been prepared on a going concern and historical cost basis, except for: </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">bonds and money market funds, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">derivative financial assets, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">liabilities related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> arrangements and derivative financial liabilities, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">lease liabilities which are measured at present value of lease payments not paid at commencement date, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-classified</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment arrangements are measured at fair value at the grant date pursuant to IFRS&#160;2, <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-based</div> Payment</div></div></div>. </div></td></tr></table> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The methods used to measure fair value are discussed further in Note 25. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Functional and presentation currency </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company&#8217;s functional currency is the United States dollar (&#8220;USD&#8221;). </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">All financial information presented in USD has been rounded to the nearest thousand. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Use of estimates and judgments </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s Financial Statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting year. </div></div></div></ix:continuation> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">9 </div> </div></div> <div></div> </div><div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of preparation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates and judgments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> <ix:continuation id="TextSelectionAppend_101086273_3" continuedAt="TextSelectionAppend_101086273_4"><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Judgments in applying accounting policies </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about critical judgments in applying accounting policies and assumptions that have the most significant effect on the amounts recognized in the Financial Statements is noted below. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestones payments </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase consideration for the oncology platform (Note 13) includes additional milestone payments based on the attainment of commercial milestones that will be settled through the issuance of the Company&#8217;s common shares, which represent a transaction in the scope of IFRS 2. Accordingly, the fair value of the oncology platform at the date of acquisition incorporates management&#8217;s judgement as to the probability of attaining the share-based milestones as well as the expected timing of the attainment of the milestones. </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Management uses judgement in determining whether milestone payments are performance-related development milestones which are capitalized as an intangible asset or are milestones related to the activity or usage of an asset which are expensed. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Key sources of estimation uncertainty </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are as follows: </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales allowances </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Management uses judgment in estimating provisions for sale allowances such as cash discounts, returns, rebates and chargebacks, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation. The product revenue recognized quarter over quarter is net of these estimated allowances. Such estimates require the need to make estimates about matters that are inherently uncertain. These estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends such as competitive pricing and new product introductions, estimated inventory levels, and the shelf life of products. If actual future results vary, these estimates need to be adjusted, with an effect on sales and earnings in the period of the adjustment. (refer to Notes 2 &#8220;Revenue recognition&#8221; and 3 for additional information). </div></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">10 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of preparation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates and judgments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <ix:continuation id="TextSelectionAppend_101086273_4"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recoverability of inventories </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company regularly reviews inventory to determine whether the inventory cost exceeds its net realizable value. The determination of the net realizable value requires management to make estimates and use judgement in considering shelf life of a product, the effects of technological changes and new product introductions. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other areas of judgment and uncertainty are related to the estimation of accruals for clinical trial expenses, the recoverability of intangible assets, the measurement of derivative financial assets, the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> arrangements, the Marathon Warrants and gain or loss on amendments to the Marathon Credit Agreement. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company is subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. Management regularly evaluates estimates and assumptions using historical experience and expectations about the future. Management adjusts estimates and assumptions when facts and circumstances indicate the need for change. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. </div></ix:continuation> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086556" id="ixv-25123">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Significant accounting policies </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The accounting policies have been applied consistently by the Company, except as otherwise noted for the initial application of new or amended accounting standards. </div> <ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086555" id="ixv-25133"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Basis of consolidation </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of the subsidiaries of the Company are included in these Financial Statements from the date on which control commences until the date on which control ceases. Subsidiaries are entities controlled by the Company. Control is present where the Company has the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable are taken into consideration. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">11 </div> </ix:exclude></ix:nonNumeric></ix:nonNumeric></div></div> <ix:continuation id="TextSelection_101086555" continuedAt="TextSelectionAppend_101086555_1"><ix:continuation id="TextSelection_101086556" continuedAt="TextSelectionAppend_101086556_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_1" continuedAt="TextSelectionAppend_101086556_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_2" continuedAt="TextSelectionAppend_101086556_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086555_1" continuedAt="TextSelectionAppend_101086555_2"><ix:continuation id="TextSelectionAppend_101086556_3" continuedAt="TextSelectionAppend_101086556_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_4" continuedAt="TextSelectionAppend_101086556_5"><ix:continuation id="TextSelectionAppend_101086555_2" continuedAt="TextSelectionAppend_101086555_3"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of consolidation </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div></div></div> </ix:exclude></ix:continuation></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_5" continuedAt="TextSelectionAppend_101086556_6"><ix:continuation id="TextSelectionAppend_101086555_3"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany balances and transactions, revenues and expenses resulting from transactions between subsidiaries and with the Company are eliminated in preparing the Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25221"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign currencies </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Transactions in foreign currencies are translated to the functional currency at exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate in effect at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the reporting year, adjusted for effective interest and payments during the reporting year, and the amortized cost in foreign currency translated at the exchange rate in effect at the end of the reporting year. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate in effect at the date on which the fair value was determined. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured at historical cost in a foreign currency are translated using the exchange rate in effect at the date of the transaction. Foreign currency differences arising on translation are recognized in net profit, except for differences arising on the translation of FVOCI financial instruments, which are recognized in other comprehensive income (loss). </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign operations </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The assets and liabilities of foreign operations whose functional currency is not the US$ are translated into US$ at the reporting date. The income and expenses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">foreign-currency</div> denominated operations are translated at average rates for each reporting period. Foreign exchange differences arising on the translation of foreign operations are recognized directly in other comprehensive income (loss). When a foreign subsidiary is disposed of, the cumulative amount recognized in the currency translative reserve forms part of the gain or loss on disposal. </div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_6" continuedAt="TextSelectionAppend_101086556_7"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">12 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_7" continuedAt="TextSelectionAppend_101086556_8"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_8" continuedAt="TextSelectionAppend_101086556_9"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_9" continuedAt="TextSelectionAppend_101086556_10"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_10" continuedAt="TextSelectionAppend_101086556_11"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_11" continuedAt="TextSelectionAppend_101086556_12"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_12" continuedAt="TextSelectionAppend_101086556_13"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086553" id="ixv-25295"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Revenue recognition </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Revenue from contracts with customers &#8211; Net sales </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </ix:nonNumeric></ix:continuation><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"></div> <ix:continuation id="TextSelection_101086553" continuedAt="TextSelectionAppend_101086553_1"><ix:continuation id="TextSelectionAppend_101086556_13" continuedAt="TextSelectionAppend_101086556_14"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">The Company derives revenue from the sales of finished goods, which include Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>and <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div>. The Company recognizes revenue at a point in time when it transfers title of the finished goods to a customer, which generally occurs upon delivery of the finished goods to the customer&#8217;s premises. Payment received from customers prior to the transfer of control of the goods is recorded as deferred revenue. </div></div></div> </ix:continuation></ix:continuation><div style="color: rgb(0, 0, 0); font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: Calibri; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_101086553_1" continuedAt="TextSelectionAppend_101086553_2"><ix:continuation id="TextSelectionAppend_101086556_14" continuedAt="TextSelectionAppend_101086556_15"><div style="font-style: normal; font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></ix:continuation></ix:continuation></div> <ix:continuation id="TextSelectionAppend_101086556_15" continuedAt="TextSelectionAppend_101086556_16"><ix:continuation id="TextSelectionAppend_101086553_2"><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Some arrangements for the sale of finished goods provide for customer cash discounts for prompt payment, allowances, rights of return, rebates on sales made under governmental and commercial rebate programs, chargebacks on sales made to government agencies and retail pharmacies and distribution fees, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation which gives rise to variable consideration. At the time of sale, estimates are made for items giving rise to variable consideration based on the terms of the arrangement. The variable consideration is estimated at contract inception using the most likely amount method and revenue is only recognized to the extent that a significant reversal of revenue is not expected to occur. The estimate is based on historical experience, current trends, contractual terms with distributors and other known factors. Sales are recorded net of customer discounts, rebates, chargebacks, distribution fees and estimated sales returns, and exclude sales taxes. A refund liability and a right to recover returned goods asset are recognized for expected returns in relation to sales made before the end of the reporting period. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of variable consideration, including expected returns, on a quarterly basis, adjusting for the amounts of the asset and liability accordingly. </div> </ix:continuation><ix:nonNumeric name="ifrs-full:DisclosureOfCostOfSalesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25323"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Cost of sales </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold includes the cost of raw materials, supplies, direct labour and overhead charges allocated to goods sold as well as write-downs of inventories. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Amortization of the other asset </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">The amortization of the other asset related to the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14). </div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_16" continuedAt="TextSelectionAppend_101086556_17"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">13 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_17" continuedAt="TextSelectionAppend_101086556_18"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_18" continuedAt="TextSelectionAppend_101086556_19"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_19" continuedAt="TextSelectionAppend_101086556_20"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_20" continuedAt="TextSelectionAppend_101086556_21"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_21" continuedAt="TextSelectionAppend_101086556_22"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_22" continuedAt="TextSelectionAppend_101086556_23"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25395"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Employee benefits </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">profit-sharing</div> or cash bonus plans if the Company has a legal or constructive obligation to pay an amount as a result of past services rendered by an employee and the obligation can be estimated reliably. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits include a defined contribution plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense when due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available. The Company&#8217;s defined contribution plan comprises the registered retirement savings plan, the Quebec Pension Plan and employment insurance. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits are recognized as an expense when the Company is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. </div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25410"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Finance income and finance costs </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Finance income comprises interest income on financial assets and gains on the disposal of financial assets and financial liabilities. Interest income is recognized as it accrues in net loss using the effective interest method. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finance costs comprise bank charges, interest and accretion expense on lease liabilities, convertible unsecured senior notes, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> loans and obligations and deferred financing costs, impairment losses on financial assets recognized in net loss, changes in fair value of liabilities and derivatives, unrealized foreign currency gain or loss on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> obligations, loss on long-term obligations modifications and other foreign currency gains and losses which are reported on a net basis. </div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_23" continuedAt="TextSelectionAppend_101086556_24"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">14 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101086556_24" continuedAt="TextSelectionAppend_101086556_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_25" continuedAt="TextSelectionAppend_101086556_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_26" continuedAt="TextSelectionAppend_101086556_27"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_27" continuedAt="TextSelectionAppend_101086556_28"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_28" continuedAt="TextSelectionAppend_101086556_29"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_29" continuedAt="TextSelectionAppend_101086556_30"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"></div> <ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25482"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Inventories </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Inventories are presented at the lower of cost, determined using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> method, and net realizable value. Inventory costs include the purchase price and other costs directly related to the acquisition of materials and other costs incurred in bringing the inventories to their present location and condition. The Company is responsible for coordinating the production and stability testing and for auditing suppliers at different times during the manufacturing process. Inventory costs also include the costs directly related to the conversion of materials into finished goods. Net realizable value is the estimated selling price in the Company&#8217;s ordinary course of business less the estimated costs of completion and selling expenses. In determining whether the inventory cost exceeds its net realizable value for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory, the Company considers whether there is a high probability of regulatory approval for the product. In making that determination, the Company considers prior history with approvals of similar products, estimated timing of obtaining regulatory approval, regulatory agencies correspondence regarding safety and efficacy of the product and current market factors. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Work in progress inventory appears from the moment third party suppliers use the material provided by the Company until the time the Company receives the finished product. The value of work in progress inventory is equal to the value of material provided by the Company plus all conversion work performed by third party suppliers. </div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086548" id="ixv-25490"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Property and equipment </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Recognition and measurement </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Items of property and equipment are recognized at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and the costs of dismantling and removing the item and restoring the site on which it is located, if any. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment and are recognized in net profit or loss. </div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101086548" continuedAt="TextSelectionAppend_101086548_1"><ix:continuation id="TextSelectionAppend_101086556_30" continuedAt="TextSelectionAppend_101086556_31"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">15 </div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101086548_1" continuedAt="TextSelectionAppend_101086548_2"><ix:continuation id="TextSelectionAppend_101086556_31" continuedAt="TextSelectionAppend_101086556_32"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_32" continuedAt="TextSelectionAppend_101086556_33"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_33" continuedAt="TextSelectionAppend_101086556_34"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086548_2" continuedAt="TextSelectionAppend_101086548_3"><ix:continuation id="TextSelectionAppend_101086556_34" continuedAt="TextSelectionAppend_101086556_35"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_35" continuedAt="TextSelectionAppend_101086556_36"><ix:continuation id="TextSelectionAppend_101086548_3" continuedAt="TextSelectionAppend_101086548_4"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property and equipment</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> (continued)</div></div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_36" continuedAt="TextSelectionAppend_101086556_37"><ix:continuation id="TextSelectionAppend_101086548_4"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Subsequent costs </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> servicing of items of property and equipment are recognized in net profit or loss as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Depreciation </div><ix:nonNumeric name="thtx:DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087553" id="ixv-25574"><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The methods of depreciation and depreciation rates and periods are as follows: </div><div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:nonNumeric><div><ix:continuation id="TextSelection_101087553">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 46%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 20%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 28%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Method</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rate/period</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DepreciationMethodPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" id="ixv-48222">Declining balance</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48223">50</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DepreciationMethodPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" id="ixv-25638">Declining balance and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div></ix:nonNumeric><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48224">20</ix:nonFraction>% <ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" format="ixt-sec:durwordsen" id="ixv-48225">5 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Office furniture and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DepreciationMethodPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" id="ixv-48226">Declining balance</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48227">20</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Leasehold improvements</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"><ix:nonNumeric name="ifrs-full:DepreciationMethodPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" id="ixv-48228">Straight-line</ix:nonNumeric></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="-sec-ix-hidden:hidden101085993;display:inline;">Lower of lease term</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">and economic life</div></td></tr></table></ix:continuation></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The method of depreciation is selected based on the most closely expected pattern of consumption of the future economic benefits embodied in the asset. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Estimates for depreciation methods, useful lives and residual values are reviewed at each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> and adjusted if appropriate. </div></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_37" continuedAt="TextSelectionAppend_101086556_38"><ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">16 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101086556_38" continuedAt="TextSelectionAppend_101086556_39"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_39" continuedAt="TextSelectionAppend_101086556_40"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_40" continuedAt="TextSelectionAppend_101086556_41"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_41" continuedAt="TextSelectionAppend_101086556_42"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_42" continuedAt="TextSelectionAppend_101086556_43"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_43" continuedAt="TextSelectionAppend_101086556_44"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087796" id="ixv-25730"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Research and development </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Development activities involve a plan or design for the production of new or substantially improved products and processes. A development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset. These criteria are usually met when a regulatory filing has been made in a major market and approval is considered highly probable. The expenditure capitalized includes the cost of materials, direct labour, and overhead costs that are directly attributable to preparing the asset for its intended use. Other development </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">expenditures are expensed as incurred. Capitalized development expenditures are measured at cost, less accumulated amortization and accumulated impairment losses.</div></div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">During the years ended November&#160;30, 2023, 2022 and 2021, <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48229"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48230"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2020To11_30_2021_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48231">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> development expenditures were capitalized. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> advance payments for good and services that will be used in future research and development activities are expenses when the activity has been performed rather than when the payment is made. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Commercialization rights and oncology platform </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights and the oncology platform acquired by the Company have finite useful lives and are measured at cost less accumulated amortization and any accumulated impairment losses. Commercialization rights&#160;&#8211; <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" format="ixt-sec:durmonth" id="ixv-48232">111</ix:nonNumeric><div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">&#160;months on a </div><div style="letter-spacing: 0px; font-size: 11pt; text-wrap: nowrap; top: 0px;;display:inline;"></div><ix:nonNumeric name="ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023" id="ixv-25753"><div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis</ix:nonNumeric><div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Commercialization rights&#160;&#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> North American Territory &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" format="ixt-sec:durmonth" id="ixv-48233">142</ix:nonNumeric><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis. Commercialization rights &#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>European Territory &#8211; were amortized at fixed rates based on their estimated useful life of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_ThtxCommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" format="ixt-sec:durmonth" id="ixv-48234">148</ix:nonNumeric><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a straight-line basis. They were fully amortized during the year ended November&#160;30, 2022. Refer to Note 13. Commercialization rights&#160;for the oncology platform will be amortized over the estimated useful life on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis when the asset is available for use. </div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101087796" continuedAt="TextSelectionAppend_101087796_1"><ix:continuation id="TextSelectionAppend_101086556_44" continuedAt="TextSelectionAppend_101086556_45"><ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">17 </div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087796_1" continuedAt="TextSelectionAppend_101087796_2"><ix:continuation id="TextSelectionAppend_101086556_45" continuedAt="TextSelectionAppend_101086556_46"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_46" continuedAt="TextSelectionAppend_101086556_47"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_47" continuedAt="TextSelectionAppend_101086556_48"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087796_2" continuedAt="TextSelectionAppend_101087796_3"><ix:continuation id="TextSelectionAppend_101086556_48" continuedAt="TextSelectionAppend_101086556_49"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_49" continuedAt="TextSelectionAppend_101086556_50"><ix:continuation id="TextSelectionAppend_101087796_3" continuedAt="TextSelectionAppend_101087796_4"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_50" continuedAt="TextSelectionAppend_101086556_51"><ix:continuation id="TextSelectionAppend_101087796_4"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The amortization method and useful life of intangible assets are reviewed every year and adjusted as required. </div> </ix:continuation><ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25855"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Asset acquisitions </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Asset acquisitions are acquisitions that do not qualify as business combinations. At the date of acquisition, the Company initially recognizes the individual identifiable assets acquired and liabilities assumed. The cost to the Company at the date of the acquisition is allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of the acquisition. Subsequent consideration for performance-related development milestones is recognized as intangible assets when the specific milestones have been achieved and other recognition criteria are met. Subsequent payments related to activity or usage of an asset, including sales royalties, are expensed as incurred. Asset acquisition transactions do not give rise to goodwill. </div> </ix:nonNumeric><ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25859"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Other asset </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other asset, which comprised the amount disbursed in connection with the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14), was amortized over its estimated useful life of<div style="display:inline;">&#160;</div><ix:nonNumeric name="thtx:UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" contextRef="P12_01_2022To11_30_2023_OtherAssetsMemberifrsfullClassesOfAssetsAxis" format="ixt-sec:durmonth" id="ixv-48235">48</ix:nonNumeric>&#160;months. Other asset was fully amortized during the year ended November&#160;30, 2022. </div> </ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-25864"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The carrying amounts of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows from other assets or groups of assets (&#8220;Cash-Generating Unit&#8221;). The recoverable amount of an asset or a Cash-Generating Unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the Cash-Generating Unit. </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Impairment losses recognized in prior years are determined by the Company at each reporting date for any indications that the loss has decreased or no longer exists. An asset&#8217;s carrying amount, increased through the reversal of an impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. </div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_51" continuedAt="TextSelectionAppend_101086556_52"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">18 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_52" continuedAt="TextSelectionAppend_101086556_53"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_53" continuedAt="TextSelectionAppend_101086556_54"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_54" continuedAt="TextSelectionAppend_101086556_55"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_55" continuedAt="TextSelectionAppend_101086556_56"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_56" continuedAt="TextSelectionAppend_101086556_57"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_57" continuedAt="TextSelectionAppend_101086556_58"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087794" id="ixv-25935"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company initially recognizes financial assets on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value through profit or loss, then the initial measurement includes transaction costs that are directly attributable to the asset&#8217;s acquisition or issue. On initial recognition, the Company classifies its financial assets as measured at amortized cost, FVOCI or fair value through profit or loss (&#8220;FVPL&#8221;), depending on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">(i) Financial assets measured at amortized cost </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial;text-align:justify">A financial asset is measured at amortized cost, using the effective interest method and net of any impairment loss, if it meets both of the following conditions and is not designated at fair value though profit or loss: </div> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is to hold assets to collect contractual cash flows;</div> </td> </tr> </table> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table> <div style="margin-top:10pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">The Company currently classifies its cash and trade and other receivables as financial assets measured at amortized cost. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">(ii) Financial assets, measured at fair value through other comprehensive income </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">A debt investment is measured at fair value through other comprehensive income if it meets both of the following conditions and is not designated at fair value through profit or loss: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101087794" continuedAt="TextSelectionAppend_101087794_1"><ix:continuation id="TextSelectionAppend_101086556_58" continuedAt="TextSelectionAppend_101086556_59"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">19 </div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101087794_1" continuedAt="TextSelectionAppend_101087794_2"><ix:continuation id="TextSelectionAppend_101086556_59" continuedAt="TextSelectionAppend_101086556_60"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_60" continuedAt="TextSelectionAppend_101086556_61"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_61" continuedAt="TextSelectionAppend_101086556_62"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_101086556_62" continuedAt="TextSelectionAppend_101086556_63"><ix:continuation id="TextSelectionAppend_101087794_2" continuedAt="TextSelectionAppend_101087794_3"><ix:exclude><div style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements (continued) </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated) </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101087794_3" continuedAt="TextSelectionAppend_101087794_4"><ix:continuation id="TextSelectionAppend_101086556_63" continuedAt="TextSelectionAppend_101086556_64"><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) Financial assets, measured at fair value through other comprehensive income (continued) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in other comprehensive income (loss). When an investment is derecognized, gains or losses accumulated in other comprehensive income (loss) are reclassified to profit or loss. </div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment&#8217;s fair value in other comprehensive income (loss). </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">This election is made on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">investment-by-investment</div></div> basis. These assets are subsequently measured at fair value. Dividends are recognized in profit or loss, unless the dividend clearly represents a repayment of part of the cost of the investment, and other net gains and losses are recognized in other comprehensive income (loss) and are never reclassified in profit or loss. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently classifies its bonds as financial assets measured at FVOCI. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) Financial assets measured at fair value through profit or loss </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">All financial assets not classified as measured at amortized cost or FVOCI as described above are measured at FVPL. These assets are subsequently measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss. The Company currently classifies its money market funds and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hedge</div> derivative financial assets as financial assets measured at FVPL. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are&#160;transferred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) Financial liabilities </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities are classified into the following categories: </div></div><div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit or loss </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>20</ix:exclude> </div></div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087794_4" continuedAt="TextSelectionAppend_101087794_5"><ix:continuation id="TextSelectionAppend_101086556_64" continuedAt="TextSelectionAppend_101086556_65"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_65" continuedAt="TextSelectionAppend_101086556_66"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_66" continuedAt="TextSelectionAppend_101086556_67"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_101086556_67" continuedAt="TextSelectionAppend_101086556_68"><ix:continuation id="TextSelectionAppend_101087794_5" continuedAt="TextSelectionAppend_101087794_6"><ix:exclude><div style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements (continued) </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated) </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101087794_6" continuedAt="TextSelectionAppend_101087794_7"><ix:continuation id="TextSelectionAppend_101086556_68" continuedAt="TextSelectionAppend_101086556_69"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;">A financial liability is classified at fair value through profit or loss if it is classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading,</div></div> it is a derivative or it is designated as such on initial recognition. Financial liabilities at fair value are measured at fair value and net gains and losses, including interest expense, are recognized in profit or loss. </div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company issued the Marathon Warrants which are classified as financial liabilities through profit or loss because the exercise can be made on a cashless basis. All transaction costs related to financial instruments designated at fair value through profit or loss are expensed as incurred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently has no other financial liabilities measured at FVPL. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities measured at amortized cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">This category includes all financial liabilities, other than those measured at FVPL. A financial liability is subsequently measured at amortized cost using the effective interest method. The Company currently classifies accounts payable and accrued liabilities, convertible unsecured senior notes and Loan Facility as financial liabilities measured at amortized cost. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) Compound financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments are instruments that contain both a liability component and an equity component, and the liability component can be converted into share capital at the option of the holder and the number of shares to be issued does not vary with changes in their fair value. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversation option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Upon repurchase, the proceeds are allocated based on the same basis that was used for the initial recognition. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) Derivative financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative financial instruments are recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. The changes in the fair value of derivatives are recognized through profit or loss in the year in which they occur.</div> </div></ix:continuation></ix:continuation><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><ix:continuation id="TextSelectionAppend_101087794_7" continuedAt="TextSelectionAppend_101087794_8"><ix:continuation id="TextSelectionAppend_101086556_69" continuedAt="TextSelectionAppend_101086556_70"><br/> <div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:continuation></ix:continuation></div><ix:continuation id="TextSelectionAppend_101087794_8" continuedAt="TextSelectionAppend_101087794_9"><ix:continuation id="TextSelectionAppend_101086556_70" continuedAt="TextSelectionAppend_101086556_71"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>21</ix:exclude> </div></div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087794_9" continuedAt="TextSelectionAppend_101087794_10"><ix:continuation id="TextSelectionAppend_101086556_71" continuedAt="TextSelectionAppend_101086556_72"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_72" continuedAt="TextSelectionAppend_101086556_73"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_73" continuedAt="TextSelectionAppend_101086556_74"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087794_10" continuedAt="TextSelectionAppend_101087794_11"><ix:continuation id="TextSelectionAppend_101086556_74" continuedAt="TextSelectionAppend_101086556_75"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_75" continuedAt="TextSelectionAppend_101086556_76"><ix:continuation id="TextSelectionAppend_101087794_11" continuedAt="TextSelectionAppend_101087794_12"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_76" continuedAt="TextSelectionAppend_101086556_77"><ix:continuation id="TextSelectionAppend_101087794_12"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vii) Offsetting of financial instruments </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position when, and only when, the Company has a legal right to set off the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At each reporting date, the Company recognizes loss allowances for expected credit losses (&#8220;ECLs&#8221;) on financial assets carried at amortized cost and debt securities at FVOCI. The Company&#8217;s trade and other receivables are accounts receivable with no financing component and which have maturities of less than 12 months and, as such, the Company has chosen to apply the simplified approach for ECL. As a result, the Company does not track changes in credit risk related to its trade and other receivables, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(viii) Impairment of financial assets </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For other financial assets subject to impairment, the Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECLs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">debt securities that are determined to have low credit risk at the reporting date; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers a debt security to have a low credit risk when its credit risk rating is equivalent or above investment grade credit rating, such as its bonds classified at FVOCI. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s approach to ECLs reflects a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">probability-weighted</div> outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future <div style="letter-spacing: 0px; top: 0px;;display:inline;">economic </div>conditions. </div></div> </ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_77" continuedAt="TextSelectionAppend_101086556_78"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">22 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_78" continuedAt="TextSelectionAppend_101086556_79"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_79" continuedAt="TextSelectionAppend_101086556_80"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_80" continuedAt="TextSelectionAppend_101086556_81"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_81" continuedAt="TextSelectionAppend_101086556_82"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_82" continuedAt="TextSelectionAppend_101086556_83"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_83" continuedAt="TextSelectionAppend_101086556_84"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087797" id="ixv-26389"> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At inception, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability at the commencement date of the lease, i.e. the date the underlying asset is available for use. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost, less any accumulated amortization and accumulated impairment losses, and adjusted for remeasurement of lease liabilities. Cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets comprises: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">the initial measurement amount of the lease liabilities recognized; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any lease payments made at or before the commencement date, less any lease incentives received; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any initial direct costs incurred; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">an estimate of costs to dismantle and remove the underlying asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease contract. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis over the lesser of (i)&#160;the estimated useful life of the underlying assets; and (ii)&#160;the lease term. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are assessed for impairment whenever there is an indication that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets may be impaired. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date over the lease term. The present value of the lease payments is determined using the lessee&#8217;s incremental borrowing rate at the commencement date if the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is a function of the lessee&#8217;s incremental borrowing rate, the nature of the underlying asset, the location of the asset, the length of the lease and the currency of the lease contract. Generally, the Company uses the lessee&#8217;s incremental borrowing rate for the present value. At the commencement date, lease payments generally include fixed payments, less any lease incentives</div></div></div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101087797" continuedAt="TextSelectionAppend_101087797_1"><ix:continuation id="TextSelectionAppend_101086556_84" continuedAt="TextSelectionAppend_101086556_85"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">23 </div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101087797_1" continuedAt="TextSelectionAppend_101087797_2"><ix:continuation id="TextSelectionAppend_101086556_85" continuedAt="TextSelectionAppend_101086556_86"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_86" continuedAt="TextSelectionAppend_101086556_87"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_87" continuedAt="TextSelectionAppend_101086556_88"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087797_2" continuedAt="TextSelectionAppend_101087797_3"><ix:continuation id="TextSelectionAppend_101086556_88" continuedAt="TextSelectionAppend_101086556_89"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_89" continuedAt="TextSelectionAppend_101086556_90"><ix:continuation id="TextSelectionAppend_101087797_3" continuedAt="TextSelectionAppend_101087797_4"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101087797_4" continuedAt="TextSelectionAppend_101087797_5"><ix:continuation id="TextSelectionAppend_101086556_90" continuedAt="TextSelectionAppend_101086556_91"><ix:exclude><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div> (continued) </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude></ix:continuation> </ix:continuation><ix:continuation id="TextSelectionAppend_101086556_91" continuedAt="TextSelectionAppend_101086556_92"><ix:continuation id="TextSelectionAppend_101087797_5"><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">receivable, variable lease payments that depend on an index (e.g. based on inflation index) or a specified rate, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising the option to terminate the lease. Lease payments also include amounts expected to be paid under residual value guarantees and the exercise price of a purchase option if the Company is reasonably certain to exercise that option. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Variable lease payments that do not depend on an index or a specified rate are not included in the measurement of lease liabilities but instead are recognized as expenses in the period in which the event or condition that triggers the payment occurs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">After the commencement date, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced to reflect lease payments made. In addition, the carrying amount of lease liabilities is remeasured when there is a change in future lease payments arising from a change in an index or specified rate, if there is a modification to the lease terms and conditions, a change in the estimate of the amount expected to be payable under residual value guarantee, or if the Company changes its assessment of whether it will exercise a termination, extension or purchase option. The remeasurement amount of the lease liabilities is recognized as an adjustment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, or in the consolidated statement of comprehensive loss when the carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is reduced to zero. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification and presentation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lease-related</div> expenses </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Amortization charge for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, expenses related to variable lease payments not included in the measurement of lease liabilities and loss (gain) related to lease modifications are allocated in the Company&#8217;s consolidated statement of comprehensive loss based on their function within the Company, while interest expense on lease liabilities is presented within finance costs. </div> </ix:continuation><ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26596"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Deferred Financing Costs </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares or debt securities. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity or debt issuance on a proportionate basis when it occurs. If at such time the Company deems that these costs are no longer recoverable, they will be expensed as a component of finance expenses. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_92" continuedAt="TextSelectionAppend_101086556_93"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">24 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_93" continuedAt="TextSelectionAppend_101086556_94"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_94" continuedAt="TextSelectionAppend_101086556_95"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_95" continuedAt="TextSelectionAppend_101086556_96"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_96" continuedAt="TextSelectionAppend_101086556_97"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_97" continuedAt="TextSelectionAppend_101086556_98"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_98" continuedAt="TextSelectionAppend_101086556_99"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26669"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Provisions </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates are estimated based on historical experience, relevant statutes with respect to governmental pricing programs, and contractual sales terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Returns </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for returns are estimated based on historical return levels, taking into account additional available information on contract changes. The Company reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical results and business practices, as necessary. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Contingent liability </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-occurrence</div> of one or more uncertain future events not wholly within the control of the Company, or a present obligation that arises from past events (and therefore exists) but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or because the amount of the obligation cannot be estimated reliably. </div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_99" continuedAt="TextSelectionAppend_101086556_100"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">25 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_100" continuedAt="TextSelectionAppend_101086556_101"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_101" continuedAt="TextSelectionAppend_101086556_102"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_102" continuedAt="TextSelectionAppend_101086556_103"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_103" continuedAt="TextSelectionAppend_101086556_104"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_104" continuedAt="TextSelectionAppend_101086556_105"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_105" continuedAt="TextSelectionAppend_101086556_106"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26748"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Income taxes </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in net loss except to the extent that they relate to items recognized directly in other comprehensive income (loss) or in&#160;equity. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Current tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Current tax is the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable in respect of previous years. The Company establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Deferred tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes and deferred tax losses that can be used against taxable profit in future years. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse and to fiscal losses when they will be used, based on the laws that have been enacted or substantively enacted by the reporting date. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A deferred tax liability is generally recognized for all taxable temporary differences. A deferred tax asset is recognized for unused tax losses and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred income tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting or taxable profit or loss at the time of the transaction, and, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising from the initial recognition of goodwill. </div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_106" continuedAt="TextSelectionAppend_101086556_107"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">26 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086556_107" continuedAt="TextSelectionAppend_101086556_108"><div></div></ix:continuation> </div> <div> <ix:continuation id="TextSelectionAppend_101086556_108" continuedAt="TextSelectionAppend_101086556_109"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_109" continuedAt="TextSelectionAppend_101086556_110"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_110" continuedAt="TextSelectionAppend_101086556_111"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_111" continuedAt="TextSelectionAppend_101086556_112"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_112" continuedAt="TextSelectionAppend_101086556_113"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_113" continuedAt="TextSelectionAppend_101086556_114"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26824"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Share option plan </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records share-based compensation related to Options granted using the fair-value-based method estimated using the Black-Scholes model. Under this method, compensation cost is measured at fair value at the date of grant and expensed over the period in which optionees unconditionally become entitled to the Options. The amount recognized as an expense is adjusted to reflect the number of Options for which the related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of Options that do meet the related service conditions at the vesting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> payment arrangements in which the Company receives services as consideration for its own equity instruments are accounted for as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-settled</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment transactions, regardless of how the equity instruments are obtained by the Company. </div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred stock unit plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred stock units (&#8220;DSUs&#8221;) are totally vested on the date of grant and are settled in cash. When DSUs are granted to officers as part of their annual bonuses, a DSU liability is recorded on the date of grant at the market value of the common shares in place of the liability for the bonus payments. When DSUs are granted to directors as part of their annual compensation in lieu of cash, the expense related to DSUs and their liabilities are recognized on the date of grant. The liability is adjusted to reflect any change in the market value of common shares, and such change is recorded in finance costs. </div></div></div> </ix:nonNumeric><ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087552" id="ixv-26846"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights (&#8220;SARs&#8221;) entitle the grantee to a cash payment based on the increase in the share price of the Company&#8217;s common shares from the grant date to the settlement date. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A liability is recognized for the services acquired and is recorded at the fair value of the SARs in other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities, with a corresponding expense recognized in selling expenses over the period that the grantees become unconditionally entitled to the payment. The fair value of the employee benefits expense of the SARs is measured using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model. </div></div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101087552" continuedAt="TextSelectionAppend_101087552_1"><ix:continuation id="TextSelectionAppend_101086556_114" continuedAt="TextSelectionAppend_101086556_115"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">27 </div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101087552_1" continuedAt="TextSelectionAppend_101087552_2"><ix:continuation id="TextSelectionAppend_101086556_115" continuedAt="TextSelectionAppend_101086556_116"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_116" continuedAt="TextSelectionAppend_101086556_117"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_117" continuedAt="TextSelectionAppend_101086556_118"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_118" continuedAt="TextSelectionAppend_101086556_119"><ix:continuation id="TextSelectionAppend_101087552_2" continuedAt="TextSelectionAppend_101087552_3"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation </div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div><br/></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">plan</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> (continued)</div></div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_119" continuedAt="TextSelectionAppend_101086556_120"><ix:continuation id="TextSelectionAppend_101087552_3"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">Estimating fair value requires determining the most ap</div>propri<div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">ate inputs to the valuation model including the expected life of the SARs, volatility, </div><div style="letter-spacing: 0px; font-size: 11pt; white-space: nowrap; top: 0px;;display:inline;">risk-free</div><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"> interest rate and dividend yield and making assumptions about them. At the end of each reporting period until the liability is settled, the fair value of the liability is remeasured, with any changes in fair value recognized in the consolidated statement of net earnings (loss) and comprehensive earnings (loss) of the current year.</div></div></ix:continuation><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26961"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Government assistance </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Government grants are recognized only when the Company has reasonable assurance that it meets the conditions and will receive the grants. Government grants related to assets are recognized in the consolidated statement of financial position as a deduction from the carrying amount of the related asset. They are then recognized in profit or loss over the estimated useful life of the amortization asset that the grants were used to acquire, as a deduction from the amortization expense. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other government grants are recognized in profit or loss as a deduction from the related expenses, such as salaries for the Canadian Emergency Wage Subsidy program. </div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26966"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Research and development tax credits </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company elected to account for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> research and development tax credits under IAS&#160;20, <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Government Grants and Disclosure of Governmental Assistance</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> research and development tax credits are included in earnings against gross research and development expenses or deducted from the related assets, provided there is reasonable assurance that the Company has complied and will comply with the conditions related to the tax credits and that the credits will be received. </div></div></ix:nonNumeric><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-26976"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Share capital </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, subscription receipts and Public Offering Warrants are classified as equity. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs directly attributable to the issue of common shares and equity classified warrants and subscription receipts are recognized in equity, net of any tax effects. </div></div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_120" continuedAt="TextSelectionAppend_101086556_121"><ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">28 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101086556_121" continuedAt="TextSelectionAppend_101086556_122"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_122" continuedAt="TextSelectionAppend_101086556_123"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_123" continuedAt="TextSelectionAppend_101086556_124"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_124" continuedAt="TextSelectionAppend_101086556_125"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_125" continuedAt="TextSelectionAppend_101086556_126"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_126" continuedAt="TextSelectionAppend_101086556_127"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27052"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Earnings per share </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for its common shares. Basic EPS is calculated by dividing the net profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders by taking the weighted average number of common shares outstanding and taking into consideration all dilutive potential common shares, which consist of the outstanding Options, warrants, subscription receipts and convertible unsecured senior notes. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:nonNumeric><ix:nonNumeric name="thtx:DescriptionOfChangesInAccountingPoliciesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27062"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Changes in accounting policies </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2022, the Company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities in the consolidated statement of cash flows. Previously, the Company elected to classify interest paid as cash flow from financing activities and interest received as cash flows from investing activities. This change was applied retrospectively. </div></div></div></ix:nonNumeric><ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27068"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">New standard adopted </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Onerous contracts &#8211; Cost of Fulfilling a Contract (Amendments to IAS 37) </div> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#8217;s annual reporting periods beginning on December&#160;1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. </div></div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_127" continuedAt="TextSelectionAppend_101086556_128"><ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">29 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101086556_128" continuedAt="TextSelectionAppend_101086556_129"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_129" continuedAt="TextSelectionAppend_101086556_130"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_130" continuedAt="TextSelectionAppend_101086556_131"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086556_131" continuedAt="TextSelectionAppend_101086556_132"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086556_132" continuedAt="TextSelectionAppend_101086556_133"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant accounting policies</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086556_133"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="thtx:DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27141"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Standards issued but not yet effective </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">A number of new standards are effective for annual periods beginning after December&#160;1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing these Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> (Amendments to IAS 1)</div> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">For the purposes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> Covenants with which a company must comply after the reporting date do not affect a liability&#8217;s classification at that date. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#8217;s own equity instruments to the counterparty; and when classifying liabilities as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> a company can ignore only those conversion options that are recognized as equity. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments will be effective for the Company&#8217;s annual reporting period beginning on December&#160;1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. </div></div></div> </ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">30 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfRevenueExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087798" id="ixv-27193">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">United States </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2014, the Company entered into a master services agreement with RxC Acquisition Company (&#8220;RxCrossroads&#8221;), along with two statements of work (&#8220;RxCrossroads Agreements&#8221;). Under the terms of the RxCrossroads Agreements, RxCrossroads acts as the Company&#8217;s exclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party</div> logistics service provider for all of the Company&#8217;s products in the United States and, as such, provides warehousing and logistical support services to the Company, including inventory control, account management, customer support, product return management and fulfillment of orders. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">Under the RxCrossroads Agreements, RxCrossroads also acts as the Company&#8217;s exclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party</div> distributor of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in the United States. In such a role, RxCrossroads purchases </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> from the Company and takes title thereto when the goods arrive in their warehouse. RxCrossroads&#8217; purchases of </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> are triggered by its expectations of market demand over a certain period of time. With respect to </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div>, RxCrossroads fulfills orders received from authorized wholesalers and delivers </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> directly to that authorized wholesaler&#8217;s client, namely, a specialty pharmacy forming part of the Company&#8217;s network of specialty pharmacies. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;1, 2017, the Company entered into amended and restated RxCrossroads Agreements to add Trogarzo<div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div> as a new product sold in the United States. These amended and restated RxCrossroads Agreements replaced the RxCrossroads Agreements entered into in May&#160;2014. On November&#160;1, 2019, the RxCrossroads Agreements were amended anew to include <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;SV</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">as an additional product distributed by RxCrossroads in the United States<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Canada </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company commercialized <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>directly in Canada using a distributor until September 2022, after which time the Company withdrew the product from the market in Canada. </div></div> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">31 </div> </ix:exclude></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101087798" continuedAt="TextSelectionAppend_101087798_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087798_1" continuedAt="TextSelectionAppend_101087798_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087798_2" continuedAt="TextSelectionAppend_101087798_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087798_3" continuedAt="TextSelectionAppend_101087798_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087798_4" continuedAt="TextSelectionAppend_101087798_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087798_5" continuedAt="TextSelectionAppend_101087798_6"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Europe </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;9, 2020, the Company entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-wholesaling</div> services agreement with Loxxess Pharma GmbH or&#160;(&#8220;Loxxess&#8221;) pursuant to which Loxxess agreed to act as our third-party service logistics provider (the &#8220;Loxxess Agreement&#8221;) in certain key European countries, including Germany, France, Italy, Austria, The Netherlands, Portugal, Switzerland, United Kingdom, Norway, Sweden, Finland and Denmark. Loxxess is also capable of serving other European countries, including Israel and Turkey. Pursuant to the Loxxess Agreement, Loxxess received customers&#8217; ordered, stored, packaged and shipped Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to European hospitals and pharmacies. Loxxess was also responsible, on our behalf, to collect payments of the goods sold to those hospitals and pharmacies. The hospitals and pharmacies dispensed Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to patients. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On April&#160;27, 2022, the Company announced that it would focus its commercial operations on the North American territory only and, as a result, would cease commercial sales of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe. At that time, the Company sent a notice of termination to TaiMed Biologics Inc. (&#8220;TaiMed&#8221;), as per the contractual terms indicating it was returning the European commercialization rights to Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to TaiMed within the next 180 days. The discontinuation became effective in December 2022. Refer to Note 13.</div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_101087798_6" continuedAt="TextSelectionAppend_101087798_7"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">32 </div> </ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087798_7" continuedAt="TextSelectionAppend_101087798_8"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087798_8" continuedAt="TextSelectionAppend_101087798_9"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087798_9" continuedAt="TextSelectionAppend_101087798_10"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087798_10" continuedAt="TextSelectionAppend_101087798_11"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087798_11" continuedAt="TextSelectionAppend_101087798_12"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></td></tr></table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087798_12"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27409"> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by product <div style="display:inline;">were</div> as follows:<br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 61%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 1%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;SV</div></div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48238">53,705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48239">50,454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48240">43,009</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trogarzo<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48241">28,059</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48242">29,603</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48243">26,814</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48244">81,764</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48245">80,057</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48246">69,823</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="thtx:DisaggregationOfRevenueByGeographicalAreaTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27572"> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by geography were as follows: </div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 90%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 5%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Canada</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_CAifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48247">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_CAifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48248">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_CAifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48249">269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">United States</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_USifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48250">81,392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48251">78,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_USifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48252">68,099</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Europe</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48253">286</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48254">1,261</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48255">1,455</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48256">81,764</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48257">80,057</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48258">69,823</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">33 </div> </div></div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements (continued)</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated)</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27782">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses</div></div></div></div> </td> </tr> </table> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-27794"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 55%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Salaries and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>employee benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48259">24,934</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48260">22,049</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48261">11,480</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48262">1,833</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48263">1,346</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48264">644</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>compensation</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20(f),(h)</td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48265">2,109</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48266">3,604</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48267">1,651</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination benefits</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48268">2,006</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48269">566</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TerminationBenefitsExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48270">209</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48271">30,882</ix:nonFraction></div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48272">27,565</ix:nonFraction></div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160; <ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48273">13,984</ix:nonFraction></div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2023, $<ix:nonFraction name="thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48274">1,963</ix:nonFraction> was recorded in termination benefits for severance and other expenses. Refer to note 16(a). </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal</div></div><div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">&#160;2022, $</div><ix:nonFraction name="thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48275">457</ix:nonFraction><div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"> was </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">recorded in termination benefits for severance and other expenses associated with the return to TaiMed of the commercial rights to Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> </div></div></div> <div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"></div></ix:nonNumeric> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">34</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/> </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28241">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Finance income and finance costs </div></div> </td> </tr> </table> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28250"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on repurchase of convertible unsecured senior notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160; &#160; &#160;<ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48276">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48277">357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48278">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net gain on financial instruments carried at fair <br/>value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48279">1,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48280">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48281">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48282">769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48283">316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48284">195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on lease termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48285">121</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48286">-</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48287">-</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48288">2,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48289">673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48290">195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense and amortization of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,&#160;18,&#160;19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48291">2,098</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48292">2,140</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48293">2,358</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest on convertible unsecured senior&#160;notes and on long-term loan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48294">8,263</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48295">4,357</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160;(<ix:nonFraction name="ifrs-full:InterestExpenseOnDebtInstrumentsIssued" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48296">3,306</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bank charges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48297">42</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48298">35</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48299">31</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net foreign currency loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48300">159</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;&#160; (<ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48301">1,027</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48302">926</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Loss on Loan Facility modifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(c)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:GainLossOnLoanFacilityModifications" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48303">3,540</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainLossOnLoanFacilityModifications" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48304">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GainLossOnLoanFacilityModifications" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48305">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Write off of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(d)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48306">954</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48307">-</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48308">-</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48309">15,056</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48310">7,559</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceCostsAndGainsLossesOnForeignCurrency" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48311">6,621</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net finance cost recognized in net&#160;profit&#160;or&#160;loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48312">12,909</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48313">6,886</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48314">6,426</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; text-indent: 0px;">&#160;</div> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">35 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28762">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Bonds and money market <div style="display:inline;">funds</div> </div></div></td></tr></table> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28772"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"/>
<td style="height:1.5pt" colspan="4"/>
<td style="height:1.5pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"/>
<td style="height:7.5pt" colspan="4"/>
<td style="height:7.5pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;<ix:nonFraction name="ifrs-full:GovernmentDebtInstrumentsHeld" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48315">6,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;<ix:nonFraction name="ifrs-full:GovernmentDebtInstrumentsHeld" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48316">8,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Guaranteed investment certificates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GuaranteedInvestmentCertificates" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48317">228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:GuaranteedInvestmentCertificates" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48318">224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="4"/>
<td style="height:9.75pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48319">6,290</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48320">9,214</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr> </table> </ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As at November&#160;30, 2023, bonds were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interest-bearing</div> financial assets with stated interest rates ranging from <ix:nonFraction name="thtx:FinancialAssetsStatedInterestPercentage" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48321">0.85</ix:nonFraction>% to <ix:nonFraction name="thtx:FinancialAssetsStatedInterestPercentage" contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48322">3.75</ix:nonFraction>% (2022&#160;&#8211; <ix:nonFraction name="thtx:FinancialAssetsStatedInterestPercentage" contextRef="PAsOn11_30_2022_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48323">0.65</ix:nonFraction>% to <ix:nonFraction name="thtx:FinancialAssetsStatedInterestPercentage" contextRef="PAsOn11_30_2022_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48324">3.90</ix:nonFraction>%) and had an average maturity of <ix:nonNumeric name="thtx:FinancialAssetsAverageMaturityTerm" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:duryear" id="ixv-48325">1.40</ix:nonNumeric>&#160;years (2022&#160;&#8211; <ix:nonNumeric name="thtx:FinancialAssetsAverageMaturityTerm" contextRef="P12_01_2021To11_30_2022" format="ixt-sec:duryear" id="ixv-48326">1.78</ix:nonNumeric>&#160;years). </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:nonNumeric><ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28862">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Trade and other receivables </div></div></td></tr></table> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-28871">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48327">12,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48328">10,659</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Sales taxes receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48329">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48330">538</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48331">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48332">848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:3.75pt">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48333">13,023</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48334">12,045</ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">36 </div> </div></div><div></div></div><div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="thtx:DisclosureOfTaxCreditsReceivableExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085391" id="ixv-28997">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Tax credits and grants receivable </div></div></td></tr></table> <ix:nonNumeric name="thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29006"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48335">441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48336">316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TaxCreditsAndGrantsReceived" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48337">442</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48338">16</ix:nonFraction>)</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48339">299</ix:nonFraction></td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax Credit and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48340">539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TaxCreditsAndGrantsReceived" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48341">324</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48342">10</ix:nonFraction></td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48343">524</ix:nonFraction></td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">37 </div> </ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_101085391" continuedAt="TextSelectionAppend_101085391_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085391_1" continuedAt="TextSelectionAppend_101085391_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085391_2" continuedAt="TextSelectionAppend_101085391_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101085391_3" continuedAt="TextSelectionAppend_101085391_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085391_4" continuedAt="TextSelectionAppend_101085391_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax credits and grants receivable </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085391_5"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Tax credits receivable comprise grants receivable, and research and development investment tax credits receivable which relate to eligible research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded. There are no unfulfilled conditions or contingencies associated with the government assistance received. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company has unused and unrecorded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> federal tax credits which may be used to reduce future federal income tax payable and expire as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29190">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFourMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48344">438</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFiveMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48345">1,306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySixMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48346">1,604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySevenMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48347">2,209</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyEightMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48348">2,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48349">1,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2030</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48350">818</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2031</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48351">572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2032</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48352">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2033</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48353">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2039</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48354">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2040</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48355">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2041</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48356">383</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2042</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48357">657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2043</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48358">728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="PAsOn11_30_2023_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48359">13,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">38 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfInventoriesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29398">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventories </div></div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085420" id="ixv-48360"></ix:nonNumeric></div> <ix:continuation id="TextSelection_101085420">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;<ix:nonFraction name="ifrs-full:RawMaterials" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48361">2,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;<ix:nonFraction name="ifrs-full:RawMaterials" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48362">2,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WorkInProgress" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48363">1,708</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WorkInProgress" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48364">5,815</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinishedGoods" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48365">2,096</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:FinishedGoods" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48366">11,290</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48367">6,066</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48368">19,688</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In fiscal 2023, inventories of $<ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P12_01_2022To11_30_2023_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48369">18,540</ix:nonFraction> (2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>$<ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P12_01_2021To11_30_2022_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48370">19,587</ix:nonFraction>) were recognized as an expense and included in cost of goods sold. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2023, inventories for an amount of $<ix:nonFraction name="thtx:InventoriesReturned" contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48371">3,295</ix:nonFraction> was returned to TaiMed. and accounts payable was reduced by a total amount of <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48372">3,179</ix:nonFraction> ($<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48373">3,399</ix:nonFraction>). </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2023, an inventory provision of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48374">220</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; </div><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48375">nil</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was recognized pending marketing approval of the F8 formulation of tesamorelin and recorded in cost of sales. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;">Inventories were written down to net realizable value by an amount of $<ix:nonFraction name="ifrs-full:InventoryWritedown2011" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48376">2,137</ix:nonFraction> in 2022, which was recorded in cost of sales. Included in the 2022 write-down is a provision of $<ix:nonFraction name="thtx:ProvisionForFormulation" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48377">1,477</ix:nonFraction> on the F8 formulation and $<ix:nonFraction name="thtx:ProvisionForTheInventoryInDevelopment" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48378">339</ix:nonFraction> on material for the pen in development to be used in conjunction with the F8 formulation, and $<ix:nonFraction name="thtx:ProvisionForTheExpiredRawMaterial" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48379">252</ix:nonFraction> on expired raw material. The 2022 write-down also includes a provision of $<ix:nonFraction name="thtx:ProvisionForExcessStock" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48380">69</ix:nonFraction> on excess stock of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> as a result of the Company&#8217;s decision to withdraw the product from the market in Canada. </div></div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">39 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29583">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Prepaid expenses and deposits </div></div> </td> </tr> </table> <ix:nonNumeric name="ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29592">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 71%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:PrepaidExpenses" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48381">2,687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:PrepaidExpenses" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48382">6,320</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Deposits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48383">467</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48384">1,345</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160; <ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48385">3,154</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48386">7,665</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">40 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29741"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-weight:bold;display:inline;"> </div> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-29761"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 53%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Office</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">furniture&#160;and</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">improvements</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48387">373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48388">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48389">332</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48390">650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48391">1,462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48392">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48393">961</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48394">-</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48395">-</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48396">1,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48397">263</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48398">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48399">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48400">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48401">263</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48402">290</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48403">1,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48404">332</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48405">650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48406">2,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48407">7</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48408">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48409">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48410">-</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48411">162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48412">46</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"><br/></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48413">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48414">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48415">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48416">46</ix:nonFraction>) </td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48417">251</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48418">1,196</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48419">359</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48420">650</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48421">2,456</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated depreciation</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48422">229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48423">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48424">157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48425">264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48426">719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48427">157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48428">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48429">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48430">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48431">390</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48432">263</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48433">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48434">- </ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48435">- </ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48436">263</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48437">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48438">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48439">195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48440">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48441">846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48442">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48443">217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48444">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48445">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48446">450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48447">46</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48448">- </ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48449">- </ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48450">- </ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48451">46</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48452">177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48453">380</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48454">227</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48455">466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="thtx:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48456">1,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48457">74</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48458">816</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48459">132</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48460">184</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48461">1,206</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48462">167</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48463">905</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48464">137</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48465">285</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48466">1,494</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">41 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div> <div style="text-align: center;"></div> <ix:nonNumeric name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-30584"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; line-height: 10pt;"><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets </div></div> </td> </tr> </table> <ix:nonNumeric name="thtx:RightOfUseAssetsTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-30597">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:3%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:75%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48467">2,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AmortizationOfRightOfUseAsset" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48468">429</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48469">87</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; <ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48470">1,595</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AmortizationOfRightOfUseAsset" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48471">352</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(a)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TerminationOfRightOfUseAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48472">799</ix:nonFraction>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(<div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48473">326</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48474">770</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">42 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Years ended November 30, 2023, 2022 and 2021 </div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 2pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 2pt solid rgb(0, 0, 0);">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086912" id="ixv-30767">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div> </td> </tr> </table> <ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-30776">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 41%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">North&#160;American</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">European&#160;Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rights&#160;&#8211;&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA&#160;SV<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">&#174;</div></div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Oncology</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">platform</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48475">11,972</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48476">7,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48477">14,041</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48478">3,488</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48479">37,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48480">2,832</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48481">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48482">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48483">-</ix:nonFraction> </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48484">2,832</ix:nonFraction></td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48485">14,804</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48486">7,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48487">14,041</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48488">3,488</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48489">39,945</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48490">7,612</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48491">7,612</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48492">14,804</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48493">14,041</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48494">3,488</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48495">32,333</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48496">3,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48497">999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48498">11,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48499">15,725</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48500">1,087</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48501">6,613</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48502">1,511</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48503">9,211</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; <ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48504">4,354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48505">7,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48506">12,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48507">24,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48508">7,612</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48509">7,612</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; <ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48510">1,442</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; <ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48511">1,071</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48512">2,513</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48513">5,796</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48514">14,041</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48515">19,837</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48516">9,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48517">3,488</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48518">12,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48519">10,450</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48520">-</ix:nonFraction></td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; <ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48521">1,071</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48522">3,488</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48523">15,009</ix:nonFraction></td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amortization expense of $</div><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48524">2,513</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022&#160;&#8211; $ </div><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48525">9,211</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">; 2021 &#8211; $ </div><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48526">3,180</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) is included in selling expenses.</div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">On March&#160;18, 2016, the Company entered into a distribution and marketing agreement with TaiMed granting the Company the exclusive right to market Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in Canada and in the United&#160;States. On March&#160;6, 2017, the Company entered into an amended and restated distribution and marketing agreement with TaiMed (&#8220;TaiMed Agreement&#8221;) granting the Company the exclusive right to market and distribute Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in Canada and in the United States (collectively, the &#8220;North&#160;American Territory&#8221;) as well as in European Union countries and other countries such as Israel, Norway, Russia and Switzerland (collectively, the &#8220;European Territory&#8221;). The TaiMed Agreement has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="thtx:IntangibleAssetsAgreementTermOfContract" contextRef="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" format="ixt-sec:duryear" id="ixv-48527">12</ix:nonNumeric>-year</div> term that will expire on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis calculated from the date of approval of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in each of the countries covered under the TaiMed Agreement. TaiMed is responsible for the manufacture and supply of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> under the TaiMed Agreement. </div> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">43 </div> </ix:exclude></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101086912" continuedAt="TextSelectionAppend_101086912_1"><div></div></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_101086912_1" continuedAt="TextSelectionAppend_101086912_2"><div> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div></ix:continuation> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086912_2" continuedAt="TextSelectionAppend_101086912_3"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_3" continuedAt="TextSelectionAppend_101086912_4"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086912_4" continuedAt="TextSelectionAppend_101086912_5"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the North American Territory </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Under the terms of the TaiMed Agreement, TaiMed was responsible for developing Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> and for seeking its approval from the US Food and Drug Administration (&#8220;FDA&#8221;). The Company is responsible, but has no obligation, to seek the approval of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> from Health Canada and must use its commercially reasonable efforts to commercialize Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>in the United States. The purchase price of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> payable to TaiMed has been determined at <ix:nonFraction name="thtx:PercentageOfPurchasePriceConsiderationOfIntangibleAssets" contextRef="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48528">52</ix:nonFraction>% of its net selling price. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Initial payments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Under the TaiMed Agreement, the Company agreed to make an initial payment of US$<ix:nonFraction name="thtx:InitialMilestonePaymentsPayable" contextRef="PAsOn03_31_2016_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48529">5,000</ix:nonFraction> and will make several further milestone payments in exchange for the right to commercialize Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> and the right to use TaiMed&#8217;s trademark in the North American Territory. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The initial payment of $<ix:nonFraction name="thtx:LaunchMilestonePayable" contextRef="PAsOn12_01_2017_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48530">5,000</ix:nonFraction> was made in accordance with the following: </div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">$<ix:nonFraction name="thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48531">1,000</ix:nonFraction> was paid in cash at the signature of the TaiMed Agreement entered into in March 2016;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> </div> </td> </tr> </table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">$<ix:nonFraction name="thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48532">4,000</ix:nonFraction> through the issuance of the Company&#8217;s common shares, payable after the first commercial sale of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the United States. The $4,000 payment was made on May&#160;15, 2018 and resulted in the issuance of <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn05_15_2018_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48533"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn05_15_2018_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48534">1,463,505</ix:nonFraction></ix:nonFraction> common shares to TaiMed. </div> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2016, the Company recorded as additions to intangible assets an amount </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48535">5,207</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">related to the TaiMed Agreement, which comprised the cash payment of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> $</div><ix:nonFraction name="thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48536">1,000</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at the signature of the TaiMed Agreement, the <div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment of</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48537">4,000</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">,</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="thtx:AcquisitionCostsForIntangibleAssets" contextRef="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48538">207</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">in</div> acquisition costs.</div></div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Further development milestone payments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Under the terms of the TaiMed Agreement, a further milestone of $<ix:nonFraction name="thtx:InitialMilestonePaymentsPayableAggregateAnnualInstallments." contextRef="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48539">7,000</ix:nonFraction> was payable in two annual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;equal</div> installments of $<ix:nonFraction name="thtx:FirstMilestoneInstallmentPaymentsPayable" contextRef="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48540">3,500</ix:nonFraction> after achieving aggregate net sales of $<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48541">20,000</ix:nonFraction> over four consecutive quarters of the Company&#8217;s financial year. The first payment of $<ix:nonFraction name="thtx:SecondMilestoneInstallmentPaymentsPayable" contextRef="PAsOn11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48542">3,500</ix:nonFraction> was made in July 2019, and the second payment was made in June 2020. The Company determined this milestone to be substantially a development milestone and recorded such amount as additions to intangible assets during 2019. The Company also paid TaiMed further development milestones for Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>in 2022. A $<ix:nonFraction name="thtx:PaymentOfUpfrontMilestones" contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48543">3,000</ix:nonFraction> milestone (payable in two annual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;equal</div> installments of $<ix:nonFraction name="thtx:DevelopmentMilestonePayableAnnualInstallment" contextRef="PAsOn12_31_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48544">1,500</ix:nonFraction>) became due upon the date of the first commercial sale of a once every two weeks <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">intravenous (IV) push</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;injection formulation. An amount of $</div><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48545">2,832</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> has been capitalized as an intangible asset in fiscal 2022 related to these milestone payments (refer to Note 15).</div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_101086912_5" continuedAt="TextSelectionAppend_101086912_6"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">44 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086912_6" continuedAt="TextSelectionAppend_101086912_7"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086912_7" continuedAt="TextSelectionAppend_101086912_8"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_8" continuedAt="TextSelectionAppend_101086912_9"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086912_9" continuedAt="TextSelectionAppend_101086912_10"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_10" continuedAt="TextSelectionAppend_101086912_11"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Further development milestone payments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_11" continuedAt="TextSelectionAppend_101086912_12"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the TaiMed Agreement, TaiMed may also launch a larger Phase III trial using Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>with a once every four weeks intramuscular, subcutaneous or intravenous-push (either fast or slow) injection formulation to address a much broader patient population. If launched, this development milestone will consist of an upfront milestone payment of up </div></div>to $<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2016To11_30_2017_EuropeMemberifrsfullGeographicalAreasAxis_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48546">50,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">depending on the size of the newly targeted population, payable quarterly, based on the percentage of net sales generated </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">by Trogarzo</div><div style="font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;">&#174;</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Further commercial milestone payments </div></div> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087076" id="ixv-31671"> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As further consideration under the TaiMed Agreement, the Company shall make the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payments upon the first occurrence of the following commercial events: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:nonNumeric><div><ix:continuation id="TextSelection_101087076">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 96%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 21%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial milestone</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial&#160;milestone&#160;payment&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(i) Upon first achieving annual net sales of $200,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$<ix:nonFraction name="thtx:InitialMilestonePaymentsPayable" contextRef="PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48547">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(ii) Upon first achieving annual net sales of $500,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$<ix:nonFraction name="thtx:InitialMilestonePaymentsPayable" contextRef="PAsOn11_30_2023_MilestoneFiveMemberTHTXMilestoneAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48548">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 4pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(iii) Upon first achieving annual net sales of $1,000,000</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">$<ix:nonFraction name="thtx:InitialMilestonePaymentsPayable" contextRef="PAsOn11_30_2023_MilestoneSixMemberTHTXMilestoneAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48549">100,000</ix:nonFraction></td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> </ix:continuation></div> <div style="margin-top:36pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> European Territory </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;17, 2022, the Company announced that it would focus its commercial operations on the North American Territory only and, as a result, would cease the commercial sale of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe. Refer to Note 3. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consequently, during the second quarter of 2022, the remaining balance of the intangible asset amounting</div></div>&#160;to $<ix:nonFraction name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="PAsOn05_31_2022_TrogarzoMemberifrsfullProductsAndServicesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48550">6,356</ix:nonFraction> was recognized as part of <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>selling <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses to accelerate and fully amortize &#8211; Commercialization rights Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> &#8211; European Territory.</div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Oncology platform </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">On February&#160;25, 2019, the Company acquired Katana Biopharma Inc. (&#8220;Katana&#8221;) through the purchase of all of its issued and outstanding shares. On May&#160;21, 2019, Katana was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wound-up</div> into the Company and then dissolved. </div> </ix:continuation><ix:continuation id="TextSelectionAppend_101086912_12" continuedAt="TextSelectionAppend_101086912_13"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">45 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086912_13" continuedAt="TextSelectionAppend_101086912_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086912_14" continuedAt="TextSelectionAppend_101086912_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_15" continuedAt="TextSelectionAppend_101086912_16"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086912_16" continuedAt="TextSelectionAppend_101086912_17"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology platform </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_17" continuedAt="TextSelectionAppend_101086912_18"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Katana (now the Company) is the worldwide exclusive licensee of a technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to Sortilin receptors, which are overexpressed on cancer cells. The licence was entered into on February&#160;25, 2019 with Transfert Plus, L.P. (&#8220;Transfert Plus&#8221;), an affiliate of Aligo Innovation, a university research company that commercializes the research results of universities and other institutional partners from various areas of innovation, including life sciences (the &#8220;Licence Agreement&#8221;). </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the acquisition agreement, part of the purchase price was to be settled through the issuance of common shares upon achieving two milestones. The first milestone consisted in initiating a Phase 1 clinical trial evaluating Sudocetaxel zendusortide for the treatment of Sortilin positive solid tumors. This milestone was achieved in March 2021 and was satisfied through the issuance </div></div>of <ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48551">120,482</ix:nonFraction> common shares (Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div>(b)). </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The second milestone payment of CA$<ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn11_30_2022_KatanaMemberifrsfullBusinessCombinationsAxis_LicenseAgreementTransferPlusLPMemberTHTXTypeOfArrangementsAxis_MilestonePhaseTwoLiveDemonstrationMemberTHTXMilestoneAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48552">2.3</ix:nonFraction>&#160;million will occur when the proof of concept will have been demonstrated in human subjects and will be satisfied through the issuance of common shares of the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">This acquisition was accounted for as an asset acquisition. During 2019, the Company recorded additions to intangible assets of $<ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48553">3,073</ix:nonFraction>, which comprised the payment at closing of $<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48554">1,965</ix:nonFraction> in cash, $<ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48555">5</ix:nonFraction> through the issuance of <ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48556">900</ix:nonFraction> common shares of the Company, the estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> contingent consideration of $<ix:nonFraction name="thtx:BusinessCombinationContingentConsiderationFairValue" contextRef="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48557">1,028</ix:nonFraction>, and $<ix:nonFraction name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" contextRef="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48558">75</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">in acquisition costs. As the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payments are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-settled,</div> the Company recognized a corresponding increase in equity, and no remeasurement of the fair value will occur regardless of the achievement of the milestones. Since the common shares for the second milestone payment have not been issued yet, the increase in equity is recorded in contributed surplus. Upon the issuance of the common shares, this amount will be reclassified to share capital. The intangible asset is currently not being amortized. Amortization will begin when the asset is available for use</div>. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">In August 2019, the acquisition agreement was amended to provide for an adjustment to the purchase price of CA$<ix:nonFraction name="thtx:BusinessCombinationIncreaseDecreaseInPurchaseConsideration" contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-48559">1.08</ix:nonFraction>&#160;million in the event the Company could indirectly benefit from a CA$<ix:nonFraction name="ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48560">1.2</ix:nonFraction>&#160;million subsidy in connection with its research and development activities. The subsidy was granted in October 2019. The adjustment will be payable in two installments. The first installment of CA$<ix:nonFraction name="ifrs-full:CashTransferred" contextRef="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentOneMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48561">500</ix:nonFraction>&#160;thousand was paid in cash in October 2019, whereas the second installment of CA$<ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48562">580</ix:nonFraction>&#160;thousand will be paid&#160;through the issuance of common shares of the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at the same time as the second milestone payment of CA$<ix:nonFraction name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" contextRef="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48563">2.3</ix:nonFraction>&#160;million. The cash<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>payment of $<ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48564">376</ix:nonFraction> (CA$<ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48565">500</ix:nonFraction>) thousand was recognized as an addition to intangible assets during&#160;2019. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The annual maintenance fees, under the Licence Agreement amount </div></div> to CA$<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="P12_01_2022To11_30_2023_FirstFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48566">25</ix:nonFraction>&#160;thousand for the first five years and CA$<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="P12_01_2022To11_30_2023_AfterFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48567">100</ix:nonFraction>&#160;thousand thereafter, until royalties become payable beginning with the first commercial sale of a product developed using the licensed technology. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The royalties payable under the Licence Agreement vary between <ix:nonFraction name="thtx:RoyaltyFeesAsAPercentageOfRevenue" contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48568">1.0</ix:nonFraction>% and <ix:nonFraction name="thtx:RoyaltyFeesAsAPercentageOfRevenue" contextRef="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48569">2.5</ix:nonFraction>% on net sales of a product based on the licensed technology. If the Company enters into a sublicence agreement, it must then pay amounts varying between <ix:nonFraction name="thtx:RoyaltyFeesAsAPercentageOfRevenue" contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48570">5</ix:nonFraction>% and <ix:nonFraction name="thtx:RoyaltyFeesAsAPercentageOfRevenue" contextRef="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48571">15</ix:nonFraction>% of revenues received fr<div style="letter-spacing: 0px; top: 0px;;display:inline;">om</div> such sublicence agreement. </div> </ix:continuation><ix:continuation id="TextSelectionAppend_101086912_18" continuedAt="TextSelectionAppend_101086912_19"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">46 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101086912_19" continuedAt="TextSelectionAppend_101086912_20"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086912_20" continuedAt="TextSelectionAppend_101086912_21"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_21" continuedAt="TextSelectionAppend_101086912_22"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_101086912_22" continuedAt="TextSelectionAppend_101086912_23"><ix:exclude> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements (continued)</div></div></div> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated)</div></div></div> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 10pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Oncology platform </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086912_23"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company must pay Transfert Plus the following milestone payments upon the occurrence of the following development milestones for the first product developed in the field of oncology: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">First milestone payment: $<ix:nonFraction name="thtx:MilestoneAmountPayable" contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48572">39</ix:nonFraction> (CA$<ix:nonFraction name="thtx:MilestoneAmountPayable" contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48573">50</ix:nonFraction>) thousand<div style="letter-spacing: 0px; top: 0px;;display:inline;">, which was paid in May 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div></div> upon the successful enrollment of the first patient in the first Phase 1 clinical trial; </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Second milestone payment: CA$<ix:nonFraction name="thtx:MilestoneAmountPayable" contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseTwoClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48574">100</ix:nonFraction>&#160;thousand upon <div style="letter-spacing: 0px; top: 0px;;display:inline;">th</div>e successful enrollment of the first patient in the first Phase 2 clinical trial; </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Third milestone payment: CA$<ix:nonFraction name="thtx:MilestoneAmountPayable" contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseThreeClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48575">200</ix:nonFraction>&#160;thousand upon the successful enrollment of the first patient in the first Phase 3 clinical trial. </div> </td> </tr> </table> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition,</div></div>&#160;the Company must pay CA$<ix:nonFraction name="thtx:RegulatoryMilestonePaymentPayable" contextRef="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48576">200</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">thousand per product upon receiving the first approval for such product by a regulatory authority. The approval shall entitle the sponsor to commercialize the product in the territory in which the approval was obtained</div></div>. </div> </ix:continuation> <div style="font-size: 36pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfOtherAssetsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087906" id="ixv-31966">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-31982">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td colspan="4" style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021, 2022 and 2023</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="thtx:OtherAssetsNonCurrentAtCost" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48577"><ix:nonFraction name="thtx:OtherAssetsNonCurrentAtCost" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48578"><ix:nonFraction name="thtx:OtherAssetsNonCurrentAtCost" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48579">19,530</ix:nonFraction></ix:nonFraction></ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="thtx:AccumulatedAmortizationOnOtherNonCurrentAssets" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48580">17,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AmortizationOfOtherNonCurrentAssets" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48581">2,441</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="thtx:AccumulatedAmortizationOnOtherNonCurrentAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48582">19,530</ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;November&#160;30, 2023 and November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"><ix:nonFraction name="thtx:NetCarryingAmount" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48583"><ix:nonFraction name="thtx:NetCarryingAmount" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48584">-</ix:nonFraction></ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>47</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101087906" continuedAt="TextSelectionAppend_101087906_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087906_1" continuedAt="TextSelectionAppend_101087906_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087906_2" continuedAt="TextSelectionAppend_101087906_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087906_3" continuedAt="TextSelectionAppend_101087906_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087906_4" continuedAt="TextSelectionAppend_101087906_5"><ix:exclude>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other asset </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087906_5"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> May&#160;29, 2018, the Company entered into an agreement with EMD Serono, Inc. (the &#8220;Renegotiated Agreement&#8221;) to settle all outstanding cash payment obligations stemming from a termination and transfer agreement dated December&#160;13, 2013, as amended (the &#8220;2013&#160;Termination Agreement&#8221;). The remaining contractual obligations under the 2013 Termination Agreement totalled approxima</div></div>tely $<ix:nonFraction name="thtx:ContractualObligations" contextRef="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48586">28,200</ix:nonFraction>, which was comprised of a $<ix:nonFraction name="thtx:ContractualObligations" contextRef="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48587">4,000</ix:nonFraction> payment due in May 2019 and $<ix:nonFraction name="thtx:ContractualObligations" contextRef="PAsOn05_29_2018_DueInNextFourToFiveYearsMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48588">24,200</ix:nonFraction> in estimated royalties on future sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> payable over the subsequent four to five years. The Renegotiated Agreement allowed the Company to make one lump sum payment of $<ix:nonFraction name="thtx:PerformanceObligationFinalSettlementAmount" contextRef="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48589">23,850</ix:nonFraction> in settlement of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> obligation of $<ix:nonFraction name="thtx:ContractualObligations" contextRef="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48590">4,000</ix:nonFraction> and to eliminate all of the royalty payments due on sales of </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the United States. The payment made in connection with the settlement of the future royalty obligation has been accounted for as &#8220;Other asset&#8221; on the consolidated statement of financial position and was amortized through &#8220;Cost of sales&#8221; on the consolidated statement of net loss. </div></div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">48 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-32190">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts payable and accrued liabilities</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <ix:nonNumeric name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-32202">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto;">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div>&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Trade payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48591">6,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48592">12,886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Accrued liabilities and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48593">15,016</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48594">18,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Salaries and benefits due to key management personnel</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48595">1,036</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48596">3,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Employee salaries and benefits payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsAccruals" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48597">3,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ShorttermEmployeeBenefitsAccruals" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48598">1,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Liability related to deferred stock unit plan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20(e)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48599">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48600">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align: top;"> <div style="text-indent: -2em; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.2em; line-height: normal;">Accrued interest payable on convertible unsecured senior notes and Loan Facility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17&#160;and&#160;18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentInterestPayable" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48601">840</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentInterestPayable" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48602">1,108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">TaiMed milestone (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48603">1,497</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48604">2,846</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48605">28,471</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48606">41,065</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">On October&#160;3, 2022, the Company announced that the United States Food and Drug Administration approved Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> (ibalizumab-uiyk) for administration by intravenous (IV)&#160;push, a method by which the undiluted medication is &#8220;pushed&#8221; by syringe for faster administration into the body&#8217;s circulation. Under the TaiMed <div style="letter-spacing: 0px; top: 0px;;display:inline;">A</div>greement, the Company ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#160;additional contingent cash-based milestones based on the attainment of the above milestones. Accordingly<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> a $<ix:nonFraction name="thtx:PaymentOfMilestones" contextRef="P10_03_2022To10_03_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48607">3,000</ix:nonFraction> cash payment, payable in two annual <div style="letter-spacing: 0px; top: 0px;;display:inline;">equal </div>installments of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:EqualAnnualInstallments" contextRef="PAsOn10_03_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48608">1,500</ix:nonFraction></div> has been accrued. The second payment has been discounted to reflect the effective interest rate of the liability due in year<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">two</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>. The first installment of $ <ix:nonFraction name="thtx:PaymentForContingentLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48609">1,500</ix:nonFraction> was paid in 2023 and the second will be paid in 2024. </div> </td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">49 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfProvisionsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-32457">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provisions</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-32469"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 88%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and&#160;rebates</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restructuring</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">(a)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2021_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48610">3,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48611">410</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2021_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48612">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48613">4,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48614">12,910</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48615">2,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48616">14,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48617">10,358</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48618">929</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2021To11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48619">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48620">11,287</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48621">233</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48622">233</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48623">6,032</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48624">1,485</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48625">-</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160; <ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48626">7,517</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48627">15,407</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48628">1,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48629">1,963</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48630">18,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48631">14,506</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48632">309</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48633">1,721</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48634">16,536</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48635">168</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48636">2</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48637">166</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48638">7,101</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48639">2,262</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48640">240</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherShorttermProvisions" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48641">9,603</ix:nonFraction></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:justify">In July 2023, the Company initiated a reorganization mainly focused on its R&amp;D activities. On October&#160;24, 2023, the Company announced changes to its operations that saw a tapering of its research and development activities. As such, for the year ended November&#160;30, 2023, $<ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_SeveranceAndOtherExpensesMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48642">1,963</ix:nonFraction> was recorded in charges related to severance and other expenses, of which an amount of $<ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_ResearchAndDevelopmentExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48643">1,384</ix:nonFraction> was recorded in research and development expenses, $<ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_SellingAndMarketingExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48644">220</ix:nonFraction> in selling expenses and $<ix:nonFraction name="ifrs-full:AdditionalProvisionsOtherProvisions" contextRef="P12_01_2022To11_30_2023_GeneralAndAdministrativeExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48645">359</ix:nonFraction> in general and administrative expenses. </div></td></tr></table></ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">50 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-indent: 0px;">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-indent: 0px;">(In thousands of United States dollars, unless otherwise stated) </div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfBorrowingsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087921" id="ixv-32867">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loan Facility</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;20, 2022, the Company entered into a credit agreement with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, &#8220;Marathon&#8221;) providing for up to $</div></div><ix:nonFraction name="thtx:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48646">100,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(the &#8220;Loan Facility&#8221; or &#8220;Marathon Credit Agreement&#8221;) in loan. The disbursement of the loan was to be made available to the Company over time in four various tranches with each bearing specific conditions to be met by the Company. </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 27, 2022, a principal amount of $<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P07_27_2022To07_27_2022_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48647">40,000</ix:nonFraction> (&#8220;Tranche 1 Loan&#8221;) was funded while on June 21, 2023, a second $<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P06_21_2023To06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48648">20,000</ix:nonFraction> (&#8216;Tranche 2 Loan&#8221;) was funded as a result of the lender removing during the first quarter of 2023 the condition related to the submission to the FDA of the results from the human factor study the Company was then conducting. Refer to Note 20(c) for a discussion on the cost of the amendment. The Company does not meet the conditions precedents to draw down the additional tranches of capital of $<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn11_30_2022_LoanFacilityTranche3LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48649">15,000</ix:nonFraction> and $<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn07_20_2022_LoanFacilityTranche4LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48650">25,000</ix:nonFraction>, respectively. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt and in making available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements. On July&#160;10, 2023, the Company and the lender amended the terms of the Marathon Credit Agreement to reduce the minimum liquidity covenant for the period of July&#160;10 to July&#160;28, 2023 as follows: </div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">From $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_10_2023To07_21_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48651">20,000</ix:nonFraction> to $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_10_2023To07_21_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48652">14,000</ix:nonFraction> between July&#160;10, 2023 up to and including July&#160;21, 2023; and </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">From $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_22_2023To07_28_2023_BottomOfRangeMemberifrsfullRangeAxis_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48653">14,000</ix:nonFraction> to $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_22_2023To07_28_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48654">16,000</ix:nonFraction> between July&#160;22, 2023 up to and including July&#160;28, 2023. </div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On July 28, 2023, the Company and the lender entered into an additional amendment to the terms of the Marathon Credit Agreement to provide, amongst other things, for the minimum liquidity covenant to be</div> $</div></div><ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_29_2023To10_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48655">15,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">from July 29, 2023, up to and including October 31, 2023. After such date, the minimum liquidity covenant was set at</div> $</div></div><ix:nonFraction name="thtx:DebtInstrumentCollateralAmount" contextRef="PAsOn07_28_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48656">20,000</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">; <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">provided, however, that if the F8 formulation of tesamorelin was not approved by the United States Food and Drug Administration by March 31, 2024, the minimum liquidity covenant was set at</div> $</div></div><ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48657">30,000</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. <div style="letter-spacing: 0px; top: 0px;;display:inline;">On September 21, 2023, the Company obtained a waiver from the lender relating to the Liquidity Breach for the period between July 3, 2023 up to end and including July 9, 2023. On October 13, 2023, the Company and the lender entered into an additional amendment to the Marathon Credit Agreement (the &#8220;Fifth Amendment&#8221;) providing for, amongst other things, the following amendments:&#160;</div></div></div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">revising the minimum liquidity requirements for all times following October 31, 2023 to be between $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P10_31_2023To10_31_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48658">15,000</ix:nonFraction> and $<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P10_31_2023To10_31_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48659">20,000</ix:nonFraction>, based on thresholds for Marathon Adjusted EBITDA over the most recently ended four fiscal quarters; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">revising the minimum revenue requirements to be based on Marathon Adjusted EBITDA-based targets instead of quarterly revenue-based targets, beginning with the quarter ending November 30, 2023; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies to the Company&#8217;s annual report. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:nonNumeric><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><ix:continuation id="TextSelection_101087921" continuedAt="TextSelectionAppend_101087921_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the Fifth Amendment, the Company agreed to (i) pay an amount equal to</div> $<ix:nonFraction name="thtx:ConsiderationPayable" contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48660">540</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">amortized value ($<ix:nonFraction name="thtx:DebtInstrumentAmortizedValue" contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48661">600</ix:nonFraction>), or</div> <ix:nonNumeric name="ifrs-full:BorrowingsInterestRateBasis" contextRef="P10_13_2023To10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis" id="ixv-48662">100</ix:nonNumeric> </div></div> </ix:continuation><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">basis points calculated on the outstanding principal amount of the funded debt as of October 13, 2023</div> <ix:continuation id="TextSelectionAppend_101087921_1" continuedAt="TextSelectionAppend_101087921_2"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">($<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48663">60,000</ix:nonFraction>),<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;</div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">which amount was added to the outstanding principal amount of the funded debt as payment in kind; and (ii) reset the exercise price of the Marathon Warrants, which are now exercisable into <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48664">1,250,000</ix:nonFraction></div> common shares at $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48665">2.30</ix:nonFraction></div> per common share, down from the previous $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48666">5.80</ix:nonFraction></div> per common share. </div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_101087921_2" continuedAt="TextSelectionAppend_101087921_3"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The salient conditions of the amounts drawn under the Loan Facility are as follows: </div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_3" continuedAt="TextSelectionAppend_101087921_4"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">51 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087921_4" continuedAt="TextSelectionAppend_101087921_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_5" continuedAt="TextSelectionAppend_101087921_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_6" continuedAt="TextSelectionAppend_101087921_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087921_7" continuedAt="TextSelectionAppend_101087921_8"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_8" continuedAt="TextSelectionAppend_101087921_9"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loan Facility </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087921_9" continuedAt="TextSelectionAppend_101087921_10"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Loan Facility has an initial term of <ix:nonNumeric name="ifrs-full:BorrowingsMaturity" contextRef="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis" id="ixv-48667">five</ix:nonNumeric> years, provides for an interest-only period of <ix:nonNumeric name="thtx:BorrowingsInterestPeriod" contextRef="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis" format="ixt-sec:durmonth" id="ixv-48668">24</ix:nonNumeric> months, and bears interest at the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) plus <ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis_SecuredOvernightFinancingRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48669">9.5</ix:nonFraction>%. <ix:nonNumeric name="ifrs-full:BorrowingsMaturity" contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis" id="ixv-48670">The Tranche 1 Loan and Tranche 2 Loan are repayable in equal monthly installments on an amortization schedule of 36 months starting in July 2024.</ix:nonNumeric> The Company is entitled to prepay the outstanding Loan Facility at any time subject to certain prepayment premium amount: for Tranche 1 Loan until <ix:nonNumeric name="thtx:DateOfCommencementOfPrincipalRepaymentInAdvance" contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis" format="ixt:date-monthname-day-year-en" id="ixv-48671">July 27, 2024</ix:nonNumeric>, an amount equal to the make whole amount, and after this date, a maximum amount of <ix:nonFraction name="thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" contextRef="PAsOn11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48672">3</ix:nonFraction>% of the principal amount being prepaid. For Tranche 2 Loan, until <ix:nonNumeric name="thtx:DateOfCommencementOfPrincipalRepaymentInAdvance" contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis" format="ixt:date-monthname-day-year-en" id="ixv-48673">June 21, 2025</ix:nonNumeric>, an amount equal to the make whole amount, and after this date, a maximum amount of <ix:nonFraction name="thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" contextRef="PAsOn11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48674">3</ix:nonFraction>% of the principal amount being prepaid; </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Loan Facility provides Marathon Adjusted EBITDA-based targets and minimum liquidity requirements (both as defined in the Marathon Credit Agreement) for all times to be between</div>&#160;$</div><ix:nonFraction name="thtx:DebtInstrumentCollateralAmount" contextRef="PAsOn10_31_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48675">15,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">and&#160;</div>$<ix:nonFraction name="thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" contextRef="P12_01_2022To11_30_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48676">20,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on thresholds for Marathon Adjusted EBITDA over the most recently ended four financial quarters;&#160;</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Loan Facility restricts the ability to incur additional debt and to make acquisitions, dispositions, in-licensing and out-licensing of products or assets, except in very limited circumstances. A breach of the terms and conditions of the Marathon Credit Agreement will create an event of default resulting in an increase of</div> </div><ix:nonNumeric name="ifrs-full:BorrowingsInterestRateBasis" contextRef="P12_01_2022To11_30_2023" id="ixv-48677">300 basis points</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;">on the outstanding loan and provide the lender with the ability to demand immediate repayment of the debt;&#160;</div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The lender has a first ranking security interest on all of the Company&#8217;s assets, subject to certain credit card arrangements restrictions. </div></td></tr></table></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_10" continuedAt="TextSelectionAppend_101087921_11"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">52 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087921_11" continuedAt="TextSelectionAppend_101087921_12"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_12" continuedAt="TextSelectionAppend_101087921_13"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_13" continuedAt="TextSelectionAppend_101087921_14"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087921_14" continuedAt="TextSelectionAppend_101087921_15"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087921_15" continuedAt="TextSelectionAppend_101087921_16"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loan Facility </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087921_16"><ix:nonNumeric name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-33137"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the Loan Facility is as follows: </div></div></div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 87%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:28.5pt">&#160;</td>
<td colspan="4" style="height:28.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Loan Facility on July&#160;27, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;<ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48678">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BorrowingCostsRecognisedAsExpense" contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48679">2,285</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:BorrowingsAccretionExpense" contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48680">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="PAsOn11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48681">37,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Tranche 2 Loan on June&#160;21, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48682">20,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Costs related to issuance of Tranche 2 Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BorrowingCostsRecognisedAsExpense" contextRef="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48683">1,182</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Costs related to Marathon Warrants (note 20(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:BorrowingCostsRecognisedAsExpense" contextRef="P06_21_2023To11_30_2023_MarathonWarrantsMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48684">78</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Consideration f<div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> the Fifth Amendment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:ProceedsFromConsiderationOfTheFifthAmendment" contextRef="P06_21_2023To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48685">540</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:BorrowingsAccretionExpense" contextRef="P06_21_2023To11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48686">800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="PAsOn11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48687">57,974</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48688">7,286</ix:nonFraction>)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48689">50,688</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"></div></ix:nonNumeric> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;">On June&#160;21, 2023, the Company drew down on the Tranche 2 Loan, for net proceeds of $<ix:nonFraction name="ifrs-full:NotionalAmount" contextRef="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48690">19,300</ix:nonFraction>. An amount of $<ix:nonFraction name="thtx:AmountReclassifiedFromDeferredFinancingCosts" contextRef="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48691">482</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was reclassed from deferred financing costs assets and applied against the loan balance.</div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Deferred financing costs in the amount of $<ix:nonFraction name="thtx:DeferredFinanceCostsWriteOff" contextRef="PAsOn11_30_2023_LoanFacilityTranche3And4LoanMemberifrsfullBorrowingsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48692">347</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">were written off in the statement of net loss of November 30, 2023 in relation to the additional tranches of the Loan Facility.&#160;</div> </div></div></div></ix:continuation> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">53 </div></div></div><div></div></div><div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-33360">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible unsecured senior notes</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <ix:nonNumeric name="thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-33372"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the convertible unsecured senior notes is as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2021 </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2021_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48693">54,227</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48694">28,546</ix:nonFraction>) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs incurred </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48695">73</ix:nonFraction>) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48696">357</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AccretionExpense" contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48697">1,644</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48698">26,895</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"/> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48699">27,452</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48700">15</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AccretionExpense" contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48701">572</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48702">-</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </ix:nonNumeric> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2023, the Company reimbursed all of the issued and outstanding convertible unsecured senior notes for proceeds of $</div></div><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48703">27,452</ix:nonFraction> and <ix:nonFraction name="thtx:ConvertibleInstrumentsNumberOfSharesIssued" contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48704">253</ix:nonFraction> shares were issued on conversion of $<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48705">15</ix:nonFraction> convertible unsecured senior notes. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">54 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfLeasesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085498" id="ixv-33664">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases liabilities</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="vertical-align: top;;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <ix:nonNumeric name="thtx:DisclosureOfLeaseLiabilitiesTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087729" id="ixv-48706"> </ix:nonNumeric></ix:nonNumeric><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><ix:continuation id="TextSelection_101087729" continuedAt="TextSelectionAppend_101087729_1"><ix:continuation id="TextSelection_101085498" continuedAt="TextSelectionAppend_101085498_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation></ix:continuation></div> <ix:continuation id="TextSelectionAppend_101085498_1"><ix:continuation id="TextSelectionAppend_101087729_1">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 86%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">Carrying</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">value</div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48707">2,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccretionExpenseOfLeasesLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48708">157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48709">605</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48710">148</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30,&#160;2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48711">1,922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:AccretionExpenseOfLeasesLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48712">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48713">452</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48714">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_101087431">920</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease (b)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_101087432">326</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;">Balance as at November 30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48717">994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48718">421</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48719">573</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;;text-indent: 0px;">On February&#160;17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets by $<ix:nonFraction name="thtx:TerminationOfLeasesOperatingLeaseRightOfUseLiability" contextRef="P02_17_2023To02_17_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48720">799</ix:nonFraction>, the lease liabilities by $<ix:nonFraction name="thtx:TerminationOfLeasesOperatingLeaseRightOfUseAssets" contextRef="P02_17_2023To02_17_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48721">920</ix:nonFraction> and recorded a gain on lease termination of $<ix:nonFraction name="thtx:GainLossOnLeaseTermination" contextRef="P02_17_2023To02_17_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48722">121</ix:nonFraction>. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The gain is presented in finance income (Note 5).&#160;</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability of $<ix:nonFraction name="thtx:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P03_01_2023To03_01_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48723">326</ix:nonFraction>. </div></div> </td> </tr> </table> </ix:continuation> </ix:continuation> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">55 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087013" id="ixv-33927">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Authorized in unlimited number and without par value </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Common shares; </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Preferred shares, issuable in one or more series. </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">All issued shares were fully paid on November&#160;30, 2023 and 2022. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shareholders are entitled to receive dividends as declared by the Company at its discretion and are entitled to one vote per share at the Company&#8217;s annual meeting of shareholders. </div></div></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">No preferred shares are outstanding. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Public offering </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">On January&#160;19, 2021, the Company completed a public offering for the sale and issuance of units. Each unit was comprised of one common share of the Company and <ix:nonNumeric name="thtx:CommonStockConversionBasis" contextRef="P01_19_2021To01_19_2021_PublicOfferingMemberTHTXIssuedCapitalAxis" id="ixv-33963">o<div style="letter-spacing: 0px; top: 0px;;display:inline;">ne half of one</div></ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">common share purchase warrant of the Company (each whole warrant, a &#8220;Public Offering Warrant&#8221;) and is classified in Share Capital and Public Offering Warrants within equity. During the year ended November 30, 2023, <ix:nonFraction name="thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised" contextRef="PAsOn11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48724">no</ix:nonFraction> Public Offering Warrant were exercised (November 30, 2022 <ix:nonFraction name="thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised" contextRef="PAsOn11_30_2022_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48725">nil</ix:nonFraction> and November 30, 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> <ix:nonFraction name="thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised" contextRef="PAsOn11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48726">233,400</ix:nonFraction> Public Offering Warrants were exercised for proceeds of $<ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="P12_01_2020To11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48727">742</ix:nonFraction>). At November 30, 2023, there were </div></div><ix:nonFraction name="thtx:ClassOfWarrantOrRightOutstanding" contextRef="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48728">8,130,550</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Public Offering Warrants outstanding. Four (4)&#160;Public Offering Warrants entitles the holder thereof to purchase one (1)&#160;common share at an exercise price of $</div></div><ix:nonFraction name="thtx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" contextRef="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48729">12.72</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time until January&#160;19, 2024<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The <ix:nonFraction name="thtx:ClassOfWarrantOrRightOutstanding" contextRef="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48730">8,130,550</ix:nonFraction> Public Offering Warrants expired on <ix:nonNumeric name="thtx:ClassOfWarrantOrRightExpirationDate" contextRef="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" format="ixt:date-monthname-day-year-en" id="ixv-33981">January <div style="letter-spacing: 0px; top: 0px;;display:inline;">19, 2024</div></ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;31, 2023, the Company completed a public offering for the sale and issuance of </div><ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48731">12,500,000</ix:nonFraction> common shares at a price of $<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48732">1.00</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per common share for gross proceeds o</div></div>f $<ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P10_31_2023To10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48733">12,500</ix:nonFraction>. On November&#160;14, 2023, the Company issued <ix:nonFraction name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48734">160,000</ix:nonFraction> common shares at a price of $<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48735">1.00</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per common share for gross proceeds of $</div><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P11_14_2023To11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48736">160</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">in relation to the partial exercise of the over-allotment option. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ompany has also completed a concurrent private placement (the &#8220;Concurrent Private Placement&#8221;) with Investissement Qu&#233;bec of</div></div>&#160;<ix:nonFraction name="thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48737">9,118,184</ix:nonFraction> common shares and <ix:nonFraction name="thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48738">3,381,816</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">fully-funded, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> subscription receipts, exchangeable at all times into common shares on a one-for-one basis in, in each case, at $</div><ix:nonFraction name="thtx:ClassOfWarrantsOrRightsExercisePricePerShare" contextRef="PAsOn11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48739">1.00</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for gross proceeds of $</div></div><ix:nonFraction name="thtx:ProceedsFromTheIssuanceOfCommonSharesAndWarrants" contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48740">12,500</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. The subscription receipts were issued to limit the share ownership of the investor to not more than <ix:nonFraction name="thtx:PercentageOfOwnershipOfTheInvestor" contextRef="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48741">19.9</ix:nonFraction>% of the issued and outstanding common shares and the subscription receipts are exchangeable at any time, provided ownership limitations are respected. The Company has also entered into an investor rights agreement pursuant to which Investissement Qu&#233;bec will be entitled to nominate one director to the Company&#8217;s board of directors for as long as it holds <ix:nonFraction name="thtx:PercentageOfOwnershipHoldingCommonShares" contextRef="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48742">50</ix:nonFraction>% of the Common Shares purchased pursuant to the Concurrent Private Placement. The cost of the offering amounted to $</div></div><ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48743">2,053</ix:nonFraction><div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>56</ix:exclude></div> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_101087013" continuedAt="TextSelectionAppend_101087013_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_1" continuedAt="TextSelectionAppend_101087013_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_2" continuedAt="TextSelectionAppend_101087013_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_3" continuedAt="TextSelectionAppend_101087013_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_4" continuedAt="TextSelectionAppend_101087013_5"><ix:exclude><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_5" continuedAt="TextSelectionAppend_101087013_6"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Milestone oncology </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">In March 2021, the Company issued <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48745">120,482</ix:nonFraction> common shares under the terms of the acquisition agreement entered into with all of the shareholders of Katana for Katana&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> oncology platform. The purchase price for the oncology platform provided for share-based consideration to be issued upon attainment of two milestones. The first milestone was achieved in March 2021. The estimated fair value of the share-based consideration of $<ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="PAsOn11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48746">668</ix:nonFraction> initially recorded in &#8220;Contributed surplus&#8221; on the date of the acquisition was reclassified to &#8220;Share capital&#8221; (Note 13). </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Marathon warrants </div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On February 27, 2023, the Company issued to Marathon an aggregate of</div></div></div> <ix:nonFraction name="thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" contextRef="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48747">5,000,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">common share purchase warrants (the &#8220;Marathon Warrants exercisable into <ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48748">1,250,000</ix:nonFraction> common shares, at an exercise price of</div></div></div> $<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48749">5.80</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">, post Consolidation. The Marathon Warrants are exercisable for a period of</div> <ix:nonNumeric name="thtx:TermOfWarrants" contextRef="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" format="ixt-sec:durwordsen" id="ixv-48750">seven years</ix:nonNumeric>. <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants are not traded on any stock exchange, are transferable only to affiliates of Marathon or to other potential lenders under the terms of the Loan Facility and their affiliates and may be exercised on a cashless basis. Accordingly, the Marathon Warrants are derivative financial liabilities measured at fair value through profit or loss.&#160;</div> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants were issued as consideration for various amendments made to the Marathon Credit Agreement, including: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">An amendment to remove a condition precedent to the disbursement of the Tranche 2 Loan requiring the Company to have filed with the FDA the results of a human factor study before June&#160;30, 2023; and </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">An amendment to allow for the inclusion of a going concern explanatory paragraph in the annual report of the independent registered public accounting firm for the fiscal year ended November&#160;30, 2022. </div></div></div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the Fifth Amendment, the Company has agreed to reset the exercise price of the</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48751">5,000,000</ix:nonFraction></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Marathon Warrants, which are now exercisable into<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48752">1,250,000</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">common shares at</div></div>&#160;</div><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">$</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ClassOfWarrantsOrRightsExercisePricePerShare" contextRef="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48753">2.30</ix:nonFraction> </div><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">per common share. (Refer to Note 17) </div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>57</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087013_6" continuedAt="TextSelectionAppend_101087013_7"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_7" continuedAt="TextSelectionAppend_101087013_8"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_8" continuedAt="TextSelectionAppend_101087013_9"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_9" continuedAt="TextSelectionAppend_101087013_10"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_10" continuedAt="TextSelectionAppend_101087013_11"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Marathon warrants (continued) </div></td></tr></table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_11" continuedAt="TextSelectionAppend_101087013_12"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The fair value of the Marathon Warrants was treated as a cash outflow in testing whether the debt modification was a substantial modification and it was concluded that the modification was not substantial. At the issuance</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, $</div><ix:nonFraction name="thtx:GainLossOnDebtModification" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48755">2,650</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">were recorded as loss on debt modification using the Black-Sholes model and the assumptions set forth in the table below. An amount </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div><ix:nonFraction name="thtx:IncreaseInTheFairValueOfLiabilityRecorded" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48756">350</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">was recorded reflecting the increase of fair value of Marathon Warrants for the repricing upon entering into the Fifth Amendment. The derivative financial liability relating to the Marathon Warrants is recorded as a liability on the consolidated statement of financial position and resulted in a gain on fair value remeasurement o</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">f $</div><ix:nonFraction name="ifrs-full:GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48757">1,525</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> for the year ended November&#160;</div>30<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div> <div><ix:nonNumeric name="thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-34212"> <div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 94%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">measurement</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-48758">4.326</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-48759">3.92</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-48760">88.568</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-48761">61.985</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;<ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48762">6.25</ix:nonFraction>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn02_27_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48763">7</ix:nonFraction>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Share price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48764">1.63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48765">3.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em;">Exercise price </div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48766">2.30</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn02_27_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48767">5.80</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate is based on the implied yield on a Canadian government zero-coupon issue, with a remaining term equal to the term of the Marathon warrant life. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of the Marathon warrant is based upon the contractual term. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">With the issuance of the Marathon Warrants, the Company incurred transaction costs totalling $</div><ix:nonFraction name="thtx:TransactionCostsOfWarrantsIssued" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48768">196</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which $</div><ix:nonFraction name="thtx:TransactionCostsAllocatedToTheLoanFacility" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48769">78</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> was allocated to the Loan Facility and $</div><ix:nonFraction name="thtx:DeferredFinancingCostsOnTheLoanFacility" contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48770">118</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">was recorded as deferred financing costs relating to the available tranches under the Loan Facility<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> Deferred financing costs were written off on November 30, 2023 (Note 17).</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>58</ix:exclude> </div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_101087013_12" continuedAt="TextSelectionAppend_101087013_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_13" continuedAt="TextSelectionAppend_101087013_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_14" continuedAt="TextSelectionAppend_101087013_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_15" continuedAt="TextSelectionAppend_101087013_16"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_16" continuedAt="TextSelectionAppend_101087013_17"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_17" continuedAt="TextSelectionAppend_101087013_18"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">ATM program </div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of a sales agreement dated July&#160;23, 2021, the Company was able to issue and sell from time to time its common shares, having an aggregate offering price of up </div></div>to $<ix:nonFraction name="thtx:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P07_23_2021To07_23_2021_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48772">50,000</ix:nonFraction>, <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">through or to the Agent, as agent or principal, in the United States for a period ending in December 2023. Sales of the common shares were to be made in transactions that were deemed to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market</div></div> distributions&#8220; (&#8220;ATM&#8220;). In the fourth quarter of 202</div>2, <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn11_30_2022_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48773">400,000</ix:nonFraction> common shares (2021 &#8211; <ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="PAsOn11_30_2021_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48774">no</ix:nonFraction> common shares) were sold for proceed<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> of $<ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48775">2,960</ix:nonFraction> under the ATM program. Commission, legal and other costs related to this equity <div style="letter-spacing: 0px; top: 0px;;display:inline;">offering</div> were charged directly to equity in the amount of $<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48776">126</ix:nonFraction> (2021 - <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48777">nil</ix:nonFraction>). The <div style="letter-spacing: 0px; top: 0px;;display:inline;">common </div>shares were sold at the prevailing market prices, which resulted in a price of $<ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48778">1.85</ix:nonFraction> per share. Deferred financing costs in the amount of $<ix:nonFraction name="thtx:DeferredFinancingCostsWrittenDown" contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48779">607</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">were written off in the statement of net loss of November&#160;30, 2023, in relation to the end of the program in December of 2023 without additional usage.</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(e)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">DSU plan </div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;10, 2010, the Board of Directors adopted the DSU Plan for the benefit of its directors and officers (the &#8220;Beneficiaries&#8221;). The goal of the DSU Plan is to increase the Company&#8217;s ability to attract and retain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">high-quality</div> individuals to act as directors or officers and to better align their interests with those of the shareholders of the Company in the creation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> value. Under the terms of the DSU Plan, Beneficiaries who are directors are entitled to elect to receive all or part of their annual retainer to act as directors in DSUs. Beneficiaries who act as officers are entitled to elect to receive all or part of their annual bonus, if any, in DSUs. The value of a DSU is used to determine the number of DSUs a Beneficiary may be granted or the value to be paid to a Beneficiary upon redemption. This value is equal to the average closing price of the common shares on the Toronto Stock Exchange on the date on which the Company is entitled to grant DSUs, or on the date on which a Beneficiary redeems them, and during the four previous trading days. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">DSUs may only be redeemed when a Beneficiary ceases to act as a director or an officer of the Company. Upon redemption, the Company must provide a Beneficiary with an amount in cash equal to the DSU value on the redemption date. Beneficiaries may not sell, transfer or otherwise assign their DSUs or any rights associated therewith other than by will or in accordance with legislation regarding the vesting and partition of successions. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">DSUs are totally vested on the grant date. When DSUs are granted to officers as part of their annual bonus, a DSU liability is recorded on the grant date in lieu of a liability for a cash bonus payment. In the case of directors, the expenses related to DSUs and their liabilities are recognized on the grant date. During the year ended </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">November&#160;30, 2023, <ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48780">nil</ix:nonFraction> (2022 -<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48781">126</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">; 2021&#160;&#8211;</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48782">78</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was recorded as an expense and is included in general and administrative expenses. The liability related to DSUs is adjusted periodically to reflect any change in the market value of the common shares. As at November&#160;30, 2023, a gain of</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48783">224</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(2022 - $<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48784">221</ix:nonFraction>; 2021&#160;&#8211; loss of</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48785">209</ix:nonFraction>)<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> was recognized within finance costs (Note </div>5)<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">. As at November&#160;</div>30<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had a total </div><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48786">24,878</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;DSUs outstanding </div>(202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211;<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48787">67,536</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> DSUs) and a liability related to the DSUs of $</div><ix:nonFraction name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" contextRef="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48788">39</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>(202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211;<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> liability of $</div><ix:nonFraction name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" contextRef="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48789">589</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">).</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>59</ix:exclude> </div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_101087013_18" continuedAt="TextSelectionAppend_101087013_19"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_19" continuedAt="TextSelectionAppend_101087013_20"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_20" continuedAt="TextSelectionAppend_101087013_21"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_21" continuedAt="TextSelectionAppend_101087013_22"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_22" continuedAt="TextSelectionAppend_101087013_23"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(e)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">DSU plan (continued) </div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_23" continuedAt="TextSelectionAppend_101087013_24"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Cash-settled</div> forward stock contracts</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">To protect against fluctuations in the value of DSUs, the Company entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts. They were not designated as hedging instruments for accounting purposes. As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts outstanding correspond to a total of <ix:nonFraction name="thtx:NumberOfCashSettledForwardStockContractsOutstanding" contextRef="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48791">67,535</ix:nonFraction> (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> &#8211; <ix:nonFraction name="thtx:NumberOfCashSettledForwardStockContractsOutstanding" contextRef="PAsOn11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48792">67,535</ix:nonFraction>) common shares at a price of $<ix:nonFraction name="thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts" contextRef="P12_01_2021To11_30_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48793">19.47</ix:nonFraction> per share (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $<ix:nonFraction name="thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts" contextRef="P12_01_2020To11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48794">19.68</ix:nonFraction> per share) expiring on December&#160;1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; December&#160;1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>). As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts was $<ix:nonFraction name="thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" contextRef="PAsOn11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48795">110</ix:nonFraction> (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $<ix:nonFraction name="thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" contextRef="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48796">603</ix:nonFraction>) and is recorded in derivative financial assets. During the year ended November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, a loss of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">$<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2022To11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48797">492</ix:nonFraction> (2022 -</div></div>$<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2021To11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48798">217</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">;2021&#160;&#8211;</div></div> gain of $<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" contextRef="P12_01_2020To11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48799">212</ix:nonFraction>) related to the change in fair value of derivative financial assets was recognized within finance costs. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(f)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">S<div style="letter-spacing: 0px; top: 0px;;display:inline;">tock</div>&#160;Appreciation Rights&#160;</div> </td> </tr> </table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;4, 2018, the Board of Directors approved a stock appreciation rights plan (the &#8220;SARs Plan&#8221;) for its consultants that entitles the grantee to receive a cash payment based on the increase in the stock price of the Company&#8217;s common shares from the grant date to the settlement date. The term of a SAR may not exceed </div></div><ix:nonNumeric name="thtx:StockAppreciationRightsContractualLife" contextRef="P10_04_2018To10_04_2018" format="ixt-sec:duryear" id="ixv-48800">10</ix:nonNumeric><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">years from the grant date. Generally, SARs vest over a period of three years. </div></div></div> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">For the year ended November&#160;30, 2023, ($<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48801">22</ix:nonFraction>) (2022 - $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48802">12</ix:nonFraction>, 2021 &#8211; $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2020To11_30_2021_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48803">53</ix:nonFraction>) was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> compensation expense for the SARs <div style="letter-spacing: 0px; top: 0px;;display:inline;">P</div>lan. Since these awards will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled,</div> <ix:nonNumeric name="thtx:DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086982" id="ixv-34597">the fair value of SARs granted is estimated at each reporting period using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. The liability is recorded in other liabilities on the statement of financial position.</ix:nonNumeric></div> <ix:continuation id="TextSelection_101086982" continuedAt="TextSelectionAppend_101086982_1"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>60</ix:exclude> </div></ix:continuation></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101086982_1" continuedAt="TextSelectionAppend_101086982_2"><ix:continuation id="TextSelectionAppend_101087013_24" continuedAt="TextSelectionAppend_101087013_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_25" continuedAt="TextSelectionAppend_101087013_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_26" continuedAt="TextSelectionAppend_101087013_27"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086982_2" continuedAt="TextSelectionAppend_101086982_3"><ix:continuation id="TextSelectionAppend_101087013_27" continuedAt="TextSelectionAppend_101087013_28"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_28" continuedAt="TextSelectionAppend_101087013_29"><ix:continuation id="TextSelectionAppend_101086982_3" continuedAt="TextSelectionAppend_101086982_4"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(f)</td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Stock Appreciation Rights (continued) </div> </td> </tr> </table> </ix:exclude></ix:continuation></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_29" continuedAt="TextSelectionAppend_101087013_30"><ix:continuation id="TextSelectionAppend_101086982_4"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 96%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted in 2019 and 2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2023</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2022</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48805">3.55</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48806">3.50</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48807">89.51</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48808">58.4</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48809">6.8</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48810">7.8</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">$</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#8195;&#8199;&#8199;<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48811">1.58</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48812">2.15</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;<div style="font-size: 13pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8199;</div><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48813">8.72</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48814">11.72</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top;text-indent: 0px;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48815">16.99</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48816">23.07</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: -webkit-right; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;">$&#8195;</div><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48817">17.16</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48818">23.07</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk-free</div> interest rate is based on the implied yield on a Canadian government <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> issue, with a remaining term equal to the expected term of a SAR. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of a SAR is estimated taking into consideration the vesting period on the grant date, the life of a SAR and the average length of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">No SARs w<div style="letter-spacing: 0px; top: 0px;;display:inline;">ere</div> granted during the years ended November&#160;30, 2023 and 2022. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>61</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101087013_30" continuedAt="TextSelectionAppend_101087013_31"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_31" continuedAt="TextSelectionAppend_101087013_32"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_32" continuedAt="TextSelectionAppend_101087013_33"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_33" continuedAt="TextSelectionAppend_101087013_34"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_34" continuedAt="TextSelectionAppend_101087013_35"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(g)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Shareholder rights plan </div> </td> </tr> </table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;3, 2022, the Board of Directors approved certain amendments and the renewal of the Company&#8217;s shareholder rights plan and, on April&#160;6, 2022, the Company and Computershare Trust Services of Canada entered into an amended and restated shareholder rights plan agreement (the &#8220;Rights Plan&#8221;). The Rights Plan was approved by the shareholders on May&#160;10, 2022. The Rights Plan <div style="letter-spacing: 0px; top: 0px;;display:inline;">is</div> designed to provide adequate time for the Board and the shareholders to assess an unsolicited takeover bid for the Company. In addition, Rights the Plan provides the Board with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, as well as provide shareholders with an equal opportunity to participate in a takeover bid to receive full and fair value for their common shares. The Rights Plan will expire at the close of the Company&#8217;s annual meeting of shareholders in 2025 unless the Rights Plan is reconfirmed and approved by shareholders at such meeting. </div></div></div> <ix:nonNumeric name="thtx:DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" contextRef="P12_01_2022To11_30_2023_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis" id="ixv-34907"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The rights issued under the Rights Plan are initially attached to and traded with the common shares, and no separate certificate is issued unless a triggering event occurs. The rights become exercisable only when an acquiring person, including any party related to it, acquires or attempts to acquire <div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>% or more of the outstanding common shares without complying with the &#8220;Permitted Bid&#8221; provisions of the Rights Plan or without approval of the Board of Directors. Subject to the terms and conditions set out in the Rights Plan, each right (other than those held by the acquiring person) will permit the holder to purchase for the exercise price that number of common shares determined as follows: a value of twice the exercise price divided by the &#8220;Market Price&#8221; (defined under the Rights Plan as being the average weighted trading price per common share for the 20 consecutive&#160;trading days through and including the trading day immediately preceding the relevant date) on the common share acquisition date (defined as &#8220;Stock Acquisition Date&#8221; under the Rights Plan). The exercise price under the Rights Plan has been set to three (3) times the Market Price. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Rights Plan, a Permitted Bid is a bid made to all holders of common shares and which is open for acceptance for no less than <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days. If, at the end of <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days, more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div>% of the outstanding common shares, other than those owned by the offeror and certain related parties, have been tendered, the offeror may take up and pay for the common shares. If more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div>% of the outstanding common shares, other than those owed by the offeror and certain related parties, have been tendered within the above mentioned <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days period, the offeror must make a public announcement of that fact and the bid must remain open for an additional ten business days from the date of the announcement. </div></div></div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Stock option plan </div> </td> </tr> </table> </ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_101087013_35" continuedAt="TextSelectionAppend_101087013_36"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established a stock option plan (the &#8220;Option Plan&#8221;) under which it can grant its directors, officers, employees, researchers and consultants non-transferable options (the &#8220;Option&#8221;) for the purchase of common shares. The exercise date of an Option may not be later than</div> <ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_Y" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48820">10</ix:nonFraction>&#160;years after the grant date. On March&#160;28, 2023, the Company&#8217;s Board of Directors <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">amended the Option Plan </div></div> to provide, among other things, that the <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum number </div></div> of common shares that may be issued under the <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Option Plan </div></div> (together with any other security-based compensation arrangements) shall not exceed <ix:nonFraction name="thtx:StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" contextRef="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48821">17</ix:nonFraction>% of the issued and outstanding common shares, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-diluted</div> basis<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">.</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The Option Plan has </div></div>a &#8220;reloading&#8221; or &#8220;evergreen&#8221; feature, so that whe</ix:continuation><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">n Options a</div>re exercised, the number of common <ix:continuation id="TextSelectionAppend_101087013_36" continuedAt="TextSelectionAppend_101087013_37"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">shares issuable under the Option Plan will be replenished and such exercised </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions will be available to be regranted in the future. Shareholders ratified this amendment on May&#160;9, 2023.&#160;<ix:nonNumeric name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" id="ixv-48822">Generally, the Options vest on the grant date or over a period of up to three years.</ix:nonNumeric></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_101087013_37" continuedAt="TextSelectionAppend_101087013_38"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"><ix:exclude>62</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101087013_38" continuedAt="TextSelectionAppend_101087013_39"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_39" continuedAt="TextSelectionAppend_101087013_40"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_40" continuedAt="TextSelectionAppend_101087013_41"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_41" continuedAt="TextSelectionAppend_101087013_42"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Stock option plan (continued) </div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_42" continuedAt="TextSelectionAppend_101087013_43"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-indent: 0px;">As at November&#160;30, 2023, <ix:nonFraction name="thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" contextRef="PAsOn11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48824">5,762,675</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions could still be granted <div style="letter-spacing: 0px; top: 0px;;display:inline;">by</div> the Company (2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8211;&#160;</div><ix:nonFraction name="thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" contextRef="PAsOn11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48825">1,091,358</ix:nonFraction>,</div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;">2021<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;&#8211;&#160;</div></div><ix:nonFraction name="thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" contextRef="PAsOn11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48826">1, 062,851</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">under the Option Plan.</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">All Options are to be settled by the physical delivery of common shares. </div></div></div> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-35025"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in the number of Options outstanding during the past two years were as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0px; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">per&#160;option</div></div></div></div> </td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="5" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of&#160;Options</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom:10pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">O</div></div></div><div style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -12px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">ptions outstanding in CA<div style="display:inline;">$</div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48827">797,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48828">15.32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48829">12.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48830">547,847</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48831">16.68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48832">13.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48833">144,213</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48834">17.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48835">13.52</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Exercised (share price: CA$<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48836">11.12</ix:nonFraction> (US$<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48837">8.24</ix:nonFraction>))</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48838">21,165</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48839">1.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48840">0.92</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48841">1,180,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48842">15,92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48843">11,84</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48844">792,193</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48845">5.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48846">3.80</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48847">197,686</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48848">12.34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48849">9.10</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48850">1,774,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48851">11.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48852">8.48</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48853">926,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48854">15.19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48855">11.19</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; line-height: normal;">Options exercisable as at November 30, 2022 &#8211; CA$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48856">554,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48857">16.32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48858">12.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding in US$</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options as at November&#160;30,&#160;2021&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2021_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48859">20,183</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2021_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48860">12.36</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48861">96,668</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48862">12.08</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48863">10,208</ix:nonFraction>)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48864">12.52</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2022_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48865">106,643</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48866">10.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48867">203,935</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48868">3.80</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48869">31,209</ix:nonFraction>)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48870">5.01</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48871">279,369</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48872">6.02</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2023_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48873">65,692</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48874">9.48</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="PAsOn11_30_2022_USsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48875">7,769</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2022_USsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48876">11.96</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"><ix:exclude>63</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101087013_43" continuedAt="TextSelectionAppend_101087013_44"><div></div></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_101087013_44" continuedAt="TextSelectionAppend_101087013_45"><div> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div></ix:continuation> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_45" continuedAt="TextSelectionAppend_101087013_46"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_46" continuedAt="TextSelectionAppend_101087013_47"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Stock option plan (continued) </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_47" continuedAt="TextSelectionAppend_101087013_48"><ix:nonNumeric name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-35888"> <div style="margin: 0pt 24% 0pt 8%; text-align: justify; font-family: arial; font-size: 11pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides Option information as at November&#160;30, 2023 (Options outstanding in&#160;CA$). </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48878">1.00</ix:nonFraction>&#160;&#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48879">4.76</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48880">0.74</ix:nonFraction>&#160;&#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48881">3.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48882">57,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48883">0.03</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48884">1.52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48885">1.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48886">4.77</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48887">8.00</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48888">3.51</ix:nonFraction> &#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48889">5.89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;<ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48890">707,695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;<ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48891">9.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48892">5.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48893">3.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48894">8.01</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48895">15.00</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48896">5.90</ix:nonFraction>&#160;&#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48897">11.04</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48898">308,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48899">5.43</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48900">11.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48901">8.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48902">15.01</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48903">24.00</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48904">11.05</ix:nonFraction>&#160;&#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48905">17.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48906">621,167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48907">7.55</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48908">16.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48909">12.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48910">24.01</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48911">36.00</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48912">17.68</ix:nonFraction>&#160;&#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48913">26.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48914">51,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48915">4.86</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48916">33.27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48917">24.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48918">36.01</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48919">40.00</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48920">26.51</ix:nonFraction> &#8211;&#8201;<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48921">29.45</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48922">28,426</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" format="ixt-sec:duryear" id="ixv-48923">4.35</ix:nonNumeric></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48924">38.24</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48925">28.16</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48926">1,774,559</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" format="ixt-sec:duryear" id="ixv-48927">7.49</ix:nonNumeric></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48928">11.51</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48929">8.48</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td colspan="24" style="padding-bottom:6pt ;vertical-align:top"> <div style="margin: 6pt 10em 0pt 3.5em; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">The following table provides Option information as at November 30, 2023 (Options outstanding in US$).</div> </td>
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48930">1.00</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48931">4.76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48932">179,185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" format="ixt-sec:duryear" id="ixv-48933">9.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48934">3.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48935">4.77</ix:nonFraction> &#8211; <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48936">15.00</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48937">100,184</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" format="ixt-sec:duryear" id="ixv-48938">8.03</ix:nonNumeric></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48939">10.00</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48940">279,369</ix:nonFraction></td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" format="ixt-sec:duryear" id="ixv-48941">8.81</ix:nonNumeric></td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48942">6.02</ix:nonFraction></td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>64</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101087013_48" continuedAt="TextSelectionAppend_101087013_49"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_49" continuedAt="TextSelectionAppend_101087013_50"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_50" continuedAt="TextSelectionAppend_101087013_51"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_51" continuedAt="TextSelectionAppend_101087013_52"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_52" continuedAt="TextSelectionAppend_101087013_53"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Stock option plan (continued) </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_53" continuedAt="TextSelectionAppend_101087013_54"><div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial">For the year ended November&#160;30, 2023, $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48944">2,237</ix:nonFraction> (2022 - $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2021To11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48945">3,860</ix:nonFraction>, 2021&#160;&#8211; $<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="P12_01_2020To11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48946">1,879</ix:nonFraction>) was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> compensation expense for the Option Plan. <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086978" id="ixv-36587">The fair value of Options granted in 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>&#160;and 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was estimated on </div></div> the grant date using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. </ix:nonNumeric></div> <ix:continuation id="TextSelection_101086978"><div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:bottom">&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;&#8194;Options granted in CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48947">3.33</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48948">1.62</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48949">64.3</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48950">65.5</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48951">9.5</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48952">9</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;&#8194;<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48953">3.80</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48954">5.16</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48955">13.00</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48956">16.68</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48957">3.80</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48958">5.16</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48959">13.00</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48960">16.68</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:20pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#8195;&#8195;&#8195;&#8195;&#8194;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:5pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48961">3.92</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48962">1.95</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48963">62</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48964">64</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_Y" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48965">9.5</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_Y" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48966">9</ix:nonFraction> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48967">3.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48968">12.08</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48969">3.80</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48970">12.08</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>65</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_101087013_54" continuedAt="TextSelectionAppend_101087013_55"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_55" continuedAt="TextSelectionAppend_101087013_56"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_56" continuedAt="TextSelectionAppend_101087013_57"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_57" continuedAt="TextSelectionAppend_101087013_58"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_58" continuedAt="TextSelectionAppend_101087013_59"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Stock option plan (continued) </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_59" continuedAt="TextSelectionAppend_101087013_60"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate is based on the implied yield on a Canadian or U.S. government <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> issue, with a remaining term equal to the expected term of an Option. The volatility is based on the weighted average historical volatility adjusted for changes expected due to publicly available information. The life of an Option is estimated taking into consideration the vesting period on the grant date, the life of the Option and the average period of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since Company policy is to retain all earnings to finance operations and future growth. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><ix:nonNumeric name="thtx:DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-36919"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the measurement date weighted average fair value of Options granted during the years ended November&#160;30, 2023 and 2022. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48972">792,193</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_USD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48973">2.77</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_CAD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48974">3.76</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48975">547,847</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_USD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48976">8.64</ix:nonFraction>&#160;(CA$<ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_CAD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48977">11.64</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 18pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48978">203,935</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis" unitRef="Unit_USD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48979">2.72</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48980">96,668</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="PAsOn11_30_2022_USDsrtCurrencyAxis" unitRef="Unit_USD" decimals="-1" scale="3" format="ixt:num-dot-decimal" id="ixv-48981">8.36</ix:nonFraction></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:nonNumeric> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model used by the Company to calculate the option values was developed to estimate the fair value of freely tradable, fully transferable Options without vesting restrictions, which significantly differs from the Company&#8217;s Option grants. This model also requires four highly subjective assumptions, including future stock price volatility and the average Option life, which greatly affect the calculated values. </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>66</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087013_60" continuedAt="TextSelectionAppend_101087013_61"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_61" continuedAt="TextSelectionAppend_101087013_62"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_62" continuedAt="TextSelectionAppend_101087013_63"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_63" continuedAt="TextSelectionAppend_101087013_64"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_64" continuedAt="TextSelectionAppend_101087013_65"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_65" continuedAt="TextSelectionAppend_101087013_66">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Loss per share </div></td></tr></table><ix:nonNumeric name="thtx:DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-37482"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">The calculation of basic loss per<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common</div></div> share was based on the net loss attributable to common shareholders of the Company of $<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48983">23,957</ix:nonFraction> (2022 &#8211; <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48984">47,237</ix:nonFraction>, 2021&#160;&#8211; $<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48985">31,725</ix:nonFraction>) and a weighted average number of common shares outstanding calculated as follows. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 58%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Issued common shares as at December&#160;1</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48986">24,201,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48987">23,780,417</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48988">19,253,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share options exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsExercised" contextRef="P12_01_2022To11_30_2023_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-48989">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsExercised" contextRef="P12_01_2021To11_30_2022_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48990">3,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsExercised" contextRef="P12_01_2020To11_30_2021_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48991">93,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of public issue common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfIssueCommonShares" contextRef="P12_01_2022To11_30_2023_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48992">1,843,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfIssueCommonShares" contextRef="P12_01_2021To11_30_2022_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-48993">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfIssueCommonShares" contextRef="P12_01_2020To11_30_2021_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48994">3,704,071</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Impact on conversion of convertible<br/> &#160;&#160;&#160;&#160;unsecured senior notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" contextRef="P12_01_2022To11_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48995">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" contextRef="P12_01_2021To11_30_2022_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-48996">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" contextRef="P12_01_2020To11_30_2021_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-48997">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share issue - ATM program</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-48998">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2021To11_30_2022_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48999">29,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-49000">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Effect of subscription receipts issue</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="thtx:EffectOfSubscriptionReceiptsIssue" contextRef="P12_01_2022To11_30_2023_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49001">287,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="thtx:EffectOfSubscriptionReceiptsIssue" contextRef="P12_01_2021To11_30_2022_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-49002">-</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="thtx:EffectOfSubscriptionReceiptsIssue" contextRef="P12_01_2020To11_30_2021_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-49003">-</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of broker warrants exercised</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="thtx:EffectOfBrokerWarrantsExercised" contextRef="P12_01_2022To11_30_2023_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-49004">-</ix:nonFraction></td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="thtx:EffectOfBrokerWarrantsExercised" contextRef="P12_01_2021To11_30_2022_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-49005">-</ix:nonFraction></td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="thtx:EffectOfBrokerWarrantsExercised" contextRef="P12_01_2020To11_30_2021_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49006">36,564</ix:nonFraction></td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="padding-bottom: 6pt; vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Weighted average number of common shares, <br/> &#160;&#160;&#160;&#160;basic&#160;and&#160;diluted</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49007">26,332,429</ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49008">23,813,344</ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49009">23,087,557</ix:nonFraction></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial">For the year ended November&#160;30, 2023, <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49010">2,053,928</ix:nonFraction> (2022 &#8211; <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49011">1,286,695</ix:nonFraction>, 2021 &#8211; <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49012">817,766</ix:nonFraction>) <div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions, <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfWarrantsShares" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49013">8,130,550</ix:nonFraction> (2022 &#8211; <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfWarrantsShares" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49014">8,130,550</ix:nonFraction>, 2021 &#8211; <ix:nonFraction name="thtx:EffectOfShareOptionsOnNumberOfWarrantsShares" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49015">8,130,550</ix:nonFraction>) Public Offering Warrants, and <ix:nonFraction name="thtx:PotentialShareIssueInTheFutureOnExerciseOfWarrants" contextRef="PAsOn11_30_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49016">5,000,000</ix:nonFraction> Marathon Warrants were excluded from the weighted average number of diluted common shares calculation as their effect would have been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-dilutive.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The convertible unsecured senior notes were also excluded from the weighted average number of diluted common share calculation for the periods they were outstanding. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The average market value of the Company&#8217;s common shares for purposes of calculating the dilutive effect of Options was based on quoted market prices for the period during which the options were outstanding. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>67</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_101087013_66" continuedAt="TextSelectionAppend_101087013_67"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_67" continuedAt="TextSelectionAppend_101087013_68"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_68" continuedAt="TextSelectionAppend_101087013_69"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087013_69" continuedAt="TextSelectionAppend_101087013_70"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087013_70" continuedAt="TextSelectionAppend_101087013_71"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087013_71" continuedAt="TextSelectionAppend_101087013_72">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(j)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"><ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086976" id="ixv-49018">Accumulated other comprehensive income (loss)</ix:nonNumeric> </div> </td> </tr> </table> </ix:continuation><ix:continuation id="TextSelection_101086976"><ix:continuation id="TextSelectionAppend_101087013_72"> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Unrealized losses on FVOCI financial assets, net of tax</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2023_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49019">256</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2022_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49020">555</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;(<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2021_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49021">195</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; line-height: normal;">Cumulative exchange difference on translation of foreign <br/>operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2023_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49022">940</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2022_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49023">940</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2021_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49024">151</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49025">684</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49026">385</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="PAsOn11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49027">44</ix:nonFraction>)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">68 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfIncomeTaxExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087011" id="ixv-37937">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <ix:nonNumeric name="thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-37950"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the components of the current and deferred tax expenses (recovery). </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49028">450</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49029">443</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49030">63</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Origination and reversal of temporary differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49031">5,972</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49032">11,705</ix:nonFraction>)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49033">7,796</ix:nonFraction>)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible <br/>temporary<div style="display:inline;">&#160;</div>differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49034">5,943</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49035">11,705</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49036">7,796</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49037">29</ix:nonFraction>)</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49038">-</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49039">-</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current and deferred tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49040">421</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49041">443</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49042">63</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <ix:nonNumeric name="thtx:DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-38252"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation between effective and applicable tax amounts. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at domestic tax statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49043">6,237</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49044">12,400</ix:nonFraction>)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49045">8,390</ix:nonFraction>)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible temporary&#160;differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49046">5,943</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49047">11,705</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49048">7,796</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of differences in statutory tax rates</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49049">130</ix:nonFraction>)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49050">102</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49051">64</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses and other</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49052">845</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49053">1,036</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49054">593</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49055">421</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49056">443</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49057">63</ix:nonFraction></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The applicable statutory tax rate was </div><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49058"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49059"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49060">26.5</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">in 2023, 2022 and 2021. The Company&#8217;s applicable tax rate is the Canadian combined rates applicable in the jurisdictions in which the Company operates.&#160;</div></div></div> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">69 </div> </ix:exclude></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101087011" continuedAt="TextSelectionAppend_101087011_1"><div></div></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_101087011_1" continuedAt="TextSelectionAppend_101087011_2"><div> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div></ix:continuation> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101087011_2" continuedAt="TextSelectionAppend_101087011_3"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087011_3" continuedAt="TextSelectionAppend_101087011_4"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income taxes </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087011_4" continuedAt="TextSelectionAppend_101087011_5"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Unrecognized deferred tax assets </div> <ix:nonNumeric name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-38581"> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As at November&#160;30, 2023 and 2022, the amounts and expiry dates of Canadian tax attributes for which no deferred tax asset was recognized were as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses,<br/> &#8195;without&#160;time&#160;limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49061">87,151</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49062">105,549</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49063">86,768</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49064">105,174</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses carried forward 2027</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49065">5,512</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49066">5,504</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49067">5,569</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49068">5,561</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49069">33,761</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49070">16,258</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49071">34,110</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49072">16,426</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49073">14,345</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49074">12,124</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49075">14,494</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49076">12,250</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2030</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49077">8,423</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49078">8,420</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49079">8,510</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49080">8,507</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2031</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49081">17,346</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49082">15,397</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49083">17,525</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49084">15,556</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2032</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49085">11,752</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49086">10,791</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49087">11,874</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49088">10,902</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2033</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49089">8,444</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49090">8,365</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49091">8,532</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49092">8,451</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2034</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49093">7,733</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49094">7,665</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49095">7,813</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49096">7,744</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2037</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49097">6,901</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49098">6,818</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49099">6,972</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49100">6,889</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2038</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49101">2,013</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49102">1,938</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49103">2,034</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49104">1,958</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2039</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49105">1,326</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49106">1,289</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49107">1,340</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49108">1,302</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2040</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49109">7,242</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49110">7,218</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49111">7,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49112">7,292</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2041</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49113">19,152</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49114">19,078</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49115">19,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49116">19,276</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2042</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49117">29,042</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49118">28,885</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49119">31,181</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49120">31,190</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2043</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49121">19,298</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49122">19,284</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49123">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49124">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other temporary differences,<br/> &#8195;without time limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of property and<br/> &#8195;equipment over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49125">435</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49126">420</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49127">1,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49128">454</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of intellectual<br/> &#8195;property and patent fees over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49129">10,660</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49130">10,656</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49131">10,765</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49132">10,765</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 3pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Available deductions and other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AvailableDeductionsAndOthers" contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49133">73,522</ix:nonFraction></div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AvailableDeductionsAndOthers" contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49134">32,536</ix:nonFraction></div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AvailableDeductionsAndOthers" contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49135">69,448</ix:nonFraction></div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AvailableDeductionsAndOthers" contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49136">28,034</ix:nonFraction></div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </ix:nonNumeric> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the Company&#8217;s past losses, management does not believe that it is probable that the Company can realize its deferred tax assets and, therefore, no amount has been recognized in the consolidated statements of financial position. The generation of future taxable profit is dependent on the successful commercialization of the Company&#8217;s products and technologies. </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_101087011_5" continuedAt="TextSelectionAppend_101087011_6"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">70 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_101087011_6" continuedAt="TextSelectionAppend_101087011_7"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087011_7" continuedAt="TextSelectionAppend_101087011_8"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101087011_8" continuedAt="TextSelectionAppend_101087011_9"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_101087011_9" continuedAt="TextSelectionAppend_101087011_10"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income taxes </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized deferred tax assets (continued) </div></div></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101087011_10"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the above attributes, as at November&#160;30, 2023, the Company had available $<ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2023_IEsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49137">8,816</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="PAsOn11_30_2022_IEsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49138">8,883</ix:nonFraction>) of losses carried forward in Ireland without expiry dates for which no deferred tax assets were recognized. As at November&#160;30, 2023, deferred tax liabilities had not been recognized for taxable temporary differences arising from investments in a subsidiary because the Company controls the decisions affecting the realization of such liabilities and it is probable that the temporary differences will not reverse in the foreseeable future. </div></div></div> </ix:continuation> <div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-39523">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supplemental cash flow disclosures</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <ix:nonNumeric name="thtx:DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-39538"> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into the following transactions, which had no impact on its cash flows. </div></div>&#160; <br/></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin: 0px auto; border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;">
<tr>
<td style="width: 660.312px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs included in accounts<br/> &#8195;payable and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49139">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49140">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49141">174</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to property and equipment included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49142">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49143">156</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49144">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of derivative financial assets included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49145">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49146">104</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49147">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to intangible assets included in accounts payable and accrued<br/> &#8195;liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49148">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49149">2,832</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49150">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of other Deferred financing costs to deficit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49151">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49152">38</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49153">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue cost included in accounts payable<br/> &#8195;and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49154">505</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49155">37</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49156">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> </ix:nonNumeric> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">71 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-indent: 0px;">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-indent: 0px;">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086274" id="ixv-39840">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overview</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">This note provides disclosures relating to the nature and extent of the Company&#8217;s exposure to risks arising from financial instruments, including credit risk, liquidity risk, currency risk and interest rate risk, and how the Company manages those risks. In addition to currency risk, the Company has exposure to risks from disputed accounts receivables. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Credit risk refers to the risk of a loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">The Company&#8217;s exposure to credit risk currently relates to accounts receivable with one major customer (refer to Note&#160;27), other receivable and derivative financial assets which it manages by dealing only with highly rated Canadian</div> financial institutions. Included in the consolidated statements of financial position are trade receivables of $<ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49157">12,798</ix:nonFraction> (2022&#160;&#8211; $<ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49158">10,659</ix:nonFraction>), all of which were aged under <ix:nonNumeric name="thtx:CurrentTradeReceivablesAgingPeriod" contextRef="P12_01_2022To11_30_2023" format="ixt-sec:durday" id="ixv-49159"><ix:nonNumeric name="thtx:CurrentTradeReceivablesAgingPeriod" contextRef="P12_01_2021To11_30_2022" format="ixt-sec:durday" id="ixv-49160">60</ix:nonNumeric></ix:nonNumeric> days or received after year end. There was <ix:nonFraction name="thtx:BadDebtExpenses" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49161"><ix:nonFraction name="thtx:BadDebtExpenses" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49162">no</ix:nonFraction></ix:nonFraction> amount recorded as bad debt expense for the years ended November&#160;30, 2023 and 2022. Financial instruments other than cash and trade and other receivables that potentially subject the Company to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>significant credit risk consists principally of bonds and money market funds. The Company invests its available cash in highly liquid fixed income instruments from governmental, paragovernmental, municipal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">high-grade</div> corporate bodies and money market funds (2023&#160;&#8211; $<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49163">6,290</ix:nonFraction>; 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $<ix:nonFraction name="ifrs-full:OtherFinancialAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49164">9,214</ix:nonFraction>). As at November&#160;30, 2023, the Company believes it was not exposed to any significant credit risk. The Company&#8217;s maximum credit exposure corresponded to the carrying amount of these financial assets. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 15pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Liquidity risk refers to the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in Note 24, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company&#8217;s operating and capital budgets, as well as any material transactions out of the ordinary course of business.</div></div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">The Company has adopted an investment policy in respect of the safety and preservation of its capital designed to ensure that the Company&#8217;s liquidity needs are met. The instruments are selected with regards to the expected timing of expenditures and prevailing interest rates. <br/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">&#160;</div> </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;">7<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk </div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:continuation id="TextSelection_101086274" continuedAt="TextSelectionAppend_101086274_1"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Marathon Credit Agreement, the Company is required to maintain cash, cash equivalents and eligible short-term investments overtime between</div></div></div> $<ix:nonFraction name="thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49165">15,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">to $<ix:nonFraction name="thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49166">20,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on the last twelve months adjusted EBITDA-based targets, which restricts the management of the Company&#8217;s liquidity. Refer to notes 1 and 17.</div></div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are amounts due on the contractual maturities of financial liabilities as at November&#160;30, 2023 and 2022. </div></div></div> <ix:nonNumeric name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086083" id="ixv-39940"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 85%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49167">28,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49168">28,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49169">28,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; <ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49170"> -</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49171">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Facility loan, including interest (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:CurrentPositionOfTermLoanIncludingInterest" contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49172">57,974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49173">80,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49174">17,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49175">50,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49176">12,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49177">994</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49178">1,108</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49179">487</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49180">516</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49181">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="thtx:NonderivativeFinancialLiabilities" contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49182">87,439</ix:nonFraction></td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49183">109,720</ix:nonFraction></td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49184">46,374</ix:nonFraction></td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49185">50,864</ix:nonFraction></td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49186">12,482</ix:nonFraction></td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49187">41,065</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49188">41,065</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49189">41,065</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49190">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49191">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan, including interest (2)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:CurrentPositionOfTermLoanIncludingInterest" contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49192">37,894</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49193">57,667</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49194">5,649</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49195">28,421</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LongTermLoanUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49196">23,597</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes, including interest</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49197">26,895</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49198">29,081</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49199">29,081</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49200">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49201">-</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49202">1,922</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49203">2,196</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49204">595</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49205">1,145</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="thtx:LeaseLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49206">456</ix:nonFraction></div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="thtx:NonderivativeFinancialLiabilities" contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49207">107,776</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49208">130,009</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49209">76,390</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49210">29,566</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<ix:nonFraction name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49211">24,053</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. The maturities above reflect the fact that the Marathon Credit Agreement has been amended in the subsequent event period and, as such, the contractual maturities are used. </div></div></div></td></tr></table></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101086083"> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="vertical-align: top; text-align: left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; display: inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; display: inline;"></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px; display: inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; display: inline;">&#160;</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">7<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: arial; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements (continued) </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands of United States dollars, unless otherwise stated) </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_101086274_1" continuedAt="TextSelectionAppend_101086274_2"><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is exposed to financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company&#8217;s business transactions denominated in currencies other than US$, primarily cash, sale of goods and expenses incurred in CA$ and euros. </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate fluctuations for foreign currency transactions can cause cash flows, as well as amounts recorded in the consolidated statements of net loss, to vary from period to period and not necessarily correspond to those forecasted in operating budgets and projections. Additional earnings variability arises from the translation of monetary assets and liabilities denominated in currencies other than the US$ at the rates of exchange at each consolidated statement of financial position date, the impact of which is reported as foreign exchange gain or loss in the consolidated statements of net loss. </div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency risk </div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"><br/></div><ix:continuation id="TextSelectionAppend_101086274_2" continuedAt="TextSelectionAppend_101086274_3"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the significant items in the original currencies exposed to currency risk as at November&#160;30, 2023 and 2022. </div></div></div><ix:nonNumeric name="thtx:DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-40769"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 67%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49213">358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49214">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49215">1,547</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Cash" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49216">236</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bonds and money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49217">8,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49218">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49219">12,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialAssets" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49220">-</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49221">296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49222">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49223">733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49224">2,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49225">497</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49226">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49227">66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:TaxCreditsAndGrantsReceivable" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49228">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accounts payables and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49229">5,395</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49230">224</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49231">10,784</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49232">5,849</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TotalLeaseLiabilities" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49233">925</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TotalLeaseLiabilities" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49234">288</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TotalLeaseLiabilities" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49235">1,362</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:TotalLeaseLiabilities" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49236">873</ix:nonFraction>)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49237">326</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49238">3,192</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49239">3,486</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Total exposure</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49240">3,048</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49241">3,434</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49242">2,587</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ifrs-full:CurrentAssetsLiabilities" contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49243">7,592</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:nonNumeric> <ix:nonNumeric name="thtx:DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101087523" id="ixv-41109"><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The following exchange rates are those applicable as at November&#160;30, 2023 and 2022.<br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">CA$ &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49244">0,7404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49245">0,7363</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49246">0,7722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49247">0,7439</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Euro &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P12_01_2022To11_30_2023_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49248">1,0792</ix:nonFraction></td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn11_30_2023_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49249">1,0903</ix:nonFraction></td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:AverageForeignExchangeRate" contextRef="P12_01_2021To11_30_2022_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49250">1,0600</ix:nonFraction></td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:ClosingForeignExchangeRate" contextRef="PAsOn11_30_2022_EURsrtCurrencyAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49251">1,0406</ix:nonFraction></td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_101087523"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></ix:continuation> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">7<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> </div></div></div><div></div></div><div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div><div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div><div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency risk </div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued)</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><ix:continuation id="TextSelectionAppend_101086274_3" continuedAt="TextSelectionAppend_101086274_4"><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Based on the Company&#8217;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a <ix:nonFraction name="thtx:PositivePercentageImpactOnForeignCurrencyExposures" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49252">5</ix:nonFraction>% strengthening of the CA$ or the euro would have an impact on net earnings for CA$ and in the accumulated other comprehensive loss for euro as follows, assuming that all other variables remained constant.</div><ix:nonNumeric name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-41391"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Positive (negative) impact</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49253">152</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49254">172</ix:nonFraction>)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_CAD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49255">129</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_EUR" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49256">380</ix:nonFraction>)</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_101086274_4"><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">An assumed <ix:nonFraction name="thtx:NegativePercentageImpactOnForeignCurrencyExposures" contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49257">5</ix:nonFraction>% <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">weakening of the CA$ or of the euro would have had an equal but opposite effect on the above currencies in the amounts shown above, assuming that all other variables remained constant.</div></div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Interest rate risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div> bonds held by the Company are invested at fixed interest rates and/or mature in the short term. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div> bonds are also instruments that bear interest at fixed rates. The risk that the Company will realize a loss as a result of a decline in the fair value of its bonds is limited because these investments, although they are classified as fair value through OCI, are generally held until close to maturity. The unrealized gains or losses on bonds are recorded in accumulated other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Based on the value of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> bonds as at November&#160;30, 2023, an assumed <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49258">0.5</ix:nonFraction>% decrease in market interest rates would have increased the fair value of these bonds and the accumulated other comprehensive income (loss) by approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49259"><ix:nonFraction name="thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" contextRef="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49260">42</ix:nonFraction></ix:nonFraction></div> </div></div> (2022&#160;&#8211; $<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49261"><ix:nonFraction name="thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" contextRef="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49262">79</ix:nonFraction></ix:nonFraction>); an assumed increase in market interest rates of <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49263">0.5</ix:nonFraction>% would have an equal but opposite effect, assuming that all other variables remained constant. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and money market funds bear interest at variable rates. Trade and other receivables, accounts payable and accrued liabilities and provisions bear no interest.</div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">7<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk </div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Based on the average value of variable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interest-bearing</div> cash and money market funds during the year ended November&#160;30, 2023 <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="thtx:VariableInterestbearingCashAndMoneyMarketFunds" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49264">20,231</ix:nonFraction> </div></div> (2022&#160;&#8211; $<ix:nonFraction name="thtx:VariableInterestbearingCashAndMoneyMarketFunds" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49265">23,505</ix:nonFraction>), an assumed <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49266">0.5</ix:nonFraction>% increase in interest rates during such year would have increased future cash flows and net profit by approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49267"><ix:nonFraction name="thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49268">101</ix:nonFraction></ix:nonFraction> </div></div>(2022&#160;&#8211; $<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" contextRef="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49269"><ix:nonFraction name="thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" contextRef="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49270">118</ix:nonFraction></ix:nonFraction>); an assumed decrease of <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49271">0.5</ix:nonFraction>% would have had an equal but opposite effect. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Based on the value of the Company&#8217;s long-term loan as at November&#160;30, 2023, an assumed <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49272">0.5</ix:nonFraction>% increase in SOFR rate during such year would have decreased future cash flows and net profit by approximately $<ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49273"><ix:nonFraction name="thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49274">300</ix:nonFraction></ix:nonFraction> and an assumed increase of <ix:nonFraction name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49275">0.5</ix:nonFraction>% would have had an equal but opposite effect. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085829" id="ixv-41646">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s objective in managing its capital is to ensure a liquidity position sufficient to finance its business activities. The Company depends primarily on revenue generated by sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>as well as sales of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in the United States, and, from time to time, on public offerings of securities in North America to finance its activities. In order to maintain or adjust its capital structure, the Company, upon approval by its Board of Directors, may issue or repay long-term debt, issue shares, repurchase shares, pay dividends or undertake other activities as deemed appropriate under the specific circumstances. The Company has also announced that it will evaluate its options in funding late stage development programs, which may include seeking a potential partner. </div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The capital management objectives remain the same as of the previous year, including that the Company&#8217;s cash deposit and brokerage accounts are subject to control agreements relating to the Loan Facility and certain credit card arrangements allowing creditors to collateralized outstanding loaned values. Furthermore, the Company is required to maintain cash, cash equivalents and eligible short-term investments over time to range of $<ix:nonFraction name="thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49276">15,000</ix:nonFraction> to $<ix:nonFraction name="thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49277">20,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on targeted Marathon Adjusted EBITDA.&#160;</div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">As at November&#160;30, 2023, cash, bonds and money market funds amounted to $<ix:nonFraction name="thtx:CashBondAndMoneyMarketFunds" contextRef="PAsOn11_30_2023_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49278">40,387</ix:nonFraction> (2022-$<ix:nonFraction name="thtx:CashBondAndMoneyMarketFunds" contextRef="PAsOn11_30_2022_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49279">33,070</ix:nonFraction>). </div> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">7<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div> </div> </ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_101085829" continuedAt="TextSelectionAppend_101085829_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085829_1" continuedAt="TextSelectionAppend_101085829_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085829_2" continuedAt="TextSelectionAppend_101085829_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101085829_3" continuedAt="TextSelectionAppend_101085829_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085829_4" continuedAt="TextSelectionAppend_101085829_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></td></tr></table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085829_5"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Currently, the Company&#8217;s general policy on dividends is to retain cash to keep funds available to finance its growth. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company defines capital to include total equity and, prior to June&#160;30, 2023, convertible unsecured senior notes. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not subject to any externally imposed capital requirements, except those disclosed in Note 17 in relation to the Marathon Credit Agreement. </div></div></div> </ix:continuation> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085828" id="ixv-41736">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Determination of fair values</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets and financial liabilities measured at fair value</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;1:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as observable inputs such as quoted prices in active markets. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;2:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;3:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other financial assets and financial liabilities</div></div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company has determined that the carrying values of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> financial assets and financial liabilities, including cash, trade and other receivables, and accounts payable and accrued liabilities approximate their fair value because of their relatively short period to maturity.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><ix:exclude>7<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></ix:exclude> </div> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_101085828" continuedAt="TextSelectionAppend_101085828_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085828_1" continuedAt="TextSelectionAppend_101085828_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085828_2" continuedAt="TextSelectionAppend_101085828_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101085828_3" continuedAt="TextSelectionAppend_101085828_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085828_4" continuedAt="TextSelectionAppend_101085828_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Determination of fair values</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> (continued) </div></div> </td> </tr> </table> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other financial assets and financial liabilities </div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085828_5"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds and money market funds and derivative financial assets and financial liabilities are stated at fair value, determined by inputs that are primarily based on broker quotes at the reporting date (Level&#160;2). </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that the carrying value of its Loan Facility approximates its fair value because the terms were&#160;modified near the end of the 2023 fiscal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> payment transactions</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Share Options is measured based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> valuation model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk-free</div> interest rate (based on government bonds). Service and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-market</div> performance conditions attached to the transactions, if any, are not taken into account in determining fair value. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the DSUs is determined using the quoted price of the common shares of the&#160;Company and considered Level&#160;2 in the fair value hierarchy. </div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Marathon Warrants </div></div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-41898"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. Reasonably possible changes at November&#160;30, 2023, to one of the significant unobservable input, holding other inputs consistent, would have the following effects: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;Increase</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Decrease</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility (<ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49280">10</ix:nonFraction>% movement (<ix:nonFraction name="thtx:SignificantUnobservableInputLiabilitiesBasisPoints" contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_pure" decimals="4" scale="-4" format="ixt:num-dot-decimal" id="ixv-49281">100</ix:nonFraction> bps))</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_pure" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49282">100</ix:nonFraction>)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<ix:nonFraction name="ifrs-full:SignificantUnobservableInputLiabilities" contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_TopOfRangeMemberifrsfullRangeAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49283">125</ix:nonFraction></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <ix:nonNumeric name="ifrs-full:DisclosureOfCommitmentsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101085439" id="ixv-42017">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div> procurement agreements and research agreements </div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;">The Company has <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">long-term</div> procurement agreements with third party suppliers in connection with the commercialization of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div> and Trogarzo<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div>. As at November&#160;30, 2023, the Company had outstanding purchase orders and minimum payments required under these agreements amounting to $<ix:nonFraction name="thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired" contextRef="PAsOn11_30_2023_TrogarzoMemberTHTXCommitmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49284">14,682</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(2022 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8211; </div></div>$<ix:nonFraction name="thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired" contextRef="PAsOn11_30_2022_TrogarzoMemberTHTXCommitmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49285">1,644</ix:nonFraction>) for the manufacture of Trogarzo<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div>, </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> </div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">and for other various services.</div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;">As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">3</div>, the Company also ha<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">d</div>&#160;research commitments and outstanding clinical material purchase orders amounting to $<ix:nonFraction name="thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired" contextRef="PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49286">807</ix:nonFraction> (2022 &#8211; $<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><ix:nonFraction name="thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired" contextRef="PAsOn11_30_2022_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49287">1,310</ix:nonFraction></div>) in connection with the oncology platform and <ix:nonFraction name="thtx:BorrowingsOutstanding" contextRef="PAsOn11_30_2023_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis" unitRef="Unit_USD" xsi:nil="true" id="ixv-49288"></ix:nonFraction>nil <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(2022 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8211;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>$<ix:nonFraction name="thtx:BorrowingsOutstanding" contextRef="PAsOn11_30_2022_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49289">868</ix:nonFraction>) in connection with a new formulation of tesamorelin and of a multi-dose pen injector developed for this new formulation. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt;text-indent: 0px;"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"><ix:exclude><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101085439" continuedAt="TextSelectionAppend_101085439_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085439_1" continuedAt="TextSelectionAppend_101085439_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085439_2" continuedAt="TextSelectionAppend_101085439_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101085439_3" continuedAt="TextSelectionAppend_101085439_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101085439_4" continuedAt="TextSelectionAppend_101085439_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101085439_5"><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Licence agreement </div> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;<div style="display:inline;">3</div>, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (&#8220;MGH&#8221;), as amended on April&#160;15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Alcoholic</div> Steatohepatitis (&#8220;NASH&#8221;) in the general population. Under the terms of the amended agreement, the MGH, through Dr.&#160;Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Alcoholic</div> Fatty Liver Disease or NASH in the general population. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">8<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div> </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-42175">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating segments</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company has a single operating segment. As described in Note 3, almost all of the Company&#8217;s revenues are generated from one customer, RxCrossroads, which is domiciled in the United States.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-42191">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 61%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">RxCrossroads</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_RxCrossRoadsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49291">81,392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_RxCrossRoadsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49292">78,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;<ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_RxCrossRoadsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49293">68,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023_AllOtherSegmentsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49294">372</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022_AllOtherSegmentsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49295">1,313</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021_AllOtherSegmentsMemberifrsfullSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49296">906</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49297">81,764</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49298">80,057</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:Revenue" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49299">69,823</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are located in Canada, the United States and Ireland. <div style="letter-spacing: 0px; top: 0px;;display:inline;">Of the Company&#8217;s total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets of $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49300">14,472</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49301">19,890</ix:nonFraction>), $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2023_CAifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49302">14,138</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2022_CAifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49303">18,980</ix:nonFraction>) are located in Canada, $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2023_USifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49304">32</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2022_USifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49305">69</ix:nonFraction>) are located in the United States and $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2023_IEifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49306">302</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="PAsOn11_30_2022_IEifrsfullGeographicalAreasAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49307">841</ix:nonFraction>) are located in&#160;Ireland. </div> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="ifrs-full:DisclosureOfRelatedPartyExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" continuedAt="TextSelection_101086547" id="ixv-42336">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Related parties</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The key management personnel of the Company are the directors, the President and Chief Executive Officer, the Senior Vice President and Chief Financial Officer, the Global Commercial Officer and the Senior Vice President and Chief Medical Officer.&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" contextRef="P12_01_2022To11_30_2023" escape="true" id="ixv-42351"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel compensation comprises: </div></div><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 91%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div> employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49308">3,259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49309">3,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49310">2,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49311">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49312">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49313">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49314">1,355</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49315">2,078</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49316">1,243</ix:nonFraction></td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P12_01_2022To11_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49317">4,709</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P12_01_2021To11_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49318">5,355</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="P12_01_2020To11_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49319">4,005</ix:nonFraction></td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:nonNumeric> <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>8<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></ix:exclude></div></div></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_101086547" continuedAt="TextSelectionAppend_101086547_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086547_1" continuedAt="TextSelectionAppend_101086547_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086547_2" continuedAt="TextSelectionAppend_101086547_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_101086547_3" continuedAt="TextSelectionAppend_101086547_4"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THERATECHNOLOGIES INC.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Notes to Consolidated Financial Statements (continued) </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">(In thousands of United States dollars, unless otherwise stated) </div> <div style="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:arial"></div> </ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_101086547_4" continuedAt="TextSelectionAppend_101086547_5"><ix:exclude> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended November 30, 2023, 2022 and 2021 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Related parties </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">(continued) </div></div> </td> </tr> </table> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_101086547_5"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As at November&#160;30, 2023, the key management personnel controlled <ix:nonFraction name="thtx:RelatedPartyPercentageOfVotingRightsHeld" contextRef="PAsOn11_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49320">1.1</ix:nonFraction>% (2022&#160;&#8211; <ix:nonFraction name="thtx:RelatedPartyPercentageOfVotingRightsHeld" contextRef="PAsOn11_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49321">0.8</ix:nonFraction>%) of the voting shares of the Company. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center">8<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> </div> </div> </div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:justify" id="tx680117_83">Item&#8201;19. Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:99%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312513078305/d489003dex11.htm">Articles of Incorporation of the Company (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the SEC on February&#160;27, 2013) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex12.htm">Amended and Restated By-laws No.3 of the Company</a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex13.htm"><span style="white-space:nowrap">By-laws</span> No.4 of the Company </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312522105638/d348334dex991.htm">Amended and Restated Shareholder Rights Plan Agreement dated April&#160;6, 2022 between Theratechnologies Inc. and Computershare Trust Company of Canada (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on April&#160;14, 2022) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex22.htm">Share Option Plan dated as of May&#160;9, 2023 of the Company </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex23.htm">Description of Securities Registered Under Section 12 of the Exchange Act </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000095012311058540/m71067exv99w1.htm">Manufacture and Supply Agreement, by and between Draxis Pharma General Partnership and Theratechnologies Inc., dated as of December&#160;23, 2009 (incorporated by reference to Exhibit 99.91 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on June&#160;13, 2011) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9959.htm">Amended and Restated Master Services Agreement made as of December&#160;14, 2016 by and between inVentiv Commercial Services, LLC and Theratechnologies Inc. (incorporated by reference to Exhibit 99.59 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9957.htm">Amended and Restated Marketing and Distribution Agreement dated March&#160;6, 2017 by and between Theratechnologies Inc. and TaiMed Biologics Inc. (incorporated by reference to Exhibit 99.57 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9961.htm">Amended and Restated Master Services Agreement made as of November&#160;1, 2017 by and between RxC Acquisition Company and Theratechnologies Inc. (incorporated by reference to Exhibit 99.61 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9962.htm">Amended and Restated Statement of Work #1 entered into as of November&#160;1, 2017 by and between RxC Acquisition Company and Theratechnologies Inc. (incorporated by reference to Exhibit 99.62 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9963.htm">Amended and Restated Statement of Work #2 entered into as of November&#160;1, 2017 by and between RxC Acquisition Company and Theratechnologies Inc. (incorporated by reference to Exhibit 99.63 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9958.htm">Amendment No.&#160;1 to Amended and Restated Marketing and Distribution Agreement effective as of November&#160;6, 2018 by and between Theratechnologies Inc. and TaiMed Biologics Inc. (incorporated by reference to Exhibit 99.58 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9966.htm">Share Purchase Agreement dated February&#160;25, 2019 by and among Transfert Plus, L.P., Aligo Innovation, L.P., Borhane Annabi, Richard B&#233;liveau, Cyndia Charfi, Jean-Christophe Currie, Alain Larocque, Michel Demeule, Sophie Kozelko and Theratechnologies Inc. (incorporated by reference to Exhibit 99.66 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9967.htm">Amendment No.&#160;1 to Share Purchase Agreement dated August&#160;12, 2019, by and among Transfert Plus, L.P., Aligo Innovation, L.P., Borhane Annabi, Richard B&#233;liveau, Cyndia Charfi, Jean-Christophe Currie, Alain Larocque, Michel Demeule, Sophie Kozelko and Theratechnologies Inc. (incorporated by reference to Exhibit 99.67 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9968.htm">Amended and Restated Exclusive License Agreement dated February&#160;25, 2019 by and between Transfert Plus, L.P. and Katana Biopharma Inc. (incorporated by reference to Exhibit 99.68 to the Company&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312519257311/d805932dex9960.htm">First Amendment to the Amended and Restated Master Services Agreement dated February&#160;27, 2019 by and between inVentiv Commercial Services, LLC and Theratechnologies Inc. (incorporated by reference to Exhibit 99.60 to the Company&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;40-F</span> filed with the SEC on September&#160;27, 2019) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312520047314/d829370dex999.htm">Amendment No.&#160;1 to Amended and Restated Statement of Work #1 made as of November&#160;1, 2019 by and between RxC Acquisition Company d/b/a RxCrossroads by McKesson and Theratechnologies Inc. (incorporated by reference to Exhibit 99.9 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on February&#160;25, 2020) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312520047314/d829370dex9910.htm">Amendment No.&#160;1 to Amended and Restated Statement of Work #2 made as of November&#160;1, 2019 by and between RxC Acquisition Company d/b/a RxCrossroads by McKesson and Theratechnologies Inc. (incorporated by reference to Exhibit 99.10 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on February&#160;25, 2020) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312520047314/d829370dex9911.htm">Second Amendment to Amended and Restated Master Services Agreement made as of February&#160;3, 2020 by and between inVentiv Commercial Services, LLC and Theratechnologies Inc. (incorporated by reference to Exhibit 99.11 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on February&#160;25, 2020) </a></p></td></tr></table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:99%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312520047314/d829370dex9912.htm">Amended and Restated License Agreement made as of February&#160;3, 2020 by and between The General Hospital Corporation d/b/a Massachusetts General Hospital and Theratechnologies Inc. (incorporated by reference to Exhibit 99.12 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">40-F</span> filed with the SEC on February&#160;25, 2020) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312522199217/d346904dex992.htm">Commitment Letter made as of July&#160;13, 2022, by and between Marathon Asset Management and Theratechnologies Inc. (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on July&#160;21, 2022) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523264313/d530607dex991.htm">Underwriting Agreement, dated October&#160;25, 2023, by and among Theratechnologies Inc., Cantor Fitzgerald&#160;&amp; Co. and Cantor Fitzgerald Canada Corporation. (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on October&#160;27, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex991.htm">First Amendment to Credit Agreement made as of February&#160;27, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex992.htm">Second Amendment to Credit Agreement made as of May&#160;15, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex993.htm">Third Amendment to Credit Agreement made as of July&#160;10, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.3 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex994.htm">Fourth Amendment to Credit Agreement made as of July&#160;28, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.4 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.22</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex995.htm">Amended and Restated Fourth Amendment to Credit Agreement made as of September&#160;21, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.5 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.23</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523270285/d522575dex996.htm">Fifth Amendment to Credit Agreement made as of October&#160;13, 2023, by and among Theratechnologies Inc., MAM Tiger Lender LLC and Marathon Healthcare Finance Fund, L.P. (incorporated by reference to Exhibit 99.6 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;3, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.24</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312523271128/d572522dex991.htm">Investor Rights Agreement dated October&#160;31, 2023, by and between Theratechnologies Inc. and Investissement Qu&#233;bec. (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form <span style="white-space:nowrap">6-K</span> filed with the SEC on November&#160;6, 2023) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.25</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="http://www.sec.gov/Archives/edgar/data/1512717/000119312513078305/d489003dex42.htm">Deferred Compensation Plan for Members of the Board of Directors and Certain Executive Officers of the Company (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">20-F</span> filed with the SEC on February&#160;27, 2013) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.26</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex426.htm">Amendment No.&#160;2 to Amended and Restated Marketing and Distribution Agreement effective as of November&#160;5, 2019 by and between Theratechnologies Inc. and TaiMed Biologics Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.27</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex427.htm">Amendment No.1 to the Manufacture and Supply Agreement made as of January&#160;7, 2020 by and between Jubilant Hollisterstier General Partnership (f/k/a Draxis Pharma General Partnership) and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.28</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex428.htm">First Amendment to the Amended and Restated License Agreement made as of April&#160;15, 2020 by and between The General Hospital Corporation d/b/a Massachusetts General Hospital and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.29</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex429.htm">Amendment No.2 to the Manufacture and Supply Agreement made as of January&#160;1, 2021 by and between Jubilant Hollisterstier General Partnership (f/k/a Draxis Pharma General Partnership) and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.30</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex430.htm">First Amendment to the Amended and Restated Exclusive License Agreement effective October&#160;26, 2020 by and between Transfert Plus, L.P. and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.31</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex431.htm">Amendment No.&#160;2 to Share Purchase Agreement dated March&#160;29, 2021, by and among Transfert Plus, L.P., Aligo Innovation, L.P., Borhane Annabi, Richard B&#233;liveau, Cyndia Charfi, Jean-Christophe Currie, Alain Larocque, Michel Demeule, Sophie Kozelko and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.32</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex432.htm">Consulting Agreement made as of May 13, 2021 by and between JP Arena Consulting, LLC, and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.33</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex433.htm">Amendment No.&#160;3 to Amended and Restated Marketing and Distribution Agreement effective as of May&#160;18, 2021 by and between Theratechnologies Inc. and TaiMed Biologics Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.34</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex434.htm">Third Amendment to Amended and Restated Master Services Agreement made as of December&#160;1, 2021 by and between Syneos Health Commercial Services (f/k/a inVentiv Commercial Services, LLC) and Theratechnologies Inc.</a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.35</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex435.htm">Amendment No.&#160;2 to Amended and Restated Statement of Work #2 made as of February&#160;17, 2023 by and between RxC Acquisition Company d/b/a RxCrossroads by McKesson and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.36</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex436.htm">Manufacturing and Supply Agreement made as of July&#160;31, 2023, by and among Theratechnologies Inc. and Bachem Americas Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.37</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex437.htm">Employment Agreement made as of March&#160;1, 2020 by and between Paul L&#233;vesque and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.38</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex438.htm">Employment Agreement made as of February&#160;24, 2016 by and between Philippe Dubuc and Theratechnologies Inc. </a></p></td></tr></table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.39</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d680117dex439.htm">Amendment No.1 to Employment Agreement made as of July 27, 2023 by and between Philippe Dubuc and Theratechnologies Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.40</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex440.htm">Amended and Restated Employment Agreement made as of December&#160;21, 2012 by and between Christian Marsolais and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex441.htm">Amendment No.1 to Amended and Restated Employment Agreement made as of July 28, 2023 by and between Christian Marsolais and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex442.htm">Employment Agreement made as of January 6, 2023 with an effective date of April&#160;11, 2022 by and between John Leasure and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex443.htm">Amendment No.1 to Employment Agreement made as of July 31, 2023 by and between John Leasure and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.44</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex444.htm">Employment Agreement made as of March&#160;29, 2007 by and between Jocelyn Lafond and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.45</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex445.htm">Amendment No.1 to Employment Agreement made as of July 5, 2012 by and between Jocelyn Lafond and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex446.htm">Amendment No.2 to Employment Agreement made as of July 27, 2023 by and between Jocelyn Lafond and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex447.htm">Amendment No.3 to Employment Agreement made as of December 15, 2023 by and between Jocelyn Lafond and Theratechnologies Inc. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">8.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex8.htm">Significant Subsidiaries of the Registrant </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">11.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex111.htm">Code of Business Conduct &amp; Ethics of the Company </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">11.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex112.htm">Insider Trading Policy, dated November&#160;29, 2021. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">12.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex121.htm">Certificate of CEO pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> or <span style="white-space:nowrap">15(d)-14(a)</span> of the Exchange Act </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">12.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex122.htm">Certificate of CFO pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> or <span style="white-space:nowrap">15(d)-14(a)</span> of the Exchange Act </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">13.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex131.htm">Certificate of CEO pursuant to 18 U.S.C. Section&#160;1350, adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">13.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex132.htm">Certificate of CFO pursuant to 18 U.S.C. Section&#160;1350, adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">15.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex15.htm">Consent of KPMG </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">17.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex17.htm">List of Subsidiary Guarantors </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">97.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d680117dex971.htm">Clawback Policy </a></p></td></tr></table> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.SCH</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Schema</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.CAL</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Calculation Linkbase</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.DEF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Definition Linkbase</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.LAB</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Label Linkbase</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.PRE</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Presentation Linkbase</p></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">104.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx680117_84">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:Times New Roman;text-align:justify">The registrant hereby certifies that it meets all of the requirements for filing on Form <span style="white-space:nowrap">20-F</span> and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. </p> <p style="font-size:28pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:100%;border:0">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:56%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">THERATECHNOLOGIES INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:28.5pt"/>
<td style="height:28.5pt" colspan="2"/>
<td style="height:28.5pt" colspan="2"/>
<td style="height:28.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top">Date:&#160;February&#160;21,&#160;2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman"><span style="font-style:italic">/s/&#160;Paul L&#233;vesque</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: Paul L&#233;vesque</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>d680117dex12.htm
<DESCRIPTION>EX-1.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 1.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>AMENDED AND
RESTATED BY-LAW NO. 3 </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>GENERAL BY-LAWS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>INTERPRETATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">1.&#8195;&#8195;<U>Definitions</U>. The definitions set out in the <I>Business Corporations Act </I>(CQLR., c. S-31.1), and in any amendment or
successor act thereto (collectively, the &#147;Act&#148;), shall apply to the terms used in these General By-Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">2.&#8195;&#8195;<U>Computation
of Time</U>. The computation of time or any period in days shall be based on the provisions of the <I>Interpretation Act </I>(CQLR, c. I-16), and any amendment or successor act thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">3.&#8195;&#8195;<U>Signature</U>. Any signature required on a notice of shareholder meeting or any other document that must be sent or provided by the
Corporation, its directors or its officers or on their behalf may be handwritten or reproduced mechanically or electronically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">4.&#8195;&#8195;<U>Certificate</U>. A transfer certificate made by the Corporate Secretary or by any other duly authorized officer of the Corporation in
office when the certificate was prepared, or by any officer, transfer agent or registrar who records the transfer of shares of the Corporation shall be conclusive evidence, enforceable against any shareholder, of the sending or delivery of any
notice of meeting or any other document that must be sent or provided by the Corporation, its directors or its officers, or on their behalf. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>SHAREHOLDERS </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">5.&#8195;&#8195;<U>Annual Meeting</U>. The annual meeting of shareholders of the Corporation shall be held each year on such date and at such time as
may be fixed by the Board of Directors, to receive and consider the financial statements of the Corporation together with the report of the Auditor&#146;s thereon, to elect directors, to appoint the Auditor and to fix or to authorize the Board of
Directors to fix its remuneration, and to consider, deal with and dispose of such other business as may lawfully come before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">The
annual meeting of shareholders shall be held at the head office of the Corporation or at any other place in the province of Quebec, which may be determined by the Board of Directors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Any annual meeting may also constitute a special meeting to consider, deal with and dispose of any
business to be considered, dealt with and disposed of at any special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">6.&#8195;&#8195; <U>Special Meeting</U>. A special meeting of
shareholders may be called at any time as determined by the President, the Chair of the Board or the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Special meetings of
shareholders shall be held at the head office of the Corporation or at such other place, within or outside Quebec, as may be determined by the Board of Directors. However, if directors are to be elected at a special meeting of shareholders, such
meeting shall be held within the province of Quebec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">7.&#8195;&#8195; <U>Special Meeting Called at the Request of Shareholders</U>. It shall be
incumbent upon the Board of Directors to call a special meeting of shareholders whenever required in writing to do so by the shareholders holding no less than one-tenth of the issued shares of the Corporation of the class or classes that, at the
date of the request, carry the right to vote at the meeting so requested. The request shall indicate the purposes of the upcoming meeting, the business of which shall lie within the competence of a meeting of the shareholders. If the meeting is not
called within 21 days from the date upon which the request for the meeting was received at the head office of the Corporation to the attention of the Corporate Secretary, any shareholder who signed the request may call such special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">8.&#8195;&#8195; <U>Notice of Meetings</U>. Notice of each annual or special meeting of shareholders shall be sent to the shareholders entitled to
attend such meeting by any means of delivery authorized by law, at the discretion of the person charged with giving such notice, to the respective address of the recipients recorded in the registers of the Corporation, at least 21 days prior to the
date fixed for such meeting. If the address of any shareholder does not appear in the registers of the Corporation, then the said notice may be sent to such address as the person sending the notice may consider to be the most likely address at which
the notice will reach such shareholder promptly. Irregularities in the notice or in the sending thereof, including the accidental omission to give notice or the non-receipt thereof by any of the shareholders, shall not invalidate any proceedings at
any such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">No notice of the date determined for any adjourned meeting need be given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">9.&#8195;&#8195; <U>Record Date</U>. The Board of Directors may fix a date no earlier than 30 days prior to the date of a meeting as the record date to
determine which shareholders are entitled to receive notice of the meeting and to vote thereat. As a result, only shareholders of record on the date so fixed shall be entitled to receive notice thereof and to vote thereat, regardless of any transfer
of shares </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">
recorded in the registers of the Corporation between the record date and the date of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">10.&#8195;&#8195; <U>Joint Shareholders</U>. In the case of joint shareholders, any notice of meeting or other document that must be sent to
shareholders may be sent to the joint shareholder whose name first appears in the registers of the Corporation in respect of such shares. Any notice or document so sent shall be deemed sufficient to release the sender from sending such notice or
document to each joint shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">11.&#8195;&#8195; <U>Chair of the Meeting</U>. The Chair of the Board of Directors or, if there is none, the
President of the Corporation, or any other person as may from time to time be appointed as such by the Board of Directors, shall preside at meetings of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">12.&#8195;&#8195; <U>Quorum</U>. One or more persons present in person or duly represented and holding not less than 10% of the aggregate number of
votes attached to all the voting shares for such meeting shall constitute a quorum at an annual or special meeting of shareholders, regardless of the actual number of persons physically present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Should a quorum exist at the commencement of a meeting, the shareholders present or represented may proceed with the business for which it was
originally called whether or not the quorum is maintained for the duration of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Should no quorum exist at the commencement of a meeting,
the shareholders present or represented may, by a majority vote to that effect, adjourn the meeting to another date and place, though they may not proceed with any other business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Should a quorum exist at a meeting so adjourned, said meeting may proceed, failing which, a new meeting shall be convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">13.&#8195;&#8195; <U>Conduct of Meetings</U>. Any meeting of shareholders may be held in person or otherwise in accordance with the provisions of the
Act, solely or in part, by the use of any equipment or medium that enables all participants to communicate directly with one another during the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Any person participating in a meeting by such means will be deemed to be present at the meeting and, provided he/she/it is entitled to vote at the
meeting, may cast his/her/its vote using any such means if it allows the vote to be verified afterwards and protects the secrecy of the vote if a ballot is requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">14.&#8195;&#8195; <U>Proxy.</U> The Board of Directors may set a date and time limit when instruments of proxy to be used at a meeting must be deposited
with the Corporation or its mandatary; such date and time limit shall not precede the meeting by more than 48 hours. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">The Board of Directors may also permit details of proxies to be used at or in connection with a
meeting and deposited with the Corporation or its mandatary at a location other than that at which such meeting shall be held to be sent by facsimile to the Corporate Secretary of the Corporation prior to the meeting. In such a case, such proxies,
if they are otherwise regular, shall be valid and the votes given under their authority shall be counted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">15.&#8195;&#8195; <U>Decisions Made by
the Majority</U>. Unless otherwise provided in the Act, any matters submitted to a meeting of shareholders will be decided by a simple majority (50% + 1) of the votes validly cast. In the case of joint shareholders, unless they indicate otherwise,
any one of such persons attending the meeting shall be authorized to cast those votes which may be cast at the meeting and, where more than one joint shareholder is in attendance, only the person whose name first appears in the securities register
of the Corporation in respect of the shares carrying votes shall be authorized to cast such vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">16.&#8195;&#8195; <U>Vote by a
Show of Hands</U>. Unless a vote by secret ballot is requested in the manner prescribed below, the vote shall be taken by a show of hands. In such a case, the shareholders shall vote by raising their hands, and the number of votes shall be
calculated in accordance with the number of raised hands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">17.&#8195;&#8195; <U>Secret Ballot</U>. If the chair of the meeting so orders or a person
holding or representing by proxy no fewer than 10% of the shares carrying votes which may be cast at the meeting so requests, the vote shall be taken by secret ballot. A request for a vote by secret ballot may be made at any time prior to the
adjournment of the meeting, even after the holding of a vote by a show of hands, and such a request may also be withdrawn. Each shareholder or proxy shall remit to the scrutineers one or more ballots, on which he shall enter the manner in which he
shall cast the votes he has and, where applicable, his name and the number of votes he has. Whether or not a vote by a show of hands has previously been taken on the same matter, the result of a secret ballot shall be deemed to represent the
resolution of the meeting in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">18.&#8195;&#8195; <U>Procedure at Meetings</U>. The chair of any meeting of shareholders shall be
responsible for conducting the procedure thereat in all respects, and his/her decision on any matter, even a matter pertaining to the validity or non-validity of a proxy and the receivability or non-receivability of a motion, shall be final and
binding on all the shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">A declaration by the chair of the meeting that a resolution has been carried or not carried, with or without
qualification of unanimity, by a particular majority, shall be conclusive evidence of the fact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">At all times during the meeting, the chair of the
meeting, of his/her own initiative or with the assent of the shareholders given by a simple majority, for a valid reason, such as a disturbance or confusion rendering the harmonious and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">
orderly conduct of the meeting impossible, has the authority to adjourn the meeting from time to time and no notice of any such adjourned meeting to a given date need be given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Should the chair of the meeting fail to carry out his/her duties loyally, the shareholders may remove him/her as chair of such meeting at any time and
replace him/her by another person chosen among them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">19.&#8195;&#8195; <U>Scrutineers</U>. The chair at any meeting of shareholders may appoint
scrutineers (who may but need not be directors, officers, employees or shareholders of the Corporation), who shall act in accordance with his/her directives. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>BOARD OF DIRECTORS </U></B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">20.&#8195;&#8195;
<U>Number</U>. The Corporation shall be managed by a Board of Directors composed of the fixed number of directors indicated in its articles of incorporation. If the articles of incorporation establish a minimum and a maximum number of directors, the
Board of Directors shall be composed of the fixed number of directors, although no less than three, established by resolution of the Board of Directors or, failing this, selected by the shareholders within such limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">21.&#8195;&#8195; <U>Resignation</U>. A director may resign his office by written notice to the Corporation. Reasons need not be given for a
resignation. Unless a subsequent date is stipulated in such notice, the resignation shall take effect on the date of its delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">22.&#8195;&#8195; <U>Removal</U>. Unless otherwise provided in the articles of incorporation of the Corporation, the shareholders may, by resolution,
remove a director at a special meeting called for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">The removal of a director, as well as his election, shall be at the discretion of
the shareholders. A director may be removed at any time and such removal need not be based on any particular grounds, whether serious or not. Neither the Corporation nor the shareholders voting in favour of the removal shall incur any liability
toward the director by the mere fact of his removal, even if there be no grounds therefore. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">23.&#8195;&#8195; <U>Vacancy</U>. The office of a director shall become vacant as of the moment that
his/her resignation or removal is effective; likewise, a vacancy shall be created the moment a director ceases to be qualified to fulfill his/her duties, or if he/she dies. Directors may continue to act despite one or several vacancies, provided a
quorum still exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">24.&#8195;&#8195; <U>Remuneration</U>. The remuneration paid to the directors shall be determined by resolution of the Board
of Directors. Such remuneration shall normally be in addition to the salary or remuneration of any officer, employee or supplier of services of the Corporation who is also a director, unless a resolution states otherwise. The directors may also be
reimbursed for travel and other expenses incurred by them in connection with their duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">25.&#8195;&#8195; <U>Irregularity</U>. Notwithstanding
the discovery of a defect in the election of the Board of Directors or in the election or appointment of a director, or in the event a director is no longer eligible to act as such pursuant to the Act, acts regularly done by any of them shall be as
valid and as binding on the Corporation as if the election or appointment had proceeded without such defect or as if each person was still eligible to act as a director of the Corporation under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">26.&#8195;&#8195;<U>Borrowing</U>. The directors may, when they deem expedient: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:ARIAL; " ALIGN="justify">borrow money upon the credit of the Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:ARIAL; " ALIGN="justify">issue debentures or other securities of the Corporation and pledge or sell same for such sums and at such prices as
may be deemed expedient; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:ARIAL; " ALIGN="justify">hypothecate the immovables and movables or otherwise affect the movable property of the Corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:ARIAL; " ALIGN="justify">delegate, in whole or in part, the powers mentioned hereinabove to one or more officers of the Corporation, subject to
the terms and conditions set out in the resolution delegating such power. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">This by-law shall be regarded as an addition to, and
not a replacement of, any borrowing by-law adopted by the Corporation for banking purposes unless otherwise specifically stipulated in such by-law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">27.&#8195;&#8195; <U>Use of Property or Information</U>. No director may mingle the Corporation&#146;s property with his/her own property or use for
his/her own profit or that of a third person any property of the Corporation, including any information he obtains by reason of his/her duties, unless he/she is expressly and specifically authorized to do so by the shareholders of the Corporation.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">28.&#8195;&#8195; <U>Conflicts of Interest</U>. A director shall avoid placing himself/herself in a
situation where his/her personal interest would conflict with his/her obligations as a director of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">He/she shall promptly declare
to the Corporation any interest he has in an enterprise or other entity that may place him/her in a situation of conflict of interest and any right he/she may set up against it, indicating their nature and value, where applicable. Such declaration
of interest shall be recorded in the minutes of the proceedings of the Board of Directors. A general declaration shall be valid as long as the facts have not changed, and the director need not repeat it for a specific subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">29.&#8195;&#8195; <U>Contracts with the Corporation</U>. A director may, even in carrying on his/her duties, directly or indirectly acquire rights in
the Corporation&#146;s property or enter into contracts with the Corporation, on condition that he immediately inform the Corporation of such fact by indicating the nature and value of the rights he/she is acquiring, and that he/she request that
such fact be recorded in the minutes of the proceedings of the Board of Directors or any written resolution in lieu thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">A director who is so
interested in an acquisition of property or a contract shall abstain, except if required, from the discussion and voting on the question and, if he/she votes, his/her vote shall not be counted. However, this rule does not apply to questions
concerning the remuneration or condition of employment of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">At the request of the Chair of the Board of Directors or of any director, the
interested director shall leave the meeting while the Board of Directors discusses and votes on the acquisition or contract in question. The same shall be applicable to any director who has an interest in an offeror making an offer to purchase the
shares of the Corporation by way of a take-over bid while the Board of Directors discusses and votes on such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Neither the Corporation nor its
shareholders may contest the validity of an acquisition of property or a contract involving the Corporation, on the one hand, and directly or indirectly a director, on the other, for the sole reason that the director is a party thereto or is
interested therein, if such director made the declaration mentioned hereinabove immediately and correctly. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>MEETINGS OF THE BOARD OF DIRECTORS
</U></B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">30.&#8195;&#8195; <U>Calling of Meetings</U>. Meetings of the Board of Directors may be called by or by order of the Chair of the Board of
Directors, if any, the President of the Corporation or two (2)&nbsp;directors, and such meetings may be held anywhere within or outside Quebec. A notice of each meeting specifying the place, date and time,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">
shall be sent to each director at the address appearing in the registers of the Corporation. Notice shall be sent no less than two (2)&nbsp;days prior to the date fixed for the meeting by any
means of delivery authorized by law. In the absence of an address for a director, the notice may be sent to the address at which the sender considers that the notice is most likely to reach the director promptly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">In any case where the convening of a meeting is considered by the Chair of the Board of Directors, if any, the President of the Corporation or a group
of two (2)&nbsp;directors, to be a matter of urgency, he/she may cause notice to be given of a meeting of the Board of Directors by telephone, e-mail, fax or any other mode of transmission, not less than three (3)&nbsp;hours before such meeting is
to be held and such notice shall be adequate for the meeting so convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">A meeting of the Board of Directors shall be held after each annual
meeting of shareholders to appoint the chair of the Board of Directors, create any committee of the Board of Directors, if need be, appoint any member thereon, appoint the officers of the Corporation and to consider any other matter it deems
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">31.&#8195;&#8195; <U>Quorum</U>. A majority of the directors in office, although no less than three (3), shall constitute a quorum for
a meeting of the Board of Directors. A quorum shall be present for the entire duration of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">32.&#8195;&#8195; <U>Meeting Chair and
Secretary</U>. Meetings of the Board of Directors shall be chaired by the Chair of the Board of Directors, if any, or, failing him/her, by any other director designated for such purpose by the directors by a majority of the votes cast. The Corporate
Secretary of the Corporation shall act as secretary of the meetings. The directors present at a meeting may nevertheless appoint any other person to act as secretary of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">33.&#8195;&#8195; <U>Procedure</U>. The chair of the meeting ensures that the meeting is conducted smoothly and submits to the Board the motions on
which a vote is to be taken and generally conducts the procedure thereat in all respects, in which regard his/her decision shall be final and binding on all the directors. Should the chair of the meeting fail to submit a motion, any director may
submit the motion himself/herself before the meeting is adjourned or closed and, if such motion lies within the competence of the Board of Directors, the Board of Directors shall consider it. Should the chair of the meeting fail to carry out his/her
duties loyally, the directors may remove him/her as chair of that meeting at any time and replace him/her by another director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">34.&#8195;&#8195;
<U>Voting</U>. Each director shall be entitled to one vote, and all matters shall be decided by the majority of the votes cast. The vote shall be taken by voice vote or by a show of hands unless the chair of the meeting or a director requests a
secret ballot, in which case the vote shall be taken by ballot. If the vote is taken by ballot, the secretary of the meeting shall act as scrutineer and count the ballots, which shall not in as much deprive him/her of his/her right to vote as a
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">
director, if such is the case. The fact of having voted by ballot shall not deprive a director of the right to express his/her dissent in respect of the resolution concerned and to cause such
dissent to be recorded. Voting by proxy shall not be permitted, and the Chair shall have no casting vote in the case of a tie vote. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>COMMITTEES
OF THE BOARD OF DIRECTORS </U></B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">35.&#8195;&#8195; <U>Committees</U>. The Board of Directors may create any committee it deems appropriate, which
may or may not be made up of members of the Board of Directors. Any such committee shall have the power vested in it by the Board of Directors. Unless the Board of Directors directs otherwise, each committee shall have the authority to set its own
quorum to elect its own chair and to determine its own governance procedures. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>OFFICERS </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">36.&#8195;&#8195; <U>Officers</U>. The Board of Directors may, by means of resolution, appoint any officer or other mandatary it may deem appropriate
and determine their title, duties and powers. With the exception of the Chair of the Board of Directors who must be a director, no other officer need be a director or shareholder of the Corporation. Any such officer or mandatary may be removed at
any time by the Board of Directors, or may resign at any time upon notice to the Corporation. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>IDEMNIFICATION AND EXEMPTION </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">37.&#8195;&#8195; <U>Indemnification and Reimbursement of Expenses</U>. The Corporation is required to indemnify a person who acts or has acted as
director, officer or other mandatary of the Corporation (hereafter the &#147;Indemnified&#148;) for any prejudice suffered by reason or in respect of the performance of such duties with the Corporation and shall also reimburse him for reasonable
expenses incurred for the same purposes, in each case in accordance with the provisions set out hereinbelow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">38.&#8195;&#8195; <U>Defense &#150;
Prosecution by Third Party</U>. The Corporation shall assume the defense of the Indemnified prosecuted by a third party for an act performed in the exercise of his/her duties and shall pay damages, if any, resulting from that act, unless it is due
to a gross fault or intentional fault on his/her part that does not fall within the exercise of his/her duties. In particular, such an offence shall include the violation, by the Indemnified, of his/her duties of loyalty and honesty toward the
Corporation, especially if he/she should place himself/herself in a situation of conflict of interest. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">Such assumption of defence shall involve the payment or reimbursement of reasonable judicial and
extra-judicial costs incurred by the Indemnified who is prosecuted by a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">The payment of damages shall include the amounts paid to
settle an action out of court and any fine imposed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">39.&#8195;&#8195; <U>Expenses &#150; Penal Proceedings</U>. However, in a penal or criminal
proceeding, the Corporation shall assume the payment of the expenses of the Indemnified only if he/she had reasonable grounds to believe that his/her conduct was in compliance with the law, or if he/she has been released or acquitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">40.&#8195;&#8195; <U>Prosecution by the Corporation</U>. If the Corporation prosecutes a director, officer or other mandatary for an act or omission in
the performance of his duties, it shall undertake to assume the reasonable judicial and extra-judicial costs reasonably incurred by such director, officer or mandatary, if it loses its case and the court so decides. If the Corporation wins its case
only in part, the court may determine the amount of the expenses it shall assume. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">41.&#8195;&#8195; <U>Director of Another Corporation</U>. The
Corporation shall indemnify, in the manner set out in sections 44 to 47 hereinabove, any person who acts at its request as a director for another legal person of which it is a shareholder or creditor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">42.&#8195;&#8195; <U>Liability Insurance</U>. The Corporation may purchase and maintain for the benefit of its directors, officers and other
mandataries, previous and actual, as well as their heirs, legatees and assigns, insurance covering their personal liability by reason of the fact that they perform such duties or act as directors of a legal person of which the Corporation is a
shareholder or creditor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">43.&#8195;&#8195; <U>Reimbursement of Expenses</U>. Subject to a contractual agreement specifying or restricting this
obligation, the Corporation is required to reimburse a director, an officer or other mandatary for reasonable and necessary expenses incurred by him/her in the exercise of his/her duties, plus interest from the date on which such expenses were paid
by him/her. Such reimbursement shall be made upon presentation of all relevant vouchers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>CAPITAL STOCK </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">44.&#8195;&#8195; <U>Share Certificates and Share Transfers</U>. Certificates representing the shares of the capital stock of the Corporation shall bear
the signature of the President or a Vice-President and that of the Corporate Secretary or an Assistant Secretary. Any certificate bearing a signature of an authorized officer shall be deemed valid, notwithstanding the fact that the signatory has
since ceased to hold such office within the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">45.&#8195;&#8195; <U>Record Date and Closing of Books</U>. The Board of Directors may fix a date
preceding by no more than thirty (30)&nbsp;days the date of payment of a dividend, an allocation of rights or any other form of distribution as the record date for determining the shareholders entitled to such dividend, right or distribution; hence,
only shareholders of record on the date so fixed shall be entitled thereto, notwithstanding any transfer of shares recorded in the registers of the Corporation between the record date and the date on which the dividend is paid, the rights allocated
or the distribution made. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">46.&#8195;&#8195; <U>Transfer Agents</U>. The Board of Directors may appoint or remove transfer agents
or registrars and make by-laws regarding share transfers and the registration of shares. Any certificate&#8195;of shares issued following such appointment shall, on pain of invalidity, be countersigned by one of the agents or registrars. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>DIVIDENDS </U></B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">47.&#8195;&#8195;
<U>Dividends</U>. The Board of Directors may, periodically and in compliance with the law, declare and pay dividends to the shareholders, in accordance with their respective rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">The Board of Directors may stipulate that a dividend be payable, in whole or in part, in Corporation stock or property. For such purpose, it may
authorize the issuance of shares of the capital stock of the Corporation as fully paid up or, with the consent of the beneficiaries of such dividend, as partially paid up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">When two or more persons are registered as joint holders of one share, each of them may give a valid receipt for any dividend payable or paid on such
share. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>FISCAL YEAR </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">48.&#8195;&#8195;<U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>CORPORATION REPRESENTATION FOR CERTAIN PURPOSES </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">49.&#8195;&#8195; <U>Declaration</U>. The President and Chief Executive Officer, the Chair of the Board of Directors, any Vice-President or the
Corporate Secretary and each of them or, any other person named by them, shall be authorized and eligible to make answer for the Corporation to all writs, orders or interrogatories upon articulated facts issued by any court and to declare for and on
behalf of the Corporation any answer to writs of attachment by way of garnishment in which the Corporation is garnishee and to make all affidavits and sworn declarations in connection therewith or any and all judicial proceedings to which the
Corporation is a party and to make demands for assignment of property or petition for winding-up or receivership orders upon any debtor of the Corporation and to attend and vote at all meetings of creditors of the Corporation&#146;s debtors and
grant proxies in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">50.&#8195;&#8195; <U>Representation at Meetings</U>. The President and Chief Executive Officer, the Chair of
the Board of Directors, any Vice-President and the Corporate Secretary, and each of them, or any other person named by them, shall represent the Corporation and attend and vote at any and all meetings of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">
shareholders or members of any firm, corporation, legal person, or syndicate in which the Corporation holds shares or is otherwise interested, and any measure taken or vote cast by them shall be
deemed to be the act or vote of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">51.&#8195;&#8195; <U>Signature of Documents</U>. Contracts, documents, written acts, including
releases and discharges, requiring the signature of the Corporation may be validly signed by any director or any officer of the Corporation as well as by any person authorized to sign for and on behalf of the Corporation pursuant to a resolution of
the Board of Directors or any policy adopted by the Corporation from time to time that addresses the execution of documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">52.&#8195;&#8195;
<U>Declarations in the Register</U>. Any director who ceased to hold such office as a result of his/her resignation, removal or for any other reason shall be authorized to sign on behalf of the Corporation and file with the enterprise registrar an
amending declaration under the <I>Act respecting the legal publicity of enterprises </I>(Quebec) to remove his/her name from the information appearing under the Corporation&#146;s filing on the enterprise register, unless he/she receives evidence
that the Corporation has filed such declaration. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">53.&#8195;&#8195; <U>Repeal</U>. On the effective date of this General By-Laws, the by-laws then in existence shall be repealed. This repeal shall not
affect any past application of the former general by-laws, nor the validity of steps taken, resolutions adopted, rights granted or general by-laws made prior to the said repeal. Any contract entered into or commitment made under the former general
by-laws shall also remain valid. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.3
<SEQUENCE>3
<FILENAME>d680117dex13.htm
<DESCRIPTION>EX-1.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 1.3</U> </B></P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(the &#147;Corporation&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BY-LAW</FONT> NO. 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ADVANCE NOTICE <FONT STYLE="white-space:nowrap">BY-LAW</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Introduction</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The
Corporation is committed to (i)&nbsp;facilitating an orderly and efficient process for holding annual general meetings and, when the need arises, special meetings of its shareholders; (ii)&nbsp;ensuring that all shareholders receive adequate advance
notice of the director nominations and sufficient information regarding all director nominees; and (iii)&nbsp;allowing shareholders to register an informed vote for directors of the Corporation after having been afforded reasonable time for
appropriate deliberation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Objectives </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The purpose of this advance notice <FONT STYLE="white-space:nowrap">by-law</FONT> (the
&#147;<B><FONT STYLE="white-space:nowrap">By-Law</FONT></B>&#148;) is to provide shareholders, directors and management of the Corporation with a clear framework for nominating directors of the Corporation. This
<FONT STYLE="white-space:nowrap">By-Law</FONT> fixes a deadline by which director nominations must be submitted by a shareholder to the Corporation prior to any annual or special meeting of shareholders, and sets forth the information that a
shareholder must include in the notice to the Corporation for the notice to be in proper written form in order for any director nominee to be eligible for election at any annual or special meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">It is the position of the Corporation that this <FONT STYLE="white-space:nowrap">By-Law</FONT> is in the best interest of the Corporation, its
shareholders and other stakeholders. This <FONT STYLE="white-space:nowrap">By-Law</FONT> may be subject to annual review at the discretion of the board of directors of the Corporation (the &#147;<B>Board</B>&#148;), and will reflect changes as
required by Applicable Securities Laws (as defined below) or stock exchanges policies, or so as to meet industry standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Interpretation </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In
this By-Law, unless the context otherwise requires: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;Act&#148; </B>means the Business Corporations Act
(Qu&eacute;bec), including the regulations under the Act, as amended form time to time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;Applicable Securities
Laws&#148; </B>means the applicable securities legislation of each relevant province and territory of Canada, as amended from time to time, the rules, regulations and forms made or promulgated under any such legislation and the published national
instruments, multilateral instruments, policies, bulletins and notices of the securities commission and similar regulatory authority of each province and territory of Canada; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;Business Day&#148; </B>means any day excluding Saturday and Sunday or any other day which in Montr&eacute;al,
Qu&eacute;bec, is a legal holiday; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;public announcement&#148; </B>means disclosure in a press release
reported by a national news service in Canada, or in a document publicly filed by the Corporation under its profile on the System of Electronic Document Analysis and Retrieval at www.sedar.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Nomination of Directors </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Nomination Procedures</U>. Subject only to the Act and the articles of the Corporation, only persons who
are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation. Nominations of persons for election to the Board may be made at any annual meeting of shareholders, or at any special meeting
of shareholders, if one of the purposes for which the special meeting was called is the election of directors. Such nominations may be made: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">by or at the direction of the Board, including pursuant to a notice of meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">by or at the direction or request of one or more shareholders pursuant to a proposal or a requisition made
in accordance with the provisions of the Act; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">by any person (a &#147;<B>Nominating Shareholder</B>&#148;): (A) who, at the close of business on the date
of the giving of the notice provided for below in this <FONT STYLE="white-space:nowrap">By-Law</FONT> and on the record date for notice of such meeting, is entered in the securities register as a holder of one or more shares carrying the right to
vote at such meeting or who beneficially owns shares that are entitled to be voted at such meeting; and (B)&nbsp;who complies with the notice procedures set forth below in this <FONT STYLE="white-space:nowrap">By-Law.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Timely Notice</U>. In addition to any other applicable requirements, for a nomination to be made by a
Nominating Shareholder, the Nominating Shareholder must have given timely notice thereof in proper written form to the Corporate Secretary of the Corporation at the head office of the Corporation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Timeliness</U>. To be timely, a Nominating Shareholder&#146;s notice to the Corporate Secretary of the
Corporation must be made: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">in the case of an annual meeting of shareholders, not less than thirty (30)&nbsp;days prior to the date of
the annual meeting of shareholders; provided, however, that in the event that the annual meeting of shareholders is to be held on a date that is less than fifty (50)&nbsp;days after the date (the &#147;<B>Notice Date</B>&#148;) on which the first
public announcement of the date of the meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day following the Notice Date;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">in the case of a special meeting (which is not also an annual meeting) of shareholders called for the
purpose of electing directors (whether or not called for other purposes), not later than the close of business on the fifteenth (15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day following the date on which the first public announcement
of the date of the meeting was made. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Proper Form of Timely Notice</U>. To be in proper written form, a Nominating Shareholder&#146;s notice to
the Corporate Secretary of the Corporation must set forth: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">as to each person (a &#147;<B>Proposed Nominee</B>&#148;) whom the Nominating Shareholder proposes to
nominate for election as a director: (A)&nbsp;the name, age, business address and residential address of the Proposed Nominee; (B)&nbsp;the principal occupation or employment of the Proposed Nominee; (C)&nbsp;the class or series and number of shares
in the capital of the Corporation which are controlled or which are owned beneficially or of record by the Proposed Nominee as of the record date for the meeting of shareholders (if such date shall then have been made publicly available and shall
have occurred) and as of the date of such notice; and (D)&nbsp;any other information relating to the Proposed Nominee that would be required to be disclosed in a dissident&#146;s proxy circular in connection with solicitations of proxies for
election of directors pursuant to the Act and Applicable Securities Laws; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">as to the Nominating Shareholder giving the notice: (A)&nbsp;the name and address of the Nominating
Shareholder and (B)&nbsp;any proxy, contract, arrangement, understanding or relationship pursuant to which such Nominating Shareholder has a right to vote any shares of the Corporation and any other information relating to such Nominating
Shareholder that would be required to be made in a dissident&#146;s proxy circular in connection with solicitations of proxies for election of directors pursuant to the Act and Applicable Securities Laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Corporation may require any Proposed Nominee to furnish such other information, including a written consent to act, as
may reasonably be required by the Corporation to determine the eligibility of such Proposed Nominee to serve as an independent director of the Corporation or that could be material to a reasonable shareholder&#146;s understanding of the
independence, or lack thereof, of such Proposed Nominee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Eligibility</U>. No person shall be eligible for election as a director of the Corporation unless
nominated in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-Law;</FONT> provided, however, that nothing in this <FONT STYLE="white-space:nowrap">By-Law</FONT> shall be deemed to preclude discussion by a shareholder (as
distinct from the nomination of directors) at a meeting of shareholders of any matter in respect of which it would have been entitled to submit a proposal pursuant to the provisions of the Act. The Chair of the meeting shall have the power and duty
to determine whether a nomination was made in accordance with the procedures set forth in the foregoing provisions and, if any proposed nomination is not in compliance with such foregoing provisions, to declare that such defective nomination shall
be disregarded. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Delivery of Notice</U>. Notwithstanding any other provision of this
<FONT STYLE="white-space:nowrap">By-Law,</FONT> notice given to the Corporate Secretary of the Corporation pursuant to this <FONT STYLE="white-space:nowrap">By-Law</FONT> may only be given by personal delivery, facsimile transmission or by email (at
such email address as stipulated from time to time by the Corporate Secretary of the Corporation for purposes of this notice), and shall be deemed to have been given and made only at the time it is served by personal
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">delivery, email (at the aforesaid address) or sent by facsimile transmission (provided that receipt of
confirmation of such transmission has been received) to the Corporate Secretary at the address of the head office of the Corporation; provided that if such delivery, transmission or electronic communication is made on a day which is a not a Business
Day or later than 5:00 p.m. (Eastern time) on a day which is a Business Day, then such delivery, transmission or electronic communication shall be deemed to have been made on the subsequent day that is a Business Day. </P></TD></TR></TABLE>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Board Discretion</U>. Notwithstanding the foregoing, the Board may, in its sole discretion, waive any
requirement of this <FONT STYLE="white-space:nowrap">By-Law.</FONT><B> </B> </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>4
<FILENAME>d680117dex22.htm
<DESCRIPTION>EX-2.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="right"><B><U>Exhibit 2.2 </U></B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:1%" ALIGN="center">


<IMG SRC="g680117g0213234749910.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B><U>S<SMALL>HARE</SMALL>
O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></U><SMALL></SMALL> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center">E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> : M<SMALL>AY</SMALL>&nbsp;9, 2023 </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">PURPOSE OF THE PLAN </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Share Option Plan (the &#147;<B>Plan</B>&#148;) is intended to attract, retain and motivate individuals to the success of Theratechnologies Inc., on
a consolidated basis (the &#147;<B>Corporation</B>&#148;), to align those individuals&#146; interests with those of the Corporation&#146;s shareholders and to allow these individuals to participate in the increased value of the Corporation&#146;s
common shares (the &#147;<B>Common Shares</B>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">CATEGORY AND NUMBER OF SHARES RESERVED UNDER THE PLAN </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Common Shares are the shares of the share capital of the Corporation that are reserved for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The maximum number of Common Shares that may be issued under this Plan, together with any other security-based compensation arrangements of the
Corporation, as defined in the Toronto Stock Exchange Company Manual, (the &#147;<B>Security-Based Compensation Arrangements</B>&#148;), shall not exceed 17%<B> </B>of the issued and outstanding Common Shares, as calculated on the date of grant (the
&#147;<B>Grant Date</B>&#148;) of each option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Upon the exercise of options or the expiry, cancellation or forfeiture, in whole or in part, of
unexercised options, the Common Shares underlying such exercised, expired, cancelled or forfeited options shall be available for future option grants under the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">ADMINISTRATION </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Board of Directors of the Corporation (the &#147;<B>Board</B>&#148;) administers the Plan, provided that, the Board may from time to time solicit
and/or accept recommendations regarding the Plan from the Compensation Committee of the Board. Subject to the terms of the Plan, the Board shall have full power and authority to (i)&nbsp;designate the persons who are to receive options under the
Plan, (ii)&nbsp;determine the number of options granted, (iii)&nbsp;establish the exercise price of such options, (iv)&nbsp;determine the term of the options, and (v)&nbsp;establish any other condition relative to such options. The Board shall have
the right to vary the terms upon which options are granted to particular optionees, provided such different terms do not increase the benefits accruing to such optionees hereunder. Any decision made by the Board regarding the Plan shall be final and
conclusive. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> administration of the Plan may be delegated to such officers and employees of the Corporation or of any subsidiary of the Corporation as the
Board in its sole discretion shall determine. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">TERMS AND CONDITIONS </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Persons Eligible to Receive Options</U>. The persons eligible to receive options under the Plan are directors,
senior executives and key employees of the Corporation and those of its subsidiaries, as well as consultants who work on behalf of the Corporation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Number of Options</U>. Each option will entitle the optionee to purchase one Common Share. The total number of
options granted to an optionee is determined by the Board, at its sole discretion, except for the following: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the total number of Common Shares set aside for the exercise of options under the Plan for any one individual shall
not represent, in any circumstances, more than 5% of the Corporation&#146;s issued and outstanding Common Shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 1</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the total number of Common Shares that may be issued to insiders, as defined in the <I>Securities Act </I>(Ontario)
(the &#147;<B>Insiders</B>&#148;), at any time, under the Plan together with all other Security-Based Compensation Arrangements, cannot exceed 17% of the issued and outstanding Common Shares (&#147;<B>Shares Outstanding</B>&#148;);<B> </B>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the total number of Common Shares issued to Insiders, within any <FONT STYLE="white-space:nowrap">one-year</FONT>
period, under the Plan together with all other Security-Based Compensation Arrangements, cannot exceed 17% of the Shares Outstanding; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the total number of Common Shares set aside for the exercise of options under the Plan to each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, within any <FONT STYLE="white-space:nowrap">one-year</FONT> period, cannot exceed a value of $100,000, calculated on the Grant Date, and an aggregate value of $150,000 under all Security-Based
Compensation Arrangements, including the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Exercise Price</U>. The price at which Common Shares may be purchased under the Plan is determined by the Board on
the relevant Grant Date; provided however, that such price may not be less than the market price of the Common Shares (the &#147;<B>Exercise Price</B>). For the purpose hereof, &#147;market price&#148; shall mean: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">for options granted to Canadian and <FONT STYLE="white-space:nowrap">non-US</FONT> resident optionees, the closing
price of the Common Shares on the Toronto Stock Exchange (&#147;<B>TSX</B>&#148;) on the last trading day immediately preceding the relevant Grant Date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">for options granted to U.S. resident optionees, the closing price of the Common Shares on the U.S. NASDAQ stock market
(&#147;<B>NASDAQ</B>&#148;) on the last trading day immediately preceding the relevant Grant Date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if there was no closing price for the Common Shares on the TSX or NASDAQ, then the market price shall be the closing
price of the Common Shares on the stock exchange on which there was a closing price on the last trading day immediately preceding the relevant Grant Date, applying the exchange rate published by Bloomberg on the last trading day preceding the
relevant Grant Date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if there is no closing price on the TSX and NASDAQ, on the last trading day immediately preceding the relevant Grant
Date, then the market price shall (i)&nbsp;for Canadian and <FONT STYLE="white-space:nowrap">non-US</FONT> resident optionees, be the last closing price of the Common Shares on the TSX (or if earlier, the NASDAQ, applying the applicable exchange
rate as set forth above) prior to the Grant Date, and (ii)&nbsp;for US resident optionees, the last closing price of the Common Shares on the NASDAQ (or if earlier, the TSX, applying the applicable exchange rate as set forth above) prior to the
Grant Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If the Common Shares are not publicly traded as of the relevant Grant Date, the fair market value of one Common Share,
as determined by the Board, in its sole discretion, by applying principles of valuation with respect thereto (and with respect to US residents, in accordance with Section&nbsp;409A of the US Internal Revenue Code). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Conditions</U>. The Board may subject the exercise of the options to certain conditions which it will determine, at
its sole discretion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Option Period</U>. The optionee may exercise an option at any time starting on the date it becomes vested until the
tenth anniversary of the Grant Date or during any other shorter period determined at the discretion of the Board on the Grant Date (the &#147;<B>Option Period</B>&#148;). All unexercised options expire, and have no effect, after the end of the
Option Period (the &#147;<B>Expiry Date</B>&#148;), except in the circumstances where the end of the Option Period falls during, or within ten business days after the end of, a &#147;blackout&#148; or similar period imposed under applicable laws or
under any insider trading policy or similar policy of the Corporation (the &#147;<B>Blackout Period</B>&#148;) (but not, for greater certainty, a restrictive period resulting from the Corporation or its Insiders being the subject of a cease trade
order of a securities regulatory authority). Where the end of the Option Period falls during, or within ten business days after the end of a Blackout Period, the Option Period shall automatically be extended to end on the tenth (10th) business day
after the end of such Blackout Period. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Vesting</U>. Unless otherwise determined by the Board at its sole discretion, all options granted to an optionee
under this Plan will vest as to 1/3 on each of the first, second and third anniversaries of their Grant Date, subject to the provisions of Sections 4.9 to 4.12. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Methods of Payment</U>. The optionee may, during the Option Period, elect to exercise any or all of the options
then granted and not previously exercised by delivering to the Corporation payment in full of the Exercise Price (in the applicable currency) accompanied by a completed purchase form, substantially in the form provided in Schedule A hereto (the
&#147;<B>Purchase Form</B>&#148;). Payment of the Exercise Price may be made by cash, cheque, certified cheque, cheque from a recognized brokerage firm, bank draft or money order payable to the Corporation, or any other method of payment approved by
the Board. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Cashless Exercise</U>. Pursuant to the Purchase Form and subject to the approval of the Board, an optionee may
choose to undertake a &#147;cashless exercise&#148; with the assistance of a broker in order to facilitate the exercise of such optionee&#146;s Options. The &#147;cashless exercise&#148; procedure may include a sale of such number of Common Shares
as is necessary to raise an amount equal to the aggregate Exercise Price for all Options being exercised by that optionee. Pursuant to the Purchase Form, the optionee may authorize the broker to sell Common Shares on the open market by means of a
short sale and forward the proceeds of such short sale to the Corporation to satisfy the Exercise Price, promptly following which the Corporation shall issue the Common Shares underlying the number of Options as provided for in the Purchase Form. A
short sale of Common Shares effected for the purpose of the foregoing cashless exercise feature shall be permissible as an exception to applicable restrictions regarding short sales contained in the Corporation&#146;s insider trading policy or
similar policies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Termination of an Optionee&#146;s Employment</U>. If the optionee (other than a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director) ceases to be an employee or consultant, as the case may be, other than for Cause (as defined below) or for death prior to the Expiry Date (a &#147;<B>Termination of
Employment</B>&#148;), the optionee may exercise any or all of the unexercised vested options as at the Date of the Termination of Employment (as defined below) at any time until the earlier of (i)&nbsp;twelve (12) months following the Date of the
Termination of Employment, and (ii)&nbsp;the Expiry Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For the purposes of the Plan, the transfer of an optionee to another position within
the Corporation or a subsidiary thereof, or from the position of employee of the Corporation to a consultant of the Corporation shall not be considered a Termination of Employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For the purposes of the Plan, the &#147;<B>Date of the Termination of Employment</B>&#148; shall mean the date on which an optionee
ceases to be an employee or consultant eligible to participate in the Plan as a result of a termination of employment or engagement with the Corporation or one of its subsidiaries for any reason, whether lawful or unlawful, including death,
retirement, disability, resignation, or termination with or without Cause. For the purposes of the Plan, an optionee&#146;s employment with the Corporation or one of its subsidiaries shall be considered to have terminated effective on the last day
of the optionee&#146;s actual and active employment with the Corporation or one of its subsidiaries, whether such day is selected by agreement with the individual, or unilaterally by the optionee or the Corporation or one of its subsidiaries, and
whether with or without advance notice. Without limiting the generality of the foregoing and subject to applicable law, no period of <FONT STYLE="white-space:nowrap">non-working</FONT> notice or payment in lieu of such notice that follows the
optionee&#146;s last day of actual and active employment shall be deemed to extend the optionee&#146;s period of employment for the purpose of determining his or her rights or entitlements under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For the purposes of the Plan, &#147;<B>Cause</B>&#148; shall include, among other things, &#147;serious reason&#148; (as defined in the
<I>Civil Code of Qu&eacute;bec</I>), dishonest acts such as gross misconduct, theft, fraud, embezzlement, misappropriation, breach of confidentiality, breach of loyalty or breach of duty of loyalty or placement in conflict of interest, or breach of
the Corporation&#146;s Code of Ethics or policies regarding insider trading and tipping, and any other reason determined by the Corporation to be cause for termination in accordance with applicable law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Ceasing to Act as Director</U>. If a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director ceases to be a director of the Corporation, other than for Cause or death prior to the Expiry Date, such <FONT STYLE="white-space:nowrap">non-employee</FONT> director may exercise any or all
unexercised options which are vested on the date he/she ceased to act as a director of the Corporation at any time until the earlier of (i)&nbsp;twelve (12) months following the date such director ceased to hold office, and (ii)&nbsp;the Expiry
Date.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Rights in the Event of an Optionee&#146;s Cessation for Cause</U>. In the event an optionee ceases to be a
director, employee or consultant, as the case may be, for Cause, unless otherwise determined by the Board, at its sole discretion, all unexercised options, whether vested or unvested, shall be forfeited, cancelled and terminated as of the Date of
the Termination of Employment or, in the case of a director, the date he or she ceases to hold office. In addition, an optionee discharged for Cause will forfeit any compensation, gain or other value realized on the vesting, exercise or settlement
of options since the date of first occurrence of the event(s), action(s) or fact(s) that gave rise to the termination for Cause or the sale or other transfer of Common Shares acquired in respect of such options, and must promptly repay such amounts
to the Corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Rights in the Event of an Optionee&#146;s Death</U>. In the event an optionee ceases to be a director, employee or
consultant, as the case may be, as a result of death, such optionee&#146;s legal personal representative(s) may exercise any or all unexercised options which are vested on the date of the optionee&#146;s death at any time until the earlier of
(i)&nbsp;twelve (12) months following the optionee&#146;s death, and (ii)&nbsp;the Expiry Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>No Employment Guaranty</U>. Nothing in the Plan shall confer upon the optionee the continued right to be employed
by the Corporation or its subsidiaries or the right to provide services to the Corporation or interfere in any way with the right of the Corporation or its subsidiaries to terminate an optionee&#146;s employment or agreement at any time and for any
reason. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>No Shareholder Rights</U>. An optionee shall have no rights as a shareholder with respect to the Common Shares
underlying such optionee&#146;s options until the date such Common Shares are issued to the optionee as fully <FONT STYLE="white-space:nowrap">paid-up</FONT> Common Shares following the exercise by the optionee of such options.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Transfer and Assignment</U>. The optionee&#146;s rights with respect to the options granted under the Plan may not
be assigned or transferred by the optionee or be subject to any form of alienation, sale, pledge, hypothec or other encumbrance. The foregoing prohibition does not prevent an optionee to transfer his/her rights to such optionee&#146;s legal personal
representative(s) by will or by law or if a court order is issued ordering the transfer of such rights to a third party. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Vested options are exercisable only by the optionee or, upon such optionee&#146;s death or incapacity, the legal representative of the
optionee&#146;s estate or having authority to deal with the property of the optionee, as applicable. The obligations of each optionee shall be binding on his/her heirs and executors. Moreover, with the Corporation&#146;s prior written approval and
subject to such conditions as the Corporation may stipulate, options may also be exercised by an optionee&#146;s retirement savings trust or any registered retirement savings plans or registered retirement income funds of which the optionee is and
remains the annuitant. In all circumstances, no exercise shall be allowed until the Corporation receives satisfactory evidence of entitlement to exercise any option, and a person exercising an option may purchase Common Shares only in the
person&#146;s own name or in the person&#146;s capacity as legal representative. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Compliance with Applicable Securities and Other Laws</U>. Options may be exercised only to the extent that the
Corporation has obtained the necessary approvals under applicable securities and other laws governing the issue and sale by the Corporation of its Common Shares to optionees. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Tax Withholding</U>. The Corporation shall have the right and power to require an optionee to remit in cash to the
Corporation promptly upon notification of the amount due, an amount to satisfy the minimum federal, state or local or foreign taxes or other obligations required by law to be withheld with respect thereto with respect to any option under this Plan.
No Common Shares shall be issued upon an exercise of an option unless and until arrangements satisfactory to the Board shall have been made to satisfy the statutory minimum withholding tax obligations applicable with respect to such exercise. The
Corporation may defer issuance or delivery of Common Shares until such requirements are satisfied. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">ADJUSTMENTS </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Subject to any regulatory approval or notification required by applicable law or stock exchange guidelines, upon the happening of any of the following
events, an optionee&#146;s rights with respect to an option granted under the Plan shall be adjusted as hereinafter provided: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Subdivision, Redivision or Change into a Greater Number</U>. In the event of any subdivision, redivision or change
of the Common Shares into a greater number of shares at any time, or in the case of the issue of shares of the Corporation to the holders of its outstanding Common Shares by way of a share dividend or share dividends, the number of Common Shares
deliverable by the Corporation upon the exercise of an option shall be increased proportionately, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, redivision or change. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Consolidation or Change into a Lesser Number</U>. In the event of any consolidation or change of the Common Shares
into a lesser number of shares at any time, the number of Common Shares deliverable by the Corporation upon the exercise of an option shall be decreased proportionately, and appropriate adjustments shall be made in the purchase price per share to
reflect such consolidation or change. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Reclassification</U>. In the event of any reclassification of the Common Shares, an optionee shall accept, at the
time of the exercise of options, in lieu of the number of Common Shares in respect of which the options are being exercised, the number of shares of the Corporation of the appropriate class or classes as the optionee would have been entitled as a
result of such reclassification had the options been exercised before such reclassification. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Amalgamation, Acquisition by an Entity, Sale of Assets</U>. Subject to Subsection 5.5, if the Corporation is to be
amalgamated with or acquired by another entity in a merger, arrangement, sale of all or substantially all of its assets or other similar transaction (an &#147;<B>Acquisition</B>&#148;), the Board shall, as to outstanding options, either:
(i)&nbsp;make appropriate provisions for the continuation of such options by substituting on an equitable basis for the shares then subject to such options the consideration payable with respect to the outstanding Common Shares in conjunction with
the Acquisition; or (ii)&nbsp;upon written notice to the optionees, provide that all options must be exercised, to the extent they are then exercisable, within a specified number of days of the date of such notice, at the end of which period the
options shall terminate; or (iii)&nbsp;terminate all options in exchange for a cash payment equal to the excess of the fair market value of the shares subject to such options (to the extent they are then exercisable) over the Exercise Price thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Offer to Purchase</U>. Notwithstanding Subsection 5.4 hereof, if an offer to purchase all of the outstanding Common
Shares is made, all options which are not vested shall, from the date of the offer, be exercisable notwithstanding any provision to the contrary at the time of the grant. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Dissolution or Liquidation</U>. In the event of the proposed dissolution or liquidation of the Corporation, all
options will terminate immediately prior to the consummation of such proposed action or at such other time and subject to such other conditions as shall be determined by the Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>No Adjustments</U>. Except as expressly provided herein, no issue by the Corporation of shares of any class, or
securities convertible into shares of any class, shall affect the number or Exercise Price of the Common Shares underlying the options and no modification shall be made with respect to the number or Exercise Price of the Common Shares underlying the
options under the Plan. No adjustments shall be made for dividends paid in cash or in property other than securities of the Corporation or its subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>No Fraction</U>. No fractional shares shall be issued under the Plan and the optionee shall receive from the
Corporation cash in lieu of such fractional shares. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Appropriate Adjustments</U>. Upon the occurrence of any of the foregoing events described in Subsections 5.1, 5.2,
5.3 and 5.4 above, the class and aggregate number of shares set forth in Section&nbsp;2 underlying the options which previously have been or subsequently may be granted under the Plan shall also be appropriately adjusted to reflect the events
described in such subsections. The Board or the successor Board shall determine the specific adjustments to be made under this Section&nbsp;5 and its determination shall be conclusive. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">AMENDMENT AND TERMINATION </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to Section&nbsp;6.3, the Board may amend, suspend or terminate the Plan, or any outstanding option, or any
portion of the Plan or of an option, at any time, and may do so without shareholder approval, subject to those provisions of applicable law, if any, that require the approval of shareholders or any governmental or regulatory body. Without limiting
the generality of the foregoing, the Board may make the following types of amendments to the Plan and options without seeking shareholder approval: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">amendments of a &#147;housekeeping&#148; or ministerial nature including, without limiting the generality of the
foregoing, any amendment for the purpose of curing any ambiguity, error or omission in the Plan or to correct or supplement any provision of the Plan that is inconsistent with any other provision of the Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">amendments necessary to comply with the provisions of applicable law (including, without limitation, the rules,
regulations and policies of the TSX and/or NASDAQ); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">amendments necessary in order for options to qualify for favourable treatment under applicable taxation laws;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">amendments respecting administration of the Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any amendment to the vesting provisions of the Plan or any option, it being understood that in the event of the
amendment to the vesting provisions of an option, the Board shall not be under any obligation to amend the vesting provisions of any other option; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any amendment which reduces the Exercise Price of an option held by an optionee who is not an Insider of the
Corporation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 7</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any amendment to the early termination provisions of the Plan or any option, whether or not such option is held by an
Insider, provided such amendment does not entail an extension beyond the original expiry date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the addition or modification of a cashless exercise feature, payable in cash or Common Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">amendments necessary to suspend or terminate the Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any other amendment, whether fundamental or otherwise, not requiring shareholder approval under applicable law or the
Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything contained to the contrary in this Plan or in any resolution of the Board implementing the
Plan or granting options under the Plan: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">in the event there occurs a transaction contemplated under Subsection 5.4 or 5.6 of the Plan, the Board shall have the
right, upon written notice to each optionee, to determine, in the Board&#146;s sole discretion, that all options held by such optionees may be exercised within a specified number of days of the date of such notice, and that upon the expiry of such
period, all rights of optionees to options under this Plan or to exercise same (to the extent not theretofore exercised) shall terminate and that all such options shall cease to have further force or effect whatsoever; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the Board may, by resolution, but subject to applicable regulatory requirements, decide that any of the provisions
hereof concerning the effect of termination of an optionee&#146;s employment for any reason, including death, shall not apply for any reason acceptable to the Board. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Except as expressly set forth herein, no action of the Board or shareholders shall alter or impair the rights of an optionee without the
consent of the affected optionee, under any option previously granted to such optionee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Approval by a majority of the voting shareholders present at a duly called shareholder meeting is required for the
following amendments: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any increase to the maximum number of Common Shares that may be issued under the Plan, including an increase to a
fixed maximum percentage of Common Shares or a change from a fixed maximum percentage of Common Shares to a fixed maximum number; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the reduction of the Exercise Price of options for Insiders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the cancellation and reissue of options to the same individual; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the extension of the Option Period of options; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any transfer and assignment of options other than pursuant to Subsection 4.15; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the removal or increase of limits to the number of options that may be granted to Insiders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 8</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the removal or increase of limits to the number of options that may be granted to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any amendment to this Section&nbsp;6. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">No amendment of the Plan or options may contravene the requirements of any competent regulatory authority to which the
Plan or the Corporation is now or may hereafter be subject to. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">With regard to shareholder approval as required pursuant to Subsections 6.3b), c) and f), votes attached to shares
held directly or indirectly by Insiders benefiting directly or indirectly from the amendment may never be included. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">With regard to shareholder approval as required pursuant to Subsections 6.3a) and h), where the amendment will
disproportionately benefit one or more Insiders over other optionees, the votes attached to shares held directly or indirectly by those Insiders receiving the disproportionate benefit may never be included. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The shareholders&#146; approval of an amendment may be given by way of confirmation at the next meeting of
shareholders after the amendment is made, provided that no Common Shares are issued pursuant to the amended terms. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">CLAWBACK </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Notwithstanding anything to the contrary contained herein, the Board may cancel an option if the optionee, without the consent of the Corporation,
(A)&nbsp;has engaged in or engages in any activity that is in conflict with or adverse to the interests of the Corporation or any subsidiary while employed by or providing services to the Corporation or any subsidiary, including fraud or conduct
contributing to any financial restatements or irregularities, or (B)&nbsp;violates a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT>
<FONT STYLE="white-space:nowrap">non-disparagement</FONT> or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> covenant or agreement with the Corporation or any subsidiary, as determined by the Board, or if the optionee&#146;s employment,
service or office is terminated for Cause as indicated herein. The Board may also provide that in any such event the optionee will forfeit any compensation, gain or other value realized thereafter on the vesting, exercise or settlement of such
option or the sale or other transfer of Common Shares acquired in respect of such option and must promptly repay such amounts to the Corporation. In addition, the Corporation and its subsidiaries shall retain the right to bring an action at equity
or law to enjoin the optionee&#146;s activity and recover damages resulting from such activity. Further, to the extent required by applicable law and/or the rules and regulations of the Exchange or any other securities exchange or inter-dealer
quotation service on which the Common Shares are listed or quoted, or if so required pursuant to a written policy adopted by the Corporation, options shall be subject (including on a retroactive basis) to clawback, forfeiture or similar requirements
(and such requirements shall be deemed incorporated by reference into all outstanding letters or agreements granting options). Each optionee, by accepting or being deemed to have accepted an option under the Plan, agrees to cooperate fully with the
Board and the Corporation, and to cause any and all permitted transferees of the optionee to cooperate fully with the Board and the Corporation, to effectuate any forfeiture or disgorgement required under this Plan. Neither the Board nor the
Corporation nor any other person, other than the optionee and his or her permitted transferees, if any, will be responsible for any adverse tax or other consequences to an optionee or his or her permitted transferees, if any, that may arise in
connection with the provisions of this Section&nbsp;7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 9</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">GOVERNING LAW </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Plan and the options granted under the Plan shall be construed in accordance with and be governed by the laws of the Province of Quebec. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#2f5496">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT COLOR="#2f5496">EFFECTIVE DATE AND TRANSITIONAL MEASURES </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Plan came in effect on December&nbsp;6,&nbsp;1993. It was approved by the Board on December&nbsp;6,&nbsp;1993, by the regulatory authorities on
December&nbsp;8,&nbsp;1993 and by the shareholders on March&nbsp;29,&nbsp;1995. It was amended by the Board on fourteen occasions, being July&nbsp;18,&nbsp;1994, February&nbsp;20,&nbsp;1995, September&nbsp;26,&nbsp;1996, July&nbsp;27,&nbsp;1998,
December&nbsp;15,&nbsp;1998, February&nbsp;16,&nbsp;1999, March&nbsp;15,&nbsp;2001, March&nbsp;14,&nbsp;2003, February&nbsp;8,&nbsp;2007, April&nbsp;15,&nbsp;2016, April&nbsp;11,&nbsp;2017, June&nbsp;12,&nbsp;2020, March&nbsp;3,&nbsp;2022, and
March&nbsp;28, 2023. These changes were approved by the shareholders on nine occasions, being March&nbsp;26,&nbsp;1997, April&nbsp;22,&nbsp;1999, May&nbsp;10,&nbsp;2001, May&nbsp;7,&nbsp;2003, March&nbsp;29,&nbsp;2007, May&nbsp;17,&nbsp;2016,
May&nbsp;16,&nbsp;2017, July&nbsp;16,&nbsp;2020 and May&nbsp;10, 2022. The effective date of this Plan shall be the date on which it is approved by the shareholders. All options granted beginning on May&nbsp;10, 2022, shall be governed by the terms
and conditions of this version of the Plan. All options granted prior to May&nbsp;10, 2022, shall be governed by the terms and conditions of the version of the Plan approved by Board on June&nbsp;12,&nbsp;2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">T<SMALL>HERATECHNOLOGIES</SMALL> <SMALL>INC</SMALL>. &#150; S<SMALL>HARE</SMALL> O<SMALL>PTION</SMALL> P<SMALL>LAN</SMALL></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">P<SMALL>AGE</SMALL> 10</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B>Schedule A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SHARE OPTION PLAN
&#150; PURCHASE FORM </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL"><B>SECTION A &#150; PURCHASE
REQUEST &#150; TO BE COMPLETED BY OPTIONEE</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="18"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Name:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="18"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Mailing Address:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8201;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="18"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Office telephone:
<U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="18"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Current Position in Corporation:
<U>&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:6pt ;"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Date of Grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:6pt ;">Number<BR>of Options<BR>Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:6pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Number of<BR>Options Exercised</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Hereby*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:6pt ;">Exercise Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:6pt ;">Purchase Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17" ALIGN="right">Total Purchase Price: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Method of Payment:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">Cashless Exercise (check if applicable) : &#8195;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">I hereby elect to exercise the number of options to purchase Common Shares of Theratechnologies Inc. as indicated
above.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Signature:&#8201;<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> Date: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17"><B>SECTION B &#150; VERIFICATION &#150; TO BE COMPLETED BY THE CORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">I hereby certify that the above individual is eligible to exercise the number of options as indicated above and
acknowledge receipt of payment therefore.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Signature:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> Date: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="18"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="17" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>INFORMATION FOR TAX PURPOSES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Market value of Common Shares on exercise date:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194; </U></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="9" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="10" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>SECTION C &#150; RECEIPT OF COMMON SHARES</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">I acknowledge receipt of certificate numbers:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">&#8194;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="10"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Signature:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> Date: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="10"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PLEASE RETAIN FOR TAX PURPOSES</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>5
<FILENAME>d680117dex23.htm
<DESCRIPTION>EX-2.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 2.3 </U></B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SECURITIES EXCHANGE ACT OF 1934 (&#147;Exchange Act&#148;) </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of which this Exhibit 2.3 is a part,
Theratechnologies Inc. (&#147;Company&#148;, &#147;Corporation&#148;, &#147;we&#148; or &#147;us&#148;) had the following securities registered pursuant to Section&nbsp;12(b) of the Exchange Act: </P>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B><U>Title of each class</U></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B><U>Trading Symbol(s)</U></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B><U>Name of each exchange on which<BR></U><U>registered</U></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Common Shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">THTX</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">NASDAQ Capital Market</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following description of our common shares (&#147;Common Shares&#148;) is a summary and does not purport to be complete. It is subject
to and qualified in its entirety by reference to our articles of amendment (&#147;</I><B><I>Articles</I></B><I>&#148;), which are filed as Exhibit 1.1 to the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of which this Exhibit
2.3 is a part. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of November&nbsp;30, 2023, there were 45,980,019 issued and outstanding Common Shares and we are authorized to
issue an unlimited number of Common Shares, without par value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agents and registrars for our Common Shares are Computershare
Trust Company of Canada at its principal offices in Montreal, Qu&eacute;bec, and Toronto, Ontario, and Computershare Trust Company, N.A. at its principal office in Canton, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences, and Restrictions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the priority rights of holders of preferred shares, holders of Common Shares are entitled to any dividend declared by the Board of
Directors of the Corporation, to one vote per share at meetings of our shareholders and, in the event of our liquidation or dissolution, to participate in the distribution of the assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Common Shares issued represent the total voting rights pertaining to our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders are not liable to capital calls by the Corporation and there exists no provision discriminating against any existing or
prospective holder of our Common Shares as a result of a shareholder owning a substantial number of our Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to Rights Attached
to Our Common Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to change the rights attached to our Common Shares the vote of at least 66 2/3% of the holders of
Common Shares must be cast at a shareholders meeting called for amending the rights attached to our Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Common Shares do not contain any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> purchase rights to any of our securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Rights to Own Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither Canadian law nor our Articles or <FONT STYLE="white-space:nowrap">By-laws</FONT> limit the right of a
<FONT STYLE="white-space:nowrap">non-resident</FONT> to hold or vote our Common Shares, other than as provided in the Investment Canada Act (&#147;Investment Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Investment Act requires any person that is a <FONT STYLE="white-space:nowrap">&#147;non-Canadian&#148;</FONT> (as defined in the
Investment Act) who acquires &#147;control&#148; (as defined in the Investment Act) of an existing Canadian business to file either a <FONT STYLE="white-space:nowrap">pre-closing</FONT> application for review or a post-closing notification with
Innovation, Science and Economic Development Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date hereof, the threshold for review of a direct acquisition of control
of a <FONT STYLE="white-space:nowrap">non-cultural</FONT> Canadian business by a World Trade Organization member country investor that is not a state-owned enterprise is an enterprise value of assets that exceeds CA$1.326&nbsp;billion. For
&#147;trade agreement investors&#148; that are not state-owned enterprises (as defined in the Investment Act), the threshold for review of a direct acquisition of control of a <FONT STYLE="white-space:nowrap">non-cultural</FONT> Canadian business is
an enterprise value of assets that exceeds CA$1.989&nbsp;billion. The enterprise value review thresholds for both World Trade Organization member countries and trade agreement investors are indexed to annual GDP growth and are adjusted accordingly
each year. For purposes of a publicly traded company, the &#147;enterprise value&#148; of the assets of the Canadian business is equal to the market capitalization of the entity, plus its liabilities (excluding its operating liabilities), minus its
cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As such, under the Investment Act, the acquisition of control of us (either through the acquisition of our
Common Shares or all or substantially all our assets) by a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> who is a World Trade Organization member country investor or a trade agreement investor, including a U.S. investor, would be reviewable
only if the enterprise value of our assets exceeds the specified threshold for review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where the acquisition of control is a reviewable
transaction, the Investment Act generally prohibits the implementation of the reviewable transaction unless, after review, the relevant Minister is satisfied or deemed to be satisfied that the acquisition is likely to be of net benefit to Canada.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The acquisition of a majority of the voting interests of an entity is deemed to be acquisition of &#147;control&#148; of that entity. The
acquisition of less than a majority but <FONT STYLE="white-space:nowrap">one-third</FONT> or more of the total number of votes attached to all of the voting shares of a corporation or of an equivalent undivided ownership interest in the total number
of votes attached to all of the voting shares of the corporation is presumed to be an acquisition of control of that corporation unless it can be established that, on the acquisition, the corporation is not controlled in fact by the acquiror through
the ownership of voting shares. The acquisition of less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of votes attached to all of the voting shares of a corporation is deemed not to be acquisition of control of that
corporation subject to certain discretionary rights relative to investments involving state-owned enterprises. Other than in connection with a &#147;national security&#148; review, discussed below, certain transactions in relation to our Common
Shares would be exempt from the Investment Act including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition of our Common Shares by a person in the ordinary course of that person&#146;s business as a
trader or dealer in securities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition or control of us in connection with the realization of security granted for a loan or other
financial assistance and not for any purpose related to the provisions of the Investment Act, if the acquisition is subject to approval under the Bank Act, the Cooperative Credit Associations Act, the Insurance Companies Act or the Trust and Loan
Companies Act; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition or control of us by reason of an amalgamation, merger, consolidation or corporate
reorganization following which the ultimate direct or indirect control in fact of us, through the ownership of our voting interests, remains unchanged. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the national security regime in the Investment Act, review on a discretionary basis
may also be undertaken by the federal government in respect of a much broader range of investments by a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> to &#147;acquire, in whole or in part, or to establish an entity carrying on all or any part
of its operations in Canada&#148;. The relevant test is whether such an investment by a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> could be &#147;injurious to national security&#148;. The Minister of Innovation, Science and Economic
Development has broad discretion to determine whether an investor is a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> and therefore may be subject to national security review. Review on national security grounds is at the discretion of the
federal government and may occur on a <FONT STYLE="white-space:nowrap">pre-</FONT> or post-closing basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Control </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Articles and <FONT STYLE="white-space:nowrap">By-laws</FONT> do not contain any provision that would have the effect of delaying,
deferring or preventing a change in control of the Corporation. However, the Corporation has a shareholder rights plan (&#147;Rights Plan&#148;) in place which could act as a deterrent to acquire the control of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I><U>Description of Rights Plan </U></I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Rights Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of the Rights Plan is to ensure equal treatment of shareholders and to give adequate time for shareholders to properly assess the
merits of a bid without undue pressure, and to allow competing bids to emerge. The Rights Plan is designed to give the Board time to consider alternatives, allowing shareholders to receive full and fair value for their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Canadian securities legislation, a takeover bid generally means an offer to acquire voting or equity voting shares of a corporation
that, together with shares already owned by the bidder and certain parties related thereto, amount to 20% or more of the outstanding shares of that class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the legislative framework for takeover bids in Canada, shareholders may not be treated equally if an important number of Common Shares
is acquired pursuant to a private agreement in which a small group of shareholders or a shareholder dispose of their Common Shares at a premium to market price, which premium is not shared with the other shareholders of the Corporation. In addition,
a person may gradually accumulate Common Shares through stock exchange acquisitions which results in an acquisition of control of the Corporation, without payment of fair value for control or a fair sharing of a control premium amongst all
shareholders. The Rights Plan addresses these concerns by applying to all acquisitions of 20% or more of the Common Shares of the Corporation, ensuring that shareholders receive equal treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Rights Plan also addresses the use of &#147;hard&#148; <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, whereby shareholders
commit to tender their Common Shares to a takeover bid in <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements which are either irrevocable or revocable but subject to restrictive termination conditions. Such agreements could have the effect
of deterring other potential bidders from bringing forward competing bids, particularly where the number of <FONT STYLE="white-space:nowrap">lock-up</FONT> shares would make it difficult or unlikely for a competing bidder&#146;s bid to achieve the
50% minimum tender requirement imposed by the takeover bid rules. The Rights Plan is designed to prevent these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements that are not in the best interest of the Corporation and its shareholders and
to encourage bidders to structure <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements so as to provide the <FONT STYLE="white-space:nowrap">locked-up</FONT> shareholders reasonable flexibility to terminate such agreements to deposit their
shares to a higher value bid or support another transaction offering greater value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issue of rights (&#147;Rights&#148;) will not in
any way adversely alter the financial condition of the Corporation and will not change the way in which shareholders trade their Common Shares. However, by permitting holders of Rights other than an &#147;Acquiring Person&#148; (as defined below) to
acquire additional Common Shares of the Corporation at a discount to market value, the Rights may cause substantial dilution to a person or group that acquires 20% or more of the outstanding Common Shares other than by way of a &#147;Permitted
Bid&#148; (as defined below). A potential bidder can avoid the dilutive features of the Rights Plan by making a bid that conforms to the requirements of a Permitted Bid. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Terms of the Rights Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of the principal terms of the Rights Plan and is provided subject to the terms and conditions thereof. A complete
copy of the Rights Plan is filed as Exhibit 2.1 to the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of which this Exhibit 2.1 is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Issue of Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
order to implement the Rights Plan, the Board authorized the Corporation to issue one right in respect of each Common Share outstanding as at the date of the adoption of the Rights Plan. One Right will also continue to be issued and attached to each
subsequently issued Common Share for as long as the Rights Plan is in place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Rights-Exercise Privilege </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Rights will be separate from the Common Shares to which they are attached and will become exercisable at the time (&#147;Separation
Time&#148;) that is ten (10)&nbsp;business days after the earlier of: (i)&nbsp;the first date of public announcement that an &#147;Acquiring Person&#148; (as defined below) has become such; (ii)&nbsp;the date of commencement of, or first public
announcement in respect of, a takeover bid which will permit an offeror to hold 20% or more of the Common Shares, other than by an acquisition pursuant to a takeover bid permitted by the Rights Plan (&#147;Permitted Bid&#148; as defined below);
(iii) the date upon which a Permitted Bid ceases to be a Permitted Bid; or (iv)&nbsp;such other date as may be determined in good faith by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The acquisition permitting a person (&#147;Acquiring Person&#148;), including others acting jointly or in concert with such person, to hold
20% or more of the outstanding Common Shares, other than by way of a Permitted Bid, is referred to as a <FONT STYLE="white-space:nowrap">&#147;Flip-in</FONT> Event.&#148; Any Rights held by an Acquiring Person on or after the earlier of the
Separation Time or the first date of a public announcement (&#147;Common Share Acquisition Date&#148;) by the Corporation or an Acquiring Person that an Acquiring Person has become such will become null and void upon the occurrence of a <FONT
STYLE="white-space:nowrap">Flip-in</FONT> Event. Ten (10)&nbsp;trading days (or such longer period as may be required to satisfy the requirements of applicable securities laws) after the occurrence of the Common Share Acquisition Date, each Right
(other than those held by the Acquiring Person) will permit the holder to purchase for the exercise price that number of Common Shares determined as follows: a value of twice the exercise price divided by the &#147;Market Price&#148; (defined under
the Rights Plan as being the average weighted trading price per Common Share for the 20 consecutive trading days through and including the trading day immediately preceding the relevant date) on the Common Share Acquisition Date. The exercise price
under the Rights Plan has been set to three (3)&nbsp;times the Market Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the occurrence of a
<FONT STYLE="white-space:nowrap">Flip-in</FONT> Event and the separation of the Rights from the Common Shares, reported earnings per share on a fully diluted or <FONT STYLE="white-space:nowrap">non-diluted</FONT> basis may be affected. Holders of
Rights who do not exercise their Rights upon the occurrence of a <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event may suffer substantial dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Permitted <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A bidder may enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the shareholders of the Corporation whereby such
shareholders agree to tender their Common Shares to the takeover bid <FONT STYLE="white-space:nowrap">(&#147;Lock-up</FONT> Bid&#148;) without a <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event occurring. Any such agreement must be made
available to the public and must permit or must have the effect to permit the shareholder to withdraw the Common Shares to tender to another takeover bid or to support another transaction that exceeds the value of the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Bid. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Certificates and Transferability </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the Separation Time, the Rights will be evidenced by a legend imprinted on certificates for Common Shares issued after the Record
Time (or, if issued in book entry form, by the book entry form registration for the associated Common Shares). Rights are also attached to Common Shares outstanding on the Record Time, although share certificates will not bear such a legend. Prior
to the Separation Time, Rights will not be transferable separately from the Common Shares. From and after the Separation Time, the Rights will be evidenced by Rights certificates (or separate book entry registration), which will be transferable and
traded separately from the Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Bid&#148; Requirements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A &#147;Permitted Bid&#148; is a takeover bid that does not trigger the exercise of Rights. A &#147;Permitted Bid&#148; is a bid that aims to
acquire shares which, together with the other securities beneficially owned by the bidder, represent not less than 20% of the outstanding Common Shares and satisfies the following requirements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the bid is made by means of a takeover bid circular; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the bid must be made to all holders of Common Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the bid must be outstanding for a minimum period of 105 days or such shorter period that a take-over bid
must remain open for deposits of securities, in the applicable circumstances, pursuant to Canadian securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Common Shares and/or Convertible Securities tendered pursuant to the bid may not be taken up prior to the
expiry of the period referred to in paragraph (iii)&nbsp;above and only if at such time more than 50% of the Common Shares and/or Convertible Securities held by the shareholders other than the bidder, its associates and affiliates, and persons
acting jointly or in concert with such persons (&#147;Independent Shareholders&#148;), have been tendered pursuant to the bid and not withdrawn; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if more than 50% of the Common Shares and/or Convertible Securities held by Independent Shareholders are
tendered to the bid within the <FONT STYLE="white-space:nowrap">105-day</FONT> period, the bidder must make a public announcement of that fact and the bid must remain open for deposits of shares for an additional ten (10)&nbsp;business days from the
date of such public announcement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Rights Plan allows for a competing Permitted Bid (&#147;Competing Permitted
Bid&#148;) to be made while a Permitted Bid is in existence. A Competing Permitted Bid must satisfy all the requirements of a Permitted Bid except that, as proposed to be amended, it must be outstanding for a minimum number of days as required under
Canadian securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Waiver and Redemptions </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board acting in good faith may, prior to a <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event, waive the dilutive effects of the Rights
Plan in respect of a particular <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event that would result from a takeover bid made by way of takeover bid circular to all holders of Common Shares, in which event such waiver would be deemed also to be a
waiver in respect of any other <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event. The Board may also waive the Rights Plan in respect of a particular <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event that has occurred through inadvertence,
provided that the Acquiring Person that inadvertently triggered such <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event reduces its beneficial holdings to less than 20% of the outstanding Common Shares within 14 days or any other period that may
be specified by the Board. At any time prior to the occurrence of a <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event, the Board may, subject to the prior approval of the holders of Common Shares, elect to redeem all, but not less than all, of
the outstanding Rights at a price of $0.0001 per right. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Exemption for Investment Managers </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investment managers (for client accounts), trust companies and pension funds (acting in their capacity as trustees and administrators)
acquiring shares permitting them to hold 20% or more of the Common Shares are exempt from triggering a <FONT STYLE="white-space:nowrap">Flip-in</FONT> Event, provided that they are not making, or are not part of a group making, a takeover bid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Supplements and Amendments </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Corporation is authorized to make amendments to the Rights Plan to correct any clerical or typographical error or to maintain the validity
of the Rights Plan as a result of changes in laws or regulations. Material amendments or supplements to the Rights Plan will require, subject to the regulatory authorities, the prior approval of the shareholders or, after the Separation Time,
holders of Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership Disclosure Threshold </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no provisions in the Corporation&#146;s Articles or under applicable corporate law requiring share ownership to be disclosed.
Securities legislation in Canada requires that shareholder ownership (as well as ownership of an interest in, or right or obligation associated with, a related financial instrument of a security of the Company) must be disclosed once a person
beneficially owns or has control or direction over, directly or indirectly, securities of a reporting issuer carrying more than 10% of the voting rights attached to all the reporting issuer&#146;s outstanding voting securities. This threshold is
higher than the 5% threshold under United States securities legislation at which shareholders must report their share ownership. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.26
<SEQUENCE>6
<FILENAME>d680117dex426.htm
<DESCRIPTION>EX-4.26
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.26</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.26</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENT&nbsp;#2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This <B>AMENDMENT #2 TO AMENDED AND RESTATED DISTRIBUTION AND MARKETING AGREEMENT</B> (the &#147;<B>Amendment</B>&#148;),
effective as of November&nbsp;5, 2019 (the &#147;<B>Amendment Effective Date</B>&#148;), is made by and between <B>TAIMED BIOLOGICS INC</B>., a Taiwan corporation with the registered company address at 3F, No.&nbsp;607, Ruiguang Road, Neihu
District, Taipei City 11492, Taiwan, R.O.C. (&#147;<B>TaiMed</B>&#148;), and <B>THERATECHNOLOGIES INC.</B>, a Canadian corporation organized under the laws of the Province of Quebec having its head office and principal place of business located at
2015 Peel Street, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, in the City of Montreal, Province of Quebec, Canada H3A 1T8 (&#147;<B>Theratechnologies</B>&#148;). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, TaiMed and Theratechnologies are parties to an Amended and Restated Distribution and Marketing Agreement dated the 6<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day of March, 2017, as amended effective November&nbsp;6, 2018 (collectively, the &#147;<B>Agreement</B>&#148;); and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, TaiMed and Theratechnologies desire to amend the terms and conditions of the Agreement governing, amongst other
things, the manufacture and delivery of the Product in the European Territory. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the
mutual covenants set forth below (and for good and valuable consideration the receipt and sufficiency of which both parties hereby acknowledge), TaiMed and Theratechnologies agree (and hereby amend the Agreement) as follows: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.<B>&#8195;&#8195;<U>Definitions</U></B>. All initially capitalized terms used but not defined in this Amendment have the meanings given in
the Agreement, except that where explicitly stated, as used in this Amendment, &#147;Sections&#148; will refer to the sections of this Amendment rather than those of the Agreement. As used in this Amendment and the Agreement, the terms
&#147;include, Includes,&#148; &#147;including&#148; and derivative forms of them shall be deemed followed by the phrase &#147;without limitation&#148;. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>2.<B>&#8195;&#8195;<U>Amendment to Section&nbsp;5.2.1</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;5.2.1 of the Agreement is hereby deleted in its entirety and replaced with the following new Section&nbsp;5.2.1: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product</B>. TaiMed shall be responsible, at its cost and expense, for the Regulatory Activities related to the packaging and Product
Labels and Inserts for the Product in the United States until Marketing Approval of the Product in the United States. Theratechnologies shall be responsible, at its cost and expense, for the Regulatory Activities related to the packaging and Product
Labels and Inserts for the Product in Canada and in the European Territory. Theratechnologies shall, at its cost and expense, provide the proposed layout for the packaging and Product Labels and Inserts for the Product and its proposed artwork,
including its corporate name and any related logos for the United States, Canada and the European Territory. After Marketing Approval of the Product in the United States, Theratechnologies shall be responsible, at its cost and expense, for the
Regulatory Activities related to the packaging and Product Labels and Inserts for the Product in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
the United States and TaiMed shall be responsible, at its cost and expense, for producing, or having produced, the packaging and Product Labels and Inserts for the Product in the United States in
accordance with any instructions communicated by Theratechnologies from time to time. TaiMed shall also be responsible, at its cost and expense, for producing, or having produced, the packaging and Product Labels and Inserts for the Product in
Canada in accordance with any instructions communicated by Theratechnologies from time to time. Theratechnologies shall be responsible, at TaiMed&#146;s cost and expenses, for producing, or having produced, the packaging and Product Labels and
Inserts for the Product in the European Territory. In the event that any changes are to be made to the packaging and/or Product Labels and Inserts for the Product after Marketing Approval of such Product in the United States, or at any time in
Canada or in the European Territory, Theratechnologies shall discuss all such changes in good faith with TaiMed and, at Theratechnologies&#146; sole cost and expense, Theratechnologies shall be responsible for ensuring compliance with all applicable
Laws and for conducting all Regulatory Activities related thereto with any Governmental Bodies. Theratechnologies shall provide to TaiMed samples of the final packaging and Product Labels and Inserts for the Product after such discussion which shall
then replace the prior version of such packaging and Product Labels and Inserts in order for TaiMed to produce, or having produced, at its cost and expense, for the United States and Canada, such final packaging and Product Labels and Inserts within
the delay prescribed by the Competent Governmental Body to implement the change or up to the date the inventory of manufactured Product as of that date is sold, without exceeding
<FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> thereafter. Theratechnologies shall be responsible, at
TaiMed&#146;s cost and expense, to produce, or having produced, such final packaging and Product Labels and Inserts for the European Territory.&#148; </FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>3.<B>&#8195;&#8195;<U>Amendment to Section&nbsp;6.1.2</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;6.1.2 of the Agreement is hereby deleted in its entirety and replaced with the following new Section&nbsp;6.1.2: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Quality Requirements</B>. All Product supplied by TaiMed will be tested, manufactured and released in accordance with all applicable
quality standards and cGMP requirements. All Product supplied to Theratechnologies for the North American Territory shall be in the relevant Product packaging and Product Labels and Inserts as provided in Section&nbsp;5.2 of the Agreement. All
Product supplied to Theratechnologies for the European Territory shall be in unmarked vials (brite stock) and Theratechnologies shall, itself or through a Designee, at TaiMed&#146;s cost and expense, test, package, label and release the Product
using the Product Labels and Inserts referred to in Section&nbsp;5.2 of the Agreement. Except as provided in this Amendment, TaiMed shall be responsible, at its cost and expense, for all Regulatory Activities related to the manufacturing and supply
of the Product.&#148; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>4.<B>&#8195;&#8195;<U>Amendment to Section&nbsp;6.2.2</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Paragraph (a)&nbsp;of Section&nbsp;6.2.2 of the Agreement is hereby deleted in its entirety and replaced with the following new paragraph (a):
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;(a) be delivered to Theratechnologies in final, finished form in the relevant product
packaging and Product Label and Insert for such Product (including all secondary packaging) for the North American Territory and in unmarked vials (brite stock) for the European Territory,&#148; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>5.<B>&#8195;&#8195;<U>Amendment to Section&nbsp;6.4.5 </U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;6.4.5 of the Agreement is hereby deleted in its entirety and replaced with the following new Section&nbsp;6.4.5: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Delivery</B>. Delivery of Product by TaiMed shall be
<B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> at Theratechnologies&#146; designated facilities in the North American
Territory as provided in the purchase order (which shall also refer to the quantity to be delivered in each Country). Delivery of Product by TaiMed for the European Territory shall be
<FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> at Theratechnologies&#146; designated European
airport entry, before custom clearance. Title of product and risk of loss shall be transferred to Theratechnologies
</FONT><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT
STYLE="font-family:Times New Roman">. TaiMed&#146;s Manufacturing Designee will include with each shipment of Product the current material safety data sheet and a certificate of analysis reasonably acceptable to Theratechnologies, which shall, among
other things, certify that each such Product meets all applicable specifications upon delivery.&#148;<B> </B> </FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>6.<B>&#8195;&#8195;<U>Amendment to Section&nbsp;6.5</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;6.5 of the Agreement is hereby deleted in its entirety and replaced with the following new Section&nbsp;6.5: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;<B>Manufacturing Designees</B> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The use
by TaiMed of a Manufacturing Designee in connection with the manufacture and supply of Product to Theratechnologies and its Affiliates and Designees for the North American Territory pursuant to this Article&nbsp;6 (including Third Parties that
manufacture, package, supply, test or release the Product, and second source suppliers of the Product) shall not relieve TaiMed of any of its obligations under this Agreement, and TaiMed shall remain primarily liable and responsible for all acts and
omissions of such Manufacturing Designees as if they were acts or omissions of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
TaiMed under this Agreement. TaiMed shall ensure that any Manufacturing Designee is bound by valid and enforceable written agreements that are not inconsistent with the applicable terms and
conditions set out in this Agreement, including all applicable obligations, covenants and agreements of TaiMed set forth in this Article 6 relating to the manufacture, testing, release, delivery and supply of the Product (regardless whether any such
obligation, covenant or agreement set forth herein refers only to TaiMed or also references a Manufacturing Designee). Theratechnologies shall have the right to request a copy of any agreement between TaiMed and a Manufacturing Designee in
connection with the manufacture and supply of Product to Theratechnologies, provided that TaiMed may redact therefrom any financial terms or other similar type of information or any confidential information in such agreement. Any such agreement with
a Manufacturing Designee shall include the right of Theratechnologies, its Affiliates and their representatives to visit and inspect the facilities of such Manufacturing Designee at which the Product (or parts thereof) are manufactured, packaged,
supplied, tested or released on, and subject to, the same terms and conditions applicable to any facility of TaiMed under Section&nbsp;6.1. The use by Theratechnologies of a Third Party Designee in connection with activities related to the
manufacture and supply of Product for the European Territory pursuant to this Article 6 (including Third Parties that package, supply, test or release the Product, and second source suppliers of the Product) shall relieve TaiMed of any of its
obligations under this Agreement for the manufacturing and supply activities carried out by such Third Party Designee, except that TaiMed shall be responsible for all costs and expenses of such Third Party Designee retained by Theratechnologies in
connection with activities related to the manufacture and supply of Product for the European Territory.&#148; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>7.<B>&#8195;&#8195;<U>New
Section&nbsp;8.9</U> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">A new Section&nbsp;8.9 shall be added to the Agreement which new section shall read as follows: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#147;<B>Full-Time Employee for European Territory</B> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In connection with the work to be carried out by Theratechnologies in the European Territory, TaiMed hereby agrees <B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B>.</B> For the
purpose of this Agreement, the <FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> and the </FONT><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> shall report to Theratechnologies without
TaiMed&#146;s supervision.&#148; The Job Description of </FONT><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> and
the </FONT><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> shall not include any activities
related to sales and marketing. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>8.<B>&#8195;&#8195;<U>Assignment</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the terms of Section&nbsp;16.2.1 of the Agreement, TaiMed hereby agrees and consents to the assignment by Theratechnologies to
its Affiliate, Theratechnologies International Limited, of its rights and obligations contained in the Agreement related to the European Territory only, provided that such assignment shall not relieve Theratechnologies of any of its obligations
under </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
this Agreement related to the European Territory; Theratechnologies hereby agrees and consents to the assignment by TaiMed to its Affiliate, TaiMed Biologics USA, Inc., of its rights and
obligations contained in the Agreement related to the United States only; provided that such assignment shall not relieve TaiMed of any of its obligations under this Agreement related to the United States. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B>9.<B>&#8195;&#8195;<U>Legal Miscellany</U> </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a)&#8195;&#8195;This Amendment shall come into effect on the Amendment Effective Date and shall terminate or expire
concurrently with the termination or expiration of the Agreement. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b)&#8195;&#8195;This Amendment amends the Agreement as
explicitly stated above, but does not otherwise alter the Agreement or its interpretation. Except as expressly modified and/or amended herein, all of the terms, covenants and conditions contained in the Agreement shall remain unchanged and in full
force and effect. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(c)&#8195;&#8195;The term &#147;Agreement&#148;, as used in the Agreement, and all other instruments
and agreements executed thereunder after the Amendment Effective Date shall for all purposes refer to the Agreement as amended by this Amendment. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>THERATECHNOLOGIES INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>TAIMED BIOLOGICS INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Per:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ Luc Tanguay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Per:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ James N. Chang</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Per:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.27
<SEQUENCE>7
<FILENAME>d680117dex427.htm
<DESCRIPTION>EX-4.27
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.27</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B><U>Exhibit 4.27</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>MANUFACTURE AND SUPPLY AGREEMENT </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>THIS
AMENDMENT</B> (the &#147;<B>Amendment</B>&#148;) is made as of the 7<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, day of January, 2020 (the &#147;<B>Execution Date</B>&#148;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>BETWEEN:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>THERATECHNOLOGIES INC., </B>a corporation incorporated under the laws of the Province of Qu&eacute;bec, having its head office at
2015 Peel St., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Montreal, Qu&eacute;bec, H3A 1T8;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">(&#147;<B>Purchaser</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>AND:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>JUBILANT HOLLISTERSTIER GENERAL PARTNERSHIP (</B>formerly known as DRAXIS PHARMA GENERAL PARTNERSHIP<B>), by way of its managing
partner, Jubilant HollisterStier Inc.</B>, a partnership constituted under the laws of the Province of Ontario, having its principal office at 16751 Trans-Canada Highway, Kirkland, Qu&eacute;bec, H9H&nbsp;4J4;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">(&#147;<B>Supplier</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>WHEREAS</B> Purchaser and Supplier signed a Manufacture and Supply Agreement dated as of December&nbsp;23, 2009, as
amended from time to time (the &#147;<B>MSA</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AND WHEREAS</B> the Parties wish to amend the MSA to update the versions of the Product
offered thereunder, to reflect discussions held in 2018 and to make certain other modifications; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AND WHEREAS</B> all defined terms not defined
in this Amendment shall have the meanings ascribed thereto in the MSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>NOW, THEREFORE,</B> in consideration of the mutual covenants and
agreements in this Agreement, Purchaser and Supplier agree with each other as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>1.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B></B><B>Annual Minimum Purchases</B>. Section&nbsp;3.2 (&#147;Annual Minimum Purchases&#148;) is eliminated and
replaced in its entirety by the following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;3.2<FONT STYLE="font-family:Times New Roman">&#8194;</FONT><FONT
STYLE="font-family:Times New Roman">&#8195;</FONT> <B><U>Annual Minimum Purchases</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(a)<FONT
STYLE="font-family:Times New Roman">&#8195;</FONT><B>&#8195;&#8201;Calendar Year 2019 and 2020</B>. For each of the Calendar Years 2019 and 2020, Purchaser shall purchase from Supplier a minimum of <B><FONT
STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> full Batches of the following Product at the prices set forth in Schedule &#147;C&#148; hereto for the Calendar Year 2020:
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="padding-bottom:18pt ;BORDER:1px solid #000000; padding-left:8pt"><B>Product Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:18pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Code</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="padding-bottom:18pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">EGRIFTA TESAMORELIN INJ. 2mg/vial 1.4 mg</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:18pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">30000002175</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Subject to Section&nbsp;4.3(a), if Purchaser fails to purchase the Annual Minimum Purchase from
Supplier in either applicable Calendar Year, Purchaser shall pay to Supplier within thirty (30)&nbsp;days of the end of such Calendar Year a penalty payment equal
<B><FONT STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B>. The penalty payment shall not be reduced in any
way if the Failure to Supply is caused by Purchaser, including, among others, delays in delivery by Purchaser of any Materials to be provided by Purchaser or by Designated Suppliers or services or approval or changes requested by Purchaser to be
provided pursuant to this Agreement. However, if the Failure to Supply is caused by Supplier&#146;s fault or negligence, the Annual Minimum Purchases and the penalty payment for the current Calendar Year shall be reduced by the number and value of
Batches of Product that Supplier failed to supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(b)<FONT STYLE="font-family:Times New Roman">&#8195;</FONT><FONT
STYLE="font-family:Times New Roman">&#8195;</FONT><FONT STYLE="font-family:Times New Roman">&#8201;</FONT><B>Materials</B>. Purchaser shall be responsible for the cost of obsolete or unused Materials reasonably procured by Supplier for the purpose
of meeting Purchaser&#146;s demand pursuant to the forecasts received by Supplier. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>2.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B></B><B>Term of Agreement</B>. The Term of the Agreement is hereby extended. Section&nbsp;11.1(a) (&#147;Initial
Term&#148;) is eliminated and replaced in its entirety by the following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;11.1 (a) <B>Initial Term</B>. This
Agreement is effective from the date of its execution and shall continue in effect until December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>, 2020, unless earlier terminated or extended in accordance with the terms of the
Agreement.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>2019 Annual Minimum Purchase Obligation</B>. Supplier hereby acknowledges that Purchaser has met its Annual Minimum
Purchase obligation for the 2019 Calendar Year. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Entire Agreement</B>. Except as amended herein, all of the other terms and conditions set forth in the Agreement
shall remain unchanged and in full force and effect. The Agreement and any and all Schedules attached thereto and this Amendment No.&nbsp;1 form the entire agreement between the Parties with respect the subject matter. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Effective Date of Amendment</B>. Notwithstanding the Execution Date of this Amendment, Purchaser and Supplier agree
that this Amendment shall have been effective as of December&nbsp;19, 2018.<B></B> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amendment as of the date written above, by
their authorized officers, who by signing confirm their authority and intention to bind the Party they represent. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="48%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>JUBILANT HOLLISTERSTIER GENERAL PARTNERSHIP,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>by way of its managing partner,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>JUBILANT HOLLISTERSTIER INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Per:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL" ALIGN="justify">/s/ Amit Arora</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Amit Arora</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>THERATECHNOLOGIES INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Per:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL" ALIGN="justify">/s/ Luc Tanguay</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Per:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL" ALIGN="justify">/s/ <FONT STYLE="white-space:nowrap">Marie-No&euml;l</FONT> Colussi</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE &#147;C&#148; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRICES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.28
<SEQUENCE>8
<FILENAME>d680117dex428.htm
<DESCRIPTION>EX-4.28
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.28</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.28</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>F<SMALL>IRST</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL>&nbsp;&amp; R<SMALL>ESTATED</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">MGH Agreement No.&nbsp;2020-1109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This F<SMALL>IRST</SMALL> A<SMALL>MENDMENT</SMALL> to the A<SMALL>MENDED</SMALL>&nbsp;&amp; R<SMALL>ESTATED</SMALL>
L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL> (&#147;<B>First Amendment</B>&#148;) is made as of the 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of April, 2020 (&#147;<B>First Amendment Effective Date</B>&#148;) between
Theratechnologies, Inc., a Qu&eacute;bec company, having a principal place of business at 2015 Peel Street, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Montr&eacute;al, Qu&eacute;bec H3A 1T8 (&#147;<B>Company</B>&#148;) and The
General Hospital Corporation, d/b/a Massachusetts General Hospital, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> Massachusetts corporation, having a principal place of business at 55 Fruit St.,
Boston, MA 02114. (&#147;<B>Institution</B>&#148;), each referred to herein individually as a &#147;<B>Party</B>&#148; or collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Institution and
Company entered into a Research Material Transfer Agreement effective on June&nbsp;4, 2015 and amended on August&nbsp;2, 2017 (&#147;<B>MTA</B>&#148;; MGH Agreement No. 2014D006969) whereby Company supplied its approved proprietary drug,
tesamorelin, and placebo, to Institution for use in a human research study funded by the National Institutes of Health, a federal agency of the United States government, and conducted at Institution through and under the direction of Dr.&nbsp;Steven
Grinspoon (the &#147;<B>Principal Investigator</B>&#148;) entitled, &#147;<I>Tesamorelin effects on liver fat and histology in HIV: A collaborative UO1 grant</I>&#148; (the &#147;<B>Study</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Institution and Company previously entered into a License Agreement effective on June&nbsp;4, 2015 (&#147;<B>Original Agreement</B>&#148;; MGH
Agreement No.&nbsp;2020-0378), whereby Institution licensed all Proprietary Rights (as defined therein) to Company that were developed in the performance of the Study (also as defined therein); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Institution and Company further amended and restated the Original Agreement effective on February&nbsp;3, 2020 (&#147;<B>A&amp;R
Agreement</B>; MGH Agreement No.&nbsp;2020-1109) licensing Institution&#146;s rights in the Patent Rights and Technological Information (both as defined in the A&amp;R Agreement) related to the use of tesamorelin in patients with fatty liver disease
and infected with the human immunodeficiency virus (&#147;<B>HIV</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Institution and Company further desire to amend the A&amp;R
Agreement to account for the development of tesamorelin as a treatment for any patient with fatty liver disease(s), including NAFLD and NASH, whether or not such patient is infected with HIV; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Parties desire to revise the Technological Information that will be provided to Company under the A&amp;R Agreement, as well as the
definition of Label Expansion stated therein, to include any patient with fatty liver disease, including NAFLD and NASH, whether or not such patient is infected with HIV; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">For good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>1.&#8194;AMENDMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The definition of &#147;Label Expansion&#148; (<U>Certain Definitions</U>; Section&nbsp;1) is hereby deleted
in its entirety and replaced with the following: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
&#147;<B>Label Expansion</B>&#148; shall mean the first date of regulatory approval, including conditional approval, of the Product by the FDA and/or the EMA, as applicable, for the treatment of
any fatty liver disease, including NASH and NAFLD, in any patient. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Exhibit &#147;B&#148; to the A&amp;R Agreement shall be deleted in its entirely and replaced with the
attached Exhibit &#147;B&#148; included in this First Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any capitalized terms not defined in this First Amendment shall have the meaning set forth in the A&amp;R
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Except as provided herein, the A&amp;R Agreement and all of its terms, covenants, and conditions are hereby
ratified and confirmed in all respects and remain in full force and effect. The A&amp;R Agreement shall, together with this First Amendment, be read and construed as a single agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This First Amendment shall be governed by and construed in accordance with the laws of the State of New
York, excluding any conflict of law principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Counterparts</U>. For the convenience of the Parties, this First Amendment may be executed electronically
by email or facsimile transmission of signature pages, and in counterparts, each of which shall be deemed to be an original, and both of which taken together, shall constitute one agreement binding on all Parties. This First Amendment may be
executed electronically/digitally in compliance with the Massachusetts Uniform Electronic Transactions Act (MUETA) Mass. Gen. Laws ch. 110G and/or The Electronic Signatures In Global And National Commerce Act (ESIGN) 15 USC ch. 96. Persons signing
this First Amendment agree that, if used, electronic/digital signatures are intended to authenticate this writing and to have the same force and effect as the use of manual signatures. </P></TD></TR></TABLE>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">[<I>The remainder of this page is intentionally left blank</I>.] </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties have caused this First Amendment to
be executed by their duly authorized representatives as of the First Amendment Effective Date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>T<SMALL>HE</SMALL> G<SMALL>ENERAL</SMALL> H<SMALL>OSPITAL</SMALL> C<SMALL>ORP</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">BY: <U>/s/ Paul&nbsp;L&eacute;vesque&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BY: <U>/s/ Daniel Castro&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Name: Paul L&eacute;vesque</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name: Daniel Castro</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">TITLE: President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TITLE: Managing Director, Licensing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">DATE: April&nbsp;15, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DATE: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8199;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">BY: <U>/s/ Christian Marsolais&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">NAME: Christian Marsolais</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">TITLE: Senior Vice President and Chief Medical Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">DATE: April&nbsp;15, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;B&#148; </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Technological Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Technological Information includes the following information that has already been provided to Company pursuant to the Original Agreement or
will be provided to Company for the design of a Pivotal Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Principal Investigator has developed unique skills and
knowledge as a highly trained neuroendocrinologist, with a longstanding interest in HIV metabolism to identify a unique strategy to augment pulsatile GH to selectively reduce visceral fat in HIV and <FONT STYLE="white-space:nowrap">non-HIV</FONT>
patients. His expertise both in neuroendocrinology, metabolism and HIV medicine has enabled the successful studies utilizing the Product. This expertise stemmed from his unique training, including as long-term prior Director of the
Neuroendocrinology Clinic at MGH, the multiple investigator-initiated NIH studies he conducted on the biological mechanisms of relative GH deficiency in HIV patients with lipodystrophy and <FONT STYLE="white-space:nowrap">non-HIV</FONT> patients
with abdominal adiposity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Information obtained from Principal Investigator in the design of investigator-initiated <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> research studies of NAFLD in patients infected with HIV to determine the biological relationship of excess liver fat to low levels of human Growth Hormone in patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Information from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research studies was used to design the Study, a human research study
using the Product as a treatment for lipodystrophy in patients infected with HIV. Such information was provided to Company pursuant to the Original Agreement, and includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Determining the appropriate patient population for human research studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Determining the properties and therapeutic levels of Growth Hormone Releasing Hormone (GHRH) analogues
necessary to augment Growth Hormone peak levels in HIV patients with lipodystrophy through detailed pulsatility studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Assessment of the relevant comorbidities, study inclusion and exclusion criteria for such patients;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Assessment of the specific safety and efficacy variables in the studies, including study duration, drug
dosing, specific study procedures, and analytical strategies to optimally assess the efficacy of the Product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Assessment of appropriate primary and secondary study endpoints; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Study Data provided to Company pursuant to the Original Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Information and <FONT STYLE="white-space:nowrap">know-how</FONT> include further assisting Company in the design of a Pivotal Clinical Trial
to formally expand the FDA approved indication for the Product to include treatment of NAFLD, NASH, or other fatty liver diseases in all patients. Such information and <FONT STYLE="white-space:nowrap">know-how</FONT> include leveraging the Principal
Investigator&#146;s unique expertise in endocrinology and HIV medicine in order to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Optimally design Pivotal Clinical Trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Determine the appropriate patient population, dosing of Study Drug, study duration, and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
safety consideration(s); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Determining the appropriate methodology and rigorous analytical strategies needed to demonstrate the safety
and efficacy of the Study Drug for novel treatment indications, including NAFLD, NASH, and other fatty liver diseases; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Meeting <FONT STYLE="white-space:nowrap">(in-person,</FONT> videoconferences or conference calls) with the FDA
and/or the EMA in connection with Pivotal Clinical Trials and/or Label Expansion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.29
<SEQUENCE>9
<FILENAME>d680117dex429.htm
<DESCRIPTION>EX-4.29
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.29</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="right"><B><U>Exhibit 4.29 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>MANUFACTURE AND SUPPLY AGREEMENT </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>THIS
AMENDMENT</B> (the &#147;<B>Amendment</B>&#148;) is made as of the 1st, day of January, 2021 (the &#147;<B>Execution Date</B>&#148;) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><B>BETWEEN:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>THERATECHNOLOGIES INC., </B>a corporation incorporated under the laws of the Province of Qu&eacute;bec, having its head office at
2015 Peel St., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Montreal, Qu&eacute;bec, H3A 1T8;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">(&#147;<B>Purchaser</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"><B>AND:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><B>JUBILANT HOLLISTERSTIER GENERAL PARTNERSHIP, by way of its managing partner, Jubilant HollisterStier Inc.</B>, a partnership
constituted under the laws of the Province of Ontario, having its principal office at 16751 Trans-Canada Highway, Kirkland, Qu&eacute;bec, H9H&nbsp;4J4;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">(&#147;<B>Supplier</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>WHEREAS</B> Purchaser and Supplier signed a Manufacture and Supply Agreement dated as of December&nbsp;23, 2009, as
amended from time to time (the &#147;<B>MSA</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AND WHEREAS</B> the Parties wish to amend the MSA to update the versions of the Product
offered thereunder, to reflect discussions held in 2020 and to make certain other modifications; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>AND WHEREAS</B> all defined terms not defined
in this Amendment shall have the meanings ascribed thereto in the MSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>NOW, THEREFORE,</B> in consideration of the mutual covenants and
agreements in this Agreement, Purchaser and Supplier agree with each other as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B></B>Section&nbsp;3.2 (&#147;Annual Minimum Purchases&#148;) is eliminated and replaced in its entirety by the
following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;3.2 <B>&#8195;<U>Annual Minimum Purchases</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(a)<FONT STYLE="font-family:Times New Roman">&#8195;</FONT><FONT STYLE="font-family:Times New Roman">&#8194;</FONT> During the Term of
this Agreement, for each period between April 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of a calendar year and March 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the ensuing calendar year (&#147;<B>Reference
Period</B>&#148;), Purchaser shall purchase from Supplier a minimum of <FONT STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:ARIAL"> full
Batches of the following Product at the prices set forth in Schedule &#147;C&#148; hereto (collectively &#147;<B>Annual Minimum Purchase</B>&#148;): </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Product Name</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Code&#8195;&#8195;&#8195;&#8201;</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">EGRIFTA TESAMORELIN INJ. 2mg/vial 1.4 mg</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:11pt; font-family:ARIAL">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right">30000002175</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:11pt; font-family:ARIAL">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Subject to Section&nbsp;4.3(a), if Purchaser fails to purchase the Annual Minimum Purchase from
Supplier during the Reference Period, Purchaser shall pay to Supplier within thirty (30)&nbsp;days of the end of such Reference Period a penalty payment equal
<B><FONT STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B>.</B> The penalty payment shall not be reduced in any way if
the Failure to Supply is caused by Purchaser, including, among others, delays in delivery by Purchaser of any Materials to be provided by Purchaser or by Designated Suppliers or services or approval or changes requested by Purchaser to be provided
pursuant to this Agreement. However, if the Failure to Supply is caused by Supplier&#146;s fault or negligence, the penalty payment for the applicable Reference Period shall be reduced by the number and value of Batches of Product that Supplier
failed to supply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(b)<FONT STYLE="font-family:Times New Roman">&#8195;</FONT><FONT STYLE="font-family:Times New Roman">&#8194;</FONT> <B>Materials</B>.
Purchaser shall be responsible for the cost of obsolete or unused Materials reasonably procured by Supplier for the purpose of meeting Purchaser&#146;s demand pursuant to the forecasts received by Supplier. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B></B><B>Term of Agreement</B>. The Term of the Agreement is hereby extended. Section&nbsp;11.1(a) (&#147;Initial
Term&#148;) is eliminated and replaced in its entirety by the following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;11.1 (a) <B>Initial Term</B>. This
Agreement is effective from the date of its execution and shall continue in effect until March 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> 2022, unless earlier terminated or extended in accordance with the terms of the Agreement.&#148;
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Annual Minimum Purchase Obligation</B>. Supplier hereby acknowledges that Purchaser has met its Annual Minimum
Purchase obligation up to March 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Entire Agreement</B>. Except as amended herein, all of the other terms and conditions set forth in the Agreement
shall remain unchanged and in full force and effect. The Agreement and any and all Schedules attached thereto and this Amendment form the entire agreement between the Parties with respect the subject matter. </P></TD></TR></TABLE>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><I>SIGNATURES LOCATED ON THE NEXT PAGE </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amendment on the Execution Date by their
authorized officers, who by signing confirm their authority and intention to bind the Party they represent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>JUBILANT HOLLISTERSTIER GENERAL
PARTNERSHIP, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>by way of its managing partner, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>JUBILANT HOLLISTERSTIER INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL">/s/ Amit Arora</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amit Arora</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>THERATECHNOLOGIES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL">/s/ Phillipe Dubuc</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:ARIAL">/s/ <FONT STYLE="white-space:nowrap">Marie-No&euml;l</FONT> Colussi</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE &#147;C&#148; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRICES </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:ARIAL;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.30
<SEQUENCE>10
<FILENAME>d680117dex430.htm
<DESCRIPTION>EX-4.30
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.30</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.30</U> </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This is a first
amendment to the amended and restated exclusive license agreement dated February&nbsp;25, 2019 (the &#147;<B>First Amendment</B>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>BETWEEN&nbsp;:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>TRANSFERT PLUS, LIMITED PARTNERSHIP, </B>a limited partnership duly constituted under the laws of the Province of
Quebec, having its principal place of business at 1405, boulevard du Parc-Technologique, Qu&eacute;bec (Qu&eacute;bec) G1P 4P5, acting through its general partner <B>ALIGO INNOVATION, LIMITED PARTNERSHIP</B>, a limited partnership duly constituted
and having its principal place of business at the same address, itself acting by its general partner <B>GESTION AXELYS INC.</B>, a corporation duly constituted and having its head office at the same address, itself represented herein by
Marie-Jos&eacute;e Lapointe, its Vice President Legal Affairs, duly authorized for the purpose hereof as she so declares;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(hereinafter referred to as &#147;<B>Transfert Plus</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>AND&nbsp;:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>THERATECHNOLOGIES INC.</B>, a corporation governed by the <I>Business Corporations Act</I> (Qu&eacute;bec), having its
principal place of business at 2015 Peel Street, Suite 1100, Montr&eacute;al (Qu&eacute;bec) H3A&nbsp;1T8, represented by Philippe Dubuc, its Senior Vice President and Chief Financial Officer, duly authorized for the purpose hereof as he so
declares;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(hereinafter referred to as &#147;<B>Thera</B>&#148;).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Individually referred to as a &#147;<B>Party</B>&#148; and collectively as &#147;<B>Parties</B>&#148;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>WHEREAS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Transfert Plus entered into a license agreement with Katana Biopharma Inc.(&#147;<B>KATANA</B>&#148;) on July 3<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP>, 2017, which was thereafter amended and restated on February&nbsp;25, 2019 (the &#147;<B>License Agreement</B>&#148;);</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>WHEREAS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">KATANA was thereafter <FONT STYLE="white-space:nowrap">wound-up</FONT> into Thera and thereafter dissolved such that Thera
assumed all rights and obligations of KATANA in the License Agreement;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>WHEREAS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Thera and Universit&eacute; du Qu&eacute;bec &agrave; Montr&eacute;al (the &#147;<B>University</B>&#148;) have recently
applied to the <I>Consortium de recherche biopharmaceutique</I>&#146;s<I> </I>(&#147;<B>CQDM</B>&#148;) SynergiQc program to conduct two research projects at the University;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>WHEREAS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">the Parties desire to amend the License Agreement to refer to Thera as a Party in the Agreement in replacement of KATANA
and to redefine the scope of the Products and the Services in the License Agreement in order to, among other things, take into consideration certain intellectual property developed at the University and during the SynergiQc research
projects;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>NOW THEREFORE IN CONSIDERATION </B>of the above recitals and the mutual benefits to be derived hereafter,
the Parties agrees as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Page <B>1</B> sur
<B>5</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>DEFINED TERMS</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated in this First Amendment, capitalized terms used herein shall have the meaning ascribed to them in
the License Agreement and the First Amendment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>AMENDMENTS</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendement to any references to KATANA</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">All references to KATANA in the License Agreement are hereby repealed and replaced with references to Thera. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendements to definitions of the License Agreement</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;1.18 of the Licence Agreement is hereby repealed and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;1.18.1 &#147;<B>Products</B>&#148; means any substance, mixture, material, movable or any product using, incorporating,
exploiting or consisting of, in whole or in part the Technology and/or any Peptides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">1.18.2 &#147;<B>Peptides</B>&#148;
means any new peptides and peptide-drug conjugates for the treatment and diagnostics of cancer through the Sortilin receptor and any peptide or peptide-drug conjugate targeting the membrane and soluble forms of Sortilin for novel therapeutic
approaches and/or novel imaging agents or biomarkers related to cancer therapies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;1.21 of the Licence Agreement is
hereby repealed and replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;1.21 &#147;<B>Services</B>&#148;<B> </B>means all services that
can be rendered using in whole or in part the Technology or in connection with the Technology and/or the Products, or rendered in respect of Products.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendment to Notices, Section</B><B></B><B>&nbsp;17.4 of the License Agreement</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;17.4 of the License Agreement is hereby repealed and replaced with the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">&#147;17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Notices</B>. All notices and all other communications hereunder shall be in writing and shall be deemed
given if delivered personally or mailed by registered or certified mail (return receipt requested), by email (with confirmation of delivery) or by overnight delivery service to the Parties at the following addresses (or at such other address for a
Party as shall be specified by like notice): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="87%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">If to Transfert Plus:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1155 Boulevard Robert Bourassa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Suite 1410</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Montreal, Quebec, H3B 3A7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email&nbsp;: <B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">If to Thera:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Peel Street, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Montreal, Quebec, H3A 1T8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email&nbsp;: <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention&nbsp;: Philippe Dubuc, Senior VP and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendment to Schedule A</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Page <B>2</B> sur
<B>5</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Schedule A of the License Agreement is hereby repealed and replaced with the
Schedule A, attached herein. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>REPRESENTATIONS AND WARRANTIES</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Mutual Representations and Warranties. </B>Each Party hereby represents and warrants to the other that:
(i)&nbsp;it has full power and authority to enter into this First Amendment and to consummate the transactions contemplated herein; and (ii)&nbsp;the person signing this First Amendment on its behalf has the authority to do so and to bind that Party
to the terms of this First Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>MISCELLANEOUS AND GENERAL PROVISIONS</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Effect of the First Amendment. </B>Except to the extent amended by this First Amendment, the provisions
of the License Agreement shall remain in full force and effect. Notwithstanding anything to the contrary, in the event of any inconsistency or conflict between any provision of this First Amendment and the provisions of the License Agreement, in all
cases the provisions of this First Amendment shall prevail. This First Amendment shall be construed and read as though it was set forth in the License Agreement and all provisions of the License Agreement shall apply equally hereto.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Effective Date</B>. Notwithstanding the date of execution of this First Amendment, this First Amendment
shall be effective as of October&nbsp;26, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Governing Law</B>. This First Amendment shall be construed and interpreted according to the laws
applicable in the Province of Quebec, Canada, without regard to conflicts of law provisions. The Parties agree that the exclusive jurisdiction for any claim, controversy or cause of action arising out of or related to the License Agreement (or any
instrument or agreement executed incident hereto, including the First Amendment) shall be the Superior Court of Quebec, District of Montreal or the Court of Quebec, District of Montreal, whichever court has jurisdiction <I>ratione materiae</I> to
hear such claim, controversy or cause of action. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Language</B>. The Parties declare that they have expressly requested and do hereby confirm their request
that this First Amendment be drafted in the English language. <I>Les Parties d&eacute;clarent qu&#146;elles ont express&eacute;ment exig&eacute; et par les pr&eacute;sentes confirment leur demande que ce premier amendement soit r&eacute;dig&eacute;
en anglais</I>.</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>[The rest of this page is intentionally left blank. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>The following page is the signatures page.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Page <B>3</B> sur
<B>5</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREOF</B>, the Parties have each caused this First Amendement to be executed as of the
dates indicated below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>TRANSFERT PLUS, LIMITED&nbsp;PARTNERSHIP,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THERATECHNOLOGIES INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">acting through its general partner, ALIGO INNOVATION, LIMITED PARTNERSHIP, itself acting through its general
partner, GESTION AXELYS INC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="19"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Nancy Rancourt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Philippe Dubuc</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Nancy Rancourt</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman">Acting President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Philippe Dubuc</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman">Senior Vice President and Chief
Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman"><B>14/10/2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman"><B>14/10/2022</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Page <B>4</B> sur
<B>5</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>INVENTION </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi and Richard B&eacute;liveau from the University
developed an invention entitled &#147;<B><I>Creation</I></B> <B><I>and Development of New Peptide-Drug Conjugates for the treatment of cancer</I></B><B> </B><B><I>through Receptor-Mediated Chemotherapy
</I></B><B><I>(RMC)</I></B><B><I>&#148;</I></B>. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Page <B>5</B> sur
<B>5</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.31
<SEQUENCE>11
<FILENAME>d680117dex431.htm
<DESCRIPTION>EX-4.31
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.31</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.31 </U></B></P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT #2 TO SHARE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AMONG: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFERT PLUS,
L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>ALIGO INNOVATION, L.P. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>BORHANE ANNABI
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>RICHARD
B&Eacute;LIVEAU </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>CYNDIA CHARFI </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>JEAN-CHRISTOPHE CURRIE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>ALAIN LAROCQUE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>MICHEL
DEMEULE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SOPHIE KOZELKO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AND
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF MARCH&nbsp;29, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>THIS AMENDMENT #2 TO SHARE PURCHASE AGREEMENT</B> dated February&nbsp;25, 2019 is made as
of the 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>&nbsp;day of March, 2021 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>AMONG:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>TRANSFERT PLUS, L.P.</B>,<B> </B>a limited partnership created under the <I>Civil Code of Qu&eacute;bec</I> having a
place of business at 355 Peel Street, Suite 503, Montr&eacute;al, Qu&eacute;bec, H3C&nbsp;2G9, herein acting through its general partner, Aligo Innovation, limited partnership, herein acting through its general partner, Aligo Corporation
Inc.;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>TP</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>ALIGO INNOVATION, L.P., </B>a limited partnerchip created under the <I>Civil Code of Qu&eacute;bec</I> having a place of
business at 355 Peel Street, Suite 503, Montreal, Qu&eacute;bec, H3C 2G9, herein acting through its general partner, Aligo Corporation Inc.;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>Aligo</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>BORHANE ANNABI, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>BA</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>RICHARD B&Eacute;LIVEAU, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>RB</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>CYNDIA CHARFI, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>CC</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>JEAN-CHRISTOPHE CURRIE, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>JCC</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>ALAIN LAROCQUE, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>AL</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>MICHEL DEMEULE, </B>domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>MD</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>SOPHIE KOZELKO</B>, domiciled and residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(&#147;<B>SK</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(TP, Aligo, BA, RB, CC, JCC, AL, MD, and SK are collectively referred to as the
&#147;<B>Vendors</B>&#148;)</P></TD></TR></TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 2 - </P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman"><B>AND</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>THERATECHNOLOGIES INC.</B>,<B> </B>a corporation duly constituted under the laws of Qu&eacute;bec, having a place of
business at 2015 Peel Street, Suite 500, Montreal, Qu&eacute;bec, H3A 1T8;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(the &#147;<B>Purchaser</B>&#148;)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> the Purchaser and the Vendors have entered into a share purschase agreement dated
February&nbsp;25, 2019 (the &#147;<B>Share Purchase Agreement</B>&#148;), as amended on August&nbsp;12, 2019 (the &#147;<B>First Amendment</B>&#148;) (the Share Purchase Agreement and the First Amendment, collectively the &#147;<B>Share Purchase
Agreement</B>&#148;), pursuant to which Purchaser purchased from the Vendors all of the issued and outstanding common shares of Katana Biopharma Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> the Purchaser has achieved the First Development Milestone on March&nbsp;23, 2021; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> the Purchaser and the Vendors desire to amend the method of calculation related to the payment of the First Development
Milestone; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>NOW THEREFORE</B>, in consideration of the premises and mutual agreements herein contained, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each Party), the Parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The capitalized words and expressions used in this Agreement or in its Schedules shall have the meaning ascribed to them in
<U>Exhibit</U><U></U><U>&nbsp;A</U> of the Share Purchase Agreement, unless otherwise expressly stated herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Articles, Sections and Headings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The division of this Agreement into Articles, Sections, Exhibits and Schedules and the insertion of headings are for
convenience of reference only and will not affect the construction or interpretation of this Agreement. The terms &#147;<B>hereof</B>&#148;, &#147;<B>hereunder</B>&#148;, &#147;<B>herein</B>&#148; and similar expressions refer to this Agreement as a
whole and not to any particular Article, Section, Exhibit, Schedule or other portion hereof. References herein to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement or of the Exhibits and
Schedules hereto unless otherwise expressly stated herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Extended Meanings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In this Agreement, words importing the singular number also include the plural and vice versa and words importing any gender
include all genders. The term &#147;<B>including</B>&#148; means &#147;<B>including, without limiting the generality of the foregoing</B>&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 3 - </P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Accounting Principles </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Wherever in this Agreement reference is made to a calculation to be made or an action to be taken in accordance with generally
accepted accounting principles, such reference will be deemed to be made to ASPE, applicable as at the date on which such calculation or action is made or taken or required to be made or taken in accordance with ASPE. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Currency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Except as expressly provided herein, all references to currency contained herein are to lawful money of Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS TO SECTION 2.3.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendment to Section&nbsp;2.3.2 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;2.3.2 of the Share Purchase Agreement shall be deleted in its entirety and shall be replaced with the following
Section&nbsp;2.3.2: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;2.3.2 <I>Second Tranche</I>. The Purchaser shall pay to the Vendors on the date the First
Development Milestone is met the amount of two million dollars (2,000,000) (the &#147;<B>Second Tranche</B>&#148;). This amount shall be paid through the issuance of such number of Consideration Shares determined by dividing: (i)&nbsp;the Second
Tranche by (ii)&nbsp;the price per Consideration Share determined based on the volume-weighted average trading price of Purchaser&#146;s common shares on the TSX for the fourteen (14)&nbsp;Business Days immediately preceding the date on which the
First Development Milestone is met; all Consideration Shares to be allocated amongst the Vendors in accordance with their respective Designated Percentages.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>For the purposes of computing the number of Consideration Shares to be issued by Purchaser in payment
of the Second Tranche, the Vendors acknowledge and agree that the date the First Development Milestone was met is March&nbsp;23, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Governing Law and Forum </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This Agreement shall be governed by and construed in accordance with the Laws of the Province of Quebec and the Laws of Canada
applicable therein (excluding any conflict of laws rule or principle, foreign or domestic, which might refer such interpretation to the laws of another jurisdiction). The Parties hereby irrevocably and unconditionally submit to the exclusive
jurisdiction of the courts of the Province of Quebec and elect domicile in the City of Montr&eacute;al with respect to any matter relating to the execution or construction of this Agreement or the exercise of any right or the enforcement of any
obligation arising hereunder (excluding any conflict of forum rule or principle, foreign or domestic, which might refer such matter to the courts of another jurisdiction). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 4 - </P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Entire Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This Agreement, the Share Purchase Agreement and the Closing Documents constitute the entire agreement between the Parties
with respect to the subject matters hereof and thereof and cancels and supersedes any prior understandings, agreements, negociations and discussions between the Parties with respect thereto. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>No Other Amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Except as provided in this Agreement, the terms and conditions set forth in the Share Purchase Agreement shall remain
unaffected by execution of this Agreement. To the extent any provisions or terms set forth in this Agreement conflict with the tersm set forth in the Share Purchase Agreement, the terms set forth in this Agreement shall govern and control. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>No Waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Failure of a Party to insist upon the strict performance of any term or condition of this Agreement or to exercise any right,
remedy or recourse hereunder shall not be construed as a waiver or relinquishment of any such term and condition. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Successors, Assigns and Assignments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This Agreement will enure to the benefit of and be binding upon the respective successors (including any successor by reason
of the amalgamation or statutory arrangement of any Party) and permitted assigns of the Parties. This Agreement may not be assigned by any Party without the prior written consent of the other Parties, except that the Purchaser may, without the prior
written consent of the other Parties, assign all or part of its rights and/or obligations under this Agreement to (i)&nbsp;an Affiliate of the Purchaser or (ii)&nbsp;to the subsequent purchaser of (a)&nbsp;the shares of the Corporation or
(b)&nbsp;all or a substantially all of its assets or of the Business. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Counterparts </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This Agreement may be executed in one or more counterparts, each of which shall conclusively be deemed to be an original but
all of which taken together shall be deemed to constitute one and the same agreement. A facsimile or electronic transmission of the Agreement bearing a signature on behalf of a Party shall be legal and binding on such Party. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B>Language </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Parties acknowledge that they have required that this Agreement and all related documents be drawn up in English. <I>Les
parties reconnaissent avoir exig&eacute; que la pr&eacute;sente convention et tous les documents connexes soient r&eacute;dig&eacute;s en anglais</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>(remainder of this page left blank intentionally) </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 5 - </P> <P STYLE="font-size:30pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>(signature page to Amendment #2 to Share Purchase Agreement) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B> the Parties have executed this Agreement on the date first written hereinabove. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;THERATECHNOLOGIES INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>TRANSFERT PLUS, L.P.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" align="left">acting through its general partner, ALIGO<BR>INNOVATION, L.P., itself acting through its<BR>general partner, ALIGO CORPORATION INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Paul L&eacute;vesque</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Anne-Marie Larose</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">&#8194;Paul L&eacute;vesque</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">&#8194;Anne-Marie Larose</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">&#8194;President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">&#8194;Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;Senior Vice President and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;Chief Financial officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;<B>ALIGO INNOVATION, L.P.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;acting through its general partner,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;ALIGO CORPORATION INC.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Anne-Marie Larose</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">&#8194;Anne-Marie Larose</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Borhane Annabi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Michel Demeule</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;BORHANE ANNABI</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;MICHEL DEMEULE</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Richard B&eacute;liveau</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Alain Larocque</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;RICHARD B&Eacute;LIVEAU</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;ALAIN LAROCQUE</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>&#8194;/</B>s<B>/ </B>Cyndia Charfi<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#8194;/s/ Sophie Kozelko</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;CYNDIA CHARFI</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;SOPHIE KOZELKO</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>&#8194;/</B>s<B>/ </B>Jean-Christophe Currie<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>&#8194;JEAN-CHRISTOPHE CURRIE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.32
<SEQUENCE>12
<FILENAME>d680117dex432.htm
<DESCRIPTION>EX-4.32
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.32 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSULTING AGREEMENT </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>CONSULTING AGREEMENT MADE AND ENTERED INTO WITH AN EFFECTIVE DATE OF MAY&nbsp;13, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>BETWEEN: </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL></B><SMALL></SMALL>., a corporation governed by the <I>Business
Corporations Act</I> (Quebec), having its principal place of business at 2015 Peel Street, 11th Floor, Montreal, Province of Qu&eacute;bec, Canada, H3A 1T8;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(hereafter &#147;<B>Thera</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>JP A<SMALL>RENA</SMALL> R<SMALL>EGULATORY</SMALL> C<SMALL>ONSULTING</SMALL>, <SMALL>LLC</SMALL></B><SMALL></SMALL>, a
corporation governed by the laws of Pennsylvania, having its principal place of business at <B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> ;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">(hereafter &#147;<B>Consultant</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">WHEREAS Thera is a Canadian biopharmaceutical company involved in research and development, manufacture and
commercialization of pharmaceutical products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">WHEREAS Consultant specializes in providing U.S. scientific and regulatory advice on the
development and commercialization of pharmaceutical products; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">WHEREAS Thera desires to retain the services of Consultant through
which Consultant will provide the services of Joseph Arena to act as a member of the board of directors of Thera; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Engagement</U>. Thera does hereby retain Consultant on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis to provide the services of Joseph Arena as a member of the board of directors of Thera for the consideration and for the terms and conditions hereinafter set forth, and Consultant hereby
accepts to provide the services of Joseph Arena to act as such, upon and subject to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Obligations of Consultant</U>. Consultant agrees that the services of Joseph Arena shall be available to
Thera upon reasonable request from Thera. Consultant acknowledges that this Agreement is entered into based on the availability of Joseph Arena to act as a director of Thera. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Term and Renewal.</U> Subject to Paragraph 14, the term of this Agreement shall be deemed to have begun
on May&nbsp;13, 2021and shall terminate on the earlier of: (i)&nbsp;the date of the annual meeting of shareholders of Thera; and (ii)&nbsp;the date Consultant is unable to provide the services of Joseph Arena because, among other things, his death,
his resignation or his disqualification to act as a director of Thera. Subject to the foregoing sentence, this Agreement will renew automatically for as long as Joseph Arena remains available to act as a director of Thera and is elected as director
of Thera by the shareholders of Thera. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Fees.</U> Consultant shall be paid the same annual fees as those paid to individuals acting as directors
of Thera and, when applicable, for acting as members of a committee of the board of directors of Thera. The annual fees paid to an individual acting as a member of the board of directors of Thera is currently set at CAN $60,000. The fee is paid in
four equal quarterly installments of CAN $15,000 the first day of each calendar quarter. Consultant acknowledges that such fees may increase or decrease during the term of this Agreement. Consultant agrees that the services of Joseph Arena may be
paid via the issuance of securities. Where the issuance of securities is made as payment for the services performed by Joseph Arena, Consultant acknowledges that such securities will be issued in the personal name of Joseph Arena only. Consultant
hereby waives any claims against Thera for unpaid fees where payment is made through the issuance of securities to Joseph Arena personally. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Expenses.</U> During the Term, Thera will reimburse Consultant for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by Joseph Arena as a director of the board of directors of Thera or as a member of any of its committees. Such reimbursement shall be made within forty-five (45)&nbsp;days from
the receipt of the documents evidencing such expenses. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Taxes</U>. All amounts paid to Consultant hereunder shall be paid net of any withholding amount that<U>
</U>may be applicable. For greater certainty, Thera will not gross up any amount to offset any applicable withholding taxes on amounts owed hereunder. Consultant shall be liable for the payment of its taxes with U.S. regulatory authorities.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Representations and Warranties</U>. Consultant and Joe Arena hereby represent and warrant that:
(i)&nbsp;they are not under investigation by the United States Food and Drug Administration, or any other governmental or equivalent authority inside or outside the United States, for any potential violation of law or professional standards which
could lead to exclusion or debarment from any federal or state health care program; (ii)&nbsp;they are not, nor have they been, convicted of or indicted for an offense, nor have they otherwise engaged in conduct, which could lead to exclusion or
debarment from any federal or state health care program. Consultant and Joseph Arena hereby agree to promptly notify Thera upon any of them becoming aware of any inquiry, or the commencement of any proceeding concerning conduct by any of you, which
could result in your exclusion, debarment, or similar action. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Confidential Information</U>. Confidential Information. In the course of the provision of the Services
hereunder, Consultant and Joseph Arena will have access to all types of information relating to the intellectual property, the technologies, the industrial secrets, clinical development plans, <FONT STYLE="white-space:nowrap">know-how,</FONT>
business plan, commercial information and other affairs of Thera and its subsidiaries. All such information is collectively referred to herein as &#147;Confidential Information&#148;. Confidential Information also includes all analyses,
compilations, data, material, studies, or other document prepared by Consultant or Joseph Arena containing or based upon, in whole or in part, any such Confidential Information, regardless of media or format. The absence of the word
&#147;Confidential&#148; does not mean that the information is not confidential. The term &#147;Confidential Information&#148; shall not include: (i)&nbsp;information which, at the time of disclosure, is or thereafter becomes public knowledge
through no breach of this Agreement; (ii)&nbsp;documented information which is rightfully in Consultant&#146;s or Joseph Arena&#146;s possession prior to the Effective Date (as defined below) of this Agreement; (iii)&nbsp;information which is
disclosed to Consultant or Joseph Arena by a third party unless such disclosure constitutes, or either directly or indirectly results from, a breach of any agreement to which Thera is a party; or (iv)&nbsp;information which is disclosed with the
prior written approval of Thera. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> and
<FONT STYLE="white-space:nowrap">Non-Use</FONT></U>. Consultant and Joseph Arena hereby agree never to disclose the Confidential Information obtained or elaborated in the course of the performance of the services under this Agreement without the
express written consent of Thera, except by order of a court. Consultant and Joseph Arena agree to use the Confidential Information for the sole benefit of Thera and its subsidiaries. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Record Retention</U>. Upon instruction from Thera, Consultant shall forthwith deliver to Thera and shall
cause Joseph Arena to deliver to Thera, any and all documents or other written Confindetial Information. Consultant undertakes not to copy, retrieve or take any drawing, plan, reproduction, formula, book or any other Confidential Information.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Intellectual Property</U>. Consultant hereby agrees and Consultant shall cause Joseph Arena to agree to
assign to Thera and does hereby assign to Thera all discoveries, inventions, processes, technologies or improvements, patentable or not, conceived by Consultant or Joseph Arena, alone or with others, relating to the affairs of Thera or of its
subsidiaries or resulting from the provision of services hereunder. Consultant hereby consents and Consultant shall cause Joseph Arena to assist Thera and any of its subsidiaries in the issuance, renewal or maintenance of domestic or foreign patents
on such inventions, processes, technologies or improvements. Consultant and Joseph Arena hereby waive any right with respect to such discoveries, inventions, processes, technologies or improvements. In addition, Consultant hereby assigns and
Consultant shall cause Joseph Arena to assign to Thera all moral rights anyone of them may have in any writing done in the performance of the Services hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Securities.</U> Consultant acknowledges that Thera is a publicly-traded company, governed by securities
laws and that such laws prohibit any person having privileged information or information not publicly known, from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in
which it is reasonably foreseeable that such person is likely to purchase or sell such securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Consultant and Joseph Arena agree to comply with all applicable laws and regulations as they pertain to the securities and
insiders (as defined under <I>Securities Act</I> (Qu&eacute;bec)) of Thera. In addition, Consultant acknowledges that its name may be disclosed in documents filed with securities regulatory authorities to the extent such disclosure is required. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Compliance with Thera&#146;s Policies and Procedures</U>. Consultant and Joseph Arena hereby agree to
comply with the current and future policies and procedures of Thera applicable to consultants and members of the board of directors of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Termination.</U> Either Party shall have the right to terminate this Agreement at any time and without
penalty or indemnity, by giving the other Party at least thirty (30)&nbsp;days prior written notice of the effective date of such termination. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Survival of Undertakings</U>. The undertakings contained in Paragraphs 8, 9, 10, 11 and 12 will survive
the termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Relationship.</U> It is expressly acknowledged and agreed by the parties hereto that the only
relationship of Consultant to Thera created by this Agreement shall, for all purposes, be that of an independent contract for services pursuant to Sections 2098 and following of the <I>Civil Code of Qu&eacute;bec</I> and that there is no direction
and control exercised by Thera over Consultant. Further, Consultant is not a mandatary of Thera and shall not represent himself as such. Unless Consultant </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">
obtains the prior written authorization of Thera, Consultant shall not be entitled to speak or act on behalf of Thera. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Waiver.</U> Any waiver or any breach or default under this Agreement shall only be effective if in
writing signed by the party against whom the waiver is sought to be enforced, and no waiver shall be implied by indulgence, delay or other act, omission or conduct. Any waiver shall only apply to the specific matter waived and only in the specific
instance in which it is waived. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>No Assignment.</U> The services were contracted for under this Agreement with respect to the personal and
professional qualities of Joseph Arena and Consultant may not delegate or subcontract any of its duties or obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Assignment by Thera.</U> Thera may assign its rights and obligations hereunder, without consent, in the
event of an amalgamation, merger, acquisition of an important part of its assets, corporate reorganization, arrangement, or take-over bid. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Interpretation.</U> Nothing in this Agreement shall be construed or interpreted as creating an
employer/employee relationship between the parties hereto or as giving Consultant the authority to engage or bind Thera or to contract on its behalf. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Laws and Courts.</U> This Agreement shall be governed by and interpreted in accordance with the laws of
the Province of Quebec and the laws of Canada applicable therein. All disputes arising under this Agreement will be referred to the courts of the Province of Quebec which will have exclusive jurisdiction, and each party hereto irrevocably submits to
the exclusive jurisdiction of such courts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Effective Date</U>. Notwithstanding the date of execution of this Agreement, Consultant and Thera agree
that this Agreement is effective as at May&nbsp;13, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><U>Language.</U> The parties hereto have required that the present Consulting Agreement and all deeds,
documents, or notices relating thereto be drafted in the English language. <I>Les parties aux pr&eacute;sentes ont exig&eacute; que la pr&eacute;sente convention et tout autre contrat, document ou avis aff&eacute;rent ou subordonn&eacute; aux
pr&eacute;sentes soient r&eacute;dig&eacute;s en langue anglaise.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the parties have
caused this Agreement to be executed as of the date first set forth above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><B>THERATECHNOLOGIES INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>JP ARENA REGULATORY</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>CONSULTING,
LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><U>&#8199;/s/ Dawn Svoronos&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&#8199;/s/ Joseph Arena&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Dawn Svoronos</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joseph Arena</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Chair of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date: September&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: September 9, 2021</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">I, Joseph Arena, hereby acknowledge having read and understood the terms and conditions of
this Agreement and I hereby agree to be bound by the terms and conditions of those provisions applicable to me. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Dated this 9th day of
September, 2021. </P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman" ALIGN="justify">/s/ Joseph Arena</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B>JOSEPH ARENA</B></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.33
<SEQUENCE>13
<FILENAME>d680117dex433.htm
<DESCRIPTION>EX-4.33
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.33</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.33</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT #3 to Amended and Restated Distribution and Marketing Agreement (the &#147;Agreement&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>TERM SHEET </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Parties</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">TaiMed and Thera.</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>Definition of
&#147;IM Mode of Administration&#148;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Article 1 of the Agreement is hereby amended by adding a definition of &#147;IM Mode of Administration&#148; and &#147;Activities&#148; which
shall read as follows:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>IM Mode of
Administration</B>&#148; means the intra-muscular injection of the Product on a <FONT STYLE="white-space:nowrap">bi-weekly</FONT> (once every two weeks) and/or monthly basis (once every four weeks or once a month).</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Activities</B>&#148; means any activities
performed by the TaiMed employees on behalf of Thera for the Development of the IM Mode of Administration which are set forth in Schedule &#147;A&#148; hereto</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Right to Develop
IM Mode of Administration</B></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Notwithstanding the terms of Section&nbsp;3.1 of the Agreement, Thera shall have a
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> right to the clinical development of the IM Mode of Administration in the Territories.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Effective Period</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Thera shall use reasonable efforts to (i)&nbsp;enroll the first patient in the clinical study within
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> of the date of Amendment # 3 (the &#147;Effective Date&#148;) and (ii)&nbsp;complete all clinical development activities
within <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> of the Effective Date.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>Development
Costs of IM Mode of Administration</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">All of the costs and expenses related to the Development of the IM Mode of Administration shall be borne by Thera.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>Services
Provided by TaiMed Employees and Costs Associated with TaiMed Employees</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">TaiMed shall support Thera in its Development of the IM Mode of Administration and shall make available to Thera certain TaiMed employees who
shall assist Thera with the Activities. Thera shall be responsible for the costs and expenses incurred by TaiMed in connection with the Activities expressly requested by Thera and undertaken by the TaiMed employees in respect to the Development of
the IM Mode of Administration and any applicable IND Regulatory Filing pertaining to the IM Mode of Administration that is required in order to maintain good IND status; <U>provided</U> <U>that</U> TaiMed shall keep and maintain complete and
accurate books and records of such costs sufficient for Thera to verify such costs. Within <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> after the end of
each quarter of the Financial Year, TaiMed shall submit to Thera a statement for such costs and expenses incurred by TaiMed for the Activities rendered by TaiMed employees to Thera during such quarter of the Financial Year, and Thera shall pay the
amount reflected on such statement within <B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> days after receipt thereof. The hourly fees associated with the TaiMed
employees are set forth in Schedule &#147;A&#148;.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Page 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>Costs for
Contract Research Organization (CRO) and other vendors</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">TaiMed shall make a request to the FDA to amend the current protocol
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> in order to include the IM Mode of Administration. TaiMed shall use the services of the Contract Research Organization and vendors set forth in Schedule &#147;B&#148;
for the purposes of the IM Mode of Administration study. Thera shall be responsible for all costs and expenses incurred by TaiMed in connection with that CRO and those vendors in respect of the IM Mode of Administration plus an administrative fee
equal to <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><B></B> percent of such costs; <U>provided</U> <U>that</U> TaiMed shall keep and maintain complete and accurate books and records
of such costs sufficient for Thera to verify such costs. Within <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> after the end of each quarter of the Financial
Year, TaiMed shall submit to Thera a statement for such costs and expenses incurred by TaiMed for the CRO and vendors set forth in Schedule &#147;B&#148; during such quarter of the Financial Year, and Thera shall pay the amount reflected on such
statement within <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> after receipt thereof.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Intellectual
Property Rights</B></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Title to the New Technology shall be governed by the terms of the Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Commercialization Rights</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Thera shall
have the exclusive right to Commercialize the IM Mode of Administration in the Territory until the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> anniversary
date of the Marketing Approval of the Product in each Country in the Territory.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman"><B>Regulatory Activities</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Thera shall be responsible for
all costs and expenses for the preparation and review of all Regulatory Filings of the IM Mode of Administration in the Territories including, but not limited to, any Regulatory Filing fees. TaiMed shall be responsible for the regular filings of the
IND to the FDA as the current holder and Thera shall be responsible for all costs and expenses incurred by TaiMed associated with such filings. Regulatory Filings with the FDA and any other Competent Regulatory Body in the Territories for Product
approval will be Thera&#146;s responsibility. Each Party shall keep the other informed of all communications with the FDA in connection with the IM Mode of Administration and shall provide the other with all documentation and communication received
from the FDA until the Regulatory Approval of the IM Mode of Administration. Thera shall be responsible for all costs and expenses related to any inspection conducted by a Competent Regulatory Body that is mandated in order to obtain a Regulatory
Approval of the IM Mode of Administration.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Regulatory Approval</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">TaiMed shall use Commercially Reasonable Efforts to assist Thera in seeking Regulatory Approval of the IM Mode of Administration in the United
States. The costs and expenses associated with obtaining such Regulatory Approval shall be borne by Thera.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Clinical Trial Insurance</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">TaiMed shall maintain an appropriate coverage of clinical trial insurance with a reputable insurer. Thera shall pay TaiMed at a rate of <FONT
STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><B></B> per month <FONT STYLE="white-space:nowrap">(pro-rated</FONT> for partial months) while any clinical trial for the IM Mode of Administration is
active. For clarity, a clinical trial is active once the first patient is screened and ends after the database is locked.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Other TaiMed Costs to be Reimbursed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Thera shall be responsible for the monthly fee of
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> incurred by TaiMed for the use of the PK modeling software beginning on the Effective Date and for the duration of the entire period
of the IM Mode of Administration development project.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Supply Price for Study Requirements</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In addition to the CRO passthrough charges in the above Section, TaiMed shall sell
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;</FONT> kits of Product to Thera for the Development of the IM Mode of Administration at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><B></B> per kit (2 vials) without returns. The Product supplied for the development shall be separately labeled and used strictly for clinical study
purposes only, independent of commercial Product supplies.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Terms of Agreement remain in Effect</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Except as amended herein, all of the terms and conditions of the Amended and Restated Distribution and Marketing Agreement (as amended by
Amendment #1 and Amendment #2) shall continue in full force and effect between the Parties.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="7"><B>Accepted and agreed to on the dates below.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>TAIMED BIOLOGICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THERATECHNOLOGIES INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ James N. Chang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Paul L&eacute;vesque</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James N. Chang</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paul L&eacute;vesque</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May&nbsp;18, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;17, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: Philippe Dubuc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date: May&nbsp;17, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE &#147;A&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF TAIMED EMPLOYEES (or their equivalent replacement), ACTIVITIES AND FEES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE &#147;B&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>CRO AND LIST OF VENDORS </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Page 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.34
<SEQUENCE>14
<FILENAME>d680117dex434.htm
<DESCRIPTION>EX-4.34
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.34</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.34</U> </B></P>
<P STYLE="margin-top:35pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD AMENDMENT TO </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED MASTER SERVICES AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This Third Amendment to Master Services Agreement (this &#147;<U>Amendment</U>&#148;) dated December&nbsp;1, 2021 (&#147;<U>Amendment
Effective Date</U>&#148;) by and between Syneos Health Commercial Services, LLC (f/k/a inVentiv Commercial Services, LLC) a Syneos Health<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> group company<B> </B>(&#147;Syneos Health&#148;) and
Theratechnologies, Inc. (&#147;<U>Client</U>&#148;). Client and Syneos Health may each be referred to herein as a &#147;<U>Party</U>&#148; and collectively, the &#147;<U>Parties</U>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS, </B>the Parties entered into that certain Amended and Restated Master Services Agreement effective as of
December&nbsp;14, 2016 as amended by the first amendment dated February&nbsp;27, 2019 and second amendment dated February&nbsp;3, 2020 (the &#147;<U>Agreement</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, the term of the Agreement expires on November&nbsp;30, 2021 and the Parties desire to extend the term of the
Agreement as set forth herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>NOW THEREFORE,</B> in consideration of the above Recitals, the mutual covenants
contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby understand and agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Capitalized Terms</U></B>. All capitalized terms used but not otherwise defined in this Amendment
shall have the same meaning given to such terms in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Term</U></B>: Section&nbsp;11 of the Agreement is hereby deleted in its entirety and replaced with the
following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>11. </B><B><U>Term.</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Agreement shall be in effect as of the Effective Date and shall remain in effect until November&nbsp;30, 2024 (the
&#147;Term&#148;) or until such later day as may be set forth in a Project Agreement (it being understood that this Agreement will not terminate in the event the term set forth in a Project Agreement is longer than the term set forth herein). The
Parties may extend this Agreement for additional periods of one year each (each an &#147;Additional Term&#148;) by mutual agreement not less than thirty (30)&nbsp;days prior to the end of the then current term.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Miscellaneous</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Except as specifically amended or modified in this Amendment, each term of the Agreement shall continue to
be in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">This Amendment may be executed simultaneously in multiple counterparts, each of which shall be deemed an
original, but all of which taken together shall constitute one and the same instrument. Execution and delivery of this Amendment via pdf file bearing the signature of a party hereto shall constitute a valid and binding execution and delivery of this
Amendment by such party. Such pdf versions shall constitute enforceable original documents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">The terms of this Amendment are intended by the Parties to be the final expression of their agreement with
respect to the subject matter hereof and may not be contradicted by evidence of any prior or contemporaneous agreement. The Parties further intend that this Amendment constitute the complete and exclusive statement of its terms and shall supersede
any prior agreement with respect to the subject matter hereof. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:6%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF,</B> the parties
hereto have executed this Amendment to the Agreement to be effective as of the Amendment Effective Date. </P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>Theratechnologies Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Syneos Health Commercial Services, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Paul L&eacute;vesque</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Phil
Moussally</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">Paul L&eacute;vesque</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">Phil Moussally</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">CFO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">January 28, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">12/08/2021</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>Theratechnologies Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">Philippe Dubuc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">SVP &amp; CFO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">27/01/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.35
<SEQUENCE>15
<FILENAME>d680117dex435.htm
<DESCRIPTION>EX-4.35
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.35</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.35</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Amendment No.&nbsp;2 to Amended and Restated Statement of Work #2 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Amendment No.&nbsp;2 to the Amended and Restated Statement of Work #2 (&#147;Amendment #1&#148;) is entered into as of the last date
signed (the &#147;Amendment #2 Effective Date&#148;) pursuant to and shall be governed by the terms and conditions set forth in that certain Amended and Restated Master Services Agreement by and between Theratechnologies Inc. (&#147;Customer&#148;)
and RxC Acquisition Company d/b/a RxCrossroads by McKesson and subsequently assigned to McKesson Specialty Care Distribution LLC (&#147;RxCrossroads&#148;) with an effective date of November 1, 2017 (the &#147;Agreement&#148;). Notwithstanding the
date of execution of this Amendment # 2, the Parties agree that this Amendment # 2 shall be deemed effective as of July&nbsp;1, 2022. Customer and RxCrossroads may be referred to individually a &#147;Party&#148; or collectively as the
&#147;Parties&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Customer and RxCrossroads entered into an Amended and Restated Statement of Work #2 with an
effective date of November&nbsp;1, 2017, amended November&nbsp;1, 2019 (collectively &#147;SOW #2&#148;) regarding distribution services to be provided by RxCrossroads; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, in order to comply with the EPA Subpart P &#150; Hazardous Waste Pharmaceuticals / Research Conservation Recovery Act
regulations, Customer desires to amend its return policies for the Products to be distributed by RxCrossroads under the SOW #2; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, All capitalized terms used herein shall have the same meanings as set forth in the Agreement unless otherwise specifically
defined herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>, for good and valuable consideration, Customer and RxCrossroads hereby agree to amend the SOW #2 as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>AMENDMENT. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.4 &#150; Products</U></B>. As of July 1, 2022, the
definition is deleted in entirety and replaced with the following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.4 &#147;<U>Products</U>&#148;
shall mean EGRIFTA SV, together with its injection kits, and Ibalizumab.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;1.5 &#150; Unit</U></B>. As of July 1, 2022, the
definition is deleted in entirety and replaced with the following </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.5 &#147;<U>Unit</U>&#148; shall
mean either a box of EGRIFTA SV, an EGRIFTA SV injection kit box, or a box of Ibalizumab. Each Unit shall be packaged and labeled in accordance with the requirements of the approval for the marketing and sale of the Products received by Customer
from the U.S. Food and Drug Administration. (&#147;FDA&#148;)&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;7.1.1 &#150; Service Fees Charged to
Customer</U></B><B>. </B>As of July&nbsp;1, 2022, the Parties agree to remove Service fees applicable to EGRIFTA and replace as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#147;Intentionally Omitted&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;7.1.2 - Pass Through Fees Charged to
Customer</U></B><B>. </B>As of July 1, 2022, the Parties agree to add pass through fees applicable to the Products, directly after the third paragraph of Section&nbsp;7.1.2, as follows: </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;Customer shall be responsible for the processing fees by the
RxCrossroads&#146; third- party vendor, Inmar RX Solutions, Inc. (&#147;Inmar&#148;), for returns of short dated or expired Products as set forth below: </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>&#147;Return Processing Fees</B> ;
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The prices set forth above are subject to change by RxCrossroads no more than once per calendar year during the Term. Should
Customer decide to use the Customer Returns Form to document the Inmar data being provided, use of Customer Returns Form is subject to the Form Processing Fee in the table above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Exhibit B</U></B><B>. </B>As of July 1, 2022, Parties hereby agree to delete in entirety and
replace with the Exhibit B, attached and incorporated herein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Exhibit C</U></B><B>. </B>As of July 1, 2022, Parties hereby agree to delete in entirety and
replace with the Exhibit C, attached and incorporated herein . </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>Notwithstanding anything to the contrary, for this SOW #2, as of July&nbsp;1, 2022, the Parties agree
to add the following new subjection 9.1: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&#147;9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Subcontractor for Returns Processing </B>The Parties expressly agree that in addition to delivery/postage
services, IT services, translation services and temporary workers, RxCrossroads shall also be entitled to subcontract services for the Returns Policy in Exhibits B and C; provided however, that RxCrossroads shall remain fully responsible and liable
for services, obligations, and functions performed by its subcontractors as if such services, obligations and functions were performed by RxCrossroads.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>No other Amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Except as amended by the terms of this Amendment #2, all of the terms and conditions of the SOW #2 remain in full force and
effect. </P> <P STYLE="margin-top:55pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Signatures on Next Page </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF, </B>the Parties have caused this Amendment No.&nbsp;2 of the SOW #2
to be duly executed by their authorized representatives as of the Effective </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Mckesson Specialty Care Distribution LLC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>&#8194;THERATECHNOLOGIES INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>BY</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ James Canham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;">&#8194;<B>BY</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:12pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ John
Leasure</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>NAME</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">James Canham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>NAME</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">John Leasure</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>TITLE</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">VP 3PL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>TITLE</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Global Commercial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>DATE</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">February&nbsp;17, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>DATE</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">15-Feb-2023</FONT></FONT></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Exhibit B </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>EGRIFTA </I></B><B>SV<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> RETURNS POLICY </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT></B><B> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Exhibit C </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>IBALIZUMAB RETURNS POLICY (Trogarzo<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT></B><B> </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.36
<SEQUENCE>16
<FILENAME>d680117dex436.htm
<DESCRIPTION>EX-4.36
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.36</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.36</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>MANUFACTURING AND SUPPLY AGREEMENT </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>ENTERED INTO</B> on the 31st day of July 2023 (&#147;<B>Effective Date</B>&#148;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>BETWEEN:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL>.</B>, a company incorporated pursuant to the laws of the Province of
Quebec, having its head office and principal place of business at 2015 Peel Street, Suite 1100 in the City of Montreal, Province of Quebec, Canada, H3A 1T8</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter referred to as &#147;<B>Thera</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>B<SMALL>ACHEM</SMALL> A<SMALL>MERICAS</SMALL> I<SMALL>NC</SMALL>.,</B> a company incorporated pursuant to the laws of
the State of California, having its head office and principal place of business at 3132&nbsp;Kashiwa Street, in the City of Torrance, State of California, United States of America, 90505</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter referred to as &#147;<B>Bachem</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> Thera is a biopharmaceutical company which specializes in the research and the development of
therapeutic peptides; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> Bachem is a company which specializes in the manufacturing of therapeutic peptides; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> on November&nbsp;6, 2001, Peptix Inc., the manufacturing subsidiary of Thera, and Bachem, Inc., entered into a Collaborative
Development and Manufacturing Agreement (hereinafter referred to as the &#147;<B>CDMA</B>&#148;) pursuant to which Bachem Inc., jointly with Peptix, developed a large scale manufacturing process for Thera&#146;s proprietary peptide, TH9507 or
tesamorelin (hereinafter referred to as the &#147;<B>Active Ingredient</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> on November&nbsp;29, 2006, Peptix
ceased its activities and transferred all of its assets and liabilities, including those pursuant to the CDMA, to Thera, its sole shareholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> in accordance with the CDMA and subsequently under the Manufacturing and Supply Agreement between Thera, Bachem and Bachem
Inc., dated March&nbsp;11, 2009 (&#147;<B>Initial Manufacturing Agreement</B>&#148;), the initial
<B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process (&#147;<B>Initial </B><B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> <B>Net Lot Manufacturing Process</B>&#148;) as of the Effective Date is the sole and exclusive
property of Thera; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> Bachem has advised Thera of the need to change the purification equipment to be used in the <FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> Net Lot Manufacturing Process (as defined below) and Thera
has agreed. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 1</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B> Bachem will perform a process validation study of Active Ingredient for the
<B></B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Times New Roman"> Net Lot Manufacturing Process following the change of the
purification equipment under the terms and conditions of this Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>DEFINITIONS AND INTERPRETATION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Definitions</U> In this Agreement, unless the context clearly indicates to the contrary, the following
words shall have the meanings set out hereunder: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.1</TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> <B>Net Lot
Manufacturing Process</B>&#148; shall mean the updated manufacturing process which meets cGMPs and Applicable Laws for the production of nominal
<FONT STYLE="background-color:#000000"><B></B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> net Lots of Active Ingredient, developed under this Agreement. For the purposes of this Agreement, reference to a Lot of <FONT
STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> shall be interpreted to mean the yield of a Lot of
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> scale which may be less or more than
<FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Active Ingredient</B>&#148; shall mean the growth hormone-releasing factor analogue peptide
developed by Thera, tesamorelin acetate, scientifically referred to as <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Affiliate</B>&#148; shall mean (i)&nbsp;any Person of which fifty percent (50%) or more of the
voting stock is owned, directly or indirectly, by the Party or (ii)&nbsp;any Person, which owns, directly or indirectly, fifty percent (50%) or more of the voting stock of a Party, or (iii)&nbsp;any Person under the direct or indirect control of a
Person described in (i)&nbsp;or (ii) herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Agreement&#148;</B> shall mean this manufacturing and supply agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Applicable Laws</B>&#148; shall mean all laws, statutes, ordinances codes, rules, regulations,
guidelines and procedures which have been enacted by Regulatory Authorities and are in effect during the Term hereof in each case to the extent applicable to the performance by the Parties of their respective obligations hereunder or otherwise to
the subject matter of this Agreement. In the case of Bachem, Applicable Laws shall be limited to the applicable laws valid at Bachem&#146;s manufacturing site. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Bachem <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean all of the
manufacturing information, analytical methods and validation, technical information, <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions, patentable and nonpatentable, relating to the manufacturing and analytical testing of peptides in
general that is owned or developed by Bachem. For the avoidance of doubt, Bachem <FONT STYLE="white-space:nowrap">Know-How</FONT> does not include any element of the Thera <FONT STYLE="white-space:nowrap">Know-How</FONT> or Thera Trade Secrets.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Best Efforts&#148;</B> of a Party shall mean those efforts by that Party similar to the efforts
that a commercially minded businessperson, duly balancing risks </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 2</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
and rewards in the best interest of the business taken as a whole, would make in similar circumstances for its own operations at that time, it being understood that such Party&#146;s efforts
would not in any event require that Party to take each and any action that (a)&nbsp;would be possible (&#147;whatever it takes&#148;), or (b)&nbsp;in such Party&#146;s reasonable opinion would likely result in a breach of any other provision of this
Agreement or any other agreement, or (c)&nbsp;in such Party&#146;s reasonable opinion may violate any applicable law, regulation, rule, order, permit, direction or license of any court or governmental authority having appropriate jurisdiction over
the Party and subject matter or (d)&nbsp;in such Party&#146;s reasonable opinion would likely be disruptive of any material service conducted at or from any of its facilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Breaching Party</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;10.2 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>cGMPs</B>&#148; shall mean current Good Manufacturing Practices, as required for active
pharmaceutical ingredients in accordance with the U.S. FDA guidance for industry Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, as the same may be amended or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from
time to time, and all equivalent guidelines and regulations as promulgated by the Regulatory Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Calendar Year</B>&#148; shall mean the period beginning on January&nbsp;1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> of one year and ending on December&nbsp;31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of that same year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Certificate of Analysis and Conformity</B>&#148; shall mean the certificate of analysis confirming
the identity, quality and purity of a Lot of Active Ingredient to which it pertains together with the certificate of conformity confirming that the same Lot of Active Ingredient was manufactured, tested, stored and supplied in compliance with the
Specifications, applicable cGMPs and Applicable Laws, each such certificate signed by an authorized employee of Bachem. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Change of Control</B>&#148; shall mean an event or series of events by which:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a) &#8195;any &#147;<B>Person</B>&#148; or &#147;<B>Group</B>&#148; (within the meaning of the
Securities Exchange Act of 1934 and the rules of the SEC thereunder), is or becomes the &#147;<B>Beneficial Owner</B>&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> under
the Securities Exchange Act of 1934, except that a Person or Group shall be deemed to have &#147;<B>Beneficial Ownership</B>&#148; of all securities that such Person or Group has the right to acquire, whether such right is exercisable immediately or
only after the passage of time (such right, an &#147;<B>Option Right</B>&#148;), directly or indirectly, beneficially or of record, of common shares representing more than 50% of the aggregate ordinary voting power represented by the issued and
outstanding common shares of Thera (and taking into account all such securities that such Person or Group has the right to acquire pursuant to any Option Right); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 3</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b) &#8195;any Person or group of Persons who are acting jointly or in
concert (as contemplated by the Securities Act (Ontario) and related regulations) shall at any time have the right to acquire, directly or indirectly, beneficially or of record, common shares of Thera having attributed to it more than 30% of the
outstanding voting rights represented by all of the issued and outstanding common shares of Thera; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(c) &#8195;a majority
of the seats (other than vacant seats) on the board of directors of Thera shall at any time be occupied by a Person or group of Persons who are not proposed for election by management of Thera at a meeting of shareholders convened for the election
of directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(d) &#8195;the API or any asset manufactured comprising the API is sold, conveyed, transferred or
otherwise disposed of (including by way of license) in any one or series of related transactions, directly or indirectly, to a Person or group of Persons. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Confidential Information</B>&#148; shall mean all data and information in oral, written, graphic,
photographic, electronic, recorded or other form hereafter disclosed by either Party (the &#147;<B>Disclosing Party</B>&#148;) to the other party (the &#147;<B>Recipient</B>&#148;) during the Term of this Agreement, including the Drug Master File,
business plans, regulatory and product strategies, the Bachem <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Thera <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Thera Trade Secrets, except for (i)&nbsp;information which, at the
time of disclosure, is, or thereafter becomes, public knowledge through no breach of this Agreement, (ii)&nbsp;documented information which is rightfully in the Recipient&#146;s possession prior to the date of this Agreement, except with respect to
information in possession of one party obtained under a <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement or any other type of agreement containing obligations of confidentiality and entered into between the Parties prior to the date
of this Agreement; (iii)&nbsp;information which is disclosed to the Recipient by a Person (other than the Disclosing Party) which is rightfully in possession of same and is not bound by confidentiality provisions, (iv)&nbsp;information which is
disclosed with the prior written approval of the Disclosing Party; (v)&nbsp;information which is independently developed by Recipient without benefit of the Confidential Information as evidenced by written records or (vi)&nbsp;information which the
Recipient is required under any Applicable Laws or legal process to disclose to any competent judicial or Regulatory Authority; provided, however, that in the event that a disclosure is required under (vi), the Recipient has complied with the terms
of Section&nbsp;7.6. Notwithstanding any of the foregoing, nothing in this Agreement or any other agreement between the Parties shall hinder Bachem to answer questions received from Regulatory Authorities (e.g., during inspections) within the
timeline requested by the respective Regulatory Authority. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 4</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Disclosing Party</B>&#148; shall have the meaning ascribed thereto in Subsection 1.1.13 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Drug Master File</B>&#148; shall mean all the documentation detailing information about facilities,
processes or articles used in the manufacturing, processing, packaging and storing of the Active Ingredient, including the analytical test methods for the Active Ingredient. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>EMEA</B>&#148; shall mean the European Medicine Evaluation Agency or any successor entity thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Executed Batch Record&#148;</B> shall mean the record prepared from the approved Master Batch
Record, containing complete information relating to the production and control of a Lot. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>FDA</B>&#148; shall mean the United States Food and Drug Administration or any successor entity
thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Finished Product</B>&#148; shall mean a product based on, or containing, the Active Ingredient and
that is approved by a Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Firm Order</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;3.4.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Gram</B>&#148; or &#147;<B>g</B>&#148; shall mean a gram of net peptide content. For the purposes
of this definition, net peptide content shall mean the peptide content obtained using the elemental analysis method, or any other method mutually agreed to between the Parties hereto. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Indemnified Party</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;9.3 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Indemnifying Party</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;9.3 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Liabilities</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;9.1 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Lot</B>&#148; shall mean a specific quantity of Active Ingredient produced pursuant to the <FONT
STYLE="background-color:#000000"><B></B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> Net Lot Manufacturing Process. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Manufacturing Cost</B>&#148; shall mean the cost of manufacturing the Active Ingredient. It shall
be comprised of the following items: cost of raw materials and direct labor costs as well as all general costs related to the manufacturing of the Active Ingredient such as indirect labor, rent, utilities, depreciation and amortization.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Master Batch Record</B>&#148; shall mean the document containing formulas and manufacturing process
for the Active Ingredient. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Minimum Purchase Obligation</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;3.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>mmole</B>&#148; shall mean millimole. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 5</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party</B>&#148; shall have the meaning
ascribed thereto in Section&nbsp;10.2 hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Notice</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;12.1 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Permitted Assignee</B>&#148; shall mean a Person to whom this Agreement, together with the Quality
Agreement, is assigned by Thera pursuant to Section&nbsp;15.6. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>&#147;Party</B>&#148; or &#147;<B>Parties</B>&#148; shall mean Thera or Bachem individually or
collectively as the context requires. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Person</B>&#148; shall mean an individual, a body corporate, a sole proprietorship, a partnership,
a trust, a fund, an association, a&nbsp;syndicate, an organization or other organized group of persons, whether constituted or not as a legal person, or whether incorporated or not, and an individual or other person in that person&#146;s capacity as
a trustee, executor, administrator or personal or other legal representative, and any Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Purchase</B>&#148; shall mean the issuance by Thera of a purchase order for the manufacture of one
or more Lots of Active Ingredient, the acceptance thereof by Bachem and the release by Bachem of the Active Ingredient referred to in such purchase order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Quality Agreement</B>&#148; shall mean the Quality Agreement attached hereto as Schedule 1.1.35.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Quarter</B>&#148; shall mean a three-month period starting on the first day of each of January,
April, July and October. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Recipient</B>&#148; shall have the meaning ascribed thereto in Subsection 1.1.13 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Regulatory Authorities</B>&#148; shall mean the FDA, Health Canada and the EMEA and any other
regulatory authority having jurisdiction over the manufacture, packaging, marketing, sale and distribution of the Active Ingredient. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Related Party</B>&#148; shall mean any Person who (i)&nbsp;owns or more of the outstanding shares
of Thera or (ii)&nbsp;is a subsidiary of Thera or (iii)&nbsp;is the partner of Thera in a strategic alliance or licensing deal to develop and/or commercialize a product containing the Active Ingredient. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Specifications</B>&#148; shall mean those specifications set forth in Schedule 1.1.40 attached
hereto, as may be modified from time to time by mutual agreement of the parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Term</B>&#148; shall mean the term of this Agreement as stipulated in Section&nbsp;10.1 or any
shorter term if terminated prematurely for any reason. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>Thera <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean the manufacturing
information, analytical methods and validation, technical information, Master Batch Record, regulatory information, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, patentable and <FONT STYLE="white-space:nowrap">non-</FONT>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 6</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
patentable relating specifically to the Initial <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> Net Manufacturing Process and
the Active Ingredient. For the avoidance of doubt, Thera <FONT STYLE="white-space:nowrap">Know-How</FONT> shall exclude (i)&nbsp;information which was at the date of the Initial Manufacturing Agreement, in the public domain or subsequently became
such through no breach of the Initial Manufacturing Agreement, and (ii)&nbsp;documented information which was rightfully in Bachem&#146;s possession prior to the CDMA or subsequently independently developed by Bachem. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>&#147;Thera Trade Secrets&#148; </B>shall mean the bioassay method developed by Thera together with all
ancillary Thera <FONT STYLE="white-space:nowrap">Know-How</FONT> and process. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Interpretation</U> This Agreement shall be governed by the following provisions: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Should any provision of this Agreement be null or without effect or deemed unwritten, it or they shall not
render the other provisions, terms and conditions hereof invalid as this Agreement is not an indivisible whole. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties acknowledge that each provision of this Agreement was negotiated in good faith, understood and
for good and valuable consideration, agreed to by them and that the agreement does not constitute an adhesion contract for it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The division of this Agreement into Articles, Sections, Subsections and other subdivisions and the
insertions of headings are for convenience of reference only and shall not affect or be utilized in the construction or the interpretation hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Where required herein, the singular shall comprise the plural and vice versa, the masculine shall include
the feminine and vice versa while the neuter shall comprise both the masculine and the feminine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement shall be governed by and construed in accordance with the laws of the State of New York
therein without giving effect to the conflict of law principles thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The schedules annexed to this Agreement are incorporated by reference herein and form a part hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise indicated herein, all references to dollars in this Agreement shall be to United States
dollars. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 7</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE 2 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>MANUFACTURING PROCESS VALIDATION FOLLOWING CHANGE OF </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>THE PURIFICATION EQUIPMENT </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties acknowledge that the
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process shall be validated following the change of the purification equipment in accordance with the
Quotation (as defined below). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall validate the
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process following the change of the purification equipment and shall, in cooperation with Thera, and
subject to Section&nbsp;2.4, obtain the approvals of the Regulatory Authorities in relation thereto. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall be responsible for the work as defined in Schedule 2.3 and shall carry out such work at its
facilities in Torrance, California in accordance with Quotation number 67949 (the &#147;<B>Quotation</B>&#148;) attached hereto as Schedule 2.3 and the Quality Agreement. Bachem shall commence the aforementioned work upon receipt of a written
purchase order by Thera. Thera shall issue such purchase order within <FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> of the Effective Date of this Agreement for <B><FONT
STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> validation lots. The <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT>
validation lot set forth in the Quotation is not yet scheduled. For greater certainty, notwithstanding the general terms and conditions referenced in the Quotation, the Quotation shall be governed by the terms of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Should any work which is not provided for in the Quotation, or which was not ordered by Thera, be required
in order to obtain Regulatory Approval for the <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> Net Lot Manufacturing Process, the Parties shall work together in good faith and Bachem
shall use commercially reasonable efforts to proceed with any subsequent requirements, including any subsequent validation lots agreed to in writing by the Parties, in a timely manner. Bachem shall not be responsible to Thera for any refusal or
delay in obtaining such Regulatory Approval, after the manufacture of only <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> validation lots, provided that such refusal or delay is not
attributable to the gross negligence of Bachem. The Parties agree that the <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> validation lot provided for in the Quotation is optional and
Thera shall not be obligated to order or purchase the <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> validation lot. Should Thera decide to order the
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> validation lot, the cost thereof will be the cost set forth in the Quotation. The cost for any subsequent requirements shall be billed to
Thera with additional costs agreed upon between the Parties beforehand in separate quotations and Firm Orders. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>MANUFACTURING OF ACTIVE INGREDIENT </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the Term of this Agreement, Bachem and any Affiliate thereof shall manufacture and sell the Active
Ingredient exclusively to Thera and its Permitted Assignees, in accordance with the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process. This
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 8</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
exclusivity shall be effective as of the Effective Date and shall continue for the Term, provided that, beginning in the Calendar Year 2025 (beginning on January&nbsp;1, 2025), Thera must meet
its Minimum Purchase Obligations, as that term is defined below. In the event that a <B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> validation lot is required by the FDA, it is
understood between the Parties that said validation lot shall be sufficient to meet the Minimum Purchase Obligation for the Calendar Year 2025. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to the terms and conditions contained herein, Thera shall Purchase from Bachem, during each Calendar
Year (beginning in Calendar Year 2025 and ending the last full Calendar Year of the Term), a minimum quantity of <B></B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> of Active
Ingredient (hereinafter the &#147;<B>Minimum Purchase Obligation</B>&#148;). Notwithstanding the foregoing, Thera shall have the right to purchase the Active Ingredient from third party suppliers. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The price for the Active Ingredient manufactured in
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lots shall be based on the prices described in Schedule 3.3 hereto. Thera shall purchase the total quantity of the
produced Lot at the price per gram as it is defined in Schedule 3.3. Beginning on the first anniversary of the Effective Date, Bachem shall be permitted to increase the Price set forth in Schedule 3.3
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> during the Term or any Renewal Term, upon
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> days written notice to Thera to take into account increases in costs to manufacture the Active Ingredient. In addition, in
the event of a change in Specifications or Thera&#146;s increase in Lot quantities forecasted, or the development of manufacturing efficiencies, the Parties shall negotiate, acting reasonably and in good faith, to effect an adjustment of the price
set forth in Schedule 3.3. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">From the Effective Date, Thera shall furnish Bachem, on the first day of each Quarter, a <FONT
STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> rolling forecast of the quantities of Active Ingredient that Thera intends to Purchase on a monthly basis during a Calendar Year.
The quantities indicated in such rolling forecast shall be binding on Thera for the first <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> and a <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> (except as otherwise stated in this Agreement) purchase order shall accompany the forecast (the &#147;<B>Firm Order</B>&#148;). Should Thera purchase quantities less than forecasted during the
binding period, Thera agrees to still pay for the quantities forecasted for such period. The remaining quantities for the following
<FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> shall not be binding on Thera and shall be used by Bachem for planning purposes only. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera shall place with Bachem written purchase orders for the Active Ingredient to be delivered hereunder at
least <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> months prior to the delivery date specified in each respective purchase order and shall request receipt
confirmation by Bachem of the purchase order within <FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> business days of sending each purchase order. The minimum quantity
ordered per purchase order shall be Lot Net <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> of the Active Ingredient. These purchase orders shall be binding upon Thera
provided Bachem accepts such purchase order and confirms in writing a targeted delivery date of the Active Ingredient ordered within
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> business days after its receipt of a written purchase order, provided that Thera has undertaken
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 9</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
reasonable efforts to ensure that Bachem has, in fact, received the purchase order. If Bachem does not confirm in writing the acceptance of a purchase order or does not confirm in writing the
targeted delivery date, then the Firm Order shall no longer be binding on Thera and the purchase order shall be deemed not accepted. Any quantity of Active Ingredient purchased from another supplier shall be computed for the purposes of determining
Thera&#146;s fulfillment of its Minimum Purchase Obligation; provided however, that only that quantity of the Active Ingredient purchased from another supplier that is less than or equal to the quantity comprising the Firm Order shall be computed
for the purposes of determining Thera&#146;s fulfillment of its Minimum Purchase Obligation. Bachem shall use its Best Efforts to accommodate any reasonable requests by Thera to increase the quantity of Active Ingredient being subject to a purchase
order accepted by Bachem. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall prepare and maintain a Master Batch Record prior to manufacturing any commercial Lot, as set
forth in the Quality Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall perform, or cause to be performed, sample tests on each Lot of Active Ingredient manufactured
pursuant to this Agreement before delivery to Thera. Each test report shall set forth the items tested, Specifications and test results in the Certificate of Analysis and Conformity (as defined in Section&nbsp;1.1.11) for each Lot. Bachem shall send
to Thera, a complete copy of the Executed Master Batch Record for each Lot manufactured as soon as it is available after Bachem&#146;s Quality Assurance review. The Certificates of Analysis and Conformity for each Lot manufactured shall be sent to
Thera prior to the delivery of any manufactured Lot. Thera Quality Assurance will make all appropriate Best Efforts to review the Certificates of Analysis and Conformity as soon as possible, but in no event later than <FONT
STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> business days of its receipt. If Thera Quality Assurance fails to review and confirm to Bachem the Certificates of Analysis and
Conformity within that <FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> business day&#146;s timeline, Bachem shall invoice the balance remaining for the Lot and, upon
Thera&#146;s written request, either ship the Lot of Active Ingredient or transfer the Lot of Active Ingredient to customer warehouse, a CMP controlled storage area at Bachem&#146;s facility, until Thera&#146;s review of the Certificate of Analysis
and Conformity is complete. A state sales tax shall also be invoiced to Thera if the Active Ingredient remains stored at Bachem&#146;s facility beyond
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> calendar days from the date Thera receives the Certificate of Analysis. For reasons of clarity, the Parties
acknowledge and agree that the timelines for delivery of Active Ingredient indicated in quotations and Firm Orders relate to the date when a Lot is released by Bachem quality assurance and ready for shipment, independent of Thera&#146;s review of
manufacturing documents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Upon either Party&#146;s discovery that a Lot of Active Ingredient does not conform to the Specifications,
or that the release documentation, including the Certificate of Analysis and Conformity and any Executed Batch Record, does not comply with cGMPs or Applicable Laws, or does not contain the quantity of Active Ingredient being subject to a purchase
order accepted by Bachem, other than normal weighing variance as per scale precision, the discovering Party will immediately notify the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 10</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
other Party of such failure to meet the Specifications, the cGMPs or the Applicable Laws, or the shortage in quantity, as the case may be, and of the nature of such failure or shortage in detail,
including, but not limited to, supplying the other with all investigatory reports, data, and communications, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-specification</FONT></FONT> reports and data and the results of all
outside laboratory testing and conclusions, if any. In such case, the Parties shall investigate the claims and determine corrective actions, according to the Quality Agreement. Bachem agrees to replace units of Active Ingredient that are confirmed
to fail to meet Specifications due to defective manufacture, storage, packaging, labeling or handling of such units by Bachem prior to delivery to Thera pursuant to Section&nbsp;3.11. For reasons of clarity, Bachem shall not be obliged to replace a
Lot of Active Ingredient if the Specifications are met and only the bioassay fails. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Lots of Active Ingredient shall be ready for delivery once the Quality Assurance Department of Bachem has
confirmed that the Lots conform to Specifications and that the manufacturing of the Lots complies with cGMPs and Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall be responsible for taking quality control stability samples in support of the regulatory
filings for the Active Ingredient, testing stability samples on a timely basis, and providing Thera with all reports and data generated therefrom. Upon learning of a stability test failure, Bachem shall notify Thera as set forth in the Quality
Agreement. Bachem shall implement a stability program as described in the Quotation. For the avoidance of doubt, any stability testing required will be ordered by Thera, as described in the Quotation and be billed to Thera by Bachem with agreement
on pricing reached before initiation of the study. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Delivery terms shall be
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Bachem manufacturing site. For avoidance of doubt,
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> means that Bachem is responsible for
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><B>.</B> Thera assumes
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B>.</B> Thera shall bear all freight charges and associated duties, taxes
and clearance charges, if any. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Payment shall be made by cheque or by wire transfer to Bachem in accordance with this Section&nbsp;3.12. The
Parties agree that within <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> days of Bachem&#146;s acceptance of a Purchase Order and issuance of an invoice, Thera shall
pay to Bachem an advance payment equal to <FONT STYLE="background-color:#000000"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT> of the price for the Lots of Active Ingredient set forth in the accepted Purchase
Order (the &#147;<B>Advance Payment</B>&#148;). Final invoices for the balance of <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> shall be prepared by Bachem in
accordance with Section&nbsp;3.7. The balance shall be paid by Thera within <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> days following receipt by Thera of each of the
Certificate of Analysis and Conformity and an invoice for the Lots of Active Ingredient. Notwithstanding anything to the contrary herein, payment for the validation lots shall be made in accordance with the line items in the Quotation. Each Advance
Payment and the balance of <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> shall be based on the corresponding line items in the Quotation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 11</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem represents and warrants that each lot of Active Ingredient manufactured by Bachem and sold to Thera
pursuant to this Agreement will meet the Specifications for such Active Ingredient in effect at the time title to such Active Ingredient passes from Bachem to Thera. Subject to Section&nbsp;5.7, Thera may amend such Specifications from time to time
only with the prior written consent of Bachem, which consent shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall ensure that it has sufficient manufacturing capacity to enable Thera to fulfill, in each
Calendar Year, Thera&#146;s Minimum Purchase Obligation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Bachem facilities shall be maintained in accordance with cGMPs and Applicable Laws as set forth in the
Quality Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem represents and warrants that all Active Ingredient will be manufactured and released in conformity
with the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Manufacturing Process, cGMPs and Applicable Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem makes no other warranties or representations of any other kind, including but not limited to any
warranty of merchantability or fitness of the Active Ingredient for any purpose or use. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera shall be responsible for all costs associated with any recalls or market withdrawals, whether
voluntary or involuntary, of the Active Ingredient or any Finished Product, provided however that Bachem shall reimburse Thera for all reasonable and documented costs (including, without limitation, replacement costs for recalled or withdrawn Active
Ingredient or Finished Product and costs associated with notifying customers, shipment of recalled Active Ingredient or Finished Product from customers and shipment of replacement Active Ingredient or Finished Product to those customers) incurred in
connection with any recalls solely caused by (i)&nbsp;the failure of the Active Ingredient to meet Specifications, cGMPs or Applicable Laws, (ii)&nbsp;defective manufacture, storage, handling, labeling or packaging by Bachem, (iii)&nbsp;any breach
by Bachem of any representation, warranty or covenant contained in this Agreement, or (iv)&nbsp;the willful misconduct or negligence of Bachem. In the event that fault for the failure which initiates the recall is split between Bachem and Thera, the
Parties shall negotiate in good faith to allocate the costs of the recall according to the allocation of fault. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall maintain all manufacturing, packaging, analytical and stability records, all records of
shipment, and all validation data relating to the Active Ingredient to the extent and for the time periods required by Applicable Laws with respect to the Active Ingredient. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall, in accordance with the terms of the Quality Agreement, advise Thera if an authorized agent of
any Regulatory Authority visits the facilities where the Active Ingredient is being manufactured, to conduct an inspection concerning the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 12</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Active Ingredient and shall furnish to Thera all material information supplied to, or supplied by, such Regulatory Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera and Bachem shall, pursuant to the terms of the Quality Agreement send and make available, or cause to
be sent or made available, to each other, regulatory correspondence directly related to the Active Ingredient or Finished Product (to the extent directly related to the Active Ingredient) or any order, request or directive of any court or Regulatory
Authority concerning the withdrawal of Active Ingredient or Finished Product (to the extent directly related to the Active Ingredient), and correspondence bearing on the safety and efficacy of the Active Ingredient or Finished Product (to the extent
directly related to the Active Ingredient). Bachem shall cooperate with Thera in the event of any recall or withdrawal of the Active Ingredient or Finished Product and provide such reasonable assistance in connection therewith as Thera may
reasonably request. All other regulatory correspondence or order, request or directive of any court or Regulatory Authority which could have a material adverse effect on the manufacture of the Active Ingredient or the Finished Product shall be sent
or made available, or cause to be sent or made available, to each other in accordance with the terms of the Quality Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to a reported complaint and/or adverse drug event, if the nature of the reported complaint and/or
adverse drug event requires testing, Bachem will, at Thera&#146;s reasonable request, perform analytical testing of corresponding retention samples, except for the bioassay, and provide the results thereto to Thera as soon as reasonably practicable;
provided, however, that Bachem shall be responsible for the reasonable costs of such testing, except for the bioassay test, and reporting to the Regulatory Agency if it is determined that Bachem is responsible for such reported complaint and/or
adverse drug event. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event that the sale or manufacture of the Active Ingredient is suspended or halted further to a
decision of a Regulatory Authority while a purchase order accepted by Bachem is outstanding, Thera shall have the right to cancel such purchase order. Upon cancellation, Bachem shall not commence the manufacturing of any Lot and shall cease
manufacturing any Lot of Active Ingredient. Thera&#146;s only liability shall be to pay to Bachem the Manufacturing Cost incurred by Bachem in relation to the Lots being manufactured which are subject to such cancellation. No Manufacturing Cost
shall be payable to Bachem if it is determined that Bachem is responsible for the issuance of such suspension or halt. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">At the end of the Term, Bachem shall immediately terminate production of the Active Ingredient and shall
transfer to Thera, at Thera&#146;s expenses, all normal and reasonable inventory of Active Ingredient and all normal and reasonable inventory of raw materials and packaging components on hand that are procured specifically for the Active Ingredient.
Thera hereby agrees to accept such transfer and pay for the inventory at the price in effect at that time between the Parties, and the raw materials and packaging components at their acquisition cost, plus any costs </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 13</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
associated with testing, storage, handling or delivery to Bachem including, without limitation, freight charges and associated duties, taxes and clearance charges and Bachem shall provide to
Thera the original invoices as evidence of the costs. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process, Bachem shall keep Thera informed of any difficulty, irregularity or problem that may have an
adverse effect on the Specifications in accordance with the provisions of the Quality Agreement, and on changes pertaining to the volume of Active Ingredients ordered or the delivery date of the Active Ingredients. If the information communicated by
Bachem to Thera relates to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the failure by Bachem to meet the Specifications for a lot of Active Ingredient, notwithstanding
Section&nbsp;3.2 herein, Thera shall have the right to retain the services of another supplier to manufacture a Lot of Active Ingredient and the quantity of Active Ingredient manufactured by such supplier shall be included as forming part of
Thera&#146;s Minimum Purchase Obligation. The right of Thera to retain the services of another supplier shall not be deemed a waiver of its other rights under this Agreement or at law against Bachem and no money shall be owed by Thera to Bachem in
connection with the Lot of Active Ingredient that does not meet the Specifications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the failure by Bachem to meet the volume of Active Ingredient ordered, notwithstanding Section&nbsp;3.2
herein, Thera shall have the right to retain the services of another supplier to manufacture a Lot of Active Ingredient for the quantity of Active Ingredient that Bachem is unable to deliver and the quantity of Active Ingredient manufactured by such
supplier shall be included as forming part of Thera&#146;s Minimum Purchase Obligation. Thera shall only pay Bachem for the Grams delivered. Thera&#146;s rights hereunder shall not be deemed a waiver of its other rights under this Agreement or at
law against Bachem; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the failure by Bachem to meet the delivery date of the Active Ingredient, then Thera shall have the right to
reschedule a delivery date for the Active Ingredient being subject to a purchase order accepted by Bachem and Thera shall remain liable to Bachem for the payment of the Lot of Active Ingredient upon delivery thereof on the rescheduled delivery date.
Furthermore, Thera shall have the right to retain the services of another supplier to manufacture a lot of Active Ingredient and the quantity of Active Ingredient manufactured by such manufacturer shall be included as forming part of Thera&#146;s
Minimum Purchase Obligation, provided, however, that Bachem&#146;s failure to meet the delivery date was solely within the control of Bachem. Thera&#146;s rights hereunder shall not be deemed a waiver of its other rights under this Agreement or at
law against Bachem. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Drug Master File regarding the Manufacturing of the Active Ingredient at Bachem&#146;s facilities shall
be the sole and exclusive property of Bachem and shall be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 14</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
deemed Confidential Information. The Drug Master File may not be sold, transferred, assigned or disclosed to a Person unless Thera consents in writing to such sale, transfer, assignment or
disclosure. Bachem shall provide Thera with a copy of the applicant&#146;s part of the Drug Master File and, shall file and maintain such Drug Master File with the Regulatory Authorities free of charge, during the Term of this Agreement. Thera
agrees to pay the annual fees and maintenance costs associated with the Drug Master File during any <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B>
period where <FONT STYLE="background-color:#000000">&#8195;&#8195;</FONT> purchases are forecasted. Bachem will authorize the Regulatory Authorities to review the Drug Master File or other pertinent information in support of a product submission
filed by Thera, a successor thereof, a partner or a licensee containing the Active Ingredient. Bachem shall respond to regulatory inquiries in compliance with the timelines presented by the Regulatory Authorities. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>OWNERSHIP
AND LICENSES </U></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall retain and own all title and interest in Bachem&#146;s
<FONT STYLE="white-space:nowrap">Know-how</FONT> and its patents owned by Bachem at the Effective Date (&#147;Bachem Background Intellectual Property&#148;). Thera shall not have a license to and Thera shall not use Bachem&#146;s Background
Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera shall retain and own all title to and interest in Thera&#146;s
<FONT STYLE="white-space:nowrap">Know-how,</FONT> Thera&#146;s Trade Secrets and its patents owned by Thera at the Effective Date (&#147;Thera&#146;s Background Intellectual Property&#148;). During the Term of this Agreement, Thera grants Bachem a
royalty-free <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use Thera <FONT STYLE="white-space:nowrap">Know-How</FONT> for the purposes of this Agreement. Bachem agrees not to use or exploit the Thera
<FONT STYLE="white-space:nowrap">Know-How</FONT> for any other purpose than as set forth in this Agreement. Bachem shall not have the right to grant sublicenses and make any publication in any form of the Thera
<FONT STYLE="white-space:nowrap">Know-How</FONT> without the prior written consent of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any manufacturing improvements or modifications, whether patentable or not, that are newly conceived or
reduced to practice in the course of the performance of this Agreement and are not included in either Bachem Background Intellectual Property or Thera&#146;s Background Intellectual Property shall be considered to be &#147;New Intellectual
Property.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">New Intellectual Property shall be assigned to, and Thera shall be the owner of New Intellectual Property if
the New Intellectual Property is specific to the Active Ingredient or if based on Thera <FONT STYLE="white-space:nowrap">Know-how</FONT> or Trade Secrets, whether patentable or not (&#147;Thera New Intellectual Property&#148;). During the Term of
this Agreement, Thera herewith grants to Bachem a worldwide, royalty-free, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-sublicensable,</FONT> <FONT STYLE="white-space:nowrap">non-transferable</FONT>
license to use the Thera New Intellectual Property solely for the purposes of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 15</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">New Intellectual Property shall be assigned to, and Bachem shall be the owner of any New Intellectual
Property if the New Intellectual Property has broad applicability to similar molecules or peptide manufacturing, or is based on Bachem <FONT STYLE="white-space:nowrap">Know-how</FONT> (&#147;Bachem New Intellectual Property&#148;). Bachem herewith
grants to Thera a worldwide, royalty-free, perpetual, irrevocable, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, with the right to grant a <FONT STYLE="white-space:nowrap">sub-license</FONT> for the Bachem New Intellectual Property,
provided however that Thera shall use such licensed Bachem New Intellectual Property solely to the extent necessary to manufacture and release the Active Ingredient or to have the Active Ingredient manufactured and released by a <FONT
STYLE="white-space:nowrap">sub-licensee</FONT> on behalf of Thera. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>COVENANTS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall manufacture the Active Ingredient at its facilities in Torrance, California.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the Term of this Agreement, the Parties agree not to directly or indirectly solicit, recruit or
otherwise seek to induce any employee of the other Party to terminate their employment or violate any agreement with or duty to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem agrees to collaborate with Thera and provide Thera with any documentation necessary in the filing of
an investigational new drug application, new drug submission or application with a Regulatory Authority Filings outside of the US, EU or Canada shall be mutually agreed to, and unforeseeable costs should be borne by Thera. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the Term of this Agreement, Bachem shall maintain an appropriate inventory system in place and shall,
upon Thera&#146;s request, provide an inventory report of the Active Ingredient. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the Term of this Agreement and thereafter, for the period required by Applicable Laws during which
Bachem shall keep documentation and records relating to the manufacture of the Active Ingredient, upon Thera&#146;s reasonable request, Bachem
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
 &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
 &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> in relation to such inventory count and access. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall maintain the Active Ingredient in a cGMP storage area and shall limit the access to the Active
Ingredient to its authorized personnel only. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event a Regulatory Authority having jurisdiction in a country where Thera sells or markets a Finished
Product requires any change to the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process and/or the Specifications, Bachem shall use commercially
reasonable efforts to make the required changes so long as such changes do not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 16</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
conflict with cGMPs. In the event amendments are required to the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> Net
Lot Manufacturing Processes and/or the Specifications, Thera and Bachem shall agree on appropriate amendments or supplements and shall incorporate or include such amendment or supplement in or as part of the Master Batch Record. In the event that
any changes described significantly influence the cost of manufacturing, Bachem and Thera shall negotiate in good faith to adjust pricing. Thera agrees to use reasonable efforts to limit the demand of a Regulatory Authority in connection with any
required changes to the <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> <B></B>Net Lot Manufacturing Process and /or the Specifications; provided, however, that Thera makes no
representation and provides no warranty in connection with such efforts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall not be entitled to subcontract any of its obligations under this Agreement, except with respect
to its purchase of the raw materials to manufacture the Active Ingredient and with respect to its subcontracting of certain analytical services. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Bachem shall follow the instructions of Thera in connection with the packaging, handling, labeling and
shipping of the Active Ingredients to Thera&#146;s designated warehouse(s) as set forth in Schedule 5.9. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>QUALITY AUDITING</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera, or any other Person designated by Thera subject to the confidentiality provisions of this Agreement
or similar provisions of a confidentiality agreement executed with Bachem, shall be allowed to conduct audits of Bachem facilities in accordance with the terms of the Quality Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any dispute of the audit responses relating to the quality systems of Bachem that cannot be resolved by the
Parties in accordance with the Quality Agreement will be submitted to arbitration pursuant to the terms of Section&nbsp;14. Until settlement of a dispute, Thera shall be entitled to have Lots of Active Ingredient manufactured by another supplier
without being in breach of any provision of this Agreement. In the event the arbitration ruling is entirely in favour of the Bachem position, the entire quantity of Active Ingredient ordered and delivered by another supplier shall be added to the
Minimum Purchase Obligation of Thera hereunder during the Calendar Year in which the ruling was issued if the ruling is issued on or before June&nbsp;30 and during the following Calendar Year if the ruling is issued after June 30.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIALITY</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties hereby agree that any Confidential Information provided to the Recipient by the Disclosing Party
hereunder shall remain the exclusive property of the Disclosing Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 17</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Recipient agrees that it will maintain all Confidential Information in strict confidence and that it
will not permit the Confidential Information in its possession to be disclosed to any third party or used for any purpose not agreed upon by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding the above, any details relating to the conclusion of this Agreement, including, technical or
financial information contained in this Agreement, may only be disclosed by a Party to a third party with the prior written consent of the other Party which shall not be unreasonably withheld. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Recipient shall not permit any employee, director, officer, agent, representative or Affiliate to have
access to the Confidential Information unless such employee, director, officer, agent, representative or affiliate (a)&nbsp;needs to know the Confidential Information for the purposes of this Agreement, (b)&nbsp;has been informed of the confidential
nature of the Confidential Information, and (c)&nbsp;agrees to act in accordance with the terms and conditions set out in this Article. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Confidential Information shall not be reproduced in any form without the permission of the Disclosing
Party in writing, except as required for the execution of activities agreed upon between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event that the Recipient is required under Applicable Laws or a legal process to disclose any of the
Confidential Information, the Recipient shall provide the Disclosing Party with prompt notice of any such requirement to allow the Disclosing Party to seek an appropriate protective order and/or waive compliance with the provisions of
Section&nbsp;7.2. The Parties agree that if the Disclosing Party does not obtain a protective order or does not provide the Recipient with a waiver and the Recipient is, nonetheless, compelled to disclose the Confidential information to any
competent judicial Authority, or else to be liable for contempt or suffer other penalty, the Recipient may disclose only that portion of the Confidential Information which it is legally required to such tribunal without liability hereunder;
provided, however, that Recipient gives the Disclosing Party advance written notice of the Confidential Information to be disclosed as far in advance of its disclosure as is practical and, at the Disclosing Party&#146;s request, seek to obtain
assurances that it will be granted confidential treatment. Bachem acknowledges that this Agreement will be filed with securities regulatory authorities having jurisdiction over Thera business and affairs including on SEDAR and EDGAR. Prior to such
filing, Thera undertakes to submit to Bachem a redacted form of this Agreement. Bachem shall have ten (10)&nbsp;business days to review such redacted version. Failure by Bachem to notify Thera that it desires to make changes to the redacted version
within such ten (10)&nbsp;business days shall allow Thera to file such redacted version with such securities regulatory authorities. If Bachem has comments on the proposed redacted version, the Parties shall cooperate to allow Thera to proceed with
its regulatory filings. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Upon termination of this Agreement, in whole or in part, the Recipient shall, upon request, forthwith return
to the Disclosing Party all Confidential Information of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 18</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Disclosing Party in the possession of the Recipient and execute a certificate attesting the complete return of the Confidential Information, except with respect to one copy which may be retained
on file in a secure location for the purposes of compliance with applicable archiving obligations and/or determining obligations related to such Confidential Information. Notwithstanding the foregoing, the Disclosing Party acknowledges that the
Recipient may maintain back up of documents held on its computer systems in accordance with its normal IT systems policy. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>INSURANCE
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Throughout the Term and for a period of
<B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> years thereafter, Bachem shall obtain and maintain comprehensive general liability
insurance (including broad form general liability, completed operations and products liability, warehousing liability, blanket contractual liability and broad form property damage liability) with limits of not less than <B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> combined single limit for bodily injury and property damage liability per occurrence and <B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> annual aggregate. With respect to all insurance coverage required under this clause: (i)&nbsp;Bachem shall, promptly
upon Thera&#146;s request, furnish Thera with certificates of insurance evidencing such insurance; and (ii)&nbsp;all policies shall include provisions for at least thirty (30)&nbsp;days&#146; prior written notice of any material change or
cancellation (whether for <FONT STYLE="white-space:nowrap">non-payment</FONT> or otherwise). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEMNIFICATION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">To the fullest extent permitted by law, and except to the extent Thera is obligated to indemnify Bachem
under Section&nbsp;9.2 herein, Bachem shall indemnify and hold harmless Thera and its Affiliates, and their respective directors, officers, employees, consultants, agents, customers, successors and assigns from and against all suits, claims, losses,
demands, liabilities, damages, costs and expenses (collectively, the &#147;<B>Liabilities</B>&#148;) in connection with any claim, charge, suit, demand, action, inspection or proceeding of any kind made or brought by any third party (a
&#147;<B>Third Party Claim</B>&#148;), including any Regulatory Authority and any customer or licensee, to the extent that such Liabilities arise from or relate to: (a)&nbsp;Bachem&#146;s failure to follow and execute or to manufacture, handle,
test, label, or store the Active Ingredient in accordance with the Quality Agreement or the Specifications, (b)&nbsp;the negligence, recklessness or willful misconduct of Bachem, its employees, suppliers or agents, (c)&nbsp;Bachem&#146;s failure to
manufacture the Active Ingredient in accordance with cGMPs, (d)&nbsp;Bachem&#146;s failure to comply with all Applicable Laws, regulatory filings applicable to its performance under this Agreement, or (e)&nbsp;breach by Bachem or its suppliers or<B>
</B>agents of any representation, warranty, covenant or agreement made by Bachem contained in the Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 19</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">To the fullest extent permitted by law, and except to the extent that Bachem is obligated to indemnify Thera
under Section&nbsp;9.1 herein, Thera shall indemnify and hold harmless Bachem and its Affiliates, and their respective directors, officers, employees, consultants, agents, successors and assigns from and against all Liabilities in connection with
any Third Party Claim to the extent that such Liabilities arise from or relates to: (a)&nbsp;the use or sale of the Finished Product containing the Active Ingredient (b)&nbsp;breach by Thera, or its agents of any representation, warranty, covenant
or agreement made by Thera contained in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">A Party that intends to claim indemnification under this Article 9 (&#147;<B>Indemnified Party</B>&#148;)
shall promptly notify the other Party (the &#147;<B>Indemnifying Party</B>&#148;) of any Liability in respect of which the Indemnified Party intends to claim such indemnification, and the Indemnifying Party shall have the right to participate in,
and, to the extent the Indemnifying Party so desires, to assume the defence thereof with counsel selected by the Indemnifying Party; provided, however, that an Indemnified Party shall have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any
other party represented by such counsel in such proceedings or if Indemnifying Party fails to act under this Section&nbsp;9.3 in a reasonably timely manner. The Indemnifying Party shall not, without the Indemnified Party&#146;s prior consent (such
consent not to be unreasonably withheld, delayed or conditioned) enter into any compromise or settlement that involves equitable or other <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief in respect of any Liability. The Indemnified Party
shall not, without the prior consent of the Indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned) enter into any compromise or settlement or any voluntary consent judgment in respect of any Third Party Claim, and
the Indemnified Party shall use reasonable efforts to mitigate losses arising from any Third Party Claim. Each of the Indemnifying Party and Indemnified Party shall not make any admission of liability in respect of any Third Party Claim without the
prior consent of the other party, such consent not to be unreasonably withheld, delayed or conditioned. The failure to deliver notice to the Indemnifying Party within a reasonable time after the commencement of any such action shall not relieve the
Indemnifying Party from any obligation under this Section&nbsp;9.3 unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby. The Indemnified Party, its employees and agents, shall at the Indemnifying Party&#146;s
expense cooperate fully with the Indemnifying Party and its legal representatives in the investigation of any action, claim or liability covered by this indemnification. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 20</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>TERM AND TERMINATION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement will begin as of the Effective Date above and shall continue in full force and effect for a
period of <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> years (the &#147;<B>Initial Term</B>&#148;). Upon mutual agreement by both Parties, this Agreement
may be extended for one additional <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> term (the &#147;<B>Renewal Term</B>&#148;) (the Initial Term and the Renewal Term,
collectively the &#147;<B>Term</B>&#148;). Either Party&#146;s request to renew shall be provided to the other Party in writing at least
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> days prior to the termination of the Initial Term. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of a material breach of any provision of this Agreement, the Party that is not in breach of the
Agreement (the &#147;<B>Non</B><B><FONT STYLE="white-space:nowrap">-</FONT></B><B>Breaching Party</B>&#148;) shall have the right to terminate this Agreement immediately upon written notice to the Party being in breach (the &#147;<B>Breaching
Party</B>&#148;) of the Agreement if the Breaching Party fails to remedy a breach within <FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT> days following receipt of a written
notice from the <FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party specifying the material breach with reasonably sufficient particulars. In the event of termination by Thera in accordance with this Section&nbsp;10.2, Thera shall have no
obligations including for the payment of any Firm Order. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either Party may terminate this Agreement on notice to the other Party in the event the other Party becomes
the subject of a petition filed for relief under any bankruptcy or insolvency law, which is not dismissed within
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> days of its filing; any general arrangement with its creditors; any liquidation, termination or cessation of
its business. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera shall have the right to terminate this Agreement upon a
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> month prior written notice to Bachem in the event of a Change of Control of Thera. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Thera shall have the right , without penalty, including for the payment of any Firm Order, to terminate this
Agreement upon written notice to Bachem in the event that (i)&nbsp;the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B> Net Lot Manufacturing Process is not
validated, (ii)&nbsp;in the event FDA approval is not obtained for any change to the <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B> Net Lot Manufacturing Process or
(iii)&nbsp;a Regulatory Authority causes the withdrawal from the market of the Finished Product, provided that, in the case of (i)&nbsp;and (ii) above, there have been three validation lots produced. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Except as otherwise expressly provided in this Agreement, termination of this Agreement for any reason,
shall not extinguish the unpaid obligations of any Party that accrued prior to the effective date of termination, including all payment obligations subject to a Firm Order. In the event of termination in accordance with Section&nbsp;10.2., 10.3, and
10.5, Thera shall have the right to <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B>. The
obligations of both Parties with respect to confidentiality under Article 7 hereof shall survive termination of this Agreement for any reason for an indefinite period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 21</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>FORCE MAJEURE </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Each
of the Parties shall be excused from the performance of its obligations hereunder, in the event that such performance is prevented by force majeure, provided that each of the Parties shall use its Best Efforts to complete such performance by other
means. For the purpose of this Agreement, force majeure is defined as follows: causes beyond the control of Thera or Bachem, including but not limited to, acts of God; acts, regulations or laws of any government; war; civil commotion; destruction of
production facilities or materials by fire or storm; epidemic, pandemic, and failure of public utilities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any payment, notice or other written communication, including a purchase order, (a
&#147;<B>Notice</B>&#148;) required or permitted to be made or given hereunder may be made or given by either Party by email at the address mentioned below; by first-class mail (postage prepaid) or by air courier to the mailing address set out below
or to such other respective addresses as either Party shall designate to the other Party, by Notice, provided that such Notice shall be effective only upon receipt thereof. Notices shall be deemed to have been received: (i)&nbsp;if mailed, seven
(7)&nbsp;days after being dispatched by mail, postage prepaid; (ii)&nbsp;if sent by air courier, three (3)&nbsp;days after delivery to the air courier company; or (iii)&nbsp;if sent by email, on the day on which such email was sent if such day is a
business day for the recipient or on the first business day next following its transmission if the email was sent on a day that is not a business day for the recipient. For the purposes of this Article, in the case of Notices sent to Thera,
&#147;<B>business day</B>&#148; shall mean every day of a week, other than Saturdays, Sundays and statutory holidays in the Province of Quebec, from 8:30&nbsp;am to 5:00&nbsp;pm (Eastern Time); and, in the case of Notices sent to Bachem,
&#147;<B>business day</B>&#148; shall mean every day of a week, other than Saturdays, Sundays and statutory holidays in the State of California, from 8:30&nbsp;am to 5:00&nbsp;pm (Pacific Time). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 22</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Notices sent to either Party shall be sent to the following address: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="93%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">If to Thera:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Theratechnologies Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">2015 Peel Street, Suite 1100</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Montr&eacute;al, Quebec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Canada, H3A 1T8</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Attention: General Counsel and Corporate Secretary</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Email:
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">If to Bachem:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Bachem Americas Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">3132 Kashiwa Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Torrance, California 90505</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">U.S.A.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Attention: President and COO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Email: <B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT></B><B></B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>LIMITATIONS OF LIABILITY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Except as required by Applicable Law, each Party&#146;s obligations under Article 7 (Confidentiality) and Article 9 (Indemnification) or due
to a Party&#146;s reckless acts or omissions or wilful misconduct, neither Party shall be liable to the other, whether based on contract law; torts or any other area of law, for loss of income, loss of profit, or any indirect or consequential loss,
cost or damages arising out of or in any way related to this Agreement or its performance.<B><I> </I></B>The maximum total liability of Bachem whether based on contract law, torts or any other area of law shall be <B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT></B><B></B><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; &#8195;&#8195;&#8195;&#8195; </FONT></B><B><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; </FONT></B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>ARBITRATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Any
dispute between the Parties arising under this Agreement, including its interpretation, shall be conclusively settled by the submission of the dispute to arbitration. Arbitration shall be conducted in accordance with the Commercial Arbitration Rules
of the American Arbitration Association (&#147;AAA&#148;) The arbitration shall take place in the English language, in New York County, New York, New York, United States of America before an arbitral tribunal consisting of one arbitrator selected by
the Parties pursuant to the rules and procedures of the AAA. The cost of the arbitration, other than attorney&#146;s fees and expenses, shall be shared equally among the Parties and each Party shall pay its own legal fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 23</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>FINAL PROVISIONS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement shall be binding upon and enure to the benefit of the Parties hereto, their successors and
permitted assigns. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement constitutes the entire agreement of the Parties with respect to the subject matter of this
Agreement and supersedes all prior and contemporaneous agreements and understandings in connection therewith. It may not be changed nor modified orally, but only by agreement in writing signed by a duly authorized representative of each of the
Parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each of the Parties upon the request of the other shall do, execute, acknowledge and deliver or cause to be
done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney and assurances as may be reasonably necessary or desirable to effect complete consummation of the transactions
contemplated by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Nothing contained herein shall constitute or create a partnership among, or a joint venture by, all or any
of the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Neither failure nor delay by either Party to exercise any right or remedy provided in this Agreement or by
statute, or law shall operate as a waiver of such right or remedy, nor shall any single or partial exercise of any such right or remedy preclude any other or further exercise of any other right or remedy. The rights and remedies set forth in this
Agreement are cumulative and enforcement of one right or remedy shall not preclude subsequent enforcement of the same or other rights and remedies provided in this Agreement or at law. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement and all rights and obligations hereunder shall not be assigned in whole or in part by either
Party to any third party without the prior written consent of the other; provided, however, that Thera shall be entitled to assign this Agreement in whole only without the prior written consent of Bachem to a Related Party or in the event of a
Change of Control of Thera and provided further that Bachem shall be entitled to assign this Agreement in whole only without the prior written consent of Thera in connection with the sale of all or substantially all of the entire company. The Party
having assigned this Agreement shall be relieved from any obligation hereunder. In the event Thera assigns this Agreement, Thera shall continue to have the right to order from Bachem the manufacture of Active Ingredients pursuant to the prices set
forth in Schedule 3.3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 24</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be executed in two
counterparts by their duly authorized representatives as of the day and year first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><B>THERATECHNOLOGIES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ John Leasure</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Leasure</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Global Commercial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ Philippe Dubuc</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Philippe Dubuc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President and CFO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Per:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ Paul Levesque</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Paul Levesque</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><B>BACHEM AMERICAS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Per&nbsp;:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ Anne-Katrin Stoller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NAME: Anne-Kathrin Stoller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">TITLE: President&nbsp;&amp; COO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Per&nbsp;:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ Christopher J. McGee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NAME: Christopher J. McGee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">TITLE:&nbsp;VP&nbsp;&amp;&nbsp;Head,&nbsp;Global&nbsp;Business&nbsp;Development</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">

<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>Manufacturing and Supply Agreement</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt"><I>between Theratechnologies Inc, and Bachem Americas Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>Page 25</I></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.1.35 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>QUALITY AGREEMENT </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.1.40 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SPECIFICATIONS ACTIVE INGREDIENT
</U><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><U> LOT </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U></U><FONT
STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><U> </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>QUOTATION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U></U><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><U> </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3.3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>PRICE FOR
</U><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><U> NET LOTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B>
<B> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 5.9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DESGINATED WAREHOUSE(S) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT>
</B><B> </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.37
<SEQUENCE>17
<FILENAME>d680117dex437.htm
<DESCRIPTION>EX-4.37
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.37</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.37</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>DATE : MARCH 1, 2020</B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT CONTRACT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">BETWEEN:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC., </B>corporation governed by the Business Corporations Act (Quebec), having its head office at
2015, Peel Street, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Montreal, Province of Quebec, H3A 1T8;</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-right:2.00em; font-size:12pt; font-family:Times New Roman" ALIGN="right">(the &#147;<B>Employer</B>&#148; or &#147;<B>Thera</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">AND:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PAUL L&Eacute;VESQUE</B>, residing at
<B><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></B><B></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-right:2.00em; font-size:12pt; font-family:Times New Roman" ALIGN="right">(the &#147;<B>Executive</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>WHEREAS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Employer is a publicly-listed company which conducts commercial-stage biopharmaceutical activities which
include the marketing and commercialization of prescription products addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, and research activities focused on specialized therapies addressing unmet
medical needs in the HIV and oncology sectors;<U> </U> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Employer wishes to retain the Executive for the position of President and Chief Executive Officer, and
the Executive agrees to be retained as such; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive and the Employer (each a &#147;<B>Party</B>&#148; and, collectively, the
&#147;<B>Parties</B>&#148;) wish to enter into this employment contract (the &#147;<B>Contract</B>&#148;) for the purpose of agreeing on the terms and conditions that will govern their employment relationship. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>DUTIES AND RESPONSIBILITIES OF THE EMPLOYEE AND EMPLOYMENT TERM </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Position</U>: The Executive is hired for the position of President and Chief Executive Officer of Thera.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Announcement</U>: The Parties agree to publicly announce the Executive&#146;s nomination as President and
Chief&nbsp;Executive Office of Thera on or around March&nbsp;2, 2020. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 2
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Hierarchical Level and Functions</U>: The Executive will report to the Board of Directors of Thera
(the &#147;<B>Board</B>&#148;). The Executive will be responsible for coordinating, managing and overseeing Thera&#146;s general activities, including revenue growth from existing products, budgetary preparation for board approval, accountability
for such budgets, clinical development for unmet medical needs, and opportunistic acquisitions of new products or assets, in addition to the functions normally associated with his position or any other functions that are assigned to him by the Board
from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Commencement Date and Term</U>: The Executive shall commence employment on April<U></U>&nbsp;6,
2020 (the &#147;<B>Commencement Date</B>&#148;) for an indefinite period of time, subject to the provisions related to termination of employment set out below. The Commencement Date also constitutes the starting point for the calculation of the
length of service for the purposes of this Contract. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Performance of Duties</U>: The Executive agrees to perform his duties to the best of his ability
and with loyalty and diligence, in the best interests of the Employer. The Executive must also safeguard the honor, dignity and reputation of Thera in its dealing with employees, shareholders, service providers and the public in general.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Evolving and Changing Business Needs</U>: Depending on how its business needs evolve or change,
the Employer may, from time to time, change the Executive&#146;s duties, tasks, title, hierarchical level and place of work, as well as the persons to whom he reports, and such changes shall not constitute a termination or breach of the Contract.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Exclusive Service</U>: During the term of the Contract, the Executive undertakes to devote all his
work time to the performance of his duties and to work exclusively for the Employer. The Executive shall not hold any other employment or engage in any other gainful activity (either for another employer, for his own business or as a self-employed
worker or consultant) without the prior written consent of the Board. Thera shall permit the Executive to serve as a director on a single board of directors for a company that is not in conflict with Thera, provided he obtains the prior consent of
Thera&#146;s Board, upon recommendation of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Conflicts of Interest</U>: The Executive shall disclose to the Board any existing or potential
conflict of interest. If the Executive is unsure of the existence of a conflict of interest, he shall submit the matter to the Board who will, acting reasonably, make a decision in that regard. The Executive shall act in such a way as to avoid any
conflict of interest. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.9.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Business Travel</U>: The Executive agrees to make any trip that the Employer could reasonably ask
the Executive to make for the purpose of performing his duties, including amongst others, United States and Europe. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 3
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>COMPENSATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Base Salary</U>: The Employer shall pay to the Executive an annual salary of $775,000 (the
&#147;<B>Base Salary</B>&#148;), less applicable deductions and withholdings. The Base Salary shall be paid in accordance with the Employer&#146;s payroll practices in effect at any time. The Base Salary shall be reviewed from time to time by the
Employer. The Employer is under no obligation to increase the Base Salary upon such review. Any such increase is at the sole discretion of the Employer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive agrees that the Employer may effect compensation (offset) between his salary or any other amount owed to him by
the Employer and any amount payable by him to the Employer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U></U><U>Short-term Incentives</U>: Upon recommendation by Thera&#146;s Compensation Committee, and subject
to approval by the Board, the Executive may be eligible to receive an annual bonus of up to 75% (target) of his Base Salary throughout the term of his employment, provided that the Executive achieves his annual operational objectives and strategic
achievements and he is still employed by Thera. For greater clarification, the Board may approve an annual bonus that is greater than the target amount of 75% of the Base Salary, in the case of exceptional performance. For the current financial
year, the Executive shall be entitled to a bonus prorated based on his Commencement Date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">As
mentioned, the decision to grant bonuses, and the amount of such bonuses shall take into consideration the achievement of certain annual operational objectives and strategic achievements set by the Board as well as other considerations such as, for
instance, rewarding strong leadership that, in the opinion of the Board, assures Thera&#146;s success. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Stock Options</U>: The following provisions shall apply with respect to stock options.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Long-term Incentives</U>: The Executive shall be eligible to long-term incentives of up to 100% of
his Base Salary, payable in the form of options issued in accordance with the terms and conditions stipulated in Thera&#146;s Share Option Plan (the &#147;<B>Plan</B>&#148;) as determined annually by the Board. The number of options to be issued, if
any, shall be determined on a price per option basis which will be calculated using the Black-Scholes option valuation model using assumptions in accordance with Thera&#146;s practice. The annual granting of options to the Executive is subject to
approval by the Board, upon recommendation by Thera&#146;s Compensation Committee, and shall take into consideration the achievement of certain annual objectives set by the Board as well as other considerations to be determined in the discretion of
the Board such as, for instance, rewarding strong leadership that, in the opinion of the Board, assures Thera&#146;s success. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 4
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Initial Grant of Options</U>. Upon the Commencement Date, the Executive
shall be entitled to a grant of approximately 330,000 options which shall automatically expire ten years after the date of grant and shall vest equally over a period of three years (1/3 per year) on the anniversary date of the date of grant. The
exact number of options to be granted to the Executive as part of the initial grant shall be determined by dividing the Executive&#146;s Base Salary by the value of an option, calculated using the Black-Scholes option valuation model using
assumptions in accordance with Thera&#146;s current practice. The exercise price of the options will be determined on the date of grant in accordance with the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Applicable Terms and Conditions</U>. The conditions pertaining to the options are set forth in the Plan, a copy of which
is attached hereto as <U>Schedule &#147;A&#148;</U>. In addition the Board may at the time of grant of any option impose additional conditions for the exercise of option. The Employer has an absolute right to modify or discontinue the Plan at any
time, and the Executive acknowledges that such modification or termination of the plan cannot be considered as a constructive dismissal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Annual Stipend for Tax Advice, Private Medical Expenses or other Ancillary Matters</U>: Upon presentation
of appropriate receipts, the Employer will reimburse the Executive for the fees engaged, up to a maximum net amount of $12,000 per year, in respect of, among other, tax advisory services for income tax reporting in Canada and the United States, if
applicable, and/or in respect of private medical expenses which are not covered by Thera&#146;s Group Benefit Plan or any other ancillary matter at the discretion of the Executive. For greater clarification, the Executive shall manage this benefit
in a tax efficient manner with the assistance of Thera&#146;s accounting department, subject to the understanding that the annual <FONT STYLE="white-space:nowrap">after-tax</FONT> benefit the Executive will receive is $12,000. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Registered Retirement Savings Plan (RRSP) Contributions</U>: On a yearly basis, the Employer will pay for
the Executive&#146;s maximum RRSP contribution, as determined by the competent Canadian tax authorities, including with respect to the 2020 fiscal year. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Benefits</U>: The Executive shall be eligible to participate in the Thera Group Benefit Plan, as amended
from time to time, subject to the terms and conditions set forth therein. The Employer reserves the right to modify, replace or discontinue, in whole or in part, the benefits associated with such plan, without any notice or any indemnification
whatsoever for the Employee. The Executive acknowledges having received and read a copy of the Thera Group Benefit Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Vacation</U>: Starting from the Commencement Date, the Executive shall be entitled to annual paid
vacation of five (5) weeks. The reference year for accrual of vacation is December 1 to November 30. Vacation must be taken based on the Employer&#146;s business needs and must be submitted for approval by the Chairperson of the Board as soon as
possible. Vacation may not be accumulated or carried forward from one year to the next, except to the extent permitted by law. Upon termination of his employment, the Executive shall be paid for any vacation accrued but unused.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 5
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>EXPENSES </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Expense account</U><U>:</U> The Executive shall reimburse the Employee, upon presentation of relevant
documents, any reasonable expenses incurred by the Executive in carrying out his duties, in accordance with the Employer&#146;s policies and procedures related to such expenses, as such policies and procedures may be revised by the Employer in its
sole discretion from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Reimbursement of Moving Fees</U>: The Employer shall reimburse the Executive for reasonable fees and
expenses incurred by the Executive to relocate his household effects from the Executive&#146;s apartment in New York City (NY) to Montr&eacute;al (QC). The Executive shall submit to the Employer, for review and approval, a summary of estimated
moving expenses before any such expenses are incurred. All moving expenses shall be accounted for and the receipts for such expenses shall be provided to the Employer. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>New York City Dwelling</U>: The Employer shall reimburse the Executive for all reasonable expenses
relating to the cost of terminating the lease of the Executive&#146;s apartment in New York City, or the Employer will pay for the remainder of the term of the lease, whichever is lower. The Executive will provide the Employer with the relevant
details regarding his lease in writing. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>APPOINTMENT TO THE BOARD OF DIRECTORS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive will be appointed as a member of the Board. No additional compensation will be payable for the
Executive&#146;s position as a director of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Employer will maintain directors&#146; and officers&#146; insurance covering the Executive, the details
of which will be provided under separate cover. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>POLICIES, RULES AND PROCEDURES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As a condition of employment, the Executive agrees that he will comply with all of the Employer&#146;s
policies, rules and procedures in effect, as adopted or modified from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive agrees to follow all guidelines and instructions that the Employer may provide to him, subject
to applicable laws. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Employer reserves the right to implement new policies, rules or procedures it deems appropriate for the
management of its working relationships. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 6
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>TERMINATION OF THE CONTRACT (TERMINATION OF EMPLOYMENT) </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either party may terminate the Contract and, as a result, terminate the Executive&#146;s employment as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1.a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Termination by the Executive (resignation)</U>: The Executive may terminate this Contract and his
employment at any time and for any reason whatsoever by giving the Employer prior written notice of no less than four (4)&nbsp;weeks before the date of such termination (resignation). The Employer reserves the right to waive such prior notice and/or
to relieve the Executive from his obligation to perform his work during such period, in whole or in part. In such event, the Executive shall be paid his Base Salary, less applicable deductions, until the effective date of his resignation. The
Executive shall have no further liability to the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1.b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Termination by the Employer without Serious Reason</U>: The Employer may terminate this Contract at any
time without serious reason by paying the Executive the equivalent of the Executive&#146;s current Base Salary for a period of 18 months (&#147;<B>Termination Base Salary Amount</B>&#148;) plus an amount equal to 150% of the Executive&#146;s annual
bonus at target, calculated at a rate of 75% of the Base Salary. The Employer may, at its option, pay such amount to the Executive as a lump sum or a salary continuance, in whole or in part. The Executive undertakes to sign, for the benefit of the
Employer, a release satisfactory to the Employer for any matter related to the Executive&#146;s employment or termination thereof. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1.c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Termination by the Employer for Serious Reason</U>: The Employer may terminate this Contract and the
Executive&#146;s employment for Serious Reason at any time, without notice or indemnity in lieu of notice. In such case, the Executive shall be paid any amount still owing to him by the Employer upon termination, as salary for work already performed
but unpaid, or as vacation accrued but unused. The Executive shall not be entitled to any other payment, except as expressly provided by applicable law. For the purposes of this Article 6, the term &#147;<B>Serious Reason</B>&#148; includes, without
limitation: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any dishonest act such as theft, fraud, embezzlement or misappropriation of funds in connection with the
Employer or its directors, shareholders, clients, suppliers, sub-contractors, consultants or employees or any attempt to commit such a dishonest act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any breach of the Executive&#146;s duty of loyalty, any conflict of interest or behaviour that adversely
affects the legitimate interests of the Employer; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">non-compliance with the requirements or legitimate expectations of the Employer, including as a result of
voluntary or involuntary underperformance or incompetence; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a breach of the obligations set forth in this Contract, including those described in Schedule &#147;B&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the refusal to follow the reasonable guidelines or instructions of the Employer; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 7
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a material breach of any policy, rule or procedure of the Employer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any other serious reason within the meaning of article 2094 of the <I>Civil Code of
Qu</I><I>&eacute;</I><I>bec</I>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Change of Control</U>: The following provisions shall apply in the case of a Change of Control (as
defined below) of Thera: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of termination of the Executive&#146;s employment by the Employer within 24 months of a Change
of Control of Thera (except if the termination is for a &#147;<B>Serious Reason</B>&#148;), the Executive will be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in an amount
equal to the aggregate of: (i) 24 months of the Executive&#146;s current Base Salary; (ii) 200% of the Executive&#146;s targeted annual bonus (Short-term Incentive) calculated at a rate of 75<U></U>&nbsp;% of the Base Salary; and (iii)&nbsp;the cash
value of the Thera benefits to which the Executive was entitled over the 24 months which precede the Executive&#146;s termination following a Change of Control. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of termination of the Executive&#146;s employment by the Executive (resignation), at his sole
discretion, within 12 months of a Change of Control of Thera, the Executive will be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in an amount equal to the aggregate of: (i)
12 months of the Executive&#146;s current Base Salary; (ii) 100% of the Executive&#146;s targeted annual bonus (Short-term Incentive) calculated on his Base Salary; and (iii)<U></U>&nbsp;the cash value of the Thera benefits to which the Executive
was entitled over the 12&nbsp;months which precede the Executive&#146;s termination following a Change of Control. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">For the purposes hereof, the term &#147;<B>Change of Control</B>&#148; shall mean the occurrence of any one
of the following: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any change of control, in fact or in law, including any purchase, sale, transfer, disposition or other
transaction, of any nature whatsoever, and whether carried out singly, in combination or as part of a series of transactions, pursuant to or as a result of which any person or group of persons acting together or in concert shall acquire, hold or
exercise, whether directly or indirectly, rights over more than forty percent (40%) of the outstanding common shares of Thera, or which entitle the holder(s) thereof to more than fifty percent (40%) of the economic value of Thera; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">those individuals who, as at the date hereof, constitute the Board of Directors of Thera (hereinafter called
the &#147;<B>Incumbent Board</B>&#148;) cease for any reason to constitute at least a majority of the Board of Directors; provided, however, that any individual becoming a director subsequent to the date hereof whose election or nomination for
election by Thera&#146;s shareholders was approved by a vote of at least a majority of the directors then comprising the Incumbent Board will be considered as though such individual were a member of the Incumbent Board. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 8
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Death</U>: The death of the Executive automatically terminates this Contract. In such case, the
Executive&#146;s estate shall not be entitled to claim any indemnity for loss of employment or any other amount, except for amounts that may still be owing to the Executive upon his death (for example, as salary for work already performed but
unpaid, or as vacation accrued but unused). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Resignation as Director or Officer</U>: In the event of termination of the Contract (termination of
employment), the Executive shall cease to act as a director or officer of the Employer and shall immediately resign from such position. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Application of Termination Provisions</U>: For greater certainty, the foregoing provisions related to the
termination of the Contract shall apply regardless of any changes to the Executive&#146;s conditions of employment that could occur after the signature of this Contract, including any promotion or transfer to another position, unless otherwise
expressly agreed to in writing by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>CONFIDENTIALITY, INTELLECTUAL PROPERTY AND RESTRICTIVE COVENANTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive agrees to be bound by the terms and conditions of the provisions set forth in <U>Schedule
&#147;B&#148;</U> of this Contract pertaining to confidentiality, intellectual property and restrictive covenants (such provisions being enforceable throughout the term and after termination of the Executive&#146;s employment). The contents of
Schedule &#147;B&#148; form an integral part of this Contract. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>RETURN OF ASSETS, DOCUMENTS AND INFORMATION BELONGING TO THE EMPLOYER </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Following termination of his employment, regardless of the reason, the Executive undertakes to immediately
return to the Employer any and all property, documents and information belonging to the Employer that the Executive has in his possession, including: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1.a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the computer, cell phone, keys, access cards, credit cards as well as identification and access codes
provided to the Executive for the performance of his duties; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1.b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">all files, manuals, guides, reports, lists of clients or suppliers, or other documents and information
related to the Employer&#146;s activities, regardless of the format thereof (paper or electronic). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>REPRESENTATIONS OF THE EXECUTIVE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive represents the following for the benefit of the Employer: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 9
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive has provided all information needed to assess his candidacy for the position of President and
Chief Executive Officer and has not omitted any information that could have led the Employer to decide not to retain his candidacy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive confirms that his employment with the Employer will not breach any verbal or written agreement
with another employer, including any <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement or any agreement to keep in confidence information obtained by the Executive prior to
his employment with the Employer. For greater certainty, the Executive confirms that by joining the Employer, he will not breach any <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> proprietary rights,
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or other covenant in favour of his current employer. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive represents that he has the experience and skills needed to perform the duties and assume the
responsibilities associated with the position offered to him by the Employer. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive represents that he has not failed to disclose information concerning his health that could
have allowed the Employer to determine that he does not have the ability to perform his duties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive represents that he is legally entitled to work in Canada and undertakes to maintain such
status for the duration of his employment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>GENERAL </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Assignment of the Contract and Alienation of the Enterprise</U>: The Executive shall not sell or assign
this Contract to any person. However, the Employer may alienate its enterprise or modify its legal structure by way of amalgamation or otherwise; in such case, the new employer may become bound by the Contract in accordance with applicable laws,
including article 2097 of the <I>Civil Code of Quebec</I>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Entire Agreement</U>: This Contract constitutes the entire agreement entered into between the Parties
regarding the subject matter hereof and cancels and supersedes any prior agreement, verbal or written, between the Parties with respect thereto. The Executive confirms that he has not relied on any undertaking or promise made orally or in writing by
or on behalf of the Employer, other than what is contained in this Contract, and that the essential terms of this Contract were the subject of discussions and negotiations between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Division and Headings</U>: The division of the Contract into sections, subsections and paragraphs, as
well as the insertion of titles, are for convenience of reference only and do not affect the Contract&#146;s interpretation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Currency</U>: Unless otherwise expressly agreed to by the Parties, any amount of money is in Canadian
dollars. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 10
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Severability</U>: If a provision of this Contract or of Schedule &#147;B&#148; is deemed invalid, illegal
or unenforceable by a court of competent jurisdiction, such decision shall not affect the validity, legality or enforceability of the remaining provisions of the Contract or of <U>Schedule &#147;B&#148;</U>, which shall be construed as if such
provision had been deleted. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Survival</U>: All of the obligations provided for in the Contract (and, in particular, those set forth in
sections 7, 8, 10.15 and 10.16 and in the restrictive covenants set out in section 3 of Schedule &#147;B&#148;) which are intended to apply after the termination of the Contract or after the termination of the Executive&#146;s employment shall
survive such termination, regardless of the reason. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Legal Compliance</U>: If a provision of the Contract violates a mandatory minimum standard imposed by
applicable law, such standard shall replace the illegal provision in the Contract and the Parties shall be bound by such standard. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Waiver</U>: The waiver by a Party to require strict compliance with any provision of this Contract or to
exercise any right or remedy provided for in this Contract shall not be construed as a waiver of the right to benefit from the Contract in the event of subsequent breach. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Copy of the Contract</U>: The Executive acknowledges having received a copy of this Contract duly
executed by the Employer. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Amendment</U>: No amendment to this Contract shall be valid unless it is made in writing and executed by
both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Applicable Law</U>: This Contract shall be subject to and interpreted in accordance with the laws in
force in the province of Qu&eacute;bec. Each Party submits to the jurisdiction of the Quebec courts for the purposes of any action, suit or proceeding arising out of or relating to this Contract. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The execution of this Contract is subject to Thera being satisfied of criminal and credit checks. The
Executive specifically consents to such checks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Notice</U>: Any notice (or prior notice) to be transmitted under this Contract shall be made in writing
and shall be delivered by hand or sent by registered mail, courier, fax or email to the following addresses: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">To the Employer: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:21%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2015, Peel Street, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Montreal, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Province of Quebec, H3A 1T8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">To the Employee: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:21%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Such addresses may be modified by each Party by notifying the other Party in accordance with this
provision. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 11
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Effective Date of the Contract</U>: The Contract takes effect on April&nbsp;6, 2020.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Independent Legal Advice</U>: The Executive acknowledges that he has read and understood this Contract
and that he has had the opportunity to seek independent legal advice regarding the interpretation and consequences of such Contract before signing it. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Confidentiality</U>: The Executive undertakes to refrain from revealing or disclosing, in any manner
whatsoever (including orally, in writing or on the Internet or social networks), all or part of the contents of this Contract to any person whomsoever, including any current or former Executive of the Employer. The Executive may, however, disclose
the contents of the Contract under the circumstances prescribed by law, as well as to the Executive&#146;s legal counsel, financial advisors or members of his immediate family, provided that they preserve the confidentiality thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Duty of Discretion</U>: The Executive shall refrain from publicly making or disseminating in any manner
whatsoever (including orally, in writing, or on the Internet or social networks) any denigrating or negative comment about the Employer, its employees, directors, officers, agents or mandataries or about a subsidiary or affiliate of the Employer and
their employees, directors, officers, agents and mandataries, regardless of the veracity of such comment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Personal Information</U>: The Executive agrees that the Employer will create and maintain a file to
contain his personal information collected during the recruitment process and during the course of his employment. The Executive agrees that such personal information will be used for the purposes of administration of his employment, including for
payroll and benefits administration, and may be communicated to third parties, whether in the Province of Quebec or outside of the Province of Quebec, for such purposes. Such file will be kept by the Employer during the course of his employment and
for up to seven (7)<U></U> years following the termination of his employment, the whole, in accordance with applicable legislation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>English Language</U>: The Parties hereby declare that they have expressly required that this Contract and
all related documents be drafted in English. <I>Les Parties d&eacute;clarent avoir express&eacute;ment requis que le pr&eacute;sent Contrat et tout document connexe soient r&eacute;dig&eacute;s en anglais.</I> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 12
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Counterparts</U>: This Contract may be executed in several counterparts, each of which shall be deemed to
be an original, and all of such counterparts shall together constitute one and the same document. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF
the Parties have executed this Contract in the city of <FONT STYLE="white-space:nowrap">New-York</FONT> City on the 1st day of March 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#8194;/s/ Paul L&eacute;vesque</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:3pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:3pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:3pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="3"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>&#8194;Witness</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:12pt"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:12pt"><B>&#8194;PAUL L&Eacute;VESQUE</B></FONT></TD></TR></TABLE></DIV>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="font-size:33pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Per:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">/s/ Dawn Svoronos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:3pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:3pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8194;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Dawn Svoronos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Chair of the Board</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 13
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE &#147;A&#148;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Share Option Plan </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[Provided under separate cover] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[See Share Option Plan dated as of February&nbsp;8, 2007 of the Company (incorporated by reference to Exhibit&nbsp;4.1 to the
Company&#146;s Annual Report on Form&nbsp;20-F filed with the SEC on February&nbsp;27, 2013)] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 14
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE &#147;B&#148;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY, INTELLECTUAL PROPERTY AND RESTRICTIVE COVENANTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>CONFIDENTIAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive will have access to Confidential Information (as defined below) as a result of or in connection with his work. By accepting this
offer of employment, the Executive agrees that Confidential Information is a valuable asset and is the sole property of the Employer, its clients or its third party providers. The unauthorized use or disclosure of such information would cause
serious harm to the Employer. At all times throughout the term of his employment and following termination thereof, the Executive shall keep in confidence all Confidential Information, and shall not use such Confidential Information (to his benefit
or to the benefit of any other party) nor disclose it to any person (including another employee or executive of the Employer), except to the extent necessary for the performance of the Executive&#146;s duties or as required by law. The Executive
shall also take reasonable precautions to prevent the inadvertent disclosure of Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Confidential
Information</B>&#148; includes, but is not limited to: any information relating to the Employer or any of its subsidiaries or affiliates that is generally not known, including, without limitation, all business plans, letters of intent, agreements,
contracts, strategies, financial information, operational and technical information, product information, marketing information, client lists and preferences, current or anticipated client requirements, price lists, marketing strategies, sales
analyses, product plans, supplier information, employees information and remuneration, employees and consultant training materials, databases, precedents, designs, improvements or developments, and any other confidential information concerning the
business or affairs of the Employer or its clients. Confidential Information also includes information of the types described above which the Employer receives from third parties (e.g. clients or potential clients, suppliers). Confidential
Information does not include any information that is or lawfully becomes public knowledge unless disclosed publicly by the Executive&#146;s fault. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Intellectual Property Right</B>&#148;: means any right acknowledged or granted, now or in the future, including any extension of a
protection granted in the future, in accordance with any law of any country concerning copyrights, patents, trade-marks, trade secrets, secret processes, industrial designs, or any other provision of a law or principle of civil or common law
relating to registered and unregistered intellectual property; &#147;Intellectual Property Right&#148; includes any right pertaining to any registration application or the securing of any one of the above rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Intellectual Property</B>&#148;: means all that is or can be protected under any Intellectual Property Right.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive acknowledges and agrees that the Employer is the first owner of any Intellectual Property Right to any Intellectual Property
that is, in whole or in part, discovered, invented, created, expressed in any material form (tangible or intangible), produced or implemented by the Employee, whether acting alone, jointly or in collaboration with any third party, (a)&nbsp;in the
context of carrying out this Contract, (b)<U></U>&nbsp;relating to the technology, activities or affairs of the Employer, its clients or suppliers, and (c)<U></U> using the Employer&#146;s equipment or facilities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 15
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">To the extent that, notwithstanding the foregoing paragraph, the Executive holds Intellectual
Property Rights to the Intellectual Property referred to in the foregoing paragraph, under a law of any country or otherwise, the Executive shall irrevocably assign such Intellectual Property Rights to the Employer, and such assignment shall take
effect as of the date on which such Intellectual Property Rights arose, having worldwide effect, for the complete period during which such Intellectual Property Rights are protected (as such period or rights may be extended from time to time in any
country) and without being subject to any restriction whatsoever, including those relating to any physical format, market sector or other restriction affecting the scope of such assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive hereby irrevocably waives any moral right he/she may hold in respect of the Intellectual Property contemplated by the foregoing
paragraphs, and this to the full extent permitted by the legislation of any country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive agrees to create and maintain on the
Employer&#146;s premises registers or documentation that comply with industry practices, which registers or documentation shall contemplate the Intellectual Property he/she will discover, design, create or express in any material form, tangible or
intangible, or that he/she will make or put into practice. These records or documentation shall include all source files or codes necessary to exploit such Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive agrees that he/she shall not incorporate into the Employer&#146;s systems, products and services any of his Intellectual
Property or Intellectual Property of a third party without disclosing to the Employer those conditions under which such Intellectual Property may be used and shall obtain the prior written consent of the Employer. Should the Executive incorporate
his own Intellectual Property into the systems, products or services of the Employer without complying with the provisions of this paragraph, the Executive shall irrevocably transfer to the Employer the Intellectual Property Rights to that
Intellectual Property, which transfer shall take effect as of the date on which the incorporation took place, and this shall apply throughout the world for the entire term of the protection afforded to the said Intellectual Property Rights (as such
term may be extended from time to time in any country), which Intellectual Property Rights shall not be subject to any restriction whatsoever, including restrictions pertaining to material supports, market sectors or other restrictions affecting the
scope of such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive undertakes throughout the term of this Contract and at all times following the termination thereof,
to fully and promptly disclose to the Employer any Intellectual Property contemplated by the above paragraphs as well as to fill out and sign, at the Employer&#146;s request, all documents that may be necessary or useful to give evidence of or
effect to the provisions of section 2 of this Schedule, including ensuring that the Employer obtains, protects or exercises these Intellectual Property Rights in any country. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 16
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>RESTRICTIVE COVENANTS APPLICABLE THROUGHOUT THE TERM AND AFTER TERMINATION OF EMPLOYMENT
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Non-solicitation of Clients</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Throughout the term of the Executive&#146;s employment with the Employer and for a period of 24 months after termination
thereof (whether such termination is initiated by the Executive or the Employer, with or without serious reason), the Executive shall comply with the following prohibitions, whether the Executive is acting on his own behalf or on the behalf of other
persons, directly or indirectly: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive shall not solicit nor attempt to solicit any &#147;Client&#148; (as defined below) of the
Employer for the purposes of selling or providing to such Client any products or services sold or provided by the Employer at the time of the termination of the Executive&#146;s employment; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive shall not encourage a Client of the Employer to cease doing business or to reduce its volume
of business with the Employer, nor shall the Executive otherwise attempt to interfere with the Employer&#146;s relations with such Client. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In this paragraph 3.1, &#147;<B>Client</B>&#148; means any client with whom the Executive had direct contact on behalf of the
Employer within the twelve (12) month period prior to the termination of the Executive&#146;s employment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Non-solicitation of Employees and Contractors</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Throughout the term of the Executive&#146;s employment with the Employer and for a period of 24 months after termination
thereof (whether such termination is initiated by the Executive or the Employer, with or without serious reason), the Executive shall comply with the following prohibitions, whether the Executive is acting on his own behalf or on the behalf of other
persons, directly or indirectly: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive shall not solicit an &#147;Employee or Contractor of the Employer&#148; (as defined below) nor
offer employment or a service contract to an Employee or Contractor of the Employer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Executive shall not encourage an Employee or Contractor of the Employer to terminate his or her
employment with, or to cease providing services to, the Employer, nor shall the Executive otherwise attempt to interfere with the Employer&#146;s relations with such Employee or Contractor. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In this paragraph 3.2, &#147;<B>Employee or Contractor of the Employer</B>&#148; means an Executive or contractor that has
been employed or retained by the Employer within the twelve (12)&nbsp;month period preceding the termination of the Executive&#146;s employment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 17
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive undertakes, throughout the course of his employment with the Employer and for a period of 18&nbsp;months
immediately following the date upon which the Executive ceases to be employed by the Employer for any reason whatsoever, to refrain from directly or indirectly performing duties or carrying out activities in the Employer&#146;s industry sector, in
any capacity whatsoever (including as a shareholder, partner, consultant, employer, employee, principal, agent, franchisee, franchisor, distributor, advisor or lender), i.e. with respect to commercial-stage biopharmaceutical activities (including
the marketing and commercialization of prescription products) addressing unmet medical needs for people living with HIV, and research activities focused on specialized therapies addressing unmet medical needs in HIV (the &#147;<B>Forbidden
Activities</B>&#148;), throughout the territory of Canada, the United States and Europe (the &#147;<B>Applicable Territory</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, if the Executive holds a passive investment representing not more than two percent (2%) of the
issued and outstanding shares in a company listed on a recognized exchange that performs, in whole or in part, directly or indirectly, Forbidden Activities, this shall not constitute a failure to meet the obligations set out in this Contract. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>ACKNOWLEDGEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Executive acknowledges that his obligations set out in this Schedule pertaining to confidentiality and restrictive covenants are
reasonable as to their scope. In addition, the Executive acknowledges that such obligations are necessary to protect the Employer&#146;s legitimate interests, including with respect to competition, and that they do not prevent the Executive from
earning a living by performing his profession or trade. The Executive also acknowledges that his breach of these obligations may cause serious or irreparable harm to the Employer and will therefore justify the institution of appropriate proceedings
by the Employer, including a provisional, interlocutory or permanent injunction. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.38
<SEQUENCE>18
<FILENAME>d680117dex438.htm
<DESCRIPTION>EX-4.38
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.38</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.38</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EMPLOYMENT CONTRACT</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>ENTERED INTO </B>at the place and date of the last signature appearing on the last page. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>BETWEEN:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL>.</B>, a corporation governed by the <I>Business Corporations Act</I>
(Qu&eacute;bec), having its head office and principal place of business at 2015 Peel Street, 5th&nbsp;Floor, Montr&eacute;al, Province of Qu&eacute;bec, H3A 1T8;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter &#147;Thera&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>AND:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>P<SMALL>HILIPPE</SMALL> D<SMALL>UBUC</SMALL></B><SMALL></SMALL>, residing and domiciled at <FONT
STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT>;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter the &#147;Employee&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>Thera wishes to hire the Employee to act as Senior Vice President and Chief Financial Officer
in accordance with the terms and conditions contained herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>the<B> </B>Employee wishes to work for Thera in
accordance with the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>,<B> </B>the parties agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Effective Date</U></B>.<B> </B>This employment contract is effective as of the last date this contract
is executed by Thera and the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Title</U></B>.<B> </B>The Employee will act as Senior Vice President and Chief Financial Officer. The
Employee shall report to the President and Chief Executive Officer or such other person as he may appoint in accordance with changes in Thera&#146;s organizational structure. The Employee shall perform the duties and functions indicated to him by
his superior, which shall depend on the position held by the Employee and on the size of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Employee Conduct</U></B>. The Employee must act with prudence and diligence in the best interests of
Thera. In addition, the Employee undertakes to comply with Thera&#146;s Code of Ethics, as it may be amended from time to time, as well as with any and all policies and procedures that may be implemented by Thera. The Employee acknowledges that a
breach of Thera&#146;s Code of Ethics may constitute reason for dismissal. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Compensation</U></B>.<B> </B>The Employee will receive the following compensation:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Base Salary</U>. The Employee shall receive an annual base salary of $275,000 less applicable tax
deductions, which shall be paid in accordance with the terms and conditions applicable to Thera&#146;s employees. The annual base salary will be subject to an annual review. However, any changes to the annual base salary will be subject to the
approval of the Compensation Committee and/or the Board of Directors of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Bonus</U>. The Employee will be eligible to participate in Thera&#146;s discretionary bonus program. As
part of his participation in this program, he may receive a bonus of up to 40% of his annual base salary earned, less applicable tax deductions. Any bonus, as the case may be, shall be assessed and determined in accordance with Thera&#146;s general
policy on discretionary bonus payments, as said policy may be amended from time to time. The Employee shall not receive any bonus if he is not employed by Thera at the time such bonus could be paid. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Stock Option Plan</U>. The Employee will be eligible to participate in Thera&#146;s stock option plan.
The Employee acknowledges that the grant of stock options is at the discretion of Thera&#146;s Board of Directors and there is no assurance that the Employee will be granted stock options under Thera&#146;s stock option plan during the term of this
contract. In addition, the Employee acknowledges that Thera may amend or terminate its stock option plan at any time without any obligation to replace it with any other plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Subject to applicable law and Thera&#146;s trading <FONT STYLE="white-space:nowrap">black-out</FONT> policy, the Employee
will be granted 125,000 stock options to purchase common shares of Thera within two days following the end of the trading <FONT STYLE="white-space:nowrap">black-out</FONT> period. These stock options will have an exercise price equal to the closing
price of Thera&#146;s common shares on the day prior to their grant and will be acquired as follows: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">41,666 on the first anniversary of their grant date; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">41,666 on the second anniversary of their grant date; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">41,668 on the third anniversary of their grant date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">All other terms and conditions of such stock options shall be determined by the Board of Directors in accordance with
Thera&#146;s current stock option plan, as it may be amended from time to time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Other Incentive Compensation Plans</U>. The Employee will be eligible to participate in any other
incentive plan established by Thera&#146;s Board of Directors from time to time in which Thera&#146;s executive officers shall be eligible to participate. However, the Employee acknowledges that the final decision as to whether or not he may
participate in such a plan remains with the Board of Directors and/or its Compensation Committee. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Other Benefits</U></B>.<B> </B>The Employee will also be entitled to the following additional
benefits: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Vacation</U>. During the term of this contract, the Employee will be entitled to 20 days of paid vacation
per Thera fiscal year, which shall be subject to Thera&#146;s general vacation policy. For fiscal year 2016, the Employee will be entitled to 15 paid vacation days. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Group Insurance Plan</U>. As an employee of Thera, the Employee will be entitled to participate in and,
if eligible, receive benefits under the group insurance plans in force from time to time at Thera in accordance with their terms and conditions. The Employee acknowledges that the terms and conditions of the group insurance plans may be amended at
Thera&#146;s discretion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Representation and Expenses</U>. Upon presentation of the requested supporting documents, the Employee
will be entitled to reimbursement of all costs and expenses reasonably incurred in the performance of his duties, subject to compliance with Thera&#146;s established budgets and policies. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Group RRSP</U>. The Employee shall be required to subscribe to Thera&#146;s Group RRSP for a minimum of
1% of his annual base salary. In accordance with its current contribution policy, as may be amended from time to time, Thera shall subscribe to the Employee&#146;s RRSP for an amount equal to the amount subscribed by the Employee, subject to the
annual limits imposed by tax laws. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Annual Health Assessment</U>. Thera will reimburse the Employee for the expenses related to an annual
health assessment at a private clinic chosen by the Employee. Reimbursement of these expenses will be made upon presentation of supporting documents and up to an amount of $1,200 per annual health assessment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Employee Representations</U></B>.<B> </B>The Employee represents the following to Thera and
acknowledges that it is an essential condition to the validity of this contract that the representations of the Employee be true on the effective date of this contract: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(i)&#8195;he is not a debarred person within the meaning of the U.S. <I>Federal Food, Drug, and Cosmetic Act</I>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(ii)&#8195;the Employee has never filed for bankruptcy or availed himself of the provisions of the <I>Bankruptcy [sic] Ac</I>t
(Canada); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(iii)&#8195;the Employee has never been convicted of an indictable offence or of an offence under any
securities legislation and, to his knowledge, he is not subject to any investigation whatsoever by any governmental authority; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(iv)&#8195;the execution by the Employee of this contract shall not
contravene any contract to which the Employee is a party or to which the Employee was a party, certain undertakings of which are still in force which would have the effect of preventing him from performing his duties at Thera as of the effective
date of this contract. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Confidential Information</U></B>.<B> </B>For the purposes of this contract &#147;confidential
information&#148; means all information concerning Thera and its subsidiaries, whether such information is in oral, written, graphic, photographic, computerized, recorded or in any other form, except for information that is freely available to the
public. Without limiting the scope of the following, &#147;confidential information&#148; includes all trade secrets, scientific data, discoveries and inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> drawings, methods, processes,
software, diagrams, technical and professional knowledge, reports, names of suppliers and customers, contents of agreements with suppliers and customers, any financial information, prices, valuations, business objectives, plans, business
opportunities and market studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the term of this contract and for a period of 10 years
following the termination of this contract, the Employee undertakes not to disclose to any person, nor to use, for himself (except during the term of this contract for the purpose of performing his duties) or on behalf of any third party, the
&#147;confidential information&#148; of Thera and its subsidiaries, except with the prior authorization of Thera. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Intellectual Property</U></B>.<B> </B>The Employee undertakes to assign to Thera all inventions,
creations, processes, technologies or improvements developed by the Employee, alone or in collaboration, and which relate to the business of Thera and its subsidiaries or result from the very nature of his duties at Thera and its subsidiaries. The
Employee agrees to assist Thera and its affiliates in obtaining, renewing or maintaining domestic or foreign patents on such inventions, creations, processes, technologies or improvements, as well as with respect to its trademarks and industrial
designs. In addition, the Employee waives any moral rights he may have in respect of inventions, creations, processes, technologies, works or other intellectual property conceived or developed during the term of this contract. This provision shall
survive termination of this contract for an indefinite period. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U></B>.<B> </B>During the term of this
employment contract and for a period of twelve (12)&nbsp;months following its termination, the Employee undertakes and agrees not to, directly or indirectly, alone or jointly with one or more legal entities or individuals, as a consultant, mandator,
principal, mandatory, agent, partner, shareholder, employee, officer or director, or in any other capacity, operate, work on, or provide services relating to the research, development or marketing of molecules or peptides related to human growth
hormone-releasing factor (GHRH) or growth hormone (GH) for the treatment of lipodystrophy in HIV patients, as well as any products that Thera may acquire or develop. The territories covered by this prohibition are Canada and the United States.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U></B>.<B> </B>During the term of this
employment contract and for a period of twelve (12)&nbsp;months following its termination, the Employee undertakes and agrees not to, directly or indirectly, alone or jointly with one or more legal entities or individuals, solicit, induce, force,
incite, promote, facilitate or encourage, either for himself or on behalf of any legal entity or individual, any of Thera&#146;s officers or employees or those of any of its subsidiaries, to resign from their employment with Thera or any of its
subsidiaries, or to change their employment relationship with Thera or any of its subsidiaries. In addition, during the same period, the Employee undertakes and agrees not to engage the services of any officer or employee of Thera or any of its
subsidiaries who was in the employ of Thera and/or any of its subsidiaries on the date this employment contract is terminated. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Term</U></B>.<B> </B>This contract shall constitute an employment contract with an indefinite term,
any of the terms or conditions of which may be amended by mutual agreement of the parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Termination</U></B>.<B> </B>Thera may terminate this contract upon: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Employee&#146;s failure to provide the agreed services based on business objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Employee&#146;s failure to comply with the Code of Ethics or any other policy adopted by Thera in
connection with the marketing of EGRIFTA&reg;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">if the Employee is charged with committing an indictable offence within the meaning of the <I>Criminal
Code</I> (Canada) (other than driving while intoxicated, except if it caused death or resulted in injury to a third party) and that such criminal charge meets any of the following criteria: (i)&nbsp;it is related to the Employee&#146;s duties at
Thera, or (ii)&nbsp;it is of a nature that may damage Thera&#146;s reputation or cause a transaction to be derailed, or (iii)&nbsp;it may have material consequences on the Employee&#146;s ability to provide the agreed services;
</P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">if the Employee breaches any of its obligations or undertakings under this contract or if any of the
representations referred to in section 16 is false or erroneous; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">for any other serious reason. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee&#146;s involvement in the violation of the U.S. <I>Federal Food Drug, and Cosmetic Act</I>, the U.S. federal<I>
Anti-Kickback Statute</I> and the U.S. <I>False Claims Act</I>, as well as any similar legislation or regulations thereunder governing the marketing of Thera&#146;s pharmaceutical products for which Thera will be responsible for the said marketing,
will constitute a serious reason for dismissal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Employee undertakes, upon termination of his employment, not to copy,
remove or take any &#147;confidential information&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Indemnity for Dismissal Without Serious Reason</U></B>.<B> </B>If the Employee&#146;s employment is
terminated without serious reason by Thera, or if it is terminated following a structural reorganization within Thera (other than as a result of one of the events described in section 14), the Employee will be entitled to an indemnity equal to
twelve (12)&nbsp;months of his annual base salary, excluding any bonuses and benefits to which this contract refers. Payment of the severance indemnity is subject to Employee&#146;s compliance with the provisions of sections 7, 8, 9 and 10 hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Indemnity in Event of a Take-Over Bid and Other Material Transactions</U></B>.<B> </B>In the event of
any of the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">i) &#8194;&#8195;a take-over bid (within the meaning of the <I>Securities</I><I>
Act</I> (Qu&eacute;bec), as in effect from time to time) (a &#147;Bid&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ii) &#8195;any transaction (amalgamation
(other than with a subsidiary), arrangement, compromise, reorganization or other transaction of this nature, including any alienation by Thera to a third party of its property if, as a result of such alienation, Thera is unable to retain a
significant part of its business activity) (a &#147;Transaction&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">pursuant to which a person or any person acting
jointly or in concert (as defined in <I>Regulation</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;62-104</FONT> respecting Take-Over Bids and Issuer Bids</I> of the <I>Securities Act</I> (Qu&eacute;bec), as in effect from time to time) with
such person acquires control of Thera and that, within 12 months of the completion of the Bid or the Transaction, the Employee&#146;s employment atThera is terminated without serious reason, the Employee will then receive on the date of termination
of his employment an amount equal to the greater of (i)&nbsp;reasonable notice provided for by law and (ii) 12 months of his annual base salary, at the time of termination plus an amount equal to 100% of the maximum bonus set out in section 4.2
hereof, calculated based on such annual base rate salary, as well as any other amounts due but unpaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">For the purposes
hereof, a person will be deemed to have acquired control of Thera if the person and/or persons acting jointly or in concert with the person own at least 40% of the voting securities of Thera or the entity resulting from the Transaction. For the
purpose of calculating the number of voting securities held by any person (including persons acting jointly or in concert with such person), all securities convertible into or exchangeable for voting securities held or controlled by such person
shall be included as if they had been converted or exchanged into voting securities, whether the conversion or exchange occurs in one or more transactions. An alienation of property includes the sale, exchange, lease of property and the granting of
a licence in respect of any property. Thera will be deemed to retain a significant part of its business activity when the activities it retains after any alienation require the use of at least 25% of the value of its assets as at the end of the
fiscal year preceding such alienation and such activities generated in the fiscal year preceding such alienation at least 25% of Thera&#146;s <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenues or earnings. Payment of the severance indemnity is
subject to the Employee&#146;s compliance with the provisions of sections 8, 9, 10 and 11 hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Survival of Undertakings</U></B>.<B> </B>The undertakings set out in sections 7, 8, 9 and 10 shall
survive termination of this employment contract for the periods described therein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Governing Law</U></B>.<B> </B>This contract shall be interpreted and governed in accordance with the
laws of the province of Qu&eacute;bec and the laws of Canada applicable in Qu&eacute;bec. The parties submit to the jurisdiction of the courts of the province of Qu&eacute;bec. This contract shall be considered in all respects as a contract of
employment within the meaning of the <I>Civil Code of Qu</I><I>&eacute;</I><I>bec</I>, except where expressly waived. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Legal Counsel</U></B>.<B> </B>The<B> </B>Employee acknowledges that he has had sufficient time to
consult with legal counsel with respect to the terms and conditions contained in this employment contract. By executing this contract, the Employee acknowledges that he understands its terms and conditions and that he participated in the
negotiations thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this employment contract at the place
and date hereinafter set forth. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Signed on February&nbsp;24, 2016 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In the city of Montr&eacute;al, province of Qu&eacute;bec, Canada </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Luc Tanguay&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Luc Tanguay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Signed on February&nbsp;24, 2016 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In the city of Montr&eacute;al, province of Qu&eacute;bec, Canada </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>/s/ Philippe Dubuc&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>PHILIPPE DUBUC</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.39
<SEQUENCE>19
<FILENAME>d680117dex439.htm
<DESCRIPTION>EX-4.39
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.39</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.39</U> </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman"><B>PERSONAL AND CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">July&nbsp;27, 2023 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Philippe Dubuc </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" BGCOLOR="#000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>RE:</U><U>&#8195;&#8195;&#8195;&#8195;Amendment to your Employment </U><U>Contract</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dear Philippe, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Following
the decision of the Board of Directors to propose amendments to management employment contracts in order to update them in accordance with current legal principles and to harmonize the terms and conditions of employment contracts of executive
officers reporting to the President and Chief Executive Officer regarding termination without a serious reason (just cause) and the consequences arising from any change or acquisition of control of Theratechnologies Inc. (&#147;<B>Thera</B>&#148;)
or a material transaction by Thera, we propose amending sections 13 and 14 of your employment contract dated February&nbsp;24, 2016 (the &#147;<B>Contract</B>&#148;) as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">-&#8195;By deleting the text of existing section 13 of the Contract and replacing it with the following text: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;13. <B><U>Indemnity for Termination Without a Serious Reason.</U></B><B> </B>If the employment of the Employee is terminated without a
serious reason, including as part of a reorganization to reduce personnel for economic reasons, but excluding a termination following a Change of Control (as defined below) in the circumstances set out below, the Employee will receive an amount
equal to the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 5 years or more but less than 10 years of continuous service: 18 months of his annual
base salary at the time of his termination plus an amount equal to 100% of his target bonus for 18 months calculated on the basis of such annual base salary, but excluding the value of the benefits offered by Thera and the value of option grants or
other stock-based incentive compensation and any other amounts that may be due and unpaid; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 10 years or more of continuous service: 24 months of his annual base salary at the time
of his termination plus an amount equal to 100% of his target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of benefits offered by Thera and the value of option grants or other stock-based incentive
compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employee will also receive an amount equal to the value of his accrued and unpaid vacation up to
the date of termination of his employment and the reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">-&#8195;By deleting the text of existing section 14 of the Contract and replacing it with the following text: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;14. <B><U>Indemnity Following a Change of Control or Any Other Material
Transaction.</U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In the event of any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a transaction (other than a transaction referred to in paragraph (b)&nbsp;below), regardless of its
structure (an &#147;<B>Acquisition</B>&#148;), pursuant to which a person or persons acting jointly or in concert (as defined in <I>Regulation <FONT STYLE="white-space:nowrap">62-104</FONT> respecting Take-Over Bids and Issuer Bids</I>, as in effect
from time to time) directly or indirectly acquire beneficial ownership of, or control over, securities of Thera representing 40% or more of the voting rights attached to all voting securities for the election of directors of Thera then outstanding;
or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of any amalgamation, arrangement, compromise, consolidation, reorganization or other
transaction or series of transactions of this nature involving directly or indirectly Thera (a &#147;<B>Combination</B>&#148;) which results in either (i)&nbsp;the shareholders of Thera immediately prior to such Combination no longer holding,
directly or indirectly, after the Combination, more than 60% of the voting rights attached to all voting securities for the purpose of electing directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, of the
ultimate parent company of such subsidiary); or (ii)&nbsp;the Board of Directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, the ultimate parent company of such subsidiary) is no longer composed of a majority of
the directors who served on Thera&#146;s Board of Directors immediately prior to the Combination; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a change in the composition of Thera&#146;s Board of Directors occurring, without the approval by a
majority vote of the directors composing Thera&#146;s Board of Directors prior to such change, at the same shareholders meeting or pursuant to a resolution of Thera&#146;s shareholders, and which results in Thera&#146;s Board of Directors no longer
being composed of a majority of the directors of Thera who were serving as directors immediately prior to such meeting or resolution (other than a change resulting from the solicitation of proxies by the management of Thera or related to death,
resignation or inability to act in such capacity) (an &#147;<B>Insurgency</B>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of the sale, exchange, lease, transfer, liquidation, grant of an exclusive license, or any
other form of alienation of Thera&#146;s assets, to a party that is not an affiliate of Thera (as defined in the <I>Business Corporations Act</I> (Qu&eacute;bec)), representing substantially all of Thera&#146;s assets (an &#147;<B>Asset
Transfer</B>&#148;); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">and that within 24 months following the occurrence of any Acquisition, Combination, Insurgency
or Asset Transfer (each representing for the purposes hereof a &#147;<B>Change of Control</B>&#148;), either (a)&nbsp;the employment of the Employee is terminated without a serious reason; or (b)&nbsp;the Employee decides to terminate his employment
of his own free will, the Employee shall then receive on the date of termination of his employment an amount equal to the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8201;&#8201;&#8194;i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8199;ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 5 years or more but less than 10 years of continuous service: 18 months of his annual
base salary at the time of his termination plus an amount equal to 100% of his target bonus for 18 months calculated on the basis of such annual base salary, but excluding the value of the benefits offered by Thera and the value of option grants or
other stock-based incentive compensation and any other amounts that may be due and unpaid; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8201;iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 10 years or more of continuous service: 24 months of his annual base salary at the time
of termination plus an amount equal to 100% of his target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of the benefits offered by Thera and the value of option grants or other stock-based incentive
compensation. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In all cases, the Employee will also receive an amount equal to the value of his accrued
and unpaid vacation up to the date of termination of his employment and reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this section, in order to calculate the percentage of the number of voting securities held by any person (including
persons acting jointly or in concert with such person) relative to the number of outstanding voting securities, such calculation shall include, both with respect to the voting securities held by such person (and persons acting jointly or in concert
with such person) and to the outstanding voting securities, all convertible or exchangeable securities within sixty (60)&nbsp;days from the date of calculation of voting securities held or controlled by such person, as if such securities had been
converted or exchanged into voting securities, whether such conversion or exchange occurs in one or more transactions. Such securities convertible or exchangeable within sixty (60)&nbsp;days shall be deemed to have been acquired and to be
beneficially owned by such person (or any person acting jointly or in concert with such person). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Thera will be deemed to have entered
into an Asset Transfer if such Asset Transfer represents more than 75% of the value of its assets calculated as at the date of the fiscal year end preceding such Asset Transfer, or if the assets transferred in connection with such Asset Transfer
represent more than 75% of the income generated by Thera during the fiscal year preceding such Asset Transfer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">-&#8195;By adding the following section 14.1 to the Contract: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;14.1 <B><U>Acceleration of Acquisition of Securities Issued as Long-Term Compensation Plans</U></B>.<B> </B>In the event of a Change
of Control, all securities and rights issued or granted to the Employee under long-term compensation plans, such as stock options, deferred share units, appreciation rights and other rights that vest over a defined period of time, whether or not
based on the achievement of performance targets, will all automatically vest as if the vesting conditions and, if applicable, the achievement of performance targets had been met.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you agree to these amendments, we ask that you return this letter to us <U>no later than August</U><U></U><U>&nbsp;3, 2023</U>, failing
which we will assume that these amendments to your employment contract are not acceptable to you and this proposal will then lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">These amendments will become effective upon the date of your execution of this letter below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Except for these amendments to your restated and amended employment contract, all other terms and conditions will remain in effect and
unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you accept these amendments, please sign this letter in the space provided below and return a duly executed copy thereof
to Mr.&nbsp;Jocelyn Lafond, General Counsel and Corporate Secretary of Thera. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Yours truly, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Paul
L&eacute;vesque</U> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Paul L&eacute;vesque </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that I have read, had the opportunity to consult with legal counsel and understand and accept the content of these amendments
to my employment contract dated February&nbsp;24, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dated and signed at Montr&eacute;al (Qu&eacute;bec), on July 27, 2023. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Philippe Dubuc</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#8201;Philippe Dubuc </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.40
<SEQUENCE>20
<FILENAME>d680117dex440.htm
<DESCRIPTION>EX-4.40
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.40</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.40</U> </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED EMPLOYMENT AGREEMENT</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>ENTERED INTO </B>at the place and date of the last signature appearing on the last page. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>BETWEEN:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL>.</B>, a corporation governed by the <I>Business Corporations Act</I>
(Qu&eacute;bec), having its head office and principal place of business at 2310 Alfred-Nobel Boulevard, Montr&eacute;al, Province of Qu&eacute;bec, H4S 2B4;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter &#147;Thera&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>C<SMALL>HRISTIAN</SMALL> M<SMALL>ARSOLAIS</SMALL></B><SMALL></SMALL>, residing and domiciled at <FONT
STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8201;&#8195;&#8195;&#8194;&#8195;</FONT>;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter the &#147;Employee&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>the Employee is employed by Thera since May&nbsp;7, 2007 following the execution of an
employment contract dated April&nbsp;13, 2007, as amended May&nbsp;23, 2012 and July&nbsp;17, 2012 (the &#147;employment contract&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>Thera and the Employee wish to amend the employment contract in accordance with the terms and conditions contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>,<B> </B>the parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Effective Date</U></B>.<B> </B>This employment contract is effective as of the last date this contract
is executed by Thera and the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Title</U></B>.<B> </B>The Employee will act as Senior Vice President Scientific Affairs and Alliances <FONT
STYLE="white-space:nowrap">(Vice-pr&eacute;sident</FONT> senior, Affaires scientifiques et alliances). The Employee shall report to the President and Chief Executive Officer or such other person as he may appoint in accordance with changes in
Thera&#146;s organizational structure. The Employee shall perform the duties and functions indicated to him by his superior, which shall depend on the position held by the Employee and on the size of Thera. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Employee Conduct</U></B>. The Employee must act with prudence and diligence in the best interests of
Thera. In addition, the Employee undertakes to comply with Thera&#146;s Code of Ethics, as it may be amended from time to time, as well as with any and all policies that may be implemented by Thera. The Employee acknowledges that a breach of
Thera&#146;s Code of Ethics may constitute just cause for dismissal. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Compensation</U></B>.<B> </B>The Employee will receive the following compensation:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Base Salary</U>. The Employee shall receive an annual base salary of $265,000 less applicable tax
deductions, which shall be paid in accordance with the terms and conditions applicable to Thera&#146;s employees. The annual base salary will be subject to an annual review. However, any changes to the annual base salary will be subject to the
approval of the Compensation Committee and/or the Board of Directors of Thera. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Bonus</U>. The Employee will be eligible to participate in Thera&#146;s discretionary bonus program. As
part of his participation in this program, he may receive a bonus of up to 40% of his annual base salary earned, less applicable tax deductions. Any bonus, as the case may be, shall be assessed and determined in accordance with Thera&#146;s general
policy on discretionary bonus payments, as said policy may be amended from time to time. The Employee shall not receive any bonus if he is not employed by Thera at the time such bonus could be paid. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Special Bonus</U>. The Employee will be entitled to receive the following amounts, less applicable tax
deductions, throughout the term of this contract upon the occurrence of any of the following events: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Bonus</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#8195;&#8195;&#8195;&#8195;Event</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">$60,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8194;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Submission to the European Medicines Agency (&#147;EMA&#148;), through the centralized approval procedure by no later
than December&nbsp;31, 2013, of an application for approval to market the administration of tesamorelin in adult patients with HIV, and EMA acceptance of the marketing authorization application submitted within the prescribed time limits based on
the date of submitting such an application.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">$65,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Marketing authorization granted by EMA for the administration of tesamorelin in adult patients with HIV no later than
December&nbsp;31, 2014.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">$25,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Approval by the Brazil regulatory agency, ANVISA, no later than December&nbsp;31, 2013, of the application for
authorization to market tesamorelin already submitted by Sanofi to ANVISA if such approval is final and may be made public, excluding, however, confirmation by ANVISA that the audit conducted with regard to Jubilant to manufacture tesamorelin at its
offices in Montr&eacute;al meets the standards prescribed by ANVISA.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">$50,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Implementation by Sanofi, and receipt by Thera or one of its subsidiaries, during the 2013 calendar year, of a marking
plan for the administration of tesamorelin in adult patients with HIV in accordance with the terms set out in the partnership agreement entered into on December&nbsp;6, 2010 between Theratechnologies Intercontinental Inc. (previously
Theratechnologies ME Inc.) and Sanofi Winthrop Industrie in respect of lead time, sales volumes and marketing efforts. The marketing plan prepared by Sanofi that is to be received by Thera or one of its subsidiaries must cover Brazil.</P></TD></TR>
</TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The payment of the above amounts will be made in the first pay period following
the occurrence of these events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee acknowledges that he is not entitled to receive the above-mentioned amounts
if Thera or the Employee terminate this employment contract prior to the occurrence of any of the above-mentioned events. Notwithstanding the foregoing, if Thera terminates this employment contract solely due to a structural reorganization, and
where, within 90 days following termination of this employment contract by Thera for such cause, one of the above-mentioned events occurs, Thera shall pay the Employee the bonus amount corresponding to the event that occurred. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Retention Bonus</U>. Thera will pay the Employee the amount of $100,000, less applicable tax deductions,
if the Employee continues to be employed by Thera until December&nbsp;31, 2012 (inclusive). The payment of this amount shall be made in the first pay period after December&nbsp;31, 2012. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Stock Option Plan</U>. The Employee will be eligible to participate in Thera&#146;s stock option plan.
The Employee acknowledges that the grant of stock options is at the discretion of Thera&#146;s Board of Directors and there is no assurance that the Employee will be granted stock options under Thera&#146;s stock option plan. In addition, the
Employee acknowledges that Thera may amend or terminate its stock option plan at any time without any obligation to replace it with any other plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Deferred Stock Units Plan</U>. The Employee will be eligible to participate in Thera&#146;s deferred
stock units plan. The Employee acknowledges that the granting of deferred stock units is at the discretion of Thera&#146;s Board of Directors and there is no assurance that the Employee will be granted deferred stock units under Thera&#146;s
deferred stock units plan. Moreover, the Employee acknowledges that Thera may amend or terminate its deferred stock units plan at any time without any obligation to replace it with any other plan. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Other Benefits</U></B>.<B> </B>The Employee will also be entitled to the following additional
benefits: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32">&nbsp;</TD>
<TD WIDTH="33" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Vacation</U>. During the term of this contract, the Employee will be entitled to 20 days of paid vacation
per year, which shall be subject to Thera&#146;s general vacation policy. The vacation days that the Employee has accumulated as of the date hereof are fully vested. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Group Insurance Plan</U>. As an employee of Thera, the Employee will be entitled to participate in and,
if eligible, receive benefits under the group insurance plans in force from time to time at Thera in accordance with their terms and conditions. The Employee acknowledges that the terms and conditions of the group insurance plans may be amended at
Thera&#146;s discretion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Representation and Expenses</U>. Upon presentation of the requested supporting documents, the Employee
will be entitled to reimbursement of all costs and expenses reasonably incurred in the performance of his duties, subject to compliance with Thera&#146;s established budgets and policies. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U>Group RRSP</U>. The Employee shall be required to subscribe to Thera&#146;s Group RRSP for a minimum of
1% of his annual base salary. In accordance with its current contribution policy, as may be amended from time to time, Thera shall subscribe to the Employee&#146;s RRSP for an amount equal to the amount subscribed by the Employee, up to the lesser
of (i)&nbsp;the maximum amount provided by tax laws and (ii) 3% of the annual base salary earned by the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Confidential Information</B></U>.<B> </B>For the purposes of this contract &#147;confidential
information&#148; means all information concerning Thera and its subsidiaries, whether such information is in oral, written, graphic, photographic, computerized, recorded or in any other form, except for information that is freely available to the
public. Without limiting the scope of the following, &#147;confidential information&#148; includes all trade secrets, scientific data, discoveries and inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> drawings, methods, processes,
software, diagrams, technical and professional knowledge, reports, names of suppliers and customers, contents of agreements with suppliers and customers, any financial information, prices, valuations, business objectives, plans, business
opportunities and market studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the term of this contract and for a period of 10 years
following the termination of this contract, the Employee undertakes not to disclose to any person, nor to use, for himself (except during the term of this contract for the purpose of performing his duties) or on behalf of any third party, the
&#147;confidential information&#148; of Thera and its subsidiaries, except with the prior authorization of Thera. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Intellectual Property</B></U>.<B> </B>The Employee undertakes to assign to Thera all inventions,
creations, processes, technologies or improvements developed by the Employee, alone or in collaboration, and which relate to the business of Thera and its subsidiaries or result from the very nature of his duties at Thera and its subsidiaries. The
Employee agrees to assist Thera and its affiliates in obtaining, renewing or maintaining domestic or foreign patents on such inventions, creations, processes, technologies or improvements, as well as with respect to its trademarks and industrial
designs. In addition, the Employee waives any moral rights he may have in respect of inventions, creations, processes, technologies, works or other intellectual property conceived or developed during the term of this contract. This provision shall
survive termination of this contract for an indefinite period. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U></B>.<B> </B>During the term of this
employment contract and for a period of twelve (12)&nbsp;months following its termination, the Employee undertakes and agrees not to, directly or indirectly, alone or jointly with one or more legal entities or individuals, as a consultant, mandator,
principal, mandatory, agent, partner, shareholder, employee, officer or director, or in any other capacity, operate, work on, or provide services relating to the research, development or marketing of molecules or peptides related to human growth
hormone-releasing factor for the treatment of (x)&nbsp;lipodystrophy in HIV patients, (y)&nbsp;excess abdominal fat and (z)&nbsp;growth hormone deficiency. The territory covered by this prohibition is the province of Qu&eacute;bec. Moreover, the
prohibited activities in this provision also cover carrying out such activities in the company, EMD Serono, Inc. at its establishments located in Canada and the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></B></U>.<B> </B>During the term of this
employment contract and for a period of twelve (12)&nbsp;months following its termination, the Employee undertakes and agrees not to, directly or indirectly, alone or jointly with one or more legal entities or individuals, solicit, induce, force,
incite, promote, facilitate or encourage, either for himself or on behalf of any legal entity or individual, any of Thera&#146;s officers or employees or those of any of its subsidiaries, to resign from their employment with Thera or any of its
subsidiaries, or to change their employment relationship with Thera or any of its subsidiaries. In addition, during the same period, the Employee undertakes and agrees not to engage the services of any officer or employee of Thera or any of its
subsidiaries who was in the employ of Thera and/or any of its subsidiaries on the date this employment contract is terminated. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B><FONT STYLE="white-space:nowrap">No-interference</FONT></B></U>. For the term of this employment
contract and for a period of eighteen (18)&nbsp;months following termination thereof, the Employee undertakes not to, directly or indirectly, alone or jointly with one or more legal entities or individuals (i)&nbsp;acquire, offer or make any
proposal to acquire any asset of Thera or any of its subsidiaries; (ii)&nbsp;solicit or participate, in any manner whatsoever, in soliciting a proxy, or seeking to advise or influence any person with regard to how to vote their Thera shares, or to
join or be part of a group seeking to influence the vote of any Thera shareholder in a manner contrary to the voting recommendations issued by management; (iii)&nbsp;assist, advise or encourage any person to acquire or propose that they acquire any
asset whatsoever of Thera of any of its subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Term</B></U>.<B> </B>This contract shall constitute an employment contract with an indefinite term,
any of the terms or conditions of which may be amended by mutual agreement of the parties. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Termination</B></U>.<B> </B>Thera may terminate this contract upon: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Employee&#146;s failure to provide the agreed services based on business objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Employee&#146;s failure to comply with Thera&#146;s Code of Ethics; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">if the Employee is charged with committing an indictable offence within the meaning of the <I>Criminal
Code</I> (Canada) (other than driving while intoxicated, except if it caused death or resulted in injury to a third party) and that such criminal charge meets any of the following criteria: (i)&nbsp;it is related to the Employee&#146;s duties at
Thera, or (ii)&nbsp;it is of a nature that may damage Thera&#146;s reputation or cause a transaction to be derailed, or (iii)&nbsp;it may have material consequences on the Employee&#146;s ability to provide the agreed services;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40">&nbsp;</TD>
<TD WIDTH="41" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">for any other serious reason. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Employee undertakes, upon termination of his employment, not to copy, remove or take any &#147;confidential information&#148;.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Indemnity for Dismissal Without Serious Reason</B></U>.<B> </B>If the Employee&#146;s employment is
terminated without serious reason by Thera, or if it is terminated following a structural reorganization within Thera (other than as a result of one of the events described in section 14), the Employee will be entitled to an indemnity equal to
eighteen (18)&nbsp;months of his annual base salary, excluding any bonuses and benefits to which this contract refers. Payment of the severance indemnity is subject to Employee&#146;s compliance with the provisions of sections 6, 7, 8, 9 and 10
hereof. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Indemnity in Event of a Take-over Bid and Other Material Transactions</B></U>.<B> </B>In the event of
any of the following: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">i) &#8195;a take-over bid (within the meaning of the <I>Securities</I><I> Act</I>
(Qu&eacute;bec), as in effect from time to time) (a &#147;Bid&#148;); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ii)&#8195;any transaction (amalgamation (other
than with a subsidiary), arrangement, compromise, reorganization or other transaction of this nature, including any alienation by Thera to a third party of its property if, as a result of such alienation, Thera is unable to retain a significant part
of its business activity) (a &#147;Transaction&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">pursuant to which a person or any person acting jointly or in
concert (as defined in <I>Regulation</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;62-104</FONT> respecting Take-Over Bids and Issuer Bids</I> of the <I>Securities Act</I> (Qu&eacute;bec), as in effect from time to time) with such person
acquires control of Thera and that, within 12 months of the completion of the Bid or the Transaction, the Employee&#146;s employment at Thera is terminated without serious reason, the Employee will then receive on the date of termination of his
employment an amount equal to the greater of (i)&nbsp;reasonable notice provided for by law and (ii) 18 months of his annual base salary, at the time of termination plus an amount equal to 100% of the maximum bonus set out in section 4.2 hereof,
calculated based on such annual base rate salary, as well as any other amounts due but unpaid. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">For the purposes hereof, a person will be deemed to have acquired control of
Thera if the person and/or persons acting jointly or in concert with the person own at least 40% of the voting securities of Thera or the entity resulting from the Transaction. For the purpose of calculating the number of voting securities held by
any person (including persons acting jointly or in concert with such person), all securities convertible into or exchangeable for voting securities held or controlled by such person shall be included as if they had been converted or exchanged into
voting securities, whether the conversion or exchange occurs in one or more transactions. An alienation of property includes the sale, exchange, lease of property and the granting of a licence in respect of any property. Thera will be deemed to
retain a significant part of its business activity when the activities it retains after any alienation require the use of at least 25% of the value of its assets as at the end of the fiscal year preceding such alienation and such activities
generated in the fiscal year preceding such alienation at least 25% of Thera&#146;s <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenues or earnings. Payment of the severance indemnity is subject to the Employee&#146;s compliance with the
provisions of sections 6, 7, 8, 9 and 10 hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Survival of Undertakings</B></U>.<B> </B>The undertakings set out in sections 6, 7, 8, 9 and 10 shall
survive termination of this employment contract for the periods described therein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Entire Agreement</B></U>. This employment contract shall cancel and replace the employment contract
entered into on April&nbsp;13, 2007, and the amendments thereof dated May&nbsp;23, 2012 and July&nbsp;17, 2012, it being agreed that the rights and obligations arising from this restated and amended employment contract shall not have any retroactive
effect and shall take effect as of the execution of this employment contract by Thera and the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Governing Law</B></U>.<B> </B>This contract shall be interpreted and governed in accordance with the
laws of the province of Qu&eacute;bec and the laws of Canada applicable in Qu&eacute;bec. The parties submit to the jurisdiction of the courts of the province of Qu&eacute;bec. This contract shall be considered in all respects as a contract of
employment within the meaning of the <I>Civil Code of Qu</I><I>&eacute;</I><I>bec</I>, except where expressly waived. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><U><B>Legal Counsel</B></U>.<B> </B>The<B> </B>Employee acknowledges that he has had sufficient time to
consult with legal counsel with respect to the terms and conditions contained in this employment contract. By executing this contract, the Employee acknowledges that he understands its terms and conditions and that he participated in the
negotiations thereof. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:92%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this employment contract at the
place and date hereinafter set forth. </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Signed on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">21-12-2012</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In the city of Montr&eacute;al, province of
Qu&eacute;bec, Canada </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ Luc Tanguay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Luc Tanguay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Signed on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">21-12-2012</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In the city of Montr&eacute;al, province of Qu&eacute;bec, Canada </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>/s/ Christian Marsolais&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>CHRISTIAN MARSOLAIS</B></TD></TR>
</TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:5%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><I>Initials</I></P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.41
<SEQUENCE>21
<FILENAME>d680117dex441.htm
<DESCRIPTION>EX-4.41
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.41</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>E<SMALL>XHIBIT</SMALL> 4.41</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">[TRANSLATION] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><B>PERSONAL AND CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">July&nbsp;27, 2023 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Christian Marsolais </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11.5pt">
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">&#8195;&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt"><FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P>
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>RE:&#8195;&#8195;&#8195;Amendment to your restated and amended Employment Contract</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dear Christian, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Following the decision of the Board of Directors to propose amendments to management employment contracts in order to
update them in accordance with current legal principles and to harmonize the terms and conditions of employment contracts of executive officers reporting to the President and Chief Executive Officer regarding termination without a serious reason
(just cause) and the consequences arising from any change or acquisition of control of Theratechnologies Inc. (&#147;<B>Thera</B>&#148;) or a material transaction by Thera, we propose amending sections 13 and 14 of your restated and amended
employment contract dated December&nbsp;21, 2012 (the &#147;<B>Contract</B>&#148;) as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">By deleting the text of existing section 13 of the Contract and replacing it with the following text:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">&#147;13. <B><U>Indemnity for Termination Without a Serious Reason.</U></B><B> </B>If the employment
of the Employee is terminated without a serious reason, including as part of a reorganization to reduce personnel for economic reasons, but excluding a termination following a Change of Control (as defined below) in the circumstances set out below,
the Employee will receive an amount equal to the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">24 months of his annual base salary at the time of his termination plus an amount equal to 100% of his
target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of benefits offered by Thera and the value of option grants or other stock-based incentive compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employee will also receive an amount equal to the value of his accrued and unpaid vacation up to the date of
termination of his employment and the reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 2
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">By deleting the text of existing section 14 of the Contract and replacing it with the following text:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;14. <B><U>Indemnity Following a Change of Control or Any Other Material Transaction.</U></B>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In the event of any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a transaction (other than a transaction referred to in paragraph (b)&nbsp;below), regardless of its
structure (an &#147;<B>Acquisition</B>&#148;), pursuant to which a person or persons acting jointly or in concert (as defined in <I>Regulation <FONT STYLE="white-space:nowrap">62-104</FONT> respecting Take-Over Bids and Issuer Bids</I>, as in effect
from time to time) directly or indirectly acquire beneficial ownership of, or control over, securities of Thera representing 40% or more of the voting rights attached to all voting securities for the election of directors of Thera then outstanding;
or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of any amalgamation, arrangement, compromise, consolidation, reorganization or other
transaction or series of transactions of this nature involving directly or indirectly Thera (a &#147;<B>Combination</B>&#148;) which results in either (i)&nbsp;the shareholders of Thera immediately prior to such Combination no longer holding,
directly or indirectly, after the Combination, more than 60% of the voting rights attached to all voting securities for the purpose of electing directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, of the
ultimate parent company of such subsidiary); or (ii)&nbsp;the Board of Directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, the ultimate parent company of such subsidiary) is no longer composed of a majority of
the directors who served on Thera&#146;s Board of Directors immediately prior to the Combination; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a change in the composition of Thera&#146;s Board of Directors occurring, without the approval by a
majority vote of the directors composing Thera&#146;s Board of Directors prior to such change, at the same shareholders meeting or pursuant to a resolution of Thera&#146;s shareholders, and which results in Thera&#146;s Board of Directors no longer
being composed of a majority of the directors of Thera who were serving as directors immediately prior to such meeting or resolution (other than a change resulting from the solicitation of proxies by the management of Thera or related to death,
resignation or inability to act in such capacity) (an &#147;<B>Insurgency</B>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of the sale, exchange, lease, transfer, liquidation, grant of an exclusive license, or any
other form of alienation of Thera&#146;s assets, to a party that is not an affiliate of Thera (as defined in the <I>Business Corporations Act</I> (Qu&eacute;bec)), representing substantially all of Thera&#146;s assets (an &#147;<B>Asset
Transfer</B>&#148;); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">and that within 24 months following the occurrence of any Acquisition,
Combination, Insurgency or Asset Transfer (each representing for the purposes hereof a &#147;<B>Change of Control</B>&#148;), either (a)&nbsp;the employment of the Employee is terminated without a serious reason; or (b)&nbsp;the Employee decides to
terminate his employment of his own free will, the Employee shall then receive on the date of termination of his employment an amount equal to the greater of: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 3
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">24 months of his annual base salary at the time of termination plus an amount equal to 100% of his target
bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of the benefits offered by Thera and the value of option grants or other stock-based incentive compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In all cases, the Employee will also receive an amount equal to the value of his accrued and unpaid vacation up to the date
of termination of his employment and reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this section, in order to calculate the percentage of the number of voting securities held by any
person (including persons acting jointly or in concert with such person) relative to the number of outstanding voting securities, such calculation shall include, both with respect to the voting securities held by such person (and persons acting
jointly or in concert with such person) and to the outstanding voting securities, all convertible or exchangeable securities within sixty (60)&nbsp;days from the date of calculation of voting securities held or controlled by such person, as if such
securities had been converted or exchanged into voting securities, whether such conversion or exchange occurs in one or more transactions. Such securities convertible or exchangeable within sixty (60)&nbsp;days shall be deemed to have been acquired
and to be beneficially owned by such person (or any person acting jointly or in concert with such person). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Thera will
be deemed to have entered into an Asset Transfer if such Asset Transfer represents more than 75% of the value of its assets calculated as at the date of the fiscal year end preceding such Asset Transfer, or if the assets transferred in connection
with such Asset Transfer represent more than 75% of the income generated by Thera during the fiscal year preceding such Asset Transfer.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">By adding the following section 14.1 to the Contract: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;14.1 <B><U>Acceleration of Acquisition of Securities Issued as Long-Term Compensation Plans</U></B>.<B> </B>In the
event of a Change of Control, all securities and rights issued or granted to the Employee under long-term compensation plans, such as stock options, deferred share units, appreciation rights and other rights that vest over a defined period of time,
whether or not based on the achievement of performance targets, will all automatically vest as if the vesting conditions and, if applicable, the achievement of performance targets had been met.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you agree to these amendments, we ask that you return this letter to us <U>no later than August</U><U></U><U>&nbsp;3,
2023</U>, failing which we will assume that these amendments to your employment contract are not acceptable to you and this proposal will then lapse. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 4
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">These amendments will become effective upon the date of your execution of
this letter below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Except for these amendments to your restated and amended employment contract, all other terms and
conditions will remain in effect and unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you accept these amendments, please sign this letter in the space
provided below and return a duly executed copy thereof to Mr.&nbsp;Jocelyn Lafond, General Counsel and Corporate Secretary of Thera. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Yours truly, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:10%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Paul L&eacute;vesque</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Paul L&eacute;vesque </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that I have read, had the opportunity to consult with legal counsel and understand and accept the content of
these amendments to my restated and amended employment contract dated December&nbsp;21, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dated and signed at
Montr&eacute;al (Qu&eacute;bec), on July&nbsp;28, 2023. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#8201;<U>/s/ Christian Marsolais</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#8201;Christian Marsolais </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.42
<SEQUENCE>22
<FILENAME>d680117dex442.htm
<DESCRIPTION>EX-4.42
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.42</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.42</U> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><B>THIS EMPLOYMENT AGREEMENT</B> is made as of the 6<SUP STYLE="font-size:75%; vertical-align:top">th </SUP>day of January 2023 with an
effective date as of April&nbsp;11, 2022 (the &#147;<B>Effective Date</B>&#148;) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">BETWEEN:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC.</B>,<B> </B>a<B> </B>corporation governed by the <I>Business Corporations Act</I> (Quebec), having
its head office at 2015 Peel Street, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Montreal, Province of Quebec, H3A 1T8;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">(the &#147;<B>Company</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="21"></TD>
<TD HEIGHT="21" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">AND:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>JOHN O. LEASURE</B>, residing at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">(the &#147;<B>Employee</B>&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman"><B>WHEREAS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company is a publicly-listed company which conducts research and development activities and commercialized
prescription products in the HIV area; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee, a U.S. citizen, has been employed by the Company&#146;s subsidiary, Theratechnologies U.S.,
Inc., in the position of Global Commercial Officer, pursuant to an employment agreement dated March&nbsp;29, 2021, which date shall continue to be recognized by the Company as the Employee&#146;s service date for all service-based entitlements
hereunder; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company and the Employee agree that the Employee shall serve as the Global Commercial Officer of the
Company as of the Effective Date; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company and the Employee (each a &#147;<B>Party</B>&#148; and, collectively, the
&#147;<B>Parties</B>&#148;) wish to enter into this employment agreement (the &#147;<B>Agreement</B>&#148;) for the purpose of agreeing on the terms and conditions that will govern their employment relationship; and </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Parties agree that this Agreement shall replace and supersede all previous agreements, contracts and
understandings related to the subject matter hereof; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman"><B>IT IS HEREBY AGREED </B>as follows:<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Definitions</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In this Agreement the following words and expressions shall have the meanings set out below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Basic Salary</B>&#148; means the annual base salary paid to Employee for the performance of his duties described in
Schedule 1, as such Basic Salary may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Board</B>&#148; shall mean the Board of
Directors of the Company (including any committee of the Board duly appointed by it). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Business Day</B>&#148; means a day other than (i)&nbsp;a Saturday
or Sunday or (ii)&nbsp;a day that is not a public holiday in Vermont, United States. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Confidential
Information</B>&#148; means all proprietary information of Company and its Group Company, in whatever form and format, and all information provided to the Company or its Group Company by third parties that Company or its Group Company must keep
confidential. Confidential Information includes Intellectual Property. Confidential Information shall not include information that was in the Employee&#146;s knowledge or possession prior to its disclosure by the Company or that is generally
available to and known by the public at the time of disclosure to the Employee; provided that, such disclosure is through no direct or indirect fault of the Employee or person(s) acting on the Employee&#146;s behalf. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Employment</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;2.1. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Group Company</B>&#148; means the Company, any company of which it is a Subsidiary (its holding company) and any
Subsidiaries of the Company or of any such holding company together with such other companies as the Board may from time to time designate as Group Companies for the purposes of this Agreement. As of the date of this agreement, Theratechnologies
U.S., Inc. and Theratechnologies Europe Limited have been designated as Group Companies. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Intellectual
Property</B>&#148; means discoveries, concepts, ideas and improvements to existing technology whether or not written down or otherwise converted to tangible form, patents, designs, trademarks, trade names, goodwill, copyrights, all rights in
inventions, designs, processes, formulae, notations, improvements, <FONT STYLE="white-space:nowrap">know-how,</FONT> goodwill, reputation, moulds, getup, computer programmes and analogous property, plans, models and all other forms of industrial or
intellectual property (in each case in any part of the world and whether or not registered or registerable and to the fullest extent thereof and for the full period thereof and all extensions and renewals thereof) and all applications for
registration thereof and all rights and interests, present and future, thereto and therein. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Option
Plan</B>&#148; has the meaning ascribed thereto in Section&nbsp;9.4. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Retirement</B> <B>Plan</B>&#148; shall
have the meaning ascribed thereto in Section&nbsp;10.1. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Subsidiary</B>&#148; means any entity directly or
indirectly owned, in whole or in part, by Company of which the stockholder is a stockholder and over the affairs of which Company directly or indirectly exercises control, and includes, without limitation, corporations, partnerships, limited
partnerships, limited liability partnerships, limited liability companies, statutory trusts and/or joint ventures. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Supervisor</B>&#148; shall have the meaning ascribed thereto in Section&nbsp;2.1. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Termination Date</B>&#148; shall mean the date upon which the Employee (i)&nbsp;gives notice of resignation or
(ii)&nbsp;is advised of the termination of his Employment with Company for any reason. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Vacation Year</B>&#148;
shall have the meaning ascribed thereto in Section&nbsp;15.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Appointment and Reporting Line</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall employ the Employee and the Employee shall serve Company as Global Commercial Officer, for
Company, on and subject to the terms and conditions specified herein (the &#147;<B>Employment</B>&#148;). This position is not eligible for the payment of overtime in accordance with applicable legislation. As of the date hereof, Employee will
report to the President and Chief Executive Officer of Company, who currently is Mr.&nbsp;Paul Levesque (the &#147;<B>Supervisor</B>&#148;). Employee acknowledges and agrees that the President and Chief Executive Officer of Company may determine, in
his sole discretion, from time to time, that Employee will cease reporting to him and will report to any other Supervisor within Company the President may appoint from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Warranties</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee represents and warrants that he: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">is not prevented by any agreement, arrangement, contract, understanding, court order or otherwise, which
in any way directly or indirectly restricts or prohibits him from fully performing the duties of the Employment, or any of them, in accordance with the terms and conditions of this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">is not aware of any investigation (administrative or criminal) being conducted involving him and has not,
in the preceding three years, been convicted of or pled guilty or <I>nolo contendere</I> to any criminal offence other than a minor misdemeanor under any criminal laws or laws having sanctions that can lead to imprisonment; </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">has never availed himself of insolvency or bankruptcy laws or similar laws; </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">has never been a director or an executive officer of a company or entity, the securities of which are
publicly traded on a stock exchange, that has availed itself of insolvency or bankruptcy laws, or similar laws, or that has been issued an order by a securities regulatory authority having jurisdiction over such company or entity prohibiting the
trading of its securities. </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:13%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employees acknowledges that the representations made in <FONT
STYLE="white-space:nowrap">sub-sections</FONT> (b), (c) and (d)&nbsp;are essential to Company as the Employee is an executive officer of a publicly-listed company. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Commencement of Employment</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employment will commence on April&nbsp;11, 2022, without regard to the date of signature of this
Agreement, it being understood that the Company will continue to recognize March&nbsp;29, 2021 (the &#147;<B>Service Date</B>&#148;)<B> </B>as the Employee&#146;s initial hire date for all service-based entitlements hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employment shall continue until the Termination Date. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company reserves the right to pay salary in lieu of any period of notice that Employee is required to give
pursuant to the terms hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Place of Work</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">At least sixty percent (60%) of the Employee&#146;s working time shall be spent at the Company&#146;s
place of business in the Province of Quebec or such other place in the Province of Quebec where the Company or Group Company that are resident of Canada for Canadian income tax purposes, as applicable, carries on business. The Employee&#146;s
secondary place of work, for the remainder of his working time, shall be at his personal residence, which in no time shall be considered at the disposition of Company, on the East Coast of the United States or such other place on the East Coast of
the United States where the Company or Group Company, as applicable, carries on business. In the performance of his duties hereunder, the Employee will be required to regularly travel in the United States, Europe and in Canada without any additional
remuneration other than standard expense reimbursement subject to Company policy. The Employee agrees to maintain his eligibility for domestic and international travel and to advise the Company of any circumstances which may affect such eligibility.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Duties</B> </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee&#146;s duties shall include in addition to those duties required to be performed in the
normal course of his Employment, as set out in Schedule 1 to the Agreement, which Schedule constitutes part of this Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">undertaking all legitimate reasonable requests made by Company taking into consideration its evolution
over time; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">reporting his own wrongdoing and any wrongdoing or proposed wrongdoing of any other employee of Company or
Group Company immediately on becoming aware of it to the Chair of the Board of Company, who is currently Ms.&nbsp;Dawn Svoronos, or to the Company&#146;s General Counsel, who is currently Mr.&nbsp;Jocelyn Lafond. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">comply with the rules, regulations and various policies of Company and those of the Group Company,
applicable to Company, currently in force and as they are updated from time to time as notified to the Employee in writing, including the <I>Code of Business Conduct and Ethics, </I>a copy of which has been provided to the Employee who hereby
acknowledges having received and read same; and </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">observe and adhere to all health and safety regulations in force from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">For the avoidance of doubt, the Employee&#146;s duties are not limited to those set out above and in
Schedule 1 to this Agreement, and the Employee shall be required to undertake any such additional or alternative duties as Company shall reasonably assign to him from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">In his capacity as Global Commercial Officer, the Employee shall devote all his business time, attention
and skill to his duties hereunder, and shall at all times act in the best interests of Company on a global scale basis. The Employee shall faithfully and diligently perform such duties and exercise such powers consistent therewith. Notwithstanding
the foregoing, while the Employee works from his personal residence in the United States, the Employee shall refrain from doing the action described in Schedule 2 hereto. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall comply with all applicable Company&#146;s rules, regulations, policies and procedures,
as well as those of any Group Company applicable to Company, from time to time in force and to any applicable regulatory obligations and codes of practice whether or not such obligations are otherwise legally binding. While the Employee is subject
to a contractual obligation under this Agreement to comply with these policies, Company nevertheless reserves the right to amend, withdraw or supplement these policies at any time. Notice of such amendment and changes, once in force, shall be given
to the Employee for compliance purposes. For the avoidance of doubt, in the event that any such changes are made or additional or replacement policies are introduced, the Employee remains contractually required under this Agreement to comply with
these policies, which may be amended or replaced. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Hours of Work and Rules</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee&#146;s normal hours of work will be 8:30 am to 5:00 pm Monday to Friday inclusive.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding the foregoing, the Employee shall work such additional hours as are necessary for the
proper performance of his duties. The Employee acknowledges that his hours of work may vary and be irregular as required by operational needs and that, he shall not receive further remuneration in respect of such additional hours. For the avoidance
of doubt, the Employee understands and agrees that the remuneration provided herein is paid to him in compensation of all the hours of work that may be required for him to satisfactorily perform his duties hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Exclusivity of Service</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">During the Employment, the Employee shall devote his full time and attention to his duties hereunder and
shall not (without the prior written consent of the Supervisor) directly or indirectly, either on his own account or on behalf of any other person, company, business entity or other organisation, engage in, or be concerned with, or provide services
to, (whether as an employee, officer, director, agent, partner, consultant or otherwise) any other business. Notwithstanding anything contained herein to the contrary, the Employee may, (A)&nbsp;upon prior written notice to the Supervisor and after
receipt of approval from Supervisor, serve as a member of the board of directors or managers or other similar governing body of a company or entity, provided such company or entity does not engage in a business competitive with the Company or Group
Company, and provided, further, that such activities do not materially interfere with the performance of the Employee&#146;s duties or responsibilities on behalf of the Company or Group Company, or (B)&nbsp;directly or indirectly, be a passive owner
of (i)&nbsp;not more than two percent (2%) of any class of stock of a corporation that is a competitor of the Company, which class of stock is publicly traded or (ii)&nbsp;not more than five percent (5%) of any class of security of any other entity
that is a competitor of the Company, in each case so long as the Employee has no active participation in the business of such corporation or entity. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Remuneration</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall pay to the Employee an annual Basic Salary of CAN$402,062, payable every two weeks pro rata
in arrears by equal instalments into the Employee&#146;s nominated bank account by electronic credit transfer subject to the deduction of income tax and any other applicable lawful deductions. The Employee&#146;s Basic Salary will be subject to
review and adjustment, if any, on a yearly basis. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee is also eligible to participate in Company&#146;s discretionary annual bonus plan subject to
the rules of the relevant bonus plan or those of Group Company applicable to Company. The target bonus rate shall be set at 40% of the Employee&#146;s annual Basic Salary. The Employee acknowledges that the amount of any bonus may vary yearly and
will be contingent upon the attainment of both corporate and personal objectives. The reference period for the Company&#146;s discretionary annual bonus plan is from December&nbsp;1 of a calendar year to November&nbsp;30 of the ensuing calendar
year. For the avoidance of doubt, any bonus payable for a partial year worked by the Employee will be prorated to take into consideration the number of days worked by Employee during the reference period. Notwithstanding the foregoing, the Employee
must be employed by Company at the time of payment of any bonus in order to be considered for the payment of a discretionary bonus hereunder. No bonus will be payable to the Employee on and after the Termination Date. For greater certainty, the
Employee will not be entitled to any bonus with respect to a period (unworked) for which he received or may claim an indemnity in lieu of prior notice of termination or severance pay, regardless of whether the termination is for cause (as defined in
Section&nbsp;16.2) or for any other reason. Moreover, the Employee will not be entitled to claim damages as a result of the loss of bonuses during any applicable notice of termination period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Employee shall not be eligible to receive a bonus under Section&nbsp;9.2, and the Company may require,
within thirty (30)&nbsp;days of written notice, repayment from Employee of the last bonus previously paid to Employee under Section&nbsp;9.2 in the event that either (i)&nbsp;the Company receives a letter from the Federal Food and Drug
Administration seeking the withdrawal of promotional documents or a change in detailing activities as a result of <FONT STYLE="white-space:nowrap">off-label</FONT> allegations for which the Employee was responsible or had direct knowledge; provided
further, however, that if the documents or detailing activities were internally approved, such provision shall not apply; or (ii)&nbsp;the Company is convicted for violations of anti-kickback statutes or other like regulation as a result of
commercialization activities engaged in by the Employee or by one of his direct reports at his urging which were not internally approved. To the extent permitted by law, any payments otherwise due to Employee may be reduced to enforce the repayment
obligations set forth in this Section&nbsp;9.3. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">In addition to the Employee&#146;s annual Basic Salary and the discretionary annual bonus plan, the
Employee will be eligible to participate in equity-based incentive plans adopted from time to time by Company. Should the Board decide to grant stock options under its share option plan (the &#147;<B>Option Plan</B>&#148;), the number of options to
be granted shall represent a target value equal to 20% to 45% of his annual Basic Salary. The value shall be computed as set forth in Schedule 4. The terms and conditions relating, namely, to the vesting and exercise of any such options will be
determined by the Board on the date of grant in accordance with the terms and conditions of the Option Plan </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee acknowledges that any grant of stock options or other equity-based incentive measures under
this Agreement does not give rise to any entitlement to additional awards under the Option Plan or any other equity-based incentive plans in the future. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall reimburse any expenses incurred by the Employee in respect of the rental of a property or
residential accommodation in the city of Montreal during the Employment. Such reimbursement shall not exceed the amount of CAN$2,000 per month. Employee acknowledges that the payment of such amount is a taxable benefit. To be eligible to receive
such reimbursement, the Employee shall provide the Company with a copy of the lease and any relevant invoice or receipt, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall reimburse any expenses incurred by the Employee in respect of the preparation of his annual
tax filings in connection with this Agreement. Notwithstanding the foregoing, such reimbursement shall not exceed an amount equal to US$5,000 per year. Employee acknowledges that the payment of this amount is a taxable benefit. To be eligible to
receive such reimbursement, the Employee shall provide the Company with a copy of any relevant invoice or receipt, as applicable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company reserves the right at any time to vary or discontinue any employee benefit plan or scheme and/or
to provide alternative benefits for and in respect of the Employee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company and the Employee agree that any remuneration paid to the Employee in the form of Basic Salary,
discretionary annual bonus plan or grant of stock options under the Option Plan is paid to the Employee in consideration only for the performance of his employment duties as described in Schedule 1 hereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Registered Retirement Savings Plan </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Company will make contributions to its Canadian group registered retirement savings plan (the
&#147;<B>Retirement Plan</B>&#148;) on behalf of the Employee in accordance with this Section. Subject to and conditional upon the terms of the Retirement Plan and applicable laws, Company will match the contribution of the Employee on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis up to an amount equal to 50% of the maximum annual contribution allowed under applicable Canadian laws. The Employee acknowledges that his contribution
to the Retirement Plan is mandatory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Health Insurance and Other Benefits</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall be entitled to participate in the medical, dental and/or vision insurance coverage
plans offered by the Company&#146;s Subsidiary, Theratechnologies, U.S., Inc. in accordance with the terms and conditions of such plans, as amended from time to time. The Employee acknowledges that Theratechnologies, U.S. Inc. reserves the right at
any time to terminate or alter its contributions to medical, dental and/or vision insurance and/or to provide alternative medical, dental and/or vision insurance for and in respect of the Employee and all of its employees. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee will be covered for long-term disability and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">death-in-service</FONT></FONT> benefits from the plan offered by the Company&#146;s Subsidiary, Theratechnologies, U.S., Inc. in accordance with the terms and conditions of such plan, as amended from time to time. The
Employee acknowledges that Theratechnologies, U.S. Inc. reserves the right at any time to terminate or alter the terms and conditions of the plan or to provide alternative plan for and in respect of the Employee and all of its employees. The Company
will cover the Employee for short-term disability until the long-term disability plan of the Company&#146;s Subsidiary becomes effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">All benefits, including the Retirement Plan, payable or otherwise made available to the Employee under any
Company or Group Company benefit plan(s) in which the Employee may be entitled to participate from time to time shall automatically cease, as shall the Employee&#146;s eligibility to participate in such plan(s), upon the Termination Date. In the
event of the termination of Employee&#146;s Employment for any reason whatsoever, Company shall be under no obligation to replace the terminated or discontinued benefit plan(s) and/or provide the same or similar benefits or compensation in lieu.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Expenses</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall reimburse to the Employee (against receipts or other satisfactory vouching evidence) all
reasonable business expenses properly and validly incurred and defrayed by him in the course of the Employment, subject to Company&#146;s rules and policies relating to expenses. Original receipts of all business expenses shall be submitted to
Company on a monthly basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee will not be entitled to any expense reimbursement related to the use of a workspace in his
personal residence on the East Coast of the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Deductions</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall be entitled at any time during the Employment, or in any event on termination of this
Agreement, to deduct from the Employee&#146;s remuneration hereunder any monies due from him to Company including but not limited to any overpayments made to him, outstanding loans and advances, and any other deductions with Employee&#146;s consent
in accordance with applicable law. By signing this Agreement, Employee hereby consents to any such deductions from his remuneration and other sums as permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Care Days and Sick Leave</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Employee shall be entitled to five (5)&nbsp;days of paid time (&#147;<B>Care Days</B>&#148;) at the
beginning of every Vacation Year to satisfy family-related obligations. The Care Days are in addition to any paid sick days or family responsibility leave days provided under applicable legislation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company has illness and absence notification requirements. The Employee must notify the Supervisor of any
unplanned absence (whether through illness or otherwise). Where there is continuing absence, the Employee shall keep Company fully informed on a regular basis of his condition and expected return to work date. A medical certificate must be produced
in respect of absence of three (3)&nbsp;consecutive days or more and afterwards, at such intervals as required by Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company reserves the right to require the Employee to undergo a medical examination by a doctor or
consultant appointed solely by Company when doing so is <FONT STYLE="white-space:nowrap">job-related</FONT> and consistent with business necessity, in which event Company will bear the cost. Any information or report arising from such examination
may be released to Company and will be treated on a confidential basis by Company to make relevant determinations based on the advice of its appointed doctor and/or consultant.<B><I> </I></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise required by applicable law, Company is not obliged to pay the Employee during any
unauthorised absence (whether through illness or otherwise) and, in such event, the Employee should avail of any appropriate social welfare benefits. However, Company may in its absolute discretion and without creating any expectation, precedent or
entitlement, decide to pay the Employee where appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Vacation and Holidays</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall be entitled to accrue twenty (20)&nbsp;working vacation days per year based on the
Company&#146;s fiscal year, accrued at the rate of 1.66 days per month. Company&#146;s fiscal year begins on December&nbsp;1 of a calendar year until November&nbsp;30 of the ensuing calendar year (the &#147;<B>Vacation Year</B>&#148;). All vacation
days for a given Vacation Year are earned based on the number of days worked in the prior Vacation Year. The Employee may only take vacation days at such times as are agreed with the Supervisor. Where the Employee has taken vacation days in excess
of his accrued entitlement up to the Termination Date, the amount of Basic Salary paid to the Employee in respect of such excess vacation days taken may be deducted by Company from any salary due to the Employee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company reserves the right, at its sole discretion, to require the Employee to take all or part of any
outstanding vacation days during any notice period or to make payment in lieu thereof. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Only up to five (5)&nbsp;vacation days earned in a prior Vacation Year can be carried over to the next
Vacation Year. Employee acknowledges that any accrued but unused vacation days in excess of the allowed five (5)&nbsp;carried over vacation days that are not taken in the appropriate Vacation Year will be forfeited entirely without any right to
payment in lieu thereof unless the Employee has been prevented from taking such vacation days. For the 2021-2022 Vacation Year, the Company acknowledges that the Employee has carried over five (5)&nbsp;vacation days. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee will be entitled to paid time off on the holidays observed by the Company&#146;s Subsidiary,
Theratechnologies, U.S., Inc. and in accordance with the terms and conditions of the applicable policy related thereto, as may be amended from time to time. Such policy currently provides for the observance of the following holidays:
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">New Year&#146;s Day </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Martin Luther King Day </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">President&#146;s Day </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Memorial Day </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Independence Day </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Labor Day </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Thanksgiving Day (US) </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Day after Thanksgiving (US) </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Christmas Eve </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Christmas Day </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Holiday Break (December 26th &#150; 30th) </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">New Year&#146;s Eve Day </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:13%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In accordance with the applicable policy, if a holiday falls on the weekend, it will be observed on the closest
corresponding day (i.e., holidays that fall on a Saturday will be observed on Friday, and holidays that fall on Sunday will be observed on Monday). </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Termination</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee agrees to give the Company at least thirty (30)&nbsp;days&#146; advance written notice in the
event Employee voluntarily terminates his employment. The Company reserves the right to waive this notice period, in whole or in part, and relieve the Employee from the requirement to provide services during the notice period by paying the Employee
his then annual Basic Salary, less applicable withholdings, for the unworked portion of the resignation notice period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Upon termination of employment &#147;for cause&#148;, Company&#146;s sole obligation under this Agreement
is to pay Employee any earned but unpaid wages through the date of termination and reimburse any authorized business expenses in accordance with Company policy (the &#147;<B>Accrued Amounts</B>&#148;). Employee is not entitled to a payout of accrued
but unused vacation upon termination unless the Employee has been prevented from taking such vacation days or unless otherwise required under applicable legislation. For the purposes of this Agreement, &#147;for cause&#148; termination includes a
termination of this Agreement as a result of the occurrence of any of the following: (i)&nbsp;death; (ii) wilful misconduct or gross negligence in the performance of Employee&#146;s material duties; (iii)&nbsp;continued material failure by Employee
to satisfactorily perform the duties of his position after receipt of written notice of such material failure from Company; (iv)&nbsp;material breach of the terms and conditions of this Agreement or any other agreement executed by the Company and
the Employee; (v)&nbsp;material failure by the Employee to comply with the Company&#146;s <I>Code of </I><I>Business Conduct and </I><I>Ethics</I>, Employee Manual and other policies adopted from time to time by the Company governing the conduct of
employees and that have been provided to the Employee in writing or were shown to the Employee as being available for review by the Employee, where, when such failure is capable of cure, such failure continues after written notice thereof and
failure to cure within 15 days of such notice; (vi)&nbsp;violation of the U.S. <I>Federal Food Drug and Cosmetic Act</I>, U.S. <I>Federal Anti-</I><I>Kickback Statute</I> and U.S. <I>False Claims Act</I>, as well as other similar laws applicable to
the commercialization of drug products in the United States or in Canada (vii)&nbsp;fraud, embezzlement, or misappropriation of property; (viii)&nbsp;conviction or pleading guilty or <I>nolo contendere</I> to a felony or other crime involving moral
turpitude; (ix)&nbsp;if the Employee is indicted for a criminal offense and that such offense (a)&nbsp;is related to the position held by the Employee, or (b)&nbsp;tarnishes the Company&#146;s reputation or goodwill or prevents the Employee from
performing his obligations under this Agreement, in either case where circumstances suggest that Employee engaged in the conduct for which he was accused and (x)&nbsp;any other act or omission by the Employee which constitutes a &#147;serious
reason&#148; to terminate employment without prior notice or pay in lieu of such notice in accordance with article 2094 of the <I>Civil Code of Qu</I><I>&eacute;</I><I>bec</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Upon termination of employment by the Company for a reason other than &#147;for cause&#148;, or by the
Employee for &#147;Good Reason&#148; prior to the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary date of Employee&#146;s Service Date, Company shall pay Employee: (a)&nbsp;the Accrued Amounts; and (b)&nbsp;a severance
payment equal to six (6)&nbsp;months of Employee&#146;s annual Basic Salary, less applicable withholdings. Beginning on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary date of the Employee&#146;s Service Date, if
Employee is terminated by the Company other than &#147;for cause&#148;, or resigns for &#147;Good Reason&#148;, Employee shall be entitled to receive the (x)&nbsp;Accrued Amounts; and (y)&nbsp;a severance payment equal to 100% of his then annual
Basic Salary, less applicable withholdings. For greater certainty, Employee will not be entitled to receive any additional payments, such as his targeted discretionary annual bonus for which active employment at the time of payment is a condition to
receiving any such payment, the value of his health and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">death-in-service</FONT></FONT> insurance benefits as well as any other benefits he may otherwise be entitled to during his
employment with Company. For purposes of this Agreement, termination for &#147;Good Reason&#148; includes a resignation by Employee as a result of the occurrence of any of the following: (i)&nbsp;the Employee&#146;s title is changed from
&#147;Global Commercial Officer&#148; to another title with a lower level of responsibility and authority without his consent, (ii)&nbsp;there is a material adverse reduction in Employee&#146;s level of responsibility and authority from that
generally associated with the officer position of &#147;Global Commercial Officer&#148; of the Company without his consent, (iii)&nbsp;Employee is required to move or report to an office location that is more than forty (40)&nbsp;kilometers from
Company&#146;s office, without permitting Employee to work remotely from his home office, without Employee&#146;s consent, or (iv)&nbsp;the Company makes a reduction in Employee&#146;s annual Basic Salary. Where the Employee has Good Reason,
Employee shall have the right to terminate his employment with the Company for Good Reason provided the following occur: (a)&nbsp;Employee gives written notice to his Supervisor within thirty (30)&nbsp;days after the date the Good Reason event
occurred; (b)&nbsp;Company fails to cure the Good Reason event specified in the written notice within fifteen (15)&nbsp;days of receipt of the written notice; and (c)&nbsp;Employee resigns within ten (10)&nbsp;days of the expiration of the cure
period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Upon termination of the employment of Employee for a reason other than &#147;for cause&#148; or by the
Employee for &#147;Good Reason&#148; at any time within twelve (12)&nbsp;months from the date of a &#147;Change of Control&#148; of Company, Employee shall be entitled to receive: (a)&nbsp;the Accrued Amounts and (b)&nbsp;an amount equal to 100% of
his annual Basic Salary, less applicable withholdings. For the purpose of this Agreement, a &#147;Change of Control&#148; shall mean the occurrence of any of the following: (i)&nbsp;any change of control, in fact or in law, including any purchase,
sale, transfer, disposition or other transaction, of any nature whatsoever, and whether carried out singly, in combination or as part of a series of transactions, pursuant to or as a result of which any person or group of persons acting together or
in concert shall acquire, hold or exercise, whether directly or indirectly, rights over more than forty percent (40%) of the outstanding common shares of Company, or which entitle the holder(s) thereof to more than seventy-five percent (75%) of the
economic value of the Company; or (ii)&nbsp;those individuals who, as at the date immediately preceding the date of the &#147;Change of Control&#148; constitute the Board (hereinafter called the &#147;<B>Incumbent Board</B>&#148;), cease for any
reason to constitute at least a majority of the Board after the date of the &#147;Change of Control&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Any payments to Employee pursuant to Sections 16.3 or 16.4 of this Agreement beyond the Accrued Amounts
are contingent upon Employee timely executing and not timely revoking a separation agreement that includes a full release of all claims by Employee against the Company, Group Company and any of their respective directors, officers and employees, to
the maximum extent permitted by law, and other standard <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT
STYLE="white-space:nowrap">non-compete</FONT> provisions (the &#147;<B>Release</B>&#148;). Any severance payments due under Sections 16.3 or 16.4 of this Agreement will commence within 30 days of the effective date of the Release, which shall be no
later than 60 days following the Employee&#146;s Termination Date. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">On termination of Employment, the Employee shall forthwith return to Company, in accordance with
Company&#146;s instructions, all equipment, correspondence, records, specifications, software, models, notes, reports and other documents and any copies thereof and any other property belonging to Company or any Group Company which are in his
possession or under his control. The Employee shall, if so required by Company, confirm in writing compliance with his obligations under this Section. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee further agrees to permanently destroy or otherwise delete all information or data belonging
to, or relating to Company, or any Group Company, or a client, or a supplier, or any of their employees, which is recorded in any other property, medium or format including without limitation on any social media site including LinkedIn in the
Employee&#146;s possession, custody or control unless the Employee has been instructed by Company not to do so. Notwithstanding the foregoing, Employee shall be entitled to reference his past experience with Company under his own social media
account but shall not represent himself as currently employed by Company under his own social media account upon termination of his Employment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company shall have the right to suspend the Employee on full pay pending any investigation and subsequent
disciplinary hearing, including any appeal hearing, into any potential dishonesty, gross misconduct or any other circumstances, including alleged violation of securities laws and regulation, violation of the Anti-kickback Statutes and similar laws,
that may give rise to a right to Company to terminate. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The termination of the Employment shall be without prejudice to any right Company may have in respect of
any breach by the Employee of any of the provisions of this Agreement that may have occurred prior to such termination. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee agrees that he will not at any time after the termination of the Employment:
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Represent as still having any connection with Company or any Group Company, save as a former employee for
the purpose of communicating with prospective employers or complying with any applicable statutory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Make or cause to be made (whether directly or indirectly) any derogatory comments or statements about
Company or any Group Company or its or their respective known officers or employees; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Make, or cause to be made (directly or indirectly), any statement or comment on behalf of the Company to
the press or other media concerning the Employment with Company. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Confidentiality</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall neither during the Employment (except in the proper performance of his duties) nor at
any time after the termination thereof (without limit), directly or indirectly: </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">use for his own purposes or those of any other person, company, business entity or other organisation
whatsoever; or </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">disclose to any person, company, business entity or other organisation whatsoever; </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:13%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">any trade secrets or Confidential Information including but not limited to any such information relating to customers,
customer lists or requirements, price lists or pricing structures, sales and marketing information, business plans or dealings, employees or officers, source codes and computer systems, software, financial information and plans, designs, formulae,
prototypes, product lines, services, research activities, any document marked &#145;Confidential&#146; (or with a similar expression), or any information which the Employee has been told is confidential or which he might reasonably expect Company or
any Group Company would regard as confidential, or any information which has been given to Company or any Group Company in confidence by customers, suppliers or other persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall not at any time during the Employment with Company make any notes or memoranda relating
to any matter within the scope of Company&#146;s business, dealings or affairs otherwise than for the benefit of Company or any Group Company and/or as part of his performance of services for the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The obligations contained in this Section shall not apply to any disclosures required by law, and shall
cease to apply to any information or knowledge which may subsequently come into the public domain after the termination of Employment other than by way of unauthorised disclosure. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee shall not make or communicate any statement (whether written or oral) on behalf of the
Company to any representative of the press, television, radio, or other media and shall not write any article for the press or otherwise for publication on behalf of the Company on any matter connected with or relating to the business of Company or
any Group Company without obtaining the prior written approval of the Supervisor. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Nothing in this Agreement will be construed to prohibit Employee from filing a charge with, reporting
possible violations to, or participating or cooperating with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or
making other disclosures that are protected under the whistle-blower, anti-discrimination, or anti-retaliation provisions of federal, state, provincial or local law or regulation; provided, however, that Employee may not disclose Company information
that is protected by the attorney-client privilege, except as expressly authorized by law. Employee does not need the prior authorization of the Company to make any such reports or disclosures and Employee is not required to notify the Company that
he has made such reports or disclosures. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Although this Agreement is governed by the laws of the Province of Quebec, the Company provides notice to
Employee pursuant to the <I>Defend Trade Secrets Act</I> that: </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">An individual will not be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret that (1)&nbsp;is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation
of law; or (2)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of
law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal; and does not disclose the trade secret,
except pursuant to court order. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Intellectual Property</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">This Section relates to all Intellectual Property, discovery, invention, process or improvement in
procedure made, created or discovered by the Employee (whether alone or jointly with others) while in the employment or service of Company or any Group Company in connection with or in any way affecting or relating to the businesses of Company or
any Group Company or capable of being used by such Company or Group Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">All such Intellectual Property to which this Section applies shall to the fullest extent permitted by law
belong to, vest in and be the absolute sole and unencumbered property of Company. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee hereby: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">undertakes to notify and disclose to Company in writing full details of all Intellectual Property to which
this Section applies forthwith upon the production, invention or discovery of the same, and promptly whenever requested by Company and in any event upon the termination of this Agreement deliver up to Company all correspondence and other documents
papers and records and all copies thereof in his possession, custody or power relating to any such Intellectual Property; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">undertakes to hold on trust for the benefit of Company any such Intellectual Property to the extent that
the same may not be, and until the same is, vested absolutely in Company; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">assigns by way of present assignment of future copyright all copyright in all such Intellectual Property
to which this Section applies; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">acknowledges that, save as provided in this Agreement no further remuneration or compensation is or may
become due to him in respect of the performance of his obligations under this Section; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">undertakes at the expense of Company to execute all such documents, make such applications, give such
assistance and do such acts and things as may in the opinion of Company be necessary or desirable to vest in and register or obtain letters patent in the name of Company and otherwise to protect and maintain such Intellectual Property.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee agrees to waive any moral rights in the Intellectual Property to which the Employee is now or
may at any future time be entitled under the laws of any jurisdiction, including (but without limitation) the right to be identified, the right of integrity and the right against false attribution, and agrees not to institute, support, maintain or
permit any action or claim to the effect that any treatment, exploitation or use of such work or other materials, infringes the Employee&#146;s moral rights. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee hereby irrevocably appoints Company to be his representative in his name and on his behalf to
execute and do any such instruments or things and generally to use his name for the purpose of giving to Company or its nominees the full benefit of the provisions of this Section. </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:13%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">This Section shall not apply to any invention that Employee developed entirely on his own time without using the
Company&#146;s or Group Company&#146;s equipment, supplies, facilities, trade secret information or Confidential Information except for those inventions that either (i)&nbsp;relate to the business of Company&#146;s or Group Company&#146;s business,
or actual or anticipated research or development of Company or Group Company, or (ii)&nbsp;result from any work performed by Employee for Company or Group Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Post Termination Obligations</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">In consideration of the salary and other benefits payable under this Agreement, the Employee covenants
with and undertakes to Company that he will observe the post termination obligations set out in Schedule 3 to this Agreement, which Schedule constitutes part of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Tax Equalization</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Company agrees to tax equalize Employee on his Basic Salary earned in Canada and on any bonus paid for his
services in Canada. The tax equalization will be assessed against tax laws in effect from time to time in the state where the main residence of Employee is located, such that Employee shall pay more or less income tax on these elements of his
compensation than if he remained working in the state of his main residence in the United States. Any increased tax costs on these elements of his compensation shall be borne by Company. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Company will not tax equalize Employee on any other elements of his compensation and benefits,
including long-term incentives and housing. Employee will bear the cost of income tax in the state of his main residence in the United States and in Qu&eacute;bec. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Employee will be responsible for any tax preparation services related to tax equalization.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">In order to determine Employee&#146;s fiscal tax obligation under this Agreement and in order to reconcile
amounts paid by Employee and Company with Employee&#146;s final tax obligation under this Agreement, Employee shall provide to Company copies of his final tax returns as well as any tax assessments received from tax authorities in order to prepare a
tax equalization calculation for each calendar year that Employee is employed by Company under the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Severability</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The various Sections and <FONT STYLE="white-space:nowrap">sub-Sections</FONT> of this Agreement and the
Schedules attached hereto are severable and if any Section or <FONT STYLE="white-space:nowrap">sub-Section</FONT> is held to be unenforceable by any court of competent jurisdiction then such unenforceability shall not affect the enforceability of
the remaining Sections or <FONT STYLE="white-space:nowrap">sub-Sections</FONT> in this Agreement or Schedules. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Notices</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Any notice to be given hereunder may be delivered (a)&nbsp;in the case of Company by post addressed to its
registered office for the time being, with a copy by email to his Supervisor (which copy shall independently constitute notice) and (b)&nbsp;in the case of the Employee, either to him personally or by post to his last known address.
</P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">Notices served by post shall be deemed served on the third
(3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Business Day after the date of posting. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Prior Agreements</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">This Agreement cancels and is in substitution for all previous letters of engagement, agreements and
arrangements, assurances, statements, warranties, promised, representations or misrepresentations (whether oral or in writing) relating to the subject matter hereof between Company and the Employee all of which shall be deemed to have been
terminated by mutual consent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">This Agreement constitutes the entire terms and conditions of the Employment with Company and no waiver or
modification thereof shall be valid unless in writing, signed by the parties and only to the extent therein set forth. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Counterparts</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Agreement may be executed in any number of counterparts, each of which, when executed, shall be an
original, and all the counterparts together shall constitute one and the same instrument. Pdf and fax copies of this signed Agreement shall be treated as originals for all purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Governing Law and Jurisdiction</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">This Agreement is governed by and construed in accordance with the laws of the Province of Quebec and the
federal laws applicable therein. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Assistance and Review by Attorney</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">26.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee hereby acknowledges his understanding of the terms and conditions of this Agreement and that
he has had an opportunity to have this Agreement reviewed by his own attorney at law. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>Personal Information</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">27.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Employee agrees that the Company will create and maintain a file to contain his personal information
collected during his Employment. The Employee agrees that such personal information will be used for the purposes of administration of his Employment, including for payroll and benefits administration, and may be communicated to third parties,
whether in the Province of Quebec or outside of the Province of Quebec, for such purposes. Such file will be kept by the Company during the Employee&#146;s Employment and for up to seven (7)&nbsp;years following termination of employment, the whole,
in accordance with applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><B>English Language</B> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">28.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">The Parties declare that they have expressly required this Agreement to be drafted in the English
language. <I>Les Parties d</I><I>&eacute;</I><I>clarent avoir express</I><I>&eacute;</I><I>ment exig</I><I>&eacute;</I><I> que ce contrat soit r</I><I>&eacute;</I><I>dig</I><I>&eacute;</I><I> en langue anglaise. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><I>[signatures on the next page] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><B>THERATECHNOLOGIES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="40"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><U>Per:&#8195;&#8199; /s/ Paul L&eacute;vesque&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;Paul Levesque, President and</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date: <U>&#8195;1/17/2023&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="40"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">&#8194;<U>/s/ John O. Leasure&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><B>JOHN O. LEASURE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date: <U>&#8195;1/17/23&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE&nbsp;1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>KEY RESPONSIBILITIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Overseeing the Global commercial HIV business; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Leading the following functions servicing the Global operations: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Global marketing; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Global Analytics; </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Global manufacturing, sourcing and drug development; </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Global pricing and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Global new product planning. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Managing expenses and budget in relation to the above functions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>PROHIBITED ACTIVITIES </B></P> <P STYLE="font-size:26pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Any strategic business development for Company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Work leading up to, and including, the negotiation and signing of any contracts with clients or main service
providers/manufacturers, distributors, key business partners or relevant governmental authorities of Company or contracts that relate to the operation of the business of Company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Discussions and determination of Company&#146;s product pricing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Work leading up to the execution of any contracts relating to the financing activities of Company;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Any significant interaction with Company&#146;s investors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11.5pt">Works leading up to the execution of any contracts related to potential expansion in new markets for Company,
merger and acquisition activities or identification of new investments/targets (should it become relevant). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTIVE COVENANTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-solicitation</FONT> of Employees</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employee shall not, during his employment with the Company or any Group Company and for a period of twelve
(12)&nbsp;months following the termination of the Employee&#146;s employment hereunder for any reason, either solely or jointly with others, including as employee, consultant, independent contractor, partner, manager, agent, employee or otherwise,
without the consent in writing of the Supervisor, directly or indirectly, solicit or entice or cause to be solicited or enticed away from the Company or a Group Company any person (i)&nbsp;who was employed by the Company or a Group Company
<I><U>and</U></I> (ii)&nbsp;with whom the Employee had direct contact on behalf of the Company or a Group Company, in both cases during the twelve-month period preceding the termination the Employee&#146;s employment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-solicitation</FONT> of Customers</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">As a distinct and separate covenant, the Employee shall not, during his employment with the Company or any Group Company and
for a period of twelve (12)&nbsp;months following the termination of the Employee&#146;s employment hereunder for any reason, either solely or jointly with others, including as employee, consultant, independent contractor, partner, manager, agent,
employee or otherwise, without the consent in writing of the Supervisor, directly or indirectly, solicit or entice or cause to be solicited or enticed away from the Company or a Group Company any customer (i)&nbsp;who was a customer of the Company
or a Group Company during the twelve-month period preceding the termination the Employee&#146;s employment <I><U>and</U></I> (ii)&nbsp;with whom the Employee had direct contact on behalf of the Company or a Group Company <I><U>or </U></I>about whom
the Employee learned Confidential Information, in both cases during the twelve-month period preceding the termination of the Employee&#146;s employment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-solicitation</FONT> of Prospective Customers</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">As a distinct and separate covenant, the Employee shall not, during his employment with the Company
or any Group Company and for a period of twelve (12)&nbsp;months following the termination of the Employee&#146;s employment hereunder for any reason, either solely or jointly with others, including as employee, consultant, independent contractor,
partner, manager, agent, employee or otherwise, without the consent in writing of the Supervisor, directly or indirectly, solicit or entice or cause to be solicited or enticed away from the Company or a Group Company any prospective customer with
whom Employee was directly involved <I><U>or</U></I> about whom Employee learned Confidential Information, in both cases during the twelve-month period preceding the termination the Employee&#146;s employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-competition</FONT></U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">As a distinct and separate covenant, the Employee shall not, during his employment with the Company or any Group Company and
for a period of twelve (12)&nbsp;months following the termination of the Employee&#146;s employment hereunder for any reason, anywhere in the United States, directly or indirectly, work for, provide services to or have an ownership interest in any
business located in the United States that competes with the Company&#146;s or a Group Company&#146;s business. For the purpose of this provision the &#147;business&#148; of the Company and of a Group Company consists in manufacturing, selling, or
distributing HIV drugs, as well as conducting research and development work in the field of (i)&nbsp;nonalcoholic steatohepatitis or (ii)&nbsp;oncology where the sortilin receptor is the main target of any anti-cancer drug. Notwithstanding the
foregoing, nothing herein will prevent Employee from being a passive owner of (i)&nbsp;not more than two percent (2%) of any class of stock of a corporation that is a competitor to Company or of a Group Company, which class of stock is publicly
traded or (ii)&nbsp;not more than five percent (5%) of any class of security of any other entity that is a competitor to Company, in each case so long as the Employee has no active participation in the business of such corporation or entity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify"><U>Acknowledgement</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Employee acknowledges and agrees that the restrictions contained in the Agreement, including this Schedule 3, are necessary
for the protection of the legitimate business interests of the Company and any Group Company, that the restrictions are no greater than necessary to protect the Company&#146;s and any Group Company&#146;s legitimate business interests, including
because the Employee&#146;s duties cover the United States, and that the Company&#146;s and any Group Company&#146;s legitimate business interests would not be adequately protected if the restrictions were narrowed or limited. Employee further
acknowledges and agrees that Employee&#146;s skills and abilities are transferable to other businesses and industries, and that the restrictions imposed hereunder will not prevent Employee from earning a livelihood. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Employee further acknowledges that failure to comply with the terms of the Agreement, including this Schedule 3, may cause
serious or irreparable harm to the Company and any Group Company.&nbsp;Employee agrees that, in addition and cumulative to any other remedies available to the Company or any Group Company under applicable law for Employee&#146;s breach or threatened
breach of the Agreement, including this Schedule 3, the Company and any Group Company is entitled to seek specific performance or injunctive relief against Employee to prevent such damage or breach, including by way of a provisional, interlocutory
and permanent injunction.&nbsp;The existence of any claim or cause of action Employee may assert against the Company or Group Company will not constitute a defence thereto.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"><B>COMPUTATION OF STOCK OPTION VALUE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The number of stock options to be granted will be determined by dividing the dollar amount of the grant by the value of an option, as
determined by the Black-Scholes method, using the closing price of the common shares of the Company on the NASDAQ stock market on the date determined by the board of directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.43
<SEQUENCE>23
<FILENAME>d680117dex443.htm
<DESCRIPTION>EX-4.43
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.43</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="justify">


<IMG SRC="g680117g0217155726321.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="justify">


<IMG SRC="g680117g0217155725978.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:ARIAL" ALIGN="right"><B><U>Exhibit 4.43</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><B>PERSONAL AND CONFIDENTIAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Montreal, July&nbsp;31, 2023 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">John Leasure </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>RE:</U><B><U>
</U></B><U>&#8195;&#8195;&#8195;&#8195;Amendment to your Employment Agreement</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dear John: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Further the decision of the board of directors of Theratechnologies Inc. (&#147;<B>Thera</B>&#148;) to harmonize the terms
and conditions of all of the employment agreements of the executive officers related to a termination without a serious reason and a termination in the event of a change of control of Thera or other material transactions involving Thera, we hereby
offer you to amend Sections 16.3 and 16.4 of your employment agreement dated January&nbsp;6, 2023 (with an effective date of April&nbsp;11, 2022) (the &#147;<B>Agreement</B>&#148;) as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">by deleting Section&nbsp;16.3 of the Agreement in its entirety and by replacing it by Section&nbsp;16.3
below: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;16.3.&#8195;Upon termination of employment by Company for a reason other than &#147;for
a serious reason&#148;, including as part of a reorganization to reduce staff for economic reasons, but excluding termination following a Change of Control (as defined below) in the circumstances set forth below, the Employee will receive an amount
equal to the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the reasonable period of time to provide the notice of termination under applicable law; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has less than 5 years of continuous service: 12 months of his annual base salary at the
time of termination plus an amount equal to 100% of his target bonus for 12 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option grants or other stock-based
incentive compensation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 5 years or more, but less than 10 years, of continuous service: 18 months of his
annual base salary at the time of termination plus an amount equal to 100% of his target bonus for 18 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option
grants or other stock-based incentive compensation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 10 or more years of continuous service: 24 months of his annual base salary at the
time of termination plus an amount equal to 100% of his target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option grants or other stock-based
incentive compensation. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 2
 - </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">&#8195;&#8195;&#8195;


<IMG SRC="g680117g40w20.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:2%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:95%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employee will also receive an amount corresponding to the value of his accrued and unpaid
vacation up to the date of termination of his employment and the reimbursement of any expenses incurred in the performance of his duties but remaining unpaid at the date of termination of his employment.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">by deleting Section&nbsp;16.4 of the Agreement in its entirety and by replacing it by Sections 16.4.1 and
16.4.2 below: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">&#147;16.4.1 In the event of the occurrence of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a transaction (other than a transaction referred to in paragraph (b)&nbsp;below), regardless of its
structure (an &#147;<B>Acquisition</B>&#148;), pursuant to which one or more persons acting jointly or in concert (within the meaning of <I>National Instrument <FONT STYLE="white-space:nowrap">62-104</FONT> Take-Over Bids and Issuer Bids</I>, as in
effect from time to time) acquire, directly or indirectly, beneficial ownership of or control over securities of Company representing 40% or more of the voting rights attached to all voting securities for the election of directors of Company then
outstanding; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of an amalgamation, arrangement, compromise, consolidation, reorganization or other
transaction or series of transactions of similar nature involving, directly or indirectly, Company (a &#147;<B>Combination</B>&#148;) which results in either: (i)&nbsp;the shareholders of Company immediately prior to such Combination no longer
holding, directly or indirectly, after the Combination, more than 60% of the voting rights attached to all voting securities for the purposes of electing directors of the entity resulting from the Combination (or, if Company becomes a subsidiary, of
the ultimate parent entity of such subsidiary); or (ii)&nbsp;the board of directors of the entity resulting from the Combination (or, if Company becomes a subsidiary, of its ultimate parent entity) is no longer comprised of a majority of the
directors who sat on the board of directors of Company immediately prior to the Combination; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a change in the composition of the board of directors of Company occurring, without the approval by a
majority vote of the directors comprising the board of directors of Company prior to such change, during a shareholders&#146; meeting or pursuant to a resolution passed by the shareholders of Company, and which results in the board of directors of
Company no longer being comprised of a majority of the directors of Company who sat as directors immediately prior to such meeting or resolution (other than a change resulting from the solicitation of proxies by the management of Company or related
to the death, resignation or inability of one or more directors to act as such) (an &#147;<B>Insurrection</B>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of the sale, exchange, lease, assignment, liquidation, grant of an exclusive license, or any
other form of disposition of assets of Company, to a party that is not an affiliate of Company (within the meaning of the <I>Business Corporations Act</I> (Qu&eacute;bec)), representing substantially all of the assets of Company (an &#147;<B>Asset
Disposition</B>&#148;); </P></TD></TR></TABLE></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g0217155726198.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 3
 - </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">&#8195;&#8195;&#8195;


<IMG SRC="g680117g40w20.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:2%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:95%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">and that, within 24 months following the occurrence of an Acquisition, a Combination, an
Insurrection or a Disposal of Assets (each of which, for the purposes hereof, represents a &#147;<B>Change of Control</B>&#148;), either: (a)&nbsp;the Employee&#146;s employment is terminated without a serious reason; or (b)&nbsp;the Employee
decides to terminate his employment on his own volition, the Employee will then receive on the date of termination of his employment an amount equal to the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the reasonable period of time to provide the notice of termination under applicable law; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has less than 5 years of continuous service: 12 months of his annual base salary at the
time of termination plus an amount equal to 100% of his target bonus for 12 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option grants or other stock-based
incentive compensation; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 5 years or more, but less than 10 years, of continuous service: 18 months of his
annual base salary at the time of termination plus an amount equal to 100% of his target bonus for 18 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option
grants or other stock-based incentive compensation; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15">&nbsp;</TD>
<TD WIDTH="31" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">if the Employee has 10 or more years of continuous service: 24 months of his annual base salary at the
time of termination plus an amount equal to 100% of his target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of any benefits offered by Company and the value of any option grants or other stock-based
incentive compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In all cases, the Employee will also receive an amount corresponding to the value of his
accrued and unpaid vacation up to the date of termination of his employment and the reimbursement of any expenses incurred in the performance of his duties but remaining unpaid at the date of termination of his employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this Section, in order to determine on any given date the percentage of voting securities held by any person (including
persons acting jointly or in concert with such person) relative to the number of issued and outstanding voting securities of Company, such person (including persons acting jointly or in concert with such person) shall be deemed to hold and own all
of the voting securities of Company that such person (and persons acting jointly or in concert) may acquire within 60 days from such given date through the exercise, exchange, conversion of other securities or through other rights or obligations
permitting or requiring such person (or persons acting jointly or in concert), whether or not on conditions, to acquire, through a single or series of linked transactions, voting securities of Company as if such exercise, exchange, conversion or
other rights or obligations had been exercised. For the purpose of determining the number of issued and outstanding voting securities of Company under this Section at any given time, the number of issued and outstanding voting securities of Company
shall be increased by the number of voting securities such person (including persons acting jointly or in concert with such person) may acquire within such <FONT STYLE="white-space:nowrap">60-day</FONT> period as contemplated in the preceding
sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Company will be deemed to have entered into an Asset Disposition if such Asset Disposition represents more than 75% of the
value of its assets calculated as at the date of the last financial year preceding such Asset Disposition, or if the assets disposed of under such Asset Disposition represent more than 75% of the revenues generated by Company during the last
financial year preceding such Asset Disposition. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g0217155726198.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 4
 - </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">&#8195;&#8195;&#8195;


<IMG SRC="g680117g40w20.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:2%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#8195;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:95%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">16.4.2&#8195; In the event of a Change of Control, all securities and rights issued or granted
to the Employee under long-term compensation plans, such as stock options, deferred share units, appreciation rights and other similar rights that vest over a defined period of time, whether or not based on the achievement of performance targets,
will all automatically vest as if the vesting conditions and, if applicable, the achievement of performance targets, had been met.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The proposed amendments will become effective upon the date of your execution of this letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Except with respect to the proposed amendments contained herein, all of the other terms and conditions of the Agreement will remain the same
and unamended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you accept the proposed amendments to the Agreement, we ask you to countersign this letter below and to return an
executed copy thereof to Jocelyn Lafond, our general counsel and corporate secretary, no later than on August&nbsp;4, 2023. If we have not received this letter duly executed by August&nbsp;4, 2023, we will deem that you have refused the present
offer and such offer will become null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Yours very truly, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Paul
L&eacute;vesque&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Paul L&eacute;vesque </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">I hereby acknowledge having read and understood the proposed amendments to my employment agreement and further acknowledge having been
offered sufficient time to consult with a legal counsel of my choice to review such proposed amendments and to agree to those. I understand that my employment with Thera is not conditional upon the acceptance of these proposed amendments and to the
execution of this letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dated and signed in Montreal (Qu&eacute;bec), on July&nbsp;31, 2023. </P>
<P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>&#8194;/s/ John Leasure&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">John Leasure </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g0217155726198.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.44
<SEQUENCE>24
<FILENAME>d680117dex444.htm
<DESCRIPTION>EX-4.44
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.44</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.44 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[TRANSLATION] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>EMPLOYMENT
</U><U>AGREEMENT</U> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>ENTERED INTO </B>at the place and date of the last signature appearing on the last page. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#8194;BETWEEN:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>T<SMALL>HERATECHNOLOGIES</SMALL> I<SMALL>NC</SMALL>.</B>, a company legally constituted under the <I>Companies Act</I>
(Qu&eacute;bec), having its head office and principal place of business at 2310 Alfred-Nobel Blvd., Montr&eacute;al, Province of Qu&eacute;bec, H3S 2A4;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter &#147;Thera&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>&#8194;AND:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>JOCELYN LAFOND</B>, residing and domiciled at
<FONT STYLE="background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT>;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">(hereinafter the &#147;Employee&#148;)</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>Thera is a Canadian biopharmaceutical company engaged in the research,
development and commercialization of therapeutic products;<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>Thera requires the services of the
Employee as Executive Director, Senior Legal Counsel and Corporate Secretary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>in the event of the
appointment of a Vice-President at Thera, Thera&#146;s management undertakes to consider the Employee&#146;s candidacy as Vice-President, Legal Affairs; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS </B>the Employee agrees to act in this capacity in accordance with the terms and conditions contained in this
contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE</B>,<B> </B>the parties agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Effective Date</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This employment contract will be effective as of April&nbsp;16, 2007. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Description of Services</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the term of this contract, the Employee will be exclusively employed by Thera and will report to the Senior Executive
Vice-President and Chief Financial Officer or such other person appointed by Thera. The Employee will act as Executive Director, Legal Services and Corporate Secretary, and will perform the duties and responsibilities inherent to this position. The
Employee shall dedicate his efforts, skill and attention to the performance of his responsibilities hereunder and to the advancement of Thera&#146;s business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:Times New Roman" ALIGN="center"> -
 2
- </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Compensation</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will receive the following compensation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Base Salary</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will receive a annual base salary of $180,000, paid in accordance with Thera&#146;s policy. This salary will be
reviewed annually in accordance with section 3.5 hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Bonus</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will be eligible for an annual bonus of up to 20% of the annual base salary earned, as determined by Thera&#146;s
general policy regarding bonuses in effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Stock Option</U><U> Grant</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Subject to approval by Thera&#146;s Board of Directors (the &#147;Board&#148;), the Employee will be granted the following
stock options: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">25,000 stock options to purchase common shares of Thera, to be granted at the Board meeting on
March&nbsp;29, 2007, at the exercise price set by the Board. These stock options will be acquired at the end of the fiscal year as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">8,333 on the first anniversary of their grant date; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">8,333 on the second anniversary of their grant date; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">8,334 on the third anniversary of their grant date. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Stock Purchase Plan </U></B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will be eligible to participate in Thera&#146;s stock purchase plan under the rules in force. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.5<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Salary Review </U></B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Review of the terms of section 3.1 shall be made at the end of Thera&#146;s next current fiscal year and shall be made at the
end of each of Thera&#146;s subsequent fiscal years in accordance with its policies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:Times New Roman" ALIGN="center"> -
 3
- </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Other Benefits</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will also be entitled to the following additional benefits: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Vacation</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the term of this contract, the Employee will be entitled to four (4)&nbsp;weeks paid vacation per year in accordance
with the terms and conditions of Thera&#146;s general vacation policy. For Thera&#146;s current fiscal year, the Employee will be entitled to his four (4)&nbsp;weeks of paid vacation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Group Insurance Plan</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will be entitled to participate in and, if eligible, receive benefits under the group insurance plan and other
benefits in force for executives at Thera in accordance with its terms and conditions as of the effective date of this contract. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Representation and Expenses</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Upon presentation of the requested supporting documents, the Employee will be entitled to reimbursement of all costs and
expenses reasonably incurred in the performance of his duties, in accordance with Thera&#146;s established budgets, processes and policies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Group RRSP</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Thera shall contribute to the Employee&#146;s RRSP based on its contribution policy to the registered retirement savings plan
of its employees, subject at all times to a minimum contribution of $2,000 per year. The Employee must comply with the terms and conditions of Thera&#146;s policy in order for Thera to be required to contribute at least $2,000 per year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Medical <FONT STYLE="white-space:nowrap">Follow-up</FONT></U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee will benefit from an annual preventive <FONT STYLE="white-space:nowrap">follow-up</FONT> program for executives
at a private health clinic of his choice and Thera shall pay all reasonable costs related to this program for the Employee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Other Employee Costs Borne by Thera</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:16%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee&#146;s professional order fees shall be borne by Thera as well as those for any liability insurance that the
Employee must maintain in force. In addition, costs related to reference books that the Employee deems necessary to have will be borne by Thera. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:Times New Roman" ALIGN="center"> -
 4
- </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> and
<FONT STYLE="white-space:nowrap">Non-Use</FONT></U> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee undertakes never to disclose
confidential information obtained or developed in the course of his employment with Thera without being expressly authorized to do so under the terms of Thera&#146;s information policy. He shall sign an undertaking to that effect on his start date
and comply at all times with this policy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Intellectual Property</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee undertakes to assign to Thera all processes, inventions, creations, technologies or improvements developed by
the Employee, alone or in collaboration, and which relate to Thera&#146;s business or result from the very nature of his duties at Thera. The Employee agrees to assist Thera in obtaining, renewing or maintaining domestic or foreign patents on such
processes, inventions, creations, technologies or improvements. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Term</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This contract shall constitute an employment contract with an indefinite term, any of the terms or conditions of which may be
amended by mutual agreement of the parties. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Termination</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This contract may be terminated as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>within three months following the effective date, with two weeks&#146; prior written notice from
Thera to the Employee; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>the Employee&#146;s resignation; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>the Employe&#146;s failure to provide the agreed services; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>the Employee&#146;s inability to provide the services inherent to his duties for a continuous period
of 180 days, or for 210 days out of a continuous period of 365 days, subject to any rights acquired under the group insurance plan then in force; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>at any time by mutual consent of the parties to that effect; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">at any time, unilaterally by any of the parties hereto, without notice, for a serious reason.
</P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Employee undertakes, upon termination of his employment, not to copy, remove or take any
confidential information described in section 5 above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Indemnities</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>If the Employee&#146;s employment is terminated without serious reason, the Employee will receive the
greater of: (i)&nbsp;twelve (12) months salary plus, if applicable, any bonus or other expenses due but unpaid; or (ii)&nbsp;any amounts payable under applicable law. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:Times New Roman" ALIGN="center"> -
 5
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of any of the following: (i)&nbsp;a take-over bid (within the meaning of the <I>Securities
Act</I> (Qu&eacute;bec), as in force on the date hereof); or ii) any transaction (merger, arrangement, compromise, reorganization or other transaction of this nature, including the sale by Thera to a third party of all or substantially all of its
assets) pursuant to which any person or joint actor (within the meaning of the <I>Securities Act</I> (Qu&eacute;bec), as in force on the date hereof) of such person acquires control of Thera, and the Employee leaves his employment within twenty-four
(24)&nbsp;months of the take-over bid or such transaction, the Employee will receive an amount equal to twelve (12)&nbsp;months&#146; salary plus, if applicable, any bonuses or other expenses due but unpaid. For the purposes of this paragraph, a
person shall be deemed to have acquired control of Thera if the person and/or any of their joint actors own securities entitling them to elect or cause to be elected a majority of the directors to Thera&#146;s Board. For the purpose of calculating
the number of voting shares held by any person (including joint actors of that person), all securities convertible or exchangeable into voting shares held or controlled by such person must be included, as if they had been converted or exchanged into
voting shares, whether the conversion or exchange takes place in one or more transactions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>Any indemnity paid pursuant to this section shall constitute the sole monetary obligation to be borne
by Thera and its payment by Thera shall release and discharge Thera from any right of or claim by the Employee as a result of the termination of employment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Survival of Undertakings</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> undertakings
set out in section 5 as well as those relating to intellectual property set out in section 6 shall survive termination under section 8. Despite the foregoing, this provision shall not be interpreted as preventing the Employee from working in his
areas of expertise, provided that at all times, he complies with the undertakings contracted herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Governing Law</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This contract shall be interpreted and governed in accordance with the laws of the province of Qu&eacute;bec and the laws of
Canada applicable in Qu&eacute;bec. The parties submit to the jurisdiction of the courts of the province of Qu&eacute;bec. This contract shall be considered in all respects as a contract of employment within the meaning of the <I>Civil Code of
Qu</I><I>&eacute;</I><I>bec</I>, except where expressly waived. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><U>Preamble</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The preamble shall form an integral part hereof as if recited herein at length. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this employment contract at the place and date hereinafter set
forth. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt; font-family:Times New Roman" ALIGN="center"> -
 6
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Signed in Montr&eacute;al, on March&nbsp;29, 2007</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Signed in Montr&eacute;al, on March&nbsp;29, 2007</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="19"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="19"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Luc
Tanguay&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><U>/s/ Jocelyn Lafond&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Luc Tanguay</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>Jocelyn Lafond</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Senior Executive Vice-President and Chief</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.45
<SEQUENCE>25
<FILENAME>d680117dex445.htm
<DESCRIPTION>EX-4.45
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.45</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.45</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[TRANSLATION] </P>
<P STYLE="margin-top:35pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PERSONAL AND CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">June&nbsp;28, 2012 </P>
<P STYLE="margin-top:32pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Jocelyn Lafond </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>RE:&#8195;&#8195;&#8194;Amendment to your Employment
Contract</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Dear Jocelyn, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Following the decision of the Board of Directors to propose amendments to management employment contracts in the event of any
member(s) of management being dismissed without a serious reason following an acquisition of control of Theratechnologies Inc. (&#147;<B>Thera</B>&#148;) or a material transaction by Thera, we propose deleting section 9.2 of your employment contract
and replacing it with the new section 9.2 set out below, as of your acceptance hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We therefore ask, if you agree to
this amendment, that you return this letter to us <U>before July</U><U></U><U>&nbsp;8, 2012</U>, failing which we will assume that this amendment to your employment contract is not acceptable to you and this proposal will then lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;9.2&#8195;In the event of: </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a take-over bid (within the meaning of the <I>Securities Act</I> (Qu&eacute;bec), as in effect from time to
time) (a &#147;<B>Bid</B>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any transaction (amalgamation, arrangement, compromise, reorganization or other similar transaction,
including any alienation by Thera to a third party of its assets if, as a result of such alienation, Thera is unable to retain a significant part of its business activities) (a &#147;<B>Transaction</B>&#148;); </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 2
- </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">pursuant to which a person or any person acting jointly or in concert (as
defined in <I>Regulation <FONT STYLE="white-space:nowrap">62-104</FONT> respecting Take-Over Bids and Issuer Bids</I> of the <I>Securities Act</I> (Qu&eacute;bec), as in effect from time to time) with such person acquires control of Thera and that,
within 24 months following the completion of the Bid or the Transaction, the Employee&#146;s employment with Thera is terminated without serious reason, or the Employee voluntarily decides to leave his employment during this <FONT
STYLE="white-space:nowrap">24-month</FONT> period, the Employee will then receive on the date of termination of his employment an amount equal to the greater of (i)&nbsp;the reasonable notice provided for by law and (ii) 12 months of his annual base
salary, at the time of termination of his employment, plus an amount equal to 100% of his annual target bonus, calculated based on such annual base salary, as well as any other amounts that may be due and unpaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">For the purposes hereof, a person will be deemed to have acquired control of Thera if the person and/or persons acting
jointly or in concert with the person own at least 40% of the voting securities of Thera or the entity resulting from the Transaction. For the purpose of calculating the number of voting securities held by any person (including persons acting
jointly or in concert with such person), all securities convertible into or exchangeable for voting securities held or controlled by such person shall be included as if they had been converted or exchanged into voting securities, whether the
conversion or exchange occurs in one or more transactions. An alienation of property includes the sale, exchange, lease of property and the granting of a licence in respect of any property. Thera will be deemed to retain a significant part of its
business activity when the activities it retains after alienation require the use of at least 25% of the value of its assets as at the end of the fiscal year preceding such alienation and such activities generated in the fiscal year preceding such
alienation at least 25% of Thera&#146;s <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenues or earnings.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Except for this amendment to your employment contract, all other terms and conditions of your employment contract will remain
in effect and unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">If you accept this amendment, please sign this offer in the space provided below and return the
duly executed document to Luc Tanguay, Senior Executive Vice-President and Chief Financial Officer of Thera. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Yours truly,
</P> <P STYLE="margin-top:15pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THERATECHNOLOGIES INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ John-Michel T.Huss&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">John-Michel T. Huss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"> -
 3
 - </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that I have read, had the opportunity to consult with legal
counsel and understand and accept the content of this amendment to my employment contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Dated and signed at
Montr&eacute;al (Qu&eacute;bec), on July&nbsp;5, 2012. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>/s/ Jocelyn Lafond&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Jocelyn Lafond</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.46
<SEQUENCE>26
<FILENAME>d680117dex446.htm
<DESCRIPTION>EX-4.46
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.46</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 4.46</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[TRANSLATION] </P>
<P STYLE="margin-top:35pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PERSONAL AND CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">July&nbsp;27, 2023 </P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Jocelyn Lafond </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="font-family:Times New Roman;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:30pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify"><U>RE:&#8195;&#8195;&#8194;Amendment to your Employment
Contract</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dear Jocelyn, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Following the decision of the Board of Directors to propose amendments to management employment contracts in order to update
them in accordance with current legal principles and to harmonize the terms and conditions of employment contracts of executive officers reporting to the President and Chief Executive Officer regarding termination without a serious reason (just
cause) and the consequences arising from any change or acquisition of control of Theratechnologies Inc. (&#147;<B>Thera</B>&#148;) or a material transaction by Thera, we propose amending section 9 of your employment contract dated March&nbsp;29,
2007, as amended on July&nbsp;5, 2012 (collectively, the &#147;<B>Contract</B>&#148;) as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">By deleting the section 9 in its entirety and replacing it with the following section 9:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;9.&#8195;<B><U>Indemnities</U></B><B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">9.1&#8195;<B><U>Indemnity</U></B><U> </U><B><U>for Termination Without a Serious Reason.</U></B> If the employment of the
Employee is terminated without a serious reason, including as part of a reorganization to reduce personnel for economic reasons, but excluding a termination following a Change of Control (as defined below) in the circumstances set out below, the
Employee will receive an amount equal to the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">24 months of his annual base salary at the time of his termination plus an amount equal to 100% of his
target bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of benefits offered by Thera and the value of option grants or other stock-based incentive compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">The Employee will also receive an amount equal to the value of his accrued and unpaid vacation up to the date of termination
of his employment and the reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 2
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">9.2.&#8195;<B><U>Indemnity Following a Change of Control or Any Other Material
Transaction.</U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In the event of any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a transaction (other than a transaction referred to in paragraph (b)&nbsp;below), regardless of its
structure (an &#147;<B>Acquisition</B>&#148;), pursuant to which a person or persons acting jointly or in concert (as defined in <I>Regulation <FONT STYLE="white-space:nowrap">62-104</FONT> respecting Take-Over Bids and Issuer Bids</I>, as in effect
from time to time) directly or indirectly acquire beneficial ownership of, or control over, securities of Thera representing 40% or more of the voting rights attached to all voting securities for the election of directors of Thera then outstanding;
or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the closing of any amalgamation, arrangement, compromise, consolidation, reorganization or other transaction
or series of transactions of this nature involving directly or indirectly Thera (a &#147;<B>Combination</B>&#148;) which results in either (i)&nbsp;the shareholders of Thera immediately prior to such Combination no longer holding, directly or
indirectly, after the Combination, more than 60% of the voting rights attached to all voting securities for the purpose of electing directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, of the ultimate parent
company of such subsidiary); or (ii)&nbsp;the Board of Directors of the entity resulting from the Combination (or, if Thera becomes a subsidiary, the ultimate parent company of such subsidiary) is no longer composed of a majority of the directors
who served on Thera&#146;s Board of Directors immediately prior to the Combination; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">a change in the composition of Thera&#146;s Board of Directors occurring, without the approval by a
majority vote of the directors composing Thera&#146;s Board of Directors prior to such change, at the same shareholders meeting or pursuant to a resolution of Thera&#146;s shareholders, and which results in Thera&#146;s Board of Directors no longer
being composed of a majority of the directors of Thera who were serving as directors immediately prior to such meeting or resolution (other than a change resulting from the solicitation of proxies by the management of Thera or related to death,
resignation or inability to act in such capacity) (an &#147;<B>Insurgency</B>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">the closing of the sale, exchange, lease, transfer, liquidation, grant of an exclusive license, or any
other form of alienation of Thera&#146;s assets, to a party that is not an affiliate of Thera (as defined in the <I>Business Corporations Act</I> (Qu&eacute;bec)), representing substantially all of Thera&#146;s assets (an &#147;<B>Asset
Transfer</B>&#148;); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">and that within 24 months following the occurrence of any Acquisition, Combination, Insurgency
or Asset Transfer (each representing for the purposes hereof a &#147;<B>Change of Control</B>&#148;), either (a)&nbsp;the employment of the Employee is terminated without a serious reason; or (b)&nbsp;the Employee decides to terminate his employment
of his own free will, the Employee shall then receive on the date of termination of his employment an amount equal to the greater of: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 3
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">reasonable notice as required by applicable law, and; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman; " ALIGN="justify">24 months of his annual base salary at the time of termination plus an amount equal to 100% of his target
bonus for 24 months calculated on the basis of such annual base salary, but excluding the value of the benefits offered by Thera and the value of option grants or other stock-based incentive compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">In all cases, the Employee will also receive an amount equal to the value of his accrued and unpaid vacation up to the date of termination
of his employment and reimbursement of any expenses incurred in the performance of his duties but unpaid at the date of termination of his employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this section, in order to calculate the percentage of the number of voting securities held by any person (including
persons acting jointly or in concert with such person) relative to the number of outstanding voting securities, such calculation shall include, both with respect to the voting securities held by such person (and persons acting jointly or in concert
with such person) and to the outstanding voting securities, all convertible or exchangeable securities within sixty (60)&nbsp;days from the date of calculation of voting securities held or controlled by such person, as if such securities had been
converted or exchanged into voting securities, whether such conversion or exchange occurs in one or more transactions. Such securities convertible or exchangeable within sixty (60)&nbsp;days shall be deemed to have been acquired and to be
beneficially owned by such person (or any person acting jointly or in concert with such person). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Thera will be deemed to have entered
into an Asset Transfer if such Asset Transfer represents more than 75% of the value of its assets calculated as at the date of the fiscal year end preceding such Asset Transfer, or if the assets transferred in connection with such Asset Transfer
represent more than 75% of the income generated by Thera during the fiscal year preceding such Asset Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">9.3&#8195;<B><U>Acceleration of Acquisition of Securities Issued as Long-Term Compensation Plans</U></B>.<B> </B>In the event of a Change of
Control, all securities and rights issued or granted to the Employee under long-term compensation plans, such as stock options, deferred share units, appreciation rights and other rights that vest over a defined period of time, whether or not based
on the achievement of performance targets, will all automatically vest as if the vesting conditions and, if applicable, the achievement of performance targets had been met.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you agree to these amendments, we ask that you return this letter to me <U>no later than August</U><U></U><U>&nbsp;3, 2023</U>, failing
which we will assume that these amendments to your employment contract are not acceptable to you and this proposal will then lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">These amendments will become effective upon the date of your execution of this letter below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Except for these amendments to your employment contract, all other terms and conditions will remain in effect and unchanged. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="center"> -
 4
 - </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">If you accept these amendments, please sign this letter in the space provided below and
return a duly executed copy thereof to the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Yours truly, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><B>THERATECHNOLOGIES INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ Paul L&eacute;vesque</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Paul L&eacute;vesque</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">President and Chief Executive Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">I acknowledge that I have read, had the opportunity to consult with legal counsel and understand and accept
the content of these amendments to my employment contract dated March&nbsp;29, 2007, as amended July&nbsp;5, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11.5pt; font-family:Times New Roman" ALIGN="justify">Dated and signed at
Montr&eacute;al (Qu&eacute;bec), on July&nbsp;27, 2023. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">/s/ Jocelyn Lafond</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman">Jocelyn Lafond</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.47
<SEQUENCE>27
<FILENAME>d680117dex447.htm
<DESCRIPTION>EX-4.47
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.47</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="right"><U><FONT STYLE="font-family:Times New Roman"><B>Exhibit 4.47</B></FONT><FONT STYLE="font-family:arial">
</FONT></U></P> <P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify"><FONT STYLE="font-family:Times New Roman">[TRANSLATION]</FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:Calibri"><B>PERSONAL AND CONFIDENTIAL</B></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="right">Friday, December&nbsp;15, 2023 </P> <P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial">Jocelyn Lafond </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial">General Counsel and Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">Theratechnologies Inc. </P>
<P STYLE="font-size:13pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="left">Salary Increase 2024 </P></TD></TR></TABLE>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">Dear Jocelyn, </P>
<P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">In recognition of your significant contributions this year, I am pleased to confirm that effective December&nbsp;1, 2023, your gross annual salary has
been increased to CA$356,723.98, which is a 3.7% increase. This new salary will be retroactive to December&nbsp;1, 2023. </P> <P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">In addition, your annual
bonus will increase from 33% to 40% in 2024. Your 2023 annual bonus will be confirmed and paid to you in the first quarter of 2024, as discussed earlier this year. </P>
<P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">I would like to thank you once again for your contribution to Theratechnologies this year and wish you a successful 2024! </P>
<P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">Best regards, </P> <P STYLE="font-size:13pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Paul L&eacute;vesque</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom">Paul L&eacute;vesque</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8
<SEQUENCE>28
<FILENAME>d680117dex8.htm
<DESCRIPTION>EX-8
<TEXT>
<HTML><HEAD>
<TITLE>EX-8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 8 </U></B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>LIST OF SIGNIFICANT SUBSIDIARIES</U> </B></P>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of November&nbsp;30, 2023, Theratechnologies had five wholly owned subsidiaries with Theratechnologies U.S. Inc. being the only significant
subsidiary among Theratechnologies&#146; affiliates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Theratechnologies U.S., Inc., </B>a company governed by the DGCL. Theratechnologies U.S., Inc. assists
Theratechnologies Inc. with its commercial activities in the United States; and </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>29
<FILENAME>d680117dex111.htm
<DESCRIPTION>EX-11.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-11.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="right"><B><U>Exhibit 11.1</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-family:Calibri; font-size:0.5pt"><FONT COLOR="#FFFFFF">Thera technologies CODE OF BUSINESS CONDUCT &amp; ETHICS Driving Innovation through Integrity </FONT></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g17j01.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-family:Calibri; font-size:0.5pt"><FONT COLOR="#FFFFFF">1. Message from the President and Chief Executive Officer 2. Purpose of the Code and its Use 2.1 Introduction 2.2
Responsibilities of Managers and Directors; Compliance Officer 2.3 Certification 2.4 Review of Code 3. Healthcare Compliance Principles 3.1 Healthcare Compliance 3.2 U.S. Pharmaceutical Industry Laws, Regulations, and Guidance 3.3 Guiding Principles
4. Compliance with Laws 4.1 Pharmaceutical Industry Laws, Regulations, and Guidance 1. Fair Competition 2. Drug Laws 3. U.S. Anti-Kickback Act, Bribery 4. U.S. Foreign Corrupt Practices Act 5. U.S. False Claims Act 6. Ineligible Persons 7.
Regulatory and Industry Guidance 4.2 Employment Policies 4.3 Political Process 5. Integrity 5.1 Conflicts of Interest 5.2 Corporate Opportunities 5.3 Fair Dealing 5.4 Proper Use of Company Assets 5.5 Confidential Information 5.6 Delegation of
Authority 6. Special Ethics Guidelines for Employees with Financial Reporting Responsibilities 7. Waivers and Approvals 8. Reporting and Investigation Process 8.1 Reporting 8.2 Contact Information (See Exhibit A) 8.3 Investigation Process 8.4
Disciplinary Action 8.5 Confidentiality 8.6 Protection against Retaliation Exhibit A &#151; Contact Information for Reporting Compliance Questions or Concerns Exhibit B &#151; Code of Business Conduct &amp; Ethics </FONT><br><FONT
STYLE="font-family:Calibri; font-size:0.5pt" COLOR="#FFFFFF">Annual Disclosure Statement Exhibit C &#151; Code of Business Conduct &amp; Ethics Annual Certification </FONT></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g17j02.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Code of Business Conduct and Ethics </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#276fb0"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Calibri; " ALIGN="left"><FONT COLOR="#276fb0"><B>Message from the President and Chief Executive Officer </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">At Theratechnologies, we are passionate about innovation and we aim at developing and commercializing cutting-edge treatments addressing unmet medical
needs which give new options to healthcare practitioners and hope to patients. We recognize that you, our exceptional team of dedicated professionals, are our most valuable asset. Working together as a dedicated team comprised of skilled people with
integrity, Theratechnologies and its employees will earn and maintain the trust of customers, patients, physicians, suppliers, investors, regulators, and fellow employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">We are relentless in pursuit of our mission to develop and commercialize cutting-edge treatments addressing unmet medical needs which give new options
for health care practitioners and hope to patients. From our inception in 1993, we have been passionate about bringing our vision to reality -- to be a biopharmaceutical company which successfully brings to market exceptional innovations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">This Code of Business Conduct and Ethics (this &#147;Code&#148;), as the center piece of our compliance program, is intended to guide us with greater
precision as we continue to pursue our vision and accomplish our mission on behalf of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Accordingly, all employees, officers and
directors have a responsibility to understand and follow this Code. I ask that you take the time to read and understand this Code. Each of us must own compliance, both individually and as a team. At Theratechnologies, compliance is about
<B><I>Driving Innovation Through Integrity</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Our continued success depends upon our continued passionate commitment to serve patients and
their families. Thank you for your continued support, cooperation and commitment to compliance, innovation and integrity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">Sincerely, </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:1%">


<IMG SRC="g680117g0117021212701.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>Paul L&eacute;vesque </I></B></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><I>President &amp; Chief Executive Officer </I></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT
 COLOR="#276fb0"><I>Theratechnologies Inc. </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">3</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#276fb0"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Calibri; " ALIGN="left"><FONT COLOR="#276fb0"><B>Purpose of the Code and its Use </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>2.1. Introduction </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">This Code applies to all directors, officers, and employees of Theratechnologies Inc. and to those of its subsidiaries (collectively, the
&#147;Company&#148; or &#147;Theratechnologies&#148;). Theratechnologies strives to uphold the highest legal and ethical principles and standards and has adopted this Code to promote, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>compliance with applicable governmental laws, rules, and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>the prompt internal reporting of any suspected violations of this Code to appropriate persons or through
the Company&#146;s Compliance Hotline/Helpline; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>complete cooperation in the investigation of reported violations and the provision of truthful, complete
and accurate information; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>accountability for adherence to this Code. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Each director, officer, and employee of Theratechnologies is responsible for understanding and following this Code. Theratechnologies provides
periodic training on the contents and importance of this Code and related policies as well as the manner in which violations must be reported and waivers or approvals must be requested. The laws and suspected regulations addressed in this Code can
be complex and are subject to change. This Code is neither a contract nor a comprehensive manual that covers every situation you might encounter. If you are unsure of how to conduct yourself in a particular situation, you should immediately discuss
it with your manager, Human Resources, the Director, U.S. Compliance, the Company&#146;s General Counsel, or anonymously, through the Compliance Hotline/Helpline (<U>See</U> Section<U></U>&nbsp;8.2 &#147;<I>Contact Information</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>2.2. Responsibilities of Managers and Directors; Director, U.S. Compliance </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">All officers and managerial employees of Theratechnologies are responsible for the enforcement of, and compliance with, this Code, including
distribution of copies of this Code to ensure employees&#146; knowledge of and familiarity with this Code. Officers and managerial employees are expected to promote honest and ethical conduct, including the ethical handling of actual or apparent
conflicts of interest between personal and professional relationships. Managerial employees may be disciplined if they condone misconduct, do not report misconduct, do not take reasonable measures to detect misconduct, or do not demonstrate the
appropriate leadership to ensure compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Board of Directors is responsible for overseeing the implementation of this Code. The Board of
Directors has designated Theratechnologies&#146; General Counsel to be the responsible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">4</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">officer with respect to the administration and enforcement of, and the Company&#146;s compliance with, this Code,
including the initial investigation and management of reports of suspected violations of this Code, unless otherwise described in Section&nbsp;8. &#147;<I>Reporting and Investigation Process</I>&#148; of this Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>2.3. Certification </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">After initial hire (or, in the case of directors, appointment or election) or first receipt of this Code, all employees, officers and directors
<B><U>must annually sign</U></B> and return the Theratechnologies Code of Business Conduct and Ethics Disclosure Statement (Exhibit B) verifying that he or she has read, understands, and will comply with this Code at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Theratechnologies Code of Business Conduct and Ethics annual certification (Exhibit C) must be signed and returned each year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>2.4. Review of Code </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Board of Directors shall review and evaluate this Code on a regular and periodic basis or as recommended by the General Counsel in consultation
with the Compliance Committee to ensure that this Code is up to date and appropriately reflects Theratechnologies&#146; commitment to conduct its business and affairs with integrity and mutual respect and in accordance with the highest ethical and
legal standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>3. Healthcare Compliance Principles </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B></B><B><I>3.1.</I></B><B> Healthcare Compliance </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Healthcare in Canada, the United States and other jurisdictions in which Theratechnologies conducts business is highly regulated. Laws and regulations
governing drug development, approval, labeling, promotion, and pricing exist to safeguard patient safety and privacy, optimize patient healthcare outcomes, and protect government programs and third-party insurers that purchase or pay for
prescription drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies is committed to performing and conducting its business with integrity as demonstrated by compliance with
Canadian and U.S. federal, state, and other applicable laws, regulations, and guidance, including the Pharmaceutical Laws, Regulations, and Guidance discussed in this Code. <B><I>However, compliance is not just about rules and laws. Compliance
encourages ethical behavior, fosters the right values, and instills a culture of integrity</I></B>. Compliance empowers Theratechnologies to operate within the laws, rules, and policies that regulate the pharmaceutical industry. Operating in
compliance with these laws, rules, and policies protects Theratechnologies, employees, third parties, shareholders, patients, and the products that Theratechnologies offers to its customers. Preventing, identifying, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">5</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">correcting non-compliant conduct is fundamental to Theratechnologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>3.2. Pharmaceutical Industry Laws, Regulations, and Guidance </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Pharmaceutical Laws, Regulations, and Guidance discussed in Section<U></U>&nbsp;4.1 set out key principles on which industry compliance programs
are based. These principles are fundamental to the compliance and ethics programs of pharmaceutical companies operating in Canada, the United States and other jurisdictions, including Theratechnologies. They are embodied in this Code and in
Theratechnologies&#146; related policy documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>3.3. Guiding Principles </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>Principle 1: Value the integrity of the healthcare system by, in part, respecting the judgment
and experience of individual physicians. </B></FONT><FONT STYLE="font-family:Calibri">Anti-bribery, anti-kickback and related laws and regulations have been enacted throughout the world to preserve the independence of medical decision-making and to
prevent even the appearance of improper influence within the healthcare system. These laws govern a broad range of activities including how we interact with healthcare providers and market access organizations as well as government payers. Our
patients expect that the decisions made by healthcare professionals regarding their medical treatment, in addition to the healthcare system they depend on, will be free from improper influence from Theratechnologies personnel. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>Principle 2: Do not pay people to prescribe or recommend Theratechnologies products.</B></FONT><FONT
STYLE="font-family:Calibri"> We do not offer remuneration (cash or anything of value) to improperly induce or reward the purchase, prescription, or recommendation of Theratechnologies products. Buying business is a violation of any Theratechnologies
policy, this Code, and the health laws of Canada, the United States and other jurisdictions. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT
STYLE="font-family:Calibri" COLOR="#276fb0"><B>Principle 3: Promote Theratechnologies products consistent with their approved product labeling, to an appropriate audience, and in an accurate and balanced manner. </B></FONT><FONT
STYLE="font-family:Calibri">The laws of Canada, the United States and other jurisdictions require that we promote our products in a manner that is accurate, balanced and consistent with the approved product labeling. To help ensure that
Theratechnologies meets this obligation, employees and third parties may use promotional materials only if the materials have been approved by Theratechnologies for product promotion, discussions, and presentations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>Principle 4: Respect people&#146;s privacy.</B></FONT><FONT STYLE="font-family:Calibri"> Canada,
Europe, the United States and many other countries have implemented, or are planning to implement, privacy and/or data protection laws that set requirements for the appropriate handling of personal data. There is a robust data protection framework
in place in Europe (the General Data Protection Regulation 2018) and similar data protection framework are being enacted and studied in various other jurisdictions. Compliance with privacy laws is an essential business practice. This includes
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">6</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">protecting the privacy of healthcare professionals and patients. Accordingly, Theratechnologies will comply with all
applicable privacy laws, as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>Principle 5: Maintain Theratechnologies&#146;
entrepreneurial spirit, commitment to quality and integrity, and shared accountability for business performance through collaboration, open communication, and ethical decision-making</B></FONT><FONT STYLE="font-family:Calibri">. Theratechnologies
empowers its employees with the tools and training they need to maintain compliant, entrepreneurial business development. Every Theratechnologies employee shares both the responsibility and personal accountability to conduct business operations in
an ethical manner to uphold the principles set out in this Code. Compliance with the laws and regulations governing Theratechnologies business operations requires collaboration and communication within and between business departments. This ensures
that compliance requirements necessitating multi-departmental participation are adhered to faithfully (for example, verifying that the requisite spend data is identified, captured and reported as required by physician payment transparency laws).
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>4. Compliance with Laws </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Laws and regulations affect virtually every functional area of Theratechnologies&#146; business. These laws and regulations can be complex and
difficult to interpret and can have both criminal and civil consequences for directors, officers, and employees and the Company. As a result, it is imperative that you be vigilant in observing these laws and regulations and contact the Legal
Department, or your manager, with any questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Not every director, officer, and employee is expected to be an expert in Canadian, U.S. federal,
state and other applicable laws and regulations, but all directors, officers, and employees should understand and be guided by the principles behind these laws and regulations. The standards and resources of Theratechnologies&#146; compliance and
ethics program are intended to advance these principles and to provide employees, officers and directors with support in performing their job responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">This Code does not and cannot cover every possible arrangement or activity governed by the laws, regulations and ethical standards applicable to
Theratechnologies and the pharmaceutical industry. Rather, it summarizes certain laws and principles of ethical business conduct. If you are in doubt about how to handle a situation or have a specific business conduct question, you should contact
the Legal Department or your manager. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>4.1. Pharmaceutical Industry Laws, Regulations, and Guidance </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies requires all employees to comply with applicable laws and regulations governing the pharmaceutical industry and to comply with
Theratechnologies&#146; own policies and procedures at all times. Failure to follow applicable laws can lead to severe penalties and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">7</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
sanctions against responsible employees of the Company, including criminal prosecutions, large fines, ineligibility to receive reimbursement from government payors, and the exclusion of
individuals from participation in government programs. Breaches may also lead to personal liability for prosecution, fines and potentially even imprisonment. Breaches of law or Theratechnologies&#146; own policies and procedures may also lead to
severe disciplinary action, up to and including termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.1. Fair Competition
</I></B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Antitrust laws and laws prohibiting anti-competitive activity are designed to protect competition in Canada, the United States,
Europe and other jurisdictions, and are implicated in many of the activities in which Theratechnologies engages. Generally speaking, the following types of topics, and any others that may limit competition, should never be discussed with a
competitor (including a <I>potential</I> or prospective competitor): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>prices, pricing policy, discounts or rebates (including competitive bidding practices);
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>costs, profits, or profit margins; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>terms or conditions of sale, including credit terms and return policies; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>division of markets, market territories, customers or sales territories; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>market share of any products; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>marketing, advertising or promotional plans; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>controlling, preventing or reducing the supply of any product; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>pricing or promotional practices of wholesalers, dealers, distributors or customers; </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>classifying, rejecting, terminating or allocating customers; or </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><U></U></B>any other <FONT STYLE="white-space:nowrap">non-public</FONT> and/or competitively sensitive information
about Theratechnologies or a competitor. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Each Theratechnologies director, officer, and employee is responsible for making sure
that his or her actions on behalf of the Company do not in any way violate or appear to violate antitrust and anti-competitive laws or regulations. <B><I>When in doubt, reach out! Seek assistance from the Legal Department or your manager.</I></B><U>
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.2. Drug Laws </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies is committed to complying fully with all applicable laws and regulations governing the development, commercialization, promotion and
sale of pharmaceutical products, including, but not limited to, the following applicable U.S. federal laws: the Food Drug and Cosmetic Act, the Prescription Drug Marketing Act, the Prescription Drug Sample Transparency provisions of Section<U></U>
6004 of the Affordable Care Act, and similar laws and regulations implemented by regulatory authorities in Canada and outside the United States where Theratechnologies does business. Compliance extends to all Company activities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">8</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
regarding our development and commercialization of products and product candidates, including research, development, manufacturing, marketing, sales and distribution. Company policies and
procedures, with which all employees, officers and directors must comply, are designed to foster such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT
STYLE="font-family:Calibri" COLOR="#276fb0"><B>In particular, Theratechnologies must comply with the U.S. Food Drug and Cosmetic Act (&#147;FDCA&#148;) and all rules and regulations issued by and/or enforced and administered by the U.S. Food and
Drug Administration (&#147;FDA&#148;) and similar requirements set by analogous regulatory authorities in Canada, Europe and outside the United States where Theratechnologies does business.</B></FONT><FONT STYLE="font-family:Calibri"> U.S. FDA
regulations govern nearly every aspect of our industry in the U.S., from the very start of research efforts and continuing through virtually every aspect of our business in the U.S., including labeling and advertising of Theratechnologies products.
The Company expends significant time and resources to effect compliance with all U.S. FDA requirements, and all materials used to promote Theratechnologies products, such as advertisements, brochures, and detail aids, must be consistent with the
approved labeling as described in applicable U.S. FDA guidance. Employees, officers and directors must ensure that their actions facilitate and do not conflict with these efforts. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.3. Anti-kickback, Bribery </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><I>General</I>. In Canada, the United States and in many other countries it is illegal and/or contrary to applicable ethical codes to provide, offer,
solicit, or accept a kickback or bribe. The U.S. federal Anti-Kickback Statute specifically prohibits anyone from offering, paying, soliciting, or receiving anything of value (such as a kickback or bribe) in return for referring an individual for an
item or service reimbursed under a federal health care program. A kickback or bribe may be defined as any money, fee, commission, credit, gift, gratuity, loan, reward, advantage, benefit, thing of value or compensation <B><I>of any kind</I></B> that
is provided, directly or indirectly, and that has as one of its purposes, the improper obtaining or rewarding of favorable treatment in a business transaction. <B><I>Theratechnologies&#146; policy strictly prohibits all kickbacks and bribes.</I></B>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Bribery, anti-kickback or similar laws are also applicable when a Theratechnologies director, officer, or employee receives or is offered
payments, gifts or gratuities that might unduly influence Theratechnologies&#146; business judgment or practices. Accordingly, employees, officers and directors must review <I>Section</I><I><U></U></I><I>&nbsp;5.1 &#147;Conflicts of
Interest&#148;</I> of this Code and, if offered payments, gifts or other gratuities that might unduly influence the conduct of Theratechnologies&#146; business, should seek guidance from the Legal Department or his/her manager. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>Healthcare Providers.</B></FONT><FONT STYLE="font-family:Calibri"> Anti-kickback laws implicate
interactions with healthcare providers and provide that <I>anyone who knowingly and willfully offers remuneration or reward in any form to induce healthcare providers to use or recommend a product that is reimbursed by government</I> is guilty of a
felony. Anti-kickback laws apply to both the party offering the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">9</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
remuneration or reward and the third party who receives it. Accordingly, there are strict limitations on when and how Theratechnologies may offer gifts or rewards to physicians or any other
health care providers or health care entities, such as pharmacies, managed care entities or others who are in a position to influence which drugs are used or to otherwise refer an individual for a health care item or service. All employees, officers
and directors must be familiar with, and must comply with this Code as well as Theratechnologies&#146; policies on Healthcare Interactions and Fee for Service Arrangements, which are incorporated by reference into this Code. No payments, gifts or
anything else of value may be offered to healthcare professionals, except as permitted by applicable law and in accordance with Theratechnologies&#146; written policies. Payments for services performed by healthcare professionals can be made only
pursuant to a signed, written agreement in a form approved by the Legal Department. Given the complexity of the applicable legal framework, you should closely review any payments you might consider with your manager and seek approval from the Legal
Department, as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.4. U.S. Foreign Corrupt Practices Act </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Many countries, including Canada, the United Kingdom and the United States, have specific laws on conducting business with foreign government
officials. Under the United States Foreign Corrupt Practices Act (the &#147;FCPA&#148;), for example, a company is prohibited from directly or indirectly offering, promising to pay, or authorizing the payment of money or anything of value to a
foreign official in order to influence official acts or decisions of that person or entity, to obtain or retain business or to secure any improper advantage. This is particularly relevant because physicians in many foreign countries are government
employees. You must consult the Legal Department before making any payment thought to be exempt from the FCPA. The Company&#146;s policy regarding compliance with the FCPA and similar foreign laws is addressed in the policy on Healthcare
Interactions and is incorporated by reference into this Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.5. False Claims Act </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">U.S. Federal and state laws prohibit the submission of false or fraudulent claims for reimbursement to the United States government. These laws also
prohibit the provision of false information to customers that cause the submission of false claims to the federal health care programs. Theratechnologies is committed to conducting its business in compliance with the U.S. federal False Claims Act
and any analogous state laws and requires that all information provided to any government agency be true and complete to our best knowledge in all materials respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.6. Ineligible Persons </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies does not hire Ineligible Persons&#151;individuals who are excluded, suspended, debarred or otherwise ineligible to participate in
U.S. federal healthcare programs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">10</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
or in federal procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs; or who have been convicted of a criminal offense related to federal healthcare programs.
Theratechnologies may not bill U.S. federal health care programs (e.g., Medicare, Medicaid or <FONT STYLE="white-space:nowrap">Tri-Care)</FONT> for items or services furnished, ordered, or prescribed by an Ineligible Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B><I>4.1.7. Regulatory and Industry Guidance </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>U.S. OIG Compliance Guidance.</B></FONT><FONT STYLE="font-family:Calibri"> The Office of
Inspector General (&#147;OIG&#148;) for the United States Department of Health and Human Services is responsible for maintaining the integrity of United States federal healthcare programs, including Medicare and Medicaid. OIG has issued Compliance
Program Guidance for pharmaceutical manufacturers that focuses on establishing and maintaining an effective compliance program, the integrity of pricing information provided to the government to establish payment amounts, and industry relationships
with healthcare professionals, particularly related to practices that have the potential to corrupt physician judgment, and compliance with the laws regulating drug samples. Theratechnologies is committed to conducting its business in compliance
with OIG&#146;s Compliance Program Guidance for Pharmaceutical Manufacturers. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri" COLOR="#276fb0"><B>The
PhRMA Code.</B></FONT><FONT STYLE="font-family:Calibri"> The Pharmaceutical Research and Manufacturers of America (&#147;PhRMA&#148;) is an industry organization comprised of research-based pharmaceutical companies in the United States that has
issued the PhRMA Code on Interactions with Healthcare Professionals (the &#147;PhRMA Code&#148;). This voluntary code for member companies focuses on interactions between pharmaceutical companies and healthcare professionals. The PhRMA Code provides
guidance on marketing medicines to healthcare professionals and developing relationships focused on informing the healthcare professionals about products, providing scientific and education information, and supporting medical research and education.
Theratechnologies adheres to the principles within the PhRMA Code. The principles within the PhRMA Code reflect our intention that our interactions with healthcare professionals are to benefit patients and to enhance the practice of medicine.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>4.2. Employment Policies</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies is an equal opportunity employer. The Company supports and complies with all applicable laws regarding nondiscrimination in
employment and does not discriminate on the basis of race, religion, color, national origin, ancestry, sex, marital status, sexual orientation, age or disability. Additionally, Theratechnologies is committed to providing a workplace free of
harassment, including but not limited to sexual harassment. The Company&#146;s policy prohibiting harassment is incorporated by reference into this Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>4.3. Political Process</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Election laws regulate contributions by Theratechnologies to political candidates. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">11</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
contribution of Company assets or services for political purposes must be reviewed by the Legal Department. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Theratechnologies&#146; policy is to comply with all applicable laws and regulations relating to lobbying or attempting to influence government
officials. Lobbying activities can include communicating with any member or employee of a legislative branch of government for the purpose of influencing legislation, communicating with certain government officials for the purpose of influencing
government action or engaging in research or other activities to support or prepare for such communications. No Theratechnologies director, officer, or employee may engage in any lobbying activity relating to Theratechnologies without prior approval
of the Legal Department and without being duly registered, where required. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#276fb0"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Calibri; " ALIGN="left"><FONT COLOR="#276fb0"><B>Integrity </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>5.1. Conflicts of Interest</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">You must ensure that any financial, business, or other activities in which you are involved outside the workplace are free of conflicts (or apparent
conflicts) with your responsibilities to the Company. A conflict of interest may occur when your private interest in any way interferes &#150; or even appears to interfere &#150; with the interests of the Company. A conflict situation can arise when
a person has interests that may impair the objective performance of his or her duties to the Company. Conflicts of interest may also arise when a person (or his or her family member) receives improper personal benefits as a result of his or her
position in the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">You must disclose any matter that you believe might raise doubt regarding your ability to act objectively and in the
Company&#146;s best interests. The following is a non - exhaustive list of examples of situations involving potential conflicts of interest that should be disclosed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>any Company loan to any director, officer, or employee, or Company guarantee of any personal obligation;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>employment by or acting independently as a consultant to a Company competitor, customer, supplier, business
partner or collaborator; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>directing Company business to any entity in which a director, officer, or employee or close family member has a
substantial interest; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>owning, or owning a substantial interest in, any competitor, customer, supplier, business partner or collaborator
of the Company; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>using Company assets, intellectual property, or other resources for personal gain; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>accepting anything of more than nominal value &#150; such as gifts, discounts, or compensation &#150; from an
individual or entity that does or seeks to do business with the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Officers must disclose any actual or apparent conflict
situation to the Legal Department whereas directors must disclose such conflict to both the Legal Department and to the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">12</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
Employees who are not officers must disclose all such situations of which they are aware to an appropriate manager or department head, or to the Legal Department. All managers and department
heads who receive such disclosure must forward them promptly to the Legal Department. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Directors of the Company who are not employees of the
Company must be sensitive to situations in which they may have business or financial interests in corporations or other business entities that, from time to time, have business dealings with the Company or that may compete with the Company. While
these relationships are not strictly prohibited, they should be avoided where reasonably practicable. Any Company director who has or becomes engaged in such a relationship must promptly bring it to the attention of the General Counsel and to the
Board. If a conflict cannot be avoided, it must be managed in an ethical and responsible manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">A conflict of interest may arise if an officer
or employee accepts (i)<U></U> any position as an officer or director of an outside public company, or (ii)<U></U> any position as an officer or director of board position with a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> entity. In each case, if there is or may be a potential conflict of interest (e.g., a Company business relationship with the entity or an expectation of
financial or other support from the Company), to accept such a position, officers must obtain Company approval from the Board; other employees must obtain such approvals from the President and Chief Executive Officer, who should consult with the
Legal Department before making any final determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Directors, officers, and employees who have obtained such approvals must promptly notify
the appropriate persons specified above in the event of any change in the nature of such business&#146; concern or entity&#146;s relationship with the Company or if such concern or entity later becomes a competitor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Please See Section<U></U>&nbsp;7. <I>Waivers and Approvals</I> for details on the waiver and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>5.2. Corporate Opportunities</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">All employees, officers and directors have a duty to advance the legitimate interests of the Company. Therefore, you may not (i)<U></U> take for
yourself corporate opportunities that are discovered through the use of Company property, information or position, without first offering such opportunities to the Company; (ii)<U></U> use corporate property, information, or position for personal
gain; or (iii)<U></U> compete with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Directors and officers must adhere to their fundamental duties of good faith, due care, and
loyalty owed to the Company , and to act at all times with the Company&#146;s, its shareholders&#146; and all stakeholders&#146; best interests in mind. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">13</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>5.3. Fair Dealing</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Each director, officer, and employee should deal fairly and in good faith with Theratechnologies&#146; customers, suppliers, regulators, business
partners, and other employees. No director, officer, or employee may take unfair advantage of anyone through manipulation, misrepresentation, inappropriate threats, fraud, and abuse of confidential information or other related conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>5.4. Proper Use of Company Assets</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Company&#146;s assets, including facilities, materials, supplies, time, information, intellectual property, software and other assets owned or
leased by the Company, or that are otherwise in the Company&#146;s possession, may be used only for legitimate business purposes. The personal use of the Company&#146;s assets without the Company&#146;s approval is prohibited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>5.5. Confidential Information</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">All employees, officers and directors must maintain the confidentiality of sensitive business, technical, or other information entrusted to them by
the Company, its customers, suppliers, business partners or collaborators, except when disclosure is authorized or legally mandated. Confidential information includes all <FONT STYLE="white-space:nowrap">non-public</FONT> information that might be
of use to competitors or harmful to the Company, its customers, suppliers, business partners or collaborators if disclosed. Of special sensitivity is financial information, which should be considered confidential under all circumstances, except
where Theratechnologies approves disclosure, or when it has been made public in a press release or a report filed with a governmental authority. The obligation to preserve such confidentiality continues even after employment ends. All employees,
officers and directors should refer to the Company&#146;s policy titled &#147;Policies and Procedures Related to the Use of Information&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT
 COLOR="#276fb0"><B>5.6. Delegation of Authority</B> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Each Company employee may delegate to his or her subordinates the authorities that
have been granted to the employee, provided that such delegation is in accordance with any delegation of authority policy of the Company. Compliance obligations, however, are <FONT STYLE="white-space:nowrap">non-delegable,</FONT> and each employee
remains responsible for compliance, regardless of the substantive responsibilities that may be delegated. In addition, each delegation must be reasonable and appropriate considering applicable laws and regulations, Company policies and procedures,
and the abilities and position of the subordinate. Each delegation should include reasonable monitoring of the subordinates carrying out delegated authorities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#276fb0"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Calibri; " ALIGN="left"><FONT COLOR="#276fb0"><B>Special Ethics Guidelines for Employees with Financial Reporting Responsibilities
</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The Finance Department bears a special responsibility for promoting integrity throughout
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">14</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
the organization, with responsibilities to Company shareholders. The President and Chief Executive Officer, Head of Finance and Finance Department personnel have special roles both to adhere to
these principles themselves and to ensure that a culture exists throughout the Company as a whole that ensures the fair and timely reporting of Company financial results and condition, as well as other information that may be required by a
governmental authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Because of this special role, the President and Chief Executive Officer, Head of Finance and all members of the
Company&#146;s Finance Department are bound by the following Financial Officer Code of Ethics. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">The President and Chief Executive Officer, Head of
Finance and each member of the Finance Department will: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>act with honesty and integrity, avoiding actual or apparent conflicts of interest in personal and professional
relationships; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>comply with laws, rules and regulations of federal, state, provincial and local governments, and appropriate
self-regulatory organizations; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or
allowing one&#146;s independent judgment to be subordinated; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>respect the confidentiality of information acquired in the course of one&#146;s work except when authorized or
otherwise legally obligated to disclose; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>refrain from using confidential information acquired in the course of employment for personal advantage;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>proactively promote and be an example of ethical behavior as a responsible partner among peers in the work
environment; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>achieve responsible use of and control over all assets and resources employed or entrusted; </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>record or participate in the recording of entries in Company&#146;s books and records that are accurate to the
best of his or her knowledge; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B></B>promptly report to the Chair of the Audit Committee any conduct that he or she believes to be a violation of law
or business ethics or of any provision of this Code, including any transaction or relationship that reasonably could be expected to give rise to such a conflict. See Schedule &#147;A&#148; hereto for details on reporting such violation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Violations of this Code, including failures to report potential violations by others, will be viewed as a severe disciplinary
matter that may result in personnel action, including termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">It is against Company policy to retaliate against any employee
for good faith reporting of violations of this Code (See also Section&nbsp;8.6 <I>Protection Against Retaliation</I>). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#276fb0"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Calibri; " ALIGN="left"><FONT COLOR="#276fb0"><B>Waivers and Approvals </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Requests for a waiver of a provision of, or approval required by, this Code must be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">15</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
submitted in writing to the General Counsel for appropriate review. The General Counsel will then forward the request, and consult with, the appropriate executive officer, Board of Directors or
committee thereof, as set forth below, who will decide the outcome. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><FONT COLOR="#276fb0">Directors</FONT></B> &#150; Any waiver of this Code for a Company director may only be granted
by the Board of Directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><FONT COLOR="#276fb0">Executive Officers</FONT></B> &#150; Any waiver of this Code for a Company executive officer may
only be granted by the Board of Directors or the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><FONT COLOR="#276fb0">Other Officers and Employees</FONT></B> &#150; Any waiver of this Code for officers, other than
executive officers, or other employees may only be granted by the President and Chief Executive Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#276fb0">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Calibri; font-size:12pt"><B><FONT COLOR="#276fb0">Required Audit Committee Approval</FONT> </B>&#150; The Audit Committee must review and, if
required by applicable law, regulation, rule or listing standard, approve any &#147;related party&#148; transaction as defined in Regulation <FONT STYLE="white-space:nowrap">61-101</FONT> respecting the protection of minority security holders in
special transactions and as defined under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> before it is consummated. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Statements in this Code to the effect that certain actions may be taken only with &#147;Theratechnologies&#146; approval&#148; will be interpreted to
mean that appropriate officers, the Board of Directors, or members of the appropriate Board of Directors committee must give prior written approval before the proposed action may be undertaken. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8. Reporting and Investigation Process</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.1. Reporting</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">All employees, officers and directors are obligated to immediately report any situation or conduct that might constitute a possible violation of this
Code or the law to the General Counsel (or, in connection with complaints or concerns regarding (i)&nbsp;harassment matters, to the Chair of the Board, and (ii)<U></U>&nbsp;accounting, internal controls or auditing matters, to the Chair of the Audit
Committee). Reports may be made anonymously orally through the Compliance Hotline/Helpline or in writing. Failure to report a violation may result in disciplinary action, which may include termination of employment. Reported violations will be
investigated and addressed promptly and will be treated confidentially to the extent possible. Whenever practical, the complaint should be made in writing. It is unacceptable to submit a complaint knowing it is false. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.2. Contact Information (See Exhibit A)</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.3. Investigation Process</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Reports of violations will be investigated promptly under the supervision of the Chair of the Board, the Chair of the Audit Committee or the General
Counsel , after consultation with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">16</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">
the President and Chief Executive Officer, to the extent that he/she is not the subject of the alleged violation, and with the recommendation of the the Board of Directors. All employees,
officers and directors are required to cooperate fully in the investigation of reported violations and to provide truthful, complete and accurate information. The investigation will be handled as discreetly as reasonably possible, allowing for a
fair investigation and any necessary corrective action. Appropriate corrective action will be taken whenever a violation of this Code is determined to have occurred. Those supervising the investigation shall be entitled to retain outside assistance
to carry out the investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.4. Disciplinary Action</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Depending on the nature of the violation, the offending individual can be subject to corrective action, such as training, or disciplinary action,
which may include termination of employment. Failure to follow applicable laws can lead to severe penalties and sanctions against the Company, including large fines, criminal prosecutions, ineligibility to receive reimbursement from government
payors, and the exclusion of individuals from participation in government programs. Violators may also be personally liable for prosecution, fines and potentially even imprisonment. In addition, anyone who violates Theratechnologies&#146; own
policies or who interferes with an investigation or provides information in an investigation that the individual knows to be untrue or inaccurate, is subject to disciplinary action, which may include termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.5. Confidentiality</B> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">Except as may be required by law or by the requirements of the resulting investigation or corrective action, the person conducting the investigation
will not disclose the identity of anyone who reports a suspected violation if confidentiality is requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>8.6.
Protection Against Retaliation</B> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri"><B>The Company prohibits any form of retaliation against employees who, for lawful purposes, report to
the Company any conduct or activity that may violate this Code, any law or regulation applicable to the Company or any other suspected improper, unethical or illegal conduct or activities by anyone at the Company.</B> The Company also prohibits any
form of retaliation against employees who provide information, cause information to be provided, or assist in an investigation conducted by the Company or any governmental body regarding a possible violation of any law or regulation relating to
fraud, any labor law, or any rule or regulation of the U.S. SEC (the US Securities and Exchange Commission), or equivalent authority in Canada and other jurisdictions, or who file, cause to be filed, or assist, participate or give testimony in any
proceeding relating to an alleged violation of any such law, rule or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">17</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">All Company officers and other managerial employees are responsible for ensuring adherence to this
Section<U></U>&nbsp;8.6. In addition, each Company officer and managerial employee is responsible for communicating the policy set forth in this Section<U></U>&nbsp;8.6 to employees under his or her supervision and for supporting programs and
practices designed to develop understanding of, commitment to and compliance with this policy. In the event that any Company officer, other managerial employee or manager believes that a violation of this Section<U></U>&nbsp;8.6 has occurred or
receives a report of a violation, he or she must immediately contact the General Counsel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Calibri">If an employee believes that he or she has been
retaliated against (including threatened or harassed) in violation of this Code, he or she should report the retaliation to the General Counsel, unless the employee believes that the General Counsel has retaliated, in which event the employee should
report the retaliation to the President and Chief Executive Officer, Human Resources and/or the Board of Directors. Once an employee reports retaliation prohibited by this Code, the Company will promptly investigate the matter in accordance with the
procedures described above. </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>Approved by the Board of Directors</B> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>Theratechnologies Inc.</B> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT COLOR="#276fb0"><B>March&nbsp;3, 2022</B> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">18</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Exhibit A </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Contact Information for Reporting Compliance Questions or Concerns </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-family:Calibri; "><B>Compliance Hotline/Helpline</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Calibri"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-family:Calibri; "><B>General Counsel</B> </FONT><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Calibri"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"><FONT STYLE="font-family:Calibri; "><B>Compliance Officer</B> </FONT><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Calibri"> </FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT><FONT STYLE="font-family:Calibri"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Calibri;background-color:#000000">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Calibri"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">Additionally, anonymous complaints may be submitted to the Compliance Hotline/Helpline or, in writing, to the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><B>Theratechnologies Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">2015 Peel Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">Suite 1100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">Montreal, Qu&eacute;bec, Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">H3A 1T8 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">Attention: General Counsel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">19</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Exhibit B </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Theratechnologies Code of Business Conduct and Ethics Annual Disclosure Statement </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Theratechnologies Code of Business Conduct and Ethics </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Initial Certification and Disclosure Statement </B></FONT></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><B>I hereby certify that (</B><B><I>check which one applies</I></B><B>): </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT
STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I am in compliance with the Theratechnologies Code of Business Conduct and Ethics (the &#147;Code&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I am not in compliance with the Code, but I have reported my
<FONT STYLE="white-space:nowrap">non-compliance</FONT> to the Chief Compliance Officer or the Compliance Hotline/Helpline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT
STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I am not in compliance with the Code, but I will report my <FONT STYLE="white-space:nowrap">non-compliance</FONT> immediately to the Chief Compliance Officer or the Compliance
Hotline/Helpline. </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><B>I hereby disclose that (</B><B><I>check all that apply</I></B><B>): </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I do not know of or suspect any violations of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I am aware of a suspected violation of the Code, which I have already reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT>&#8194;&#8195;I am aware of a suspected violation of the Code that I have not yet reported, but which I intend
to report promptly. </P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Signature:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Print&nbsp;Name:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Date:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">20</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Exhibit C </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#276fb0"><B>Theratechnologies Code of Business Conduct and Ethics Annual Certification </B></FONT></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:12pt; font-family:Calibri">I certify that I have read, that I understand, and that I will comply with the Theratechnologies Code of Business Conduct and Ethics. </P>
<P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Signature:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Print&nbsp;Name:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Calibri; "><B>Date:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1.50pt solid #a0d01c"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Calibri" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">21</FONT></B></FONT></P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR BGCOLOR="#040c28" STYLE="page-break-inside:avoid ; font-family:Calibri; font-size:12pt">
<TD VALIGN="top">&#8195;</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.2
<SEQUENCE>30
<FILENAME>d680117dex112.htm
<DESCRIPTION>EX-11.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-11.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 11.2 </U></B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g680117g40w20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:42pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INSIDER TRADING POLICY </B></P>
<P STYLE="margin-top:42pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DATED NOVEMBER 29, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">I. &#8195;&#8195;&#8201;INTRODUCTION AND PURPOSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">II. &#8195;&#8194;&#8196;DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">III. &#8195;&#8194;GENERAL RESTRICTIONS APPLICABLE TO ALL THERATECHNOLOGIES PERSONNEL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;A. &#8195;Insider Trading</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;B. &#8195;Confidentiality of <FONT STYLE="white-space:nowrap">Non-Public</FONT>
Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;C. &#8195;Tipping</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;D. &#8195;Consequences of
<FONT STYLE="white-space:nowrap">Non-Compliance</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">IV. &#8195;&#8196;ADDITIONAL RESTRICTIONS APPLICABLE TO REPORTING INSIDERS, DESIGNATED INSIDERS AND DESIGNATED PERSONNEL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;A. &#8195;Trading Restrictions and Blackout Periods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;B. &#8195;Anti-Hedging Restrictions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;C. &#8195;Speculative Trades</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;D. <FONT STYLE="white-space:nowrap">&#8195;Pre-Clearance</FONT> of Trades</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">&#8195;&#8201;E. &#8195;Filing Insider Reports</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman">Schedule A Examples of Privileged Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman">Schedule B Notification of Intention to Trade in Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>INTRODUCTION AND PURPOSES </B></P></TD></TR></TABLE>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This insider trading policy (the
&#147;<B>Policy</B>&#148;) provides guidelines for directors, officers, executives, employees and consultants (collectively, &#147;<B>Theratechnologies Personnel</B>&#148;) of Theratechnologies Inc. and to those of its direct and indirect
subsidiaries (collectively, &#147;<B>Theratechnologies</B>&#148; or the &#147;<B>Corporation</B>&#148;) concerning transactions in securities of the Corporation and related financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">It is illegal under Canada&#146;s securities laws and regulations and those of other jurisdictions for persons in possession of privileged or
undisclosed material information relating to an issuer to (i)&nbsp;trade in shares and other securities of such issuer or (ii)&nbsp;communicate such information to others or recommend that another person trade in the securities of such information.
The prohibited activities are called &#147;insider trading&#148; and &#147;tipping.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The rules and procedures outlined in this
Policy have been implemented in order to prevent improper trading in the securities of the Corporation and the improper communication of privileged or undisclosed material information by Theratechnologies Personnel. This Policy is also intended to
ensure that Theratechnologies Personnel act in accordance with applicable laws and the highest standards of ethical and business conduct. Finally, this Policy aims to prevent Theratechnologies Personnel from engaging in activities that, although not
illegal, may expose them or the Corporation to potential reputational risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Vice President, Legal Affairs of the Corporation is
responsible for this Policy (the &#147;<B>Trading Officer</B>&#148;). If any authorization referenced herein is required to be obtained from the Trading Officer and such officer is not available, then such authorization may be obtained from the
Corporation&#146;s Senior Vice President and Chief Financial Officer or, in the absence of both, the President and Chief Executive Officer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Designated Insider</B>&#148;
means Theratechnologies Personnel that the Corporation has designated as a person who is subject to certain trading restrictions due to their access to Privileged Information about Theratechnologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Designated Personnel</B>&#148; means Theratechnologies Personnel who, as a participant in a material acquisition, outsourcing project
or other material event or transaction has been identified as a Designated Personnel by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Privileged
Information</B>&#148; means any information or change relating to the business, activities, affairs, operations, capital or financial position of the Corporation which has not been generally disclosed that would reasonably be expected to have a
significant effect on the market price or value of the Corporation&#146;s securities or that could affect the investment decision of a reasonable investor, and<B> </B>includes a decision to implement such a change made by the Board of Directors or
senior management who believe that confirmation of the decision by the Board of Directors is probable. <U>Schedule A</U> to this Policy presents various examples of the types of events or information which may constitute Privileged Information. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Related Financial Instrument</B>&#148; means (1)&nbsp;any instrument, agreement or
security whose value, market price or payment obligations are based on the value, market price or payment obligations of a security of the Corporation; and (2)&nbsp;any other instrument, agreement or understanding that affects, directly or
indirectly, a person&#146;s economic interest in a security of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Reporting Insider</B>&#148; means that certain
Theratechnologies Personnel who are directors or executive officers designated by the Corporation as a reporting insider within the meaning of <I>National Instrument <FONT STYLE="white-space:nowrap">55-104</FONT> &#150; Insider Reporting
Requirements and Exemptions</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Theratechnologies Securities</B>&#148; means shares, options, warrants, notes and any other
securities that the Corporation may issue from time to time (such as bonds, debentures, convertible debentures, subscription receipts and other convertible securities) and includes, for the purposes of this Policy, any Related Financial Instrument.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Trading Day</B>&#148; means a day on which the Toronto Stock Exchange or the NASDAQ Stock Market is open for trading. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>GENERAL RESTRICTIONS APPLICABLE TO ALL THERATECHNOLOGIES PERSONNEL </B></P></TD></TR></TABLE>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>INSIDER TRADING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel shall not, directly or indirectly, engage in any transaction involving Theratechnologies
Securities, including changing an economic interest in a Related Financial Instrument, during any period commencing on the date that he, she or they possess Privileged Information and ending at the close of business on the first Trading Day
following public disclosure of the Privileged Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel are also prohibited from trading
in another public company&#146;s securities or changing an economic interest in any related financial instrument pertaining to such public company&#146;s securities while in possession of privileged information regarding that public company gained
during the course of the work of Theratechnologies Personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">There are very limited exemptions to the foregoing
restrictions under applicable laws, and any trading in reliance on such statutory exemptions should first be authorized under the <FONT STYLE="white-space:nowrap">pre-clearance</FONT> procedure contained herein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY OF <FONT STYLE="white-space:nowrap">NON-PUBLIC</FONT> INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Disclosure of Privileged Information relating to Theratechnologies is prohibited, except as explicitly permitted herein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TIPPING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel are prohibited from disclosing (&#147;<B>Tip</B>&#148;) Privileged Information to any other person
(including members of his or her immediate family or household), and Theratechnologies Personnel shall not make recommendations or express </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">opinions as to trading in securities of Theratechnologies or other companies
while having Privileged Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Tipping is a violation of law, even if the person disclosing the information does
not personally make a trade or otherwise benefit from disclosing the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">There are limited circumstances in
which Privileged Information may be disclosed in the necessary course of business if there are no grounds to believe the Privileged Information will be used or disclosed contrary to applicable law. The question of whether a particular disclosure is
being made in the necessary course of business is a mixed question of law and facts that must be determined on a case-by-case basis. However, the necessary course of business exception may, depending on the circumstances, cover communications with:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">vendors, suppliers or strategic partners on issues such as research and development, sales and marketing,
and supply contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">employees, officers, and board members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">lenders, legal counsel, auditors, underwriters, and financial and other professional advisors to the
Corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">parties to negotiations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">labour unions and industry associations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">government agencies and <FONT STYLE="white-space:nowrap">non-governmental</FONT> regulators; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">credit rating agencies (provided that the information is disclosed to assist the agency in formulating a
credit rating and the agency&#146;s ratings generally are or will be publicly available). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">No
Theratechnologies Personnel may disclose Privileged Information under the exception of the necessary course of business unless it has been previously authorized under this policy. If Theratechnologies Personnel disclose Privileged Information under
the exception of the necessary course of business, the Corporation should ensure that those receiving the information under such exception cannot pass the information to anyone else or trade on the basis of that information until the information has
been generally disclosed. Obtaining a confidentiality agreement in these circumstances is considered a good practice and may help safeguard the confidentiality of the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">If Theratechnologies Personnel believe they are faced with the circumstances described above, they should send a request to
the Trading Officer to confirm whether such Privileged Information may be disclosed and the conditions under which it may so be communicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>CONSEQUENCES OF <FONT STYLE="white-space:nowrap">NON-COMPLIANCE</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>The consequences of insider trading and tipping can be severe. </B>Theratechnologies Personnel who contravene applicable
laws and regulations will be subject to disciplinary actions, which may include restrictions on future participation in equity-based incentive plans or termination of employment without notice or payment in lieu of notice, and expose themselves to
criminal, penal and administrative actions by the relevant authorities, which could lead to substantial fines and imprisonment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ADDITIONAL RESTRICTIONS APPLICABLE TO REPORTING INSIDERS, DESIGNATED INSIDERS AND DESIGNATED PERSONNEL
</B></P></TD></TR></TABLE> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRADING RESTRICTIONS AND BLACKOUT PERIODS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Reporting Insiders and Designated Insiders shall not trade in Theratechnologies Securities during the period (each, a
&#147;<B>Regularly Scheduled Blackout Period&#148;</B>) <B>beginning on the day immediately following the end of a fiscal quarter and ending on and including the first (1st) Trading Day following the date of public disclosure of the financial
results for that quarter</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Blackout periods may also be prescribed from time to time, for such length of time as is
deemed necessary, as a result of special circumstances relating to the Corporation (each a &#147;<B>Discretionary Blackout Period&#148; </B>and, together with Regularly Scheduled Blackout Periods, a &#147;<B>Blackout Period</B>&#148;). The Trading
Officer shall determine the Theratechnologies Personnel to which such Discretionary Blackout Period applies and such personnel shall become Designated Personnel which will be prohibited from trading in Theratechnologies Securities during the
Discretionary Blackout Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, the Blackout Periods shall not prohibit the Corporation
from (i)&nbsp;granting stock options and other equity awards to Theratechnologies Personnel as part of the yearly operational and planning and budget approval processes, as approved by the Board of Directors in accordance with applicable laws and
regulations; (ii)&nbsp;automatic purchases or dispositions in accordance with applicable laws and regulations pursuant to any written automatic plan established by Theratechnologies prior to the relevant periods; and (iii)&nbsp;issuing deferred
share units to the Corporation&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in accordance with the Corporation&#146;s Deferred Share Unit Plan, as may be amended and/or restated from time to time, and the compensation
policies of the board of directors which may then be in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel who have signed a
Confidentiality or Non-Disclosure Agreement and are as such Designated Personnel may only trade Theratechnologies Securities in accordance with the terms and conditions of such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Blackout Periods will also apply to all Theratechnologies Personnel with access to Privileged Information, such as during
periods when certain Theratechnologies Personnel prepare financial statements, but results have not yet been publicly disclosed. Notice of such blackouts may or may not be communicated by the issuance of a formal notice. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ANTI-HEDGING RESTRICTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel shall not in respect of Theratechnologies Securities engage in: (i)&nbsp;short sales;
(ii)&nbsp;transactions in derivatives in respect of Theratechnologies Securities such as put and call options; or (iii)&nbsp;any other hedging or equity monetization transaction in which the individual&#146;s economic interest and risk exposure in
Theratechnologies Securities is changed, such as collars or forward sales contracts. The foregoing restrictions shall not prohibit Theratechnologies Personnel from effecting a &#147;cashless exercise&#148; of options granted under the
Corporation&#146;s Stock Option Plan in accordance with the terms </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">of the Stock Option Plan and the usual procedures of the broker used to
facilitate the exercise of such Theratechnologies Personnel&#146;s options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">There may be limited circumstances under
which personal factors such as estate planning may lead a Theratechnologies Personnel to consider certain hedging or equity monetization transactions. The Board of Directors may, considering all relevant circumstances, determine if any such
transaction may be allowed notwithstanding the general principle described above, and the conditions attaching to any such transaction before it may be implemented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>SPECULATIVE TRADES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies Personnel must not engage in speculative trading in short-term price fluctuations in the value of securities
of the Corporation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">PRE-CLEARANCE</FONT> OF TRADES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">All Reporting Insiders, Designated Insiders and Designated Personnel who wish to make a transaction involving
Theratechnologies Securities must first submit a <B>written </B>request to the Trading Officer. A request should specify the type of transaction (e.g., purchase or sale of shares or exercise of stock options and, in the case of the exercise of stock
options, provide a confirmation of the intention to subsequently hold or sell the underlying shares). <U>Schedule B</U> hereto contains a suggested form of notification for <FONT STYLE="white-space:nowrap">pre-clearance</FONT> for a trade. <B>No
trade may be carried out without the pre-clearance of the Trading Officer.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Any approval granted for any proposed
transaction will be valid for a period of three (3)&nbsp;Trading Days, unless revoked prior to that time. No transaction may be carried out after the expiry of three (3)&nbsp;Trading Days following the receipt of approval unless such approval is
renewed. To the extent that a material information remains non-public, Theratechnologies Personnel subject to a Blackout Period may not be given permission to trade in Theratechnologies Securities and may not be informed of the reason they may not
trade. Any person that is made aware of the reason for an event-specific prohibition on trading shall not disclose the reason for the prohibition to third parties and should avoid disclosing the existence of the prohibition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Theratechnologies Personnel are reminded that, notwithstanding the pre-clearance of a trade by the Trading Officer, the
ultimate responsibility for complying with the insider trading restrictions rests with the individual trading in Theratechnologies Securities. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>FILING INSIDER REPORTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Under applicable Canadian securities legislation, a person or corporation who becomes a Reporting Insider of the Corporation
must file an insider report within ten (10)&nbsp;days of the date of becoming a Reporting Insider electronically through the System for Electronic Disclosure by Insiders (&#145;&#145;<B>SEDI</B>&#148;) at <FONT
STYLE="font-family:Times New Roman; font-size:12pt" COLOR="#0000ff"><U>www.sedi.ca</U></FONT><FONT STYLE="font-family:Times New Roman">. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In addition, a Reporting Insider must file an insider trading report on SEDI
within five (5)<B>&nbsp;calendar </B>days of the date of any change in the beneficial ownership of, or control or direction over, whether direct or indirect, Theratechnologies Securities or any interest in, or right or obligation associated with, a
Related Financial Instrument. This includes, without limitation, the acquisition or the disposition of shares and options of the Corporation, as well as the entering into, amendment or termination of a Related Financial Instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Trading Officer may assist any Reporting Insiders in completing and filing insider reports provided such Reporting
Insiders provide the necessary information to the Trading Officer, in a timely manner (immediately after the transaction in the case of a purchase or sale). <B>However, the ultimate responsibility for complying with the insider filing requirements
rests with the individual trading in Theratechnologies Securities</B>. A failure to set up and maintain his or her SEDI profile and file the required insider reports within the appropriate deadline will result in a fine (currently 100$) for the
Insider for each day in arrears. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Examples of Privileged Information </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The examples below are merely examples of Priviliged
Information and are not an exhaustive list. The examples below should be read in conjunction with the Insider Traditing Policy in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Changes in Corporate Structure </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Change in share ownership that may affect control of the Corporation </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Major reorganizations, amalgamations or mergers </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Take-over bids, issuer bids or insider bids </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Changes in Capital Structure </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Public or private sale of additional Theratechnologies Securities </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Planned repurchases or redemptions of Theratechnologies Securities </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Planned splits of common shares or offerings of warrants or rights to buy shares </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Share consolidation, share exchange or stock dividend </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Changes in Theratechnologies&#146;s dividend payment or policies </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Possible initiation of a proxy fight </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Material modifications to the rights of security holders </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Changes in financial Results </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant increase or decrease in near-term earnings prospects </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Unexpected changes in the financial results for any periods </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Shifts in financial circumstances, such as cash flow reductions, major asset write-offs or write-down
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Changes in the value or composition of the company&#146;s assets </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Any material change in the company&#146;s accounting policy </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Changes in Business Operations </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Any development that affects the company&#146;s resources, technology, products or markets
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant change in capital investment plans or corporate objectives </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Major labour disputes or disputes with major contractors or suppliers </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant new contracts, products, patents, or services or significant losses of contracts or business
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant discoveries by resource companies </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Changes to the board of directors or executive management, including the departure of the company&#146;s CEO or
CFO (or persons in equivalent positions) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Commencement of, or developments in, material legal proceedings or regulatory matters </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Waivers of corporate ethics and conduct rules for officers, directors, and other key employees
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Notice that reliance on a prior audit is no longer permissible </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt"><FONT STYLE="white-space:nowrap">De-listing</FONT> of the company&#146;s securities or their movement from one
quotation system or exchange to another </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Acquisitions and Dispositions </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant acquisitions or dispositions of assets, property or joint venture interests </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Acquisitions of other companies, including a take-over bid for, or merger with, another company
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Changes in Credit Agreements </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Borrowing or lending of a significant amount of money </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Any mortgaging or encumbering of the company&#146;s assets </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Defaults under debt obligations, agreements to restructure debt, or planned enforcement procedures by a bank or
any other creditors </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Changes in rating agency decisions </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10.5pt">Significant new credit arrangements </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Schedule B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Notification of Intention to Trade in Securities </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Attention: Vice President, Legal Affairs, of
Theratechnologies Inc. (the &#147;Corporation&#148;) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Corporation&#146;s Insider Trading Policy (the
&#145;&#145;<B>Policy&#146;&#146;</B>), I hereby notify you of my intention to execute the following transaction in securities of the Corporation and request approval of such transaction. Defined terms not otherwise defined herein have the meanings
set out in the Policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Type of transaction (check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><U>&#8195;&#8194;</U>&#8195;&#8195;&#8195;Purchase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><U>&#8195;&#8194;</U>&#8195;&#8195;&#8195;Sale&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8194;</U>&#8195;&#8195;&#8194;Exercise of stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt"><U>&#8195;&#8194;</U>&#8195;&#8195;&#8195;&#8195;Other</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8194;options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">If&nbsp;you&nbsp;selected&nbsp;&#147;Other&#148;,&nbsp;please&nbsp;explain:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:-2.33em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&nbsp;
&#8195;&#8195;&#8195;&#8195;&#8195;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Type&nbsp;of&nbsp;shares&nbsp;to&nbsp;be&nbsp;traded:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:-2.00em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&nbsp;
&#8195;&#8195;&#8195;&#8195;&#8195;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Number&nbsp;of&nbsp;shares&nbsp;to&nbsp;be&nbsp;traded:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:-1.83em; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&#8195;&#8195;&#8195;&#8195;&#8195;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">I confirm that I am aware of the legal prohibitions against insider trading and confirm that I am not in
possession of any material information relating to the Corporation (and any of its subsidiaries) or any of its operations which has not been disclosed to the public generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">I understand that the Policy supplements, and does not replace, applicable insider trading laws. I understand that a violation of insider
trading or tipping laws and regulations may subject me to severe civil and/or criminal penalties, and that violation of the terms of the Policy may subject me to disciplinary action by the Corporation, up to and including termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">I understand that, notwithstanding any trading authorization granted upon approval of this form, I remain personally responsible for complying
with the Policy and applicable securities laws and regulations. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Name (please
print)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="21"></TD>
<TD HEIGHT="21" COLSPAN="2"></TD>
<TD HEIGHT="21" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">&#8194;Authorized by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Name (please
print)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This authorization is valid for three (3)&nbsp;Trading Days on the Toronto Stock Exchange or the NASDAQ Stock
Market, unless revoked prior to that time. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>31
<FILENAME>d680117dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 12.1</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION REQUIRED BY RULE <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I, Paul L&eacute;vesque, certify that: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Theratechnologies Inc.; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The issue&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the issuer and have: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during
the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
issuer&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;21, 2024 </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8194;/s/ Paul L&eacute;vesque</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8194;Paul L&eacute;vesque</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8194;President
and Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8194;(Principal Executive Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>32
<FILENAME>d680117dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 12.2</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION REQUIRED BY RULE <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I, Philippe Dubuc, certify that: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1 I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Theratechnologies Inc.; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The issue&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the issuer and have: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during
the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
issuer&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;21, 2024 </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8194;/s/ Philippe Dubuc</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8194;Philippe Dubuc</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8194;Senior Vice
President and Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#8194;(Principal Financial Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>33
<FILENAME>d680117dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 13.1</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES&#150;OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In connection with the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Theratechnologies Inc. (the &#147;Company&#148;)
for the fiscal year ended November&nbsp;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Paul L&eacute;vesque, President and Chief Executive Officer of the Company certify pursuant to 18
U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended; and </P></TD>
<TD WIDTH="7%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company. </P></TD>
<TD WIDTH="7%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date: February&nbsp;21, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><U>/s/ Paul L&eacute;vesque&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Name: Paul L&eacute;vesque</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">A signed original of this written statement required by Section&nbsp;906 has been provided to Theratechnologies
Inc. and will be retained by Theratechnologies Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>34
<FILENAME>d680117dex132.htm
<DESCRIPTION>EX-13.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 13.2</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES&#150;OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In connection with the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Theratechnologies Inc. (the &#147;Company&#148;)
for the fiscal year ended November&nbsp;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of the Company certify pursuant
to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended; and </P></TD>
<TD WIDTH="7%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company. </P></TD>
<TD WIDTH="7%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Date: February&nbsp;21, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"><U>/s/ Philippe Dubuc&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Name: Philippe Dubuc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">Title: Senior Vice President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify">A signed original of this written statement required by Section&nbsp;906 has been provided to Theratechnologies
Inc. and will be retained by Theratechnologies Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>35
<FILENAME>d680117dex15.htm
<DESCRIPTION>EX-15
<TEXT>
<HTML><HEAD>
<TITLE>EX-15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B><U>Exhibit 15 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Theratechnologies Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We consent to the incorporation by reference in the Registration Statement (No. <FONT STYLE="white-space:nowrap">333-276196)</FONT> on Form <FONT
STYLE="white-space:nowrap">F-3</FONT> of Theratechnologies Inc. of our report dated February&nbsp;20, 2024 on the consolidated financial statements of Theratechnologies Inc<B> </B>(the &#147;Entity&#148;) which comprise the consolidated financial
position as of November&nbsp;30, 2023 and 2022, the related consolidated statements of net loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended November&nbsp;30, 2023, and the related
notes, which is included in the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of the Entity for the fiscal year ended November&nbsp;30, 2023. </P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ KPMG LLP </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">February&nbsp;21, 2024 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Montr&eacute;al, Canada </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-17
<SEQUENCE>36
<FILENAME>d680117dex17.htm
<DESCRIPTION>EX-17
<TEXT>
<HTML><HEAD>
<TITLE>EX-17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 17 </U></B></P>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBSIDIARY GUARANTORS</U> </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><U>Issuer</U></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8201;Number
of&#8195;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&#8201;Shares&nbsp;Owned</U>&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8201;<U>Total&nbsp;Shares</U>&#8195;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>&#8201;Outstanding</U>&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><U>%&nbsp;of&nbsp;Interest&nbsp;Pledged</U>&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><U>Certificate&nbsp;No.</U>&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><U>Par&nbsp;Value</U>&#8195;&#8195;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Theratechnologies Europe&nbsp;Limited</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&#128;1.00</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER:1px solid #000000; padding-left:8pt">Theratechnologies U.S., Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="padding-bottom:6pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="padding-bottom:6pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="padding-bottom:6pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="padding-bottom:6pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">C-1</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="padding-bottom:6pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$0.01</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Theratechnologies
Intercontinental&nbsp;Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT>&#8194;100&nbsp;Class&nbsp;A&nbsp;shares;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT>&#8194;140,130,000&nbsp;Class&nbsp;C<BR>&#8195;Shares</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">100 Class&nbsp;A shares and<BR>140,130,000 Class&nbsp;C<BR>shares</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100%</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-1</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">C-1</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">N.A.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Theratechnologies
Europe Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT>&#8194;100&nbsp;Class&nbsp;A&nbsp;Shares</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT>&#8194;39,000,000&nbsp;Class&nbsp;C<BR>&#8195;Shares</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">100 Class&nbsp;A shares and<BR>39,000,000&nbsp;Class&nbsp;C&nbsp;shares&#8201;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100%</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-1</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">C-1</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">N.A.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Pharma-G</FONT> Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:SYMBOL; font-size:8pt" COLOR="#000000">&#183;</FONT>&#8194;2,244,027&nbsp;Common<BR>&#8195;Shares</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">2,244,027&nbsp;Common</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Shares</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">100%</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">O-7</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">N.A.</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>37
<FILENAME>d680117dex971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-97.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 97.1</U> </B></P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>RESTATEMENT CLAWBACK POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Adopted on November&nbsp;30, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Restatement Clawback Policy (this &#147;<U>Policy</U>&#148;) has been established and adopted by the Board of Directors (the
&#147;<U>Board</U>&#148;) of Theratechnologies Inc. (the &#147;Company&#148;) and will be administered by the Compensation Committee (the &#147;<U>Committee</U>&#148;) of the Board. Defined terms used in this Policy shall have the respective
meanings set forth in Section&nbsp;11 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Restatement Clawback Policy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">1.&#8194; <U>Name and Purpose</U>. This Policy is intended to satisfy the Company&#146;s obligations pursuant to Section&nbsp;10D of the
Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> of the Exchange Act, and other applicable rules of the Securities and Exchange Commission (&#147;<U>SEC</U>&#148;)
and Nasdaq (&#147;<U>Nasdaq</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">2.&#8194; <U>Authority; Administration</U>. This Policy shall be administered by the Committee,
except as otherwise set forth herein. The Committee is authorized to administer, interpret, issue and revoke rules and construe this Policy and the terms hereof. In furtherance of this authority, the Committee is authorized to make all
determinations advisable, appropriate, necessary or useful for the administration of this Policy, including any factual determinations and to correct any defect, ambiguity, omission or inconsistency in this Policy. Any interpretations, rules or
determinations made by the Committee shall be final and binding on the Company and all affected individuals and need not be consistent or uniform with respect to each Executive Officer subject to this Policy. Notwithstanding the foregoing, except as
set forth in Section&nbsp;9 below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer&#146;s obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">3.&#8194; <U>Delegation; Cooperation</U>. To the extent permitted by applicable law and policies of the Company, the Committee may authorize
and delegate to any officer or employee of the Company or any subsidiary to take all actions necessary or appropriate to carry out the objectives, purpose and intent of this Policy. The Committee is directed and permitted to consult with the Board,
the Audit Committee and any other committee of the Board, as may be necessary or appropriate, as to matters within their respective responsibility and authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">4.&#8194; <U>Subject Individuals</U>. This Policy shall be binding and enforceable against all Executive Officers of the Company and, to the
extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">5.&#8194; <U>Clawback Requirement</U>. The Company will recover, recoup, cancel or forfeit reasonably promptly the amount of Erroneously
Awarded Compensation in the event that the Company is required to prepare a Restatement (the &#147;<U>Clawback Requirement</U>&#148;) in accordance with the terms of this Policy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">6.&#8194; <U>Timing</U>. The Clawback Requirement applies to all Incentive Compensation
Received by an Executive Officer subject to this Policy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">after beginning service as an Executive Officer of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">who served as an Executive Officer of the Company at any time during the performance period for a particular
element of Incentive Compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">while the Company has a class of securities listed on a national securities exchange or a national securities
association; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">during the three completed fiscal years immediately preceding the date that the Company is required to prepare
an applicable Restatement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">The Company&#146;s obligation to recover Erroneously Awarded Compensation is not dependent on when or if the
restated financial statements are filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">7.&#8194; <U>Clawback Amount</U>. Erroneously Awarded Compensation as determined under this
Policy shall be subject to the Clawback Requirement. Erroneously Awarded Compensation shall be computed without regard to any taxes paid by or on behalf of the Executive Officer on such Erroneously Awarded Compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">For Incentive Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to
mathematical recalculation directly from the information in the Restatement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">the amount must be based on a reasonable estimate of the effect of the Restatement on the stock price or total
shareholder return upon which the Incentive Compensation was Received; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">the Company must maintain documentation of the determination of that reasonable estimate and provide such
documentation, as required, to Nasdaq. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">The Board or Committee may engage such compensation consultants, external legal advisors,
accountants and other advisors as it shall deem desirable from time to time at the cost and expense of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">8. &#8194;<U>Manner
of Enforcement</U>. Subject to Section&nbsp;9 below, the Committee shall determine, in its sole discretion, the method, timing and manner for recovering Incentive Compensation in accordance with this Policy, which may include without limitation:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">seeking recovery or reimbursement of any cash (including bonus or retention awards) and equity-based award made
to the Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">cancelling or offsetting against any contractually required or planned future cash (including bonus or
retention awards) or equity-based awards made to the Executive Officer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">requiring the forfeiture of or cancelling any previously-granted or awarded cash (including bonus or retention
awards) or equity-based awards made to the Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">offsetting amounts paid in salary or commissions to the Executive Officer or director fees if the Executive
Officer is serving as a director of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">offsetting, requiring the forfeiture of or cancelling amounts paid or to be paid in severance to the Executive
Officer pursuant to any severance or similar policy of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">forfeiture of or cancelling any dividend equivalents or dividend equivalent rights on any equity-based award;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">forfeiture of deferred compensation, subject to compliance with Section&nbsp;409A of the Internal Revenue Code
of 1986, as amended (the &#147;<U>Code</U>&#148;), and regulations thereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">any other manner or method authorized by applicable law, plan or contract as may be approved by the Committee
in its sole discretion. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">For the avoidance of doubt, any compensation paid or granted to any Executive Officer which is subject to the
Clawback Requirement shall not trigger any &#147;Good Reason,&#148; &#147;Good Leaver&#148; or similar provision under any plan, contract, employment agreement or other compensation arrangement between the Company and the Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:12pt; font-family:Times New Roman">9.&#8194; <U>Exceptions to the Clawback Requirement</U>. The Company must recover Erroneously Awarded Compensation in compliance with this
Policy, except to the extent that the conditions in clauses (a), (b) or (c)&nbsp;set forth below are met, and the Committee, or in the absence of such a committee, a majority of the independent directors serving on the Board, has made a
determination that recovery would be impracticable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be
recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation,
document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recovery would violate home country law where that law was adopted prior to November&nbsp;28, 2022. Before
concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result
in such a violation, and must provide such opinion to Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recovery would likely cause an otherwise <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan,
under which benefits are broadly available to employees of the Company, to fail to meet </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
the requirements of Sections 401(a)(13) or 411(a) of the Code and regulations thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure in SEC Filings</U>. The Company must file all disclosures with respect to this Policy in
accordance with the requirements of the Federal securities laws, including the disclosure required by the Exchange Act and any applicable SEC filings. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions and Rules</U>. Unless the context otherwise requires, the following definitions and rules apply
for purposes of this Policy: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Erroneously Awarded Compensation</U>&#148; means the amount of Incentive Compensation Received that
exceeds the amount of Incentive Compensation that otherwise would have been Received had it been determined based on the restated performance metrics and/or restated financial statements or information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Executive Officer</U>&#148; means an current or former officer of the Company as defined in the rules
promulgated under Section&nbsp;16 of the Exchange Act, including the Company&#146;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company
in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company.
Executive officers of the Company&#146;s subsidiaries are deemed executive officers of the Company if they perform such policy making functions for the Company. Policy-making function is not intended to include policy-making functions that are not
significant. Identification of an executive officer for purposes of Nasdaq Listing Rule 5608 would include at a minimum executive officers identified by the Company pursuant to 17 CFR 229.401(b) (Item 401(b) of Regulation <FONT
STYLE="white-space:nowrap">S-K).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Financial Reporting Measure</U>&#148; means a measure that is determined and presented in accordance
with the accounting principles used in preparing the Company&#146;s financial statements, and any measure that is derived wholly or in part from any such measure. Stock price and total shareholder return are also Financial Reporting Measures. A
Financial Reporting Measure need not be presented within the financial statements or included in a filing with the SEC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Incentive Compensation</U>&#148; means any compensation, cash or equity, that is granted, earned, or
vested based wholly or in part upon the attainment of a Financial Reporting Measure. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Restatement</U>&#148; means an accounting restatement due to the material noncompliance of the Company
with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Incentive Compensation is deemed &#147;<U>Received</U>&#148; in the Company&#146;s fiscal period during which
the financial reporting measure specified in the Incentive Compensation award is attained, even if the payment or grant of the incentive- based compensation occurs after the end of that period. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining the relevant recovery period, the date that the Company is required to prepare a
Restatement is the earlier to occur of: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such
action if board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Transition</U>. This Policy shall apply to Incentive Compensation Received by Executive Officers on or after
October&nbsp;2, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law</U>. This Policy shall be governed by the laws of the Province of Qu&eacute;bec, excluding
any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Policy to the substantive law of another jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>No Indemnification</U>. Notwithstanding the terms of any (a)&nbsp;provision of the Company&#146;s Articles
of Incorporation (as amended from time to time, the &#147;<U>Articles of Incorporation</U>&#148;), (b) the Company&#146;s Bylaws (&#147;<U>Bylaws</U>&#148;), (c) indemnification agreement entered into with the Company by any Executive Officer or
(d)&nbsp;insurance policy maintained by or on behalf of the Company for the benefit of the Company or any Executive Officer, the Company shall not indemnify or reimburse (or cause to be reimbursed through any existing or new compensation
arrangement) any Executive Officer against the loss of any Incentive Compensation, including any payment or reimbursement for the cost of third-party insurance or other indemnification arrangement purchased by any Executive Officer to fund any
Clawback Requirement under this Policy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Actions in Furtherance of Policy</U>. Subject to requirements of the (a)&nbsp;laws of the Province of
Qu&eacute;bec, (b)&nbsp;the Articles of Incorporation and Bylaws of the Company and (c)&nbsp;any other applicable policy of the Company, each individual who is or was a member of the Board or the Committee (in his or her capacity as such) shall be
indemnified and held harmless by the Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit or proceeding to which he
or she may be a party or in which he or she may be involved by reason of any action </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
taken under this Policy and against and from any and all amounts paid by him or her in settlement thereof. The foregoing right of indemnification shall not be exclusive of any other rights of
indemnification to which such individuals may be entitled as a matter of law or otherwise, or any power that the Company may have to indemnify them or hold them harmless. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment, Termination</U>. The Board may amend, modify or supplement any provision of this Policy at any
time and from time to time in its sole discretion. The Board shall amend the Policy, to take effect retroactively or otherwise, as deemed necessary or advisable for the purpose of conforming this Policy to any applicable law or any rules, standards
or interpretations adopted by a national securities exchange on which the Company&#146;s securities are listed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT></U>. This Policy shall not be construed as creating
any limitations on the power of the Board or Committee to adopt such other clawback or recoupment compensation policies, agreements or arrangements as it may deem desirable for any individual or enable the Company to pursue any remedies or rights
that may be available to the Company under applicable law to recoup or clawback compensation of any type. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><U>Application</U>. For the avoidance of doubt, this Policy shall apply to any Incentive Compensation paid
pursuant to or in accordance with the Company&#146;s share option plan and any other equity-based incentive compensation plan applicable to Executive Officers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>thtx-20231130.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 21-February-2024 [08:06:32] {AM}-->
<schema targetNamespace="http://www.theratech.com/20231130" elementFormDefault="qualified" xmlns:thtx="http://www.theratech.com/20231130" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://www.xbrl.org/2003/XLink" xmlns:currency="http://www.xbrl.org/2003/XLink" xmlns:exch="http://www.xbrl.org/2003/XLink" xmlns:naics="http://www.xbrl.org/2003/XLink" xmlns:sic="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://www.xbrl.org/2003/XLink" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.theratech.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
<link:definition>1002 - Statement - Consolidated Statements of Financial Position</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss" id="ConsolidatedStatementsOfNetLossAndComprehensiveLoss">
<link:definition>1003 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical" id="ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical">
<link:definition>1004 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
<link:definition>1005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BasisOfPreparation" id="BasisOfPreparation">
<link:definition>1007 - Disclosure - Basis of preparation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1008 - Disclosure - Significant accounting policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/Revenue" id="Revenue">
<link:definition>1009 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PersonnelExpenses" id="PersonnelExpenses">
<link:definition>1010 - Disclosure - Personnel expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCosts" id="FinanceIncomeAndFinanceCosts">
<link:definition>1011 - Disclosure - Finance income and finance costs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFunds" id="BondsAndMoneyMarketFunds">
<link:definition>1012 - Disclosure - Bonds and money market funds</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TradeAndOtherReceivables" id="TradeAndOtherReceivables">
<link:definition>1013 - Disclosure - Trade And Other Receivables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivable" id="TaxCreditsAndGrantsReceivable">
<link:definition>1014 - Disclosure - Tax credits and grants receivable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/Inventories" id="Inventories">
<link:definition>1015 - Disclosure - Inventories</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PrepaidExpensesAndDeposits" id="PrepaidExpensesAndDeposits">
<link:definition>1016 - Disclosure - Prepaid Expenses and Deposits</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1017 - Disclosure - Property and equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RightOfUseAssets" id="RightOfUseAssets">
<link:definition>1018 - Disclosure - Right-of-use assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IntangibleAssets" id="IntangibleAssets">
<link:definition>1019 - Disclosure - Intangible assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OtherAsset" id="OtherAsset">
<link:definition>1020 - Disclosure - Other asset</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities" id="AccountsPayableAndAccuredLiabilities">
<link:definition>1021 - Disclosure - Accounts payable and accured liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/Provisions" id="Provisions">
<link:definition>1022 - Disclosure - Provisions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LoanFacility" id="LoanFacility">
<link:definition>1023 - Disclosure - Loan Facility</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes" id="ConvertibleUnsecuredSeniorNotes">
<link:definition>1024 - Disclosure - Convertible unsecured senior notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LeasesLiabilities" id="LeasesLiabilities">
<link:definition>1025 - Disclosure - Leases liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts" id="ShareCapitalWarrantsAndSubscriptionReceipts">
<link:definition>1026 - Disclosure - Share capital warrants and subscription receipts</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1027 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SupplementalCashFlowDisclosures" id="SupplementalCashFlowDisclosures">
<link:definition>1028 - Disclosure - Supplemental cash flow disclosures</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstruments" id="FinancialInstruments">
<link:definition>1029 - Disclosure - Financial instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/CapitalManagement" id="CapitalManagement">
<link:definition>1030 - Disclosure - Capital management</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/DeterminationOfFairValues" id="DeterminationOfFairValues">
<link:definition>1031 - Disclosure - Determination of fair values</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/Commitments" id="Commitments">
<link:definition>1032 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OperatingSegments" id="OperatingSegments">
<link:definition>1033 - Disclosure - Operating segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RelatedParties" id="RelatedParties">
<link:definition>1034 - Disclosure - Related parties</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1035 - Disclosure - Significant accounting policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
<link:definition>1036 - Disclosure - Significant accounting policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RevenueTables" id="RevenueTables">
<link:definition>1037 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PersonnelExpensesTables" id="PersonnelExpensesTables">
<link:definition>1038 - Disclosure - Personnel expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables" id="FinanceIncomeAndFinanceCostsTables">
<link:definition>1039 - Disclosure - Finance income and finance costs (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsTables" id="BondsAndMoneyMarketFundsTables">
<link:definition>1040 - Disclosure - Bonds and money market funds (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TradeAndOtherReceivablesTables" id="TradeAndOtherReceivablesTables">
<link:definition>1041 - Disclosure - Trade and other receivables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables" id="TaxCreditsAndGrantsReceivableTables">
<link:definition>1042 - Disclosure - Tax credits and grants receivable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1043 - Disclosure - Inventories (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PrepaidExpensesAndDepositsTables" id="PrepaidExpensesAndDepositsTables">
<link:definition>1044 - Disclosure - Prepaid Expenses and Deposits (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1045 - Disclosure - Property and equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RightOfUseAssetsTables" id="RightOfUseAssetsTables">
<link:definition>1046 - Disclosure - Right-of-use assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
<link:definition>1047 - Disclosure - Intangible assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OtherAssetTables" id="OtherAssetTables">
<link:definition>1048 - Disclosure - Other asset (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables" id="AccountsPayableAndAccuredLiabilitiesTables">
<link:definition>1049 - Disclosure - Accounts Payable and accured liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ProvisionsTables" id="ProvisionsTables">
<link:definition>1050 - Disclosure - Provisions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LoanFacilityTables" id="LoanFacilityTables">
<link:definition>1051 - Disclosure - Loan Facility (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables" id="ConvertibleUnsecuredSeniorNotesTables">
<link:definition>1052 - Disclosure - Convertible unsecured senior notes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LeasesLiabilitiesTables" id="LeasesLiabilitiesTables">
<link:definition>1053 - Disclosure - Leases liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables" id="ShareCapitalWarrantsAndSubscriptionReceiptsTables">
<link:definition>1054 - Disclosure - Share capital warrants and subscription receipts (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1055 - Disclosure - Income taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
<link:definition>1056 - Disclosure - Financial instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/DeterminationOfFairValuesTables" id="DeterminationOfFairValuesTables">
<link:definition>1057 - Disclosure - Determination of fair values (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OperatingSegmentsTables" id="OperatingSegmentsTables">
<link:definition>1058 - Disclosure - Operating segments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RelatedPartiesTables" id="RelatedPartiesTables">
<link:definition>1059 - Disclosure - Related parties (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail" id="BasisOfPreparationAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Basis of preparation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail" id="SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail">
<link:definition>1061 - Disclosure - Significant accounting policies - Summary of methods of depreciation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" id="SignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Significant accounting policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail" id="RevenueScheduleOfNetSaleByProductDetail">
<link:definition>1063 - Disclosure - Revenue - Schedule of net sale by product (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail" id="RevenueScheduleOfNetRevenueByGeographicalAreaDetail">
<link:definition>1064 - Disclosure - Revenue - Schedule of net revenue by geographical area (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail" id="PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail">
<link:definition>1065 - Disclosure - Personnel expenses - Summary of detailed information about personnel expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail" id="PersonnelExpensesAdditionalInformationDetail">
<link:definition>1066 - Disclosure - Personnel expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail" id="FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail">
<link:definition>1067 - Disclosure - Finance income and finance costs - Summary of detailed information about finance income and cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail" id="BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail">
<link:definition>1068 - Disclosure - Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail" id="BondsAndMoneyMarketFundsAdditionalInformationDetail">
<link:definition>1069 - Disclosure - Bonds and money market funds - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail" id="TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail">
<link:definition>1070 - Disclosure - Trade and other receivables -Summary of detailed information about trade and other receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail" id="TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail">
<link:definition>1071 - Disclosure - Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail" id="TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail">
<link:definition>1072 - Disclosure - Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail" id="InventoriesSummaryOfDetailedInformationAboutInventoriesDetail">
<link:definition>1073 - Disclosure - Inventories - Summary of detailed information about inventories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/InventoriesAdditionalInformationDetail" id="InventoriesAdditionalInformationDetail">
<link:definition>1074 - Disclosure - Inventories - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail" id="PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail">
<link:definition>1075 - Disclosure - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail" id="PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail">
<link:definition>1076 - Disclosure - Property and equipment - Summary of information about property plant equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail" id="RightOfUseAssetsDisclosureOfRightOfUseAssetDetail">
<link:definition>1077 - Disclosure - Right-of-use assets - Disclosure of right of use asset (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail" id="IntangibleAssetSummaryOfIntangibleAssetsDetail">
<link:definition>1078 - Disclosure - Intangible asset - Summary of Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail" id="IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail">
<link:definition>1079 - Disclosure - Intangible assets - Summary of Commercial Milestone Payment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail" id="IntangibleAssetsAdditionalInformationDetail">
<link:definition>1080 - Disclosure - Intangible assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail" id="OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail">
<link:definition>1081 - Disclosure - Other asset - Summary of detailed information about other asset (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OtherAssetAdditionalInformationDetail" id="OtherAssetAdditionalInformationDetail">
<link:definition>1082 - Disclosure - Other asset - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" id="AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<link:definition>1083 - Disclosure - Accounts payable and accrued liabilities - Summary of 	accounts payable and accrued liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail" id="AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail">
<link:definition>1084 - Disclosure - Accounts payable and accrued liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail" id="ProvisionsSummaryOfProvisionDetail">
<link:definition>1085 - Disclosure - Provisions - Summary of provision (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail" id="ProvisionsSummaryOfProvisionParentheticalDetail">
<link:definition>1086 - Disclosure - Provisions - Summary of provision (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail" id="LoanFacilityAdditionalInformationDetail">
<link:definition>1087 - Disclosure - Loan Facility - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail" id="LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail">
<link:definition>1088 - Disclosure - Loan Facility - Summary of movement in the carrying value of the long term loan (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail" id="ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail">
<link:definition>1089 - Disclosure - Convertible unsecured senior notes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail" id="ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail">
<link:definition>1090 - Disclosure - Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail" id="LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail">
<link:definition>1091 - Disclosure - Leases liabilities - Summary of lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail" id="LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail">
<link:definition>1092 - Disclosure - Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail">
<link:definition>1093 - Disclosure - Share capital warrants and subscription receipts - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail">
<link:definition>1094 - Disclosure - Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail">
<link:definition>1095 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail">
<link:definition>1096 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail">
<link:definition>1097 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail">
<link:definition>1098 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail">
<link:definition>1099 - Disclosure - Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail">
<link:definition>1100 - Disclosure - Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail">
<link:definition>1101 - Disclosure - Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail" id="ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail">
<link:definition>1102 - Disclosure - Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail" id="IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail">
<link:definition>1103 - Disclosure - Income Taxes - Summary of components of the current and deferred tax expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail" id="IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail">
<link:definition>1104 - Disclosure - Income Taxes - Summary of reconciliation between effective and applicable tax (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1105 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail" id="IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail">
<link:definition>1106 - Disclosure - Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail" id="SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail">
<link:definition>1107 - Disclosure - Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail" id="FinancialInstrumentsAdditionalInformationDetail">
<link:definition>1108 - Disclosure - Financial instruments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" id="FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail">
<link:definition>1109 - Disclosure - Financial instruments - Summary of the contractual maturities of financial liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" id="FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail">
<link:definition>1110 - Disclosure - Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail" id="FinancialInstrumentsSummaryOfExchangeRatesDetail">
<link:definition>1111 - Disclosure - Financial instruments - Summary of exchange rates (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail" id="FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail">
<link:definition>1112 - Disclosure - Financial instruments - Summary of Company's foreign currency exposures (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail" id="CapitalManagementAdditionalInformationDetail">
<link:definition>1113 - Disclosure - Capital management - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail" id="DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail">
<link:definition>1114 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail" id="DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail">
<link:definition>1115 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/CommitmentsAdditionalInformationDetail" id="CommitmentsAdditionalInformationDetail">
<link:definition>1116 - Disclosure - Commitments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail" id="OperatingSegmentsSummaryOfSingleOperatingSegmentDetail">
<link:definition>1117 - Disclosure - Operating segments - Summary of single operating segment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail" id="OperatingSegmentsAdditionalInformationDetail">
<link:definition>1118 - Disclosure - Operating segments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail" id="RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail">
<link:definition>1119 - Disclosure - Related parties - Summary of key management personnel compensation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail" id="RelatedPartiesAdditionalInformationDetail">
<link:definition>1120 - Disclosure - Related parties - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="thtx-20231130_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="thtx-20231130_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="thtx-20231130_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="thtx-20231130_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="IncomeTaxReceivableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_IncomeTaxReceivableCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxCreditsAndGrantsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_TaxCreditsAndGrantsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LoanFacilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LoanFacilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_WarrantsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LoanFacilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LoanFacilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OperatingExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="AmortizationOfOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AmortizationOfOtherAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FinanceCostsAndGainsLossesOnForeignCurrency" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_FinanceCostsAndGainsLossesOnForeignCurrency" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FinanceIncomeCostAndGainsLossesOnForeignCurrency" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ResearchAndDevelopmentExpenseNetOfTaxCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExerciseOfStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExerciseOfStockOptionsAbstract" substitutionGroup="xbrli:item" />
<element name="ExerciseOfStockOptionsAttributedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ExerciseOfStockOptionsAttributedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughExerciseOfOptionsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseThroughSharesIssuedAtmProgramValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSharesIssuedThroughAtmProgram" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_NumberOfSharesIssuedThroughAtmProgram" substitutionGroup="xbrli:item" />
<element name="ShareIssueCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ShareIssueCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockAndWarrantsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringPeriodSharesAcquisitions" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueAcquisitions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringPeriodValueAcquisitions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringThePeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringThePeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringThePeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockIssuedDuringThePeriodValueNewIssues" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedCompensationPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ShareBasedCompensationPlanAbstract" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdjustmentsForDeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromIssuingSharesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProceedsFromIssuingSharesAndWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfOtherObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_RepaymentOfOtherObligations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsToAcquireDerivativeFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PaymentsToAcquireDerivativeFinancialAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsForAmortizationOfRightofuseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdjustmentsForAmortizationOfRightofuseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnLeaseTermination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_GainLossOnLeaseTermination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossOnLoanFacilityModifications" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_GainLossOnLoanFacilityModifications" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForTaxCreditsAndGrantsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TextBlockAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherReceivablesExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TradeAndOtherReceivablesExplanatoryAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTaxCreditsReceivableExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTaxCreditsReceivableExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" substitutionGroup="xbrli:item" />
<element name="TradeAndAccruedPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TradeAndAccruedPayablesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="ConvertibleUnsecuredSeniorNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ConvertibleUnsecuredSeniorNotesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="SupplementalCashFlowDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SupplementalCashFlowDisclosuresAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfSupplementalInformationOnCashFlowexplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfFairValueMeasurementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfFairValueMeasurementAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfCommitmentsAbstract" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfChangesInAccountingPoliciesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" substitutionGroup="xbrli:item" />
<element name="DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" substitutionGroup="xbrli:item" />
<element name="DisaggregationOfRevenueByGeographicalAreaTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfTaxCreditsRollForwardTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfRightOfUseAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfRightOfUseAssetAbstract" substitutionGroup="xbrli:item" />
<element name="RightOfUseAssetsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_RightOfUseAssetsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfLeaseLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ShareCapitalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ShareCapitalTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ShareCapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ShareCapitalLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BasisOfPresentationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="MinimumLiquidityRequirementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_MinimumLiquidityRequirementAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="StatementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_StatementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommercializationRightsEgriftaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommercializationRightsEgriftaMember" substitutionGroup="xbrli:item" />
<element name="CommercializationRightsTrogarzoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommercializationRightsTrogarzoMember" substitutionGroup="xbrli:item" />
<element name="ThtxCommercializationRightsTrogarzoNorthAmericaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" substitutionGroup="xbrli:item" />
<element name="UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" substitutionGroup="xbrli:item" />
<element name="EgriftaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_EgriftaMember" substitutionGroup="xbrli:item" />
<element name="TrogarzoNetSalesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TrogarzoNetSalesMember" substitutionGroup="xbrli:item" />
<element name="DisaggregationOfRevenueByGeographicalAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisaggregationOfRevenueByGeographicalAreaTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisaggregationOfRevenueByGeographicalAreaLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPersonnelExpensesExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" substitutionGroup="xbrli:item" />
<element name="AmountOfChargesRelatedToSeveranceAndOtherExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" substitutionGroup="xbrli:item" />
<element name="AccretionExpenseAndAmortizationOfDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetGainLossOnFinancialInstrumentsCarriedAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GuaranteedInvestmentCertificates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_GuaranteedInvestmentCertificates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAverageMaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_FinancialAssetsAverageMaturityTerm" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsStatedInterestPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_FinancialAssetsStatedInterestPercentage" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTaxCreditsAndGrantsReceivableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxCreditsAndGrantsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TaxCreditsAndGrantsReceived" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncomeTaxExpireTwoThousandFortyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandFortyMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandFortyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandFortyOneMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandFortyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandFortyThreeMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandFortyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandFortyTwoMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandThirtyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandThirtyMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandThirtyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandThirtyNineMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandThirtyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandThirtyOneMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandThirtyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandThirtyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentyEightMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentyNineMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpireTwoThousandTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxExpireTwoThousandTwentySixMember" substitutionGroup="xbrli:item" />
<element name="StatementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_StatementLineItems" substitutionGroup="xbrli:item" />
<element name="UnusedAndUnrecordedTaxCreditsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_UnusedAndUnrecordedTaxCreditsMember" substitutionGroup="xbrli:item" />
<element name="TaiMedBiologicsInc.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TaiMedBiologicsInc.Member" substitutionGroup="xbrli:item" />
<element name="LocationInIncomeStatementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LocationInIncomeStatementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LocationInIncomeStatementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LocationInIncomeStatementDomain" substitutionGroup="xbrli:item" />
<element name="CostOfGoodsSoldMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CostOfGoodsSoldMember" substitutionGroup="xbrli:item" />
<element name="InventoriesReturned" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_InventoriesReturned" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProvisionForExcessStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProvisionForExcessStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProvisionForFormulation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProvisionForFormulation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProvisionForTheExpiredRawMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProvisionForTheExpiredRawMaterial" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProvisionForTheInventoryInDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProvisionForTheInventoryInDevelopment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_PrepaidExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" substitutionGroup="xbrli:item" />
<element name="AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PropertyPlantAndEquipmentAccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetCarryingAmountAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NetCarryingAmountAbstract" substitutionGroup="xbrli:item" />
<element name="AmortizationOfRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AmortizationOfRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TerminationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TerminationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetCarryingAmountMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NetCarryingAmountMember" substitutionGroup="xbrli:item" />
<element name="CommercializationRightsTrogarzoEuropeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommercializationRightsTrogarzoEuropeMember" substitutionGroup="xbrli:item" />
<element name="CommercializationRightsTrogarzoNorthAmericaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommercializationRightsTrogarzoNorthAmericaMember" substitutionGroup="xbrli:item" />
<element name="OncologyPlatformMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OncologyPlatformMember" substitutionGroup="xbrli:item" />
<element name="AccumulatedAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AccumulatedAmortizationAbstract" substitutionGroup="xbrli:item" />
<element name="AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InitialMilestonePaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_InitialMilestonePaymentsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestoneAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneDomain" substitutionGroup="xbrli:item" />
<element name="MilestoneFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneFiveMember" substitutionGroup="xbrli:item" />
<element name="MilestoneFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneFourMember" substitutionGroup="xbrli:item" />
<element name="MilestoneSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneSixMember" substitutionGroup="xbrli:item" />
<element name="TypeOfArrangementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfArrangementsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfArrangementsMemberDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfArrangementsMemberDomain" substitutionGroup="xbrli:item" />
<element name="BasisOfRoyaltyPaymentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BasisOfRoyaltyPaymentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BasisOfRoyaltyPaymentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BasisOfRoyaltyPaymentMember" substitutionGroup="xbrli:item" />
<element name="NetSalesBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NetSalesBasisMember" substitutionGroup="xbrli:item" />
<element name="RoyaltyRevenueSublicenseBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_RoyaltyRevenueSublicenseBasisMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAdjustmentToPurchaseConsiderationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BusinessCombinationAdjustmentToPurchaseConsiderationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" substitutionGroup="xbrli:item" />
<element name="KatanaAmendmentAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_KatanaAmendmentAgreementMember" substitutionGroup="xbrli:item" />
<element name="KatanaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_KatanaMember" substitutionGroup="xbrli:item" />
<element name="AcquisitionCostsForIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AcquisitionCostsForIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationContingentConsiderationFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_BusinessCombinationContingentConsiderationFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationIncreaseDecreaseInPurchaseConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DevelopmentMilestonePayableAnnualInstallment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DevelopmentMilestonePayableAnnualInstallment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FirstMilestoneInstallmentPaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_FirstMilestoneInstallmentPaymentsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InitialMilestonePaymentsPayableAggregateAnnualInstallments." type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IntangibleAssetsAgreementTermOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IntangibleAssetsAgreementTermOfContract" substitutionGroup="xbrli:item" />
<element name="LaunchMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LaunchMilestonePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestoneAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_MilestoneAmountPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOfUpfrontMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PaymentOfUpfrontMilestones" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfPurchasePriceConsiderationOfIntangibleAssets" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" substitutionGroup="xbrli:item" />
<element name="RegulatoryMilestonePaymentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_RegulatoryMilestonePaymentPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RoyaltyFeesAsAPercentageOfRevenue" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_RoyaltyFeesAsAPercentageOfRevenue" substitutionGroup="xbrli:item" />
<element name="SecondMilestoneInstallmentPaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_SecondMilestoneInstallmentPaymentsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FeesPeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FeesPeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FeesPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FeesPeriodMember" substitutionGroup="xbrli:item" />
<element name="AfterFiveYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AfterFiveYearsMember" substitutionGroup="xbrli:item" />
<element name="FirstFiveYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FirstFiveYearsMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentMilestonePhaseOneClinicalTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentMilestonePhaseThreeClinicalTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentMilestonePhaseTwoClinicalTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" substitutionGroup="xbrli:item" />
<element name="MilestoneOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestoneOneMember" substitutionGroup="xbrli:item" />
<element name="MilestonePhaseTwoLiveDemonstrationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MilestonePhaseTwoLiveDemonstrationMember" substitutionGroup="xbrli:item" />
<element name="NatureOfFeesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NatureOfFeesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="NatureOfFeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NatureOfFeesMember" substitutionGroup="xbrli:item" />
<element name="RoyaltyRelatedLicensePeptidesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_RoyaltyRelatedLicensePeptidesMember" substitutionGroup="xbrli:item" />
<element name="TrogarzoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TrogarzoMember" substitutionGroup="xbrli:item" />
<element name="ScenariosAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScenariosAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ScenariosDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScenariosDomain" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementTransferPlusLPMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LicenseAgreementTransferPlusLPMember" substitutionGroup="xbrli:item" />
<element name="TaimedAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TaimedAgreementMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInformationAboutOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ScheduleOfInformationAboutOtherAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfDetailedInformationAboutOtherAssetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInformationAboutOtherAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureInformationAboutOtherAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" substitutionGroup="xbrli:item" />
<element name="AccumulatedAmortizationOnOtherNonCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortizationOfOtherNonCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AmortizationOfOtherNonCurrentAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetCarryingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_NetCarryingAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReconciliationOfChangesInOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ReconciliationOfChangesInOtherAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="OtherAssetsNonCurrentAtCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_OtherAssetsNonCurrentAtCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeronoIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SeronoIncMember" substitutionGroup="xbrli:item" />
<element name="ContractualObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ContractualObligations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PerformanceObligationFinalSettlementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_PerformanceObligationFinalSettlementAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DueInNextFourToFiveYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DueInNextFourToFiveYearsMember" substitutionGroup="xbrli:item" />
<element name="DueWithOneYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DueWithOneYearMember" substitutionGroup="xbrli:item" />
<element name="TypeOfArrangementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfArrangementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfArrangementMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirteenTerminationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TwoThousandThirteenTerminationAgreementMember" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TradeAndOtherPayablesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TradeAndOtherPayablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TradeAndOtherPayablesLineItems" substitutionGroup="xbrli:item" />
<element name="EqualAnnualInstallments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_EqualAnnualInstallments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentForContingentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PaymentForContingentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentOfMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PaymentOfMilestones" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChargebacksAndRebatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ChargebacksAndRebatesMember" substitutionGroup="xbrli:item" />
<element name="OtherAdditionalProvisionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OtherAdditionalProvisionMember" substitutionGroup="xbrli:item" />
<element name="GeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_GeneralAndAdministrativeExpenseMember" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
<element name="SellingAndMarketingExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SellingAndMarketingExpenseMember" substitutionGroup="xbrli:item" />
<element name="SeveranceAndOtherExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SeveranceAndOtherExpensesMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche1And2LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche1And2LoanMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche1LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche1LoanMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche2LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche2LoanMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche3And4LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche3And4LoanMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche3LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche3LoanMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTranche4LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTranche4LoanMember" substitutionGroup="xbrli:item" />
<element name="CashCashEquivalentsAndEligibleShortTermInvestmentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="AmountReclassifiedFromDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_AmountReclassifiedFromDeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BorrowingsInterestPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_BorrowingsInterestPeriod" substitutionGroup="xbrli:item" />
<element name="CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" substitutionGroup="xbrli:item" />
<element name="ConsiderationPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ConsiderationPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DateOfCommencementOfPrincipalRepaymentInAdvance" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentAmortizedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DebtInstrumentAmortizedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentCollateralAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DebtInstrumentCollateralAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredFinanceCostsWriteOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DeferredFinanceCostsWriteOff" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LineOfCreditFacilityMaximumBorrowingCapacity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LineOfCreditFacilityMaximumBorrowingCapacity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FifthAmendmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FifthAmendmentMember" substitutionGroup="xbrli:item" />
<element name="SecuredOvernightFinancingRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SecuredOvernightFinancingRateMember" substitutionGroup="xbrli:item" />
<element name="LoanFacilityTrancheTwoLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LoanFacilityTrancheTwoLoanMember" substitutionGroup="xbrli:item" />
<element name="MarathonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MarathonWarrantsMember" substitutionGroup="xbrli:item" />
<element name="BorrowingsAccretionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_BorrowingsAccretionExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromConsiderationOfTheFifthAmendment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProceedsFromConsiderationOfTheFifthAmendment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConvertibleUnsecuredSeniorNotesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ConvertibleUnsecuredSeniorNotesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ConvertibleUnsecuredSeniorNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ConvertibleUnsecuredSeniorNotesMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleUnsecuredSeniorNotesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ConvertibleUnsecuredSeniorNotesLineItems" substitutionGroup="xbrli:item" />
<element name="ConvertibleInstrumentsNumberOfSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ConvertibleInstrumentsNumberOfSharesIssued" substitutionGroup="xbrli:item" />
<element name="LiabilityComponentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_LiabilityComponentMember" substitutionGroup="xbrli:item" />
<element name="AccretionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AccretionExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangesFromFinancingCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ChangesFromFinancingCashFlowsAbstract" substitutionGroup="xbrli:item" />
<element name="AccretionExpenseOfLeasesLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AccretionExpenseOfLeasesLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeasesLiabilitiesEffectOfChangeInExchangeRates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TerminationOfLeasesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TerminationOfLeasesOperatingLeaseRightOfUseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AgreementMember" substitutionGroup="xbrli:item" />
<element name="FifthAmendmentOfTheLoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FifthAmendmentOfTheLoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="CategoryOfBorrowingsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CategoryOfBorrowingsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CategoryOfBorrowingsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CategoryOfBorrowingsDomain" substitutionGroup="xbrli:item" />
<element name="CashSettledForwardContractsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CashSettledForwardContractsMember" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfWarrantsOrRightsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ClassOfWarrantsOrRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfWarrantsOrRightsMember" substitutionGroup="xbrli:item" />
<element name="NonVotingSubscriptionReceiptsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_NonVotingSubscriptionReceiptsMember" substitutionGroup="xbrli:item" />
<element name="ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfWarrantOrRightExpirationDate" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightNumberOfSecuritiesExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ClassOfWarrantOrRightOutstanding" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExercisePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ClassOfWarrantsOrRightsExercisePricePerShare" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="CommonStockConversionBasis" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_CommonStockConversionBasis" substitutionGroup="xbrli:item" />
<element name="DeferredFinancingCostsOnTheLoanFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DeferredFinancingCostsOnTheLoanFacility" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredFinancingCostsWrittenDown" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DeferredFinancingCostsWrittenDown" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" substitutionGroup="xbrli:item" />
<element name="EffectOfShareOptionsOnNumberOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" substitutionGroup="xbrli:item" />
<element name="EffectOfShareOptionsOnNumberOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" substitutionGroup="xbrli:item" />
<element name="GainLossOnDebtModification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_GainLossOnDebtModification" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInTheFairValueOfLiabilityRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseInTheFairValueOfLiabilityRecorded" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfCashSettledForwardStockContractsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_NumberOfCashSettledForwardStockContractsOutstanding" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipHoldingCommonShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PercentageOfOwnershipHoldingCommonShares" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipOfTheInvestor" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PercentageOfOwnershipOfTheInvestor" substitutionGroup="xbrli:item" />
<element name="PotentialShareIssueInTheFutureOnExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="PricePerShareForTheSettlementOfCashsettledForwardStockContracts" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" substitutionGroup="xbrli:item" />
<element name="ProceedsFromTheIssuanceOfCommonSharesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" substitutionGroup="xbrli:item" />
<element name="SaleOfStockConsiderationReceivedOnTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_SaleOfStockConsiderationReceivedOnTransaction" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockAppreciationRightsContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_StockAppreciationRightsContractualLife" substitutionGroup="xbrli:item" />
<element name="StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TermOfWarrants" substitutionGroup="xbrli:item" />
<element name="TransactionCostsAllocatedToTheLoanFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TransactionCostsAllocatedToTheLoanFacility" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionCostsOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_TransactionCostsOfWarrantsIssued" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_EventDomain" substitutionGroup="xbrli:item" />
<element name="InvesteeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_InvesteeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvesteeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_InvesteeMember" substitutionGroup="xbrli:item" />
<element name="AffiliatesOfMarathonAssetManagementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AffiliatesOfMarathonAssetManagementMember" substitutionGroup="xbrli:item" />
<element name="InvestmentQuebecMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_InvestmentQuebecMember" substitutionGroup="xbrli:item" />
<element name="IssuedCapitalAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IssuedCapitalAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="IssuedCapitalDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IssuedCapitalDomain" substitutionGroup="xbrli:item" />
<element name="OverallotmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OverallotmentMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_PrivatePlacementMember" substitutionGroup="xbrli:item" />
<element name="PublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_PublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="PlanAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_PlanAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PlanDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_PlanDomain" substitutionGroup="xbrli:item" />
<element name="StockAppreciationRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_StockAppreciationRightsMember" substitutionGroup="xbrli:item" />
<element name="StockOptionPlanTwoThousandAndNineteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_StockOptionPlanTwoThousandAndNineteenMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSixteenShareholdersPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TwoThousandAndSixteenShareholdersPlanMember" substitutionGroup="xbrli:item" />
<element name="ProgramNameAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ProgramNameAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ProgramNameMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ProgramNameMember" substitutionGroup="xbrli:item" />
<element name="AtmProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AtmProgramMember" substitutionGroup="xbrli:item" />
<element name="SchemeOfShareIssueAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SchemeOfShareIssueAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SchemeOfShareIssueDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SchemeOfShareIssueDomain" substitutionGroup="xbrli:item" />
<element name="DeferredStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DeferredStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="AverageOptionLifeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_AverageOptionLifeMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceToAcquireOneCommonShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceToAcquireOneCommonShareMember" substitutionGroup="xbrli:item" />
<element name="SharePriceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SharePriceMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" substitutionGroup="xbrli:item" />
<element name="NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" substitutionGroup="xbrli:item" />
<element name="ExercisePriceFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceFiveMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceFourMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceOneMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceSixMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceThreeMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ExercisePriceTwoMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageFairValueOfStockOptionsGrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BrokersWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BrokersWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PublicIssueOfSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_PublicIssueOfSharesMember" substitutionGroup="xbrli:item" />
<element name="ShareOptionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ShareOptionMember" substitutionGroup="xbrli:item" />
<element name="SubscriptionReceiptsIssueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SubscriptionReceiptsIssueMember" substitutionGroup="xbrli:item" />
<element name="EffectOfBrokerWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfBrokerWarrantsExercised" substitutionGroup="xbrli:item" />
<element name="EffectOfIssueCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfIssueCommonShares" substitutionGroup="xbrli:item" />
<element name="EffectOfShareOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfShareOptionsExercised" substitutionGroup="xbrli:item" />
<element name="EffectOfSubscriptionReceiptsIssue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_EffectOfSubscriptionReceiptsIssue" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfDetailedInformationAboutIncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfDetailedInformationAboutIncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="OffsettingOfDeferredTaxLiabilityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OffsettingOfDeferredTaxLiabilityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="OffsettingOfDeferredTaxLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_OffsettingOfDeferredTaxLiabilityMember" substitutionGroup="xbrli:item" />
<element name="TypeOfReversalOfDeferredTaxLiabilityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TypeOfReversalOfDeferredTaxLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TypeOfReversalOfDeferredTaxLiabilityMember" substitutionGroup="xbrli:item" />
<element name="AvailableDeductionsAndOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_AvailableDeductionsAndOthers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxJurisdictionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxJurisdictionAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="IncomeTaxJurisdictionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_IncomeTaxJurisdictionMember" substitutionGroup="xbrli:item" />
<element name="FederalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_FederalMember" substitutionGroup="xbrli:item" />
<element name="ProvincialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_ProvincialMember" substitutionGroup="xbrli:item" />
<element name="TaxBenefitCarryForwardYearAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TaxBenefitCarryForwardYearAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TaxBenefitCarryForwardYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_TaxBenefitCarryForwardYearMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndFortyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndFortyMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndFortyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndFortyOneMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndFortyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndFortyThreeMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndFortyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndFortyTwoMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyEightMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyFourMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyNineMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyOneMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtySevenMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyThreeMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndThirtyTwoMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndTwentyEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndTwentyEightMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndTwentyNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndTwentyNineMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndTwentySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_YearTwoThousandAndTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReclassificationOfOtherDeferredFinancingCostsToDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BondsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_BondsMember" substitutionGroup="xbrli:item" />
<element name="VariableInterestRateCashAndMarketFundsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_VariableInterestRateCashAndMarketFundsMember" substitutionGroup="xbrli:item" />
<element name="BadDebtExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_BadDebtExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CurrentTradeReceivablesAgingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_CurrentTradeReceivablesAgingPeriod" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NegativePercentageImpactOnForeignCurrencyExposures" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_NegativePercentageImpactOnForeignCurrencyExposures" substitutionGroup="xbrli:item" />
<element name="PositivePercentageImpactOnForeignCurrencyExposures" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PositivePercentageImpactOnForeignCurrencyExposures" substitutionGroup="xbrli:item" />
<element name="VariableInterestbearingCashAndMoneyMarketFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_VariableInterestbearingCashAndMoneyMarketFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrentPositionOfTermLoanIncludingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_CurrentPositionOfTermLoanIncludingInterest" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseLiabilitiesUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LeaseLiabilitiesUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermLoanUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LongTermLoanUndiscountedCashFlows" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonderivativeFinancialLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_NonderivativeFinancialLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TotalLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_TotalLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashbondAndMoneyMarketFundsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CashbondAndMoneyMarketFundsMember" substitutionGroup="xbrli:item" />
<element name="CashBondAndMoneyMarketFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_CashBondAndMoneyMarketFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SaleOfStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SaleOfStockAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SaleOfStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_SaleOfStockMember" substitutionGroup="xbrli:item" />
<element name="SignificantUnobservableInputLiabilitiesBasisPoints" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_SignificantUnobservableInputLiabilitiesBasisPoints" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCommitmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfCommitmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommitmentsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CommitmentsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CommitmentsDomain" substitutionGroup="xbrli:item" />
<element name="MultidosePassInjectorDevelopedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_MultidosePassInjectorDevelopedMember" substitutionGroup="xbrli:item" />
<element name="CreditFacilityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CreditFacilityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CreditFacilityDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_CreditFacilityDomain" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCommitmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_DisclosureOfCommitmentsLineItems" substitutionGroup="xbrli:item" />
<element name="BorrowingsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_BorrowingsOutstanding" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermPurchaseCommitmentsMinimumPaymentsRequired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RxCrossRoadsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="thtx_RxCrossRoadsMember" substitutionGroup="xbrli:item" />
<element name="RelatedPartyPercentageOfVotingRightsHeld" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="thtx_RelatedPartyPercentageOfVotingRightsHeld" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>thtx-20231130_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 21-February-2024 [08:06:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfNetLossAndComprehensiveLoss" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail" roleURI="http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail" roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail" roleURI="http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#InventoriesSummaryOfDetailedInformationAboutInventoriesDetail" roleURI="http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail" roleURI="http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail" roleURI="http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_NoncurrentAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCosts" xlink:label="loc_THTX_DeferredFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_THTX_DeferredFinancingCosts" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_RightofuseAssets" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets" xlink:to="loc_ifrs-full_CurrentAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxReceivableCurrent" xlink:label="loc_THTX_IncomeTaxReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_THTX_IncomeTaxReceivableCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_DeferredTaxAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_THTX_TaxCreditsAndGrantsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_THTX_TaxCreditsAndGrantsReceivable" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-full_InventoriesTotal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_InventoriesTotal" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="loc_ifrs-full_Cash" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="loc_ifrs-full_Equity" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_RetainedEarnings" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_AdditionalPaidinCapital" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity" xlink:to="loc_ifrs-full_IssuedCapital" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="loc_ifrs-full_Liabilities" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_NoncurrentLiabilities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityNoncurrent" xlink:label="loc_THTX_LoanFacilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_THTX_LoanFacilityNoncurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities" xlink:to="loc_ifrs-full_CurrentLiabilities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityCurrent" xlink:label="loc_THTX_LoanFacilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_THTX_LoanFacilityCurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WarrantsCurrent" xlink:label="loc_THTX_WarrantsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_THTX_WarrantsCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_OtherShorttermProvisions" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables" use="optional" order="35" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsToAcquireDerivativeFinancialAssets" xlink:label="loc_THTX_PaymentsToAcquireDerivativeFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_THTX_PaymentsToAcquireDerivativeFinancialAssets" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_THTX_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_THTX_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RepaymentOfOtherObligations" xlink:label="loc_THTX_RepaymentOfOtherObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_THTX_RepaymentOfOtherObligations" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromIssuingSharesAndWarrants" xlink:label="loc_THTX_ProceedsFromIssuingSharesAndWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_THTX_ProceedsFromIssuingSharesAndWarrants" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForDeferredFinancingCosts" xlink:label="loc_THTX_AdjustmentsForDeferredFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_THTX_AdjustmentsForDeferredFinancingCosts" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xlink:label="loc_THTX_AdjustmentsForTaxCreditsAndGrantsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_THTX_AdjustmentsForTaxCreditsAndGrantsReceivable" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForProvisions" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" use="optional" order="25" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_THTX_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_THTX_GainLossOnLeaseTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_GainLossOnLeaseTermination" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLoanFacilityModifications" xlink:label="loc_THTX_GainLossOnLoanFacilityModifications" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_GainLossOnLoanFacilityModifications" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xlink:label="loc_THTX_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" use="optional" order="43" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_THTX_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" use="optional" order="45" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForInterestIncome" use="optional" order="46" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAmortizationOfRightofuseAssets" xlink:label="loc_THTX_AdjustmentsForAmortizationOfRightofuseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_THTX_AdjustmentsForAmortizationOfRightofuseAssets" use="optional" order="47" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts" use="optional" order="48" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="loc_ifrs-full_ProfitLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="loc_ifrs-full_ProfitLossBeforeTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:label="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:label="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:to="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_FinanceIncome" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_Revenue" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="loc_ifrs-full_OperatingExpense" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense" xlink:label="loc_ifrs-full_SellingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="loc_ifrs-full_SellingExpense" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xlink:label="loc_THTX_ResearchAndDevelopmentExpenseNetOfTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="loc_THTX_ResearchAndDevelopmentExpenseNetOfTaxCredits" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherAssets" xlink:label="loc_THTX_AmortizationOfOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="loc_THTX_AmortizationOfOtherAssets" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="loc_ifrs-full_CostOfSales" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_TerminationBenefitsExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:label="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:label="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:to="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_THTX_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_THTX_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLoanFacilityModifications" xlink:label="loc_THTX_GainLossOnLoanFacilityModifications" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_THTX_GainLossOnLoanFacilityModifications" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_NetForeignExchangeLoss" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankAndSimilarCharges" xlink:label="loc_ifrs-full_BankAndSimilarCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_BankAndSimilarCharges" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:to="loc_ifrs-full_FinanceIncome" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_THTX_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_THTX_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xlink:label="loc_THTX_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_THTX_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_THTX_GainLossOnLeaseTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_THTX_GainLossOnLeaseTermination" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="loc_ifrs-full_RevenueFromInterest" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="loc_ifrs-full_OtherCurrentReceivables" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="loc_ifrs-full_CurrentTradeReceivables" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-full_InventoriesTotal" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal" xlink:to="loc_ifrs-full_FinishedGoods" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal" xlink:to="loc_ifrs-full_WorkInProgress" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials" xlink:label="loc_ifrs-full_RawMaterials" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal" xlink:to="loc_ifrs-full_RawMaterials" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_OtherCurrentPayables" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestPayable" xlink:label="loc_ifrs-full_CurrentInterestPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_CurrentInterestPayable" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonderivativeFinancialLiabilities" xlink:label="loc_THTX_NonderivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentPositionOfTermLoanIncludingInterest" xlink:label="loc_THTX_CurrentPositionOfTermLoanIncludingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_NonderivativeFinancialLiabilities" xlink:to="loc_THTX_CurrentPositionOfTermLoanIncludingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_NonderivativeFinancialLiabilities" xlink:to="loc_ifrs-full_LeaseLiabilities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_NonderivativeFinancialLiabilities" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_THTX_NonderivativeFinancialLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermLoanUndiscountedCashFlows" xlink:label="loc_THTX_LongTermLoanUndiscountedCashFlows" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="loc_THTX_LongTermLoanUndiscountedCashFlows" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeaseLiabilitiesUndiscountedCashFlows" xlink:label="loc_THTX_LeaseLiabilitiesUndiscountedCashFlows" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="loc_THTX_LeaseLiabilitiesUndiscountedCashFlows" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xlink:label="loc_THTX_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="loc_THTX_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="loc_ifrs-full_CurrentProvisions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_ifrs-full_CurrentProvisions" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TotalLeaseLiabilities" xlink:label="loc_THTX_TotalLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_THTX_TotalLeaseLiabilities" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_THTX_TaxCreditsAndGrantsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_THTX_TaxCreditsAndGrantsReceivable" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_ifrs-full_Cash" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xlink:label="loc_THTX_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="loc_THTX_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xlink:label="loc_THTX_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_THTX_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrepaidExpenses" xlink:label="loc_THTX_PrepaidExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="loc_THTX_PrepaidExpenses" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>40
<FILENAME>thtx-20231130_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 21-February-2024 [08:06:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CoverPage" roleURI="http://www.theratech.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsTables" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BasisOfPreparationAdditionalInformationDetail" roleURI="http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RevenueScheduleOfNetSaleByProductDetail" roleURI="http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RevenueScheduleOfNetRevenueByGeographicalAreaDetail" roleURI="http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BondsAndMoneyMarketFundsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#InventoriesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/InventoriesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail" roleURI="http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetSummaryOfIntangibleAssetsDetail" roleURI="http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail" roleURI="http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail" roleURI="http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAssetAdditionalInformationDetail" roleURI="http://www.theratech.com/role/OtherAssetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ProvisionsSummaryOfProvisionDetail" roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ProvisionsSummaryOfProvisionParentheticalDetail" roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacilityAdditionalInformationDetail" roleURI="http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail" roleURI="http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfExchangeRatesDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CapitalManagementAdditionalInformationDetail" roleURI="http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail" roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail" roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegmentsSummaryOfSingleOperatingSegmentDetail" roleURI="http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegmentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1279586" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1279581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentInformationTable_1279581" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1279589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1279581" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1279589" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1279590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1279589" xlink:to="loc_dei_AddressTypeDomain_1279590" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1279590_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1279589" xlink:to="loc_dei_AddressTypeDomain_1279590_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1279591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1279590" xlink:to="loc_dei_BusinessContactMember_1279591" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_550085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AmendmentFlag_550085" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1306649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorName_1306649" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1306650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorFirmId_1306650" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1306651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorLocation_1306651" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_550083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentType_550083" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_550086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentPeriodEndDate_550086" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_550087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFiscalYearFocus_550087" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_550088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFiscalPeriodFocus_550088" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_550089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityRegistrantName_550089" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_550090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCentralIndexKey_550090" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_550104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCurrentReportingStatus_550104" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_550108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityEmergingGrowthCompany_550108" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_550109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_CurrentFiscalYearEndDate_550109" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_1279641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentRegistrationStatement_1279641" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_550111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentAnnualReport_550111" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_550678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_550678" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_551052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_Security12bTitle_551052" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_551065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityInteractiveDataCurrent_551065" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_603583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityExTransitionPeriod_603583" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_603670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_TradingSymbol_603670" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_842211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_SecurityExchangeName_842211" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_842213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_IcfrAuditorAttestationFlag_842213" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1279560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityFileNumber_1279560" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1279561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1279561" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_550102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_550102" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_550103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityVoluntaryFilers_550103" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_550105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityShellCompany_550105" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_550106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityFilerCategory_550106" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_550112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentTransitionReport_550112" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_550663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentShellCompanyReport_550663" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1279612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_ContactPersonnelName_1279612" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1279576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressAddressLine1_1279576" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1279599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressAddressLine2_1279599" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1279601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressCityOrTown_1279601" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1279602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressStateOrProvince_1279602" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_551068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressCountry_551068" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1279605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressPostalZipCode_1279605" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1279606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_CityAreaCode_1279606" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1279607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_LocalPhoneNumber_1279607" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_2147462828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_ContactPersonnelFaxNumber_2147462828" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147462827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147462827" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_2147462834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentAccountingStandard_2147462834" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_549000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_549000" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_549001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_549000" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_549001" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_549003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_549001" xlink:to="loc_ifrs-full_EquityMember_549003" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_549003_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_549001" xlink:to="loc_ifrs-full_EquityMember_549003_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_549530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_IssuedCapitalMember_549530" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_549532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_549532" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_549004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_549004" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_549006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_RetainedEarningsMember_549006" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_549007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_549007" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_549011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_Equity_549011" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_549013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_549013" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_549015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" xlink:to="loc_ifrs-full_ProfitLoss_549015" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_549020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_549020" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_549021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_549021" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_549022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_ComprehensiveIncome_549022" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousComponentsOfEquityAbstract" xlink:label="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1277833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1277833" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_1277834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_1277834" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareIssueCosts" xlink:label="loc_thtx_ShareIssueCosts_1277811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_ShareIssueCosts_1277811" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_1277813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_1277813" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue_1277815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue_1277815" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodValueAcquisitions_1277835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringPeriodValueAcquisitions_1277835" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions_1277836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions_1277836" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueNewIssues_2147462978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodValueNewIssues_2147462978" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues_2147462975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues_2147462975" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities_2147462971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities_2147462971" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities_2147462966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities_2147462966" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xlink:label="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue_2147463311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue_2147463311" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfSharesIssuedThroughAtmProgram" xlink:label="loc_thtx_NumberOfSharesIssuedThroughAtmProgram_2147463305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_NumberOfSharesIssuedThroughAtmProgram_2147463305" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147463317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147463317" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareBasedCompensationPlanAbstract" xlink:label="loc_thtx_ShareBasedCompensationPlanAbstract_549031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_thtx_ShareBasedCompensationPlanAbstract_549031" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_549032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareBasedCompensationPlanAbstract_549031" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_549032" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAbstract" xlink:label="loc_thtx_ExerciseOfStockOptionsAbstract_549033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_thtx_ExerciseOfStockOptionsAbstract_549033" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue_549034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue_549034" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares_549035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares_549035" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAttributedValue" xlink:label="loc_thtx_ExerciseOfStockOptionsAttributedValue_549036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_ExerciseOfStockOptionsAttributedValue_549036" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_549042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_549042" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares_549687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares_549687" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalLineItems" xlink:label="loc_thtx_ShareCapitalLineItems_551015" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities_2147462841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities_2147462841" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalTable" xlink:label="loc_thtx_ShareCapitalTable_551011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_ShareCapitalTable_551011" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_ShareCapitalTable_551011" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_551013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_551013" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_551013_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_551013_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock_572676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock_572676" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock_585341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock_585341" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_585376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_585376" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock_585513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock_585513" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock_585631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock_585631" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock_585632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock_585632" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock_572673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock_572673" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationLineItems" xlink:label="loc_thtx_BasisOfPresentationLineItems_820286" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationTable" xlink:label="loc_thtx_BasisOfPresentationTable_820284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_thtx_BasisOfPresentationTable_820284" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_820288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" xlink:to="loc_ifrs-full_RestatedMember_820288" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_820288_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" xlink:to="loc_ifrs-full_RestatedMember_820288_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147463385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147463385" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147463386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147463385" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147463386" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147463386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147463385" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147463386_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_RangeAxis_2147462970" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2147462970" xlink:to="loc_ifrs-full_RangesMember_2147462969" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2147462970" xlink:to="loc_ifrs-full_RangesMember_2147462969_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462969" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462967" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462969" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462968" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumLiquidityRequirementAmount" xlink:label="loc_thtx_MinimumLiquidityRequirementAmount_2147462972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_thtx_MinimumLiquidityRequirementAmount_2147462972" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRateBasis" xlink:label="loc_ifrs-full_BorrowingsInterestRateBasis_2147462976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_BorrowingsInterestRateBasis_2147462976" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2147463048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2147463048" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_2147463049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_ProfitLoss_2147463049" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_2147462990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_Cash_2147462990" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_2147462989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_2147462989" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_549100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_ComputerEquipmentMember_549100" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaboratoryEquipmentMember" xlink:label="loc_thtx_LaboratoryEquipmentMember_549102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_thtx_LaboratoryEquipmentMember_549102" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_549103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_OfficeEquipmentMember_549103" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_549104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_549104" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment_549105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment_549105" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment_549108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment_549108" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_549110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_549110" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_549109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_549109" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_thtx_StatementTable_549060" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsEgriftaMember" xlink:label="loc_thtx_CommercializationRightsEgriftaMember_549066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_CommercializationRightsEgriftaMember_549066" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoMember_549067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_CommercializationRightsTrogarzoMember_549067" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember_550377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember_550377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember_1306219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember_1306219" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_549068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_549068" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549068" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549069" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549069_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549068" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549069_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_549071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_549069" xlink:to="loc_ifrs-full_OtherAssetsMember_549071" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_2147463016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" xlink:to="loc_ifrs-full_RestatedMember_2147463016" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_2147463016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" xlink:to="loc_ifrs-full_RestatedMember_2147463016_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill_549073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill_549073" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550366" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_549072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_549072" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xlink:label="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets_549074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets_549074" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_584834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_584834" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_584835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_584834" xlink:to="loc_ifrs-full_ProductsAndServicesMember_584835" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_584835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_584834" xlink:to="loc_ifrs-full_ProductsAndServicesMember_584835_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EgriftaMember" xlink:label="loc_thtx_EgriftaMember_584836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_584835" xlink:to="loc_thtx_EgriftaMember_584836" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoNetSalesMember" xlink:label="loc_thtx_TrogarzoNetSalesMember_584838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_584835" xlink:to="loc_thtx_TrogarzoNetSalesMember_584838" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_797437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xlink:to="loc_ifrs-full_GeographicalAreasAxis_797437" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_797438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_797437" xlink:to="loc_ifrs-full_GeographicalAreasMember_797438" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_797438_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_797437" xlink:to="loc_ifrs-full_GeographicalAreasMember_797438_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_797454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_797438" xlink:to="loc_srt_EuropeMember_797454" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_584842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" xlink:to="loc_ifrs-full_Revenue_584842" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaTable" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" xlink:to="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_584864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" xlink:to="loc_ifrs-full_GeographicalAreasAxis_584864" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_584865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_584864" xlink:to="loc_ifrs-full_GeographicalAreasMember_584865" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_584865_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_584864" xlink:to="loc_ifrs-full_GeographicalAreasMember_584865_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_584867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_country_CA_584867" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_584869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_country_US_584869" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_584872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_srt_EuropeMember_584872" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_584874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" xlink:to="loc_ifrs-full_Revenue_584874" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsStatedInterestPercentage" xlink:label="loc_thtx_FinancialAssetsStatedInterestPercentage_550130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" xlink:to="loc_thtx_FinancialAssetsStatedInterestPercentage_550130" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsAverageMaturityTerm" xlink:label="loc_thtx_FinancialAssetsAverageMaturityTerm_550131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" xlink:to="loc_thtx_FinancialAssetsAverageMaturityTerm_550131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_550133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" xlink:to="loc_thtx_StatementTable_550133" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_550134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_550133" xlink:to="loc_ifrs-full_RangeAxis_550134" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_550134" xlink:to="loc_ifrs-full_RangesMember_550137" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550137_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_550134" xlink:to="loc_ifrs-full_RangesMember_550137_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_550138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_550137" xlink:to="loc_ifrs-full_BottomOfRangeMember_550138" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_550139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_550137" xlink:to="loc_ifrs-full_TopOfRangeMember_550139" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xlink:label="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_818853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_818853" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_818855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_818855" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xlink:label="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss_818856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss_818856" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceived" xlink:label="loc_thtx_TaxCreditsAndGrantsReceived_1305948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsReceived_1305948" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable_818857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable_818857" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementLineItems" xlink:label="loc_thtx_StatementLineItems_550217" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_StatementLineItems_550217" xlink:to="loc_thtx_StatementTable_549384" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_549390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549384" xlink:to="loc_ifrs-full_MaturityAxis_549390" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_549390" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549401" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549401_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_549390" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549401_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember_549406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember_549406" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember_549407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember_549407" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySixMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember_549409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember_549409" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember_549410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember_549410" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember_549412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember_549412" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember_549417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember_549417" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember_549422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember_549422" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember_549427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember_549427" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember_549430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember_549430" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember_549437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember_549437" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember_836979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember_836979" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyMember_836983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyMember_836983" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember_1305951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember_1305951" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember_2147468377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember_2147468377" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember_2147462988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember_2147462988" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549384" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnusedAndUnrecordedTaxCreditsMember" xlink:label="loc_thtx_UnusedAndUnrecordedTaxCreditsMember_549905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" xlink:to="loc_thtx_UnusedAndUnrecordedTaxCreditsMember_549905" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_550218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550217" xlink:to="loc_ifrs-full_DeferredTaxAssets_550218" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/InventoriesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementLineItems" xlink:label="loc_thtx_StatementLineItems_550220" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_StatementTable_549958" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementAxis" xlink:label="loc_thtx_LocationInIncomeStatementAxis_549963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549958" xlink:to="loc_thtx_LocationInIncomeStatementAxis_549963" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementDomain" xlink:label="loc_thtx_LocationInIncomeStatementDomain_549965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_LocationInIncomeStatementAxis_549963" xlink:to="loc_thtx_LocationInIncomeStatementDomain_549965" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementDomain" xlink:label="loc_thtx_LocationInIncomeStatementDomain_549965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_LocationInIncomeStatementAxis_549963" xlink:to="loc_thtx_LocationInIncomeStatementDomain_549965_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CostOfGoodsSoldMember" xlink:label="loc_thtx_CostOfGoodsSoldMember_549968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_LocationInIncomeStatementDomain_549965" xlink:to="loc_thtx_CostOfGoodsSoldMember_549968" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_StatementTable_549958" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaiMedBiologicsInc.Member" xlink:label="loc_thtx_TaiMedBiologicsInc.Member_2147462959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" xlink:to="loc_thtx_TaiMedBiologicsInc.Member_2147462959" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_2147462963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_2147462963" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InventoriesReturned" xlink:label="loc_thtx_InventoriesReturned_2147462962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_InventoriesReturned_2147462962" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2147462961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2147462961" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="loc_ifrs-full_InventoryWritedown2011_550221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_InventoryWritedown2011_550221" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForFormulation" xlink:label="loc_thtx_ProvisionForFormulation_2147468517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForFormulation_2147468517" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheInventoryInDevelopment" xlink:label="loc_thtx_ProvisionForTheInventoryInDevelopment_2147468561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForTheInventoryInDevelopment_2147468561" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheExpiredRawMaterial" xlink:label="loc_thtx_ProvisionForTheExpiredRawMaterial_2147468564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForTheExpiredRawMaterial_2147468564" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForExcessStock" xlink:label="loc_thtx_ProvisionForExcessStock_836974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForExcessStock_836974" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_549703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_ComputerEquipmentMember_549703" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaboratoryEquipmentMember" xlink:label="loc_thtx_LaboratoryEquipmentMember_549704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_thtx_LaboratoryEquipmentMember_549704" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_549705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_OfficeEquipmentMember_549705" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_549706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_549706" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_549732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" xlink:to="loc_ifrs-full_CarryingAmountMember_549732" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_549732_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" xlink:to="loc_ifrs-full_CarryingAmountMember_549732_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_550822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_549732" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_550822" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_549736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_549732" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_549736" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_549769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_549769" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_549753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_549753" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_549750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_549750" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xlink:label="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_549778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_549778" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_549755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_549755" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xlink:label="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment_549756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment_549756" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountAbstract" xlink:label="loc_thtx_NetCarryingAmountAbstract_549764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_thtx_NetCarryingAmountAbstract_549764" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" xlink:to="loc_ifrs-full_CarryingAmountMember_550234" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550234_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" xlink:to="loc_ifrs-full_CarryingAmountMember_550234_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_550852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_550852" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_550235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_550235" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountMember" xlink:label="loc_thtx_NetCarryingAmountMember_550236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_thtx_NetCarryingAmountMember_550236" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550260" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoEuropeMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoEuropeMember_550261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsTrogarzoEuropeMember_550261" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsEgriftaMember" xlink:label="loc_thtx_CommercializationRightsEgriftaMember_550263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsEgriftaMember_550263" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OncologyPlatformMember" xlink:label="loc_thtx_OncologyPlatformMember_585296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_OncologyPlatformMember_585296" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549249" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585293" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2147462955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2147462955" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationAbstract" xlink:label="loc_thtx_AccumulatedAmortizationAbstract_549414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_thtx_AccumulatedAmortizationAbstract_549414" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550229" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_549276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_549276" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill_2147462839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill_2147462839" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountAbstract" xlink:label="loc_thtx_NetCarryingAmountAbstract_549440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_thtx_NetCarryingAmountAbstract_549440" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAxis" xlink:label="loc_thtx_MilestoneAxis_550274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xlink:to="loc_thtx_MilestoneAxis_550274" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_MilestoneAxis_550274" xlink:to="loc_thtx_MilestoneDomain_550276" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_MilestoneAxis_550274" xlink:to="loc_thtx_MilestoneDomain_550276_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFourMember" xlink:label="loc_thtx_MilestoneFourMember_550280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneFourMember_550280" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFiveMember" xlink:label="loc_thtx_MilestoneFiveMember_550281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneFiveMember_550281" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneSixMember" xlink:label="loc_thtx_MilestoneSixMember_550282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneSixMember_550282" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xlink:to="loc_thtx_TypeOfArrangementsAxis_550309" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementsAxis_550309" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550310" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementsAxis_550309" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550310_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayable" xlink:label="loc_thtx_InitialMilestonePaymentsPayable_550273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" xlink:to="loc_thtx_InitialMilestonePaymentsPayable_550273" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_TypeOfArrangementsAxis_550442" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementsAxis_550442" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550443" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550443_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementsAxis_550442" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550443_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaimedAgreementMember" xlink:label="loc_thtx_TaimedAgreementMember_550444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550443" xlink:to="loc_thtx_TaimedAgreementMember_550444" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LicenseAgreementTransferPlusLPMember" xlink:label="loc_thtx_LicenseAgreementTransferPlusLPMember_585051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550443" xlink:to="loc_thtx_LicenseAgreementTransferPlusLPMember_585051" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_585054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_585054" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585054" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585054" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaMember" xlink:label="loc_thtx_KatanaMember_585057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" xlink:to="loc_thtx_KatanaMember_585057" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaAmendmentAgreementMember" xlink:label="loc_thtx_KatanaAmendmentAgreementMember_585101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" xlink:to="loc_thtx_KatanaAmendmentAgreementMember_585101" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" xlink:to="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550449" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoMember_550463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" xlink:to="loc_thtx_CommercializationRightsTrogarzoMember_550463" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550553" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550553_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_550554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_550553" xlink:to="loc_ifrs-full_OrdinarySharesMember_550554" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheAxis" xlink:label="loc_thtx_TrancheAxis_550556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_TrancheAxis_550556" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheDomain" xlink:label="loc_thtx_TrancheDomain_550557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TrancheAxis_550556" xlink:to="loc_thtx_TrancheDomain_550557" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheDomain" xlink:label="loc_thtx_TrancheDomain_550557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TrancheAxis_550556" xlink:to="loc_thtx_TrancheDomain_550557_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_550561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_RangeAxis_550561" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_550561" xlink:to="loc_ifrs-full_RangesMember_550563" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_550561" xlink:to="loc_ifrs-full_RangesMember_550563_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_550564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_550563" xlink:to="loc_ifrs-full_TopOfRangeMember_550564" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_585190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_550563" xlink:to="loc_ifrs-full_BottomOfRangeMember_585190" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosAxis" xlink:label="loc_thtx_ScenariosAxis_550567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_ScenariosAxis_550567" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosDomain" xlink:label="loc_thtx_ScenariosDomain_550568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_ScenariosAxis_550567" xlink:to="loc_thtx_ScenariosDomain_550568" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosDomain" xlink:label="loc_thtx_ScenariosDomain_550568_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_ScenariosAxis_550567" xlink:to="loc_thtx_ScenariosDomain_550568_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAxis" xlink:label="loc_thtx_MilestoneAxis_550578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_MilestoneAxis_550578" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_MilestoneAxis_550578" xlink:to="loc_thtx_MilestoneDomain_550579" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_MilestoneAxis_550578" xlink:to="loc_thtx_MilestoneDomain_550579_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneOneMember" xlink:label="loc_thtx_MilestoneOneMember_585027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_MilestoneOneMember_585027" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestonePhaseTwoLiveDemonstrationMember" xlink:label="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember_585063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember_585063" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember_585211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember_585211" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember_585212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember_585212" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember_585213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember_585213" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_550586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_GeographicalAreasAxis_550586" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_550587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_550586" xlink:to="loc_ifrs-full_GeographicalAreasMember_550587" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_550587_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_550586" xlink:to="loc_ifrs-full_GeographicalAreasMember_550587_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_550591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_550587" xlink:to="loc_srt_EuropeMember_550591" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_550597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_550597" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_550598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_550597" xlink:to="loc_ifrs-full_ProductsAndServicesMember_550598" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_550598_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_550597" xlink:to="loc_ifrs-full_ProductsAndServicesMember_550598_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoMember" xlink:label="loc_thtx_TrogarzoMember_550602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_550598" xlink:to="loc_thtx_TrogarzoMember_550602" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesAxis" xlink:label="loc_thtx_NatureOfFeesAxis_585153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_NatureOfFeesAxis_585153" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesMember" xlink:label="loc_thtx_NatureOfFeesMember_585155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_NatureOfFeesAxis_585153" xlink:to="loc_thtx_NatureOfFeesMember_585155" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesMember" xlink:label="loc_thtx_NatureOfFeesMember_585155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_NatureOfFeesAxis_585153" xlink:to="loc_thtx_NatureOfFeesMember_585155_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRelatedLicensePeptidesMember" xlink:label="loc_thtx_RoyaltyRelatedLicensePeptidesMember_585157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_NatureOfFeesMember_585155" xlink:to="loc_thtx_RoyaltyRelatedLicensePeptidesMember_585157" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodAxis" xlink:label="loc_thtx_FeesPeriodAxis_585159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_FeesPeriodAxis_585159" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodMember" xlink:label="loc_thtx_FeesPeriodMember_585161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_FeesPeriodAxis_585159" xlink:to="loc_thtx_FeesPeriodMember_585161" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodMember" xlink:label="loc_thtx_FeesPeriodMember_585161_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_FeesPeriodAxis_585159" xlink:to="loc_thtx_FeesPeriodMember_585161_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstFiveYearsMember" xlink:label="loc_thtx_FirstFiveYearsMember_585162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_FeesPeriodMember_585161" xlink:to="loc_thtx_FirstFiveYearsMember_585162" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AfterFiveYearsMember" xlink:label="loc_thtx_AfterFiveYearsMember_585165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_FeesPeriodMember_585161" xlink:to="loc_thtx_AfterFiveYearsMember_585165" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentAxis" xlink:label="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentMember" xlink:label="loc_thtx_BasisOfRoyaltyPaymentMember_585179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" xlink:to="loc_thtx_BasisOfRoyaltyPaymentMember_585179" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentMember" xlink:label="loc_thtx_BasisOfRoyaltyPaymentMember_585179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" xlink:to="loc_thtx_BasisOfRoyaltyPaymentMember_585179_default" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetSalesBasisMember" xlink:label="loc_thtx_NetSalesBasisMember_585181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfRoyaltyPaymentMember_585179" xlink:to="loc_thtx_NetSalesBasisMember_585181" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRevenueSublicenseBasisMember" xlink:label="loc_thtx_RoyaltyRevenueSublicenseBasisMember_585183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BasisOfRoyaltyPaymentMember_585179" xlink:to="loc_thtx_RoyaltyRevenueSublicenseBasisMember_585183" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" xlink:to="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" xlink:to="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember_585124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" xlink:to="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember_585124" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember_585130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" xlink:to="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember_585130" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IntangibleAssetsAgreementTermOfContract" xlink:label="loc_thtx_IntangibleAssetsAgreementTermOfContract_550417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_IntangibleAssetsAgreementTermOfContract_550417" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xlink:label="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets_550422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets_550422" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_550431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AmortisationExpense_550431" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayable" xlink:label="loc_thtx_InitialMilestonePaymentsPayable_550481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_InitialMilestonePaymentsPayable_550481" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentOfUpfrontMilestones" xlink:label="loc_thtx_PaymentOfUpfrontMilestones_550486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_PaymentOfUpfrontMilestones_550486" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_FirstMilestoneInstallmentPaymentsPayable_2147463000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_FirstMilestoneInstallmentPaymentsPayable_2147463000" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecondMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_SecondMilestoneInstallmentPaymentsPayable_2147462999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_SecondMilestoneInstallmentPaymentsPayable_2147462999" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_550531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfSharesIssued_550531" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550532" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AcquisitionCostsForIntangibleAssets" xlink:label="loc_thtx_AcquisitionCostsForIntangibleAssets_550539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AcquisitionCostsForIntangibleAssets_550539" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_550540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_Revenue_550540" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaunchMilestonePayable" xlink:label="loc_thtx_LaunchMilestonePayable_550541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_LaunchMilestonePayable_550541" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePayableAnnualInstallment" xlink:label="loc_thtx_DevelopmentMilestonePayableAnnualInstallment_550547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_DevelopmentMilestonePayableAnnualInstallment_550547" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment_550941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment_550941" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment_550942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment_550942" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAmountPayable" xlink:label="loc_thtx_MilestoneAmountPayable_585006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_MilestoneAmountPayable_585006" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_585047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_585047" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585064" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_585066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_CashTransferred_585066" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_585067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_585067" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_585068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_585068" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_585070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_585070" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationContingentConsiderationFairValue" xlink:label="loc_thtx_BusinessCombinationContingentConsiderationFairValue_585072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_BusinessCombinationContingentConsiderationFairValue_585072" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xlink:label="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration_585091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration_585091" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities_585093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities_585093" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_585147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_585147" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyFeesAsAPercentageOfRevenue" xlink:label="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue_585174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue_585174" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RegulatoryMilestonePaymentPayable" xlink:label="loc_thtx_RegulatoryMilestonePaymentPayable_585224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_RegulatoryMilestonePaymentPayable_585224" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277921" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2147463012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2147463012" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xlink:label="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments._2147463456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments._2147463456" use="optional" order="97" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:label="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" xlink:to="loc_ifrs-full_CarryingAmountMember_550769" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" xlink:to="loc_ifrs-full_CarryingAmountMember_550769_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ReconciliationOfChangesInOtherAssetsAbstract" xlink:label="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAssetsNonCurrentAtCost" xlink:label="loc_thtx_OtherAssetsNonCurrentAtCost_550744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" xlink:to="loc_thtx_OtherAssetsNonCurrentAtCost_550744" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" xlink:to="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550760" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherNonCurrentAssets" xlink:label="loc_thtx_AmortizationOfOtherNonCurrentAssets_550763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" xlink:to="loc_thtx_AmortizationOfOtherNonCurrentAssets_550763" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmount" xlink:label="loc_thtx_NetCarryingAmount_550767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_NetCarryingAmount_550767" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAssetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:label="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_550063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_ifrs-full_CounterpartiesAxis_550063" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_550064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_550063" xlink:to="loc_ifrs-full_CounterpartiesMember_550064" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_550064_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_550063" xlink:to="loc_ifrs-full_CounterpartiesMember_550064_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeronoIncMember" xlink:label="loc_thtx_SeronoIncMember_550065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_550064" xlink:to="loc_thtx_SeronoIncMember_550065" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementAxis" xlink:label="loc_thtx_TypeOfArrangementAxis_550571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_thtx_TypeOfArrangementAxis_550571" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_550572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementAxis_550571" xlink:to="loc_thtx_TypeOfArrangementMember_550572" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_550572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementAxis_550571" xlink:to="loc_thtx_TypeOfArrangementMember_550572_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandThirteenTerminationAgreementMember" xlink:label="loc_thtx_TwoThousandThirteenTerminationAgreementMember_550574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TypeOfArrangementMember_550572" xlink:to="loc_thtx_TwoThousandThirteenTerminationAgreementMember_550574" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_550784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_ifrs-full_MaturityAxis_550784" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_550785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_550784" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_550785" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_550785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_550784" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_550785_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueWithOneYearMember" xlink:label="loc_thtx_DueWithOneYearMember_550786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_550785" xlink:to="loc_thtx_DueWithOneYearMember_550786" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueInNextFourToFiveYearsMember" xlink:label="loc_thtx_DueInNextFourToFiveYearsMember_550787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_550785" xlink:to="loc_thtx_DueInNextFourToFiveYearsMember_550787" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ContractualObligations" xlink:label="loc_thtx_ContractualObligations_603122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" xlink:to="loc_thtx_ContractualObligations_603122" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PerformanceObligationFinalSettlementAmount" xlink:label="loc_thtx_PerformanceObligationFinalSettlementAmount_550783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" xlink:to="loc_thtx_PerformanceObligationFinalSettlementAmount_550783" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesLineItems" xlink:label="loc_thtx_TradeAndOtherPayablesLineItems_549910" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesTable" xlink:label="loc_thtx_TradeAndOtherPayablesTable_549907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_thtx_TradeAndOtherPayablesTable_549907" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_549911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_549911" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_549912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_549912" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_549914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_549914" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_549916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_549916" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_549917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_549917" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestPayable" xlink:label="loc_ifrs-full_CurrentInterestPayable_549918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_CurrentInterestPayable_549918" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_2147463480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_OtherCurrentPayables_2147463480" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_549919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_549919" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_549786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_549786" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_549863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_549786" xlink:to="loc_ifrs-full_OtherProvisionsMember_549863" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_549863_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_549786" xlink:to="loc_ifrs-full_OtherProvisionsMember_549863_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChargebacksAndRebatesMember" xlink:label="loc_thtx_ChargebacksAndRebatesMember_549866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_thtx_ChargebacksAndRebatesMember_549866" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RefundsProvisionMember" xlink:label="loc_ifrs-full_RefundsProvisionMember_549864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_ifrs-full_RefundsProvisionMember_549864" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAdditionalProvisionMember" xlink:label="loc_thtx_OtherAdditionalProvisionMember_585252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_thtx_OtherAdditionalProvisionMember_585252" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_549796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_OtherShorttermProvisions_549796" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_549799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_549799" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_549800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_549800" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_549801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_549801" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_2147462838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_2147462838" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_2147462945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_2147462945" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_2147462945_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_2147462945_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeveranceAndOtherExpensesMember" xlink:label="loc_thtx_SeveranceAndOtherExpensesMember_2147462835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_SeveranceAndOtherExpensesMember_2147462835" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_thtx_ResearchAndDevelopmentExpenseMember_2147462944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_ResearchAndDevelopmentExpenseMember_2147462944" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SellingAndMarketingExpenseMember" xlink:label="loc_thtx_SellingAndMarketingExpenseMember_2147462943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_SellingAndMarketingExpenseMember_2147462943" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_thtx_GeneralAndAdministrativeExpenseMember_2147462942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_GeneralAndAdministrativeExpenseMember_2147462942" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xlink:label="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance_2147462760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance_2147462760" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xlink:label="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent_2147462761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent_2147462761" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462762" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462763" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConsiderationPayable" xlink:label="loc_thtx_ConsiderationPayable_2147462765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_ConsiderationPayable_2147462765" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinanceCostsWriteOff" xlink:label="loc_thtx_DeferredFinanceCostsWriteOff_2147462826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DeferredFinanceCostsWriteOff_2147462826" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentAmortizedValue" xlink:label="loc_thtx_DebtInstrumentAmortizedValue_2147462925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentAmortizedValue_2147462925" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmountReclassifiedFromDeferredFinancingCosts" xlink:label="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts_2147462926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts_2147462926" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRateBasis" xlink:label="loc_ifrs-full_BorrowingsInterestRateBasis_2147463032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsInterestRateBasis_2147463032" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmount" xlink:label="loc_thtx_DebtInstrumentCollateralAmount_2147463033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentCollateralAmount_2147463033" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xlink:label="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained_2147463008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained_2147463008" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147464776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147464776" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147464776" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466055" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147464776" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466055_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityMember" xlink:label="loc_thtx_LoanFacilityMember_2147466056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityMember_2147466056" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1LoanMember_2147462802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche1LoanMember_2147462802" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche2LoanMember_2147466098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche2LoanMember_2147466098" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3LoanMember_2147466095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche3LoanMember_2147466095" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche4LoanMember_2147466094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche4LoanMember_2147466094" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1And2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1And2LoanMember_2147466062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche1And2LoanMember_2147466062" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3And4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3And4LoanMember_2147462825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche3And4LoanMember_2147462825" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2147466064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" xlink:to="loc_ifrs-full_InterestRateTypesMember_2147466064" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2147466064_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" xlink:to="loc_ifrs-full_InterestRateTypesMember_2147466064_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateMember_2147466065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_2147466064" xlink:to="loc_thtx_SecuredOvernightFinancingRateMember_2147466065" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463006" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463006_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xlink:label="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember_2147463005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2147463006" xlink:to="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember_2147463005" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_RangeAxis_2147462932" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2147462932" xlink:to="loc_ifrs-full_RangesMember_2147462931" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2147462932" xlink:to="loc_ifrs-full_RangesMember_2147462931_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462931" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462929" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462931" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462930" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementAxis" xlink:label="loc_thtx_TypeOfArrangementAxis_2147462924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_thtx_TypeOfArrangementAxis_2147462924" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_2147462923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementAxis_2147462924" xlink:to="loc_thtx_TypeOfArrangementMember_2147462923" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_2147462923_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementAxis_2147462924" xlink:to="loc_thtx_TypeOfArrangementMember_2147462923_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentMember" xlink:label="loc_thtx_FifthAmendmentMember_2147462922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TypeOfArrangementMember_2147462923" xlink:to="loc_thtx_FifthAmendmentMember_2147462922" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_2147462919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" xlink:to="loc_ifrs-full_EquityMember_2147462919" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_2147462919_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" xlink:to="loc_ifrs-full_EquityMember_2147462919_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_2147462912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" xlink:to="loc_ifrs-full_OrdinarySharesMember_2147462912" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity_2147466034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity_2147466034" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147466036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147466036" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2147466038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_NotionalAmount_2147466038" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity_2147466043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsMaturity_2147466043" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsInterestPeriod" xlink:label="loc_thtx_BorrowingsInterestPeriod_2147466048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_BorrowingsInterestPeriod_2147466048" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate_2147466080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsInterestRate_2147466080" use="optional" order="52" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147465413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147465413" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_2147465414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_2147465414" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsAccretionExpense" xlink:label="loc_thtx_BorrowingsAccretionExpense_2147465415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_thtx_BorrowingsAccretionExpense_2147465415" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromConsiderationOfTheFifthAmendment" xlink:label="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment_2147462933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment_2147462933" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147466051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147466051" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147466051" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466053" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466053_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147466051" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466053_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityMember" xlink:label="loc_thtx_LoanFacilityMember_2147466054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_LoanFacilityMember_2147466054" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTrancheTwoLoanMember" xlink:label="loc_thtx_LoanFacilityTrancheTwoLoanMember_2147462935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_LoanFacilityTrancheTwoLoanMember_2147462935" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_MarathonWarrantsMember_2147462934" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="loc_ifrs-full_LoansReceived_2147462759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_LoansReceived_2147462759" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived_2147462758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived_2147462758" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2147462757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2147462757" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_572867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" xlink:to="loc_ifrs-full_LiabilitiesMember_572867" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_572867_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" xlink:to="loc_ifrs-full_LiabilitiesMember_572867_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_572867" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462939" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_550298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_550298" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_550299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_550298" xlink:to="loc_ifrs-full_EquityMember_550299" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_550299_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_550298" xlink:to="loc_ifrs-full_EquityMember_550299_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleInstrumentsNumberOfSharesIssued" xlink:label="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued_550192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued_550192" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462938" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_2147464143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_2147464143" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_550093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" xlink:to="loc_ifrs-full_LiabilitiesMember_550093" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_550093_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" xlink:to="loc_ifrs-full_LiabilitiesMember_550093_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LiabilityComponentMember" xlink:label="loc_thtx_LiabilityComponentMember_550096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_550093" xlink:to="loc_thtx_LiabilityComponentMember_550096" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_550084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_550084" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpense" xlink:label="loc_thtx_AccretionExpense_550078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_thtx_AccretionExpense_550078" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChangesFromFinancingCashFlowsAbstract" xlink:label="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463486" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" xlink:to="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463489" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" xlink:to="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463495" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462940" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueAxis" xlink:label="loc_thtx_SchemeOfShareIssueAxis_550653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_SchemeOfShareIssueAxis_550653" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueDomain" xlink:label="loc_thtx_SchemeOfShareIssueDomain_550654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_SchemeOfShareIssueAxis_550653" xlink:to="loc_thtx_SchemeOfShareIssueDomain_550654" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueDomain" xlink:label="loc_thtx_SchemeOfShareIssueDomain_550654_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_SchemeOfShareIssueAxis_550653" xlink:to="loc_thtx_SchemeOfShareIssueDomain_550654_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_TypeOfArrangementsAxis_550679" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementsAxis_550679" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550680" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550680_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementsAxis_550679" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550680_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentMember" xlink:label="loc_thtx_FifthAmendmentMember_2147462752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550680" xlink:to="loc_thtx_FifthAmendmentMember_2147462752" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_550850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_550850" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_550850_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_550850_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_572839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_MeasurementAxis_572839" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_572840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_572839" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_572840" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_572840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_572839" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_572840_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsAxis" xlink:label="loc_thtx_CategoryOfBorrowingsAxis_550712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_CategoryOfBorrowingsAxis_550712" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsDomain" xlink:label="loc_thtx_CategoryOfBorrowingsDomain_550713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_CategoryOfBorrowingsAxis_550712" xlink:to="loc_thtx_CategoryOfBorrowingsDomain_550713" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsDomain" xlink:label="loc_thtx_CategoryOfBorrowingsDomain_550713_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_CategoryOfBorrowingsAxis_550712" xlink:to="loc_thtx_CategoryOfBorrowingsDomain_550713_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventAxis" xlink:label="loc_thtx_EventAxis_550965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_EventAxis_550965" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventDomain" xlink:label="loc_thtx_EventDomain_550966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_EventAxis_550965" xlink:to="loc_thtx_EventDomain_550966" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventDomain" xlink:label="loc_thtx_EventDomain_550966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_EventAxis_550965" xlink:to="loc_thtx_EventDomain_550966_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanAxis" xlink:label="loc_thtx_PlanAxis_550707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_PlanAxis_550707" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_550708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_PlanAxis_550707" xlink:to="loc_thtx_PlanDomain_550708" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_550708_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_PlanAxis_550707" xlink:to="loc_thtx_PlanDomain_550708_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandAndSixteenShareholdersPlanMember" xlink:label="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember_550709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember_550709" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockOptionPlanTwoThousandAndNineteenMember" xlink:label="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember_550710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember_550710" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsMember" xlink:label="loc_thtx_StockAppreciationRightsMember_585260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_StockAppreciationRightsMember_585260" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" xlink:to="loc_ifrs-full_FinancialAssetsMember_550693" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" xlink:to="loc_ifrs-full_FinancialAssetsMember_550693_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashSettledForwardContractsMember" xlink:label="loc_thtx_CashSettledForwardContractsMember_550694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_550693" xlink:to="loc_thtx_CashSettledForwardContractsMember_550694" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredStockUnitsMember" xlink:label="loc_thtx_DeferredStockUnitsMember_550691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" xlink:to="loc_thtx_DeferredStockUnitsMember_550691" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameAxis" xlink:label="loc_thtx_ProgramNameAxis_1277961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_ProgramNameAxis_1277961" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_1277962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_ProgramNameAxis_1277961" xlink:to="loc_thtx_ProgramNameMember_1277962" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_1277962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_ProgramNameAxis_1277961" xlink:to="loc_thtx_ProgramNameMember_1277962_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AtmProgramMember" xlink:label="loc_thtx_AtmProgramMember_1277965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ProgramNameMember_1277962" xlink:to="loc_thtx_AtmProgramMember_1277965" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementAxis" xlink:label="loc_thtx_AgreementAxis_2147462882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_AgreementAxis_2147462882" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementMember" xlink:label="loc_thtx_AgreementMember_2147462881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_AgreementAxis_2147462882" xlink:to="loc_thtx_AgreementMember_2147462881" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementMember" xlink:label="loc_thtx_AgreementMember_2147462881_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_AgreementAxis_2147462882" xlink:to="loc_thtx_AgreementMember_2147462881_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentOfTheLoanFacilityMember" xlink:label="loc_thtx_FifthAmendmentOfTheLoanFacilityMember_2147462880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_AgreementMember_2147462881" xlink:to="loc_thtx_FifthAmendmentOfTheLoanFacilityMember_2147462880" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887_default" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462886" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550495" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550495_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550495_default" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_550525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_550495" xlink:to="loc_ifrs-full_OrdinarySharesMember_550525" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_585275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_585275" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585275" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585275" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaMember" xlink:label="loc_thtx_KatanaMember_585278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" xlink:to="loc_thtx_KatanaMember_585278" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsAxis" xlink:label="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonVotingSubscriptionReceiptsMember" xlink:label="loc_thtx_NonVotingSubscriptionReceiptsMember_2147462897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" xlink:to="loc_thtx_NonVotingSubscriptionReceiptsMember_2147462897" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" xlink:to="loc_thtx_MarathonWarrantsMember_2147462893" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeAxis" xlink:label="loc_thtx_InvesteeAxis_2147462903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_InvesteeAxis_2147462903" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeMember" xlink:label="loc_thtx_InvesteeMember_2147462901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_InvesteeAxis_2147462903" xlink:to="loc_thtx_InvesteeMember_2147462901" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeMember" xlink:label="loc_thtx_InvesteeMember_2147462901_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_InvesteeAxis_2147462903" xlink:to="loc_thtx_InvesteeMember_2147462901_default" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvestmentQuebecMember" xlink:label="loc_thtx_InvestmentQuebecMember_2147462900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_InvesteeMember_2147462901" xlink:to="loc_thtx_InvestmentQuebecMember_2147462900" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AffiliatesOfMarathonAssetManagementMember" xlink:label="loc_thtx_AffiliatesOfMarathonAssetManagementMember_2147462892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_InvesteeMember_2147462901" xlink:to="loc_thtx_AffiliatesOfMarathonAssetManagementMember_2147462892" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalAxis" xlink:label="loc_thtx_IssuedCapitalAxis_1277928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_IssuedCapitalAxis_1277928" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalDomain" xlink:label="loc_thtx_IssuedCapitalDomain_1308330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_IssuedCapitalAxis_1277928" xlink:to="loc_thtx_IssuedCapitalDomain_1308330" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalDomain" xlink:label="loc_thtx_IssuedCapitalDomain_1308330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_IssuedCapitalAxis_1277928" xlink:to="loc_thtx_IssuedCapitalDomain_1308330_default" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicOfferingMember" xlink:label="loc_thtx_PublicOfferingMember_1277931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_PublicOfferingMember_1277931" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OverallotmentMember" xlink:label="loc_thtx_OverallotmentMember_2147462842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_OverallotmentMember_2147462842" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrivatePlacementMember" xlink:label="loc_thtx_PrivatePlacementMember_2147462904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_PrivatePlacementMember_2147462904" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommonStockConversionBasis" xlink:label="loc_thtx_CommonStockConversionBasis_1277940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_CommonStockConversionBasis_1277940" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightOutstanding" xlink:label="loc_thtx_ClassOfWarrantOrRightOutstanding_1277946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightOutstanding_1277946" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1277948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1277948" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277923" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_585254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ParValuePerShare_585254" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1277925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1277925" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod_2147462885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod_2147462885" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:label="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare_2147462896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare_2147462896" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xlink:label="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants_2147462895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants_2147462895" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_2147466137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_2147466137" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsWrittenDown" xlink:label="loc_thtx_DeferredFinancingCostsWrittenDown_2147462867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DeferredFinancingCostsWrittenDown_2147462867" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_550717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfSharesIssued_550717" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_1277949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_IssuedCapital_1277949" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TermOfWarrants" xlink:label="loc_thtx_TermOfWarrants_2147462884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TermOfWarrants_2147462884" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsOutstanding" xlink:label="loc_thtx_ClassOfWarrantsOrRightsOutstanding_2147462869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantsOrRightsOutstanding_2147462869" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnDebtModification" xlink:label="loc_thtx_GainLossOnDebtModification_2147462883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_GainLossOnDebtModification_2147462883" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseInTheFairValueOfLiabilityRecorded" xlink:label="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded_2147462879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded_2147462879" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently_2147462878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently_2147462878" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsOfWarrantsIssued" xlink:label="loc_thtx_TransactionCostsOfWarrantsIssued_2147462877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TransactionCostsOfWarrantsIssued_2147462877" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsAllocatedToTheLoanFacility" xlink:label="loc_thtx_TransactionCostsAllocatedToTheLoanFacility_2147462876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TransactionCostsAllocatedToTheLoanFacility_2147462876" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsOnTheLoanFacility" xlink:label="loc_thtx_DeferredFinancingCostsOnTheLoanFacility_2147462875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DeferredFinancingCostsOnTheLoanFacility_2147462875" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction_1277955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction_1277955" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_550745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_550745" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_550755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_550755" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_550749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_550749" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_550750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_550750" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfCashSettledForwardStockContractsOutstanding" xlink:label="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding_550716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding_550716" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xlink:label="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts_2147463029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts_2147463029" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xlink:label="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging_550754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging_550754" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsContractualLife" xlink:label="loc_thtx_StockAppreciationRightsContractualLife_610553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_StockAppreciationRightsContractualLife_610553" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550761" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xlink:label="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding_2147462865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding_2147462865" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_550764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_550764" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xlink:label="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares_550770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares_550770" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_550774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProfitLoss_550774" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_550776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_550776" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares_1303086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares_1303086" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xlink:label="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants_2147462862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants_2147462862" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xlink:label="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions_603436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions_603436" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462754" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462755" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipHoldingCommonShares" xlink:label="loc_thtx_PercentageOfOwnershipHoldingCommonShares_2147462810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PercentageOfOwnershipHoldingCommonShares_2147462810" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipOfTheInvestor" xlink:label="loc_thtx_PercentageOfOwnershipOfTheInvestor_2147462811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PercentageOfOwnershipOfTheInvestor_2147462811" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExpirationDate" xlink:label="loc_thtx_ClassOfWarrantOrRightExpirationDate_2147462812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightExpirationDate_2147462812" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2147462814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2147462814" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:label="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised_2147462815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised_2147462815" use="optional" order="119" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462856" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" xlink:to="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462849" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462849" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462848" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462848_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462849" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462848_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_2147462847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_2147462847" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462846" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AverageOptionLifeMember" xlink:label="loc_thtx_AverageOptionLifeMember_2147462845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_AverageOptionLifeMember_2147462845" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SharePriceMember" xlink:label="loc_thtx_SharePriceMember_2147462844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_SharePriceMember_2147462844" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceToAcquireOneCommonShareMember" xlink:label="loc_thtx_ExercisePriceToAcquireOneCommonShareMember_2147462843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_ExercisePriceToAcquireOneCommonShareMember_2147462843" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462850" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsAxis" xlink:label="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" xlink:to="loc_thtx_MarathonWarrantsMember_2147462853" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanAxis" xlink:label="loc_thtx_PlanAxis_585362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" xlink:to="loc_thtx_PlanAxis_585362" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_585364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_PlanAxis_585362" xlink:to="loc_thtx_PlanDomain_585364" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_585364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_PlanAxis_585362" xlink:to="loc_thtx_PlanDomain_585364_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsMember" xlink:label="loc_thtx_StockAppreciationRightsMember_585366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_PlanDomain_585364" xlink:to="loc_thtx_StockAppreciationRightsMember_585366" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550156" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550157" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550158" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610593" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550160" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_550198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_550198" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550199" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_818909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_818909" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1279261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1279261" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_550208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_550208" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_550243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_550243" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550242" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_550214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_550214" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_821284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_821284" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1279265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1279265" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_821273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" xlink:to="loc_srt_CurrencyAxis_821273" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_821273" xlink:to="loc_currency_AllCurrenciesDomain_821274" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821274_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_821273" xlink:to="loc_currency_AllCurrenciesDomain_821274_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_821275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_821274" xlink:to="loc_currency_CAD_821275" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_821322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_821274" xlink:to="loc_country_US_821322" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_550216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_550216" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_550248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_550248" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceOneMember" xlink:label="loc_thtx_ExercisePriceOneMember_550283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceOneMember_550283" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceTwoMember" xlink:label="loc_thtx_ExercisePriceTwoMember_550284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceTwoMember_550284" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceThreeMember" xlink:label="loc_thtx_ExercisePriceThreeMember_550285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceThreeMember_550285" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFourMember" xlink:label="loc_thtx_ExercisePriceFourMember_550286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceFourMember_550286" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFiveMember" xlink:label="loc_thtx_ExercisePriceFiveMember_550287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceFiveMember_550287" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceSixMember" xlink:label="loc_thtx_ExercisePriceSixMember_550288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceSixMember_550288" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_585461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_ifrs-full_RangeAxis_585461" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_585462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_585461" xlink:to="loc_ifrs-full_RangesMember_585462" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_585462_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_585461" xlink:to="loc_ifrs-full_RangesMember_585462_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_585464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_585462" xlink:to="loc_ifrs-full_TopOfRangeMember_585464" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_585465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_585462" xlink:to="loc_ifrs-full_BottomOfRangeMember_585465" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_819064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_srt_CurrencyAxis_819064" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_819064" xlink:to="loc_currency_AllCurrenciesDomain_819066" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819066_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_819064" xlink:to="loc_currency_AllCurrenciesDomain_819066_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_819067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_819066" xlink:to="loc_currency_USD_819067" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_819068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_819066" xlink:to="loc_currency_CAD_819068" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_550295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_550295" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_550296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_550296" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550297" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550304" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550305" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550306" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610594" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550308" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_821369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" xlink:to="loc_srt_CurrencyAxis_821369" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_821369" xlink:to="loc_currency_AllCurrenciesDomain_821374" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821374_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_821369" xlink:to="loc_currency_AllCurrenciesDomain_821374_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_821370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_821374" xlink:to="loc_currency_USD_821370" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_821371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_821374" xlink:to="loc_currency_CAD_821371" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xlink:label="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" xlink:to="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_819111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" xlink:to="loc_srt_CurrencyAxis_819111" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_819111" xlink:to="loc_currency_AllCurrenciesDomain_819112" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819112_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_819111" xlink:to="loc_currency_AllCurrenciesDomain_819112_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_819113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_819112" xlink:to="loc_currency_USD_819113" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_819114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_819112" xlink:to="loc_currency_CAD_819114" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550322" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_550323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_550323" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_550371" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_550368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_EarningsPerShareTable_550368" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_550368" xlink:to="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_551050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" xlink:to="loc_ifrs-full_OrdinarySharesMember_551050" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_551050_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" xlink:to="loc_ifrs-full_OrdinarySharesMember_551050_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareOptionMember" xlink:label="loc_thtx_ShareOptionMember_551051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_ShareOptionMember_551051" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicIssueOfSharesMember" xlink:label="loc_thtx_PublicIssueOfSharesMember_551054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_PublicIssueOfSharesMember_551054" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BrokersWarrantsMember" xlink:label="loc_thtx_BrokersWarrantsMember_551055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_BrokersWarrantsMember_551055" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SubscriptionReceiptsIssueMember" xlink:label="loc_thtx_SubscriptionReceiptsIssueMember_2147462750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_SubscriptionReceiptsIssueMember_2147462750" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462871" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameAxis" xlink:label="loc_thtx_ProgramNameAxis_2147468974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_550368" xlink:to="loc_thtx_ProgramNameAxis_2147468974" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_2147468975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_ProgramNameAxis_2147468974" xlink:to="loc_thtx_ProgramNameMember_2147468975" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_2147468975_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_ProgramNameAxis_2147468974" xlink:to="loc_thtx_ProgramNameMember_2147468975_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AtmProgramMember" xlink:label="loc_thtx_AtmProgramMember_2147468976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_ProgramNameMember_2147468975" xlink:to="loc_thtx_AtmProgramMember_2147468976" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_551041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_WeightedAverageShares_551041" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsExercised" xlink:label="loc_thtx_EffectOfShareOptionsExercised_572760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfShareOptionsExercised_572760" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfIssueCommonShares" xlink:label="loc_thtx_EffectOfIssueCommonShares_572761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfIssueCommonShares_572761" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_2147462873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_2147462873" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_572759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_572759" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfSubscriptionReceiptsIssue" xlink:label="loc_thtx_EffectOfSubscriptionReceiptsIssue_2147462751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfSubscriptionReceiptsIssue_2147462751" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfBrokerWarrantsExercised" xlink:label="loc_thtx_EffectOfBrokerWarrantsExercised_1279324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfBrokerWarrantsExercised_1279324" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_550388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_550388" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_586035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_586035" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_586037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_586035" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_586037" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_586038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_586037" xlink:to="loc_ifrs-full_EquityMember_586038" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_586038_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_586037" xlink:to="loc_ifrs-full_EquityMember_586038_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_586042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_586038" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_586042" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_586044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_586038" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_586044" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_586048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_586048" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" xlink:to="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" xlink:to="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" xlink:to="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" xlink:to="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2147463041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_srt_StatementGeographicalAxis_2147463041" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2147463040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2147463041" xlink:to="loc_srt_SegmentGeographicalDomain_2147463040" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2147463040_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2147463041" xlink:to="loc_srt_SegmentGeographicalDomain_2147463040_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE" xlink:label="loc_country_IE_2147463038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2147463040" xlink:to="loc_country_IE_2147463038" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_550091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" xlink:to="loc_ifrs-full_ApplicableTaxRate_550091" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_2147463039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_2147463039" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearAxis" xlink:label="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xlink:to="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearMember" xlink:label="loc_thtx_TaxBenefitCarryForwardYearMember_550010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" xlink:to="loc_thtx_TaxBenefitCarryForwardYearMember_550010" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearMember" xlink:label="loc_thtx_TaxBenefitCarryForwardYearMember_550010_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" xlink:to="loc_thtx_TaxBenefitCarryForwardYearMember_550010_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentySevenMember" xlink:label="loc_thtx_YearTwoThousandAndTwentySevenMember_550011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentySevenMember_550011" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyEightMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyEightMember_550012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentyEightMember_550012" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyNineMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyNineMember_550013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentyNineMember_550013" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyMember_550014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyMember_550014" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyOneMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyOneMember_550015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyOneMember_550015" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyTwoMember_550016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyTwoMember_550016" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyThreeMember_550017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyThreeMember_550017" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyFourMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyFourMember_550018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyFourMember_550018" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtySevenMember" xlink:label="loc_thtx_YearTwoThousandAndThirtySevenMember_550019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtySevenMember_550019" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyEightMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyEightMember_550020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyEightMember_550020" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyNineMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyNineMember_602692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyNineMember_602692" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyMember" xlink:label="loc_thtx_YearTwoThousandAndFortyMember_836488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyMember_836488" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyOneMember" xlink:label="loc_thtx_YearTwoThousandAndFortyOneMember_1265815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyOneMember_1265815" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndFortyTwoMember_2147463037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyTwoMember_2147463037" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndFortyThreeMember_2147462749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyThreeMember_2147462749" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionAxis" xlink:label="loc_thtx_IncomeTaxJurisdictionAxis_550022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xlink:to="loc_thtx_IncomeTaxJurisdictionAxis_550022" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionMember" xlink:label="loc_thtx_IncomeTaxJurisdictionMember_550024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_IncomeTaxJurisdictionAxis_550022" xlink:to="loc_thtx_IncomeTaxJurisdictionMember_550024" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionMember" xlink:label="loc_thtx_IncomeTaxJurisdictionMember_550024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_IncomeTaxJurisdictionAxis_550022" xlink:to="loc_thtx_IncomeTaxJurisdictionMember_550024_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FederalMember" xlink:label="loc_thtx_FederalMember_550026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_IncomeTaxJurisdictionMember_550024" xlink:to="loc_thtx_FederalMember_550026" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvincialMember" xlink:label="loc_thtx_ProvincialMember_550027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_IncomeTaxJurisdictionMember_550024" xlink:to="loc_thtx_ProvincialMember_550027" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xlink:label="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation_550033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation_550033" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_550077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_550077" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue_550038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue_550038" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue_550040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue_550040" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AvailableDeductionsAndOthers" xlink:label="loc_thtx_AvailableDeductionsAndOthers_550041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_AvailableDeductionsAndOthers_550041" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_550507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_srt_CurrencyAxis_550507" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_550508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_550507" xlink:to="loc_currency_AllCurrenciesDomain_550508" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_550508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_550507" xlink:to="loc_currency_AllCurrenciesDomain_550508_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_550509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_550508" xlink:to="loc_currency_CAD_550509" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_550511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_UnobservableInputsAxis_550511" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_550517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_550511" xlink:to="loc_ifrs-full_UnobservableInputsMember_550517" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_550517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_550511" xlink:to="loc_ifrs-full_UnobservableInputsMember_550517_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_550519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_550517" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_550519" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" xlink:to="loc_ifrs-full_FinancialAssetsMember_550524" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" xlink:to="loc_ifrs-full_FinancialAssetsMember_550524_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BondsMember" xlink:label="loc_thtx_BondsMember_550570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_550524" xlink:to="loc_thtx_BondsMember_550570" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestRateCashAndMarketFundsMember" xlink:label="loc_thtx_VariableInterestRateCashAndMarketFundsMember_550530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_550524" xlink:to="loc_thtx_VariableInterestRateCashAndMarketFundsMember_550530" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_550890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_550890" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_550891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_550890" xlink:to="loc_ifrs-full_InterestRateTypesMember_550891" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_550891_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_550890" xlink:to="loc_ifrs-full_InterestRateTypesMember_550891_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_2147463238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_550891" xlink:to="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_2147463238" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463003" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463003_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463003_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_RangeAxis_2147462824" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2147462824" xlink:to="loc_ifrs-full_RangesMember_2147462823" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2147462824" xlink:to="loc_ifrs-full_RangesMember_2147462823_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462823" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462821" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462823" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462822" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_550392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_CurrentTradeReceivables_550392" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentTradeReceivablesAgingPeriod" xlink:label="loc_thtx_CurrentTradeReceivablesAgingPeriod_550402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_CurrentTradeReceivablesAgingPeriod_550402" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BadDebtExpenses" xlink:label="loc_thtx_BadDebtExpenses_550409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_BadDebtExpenses_550409" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets_550414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_OtherFinancialAssets_550414" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PositivePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures_550424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures_550424" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NegativePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures_550429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures_550429" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_550438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_550438" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets_550886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets_550886" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_550889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_550889" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestbearingCashAndMoneyMarketFunds" xlink:label="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds_550474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds_550474" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows_550479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows_550479" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets_550484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets_550484" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:label="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462964" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets_550455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets_550455" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_549740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xlink:to="loc_ifrs-full_MaturityAxis_549740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_549740" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549741" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549741_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_549740" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549741_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_549742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_549742" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_549745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_549745" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsMember_549747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_LaterThanThreeYearsMember_549747" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_549737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xlink:to="loc_ifrs-full_MeasurementAxis_549737" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_549738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_549737" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_549738" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_549738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_549737" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_549738_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_549739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_549738" xlink:to="loc_ifrs-full_CarryingAmountMember_549739" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_549762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_549762" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermLoanUndiscountedCashFlows" xlink:label="loc_thtx_LongTermLoanUndiscountedCashFlows_2147463178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_LongTermLoanUndiscountedCashFlows_2147463178" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows_549763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows_549763" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeaseLiabilitiesUndiscountedCashFlows" xlink:label="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows_838046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows_838046" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_549765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_549765" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_820357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_820357" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentPositionOfTermLoanIncludingInterest" xlink:label="loc_thtx_CurrentPositionOfTermLoanIncludingInterest_2147463047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_CurrentPositionOfTermLoanIncludingInterest_2147463047" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_820358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_820358" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_821396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_LeaseLiabilities_821396" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonderivativeFinancialLiabilities" xlink:label="loc_thtx_NonderivativeFinancialLiabilities_820363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_NonderivativeFinancialLiabilities_820363" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_549772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" xlink:to="loc_ifrs-full_TypesOfRisksAxis_549772" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_549773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_549772" xlink:to="loc_ifrs-full_TypesOfRisksMember_549773" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_549773_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_549772" xlink:to="loc_ifrs-full_TypesOfRisksMember_549773_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_549774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_549773" xlink:to="loc_ifrs-full_CurrencyRiskMember_549774" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_572698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_Cash_572698" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_549784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_549784" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_549789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_549789" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_836446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_836446" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_549790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_549790" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TotalLeaseLiabilities" xlink:label="loc_thtx_TotalLeaseLiabilities_836448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_thtx_TotalLeaseLiabilities_836448" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="loc_ifrs-full_CurrentProvisions_1303197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_CurrentProvisions_1303197" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_549792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_549792" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_585116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" xlink:to="loc_srt_CurrencyAxis_585116" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_585126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_585116" xlink:to="loc_currency_AllCurrenciesDomain_585126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_585126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_585116" xlink:to="loc_currency_AllCurrenciesDomain_585126_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_585127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_585126" xlink:to="loc_currency_CAD_585127" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_585129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_585126" xlink:to="loc_currency_EUR_585129" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_549797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_549797" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_549798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_549798" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_549628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_549628" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549628" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549629_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549628" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549629_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashbondAndMoneyMarketFundsMember" xlink:label="loc_thtx_CashbondAndMoneyMarketFundsMember_549630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_549629" xlink:to="loc_thtx_CashbondAndMoneyMarketFundsMember_549630" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockAxis" xlink:label="loc_thtx_SaleOfStockAxis_1306034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_thtx_SaleOfStockAxis_1306034" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockMember" xlink:label="loc_thtx_SaleOfStockMember_1306035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_SaleOfStockAxis_1306034" xlink:to="loc_thtx_SaleOfStockMember_1306035" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockMember" xlink:label="loc_thtx_SaleOfStockMember_1306035_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_SaleOfStockAxis_1306034" xlink:to="loc_thtx_SaleOfStockMember_1306035_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_ifrs-full_RangeAxis_2147462808" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2147462808" xlink:to="loc_ifrs-full_RangesMember_2147462807" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2147462808" xlink:to="loc_ifrs-full_RangesMember_2147462807_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462807" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462805" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462807" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462806" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashBondAndMoneyMarketFunds" xlink:label="loc_thtx_CashBondAndMoneyMarketFunds_549636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" xlink:to="loc_thtx_CashBondAndMoneyMarketFunds_549636" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:label="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" xlink:to="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462820" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462794" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462789" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462789" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462788" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462788_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462789" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462788_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueMultipleMeasurementInputMember" xlink:label="loc_ifrs-full_RevenueMultipleMeasurementInputMember_2147462787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462788" xlink:to="loc_ifrs-full_RevenueMultipleMeasurementInputMember_2147462787" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462785" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462785_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_2147462784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_2147462785" xlink:to="loc_ifrs-full_WarrantReserveMember_2147462784" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2147462783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_MeasurementAxis_2147462783" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_2147462783" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462782" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462782_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_2147462783" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462782_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2147462781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2147462782" xlink:to="loc_ifrs-full_AtFairValueMember_2147462781" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_RangeAxis_2147462793" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_2147462793" xlink:to="loc_ifrs-full_RangesMember_2147462792" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_2147462793" xlink:to="loc_ifrs-full_RangesMember_2147462792_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462792" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462791" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2147462792" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462790" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462776" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xlink:label="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints_2147462775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" xlink:to="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints_2147462775" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462774" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462774" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462773" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462773_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462774" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462773_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462773" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462772" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462770" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462770_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462770_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_2147462769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_2147462770" xlink:to="loc_ifrs-full_WarrantReserveMember_2147462769" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2147462768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_MeasurementAxis_2147462768" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_2147462768" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462767" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_2147462768" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462767_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2147462766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2147462767" xlink:to="loc_ifrs-full_AtFairValueMember_2147462766" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsLineItems" xlink:label="loc_thtx_DisclosureOfCommitmentsLineItems_549502" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsTable" xlink:label="loc_thtx_DisclosureOfCommitmentsTable_549500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems_549502" xlink:to="loc_thtx_DisclosureOfCommitmentsTable_549500" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_549503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_549503" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_549504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_549503" xlink:to="loc_ifrs-full_InterestRateTypesMember_549504" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_549504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_549503" xlink:to="loc_ifrs-full_InterestRateTypesMember_549504_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityAxis" xlink:label="loc_thtx_CreditFacilityAxis_549507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_CreditFacilityAxis_549507" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityDomain" xlink:label="loc_thtx_CreditFacilityDomain_549508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_CreditFacilityAxis_549507" xlink:to="loc_thtx_CreditFacilityDomain_549508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityDomain" xlink:label="loc_thtx_CreditFacilityDomain_549508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_CreditFacilityAxis_549507" xlink:to="loc_thtx_CreditFacilityDomain_549508_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsAxis" xlink:label="loc_thtx_CommitmentsAxis_549516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_CommitmentsAxis_549516" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsDomain" xlink:label="loc_thtx_CommitmentsDomain_572643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_CommitmentsAxis_549516" xlink:to="loc_thtx_CommitmentsDomain_572643" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsDomain" xlink:label="loc_thtx_CommitmentsDomain_572643_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_CommitmentsAxis_549516" xlink:to="loc_thtx_CommitmentsDomain_572643_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoMember" xlink:label="loc_thtx_TrogarzoMember_572647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_CommitmentsDomain_572643" xlink:to="loc_thtx_TrogarzoMember_572647" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MultidosePassInjectorDevelopedMember" xlink:label="loc_thtx_MultidosePassInjectorDevelopedMember_818949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_CommitmentsDomain_572643" xlink:to="loc_thtx_MultidosePassInjectorDevelopedMember_818949" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_1305999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_TypeOfArrangementsAxis_1305999" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_1306001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_thtx_TypeOfArrangementsAxis_1305999" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_1306001" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_1306001_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_thtx_TypeOfArrangementsAxis_1305999" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_1306001_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1306004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1306004" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1306004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1306004_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OncologyPlatformMember" xlink:label="loc_thtx_OncologyPlatformMember_1304768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1306004" xlink:to="loc_thtx_OncologyPlatformMember_1304768" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xlink:label="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired_550350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems_549502" xlink:to="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired_550350" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsOutstanding" xlink:label="loc_thtx_BorrowingsOutstanding_549526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems_549502" xlink:to="loc_thtx_BorrowingsOutstanding_549526" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_549375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" xlink:to="loc_ifrs-full_SegmentsAxis_549375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_549376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_549375" xlink:to="loc_ifrs-full_SegmentsMember_549376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_549376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_549375" xlink:to="loc_ifrs-full_SegmentsMember_549376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RxCrossRoadsMember" xlink:label="loc_thtx_RxCrossRoadsMember_549378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_549376" xlink:to="loc_thtx_RxCrossRoadsMember_549378" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_549377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_549376" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_549377" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_549380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" xlink:to="loc_ifrs-full_Revenue_549380" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_836290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" xlink:to="loc_ifrs-full_GeographicalAreasAxis_836290" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_836291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_836290" xlink:to="loc_ifrs-full_GeographicalAreasMember_836291" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_836291_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_836290" xlink:to="loc_ifrs-full_GeographicalAreasMember_836291_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_836292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_CA_836292" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_2147463053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_US_2147463053" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE" xlink:label="loc_country_IE_836293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_IE_836293" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_836288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" xlink:to="loc_ifrs-full_NoncurrentAssets_836288" use="optional" order="8" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>41
<FILENAME>thtx-20231130_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 21-February-2024 [08:06:33] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber" xml:lang="en-US">Contact Personnel Fax Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber" xlink:to="lab_dei_ContactPersonnelFaxNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of financial position [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xml:lang="en-US">Current derivative financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xml:lang="en-US">Derivative financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xml:lang="en-US">Current prepaid expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xml:lang="en-US">Prepaid expenses and deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xml:lang="en-US">Prepaid Expenses and Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxAssets" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxReceivableCurrent" xlink:label="loc_thtx_IncomeTaxReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxReceivableCurrent" xml:lang="en-US">Income Tax Receivable Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxReceivableCurrent" xml:lang="en-US">Income taxes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxReceivableCurrent" xlink:to="lab_thtx_IncomeTaxReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxReceivableCurrent" xml:lang="en-US">Income tax receivable current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-full_InventoriesTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InventoriesTotal" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InventoriesTotal" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_InventoriesTotal" xml:lang="en-US">Total Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoriesTotal" xlink:to="lab_ifrs-full_InventoriesTotal" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Other current financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xml:lang="en-US">Bonds and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Tax credits and grants receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Tax credits and grants receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Tax credits and grants receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaxCreditsAndGrantsReceivable" xlink:to="lab_thtx_TaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaxCreditsAndGrantsReceivable" xml:lang="en-US">Tax credits and grants receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCosts" xlink:label="loc_thtx_DeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredFinancingCosts" xml:lang="en-US">Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_DeferredFinancingCosts" xml:lang="en-US">Deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredFinancingCosts" xlink:to="lab_thtx_DeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredFinancingCosts" xml:lang="en-US">Deferred financing costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Total non-current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentAssets" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Right-of-use-assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_RightofuseAssets" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xml:lang="en-US">Liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xml:lang="en-US">Current deferred income other than current contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Current portion of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Current notes and debentures issued and current portion of non-current notes and debentures issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:to="lab_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xml:lang="en-US">Current tax liabilities, current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityCurrent" xlink:label="loc_thtx_LoanFacilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityCurrent" xml:lang="en-US">Loan Facility Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LoanFacilityCurrent" xml:lang="en-US">Current portion of Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityCurrent" xlink:to="lab_thtx_LoanFacilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityCurrent" xml:lang="en-US">Loan facility current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Other current provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_OtherShorttermProvisions" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherShorttermProvisions" xlink:to="lab_ifrs-full_OtherShorttermProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Trade and other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Accounts payable and accrued liabilities carrying amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WarrantsCurrent" xlink:label="loc_thtx_WarrantsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_WarrantsCurrent" xml:lang="en-US">Warrants Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_WarrantsCurrent" xml:lang="en-US">Marathon Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_WarrantsCurrent" xlink:to="lab_thtx_WarrantsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_WarrantsCurrent" xml:lang="en-US">Warrants current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityAbstract" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xml:lang="en-US">Accumulated other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xml:lang="en-US">Accumulated other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xml:lang="en-US">Contributed surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Issued capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Share capital, warrants and subscription receipts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssuedCapital" xml:lang="en-US">Issued capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xml:lang="en-US">Reserve of equity component of convertible instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xml:lang="en-US">Equity component of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:to="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Retained earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarnings" xml:lang="en-US">Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilities" xml:lang="en-US">Equity and liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAndLiabilities" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xml:lang="en-US">Non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityNoncurrent" xlink:label="loc_thtx_LoanFacilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityNoncurrent" xml:lang="en-US">Loan Facility Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LoanFacilityNoncurrent" xml:lang="en-US">Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityNoncurrent" xlink:to="lab_thtx_LoanFacilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityNoncurrent" xml:lang="en-US">Loan facility noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Non-current lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xml:lang="en-US">Non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xml:lang="en-US">Total non-current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other non-current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xml:lang="en-US">Statement of comprehensive income [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xml:lang="en-US">Loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xml:lang="en-US">Basic earnings (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings (loss) per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xml:lang="en-US">Diluted earnings (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OperatingExpensesAbstract" xlink:label="loc_thtx_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OperatingExpensesAbstract" xlink:to="lab_thtx_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OperatingExpensesAbstract" xml:lang="en-US">Operating expeneses</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherAssets" xlink:label="loc_thtx_AmortizationOfOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AmortizationOfOtherAssets" xml:lang="en-US">Amortization Of Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AmortizationOfOtherAssets" xml:lang="en-US">Amortization of other asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AmortizationOfOtherAssets" xlink:to="lab_thtx_AmortizationOfOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AmortizationOfOtherAssets" xml:lang="en-US">Amortization of other assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfSales" xml:lang="en-US">Cost of sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CostOfSales" xml:lang="en-US">Cost of goods sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance Costs And Gains Losses On Foreign Currency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:to="lab_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance costs and gains losses on foreign currency.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncome" xml:lang="en-US">Finance income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance Income Cost And Gains Losses On Foreign Currency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance income cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:to="lab_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xml:lang="en-US">Finance income cost and gains losses on foreign currency.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xml:lang="en-US">Total current and deferred tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OperatingExpense" xml:lang="en-US">Operating expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OperatingExpense" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Profit (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Profit (loss) before tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Profit (loss) from operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xml:lang="en-US">Loss from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xlink:label="loc_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xml:lang="en-US">Research And Development Expense Net of Tax Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xml:lang="en-US">Research and development expenses, net of tax credits of $ 539 (2022 - $ 316; 2021 &#8211; $ 277)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xlink:to="lab_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xml:lang="en-US">Research and development expense net of tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense" xlink:label="loc_ifrs-full_SellingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SellingExpense" xml:lang="en-US">Selling expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SellingExpense" xml:lang="en-US">Selling expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingExpense" xlink:to="lab_ifrs-full_SellingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income (loss), net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xml:lang="en-US">Items that may be reclassified to net profit (loss) in the future</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xml:lang="en-US">Gains (losses) on remeasuring available-for-sale financial assets, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xml:lang="en-US">Net change in fair value of financial assets at fair value through other comprehensive income ("FVOCI")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xml:lang="en-US">Net change in fair value of FVOCI financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:to="lab_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Exchange differences on translation of foreign operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xml:lang="en-US">Exchange differences on translation of foreign operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Revenue" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Revenue" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Revenue" xml:lang="en-US">Net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xlink:label="loc_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xml:lang="en-US">Other Comprehensive Income Net Of Tax Research And Development Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xml:lang="en-US">Other Comprehensive Income Net Of Tax Research and Development Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xlink:to="lab_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xml:lang="en-US">Other comprehensive income net of tax research and development cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xml:lang="en-US">Statement of changes in equity [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xml:lang="en-US">Statement of changes in equity [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xml:lang="en-US">Components of equity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityMember" xml:lang="en-US">Equity [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated other comprehensive income [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xml:lang="en-US">Additional paid-in capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xml:lang="en-US">Contributed surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Issued capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IssuedCapitalMember" xml:lang="en-US">Share capital Subscription receipts and Public Offering Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xml:lang="en-US">Reserve of equity component of convertible instruments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xml:lang="en-US">Equity component of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:to="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Retained earnings [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RetainedEarningsMember" xml:lang="en-US">Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xml:lang="en-US">Statement of changes in equity [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAbstract" xml:lang="en-US">Comprehensive income [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAbstract" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAbstract" xlink:label="loc_thtx_ExerciseOfStockOptionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExerciseOfStockOptionsAbstract" xml:lang="en-US">Exercise Of Stock Options [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExerciseOfStockOptionsAbstract" xml:lang="en-US">Exercise of Options:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract" xlink:to="lab_thtx_ExerciseOfStockOptionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExerciseOfStockOptionsAbstract" xml:lang="en-US">IncreaseDecreaseThroughSharebasedPaymentTransactions</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAttributedValue" xlink:label="loc_thtx_ExerciseOfStockOptionsAttributedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExerciseOfStockOptionsAttributedValue" xml:lang="en-US">Exercise Of Stock Options Attributed Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExerciseOfStockOptionsAttributedValue" xml:lang="en-US">Attributed value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExerciseOfStockOptionsAttributedValue" xlink:to="lab_thtx_ExerciseOfStockOptionsAttributedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExerciseOfStockOptionsAttributedValue" xml:lang="en-US">Exercise of stock options attributed value</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xml:lang="en-US">Increase Decrease Through Exercise Of Options Number Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xml:lang="en-US">Monetary consideration Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xlink:to="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xml:lang="en-US">Increase decrease through exercise of options number of shares</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xml:lang="en-US">Increase Decrease Through Exercise Of Options Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xml:lang="en-US">Monetary consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xlink:to="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xml:lang="en-US">Increase decrease through exercise of options value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xml:lang="en-US">Total contributions by owners</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xml:lang="en-US">Increase Decrease Through Transactions With Owners Number Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xml:lang="en-US">Total contributions by owners shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xlink:to="lab_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xml:lang="en-US">Increase decrease through transactions with owners number of shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousComponentsOfEquityAbstract" xlink:label="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MiscellaneousComponentsOfEquityAbstract" xml:lang="en-US">Miscellaneous components of equity [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MiscellaneousComponentsOfEquityAbstract" xml:lang="en-US">Transactions with owners, recorded directly in equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract" xlink:to="lab_ifrs-full_MiscellaneousComponentsOfEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Repurchase of convertible unsecured senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Increase Decrease Through Conversion Of Convertible Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xml:lang="en-US">Conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xml:lang="en-US">Increase Decrease Through Exercise of Warrants Equity Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xml:lang="en-US">Exercise of warrants (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:to="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xml:lang="en-US">Increase decrease through exercise of warrants equity shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xml:lang="en-US">Increase Decrease Through Exercise Of Warrants Equity Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xml:lang="en-US">Exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xlink:to="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xml:lang="en-US">Increase decrease through exercise of warrants equity value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xlink:label="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xml:lang="en-US">Increase Decrease Through Shares Issued ATM Program Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xml:lang="en-US">Share issue - ATM program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xlink:to="lab_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xml:lang="en-US">Increase decrease through shares issued atm program value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfSharesIssuedThroughAtmProgram" xlink:label="loc_thtx_NumberOfSharesIssuedThroughAtmProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NumberOfSharesIssuedThroughAtmProgram" xml:lang="en-US">Number Of Shares Issued Through ATM Program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NumberOfSharesIssuedThroughAtmProgram" xml:lang="en-US">Share issue - ATM program (shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NumberOfSharesIssuedThroughAtmProgram" xlink:to="lab_thtx_NumberOfSharesIssuedThroughAtmProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NumberOfSharesIssuedThroughAtmProgram" xml:lang="en-US">Number of shares issued through atm program.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareIssueCosts" xlink:label="loc_thtx_ShareIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareIssueCosts" xml:lang="en-US">Share Issue Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ShareIssueCosts" xml:lang="en-US">Share issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareIssueCosts" xlink:to="lab_thtx_ShareIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareIssueCosts" xml:lang="en-US">Share issue costs.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock And Warrants Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Public issue of common shares and&#160;warrants (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:to="lab_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock and warrants issued during period shares new issues.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Public issue of common shares and&#160;warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:to="lab_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock and warrants issued during period value new issues.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period Shares Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Share issue &#8211; Oncology (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_thtx_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period Shares Acquisitions</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period Value Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Share issue &#8211; Oncology</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_thtx_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period Value Acquisitions</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During the Period Shares Conversion Of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of convertible unsecured senior notes (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock issued during the period shares conversion of convertible securities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesNewIssues" xml:lang="en-US">Stock Issued During the Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesNewIssues" xml:lang="en-US">Public issue of common shares (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues" xlink:to="lab_thtx_StockIssuedDuringThePeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringThePeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares new issues.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During the Period Value Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xlink:to="lab_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock issued during the period value conversion of convertible securities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueNewIssues" xml:lang="en-US">Stock Issued During the Period Value New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueNewIssues" xml:lang="en-US">Public issue of common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuedDuringThePeriodValueNewIssues" xlink:to="lab_thtx_StockIssuedDuringThePeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuedDuringThePeriodValueNewIssues" xml:lang="en-US">Stock issued during the period value new issues.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Beginning balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xml:lang="en-US">Ending Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareBasedCompensationPlanAbstract" xlink:label="loc_thtx_ShareBasedCompensationPlanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareBasedCompensationPlanAbstract" xml:lang="en-US">Share Based Compensation Plan [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ShareBasedCompensationPlanAbstract" xml:lang="en-US">Share-based compensation plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareBasedCompensationPlanAbstract" xlink:to="lab_thtx_ShareBasedCompensationPlanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareBasedCompensationPlanAbstract" xml:lang="en-US">Share based compensation plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xml:lang="en-US">Share-based compensation for stock option plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of cash flows [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash, beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xml:lang="en-US">Cash, end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForDeferredFinancingCosts" xlink:label="loc_thtx_AdjustmentsForDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdjustmentsForDeferredFinancingCosts" xml:lang="en-US">Adjustments For Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AdjustmentsForDeferredFinancingCosts" xml:lang="en-US">Deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdjustmentsForDeferredFinancingCosts" xlink:to="lab_thtx_AdjustmentsForDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdjustmentsForDeferredFinancingCosts" xml:lang="en-US">Adjustments for deferred financing costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Cash flows from (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xml:lang="en-US">Total cash from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Payments For Costs Related To Repurchase Of Convertible Unsecured Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Costs related to repurchase of convertible unsecured senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Transaction costs incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:to="lab_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Payments for costs related to repurchase of convertible unsecured senior notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xml:lang="en-US">Payments for debt issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xml:lang="en-US">Costs related to issuance of Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForDebtIssueCosts" xlink:to="lab_ifrs-full_PaymentsForDebtIssueCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xml:lang="en-US">Payments for share issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xml:lang="en-US">Costs related to issuance of common shares, Public Offering Warrants and subscription receipts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xml:lang="en-US">Payments for share issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xml:lang="en-US">Payment of lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xml:lang="en-US">Proceeds from exercise of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xml:lang="en-US">Proceeds from exercise of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xml:lang="en-US">Proceeds from exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xml:lang="en-US">Proceeds from exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromIssuingSharesAndWarrants" xlink:label="loc_thtx_ProceedsFromIssuingSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProceedsFromIssuingSharesAndWarrants" xml:lang="en-US">Proceeds From Issuing Shares And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProceedsFromIssuingSharesAndWarrants" xml:lang="en-US">Proceeds from issue of common shares, Public Offering Warrants and subscription receipts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProceedsFromIssuingSharesAndWarrants" xlink:to="lab_thtx_ProceedsFromIssuingSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProceedsFromIssuingSharesAndWarrants" xml:lang="en-US">Proceeds from issuing shares and warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from non-current borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from issuance of Loan Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from issuance of long-term loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xml:lang="en-US">Proceeds from Loan Facility on July&#160;27,&#160;2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RepaymentOfOtherObligations" xlink:label="loc_thtx_RepaymentOfOtherObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RepaymentOfOtherObligations" xml:lang="en-US">Repayment Of Other Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_RepaymentOfOtherObligations" xml:lang="en-US">Repayment of other obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RepaymentOfOtherObligations" xlink:to="lab_thtx_RepaymentOfOtherObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RepaymentOfOtherObligations" xml:lang="en-US">Repayment of other obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xml:lang="en-US">Repayments of bonds, notes and debentures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xml:lang="en-US">Repurchase of convertible unsecured senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xml:lang="en-US">Cash paid on repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Cash flows from (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xml:lang="en-US">Total cash from (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsToAcquireDerivativeFinancialAssets" xlink:label="loc_thtx_PaymentsToAcquireDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PaymentsToAcquireDerivativeFinancialAssets" xml:lang="en-US">Payments To Acquire Derivative Financial Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_PaymentsToAcquireDerivativeFinancialAssets" xml:lang="en-US">Acquisition of derivative financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PaymentsToAcquireDerivativeFinancialAssets" xlink:to="lab_thtx_PaymentsToAcquireDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PaymentsToAcquireDerivativeFinancialAssets" xml:lang="en-US">Payments To Acquire Derivative Financial Assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sales or maturity of financial instruments, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from sale of bonds and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xml:lang="en-US">Acquisition of bonds and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xml:lang="en-US">Acquisition of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xml:lang="en-US">Acquisition of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash&#160;flows&#160;from&#160;(used&#160;in) Operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xml:lang="en-US">Adjustments for</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Adjustments For Accretion Expense And Amortization Of Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Accretion expense and amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:to="lab_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Adjustments for accretion expense and amortization of deferred financing costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xml:lang="en-US">Adjustments for amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xml:lang="en-US">Amortization of intangible assets and other asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForAmortisationExpense" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAmortizationOfRightofuseAssets" xlink:label="loc_thtx_AdjustmentsForAmortizationOfRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdjustmentsForAmortizationOfRightofuseAssets" xml:lang="en-US">Adjustments For Amortization of rightofuse assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AdjustmentsForAmortizationOfRightofuseAssets" xml:lang="en-US">Amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdjustmentsForAmortizationOfRightofuseAssets" xlink:to="lab_thtx_AdjustmentsForAmortizationOfRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdjustmentsForAmortizationOfRightofuseAssets" xml:lang="en-US">Adjustments For Amortization of right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xml:lang="en-US">Adjustments for decrease (increase) in derivative financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xml:lang="en-US">Change in fair value of derivative financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xml:lang="en-US">Adjustments for depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xml:lang="en-US">Depreciation of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xml:lang="en-US">Adjustments for finance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xml:lang="en-US">Write off of deferred financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xml:lang="en-US">Write off of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xml:lang="en-US">Adjustments for income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xml:lang="en-US">Change in fair value of liability related to deferred stock&#160;unit&#160;plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForInterestIncome" xml:lang="en-US">Adjustments for interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForInterestIncome" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForInterestIncome" xlink:to="lab_ifrs-full_AdjustmentsForInterestIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Adjustments for share-based payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xml:lang="en-US">Share-based compensation for stock option plan&#160;and stock appreciation rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xml:lang="en-US">Foreign exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_thtx_GainLossOnLeaseTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GainLossOnLeaseTermination" xml:lang="en-US">Gain Loss On Lease Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_GainLossOnLeaseTermination" xml:lang="en-US">Gain on lease termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_GainLossOnLeaseTermination" xml:lang="en-US">Gain on lease termination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GainLossOnLeaseTermination" xlink:to="lab_thtx_GainLossOnLeaseTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GainLossOnLeaseTermination" xml:lang="en-US">Gain loss on lease termination.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLoanFacilityModifications" xlink:label="loc_thtx_GainLossOnLoanFacilityModifications" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GainLossOnLoanFacilityModifications" xml:lang="en-US">Gain Loss On Loan Facility Modifications</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_GainLossOnLoanFacilityModifications" xml:lang="en-US">Loss on Loan Facility modifications</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_GainLossOnLoanFacilityModifications" xml:lang="en-US">Loss on Loan Facility modifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GainLossOnLoanFacilityModifications" xlink:to="lab_thtx_GainLossOnLoanFacilityModifications" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GainLossOnLoanFacilityModifications" xml:lang="en-US">Gain loss on loan facility modifications.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Gain On Repurchase Of Convertible Unsecured Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Gain on repurchase of convertible unsecured senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Gain on repurchase of convertible unsecured senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Gain on repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:to="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xml:lang="en-US">Gain on repurchase of convertible unsecured senior notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gains on change in fair value of derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xml:lang="en-US">Change in fair value of Marathon Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xml:lang="en-US">Income taxes paid, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xlink:label="loc_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xml:lang="en-US">Interest On Convertible Unsecured Senior Notes And Long Term Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xml:lang="en-US">Interest on convertible unsecured senior notes and Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xlink:to="lab_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xml:lang="en-US">Interest on convertible unsecured senior notes and long term loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xml:lang="en-US">Interest paid, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xml:lang="en-US">Interest paid on convertible unsecured senior notes and Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xml:lang="en-US">Interest received, classified as operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xml:lang="en-US">Interest received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Cash flows from (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Total cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xml:lang="en-US">Negative operating cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Change In Operating Assets And Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Change in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="lab_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Change in operating assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xml:lang="en-US">Prepaid expenses and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xml:lang="en-US">Adjustments for increase (decrease) in deferred income other than contract liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xml:lang="en-US">Adjustments for provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xml:lang="en-US">Adjustments for Tax credits and grants receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xml:lang="en-US">Tax credits and grants receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xlink:to="lab_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xml:lang="en-US">Adjustments for Tax credits and grants receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xml:lang="en-US">Increase (decrease) in working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xml:lang="en-US">Increase (decrease) in working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xml:lang="en-US">Effect of foreign exchange on cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TextBlockAbstract" xlink:to="lab_thtx_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xml:lang="en-US">Basis of preparation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xml:lang="en-US">Disclosure of material accounting policy information [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xml:lang="en-US">Significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xml:lang="en-US">Disclosure of revenue [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xml:lang="en-US">Personnel expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xml:lang="en-US">Finance income and finance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xml:lang="en-US">Schedule Of Detailed Information About Bonds And Money Market Funds [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xml:lang="en-US">Schedule of Detailed Information About Bonds and Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xlink:to="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xml:lang="en-US">Disclosure of financial assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xml:lang="en-US">Bonds and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherReceivablesExplanatoryAbstract" xlink:label="loc_thtx_TradeAndOtherReceivablesExplanatoryAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TradeAndOtherReceivablesExplanatoryAbstract" xml:lang="en-US">Trade And Other Receivables Explanatory [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TradeAndOtherReceivablesExplanatoryAbstract" xml:lang="en-US">Trade And Other Receivables Explanatory [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TradeAndOtherReceivablesExplanatoryAbstract" xlink:to="lab_thtx_TradeAndOtherReceivablesExplanatoryAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TradeAndOtherReceivablesExplanatoryAbstract" xml:lang="en-US">Trade and other receivables explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xml:lang="en-US">Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xml:lang="en-US">Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xlink:to="lab_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xml:lang="en-US">Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTaxCreditsReceivableExplanatory" xlink:label="loc_thtx_DisclosureOfTaxCreditsReceivableExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTaxCreditsReceivableExplanatory" xml:lang="en-US">Disclosure Of Tax Credits Receivable Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTaxCreditsReceivableExplanatory" xml:lang="en-US">Tax credits and grants receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTaxCreditsReceivableExplanatory" xlink:to="lab_thtx_DisclosureOfTaxCreditsReceivableExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTaxCreditsReceivableExplanatory" xml:lang="en-US">Disclosure of tax credits receivable explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xml:lang="en-US">Classes of current inventories [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xml:lang="en-US">Classes of current inventories [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xml:lang="en-US">Disclosure of inventories [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract" xlink:label="loc_ifrs-full_CurrentPrepaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPrepaymentsAbstract" xml:lang="en-US">Current prepayments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract" xlink:to="lab_ifrs-full_CurrentPrepaymentsAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xlink:label="loc_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xml:lang="en-US">Disclosure Details Of Current Prepaid Expenses And Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xml:lang="en-US">Prepaid expenses and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xlink:to="lab_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xml:lang="en-US">Disclosure Details Of Current Prepaid Expenses And Deposits</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xml:lang="en-US">Right-of-use assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xml:lang="en-US">Disclosure of other assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xml:lang="en-US">Other asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndAccruedPayablesAbstract" xlink:label="loc_thtx_TradeAndAccruedPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TradeAndAccruedPayablesAbstract" xml:lang="en-US">Trade and Accrued Payables [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TradeAndAccruedPayablesAbstract" xml:lang="en-US">Trade and other payables (Abstract)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TradeAndAccruedPayablesAbstract" xlink:to="lab_thtx_TradeAndAccruedPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TradeAndAccruedPayablesAbstract" xml:lang="en-US">Trade and accrued payables.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Trade And Accrued Payables Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xml:lang="en-US">Accounts payable and accured liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xml:lang="en-US">Disclosure of trade and accrued payables explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xml:lang="en-US">Disclosure of other provisions [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xml:lang="en-US">Provisions [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xml:lang="en-US">Disclosure of provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xml:lang="en-US">Disclosure of borrowings [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xml:lang="en-US">Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesAbstract" xml:lang="en-US">Convertible Unsecured Senior Notes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesAbstract" xml:lang="en-US">Convertible senior notes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:to="lab_thtx_ConvertibleUnsecuredSeniorNotesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesAbstract" xml:lang="en-US">Convertible unsecured senior notes.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Convertible Senior Notes Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xml:lang="en-US">Convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xml:lang="en-US">Disclosure of convertible senior notes explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xml:lang="en-US">Lease liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xml:lang="en-US">Disclosure of leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xml:lang="en-US">Leases liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xml:lang="en-US">Disclosure of classes of share capital [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xml:lang="en-US">Disclosure of classes of share capital [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xml:lang="en-US">Share capital warrants and subscription receipts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xml:lang="en-US">Major components of tax expense (income) [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Disclosure of income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SupplementalCashFlowDisclosuresAbstract" xlink:label="loc_thtx_SupplementalCashFlowDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SupplementalCashFlowDisclosuresAbstract" xml:lang="en-US">Supplemental cash flow disclosures [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract" xlink:to="lab_thtx_SupplementalCashFlowDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SupplementalCashFlowDisclosuresAbstract" xml:lang="en-US">Supplemental Cash Flow Disclosures.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xlink:label="loc_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xml:lang="en-US">Disclosure Of Supplemental Information On Cash Flow Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xml:lang="en-US">Supplemental cash flow disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xlink:to="lab_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xml:lang="en-US">Disclosure Of Supplemental Information On Cash Flow [Explanatory]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xml:lang="en-US">Captital management</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfFairValueMeasurementAbstract" xlink:label="loc_thtx_DisclosureOfFairValueMeasurementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfFairValueMeasurementAbstract" xml:lang="en-US">Disclosure of Fair Value Measurement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfFairValueMeasurementAbstract" xml:lang="en-US">Disclosure of fair value measurement [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfFairValueMeasurementAbstract" xlink:to="lab_thtx_DisclosureOfFairValueMeasurementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfFairValueMeasurementAbstract" xml:lang="en-US">Disclosure of fair value measurement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xml:lang="en-US">Disclosure of fair value measurement [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xml:lang="en-US">Determination of fair values</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsAbstract" xlink:label="loc_thtx_DisclosureOfCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfCommitmentsAbstract" xml:lang="en-US">Disclosure of commitments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfCommitmentsAbstract" xlink:to="lab_thtx_DisclosureOfCommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfCommitmentsAbstract" xml:lang="en-US">Disclosure of commitments abstract.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Disclosure of commitments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xml:lang="en-US">Disclosure of operating segments [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xml:lang="en-US">Disclosure of entity's operating segments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xml:lang="en-US">Operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related party transactions [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Disclosure of related party [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xml:lang="en-US">Related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xml:lang="en-US">Description Of Accounting Policy For Adopted The New Or Amended Standards [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xml:lang="en-US">Standards issued but not yet effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xml:lang="en-US">Description of accounting policy for adopted the new or amended standards.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xml:lang="en-US">Description Of Accounting Policy For Asset Acquisiitons Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xml:lang="en-US">Asset acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xml:lang="en-US">Description of accounting policy for asset acquisiitons explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Explanatory [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xml:lang="en-US">Basis of consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xml:lang="en-US">Description of accounting policy for basis of consolidation.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xml:lang="en-US">Description Of Accounting Policy For Deferred Financing Costs Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xml:lang="en-US">Deferred Financing Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xml:lang="en-US">Description of accounting policy for deferred financing costs explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xml:lang="en-US">Employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xml:lang="en-US">Finance income and finance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xml:lang="en-US">Foreign currencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xml:lang="en-US">Description of accounting policy for government grants [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xml:lang="en-US">Government assistance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xml:lang="en-US">Impairment of non-financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Inventories Explanatory [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xml:lang="en-US">Description of accounting policy for inventories explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xml:lang="en-US">Description of accounting policy for issued capital [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xml:lang="en-US">Share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xml:lang="en-US">Description Of Accounting Policy For New Accounting Standards Adopted Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xml:lang="en-US">New standard adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xml:lang="en-US">Description of accounting policy for new accounting standards adopted explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Other Assets Explanatory [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xml:lang="en-US">Other asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xml:lang="en-US">Description of accounting policy for other assets explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xml:lang="en-US">Description Of Accounting Policy For Stock Appreciation Rights Plan Explanatory [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xml:lang="en-US">Stock appreciation rights plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xlink:to="lab_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xml:lang="en-US">Description of accounting policy for stock appreciation rights plan explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xml:lang="en-US">Description Of Changes In Accounting Policies Explanatory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xml:lang="en-US">Changes in accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xlink:to="lab_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xml:lang="en-US">Description of changes in accounting policies explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCostOfSalesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCostOfSalesExplanatory" xml:lang="en-US">Disclosure of cost of sales [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCostOfSalesExplanatory" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCostOfSalesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xlink:label="loc_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xml:lang="en-US">Disclosure Of Estimated Useful Lives Methods Of Depreciation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xml:lang="en-US">Summary of estimated useful lives, methods of depreciation and depreciation rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xlink:to="lab_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xml:lang="en-US">Disclosure of estimated useful lives methods of depreciation.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xml:lang="en-US">Disaggregation Of Revenue By Geographical Area [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xml:lang="en-US">Summary of revenue by geographical area</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xlink:to="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xml:lang="en-US">Disaggregation of revenue by geographical area.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xml:lang="en-US">Summary of net sales by product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Personnel Expenses Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xml:lang="en-US">Summary of detailed information about personnel expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about personnel expenses.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income And Cost Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xml:lang="en-US">Summary of detailed information about finance income and cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about finance income and cost</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Bonds And Money Market Funds Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xml:lang="en-US">Detailed Information About Bonds And Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about bonds and money market funds explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Receivables Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xml:lang="en-US">Summary of detailed information about trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about trade and other receivables explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xlink:label="loc_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xml:lang="en-US">Disclosure Details Of Tax Credits Roll Forward [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xml:lang="en-US">Disclosure Details Of Tax Credits Roll Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xlink:to="lab_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xml:lang="en-US">Disclosure Details Of Tax Credits Roll Forward.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Unused And Unrecorded Non Refundable Federal Tax Credit Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xml:lang="en-US">Summary of information about unused and unrecorded non refundable federal tax credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about unused and unrecorded non refundable federal tax credit explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Inventories Explanatory Text [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xml:lang="en-US">Summary of detailed information about inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xml:lang="en-US">Disclosure of detailed information about inventories explanatory text.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xml:lang="en-US">Disclosure of prepayments and other assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xml:lang="en-US">Summary of prepaid expenses and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xml:lang="en-US">Summary of information about property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfRightOfUseAssetAbstract" xlink:label="loc_thtx_DisclosureOfRightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfRightOfUseAssetAbstract" xml:lang="en-US">Disclosure of right of use Asset [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfRightOfUseAssetAbstract" xml:lang="en-US">Right Of use Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract" xlink:to="lab_thtx_DisclosureOfRightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfRightOfUseAssetAbstract" xml:lang="en-US">Disclosure of right Of use Asset.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RightOfUseAssetsTableTextBlock" xlink:label="loc_thtx_RightOfUseAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RightOfUseAssetsTableTextBlock" xml:lang="en-US">Right of use Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RightOfUseAssetsTableTextBlock" xml:lang="en-US">Summary of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RightOfUseAssetsTableTextBlock" xlink:to="lab_thtx_RightOfUseAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RightOfUseAssetsTableTextBlock" xml:lang="en-US">Right-of-use&#160;assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xml:lang="en-US">Disclosure of Detailed Information About In Commercial Milestone Payment Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xml:lang="en-US">Schedule of Commercial Milestone Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xml:lang="en-US">Detailed Information About In Commercial Milestone Payment Explanatory</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xml:lang="en-US">Schedule of Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Other Asset Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xml:lang="en-US">Summary of other asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about other asset explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract" xml:lang="en-US">Trade and other payables [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract" xml:lang="en-US">Trade and other payables (Abstract)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract" xml:lang="en-US">Trade and other payables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherPayablesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Provisions Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xml:lang="en-US">Summary of provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about provisions explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xml:lang="en-US">Summary of movement in the carrying value of the term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Deferred Tax Related To Equity Component Of Convertible Notes Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xml:lang="en-US">Summary of deferred tax related to equity component of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of deferred tax related to equity component of convertible notes explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesAbstract" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfLeaseLiabilitiesAbstract" xml:lang="en-US">Disclosure of Lease Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract" xlink:to="lab_thtx_DisclosureOfLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfLeaseLiabilitiesAbstract" xml:lang="en-US">Disclosure of Lease Liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of Lease Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Summary of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:to="lab_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xml:lang="en-US">Disclosure of Lease Liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalTable" xlink:label="loc_thtx_ShareCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareCapitalTable" xml:lang="en-US">Share Capital [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareCapitalTable" xlink:to="lab_thtx_ShareCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareCapitalTable" xml:lang="en-US">Share capital [table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="lab_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInstrumentMember" xml:lang="en-US">Types of instrument [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInstrumentMember" xlink:to="lab_ifrs-full_TypesOfInstrumentMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalLineItems" xlink:label="loc_thtx_ShareCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareCapitalLineItems" xml:lang="en-US">Share Capital [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareCapitalLineItems" xlink:to="lab_thtx_ShareCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareCapitalLineItems" xml:lang="en-US">Share capital [line items]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xml:lang="en-US">Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xml:lang="en-US">Summary of measurement of fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xlink:to="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xml:lang="en-US">Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xml:lang="en-US">Disclosure of Detailed Information About In Accumulated Other Comprehensive Income Loss Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xml:lang="en-US">Summary of Accumulated other comprehensive income (loss) (Detail)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xml:lang="en-US">Disclosure of detailed information about in accumulated other comprehensive income loss explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information For Changes In The Number Of Options Outstanding Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xml:lang="en-US">Summary of changes in the number of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information for changes in the number of options outstanding explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information For Share Based Compensation Expense Stock Option Plan Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xml:lang="en-US">Summary of the share-based compensation expense for the stock option plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information for share based compensation expense stock option plan explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xml:lang="en-US">Summary of the following table provides stock option information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xml:lang="en-US">Disclosure Of The Model Used To Determine Fiar Value Of Stock Appreciation Rights [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xml:lang="en-US">Summary of the model used to determine fiar value of stock appreciation rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xlink:to="lab_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xml:lang="en-US">Disclosure of the model used to determine fiar value of stock appreciation rights explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Weighted Average Fair Value Of Options Granted And Number Of Options Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xml:lang="en-US">Summary of the measurement date weighted average fair value of stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xml:lang="en-US">Disclosure of weighted average fair value of options granted and number of options [Explanatory].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xml:lang="en-US">Disclosure Of Weighted Average Number Of Shares Outstanding Explanatory [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xml:lang="en-US">Summary of earnings per share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xlink:to="lab_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xml:lang="en-US">Disclosure of weighted average number of shares outstanding [Explanatory].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Amounts And Expiry Dates Of Tax Attributes Carry Forward Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xml:lang="en-US">Summary of amounts and expiry dates of tax attributes carry forward explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of amounts and expiry dates of tax attributes carry forward explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Major Component Of Income Tax And Deferred Tax Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xml:lang="en-US">Summary of major component of income tax and deferred tax explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of major component of income tax and deferred tax explanatory.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Reconciliation Between Effective And Income Tax Amounts Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xml:lang="en-US">Summary of reconciliation between effective and income tax amounts explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of reconciliation between effective and income tax amounts explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xml:lang="en-US">Summary of temporary difference, unused tax losses and unused tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Applicable Exchange Rates Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xml:lang="en-US">Summary of applicable exchange rates explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Applicable Exchange Rates [Explanatory]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Currency Risk Exposure Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xml:lang="en-US">Summary of currency risk exposure explanatory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Currency Risk Exposure [Explanatory].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xml:lang="en-US">Summary of maturity analysis for non-derivative financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xml:lang="en-US">Summary of marathon warrants recognized at fair value and considered level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure Of Detailed Information About Operating Segments Explanatory [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xml:lang="en-US">Summary of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xml:lang="en-US">Disclosure of detailed information about operating segments explanatory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xml:lang="en-US">Summary of key management personnel compensation comprises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationTable" xlink:label="loc_thtx_BasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BasisOfPresentationTable" xml:lang="en-US">Basis of Presentation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BasisOfPresentationTable" xlink:to="lab_thtx_BasisOfPresentationTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationLineItems" xlink:label="loc_thtx_BasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BasisOfPresentationLineItems" xml:lang="en-US">Basis of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BasisOfPresentationLineItems" xlink:to="lab_thtx_BasisOfPresentationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRateBasis" xlink:label="loc_ifrs-full_BorrowingsInterestRateBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsInterestRateBasis" xml:lang="en-US">Borrowings, interest rate basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BorrowingsInterestRateBasis" xml:lang="en-US">Borrowings, interest rate basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRateBasis" xlink:to="lab_ifrs-full_BorrowingsInterestRateBasis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumLiquidityRequirementAmount" xlink:label="loc_thtx_MinimumLiquidityRequirementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MinimumLiquidityRequirementAmount" xml:lang="en-US">Minimum Liquidity Requirement Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MinimumLiquidityRequirementAmount" xml:lang="en-US">Minimum liquidity requirement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MinimumLiquidityRequirementAmount" xlink:to="lab_thtx_MinimumLiquidityRequirementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MinimumLiquidityRequirementAmount" xml:lang="en-US">Minimum liquidity requirement amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xml:lang="en-US">Borrowings by name [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xml:lang="en-US">Borrowings by name [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis" xml:lang="en-US">Range [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesMember" xml:lang="en-US">Ranges [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_BottomOfRangeMember" xml:lang="en-US">Bottom of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_TopOfRangeMember" xml:lang="en-US">Top of range [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RestatedMember" xml:lang="en-US">Currently stated [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xml:lang="en-US">Subsidiaries [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xml:lang="en-US">Entity's total for subsidiaries [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xml:lang="en-US">Computer equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xml:lang="en-US">Computer equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xml:lang="en-US">Computer equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaboratoryEquipmentMember" xlink:label="loc_thtx_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LaboratoryEquipmentMember" xlink:to="lab_thtx_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xml:lang="en-US">Office equipment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xml:lang="en-US">Office furniture and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xml:lang="en-US">Office furniture and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xml:lang="en-US">Depreciation method, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xml:lang="en-US">Depreciation method, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationMethodPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationRatePropertyPlantAndEquipment" xml:lang="en-US">Depreciation rate, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationRatePropertyPlantAndEquipment" xml:lang="en-US">Depreciation rate, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationRatePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xml:lang="en-US">Description of useful life, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xml:lang="en-US">Description of useful life, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StatementTable" xml:lang="en-US">Statement [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StatementTable" xlink:to="lab_thtx_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StatementTable" xml:lang="en-US">Statement Table.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xml:lang="en-US">Classes of assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xml:lang="en-US">Assets [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherAssetsMember" xml:lang="en-US">Other assets [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherAssetsMember" xml:lang="en-US">Other Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsMember" xlink:to="lab_ifrs-full_OtherAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalisedDevelopmentExpenditureMember" xml:lang="en-US">Capitalised development expenditure [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:to="lab_ifrs-full_CapitalisedDevelopmentExpenditureMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsEgriftaMember" xlink:label="loc_thtx_CommercializationRightsEgriftaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommercializationRightsEgriftaMember" xml:lang="en-US">Commercialization Rights EGRIFTA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CommercializationRightsEgriftaMember" xml:lang="en-US">Commercialization Rights EGRIFTA SV&#174;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_CommercializationRightsEgriftaMember" xml:lang="en-US">Commercialization rights &#8211; EGRIFTA SV&#174;</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommercializationRightsEgriftaMember" xlink:to="lab_thtx_CommercializationRightsEgriftaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CommercializationRightsEgriftaMember" xml:lang="en-US">Commercialization Rights EGRIFTA [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommercializationRightsTrogarzoMember" xml:lang="en-US">Commercialization Rights Trogarzo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CommercializationRightsTrogarzoMember" xml:lang="en-US">Commercialization Rights Trogarzo</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommercializationRightsTrogarzoMember" xlink:to="lab_thtx_CommercializationRightsTrogarzoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CommercializationRightsTrogarzoMember" xml:lang="en-US">Commercialization Rights Trogarzo [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xml:lang="en-US">THTX Commercialization Rights Trogarzo North America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xml:lang="en-US">THTX Commercialization Rights Trogarzo&#174; North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xlink:to="lab_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Development expenditures capitalized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Additions to intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation method, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets amortization method</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets finite useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xlink:label="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xml:lang="en-US">Useful Life Measured As Period Of Time Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xml:lang="en-US">Amortization of other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xlink:to="lab_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xml:lang="en-US">Useful life measured as period of time other assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xml:lang="en-US">Geographical areas [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GeographicalAreasMember" xml:lang="en-US">Geographical areas [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xml:lang="en-US">Products and services [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xml:lang="en-US">Products and services [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EgriftaMember" xlink:label="loc_thtx_EgriftaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EgriftaMember" xml:lang="en-US">EGRIFTA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EgriftaMember" xml:lang="en-US">EGRIFTA&#174; net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EgriftaMember" xlink:to="lab_thtx_EgriftaMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoNetSalesMember" xlink:label="loc_thtx_TrogarzoNetSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TrogarzoNetSalesMember" xml:lang="en-US">Trogarzo Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TrogarzoNetSalesMember" xml:lang="en-US">Trogarzo&#174; net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TrogarzoNetSalesMember" xlink:to="lab_thtx_TrogarzoNetSalesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaTable" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTable" xml:lang="en-US">Disaggregation Of Revenue By Geographical Area [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable" xlink:to="lab_thtx_DisaggregationOfRevenueByGeographicalAreaTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xml:lang="en-US">Disaggregation Of Revenue By Geographical Area [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xml:lang="en-US">Disaggregation Of Revenue By Geographical Area [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xlink:to="lab_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xml:lang="en-US">Disaggregation of revenue by geographical area.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CA" xml:lang="en-US">CANADA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CA" xml:lang="en-US">Canada [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_CA" xml:lang="en-US">Canada</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_US" xml:lang="en-US">US$</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_country_US" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xlink:label="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xml:lang="en-US">Disclosure Of Personnel Expenses Explanatory [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xml:lang="en-US">Disclosure Of Personnel Expenses Explanatory [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xlink:to="lab_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xml:lang="en-US">Disclosure of personnel expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xml:lang="en-US">Employee benefits expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xml:lang="en-US">Share based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xml:lang="en-US">Post-employment benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xml:lang="en-US">Short-term employee benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xml:lang="en-US">Salaries and short-term employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TerminationBenefitsExpense" xml:lang="en-US">Termination benefits expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TerminationBenefitsExpense" xml:lang="en-US">Termination benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TerminationBenefitsExpense" xlink:to="lab_ifrs-full_TerminationBenefitsExpense" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xlink:label="loc_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xml:lang="en-US">Amount Of Charges Related To Severance And Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xml:lang="en-US">Amount of charges related to severance and other expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xlink:to="lab_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xml:lang="en-US">Amount of charges related to severance and other expenses.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xlink:label="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xml:lang="en-US">Schedule Of Detail Information About Finance Income And Costs [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xml:lang="en-US">Scheduled of Detailed Information About Finance Costs [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xlink:to="lab_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xml:lang="en-US">Schedule of detail information about finance income and costs abstract.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Accretion Expense And Amortization Of Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Accretion expense and amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:to="lab_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xml:lang="en-US">Accretion expense and amortization of deferred financing costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankAndSimilarCharges" xlink:label="loc_ifrs-full_BankAndSimilarCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BankAndSimilarCharges" xml:lang="en-US">Bank and similar charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_BankAndSimilarCharges" xml:lang="en-US">Bank charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankAndSimilarCharges" xlink:to="lab_ifrs-full_BankAndSimilarCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xml:lang="en-US">Interest expense on debt instruments issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xml:lang="en-US">Interest on convertible unsecured senior notes and on long-term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:to="lab_ifrs-full_InterestExpenseOnDebtInstrumentsIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xml:lang="en-US">Net foreign exchange loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xml:lang="en-US">Net foreign currency loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xlink:label="loc_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xml:lang="en-US">Net Gain Loss On Financial Instruments Carried At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xml:lang="en-US">Net gain on financial instruments carried at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xlink:to="lab_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xml:lang="en-US">Net gain loss on financial instruments carried at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromInterest" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RevenueFromInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentDebtInstrumentsHeld" xlink:label="loc_ifrs-full_GovernmentDebtInstrumentsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GovernmentDebtInstrumentsHeld" xml:lang="en-US">Government debt instruments held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GovernmentDebtInstrumentsHeld" xml:lang="en-US">Bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GovernmentDebtInstrumentsHeld" xlink:to="lab_ifrs-full_GovernmentDebtInstrumentsHeld" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GuaranteedInvestmentCertificates" xlink:label="loc_thtx_GuaranteedInvestmentCertificates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GuaranteedInvestmentCertificates" xml:lang="en-US">Guaranteed Investment Certificates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_GuaranteedInvestmentCertificates" xml:lang="en-US">Guaranteed investment certificates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GuaranteedInvestmentCertificates" xlink:to="lab_thtx_GuaranteedInvestmentCertificates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GuaranteedInvestmentCertificates" xml:lang="en-US">Guaranteed investment certificates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFinancialAssets" xml:lang="en-US">Other financial assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherFinancialAssets" xml:lang="en-US">Bonds and money market funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherFinancialAssets" xml:lang="en-US">Bonds and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinancialAssets" xlink:to="lab_ifrs-full_OtherFinancialAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xml:lang="en-US">Schedule Of Detailed Information About Bonds And Money Market Funds1 [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xml:lang="en-US">Schedule of Detailed Information About Bonds and Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xlink:to="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xml:lang="en-US">Schedule of detailed information about bonds and money market funds.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xml:lang="en-US">Disclosure of financial assets [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xml:lang="en-US">Disclosure of detailed information about Financial Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsAverageMaturityTerm" xlink:label="loc_thtx_FinancialAssetsAverageMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FinancialAssetsAverageMaturityTerm" xml:lang="en-US">Financial Assets Average Maturity Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FinancialAssetsAverageMaturityTerm" xml:lang="en-US">Average maturity period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FinancialAssetsAverageMaturityTerm" xlink:to="lab_thtx_FinancialAssetsAverageMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FinancialAssetsAverageMaturityTerm" xml:lang="en-US">Financial assets average maturity term.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsStatedInterestPercentage" xlink:label="loc_thtx_FinancialAssetsStatedInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FinancialAssetsStatedInterestPercentage" xml:lang="en-US">Financial Assets Stated Interest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FinancialAssetsStatedInterestPercentage" xml:lang="en-US">Stated interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FinancialAssetsStatedInterestPercentage" xlink:to="lab_thtx_FinancialAssetsStatedInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FinancialAssetsStatedInterestPercentage" xml:lang="en-US">Financial assets, stated interest percentage.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" xml:lang="en-US">Schedule of Detailed Information About Trade and Other Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" xlink:to="lab_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" xml:lang="en-US">Disclosure of detailed information about trade and other receivables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Current trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xml:lang="en-US">Trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xml:lang="en-US">Current value added tax receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xml:lang="en-US">Sales taxes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xml:lang="en-US">Other current receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xlink:label="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xml:lang="en-US">Disclosure Of Tax Credits And Grants Receivable [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xml:lang="en-US">Disclosure of Tax Credits and Grants Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xlink:to="lab_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xml:lang="en-US">Disclosure of tax credits and grants receivable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xml:lang="en-US">Increase Decrease Through Net Exchange Differences Tax Credits And Grants Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xml:lang="en-US">Effect of change in exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xlink:to="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xml:lang="en-US">Increase decrease through net exchange differences tax credits and grants receivable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceived" xlink:label="loc_thtx_TaxCreditsAndGrantsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaxCreditsAndGrantsReceived" xml:lang="en-US">Tax Credits And Grants Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsReceived" xml:lang="en-US">Tax credits and grants received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaxCreditsAndGrantsReceived" xlink:to="lab_thtx_TaxCreditsAndGrantsReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaxCreditsAndGrantsReceived" xml:lang="en-US">Tax credits and grants received.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xlink:label="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xml:lang="en-US">Tax Credits and Grants Recognized in Net Profit or Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xml:lang="en-US">Tax credits and grants recognized in net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xlink:to="lab_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xml:lang="en-US">Tax credits and grants recognized in net profit or loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAxis" xml:lang="en-US">Maturity [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xml:lang="en-US">Aggregated time bands [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyMember" xml:lang="en-US">Income Tax Expire Two Thousand Forty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyMember" xml:lang="en-US">Income tax expire 2040</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandFortyMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandFortyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyMember" xml:lang="en-US">Income tax expire two thousand forty member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyOneMember" xml:lang="en-US">Income Tax Expire Two Thousand Forty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyOneMember" xml:lang="en-US">Income tax expire 2041</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandFortyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyOneMember" xml:lang="en-US">Income Tax Expire Two Thousand Forty One</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xml:lang="en-US">Income Tax Expire Two Thousand Forty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xml:lang="en-US">Income tax expire 2043</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandFortyThreeMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xml:lang="en-US">Income Tax Expire Two Thousand Forty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xml:lang="en-US">Income tax expire 2042</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandFortyTwoMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyMember" xml:lang="en-US">Income Tax Expire Two Thousand Thirty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyMember" xml:lang="en-US">Income tax expire 2030</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyMember" xml:lang="en-US">Income tax expire two thousand thirty member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xml:lang="en-US">Income Tax Expire Two Thousand Thirty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xml:lang="en-US">Income tax expire 2039</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xml:lang="en-US">Income tax expire two thousand thirty nine member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xml:lang="en-US">Income Tax Expire Two Thousand Thirty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xml:lang="en-US">Income tax expire 2031</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xml:lang="en-US">Income tax expire two thousand thirty one member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xml:lang="en-US">Income Tax Expire Two Thousand Thirty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xml:lang="en-US">Income tax expire 2033</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xml:lang="en-US">Income tax expire two thousand thirty three member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xml:lang="en-US">Income Tax Expire Two Thousand Thirty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xml:lang="en-US">Income tax expire 2032</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xml:lang="en-US">Income tax expire two thousand thirty two member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xml:lang="en-US">Income tax expire 2028</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xml:lang="en-US">Income tax expire two thousand twenty eight member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xml:lang="en-US">Income tax expire 2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xml:lang="en-US">Income tax expire two thousand twenty five [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xml:lang="en-US">Income tax expire 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xml:lang="en-US">Income tax expire two thousand twenty four [Member]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xml:lang="en-US">Income tax expire 2029</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xml:lang="en-US">Income tax expire two thousand twenty nine member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xml:lang="en-US">Income tax expire 2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xml:lang="en-US">Income tax expire two thousand twenty seven member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySixMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySixMember" xml:lang="en-US">Income Tax Expire Two Thousand Twenty Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySixMember" xml:lang="en-US">Income tax expire 2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember" xlink:to="lab_thtx_IncomeTaxExpireTwoThousandTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxExpireTwoThousandTwentySixMember" xml:lang="en-US">Income tax expire two thousand twenty six member</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementLineItems" xlink:label="loc_thtx_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StatementLineItems" xml:lang="en-US">Statement [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StatementLineItems" xlink:to="lab_thtx_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnusedAndUnrecordedTaxCreditsMember" xlink:label="loc_thtx_UnusedAndUnrecordedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_UnusedAndUnrecordedTaxCreditsMember" xml:lang="en-US">Unused And Unrecorded Tax Credits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_UnusedAndUnrecordedTaxCreditsMember" xml:lang="en-US">Unused tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_UnusedAndUnrecordedTaxCreditsMember" xlink:to="lab_thtx_UnusedAndUnrecordedTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_UnusedAndUnrecordedTaxCreditsMember" xml:lang="en-US">Unused and unrecorded tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinishedGoods" xml:lang="en-US">Current finished goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials" xlink:label="loc_ifrs-full_RawMaterials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RawMaterials" xml:lang="en-US">Current raw materials</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RawMaterials" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterials" xlink:to="lab_ifrs-full_RawMaterials" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WorkInProgress" xml:lang="en-US">Current work in progress</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WorkInProgress" xml:lang="en-US">Work in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xml:lang="en-US">Categories of related parties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xml:lang="en-US">Entity's total for related parties [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaiMedBiologicsInc.Member" xlink:label="loc_thtx_TaiMedBiologicsInc.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaiMedBiologicsInc.Member" xml:lang="en-US">TaiMed Biologics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaiMedBiologicsInc.Member" xml:lang="en-US">TaiMed Biologics Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaiMedBiologicsInc.Member" xlink:to="lab_thtx_TaiMedBiologicsInc.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaiMedBiologicsInc.Member" xml:lang="en-US">TaiMed Biologics Inc.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementAxis" xlink:label="loc_thtx_LocationInIncomeStatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LocationInIncomeStatementAxis" xml:lang="en-US">Location In Income Statement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LocationInIncomeStatementAxis" xlink:to="lab_thtx_LocationInIncomeStatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LocationInIncomeStatementAxis" xml:lang="en-US">Location in income statement [Axis].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementDomain" xlink:label="loc_thtx_LocationInIncomeStatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LocationInIncomeStatementDomain" xml:lang="en-US">Location In Income Statement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LocationInIncomeStatementDomain" xlink:to="lab_thtx_LocationInIncomeStatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LocationInIncomeStatementDomain" xml:lang="en-US">Location in income statement domain.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CostOfGoodsSoldMember" xlink:label="loc_thtx_CostOfGoodsSoldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CostOfGoodsSoldMember" xml:lang="en-US">Cost Of Goods Sold [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CostOfGoodsSoldMember" xml:lang="en-US">Cost of goods sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CostOfGoodsSoldMember" xlink:to="lab_thtx_CostOfGoodsSoldMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xml:lang="en-US">Reduction in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xml:lang="en-US">Cost of inventories recognised as expense during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xml:lang="en-US">Cost of inventories recognised as expense during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InventoriesReturned" xlink:label="loc_thtx_InventoriesReturned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InventoriesReturned" xml:lang="en-US">Inventories Returned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_InventoriesReturned" xml:lang="en-US">Inventories returned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InventoriesReturned" xlink:to="lab_thtx_InventoriesReturned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InventoriesReturned" xml:lang="en-US">Inventories returned.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="loc_ifrs-full_InventoryWritedown2011" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InventoryWritedown2011" xml:lang="en-US">Inventory write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InventoryWritedown2011" xml:lang="en-US">Inventory writedown</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoryWritedown2011" xlink:to="lab_ifrs-full_InventoryWritedown2011" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForExcessStock" xlink:label="loc_thtx_ProvisionForExcessStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProvisionForExcessStock" xml:lang="en-US">Provision For Excess Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProvisionForExcessStock" xml:lang="en-US">Provision of inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProvisionForExcessStock" xlink:to="lab_thtx_ProvisionForExcessStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProvisionForExcessStock" xml:lang="en-US">Provision for excess stock.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForFormulation" xlink:label="loc_thtx_ProvisionForFormulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProvisionForFormulation" xml:lang="en-US">Provision For Formulation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProvisionForFormulation" xml:lang="en-US">Provision for formulation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProvisionForFormulation" xlink:to="lab_thtx_ProvisionForFormulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProvisionForFormulation" xml:lang="en-US">Provision for formulation.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheExpiredRawMaterial" xlink:label="loc_thtx_ProvisionForTheExpiredRawMaterial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProvisionForTheExpiredRawMaterial" xml:lang="en-US">Provision For The Expired Raw Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProvisionForTheExpiredRawMaterial" xml:lang="en-US">Provision for the expired raw material</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProvisionForTheExpiredRawMaterial" xlink:to="lab_thtx_ProvisionForTheExpiredRawMaterial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProvisionForTheExpiredRawMaterial" xml:lang="en-US">Provision for the expired raw material.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheInventoryInDevelopment" xlink:label="loc_thtx_ProvisionForTheInventoryInDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProvisionForTheInventoryInDevelopment" xml:lang="en-US">Provision For The Inventory In Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProvisionForTheInventoryInDevelopment" xml:lang="en-US">Provision for the inventory in development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProvisionForTheInventoryInDevelopment" xlink:to="lab_thtx_ProvisionForTheInventoryInDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProvisionForTheInventoryInDevelopment" xml:lang="en-US">Provision for the inventory in development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xml:lang="en-US">Current advances to suppliers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrepaidExpenses" xlink:label="loc_thtx_PrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PrepaidExpenses" xml:lang="en-US">Prepaid Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_PrepaidExpenses" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PrepaidExpenses" xlink:to="lab_thtx_PrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PrepaidExpenses" xml:lang="en-US">Prepaid Expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CarryingAmountMember" xml:lang="en-US">Carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Gross carrying amount [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xml:lang="en-US">Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xlink:label="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Accumulated Depreciation On Property Plant And Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xlink:to="lab_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Accumulated depreciation on property plant and equipment [abstract].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xlink:label="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation Disposals Property Plant And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xlink:to="lab_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation disposals property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xml:lang="en-US">Property Plant And Equipment Accumulated Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="lab_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xml:lang="en-US">Proprety Plant And Equipment Accumulated Depreciation.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountAbstract" xlink:label="loc_thtx_NetCarryingAmountAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NetCarryingAmountAbstract" xml:lang="en-US">Net Carrying Amount [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NetCarryingAmountAbstract" xml:lang="en-US">Net carrying amounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_NetCarryingAmountAbstract" xml:lang="en-US">Net carrying amounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NetCarryingAmountAbstract" xlink:to="lab_thtx_NetCarryingAmountAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NetCarryingAmountAbstract" xml:lang="en-US">xxx_Net Carrying Amount Abstract</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xml:lang="en-US">Disposals, property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">Additions to right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">New lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xml:lang="en-US">New lease (b)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfRightOfUseAsset" xlink:label="loc_thtx_AmortizationOfRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AmortizationOfRightOfUseAsset" xml:lang="en-US">Amortization of Right of use asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AmortizationOfRightOfUseAsset" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AmortizationOfRightOfUseAsset" xlink:to="lab_thtx_AmortizationOfRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AmortizationOfRightOfUseAsset" xml:lang="en-US">Amortization of Right of use asset.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xlink:label="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xml:lang="en-US">Increase Decrease Through Net Exchange Differences of Right to use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xml:lang="en-US">Effect of change in exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xlink:to="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xml:lang="en-US">Increase Decrease Through Net Exchange Differences of Right to use Asset.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfRightOfUseAssets" xlink:label="loc_thtx_TerminationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TerminationOfRightOfUseAssets" xml:lang="en-US">Termination Of Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TerminationOfRightOfUseAssets" xml:lang="en-US">Termination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TerminationOfRightOfUseAssets" xlink:to="lab_thtx_TerminationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TerminationOfRightOfUseAssets" xml:lang="en-US">Termination of right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountMember" xlink:label="loc_thtx_NetCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NetCarryingAmountMember" xml:lang="en-US">Net Carrying Amount [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NetCarryingAmountMember" xlink:to="lab_thtx_NetCarryingAmountMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NetCarryingAmountMember" xml:lang="en-US">Net Carrying Amount [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoEuropeMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoEuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommercializationRightsTrogarzoEuropeMember" xml:lang="en-US">Commercialization Rights Trogarzo Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CommercializationRightsTrogarzoEuropeMember" xml:lang="en-US">Commercialization rights- Trogarzo&#174; European Territory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommercializationRightsTrogarzoEuropeMember" xlink:to="lab_thtx_CommercializationRightsTrogarzoEuropeMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommercializationRightsTrogarzoNorthAmericaMember" xml:lang="en-US">Commercialization Rights Trogarzo North America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_CommercializationRightsTrogarzoNorthAmericaMember" xml:lang="en-US">Commercialization rights- Trogarzo&#174; North America</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CommercializationRightsTrogarzoNorthAmericaMember" xml:lang="en-US">Commercialization rights- Trogarzo&#174; North American Territory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:to="lab_thtx_CommercializationRightsTrogarzoNorthAmericaMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OncologyPlatformMember" xlink:label="loc_thtx_OncologyPlatformMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OncologyPlatformMember" xml:lang="en-US">Oncology Platform [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OncologyPlatformMember" xml:lang="en-US">Oncology Platform</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OncologyPlatformMember" xlink:to="lab_thtx_OncologyPlatformMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationAbstract" xlink:label="loc_thtx_AccumulatedAmortizationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedAmortizationAbstract" xml:lang="en-US">Accumulated Amortization [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AccumulatedAmortizationAbstract" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedAmortizationAbstract" xlink:to="lab_thtx_AccumulatedAmortizationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedAmortizationAbstract" xml:lang="en-US">Accumulated amortization.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Accumulated Amortization Disposals Intangible Assets Other Than Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Accumulated amortization disposals, intangible assets other than goodwill.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Accumulated Amortization Of Intangible Assets Other Than Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xlink:to="lab_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Accumulated Amortization Of Intangible Assets Other Than Goodwill.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xml:lang="en-US">Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Disposals, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayable" xlink:label="loc_thtx_InitialMilestonePaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InitialMilestonePaymentsPayable" xml:lang="en-US">Initial Milestone Payments Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_InitialMilestonePaymentsPayable" xml:lang="en-US">Initial Milestone Payments Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_InitialMilestonePaymentsPayable" xml:lang="en-US">Initial payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InitialMilestonePaymentsPayable" xlink:to="lab_thtx_InitialMilestonePaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InitialMilestonePaymentsPayable" xml:lang="en-US">Initial Milestone Payments Payable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAxis" xlink:label="loc_thtx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneAxis" xml:lang="en-US">Milestone [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneAxis" xlink:to="lab_thtx_MilestoneAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneDomain" xml:lang="en-US">Milestone [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneDomain" xlink:to="lab_thtx_MilestoneDomain" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFiveMember" xlink:label="loc_thtx_MilestoneFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneFiveMember" xml:lang="en-US">Milestone Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_MilestoneFiveMember" xml:lang="en-US">Upon first achieving annual net sales of US$ 500,000</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneFiveMember" xlink:to="lab_thtx_MilestoneFiveMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFourMember" xlink:label="loc_thtx_MilestoneFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneFourMember" xml:lang="en-US">Milestone Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_MilestoneFourMember" xml:lang="en-US">Upon first achieving annual net sales of US$ 200,000</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneFourMember" xlink:to="lab_thtx_MilestoneFourMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneSixMember" xlink:label="loc_thtx_MilestoneSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneSixMember" xml:lang="en-US">Milestone Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_MilestoneSixMember" xml:lang="en-US">Upon first achieving annual net sales of US$ 1,000,000</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneSixMember" xlink:to="lab_thtx_MilestoneSixMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfArrangementsAxis" xml:lang="en-US">Type of arrangements [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TypeOfArrangementsAxis" xml:lang="en-US">Type of arrangements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfArrangementsAxis" xlink:to="lab_thtx_TypeOfArrangementsAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfArrangementsMemberDomain" xml:lang="en-US">Type of arrangements Member [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TypeOfArrangementsMemberDomain" xml:lang="en-US">Type of arrangements [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain" xlink:to="lab_thtx_TypeOfArrangementsMemberDomain" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentAxis" xlink:label="loc_thtx_BasisOfRoyaltyPaymentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BasisOfRoyaltyPaymentAxis" xml:lang="en-US">Basis Of Royalty Payment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BasisOfRoyaltyPaymentAxis" xlink:to="lab_thtx_BasisOfRoyaltyPaymentAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentMember" xlink:label="loc_thtx_BasisOfRoyaltyPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BasisOfRoyaltyPaymentMember" xml:lang="en-US">Basis Of Royalty Payment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BasisOfRoyaltyPaymentMember" xlink:to="lab_thtx_BasisOfRoyaltyPaymentMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetSalesBasisMember" xlink:label="loc_thtx_NetSalesBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NetSalesBasisMember" xml:lang="en-US">Net Sales Basis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NetSalesBasisMember" xml:lang="en-US">Net Sales Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NetSalesBasisMember" xlink:to="lab_thtx_NetSalesBasisMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRevenueSublicenseBasisMember" xlink:label="loc_thtx_RoyaltyRevenueSublicenseBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RoyaltyRevenueSublicenseBasisMember" xml:lang="en-US">Royalty Revenue Sublicense Basis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RoyaltyRevenueSublicenseBasisMember" xml:lang="en-US">Royalty Revenue Sublicense Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RoyaltyRevenueSublicenseBasisMember" xlink:to="lab_thtx_RoyaltyRevenueSublicenseBasisMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" xml:lang="en-US">Business Combination Adjustment To Purchase Consideration [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" xlink:to="lab_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xml:lang="en-US">Business Combination Adjustment To Purchase Consideration [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xlink:to="lab_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xml:lang="en-US">Business Combination Adjustment To Consideration Installment One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xml:lang="en-US">Business Combination Adjustment To Consideration Installment One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xlink:to="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xml:lang="en-US">Business Combination Adjustment To Consideration Installment Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xml:lang="en-US">Business Combination Adjustment To Consideration Installment Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xlink:to="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xml:lang="en-US">Business combination adjustment to consideration installment two.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xml:lang="en-US">Business combinations [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xml:lang="en-US">Entity's total for business combinations [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaAmendmentAgreementMember" xlink:label="loc_thtx_KatanaAmendmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_KatanaAmendmentAgreementMember" xml:lang="en-US">Katana Amendment Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_KatanaAmendmentAgreementMember" xml:lang="en-US">Katana Amendment Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_KatanaAmendmentAgreementMember" xlink:to="lab_thtx_KatanaAmendmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_KatanaAmendmentAgreementMember" xml:lang="en-US">Katana amendment agreement.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaMember" xlink:label="loc_thtx_KatanaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_KatanaMember" xml:lang="en-US">Katana</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_KatanaMember" xml:lang="en-US">Katana [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_KatanaMember" xlink:to="lab_thtx_KatanaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_KatanaMember" xml:lang="en-US">Katana.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xml:lang="en-US">Classes of share capital [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xml:lang="en-US">Share capital [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OrdinarySharesMember" xml:lang="en-US">Ordinary shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AcquisitionCostsForIntangibleAssets" xlink:label="loc_thtx_AcquisitionCostsForIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AcquisitionCostsForIntangibleAssets" xml:lang="en-US">Acquisition Costs For Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AcquisitionCostsForIntangibleAssets" xml:lang="en-US">Acquisition costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AcquisitionCostsForIntangibleAssets" xlink:to="lab_thtx_AcquisitionCostsForIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AcquisitionCostsForIntangibleAssets" xml:lang="en-US">Acquisition costs for intangible assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xml:lang="en-US">Business combination acquisition costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Acquisition of intangible assets during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xml:lang="en-US">Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill Cash Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xml:lang="en-US">Additions to intangibles Through cash payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xlink:to="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xml:lang="en-US">Additions other than through business combinations intangible assets other than goodwill cash payment.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xml:lang="en-US">Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill Share Based Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xml:lang="en-US">Additions to intangibles Through share based payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xlink:to="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xml:lang="en-US">Additions other than through business combinations intangible assets other than goodwill share based payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationExpense" xml:lang="en-US">Amortisation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AmortisationExpense" xml:lang="en-US">Amortisation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationContingentConsiderationFairValue" xlink:label="loc_thtx_BusinessCombinationContingentConsiderationFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationContingentConsiderationFairValue" xml:lang="en-US">Business Combination Contingent Consideration Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BusinessCombinationContingentConsiderationFairValue" xml:lang="en-US">Business combination contingent consideration fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationContingentConsiderationFairValue" xlink:to="lab_thtx_BusinessCombinationContingentConsiderationFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BusinessCombinationContingentConsiderationFairValue" xml:lang="en-US">Business combination contingent consideration fair value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xlink:label="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xml:lang="en-US">Business Combination Increase Decrease In Purchase Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xml:lang="en-US">Business combination adjustment to the purchase consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xlink:to="lab_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xml:lang="en-US">Business combination increase decrease in purchase consideration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashTransferred" xml:lang="en-US">Cash transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashTransferred" xml:lang="en-US">Business combination cash consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xml:lang="en-US">Contingent consideration recognised as of acquisition date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xml:lang="en-US">Business combination contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePayableAnnualInstallment" xlink:label="loc_thtx_DevelopmentMilestonePayableAnnualInstallment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DevelopmentMilestonePayableAnnualInstallment" xml:lang="en-US">Development Milestone Payable Annual Installment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DevelopmentMilestonePayableAnnualInstallment" xml:lang="en-US">Milestone Payments annual installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DevelopmentMilestonePayableAnnualInstallment" xlink:to="lab_thtx_DevelopmentMilestonePayableAnnualInstallment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DevelopmentMilestonePayableAnnualInstallment" xml:lang="en-US">Development milestone payable annual installment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xml:lang="en-US">Equity interests of acquirer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xml:lang="en-US">Business combination shares value of consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FeeAndCommissionExpense" xml:lang="en-US">Fee and commission expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FeeAndCommissionExpense" xml:lang="en-US">Annual maintenance fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FeeAndCommissionExpense" xlink:to="lab_ifrs-full_FeeAndCommissionExpense" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_FirstMilestoneInstallmentPaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FirstMilestoneInstallmentPaymentsPayable" xml:lang="en-US">First Milestone Installment Payments Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_FirstMilestoneInstallmentPaymentsPayable" xml:lang="en-US">First milestone installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FirstMilestoneInstallmentPaymentsPayable" xlink:to="lab_thtx_FirstMilestoneInstallmentPaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FirstMilestoneInstallmentPaymentsPayable" xml:lang="en-US">First milestone installment payments payable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xlink:label="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xml:lang="en-US">Initial Milestone Payments Payable Aggregate Annual Installments.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xml:lang="en-US">Initial Milestone Payments Payable Aggregate Annual Installments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xlink:to="lab_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xml:lang="en-US">Initial milestone payments payable aggregate annual installments.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IntangibleAssetsAgreementTermOfContract" xlink:label="loc_thtx_IntangibleAssetsAgreementTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IntangibleAssetsAgreementTermOfContract" xml:lang="en-US">Intangible Assets Agreement Term Of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_IntangibleAssetsAgreementTermOfContract" xml:lang="en-US">Intangible Assets Agreement Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IntangibleAssetsAgreementTermOfContract" xlink:to="lab_thtx_IntangibleAssetsAgreementTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IntangibleAssetsAgreementTermOfContract" xml:lang="en-US">Intangible Assets Agreement Term Of Contract.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaunchMilestonePayable" xlink:label="loc_thtx_LaunchMilestonePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LaunchMilestonePayable" xml:lang="en-US">Launch Milestone Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_LaunchMilestonePayable" xml:lang="en-US">Launch milestone payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LaunchMilestonePayable" xlink:to="lab_thtx_LaunchMilestonePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LaunchMilestonePayable" xml:lang="en-US">Launch milestone payable
..</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAmountPayable" xlink:label="loc_thtx_MilestoneAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneAmountPayable" xml:lang="en-US">Milestone Amount Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MilestoneAmountPayable" xml:lang="en-US">Milestone amount payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneAmountPayable" xlink:to="lab_thtx_MilestoneAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MilestoneAmountPayable" xml:lang="en-US">Milestone amount payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xml:lang="en-US">Number of instruments or interests issued or issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xml:lang="en-US">Business combination number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Number of shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Number of shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xml:lang="en-US">Shares issued during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Number of shares issued and fully paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xml:lang="en-US">Number of shares issued and fully paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentOfUpfrontMilestones" xlink:label="loc_thtx_PaymentOfUpfrontMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PaymentOfUpfrontMilestones" xml:lang="en-US">Payment Of Upfront Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_PaymentOfUpfrontMilestones" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PaymentOfUpfrontMilestones" xlink:to="lab_thtx_PaymentOfUpfrontMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PaymentOfUpfrontMilestones" xml:lang="en-US">Payment Of Upfront Milestones.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xlink:label="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xml:lang="en-US">Percentage Of Purchase Price Consideration Of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xml:lang="en-US">Intangible Asset Purchase Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xlink:to="lab_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xml:lang="en-US">Percentage Of Purchase Price Consideration Of Intangible Assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xml:lang="en-US">Proceeds from government grants, classified as investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xml:lang="en-US">Subsidy or grants received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RegulatoryMilestonePaymentPayable" xlink:label="loc_thtx_RegulatoryMilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RegulatoryMilestonePaymentPayable" xml:lang="en-US">Regulatory Milestone Payment Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RegulatoryMilestonePaymentPayable" xml:lang="en-US">Regulatory payable milestone related</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RegulatoryMilestonePaymentPayable" xlink:to="lab_thtx_RegulatoryMilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RegulatoryMilestonePaymentPayable" xml:lang="en-US">Regulatory payable milestone related.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyFeesAsAPercentageOfRevenue" xlink:label="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RoyaltyFeesAsAPercentageOfRevenue" xml:lang="en-US">Royalty Fees As A Percentage Of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RoyaltyFeesAsAPercentageOfRevenue" xml:lang="en-US">Royalty fees in percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue" xlink:to="lab_thtx_RoyaltyFeesAsAPercentageOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RoyaltyFeesAsAPercentageOfRevenue" xml:lang="en-US">Royalty fees as a percentage of revenue.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecondMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_SecondMilestoneInstallmentPaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SecondMilestoneInstallmentPaymentsPayable" xml:lang="en-US">Second Milestone Installment Payments Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_SecondMilestoneInstallmentPaymentsPayable" xml:lang="en-US">Second milestone installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SecondMilestoneInstallmentPaymentsPayable" xlink:to="lab_thtx_SecondMilestoneInstallmentPaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SecondMilestoneInstallmentPaymentsPayable" xml:lang="en-US">Second milestone installment payments payable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodAxis" xlink:label="loc_thtx_FeesPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FeesPeriodAxis" xml:lang="en-US">Fees Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FeesPeriodAxis" xlink:to="lab_thtx_FeesPeriodAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodMember" xlink:label="loc_thtx_FeesPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FeesPeriodMember" xml:lang="en-US">Fees Period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FeesPeriodMember" xlink:to="lab_thtx_FeesPeriodMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AfterFiveYearsMember" xlink:label="loc_thtx_AfterFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AfterFiveYearsMember" xml:lang="en-US">After Five Years [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AfterFiveYearsMember" xml:lang="en-US">After Five Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AfterFiveYearsMember" xlink:to="lab_thtx_AfterFiveYearsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstFiveYearsMember" xlink:label="loc_thtx_FirstFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FirstFiveYearsMember" xml:lang="en-US">First Five Years [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FirstFiveYearsMember" xml:lang="en-US">First Five Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FirstFiveYearsMember" xlink:to="lab_thtx_FirstFiveYearsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xml:lang="en-US">Development Milestone Phase One Clinical Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xml:lang="en-US">Development Milestone Phase One Clinical Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xlink:to="lab_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xml:lang="en-US">Development Milestone Phase Three Clinical Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xml:lang="en-US">Development Milestone Phase Three Clinical Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xlink:to="lab_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xml:lang="en-US">Development Milestone Phase Two Clinical Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xml:lang="en-US">Development Milestone Phase Two Clinical Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xlink:to="lab_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneOneMember" xlink:label="loc_thtx_MilestoneOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestoneOneMember" xml:lang="en-US">Milestone One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MilestoneOneMember" xml:lang="en-US">Milestone One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestoneOneMember" xlink:to="lab_thtx_MilestoneOneMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestonePhaseTwoLiveDemonstrationMember" xlink:label="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MilestonePhaseTwoLiveDemonstrationMember" xml:lang="en-US">Milestone Phase Two Live Demonstration [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MilestonePhaseTwoLiveDemonstrationMember" xml:lang="en-US">Milestone Phase Two Live Demonstration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember" xlink:to="lab_thtx_MilestonePhaseTwoLiveDemonstrationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MilestonePhaseTwoLiveDemonstrationMember" xml:lang="en-US">Milestone phase two live demonstration.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesAxis" xlink:label="loc_thtx_NatureOfFeesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NatureOfFeesAxis" xml:lang="en-US">Nature of Fees [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NatureOfFeesAxis" xlink:to="lab_thtx_NatureOfFeesAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesMember" xlink:label="loc_thtx_NatureOfFeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NatureOfFeesMember" xml:lang="en-US">Nature of Fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NatureOfFeesMember" xlink:to="lab_thtx_NatureOfFeesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRelatedLicensePeptidesMember" xlink:label="loc_thtx_RoyaltyRelatedLicensePeptidesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RoyaltyRelatedLicensePeptidesMember" xml:lang="en-US">Royalty Related License Peptides [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RoyaltyRelatedLicensePeptidesMember" xml:lang="en-US">Royalty Related License Peptides</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RoyaltyRelatedLicensePeptidesMember" xlink:to="lab_thtx_RoyaltyRelatedLicensePeptidesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoMember" xlink:label="loc_thtx_TrogarzoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TrogarzoMember" xml:lang="en-US">Trogarzo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TrogarzoMember" xml:lang="en-US">Trogarzo&#174;</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TrogarzoMember" xlink:to="lab_thtx_TrogarzoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TrogarzoMember" xml:lang="en-US">Trogarzo</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosAxis" xlink:label="loc_thtx_ScenariosAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScenariosAxis" xml:lang="en-US">Scenarios [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScenariosAxis" xlink:to="lab_thtx_ScenariosAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosDomain" xlink:label="loc_thtx_ScenariosDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScenariosDomain" xml:lang="en-US">Scenarios [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScenariosDomain" xlink:to="lab_thtx_ScenariosDomain" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheAxis" xlink:label="loc_thtx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TrancheAxis" xlink:to="lab_thtx_TrancheAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheDomain" xlink:label="loc_thtx_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TrancheDomain" xlink:to="lab_thtx_TrancheDomain" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LicenseAgreementTransferPlusLPMember" xlink:label="loc_thtx_LicenseAgreementTransferPlusLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LicenseAgreementTransferPlusLPMember" xml:lang="en-US">License Agreement Transfer Plus L P [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LicenseAgreementTransferPlusLPMember" xml:lang="en-US">License Agreement Transfer Plus L P</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LicenseAgreementTransferPlusLPMember" xlink:to="lab_thtx_LicenseAgreementTransferPlusLPMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LicenseAgreementTransferPlusLPMember" xml:lang="en-US">License agreement transfer plus L P.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaimedAgreementMember" xlink:label="loc_thtx_TaimedAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaimedAgreementMember" xml:lang="en-US">Taimed Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaimedAgreementMember" xml:lang="en-US">Taimed Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaimedAgreementMember" xlink:to="lab_thtx_TaimedAgreementMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xml:lang="en-US">Schedule Of Information About Other Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xml:lang="en-US">Other asset [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xlink:to="lab_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xml:lang="en-US">Schedule of information about other assets.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xml:lang="en-US">Disclosure of Detailed Information About Other Asset [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:label="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureInformationAboutOtherAssetsLineItems" xml:lang="en-US">Disclosure Information About Other Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DisclosureInformationAboutOtherAssetsLineItems" xml:lang="en-US">Other asset [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:to="lab_thtx_DisclosureInformationAboutOtherAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureInformationAboutOtherAssetsLineItems" xml:lang="en-US">Disclosure Information About Other Assets [Line item].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xml:lang="en-US">Accumulated Amortization On Other Assets Non Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xlink:to="lab_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xml:lang="en-US">Accumulated Amortization On Other Non Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xlink:to="lab_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xml:lang="en-US">Accumulated Amortization On Other Non Current Assets.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherNonCurrentAssets" xlink:label="loc_thtx_AmortizationOfOtherNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AmortizationOfOtherNonCurrentAssets" xml:lang="en-US">Amortization Of Other Non Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AmortizationOfOtherNonCurrentAssets" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AmortizationOfOtherNonCurrentAssets" xlink:to="lab_thtx_AmortizationOfOtherNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AmortizationOfOtherNonCurrentAssets" xml:lang="en-US">Amortization Of Other Non Current Assets.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmount" xlink:label="loc_thtx_NetCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NetCarryingAmount" xml:lang="en-US">Net Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NetCarryingAmount" xml:lang="en-US">Net carrying amounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NetCarryingAmount" xlink:to="lab_thtx_NetCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NetCarryingAmount" xml:lang="en-US">Net carrying amount.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ReconciliationOfChangesInOtherAssetsAbstract" xlink:label="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ReconciliationOfChangesInOtherAssetsAbstract" xml:lang="en-US">Reconciliation Of Changes In Other Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ReconciliationOfChangesInOtherAssetsAbstract" xml:lang="en-US">Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract" xlink:to="lab_thtx_ReconciliationOfChangesInOtherAssetsAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAssetsNonCurrentAtCost" xlink:label="loc_thtx_OtherAssetsNonCurrentAtCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OtherAssetsNonCurrentAtCost" xml:lang="en-US">Other Assets Non Current at Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OtherAssetsNonCurrentAtCost" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OtherAssetsNonCurrentAtCost" xlink:to="lab_thtx_OtherAssetsNonCurrentAtCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OtherAssetsNonCurrentAtCost" xml:lang="en-US">Other Assets non current at cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CounterpartiesAxis" xml:lang="en-US">Counterparties [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CounterpartiesMember" xml:lang="en-US">Counterparties [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeronoIncMember" xlink:label="loc_thtx_SeronoIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SeronoIncMember" xml:lang="en-US">Serono Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SeronoIncMember" xml:lang="en-US">Serono Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SeronoIncMember" xlink:to="lab_thtx_SeronoIncMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ContractualObligations" xlink:label="loc_thtx_ContractualObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ContractualObligations" xml:lang="en-US">Contractual Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ContractualObligations" xml:lang="en-US">Contractual obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ContractualObligations" xlink:to="lab_thtx_ContractualObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ContractualObligations" xml:lang="en-US">Contractual obligations.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PerformanceObligationFinalSettlementAmount" xlink:label="loc_thtx_PerformanceObligationFinalSettlementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PerformanceObligationFinalSettlementAmount" xml:lang="en-US">Performance Obligation Final Settlement Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_PerformanceObligationFinalSettlementAmount" xml:lang="en-US">Performance obligation final settlement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PerformanceObligationFinalSettlementAmount" xlink:to="lab_thtx_PerformanceObligationFinalSettlementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PerformanceObligationFinalSettlementAmount" xml:lang="en-US">Performance obligation final settlement amount.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueInNextFourToFiveYearsMember" xlink:label="loc_thtx_DueInNextFourToFiveYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DueInNextFourToFiveYearsMember" xml:lang="en-US">Due In Next Four To Five Years [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DueInNextFourToFiveYearsMember" xml:lang="en-US">Due in next four to five years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DueInNextFourToFiveYearsMember" xlink:to="lab_thtx_DueInNextFourToFiveYearsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueWithOneYearMember" xlink:label="loc_thtx_DueWithOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DueWithOneYearMember" xml:lang="en-US">Due With One Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DueWithOneYearMember" xml:lang="en-US">Due with one year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DueWithOneYearMember" xlink:to="lab_thtx_DueWithOneYearMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementAxis" xlink:label="loc_thtx_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfArrangementAxis" xml:lang="en-US">Type of arrangement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfArrangementAxis" xlink:to="lab_thtx_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfArrangementMember" xml:lang="en-US">Type of arrangement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfArrangementMember" xlink:to="lab_thtx_TypeOfArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TypeOfArrangementMember" xml:lang="en-US">Type of arrangement Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandThirteenTerminationAgreementMember" xlink:label="loc_thtx_TwoThousandThirteenTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TwoThousandThirteenTerminationAgreementMember" xml:lang="en-US">Two Thousand Thirteen Termination agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TwoThousandThirteenTerminationAgreementMember" xml:lang="en-US">2013 Termination agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TwoThousandThirteenTerminationAgreementMember" xlink:to="lab_thtx_TwoThousandThirteenTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TwoThousandThirteenTerminationAgreementMember" xml:lang="en-US">Two thousand thirteen termination agreement member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesTable" xlink:label="loc_thtx_TradeAndOtherPayablesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TradeAndOtherPayablesTable" xml:lang="en-US">Trade And Other Payables [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TradeAndOtherPayablesTable" xlink:to="lab_thtx_TradeAndOtherPayablesTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesLineItems" xlink:label="loc_thtx_TradeAndOtherPayablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TradeAndOtherPayablesLineItems" xml:lang="en-US">Trade And Other Payables [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems" xlink:to="lab_thtx_TradeAndOtherPayablesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Amounts payable, related party transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xml:lang="en-US">Salaries and benefits due to key management personnel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US">Accrued liabilities and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestPayable" xlink:label="loc_ifrs-full_CurrentInterestPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentInterestPayable" xml:lang="en-US">Current interest payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentInterestPayable" xml:lang="en-US">Accrued interest payable on convertible unsecured senior notes and Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInterestPayable" xlink:to="lab_ifrs-full_CurrentInterestPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xml:lang="en-US">Liabilities from share-based payment transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xml:lang="en-US">Liability related to deferred stock unit plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xml:lang="en-US">Deferred stock liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentPayables" xml:lang="en-US">Other current payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherCurrentPayables" xml:lang="en-US">TaiMed milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables" xlink:to="lab_ifrs-full_OtherCurrentPayables" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xml:lang="en-US">Short-term employee benefits accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xml:lang="en-US">Employee salaries and benefits payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Current trade payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xml:lang="en-US">Trade payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EqualAnnualInstallments" xlink:label="loc_thtx_EqualAnnualInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EqualAnnualInstallments" xml:lang="en-US">Equal Annual Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EqualAnnualInstallments" xml:lang="en-US">Equal annual installments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EqualAnnualInstallments" xlink:to="lab_thtx_EqualAnnualInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EqualAnnualInstallments" xml:lang="en-US">Equal annual installments.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentForContingentLiabilities" xlink:label="loc_thtx_PaymentForContingentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PaymentForContingentLiabilities" xml:lang="en-US">Payment for Contingent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PaymentForContingentLiabilities" xml:lang="en-US">payment for Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PaymentForContingentLiabilities" xlink:to="lab_thtx_PaymentForContingentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PaymentForContingentLiabilities" xml:lang="en-US">Payment for Contingent liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentOfMilestones" xlink:label="loc_thtx_PaymentOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PaymentOfMilestones" xml:lang="en-US">Payment Of Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PaymentOfMilestones" xml:lang="en-US">Payment of milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PaymentOfMilestones" xlink:to="lab_thtx_PaymentOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PaymentOfMilestones" xml:lang="en-US">Payment of milestones.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xml:lang="en-US">Disclosure of other provisions [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xml:lang="en-US">Classes of other provisions [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherProvisionsMember" xml:lang="en-US">Other provisions [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChargebacksAndRebatesMember" xlink:label="loc_thtx_ChargebacksAndRebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ChargebacksAndRebatesMember" xml:lang="en-US">Chargebacks And Rebates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ChargebacksAndRebatesMember" xml:lang="en-US">Chargebacks and rebates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ChargebacksAndRebatesMember" xlink:to="lab_thtx_ChargebacksAndRebatesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAdditionalProvisionMember" xlink:label="loc_thtx_OtherAdditionalProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OtherAdditionalProvisionMember" xml:lang="en-US">Other Additional Provision [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OtherAdditionalProvisionMember" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OtherAdditionalProvisionMember" xlink:to="lab_thtx_OtherAdditionalProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OtherAdditionalProvisionMember" xml:lang="en-US">Other additional provision.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RefundsProvisionMember" xlink:label="loc_ifrs-full_RefundsProvisionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RefundsProvisionMember" xml:lang="en-US">Refunds provision [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RefundsProvisionMember" xml:lang="en-US">Returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RefundsProvisionMember" xlink:to="lab_ifrs-full_RefundsProvisionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xml:lang="en-US">Disclosure of other provisions [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xml:lang="en-US">Disclosure of other provisions [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xml:lang="en-US">Additional provisions, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xml:lang="en-US">Provisions made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="lab_ifrs-full_AdditionalProvisionsOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xml:lang="en-US">Effect of change in exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xml:lang="en-US">Provision used, other provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xml:lang="en-US">Provisions used</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xml:lang="en-US">Line items by function [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_thtx_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GeneralAndAdministrativeExpenseMember" xlink:to="lab_thtx_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_thtx_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ResearchAndDevelopmentExpenseMember" xlink:to="lab_thtx_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SellingAndMarketingExpenseMember" xlink:label="loc_thtx_SellingAndMarketingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SellingAndMarketingExpenseMember" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SellingAndMarketingExpenseMember" xlink:to="lab_thtx_SellingAndMarketingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SellingAndMarketingExpenseMember" xml:lang="en-US">Selling and Marketing Expense.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeveranceAndOtherExpensesMember" xlink:label="loc_thtx_SeveranceAndOtherExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SeveranceAndOtherExpensesMember" xml:lang="en-US">Severance And Other Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SeveranceAndOtherExpensesMember" xml:lang="en-US">Severance And Other Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SeveranceAndOtherExpensesMember" xlink:to="lab_thtx_SeveranceAndOtherExpensesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityMember" xlink:label="loc_thtx_LoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityMember" xml:lang="en-US">Loan Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityMember" xlink:to="lab_thtx_LoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityMember" xml:lang="en-US">Loan facility.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1And2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1And2LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche1And2LoanMember" xml:lang="en-US">Loan Facility Tranche 1 and 2 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche1And2LoanMember" xlink:to="lab_thtx_LoanFacilityTranche1And2LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche1And2LoanMember" xml:lang="en-US">Loan facility tranche 1 and 2 loan.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche1LoanMember" xml:lang="en-US">Loan Facility Tranche 1 Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LoanFacilityTranche1LoanMember" xml:lang="en-US">Loan Facility Tranche 1 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche1LoanMember" xlink:to="lab_thtx_LoanFacilityTranche1LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche1LoanMember" xml:lang="en-US">Loan facility tranche 1 loan.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche2LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche2LoanMember" xml:lang="en-US">Loan Facility Tranche 2 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche2LoanMember" xlink:to="lab_thtx_LoanFacilityTranche2LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche2LoanMember" xml:lang="en-US">Loan facility tranche 2 loan.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3And4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3And4LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche3And4LoanMember" xml:lang="en-US">Loan Facility Tranche 3 and 4 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche3And4LoanMember" xlink:to="lab_thtx_LoanFacilityTranche3And4LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche3And4LoanMember" xml:lang="en-US">Loan facility tranche 3 and 4 loan member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche3LoanMember" xml:lang="en-US">Loan Facility Tranche 3 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche3LoanMember" xlink:to="lab_thtx_LoanFacilityTranche3LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche3LoanMember" xml:lang="en-US">Loan facility tranche 3 loan.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche4LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTranche4LoanMember" xml:lang="en-US">Loan Facility Tranche 4 Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTranche4LoanMember" xlink:to="lab_thtx_LoanFacilityTranche4LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTranche4LoanMember" xml:lang="en-US">Loan facility tranche 4 loan.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xlink:label="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xml:lang="en-US">Cash Cash Equivalents And Eligible Short Term Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xml:lang="en-US">Cash, Cash Equivalents and Eligible Short-term Investments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xlink:to="lab_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xml:lang="en-US">Cash, cash equivalents and eligible short-term investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmountReclassifiedFromDeferredFinancingCosts" xlink:label="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AmountReclassifiedFromDeferredFinancingCosts" xml:lang="en-US">Amount Reclassified From Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AmountReclassifiedFromDeferredFinancingCosts" xml:lang="en-US">Amount reclassified from deferred financing costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts" xlink:to="lab_thtx_AmountReclassifiedFromDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AmountReclassifiedFromDeferredFinancingCosts" xml:lang="en-US">Amount reclassified from deferred financing costs.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsInterestPeriod" xlink:label="loc_thtx_BorrowingsInterestPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BorrowingsInterestPeriod" xml:lang="en-US">Borrowings Interest Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BorrowingsInterestPeriod" xml:lang="en-US">Borrowings interest period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BorrowingsInterestPeriod" xlink:to="lab_thtx_BorrowingsInterestPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BorrowingsInterestPeriod" xml:lang="en-US">Borrowings interest period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xml:lang="en-US">Borrowings, interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xml:lang="en-US">Borrowings, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsMaturity" xml:lang="en-US">Borrowings, maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BorrowingsMaturity" xml:lang="en-US">Borrowings, maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsMaturity" xlink:to="lab_ifrs-full_BorrowingsMaturity" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xlink:label="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xml:lang="en-US">Ceiling Limit for Prepayment of Principal Amount Outstanding Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xml:lang="en-US">Ceiling limit for prepayment of principal amount outstanding, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xlink:to="lab_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xml:lang="en-US">Ceiling limit for prepayment of principal amount outstanding percent.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConsiderationPayable" xlink:label="loc_thtx_ConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConsiderationPayable" xml:lang="en-US">Consideration Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ConsiderationPayable" xml:lang="en-US">Consideration payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConsiderationPayable" xlink:to="lab_thtx_ConsiderationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ConsiderationPayable" xml:lang="en-US">Consideration payable.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xlink:label="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xml:lang="en-US">Date of Commencement of Principal Repayment In Advance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xml:lang="en-US">Date of commencement of principal repayment in advance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xlink:to="lab_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xml:lang="en-US">Date of commencement of principal repayment in advance.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentAmortizedValue" xlink:label="loc_thtx_DebtInstrumentAmortizedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DebtInstrumentAmortizedValue" xml:lang="en-US">Debt Instrument Amortized Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DebtInstrumentAmortizedValue" xml:lang="en-US">Debt instrument amortized value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DebtInstrumentAmortizedValue" xlink:to="lab_thtx_DebtInstrumentAmortizedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DebtInstrumentAmortizedValue" xml:lang="en-US">Debt instrument amortized value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmount" xlink:label="loc_thtx_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt Instrument Collateral Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt instrument collateral amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DebtInstrumentCollateralAmount" xlink:to="lab_thtx_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DebtInstrumentCollateralAmount" xml:lang="en-US">Amount of assets pledged to secure a debt instrument.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xlink:label="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xml:lang="en-US">Debt Instrument Collateral Amount If FDA Approval Not Obtained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xml:lang="en-US">Debt instrument collateral amount if FDA approval not obtained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xlink:to="lab_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xml:lang="en-US">Amount of assets pledged to secure a debt instrument if FDA approval not obtained.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinanceCostsWriteOff" xlink:label="loc_thtx_DeferredFinanceCostsWriteOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredFinanceCostsWriteOff" xml:lang="en-US">Deferred Finance costs Write Off</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DeferredFinanceCostsWriteOff" xml:lang="en-US">Deferred Finance costs Write Off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredFinanceCostsWriteOff" xlink:to="lab_thtx_DeferredFinanceCostsWriteOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredFinanceCostsWriteOff" xml:lang="en-US">Deferred finance costs write off.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line Of Credit Facility Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line o cCredit facility maximum borrowing capacity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotionalAmount" xml:lang="en-US">Notional amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_NotionalAmount" xml:lang="en-US">Notional amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">Warrants exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">Warrants exercisable price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentMember" xlink:label="loc_thtx_FifthAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FifthAmendmentMember" xml:lang="en-US">Fifth Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FifthAmendmentMember" xml:lang="en-US">Fifth Amendment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FifthAmendmentMember" xlink:to="lab_thtx_FifthAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FifthAmendmentMember" xml:lang="en-US">Fifth amendment member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xml:lang="en-US">Types of interest rates [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateTypesMember" xml:lang="en-US">Interest rate types [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SecuredOvernightFinancingRateMember" xml:lang="en-US">Secured Overnight Financing Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SecuredOvernightFinancingRateMember" xlink:to="lab_thtx_SecuredOvernightFinancingRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SecuredOvernightFinancingRateMember" xml:lang="en-US">Secured overnight financing rate.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTrancheTwoLoanMember" xlink:label="loc_thtx_LoanFacilityTrancheTwoLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LoanFacilityTrancheTwoLoanMember" xml:lang="en-US">Loan Facility Tranche Two Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LoanFacilityTrancheTwoLoanMember" xml:lang="en-US">Loan Facility Tranche 2 Loan [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LoanFacilityTrancheTwoLoanMember" xlink:to="lab_thtx_LoanFacilityTrancheTwoLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LoanFacilityTrancheTwoLoanMember" xml:lang="en-US">Loan facility tranche two loan member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MarathonWarrantsMember" xml:lang="en-US">Marathon Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MarathonWarrantsMember" xml:lang="en-US">Marathon Warrants [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MarathonWarrantsMember" xlink:to="lab_thtx_MarathonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MarathonWarrantsMember" xml:lang="en-US">Marathon warrants member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" xml:lang="en-US">Borrowing costs recognised as expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:to="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsAccretionExpense" xlink:label="loc_thtx_BorrowingsAccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BorrowingsAccretionExpense" xml:lang="en-US">Borrowings Accretion Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BorrowingsAccretionExpense" xml:lang="en-US">Accretion expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BorrowingsAccretionExpense" xlink:to="lab_thtx_BorrowingsAccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BorrowingsAccretionExpense" xml:lang="en-US">Borrowings accretion expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xml:lang="en-US">Current loans received and current portion of non-current loans received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xlink:to="lab_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="loc_ifrs-full_LoansReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LoansReceived" xml:lang="en-US">Loans received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LoansReceived" xml:lang="en-US">Term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LoansReceived" xlink:to="lab_ifrs-full_LoansReceived" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xml:lang="en-US">Non-current portion of non-current loans received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xml:lang="en-US">Non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromConsiderationOfTheFifthAmendment" xlink:label="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProceedsFromConsiderationOfTheFifthAmendment" xml:lang="en-US">Proceeds From Consideration Of The Fifth Amendment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProceedsFromConsiderationOfTheFifthAmendment" xml:lang="en-US">Consideration for the Fifth Amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment" xlink:to="lab_thtx_ProceedsFromConsiderationOfTheFifthAmendment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProceedsFromConsiderationOfTheFifthAmendment" xml:lang="en-US">Proceeds from consideration of the fifth amendment.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesTable" xml:lang="en-US">Convertible Unsecured Senior Notes [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:to="lab_thtx_ConvertibleUnsecuredSeniorNotesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xml:lang="en-US">Classes of liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesMember" xml:lang="en-US">Liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesMember" xml:lang="en-US">Convertible Unsecured Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesMember" xml:lang="en-US">Convertible Unsecured Senior Notes [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:to="lab_thtx_ConvertibleUnsecuredSeniorNotesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesLineItems" xml:lang="en-US">Convertible unsecured senior notes [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:to="lab_thtx_ConvertibleUnsecuredSeniorNotesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesLineItems" xml:lang="en-US">Convertible unsecured senior notes.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleInstrumentsNumberOfSharesIssued" xlink:label="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleInstrumentsNumberOfSharesIssued" xml:lang="en-US">Convertible Instruments Number Of Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ConvertibleInstrumentsNumberOfSharesIssued" xml:lang="en-US">Convertible instruments number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued" xlink:to="lab_thtx_ConvertibleInstrumentsNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ConvertibleInstrumentsNumberOfSharesIssued" xml:lang="en-US">Convertible instruments number of shares issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xml:lang="en-US">Proceeds from issue of bonds, notes and debentures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xml:lang="en-US">Proceeds from issue of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LiabilityComponentMember" xlink:label="loc_thtx_LiabilityComponentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LiabilityComponentMember" xml:lang="en-US">Liability Component [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LiabilityComponentMember" xml:lang="en-US">Liability component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LiabilityComponentMember" xlink:to="lab_thtx_LiabilityComponentMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpense" xlink:label="loc_thtx_AccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccretionExpense" xml:lang="en-US">Accretion Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AccretionExpense" xml:lang="en-US">Accretion expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccretionExpense" xlink:to="lab_thtx_AccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccretionExpense" xml:lang="en-US">Accretion expense.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChangesFromFinancingCashFlowsAbstract" xlink:label="loc_thtx_ChangesFromFinancingCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ChangesFromFinancingCashFlowsAbstract" xml:lang="en-US">Changes From Financing Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ChangesFromFinancingCashFlowsAbstract" xml:lang="en-US">Changes from financing cash flows:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ChangesFromFinancingCashFlowsAbstract" xlink:to="lab_thtx_ChangesFromFinancingCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ChangesFromFinancingCashFlowsAbstract" xml:lang="en-US">Changes from financing cash flows.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xml:lang="en-US">Changes in net defined benefit liability (asset) resulting from miscellaneous other changes [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xml:lang="en-US">Other changes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xlink:to="lab_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Non-current portion of non-current notes and debentures issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Convertible unsecured senior notes, Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Convertible unsecured senior notes, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xml:lang="en-US">Convertible unsecured senior notes including interest carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpenseOfLeasesLiabilities" xlink:label="loc_thtx_AccretionExpenseOfLeasesLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AccretionExpenseOfLeasesLiabilities" xml:lang="en-US">Accretion expense of Leases liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_AccretionExpenseOfLeasesLiabilities" xml:lang="en-US">Accretion expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AccretionExpenseOfLeasesLiabilities" xlink:to="lab_thtx_AccretionExpenseOfLeasesLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AccretionExpenseOfLeasesLiabilities" xml:lang="en-US">Accretion expense of Leases liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashOutflowForLeases" xml:lang="en-US">Cash outflow for leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CashOutflowForLeases" xml:lang="en-US">Lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="loc_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xml:lang="en-US">Gains (losses) arising from sale and leaseback transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xml:lang="en-US">Termination (a)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:to="lab_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LeaseLiabilities" xml:lang="en-US">Lease liabilitites</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xlink:label="loc_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xml:lang="en-US">Leases liabilities Effect of change in exchange rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xml:lang="en-US">Effect of change in exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xlink:to="lab_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xml:lang="en-US">Leases liabilities Effect of change in exchange rates.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Operating Lease Liability.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xlink:label="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xml:lang="en-US">Termination Of Leases Operating Lease Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xml:lang="en-US">Termination Of Leases Operating Lease Right Of Use Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xlink:to="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xml:lang="en-US">Termination of leases operating lease right of use asset.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" xlink:label="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" xml:lang="en-US">Termination Of Leases Operating Lease Right Of Use Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" xlink:to="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" xml:lang="en-US">Termination of leases operating lease right of use liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xml:lang="en-US">Disclosure of classes of share capital [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementAxis" xlink:label="loc_thtx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AgreementAxis" xlink:to="lab_thtx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementMember" xlink:label="loc_thtx_AgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AgreementMember" xml:lang="en-US">Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AgreementMember" xlink:to="lab_thtx_AgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AgreementMember" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentOfTheLoanFacilityMember" xlink:label="loc_thtx_FifthAmendmentOfTheLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FifthAmendmentOfTheLoanFacilityMember" xml:lang="en-US">Fifth Amendment Of The Loan Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FifthAmendmentOfTheLoanFacilityMember" xml:lang="en-US">Fifth Amendment of the Loan facility [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FifthAmendmentOfTheLoanFacilityMember" xlink:to="lab_thtx_FifthAmendmentOfTheLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FifthAmendmentOfTheLoanFacilityMember" xml:lang="en-US">Fifth amendment of the loan facility member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xml:lang="en-US">Categories of financial liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xml:lang="en-US">Financial liabilities, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsAxis" xlink:label="loc_thtx_CategoryOfBorrowingsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CategoryOfBorrowingsAxis" xml:lang="en-US">Category of borrowings [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CategoryOfBorrowingsAxis" xlink:to="lab_thtx_CategoryOfBorrowingsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CategoryOfBorrowingsAxis" xml:lang="en-US">Category Of Borrowings Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsDomain" xlink:label="loc_thtx_CategoryOfBorrowingsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CategoryOfBorrowingsDomain" xml:lang="en-US">Category of borrowings [domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CategoryOfBorrowingsDomain" xlink:to="lab_thtx_CategoryOfBorrowingsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CategoryOfBorrowingsDomain" xml:lang="en-US">Category Of Borrowings Domain.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xml:lang="en-US">Classes of financial assets [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialAssetsMember" xml:lang="en-US">Financial assets, class [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashSettledForwardContractsMember" xlink:label="loc_thtx_CashSettledForwardContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CashSettledForwardContractsMember" xml:lang="en-US">Cash Settled Forward Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_CashSettledForwardContractsMember" xml:lang="en-US">Cash Settled Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CashSettledForwardContractsMember" xlink:to="lab_thtx_CashSettledForwardContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CashSettledForwardContractsMember" xml:lang="en-US">Cash Settled Forward Contracts Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsAxis" xlink:label="loc_thtx_ClassOfWarrantsOrRightsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantsOrRightsAxis" xml:lang="en-US">Class Of Warrants Or Rights [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis" xlink:to="lab_thtx_ClassOfWarrantsOrRightsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantsOrRightsAxis" xml:lang="en-US">Class of warrants or rights.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantsOrRightsMember" xml:lang="en-US">Class Of Warrants Or Rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember" xlink:to="lab_thtx_ClassOfWarrantsOrRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantsOrRightsMember" xml:lang="en-US">Class of warrants or rights.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonVotingSubscriptionReceiptsMember" xlink:label="loc_thtx_NonVotingSubscriptionReceiptsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NonVotingSubscriptionReceiptsMember" xml:lang="en-US">Non Voting Subscription Receipts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NonVotingSubscriptionReceiptsMember" xml:lang="en-US">Non-voting Subscription Receipts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NonVotingSubscriptionReceiptsMember" xlink:to="lab_thtx_NonVotingSubscriptionReceiptsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NonVotingSubscriptionReceiptsMember" xml:lang="en-US">Non voting subscription receipts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Disclosure of classes of share capital [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Class Of Number Warrants Or Rights Issued During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Class of number warrants or rights issued during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xlink:to="lab_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Class of number warrants or rights issued during the period.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US">Exercise price of each warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="lab_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US">Class of warrant or right exercise price of warrants or rights.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExpirationDate" xlink:label="loc_thtx_ClassOfWarrantOrRightExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantOrRightExpirationDate" xml:lang="en-US">Class Of Warrant Or Right Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfWarrantOrRightExpirationDate" xml:lang="en-US">Class Of Warrant Or Right Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantOrRightExpirationDate" xlink:to="lab_thtx_ClassOfWarrantOrRightExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantOrRightExpirationDate" xml:lang="en-US">Class of warrant or right expiration date.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:label="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xml:lang="en-US">Class Of Warrant Or Right Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:to="lab_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xml:lang="en-US">Class of warrant or right number of securities exercised.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightOutstanding" xlink:label="loc_thtx_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class Of Warrant Or Right Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of warrant or right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantOrRightOutstanding" xlink:to="lab_thtx_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of warrant or right, Outstanding.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:label="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xml:lang="en-US">Class Of Warrants Or Rights Exercise Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xml:lang="en-US">Class of warrants or rights exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:to="lab_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xml:lang="en-US">Class of warrants or rights exercise price per share.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsOutstanding" xlink:label="loc_thtx_ClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Class Of Warrants Or Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Class of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ClassOfWarrantsOrRightsOutstanding" xlink:to="lab_thtx_ClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Class of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommonStockConversionBasis" xlink:label="loc_thtx_CommonStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommonStockConversionBasis" xml:lang="en-US">Common Stock Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CommonStockConversionBasis" xml:lang="en-US">Common stock, Conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommonStockConversionBasis" xlink:to="lab_thtx_CommonStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CommonStockConversionBasis" xml:lang="en-US">Common stock, Conversion basis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsOnTheLoanFacility" xlink:label="loc_thtx_DeferredFinancingCostsOnTheLoanFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredFinancingCostsOnTheLoanFacility" xml:lang="en-US">Deferred Financing Costs On The Loan Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DeferredFinancingCostsOnTheLoanFacility" xml:lang="en-US">Deferred financing costs on the loan facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredFinancingCostsOnTheLoanFacility" xlink:to="lab_thtx_DeferredFinancingCostsOnTheLoanFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredFinancingCostsOnTheLoanFacility" xml:lang="en-US">Deferred financing costs on the loan facility.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsWrittenDown" xlink:label="loc_thtx_DeferredFinancingCostsWrittenDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredFinancingCostsWrittenDown" xml:lang="en-US">Deferred Financing Costs Written Down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DeferredFinancingCostsWrittenDown" xml:lang="en-US">Deferred financing costs written down</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredFinancingCostsWrittenDown" xlink:to="lab_thtx_DeferredFinancingCostsWrittenDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredFinancingCostsWrittenDown" xml:lang="en-US">Deferred financing costs written down.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xlink:label="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xml:lang="en-US">Derivative Financial Assets At Fair Value Not Designated As Hedging</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xml:lang="en-US">Fair value of cash settled forward contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xlink:to="lab_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xml:lang="en-US">Derivative financial assets at fair value not designated as hedging.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xlink:label="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xml:lang="en-US">Description Of Covenants Under Shareholder Rights On Bidding Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xml:lang="en-US">Shareholders rights covenants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xlink:to="lab_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xml:lang="en-US">Description of covenants under shareholder rights on bidding options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Option life, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Exercise period of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xml:lang="en-US">Average option life in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xml:lang="en-US">Period of vesting of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Effect of Share Options on Number of Ordinary Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Effect of share options number of ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Effect of share issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xml:lang="en-US">Effect of share options on number of ordinary shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xml:lang="en-US">Effect of Share Options on Number of Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xml:lang="en-US">Effect of share options number of Warrants shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xlink:to="lab_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xml:lang="en-US">Effect of share options on number of warrants shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnDebtModification" xlink:label="loc_thtx_GainLossOnDebtModification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_GainLossOnDebtModification" xml:lang="en-US">Gain Loss On Debt Modification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_GainLossOnDebtModification" xml:lang="en-US">Gain (loss) on debt modification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_GainLossOnDebtModification" xlink:to="lab_thtx_GainLossOnDebtModification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_GainLossOnDebtModification" xml:lang="en-US">Gain loss on debt modification.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xml:lang="en-US">Gains (losses) recognised in profit or loss on financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xml:lang="en-US">Gain (loss) due to changes in fair value of financial liabilities at fair value through profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseInTheFairValueOfLiabilityRecorded" xlink:label="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseInTheFairValueOfLiabilityRecorded" xml:lang="en-US">Increase In The Fair Value Of Liability Recorded</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_IncreaseInTheFairValueOfLiabilityRecorded" xml:lang="en-US">Increase in the fair value of liability recorded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded" xlink:to="lab_thtx_IncreaseInTheFairValueOfLiabilityRecorded" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseInTheFairValueOfLiabilityRecorded" xml:lang="en-US">Increase in the fair value of liability recorded.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfCashSettledForwardStockContractsOutstanding" xlink:label="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NumberOfCashSettledForwardStockContractsOutstanding" xml:lang="en-US">Number of Cash Settled Forward Stock Contracts Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_NumberOfCashSettledForwardStockContractsOutstanding" xml:lang="en-US">Shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding" xlink:to="lab_thtx_NumberOfCashSettledForwardStockContractsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NumberOfCashSettledForwardStockContractsOutstanding" xml:lang="en-US">Number of cash settled forward stock contracts outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xml:lang="en-US">Deferred stock units outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ParValuePerShare" xml:lang="en-US">Par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipHoldingCommonShares" xlink:label="loc_thtx_PercentageOfOwnershipHoldingCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PercentageOfOwnershipHoldingCommonShares" xml:lang="en-US">Percentage Of Ownership Holding Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PercentageOfOwnershipHoldingCommonShares" xml:lang="en-US">Percentage Of Ownership Holding Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PercentageOfOwnershipHoldingCommonShares" xlink:to="lab_thtx_PercentageOfOwnershipHoldingCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PercentageOfOwnershipHoldingCommonShares" xml:lang="en-US">Percentage of ownership holding common shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipOfTheInvestor" xlink:label="loc_thtx_PercentageOfOwnershipOfTheInvestor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PercentageOfOwnershipOfTheInvestor" xml:lang="en-US">Percentage Of Ownership Of The Investor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PercentageOfOwnershipOfTheInvestor" xml:lang="en-US">Percentage Of Ownership Of The Investor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PercentageOfOwnershipOfTheInvestor" xlink:to="lab_thtx_PercentageOfOwnershipOfTheInvestor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PercentageOfOwnershipOfTheInvestor" xml:lang="en-US">Percentage of ownership of the investor.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xlink:label="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xml:lang="en-US">Potential Share Issue In The Future On Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xml:lang="en-US">Potential share issue in the future on exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xlink:to="lab_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xml:lang="en-US">Potential share issue in the future on exercise of warrants.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xlink:label="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xml:lang="en-US">Price Per Share For The Settlement Of Cashsettled Forward Stock Contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xml:lang="en-US">Price per share for the settlement of cash-settled forward stock contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xlink:to="lab_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xml:lang="en-US">Price per share for the settlement of cash-settled forward stock contracts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuing shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xml:lang="en-US">Proceeds from issuing shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xlink:label="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xml:lang="en-US">Proceeds From The Issuance Of Common Shares And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xml:lang="en-US">Proceeds from the issuance of common shares and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xlink:to="lab_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xml:lang="en-US">Proceeds from the issuance of common shares and warrants.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xlink:label="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xml:lang="en-US">Remaining Shares Reserved For Issue Under Options And Contract For Sale Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xml:lang="en-US">Remaining options available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xlink:to="lab_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xml:lang="en-US">Remaining shares reserved for issue under options and contract for sale of shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale Of Stock Consideration Received On Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Potential aggregate offering price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_thtx_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of stock consideration received on transaction.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsContractualLife" xlink:label="loc_thtx_StockAppreciationRightsContractualLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockAppreciationRightsContractualLife" xml:lang="en-US">Stock Appreciation Rights Contractual Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_StockAppreciationRightsContractualLife" xml:lang="en-US">SAR Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockAppreciationRightsContractualLife" xlink:to="lab_thtx_StockAppreciationRightsContractualLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockAppreciationRightsContractualLife" xml:lang="en-US">Stock appreciation rights contractual life.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xlink:label="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xml:lang="en-US">Stock Issuable As A Percentage Of Total Shares Issued And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xml:lang="en-US">Stock issuable as a percentage of total shares issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xlink:to="lab_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xml:lang="en-US">Stock issuable as a percentage of total shares issued and outstanding.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TermOfWarrants" xlink:label="loc_thtx_TermOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TermOfWarrants" xml:lang="en-US">Term Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TermOfWarrants" xml:lang="en-US">Term of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TermOfWarrants" xlink:to="lab_thtx_TermOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TermOfWarrants" xml:lang="en-US">Term of warrants.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsAllocatedToTheLoanFacility" xlink:label="loc_thtx_TransactionCostsAllocatedToTheLoanFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TransactionCostsAllocatedToTheLoanFacility" xml:lang="en-US">Transaction Costs Allocated To The Loan Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TransactionCostsAllocatedToTheLoanFacility" xml:lang="en-US">Transaction costs allocated to the loan facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TransactionCostsAllocatedToTheLoanFacility" xlink:to="lab_thtx_TransactionCostsAllocatedToTheLoanFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TransactionCostsAllocatedToTheLoanFacility" xml:lang="en-US">Transaction costs allocated to the loan facility.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsOfWarrantsIssued" xlink:label="loc_thtx_TransactionCostsOfWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TransactionCostsOfWarrantsIssued" xml:lang="en-US">Transaction Costs Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_TransactionCostsOfWarrantsIssued" xml:lang="en-US">Transaction cost of warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TransactionCostsOfWarrantsIssued" xlink:to="lab_thtx_TransactionCostsOfWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TransactionCostsOfWarrantsIssued" xml:lang="en-US">Transaction costs of warrants issued.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventAxis" xlink:label="loc_thtx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EventAxis" xlink:to="lab_thtx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EventAxis" xml:lang="en-US">Event [Axis].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventDomain" xlink:label="loc_thtx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EventDomain" xlink:to="lab_thtx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EventDomain" xml:lang="en-US">Event [Domain].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeAxis" xlink:label="loc_thtx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InvesteeAxis" xml:lang="en-US">Investee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InvesteeAxis" xlink:to="lab_thtx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InvesteeAxis" xml:lang="en-US">Investee axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeMember" xlink:label="loc_thtx_InvesteeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InvesteeMember" xml:lang="en-US">Investee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InvesteeMember" xlink:to="lab_thtx_InvesteeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InvesteeMember" xml:lang="en-US">Investee.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AffiliatesOfMarathonAssetManagementMember" xlink:label="loc_thtx_AffiliatesOfMarathonAssetManagementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AffiliatesOfMarathonAssetManagementMember" xml:lang="en-US">Affiliates Of Marathon Asset Management [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AffiliatesOfMarathonAssetManagementMember" xml:lang="en-US">Affiliates of Marathon Asset Management [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AffiliatesOfMarathonAssetManagementMember" xlink:to="lab_thtx_AffiliatesOfMarathonAssetManagementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AffiliatesOfMarathonAssetManagementMember" xml:lang="en-US">Affiliates of Marathon asset management.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvestmentQuebecMember" xlink:label="loc_thtx_InvestmentQuebecMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_InvestmentQuebecMember" xml:lang="en-US">Investment Quebec [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_InvestmentQuebecMember" xml:lang="en-US">Investment Quebec [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_InvestmentQuebecMember" xlink:to="lab_thtx_InvestmentQuebecMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_InvestmentQuebecMember" xml:lang="en-US">Investment quebec member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalAxis" xlink:label="loc_thtx_IssuedCapitalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IssuedCapitalAxis" xml:lang="en-US">Issued Capital [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IssuedCapitalAxis" xlink:to="lab_thtx_IssuedCapitalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IssuedCapitalAxis" xml:lang="en-US">Issued capital.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalDomain" xlink:label="loc_thtx_IssuedCapitalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IssuedCapitalDomain" xml:lang="en-US">Issued Capital [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IssuedCapitalDomain" xlink:to="lab_thtx_IssuedCapitalDomain" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OverallotmentMember" xlink:label="loc_thtx_OverallotmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OverallotmentMember" xml:lang="en-US">Overallotment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_OverallotmentMember" xml:lang="en-US">Over-allotment [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OverallotmentMember" xlink:to="lab_thtx_OverallotmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OverallotmentMember" xml:lang="en-US">Over-allotment.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrivatePlacementMember" xlink:label="loc_thtx_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PrivatePlacementMember" xlink:to="lab_thtx_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PrivatePlacementMember" xml:lang="en-US">Private Placement.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicOfferingMember" xlink:label="loc_thtx_PublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PublicOfferingMember" xml:lang="en-US">Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PublicOfferingMember" xlink:to="lab_thtx_PublicOfferingMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MeasurementAxis" xml:lang="en-US">Measurement [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xml:lang="en-US">Aggregated measurement [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanAxis" xlink:label="loc_thtx_PlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PlanAxis" xml:lang="en-US">Plan [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PlanAxis" xml:lang="en-US">Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PlanAxis" xlink:to="lab_thtx_PlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PlanAxis" xml:lang="en-US">Plan Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PlanDomain" xml:lang="en-US">Plan [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PlanDomain" xml:lang="en-US">Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PlanDomain" xlink:to="lab_thtx_PlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PlanDomain" xml:lang="en-US">Plan Domain.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsMember" xlink:label="loc_thtx_StockAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockAppreciationRightsMember" xml:lang="en-US">Stock Appreciation Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_thtx_StockAppreciationRightsMember" xml:lang="en-US">Stock Appreciation Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_thtx_StockAppreciationRightsMember" xml:lang="en-US">Stock Appreciation Rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockAppreciationRightsMember" xlink:to="lab_thtx_StockAppreciationRightsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockOptionPlanTwoThousandAndNineteenMember" xlink:label="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_StockOptionPlanTwoThousandAndNineteenMember" xml:lang="en-US">Stock Option Plan Two Thousand And Nineteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_StockOptionPlanTwoThousandAndNineteenMember" xml:lang="en-US">Stock Option Plan Two Thousand And Nineteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember" xlink:to="lab_thtx_StockOptionPlanTwoThousandAndNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_StockOptionPlanTwoThousandAndNineteenMember" xml:lang="en-US">Stock Option Plan Two Thousand And Nineteen Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandAndSixteenShareholdersPlanMember" xlink:label="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TwoThousandAndSixteenShareholdersPlanMember" xml:lang="en-US">Two Thousand And Sixteen Shareholders Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TwoThousandAndSixteenShareholdersPlanMember" xml:lang="en-US">Two Thousand And Sixteen Shareholders Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember" xlink:to="lab_thtx_TwoThousandAndSixteenShareholdersPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TwoThousandAndSixteenShareholdersPlanMember" xml:lang="en-US">Two Thousand And Sixteen Shareholders Plan Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameAxis" xlink:label="loc_thtx_ProgramNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProgramNameAxis" xml:lang="en-US">Program Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProgramNameAxis" xlink:to="lab_thtx_ProgramNameAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProgramNameMember" xml:lang="en-US">Program Name [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProgramNameMember" xlink:to="lab_thtx_ProgramNameMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AtmProgramMember" xlink:label="loc_thtx_AtmProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AtmProgramMember" xml:lang="en-US">ATM program [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AtmProgramMember" xml:lang="en-US">ATM program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AtmProgramMember" xlink:to="lab_thtx_AtmProgramMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueAxis" xlink:label="loc_thtx_SchemeOfShareIssueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SchemeOfShareIssueAxis" xml:lang="en-US">Scheme Of Share Issue [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SchemeOfShareIssueAxis" xml:lang="en-US">Scheme Of Share Issue [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SchemeOfShareIssueAxis" xlink:to="lab_thtx_SchemeOfShareIssueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SchemeOfShareIssueAxis" xml:lang="en-US">Scheme Of Share Issue Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueDomain" xlink:label="loc_thtx_SchemeOfShareIssueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SchemeOfShareIssueDomain" xml:lang="en-US">Scheme Of Share Issue [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SchemeOfShareIssueDomain" xml:lang="en-US">Scheme Of Share Issue [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SchemeOfShareIssueDomain" xlink:to="lab_thtx_SchemeOfShareIssueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SchemeOfShareIssueDomain" xml:lang="en-US">Scheme Of Share Issue Domain.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xml:lang="en-US">Share-based payment arrangements [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredStockUnitsMember" xlink:label="loc_thtx_DeferredStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredStockUnitsMember" xml:lang="en-US">Deferred Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_DeferredStockUnitsMember" xml:lang="en-US">Deferred Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredStockUnitsMember" xlink:to="lab_thtx_DeferredStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredStockUnitsMember" xml:lang="en-US">Deferred Stock Units Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xml:lang="en-US">Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xlink:to="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xml:lang="en-US">Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xlink:to="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xml:lang="en-US">Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xml:lang="en-US">Significant unobservable input, liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xml:lang="en-US">Measurement&#160;date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xml:lang="en-US">Expected volatility unobservable input, liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="lab_ifrs-full_SignificantUnobservableInputLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xml:lang="en-US">Unobservable inputs [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnobservableInputsMember" xml:lang="en-US">Unobservable inputs [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AverageOptionLifeMember" xlink:label="loc_thtx_AverageOptionLifeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AverageOptionLifeMember" xml:lang="en-US">Average Option Life [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AverageOptionLifeMember" xml:lang="en-US">Average option life in years [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AverageOptionLifeMember" xlink:to="lab_thtx_AverageOptionLifeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AverageOptionLifeMember" xml:lang="en-US">Average option life.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceToAcquireOneCommonShareMember" xlink:label="loc_thtx_ExercisePriceToAcquireOneCommonShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceToAcquireOneCommonShareMember" xml:lang="en-US">Exercise Price To Acquire One Common Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceToAcquireOneCommonShareMember" xml:lang="en-US">Exercise price to acquire one common share with four Marathon Warrants [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceToAcquireOneCommonShareMember" xlink:to="lab_thtx_ExercisePriceToAcquireOneCommonShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceToAcquireOneCommonShareMember" xml:lang="en-US">Exercise price to acquire one common share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xml:lang="en-US">Historical volatility for shares, measurement input [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xml:lang="en-US">Expected volatility [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xml:lang="en-US">Historical volatility for shares, measurement input [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xml:lang="en-US">Interest rate, measurement input [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xml:lang="en-US">Risk-free&#160;interest rate [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xml:lang="en-US">Interest rate, measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateMeasurementInputMember" xlink:to="lab_ifrs-full_InterestRateMeasurementInputMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SharePriceMember" xlink:label="loc_thtx_SharePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SharePriceMember" xml:lang="en-US">Share Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SharePriceMember" xml:lang="en-US">Share price [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SharePriceMember" xlink:to="lab_thtx_SharePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SharePriceMember" xml:lang="en-US">Share price.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xml:lang="en-US">Disclosure Of The Model Used To Determine Fair Value Of Options [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xml:lang="en-US">Disclosure Of The Model Used To Determine Fair Value Of Options [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xlink:to="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xml:lang="en-US">Disclosure of the model used to determine Fair value of options [Table].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xml:lang="en-US">Disclosure Of The Model Used To Determine Fair Value Of Options [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xml:lang="en-US">Disclosure Of The Model Used To Determine Fair Value Of Options [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xlink:to="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xml:lang="en-US">Disclosure Of The Model Used To Determine Fair Value Of Options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Expected volatility, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk free interest rate, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Exercise price, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Option exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xml:lang="en-US">Option exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xml:lang="en-US">Weighted average share price, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xml:lang="en-US">Grant-date share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_CAD" xml:lang="en-US">Canada, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_CAD" xml:lang="en-US">CA$</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_currency_CAD" xml:lang="en-US">CA$</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_currency_CAD" xml:lang="en-US">CA$ &#8211; US$</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of options beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number of options ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xml:lang="en-US">Number&#160;of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xml:lang="en-US">Options exercisable outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xml:lang="en-US">Number of options, exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Number Of Share Options Forfeited and Expired In Share based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Number of options,Forfeited&#160;and expired &#8211; CAD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:to="lab_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Number Of Share Options Forfeited and Expired In Share based Payment Arrangement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xml:lang="en-US">Number of options, Forfeited &#8211; USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of options, granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xml:lang="en-US">Number of Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average, exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average, granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Weighted Average Share Options Forfeited and Expired In Share based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Weighted average,Forfeited and expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:to="lab_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xml:lang="en-US">Weighted Average Share Options Forfeited and Expired In Share based Payment Arrangement .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xml:lang="en-US">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xml:lang="en-US">Weighted average share price of options excercised on the exercise date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD" xml:lang="en-US">United States of America, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_USD" xml:lang="en-US">US$</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xml:lang="en-US">Weighted average remaining life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFiveMember" xlink:label="loc_thtx_ExercisePriceFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceFiveMember" xml:lang="en-US">Exercise Price Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceFiveMember" xml:lang="en-US">Exercise Price 5</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceFiveMember" xlink:to="lab_thtx_ExercisePriceFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceFiveMember" xml:lang="en-US">Exercise Price Five Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFourMember" xlink:label="loc_thtx_ExercisePriceFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceFourMember" xml:lang="en-US">Exercise Price Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceFourMember" xml:lang="en-US">Exercise Price 4</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceFourMember" xlink:to="lab_thtx_ExercisePriceFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceFourMember" xml:lang="en-US">Exercise Price Four Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceOneMember" xlink:label="loc_thtx_ExercisePriceOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceOneMember" xml:lang="en-US">Exercise Price One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceOneMember" xml:lang="en-US">Exercise Price 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceOneMember" xlink:to="lab_thtx_ExercisePriceOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceOneMember" xml:lang="en-US">Exercise Price One Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceSixMember" xlink:label="loc_thtx_ExercisePriceSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceSixMember" xml:lang="en-US">Exercise Price Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceSixMember" xml:lang="en-US">Exercise Price 6</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceSixMember" xlink:to="lab_thtx_ExercisePriceSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceSixMember" xml:lang="en-US">Exercise Price Six Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceThreeMember" xlink:label="loc_thtx_ExercisePriceThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceThreeMember" xml:lang="en-US">Exercise Price Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceThreeMember" xml:lang="en-US">Exercise Price 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceThreeMember" xlink:to="lab_thtx_ExercisePriceThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceThreeMember" xml:lang="en-US">Exercise Price Three Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceTwoMember" xlink:label="loc_thtx_ExercisePriceTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExercisePriceTwoMember" xml:lang="en-US">Exercise Price Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExercisePriceTwoMember" xml:lang="en-US">Exercise Price 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExercisePriceTwoMember" xlink:to="lab_thtx_ExercisePriceTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExercisePriceTwoMember" xml:lang="en-US">Exercise Price Two Member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xlink:label="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xml:lang="en-US">Weighted Average Fair Value Of Stock Options Granted [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xml:lang="en-US">Weighted Average Fair Value Of Stock Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xlink:to="lab_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xml:lang="en-US">weighted average fair value of stock options granted.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xml:lang="en-US">Weighted average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareTable" xml:lang="en-US">Earnings per share [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfOrdinarySharesAxis" xml:lang="en-US">Classes of ordinary shares [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="lab_ifrs-full_ClassesOfOrdinarySharesAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BrokersWarrantsMember" xlink:label="loc_thtx_BrokersWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BrokersWarrantsMember" xml:lang="en-US">Brokers Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BrokersWarrantsMember" xml:lang="en-US">Brokers warrants [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BrokersWarrantsMember" xlink:to="lab_thtx_BrokersWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BrokersWarrantsMember" xml:lang="en-US">Brokers Warrants [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicIssueOfSharesMember" xlink:label="loc_thtx_PublicIssueOfSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PublicIssueOfSharesMember" xml:lang="en-US">Public Issue Of Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PublicIssueOfSharesMember" xml:lang="en-US">public issue common shares [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PublicIssueOfSharesMember" xlink:to="lab_thtx_PublicIssueOfSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PublicIssueOfSharesMember" xml:lang="en-US">Public Issue Of Shares [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareOptionMember" xlink:label="loc_thtx_ShareOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareOptionMember" xml:lang="en-US">Share Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ShareOptionMember" xml:lang="en-US">Share options [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareOptionMember" xlink:to="lab_thtx_ShareOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareOptionMember" xml:lang="en-US">Share Option [Member]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SubscriptionReceiptsIssueMember" xlink:label="loc_thtx_SubscriptionReceiptsIssueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SubscriptionReceiptsIssueMember" xml:lang="en-US">Subscription Receipts Issue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SubscriptionReceiptsIssueMember" xml:lang="en-US">Subscription Receipts Issue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SubscriptionReceiptsIssueMember" xlink:to="lab_thtx_SubscriptionReceiptsIssueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SubscriptionReceiptsIssueMember" xml:lang="en-US">Subscription receipts issue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xml:lang="en-US">Earnings per share [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xml:lang="en-US">Weighted average number of common shares, basic&#160;and&#160;diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xml:lang="en-US">Dilutive effect of convertible instruments on number of ordinary shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xml:lang="en-US">Impact on conversion of convertible unsecured senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfBrokerWarrantsExercised" xlink:label="loc_thtx_EffectOfBrokerWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfBrokerWarrantsExercised" xml:lang="en-US">Effect Of Broker Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_thtx_EffectOfBrokerWarrantsExercised" xml:lang="en-US">Effect of broker warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfBrokerWarrantsExercised" xlink:to="lab_thtx_EffectOfBrokerWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfBrokerWarrantsExercised" xml:lang="en-US">Effect of broker warrants exercised.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfIssueCommonShares" xlink:label="loc_thtx_EffectOfIssueCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfIssueCommonShares" xml:lang="en-US">Effect of Issue Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EffectOfIssueCommonShares" xml:lang="en-US">Effect of issue common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfIssueCommonShares" xlink:to="lab_thtx_EffectOfIssueCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfIssueCommonShares" xml:lang="en-US">Effect of issue common shares.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsExercised" xlink:label="loc_thtx_EffectOfShareOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfShareOptionsExercised" xml:lang="en-US">Effect of Share Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EffectOfShareOptionsExercised" xml:lang="en-US">Effect of share options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfShareOptionsExercised" xlink:to="lab_thtx_EffectOfShareOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfShareOptionsExercised" xml:lang="en-US">Effect of share options exercised.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfSubscriptionReceiptsIssue" xlink:label="loc_thtx_EffectOfSubscriptionReceiptsIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_EffectOfSubscriptionReceiptsIssue" xml:lang="en-US">Effect of Subscription Receipts Issue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_EffectOfSubscriptionReceiptsIssue" xml:lang="en-US">Effect of subscription receipts issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_EffectOfSubscriptionReceiptsIssue" xlink:to="lab_thtx_EffectOfSubscriptionReceiptsIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_EffectOfSubscriptionReceiptsIssue" xml:lang="en-US">Effect of subscription receipts issue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Weighted average number of ordinary shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares" xml:lang="en-US">Issued common shares as at December 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xml:lang="en-US">Cumulative exchange difference on translation of foreign operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xml:lang="en-US">Unrealized losses on FVOCI financial assets, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xml:lang="en-US">Current tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" xml:lang="en-US">Deferred tax expense (income) [abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" xml:lang="en-US">Deferred tax expense (recovery)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xml:lang="en-US">Total deferred tax expense (recovery)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xml:lang="en-US">Deferred tax expense (income) relating to origination and reversal of temporary differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xml:lang="en-US">Origination and reversal of temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xlink:label="loc_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xml:lang="en-US">Increase Decrease In Unrecognized Deductable Temporary Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xml:lang="en-US">Change in unrecognized deductible temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xlink:to="lab_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xml:lang="en-US">Increase decrease in unrecognized deductable temporary differences.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xlink:label="loc_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xml:lang="en-US">Increase Decrease In Unrecognized Deductible Temporary Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xml:lang="en-US">Change in unrecognized deductible temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xlink:to="lab_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xml:lang="en-US">Increase decrease in unrecognized deductible temporary differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xml:lang="en-US">Tax effect from change in tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xml:lang="en-US">Impact of differences in statutory tax rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xml:lang="en-US">Non-deductible&#160;expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Tax expense (income) at applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xml:lang="en-US">Income taxes at domestic tax statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xml:lang="en-US">Disclosure of Detailed Information About Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xml:lang="en-US">Disclosure of Detailed Information About Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xml:lang="en-US">Disclosure of Detailed Information About Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xlink:to="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xml:lang="en-US">Disclosure of Detailed Information About Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Applicable tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate" xml:lang="en-US">Effective applicable income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xml:lang="en-US">Losses carried forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OffsettingOfDeferredTaxLiabilityAxis" xml:lang="en-US">Offsetting of Deferred Tax Liability [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis" xlink:to="lab_thtx_OffsettingOfDeferredTaxLiabilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OffsettingOfDeferredTaxLiabilityAxis" xml:lang="en-US">Offsetting of Deferred Tax Liability [Axis]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_OffsettingOfDeferredTaxLiabilityMember" xml:lang="en-US">Offsetting of Deferred Tax Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_OffsettingOfDeferredTaxLiabilityMember" xlink:to="lab_thtx_OffsettingOfDeferredTaxLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_OffsettingOfDeferredTaxLiabilityMember" xml:lang="en-US">Offsetting of Deferred Tax Liability [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE" xlink:label="loc_country_IE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IE" xml:lang="en-US">IRELAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IE" xml:lang="en-US">Ireland</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xlink:to="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xlink:to="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xml:lang="en-US">Type Of Reversal Of Deferred Tax Liability Member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AvailableDeductionsAndOthers" xlink:label="loc_thtx_AvailableDeductionsAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AvailableDeductionsAndOthers" xml:lang="en-US">Available Deductions And Others</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AvailableDeductionsAndOthers" xml:lang="en-US">Available deductions and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AvailableDeductionsAndOthers" xlink:to="lab_thtx_AvailableDeductionsAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AvailableDeductionsAndOthers" xml:lang="en-US">Available deductions and others.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xml:lang="en-US">Excess Of Tax Value Of Intellectual Property And Fees Over Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xml:lang="en-US">Excess of tax value of intellectual property and patent fees over carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xlink:to="lab_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xml:lang="en-US">Excess of tax value of intellectual, Property,and fees over carrying value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xml:lang="en-US">Excess Of Tax Value Of Property Plant And Equipment Over Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xml:lang="en-US">Excess of tax value of property and equipment over carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xlink:to="lab_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xml:lang="en-US">Excess of tax value of property,plant and equipment over carrying value.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xlink:label="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xml:lang="en-US">Unutilised Research And Development Expenses With No Time Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xml:lang="en-US">Research and development expenses, without&#160;time&#160;limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xlink:to="lab_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xml:lang="en-US">Unutilised Research And Development Expenses With No Time Limitation.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionAxis" xlink:label="loc_thtx_IncomeTaxJurisdictionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxJurisdictionAxis" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxJurisdictionAxis" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxJurisdictionAxis" xlink:to="lab_thtx_IncomeTaxJurisdictionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxJurisdictionAxis" xml:lang="en-US">Income Tax Jurisdiction Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionMember" xlink:label="loc_thtx_IncomeTaxJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncomeTaxJurisdictionMember" xml:lang="en-US">Income Tax Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncomeTaxJurisdictionMember" xml:lang="en-US">Income Tax Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncomeTaxJurisdictionMember" xlink:to="lab_thtx_IncomeTaxJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncomeTaxJurisdictionMember" xml:lang="en-US">Income Tax Jurisdiction Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FederalMember" xlink:label="loc_thtx_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_FederalMember" xml:lang="en-US">Federal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_FederalMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_FederalMember" xlink:to="lab_thtx_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_FederalMember" xml:lang="en-US">Federal Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvincialMember" xlink:label="loc_thtx_ProvincialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ProvincialMember" xml:lang="en-US">Provincial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ProvincialMember" xml:lang="en-US">Provincial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ProvincialMember" xlink:to="lab_thtx_ProvincialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ProvincialMember" xml:lang="en-US">Provincial Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearAxis" xlink:label="loc_thtx_TaxBenefitCarryForwardYearAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaxBenefitCarryForwardYearAxis" xml:lang="en-US">Tax Benefit Carry Forward Year [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaxBenefitCarryForwardYearAxis" xml:lang="en-US">Tax Benefit Carry Forward Year [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaxBenefitCarryForwardYearAxis" xlink:to="lab_thtx_TaxBenefitCarryForwardYearAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaxBenefitCarryForwardYearAxis" xml:lang="en-US">Tax Benefit Carry Forward Year Axis.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearMember" xlink:label="loc_thtx_TaxBenefitCarryForwardYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TaxBenefitCarryForwardYearMember" xml:lang="en-US">Tax Benefit Carry Forward Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_TaxBenefitCarryForwardYearMember" xml:lang="en-US">Tax Benefit Carry Forward Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember" xlink:to="lab_thtx_TaxBenefitCarryForwardYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TaxBenefitCarryForwardYearMember" xml:lang="en-US">Tax Benefit Carry Forward Year Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyMember" xlink:label="loc_thtx_YearTwoThousandAndFortyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndFortyMember" xml:lang="en-US">Year Two Thousand And Forty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndFortyMember" xml:lang="en-US">2040</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndFortyMember" xlink:to="lab_thtx_YearTwoThousandAndFortyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndFortyMember" xml:lang="en-US">Year two thousand and forty.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyOneMember" xlink:label="loc_thtx_YearTwoThousandAndFortyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndFortyOneMember" xml:lang="en-US">Year Two Thousand And Forty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndFortyOneMember" xml:lang="en-US">2041</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndFortyOneMember" xlink:to="lab_thtx_YearTwoThousandAndFortyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndFortyOneMember" xml:lang="en-US">Year Two Thousand And Forty [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndFortyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndFortyThreeMember" xml:lang="en-US">Year Two Thousand And Forty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndFortyThreeMember" xml:lang="en-US">2043</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndFortyThreeMember" xlink:to="lab_thtx_YearTwoThousandAndFortyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndFortyThreeMember" xml:lang="en-US">Year two thousand and forty three.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndFortyTwoMember" xml:lang="en-US">Year Two Thousand And Forty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndFortyTwoMember" xml:lang="en-US">2042</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndFortyTwoMember" xlink:to="lab_thtx_YearTwoThousandAndFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndFortyTwoMember" xml:lang="en-US">2042 [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyEightMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyEightMember" xml:lang="en-US">Year Two Thousand And Thirty Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyEightMember" xml:lang="en-US">2038</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyEightMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyEightMember" xml:lang="en-US">Year Two Thousand And Thirty Eight Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyFourMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">Year Two Thousand And Thirty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">2034</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyFourMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">Year Two Thousand And Thirty Four Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyMember" xml:lang="en-US">Year Two Thousand And Thirty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyMember" xml:lang="en-US">2030</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyMember" xml:lang="en-US">Year Two Thousand And Thirty Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyNineMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyNineMember" xml:lang="en-US">Year Two Thousand And Thirty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyNineMember" xml:lang="en-US">2039</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyNineMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyNineMember" xml:lang="en-US">Year two thousand and thirty nine</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyOneMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">Year Two Thousand And Thirty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">2031</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyOneMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">Year Two Thousand And Thirty One Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtySevenMember" xlink:label="loc_thtx_YearTwoThousandAndThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtySevenMember" xml:lang="en-US">Year Two Thousand And Thirty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtySevenMember" xml:lang="en-US">2037</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtySevenMember" xlink:to="lab_thtx_YearTwoThousandAndThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtySevenMember" xml:lang="en-US">Year Two Thousand And Thirty Seven Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyThreeMember" xml:lang="en-US">Year Two Thousand And Thirty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyThreeMember" xml:lang="en-US">2033</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyThreeMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyThreeMember" xml:lang="en-US">Year Two Thousand And Thirty Three Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndThirtyTwoMember" xml:lang="en-US">Year Two Thousand And Thirty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndThirtyTwoMember" xml:lang="en-US">2032</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndThirtyTwoMember" xlink:to="lab_thtx_YearTwoThousandAndThirtyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndThirtyTwoMember" xml:lang="en-US">Year Two Thousand And Thirty Two Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyEightMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndTwentyEightMember" xml:lang="en-US">Year Two Thousand And Twenty Eight [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndTwentyEightMember" xml:lang="en-US">2028</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndTwentyEightMember" xlink:to="lab_thtx_YearTwoThousandAndTwentyEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndTwentyEightMember" xml:lang="en-US">Year Two Thousand And Twenty Eight [Member].</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyNineMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndTwentyNineMember" xml:lang="en-US">Year Two Thousand And Twenty Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndTwentyNineMember" xml:lang="en-US">2029</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndTwentyNineMember" xlink:to="lab_thtx_YearTwoThousandAndTwentyNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndTwentyNineMember" xml:lang="en-US">Year Two Thousand And Twenty Nine Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentySevenMember" xlink:label="loc_thtx_YearTwoThousandAndTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_YearTwoThousandAndTwentySevenMember" xml:lang="en-US">Year Two Thousand And Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_YearTwoThousandAndTwentySevenMember" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_YearTwoThousandAndTwentySevenMember" xlink:to="lab_thtx_YearTwoThousandAndTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_YearTwoThousandAndTwentySevenMember" xml:lang="en-US">Year Two Thousand And Twenty Seven Member.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Acquisition of Derivative Financial Assets Included in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Acquisition of derivative financial assets included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Acquisition of derivative financial assets included in accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions To Intangibles Included In Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions to intangible assets included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions To intangibles included in accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions To Property And Equipment Included In Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions to property and equipment included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Additions to property and equipment included in accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Deferred financing costsincluded in accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Deferred financing costs&#160;included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Deferred financing costs&#160;included in accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xlink:label="loc_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xml:lang="en-US">Reclassification of Other Deferred Financing Costs to Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xml:lang="en-US">Reclassification of other Deferred financing costs to deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xlink:to="lab_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xml:lang="en-US">Reclassification of other deferred financing costs to deficit.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Share Issue Cost Included in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Share issue cost included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Share issue cost included in accounts payable and accrued liabilities</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BondsMember" xlink:label="loc_thtx_BondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BondsMember" xml:lang="en-US">Bonds [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BondsMember" xml:lang="en-US">Bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BondsMember" xlink:to="lab_thtx_BondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BondsMember" xml:lang="en-US">Bonds [member]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestRateCashAndMarketFundsMember" xlink:label="loc_thtx_VariableInterestRateCashAndMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_VariableInterestRateCashAndMarketFundsMember" xml:lang="en-US">Variable Interest Rate Cash And Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_VariableInterestRateCashAndMarketFundsMember" xml:lang="en-US">Cash and market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_VariableInterestRateCashAndMarketFundsMember" xlink:to="lab_thtx_VariableInterestRateCashAndMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BadDebtExpenses" xlink:label="loc_thtx_BadDebtExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BadDebtExpenses" xml:lang="en-US">Bad Debt Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BadDebtExpenses" xml:lang="en-US">Bad debt expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BadDebtExpenses" xlink:to="lab_thtx_BadDebtExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BadDebtExpenses" xml:lang="en-US">Bad debt expenses.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentTradeReceivablesAgingPeriod" xlink:label="loc_thtx_CurrentTradeReceivablesAgingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CurrentTradeReceivablesAgingPeriod" xml:lang="en-US">Current Trade Receivables Aging Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CurrentTradeReceivablesAgingPeriod" xml:lang="en-US">Current trade receivables aging period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CurrentTradeReceivablesAgingPeriod" xlink:to="lab_thtx_CurrentTradeReceivablesAgingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CurrentTradeReceivablesAgingPeriod" xml:lang="en-US">Current trade receivables aging period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xml:lang="en-US">Increase (decrease) in fair value of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xml:lang="en-US">Increase Decrease In Fair Value Measurement Due To Reasonably Possible Increase In Unobservable Input Recognised In Cash Flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xml:lang="en-US">Increase (decrease) in cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xlink:to="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xml:lang="en-US">Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in cash flows</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, after tax, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xml:lang="en-US">Increase (decrease) in profit or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xml:lang="en-US">Increase Decrease In Fair Value Measurement Due To Reasonably Possible Increase In Unobservable Input Recognized In Accumulated Other Comprehensive Income After Tax Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xml:lang="en-US">Increase (decrease) in accumulated other comprehensive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xlink:to="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xml:lang="en-US">Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in accumulated other comprehensive income after tax assets.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:label="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xml:lang="en-US">Minimum Cash Cash Equivalents And Short Term Investments To Be Maintained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xml:lang="en-US">Minimum cash cash equivalents and short term investments to be maintained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:to="lab_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xml:lang="en-US">Minimum cash cash equivalents and short term investments to be maintained.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NegativePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NegativePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Negative Percentage Impact On Foreign Currency Exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_NegativePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Negative percentage impact on foreign currency exposures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures" xlink:to="lab_thtx_NegativePercentageImpactOnForeignCurrencyExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NegativePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Negative percentage impact on foreign currency exposures</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xml:lang="en-US">Percentage of reasonably possible decrease in unobservable input, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xml:lang="en-US">Negative impact of market interest rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xml:lang="en-US">Positive impact of market interest rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PositivePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PositivePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Positive Percentage Impact On Foreign Currency Exposures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PositivePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Positive percentage impact on foreign currency exposures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures" xlink:to="lab_thtx_PositivePercentageImpactOnForeignCurrencyExposures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PositivePercentageImpactOnForeignCurrencyExposures" xml:lang="en-US">Positive percentage impact on foreign currency exposures.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestbearingCashAndMoneyMarketFunds" xlink:label="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_VariableInterestbearingCashAndMoneyMarketFunds" xml:lang="en-US">Variable InterestBearing Cash And Money Market Funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_VariableInterestbearingCashAndMoneyMarketFunds" xml:lang="en-US">Cash and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds" xlink:to="lab_thtx_VariableInterestbearingCashAndMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_VariableInterestbearingCashAndMoneyMarketFunds" xml:lang="en-US">Variable Interest-Bearing Cash And Money Market Funds</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">SOFR</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">Secured overnight financing rate sofr overnight index Swap rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xml:lang="en-US">Convertible Unsecured Senior Notes Including Interest Undiscounted Cash Flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xml:lang="en-US">Convertible unsecured senior notes including interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xlink:to="lab_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xml:lang="en-US">Convertible unsecured senior notes including interest undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentPositionOfTermLoanIncludingInterest" xlink:label="loc_thtx_CurrentPositionOfTermLoanIncludingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CurrentPositionOfTermLoanIncludingInterest" xml:lang="en-US">Current Position Of Term Loan, Including Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CurrentPositionOfTermLoanIncludingInterest" xml:lang="en-US">Term loan, including interest, Carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CurrentPositionOfTermLoanIncludingInterest" xlink:to="lab_thtx_CurrentPositionOfTermLoanIncludingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CurrentPositionOfTermLoanIncludingInterest" xml:lang="en-US">Current position of term loan, including interest.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeaseLiabilitiesUndiscountedCashFlows" xlink:label="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LeaseLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Lease Liabilities Undiscounted Cash Flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LeaseLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows" xlink:to="lab_thtx_LeaseLiabilitiesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LeaseLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Lease liabilities undiscounted cash flows.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermLoanUndiscountedCashFlows" xlink:label="loc_thtx_LongTermLoanUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LongTermLoanUndiscountedCashFlows" xml:lang="en-US">Long term loan undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LongTermLoanUndiscountedCashFlows" xml:lang="en-US">Facility loan / Term loan, including interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LongTermLoanUndiscountedCashFlows" xlink:to="lab_thtx_LongTermLoanUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LongTermLoanUndiscountedCashFlows" xml:lang="en-US">Long term loan undiscounted cash flows</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonderivativeFinancialLiabilities" xlink:label="loc_thtx_NonderivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_NonderivativeFinancialLiabilities" xml:lang="en-US">Nonderivative Financial Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_thtx_NonderivativeFinancialLiabilities" xml:lang="en-US">Financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_NonderivativeFinancialLiabilities" xlink:to="lab_thtx_NonderivativeFinancialLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_NonderivativeFinancialLiabilities" xml:lang="en-US">Nonderivative financial liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xml:lang="en-US">Financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xml:lang="en-US">Trade and other payables, undiscounted cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="lab_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">Later than one year and not later than two years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xml:lang="en-US">From 1 to 2 Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanThreeYearsMember" xml:lang="en-US">Later than three years [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanThreeYearsMember" xml:lang="en-US">More than 3 Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Not later than one year [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xml:lang="en-US">Less than 1 year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xml:lang="en-US">Current assets (liabilities)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xml:lang="en-US">Total exposure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="lab_ifrs-full_CurrentAssetsLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="loc_ifrs-full_CurrentProvisions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentProvisions" xml:lang="en-US">Current provisions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentProvisions" xml:lang="en-US">Provisions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TotalLeaseLiabilities" xlink:label="loc_thtx_TotalLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_TotalLeaseLiabilities" xml:lang="en-US">Total Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_thtx_TotalLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_TotalLeaseLiabilities" xlink:to="lab_thtx_TotalLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_TotalLeaseLiabilities" xml:lang="en-US">Total lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xml:lang="en-US">Types of risks [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksMember" xml:lang="en-US">Risks [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrencyRiskMember" xml:lang="en-US">Currency risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro Member Countries, Euro</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_currency_EUR" xml:lang="en-US">Euro &#8211; US$</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average foreign exchange rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xml:lang="en-US">Average rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Closing foreign exchange rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xml:lang="en-US">Reporting date rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xlink:label="loc_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xml:lang="en-US">Positive Negative Impact of Foreign Exchange Gain loss Sensitivity Analysis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xml:lang="en-US">Positive (negative) impact</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xlink:to="lab_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xml:lang="en-US">Positive negative impact of foreign exchange gain loss sensitivity analysis.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashbondAndMoneyMarketFundsMember" xlink:label="loc_thtx_CashbondAndMoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CashbondAndMoneyMarketFundsMember" xml:lang="en-US">Cash Bond And Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_CashbondAndMoneyMarketFundsMember" xml:lang="en-US">Cash bond and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CashbondAndMoneyMarketFundsMember" xlink:to="lab_thtx_CashbondAndMoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CashbondAndMoneyMarketFundsMember" xml:lang="en-US">Cash,Bond And Money Market Funds.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashBondAndMoneyMarketFunds" xlink:label="loc_thtx_CashBondAndMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CashBondAndMoneyMarketFunds" xml:lang="en-US">Cash Bond and Money Market Funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_thtx_CashBondAndMoneyMarketFunds" xml:lang="en-US">Cash,bond and money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CashBondAndMoneyMarketFunds" xlink:to="lab_thtx_CashBondAndMoneyMarketFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CashBondAndMoneyMarketFunds" xml:lang="en-US">Cash bond and money market funds.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockAxis" xlink:label="loc_thtx_SaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SaleOfStockAxis" xml:lang="en-US">Sale Of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SaleOfStockAxis" xlink:to="lab_thtx_SaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockMember" xlink:label="loc_thtx_SaleOfStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SaleOfStockMember" xml:lang="en-US">Sale Of Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SaleOfStockMember" xlink:to="lab_thtx_SaleOfStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WarrantReserveMember" xml:lang="en-US">Warrant reserve [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WarrantReserveMember" xml:lang="en-US">Warrant reserve [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserveMember" xlink:to="lab_ifrs-full_WarrantReserveMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AtFairValueMember" xml:lang="en-US">At fair value [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueMultipleMeasurementInputMember" xlink:label="loc_ifrs-full_RevenueMultipleMeasurementInputMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueMultipleMeasurementInputMember" xml:lang="en-US">Revenue multiple, measurement input [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueMultipleMeasurementInputMember" xml:lang="en-US">Revenue multiple, measurement input [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueMultipleMeasurementInputMember" xlink:to="lab_ifrs-full_RevenueMultipleMeasurementInputMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xlink:label="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xml:lang="en-US">Significant Unobservable Input Liabilities Basis Points</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xml:lang="en-US">Expected volatility unobservable input, liabilities, basis points</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xlink:to="lab_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xml:lang="en-US">Significant unobservable input liabilities basis points.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xml:lang="en-US">Disclosure of contingent liabilities [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsTable" xlink:label="loc_thtx_DisclosureOfCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfCommitmentsTable" xml:lang="en-US">Disclosure of Commitments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfCommitmentsTable" xlink:to="lab_thtx_DisclosureOfCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfCommitmentsTable" xml:lang="en-US">Disclosure of Commitments [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xml:lang="en-US">Classes of contingent liabilities [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xml:lang="en-US">Contingent liabilities [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember" xlink:to="lab_ifrs-full_ContingentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsAxis" xlink:label="loc_thtx_CommitmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommitmentsAxis" xml:lang="en-US">Commitments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommitmentsAxis" xlink:to="lab_thtx_CommitmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CommitmentsAxis" xml:lang="en-US">Commitments [Axis]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsDomain" xlink:label="loc_thtx_CommitmentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CommitmentsDomain" xml:lang="en-US">Commitments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CommitmentsDomain" xlink:to="lab_thtx_CommitmentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CommitmentsDomain" xml:lang="en-US">Commitments [Line Items]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MultidosePassInjectorDevelopedMember" xlink:label="loc_thtx_MultidosePassInjectorDevelopedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_MultidosePassInjectorDevelopedMember" xml:lang="en-US">Multidose pass injector developed [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_MultidosePassInjectorDevelopedMember" xml:lang="en-US">Multidose pass injector developed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_MultidosePassInjectorDevelopedMember" xlink:to="lab_thtx_MultidosePassInjectorDevelopedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_MultidosePassInjectorDevelopedMember" xml:lang="en-US">Multi-dose pass injector developed.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityAxis" xlink:label="loc_thtx_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CreditFacilityAxis" xlink:to="lab_thtx_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CreditFacilityAxis" xml:lang="en-US">Credit Facility</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityDomain" xlink:label="loc_thtx_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_CreditFacilityDomain" xlink:to="lab_thtx_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_CreditFacilityDomain" xml:lang="en-US">Credit Facility</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsLineItems" xlink:label="loc_thtx_DisclosureOfCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_DisclosureOfCommitmentsLineItems" xml:lang="en-US">Disclosure of Commitments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems" xlink:to="lab_thtx_DisclosureOfCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_DisclosureOfCommitmentsLineItems" xml:lang="en-US">Disclosure of Commitments [Line Items]</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsOutstanding" xlink:label="loc_thtx_BorrowingsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_BorrowingsOutstanding" xml:lang="en-US">Borrowings Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_BorrowingsOutstanding" xml:lang="en-US">Line of credit facility outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_BorrowingsOutstanding" xlink:to="lab_thtx_BorrowingsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_BorrowingsOutstanding" xml:lang="en-US">Borrowings outstanding.</label>
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xlink:label="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xml:lang="en-US">Long Term Purchase Commitments Minimum Payments Required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xml:lang="en-US">Long term purchase commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xlink:to="lab_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xml:lang="en-US">Long term purchase commitments minimum payments required</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xml:lang="en-US">Disclosure of operating segments [table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xml:lang="en-US">Disclosure of operating segments [line items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SegmentsAxis" xml:lang="en-US">Segments [axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SegmentsMember" xml:lang="en-US">Segments [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsMember" xlink:to="lab_ifrs-full_SegmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember" xlink:label="loc_ifrs-full_AllOtherSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xml:lang="en-US">All other segments [member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllOtherSegmentsMember" xlink:to="lab_ifrs-full_AllOtherSegmentsMember" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RxCrossRoadsMember" xlink:label="loc_thtx_RxCrossRoadsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RxCrossRoadsMember" xml:lang="en-US">Rx Cross Roads [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RxCrossRoadsMember" xml:lang="en-US">RxCrossroads</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RxCrossRoadsMember" xlink:to="lab_thtx_RxCrossRoadsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RxCrossRoadsMember" xml:lang="en-US">Rx Cross Roads.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xml:lang="en-US">Key management personnel compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xml:lang="en-US">Post-employment benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xml:lang="en-US">Short-term employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RelatedPartyPercentageOfVotingRightsHeld" xlink:label="loc_thtx_RelatedPartyPercentageOfVotingRightsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_thtx_RelatedPartyPercentageOfVotingRightsHeld" xml:lang="en-US">Related Party Percentage Of Voting Rights Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_thtx_RelatedPartyPercentageOfVotingRightsHeld" xml:lang="en-US">Related party percentage of voting shares held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_thtx_RelatedPartyPercentageOfVotingRightsHeld" xlink:to="lab_thtx_RelatedPartyPercentageOfVotingRightsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_thtx_RelatedPartyPercentageOfVotingRightsHeld" xml:lang="en-US">Related party percentage of voting shares held.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>42
<FILENAME>thtx-20231130_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 21-February-2024 [08:06:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CoverPage" roleURI="http://www.theratech.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfNetLossAndComprehensiveLoss" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BasisOfPreparation" roleURI="http://www.theratech.com/role/BasisOfPreparation" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPolicies" roleURI="http://www.theratech.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#Revenue" roleURI="http://www.theratech.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PersonnelExpenses" roleURI="http://www.theratech.com/role/PersonnelExpenses" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinanceIncomeAndFinanceCosts" roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCosts" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BondsAndMoneyMarketFunds" roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFunds" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TradeAndOtherReceivables" roleURI="http://www.theratech.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivable" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivable" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#Inventories" roleURI="http://www.theratech.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PrepaidExpensesAndDeposits" roleURI="http://www.theratech.com/role/PrepaidExpensesAndDeposits" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PropertyAndEquipment" roleURI="http://www.theratech.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RightOfUseAssets" roleURI="http://www.theratech.com/role/RightOfUseAssets" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssets" roleURI="http://www.theratech.com/role/IntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAsset" roleURI="http://www.theratech.com/role/OtherAsset" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccuredLiabilities" roleURI="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#Provisions" roleURI="http://www.theratech.com/role/Provisions" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacility" roleURI="http://www.theratech.com/role/LoanFacility" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotes" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LeasesLiabilities" roleURI="http://www.theratech.com/role/LeasesLiabilities" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceipts" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxes" roleURI="http://www.theratech.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SupplementalCashFlowDisclosures" roleURI="http://www.theratech.com/role/SupplementalCashFlowDisclosures" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstruments" roleURI="http://www.theratech.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CapitalManagement" roleURI="http://www.theratech.com/role/CapitalManagement" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValues" roleURI="http://www.theratech.com/role/DeterminationOfFairValues" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#Commitments" roleURI="http://www.theratech.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegments" roleURI="http://www.theratech.com/role/OperatingSegments" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RelatedParties" roleURI="http://www.theratech.com/role/RelatedParties" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RevenueTables" roleURI="http://www.theratech.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PersonnelExpensesTables" roleURI="http://www.theratech.com/role/PersonnelExpensesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinanceIncomeAndFinanceCostsTables" roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BondsAndMoneyMarketFundsTables" roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.theratech.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivableTables" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#InventoriesTables" roleURI="http://www.theratech.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PrepaidExpensesAndDepositsTables" roleURI="http://www.theratech.com/role/PrepaidExpensesAndDepositsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PropertyAndEquipmentTables" roleURI="http://www.theratech.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RightOfUseAssetsTables" roleURI="http://www.theratech.com/role/RightOfUseAssetsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetsTables" roleURI="http://www.theratech.com/role/IntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAssetTables" roleURI="http://www.theratech.com/role/OtherAssetTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccuredLiabilitiesTables" roleURI="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ProvisionsTables" roleURI="http://www.theratech.com/role/ProvisionsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacilityTables" roleURI="http://www.theratech.com/role/LoanFacilityTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotesTables" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LeasesLiabilitiesTables" roleURI="http://www.theratech.com/role/LeasesLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsTables" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesTables" roleURI="http://www.theratech.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsTables" roleURI="http://www.theratech.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValuesTables" roleURI="http://www.theratech.com/role/DeterminationOfFairValuesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegmentsTables" roleURI="http://www.theratech.com/role/OperatingSegmentsTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RelatedPartiesTables" roleURI="http://www.theratech.com/role/RelatedPartiesTables" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BasisOfPreparationAdditionalInformationDetail" roleURI="http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RevenueScheduleOfNetSaleByProductDetail" roleURI="http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RevenueScheduleOfNetRevenueByGeographicalAreaDetail" roleURI="http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail" roleURI="http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PersonnelExpensesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail" roleURI="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail" roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#BondsAndMoneyMarketFundsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail" roleURI="http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail" roleURI="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#InventoriesSummaryOfDetailedInformationAboutInventoriesDetail" roleURI="http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#InventoriesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/InventoriesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail" roleURI="http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail" roleURI="http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RightOfUseAssetsDisclosureOfRightOfUseAssetDetail" roleURI="http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetSummaryOfIntangibleAssetsDetail" roleURI="http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail" roleURI="http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IntangibleAssetsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail" roleURI="http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OtherAssetAdditionalInformationDetail" roleURI="http://www.theratech.com/role/OtherAssetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ProvisionsSummaryOfProvisionDetail" roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ProvisionsSummaryOfProvisionParentheticalDetail" roleURI="http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacilityAdditionalInformationDetail" roleURI="http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail" roleURI="http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail" roleURI="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail" roleURI="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail" roleURI="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail" roleURI="http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail" roleURI="http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfExchangeRatesDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail" roleURI="http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CapitalManagementAdditionalInformationDetail" roleURI="http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail" roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail" roleURI="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegmentsSummaryOfSingleOperatingSegmentDetail" roleURI="http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#OperatingSegmentsAdditionalInformationDetail" roleURI="http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail" roleURI="http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail" />
<roleRef xlink:type="simple" xlink:href="thtx-20231130.xsd#RelatedPartiesAdditionalInformationDetail" roleURI="http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_550080" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1279581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_550080" xlink:to="loc_dei_DocumentInformationTable_1279581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1279589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1279581" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1279589" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1279590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1279589" xlink:to="loc_dei_AddressTypeDomain_1279590" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1279591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1279590" xlink:to="loc_dei_BusinessContactMember_1279591" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1279586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1279581" xlink:to="loc_dei_DocumentInformationLineItems_1279586" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_550083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentType_550083" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_550085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AmendmentFlag_550085" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_550086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentPeriodEndDate_550086" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_550087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFiscalYearFocus_550087" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_550088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFiscalPeriodFocus_550088" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_550089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityRegistrantName_550089" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_550090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCentralIndexKey_550090" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_550104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCurrentReportingStatus_550104" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_550108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityEmergingGrowthCompany_550108" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_550109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_CurrentFiscalYearEndDate_550109" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_1279641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentRegistrationStatement_1279641" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_550111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentAnnualReport_550111" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_550678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_550678" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_551052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_Security12bTitle_551052" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_551065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityInteractiveDataCurrent_551065" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_603583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityExTransitionPeriod_603583" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_603670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_TradingSymbol_603670" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_842211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_SecurityExchangeName_842211" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_842213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_IcfrAuditorAttestationFlag_842213" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1279560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityFileNumber_1279560" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1279561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1279561" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_550102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_550102" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_550103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityVoluntaryFilers_550103" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_550105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityShellCompany_550105" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_550106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityFilerCategory_550106" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_550112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentTransitionReport_550112" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_550663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentShellCompanyReport_550663" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1279612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_ContactPersonnelName_1279612" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1279576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressAddressLine1_1279576" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1279599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressAddressLine2_1279599" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1279601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressCityOrTown_1279601" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1279602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressStateOrProvince_1279602" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_551068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressCountry_551068" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1279605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_EntityAddressPostalZipCode_1279605" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1279606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_CityAreaCode_1279606" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1279607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_LocalPhoneNumber_1279607" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_2147462828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_ContactPersonnelFaxNumber_2147462828" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1306649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorName_1306649" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1306650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorFirmId_1306650" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1306651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_AuditorLocation_1306651" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147462827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147462827" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_2147462834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1279586" xlink:to="loc_dei_DocumentAccountingStandard_2147462834" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_548653" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_548656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_548653" xlink:to="loc_ifrs-full_AssetsAbstract_548656" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_548657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_548656" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_548657" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_548658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_Cash_548658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_548659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_548659" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_548660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_548660" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_818841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_818841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxReceivableCurrent" xlink:label="loc_thtx_IncomeTaxReceivableCurrent_2147462804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_thtx_IncomeTaxReceivableCurrent_2147462804" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_2147462803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_DeferredTaxAssets_2147462803" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-full_InventoriesTotal_548662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_InventoriesTotal_548662" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_548669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_548669" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_548673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_548673" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_548681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_548657" xlink:to="loc_ifrs-full_CurrentAssets_548681" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_548686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_548656" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_548686" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_548693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_548686" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_548693" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_818842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_548686" xlink:to="loc_ifrs-full_RightofuseAssets_818842" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_548694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_548686" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_548694" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCosts" xlink:label="loc_thtx_DeferredFinancingCosts_1277742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_548686" xlink:to="loc_thtx_DeferredFinancingCosts_1277742" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_548697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_548686" xlink:to="loc_ifrs-full_NoncurrentAssets_548697" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_548698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_548656" xlink:to="loc_ifrs-full_Assets_548698" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract_548699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_548653" xlink:to="loc_ifrs-full_LiabilitiesAbstract_548699" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_548699" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_548701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_548701" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_548702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_OtherShorttermProvisions_548702" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued_2147468213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued_2147468213" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityCurrent" xlink:label="loc_thtx_LoanFacilityCurrent_2147462987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_thtx_LoanFacilityCurrent_2147462987" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_818843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_818843" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WarrantsCurrent" xlink:label="loc_thtx_WarrantsCurrent_2147462986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_thtx_WarrantsCurrent_2147462986" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_818844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_818844" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_548704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities_548704" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_548705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_548700" xlink:to="loc_ifrs-full_CurrentLiabilities_548705" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_548699" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityNoncurrent" xlink:label="loc_thtx_LoanFacilityNoncurrent_2147462985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" xlink:to="loc_thtx_LoanFacilityNoncurrent_2147462985" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_818845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_818845" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_548714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_548714" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_548715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_548706" xlink:to="loc_ifrs-full_NoncurrentLiabilities_548715" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_548716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_548699" xlink:to="loc_ifrs-full_Liabilities_548716" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_548734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_548699" xlink:to="loc_ifrs-full_EquityAbstract_548734" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_548720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_IssuedCapital_548720" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_548721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_548721" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_548722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_548722" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_548724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_RetainedEarnings_548724" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_548725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_548725" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_548726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_548734" xlink:to="loc_ifrs-full_Equity_548726" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_548739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_548699" xlink:to="loc_ifrs-full_EquityAndLiabilities_548739" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_548933" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_548938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_548933" xlink:to="loc_ifrs-full_Revenue_548938" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OperatingExpensesAbstract" xlink:label="loc_thtx_OperatingExpensesAbstract_548939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_548933" xlink:to="loc_thtx_OperatingExpensesAbstract_548939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_548941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_CostOfSales_548941" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherAssets" xlink:label="loc_thtx_AmortizationOfOtherAssets_548946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_thtx_AmortizationOfOtherAssets_548946" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits" xlink:label="loc_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits_548951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits_548951" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense" xlink:label="loc_ifrs-full_SellingExpense_548952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_SellingExpense_548952" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_548953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_548953" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_548967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_OperatingExpense_548967" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_548970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_548970" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_548974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_FinanceIncome_548974" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency_548976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency_548976" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency_548979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency_548979" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_548978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_548978" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_548993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_548993" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_548980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OperatingExpensesAbstract_548939" xlink:to="loc_ifrs-full_ProfitLoss_548980" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_548981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_548933" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_548981" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_548981" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_548983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" xlink:to="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_548983" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_548984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_548984" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_548985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_548985" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_548987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_548982" xlink:to="loc_ifrs-full_ComprehensiveIncome_548987" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_548989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_548933" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_548989" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_2147462837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_548989" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_2147462837" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_2147462836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_548989" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_2147462836" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_836035" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost" xlink:label="loc_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost_836037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_836035" xlink:to="loc_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost_836037" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_548998" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_549000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_548998" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_549000" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_549001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_549000" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_549001" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_549003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_549001" xlink:to="loc_ifrs-full_EquityMember_549003" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_549530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_IssuedCapitalMember_549530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_549532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_549532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_549004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_549004" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_549006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_RetainedEarningsMember_549006" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_549007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_549003" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_549007" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_549000" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_549011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_Equity_549011" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_549013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_549013" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_549015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAbstract_550222" xlink:to="loc_ifrs-full_ProfitLoss_549015" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax" xlink:label="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_549020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax_549020" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_549021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_549021" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_549022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_549018" xlink:to="loc_ifrs-full_ComprehensiveIncome_549022" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousComponentsOfEquityAbstract" xlink:label="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1277833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1277833" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_1277834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_1277834" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareIssueCosts" xlink:label="loc_thtx_ShareIssueCosts_1277811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_ShareIssueCosts_1277811" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_1277813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_1277813" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue_1277815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue_1277815" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodValueAcquisitions_1277835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringPeriodValueAcquisitions_1277835" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions_1277836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringPeriodSharesAcquisitions_1277836" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueNewIssues_2147462978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodValueNewIssues_2147462978" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesNewIssues" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues_2147462975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodSharesNewIssues_2147462975" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities_2147462971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities_2147462971" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities_2147462966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities_2147462966" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue" xlink:label="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue_2147463311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue_2147463311" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfSharesIssuedThroughAtmProgram" xlink:label="loc_thtx_NumberOfSharesIssuedThroughAtmProgram_2147463305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_thtx_NumberOfSharesIssuedThroughAtmProgram_2147463305" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147463317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MiscellaneousComponentsOfEquityAbstract_549023" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147463317" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareBasedCompensationPlanAbstract" xlink:label="loc_thtx_ShareBasedCompensationPlanAbstract_549031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_thtx_ShareBasedCompensationPlanAbstract_549031" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_549032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareBasedCompensationPlanAbstract_549031" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_549032" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAbstract" xlink:label="loc_thtx_ExerciseOfStockOptionsAbstract_549033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_thtx_ExerciseOfStockOptionsAbstract_549033" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsValue" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue_549034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue_549034" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares_549035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares_549035" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExerciseOfStockOptionsAttributedValue" xlink:label="loc_thtx_ExerciseOfStockOptionsAttributedValue_549036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_ExerciseOfStockOptionsAttributedValue_549036" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_549042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_549042" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares" xlink:label="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares_549687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ExerciseOfStockOptionsAbstract_549033" xlink:to="loc_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares_549687" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_549043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_Equity_549043" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_549445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_549009" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_549445" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_548775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" xlink:to="loc_ifrs-full_ProfitLoss_548775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_548780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_548780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_548782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_548782" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAmortizationOfRightofuseAssets" xlink:label="loc_thtx_AdjustmentsForAmortizationOfRightofuseAssets_818846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_AdjustmentsForAmortizationOfRightofuseAssets_818846" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_548784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_548784" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_thtx_GainLossOnLeaseTermination_2147462979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_GainLossOnLeaseTermination_2147462979" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets_548787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets_548787" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_548790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_548790" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan" xlink:label="loc_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan_548793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan_548793" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_2147463028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_2147463028" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestIncome" xlink:label="loc_ifrs-full_AdjustmentsForInterestIncome_610478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForInterestIncome_610478" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_2147463027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_2147463027" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_2147463051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_2147463051" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2147463050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_2147463050" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_548799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_548799" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463337" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts_548796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts_548796" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_2147462977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_2147462977" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLoanFacilityModifications" xlink:label="loc_thtx_GainLossOnLoanFacilityModifications_2147462974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_thtx_GainLossOnLoanFacilityModifications_2147462974" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_2147462973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_2147462973" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_548808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_548778" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_548808" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" xlink:to="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_548825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_548825" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForTaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable_818847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable_818847" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_548826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_548826" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_548832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_548832" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_548834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_548834" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_548836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_548836" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities_584667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities_584667" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_548838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract_550150" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_548838" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_548845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_548774" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_548845" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463348" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463350" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147463353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147463353" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_2147463354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_2147463354" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RepaymentOfOtherObligations" xlink:label="loc_thtx_RepaymentOfOtherObligations_2147463026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_thtx_RepaymentOfOtherObligations_2147463026" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_548869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_548869" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1277901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1277901" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromIssuingSharesAndWarrants" xlink:label="loc_thtx_ProceedsFromIssuingSharesAndWarrants_1277903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_thtx_ProceedsFromIssuingSharesAndWarrants_1277903" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1278438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1278438" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdjustmentsForDeferredFinancingCosts" xlink:label="loc_thtx_AdjustmentsForDeferredFinancingCosts_1277890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_thtx_AdjustmentsForDeferredFinancingCosts_1277890" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_836049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_836049" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_548889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_548853" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_548889" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_548895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_548895" use="optional" order="48" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_548897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_548897" use="optional" order="49" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_548899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_548899" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_548901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_548901" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsToAcquireDerivativeFinancialAssets" xlink:label="loc_thtx_PaymentsToAcquireDerivativeFinancialAssets_548904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_thtx_PaymentsToAcquireDerivativeFinancialAssets_548904" use="optional" order="52" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_548905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_548891" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_548905" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_548909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_548909" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_548915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_CashAndCashEquivalents_548915" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_548917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_548917" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_548919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_548773" xlink:to="loc_ifrs-full_CashAndCashEquivalents_548919" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BasisOfPreparation">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_548761" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_548770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548761" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_548770" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_548777" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_548779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548777" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_548779" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/Revenue">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549128" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_549129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549128" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_549129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PersonnelExpenses">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549131" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_549132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549131" xlink:to="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_549132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinanceIncomeAndFinanceCosts">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549169" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_549170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549169" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_549170" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BondsAndMoneyMarketFunds">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549207" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_550153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549207" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_550153" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TradeAndOtherReceivables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherReceivablesExplanatoryAbstract" xlink:label="loc_thtx_TradeAndOtherReceivablesExplanatoryAbstract_549564" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_549566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherReceivablesExplanatoryAbstract_549564" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_549566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivable">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549890" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTaxCreditsReceivableExplanatory" xlink:label="loc_thtx_DisclosureOfTaxCreditsReceivableExplanatory_572595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549890" xlink:to="loc_thtx_DisclosureOfTaxCreditsReceivableExplanatory_572595" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_549575" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_549576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549575" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_549576" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PrepaidExpensesAndDeposits">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract" xlink:label="loc_ifrs-full_CurrentPrepaymentsAbstract_1303000" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits" xlink:label="loc_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits_1306066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract_1303000" xlink:to="loc_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits_1306066" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549602" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_549603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549602" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_549603" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RightOfUseAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_818864" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_818865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_818864" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_818865" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssets">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549242" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_549243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549242" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_549243" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAsset">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549573" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_549953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549573" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_549953" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndAccruedPayablesAbstract" xlink:label="loc_thtx_TradeAndAccruedPayablesAbstract_549647" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock_572598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndAccruedPayablesAbstract_549647" xlink:to="loc_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock_572598" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/Provisions">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549853" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_549854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549853" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_549854" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacility">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_2147463490" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_2147463498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_2147463490" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_2147463498" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_549898" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock_549900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_549898" xlink:to="loc_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock_549900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LeasesLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_818885" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_818888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_818885" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_818888" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550114" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_550115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550114" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_550115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549851" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_549852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549851" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_549852" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SupplementalCashFlowDisclosures">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SupplementalCashFlowDisclosuresAbstract" xlink:label="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549656" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory" xlink:label="loc_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory_549658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549656" xlink:to="loc_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory_549658" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549708" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_549709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549708" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_549709" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CapitalManagement">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_549621" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_549622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_549621" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_549622" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValues">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfFairValueMeasurementAbstract" xlink:label="loc_thtx_DisclosureOfFairValueMeasurementAbstract_549585" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_549587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfFairValueMeasurementAbstract_549585" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_549587" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/Commitments">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsAbstract" xlink:label="loc_thtx_DisclosureOfCommitmentsAbstract_550333" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_550339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsAbstract_550333" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_550339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegments">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549300" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_549301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549300" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_549301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RelatedParties">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_549087" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_549088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549087" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_549088" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_548798" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_548810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_548810" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_548822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_548822" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_548824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_548824" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCostOfSalesExplanatory_548829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DisclosureOfCostOfSalesExplanatory_548829" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_548830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_548830" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_548835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_548835" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock_548837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock_548837" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_548846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_548846" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_548847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_548847" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory_2147463389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory_2147463389" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock_548848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock_548848" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_584812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_584812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_548856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_548856" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_548877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_548877" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory_1304624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory_1304624" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_548882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_548882" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_548884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_548884" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_548887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_548887" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock_548892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock_548892" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_836064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_836064" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_548896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_548896" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_548900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_548900" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_548903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_548903" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory_2147463023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory_2147463023" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory_2147462982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory_2147462982" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock" xlink:label="loc_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock_836065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548798" xlink:to="loc_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock_836065" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_548913" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock" xlink:label="loc_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock_548914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_548913" xlink:to="loc_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock_548914" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_584823" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_584826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_584823" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_584826" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock_584854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_584823" xlink:to="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock_584854" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PersonnelExpensesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549140" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock_549143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549140" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock_549143" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549188" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock_549191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549188" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock_549191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BondsAndMoneyMarketFundsTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549215" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock_572605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549215" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock_572605" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TradeAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549571" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock_572610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549571" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock_572610" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549893" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock" xlink:label="loc_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock_819009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549893" xlink:to="loc_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock_819009" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock_572614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549893" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock_572614" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_549936" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock_572618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549936" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock_572618" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PrepaidExpensesAndDepositsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract" xlink:label="loc_ifrs-full_CurrentPrepaymentsAbstract_1303043" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_1303049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract_1303043" xlink:to="loc_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_1303049" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549607" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_549619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549607" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_549619" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RightOfUseAssetsTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfRightOfUseAssetAbstract" xlink:label="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818867" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RightOfUseAssetsTableTextBlock" xlink:label="loc_thtx_RightOfUseAssetsTableTextBlock_818868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818867" xlink:to="loc_thtx_RightOfUseAssetsTableTextBlock_818868" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549239" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_549240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549239" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_549240" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock_550189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549239" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock_550189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAssetTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_549945" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock_572628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_549945" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock_572628" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_549653" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_549897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_549653" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_549897" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ProvisionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549860" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock_572630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549860" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock_572630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacilityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_2147464790" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_2147464794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_2147464790" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_2147464794" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_549930" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock_572670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_549930" xlink:to="loc_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock_572670" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LeasesLiabilitiesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesAbstract" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818891" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesTableTextBlock" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock_818892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818891" xlink:to="loc_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock_818892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550120" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalTable" xlink:label="loc_thtx_ShareCapitalTable_551011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550120" xlink:to="loc_thtx_ShareCapitalTable_551011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalTable_551011" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_551013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_551012" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_551013" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareCapitalLineItems" xlink:label="loc_thtx_ShareCapitalLineItems_551015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalTable_551011" xlink:to="loc_thtx_ShareCapitalLineItems_551015" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities_2147462841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities_2147462841" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock_572676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock_572676" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock_585341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock_585341" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_585376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_585376" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock_585513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock_585513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock_585631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock_585631" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock" xlink:label="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock_585632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock_585632" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock_572673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ShareCapitalLineItems_551015" xlink:to="loc_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock_572673" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549856" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock_572685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549856" xlink:to="loc_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock_572685" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock_572689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549856" xlink:to="loc_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock_572689" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_549882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549856" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_549882" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock_572690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549856" xlink:to="loc_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock_572690" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549712" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_549714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549712" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_549714" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock_549718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549712" xlink:to="loc_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock_549718" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock_549720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549712" xlink:to="loc_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock_549720" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_549722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549712" xlink:to="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_549722" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValuesTables">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfFairValueMeasurementAbstract" xlink:label="loc_thtx_DisclosureOfFairValueMeasurementAbstract_2147462800" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_2147462799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfFairValueMeasurementAbstract_2147462800" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_2147462799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549321" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock_572691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549321" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock_572691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RelatedPartiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_549090" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_549091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549090" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_549091" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_796474" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationTable" xlink:label="loc_thtx_BasisOfPresentationTable_820284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_796474" xlink:to="loc_thtx_BasisOfPresentationTable_820284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_820288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_820287" xlink:to="loc_ifrs-full_RestatedMember_820288" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_837254" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_837255" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147463385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147463385" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147463386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147463385" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147463386" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_ifrs-full_RangeAxis_2147462970" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2147462970" xlink:to="loc_ifrs-full_RangesMember_2147462969" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462969" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462967" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462969" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462968" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfPresentationLineItems" xlink:label="loc_thtx_BasisOfPresentationLineItems_820286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationTable_820284" xlink:to="loc_thtx_BasisOfPresentationLineItems_820286" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumLiquidityRequirementAmount" xlink:label="loc_thtx_MinimumLiquidityRequirementAmount_2147462972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_thtx_MinimumLiquidityRequirementAmount_2147462972" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRateBasis" xlink:label="loc_ifrs-full_BorrowingsInterestRateBasis_2147462976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_BorrowingsInterestRateBasis_2147462976" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2147463048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2147463048" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_2147463049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_ProfitLoss_2147463049" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_2147462990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_Cash_2147462990" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_2147462989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfPresentationLineItems_820286" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_2147462989" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549076" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549076" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549095" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_549100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_ComputerEquipmentMember_549100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaboratoryEquipmentMember" xlink:label="loc_thtx_LaboratoryEquipmentMember_549102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_thtx_LaboratoryEquipmentMember_549102" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_549103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_OfficeEquipmentMember_549103" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_549104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549099" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_549104" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549078" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationMethodPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment_549105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DepreciationMethodPropertyPlantAndEquipment_549105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment_549108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DepreciationRatePropertyPlantAndEquipment_549108" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_549109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_549109" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_549110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549081" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_549110" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549049" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549049" xlink:to="loc_thtx_StatementTable_549060" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_549064" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsEgriftaMember" xlink:label="loc_thtx_CommercializationRightsEgriftaMember_549066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_CommercializationRightsEgriftaMember_549066" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoMember_549067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_CommercializationRightsTrogarzoMember_549067" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember_550377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_ifrs-full_CapitalisedDevelopmentExpenditureMember_550377" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember_1306219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_549065" xlink:to="loc_thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember_1306219" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_549068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_549068" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549068" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549069" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember" xlink:label="loc_ifrs-full_OtherAssetsMember_549071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_549069" xlink:to="loc_ifrs-full_OtherAssetsMember_549071" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_2147463016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_2147463017" xlink:to="loc_ifrs-full_RestatedMember_2147463016" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549060" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_549072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_549072" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill_549073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill_549073" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets" xlink:label="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets_549074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets_549074" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549063" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550366" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_584832" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_584832" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_584834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_584834" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_584835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_584834" xlink:to="loc_ifrs-full_ProductsAndServicesMember_584835" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EgriftaMember" xlink:label="loc_thtx_EgriftaMember_584836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_584835" xlink:to="loc_thtx_EgriftaMember_584836" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoNetSalesMember" xlink:label="loc_thtx_TrogarzoNetSalesMember_584838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_584835" xlink:to="loc_thtx_TrogarzoNetSalesMember_584838" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_797437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xlink:to="loc_ifrs-full_GeographicalAreasAxis_797437" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_797438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_797437" xlink:to="loc_ifrs-full_GeographicalAreasMember_797438" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_797454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_797438" xlink:to="loc_srt_EuropeMember_797454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_584833" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_584842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_584840" xlink:to="loc_ifrs-full_Revenue_584842" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_584860" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaTable" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_584860" xlink:to="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_584864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" xlink:to="loc_ifrs-full_GeographicalAreasAxis_584864" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_584865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_584864" xlink:to="loc_ifrs-full_GeographicalAreasMember_584865" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_584867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_country_CA_584867" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_584869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_country_US_584869" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_584872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_584865" xlink:to="loc_srt_EuropeMember_584872" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisaggregationOfRevenueByGeographicalAreaLineItems" xlink:label="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaTable_584862" xlink:to="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_584874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems_584873" xlink:to="loc_ifrs-full_Revenue_584874" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xlink:label="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_549163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_549163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_549164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_549164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_549165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_549165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TerminationBenefitsExpense" xlink:label="loc_ifrs-full_TerminationBenefitsExpense_584879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" xlink:to="loc_ifrs-full_TerminationBenefitsExpense_584879" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_549166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_549157" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_549166" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract" xlink:label="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_2147463433" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses" xlink:label="loc_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses_2147463435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract_2147463433" xlink:to="loc_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses_2147463435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract" xlink:label="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463443" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue" xlink:label="loc_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue_2147462984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue_2147462984" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_549200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_RevenueFromInterest_549200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_thtx_GainLossOnLeaseTermination_2147462983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_GainLossOnLeaseTermination_2147462983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_584885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_FinanceIncome_584885" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts" xlink:label="loc_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts_2147463444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts_2147463444" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_549202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_InterestExpenseOnDebtInstrumentsIssued_549202" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankAndSimilarCharges" xlink:label="loc_ifrs-full_BankAndSimilarCharges_549204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_BankAndSimilarCharges_549204" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_1278719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_1278719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLoanFacilityModifications" xlink:label="loc_thtx_GainLossOnLoanFacilityModifications_2147462981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_GainLossOnLoanFacilityModifications_2147462981" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_2147462980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_2147462980" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceCostsAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency_549209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_FinanceCostsAndGainsLossesOnForeignCurrency_549209" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency" xlink:label="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency_549211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract_549194" xlink:to="loc_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency_549211" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549223" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentDebtInstrumentsHeld" xlink:label="loc_ifrs-full_GovernmentDebtInstrumentsHeld_549224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549223" xlink:to="loc_ifrs-full_GovernmentDebtInstrumentsHeld_549224" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GuaranteedInvestmentCertificates" xlink:label="loc_thtx_GuaranteedInvestmentCertificates_2147463447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549223" xlink:to="loc_thtx_GuaranteedInvestmentCertificates_2147463447" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets_549226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract_549223" xlink:to="loc_ifrs-full_OtherFinancialAssets_549226" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract_550128" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_550133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract_550128" xlink:to="loc_thtx_StatementTable_550133" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_550134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_550133" xlink:to="loc_ifrs-full_RangeAxis_550134" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_550134" xlink:to="loc_ifrs-full_RangesMember_550137" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_550138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_550137" xlink:to="loc_ifrs-full_BottomOfRangeMember_550138" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_550139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_550137" xlink:to="loc_ifrs-full_TopOfRangeMember_550139" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_550133" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsStatedInterestPercentage" xlink:label="loc_thtx_FinancialAssetsStatedInterestPercentage_550130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" xlink:to="loc_thtx_FinancialAssetsStatedInterestPercentage_550130" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FinancialAssetsAverageMaturityTerm" xlink:label="loc_thtx_FinancialAssetsAverageMaturityTerm_550131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_550136" xlink:to="loc_thtx_FinancialAssetsAverageMaturityTerm_550131" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract" xlink:label="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract_549284" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_549288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract_549284" xlink:to="loc_ifrs-full_CurrentTradeReceivables_549288" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_549857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract_549284" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_549857" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_549858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract_549284" xlink:to="loc_ifrs-full_OtherCurrentReceivables_549858" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_549859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract_549284" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_549859" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_818852" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_818853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_818852" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_818853" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems" xlink:label="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_818853" xlink:to="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_818855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_818855" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss" xlink:label="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss_818856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss_818856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceived" xlink:label="loc_thtx_TaxCreditsAndGrantsReceived_1305948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsReceived_1305948" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable_818857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable_818857" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_818906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems_818854" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_818906" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549345" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract_549345" xlink:to="loc_thtx_StatementTable_549384" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_549390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549384" xlink:to="loc_ifrs-full_MaturityAxis_549390" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_549390" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549401" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFourMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember_549406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyFourMember_549406" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyFiveMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember_549407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyFiveMember_549407" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySixMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember_549409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentySixMember_549409" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentySevenMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember_549410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentySevenMember_549410" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyEightMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember_549412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyEightMember_549412" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandTwentyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember_549417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandTwentyNineMember_549417" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember_549422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyMember_549422" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember_549427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyOneMember_549427" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember_549430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyTwoMember_549430" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember_549437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyThreeMember_549437" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandThirtyNineMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember_836979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandThirtyNineMember_836979" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyMember_836983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyMember_836983" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyOneMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember_1305951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyOneMember_1305951" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyTwoMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember_2147468377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyTwoMember_2147468377" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxExpireTwoThousandFortyThreeMember" xlink:label="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember_2147462988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549401" xlink:to="loc_thtx_IncomeTaxExpireTwoThousandFortyThreeMember_2147462988" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549384" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_549903" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnusedAndUnrecordedTaxCreditsMember" xlink:label="loc_thtx_UnusedAndUnrecordedTaxCreditsMember_549905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_549904" xlink:to="loc_thtx_UnusedAndUnrecordedTaxCreditsMember_549905" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementLineItems" xlink:label="loc_thtx_StatementLineItems_550217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549384" xlink:to="loc_thtx_StatementLineItems_550217" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-full_DeferredTaxAssets_550218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550217" xlink:to="loc_ifrs-full_DeferredTaxAssets_550218" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_549506" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials" xlink:label="loc_ifrs-full_RawMaterials_549509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549506" xlink:to="loc_ifrs-full_RawMaterials_549509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress_549510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549506" xlink:to="loc_ifrs-full_WorkInProgress_549510" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods_549514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549506" xlink:to="loc_ifrs-full_FinishedGoods_549514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-full_InventoriesTotal_549511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549506" xlink:to="loc_ifrs-full_InventoriesTotal_549511" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/InventoriesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_549521" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementTable" xlink:label="loc_thtx_StatementTable_549958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_549521" xlink:to="loc_thtx_StatementTable_549958" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementAxis" xlink:label="loc_thtx_LocationInIncomeStatementAxis_549963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549958" xlink:to="loc_thtx_LocationInIncomeStatementAxis_549963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LocationInIncomeStatementDomain" xlink:label="loc_thtx_LocationInIncomeStatementDomain_549965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_LocationInIncomeStatementAxis_549963" xlink:to="loc_thtx_LocationInIncomeStatementDomain_549965" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CostOfGoodsSoldMember" xlink:label="loc_thtx_CostOfGoodsSoldMember_549968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_LocationInIncomeStatementDomain_549965" xlink:to="loc_thtx_CostOfGoodsSoldMember_549968" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549958" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2147462960" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaiMedBiologicsInc.Member" xlink:label="loc_thtx_TaiMedBiologicsInc.Member_2147462959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2147462958" xlink:to="loc_thtx_TaiMedBiologicsInc.Member_2147462959" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StatementLineItems" xlink:label="loc_thtx_StatementLineItems_550220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementTable_549958" xlink:to="loc_thtx_StatementLineItems_550220" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_2147462963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_2147462963" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InventoriesReturned" xlink:label="loc_thtx_InventoriesReturned_2147462962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_InventoriesReturned_2147462962" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2147462961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2147462961" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011" xlink:label="loc_ifrs-full_InventoryWritedown2011_550221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_ifrs-full_InventoryWritedown2011_550221" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForFormulation" xlink:label="loc_thtx_ProvisionForFormulation_2147468517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForFormulation_2147468517" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheInventoryInDevelopment" xlink:label="loc_thtx_ProvisionForTheInventoryInDevelopment_2147468561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForTheInventoryInDevelopment_2147468561" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForTheExpiredRawMaterial" xlink:label="loc_thtx_ProvisionForTheExpiredRawMaterial_2147468564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForTheExpiredRawMaterial_2147468564" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvisionForExcessStock" xlink:label="loc_thtx_ProvisionForExcessStock_836974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_StatementLineItems_550220" xlink:to="loc_thtx_ProvisionForExcessStock_836974" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract" xlink:label="loc_ifrs-full_CurrentPrepaymentsAbstract_1303057" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrepaidExpenses" xlink:label="loc_thtx_PrepaidExpenses_1306677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract_1303057" xlink:to="loc_thtx_PrepaidExpenses_1306677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_1303061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract_1303057" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_1303061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_1303060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentPrepaymentsAbstract_1303057" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_1303060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549634" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_549634" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_549643" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_549703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_ComputerEquipmentMember_549703" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaboratoryEquipmentMember" xlink:label="loc_thtx_LaboratoryEquipmentMember_549704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_thtx_LaboratoryEquipmentMember_549704" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_549705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_OfficeEquipmentMember_549705" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_549706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_549699" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_549706" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_549732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_549731" xlink:to="loc_ifrs-full_CarryingAmountMember_549732" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_550822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_549732" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_550822" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_549736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_549732" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_549736" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_549638" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_549769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_549769" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_549753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_549753" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_549750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_549750" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_549777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_549710" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_549777" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract" xlink:label="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_550066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_550066" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_549755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_549755" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment" xlink:label="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment_549756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment_549756" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_549778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract_549748" xlink:to="loc_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation_549778" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountAbstract" xlink:label="loc_thtx_NetCarryingAmountAbstract_549764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_549641" xlink:to="loc_thtx_NetCarryingAmountAbstract_549764" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_549776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_NetCarryingAmountAbstract_549764" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_549776" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfRightOfUseAssetAbstract" xlink:label="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_818872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_ifrs-full_RightofuseAssets_818872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfRightOfUseAsset" xlink:label="loc_thtx_AmortizationOfRightOfUseAsset_818874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_thtx_AmortizationOfRightOfUseAsset_818874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset" xlink:label="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset_818875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset_818875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfRightOfUseAssets" xlink:label="loc_thtx_TerminationOfRightOfUseAssets_2147462957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_thtx_TerminationOfRightOfUseAssets_2147462957" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_2147462956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_2147462956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_820469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfRightOfUseAssetAbstract_818870" xlink:to="loc_ifrs-full_RightofuseAssets_820469" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549233" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_549233" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550233" xlink:to="loc_ifrs-full_CarryingAmountMember_550234" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_550852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_550852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_550235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_550235" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountMember" xlink:label="loc_thtx_NetCarryingAmountMember_550236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_550234" xlink:to="loc_thtx_NetCarryingAmountMember_550236" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550258" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoEuropeMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoEuropeMember_550261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsTrogarzoEuropeMember_550261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsEgriftaMember" xlink:label="loc_thtx_CommercializationRightsEgriftaMember_550263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_CommercializationRightsEgriftaMember_550263" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OncologyPlatformMember" xlink:label="loc_thtx_OncologyPlatformMember_585296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550259" xlink:to="loc_thtx_OncologyPlatformMember_585296" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_549392" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549249" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585293" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2147462955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2147462955" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_550232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_550223" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_550232" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationAbstract" xlink:label="loc_thtx_AccumulatedAmortizationAbstract_549414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_thtx_AccumulatedAmortizationAbstract_549414" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550229" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_549276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_549276" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill_2147462839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill_2147462839" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill" xlink:label="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationAbstract_549414" xlink:to="loc_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill_550230" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmountAbstract" xlink:label="loc_thtx_NetCarryingAmountAbstract_549440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_549408" xlink:to="loc_thtx_NetCarryingAmountAbstract_549440" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_NetCarryingAmountAbstract_549440" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_549272" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_550267" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_550267" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAxis" xlink:label="loc_thtx_MilestoneAxis_550274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xlink:to="loc_thtx_MilestoneAxis_550274" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneAxis_550274" xlink:to="loc_thtx_MilestoneDomain_550276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFourMember" xlink:label="loc_thtx_MilestoneFourMember_550280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneFourMember_550280" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneFiveMember" xlink:label="loc_thtx_MilestoneFiveMember_550281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneFiveMember_550281" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneSixMember" xlink:label="loc_thtx_MilestoneSixMember_550282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550276" xlink:to="loc_thtx_MilestoneSixMember_550282" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xlink:to="loc_thtx_TypeOfArrangementsAxis_550309" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsAxis_550309" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550310" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550268" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayable" xlink:label="loc_thtx_InitialMilestonePaymentsPayable_550273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550270" xlink:to="loc_thtx_InitialMilestonePaymentsPayable_550273" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_550410" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_550410" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_TypeOfArrangementsAxis_550442" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsAxis_550442" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550443" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaimedAgreementMember" xlink:label="loc_thtx_TaimedAgreementMember_550444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550443" xlink:to="loc_thtx_TaimedAgreementMember_550444" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LicenseAgreementTransferPlusLPMember" xlink:label="loc_thtx_LicenseAgreementTransferPlusLPMember_585051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550443" xlink:to="loc_thtx_LicenseAgreementTransferPlusLPMember_585051" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_585054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_585054" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585054" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaMember" xlink:label="loc_thtx_KatanaMember_585057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" xlink:to="loc_thtx_KatanaMember_585057" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaAmendmentAgreementMember" xlink:label="loc_thtx_KatanaAmendmentAgreementMember_585101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585055" xlink:to="loc_thtx_KatanaAmendmentAgreementMember_585101" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_550446" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoNorthAmericaMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" xlink:to="loc_thtx_CommercializationRightsTrogarzoNorthAmericaMember_550449" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommercializationRightsTrogarzoMember" xlink:label="loc_thtx_CommercializationRightsTrogarzoMember_550463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_550447" xlink:to="loc_thtx_CommercializationRightsTrogarzoMember_550463" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550552" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550553" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_550554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_550553" xlink:to="loc_ifrs-full_OrdinarySharesMember_550554" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheAxis" xlink:label="loc_thtx_TrancheAxis_550556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_TrancheAxis_550556" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrancheDomain" xlink:label="loc_thtx_TrancheDomain_550557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TrancheAxis_550556" xlink:to="loc_thtx_TrancheDomain_550557" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_550561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_RangeAxis_550561" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_550563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_550561" xlink:to="loc_ifrs-full_RangesMember_550563" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_550564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_550563" xlink:to="loc_ifrs-full_TopOfRangeMember_550564" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_585190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_550563" xlink:to="loc_ifrs-full_BottomOfRangeMember_585190" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosAxis" xlink:label="loc_thtx_ScenariosAxis_550567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_ScenariosAxis_550567" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScenariosDomain" xlink:label="loc_thtx_ScenariosDomain_550568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScenariosAxis_550567" xlink:to="loc_thtx_ScenariosDomain_550568" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAxis" xlink:label="loc_thtx_MilestoneAxis_550578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_MilestoneAxis_550578" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneDomain" xlink:label="loc_thtx_MilestoneDomain_550579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneAxis_550578" xlink:to="loc_thtx_MilestoneDomain_550579" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneOneMember" xlink:label="loc_thtx_MilestoneOneMember_585027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_MilestoneOneMember_585027" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestonePhaseTwoLiveDemonstrationMember" xlink:label="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember_585063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_MilestonePhaseTwoLiveDemonstrationMember_585063" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseOneClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember_585211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseOneClinicalTrialMember_585211" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember_585212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember_585212" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember" xlink:label="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember_585213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_MilestoneDomain_550579" xlink:to="loc_thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember_585213" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_550586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_GeographicalAreasAxis_550586" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_550587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_550586" xlink:to="loc_ifrs-full_GeographicalAreasMember_550587" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_550591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_550587" xlink:to="loc_srt_EuropeMember_550591" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_550597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_550597" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-full_ProductsAndServicesMember_550598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_550597" xlink:to="loc_ifrs-full_ProductsAndServicesMember_550598" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoMember" xlink:label="loc_thtx_TrogarzoMember_550602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_550598" xlink:to="loc_thtx_TrogarzoMember_550602" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesAxis" xlink:label="loc_thtx_NatureOfFeesAxis_585153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_NatureOfFeesAxis_585153" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NatureOfFeesMember" xlink:label="loc_thtx_NatureOfFeesMember_585155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_NatureOfFeesAxis_585153" xlink:to="loc_thtx_NatureOfFeesMember_585155" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRelatedLicensePeptidesMember" xlink:label="loc_thtx_RoyaltyRelatedLicensePeptidesMember_585157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_NatureOfFeesMember_585155" xlink:to="loc_thtx_RoyaltyRelatedLicensePeptidesMember_585157" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodAxis" xlink:label="loc_thtx_FeesPeriodAxis_585159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_FeesPeriodAxis_585159" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FeesPeriodMember" xlink:label="loc_thtx_FeesPeriodMember_585161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_FeesPeriodAxis_585159" xlink:to="loc_thtx_FeesPeriodMember_585161" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstFiveYearsMember" xlink:label="loc_thtx_FirstFiveYearsMember_585162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_FeesPeriodMember_585161" xlink:to="loc_thtx_FirstFiveYearsMember_585162" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AfterFiveYearsMember" xlink:label="loc_thtx_AfterFiveYearsMember_585165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_FeesPeriodMember_585161" xlink:to="loc_thtx_AfterFiveYearsMember_585165" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentAxis" xlink:label="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BasisOfRoyaltyPaymentMember" xlink:label="loc_thtx_BasisOfRoyaltyPaymentMember_585179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfRoyaltyPaymentAxis_585178" xlink:to="loc_thtx_BasisOfRoyaltyPaymentMember_585179" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetSalesBasisMember" xlink:label="loc_thtx_NetSalesBasisMember_585181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfRoyaltyPaymentMember_585179" xlink:to="loc_thtx_NetSalesBasisMember_585181" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyRevenueSublicenseBasisMember" xlink:label="loc_thtx_RoyaltyRevenueSublicenseBasisMember_585183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BasisOfRoyaltyPaymentMember_585179" xlink:to="loc_thtx_RoyaltyRevenueSublicenseBasisMember_585183" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis_585117" xlink:to="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember_585124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" xlink:to="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember_585124" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember" xlink:label="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember_585130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember_585119" xlink:to="loc_thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember_585130" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_550411" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IntangibleAssetsAgreementTermOfContract" xlink:label="loc_thtx_IntangibleAssetsAgreementTermOfContract_550417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_IntangibleAssetsAgreementTermOfContract_550417" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets" xlink:label="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets_550422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets_550422" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_550431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AmortisationExpense_550431" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayable" xlink:label="loc_thtx_InitialMilestonePaymentsPayable_550481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_InitialMilestonePaymentsPayable_550481" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentOfUpfrontMilestones" xlink:label="loc_thtx_PaymentOfUpfrontMilestones_550486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_PaymentOfUpfrontMilestones_550486" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FirstMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_FirstMilestoneInstallmentPaymentsPayable_2147463000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_FirstMilestoneInstallmentPaymentsPayable_2147463000" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecondMilestoneInstallmentPaymentsPayable" xlink:label="loc_thtx_SecondMilestoneInstallmentPaymentsPayable_2147462999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_SecondMilestoneInstallmentPaymentsPayable_2147462999" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_550531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfSharesIssued_550531" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_550532" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AcquisitionCostsForIntangibleAssets" xlink:label="loc_thtx_AcquisitionCostsForIntangibleAssets_550539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AcquisitionCostsForIntangibleAssets_550539" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_550540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_Revenue_550540" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LaunchMilestonePayable" xlink:label="loc_thtx_LaunchMilestonePayable_550541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_LaunchMilestonePayable_550541" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DevelopmentMilestonePayableAnnualInstallment" xlink:label="loc_thtx_DevelopmentMilestonePayableAnnualInstallment_550547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_DevelopmentMilestonePayableAnnualInstallment_550547" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment_550941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment_550941" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment" xlink:label="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment_550942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment_550942" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MilestoneAmountPayable" xlink:label="loc_thtx_MilestoneAmountPayable_585006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_MilestoneAmountPayable_585006" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_585047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_585047" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_585064" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_585066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_CashTransferred_585066" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_585067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_585067" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_585068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_585068" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_585070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_585070" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationContingentConsiderationFairValue" xlink:label="loc_thtx_BusinessCombinationContingentConsiderationFairValue_585072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_BusinessCombinationContingentConsiderationFairValue_585072" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration" xlink:label="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration_585091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration_585091" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities_585093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities_585093" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_585147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_585147" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RoyaltyFeesAsAPercentageOfRevenue" xlink:label="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue_585174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_RoyaltyFeesAsAPercentageOfRevenue_585174" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RegulatoryMilestonePaymentPayable" xlink:label="loc_thtx_RegulatoryMilestonePaymentPayable_585224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_RegulatoryMilestonePaymentPayable_585224" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277921" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2147463012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_2147463012" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments." xlink:label="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments._2147463456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_550413" xlink:to="loc_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments._2147463456" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract_550737" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract_550737" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_550769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_550768" xlink:to="loc_ifrs-full_CarryingAmountMember_550769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:label="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_550739" xlink:to="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ReconciliationOfChangesInOtherAssetsAbstract" xlink:label="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAssetsNonCurrentAtCost" xlink:label="loc_thtx_OtherAssetsNonCurrentAtCost_550744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ReconciliationOfChangesInOtherAssetsAbstract_550741" xlink:to="loc_thtx_OtherAssetsNonCurrentAtCost_550744" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" xlink:to="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550760" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmortizationOfOtherNonCurrentAssets" xlink:label="loc_thtx_AmortizationOfOtherNonCurrentAssets_550763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" xlink:to="loc_thtx_AmortizationOfOtherNonCurrentAssets_550763" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccumulatedAmortizationOnOtherNonCurrentAssets" xlink:label="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract_550758" xlink:to="loc_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets_550766" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NetCarryingAmount" xlink:label="loc_thtx_NetCarryingAmount_550767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_550740" xlink:to="loc_thtx_NetCarryingAmount_550767" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OtherAssetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ScheduleOfInformationAboutOtherAssetsAbstract" xlink:label="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract_549808" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutOtherAssetTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ScheduleOfInformationAboutOtherAssetsAbstract_549808" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_550063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_ifrs-full_CounterpartiesAxis_550063" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_550064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_550063" xlink:to="loc_ifrs-full_CounterpartiesMember_550064" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeronoIncMember" xlink:label="loc_thtx_SeronoIncMember_550065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_550064" xlink:to="loc_thtx_SeronoIncMember_550065" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementAxis" xlink:label="loc_thtx_TypeOfArrangementAxis_550571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_thtx_TypeOfArrangementAxis_550571" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_550572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementAxis_550571" xlink:to="loc_thtx_TypeOfArrangementMember_550572" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandThirteenTerminationAgreementMember" xlink:label="loc_thtx_TwoThousandThirteenTerminationAgreementMember_550574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementMember_550572" xlink:to="loc_thtx_TwoThousandThirteenTerminationAgreementMember_550574" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_550784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_ifrs-full_MaturityAxis_550784" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_550785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_550784" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_550785" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueWithOneYearMember" xlink:label="loc_thtx_DueWithOneYearMember_550786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_550785" xlink:to="loc_thtx_DueWithOneYearMember_550786" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DueInNextFourToFiveYearsMember" xlink:label="loc_thtx_DueInNextFourToFiveYearsMember_550787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_550785" xlink:to="loc_thtx_DueInNextFourToFiveYearsMember_550787" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInformationAboutOtherAssetsLineItems" xlink:label="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutOtherAssetTable_549810" xlink:to="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ContractualObligations" xlink:label="loc_thtx_ContractualObligations_603122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" xlink:to="loc_thtx_ContractualObligations_603122" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PerformanceObligationFinalSettlementAmount" xlink:label="loc_thtx_PerformanceObligationFinalSettlementAmount_550783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInformationAboutOtherAssetsLineItems_549838" xlink:to="loc_thtx_PerformanceObligationFinalSettlementAmount_550783" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_549659" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesTable" xlink:label="loc_thtx_TradeAndOtherPayablesTable_549907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_549659" xlink:to="loc_thtx_TradeAndOtherPayablesTable_549907" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TradeAndOtherPayablesLineItems" xlink:label="loc_thtx_TradeAndOtherPayablesLineItems_549910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesTable_549907" xlink:to="loc_thtx_TradeAndOtherPayablesLineItems_549910" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_549911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_549911" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_549912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_549912" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_549914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_549914" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_549916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_549916" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_549917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_549917" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestPayable" xlink:label="loc_ifrs-full_CurrentInterestPayable_549918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_CurrentInterestPayable_549918" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_2147463480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_OtherCurrentPayables_2147463480" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_549919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TradeAndOtherPayablesLineItems_549910" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_549919" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_2147463477" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentForContingentLiabilities" xlink:label="loc_thtx_PaymentForContingentLiabilities_2147462953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_2147463477" xlink:to="loc_thtx_PaymentForContingentLiabilities_2147462953" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentOfMilestones" xlink:label="loc_thtx_PaymentOfMilestones_2147462996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_2147463477" xlink:to="loc_thtx_PaymentOfMilestones_2147462996" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EqualAnnualInstallments" xlink:label="loc_thtx_EqualAnnualInstallments_2147462995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_2147463477" xlink:to="loc_thtx_EqualAnnualInstallments_2147462995" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549783" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_549783" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_549786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_549786" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_549863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_549786" xlink:to="loc_ifrs-full_OtherProvisionsMember_549863" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChargebacksAndRebatesMember" xlink:label="loc_thtx_ChargebacksAndRebatesMember_549866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_thtx_ChargebacksAndRebatesMember_549866" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RefundsProvisionMember" xlink:label="loc_ifrs-full_RefundsProvisionMember_549864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_ifrs-full_RefundsProvisionMember_549864" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OtherAdditionalProvisionMember" xlink:label="loc_thtx_OtherAdditionalProvisionMember_585252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_549863" xlink:to="loc_thtx_OtherAdditionalProvisionMember_585252" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_549785" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_549796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_OtherShorttermProvisions_549796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_549799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_549799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_549800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_549800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_549801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_549801" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="loc_ifrs-full_OtherShorttermProvisions_549867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_549793" xlink:to="loc_ifrs-full_OtherShorttermProvisions_549867" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_2147462951" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_2147462951" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_2147462945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_2147462946" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_2147462945" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SeveranceAndOtherExpensesMember" xlink:label="loc_thtx_SeveranceAndOtherExpensesMember_2147462835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_SeveranceAndOtherExpensesMember_2147462835" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ResearchAndDevelopmentExpenseMember" xlink:label="loc_thtx_ResearchAndDevelopmentExpenseMember_2147462944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_ResearchAndDevelopmentExpenseMember_2147462944" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SellingAndMarketingExpenseMember" xlink:label="loc_thtx_SellingAndMarketingExpenseMember_2147462943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_SellingAndMarketingExpenseMember_2147462943" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GeneralAndAdministrativeExpenseMember" xlink:label="loc_thtx_GeneralAndAdministrativeExpenseMember_2147462942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_2147462945" xlink:to="loc_thtx_GeneralAndAdministrativeExpenseMember_2147462942" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_2147462950" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_2147462838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2147462949" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_2147462838" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TextBlockAbstract" xlink:label="loc_thtx_TextBlockAbstract_2147464158" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TextBlockAbstract_2147464158" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147464776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147464776" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147464776" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityMember" xlink:label="loc_thtx_LoanFacilityMember_2147466056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityMember_2147466056" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1LoanMember_2147462802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche1LoanMember_2147462802" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche2LoanMember_2147466098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche2LoanMember_2147466098" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3LoanMember_2147466095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche3LoanMember_2147466095" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche4LoanMember_2147466094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche4LoanMember_2147466094" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche1And2LoanMember" xlink:label="loc_thtx_LoanFacilityTranche1And2LoanMember_2147466062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche1And2LoanMember_2147466062" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTranche3And4LoanMember" xlink:label="loc_thtx_LoanFacilityTranche3And4LoanMember_2147462825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466055" xlink:to="loc_thtx_LoanFacilityTranche3And4LoanMember_2147462825" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_2147466064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_2147466063" xlink:to="loc_ifrs-full_InterestRateTypesMember_2147466064" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateMember_2147466065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_2147466064" xlink:to="loc_thtx_SecuredOvernightFinancingRateMember_2147466065" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463007" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463006" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember" xlink:label="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember_2147463005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_2147463006" xlink:to="loc_thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember_2147463005" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_RangeAxis_2147462932" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2147462932" xlink:to="loc_ifrs-full_RangesMember_2147462931" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462931" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462929" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462931" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462930" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementAxis" xlink:label="loc_thtx_TypeOfArrangementAxis_2147462924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_thtx_TypeOfArrangementAxis_2147462924" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementMember" xlink:label="loc_thtx_TypeOfArrangementMember_2147462923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementAxis_2147462924" xlink:to="loc_thtx_TypeOfArrangementMember_2147462923" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentMember" xlink:label="loc_thtx_FifthAmendmentMember_2147462922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementMember_2147462923" xlink:to="loc_thtx_FifthAmendmentMember_2147462922" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_2147462919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2147462920" xlink:to="loc_ifrs-full_EquityMember_2147462919" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_2147462914" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_2147462912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2147462913" xlink:to="loc_ifrs-full_OrdinarySharesMember_2147462912" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147464161" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DateOfCommencementOfPrincipalRepaymentInAdvance" xlink:label="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance_2147462760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance_2147462760" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent" xlink:label="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent_2147462761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent_2147462761" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462762" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462763" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConsiderationPayable" xlink:label="loc_thtx_ConsiderationPayable_2147462765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_ConsiderationPayable_2147462765" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinanceCostsWriteOff" xlink:label="loc_thtx_DeferredFinanceCostsWriteOff_2147462826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DeferredFinanceCostsWriteOff_2147462826" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentAmortizedValue" xlink:label="loc_thtx_DebtInstrumentAmortizedValue_2147462925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentAmortizedValue_2147462925" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AmountReclassifiedFromDeferredFinancingCosts" xlink:label="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts_2147462926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_AmountReclassifiedFromDeferredFinancingCosts_2147462926" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRateBasis" xlink:label="loc_ifrs-full_BorrowingsInterestRateBasis_2147463032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsInterestRateBasis_2147463032" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmount" xlink:label="loc_thtx_DebtInstrumentCollateralAmount_2147463033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentCollateralAmount_2147463033" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained" xlink:label="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained_2147463008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained_2147463008" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity_2147466034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_LineOfCreditFacilityMaximumBorrowingCapacity_2147466034" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147466036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147466036" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="loc_ifrs-full_NotionalAmount_2147466038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_NotionalAmount_2147466038" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-full_BorrowingsMaturity_2147466043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsMaturity_2147466043" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsInterestPeriod" xlink:label="loc_thtx_BorrowingsInterestPeriod_2147466048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_thtx_BorrowingsInterestPeriod_2147466048" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate_2147466080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147466033" xlink:to="loc_ifrs-full_BorrowingsInterestRate_2147466080" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_2147465408" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_2147465408" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2147466051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2147466051" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2147466053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2147466051" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2147466053" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityMember" xlink:label="loc_thtx_LoanFacilityMember_2147466054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_LoanFacilityMember_2147466054" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LoanFacilityTrancheTwoLoanMember" xlink:label="loc_thtx_LoanFacilityTrancheTwoLoanMember_2147462935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_LoanFacilityTrancheTwoLoanMember_2147462935" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2147466053" xlink:to="loc_thtx_MarathonWarrantsMember_2147462934" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2147465411" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147465413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_2147465413" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_2147465414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_2147465414" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsAccretionExpense" xlink:label="loc_thtx_BorrowingsAccretionExpense_2147465415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_thtx_BorrowingsAccretionExpense_2147465415" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromConsiderationOfTheFifthAmendment" xlink:label="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment_2147462933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_thtx_ProceedsFromConsiderationOfTheFifthAmendment_2147462933" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="loc_ifrs-full_LoansReceived_2147462759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_LoansReceived_2147462759" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived_2147462758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived_2147462758" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2147462757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2147465412" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2147462757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_550162" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_550162" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_572867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550170" xlink:to="loc_ifrs-full_LiabilitiesMember_572867" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_572867" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462939" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_550298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_550298" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_550299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_550298" xlink:to="loc_ifrs-full_EquityMember_550299" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550168" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleInstrumentsNumberOfSharesIssued" xlink:label="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued_550192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_thtx_ConvertibleInstrumentsNumberOfSharesIssued_550192" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462938" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_2147464143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550169" xlink:to="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_2147464143" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesAbstract" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_550035" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesTable" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesAbstract_550035" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_550093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_550092" xlink:to="loc_ifrs-full_LiabilitiesMember_550093" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LiabilityComponentMember" xlink:label="loc_thtx_LiabilityComponentMember_550096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_550093" xlink:to="loc_thtx_LiabilityComponentMember_550096" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesLineItems" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesTable_550039" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_1279393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_1279393" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpense" xlink:label="loc_thtx_AccretionExpense_550078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_thtx_AccretionExpense_550078" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ChangesFromFinancingCashFlowsAbstract" xlink:label="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_2147463486" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ChangesFromFinancingCashFlowsAbstract_2147463481" xlink:to="loc_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463489" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract" xlink:label="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes" xlink:label="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract_2147463492" xlink:to="loc_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes_2147463495" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_2147462940" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_550084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ConvertibleUnsecuredSeniorNotesLineItems_550068" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_550084" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesAbstract" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_818896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_LeaseLiabilities_818896" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AccretionExpenseOfLeasesLiabilities" xlink:label="loc_thtx_AccretionExpenseOfLeasesLiabilities_818897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_thtx_AccretionExpenseOfLeasesLiabilities_818897" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_818898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_CashOutflowForLeases_818898" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates" xlink:label="loc_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates_818899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates_818899" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="loc_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions_2147462937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions_2147462937" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_2147462936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_2147462936" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_818900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_LeaseLiabilities_818900" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_818901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_818901" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_818902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_818895" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_818902" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfLeaseLiabilitiesAbstract" xlink:label="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_2147462910" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability" xlink:label="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability_2147462908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_2147462910" xlink:to="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability_2147462908" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets" xlink:label="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets_2147462909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_2147462910" xlink:to="loc_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets_2147462909" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnLeaseTermination" xlink:label="loc_thtx_GainLossOnLeaseTermination_2147462907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_2147462910" xlink:to="loc_thtx_GainLossOnLeaseTermination_2147462907" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2147462906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfLeaseLiabilitiesAbstract_2147462910" xlink:to="loc_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2147462906" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550475" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550475" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueAxis" xlink:label="loc_thtx_SchemeOfShareIssueAxis_550653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_SchemeOfShareIssueAxis_550653" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SchemeOfShareIssueDomain" xlink:label="loc_thtx_SchemeOfShareIssueDomain_550654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SchemeOfShareIssueAxis_550653" xlink:to="loc_thtx_SchemeOfShareIssueDomain_550654" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_550679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_TypeOfArrangementsAxis_550679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_550680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsAxis_550679" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_550680" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentMember" xlink:label="loc_thtx_FifthAmendmentMember_2147462752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsMemberDomain_550680" xlink:to="loc_thtx_FifthAmendmentMember_2147462752" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:label="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember" xlink:label="loc_ifrs-full_TypesOfInstrumentMember_550850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_550849" xlink:to="loc_ifrs-full_TypesOfInstrumentMember_550850" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_572839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_MeasurementAxis_572839" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_572840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_572839" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_572840" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsAxis" xlink:label="loc_thtx_CategoryOfBorrowingsAxis_550712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_CategoryOfBorrowingsAxis_550712" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CategoryOfBorrowingsDomain" xlink:label="loc_thtx_CategoryOfBorrowingsDomain_550713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_CategoryOfBorrowingsAxis_550712" xlink:to="loc_thtx_CategoryOfBorrowingsDomain_550713" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_550961" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_550963" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventAxis" xlink:label="loc_thtx_EventAxis_550965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_EventAxis_550965" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EventDomain" xlink:label="loc_thtx_EventDomain_550966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_EventAxis_550965" xlink:to="loc_thtx_EventDomain_550966" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanAxis" xlink:label="loc_thtx_PlanAxis_550707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_PlanAxis_550707" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_550708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanAxis_550707" xlink:to="loc_thtx_PlanDomain_550708" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TwoThousandAndSixteenShareholdersPlanMember" xlink:label="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember_550709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_TwoThousandAndSixteenShareholdersPlanMember_550709" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockOptionPlanTwoThousandAndNineteenMember" xlink:label="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember_550710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_StockOptionPlanTwoThousandAndNineteenMember_550710" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsMember" xlink:label="loc_thtx_StockAppreciationRightsMember_585260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanDomain_550708" xlink:to="loc_thtx_StockAppreciationRightsMember_585260" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550692" xlink:to="loc_ifrs-full_FinancialAssetsMember_550693" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashSettledForwardContractsMember" xlink:label="loc_thtx_CashSettledForwardContractsMember_550694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_550693" xlink:to="loc_thtx_CashSettledForwardContractsMember_550694" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_550682" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredStockUnitsMember" xlink:label="loc_thtx_DeferredStockUnitsMember_550691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_550686" xlink:to="loc_thtx_DeferredStockUnitsMember_550691" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameAxis" xlink:label="loc_thtx_ProgramNameAxis_1277961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_ProgramNameAxis_1277961" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_1277962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ProgramNameAxis_1277961" xlink:to="loc_thtx_ProgramNameMember_1277962" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AtmProgramMember" xlink:label="loc_thtx_AtmProgramMember_1277965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ProgramNameMember_1277962" xlink:to="loc_thtx_AtmProgramMember_1277965" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementAxis" xlink:label="loc_thtx_AgreementAxis_2147462882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_AgreementAxis_2147462882" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AgreementMember" xlink:label="loc_thtx_AgreementMember_2147462881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AgreementAxis_2147462882" xlink:to="loc_thtx_AgreementMember_2147462881" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FifthAmendmentOfTheLoanFacilityMember" xlink:label="loc_thtx_FifthAmendmentOfTheLoanFacilityMember_2147462880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_AgreementMember_2147462881" xlink:to="loc_thtx_FifthAmendmentOfTheLoanFacilityMember_2147462880" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462891" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462887" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462886" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_550495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_550494" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_550495" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_550525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_550495" xlink:to="loc_ifrs-full_OrdinarySharesMember_550525" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_585275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_585275" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_585275" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_KatanaMember" xlink:label="loc_thtx_KatanaMember_585278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_585276" xlink:to="loc_thtx_KatanaMember_585278" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsAxis" xlink:label="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462899" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonVotingSubscriptionReceiptsMember" xlink:label="loc_thtx_NonVotingSubscriptionReceiptsMember_2147462897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" xlink:to="loc_thtx_NonVotingSubscriptionReceiptsMember_2147462897" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462898" xlink:to="loc_thtx_MarathonWarrantsMember_2147462893" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeAxis" xlink:label="loc_thtx_InvesteeAxis_2147462903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_InvesteeAxis_2147462903" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvesteeMember" xlink:label="loc_thtx_InvesteeMember_2147462901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_InvesteeAxis_2147462903" xlink:to="loc_thtx_InvesteeMember_2147462901" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_InvestmentQuebecMember" xlink:label="loc_thtx_InvestmentQuebecMember_2147462900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_InvesteeMember_2147462901" xlink:to="loc_thtx_InvestmentQuebecMember_2147462900" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AffiliatesOfMarathonAssetManagementMember" xlink:label="loc_thtx_AffiliatesOfMarathonAssetManagementMember_2147462892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_InvesteeMember_2147462901" xlink:to="loc_thtx_AffiliatesOfMarathonAssetManagementMember_2147462892" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalAxis" xlink:label="loc_thtx_IssuedCapitalAxis_1277928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_thtx_IssuedCapitalAxis_1277928" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IssuedCapitalDomain" xlink:label="loc_thtx_IssuedCapitalDomain_1308330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IssuedCapitalAxis_1277928" xlink:to="loc_thtx_IssuedCapitalDomain_1308330" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicOfferingMember" xlink:label="loc_thtx_PublicOfferingMember_1277931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_PublicOfferingMember_1277931" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OverallotmentMember" xlink:label="loc_thtx_OverallotmentMember_2147462842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_OverallotmentMember_2147462842" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PrivatePlacementMember" xlink:label="loc_thtx_PrivatePlacementMember_2147462904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IssuedCapitalDomain_1308330" xlink:to="loc_thtx_PrivatePlacementMember_2147462904" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_550491" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommonStockConversionBasis" xlink:label="loc_thtx_CommonStockConversionBasis_1277940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_CommonStockConversionBasis_1277940" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightOutstanding" xlink:label="loc_thtx_ClassOfWarrantOrRightOutstanding_1277946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightOutstanding_1277946" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1277948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_1277948" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1277923" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-full_ParValuePerShare_585254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ParValuePerShare_585254" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1277925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1277925" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod_2147462885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod_2147462885" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:label="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare_2147462896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantsOrRightsExercisePricePerShare_2147462896" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants" xlink:label="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants_2147462895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants_2147462895" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_2147466137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_2147466137" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsWrittenDown" xlink:label="loc_thtx_DeferredFinancingCostsWrittenDown_2147462867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DeferredFinancingCostsWrittenDown_2147462867" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_550717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfSharesIssued_550717" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_1277949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_IssuedCapital_1277949" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TermOfWarrants" xlink:label="loc_thtx_TermOfWarrants_2147462884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TermOfWarrants_2147462884" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsOutstanding" xlink:label="loc_thtx_ClassOfWarrantsOrRightsOutstanding_2147462869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantsOrRightsOutstanding_2147462869" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_GainLossOnDebtModification" xlink:label="loc_thtx_GainLossOnDebtModification_2147462883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_GainLossOnDebtModification_2147462883" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseInTheFairValueOfLiabilityRecorded" xlink:label="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded_2147462879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_IncreaseInTheFairValueOfLiabilityRecorded_2147462879" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently_2147462878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently_2147462878" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsOfWarrantsIssued" xlink:label="loc_thtx_TransactionCostsOfWarrantsIssued_2147462877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TransactionCostsOfWarrantsIssued_2147462877" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TransactionCostsAllocatedToTheLoanFacility" xlink:label="loc_thtx_TransactionCostsAllocatedToTheLoanFacility_2147462876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_TransactionCostsAllocatedToTheLoanFacility_2147462876" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsOnTheLoanFacility" xlink:label="loc_thtx_DeferredFinancingCostsOnTheLoanFacility_2147462875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DeferredFinancingCostsOnTheLoanFacility_2147462875" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction_1277955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_SaleOfStockConsiderationReceivedOnTransaction_1277955" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_550745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_550745" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_550755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_550755" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_550749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_550749" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_550750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_550750" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfCashSettledForwardStockContractsOutstanding" xlink:label="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding_550716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_NumberOfCashSettledForwardStockContractsOutstanding_550716" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts" xlink:label="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts_2147463029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts_2147463029" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging" xlink:label="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging_550754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging_550754" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsContractualLife" xlink:label="loc_thtx_StockAppreciationRightsContractualLife_610553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_StockAppreciationRightsContractualLife_610553" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550761" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding" xlink:label="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding_2147462865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding_2147462865" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_550764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_550764" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares" xlink:label="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares_550770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares_550770" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_550774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProfitLoss_550774" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_550776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_550776" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfWarrantsShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares_1303086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares_1303086" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants" xlink:label="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants_2147462862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants_2147462862" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions" xlink:label="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions_603436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions_603436" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2147462754" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2147462755" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipHoldingCommonShares" xlink:label="loc_thtx_PercentageOfOwnershipHoldingCommonShares_2147462810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PercentageOfOwnershipHoldingCommonShares_2147462810" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PercentageOfOwnershipOfTheInvestor" xlink:label="loc_thtx_PercentageOfOwnershipOfTheInvestor_2147462811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_PercentageOfOwnershipOfTheInvestor_2147462811" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightExpirationDate" xlink:label="loc_thtx_ClassOfWarrantOrRightExpirationDate_2147462812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightExpirationDate_2147462812" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2147462814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2147462814" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:label="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised_2147462815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_550715" xlink:to="loc_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised_2147462815" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2147462859" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2147462859" xlink:to="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462849" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462849" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462848" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_2147462847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_2147462847" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AverageOptionLifeMember" xlink:label="loc_thtx_AverageOptionLifeMember_2147462845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_AverageOptionLifeMember_2147462845" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SharePriceMember" xlink:label="loc_thtx_SharePriceMember_2147462844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_SharePriceMember_2147462844" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceToAcquireOneCommonShareMember" xlink:label="loc_thtx_ExercisePriceToAcquireOneCommonShareMember_2147462843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462848" xlink:to="loc_thtx_ExercisePriceToAcquireOneCommonShareMember_2147462843" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_2147462852" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2147462851" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_2147462850" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsAxis" xlink:label="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ClassOfWarrantsOrRightsMember" xlink:label="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ClassOfWarrantsOrRightsAxis_2147462855" xlink:to="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MarathonWarrantsMember" xlink:label="loc_thtx_MarathonWarrantsMember_2147462853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ClassOfWarrantsOrRightsMember_2147462854" xlink:to="loc_thtx_MarathonWarrantsMember_2147462853" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems" xlink:label="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable_2147462858" xlink:to="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems_2147462857" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462856" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550141" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550141" xlink:to="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanAxis" xlink:label="loc_thtx_PlanAxis_585362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" xlink:to="loc_thtx_PlanAxis_585362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PlanDomain" xlink:label="loc_thtx_PlanDomain_585364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanAxis_585362" xlink:to="loc_thtx_PlanDomain_585364" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_StockAppreciationRightsMember" xlink:label="loc_thtx_StockAppreciationRightsMember_585366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_PlanDomain_585364" xlink:to="loc_thtx_StockAppreciationRightsMember_585366" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems" xlink:label="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable_550147" xlink:to="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550156" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550158" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610593" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems_550154" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550195" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550195" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_821273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" xlink:to="loc_srt_CurrencyAxis_821273" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_821273" xlink:to="loc_currency_AllCurrenciesDomain_821274" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_821275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_821274" xlink:to="loc_currency_CAD_821275" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_821322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_821274" xlink:to="loc_country_US_821322" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_821272" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_550198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_550198" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550199" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_818909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_818909" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1279261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1279261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_550208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_550208" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_550240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_550240" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_550243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_550243" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_551024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_551024" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_550214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_550214" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:label="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_821284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_821284" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1279265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1279265" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_550216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_550216" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_550248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_550248" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550242" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550264" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_550265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550264" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_550265" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550271" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550271" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_550277" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceOneMember" xlink:label="loc_thtx_ExercisePriceOneMember_550283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceOneMember_550283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceTwoMember" xlink:label="loc_thtx_ExercisePriceTwoMember_550284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceTwoMember_550284" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceThreeMember" xlink:label="loc_thtx_ExercisePriceThreeMember_550285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceThreeMember_550285" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFourMember" xlink:label="loc_thtx_ExercisePriceFourMember_550286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceFourMember_550286" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceFiveMember" xlink:label="loc_thtx_ExercisePriceFiveMember_550287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceFiveMember_550287" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExercisePriceSixMember" xlink:label="loc_thtx_ExercisePriceSixMember_550288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_550278" xlink:to="loc_thtx_ExercisePriceSixMember_550288" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_585461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_ifrs-full_RangeAxis_585461" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_585462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_585461" xlink:to="loc_ifrs-full_RangesMember_585462" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_585464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_585462" xlink:to="loc_ifrs-full_TopOfRangeMember_585464" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_585465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_585462" xlink:to="loc_ifrs-full_BottomOfRangeMember_585465" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_819064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_srt_CurrencyAxis_819064" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_819064" xlink:to="loc_currency_AllCurrenciesDomain_819066" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_819067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_819066" xlink:to="loc_currency_USD_819067" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_819068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_819066" xlink:to="loc_currency_CAD_819068" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_550275" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_550295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_550295" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_550296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_550296" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_550294" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_550297" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550303" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550303" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_821369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" xlink:to="loc_srt_CurrencyAxis_821369" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_821374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_821369" xlink:to="loc_currency_AllCurrenciesDomain_821374" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_821370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_821374" xlink:to="loc_currency_USD_821370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_821371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_821374" xlink:to="loc_currency_CAD_821371" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_821368" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_550304" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_550305" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_550306" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_610594" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821373" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_550308" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550321" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_WeightedAverageFairValueOfStockOptionsGrantedTable" xlink:label="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550321" xlink:to="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_819111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" xlink:to="loc_srt_CurrencyAxis_819111" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_819112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_819111" xlink:to="loc_currency_AllCurrenciesDomain_819112" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_819113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_819112" xlink:to="loc_currency_USD_819113" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_819114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_819112" xlink:to="loc_currency_CAD_819114" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_WeightedAverageFairValueOfStockOptionsGrantedTable_819109" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_550322" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_550323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_821385" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_550323" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550335" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable" xlink:label="loc_ifrs-full_EarningsPerShareTable_550368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_550335" xlink:to="loc_ifrs-full_EarningsPerShareTable_550368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_550368" xlink:to="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-full_OrdinarySharesMember_551050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOrdinarySharesAxis_551049" xlink:to="loc_ifrs-full_OrdinarySharesMember_551050" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareOptionMember" xlink:label="loc_thtx_ShareOptionMember_551051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_ShareOptionMember_551051" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PublicIssueOfSharesMember" xlink:label="loc_thtx_PublicIssueOfSharesMember_551054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_PublicIssueOfSharesMember_551054" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BrokersWarrantsMember" xlink:label="loc_thtx_BrokersWarrantsMember_551055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_BrokersWarrantsMember_551055" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SubscriptionReceiptsIssueMember" xlink:label="loc_thtx_SubscriptionReceiptsIssueMember_2147462750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_SubscriptionReceiptsIssueMember_2147462750" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesMember" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OrdinarySharesMember_551050" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesMember_2147462871" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameAxis" xlink:label="loc_thtx_ProgramNameAxis_2147468974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_550368" xlink:to="loc_thtx_ProgramNameAxis_2147468974" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProgramNameMember" xlink:label="loc_thtx_ProgramNameMember_2147468975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ProgramNameAxis_2147468974" xlink:to="loc_thtx_ProgramNameMember_2147468975" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AtmProgramMember" xlink:label="loc_thtx_AtmProgramMember_2147468976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_ProgramNameMember_2147468975" xlink:to="loc_thtx_AtmProgramMember_2147468976" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_550371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_550368" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_550371" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_551041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_WeightedAverageShares_551041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsExercised" xlink:label="loc_thtx_EffectOfShareOptionsExercised_572760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfShareOptionsExercised_572760" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfIssueCommonShares" xlink:label="loc_thtx_EffectOfIssueCommonShares_572761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfIssueCommonShares_572761" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_2147462873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_2147462873" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_572759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares_572759" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfSubscriptionReceiptsIssue" xlink:label="loc_thtx_EffectOfSubscriptionReceiptsIssue_2147462751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfSubscriptionReceiptsIssue_2147462751" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_EffectOfBrokerWarrantsExercised" xlink:label="loc_thtx_EffectOfBrokerWarrantsExercised_1279324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_thtx_EffectOfBrokerWarrantsExercised_1279324" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_550388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_550371" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_550388" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_585529" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_586035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_585529" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_586035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_586037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_586035" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_586037" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_586038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_586037" xlink:to="loc_ifrs-full_EquityMember_586038" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_586042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_586038" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_586042" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_586044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_586038" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_586044" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_586035" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_586048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_586036" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_586048" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549909" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_549913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549909" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_549913" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_549915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549909" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_549915" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_549920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_549915" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_549920" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences" xlink:label="loc_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences_550808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_549915" xlink:to="loc_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences_550808" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_549922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_549915" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_549922" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_549923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549909" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_549923" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_549927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_549927" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences" xlink:label="loc_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences_550796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" xlink:to="loc_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences_550796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_602680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_602680" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_549929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_549929" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_549931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549926" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_549931" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_550048" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_550048" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfReversalOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityAxis_550054" xlink:to="loc_thtx_TypeOfReversalOfDeferredTaxLiabilityMember_550055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityAxis" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OffsettingOfDeferredTaxLiabilityMember" xlink:label="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_OffsettingOfDeferredTaxLiabilityAxis_572726" xlink:to="loc_thtx_OffsettingOfDeferredTaxLiabilityMember_572727" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2147463041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_srt_StatementGeographicalAxis_2147463041" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2147463040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2147463041" xlink:to="loc_srt_SegmentGeographicalDomain_2147463040" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE" xlink:label="loc_country_IE_2147463038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2147463040" xlink:to="loc_country_IE_2147463038" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems" xlink:label="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable_550050" xlink:to="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_550091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" xlink:to="loc_ifrs-full_ApplicableTaxRate_550091" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_2147463039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems_550053" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_2147463039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549996" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_549996" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearAxis" xlink:label="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xlink:to="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxBenefitCarryForwardYearMember" xlink:label="loc_thtx_TaxBenefitCarryForwardYearMember_550010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearAxis_550002" xlink:to="loc_thtx_TaxBenefitCarryForwardYearMember_550010" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentySevenMember" xlink:label="loc_thtx_YearTwoThousandAndTwentySevenMember_550011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentySevenMember_550011" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyEightMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyEightMember_550012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentyEightMember_550012" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndTwentyNineMember" xlink:label="loc_thtx_YearTwoThousandAndTwentyNineMember_550013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndTwentyNineMember_550013" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyMember_550014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyMember_550014" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyOneMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyOneMember_550015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyOneMember_550015" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyTwoMember_550016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyTwoMember_550016" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyThreeMember_550017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyThreeMember_550017" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyFourMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyFourMember_550018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyFourMember_550018" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtySevenMember" xlink:label="loc_thtx_YearTwoThousandAndThirtySevenMember_550019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtySevenMember_550019" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyEightMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyEightMember_550020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyEightMember_550020" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndThirtyNineMember" xlink:label="loc_thtx_YearTwoThousandAndThirtyNineMember_602692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndThirtyNineMember_602692" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyMember" xlink:label="loc_thtx_YearTwoThousandAndFortyMember_836488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyMember_836488" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyOneMember" xlink:label="loc_thtx_YearTwoThousandAndFortyOneMember_1265815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyOneMember_1265815" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyTwoMember" xlink:label="loc_thtx_YearTwoThousandAndFortyTwoMember_2147463037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyTwoMember_2147463037" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_YearTwoThousandAndFortyThreeMember" xlink:label="loc_thtx_YearTwoThousandAndFortyThreeMember_2147462749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TaxBenefitCarryForwardYearMember_550010" xlink:to="loc_thtx_YearTwoThousandAndFortyThreeMember_2147462749" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionAxis" xlink:label="loc_thtx_IncomeTaxJurisdictionAxis_550022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xlink:to="loc_thtx_IncomeTaxJurisdictionAxis_550022" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncomeTaxJurisdictionMember" xlink:label="loc_thtx_IncomeTaxJurisdictionMember_550024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IncomeTaxJurisdictionAxis_550022" xlink:to="loc_thtx_IncomeTaxJurisdictionMember_550024" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_FederalMember" xlink:label="loc_thtx_FederalMember_550026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IncomeTaxJurisdictionMember_550024" xlink:to="loc_thtx_FederalMember_550026" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ProvincialMember" xlink:label="loc_thtx_ProvincialMember_550027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_IncomeTaxJurisdictionMember_550024" xlink:to="loc_thtx_ProvincialMember_550027" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_550000" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation" xlink:label="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation_550033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation_550033" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_550077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_550077" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue_550038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue_550038" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue" xlink:label="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue_550040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue_550040" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AvailableDeductionsAndOthers" xlink:label="loc_thtx_AvailableDeductionsAndOthers_550041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_550032" xlink:to="loc_thtx_AvailableDeductionsAndOthers_550041" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail">
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SupplementalCashFlowDisclosuresAbstract" xlink:label="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities_1277974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities_1277974" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_549678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_549678" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities_2147463189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities_2147463189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities_549679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities_549679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit" xlink:label="loc_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit_2147463196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit_2147463196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities_2147463193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SupplementalCashFlowDisclosuresAbstract_549677" xlink:to="loc_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities_2147463193" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_550386" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_550386" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_550507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_srt_CurrencyAxis_550507" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_550508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_550507" xlink:to="loc_currency_AllCurrenciesDomain_550508" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_550509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_550508" xlink:to="loc_currency_CAD_550509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_550511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_UnobservableInputsAxis_550511" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_550517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_550511" xlink:to="loc_ifrs-full_UnobservableInputsMember_550517" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_550519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_550517" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_550519" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_550524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_550521" xlink:to="loc_ifrs-full_FinancialAssetsMember_550524" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BondsMember" xlink:label="loc_thtx_BondsMember_550570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_550524" xlink:to="loc_thtx_BondsMember_550570" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestRateCashAndMarketFundsMember" xlink:label="loc_thtx_VariableInterestRateCashAndMarketFundsMember_550530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_550524" xlink:to="loc_thtx_VariableInterestRateCashAndMarketFundsMember_550530" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_550890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_550890" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_550891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_550890" xlink:to="loc_ifrs-full_InterestRateTypesMember_550891" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_2147463238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_550891" xlink:to="loc_thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_2147463238" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_2147463003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_2147463004" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_2147463003" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_RangeAxis_2147462824" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2147462824" xlink:to="loc_ifrs-full_RangesMember_2147462823" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462823" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462821" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462823" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462822" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_550389" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-full_CurrentTradeReceivables_550392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_CurrentTradeReceivables_550392" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentTradeReceivablesAgingPeriod" xlink:label="loc_thtx_CurrentTradeReceivablesAgingPeriod_550402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_CurrentTradeReceivablesAgingPeriod_550402" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BadDebtExpenses" xlink:label="loc_thtx_BadDebtExpenses_550409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_BadDebtExpenses_550409" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets" xlink:label="loc_ifrs-full_OtherFinancialAssets_550414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_OtherFinancialAssets_550414" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PositivePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures_550424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_PositivePercentageImpactOnForeignCurrencyExposures_550424" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NegativePercentageImpactOnForeignCurrencyExposures" xlink:label="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures_550429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_NegativePercentageImpactOnForeignCurrencyExposures_550429" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_550438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets_550438" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets_550886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets_550886" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_550889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets_550889" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_VariableInterestbearingCashAndMoneyMarketFunds" xlink:label="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds_550474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_VariableInterestbearingCashAndMoneyMarketFunds_550474" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows" xlink:label="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows_550479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows_550479" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets_550484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets_550484" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:label="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462964" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets_550455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_550391" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets_550455" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549729" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549729" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_549740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xlink:to="loc_ifrs-full_MaturityAxis_549740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_549741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_549740" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_549741" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_549742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_549742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_549745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_549745" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsMember_549747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_549741" xlink:to="loc_ifrs-full_LaterThanThreeYearsMember_549747" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_549737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xlink:to="loc_ifrs-full_MeasurementAxis_549737" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_549738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_549737" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_549738" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_549739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_549738" xlink:to="loc_ifrs-full_CarryingAmountMember_549739" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_549735" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_549762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_549762" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermLoanUndiscountedCashFlows" xlink:label="loc_thtx_LongTermLoanUndiscountedCashFlows_2147463178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_LongTermLoanUndiscountedCashFlows_2147463178" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows" xlink:label="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows_549763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows_549763" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LeaseLiabilitiesUndiscountedCashFlows" xlink:label="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows_838046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_LeaseLiabilitiesUndiscountedCashFlows_838046" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_549765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_549765" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_820357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_820357" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CurrentPositionOfTermLoanIncludingInterest" xlink:label="loc_thtx_CurrentPositionOfTermLoanIncludingInterest_2147463047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_CurrentPositionOfTermLoanIncludingInterest_2147463047" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_820358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued_820358" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_821396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_ifrs-full_LeaseLiabilities_821396" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_NonderivativeFinancialLiabilities" xlink:label="loc_thtx_NonderivativeFinancialLiabilities_820363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_549758" xlink:to="loc_thtx_NonderivativeFinancialLiabilities_820363" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549770" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549770" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_549772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" xlink:to="loc_ifrs-full_TypesOfRisksAxis_549772" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_549773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_549772" xlink:to="loc_ifrs-full_TypesOfRisksMember_549773" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_549774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_549773" xlink:to="loc_ifrs-full_CurrencyRiskMember_549774" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_549771" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_572698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_Cash_572698" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_549784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_549784" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_549789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_549789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TaxCreditsAndGrantsReceivable" xlink:label="loc_thtx_TaxCreditsAndGrantsReceivable_836446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_thtx_TaxCreditsAndGrantsReceivable_836446" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_549790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_549790" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TotalLeaseLiabilities" xlink:label="loc_thtx_TotalLeaseLiabilities_836448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_thtx_TotalLeaseLiabilities_836448" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="loc_ifrs-full_CurrentProvisions_1303197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_CurrentProvisions_1303197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_549792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_549780" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_549792" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549795" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549795" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_585116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" xlink:to="loc_srt_CurrencyAxis_585116" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_585126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_585116" xlink:to="loc_currency_AllCurrenciesDomain_585126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_585127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_585126" xlink:to="loc_currency_CAD_585127" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_585129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_585126" xlink:to="loc_currency_EUR_585129" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_585109" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_549797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_549797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_549798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_585112" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_549798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549803" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis" xlink:label="loc_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis_549816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_549803" xlink:to="loc_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis_549816" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_549625" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_549625" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_549628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_549628" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_549629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_549628" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_549629" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashbondAndMoneyMarketFundsMember" xlink:label="loc_thtx_CashbondAndMoneyMarketFundsMember_549630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_549629" xlink:to="loc_thtx_CashbondAndMoneyMarketFundsMember_549630" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockAxis" xlink:label="loc_thtx_SaleOfStockAxis_1306034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_thtx_SaleOfStockAxis_1306034" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SaleOfStockMember" xlink:label="loc_thtx_SaleOfStockMember_1306035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_SaleOfStockAxis_1306034" xlink:to="loc_thtx_SaleOfStockMember_1306035" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_ifrs-full_RangeAxis_2147462808" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2147462808" xlink:to="loc_ifrs-full_RangesMember_2147462807" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462807" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462807" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable_549626" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CashBondAndMoneyMarketFunds" xlink:label="loc_thtx_CashBondAndMoneyMarketFunds_549636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" xlink:to="loc_thtx_CashBondAndMoneyMarketFunds_549636" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained" xlink:label="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems_549635" xlink:to="loc_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained_2147462820" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract_2147462797" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract_2147462797" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462789" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462788" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueMultipleMeasurementInputMember" xlink:label="loc_ifrs-full_RevenueMultipleMeasurementInputMember_2147462787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462788" xlink:to="loc_ifrs-full_RevenueMultipleMeasurementInputMember_2147462787" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462786" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462785" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_2147462784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_2147462785" xlink:to="loc_ifrs-full_WarrantReserveMember_2147462784" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2147462783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_MeasurementAxis_2147462783" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_2147462783" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462782" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2147462781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2147462782" xlink:to="loc_ifrs-full_AtFairValueMember_2147462781" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_2147462793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_RangeAxis_2147462793" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2147462792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_2147462793" xlink:to="loc_ifrs-full_RangesMember_2147462792" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_2147462791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462792" xlink:to="loc_ifrs-full_BottomOfRangeMember_2147462791" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2147462790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2147462792" xlink:to="loc_ifrs-full_TopOfRangeMember_2147462790" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462796" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462795" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462794" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract_2147462779" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract_2147462779" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="loc_ifrs-full_UnobservableInputsAxis_2147462774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_UnobservableInputsAxis_2147462774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="loc_ifrs-full_UnobservableInputsMember_2147462773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_2147462774" xlink:to="loc_ifrs-full_UnobservableInputsMember_2147462773" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_2147462773" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2147462772" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_2147462770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2147462771" xlink:to="loc_ifrs-full_LiabilitiesMember_2147462770" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_2147462769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_2147462770" xlink:to="loc_ifrs-full_WarrantReserveMember_2147462769" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_2147462768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_MeasurementAxis_2147462768" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2147462767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_2147462768" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2147462767" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_2147462766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2147462767" xlink:to="loc_ifrs-full_AtFairValueMember_2147462766" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_2147462778" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_2147462776" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_SignificantUnobservableInputLiabilitiesBasisPoints" xlink:label="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints_2147462775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_2147462777" xlink:to="loc_thtx_SignificantUnobservableInputLiabilitiesBasisPoints_2147462775" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_549499" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsTable" xlink:label="loc_thtx_DisclosureOfCommitmentsTable_549500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesAbstract_549499" xlink:to="loc_thtx_DisclosureOfCommitmentsTable_549500" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_549503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_549503" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="loc_ifrs-full_InterestRateTypesMember_549504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_549503" xlink:to="loc_ifrs-full_InterestRateTypesMember_549504" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityAxis" xlink:label="loc_thtx_CreditFacilityAxis_549507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_CreditFacilityAxis_549507" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CreditFacilityDomain" xlink:label="loc_thtx_CreditFacilityDomain_549508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_CreditFacilityAxis_549507" xlink:to="loc_thtx_CreditFacilityDomain_549508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsAxis" xlink:label="loc_thtx_CommitmentsAxis_549516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_CommitmentsAxis_549516" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_CommitmentsDomain" xlink:label="loc_thtx_CommitmentsDomain_572643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_CommitmentsAxis_549516" xlink:to="loc_thtx_CommitmentsDomain_572643" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TrogarzoMember" xlink:label="loc_thtx_TrogarzoMember_572647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_CommitmentsDomain_572643" xlink:to="loc_thtx_TrogarzoMember_572647" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_MultidosePassInjectorDevelopedMember" xlink:label="loc_thtx_MultidosePassInjectorDevelopedMember_818949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_CommitmentsDomain_572643" xlink:to="loc_thtx_MultidosePassInjectorDevelopedMember_818949" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsAxis" xlink:label="loc_thtx_TypeOfArrangementsAxis_1305999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_TypeOfArrangementsAxis_1305999" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_TypeOfArrangementsMemberDomain" xlink:label="loc_thtx_TypeOfArrangementsMemberDomain_1306001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_TypeOfArrangementsAxis_1305999" xlink:to="loc_thtx_TypeOfArrangementsMemberDomain_1306001" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1306004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1306003" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1306004" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_OncologyPlatformMember" xlink:label="loc_thtx_OncologyPlatformMember_1304768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_1306004" xlink:to="loc_thtx_OncologyPlatformMember_1304768" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_DisclosureOfCommitmentsLineItems" xlink:label="loc_thtx_DisclosureOfCommitmentsLineItems_549502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsTable_549500" xlink:to="loc_thtx_DisclosureOfCommitmentsLineItems_549502" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired" xlink:label="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired_550350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems_549502" xlink:to="loc_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired_550350" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_BorrowingsOutstanding" xlink:label="loc_thtx_BorrowingsOutstanding_549526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_thtx_DisclosureOfCommitmentsLineItems_549502" xlink:to="loc_thtx_BorrowingsOutstanding_549526" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549368" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_549368" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-full_SegmentsAxis_549375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" xlink:to="loc_ifrs-full_SegmentsAxis_549375" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-full_SegmentsMember_549376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_549375" xlink:to="loc_ifrs-full_SegmentsMember_549376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RxCrossRoadsMember" xlink:label="loc_thtx_RxCrossRoadsMember_549378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_549376" xlink:to="loc_thtx_RxCrossRoadsMember_549378" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_549377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_549376" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_549377" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_549369" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_549380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_549374" xlink:to="loc_ifrs-full_Revenue_549380" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_836284" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_836284" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_836290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" xlink:to="loc_ifrs-full_GeographicalAreasAxis_836290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="loc_ifrs-full_GeographicalAreasMember_836291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_836290" xlink:to="loc_ifrs-full_GeographicalAreasMember_836291" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_836292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_CA_836292" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_2147463053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_US_2147463053" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IE" xlink:label="loc_country_IE_836293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_836291" xlink:to="loc_country_IE_836293" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_836286" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_836288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_836287" xlink:to="loc_ifrs-full_NoncurrentAssets_836288" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_549101" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_549106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549101" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_549106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_549112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549101" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_549112" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_549115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549101" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_549115" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_549124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_549101" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_549124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_549270" />
<loc xlink:type="locator" xlink:href="thtx-20231130.xsd#thtx_RelatedPartyPercentageOfVotingRightsHeld" xlink:label="loc_thtx_RelatedPartyPercentageOfVotingRightsHeld_549281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_549270" xlink:to="loc_thtx_RelatedPartyPercentageOfVotingRightsHeld_549281" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g680117dsp18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117dsp18.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M(23DXW,>>,[: .VH * "@ H RM#Z:C_U^R_TH U: "@ H * "@ H * "@ H
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M^8L2".(Y(P"S;N>G'!H VX/&NB70_P!%FFN"9#&@AMW<O@ EEP.5 898<#-
M"V'B>&\U"UL]HW3O=1@J?XH7"G\#F@#?H * "@ H * "@ H * ,K0^FH_P#7
M[+_2@#5H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H P%U*PL/$FIK>7MO;,T<)42RJ
MA(PW3)H N_\ "1:)_P!!BP_\"4_QH /^$BT3_H,6'_@2G^- !_PD6B?]!BP_
M\"4_QH /^$BT3_H,6'_@2G^- !_PD6B?]!BP_P# E/\ &@ _X2+1/^@Q8?\
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M\"4_QH /^$BT3_H,6'_@2G^- !_PD6B?]!BP_P# E/\ &@ _X2+1/^@Q8?\
M@2G^- $/AV:*X@OIH)$EB>\E*NC JPR.A% &Q0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 A4'J : #8O]T?E0 ;%_NC\J #8O]T?E0 ;%_NC\J #8O\ ='Y4 &Q?
M[H_*@!-J@9*@?A0!FR:YIRR&*W8WDPZQVJ>81]2.!^)% %>ZO=06W>>6*UTN
MV7K)<MYC_P#?*G&?^!'Z4 9R:+<ZZ ;R>Z%F?^>QV/)](Q@(/]X%OIUH KP>
M"]#GOM2@AL8[5[66/R)8%"O'F-2>>^>^>OUH LQ_VEI4J6]Q?>7D[8Y+A?-@
MD/8;LAD;V8GVS0!K?VE<VO&H:7(B_P#/6V_?)^0 8?\ ?- %RSOK&_0M:3Q3
M =0A!*_4=1^- %G8O]T?E0 ;%_NC\J #8O\ ='Y4 &Q?[H_*@ V+_='Y4 &Q
M?[H_*@ V+_='Y4 *!C@<4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M A(4$D@ =2: ,Q]?L2YCM3)?2CC;:IY@'U;[H_$B@!-^M7?W([?3XSWD/G2?
MD,*/S-  -!MY3NU"::_;TG;Y/^^!A?TH )-2BAE.GZ5;+<7$?#(GRQP_[[#@
M?09/M0 ^WTD?:5O+^7[5=K]PD82+_<7M]3D^] &E0!E:;_R&M9_ZZQ_^BEH
MTI8HYXFBEC62-QAE89!'H10!E?9;S1^;$-=V0ZVK-\\8_P"F;'J/]D_@1TH
M>(-(UZ,7 B221#M+@%)8R.Q/#*?:@ ^P:E:<V6I&5!TBO%W_ ).,,/QW4 ']
MKSVO&HZ=- !UEA_?1_\ CHW#\5% %VTOK6^C\RTN(YD[F-@<?7TH L4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M(_$"@"_;7=O>1"6UGCFC_O1L&'Z4 34 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 -
MDDCAC:25U1%&2S' % &;_;UM*2MA'-?MTS;IE/\ OLX7]: $"ZU=_>>WT^,]
MD_?2?F<*/R- "IH%DSB2[$E](.0UT^\#Z+]T?@!0!IJH10J@!1P .U "T %
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M SS;WVK_ /'T7LK(_P#+!&Q+(/\ ;8?='LO/OVH U+>WAM8$@MXDBB085$&
M!]* )* "@ H * "@#*TW_D-:S_UUC_\ 12T :M !0 4 % !0!FW>E![AKRQE
M^R7IZN!E),=G7^+Z\$=C0 6NJYN%L[^+[)>'[JDY27W1N_TX(]* -*@ H *
M"@#.GT.PFE:=(C;W!ZS6[&-S]2.OXYH C\C6;/\ U-S#?1C^"X'ER?\ ?:C!
M_P"^?QH /[=A@.W4;>>Q/]Z5<Q_]]KE1^)% &E%+'/&LD,BR1MT9#D'\: 'T
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MZT ::.DB!T8,A&05.0: '4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 0W-W;V<7FW,\<,?]Z1@H_6@"@-:-SQIUC<7?I(5\J/\ [Z;&?P!H
M /LNKW9_TB^CLXS_ ,L[5-S?]]L/Y** )+?0]/@E$YA\^X'2:X8RN/H6SC\,
M4 :- !0 4 % !0 4 % %6]U"WL$4S.=[G$<:C<[GT51R: *!LKS5CNU$FVL^
MUI&WS/\ ]=&'_H(X]2: -:**.")8HD6.-!A548 'L* 'T % !0 4 % !0 4
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MEON@ #DGL!F@!(M<TV:>"".Z5I)U#( IP<YP"<8!^5N#SP?2@#0H * "@ H
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M+M%DA.TX*M]TDX^7/;.,GB@":QU.SU)7:TF\P(0#\I'49!&>H(Z$<'M0!;H
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M]1F@""Q\)W-I=PLUQ&T)G2ZF()W>8N[Y5&/N_,/?CWX .LH * "@"G?:E;V
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MXT 6?[>L_P#GC?\ _@OG_P#B* #^WK/_ )XW_P#X+Y__ (B@ _MZS_YXW_\
MX+Y__B* #^WK/_GC?_\ @OG_ /B* +EG=P7UJMQ;L6B8D E2IR"000<$<@]:
M )Z "@"O>7L&GVQN+AF6/<J_*C.26(  "@D\D4 5/[>L_P#GC?\ _@OG_P#B
M* #^WK/_ )XW_P#X+Y__ (B@ _MZS_YXW_\ X+Y__B* #^WK/_GC?_\ @OG_
M /B* #^WK/\ YXW_ /X+Y_\ XB@ _MZS_P">-_\ ^"^?_P"(H /[>L_^>-__
M ."^?_XB@#-N/$4MU<-;6EM?6L"\/=2:?,Q/LB[/U;CV- %BRO=+T]6\FWU
MR.<R2O87#/(?5B4YH M?V]9_\\;_ /\ !?/_ /$4 ']O6?\ SQO_ /P7S_\
MQ% !_;UG_P \;_\ \%\__P 10 ?V]9_\\;__ ,%\_P#\10 ?V]9_\\;_ /\
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M #^WK/\ YXW_ /X+Y_\ XB@!T.MV<US%;@7*23$JGFVDL88@%L990,X!/X4
M:- !0!1NM7M+2Z-M)Y[3! Y6&VDEPI) )VJ<?=/Y4 1?V]9_\\;_ /\ !?/_
M /$4 ']O6?\ SQO_ /P7S_\ Q% !_;UG_P \;_\ \%\__P 10 ?V]9_\\;__
M ,%\_P#\10 ?V]9_\\;_ /\ !?/_ /$4 4[Z[TR_"%X=1CFCYCGCL)U>,^QV
M?H>#W% $=EXBEBF^S7UK>RC&4NHM/G"M[,NWY6^F0?;I0!H?V]9_\\;_ /\
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M 7O\9@\_ B<D+C/( R#CG'6@!;OQCI=I(\+"Z:Y14<P"W</AF50<$>KKGZT
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M84 :5 !0!F:I_P A#1?^OQO_ $1+0!IT % &9!_R,]__ ->EO_Z'-0!IT %
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MM]H?Y\G///(R20.V3ZT :J1(D83E@%"Y8Y)QZGO0 _([4 % !0!E/_R-D/\
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M_P#Z'-0!IT % !0!RMIKM]K6I"WLWCM+=[<70D>/<WEERJ<9Q\VTL?08'4Y
M!*WBZ"RBV7<4LTL:,&E@0>7(ZE5<("V>"X'IGC)- #X_&%M,FZ'3[V3YPF J
M#KOYY;&!Y9R: (W\;Z>MLEPEK=R0M&7WJJ#&$#%<%@20"!QD9(&<T 23>+K6
M &6:*6"%-P;S%4%F#A%4'=P2Q[^ASC% %S3=>CU.Y6&.SN(MT FW2A0 "<8Q
MNR3QU Q[T 4CXH5=:O+;R7:V@CC"80AYI7=E 7. 1\IYSC@\X% &CI^JR7U[
M<P&PFMT@1-SR,A^=ADIA2>0"/SH TJ "@ H RO#7_(MZ?_UR% &K0!E>(O\
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M/'0LBMCZC/ZT :% !0 4 93_ /(V0_\ 7D__ *&M #I_^1GL/^O.X_\ 0X:
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M5+B:4Q.[M]YE*MGC<R@$<^N: +T'A][?0[*R*Q!ENUN+D0C:LIW[B?SP3]*
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M^NKPW4)DNH8DE4ROABK[G4<?*A'R\>GN: -"QT![&349HEMHIIX%AA:%"#&
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M^_,/_P 10 ?V9J'_ $'KK_OS#_\ $4 ']F:A_P!!ZZ_[\P__ !% !_9FH?\
M0>NO^_,/_P 10 ?V9J'_ $'KK_OS#_\ $4 ']F:A_P!!ZZ_[\P__ !% !_9F
MH?\ 0>NO^_,/_P 10 ?V9J'_ $'KK_OS#_\ $4 ']F:A_P!!ZZ_[\P__ !%
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M@4 5/[,U#_H/77_?F'_XB@ _LS4/^@]=?]^8?_B* #^S-0_Z#UU_WYA_^(H
M/[,U#_H/77_?F'_XB@ _LS4/^@]=?]^8?_B* #^S-0_Z#UU_WYA_^(H /[,U
M#_H/77_?F'_XB@ _LS4/^@]=?]^8?_B* #^S-0_Z#UU_WYA_^(H /[,U#_H/
M77_?F'_XB@ _LS4/^@]=?]^8?_B* #^S-0_Z#UU_WYA_^(H /[,U#_H/77_?
MF'_XB@ _LS4/^@]=?]^8?_B* 'VFE207_P!LN-0GNI1$8E$BHH4$@G[JCT%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g680117g0117021212701.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g0117021212701.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q ' # 2(  A$! Q$!_\0
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MO-P/K4UIZV-:-.^O4BM+AV1WDE#1^K'%7++4;JT9I(+:X>+NN,J?PKT7P_\
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H**YW)LT"BBBD E%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g680117g0213234749910.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g0213234749910.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !P 0T# 2(  A$! Q$!_\0
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MJ,DDX %5;/5-/U%G6ROK:Y9/O"&57*_7!KSSXP:ZUO86NB02%6N<RS@'K&.
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MO(+V'S8'W+G!]0?>IZYVK%A1110!\V:[XHUC5=:GNIKZYB*RL(HXY658@#@
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MK7%ZU\,]%US76U2>2YC:0@S11L LA'X9&<<XI8*O"C-N?8,71E5@E$ZC1_\
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M1UQWKH*Y[PMX@DUF&6.Y51<0X)*C 8'OCM70USU;\[YBXVMH%%%%9E!1110
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M\4]'FL56(:E"\=S&@P'QT8CUZ?E2^ X(M2U37]9NT66]:^:%6<9,:+T ]/\
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M^(E[K+(GV*6R6%&W_-N!';\*/$^C7NJ:QX>N;5$:.RN_-G+/@A>.GKTKIJ*
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g680117g0217155725978.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g0217155725978.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 0T# 2(  A$! Q$!_\0
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g680117g0217155726198.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g0217155726198.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ FX# 2(  A$! Q$!_\0
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M/=L;IN4J?R-94VD.3<;8XI%>)%VL<;BO7-3Z?;W5O;O;2J I#,I#9"9Z+^%
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MM.W=Z9Z9JA_9]Q;Z2R-AY!<"8A?XANS4,NFZCY LHTB:U,_F-(6P^"V[IZT
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MZ#F@#CVN&&GMBX?S(IF,.'.UUR.A[FM>*6ZAU*\8":Y!2,K'D#;G.<5L>6F
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I"=;G:60J057'#*&Q^&:T B*,!5 ]A2\#I0 M%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g680117g0217155726321.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g0217155726321.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 -,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V*BBBMS,*
M<CF.17'8YIM':@#='(S5.[;,@7L!5I!A%![ 53N?]>?H*RCN6R&BBBK$%%%%
M "@E2".HYK2!R ?6LRM*,8B4>PJ9#1#<'D+^-0U+/_K/PJ*A; PHHHIB"BBB
M@"ZIW*#ZBEID?^K7Z4^LR@HHHH **** "BBB@ HHHH PJ***W,PJ6VB,LZCL
M.3]*;%"\S809]3V%:MO L"8')/4^M3*5AI$M5KM,@..W!JS2$ C!&0:S3L69
ME%32V[(<KRO\JAK1.Y(444Y$:0X49H 6-#)(%_.M&HX8A$OJQZFI*S;N4B&=
M<J&].M5ZO56DA*G*\C^5-,3(J***H04JJ68*.]"J6. ,U9CC"#U)I-C).@Q1
M114#"BBB@ HHHH **** "BBB@")K:%SEHUS2"T@!SY8_&HFOES\J$_4XI!?>
ML?Y&JM(6A;  &  !Z"EJ*.>.7A3SZ&I:D84444 %,:&-CDH*<6"C).*B-P.P
M)IJX"_9XA_ *D  & ,5#]H]5_6I%E5^ <'T-&H#Z***0!1110 TQHW512>3'
M_=I]% "  =!BEHHH **** "BBB@ HHHH **** "BBB@#'HHHK4@.^:OVL_F#
M8WWAW]:H4Z-BDBL.QI-7&F:U-=@BY-.JO<-E@OI4(HB9BYR:2BBJ)"BBBF!8
MADW?*W7M4U4@2I!':KH.1FH:&@HHHI#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#'HHHK4@*.U%20IYDJKVSD_2@#33[BY]*K3?ZTU:J"X7HWX&LUN4
MR"BBBK$%%%% !5Q/N+]*J*NY@/6KM3(:"BBBI&%%%% !1110 4444 %%%% !
M1110 4444 %%%% &/16DUK"W\./H:06<([$_4U?,B;%!$9VVJ,FM&" 0KZL>
MIJ145!A5 'M2TG*XT@I" PP>AI:*D94DC*'U7UIE7J884/;'TJKBL5*4 L<
M9-6! GN?QJ0*%'  HN%AD4>P9/WC4E%%2,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"!KN,= 32"[3/*L*IT5IRH5S121)/NMGVI]9@)!R#@U=
M@F\P8/WA^M2XV"Y-117#_$T^(1HUL=!^U;1*?M/V7/F8Q\N,<XSUQ[4Z<.>:
MC>UR:D^2+E:YW%%>57?_  FW_"&:/YGV[[1F3[1Y6?.QG]WOQST_^O6U=?\
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MPIZB'I&B#"J!3J0,&&0<TM(84444 %%%1F9!WS]* )**B\]/?\JD5@PX.:+
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g680117g17j01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g17j01.jpg
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M  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!9&]B90!DP
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MX8)#4Y.T-74VHM)CTT1D51<W&/&#HY0EPL/C982D)M1%_]H # ,!  (1 Q$
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M2@"%00C>6GD #VP)%CR^PX^C],"49K/EJYX=D"E\WL0\L<\1V2_3 HD/+'+
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MFE2$C!/^Q'Y1,W+&M5"Z@=@L^0E.$P/5^0AV':DJL_+@<,H]7Z(,.U%4JEM
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M*:8IFBKF.#>T$?@5533J6,R2E0E-)2I*@M/-2"#)21VC")= 3$D4*3B00(-
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M5MMA_-2H0BLK*\SJ*FJ5F=JZAU;SBE+6I1T.[NKB]N7W5TXNN'N)<3G4_BR
MX#!;-!#%;PMA@ $310 <E\J'U?\ HJZ3=POK<?2K<UK:-.4+O4W?M4T>_NE$
M--TM%N4SM2:&[;;5.IZ1@M"IJ-;7FH.G*IY4EUU*RVRHJ+<XZ5TMNVYP=(;E
MY)<1;-'E'\S74/I_!'>'(XK3M[L+*3?[/S !YI.L?G:<6U]I[O:OKLHK3:K;
M:Z6QVZV6^@LE#0,VNBL]%14U+:Z.V4[":6GMU+;V&VZ2GH&*5 ;0RA ;2V D
M #".7ESG.+W$EY-:\:\Z\UNH:T#2  VF2_*9_F -B]H>GKZH74AMYL?:[3IW
M1-6O0FOZO2=@;IV;/I/5NX.C+3J?5=DMM+3!+-LHU7BM<K6Z-L):I$UOE(2E
M"4I'H?I.\NK[INWGO"72@.;J.;FM<0TGGAA7C2JY?N\,%MN\T4  95IH,@7"
MI'RXTX57AG5)RO+,AQY1?D!+B EB-&U38)5.<\.R9[.SA$>@J36.U'D8-!2A
MXKQ1D EYN7[0B7@HIUM.T)FV!A.:0#WR'/C&9B^K;[!]"Q%QE[E<*9L**LZ"
MXC$*;2O(MT33F:0X1^[6XB:0K]4F<3!X#:<5BSXE^H_TI_5S^D;:.G'9VUZ(
MZG-A-DM,V?0NG[+2;5ZDN]OV^OFAJJV6FD9N.G[KIFN8H76*VBJTK2Y4I2XS
M6N9GFW7@O.?.FX],=3R7\KY;>>:0O)U@%P=4X$''Y.&5 NNV6][(+6,1S1QL
M#0-)-"*<"/W57>.PG7AT:]4FJ;IHCIVZE=H=Y=7V2QN:ENVG- ZQME_N]!I]
MJMI+:[>*FBI'%/(H&Z^O9:4Y+*%NI!XB,->[+NVVQB:_MY8HBZ@+FD FE:>V
M@61MMQL+QYCM9622 5H#4TYK;^\F^&T'3SH:LW,WRW'TEM5M_;ZZW6RMUAK:
M\4MBL--<+O4BDM=&]<*Q:&45%=4J"&DSFI6 BI:6=U?S"WLHWRSD$Z6BIH,\
M.Q3SW$%K'YUP]K(@<R:#%<9*^L%]+M 45==W37)*2HY=RK*LR2"3)*'5*49#
M@ 3&7_NKU)_4KC] JA^W-H'_ &F+](+X<>JW7/1WUO?7SV:NO3Y8+'?NGK<_
MJ(Z<-(:UJ:&PFP:9W8U#2:CLU)K_ %32V9RFHGUV?512W3.U#C+*[F6''UI4
M'RI?8]M@W79^B9FW[G-OXX)7-J:E@H=(KS;G3A4#@N?7DECN'4D9M0#:OE8#
MA0.-1J-.1R[<U^@MU?[5Z%W7Z2.H;:G6NG;7>-$:DV1W!LU98JBD9-"RQ3:2
MN+UK>HV$I2BDJ++6TK%11K;RJIWV&UH*5(!'#-JN9K7=(+F%Q$S9FFO'Q"OR
MY'G5=,O8HYK.6&0 QF,X>[\"_&M3G4TVI20%%AK-E!DI0:2%*X<5D3/>8]7K
MB&L)4)66E)GE"#))&"TYP$E2#(Y5@' \CC"8(UCM7[,/3#MIH?;WI<V,VMTI
MIFT6O0EAV7T'IVBTTU;Z06M=L<TC;FZUFMH@R*:L7=5ONN5BG$*-4\\XMS,I
M:B?)^XW$T^Y37,KB9G3.-:XUU'Z.')=PM(HX[2.)@ C$8%/=^ZJ_)4Z\=OM,
M;/\ 6_U;[;:'H$6?1.A>I/>32FE+.U-#-IL5GUU=6+;;6$35DI*"E4EEE,SD
M:0D1Z6VDRW^T6T\YK));QN<>).D5/OXKD-\([7<)F-%(VRN '94K],CZ'NT&
MWVU7TP^DBLT5I>R62Z[E[2:<W.UW>+=;:6DN>JM7ZV:<OURNMZK6FDU->ZP:
MT4U.'%*#%*RVT@)0D"//O5<TLN_W+)'$MCE+&@G(-P 'R?*NH[''&S:X71@
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M%&)QE$[FR::L!S3 W'O8-4;:[N_2@,N&;.:2P?[1*B3@!^R(MP2.% _ *G-
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M&AP)!S%,D7&[[7;3&"XE:V=M*@@U%<1PY+3J?K;?1H4)IZM=FR/_ $AZ]_\
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MVSTJ2<]1<+Q>;BS3L-H!4I:QA($CEW3;7NWVTT DB=IPY U)]P"W?>W-&T7
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M-T= JK0B\L[6-MWJXU-SH;:XI-0Y:;IJU3::FH0DH2]3L(5E)1FZ9ZIR7/\
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MG$5R32DN5QM3CCENJZVWO.H"'7J&JJ:)YQ S20XY3.-*<0F<P#.7*$<UKO$
M1VJ0$C+!.1J34H,QJ+4@)XRO]X$_96"$\N/\UOR!+J=S/RE$5J34DQ/46I9
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M-;CCFC\064)9^0:IVTN4A+XL>/=&1;.0T"G!1EE37BH^Y6IFN:4L("74R&8
M$@>N7&+D$NL4.!4;FZ314=3-5:W\26SF3*7[/MYQ=P8,,:J&3@KQ:;NU4)2V
MX?&KP2G.?+WQ)"XN=CR4:_1*^BG]9[H\U!T<[-]/N_F\.AMA]Y]B='6W;-^C
MW)O-+I'3&N-,:3IC0Z8U3I74]V-+I]UUS3].PU743M2BK9K&G%)0II:%'A?6
M71V[Q[O-?V$+Y[.=Y?W!J<USL7-<!CGD:4IVKI^P;_8.L([6ZD;%<1-#>\:
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M4MK6ZV/F4Z>D6U>8EH@@'0O_ #*AIY[;"Z-@#]9A2G/+3[M?O6U?W3D^J-U
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M'R^ PIE3!Q&-<5UOM+T*_1IZ?]^-%]5UI^J_INLVWVXUK1;F:1VSM%PT\SN
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MCDH&K4LON9L#/AP !XR!QQG&C;O<R3W3FS^('!9&(,$=6YKLGI9_Y"?J4?\
M>9[=?_9#NAB,.6FH]OX"@+TQ<8RF1'AY=L_NCM="N.)(4QQF%*09^$XB1X >
M'D81(J[<]/MO_O6$*2Z 9&<L<98 =L2L(TJ:,C3CS4)2UU1;W!2UZ5EL$H2K
MCEX3/#&<28%(_A1/:VSL5S/G,Y%+4DG #@1Q''&%#]!J%'0\<EK>X6AZD4HY
M3EF>1GRGP C*VUS2G-1RC5&6\PHM(4V"".)YS[(SUO=89K!7%J2:4*?,@*)[
MAR],9.H.1"QA:1F"G"6@5"8)'N^Z(3F?:BE<% WFP-5X4ZV@I=2)X<")&>
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M<[2*A9\L]AEVP)C7DFF"26V2M(2)B1S$\4C'$2[X%(4*:WH25NK277C,YR?
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ML%6'5\RQ4;72G]7BMXTS]+5,H=8<;>:6E*DN(*5)4")@A29@S'9&$?&826'
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MV=\"$[#> \(X#L[(4 G (1?+252( )[NZ%+'#$A+1+-MA (P,SV"&I,$Y\I
M[#ZI0*P)&\4@Z@9%>$2. X0*!Q!<2,DQ=2 A"0 "000!R_6]HAWA='*?JVDU
M25,;'N=@'@ >U:GN5(#>:XK&3QIR8 S0H#TB6'ICBO6[GMW<RCZJ0&AYTS^E
M=JZ5_6;3#"SQM&(]JAZFQ-OA1#""XE0!4$9'',!E*5(RKFE( QXR X1H%V(7
M,H3WZK<VLE;1H'?43<M&45<XCYEE-.O)F;KVDK9JV'0G*,E4V0^@+GXD*"D&
M6.$8&>W8X'S,(^=*T]RR$4CXQ4C%:QU#HG6VG7V+O8@SJ2DIRYG^7;;37LB0
M46ZBE;6DO-NSQ4T$D'&1C$3;<UV,/>_Y/TK(0WX:*/'S*'IKSHK6"?(NU(W9
M[\PC+5M5(-%5+<23E=8>4&45Z42(S -O)E(I/&*+H[EGB&/M4S6Q/\.*IVI-
MOJ&L<)I:^@6ZK.E#]4VBBJW\I*D!;BE):J4\BI*@YVI/&&12O8[O)AM*FM%I
MVZZ.O%(M35;;GJAMD22[0*0ZXVGXC@02ZQEX":C.,M%.QS*DJK):R!Y#1@JR
MNGN5*IMAT5M33)47&AD4W4M!(Q2V7D_$!^KB#%ADD)%2<:\E$8)!F$^;2\^E
MU5,M-S9(3YK*Z8T]:R9$$O4JPM1=;G\2/"KC$0D<74=X$ACD&847YJ6%@OTB
M74I_:"F7"@&0'F("D!1/,"<2M>"X:<U&]CM)1''K55J45,/4CW$/-J#M,\2)
M9'4$AQM:1P4F84<2(FJ_\WYU 6.Y)@I-*VM8<%2@)DF>5"TF0G,*"D)X''$P
M5DY(T.X!$(H.)<J)<1^Y;$^8Q#Q,/X=J;6B40[1I3) J$D@@J2A&/J*E"%I\
MB3"N:;N5#:5!00VK# .IDI6/%4L 8D8X ):A86]F 'EI3/$97"2?5"F1K<:I
M6C4:!!+;BL4M(']93DO:#S,()F'"J70Y AX8<1_4\2?1.4.U-(H$A:ZB+D5.
M0D3B<H(*A+M'&(M#DRA1?+4>(4GU$'\#$VMN54Y.&J.I<(\ME:QR.4D'U<3C
M#@01@A3M%I:MJS-PEA *9CRU+<5FP2$- !4I@^*<H4!QR2%P&:L;>F'*=LRI
M7E (FXZ]E0IPCAY;:2I24D]YBS;L?4X<%#)(T4Q5:JFE>>*925,I,_W* HJ6
M29 *41@4F)'N:T4.:DMXG2O  JK[9;73T- ]7/TI6AI$\BR<RUY24(;"9$%9
M':8Q<P))<,ELELQL<7?P=1"R:DOM*\"*%316]G2D,. H"B9)S#%4@!C%)&MN
M2M^H;9>M14R:TT3B#D_>*#9$I ^+'B?? EUMYK1ERM]11/.!Y"T*1,*)3(R'
M9SEC%AGA"C()-1DMDT]4;KH@L8./LT:TD*.8SI5)?;S&<P .?*-FZ9TNNR&N
M_6MQ([.?)4;Z0,A,;Q@>*D+16M:RL3UCK?+&H+;2!ZDJ2 5W2A8;&=#KF*A6
MTJ#BK$.) )QG'1X]P9<,=&X C(>WBM*=:R6\WQ,&+''O=BKNFK<^U<4LE&5]
MM80XA(*'6DI>D' /"<JI8$<9QF]FL)&2":BJ;M<0RVKGAV("]#-N;8JCL["%
MH+;M7E=<"T$*4ZM&0.*5+,,HP[%".ELQ@ &8"X6^9]Q>25Q:TE>@NP%./\&N
MN-L)(4.F+13:N\GK+Z3Y$<\LA&&W'^F[>/\ O;O]6N%E;'^BWO\ 9F_ZQ J'
MK;9[3^JVG7:6G10UN"DA!\IM2R#XVB$DTSZQQ']FH\@8Y]!.X9K>67#YO'4>
MU<<ZIV]O.F:EUNH8>^7;4H>>X@I*0#(>:@X@D?K E!Y&,B+C(UQ5UHHV@Q"I
MZTEM(D,QPEEQ"NV4N)AWQ .*ADQ=[D1#A!F674D</A/IB:&5KJU(3,E)L590
M4B1' X))5/OXRBPV5H-015,D;K;1;+T_6MW:DJ+<\DI>2T76U$_$$$*'KFD1
ME+>Y!H"1\JPMS;E@+P#48J@WW2S]7?;9E22U4N%MX@&00U)2ED@2D4J(](BD
M6N-T7 $MJKC;@_"@'---8-IJJSY= DU3Y4)2. 0V@(;3W!,L(MW#VTS"FL&D
M'$%+:-U_>]&U3=,\I5=9W5S<HWEJFTG*F:J94CD5XC(' \(UZYA#R2,:E9J>
MWBGC#6BCZ9]JZVL-_M>HZ!NOM=0*EI21G!\#K"R)^6^V3-#B>S@>48PQEF%"
ML)):26QT&I&=5,8$@X&7K'VPABKZ@.(JF[U,%^)'A6.S 2]$*EU-/$)#.4)R
MND CXN1XS[>8@TEQTYU14$X$+)#3Z E:4A/)>$_9SBPRX?:Y I3BH.IH7:,E
MQ *F7#F 'B"1S*9<I&-AVW<C(?UIT^W#Z5BY[>N2,VA*LJA/+(8\A,83PPG.
M,Z'L>:M(/L*P[VEKB"#FG :)D !(F4S.?Y0^G--"@[UIEFYM%:045*,4+2!,
MGF#.4QA"9*1DA9DJO;*"JI:GY5]LI4V9\"<WB S)/9 E=*7"A3O5;J:>C*%$
M$K!XG@5"6'JADCM+"Y+%7S !FN:;[:67T*RR!42HB4YS)XX<8J&? A9J"H%#
MR5(;TZ//!"2!V\![92BDK]OAG@K+2V1D2F92P/APGZ918! 'N4=QD58Z:QMJ
M(RIS)D!F(P'IPY&%SR5 *138$C#(%3_92#W=D+0G)*I)%C0D22B?I3."A0G*
M;.D >!(/^0(*%"<(M20,4IP/#(GA!0H2@M8_43E[9(X]G(04*34.83A-M&$D
MC-+&8)].!PA$:F\PG": !(! GC^KW^@P5"2K>?SI9%"D#&7'L_1!4(JWG\Z7
M32I)QR >@#\(!CDEJ#Q1RRA(\/$2$TRGZI"%H45'-92VDCQ3G/G*?O$%"C4.
M81PE">$L?1!0HU#F$H3AB /5*#2[D4:F\PBS@TNY%&IO,(Z0DC$\^T0NEW(H
MJ.:P)'B?>!"B(OS44A!I1'"$GE/TXC[HD9;5<D90.Q2+P0D$2 )XCF!+L]$6
M/A3R^93%P K51+E4ADD 8=IG]XP@^&/+YDSST4UX4) #W\/7 +1W(_(G@A1K
MSQ4<H*<JN/#"6(Q@^$=R/R*N\MJ?:@U(B1,YJEQY$"*\L+V.I0Y<DW/)+Y?+
MD43G.?;P_IB&AU 42_DGFKO8+AP3/$91CQ)_6]<XOM(#:56.F:ZN *VK297F
MTF>,AS&''C$C:U[%6=6E.Q(/4TE\9#M) B=5])414MDYA*7?+E D*A'&525@
MKCQ(PX]LH$B;^60<>/'#A"T/!'L4BP@J2209X<!Z>Z$I1*4Z\M9  !'>090^
M/Q(")Y2LW YO09</;$SO"4J60TLJ 4D^H'A%9)@G7E=ROMZH$B3=9)00 9S'
M'T^B!"C7VB"@&>83]&/"8B4#6S1P0[2]H82*#%5.\VL/5::@)*?,1+,!.:D#
MX2B4S/C/E'.>O=M:+>.Y8*EK79>T+I70M^7^9"3X7-IVX')&HK8I8"7&O,RI
M!22 %YB?VL 91QB)GG,U'.JZ;).\38U!HIUNPJ=2<[<B>$TIS \$S.4]L+Y#
M!XA4<DAO/+&MV(";.:-K7U>?2+73.M'Q!UML!0$@5>6 E;R2>0(E$4FV>=5T
M7=^9(-WB)II*UMK+;2UW>G6B]6.@KU_#YC:335B<A/[Q%25(#N:<\I\<P,I$
MA&#N+8Y.!JLQ;W3<VD$>U<T7W;:_6'.W8[TNKH\Q4FTWI)4M=/\ "D,.OJ6H
MY5^$E"@L$8@\8UF5CFR.P-*E; QP<T$'@%IZ[.7ZVNJ:JV+C:7&_U@RY64"R
M!-2DY?,DA/+$&)X2T1@$BJ8]KB[(JJ/7^Y/ -U=0S5-H45('G.4#X ,RI'G-
MK0% <$S 4<.^+</>!TX^Q02M<TBH(4:]7/..I6I.9 4I;=6S4TJ7 3B0J>1Q
M*\/$E4\>&$3:7<C55I*::GFGC.H"!*H>1423D":BDHWW.$A.I:5YZO0K,G#A
MSA#K:-0!4-&NP)353%CK %_-IH7R5>< TVXP2>"LH1YS9)..4+]7&&":0'BG
M>3'^</E3-VA6RWE15)=9DJ:A1L5*%(!F%AU P)F<%R($6/B3V)_PP[5'?*I=
M_>!E3Z$DC.AD-)GP_P!S7AZ.$)\4>Q0>0ZO9[$Y9L=54J(:M-0ZA23BEMT$=
M^?$'VP?%'L2>2Y/6-*U:T**+9Y8G_:5"UY1(?U5@^Z%%PX^$5]B/)=QHG"=*
MU@3-T6YHC Y05*2.T$RF8<)'284R3F0X][!'&EFU$%=4E:9>+(E2?1(2QQB1
M@.I.?$UK*@U*.JST-(A133FJ64G*%**0D@&>8 # Q.,U6(-#@H@UGRN=+--2
MIG\2"A*B.21-22KG(19&.2K'#-22;Z*)@FKLMI4^XF5,TXRH5$I85#X#_P"Z
M0K]5."CQPAWPXIBD!!XA-V]:/-G"SVQ)'ZZ#4)*3VI\Q;DY>F&Z=. Q"5$=U
MU?5']Q4JIF^2&::C(![<ZFU+) [XFC!H<.*B>#5,*Z_W:Y(0FJ?552.5)R-I
M>1FD!XFT),O5$K7NCJ>:1L1D=0J]Z.TF\^M-54A12J1&?.L@RGCGF#,Q2=*7
MR8Y+,6<>EP(R"ONLK<6-/J;I'?(=:4R\TML9%!:% _%SQ&'9"/(T'V+(.( J
M5J%G6NKK4O+_ !QTR$@'VJ6J5(8> N,DIE%"A[56U-YBJF:/=#5@<G47MQQ"
M@? ZS3EF8$TYFTMI\)E*"AY)0YIPS*MM)6VK<*UUJ:VGHZ._T* MQRG!0U74
MRA+S@VJ7ENB6($P(F:: 5S5AGA"J-B8^4ME^94?!3-5*"4@I.0*::4D'M*5Q
MMO2+&OO97#QB/WK$;M]7[E3K-=:JQW>CKJ62WJ!]MU05,I<:2Z4NM]Z%T[BD
MJY&,K:W+FSAAJ.^5@G"MD_\ .HNQ-.:0M-9=6+KD#E*X&:ILM))4TUY8<4TK
MB5-*41*?".Z]-6\<T+7$C3IYA<GW[<I+:V?'CJ+P*<<UU3III\VULN,.MNYD
M8%,_+"5$(2%#@D) C8Y&B.K6XA:!'W7EXS<NU]@:1P;1=<)^947U],>BIIEX
M$RZS.E!0,I8D@2X\XU_<?Z9MY_[V[_5KA9JQ_HM[_9F_ZQ K6EI1.*5<.0G'
M.UNRB[QIRW7VE727&E#R%)4E#D@7F@KX@D&:5H/-"@4GLA5,V;2 .2YHU5LL
MW9DN5%JIEN4:E3 :4"A*E$GRPE0)I5F4Y'P<@>43Q301MTR>).UZ\5J2LTH6
MG5-J:=IWD@DM/4RRHSX' @9.^+,=S:8I,%!NZ<>IU36TA*E8@3*%%)QS(2X$
M*6/\F<3MG@D.F/Q)<TM0T2J1_P UM!\Q+;@S#,D@*'ZX,IC")0[2=7),D&IA
M;S"L-.X%--5"TI*J5;B"5*D076G!F&!X=G.,G;W)HJ'PZU!=ZCY5]ZIJFJA;
M2U'S#3@*<; 5+/D.*T#G+$16N%D+?-0U52"I;144KGFLNM$H/AS2G($R)GAZ
MQSBHK9GTFG),+3=;_I6XM5]IK:BG>2#F05*<8?1B"RZQ/*XVN?I[#"/BULU*
M4.\Z+2NHM(;FT.I:8(4CY&[M)G4V]:QE>2D2-10.$!+S:E"91@M/9&)EC\MW
MM6(N;+RG \U=6M4T+A+:G4M+29!+BP,Q'9/&<5WN+&ZE6^'2=3>J)P95.I!5
M@9+!(]'+@(8VZT'7R1Y(;WN2K-7JNFH"1YTT<<7$@_LR]T6!*;C%(*)*W[H6
M-QY-'5K=&9>3QB0"3P ,L)18S5KX>BO26Z=]":RW.!^E7E4$H5F,C(@$#FD1
MD+&^T/T\L/D6+N=OJ2>=4Y96AS@2)$X$2,Y\/;&UQ2^<P2<U@)H?)D+$\2G-
MSE$BA36JMZ'P%I*@^V)I7@9R,Y$880)P6IMQ7G*>D#CS90/,;0I8^$*E)(F
M0,_?SBO=NT6SW=GX0K=DW7=,;S/X"M&OOA\')XE2/X]W'&,&+FIHMC^'HHY"
M5)6B8(F8LI%+TP"C(XB8@"CF\/N5EHU(1X3S'#N/KYQ.SPJB,E9*5#:BDI]'
MVE$\>12I\EA"3/C$E4E4<,H)E*"J*HYIT $]@)^V,%4$X)%*<L\9SARKI4I
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M)[8S5M;<%C[CPA5>J8JRE-54HJ<E0I?DU+S3@;>R!*G$(?*0T\ZSYJ<R4DE
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M!+CV=\:GK:>*V"E%$5U"$-. 9RE2LTI%8Q/M&$8NXC':I;:X<3D%1;G0A*5
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M!1\K10IO\NL8^'+R.8$RY>'C&?M.A-XF<'2TBCXD@FGR+7;OKC:(6ED),DO
M @$_+V():6%3"Q*4I2,^_NQC)?\ E[='!US$6\>Z[+CQ55GJ)!$TEMO+KIAW
MFTKPX)ZW++*1PB7_ ,N+3_._,?QJ'_S1W'_-_0ED'Q>J+(].MJIBXU]ZJ'U%
MW=QJ *%*$D@CMBTSH':&-#3J-%6?Z@;^7$L<T-]B3RGM]D._N#L9\8<2F_\
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M7:E)N5/E$_&33S=0G_*0([ETYZT^F_430X;E%;N.0?CCP&%$>8%3$M+0I:'
M6UI,EMK!2X@B>"T$!23Z9&.FLNK>2+S(9(Y3RC<'G_DIZ,42'&(G7L56L8'&
M1V8I0M/(UXA"C7V\I)G\7=PBZ06FASI51/\ $FA3EYSG#X^*84FTWF=;"P<N
M83]\L89._0RM*XJ[8M!E(=^:?P*7**BD4U7T)"*NG6'$YE94.M\%L/J/^XN#
M#N,:KO.V#<[*6 $-G>V@<14#$'+-;5M-_P#L^9KGU,0.(&"V':-3T]R82]D<
M8J,&JRA="0NG<EB"!Q9"CX5# B4<+OH+S;;IT%U&YL;<G_DGV#-=2LPV^@$T
M+ACP5C76-^4$2,W!AB)#TF*CYV30>:WY%-':2Q3^5)ACFJY7,-O.%1\*0E.0
M#@5@>(GM),8N1WF#DLDQGE.()K0JDWNB4M!<&"0<BSSEP&4<3@8HR,T-#:XJ
M[ 7/D[N2U1>VVZ8.&L>:0PG$.+6,S9F.$CB ,3&-DD8Q]''%9V&*1HH 2#\R
MT!>=7T%&76J:;^5Q8#C2BMLA,_&!F"Q,]T5I[IC&BF.*R4=JX8N(%5J*Z[FT
MY4\VN@4ZZE7E@*<2$N,J$BZE*L0L$\"9PULP<W53!2BVJ:!PJM87753E5F-/
M0NA+:B$A2O$9F>$E'-(F+,;=>(./TJ*2(QYD*&I/[T7I4J6U/EHJ*2XM 2F?
M=S(B8-DXMI[54-Q",G K:FG-JM55:J2MK:5-L92XAQJON -,WYP4E;/RC0_T
MJK<+@  0GQ3E/&+]I$9)A'(*55:>^LO++A(*CA1=G6/I/V^K6WDZAU7>Z*]A
MARX/V^CH;?2L4Q2 _64(4\M\KJZ8*.=I*@ZVDS(CH=IT_8&U:^4!SC7&G:5H
M]SU3N$$SHK,M\@95&/;\ZLU9TK;87FC?30WFNT\X]Y+-CU!2W%=ZM].HMK;"
M+Q;:Q%*6Q4&>+9;4VJ<E$819;LVU%IA:RDAQ#N 50=5;G+*#.,,J#!<!WW3=
M7I+5-YT[455'7U=BO-9:S5V]SS:.MJ*&H6PE^G<7E4XVZM$^!'%)GC&A7\<E
ME>NBB=J Y+=K:3XJU;+I+7'FI1;-->D*IZH?+5307)3R0%,* 2?)=D$NNT*G
M%<AGIIY25-A(1&;N[EC\EATN/'A@E9;L\_7-WHL</=A\Z+4MIN,K)J7-2W2E
M;#%IO3Y"AXDCRK==G")NT;N'DU!/AX9BF+[7-D:ULF$M1WN [?=FHO(DBD,N
MH?#C$MXTXCY%7!1^63I?5+3K#=.M0H:]227[(XY/RUI60%U5G?F"4SD@',DP
MXW8?)\),PN9_G01I]M,U*UC3_.;:@CST\5,Z,L%?;ZVYJO5*R_9+#2U58S6(
M6VL,U2F2JDJ+>^H+;<I*LE*5MRDL+D)*XWX *T.)&15'<)*$1MR=FK_7:4<L
MFU%SOU;5LT-=KBK;J*)MP@U=;;[76I0];D-3"D,BI=S*5*0R <S&3?\ JK?S
M7&I/!8NVB<^], \+",>?'#Y5HGY;*A*LAD,7/ZPPF!V$1ISC61Q[5MSW-(:U
MHII%$CY84H!.!3F)[\QG[IP!M<$S--_EW"H@2DHE,^$_VAW8<(>&4SR22$::
M)S2N_+(4LJR%@G)/M1BDB<^!$6XK=LCARJH*T-1FM0U555/W2H>J7W:AQ;RR
M%O+4I64*DE(F2 @#A*44+U@9-Y4>!YG%31F23#512Z'04%,C@,T_5+\8K6[]
M+M/%/E[XHF2G F>!,HV6R>11U<%0N(R6TY)F^Z"9@&<I<A+CC.,]\6-.G'Y5
MCV#2*=J@ZAW$@G-/LY>WMB#X@,K6IJGYJ.4L24)?"!ZYQ6=('5<.13V-UNTA
M)TSBU9VT@Y5Y5*X8%"B9GU"'[*77CWQ%I:TX8J%[@W!=M]+J/^P5]2'M/1UM
MX)S/#_P@O0\92X<HW.ZLH1:6T-,3.1_]&;\21LK]+FX:*?A"[/K.FR^:<M[U
MTOU?24%&U(.OK)6E()F)E(F.$8]<[C!E?Y;/&J7_ '2T?3YO,U&R\4_"6$N8
M@F6$T8^N*,CW!Y':K+F743C&6BK<,PE19M"-B2[L\XJ4YAE1GW?!QA&N>X5
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MQ9R@J,^Q4R.>(Y<(J%CAB00I#([40RI'9B/E3]BPN.>):29X"9!/=]\-%2<
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M1"ZN@0\<#FJ=P_3'@16JF0@IPD4@<I$2PCIHA A#3^2,%1\TDT.2[-Z7R/\
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MKOC-5:J;RA6/"1]YG%]LM"(^RJQ#VZ'4R453TBZQY1F<@4)X3D)]A,;?T_L
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M)U)KP-)3#GZ_MQQB=5G9'V+,(H$LG"1X$ <@9]QGR@4[<@H6X6]R9J;:?+J
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MQ+#EZHQ(P%%<MY7R&KCF5!U5N3E*\H !(D<,)8C'M,1.<X&@*MEK:Y8JG5-
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MWS05,S!&/+'#T8P\/+10)A%#0*OK2ME101WX@^C\(E8[4,4!'AR%@B8E A8
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M)S0ARDJ1Q6 ,L.4_1WQ6?&6BJL-E:30J=2<R0<)\Y1'H<!525!R68:E0@0A
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MIW5B4C5MFM[[S8(J*VDI&F;TVD>$.N-I2VFI">9Q[82VZAO+J)@NGUTNK_\
M%1W?3L-K*Y]FRATIQ?[$K3-NM&JK1<6*W2FH4%R@K&ES9F#XZ9YP94HJVA@M
ML\XW*WC?ND0>-.@#,9K7!,8GF.1O\XK@*8>]731FNRP*=#50S54Q"5&D4\GR
MU D @%));X?JF&2R7-@:1DD!3:(YQ^L&EQ'#FNEK3?-.W1EM3;CU#5+2/]&J
MO&R',9!E\3!"CPG*<9*"XM+Z'5(2V7D,/I6&NK6]B^I /MK^-)7=E](RII'%
M!8F%?JJ$YDI()$\L13V!<WN%/MIVLH)1WA2OMXK4=]IJHK> HW?*)5D.7-)!
M$TXS&,N/?&+=9S,.FBSD=W;E@H2M<5=.@J3G;<21.>::<9\I<O3#1 YL@#P:
M*0SA[#Y1&GM4S8K/3HJ5MK*VFKHEME];?B"*@9TT57E/ZU.XN4QQ02#.-EL+
M*.1P$1-?RJ\NQ:[N4XB#729ZL*<Z<>Q1>I-1MZ*_ZE6&H9K=1J2V+G<$ EM@
M9BHTS>>69+A_M>WX>$5=\W1VVO\ (M""2,SG\U%D=MVP;MIDO X,_>X>RM05
MJ)]NNNM4NXW-Y=565*E*?<4E+:3C,(;9; ;:82/A0 $@XRG&BR3S2R&21Q+B
MMO:6V<;886MH#F1BBKMTI9&U&8(/+C*(@#2BB+=4OFNQ=RX*)>MGF9IH<3*<
MRJ24R&&!!G.(O,.2GC:&8MS*@*ZT(+> FE1)*29X@REAC#":XE6@214JL55I
M4"H-MIXS&9)D!W2EV0B8]VDT"BUVKQ)\,RI,R#V]V';$D>94,CW4P39=J!;<
M*D 9/$))\1)XX&4XE46MRAZFA3Y69*,!(',)&7ZQER$-?X3RH4K7DD#F5KB\
M4Q%0D);!D2A67B%3&;MP[(P=PYG,K+6\+J*M7BJ9H*-;SZLJ$-E1!EF*I$!(
MX'G#8F%TXA<"2>2FNB^W9YA(T#FM96>T/WRL7=JIN2 HIIVU A(;G-(2#B.$
MX])>E_14FF/<;II$#AJ:>-*G/!<4Z[ZD@<YUK92?SBM'#A7L5P=ILAR)   F
M9$D B8(QG(2'".^2-8PAC/"!1<QC,S._(:O./RJ)K*9*T%0.4B<^./LEPBG<
M^$>]9JPN-;G"6@H!2BJ5<K(DA>  E/A,C $3C7[IY8"X9K:K(:W@?DJT;9:-
M<U#<UWJI:*K79UA1SHS)JJTD>6WC@I+( )PC7I27S#5S5F_N_(;Y=O0APH:K
MTXZ<6%#:+K]3+CTJ:$EQS'_MYNCHS//@(K7P'Q-FWA\2[_5YUB+8=VXDQU>4
M/M8T^0K()3 [S]T;<M6\L\T8NR$_,&'=!5'EGFG352E0"ISEAQ'*1@.+:)CF
MD&B>,U"22.$Y<Y]L5'-;'XN]5((FR'O<%:;1?*ZV.!VF=4 B2LN8B83*8!$N
M,8ZXAC<VM,*JY$&-P8*%="Z.W,35>4S7@)6#E\:E#AB) \9@QK=W:R&OE\LJ
M8GWJS&3K%3A5;YMETIJYM*VUMD$#+E("DJXA23R,HQ3F-B'ZYVEW*BO N)P&
M">7K<^RZ'H14ZDJ?,:6DBAI&B%72K4F<FJ5G,%+2%"1<7E;[51FM@Z;W3J6[
M%OM4;GVY/UA! ^3_  K'[QOVV[-:F:XD!N1_DZT)]_\ @7(6X6]FI=P"]0-J
M%ETUF(9LU,H^:^D&6>XU:<CKZU)$RVDAD'DHXQZ+Z5].-GZ<(FOF";<P,3D
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M,3[MM<;)O,V^1@;R6,-TR/&<D>Y=(T&L[K0("$.HJ&3E_<5*5.-R(^%!R%:
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M]E!\JU5<[_<KU6/7&[UK]?6O*!6_4*SKE+X6Y94,LH."4)  CO.WV5IM=O\
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M1-]$L5-G6NF RK2EQ*D)!;4V25)((P6,8\D=4L,(%M,UPE:"#AAGP/%>JNG
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M0GE&ERPRPW?ZUI::\11;9;WC+L:PX%O85LBQ:O=;:%/4F2$* 6M)DE:. ()
MQ[HO17<C7<=*BGM(GXBA5F1?G"24*2ML&90%#!,^0'%4O?%D7<ID+@#I5#X3
M3@ :)9=T8<XJ3(\4YP)<\8R4=W5O?.*@EMY01H:XCV*MW0,NS\&9O&9S=@/
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M8HXI@D? )<9^+#WP(Q6?)1W^V!(CA"1*7$<#,P(3I+ZIC,)\)GG^4"$_"@H
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M"!"52HJG/E*!"52HH(4"01B".(,,F@#F52*88K@^KRW?"X$I"5<G)#M_:,4
MW1W5>@^K]Z?"(I<PK4>11<@[_=^41*1$(D2($+*4@@DSA#D4JU1O!1AZP6YX
M3"F+LA,P!@E]AQ"Q/OR@^J/6OW/-R+?4F>TKA^S'?@1@M'TB1)*9X"?N$?0N
M#ZIO\$*L[,^U2Z&R4@\OR./*&O\ $FE86A0EEQ[9_HAB1+MH$SB>$"EBS*6R
MJ Y9>WGQ_.% )-&Y_NK\RLQB-SP)?!^ZGSIW3U;U.]3OD)>53ESR4N@%*,[>
M102>("N,:AU%TILW4+"S;6@;A0U/;1;KT[UCN&T/\G<7$[?44'8M):UTYJ&I
MJ:B\,VNI?HGEOA;M*/-8!029F7PJQ]<>8>JNA=QVF[_G))7IGI3J';=VM?YL
M %SQ4ZJK=/.UPN%%7N6L.,L_,MT;SIHZM]?EM-*<" E*5NJ Q,:0=JN:TQHM
M_;8-+0[@0H6W[XBF_C=,+'=[E7V.DJ:NJH7V6[955K-'Y"ZI-O\ FU)^:?8I
MZE#N48K;FH<#%V&T,<88_P 05&?;)C*2SP_X%LO2^XUHOE2:2NIE6JK6TS4I
MITU+=:XVU4-(>:4]Y<DH.1?B )*3@8222*V(9)2IQ5.;;[F,4KF%LOY45+97
M;:]JI92"5M%>9X2')"L9=\-9=Q./ZO K#2V\L3JR' X*JU],\E2LP!G,D_LG
MN[IQF+>?6-/-1*H5*1CG .)'H'&?IBP<D*,<<;!41AE &'=/C$" L,NK<<*<
M#ED1RGP_.$S".Q2"49DE1\)!D0,>0BY;PAQ#N)44TVAM.2D+59;A?*YBW6QA
M3]0^J78VRV,5OOKX-M(!Q)C;-AV67<[]MLRNDYK5=\WF/;+0SR>-4?<[4.G-
MK;FS9-3IJLCS:5_Q6F;#K3<_"LN-Y@X&DGF)RC<^INA[S;K!KH<C6OLI5:]T
MYU=97<[W3"I(%/E59<39=1VD7;3%VH;S;W4>%ZBJ$O!$QFR.-I)6RL#DL3GA
M'![I@L7O;-B\G3[S@%V';7&^C!A\ &KW#$K7UFV\?K[FB]7(966YBA;6F9 4
MK%V7PE2Y83X1W'T@]/FN<=UW<:JG5'7@X8M^=<(]5?4!Y)VC9SIP+)*<C@?F
M6RG;&A#82IPDRD L"2I8$X8 QZDCD,-O\*O,LFWW$US\6,U7'[5XBV0XA*B1
M,@2[8F";.PP"KN[\_P!"C7;8TE65M)+I\().&.&">'"+#/"M:OOYQ(.(JG=+
M9'54ZG$L.ES(YY<L%%2#($#@4B<XC$\(G\F3/357V[9*R%LL6 ."Z2Z>MOZE
M3%SUA=F5(=J75V^U(=0 Z*=L)35U$B))+C@RB7*<<XZQWMCR+&/(%WT!=7Z.
MZ?? PWTF9 ^:JZA3:/):6ZL$@3(493QQ&([8Y] WRP6<S5= F/F.#^0HH&K:
M\MMTSG-*BGAQE.1 $6&GO!0.\)]BW%L@X/\ #+K%<GX/]7G2('>?];3IF$Y]
MQB"[_I-K_+N^QE4EK]3<_P B/M8EUQ\N/V?M[(IT]JO512R!,9/RA*>U%?W8
M*B[@ZUTSM_8'KUJ1XH;(6W;[>T4FNNE6$^&DHVE<22?&L^!M.*C&<V+IW<^H
MKQMG TFQU8GMX_@6)WCJ"QZ?MG74SA\33 'EP7E5N)K"Z;CWM^[W)+5$RE2T
M6ZV4B0BDH*4J!2@2 4_4+E-;JYJ4<)R $>K>G>E;'IFQ;%;T-P\#7S%,OI*\
MS]0]17/4%YY\M1""=/;7/Z%K9RB4U\/BEV3X=N/&-B..)S6MR>&@YI%*%3$\
M,>!X_C"99*%OB%4\0T"#FXSY'T0*RG"*8 \)X<C+[Y0J5+):$P"</V>?#A/A
MA D2GE-\YCTJ$X$J*4LCBHCU'\X,$E4F54Z<5$I'":B />81"+YU)_TP'T+!
M/WP(2B*BG DE6$_3CAV0):)1+[:S(3]8E^,"$[2H&0[N/+ 0)$>!"$"$($(0
M(0@0A A"!"$"$($)@_0-N@J2<KG*<Y*,N D,#AZ($JCTAUCP.I*0,/R]\"12
M:%H6  >7/[H$J:55"AT9FB4+D9\)$\L!V0M4F"A%,.,J(<&/;V]_KBR#@JYS
M61$[/"FHBT)<&57PGC$<@Q]R4)F2Y1+Q4I;1D)\>??#,%)'FI)#B'!-*I\Y<
MX6JDD\*4A1F/:JZPM 6D@^K\8G2!5ZNH'%**DRPQ(QX8]W;%@%0<57G4*0HY
M@1RA4JRCAZ_P$"$%)*I2A4(DBG$\.Z!/9FIC3^55]L4QX3>[0".[^(TP,:[U
MA_PGN?\ 8)_LW*Y;?TF/^&/I7L@L *4!.25%(GQP(_./SP/PIS\VZ_C.73HC
M6T[*(AXF&C)2H0J$($(0(0@0A A"!"$"$($(0(0@0@(>SQ(68E2(0(1TJ"9S
MYR@0C\<8@.92K(,C/L[81"EJ6M&4-NDX2"5GL/$'N'**T\'FT..'8IH9-!Q4
MG@<1[>WT=T8][2W##Y5EA*'LHA#$B$"%KG=1.;2BN&%QH./^4Y'I#[K6'JF:
M?^#W?T1H"T#3(.1/ _T1].)L)WT_./TJL<_>IQM!R)X#CQ])[HJ/\2:<UAQ"
ML,)\>'Z88A*L@KF0)8<_5V3@0E\BNX]P@3X_&$"VN1\/* .T'6SQC$>U6':J
M8>+@G=+>+I::9]JF::JV'U!;U*\D*"YE/F)0.Q:$RCG_ %CT_<7[3NUL*[E^
M;V^Q=3Z"WVTMV"UW-V@_(M!;WZUJ7K?=[?:-)L4+-XI&F76Z>A\QQ%2W)::A
M,F5-S14M(<_:F")QP+=IM\<"RYLWBA(/=I7FO273-GM5X/B&W;= R&KY%PK5
M:%U5?[T_=JIBJ4MQ2UM/O-N,MH2ZE22@H4$E!90XIM)'^YG+P C4WMNC'X"S
ML/!;K)N&V6T>B*1KY&\0<U>]-: K;2DODN*J<A3YGB"@D2RH!5,%*!@,8P-U
M%*^0&08T6'=O#;FH'#!;8H'KC0%MT.*0H'&:BB8YB?.(HH]#B54EC\SO=J=W
M*ZO.-YE349 @@@R,Q\1PGC%R!VB4.Y?B59]N:'!4JKN;Q*@,)@E1(XD\><XR
M GJ:5S4!MR!50(JZE:U()!1*8XS(''LQB90J;HB3EFA:9B<RJ8Y<N$7+> ^(
MJ&X\/:KA:;;6WBKI[;;J;YBJ?6)2GE;3@%.O*^%#;?$D^J-JV?9KS<;IL=BV
MKB>]V8_B6K;SN5IM]L^2^(:T#N_)^-=4Z0TK1Z4MY82//N#\E5]:I(S/+'^Y
MM*&+=,@\!SXQZ*V3IJ#8;9L<-"]_?=V.I0CYEYVWCJ*?>KPS38,9W&=K0:U^
M4KAOK6TL\X]9M0,HST[S:J9]23^["D@9$'O4!+TQE-ZA-]8:1G'4_***WTW>
M!E^&_G4'SKA#IQTGK1[?*W6_3+M32V%]NHKM7,+4I5M<LK&8N%;:B6A4E]Q(
M;4)*G'#F=',WC=VNFPA#B3[L0NN[GU6_9++]3]<6T]QP*]/+C:OEWG*2G82E
MA*<R F0 0KB.TJ&:/0MHR+;=OBM(,FT"\WWIFW.]FNIO$\.50K[8IM*E%,I$
M\9X\>$9BWN L4R$V^!5-K<4D(& ,\F&:?"?9*<9*W@)-5KVYW8G!:$SHK>VZ
M^AUU)SH*9A4R)DRY X2,33R^4-')4]NLR'"4\<5M:PZ=K;S54%);:;.[55=/
M3@H4)):6X$O.J$YY4)\7H$:_N%\+>W=,?8MUL;4WMPV,+N>W:=IK1;Z*VTS2
M&J>C82RA*9("E#%QPSQ)<623Z8X_=W N;I\O E=;M[<VUJR+D$TNR6V4H83@
MI8&$^SC$3/$G*JUEO;<1Y:@98R(.$SC/T3BP/$$UV1]BW7LE:4IVOZPFPD_O
M-@-(@]TNJ_IJ6/\ R$078_G%K_+N^QE4MK]1<_R(^UB76WRQ' 3[C*,7J=S6
M7TCDM;[E[A:?VRL#U[OK@54.%UJT6IE2?GKQ6)3X*>G020EI!(+KI&1I!F9D
M@'8NF>G-SZAW%L<0<+8.Q/ A8/J#?MNV&P=+*6FX(P'$%>5&O->:@W'OU1?]
M0OYUJ*FJ&WM%0H+51!4VZ.B:),FQQ6L^-U7B5V#UML73EITS:,MK5C&RTU$@
M8U.?T+RYO74-YU#<.FN7O=#X0TG"@_\ BJ7E3V",S0%Q?^6<SS6'J0T,_(&0
M6"A*N,AW_AP,"2@.!R3*HH4KFIM023S E+#CR@3'-%#I\2K5:F\T<U(2VZU.
M84DG..[+\)A1BJ])OSBH1^^W(22,B5 S(R&<O0HIBU\+^^4FMR:F^7)0(#H!
M/((2".<L3$@B8!0@$HUNYINY=;FJ<ZI8F)2 3[B"90>5'R"0O=VIO\[6J^.I
M>,N$W"?3SA?*CY!&MXXHQ>>4D9G7#P.*U'&7IA\<,1=BT9(#W<THVXM.504J
M8/:>TQ(Z"(-)#15+J=S4Q3U^3!<S,SQF<9#L'=%<QLID$FL\U/4]4@@35)1X
M&*?DO2ZG<U+,5)EQG(@ D\NWV0T@C YJ=N('-2C;B7!-)'#$<.'IA$J/ D1L
MBNSWC\X$(9%=GO'YP(0R*[/>/S@0AD5V>\?G A#(KL]X_.!"&179[Q^<"$,B
MNSWC\X$+(2H<![Q A(O4X>24K0%< "98>^!*HMRF>I9K3F6D2,^0QX2$SA"I
M$LQ49L"2%B1$P9\^Z4A")4J[3I?3E(&)S3P))^QAVH\TW2.(4&_3.,*5X2I.
M&,QX00,1C%ACCI&*A< '%-?3"UJFK,O,!2HX<<<8$H)&2;*96TOS&P93,Y$#
MCAV]\)DEU$BA*=-/)<P!\0XB1'KQ&,+6B:G&54@98'AB/SA=1YH0+95\7MGQ
M[N<6 YU,TV@4+<+:A:5*; G*9E^F)FUTU43ACADJJXA;2R@@B1]1QX\QRAR
MC @\($(2!P.,/9B4M2,D^MCJ::Y6VHP2*>XT#Y/[(:JV7"KGPRSC'[Y:MO-E
MN[6@/F6TC:<ZL(HIK9SOB&8GQCZ5[))6'$A8,PM*5A4YS*TI<F/]E+U1^<R:
M&6WN)K>:NMFHCL+IJ./O!(*ZM:=ZT%<4(12H0(0@0A A"!"$"$($(0(0@0A
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MO(BYL.T7?4>ZV&S;>W5>[C,UD;#@15P:2_/2,:UQPQ271-K"97D8-)%.P57
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M "VCIG=7%IM3D5UZ4 XXX]TO<<1./F8&SMHR?Z[Z1^2?>VA6]-:&-TC@CI
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MJ&F*AI:B1F6A 3P&8F8/NBK9^6(C-(,1DI[IU)1%P=@O,[J<W+3L;IG6FXE
MRS5:AK+NQ8K0AY.9+2'%BHN%1*6.2G0H>F.F].64NZV3G.^I#2?D%0M"O;:5
MV^1V<!I(^I]P%4YW^WP9MFVV@F-$W!BLNVY]CLRM/U++[;CM-;[I3-.NU[*D
M**E.%#WD\BA8GRBYTAL[+Z^FDD&%O5P_Q:G\"Q/6-]=VMJ;22NLL(/OP47J'
MI_:U#I#;_13+BJ*W(8:NFI*M,E.W"K6"Y4^>[\2WWGYA2U3F(G@ZA@VY]UI'
M$K$GIZ>:"UNJXZ0NZ]E-L[%H33[+=HMS5 RAANEI4,MA 2T@>-Z?ZZWB./$B
M.2]1[S=[C-0DT)75>G=I;MT6L9K<RU!3I;23,&:C/Q)43A)1X2G&OQ M=1V8
M6?+]9U<2O,?JR5J;0VM4FQ:MO5OL]ZI%WAFR6NYUM$U;JDD(JU&G8=0B=6OQ
M@CXC&[[+:02VSII1W@XCY@L3=SSMN1%$:-+0?G*Z;VPLUSTQM%I2EO=767#4
M%[I#>KK5W.H?K*P+N9^8;IO-J7%NH334I0,LY F,-=>4+ES8ADK;8Y&M#I#6
MJG]/6VE=N1><82KQ#%0S?%,DR5.9BN_PI5.W>IITDMMMLH P 2RW/VY9Q''X
MQ[4UWA*VWM$EK_#KJE<#:9?X':8S*R(X_P"LKL 0D^'M$%W_ $BU_EW?8RJ6
MUIY%S_(C[6)>*\>WEX^6")B4"$3R^_W?I@0AY??[OTP(0\OO]WZ8$(>7W^[]
M,"$/+[_=^F!"'E]_N_3 A#R^_P!WZ8$(>7W^[],"$/+[_=^F!"'E]_N_3 A#
MR^_W?I@0BJ&4RXP(18$+"DA0D>$"$V>ID.((E,2,P><P9CUP)54+EIME\9D)
M\M9G,IG*?:1C$T4F@'M44F85'J[9649/F-*4B?Q)$_=Z(L1R:S3L45%'C$<"
M.XX$>F)4B$"$HWS]7XP(3IMP#PR/;]PBRT8>Y*,D\;6)),P)&>,N1A20E4E2
MUKC"LZ'""#\,QE/#CWQ7EC\PU'))BK;0WIMTI0ZL(=[#(S]8BI/'H:#VJ6/.
MJLC;[2C/."1V8S)[/;%52IY,&1!GA]A D0@0A A"!"$"$($(0(0@0F;]&AWQ
M)44+_:Y>L0(3-"UM'RW@4G&7898 SX<($JR\VAP>K$\C[XL,'="**'>IBV24
MX@X_?^46(\&^]02CO>Y-A#BJ[^";K9)*CF&))]IAK\DC/$CMIR) G/&(QF%,
ME(G2)>GJ'J1]BKIG%LU-*ZW44SS:BAQFH94%LNI4.!;6 8I7FWQ;M:WFV7^&
MUWL1C-<J$4*J-?HO&W/(KT+VOW#I=P; EQU:&[_;$MM7FE\*3YI&5%>PD?%3
M5A!/]1R:>R/BQ]X?T6WCTCZX='MK3^R+B8NLKG\B*%U#I)RP<7!=4V/<K7<H
MPTGOM&/N6R2B7/@.R//CWZY'ZA^O#B'NX2/XO'8[#Y%EI'QO=^K\(P2<(F)=
M/ >@?=#V>)"-$J1"!"37P]?X&*Z5)0(0@0A A.!R]$.9FDX+,3(0@.2$VBNE
M0@0A A"!",@Y3P)F)2$I^J</BCCFE;'<-,ED3^M8,WL_-][M*4"*NN7PMQ]X
M7$'4!NRW?JQ>AM/U(<M-LJ<U\JV' INX7%DG+1MJ3@NDMZOB(P4Z>Z/J?]SS
MT('3.U,]3NL+9T.^7<A;M\+A1T$-#1Y!R!;45[5H75>^/NY1:Q_59']WN7,H
M,\1'OA::LP(3AG@KTQ7.9]J7@M_['[@#3-X38;J_ELEZ?2VRZXK]U;;D[X67
MB>"*>K4D(<G@%25&E=9;)'?V7GM^MI]"VGIC>Y+&Z^'/U7XUVT^B8RSE(D<,
M,,)@\P3]L8XNT3,)BE_(- NEM,3ZRQ&NO$I(-3P!]T/4B5#0 [^V!*WQ(9!(
MSQ/;]C!2JE.2;*:*I25PGR@4*RE,S*? ?=A%8YJ4(+;\*C/NX=T3L/="7@F2
MV\>/+L[SWP]*DT#-,<(0IC\EE2)))G[N_P!,":WQ)BIN2N/''A^F%!H:J4"I
MHKOMO;!7:E2I0FFG:4X<.!)$ONC"]17 ^%65Z;MS^UJ=JW]?5)HJ5TF>8H*?
M<>WCP$<_L<7X<UT"Y%,%H*XN!2G7"<"53/+%)$_5&R6OC<L<_P"K6X=G6JAS
M3;Y?$FS7/+II@SRJ5AZ9\8UO<_Z8/X/X2KNU_4NK^?\ @"&XI^6;6M \3>50
M/H/WQ<L30.',!/O/-=)%#%F]QK[A5>!WU--?51J],Z)I)K0BWJO%S*3(A^XN
MR94I,B"M#+4IGD8[/M$,UOTK)=6X_6!S!\KJ%8GH]MIO'6)O)J5LV21G_&:0
MO-S;G5E]IK[I"W.W*XU*[5<K9266EJJJIJ$6U+E>WEHZ%IQ2DTU.7'R0V@
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M3(B1$:/ZC>G'3_JGTZ[HOK!D<5O-$3;3!H+FYT&K,8U3+7<)-LNJQ5:PG&F
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M-Q 5YU(\EPMYOU7FI^:RX.84 08^>7471W5?2.Y2;1U+87%I>M):S6TALCN
M:XT&/-;C;7-O=1ZXG FF 3M2<I G.<8)T'=T->P7?%CC^%NI/(G_ "6@^]8E
MC*(9!Y8YIU5B&@U%4J$*A"!".W\7J_$0]GB0EHF!C::RDMCXD"M/<@8G%"#R
M;DG6 P6W!SG4/R43]#:9XH8\A,G!(&)*N0D,<?=".+8FZWU>W_HQJ/Z.#O\
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M6,[0[3I?7L:7?Q:T]Z0F(?Y2/Y?\"34_3T^9=344].A*25+J'VF4"4N*G%)
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M9, <9B<(H7QN9XJ*STRQE"IS)RG#CCQB,M<5&IA)S 2YRXPPBF!0CY#W>_\
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MRGZ3#F6_>0L?/U1&)RSY&<Q[Q$Q@ 1@B?.5'[?W_ )PGD!&",FKJ"9%?+O\
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MC[9MXPVSLG _-C^!/9.;=XF&;3_@7I]MAK%.N=$V>]J4DUR63;[J@$$HN-$
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M*1+B%(*.)((G.<_?$K6@A0/<X$T."84]!472OI+;2I*ZBK>2TA(G@F<UJPY
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M(:0HR);;!\1GWF9]<7K84;HQTGM5>=C:Z_REI>ZUCE0[ESYBTDIGR,N/"0)
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MH*+K,ZCZ:AMVX&MJ"AH6MU=3HIJ6BH=4W6EI*.G9%:$MT]/3M);0D2"4I &
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M3ZPU3=JN_P"J]67F]ZHU+?:]9=KKQJ"^UM5=;O=*M<Y*?KKC5..*E( JD)
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M@.TXD$@U&&7:OEY2MXI2 )Y4]OHY 81Z"XKB."=-KJ$#-/B/AX2A$E5]=?\
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MMMA]1^O'>+=;OY6_\U5/<3Z@/6IKJU/6G7'5;OY?+56(4W56T;D:@L]LJVU
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MUJ:6L *NUAQ2G@1_P>$XU\^G?044SF/VJT^1W_.6?;UWU8ZW!&X7&LC.K?\
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MN19+92M8-TEMH]Q;7JG^'4;:<$LTZFFDC ) C5-U]/>BMZD,^X;;;FX<:ES
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M,X]2U5.XEQIQ:%!1]#;7NNW;WM\6Z[3,RXVZ9NICV&H(R(X$.!J'-(#FD$$
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MBG2S4/7/YJHJ'$J6M1"@![RZ?](O3.#8K:./;K:\CD@8[SY-3WRZF@^8'AV
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M/ZD7YC-0QL#3[1"RH]U5Y"I4ATH=9<0KRW$.-NM+Q;>:6%(<;<;,T.M+ *5
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M2O3"X 9#8W5B"1P$]?!0^Z/3/W8/^&]S_M\?V2\[?>-C+]_VXC^IO^U78?\
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M'4]Q<<'2.J=+!B2<0&U(V_JSJ_8N@MEK(8Q.R+3;V[2-3M(HP!HQ;&W#4XX
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M($$5%"F_RROL1"IGEM1OET=H]IAVMW-+I"-Y:1A+AAS@UNYHTMY+$F@H!0F
M1,8\)@RGWP^-[A<1D',%$CF-LY13'!>\/T]*NA5TVT2'UH+E-K?5S(42 1-V
MA?(EA^L_/UQY0]5X'.ZH)CPK'C^D5Z*]-YHG=.-\RA.O_P#2%V;4WR@9'A4P
M1R&88'MQXQS1MK*XT=B%OWQ,,>+,"J1>=:-,*_=2S(/ARD2)'"6$L>47V;;5
ME0.]3M4$]Z#$0TXU'TKHO3-Q1=+#;JU!!\^F2K YID"1Q_R@8P3H],SFR8D+
M-6,HF@_68T&"E%M)/!/'CB?5SAB%6KY2!ZV5Z%MDI+9(&/ZN/(CG%B![JJO<
M-;1:<0PEIM2TX>%<\3QD>WF#&2/?: _%8[46$AN 5\VSH$-6:X54LCEQNU20
MJ9Q0P$--G$G# QC+][A*T X!OX2KEDT-C=I&;OP!;&+"4 E83+N4H^W&*C"3
MFKJK-T4PD*4YEDE2I3)EES&7NB3\:1U-/:N#^H2\U-;JFXVA"<M/5VG0=8V[
MY:3G^3U-54KH2HD?V9J4DD#"-VVB")MLYX%':3SY+ 7\CI) UYJ*K==#:Z-Z
MW4R*IAMZ2 2HB3@("9%)200<>,Q&#?(]EWW2I80'MT/Q:HJKTO2%:EL$3QFA
M\!WD3@N04#ASY1*Z:1_B*C,,?+!:MU-1FCI*G,/+9:S)64D%*0L$ 3E*1G%^
MQ:TN!.:QTQ+9"T>$%>>^Y%**BO?RMMJ2E:TA>?DE/@3S,PCLC=[$EK &Y56#
MW)KY3CX=*Y]N5N 4"D*5-<@)E:BL8J".\<I]\9L.=I"P8CQH_(9)E4TU0$-I
M$DJ,E.).602H3.(45#AA!K<:#A5/I@1PHMH;.W!5NO"5H64*\Q*B20 D)DH9
M93!S\8J;Q&U\5'"N"N;.]XEH#Q7MCM[?TKV3WVO&<>8SLY9%?&)@+WHVB;(G
MP'B,O7')[J$C=K:/\DS'#_Y4BWZU)^$N?Y%OVL2^;F/<"\G(0(0@0A A"!"$
M"$($(I$Q*!1^4WM1%( !,S D\H=J3@2%QC.D9(0)CG%V:36D#''$_G FI.!"
M$"$FYR]?X0(1)P\/(P2))7Q'U?=$C3450BPJ16O1>X^XNVU967';G<'76WMP
MN-.BCN-=H75^HM(5EPI&W"ZU2U]3IVY6YZLIFG25)0Z5)2HD@ F*=[MVW;DQ
ML>XV\%Q&TU EC9( >8#P:'M"G@W"_P!O)DV^>:"1V!,;W,)'(EI%1[5L)?5/
MU12)_P!9CJ&X</\ &W<R7_&>,>WI7I8NH=LV[_[:'_F*S_>7J7_Q&_\ _N)?
M^>M<:PW0W.W"0&]P-R]Q-=M"1#.M-<ZJU6P"."@Q?KM<&0H=N6<9:SV?:MN-
M=OMK> \XXHXS\K&@JC=[CN-\*7UQ<3CE)(]X^1SBM?       2 &  '  =D9
M%5$M*:0#V#[H$*];>;K;I;/WA=_VFW+U_MC>W"@O730&L-0:0K*K(!D%8Y8;
MA0BM2B6 >"P.R,?N.T[5O$/P^[6MO=0#)LL;) /9J!I[J*]8;GN6U2^?M=Q/
M;3'\J*1S"?;I(K[UT#<OJ+=?-THWK97=9/48[0NH++K36Y^H*)UQI2<JD+K:
M"HI:\A0XGS9F-?@].>@(GB5FR[;Y@-<8&'YB"/F6;FZ_ZW>WRG[M?EA'^>>/
MG!!^=<@7V\WK4EVK=0ZEO=ZU+J"YN>;<K]J*ZU]\O5P<))\RNNUTJ*NX5:P3
M@7'%2C<H((+:%MO:L9%;MR:QH:T>QK0 /<%J<]Q/=2F>Y>Z2=QQ<XESC[7.)
M)]Y4"L3S#O\ QB=GB"KO\)6P=M=Y=X-E+HY>=G=UMR-J[H^H.5-;M[K746D'
M*MP<%US=CN%$Q7D2_P!W0Y%7=-EV;>XA!O-I;7<0R$T3)*>S4"1[J*UMV[[M
ML\AFVFZN+60YF*1\=?;I(!]]5O+4_P!03KKUG:7[#J;K!ZB[I9ZIHLU5O&ZF
MI[<S5,J3E4U5+M%;;WZEM23(A:U \XP%KZ>=!64PN+79MM9,#4'R&$@]FH$#
MW!9JYZ[ZUNXC!<[MN#H2,1YSQ7VZ2"5QZ\XZ_45%34//5-55/N5%555+KE15
M552ZK,[4U52\I;U14.JQ4M:E*4<23&X@!K0UH :!0 8 #D , .P+522YQ<XD
MN)J2<23S)XGM4_I'66L-O=16_6.@-6ZGT-JZSJ=<M.J-'7ZZ:9U#;%O,KIWS
M07FS55%<:4/L.*;<"' '$**5 I)$5KRRLMQMG6>X0Q3VC_$R1C7L=3$5:X$&
MAQ&&!Q"GM+N[L+AMW8RR0W3/"^-SF/'#!S2"*C XXA7O<WJ,Z@]ZJ&WVO>/?
M3=_=6UVJJ^>MEKW#W&U;J^V6^N\I; KJ.W7VZUM$Q6AAU2 \EL.!"U)"I*(-
M#:NG>GMB>Z79;"SM)7BCG0PQQN(SH7,:"17&E:55[<=_WW>&-CW:]N[J-AJ&
MRROD /,!SB :85I54[0.Y.XNU&HV-8[6Z]UGMMJVFIZBCI]3Z#U->=)7]JCJ
MP@55&FZV*LH:TT=5Y:?,:*RVLI25)) E>W"PV_=[8V6ZV\%S9D@EDK&R,J,C
MI>"*C@:5"J6.X7^V7 N]MGFM[H @/B>YCJ',:FD&AXC(J4W+WDW>WINM%?=X
MMT]Q-U;U;:1=!;+KN+K/4.LJZVT+C@>=H[=4:@N%>N@I7G@%K0SD2M0!4"0(
MK[?M&T;+ ;?9;2VM('O!<V&-D8<>9# *FF%353;ANNZ;Q*)MWN;BZE:T@&61
MTA Y#4305X#-:=OE&*FB63@4$%"AR(QQXX3$1]4V[)8&2-:"YE"?=BL[T->R
M079A>:1O('RX*#TKO;O;M.BLH-KMY=V]M+7=*@U]?:MO]R];:*ME57R2VY4U
M=OTU?+91U%:I"$A3JT%9 $R9".?7&U[5NC@^_M;:5X% 7Q,>0.0+VDT761N&
MXV<ICM9IHH*_D/<VO;0$#YDWN6N=7:]O#NKM=:LU/K753[C*+GJ;6&H;QJC4
M->RE :I$5MZOU;7W*I13)2$-I6ZH(1@ !$>W1Q;=<-AM8XX;=KL&L:&-'^*T
M *3>/,O[5TDSG22$>(DDG#B34K?&A-S=R=M7ZNY;9[CZ_P!N:V[4C%+<ZS0.
MM-2:-J;E3,*+K5-<']-W.VNUU.P\I2D(=*TH420 28Z7\#M>^VS&;I;6URUF
M+1+&R0 G D!X=0GC1<0GN=SV:^F?8SW%L7&A,<CXRX9T)814 Y56QU]6'56D
MR_UG^HSA/_EQW0[3_P#-3&.'2G2KB=6U;8*&G]%@_P"8FMZHZG(K^TMP_P#N
M)O\ GHHZLNJP$$=4'4:"#,$;Y;H @C@0?[U8$0O]TND__"]M_P#M8/\ JT[^
M\_4__B6X?_<3?\]:(N5977JON%UO-?77>Z7:KJKA=;G=:M^XW&Z5]<\NHKJZ
MXUU8X_55U965#JEO.NK6XZM14HDDF,_"QENQL<#6LB8 &M:  T#   4  &
MP R6%D>^9[I)G%\CB2XN))).)))Q))Q).)XK>FUW5KU3['4(M&SG4?O;MI9D
M )18M);DZHMNGVTX&3.GOXB[9&1/]BG3&"W7I/I7?I?-WK;+"ZF/Y4D+'/\
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M)5G2R6?"LDGC,XX2A/+-3BJIS6LM2L*71UC(FH%M("CV%!#@]<HO6PH HR\
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M/APJYJNISU 9"L$I E/XE3$Q+G*+-JQS22<B%C[AP)PYJIMI<2[Y22I)7EX
MF1[ !%VK&DF3P455S2X4;G5-[_HFKU?9;QIRM<4BWWFUUM"\I(_>)+U,MM"D
MGB).*'LAMA<,M[H.)HS4/DJGW+#)$&LQ-%S/HUFJJ],V2GKUDUMKHQ8*_&:T
MW'3K[]FJ0HS)'F&D"_0H1L,Q'Q;?^D\*PCFEK_+/B5K;9+-*^04!>;'*HE67
M@>,Y8F( ]CG$-/%-5.U%3-)MJG?+"5*66R!QRRG,J3CS,6H7M!H5 [Q%<A:A
MHP*NIIW%YPE+KI"1/(5K.09E<5 <APC-P=X:ADHWD::<5K>XT #(;,D3(FK
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M5,%(*L<> )&&,$Q&@BO%,9FK355R*.F5F6$!1RYBH)E/"84>'&*E'TJT$N[
MI=3<RN(K(@VK<C<+3&18HJR[-:RLA&;(]1:@:+-Q2U/BIB[4I4J7#.!&XSZ)
M+>WGA(?(P#53$M]M,O>L%-_2B[\E;#KJ)NG8=3EE/-CVIFG+,QCH'!SR01GP
M4;L,UI_6ET33V];""7'E)!0E !2 H$3)'ZV'L$9RW@U4/-5WXN-,ERU<W%52
MC4.9$^<I31*9*4"/"2I(X!7*,Q&T1MTY*O)FJZ[0MNME"@I1&9+84F4U)YSY
M@P\O((TXIG"BI-RMCU00F4DR4VL 2&!Y*'"4N/.+\4VH:2L;/&]QP!*CFK2I
MLO+;"G2D)3G*2,XEF 6.1/W1+5M<U-&TAF(*Z*VAIUIVAZJ*0Y2ZYLOI5X I
M\*0GJ3V")">64@=D8?<"/VA8FN'Q+O\ 5YUEK(CX*[Y^0W[:%>#Z/[=S_*_&
M/9J\@A30X#T#[H$B,.(](^^!">.8$#NG[8$J;)^-7K^^!(EPB8G/W?IA4+/E
M]_N_3 A#R^_W?I@0LA!!F%2/H_3"(0*EI,BHG[<(*!"QYG=[_P!$*A9S]WO_
M $0A9KP0AG/H]<)Y'L1J#>]R1<Z^T^V#R/8E^)',IY04URN==0VNTT=;<[K=
M*VDMMLMENI7Z^XW*XU]0W24-NM]#2MNU5;75M4\AIEEM*G''%!*020(J/CCB
MC=+,YK8F-+G.) #0!4DDX  8DG #%6HY))'MBB#G2N(  !)))H  !4DG  8D
MKZ?NC3^70U?KG35DU[UD[D7O; 7>FIKA3[-;;-VBIUM04=0CS&V=::UN]/=[
M'8[N6RGS*"@H:TL9LJZI+@4VGRYUI]XRRL+I^W]&6T=UH)!N9M0B)'&.-I:Y
MS>3W.;7@RE"?2'27H+>7MNR^ZMN'VVL BWBTF0 \))'!S6NYM:UU.+JX+TU>
M_EY/IYKMAH66=]*2L\O(F^,[M5+ER2N6#WR]59:BQER>,C1Y/ZLHY</O"^H7
MG>8XV!97P^0-/LJ'!W_*JNB.]">A#'H O0_\[SS7Y"TM_P"2O##ZG?T9;ST-
MZ 7OUMCNC5[F;,,:@L]@U!:=7VZDMFX.BZC4=;_#[)6+KK.AJPZKLE1<5M4S
MKJ*>W5-.Z\W^Y=05N-]S],O6:'KC<!L.YVK;7>3&YS71DNBD#!5PH[O1N J0
M"7@@'O T!XQZB^DDW1MB=[VZY-QM D:UP> )8R\T::M[KVDT!-&D$C BI'C)
MMSMWKW=[76F-L]LM+WC6VO=9W1JS:9TO8V!47&Z5[J5.*"<ZFZ>EI*2G;6]4
MU+ZVZ:EIVUNNK0VA2AV7<=QL=HL9=SW.5D%A"W4][L T?223@  2XD  D@+D
MFWV%]NM['MVW1OFOIG:6,:*DGZ  ,230  DD +ZFNF;^6[L*K!:[[U<[S:@=
MU#64[516;<[*JMMMM5D6XA#@H+CK_45JN]9?:M@J*'C16^A92M)\MUU,EGRY
MU-]Y"X\]UOTC91BW!H)KFI<[M$3'-#0<QJ>X\P#@O273OW?8#"V?JF[D^((J
M8K>@:WL,KFN+CSTM:.1.:[:J/Y>SZ=[U$:5JV[UTE0491<Z?=NYKK0J7]J&J
MRVU5LSSQD:<I[I1I#?O">H8?K+K(M_--NVGS$.^=;B?0CH(LTAMX'<_/-?G!
M'S+S0ZO_ .73U/HG3-YUST?[EWG<Q=HIZBX/;/[DT]HI=8W*CIT>8MC1^M;-
M3VFR7>\9 ?*HJZ@HO/*<J:KS"E"NE](?>*M;ZZ98]86S+8/('Q$)<8VD\9(W
M%SFMYN:YU/S*8KG?57H'<V=N^]Z5N7W!8"?(E#1(0.$<C0UKG<FN:VOYU<%\
MT=;05MMJZNUW*CJ[;<K95U-NN5NN%*]17"WW"@><I*Z@KZ*I0W44=;1U32VW
M6G$I6VXDI4 01'IECV2,;+&X.C< 0000014$$8$$8@C A>=7L?&]T<@+9&D@
M@BA!!H00<00<"#B"O?#Z3_TA]H.NO9'6N]>[^Y&Y&G::V;D73;O3FG-NGM-V
MM:38+'IV\7*\WJY:AT]J4U:JQS4266&&6F TE@J4I96 C@WJOZP;QT'O4&Q[
M/;6TCGVPF>^8/=XWO:&M:Q[*4T$DDFM: "F/<O2_TLVKK39IMXW:XN(VMN'1
M,9$6-\+6N+G%S'UKKH  *4S-<-R?4"^@3I/8KI_UEOETQ;A;FZVN^V-K?U1K
M';O7Z=.WJJONC+:@OZBNFE;GIG3VG7Z6\:;MJ%UJZ5YFH15TS+J4*;=" O$>
MGGW@;O?>H8=BZHMK6"&Z>&1S1:VALCL&-D:][P6O=1NH$%KB*@BM,MUWZ'6N
MS;%+O/3D]S-+;-+Y(I=+BZ,8N+"QK*.8*NH00X TH:5^7;YUMQ*2F12H!25!
M0(4")@@C @@QZDH1@<UYOSQ7TT_2A^CSTM=:W291[\;S:BWB9U5>-?ZYTRQ;
MM$ZML6G+#;K7I2Y-VND4W3U6D[S6U5=5+2MUUQU\H\02EM(22KS'ZL>LO5?1
M'5QV'9([(VC+>)]98W/<72-U'$2-  R  KQ)Y>B/3+TFZ:ZPZ7&];Q)=BY?/
M(RD;VL:&L-!@6.))S))IPHO SJPVKL.P74UU [)Z:N%UNVG-I=V=;:$L5ROB
MZ1R]5UHT[=ZBCH'[J[14]'1NW!5,A(=6TRTA:P5!"09#T+TCO$_4'2^W;Y=-
M:RYO+.*5[6UTASV@D-J2:5RJ2>TKA75&UP[%U'?[/;.<^WM;J2-I=346L<0"
MZ@ K3.@ [%]-72C_ "^'2_O'TU;&[M[B;O;[#6.Z.V.CMQ+S3Z/NFA++IRW.
MZSL=%J%BTVNANNA;_<?)M=-<$,%UZK<4^M!<D@*"$^7^K?O%=5;-U/?[/MMG
MM_P5I=20M,C97//EN+"YQ;*P5<16@:*5ICFO1O2_H-TUNW3MENNX7=]\7<VT
M<KA&Z-K!YC0[2T.C<:-!I4N-:5PR6_G/Y:?HM4A8:W?ZFFW"DA"U:FVT<2E7
M)1;_ ,+D9P.R8C7A]YSK>N-EM9'\"?\ Z]9T_=VZ/IA=[E7^'#_U*Y-WS_EE
M:VDLU?<^FWJ6=N]Z8;==H]';TZ8I:*EN)0A2T4J-<Z*"3;WW5#*A3ED>;F1F
M4D3(VW8?O0L?,V+J;; R G&2V>21V^5)F/9*#R!6K[U]W)[(G2]/;B7S#*.X
M8 #V>9'D?;&1VA?,WOEL/N[TU[E7[:+?#0]WV_U_IU2%5EFNB676*V@?4XFB
MOE@NU&X_:]0Z>N0:4::MI'76'<JDY@M"T)]/;%O^S]3;9'O&Q3LN-ODR<W,$
M9M>TT<Q[?RFN (]A!/G7>MDW7IW<7[5O,+X+Z/-IR(.3FN%0YIX.:2#[00NI
MOI@]*6W_ %I]8NAM@MT+QJNR:)O>F==ZDN]5HJMMMMU$^K2=B7<J.@I+A=;7
M>J2B9JZI20\OY9QSRTD(*2<PU3U2ZMW#HGHRXZ@VID+[Z.6)C1*'%@\Q^DDA
MKFDD#(:@*YUR6S>F_3%CUAU;#L>Y/E99OCD>XQD!QT-J "X. J<\#AES7J)]
M8#Z1/3-T+]-VE-[-D-1[MOWVX;MZ;V^NMFUYJBQZELM5:]0:?U7=55U-\II>
MR7"BN-'4Z>0$D/+:6AQ0*)A*AROT<]8>J.O.I9MCWV.S%NVS?,UT3',<',?&
MVAJ]P((>> ((&*Z3ZK^E73G173T6\;-)=F=UTR)S97M>TM<U[JBC&D$%O,@@
MY+YNH]+$:A3FO/==./)>S?T:_IW;(?4(UYOI8=\[WN%;+#M?I+1ESM-#M[>[
M3I^HN=PU;==04-0NZW"YV"_.FEHJ:QCRVF$LJ4MTE2R$A)XKZY^H6\]";-8-
MV:.W?)=RRM>96N=I;&UA&D->T5)?B37 8#BNQ>B_1&U]8;I>R;H^=C+:.-S1
M&YK:E[G ZB6N- &X 4SQ*TO]=/Z;NQGTZ]Q]@;3L1?-QKK8-V=&ZXNU[H=Q+
MW:-0U5LNNCKSIVAIW+5<K78-/NBEN%)J ^8T^AY2%L I6 HI&A^DG6VY]66U
MU^U&0-DAE8&F-I:"'AQ-07.R+<"*8')=?Z[Z9L]GGMQ9ND<Q\;B=9!II+0*$
M 9@\5XR;9Z:U/KK6^F- Z*TY>=7ZLUO=J/26F]+:=H7[G?-07B^NII*&V6R@
MITJ=J:I^H6,HP2A(*U%*4J4.I;P8-MA=>W3VQVT;2YSG&C6M&)))X#_X+3K
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M)2[_ ,(1"*@@&:CR]\/:*G%"5#Z 0B8X\<>>,/<&@(2V=)X&(:A"-"H0@0A
MA"!"$"$($(0(7W&_RX-GH:+H*U7=F&VQ77[J,W$>N#R0/,<_ANF]!6JC;</$
MAFFI04CEG[X\)?>7GDE]0(87DZ(]MA _QGRN/RDKVA]WN%C.AY96^.3<)2?<
MR)H^8+QT_F1;Y<;AUT;>66I4O^':>Z;])&U-&?EA=ZUYN'4W)] X9WG*1I"C
MQ(:2.0CM7W9((H^@;F=OUDFYR:O\6*$-'NJ?E7)?O"S22=:V\+OJX]O9I_QI
M)2?EH/D7SY+!G,<)=W*/1#_ 5P4$^93@KE:D@LH)'(?A&%N/$%F+8  T7Z'G
MT@+926KZ;72BQ1MH0FJT'=+J^4 #S*V\ZTU1=*YQ9'Q.*JZM<R<8^=GK#(^7
MU*W8OX7#6CV-C8T?,%[P]*HVQ^GVV!N1@+C[72/)^<KXS?JM5U=>OJ+]7-7<
M''''J?=/^%-%<R44%FTKIJU6UI.;@VBAI&\LL)1[%]*V-@].MH9%0--KJ][G
MO<[YR5Y-]2W&;KW='2XN%SI]S6,:/F 7G^PP0J<SEYX".@:G<UH^AO!?3'_+
M5W"M:WHZIK0VIS^&U>V&W-RJ&P5>5\]0:KU%2T:U#X?,^7N+X!XRG'FK[R<;
M#LNUS&GF"ZF:/88V$_. O0OW?)'C=]RB'U9MHB?:'O ^8E;Z_F8::E5MWTD5
MBLOSK6OMT:5DX9S25.F--/50!XY ]1L3Y3E&$^[,YW[0W=@\!MX"?:'O ^8E
M9O[PK6_ [6_\L3S#W%C*_. NC/Y=#_F)ZS_[Y/<+_B;MI&N?>-_X[@_W9#]K
M.L_Z"_\ !DW^\)?LX5P[MIUJ(Z3OKL=56AM7784&SG4?N=I;;W5JJI_RK;I_
M7)T;I1.VVLG<[C5/3H;N]R=M56ZKPHI+F75X,)EONX]#_P![O03:MPLV:MZV
MRVDFCH,7Q>9)YT?,]T"1H_.90>):18=8_P!UO6S<K*Z=IVC<;AD3ZG!DFAGD
MR<AWB6./YKZGPKU7^M)T4#K Z0K_ '32EI%=O-L*+ENAMH:=H+N%ZHJ*AGKO
M0K)S!3@U7IRE*Z=H!1<NE#1@83CE/HAUP.C>LHX;Q^G9-PTP3UR:2?U4O_RW
MFA/"-SUTSUAZ._O9TG)+:MU;O8UFAIFX ?K(_P#'8*@<7M8M:?R\JTN?3<TJ
MM!FE6[N\*A@09*U.%"8(!!D1A&4^\>W3ZFS#_N=M_$6.]!#7T\B/_>Y_XZ^/
M[ZE#<^O_ *UB4S_[8W=3GR_C]3WQ[*],FC_R\V/_ '9!_$"\H>H?_'6\?[PF
M_C%?H)]!(ET0=((' =-&R('_ ++C3L?.SU!_X[WG_>EU]L]>[NA_^#-J_P!W
M6_V3%^;'O6VC_&K>?PC_ )7]T?\ CW?X^FVQM'[#L?[%!]DQ?//>/]L7G]KF
M^U<HC;&XW+3^Z.V6H+(ZXQ=['N3H&\6EQ@J2ZU<[9JVSUM"MI2?$%BJ83*6,
MXFW2"*XVJZMI@#!):RM<#EI=&X'YBH]ME?!N-M/$2)F7$3FD<Q(TCYPOU!.H
M>AHKGL!OG;;DE"[=<-G=S:&X(< +:J*KT5>V*I*P<"A3#B@9\H^5W3;Y(NH;
M"6+ZUM[ 1[1*TCYU](]_8R38KV.3ZMUI,#[#&X'YE\+?\ODVH?4GVH44D'_"
MC=V9)/$Z.;[3'O7[Q7_IC>?VRW^T7BOT(_\ 4.U_LL_V:]_?YDU)5T"Z,D)D
M=3.W)_\ H-W,CSQ]V7_U"G_W7-]I NZ?>%_X'A_WC%]G,OA@*@,"8]Y+Q>OJ
M7_E>U [G=84C_P#()L]_U_U]'E+[U'^RMF_M%Q_$B7I7[MW^TMV_D(/XTJ9_
MS1=O8N6Z?1Y3U "DC0&\2TA1(25#46@!)1&.50,HP?W<[,W>Q[N&COBXMZ'E
MW)5G_6_=_P!D]0;0XG!T$_S/B7L)] 71]NT?]+S8MN@::;=O^H]X=27-34CY
MMQK=V=8494M0)*EMT5O8;F<<K8$<@]9C./4&\@N"2^)D+!7EY+#_ /J*ZUZ<
MW,=[TE;WL5*3.D<?;YCF_@7S$?7RN#U=]3O>95PK:M;ECT%LOI^QT68^12VQ
M6@+;?UKF3)+:[K?ZMR0'Q+)CT9Z!]-NN>E;3=:TA=+-J',B4BOR #W+S[ZW]
M2MM=^N-JI68114/(%@-/E)*\85.*XJ5[>_U1ZB$<;3H:.Z O-,9+JO<>\5G,
MKD?NAVEJE1P[X9%7BD<.>/" -;5"_2^^F'_XO+HS_P"]XVT_XNTD?+SU5 'J
M1O8&7[2G_CE?17TV_P" =H_L$/\ $"_/(ZOZA(ZMNJ<2.'4?O@.?+<W4\?1G
MHVO]T-I_W9:_8,7@'JQ[_P"]>Z4.'[1N?MGKG8U(EX0)\N,;2T C'-:_K?S1
M/F%' @2.$+I:C6_FNB^E7IEWGZO-Y].;,[%::&H=7W0+N-PK:UYV@TUH_35*
MZRS==6ZPO*&7Q:+!;OF$)*DH<J*BH<;8IVW7W$-G5>L>IMBZ/V1^^;])Y=I&
M:- Q?(\^&.-M1J>ZG8  7.(:"5L/2W3V]=5[S'L^R1^9=NJ23@R-@IJDD=0Z
M6BO(DDAK07$!?I:=.V@]<;/[%[5[:[K;FIW7UWH[2UITO>]Q:JV(L+VJJVB0
MIBB4JC76UKM14T]$EJF^8<<54UQ8^8= =<6(^8G4FX6&\[]=[GM-K\)832N>
MV$.U^6#B<:"@)JZ@&EM=(P 7T9Z?L;[:MDM=NW2Y^*OH8FL=*6Z=9& PJ<0*
M"I-74U'$E:KZZ]QNIC:/IMUOKSI.VXTWN9NCI^G%4=/WU=QJ*BATTBGJ3>;_
M *9TU;$LN:SU%8T!#[%I-32_,H2O(7G$HIG\IT)MO3.[]2P6'5MS);;7(::V
MT +ZC2Q[W?5L=B#)I=IPK05<W'=:;AU%M?3\U[TQ;QW&Y1BNEU20RAU.8P?6
M.;F&5;45I4T:?B Z;-":_P#J@]=>D-&;];MZRKM2[L*U57ZMW#^6H;I?+5:M
M&Z3ONI&K38[15(8L=@M3"[8FCIJ1IANCH4NG(R53"O<?4U_M_I=T)->[!9PM
MM;3RQ'#4M:YTDC6:G.%7/<=6ISB2YU,7+QUT_97WJ-UG%:;W=2NN+K67RT!<
MUL;'/TM::-:T4TAH :VN 75GU5OI3;:_3]VVVMW T#NUKO7CVO=?5FB:^R:V
MMNF6/EFF=-7._MW6W5E@HK8K,TNV>4XTXTX%!X*"DE,E:EZ4^JVY>H.Y76WW
M]G!;MM[<2AT3GFM7M9I(>79ZJ@@C+(\-E]2_3';>A]OMKZRN9IS/.8RV0,%.
MX7:@6@<J$$'/->'RVS(G+CAS_3';UQ=V#B D%H5(X<CS'?WQ8C\*0)HI'#,/
M1C^1AZ58(!$N4"%@H3(X<CS/YP(31;6/P\NWO/? A% )X0(62DC$C[H$(L"$
M($(CA(29?; P%"5M_B"@3S,SZX:EX!1M6UY-9F DE1X\ISG+B85"+5-A:0YE
MGQFKV&%X89H2=MJ '"W.1S #\?;")$C<VU-US%0)IRJ3G5W9@1VX$05-*<$4
MQJ,U/O5ZD!HI/A*4DG^F&Z&\D_4[FLO$/M*)5\23X>T2,%&C$)*EV:HM"^[;
M+YE2M26*B25(GX,X"I*QY\HM&-ODDTQ576XRAM3I6PZA14D*)F2$^KN]\50U
MO)6$PS)!E/'UP]"3="%CD2(F#6T0,\<DYLE"NX7BSVU"9N5]VMU"E)QS*JZU
MBG _SO,PBE?.%OMEW.<"&X'E@K$$8GOK2$"H+L>WO+V]OB44[;5&ROP4U.RP
MVG&8;80&$I/'Q)2T)COCSA#"9I7S/Q<Y]:KN$[V,C;$,F-H!R5&73+6I:CF4
M,.7*8[.\QF[:S:<P%A))B"?+-"1BCH1DDD"9/$\)$8]W9&PV\;HV_O5@[@DN
M+CFI9C$&4CX>?;C[IQ*6-<:$9JMK+<> 6Q]F+\=,[M:2KRZ6*>MK?X35*G)H
MHK4%"0HE4\H<2/7&M=9VK-QZ:G\QH=<PCN$YM]E%MO2]ZVPZ@MIV'3&XC5VK
MV3:!<2E9$PM*5 ]N<3!P[8\PY"AS"]#EVLZQD<?E6A=T1\OJBPSGEJE4Z#V>
M&H093[N,92T^J/L6(O/K1[5NBMR@(&$I IPGR F.,8]F;OX2R#O"WGI59>84
M,R2,PXRPX\S$H)&2KR@$"JAD-@.B:<,ZP?\ ).:4+K=S4.D<,T%,3<:6GPE)
M\9/ 2PF._+!K>,0<4K6C4.=4I>:X-T:FVSG*&SPP^),E<OUDQ)#%&]VMXJ[F
MBX7D1NVQ<=+:RO5GR*-O??J+Q875 @BEKGE/5]"VDXENBK7#E($LJHZEL\D,
M]OIH#0+1MV);.-.:U&B].^8/-S&1.>7<2#(GC(B+_P /",-(5=L]!0G%6JUW
MI*P@',1(3SIF>[*<!.<1R6S*:F!2,N>]IK@KO1W-HD!P@I! (,^9P&&.,8V2
M.0' J\',>.U6'Y:GJD>'Q)<$B)3 "L9#GA.&L$C34G!+I;R5-N>G%E3Q3/@0
M"$F4@F0&'9*43,>X.!KQ06-. "N^U%JJ4Z+ZFJ4H,G-EM-I29*E,=1VPRSX>
M)P23$=_,#/8NXBZ=_J\ZFLX2(KL</AV_;PKYUDUZU.J05&23AA(^L\#'LSRP
MO(.MRG&WRI"9%1,AB?QB=K!I&:837%'\Q7;]_P"<.\L=J2J2<=7ACV]O=WPU
MS0,D564J40#,\(5@Q02@4N$Y@??V1(1P15+(S@>(XSY>@0WRQVHJGS2E2S'B
M<,8B2E.AB >Z!(A A"!"$"$($(0(7V0?RS^\%LNVQ/4#L._5LHOVA=TZ'<JA
MH5.)%14:;W#TW;;,]5,-3S.,T5]T2ZEU0P0JH;G\8CQ;]Y_9I8=_V[?V@_#W
M%H82> ?"]S@#VEDHISH>2];_ '<]VCEV2_V1Q'GP7(F XEDK VON=&:^T<UJ
M+^94Z7M67.IV8ZO=-6>KNFF-,Z=J]G]U*NAIE/#3%,Y?*C4.@=0W7R@I;%FJ
M[C>;E0/5*P&F*ARE0I0+R8SGW8.J[.)M]T;=/:RZEE%S ":>8=(9,QO-P:UC
MPW,M#R,BL5]XGIJZD=9]66S"ZVCC,$Q \ U%\3W<FDN>TG($M'%?)JK&7>#'
MKM_@*\L#ZSW+:>F=&ZQNNCKUKRV:3U-<=#Z7N%LM&I=9T-BNE5I/3]UO3JF;
M/:[UJ)FE7:+;<;HZ@I88>>0ZZK!*3,1KEW>V<5['82RQ-OI6N<R,N:)'M;BY
MS6$ZB&\2!0+8;2TNY;22]CBD=9QEK7R!KBQKG>$.?32"> )J5]W7T+MT;=N'
M]/';/3[%0TN[;0ZDUWMG?*9+B2_3KI]2UNJ[*MYK,5H;J--ZJI"@D *D0)Y3
M'@WUWVJ3;O46ZN' ^3>113-/ U8(W4]CXW57M/T8W*._Z#MX&D>;:220N'$4
M>7M^5CVT7SK?75Z?M0[2]=.KMQG[34-:&Z@[38=<:7O894:"IU%9K#:]+ZVL
M7S00&1=:"NM#-<MDG/\ +7!I<B"2/0WH7O\ ;;OT+#MS7@WVWO=$]M<0QSG/
MB=3/20XM!RJPA<&]9]CGVOK.6_+2+*^:V1CN!<UK62-K^<"T.IR<"O&?RT@=
M@XG@!Z>$=FH5R5?83_+K=-NI= [-[M]1>J[156EK?&[:;L&W::YARGJ+EH70
M:;RNJU+3MNH2I5IO^I+\\U3.?"\BW^:F;:T*/C[[Q/4EM?[S:=.6CP\V+'OF
MH:ALLNFC#^^8QH+AP+Z'$$+U7Z"]/W%EM-UO]TPM%XYC8JBA,<>JKQ^]<]Q
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MW)-K":JMJ7'%(\H-#-()"9"-AA]5_6-D#+.WO;P1,8UC0VWBJ&M :T B'5@
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M94M*4K4RZXRI:1,A*U-J25I!)D#,8Q98 6 $ CM4#R0ZHJ"H.K2D3 2 !FD
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M4_Z"TCNF91S#J.X^(W*2$&L+=-#P\(6\;7;L&VQR'QG5_&*Z2I__ "HC#L.
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M!(@E4@ )$"!*O;7Z "BKZ@U-/EL7NA_UPT9'%OO - ]/"1QOH/HD77_0X?\
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MUD&MU&B,GXA!P3C'05JH^K3F2HSEZH!FHDR;^&79+UP)5[<_R_W_ (P6G_\
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MI=$,O/7*E9M NKVJE)LB''+NXPFG\TS-04!'CRQ\^MH@WBXOV1;"VX?N9#M
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MWTZ-E*"GKVZG4NRU-<=D]8T1=0JJH*S1=4K^[:WF@HN(9N6AZ^V5#:B)*SJ
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MWG:LRIPVTE;OJWT7](M[Z0V+=F]2/CBO]VMQ#Y;'!YA8&2MJ]P[I>3)X6.<
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MJI-7:.MJ+JM*05TMWH&44U>RZA/PNMU32P0HSCQ9^RW[5O5[M^)'Q+G,[8Z
M!P[*@KZ [9N<.Y=/V&XZA5]LW6>3ZG ]M*+E'1=<XW<&VG)E"P<V=1)!$I$<
MYS,7)N]&-.-*JQ(1@..:Z3I+ BYM)=IBH+RI,L1.8!Y8SC"2.:'T)Q36>)-*
MRSW.W$)* I,QE)!!F>0GA.$#FZABIG8A5NJ55 J"TE!!,E"1R]H,DR'"+&IO
M/%0Z7<BJB]?'F70RHE)$\3(%P3XC#E%IO>P;BJASIVIXW>W%(FVM)).(<(
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MZ@J.:&$@>5FJW_!T!U:E)0ML2F%*&9./A"4\\91*%5?;]U/*:UMB2/!B$@$
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MG' 82QX0K?$/:H3DMMZ"&:S$)&(JJ@'ECE2>[D(U;>?Z6?:MFV_^A]M%9W@
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MC4',?4TRJMQ88] K6M$4A))),N1Q&![(;0C YH=IKW<DW?<:81YBU )!D25
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MI>!F6-<X.>#3 M%'?DU7'6T>QF[>[^Z='M#MUMUJK5FYSU?6V_\ N5;K4_\
MQFBJK:M3=R5=6:@,(M%/;%(/S#U2IIID":E#".I=4>IO0?3'1T'66X[G;NZ9
MNVQFUFA)G-WYK2^)MI'"'ON'O8"X-C:2&M<Y^EK'D:=LVR;GN^ZC;[""63<7
M.(\IK275&=1P XDT XE=^:_^EAU][77_ $!I/5.PUW%UW0NR-.:-J++J+3=\
MLM3J)=#57%JR7.]VZZ/6VP7%VCHGEMIK'&4.>6H)42(XI#]Z3T@-K+/N,^Y6
M$T>CRX;BS>V:Y+WMC#;1L;I6SR N#G0AXF;&'2F/RV/<WHNX>G76^UW%O:W=
MA()+EX9'1S'-<^A(:7-<6M=0$T<1D>2YBW8V?W,Z?M67+;C=W2]3I36MF6E-
MSM515T5>EM[*VXXTW<+:_66^J73EP)=\IU8;<FE4E B-_P"@O4SHGU4V^YW;
MHJ\-Q%9W3K:YC>PQ3V\[17RYX7]^(N;1[-0H]A#FU!6N[AM^X;-=OV_<XC%>
M1FCFD@T/*H)!I7&A/)>GWT0]A=+[\=:=([KC2UFUEHG;W;36&J[YI_4EJH[U
M8:RKN HM,V1%PMMP8J**J\JMNQ>;#B#);0(Q$<7^]/N;H^F]EZ7C?(T;ENKI
M90Q[F%T%E;R/():0=!N)K74*T-*%=(]'MDMM^ZP:V^B9-90022/8]H<TX!C:
M@X'O.!Q'!,>J/INUQU/]66^M#TF;-V>IL6@&ZN_:DM>DCIW25BT_IEZ]7BAL
M-2*2IJK5::=ANR6EI62F2%$%2RDS)CS]]UKUOVGHOTJW#?O4._W*;9MSZHWE
MVTP,@EN_A]NV]T,4[FE@+F1.N)'.K(XU>2V, -(%+>=DN^H>I=P=TQ:!UO"]
M[BV/2QK(@XAIH2UH&D# =I6@!]*;KWU#M74;P6KI[U$-*T-K>O[=-6W.Q6_5
M5PLU.T:I5QM6D*RXM:@K:=VD3YK0# <>:(4VE0(CT_\ ^Z;TC,C&QS;E)LTC
M6N-\VRF^$8QP#O,<YVF8QM!J^6.!\;0"[46@N6,'IQUK<;6[>(MOF-F&:\=(
M<6TKJ$9(>13$4;B,15:!Z=>FO?7J>O&H=,;*:!K]::AT=9O[P:HMJ:ZV6=RR
MVI%:FW.5%8[?:RW,MEJL5D4C-Y@,_#@8WGKSU8Z'].;2QOM_N)Y;;<F2/MC:
M0ON_,BB9'(^8>3J'DZ98RV2NE^MH:3587I_9-YZ@FDMMGMW3S1,UO (&EH(%
M3J(%*FF=5U#I?Z6G7EK#;VLW/L?3]?W-*TU'4W&F%;=;!;+]>[=2I6XJX:?T
MW77)B]7>DJ6D%RG6VS_I39"F@L*$^>_^Z7TBD$5Q9R[I<[/+&R3XN*PF-LQC
MVAP<XNT3/# ?UCH(9FM(<*G25M%KZ?=97FWG=+>PF-F&Z@3I#G-'%K"0]PIB
M"!B,JKCO;[:'<[=W7%%MIMIH74VL]?7"I?IV-*62U5%1=FW*5136KK65!M-N
MIZ$@^>[4%MMF7C4(ZQU#Z@]%]+=.P]5[SN-NW8;H,^'EC)G-T9&ZXVVC(1(^
MY=(SOM$+7]RKS1@+AI]GMU_N=ZVPVZ&2:]>2 QC27&F>'"G$G <5V%N=]*#K
MYVET1<-P]6[!W5W35IH';G>%:9O^FM676T6^G9+U35U]DL%TK;FBGI6DE3JF
MVW VD$JD 8YGMWWF_2Z[NV6EZ=TVZW>X-%Q>6CHK8$F@,DK'R^0TDCOSMBC;
M^6YH6U[CZ:];[59NO[RPD%JUM7%KF/+0,RYK'.< .)IAQ7,>T725U!]0>C=P
M=?[/;?5.M=+;6L*J=>UU%=K+2OZ>83;*J[I=>MM?7TUPJDNT%"\I'D-.E:FE
M) S"4;9USZZ>G7ICNK-IZRGNX)G6C;HR1VLLT$=LZ1\?G2SQ@L8QIC>YY).B
M-NMU&D$Z_MW3V];S:7%[M=NZ>UMFZI7!S1H%":D$@D4:3@#DJ+LSTV[R]2VO
M'MK=EM!776VO&;;<[M56"F71VYV@M]G6AFXU%PJ[K44-%0?+ON):D\X@J=4$
M)!491MO67JKT7T%LEGO^_7+G;;?R,9:_"QNNGW.N,S!\+(=1?$(AYKI1^K:P
MM)=WVAV+VOI_=>H+W]G;/ ^>^+2[0V@(#<R2X@"F6)SPS4E8/IW=8>X6\U[V
M+T%LI?\ 4FX^FFUO:DH[=5VES3E@IVZM= [57;61KAI:GIVK@TNG*A5*"GVU
MMIS*2H#3+'[UGHA?=,CJ;;=V==,==36PM(H9)+_S[=P;,Q]HT&2%K*M)EF,<
M6E\9\S]8S5';="=3;KN[]CLK.27<(ZZPW26LH:$N?70 #A752HH%O'>#Z7_5
M?TC:,I-<;Y[+.VVQ&J135FM;+=[-JRR6JLKEGY2EN538ZZM-I#BOW:%U"$-K
M4)!4\(.E_O%]"];[W'TY:OO]NW6Y); R]M_);</H7>5%*U\L)F+0XMA=(V5X
M!\MCB"!L>Z^G'4725JV[WFS>RW+@-8+7M!.0+F.=3LK2O!>G/TW?I++WST+J
M;J-W[T;JFNT=;](#4.QN@[9<+9246\=>];KR]3.W.HIZK^)TMJI+M;&&/E5&
MD-27P5+\L'-YP]>?7;J>Z9N?2GI5/<P-L;:[BN;J.(QW,U]$Z:(6EA-*=#&,
M?'26ZC87E[@R&6(M<X]$Z"]+W[Y83[]NT,QLF0E]O&T@?$OH^@K6H:'- IW=
M1.=,V?0QLGJ'9_J"ZI[]J?HSI-[-([96.LT]>++J^ITM4:;VZJ45KMZJ;Y4T
M=[H[RS=:EUC3]6A/R3:DTJ6WFLR2$ICSEZF^M&]=0>A'15[\6SJ#KS;+&X?O
M=HQ\MJ8+EOZB1]W-&'11NL?*EC,4Q,MPV3XICG N>ZET=MUUM>[;A<76SMW"
M&TB<V1DA9HA(-2]VH.!(#'#NY8XKSXM?3'O)U>[W;A4/3+LQ?=04=%>/.NC5
M#;&],V'3E14(0JK-[J[T]06O3KU5<?.+=*MQ"PD20V$B4>MO1[U#MO23T*Z6
MVOU;WD[MUU<;<9VLLW#<I9+:2:0VIBDMP8W6L=N8HH[J61L<A:0)9'ARU"PV
M#=^IMQEAV&TDF<#5P: UK:_G$T:S&M 2.S))]0_0!U<]+%B9U3O1LY==/Z1J
MGF:$ZLM5SL^J=-T=949A3TMTNE@K*YJU/U)!#8J V'%"223A'6.CO73T^ZUW
MJ+8K.6]L=\FJ(8;VW,!N' %Q9!*'2022:07>2)?-+02UC@UQ#NH>B^I^F[<2
M[S9OBM7&GF M>P$Y N87 $\*TKP6H-H.CWJ WNT7KO</:C;>NU7HW;1:1K:\
M4MQL](W9ENT;MS:9%+75U/67!]ZE22ANF;><4J20G,H Y'U#]>?3STSOV;/U
MC<74-Q\,RX>Z*VFFCAADD?$R2>2-I;$"^.3 U.ECG4IB=6V_HW?-TMKC=-I@
M=/:VX'FN&D!F!(S-230X-!*WOJWZ7777H7::LWJU7T_ZAM.B+7;A>KLR[=+$
M]JRT6<(#KEQNFC::X/:AHZ>F:.9X*8\UE()6A(!EK,/WE_2RXW5FVR3;A;V4
MDHC;>SVDD-EJ<[2TNED+9(HW.( FFACAQ!<]K3J6=F]-.N++;#O-]M\D6W-;
MJ<26E[6\W1UU@<ZC#BN$6:<IFK($%2@3CC('ARCO6-:%:XQH8*+W6^F)]*9[
MJ.L5YWZW[TKJIW:&@TY_>#:K3=EN5NH&]Y;O3/7NFJ+95U;-4J[VZU45QLZ&
M7&P*9547@ ZE,U1XO]=/73?FW=]T7Z92SP3V$=S'?73(=,WQ4?=99V$LU8@Z
MNOSKEK'F-P;'$^-]9&]C].O3.3J.&3>MXBF_9#(BZ%K2!\0\:AHK6K6AS:'
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MK;77'2=IW=_A T+6_P 3L]V-S8U"NVLVFJ?8M%=6U%J16.7AA#8JDLJ6ZO(
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MV\S4*0\/"DE9RQL^X?>)]-;?T[?ZD6%Q/=[?\2;-MLR"3XP7YB?*RSFMZ>9
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MC"^XGDC\4;/(+@/.:L!]WW8YK?<[SK*]_5[/:VKXP\X!SG$.?0G,,8TZJ<7
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MP[LT7FZ[#Z?;'MS(YAY@==7L/QK8'-=4/#6[E:Q.8<VPAAP"D],71[!T+O\
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M7M 9V:1_;_1-+IZQ%:1X6\FN=;5>3L6C#$1JG1@&X=0]==1M\,VZ;#T]"?\
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M+JZDE[S=SZBF<Z6-LA.$GD2%]U<#$>8"T]V8+5_67J6TV^"WZ)V$AFV6,?E
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M/=AS5^"UD##DIFF0K]VJ?Q!1( !\6 &!_J@>N#RSS"-!3U29RER$C/ @B6)
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MM#G:-+CJ6:WGJKJ'J1M-XN'S84JXDFF>FI)HVN-!2IS7'!2")'[C'JBJUKR
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MC,P8)*CM6/+/-,_7*"H*4D'FAY8YIEZS *% H48(2#.7O,+1&D(*2"<,/?\
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MEO;BK4UE \0'=,3AP4[P TJQT!!HFI?LD=G,Q2E^L'M4\?U1]B@[."FIJ9\
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M,4KB@#,)61ASGAA$D&=%!<@/@<]WB"JKLRV#QFF<^7 S]\7BM8:2X5.=?PK
M_P!Z-_\ HI]AE#FN(?09*6-H)J<Z*M5:0FJ>PD<TO<#&7MG$Y\EI&_- FPYE
M%944NH(XY@/;@?OB>1H>PM=DL-;.+)VN;G56T)FY2*D<%IQQ_:3& +B7.;P
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M\9@I)]4<<W2WDAW6Y;+Q>N];7=-NMIMI&G$,_ GM8RNN;47W,HP 2E666&/
M@F440UH((S5TN)%$Q:_AEIFZA"5U$O"X$AQS,,,"9F)?,>HO+:J-J2K\NH+K
MK8I6ZML+996M+U2Z1/,M93@DA7+B(LV[&U5:X>0*#)<<;T4J7J-]M<E%<W4
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M:KCK7<W].[2\0[?$:>8QQ+GM&8(. J*@T7T.]#_1F#I#;6]1;M&Z6_F'U;V
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MM-[M=-MO3?FE(?U5N7U&[-:"N(:;=4P]3,Z9ONJ4ZJLE %I,DN43;KH&<@S
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M>EKBT-%!V)XL6N&HNH3VI0Z+LZO[5V\O<CYEYK9$'GE;=: ]4-^/=^:/D2_
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MK204=G8(0 #$#%3MD+#J!*?4;MV94X*=Q]6>82E2LY"#XCE4,I3FG,3GC"$
MY@*3XEQPJ?E2%P:K0A*ZE0;))P5F\P3&;,#,(!F,>XQ;M@!@,%2N'OYE0]DW
M$MVB;Y35US>0Y:JAFJM>H:+.1\[8KDTY37)K* H*<0VX748$A: 1C'4_2SJ"
M[Z?ZWM]SC<^-C7"I:2VH'.E*^]<D]6-@M^L.DKS9Y V5WDNTAP#J&F8!K0^Q
M:@U_I'3E'=S5V.OI;G8W4_-TMQ:53I2:%2P:>M4ZV0A;;Z#B% *0?"?$"(^S
MG274ECU3M$&[0O[\T=2 <B*M_ O@MU?L]QT7OEYTE*RXDW,3%K7.U%N-'#3V
M4(R6LK[KO3M$TI+#K"E.I":BH64E1\L%!4PV1D("D\2,8S\]W;O?5Y <T4]J
MCM^D.I[B**.XA(>&TK3&E:XGFN<]<;TU--3MT=IK PP#Y<Y!!<1G,U99I*5"
M7",/?;K9P1D@@./$9KMG1WI3*YHN-TC+F4! (K0\<^Q:[MF\UW6AI3]P6I33
MBE*:;=*,XS.#/FGF*RA<SC(<HQMMU!;"-SM=3[5NF[>E>V79&F$AO8T?B3JZ
M[ZWZL<R(O5<590VIPU=0A;;81DDTGS4I\8P([#%&;>;"4^0]L?EN-#@./')7
MMJ]+;7;1\320S 5;6N8R7M%TS=8==NGM!8M'T]8VQN!H&Q4UGO1=>2Y5ZCL%
MO;32674%,7B%52Z1D-4E<,5(<0VXHR=G' ^JNF/A]X=NT1U6A.6;?DR75+&:
M>QV\6KQWJ)IK*^7URK<567!Q:WB0I!60%%4U'P\!,^[OC7]+.  ]RR0<X@&I
MJM45:UOS4^M2$^)1FM:BHX@C*?A21P$.[."G:3I"@ZVJ989+#2"XVM:7'L/,
M\:4DM+3/%'B,C(8@P^-K2*T"?4\U 5&I::DM[XKJIE-*VE>1Q2PE=.!Q2$C]
MXL@@# 1*US69@8ID@D=&0P5*U96[G:=HRH5-THLPF4YG GPG@4R[1VR,/\Z/
M\J@"DLMKO)XBXM)Q6N;QOAIJB#BDUK#Y)(2E#PD21@")S2(8^>W#2[5D.:MC
M9;VM0W%;?V!WXMU7MAUPK2ED4UKZ9=%UZV_#E4'.L[I/MH,\Q! 5<!CQG&!W
M"^A-Y8D/-!=..?\ W:<?A61M-JO6V]TT@U= T#_31'Z 5]W*2@F1*>Z04/>H
MRCBRO)RF4P#P_1#M1 HA&);!XB?9,F$))S4S&M+:D8HR'9SP2C #@!/CVCE
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M0!C("9C&W$5Y?-\J6X+&@UK@LQ%+M3.ZR5@_Q6_B6N+O]&/ZA5H*4UVT5>L
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MRF5US]'3*"J2<DDON(./9&OW^[["Z]LM!BT-N7%WL^'G&/O(]ZV^VV_>A;7
M?YGG&(!H[?-C/T ^ZJ_08;O3Q)FE/#]G+]\<V$0[%@1)R2_\:<2I/''L7@,.
MPB4+Y0[%()V@4H:I4WE;B0"V58_$0"!Z2.R#RF]B:^5I*35<E*E)2$R_JS^_
MA*',C:W--UA-W+DJ4E3(GR /N'*%<T$8(+QR2!N2Y$)*Y<@3(?['TPUK"#4I
M0\4R***U]7 $^M(^^42&@2&0!)&J5VK5_E2,%%'1.6ZIW*,JI)3E\.$\<%3
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MS5>;J/IF$4$S7TY+:EAZ#NI;4#C:JK3U%9&74J4%WB](0I  Q"VF4U#J5$G
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MNGVCTXM3;J]-VXTM^U]6,*(66G4-.O6/3Y6W,$NN5+R3Q:!CD'5GK;TU;L^
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M+6BM"A46ZG6#.?[ML3G^UX<8$TRW#<(_",E5*S:G3-8%2I"P5&<V?#C_ )I
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MSWF 9\^WWJ?1MA:V!G6A/EXR\*$Y0#B!(8 <NR*LF\7&K]6>ZKK.F+*-OF-
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MDLX4H#[\02DNNONG(VAQEJX#AR]RW1IOZ:^\E\+1KWFJ%"U? BE<2L ]A=
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MRC*5]T+^MKG\P6)N+:\NL+B5[O\ &(^@K9EOVBTC;DMBCL%M84A 0E0IFP0
M)#Q95<HE:R0BM<5*VP_4-A<XD-%,S^.JNM'I*DHD(;8IZ9L3"CD;1QX8&298
M0[R@?'6OM*A%A;Q=TBISS)_"I1-C90$A;;:LLLDP#("9ESGQA6Q,9X:X]I/T
MJ5L$+35K17V*33;V F65)$A-*0.7=@,(5K6M.H9_*K+YI'Q>4XCRZUI0#YP
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M*X* &8&>5)&'?+E VV#<A14;B<*#U$LJ*OUY8J0%A/A$\"9' 3X81MNU-$=
MS +3-_<=;2#P"IZ4J"1()YR.;Q8SPE+EPC+24$A"UMV)J5"7!LB<@0K&<CSG
MZ>,*QH(J5$\D'!59\)*\>[B3Z^<#P ,%'J=J&."5I43=3+ >(3XXRP[>,02^
M K*V^J2C2ML:9I5!;9""1ES%4IB?$&4\<8U:_D<*CA1;780T97DMCH*PA(P[
M) (1(GEB9F<819!,:EP9D@+RDS253^$B1Y<81"@Z]X>7G PEBH8SQ*2>,2-$
ME.Z<$+4U\45NS/ F1F>TF2NWPR]\7K=I\OOXFJAD\7N59J'!+*A0S242!(X
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M9"1.>"0D!/JB=KY6M#1P40MH *:11,V]'6UK^SH&4$'BEAO[\G")F-;(W5*
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MJ#86<1X3FXGT\_3"Q^+(J.1^AM2F:W!/,53S$_D/=$XJ<%$+@ UHD5.B8RJ
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M #EHJ[!4N0EY<^?")V;_ -.C$WEO^F%4?L._#PV=Q7^ 4<](/5EER'ITWA)
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M/1SU;@X].6\> )E_<NZD<#*1+64D$0\=6=+5QW"TI_*-0SHSJ.-VL6-V2/\
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M&/5NA"\W3?O$VO*2"=#W0R.$D@*:*C.>,0GJ+80?Z9;_ *83F].[[45M+C]
MK;^W'23U0V[2&_U'7]/F[-'57[:>Q6NRT]1I&Y-NW:Z,;Y[.WQZAH I'^D53
M5GL]75*;&(8IW%<$F*%WO^R/N+5S;J AL[B3J& \F5M3V5('M(64M-BWED%T
4UUM,'.@:!W3B?.B-!VT!/L!7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g680117g17j02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g17j02.jpg
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M  ( .$))300E       0_.$?B<BWR7@O-&(T!UAWZ__N  Y!9&]B90!DP
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M>X?L'1$M$2 1#EHB<7]0>O[AT1%T1 H/</V#HB5![A^S1%C1$M$2T1#,4*<
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M38W34*5X]_HT6G%66JKH2T18$::D"JJYVE!.M0!^'D/?XT[M %1SJBB#Y_\
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M1_HA[-14*VEQQ6!* =@?8&B@@C-*@=P?8&I4)4#N#[ T1*@=P?8&B)4#N#[
MT1*@=P?8&B)4#N#[ T1+1$J!W!]@:(A"4:C0.%?#1%);E-Y3[A_]E)VA_P :
MSUF_U-_[OR*T9Z7_ /;_ .356] >/L]VI6B=2A1#P'1$#1$M$2T1+1$M$2T1
M+1$M$2T1&)^D/7]XZ(LB4#<Z\-$3>@/'V>[1$N@/'V>[1%D"@'$*Z(G:(F'.
M!:5[:^RF@6D8S4%5V  8 H%!I7CV&]&I6M/%1!<UXB;VCI@I^U!^;,/+B.E
MK& )Q')Q,7A_:#M'O#3!4(+3IX*X1,(]WQ4_CVZ9K.04HI(\!$/'4+)8T1",
M4 "H5YZ(F:(EHB"->H>GGU?CQ]FK-;J=12':3J5^S7 Q  P\0'B/J#OKKDN+
M<57IV]QA0J=KF54WI"M>->'LT18.82TI3C73^H(<DXO(/1KTF>A>=)_<12E
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M$*):U[:?CJ"JOX)^BS2T1+1$M$2T18,%0$-$0^@?#V^[1$N@?#V^[1$0H4
MT19T1+1$M$2T19#CPT117)@ *<>0_AHG]06OK?&8:<./;^5=2O09Z4'H'P]O
MNT5TN@?#V^[1$],@]9>(?J*/;WAX:+9P_9'/%;$A_8] _CHO/&:GFY#_ !VZ
M*CO2F 41"OWZA8INE"B>!!$*\/X]6B+ I=7,>7=HB0D$H<^ ?;W:(FAP.!NS
MAZ>==%(S5X0Y3A4O\?977G+T4\>("'AJ$01*)>?;HB)_9#T!J[/4%5_I3RF
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MX<*U#NKH>*CB%0'X','+XAIZ-2O1C]*;HKI:(G$_67_6+]X:*VIVG3P"V%J
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M%BF'Y>O\!T11S&I4*=G.O>&B(!C=-.%:Z(F^8':% ].B)>8'9Q]?_+HBC@H
M"'2/$!KV<O5JTAUJ(P68UJK5FY U2B'Q4IS^SLUPR1EN*[HY-0HIVN9CM501
M2BZ'LT@&N:0\M:*8W:7@K%=**LD6OC1+W5UTKADCZ?&J:)J>_5PRHK58UJF"
M(CS&NKM;I18U9$,P")@X#R#CZ]*%$?H\?9^>L^IX*:)HI5K\7/P_/4]7P69C
MJ:U6"(@6M1 U:=G*E?'3J>"CI5S**0A>H*  <^SPU'4\%+8PTU1NCQ]GYZ=3
MP6E$TH=0TY<-.IX+7J#DG='C[/STZG@LW8FJ:8.FG;73J>"BB:/$*<M2'5-$
M4<Z?'GV=WB/CJZA0S%Z0K6O'NT1!,6M1K[.X-$4I$O40.-* 'XZ'-%-(2G2-
M>SN\/3HB)HBQ76?4\%-$M4)J:HEJ$33<A_CMU9GJ1"ULH2T1+1$M$1PY!Z ^
M[1%G1$M$2T1+1$M$2T1*H=X:++JGD@J+E3&E!,/<'/U!VZF@YJ6O<XTH54/)
MQBV'H46 % K5,GQT])@#@/AJCG!JZVP.<*K6W=S]8"#1$I1K3K.(G'F-1Y!0
M=9OG#&UI5;Q6@+Z2>FBHSS$D<1$72@5X4J'#P#AK#WN%-/XKL%I;C^E13O7B
M@4.Y5,'<)A]^N;JN6_2M_P#9^*%U'Z:BH(<.(U-_UM:-)(K7!3TX^#11,\P@
M?K5 W<)D^OV]FH>XMR*:&#(!$\Y,.-:>)2EKZ0"G#4-E(-55T3'"@ ",G(G2
M, I.7! X<AXU[?"GJUH+AU<OQ67M@KA*XGA*!YA%0#C_ 'J0 8?28@!771[C
MP6?LQSHKIK<!#A5RF*?7R.3XBAX]-*@'#70TAS0X857-+9EIU X?)7S9VW6*
M(D6*;CPK\(\N[GK1K [&JX'ES#2E5-KHY@:*U56O<30BGQ\DM9JZ6B):(EHB
M;T\1&O/P\:Z!01442Z?'V:FJIT_%-,GU=M/5^>E4Z?B@"%!$.X::E4(H:*4W
M#^X?&K_]G(%/_P!,:#K-_J9_W?\ B5HP>1Y_Z?\ R:M(6;F9J_W8F @!_9$0
M"M>0@'HU.MM,UW:'5JI[5Z52@"-!Y4&O"G"M1#4@@BH6+V.U9*R PB%0$:#X
MCHLR",UC10EHB0B <]$60 3!4.(#HBST&[O:'OT18 HF'II4>[AV>GAV:(G>
M0;^0/^C[]$2%N<?[(%\>'X#I\T1"H](  E*(AVT#OT1.\L?Y0]FB(Q2A0 Z0
MK3N#NT1&(4 #B4.?<&B)U [@^P-$3BAQ .RH??HBK7P!3D'$!^XNI/%.(6I*
M\%3]E3#3T!_R:+T(_0AZ*Z6B)Q/UE_UB_>&B+8FG(/1^ Z+)^?QX*U :#HN=
MPJ*!.ZA[Q^T=0L]+DPXC3F//O'N'1540YAZAXC]H]VB*.HH'#XA[>_PT11Q.
M81'XC4KWCHBQU&#D8WVCHB;6G(=%;2Y9(L*9P,!S%H("(@)N-*=VKEK#'0^I
M;Q>7/);,W6*JF6@U-V]X^S7GR,TGYKM?(U[6Z36@4@0[-9JC30U*8(@'/1:Z
MFIW9ZA^_6^MO-<<S7/'E2  X (!7T:W:YM%R]-XP(Q3^C_1#V:G4U06D9I='
M^B'LTUM4)= AR#[M-;462E&O$.%/ =8J4\2A0: %:=P:(A]!N[VA[]$1
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MU1-XCSK]NNG6WFIJG$J!@H(AX@/AW#P'6K7NIADK.#"WQ4Y-PLC4R:I@&O\
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M4<Z8@0#@4P%$W2!J#TB8 J):\J@&M:BM.*BG'@@=(5K3CJ41DP$P])0$3&$
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MX<>7'OIQT5@*8!2$0'H=A0?_ $8O"G_K;75'YM_[O_$JS/ZA_P!/_DU52K<
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M!B#(M,1:\AC?-+%K+: M:XUU# !?/M[W[OWBPEO+&:"RZ';L.XN;T!(7R:I
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M&1:)MO(B7CG^]7:F$[=PJ(G4(8YC&'OL^].[]ON;B\LMSO8[NZ=JF>)7:I'
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M-&(8  "\:^\1ULWTK-S=!THFK*J&HF4Q3<ZCV4J%:ZAU-*O&[2\.5>JET<0
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MMU:5-U<""/1+#)^^<H7F.1PCD/\ M>6G/DLK'OOM:^%P^VNJ"V@,\FN.6/\
M9&<K1)&TR1C_ ',#AES"N+#WI[8<A+7\A:N8K?>)8QLTV1;QD)!A/P$.TQ\F
M!P7OF)EY^'C8^YK3;+I&14?1JCI J_\ =]76( /#NG8/=FUBU==6,K3=S]"-
MK2Q[C-PB<UCG.CD(Q#'AIICDNRP[Z[7W1UPVVO8W"T@ZTA(>QHAXRM<]K0^,
M$4+V%PKA6JYCA'?#:VX?=+,XFQ1(15QXHB]NL=E8;B=VS>5K7HE>3V_R6\6,
M=1MV-H90EM/;8=MG[-0& ?-$7(LFN=(P 'J]P?3Z\[8[/CWK>6OBWE^Z.M]
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MQ H&A@:YND _TT(  7E';YL7RICJW_Z:R)B;!=\2UB[>;_PG9-]7'N&W!WS
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M1Y+7DT:QH\U7&G@]T=A[WW7;64<QV^R.WVSG0LA#G1^Z+VZ&$.C!%HV-@#F
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M(OVS1(ZC(ZI.OAU"6;'MG==S9:';1%<7-[)*R.%DC#,#$-3C)&2.FTBI8YQ
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M+P7NGDIXA7@.N50A4H8 \0_#1%8H'$1Z*!0 \:_?K:/+[5E)P4K6JS2T1,Z
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MGNT1+H#Q]GNT1/T1+1$M$2T1+1$M$2T1+1$M$2T19#5V>I%G6PS4(J2IB@(
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MI0$ $0^_OU*V32<_5^(:(BZ(F*'323.JH?H!,.JG#XJ=G'1.*Y]+.C2+@%A
M 23+T)) /50 &O5VC4VLW^E>E!&RFJGF5"J40,( 40"@#P 0]H<=8E=8);DH
MIOB^$W&G'CS[N(\QUSZW<U11S<#" <@I]VL7/=J*E-U0DG-$M0B6B):(EHB6
MB):(EHB6B):(EHB6B):(EHB90>NM!IW^K1$X0*//U<::(F])!Y4^W\]$3P"G
M -$2T1+1$M$2T1+1$M$2T1+4@D9(E74ZW(C$-R"H5[N%>8ZZH 'BKLZJ#@*I
MQQ4H A6@U#ES]FNW0WDN?J/YJ/KRYL)74YK=I):"<U8,?\"9_P#N6E_]^(K6
M2LO1B\@R;@8RKML4I/UB*H<.8]@" \ '5M#^2+GDG<:J\@59J<Q6B% 2"H44
MY=2H@%0$#=@=VMFP:FU)H5FY]'4HMFBIU!Z0"G,4BE:#4P  ]G .X*:I)'TZ
M8U4"3P5\!JFH'$.-! > ^/KUDFK7Y.:PHF50*#H@B\55'(=$X" ?#VAR]?LU
MKU/!9HGF%4 U1X](^-:!RKW\-:--15%7J-P$!,7A3F%/L]6M8Y.G7"M5G)'U
M*8THH@E, B AP 1XUUJVX)--*Q=!05JE36G5\%GT_%(H=0TY:U6:PH@"A1+6
M@B A6G:-0#[*Z*[7T%**I5:BD8 $PTXU&G$*>%=15'.U(0&"O2'$ J #7F =
MOKIJ51<YF,\8=M7(-N8<N'-6,+:RM>*95K2Q3-9*M2%R'="3@CA1(]OV,^FF
MUQS .R-5A2^7:J><"1^CJZ#4H>GJHZFI3I<1J P3\G9@Q?@Z 2O#+V6<?XBM
M8[I&(1NC)=]VYC^"4>JD571BV\S<\K%,5W9T4#J @10Q_+(8_3TE,(:.D8!Y
MP*54!I.5:K=(R493[%C-1LJSFHJ79LY.-F(V0;RL;+QC]NFZ824=*-%EVDA'
MOF:I%$5TCG252,4Q#"40'63FAQJW!M$Q&"G%:(U&GQ5&O?3T<]5$9_W(N50&
MX7;K=F2)G"MKY]PW<V8[=/)LKCQ)!93LF7R5!N+= AIMC+6&QG%[F9.(#K 7
M:*C4IV@" J%(&H:&A_JJ5<:FC70T73WQA U"J*!YA 35HH8/,*6G20_'XBE
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M6ZK12I^D.H<0 6ZJX8_@A!!TTQ5+:&YS;;?-CW9DNR-PF#KQQOCUNL\R!?\
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M@Y.WW=HO&4:[0N&TR/FRZKJ(A8TS&B2;0% VC:]CB2*/-.',M\?GPX9K%]'
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M$IC-N0<E8(PF.W"[9YM:,CN)R-@*P;\>63?&Y*.@6LA<["'>JVLUEE8I26;
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M[0-:TU  )0N<10DD!.!RX( HD65(F;@)"J'*4>H/BJ4#=(U]&H+&DU(%4#G
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M2Y\EFY%>X:YLH+CF#^6"UJ"PT'%?.*P2Y7E,?7%N6=9 R"UOZ-__ !=*=O\
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M\-1@JHOR8_RA_P!+W:FH\5*(FT'CP#L_F\?#3#Q1%!F(C2@?]+W:8>*(Q65
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M3W&1\>QV0(?%+O(=DL<JSUNR-VP.-%[L@FV0IFTHQ46DK<L59AY EQO[<8+
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M3Z0 #@4:U$2?$'H 0J.K#\5+2X^I9 #&X@<% [?@Z#@/<)>8B':.IJ0<,%)
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M2KU/!,%H<:F(82 ', #B-1'E4>6JN9I%4ZG@J]]&(K%HJB4QJ?K H%4[:?$
M]FL_FIZBU5U%+-N"*QC5$0%%?B;M'X3!P W#OT6BI5E'"/\ =K LET=E!.3O
MKP"HEUHUU, %."A&=FK0#D-W 6A3#ZCE *^O6[!K&."PEK4:15,%0YN)S#X
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MPH !41#F%>^@UKWZL*5\V2CAAFAI.5VJQ543B42A40&HE/Q'X3EK00U?]I2
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M<3,D+PJJ@BH?J$:%IZT/?>X6V[[/O38(#/LMO'#$TE^F1L9>09,:@G6:Z:#
M47CW/8]A-LV\;.9YA#O-S)-(ZC=4;I P$1X4(&@4U5.)JJ6\MB>/KUMS=!;3
MV^;U9-MU$;AN,NQRT;P!W%K)85@H2!@E+:!=B9)=2:;P::CSYL% *=0P)=(
M&M+'ZB[E876TW4=M;N?M#KET8)?23W3W/?KH<-)>0W33 "M5Q7O8.W7UMNMM
M)/.UN[-MFR$!E8Q;,:QNBHQU!H+M5<2:45_";4)"S<WWOE7'>=;]LBSLKW/!
MWOEK#3.W+*E[=O:[X.VT+6/)-[JF(UQ<]J,;@C6B R;5B8/F5$@Z5$RC0.:?
MO2.^V"WV?<]NMKB^LXGQ6]R7RM?%&]YDTF-I$<A8XG0YWI!Q!7=!V7)9;[/N
MVV[A<065W*V6XM@R)S)9&L$>H2.!?&'M UM;F1@0O(Q]@&3++RKMRMC"N7+\
MQWCC#VU?,F*ULXM66/9JZ33]^Y-+<I+8E[)FD/DY)K*Q$P[43<M6Z0,EVC=4
M%R*DZ3_:#ZE;5?;/NEYOUE;W.Z7V\6UP+0F9L>B&#I]1LK<6EKFM!:YQU!SA
MI(-1\<?IONMCN^V6NQWEQ;;99[3<P&Z A<_7+/KT.B=@X.:YQ#FM&DM:=0(Q
M[:E]-3!);9@;)4F[X6M&$VI7+M-/$F=Q97,G;EUWHGD*4O\ <RQ6'S25\A=I
M3.D^@OR13&H*0@%!\(?53N%UU)?B.W%Y)O$>X:J.HU\<71;"&UITNGY37S>*
M]T?2S8!:QV)DG-FS:'V&FK:N9)+UG3%U*]7J>84\O@KNU-H.1K/L*[;-0W.2
M+MW,Q5K0-OW$AMSV]PYXB(MM[YKIE=<*PM7]NR>A=D>!6DH26'H43+YB94UA
M,<>>][UVR]W&&^=M+1'&^1[V&]O':G/% 8W&35 8W>:,QX@X&K<%T6G96XV.
MW363=U<7O9&QCQ9V;=+6'$2-$=)Q(WROZF!&(H[%=7VT;>[?VP8EC,2VW.2E
MQLVL_=5U/YB48Q4/\W.WG-.9V9_:K=@6[6"M>!2>.!(SC6296[5(  M1$1'P
MNZ^Y;KNW>G[S=QLBD=''&&M+G49$T,;J>\E\CZ#S/<=3CFO7[7[<MNU=G9L]
MK(Z5@DDD+G!K:OD<7NTL8 R-@)\K&BC0N^:^<7T"R',/2'WZ(I)3=->%:Z(L
MB>H4I[?RT1,T18,'4%.6B)GE^/L_/1$XI>FO&M=$4XIZ@4*<P#M\/1J"*BBE
M/IJG3"54]LL(B!1&@!QKQ&OJX:R_BI5V0]0+VUIQKJ43%$^-:\Z]GY^.B)@$
MH-:^S\]$3]$3#\O7^ Z(LD_2'K^\=$3M$2T1"/S]7XCHB6H7.LEX&_CNKHM&
M-H=2, G+_>$X"4P#7O\ ]&OCKCNX#-0UR"]*WN= +:9^*MD7!%  P?K#]9!&
M@A4.S@->.O)D9TP25Z(E!QX*1Y@_R^W\M9!\1&+J%=D<;7BM5'/R]?X#K!9*
M$N%0IW\/MIJ5JWTJL6Z"5 XEI_,8:4X]@=HZ*RUY9XF0Q@*-:B/$!H'/UUJ&
MB*H/)% P@)#&'O 1$/NTJ,D4!=WUT$I#AQX\*]@=U-:F(\TJWFHQ175,-$S=
M/>("(4ISX!75Q@*+,R4-."M6\<Y5$!Z!3 ! >I2@%$:AP#CU"/JU8"ITK-[L
M-7);<A;+!0 %P[636 GF43(D4H"'ZBF >/4 <1XUIK;HU;JKQ7,Z8AVD"I4H
M;9CURG,"IT1'I*U7*<5DB4X#YA34$.H1X]@:KT_%.L^M-/XK1W#<6KI=J<Y3
M&15%+K)Q*82\:@(<*:=3A1=!Q63%35'H4#CRI7B T#D/ 0'AIU/!:!E16N:R
M8/.HBX$2J$#I24$ ,8 #@0BAN'4%/[6K-=JQ57-TH)DR@ H. ^$1H0P#44Q'
MMZN8D'5E1PU!%9(*$,<%J"DCU&3./Q"4U! !(/8!@X#SU*SZ>&:E':&1C%%S
MF3(=XH842B;XS))'*!R!RYUU?J'DLU3 3I'NI_9'LX<J^&J$U-5TL](63%ZJ
M<:4U"LF"2@5K[/ST1(I^GEWUKHBKCF$YCB(F >L:_$-/4'(-9"/Q441 #X0
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MB/1<$4?1O4H0/C<-#5,NW-_;4+VJ)5[JB4-<RTT.53TU.2H#_> (E. 5 >D
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M!J5LG!2O&O'E3O\ 7X:@HK1G''6#S#_H"IA .%0 ?'CR#2J*\*   %*%"@
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MQ59."U@Z9TS"50HD,'"@@(5]&M5DF:E$M$3ND:5X4X^S1$W1$4I@X!RX<QH
M< [ZZA%)3055&B91,/AW=]>6E45^VBR(CUJ""AJ4H->D.-:ZY5%5:E "@
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M(R*0IPJYY!"YEQ<.1'/C3P//XS4],T!Y@Y4\5Z/;;TML[^^<F6!&9"E)*6Q
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MKJI)-W)DMF2QC G&OQ_%5TN1T=PCI;>L[VC%M-M\JVVGQVY<M]!+JB\4>O\
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MK;CNQ+6MHL"VC[.MFW8I5D!#^64"IMT:BV<2=9P_F#SRPY*QN#3RBA6J;?\
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MMOO2-R79L7&J7K)BXF&K:9CG*L+,OG*J+I5JJ5FG5T#JX$D'XQQ'X?/P5Q.
M,L0/BGW?=]ZVW*GT]<P7AE#(CVS]P5BVS@O+.Z_:+O"O>R)W#LO<.3QR%M:4
MP0R7LVW\A-<BQ-MQEB7]$;?XAR*JL"XDX^0.LF511LK\&AB<9-7"M?X>/@LV
MRM#--,:$?Q_5:W#_ $W<R8TNQ/(>$-QF/[7OR>B-[V-K[>9 PQ.7W +8HWA[
MI[AW213JS8>+R79SF)RAB.?G18$</7+R%G$3&,X:) FB4*O@+J?,_B:\U9L^
MFOR'X"BX_=_T>\M7-;FWK'BN["/D\:8+Q)L<Q_&6Y<UM9C.A;$_LZN&S)ZXI
M[&5IVCG:TL2H);@EK-;GF%[IMNY)*+43(5LL=,J)6SHNJ,Z4'X4\?U03-H<,
M23^-5[,C=A<E&C8AO\SX]7^C/J?99^H@H 6L[)^X1630S,5+%*?_ +[-\M*0
MX99)URX]:*WR1J-B>:'146QY\*9?/'-6-Q4UIAGG\O#P7FY[]+3*L[M#B=CM
MV[B<93N"L*3&.9_;"5; ]QA<Z4AB',D1E?'+;<DX2S&VC<DP;"'B1MB4;6ZE
M;"\LU=*20N&[TB1"R(' $89_IX^''\U!G&=#6G/Y_J5[RV?;;&^V/&]P6LI
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MV@:S<*&B+"RGP\O;XAX:#(J%4K%I4*]M?;J,E(-#55BU>H +3E\0&"H' ?[
M]Q![= 5?7X)O06@&#])A_33]/3P$@^@>7AK;ICFJ+!FP& 3$#CS$*?I+P^+5
MP*"BH^6HT4R5LD\39,E .J4QJ433. ]0FH-!"@#P#4.=15CBZ@)K2BUERNL[
M/UJJ"(]@?V0#P+PH.LR^HHMF1!CM55'\OQ]GYZHME%,7I"M:^K1$$Y*]0U[.
M[P].B*/Y?C[/ST1+R_'V?GJ6G2:J"*X(1T_B#CV!V>(ZN9*C)5TA".3@''M_
M =944: @B3F->SN[@].BN!044)RIT$H 5$PT *TU>-KC)4#!9R2Z/+3-1DR!
M41'B8W&O=RX>.O?@M QFLNQY47BW$U06@<482\!\/#7<PAHI1<8=YA\U$4[/
M7^&H7H+ =FN=WJ*JKYDU,$?+FI_>FCT@Z>X E8TU*^--9.S;\_R*L.(\/S6W
MZT6*S4>0"/HKHB,F90E:"/9V^GQU!:'9JS2!FKAI)&3+TJ"/"@!S-P#U]FLY
M&#0:9J^IJOT71%B@-0 >ZE*A0.(_;KET.4:VJ>140^*HF >'$1'V=_#7+H<N
MK6U2"'*< J =0C3EXT#C330Y1K:G')6GPAV]WAJI!&:L"#D@&+P$  *^KOU"
ME"$G> >L0]^B()BE$/A*6M>P _#1$SRS"' @C7E0O;]FB(B3%900ZO[LO:(\
M_LX]VB*T2:-T0J!>H_#XS '/M$.[1%\M-[&QS+>[;*%FO&+C:_8=MVE=N(+I
MM+<>WQG=:F^+#3+'%\15\W/;.(<DM9Q&)C/Z^78.XX'H+L&K",F7J+F,E 4/
MYI%U[<+A?<EFO'MQV3<=G;"LTPCS+5T2$1CK<-B"_+MQX[Q":-3;XZ_J%N\G
M;H;&RW;4@LZ4DGB46>,D6RP(MDX\W4L8BZOLPV_3NU;:WAC;W<V293+DYBZU
M#0,A?DH@_9_N9UY:2EDHN%CY::N.4B;.M1O(DB()DYD'SAE"L6J"CA8Z8J&(
MO3U I2@4[J<-6::(O VZK:A?V1\K8OW'8(N7&D3EK'6.<KX/NJPLW6E*WAA;
M.6!LU/+/F+UQO>[: ?-)^W'S&YK#C)&+E6J4@B3I=-'<>[;NQ\D37YJ",/%>
M&<3?3*SGM_88@OO$-];9[8S)CC=;NDW#JXZ:8NO2W-LT-:>["S1LFX\96+#6
MU.L;MC"8W08L7\8[!)LWDUDG#=5LR(X(LA51YJK2XOZ-%^OL'$Q'<NX"SSSR
M.R^Y]O!+QB+"F"QJV4W&\4N[6V+]<V>_G1!QC_\ =V+5A)P9I'YE=L99$CH2
MF!711K9S7<#?3SW*9&RW>V=LWY3P8E>]^[@?IRYB=VYBNT;Z8VI;EO[&[[O*
MZ9FU6TG=4O(3=RS%\M;HJUDEDF*;=0WDG; FB554K"AQ"Y/EWZ;N6;(VA8NM
M2U96&R;>FV?'WU.Y5I9MM02(268)S>%CK<!&V7:%JHW.LG M91A+Y4:$=EEA
M,T>J('"ANLH:W:T/JX+.1X:0.:F?2#L[+F/9[*\3D'&N1I%@]Q+MU;O-RN5;
M9W+8SNNYKBQ\PNRU8[;NQQWNF=.[R>6MAJ!<*/VL[#@2(<KSK@BQW+TZBXZ,
M;0X#A\8+![JC$_G^*]-;6?IS8GV\I9GO61M/&ER;A,KY;W=7TAFYO;*ZET0=
MI[D\K7Q?<3:C.1F3.7T,I"V_<C*-E31ORR<C\@%>LG3J1'F>-?S4&3(#*GY+
ME$Y]-6[I3;IL7P@VR59[)]M'VDYOVWSTP2"ER1=VS66-HJVVYE<\ S1%->.B
M8N>6&5<(K@"ZC41(6JHZJ8CA3D/O"L)14UYG\5KF8_I?7!E.TT+/=Y:@;6;-
M/IR84V8Q4RRM-_-),LFX/R[:68K9R%)02CZ+;2^-GD[9S=J]AA<-WCABJLD5
M1/S.L*F%W!6$P H5M^XO;+NHS-:YLS9>N7#]RY%QCM:^H+CN-QG@.U<@D:W"
M?<5AK'-NV7 VN_O&3E)NX+@)<6.7JRRBK9D!_P!W:LV[<XMCN'$%A:,1\5')
M6#PYV!^*%>:[9^FCN?SQ@BR7V>LF8AL^_(789MZVH8PMNT,;7M;!(& @\IX%
MSSD*=S-&3UPS+QG?9GF&(R":0\8)V,6JF\7,L/S?R[4UE<D+N'"B[CC#Z7LM
MC7<M>V2UUL(9"Q[+;BL_;H[&F\A.-Q\SDNR[_P [*W[.+P!L9H9?:[>9!&UK
MHR)(-TY\(U-Z\ME0S!1F5X<TD.@8_5CE^'Z_'VJA/EPS_']%Z)V-;3LN;8K=
MR1 W_?%FKV9/2]H#B/!>+I/*DYB+ ,!;5N*P\]&8SD,T7)<][6_;M^2ITWQ+
M6:K(VY:Z;5)K&)=!EE%-X:MK4D#[%SS><C3\?>O:AP$AS$,%! >(=GA0>0Z[
M6/;I"YB"#1-UH"#DH2U*A+1$XH@ \>[1=/49S2,-1&@C3\M%8&HJ%DA@"M=%
ME+P1=%BEHB6B):(EHB$(&$1YTKW_ )Z(GD 0#CWZ(G\2\>7K]VJZVJ40I@H%
M1X^OOU8&N(19ZR]_L'W:*$[1$,Y1$> =FB*$<AJ<NWO#N'QT1 , A4.VGX:(
MF (E_4(\>7;Z>_1$\.P?0.JN!+2!FI5FW7H-"FX>L-9:'*5?)J%$@?%4>WGJ
M$2, B(F#EW^@-$3-$1C_ *1]7WAHB#HH.2%J%@EHB:.@6C.*QJ5HGE U2TK2
MH=OCZ=$4W1%(;FZ7":@#01H0W^D CS-3GKGN6 1ZJ_8M;9SNM0^FJKI8#LG'
MF(""?48#" !0 ^RE*Z\-TY#B" *+Z.../2#Q5>,@@Z"CE,IA*)NHQ2T$!#M[
MQU9LP)Q21K&-U#-)RW% J3A$Y1;J!\(\RB8.9 Y_&'=K36W)8ZVJ4U=" E_2
M8 _47JIP]>KO!C]:LMA(L@H 4'H&GZ!J( /^M2@AZ]8%I?YFY%$Q7B7@ CZ
M$>T/#4!CA5%6*5&O/GV@/ *^/+3IN0D#$J"?I$W9R[M!&ZJKK:BH)% WQ_H/
MS$0$>(!0!IWZZNFY.HU#6<?+#Y2 @941$!.<M2E)SZ>D:@/IUFYP:=)S"J8W
MN\S<BJ\Y!4-UG,/5SX5H _Z(?V=9/(.2WA:Y@(<F"F/'X0'QX<=9D@9K58Z/
M]$/9J-;440Z0" 5X<>RFFIO-$(4N @  /#F-/QU.>2(0HB']DOLT52X#--%.
M@5Z0]FE4UM0CIU&O2' /#2J:@H!^/ .8#Q]H:KK:K*.J8"$.(B'PEJ(?QSU=
M@UFC58M+6ZSZ55)IG7.*AJ]%:%J/9Z.S7NV%MTV.,P\Q.''!>+N%RW4UK3P4
MGI H#PXA[]=PP-!Z5Y&HD^"8/(?0.K98J[?4/FH:@#P]?X:C6WFO1JIK!L*Q
M^OIJ1/B->TX=E!YA[-8.-24P6SM"CY,F%.;$G=V24?K-V;?G^14#\OS"M]:+
M)9#AQT1.ZQ\/;[]$3B'$3 '#M^X?'5'GRE"I9%E$_P!(_;4?QU@JJ^:2 '$$
MS?JI4>SAP^P>.N?%=*N2'(( 8!&O,.5*@/#1%)36Y]8]U*!Z:ZRD&2TCXJ6!
MP$ $ +Q .SCK):U"<!"'XF(41Y<NS^!T1/Z$^Q,@>@H:(L@%*4X '(  *?=H
MBSVB-1&OV>H.S1$M$2T1+1$M$2T19 :<0T11UVR3G@<M5*<#  !P"H\1].B*
MA635;B%0ZJ#P4 !Z:^_1<M*9*4W>#T!YHU[C=H\1YC7CHNAGI5A\"I! 0 Q3
M!R'Q^X=6:]S,D<QK\^"IGC!1(/,1**I #B2OQ$#L&O"H>&MHY'.> 3@L9(FM
M82,U6 (" 4 0&GQ /,#5&H:Z:A<U"EHH33$(<.E3XDQX&*/$HAVC3O -2BKS
M)+1I_-;"*S81J)!$1$H&XU"E. :SDX%:1\5<MUT72/60XB8>9>[[0KJK/4M$
M3RP#O_CU:W4+(?'P,'#GJJP5>]CR+@82%H>@C7QIP[-;LKI"P?ZEJRJ)T3F(
M8.0TKKHCXJA0]:*$M$2T1+1=+"-(2T5)>".'(/0'W:+)9T2A2T2A2T2A2T2A
M2T2A2T2A11+7@-=<ZFA0Q"@TXZV9Z5%"L:LB(4PU .%/<&BA$T11#\O7^ Z(
MH9^ F'P_#1$ 3";G3AHB<4PU .%/<&B(I1$H@(".BFJO&BW50 [J#7N[_3KG
MR4JW+Q+3TAHB88H%I2O&NB)Y_P!(^K[PT1!T4')"U"P2T1-'0+1G%8U*T1T^
M1?3^.B*3HB,E_B)_ZQ?OUE<_V?L6MM_=^W\DR:* AU"'$"@/@-!]'+7S,OK/
MS7TD7H'R7,W:B@+"4HB ")A'IX<AK3T#J&9K4-U&BFM919!LHV5**S54:BEV
MD.' %""/Z3!X:VU#FK=%M$-$YS',=!?B T!,_P"NG/ER#CKI8[K8\2N/%; P
M>N"T(LF(TX ( -!Y\1X\=7+0PZ1P2BV!-X8@5J/'D AP#T:K@IQ4XB[=4O\
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M)0. ]-!^S7TT4?2C$9X!?*3R=:4R#(E!-S]6KE5;D@F"E1_CGJ%M&<:*,?\
M4'H#[QT6RV&"8U\QV8HUKTDJ'.H<3 /*G9Z=<]Q1==MZ@KLS3@:A>_A7CQUR
M#)=;B=11&S2B#\>D:BU(4./_ *\S,/'_ )NH.8^?Y%!7%7;RW5V_]XW."A#"
M%2C^H@<:A0 \-3[D<UATI%5&2\H:'*(&"G,*"(\^'?JPD+L0<%0@M-#FG%.
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MXJI:#B5@*]OM#5VXYK*1C<,$!PW(N00,4.KA0?0-=;18/!"STMY+7W+,Z0U
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M^:<GYEOJ'Q?@2W[KP3%Y4S)9.8E\G7K?:TG=.9+4<0T=(V-G".*X=JQD[#7
ML8C"%C^@HHE.0P>#M4&V]Q;7O\^UV%I8[?)=WCX[MUO:RVPMXH0V.VD#W-EM
M'4 DAEA +Y7U.H@A>UNDVX]O[GL<&YWUW?7[+2T9):-N+F*X,\DI=)<QEH=%
M=-J2R6.8T;$RGEJ"OT)E<F;+'05Y%5,3S"?X9B]8A4@<?@IRXC0-?S&,/N7]
M&/?1Q&&:L2F*H%2C4-6:ZBCU_8FB/$0_CAK1DE'9*"S2*H9TBJ!0?MIK;J^"
MS56HT%,QNGESI0.'KKJ>H>2SZ8YJD>5!0*AQZ3?=K9DF&2S<*&BA:U:[4JI:
MLH2T4I:+;I#FEHM *"B6BE$ E0 :\_#\]$2\OQ]GYZ(GTU30$JD/(?0.K 4%
M$0-2J.9J2T6;H](K5+19(GF>'M_+1$\/B+W5K[M$0C%Z:<:UT10S$J8PUYF'
ML\?3HBR 4"FB)&'I"O/CHB<F;I^+E40'T4X?AJA94U4J\:..7Q#K-S=-%*N:
MUX\Z\?MU"(1^?J_$=$4<Q>D*UKZM$3:ZBBH65-4A'4J6MTK&BLC$_2'K^\=$
M1D^WU?CHB)HB6BNQ^E&*:HTIV>[1'/U"B=H<E0+(GZ1(:E>GA2O.H"&N1]HU
MYS7HMF<T*L=IK?X@$ZDS /Q%J(E'CP,  .O$N+(->[23@>2]>VN=;0#@:*E,
MY%#K%4#] 4$! IN%1 H!R[1'7*UNFH7>*<$%.4 /.#R%C&1*)S$ITB< 'DGU
M<#"%=75'"H4]!ZFJ8"* *)Q !Z1$#<#4IR'QT5>GXJ=TE[#E'UZC'BLE&4YF
M]'X:E%&T18$:!71$BCU4[*^^FB)_3XZOH"SZG@G)D.J?RR%KPXCVA7PIK:&-
MTCM)P;7-<TDVFI(4)ZN@Q6!-QU=(T#K  'H$?YB\Z>(:[9K(1 %IK4<EE%<]
M2N&28)4W"0J-U2*ICRZ1^(/]8 Y!KA<',. JO1B:P^8NI@J\&=3@<_Z0$:4
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MX9:0>53\"F2H&U&6-/S0L2;G-Y>X^[L*8GMG=%&V5;L];7U.'[;<E8^#\4W
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MPS5LQA[2MB)8LEF;EFSC(")8-6CB.475CW#9NU:)(H+L57*AD3D #)&4,)1
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M2JLB-(I(S,Z49'I'CF)XN-.E'LDCQL6H5N52+CC)I%,QC5"LT0,W2Z$3 BF
ME^ M)#0,D5&ZM.UUZK-X**B)-*WG]JQ=PP45%Q%SV[!2+91JLPM>X&C,DC;R
M*)5.M%-L<B22I2G E2AJI8T_.GBIJ518WQ?C[$>,;/PUC^UX^"QI8EIL+(MR
MU?*!^Q1MQ@S^2^4D1D!<J3+B2*915^NZ%55^Y7567,=14YAEK&M;I&2QF))!
M.:VEA;=M1:#)O%6U;D4VCE47$:VC(&(CF\<N@Q&,;N(]!FS128N$(LPM2'2
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M8<EOD*<$PH!TB(_K]M/1JP1#4-0H@ @ \?NT11DR5$1$O$1J ^L?LT')%.3
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MYH=JDU'DKN9I%4,P=/;V5ULJ*(("J(B'(!$ [:\O1JM41"!00#NX?8&K(IA
M_NUA_P!  _\ SJ6J$^8!!Q^2O=<ZZ4M$2T1+1$M$6*!W!]@:(AF*-1$ X>KN
MT1,T1+1$M$2T1+1$PZ9#E$! *]G"M:\]*D)0'-:^]@6[CJ.4G0<:C4H@'Q#V
MC36L+PR0.=DLY&U80T8K3WL.[:B(T%4G/J+Q$H5'X1#GPUW^ZAYG[ES]&3BJ
MD0$!H(4'N'70LM0"*7](>O[]%(-<0L'[/7^&BFE4(!"M.W578MH%(!!JOD/E
MZS<?Y%^I!@5CMU6FH[/>&,H0V:-[&8HO)-ZJ6]:N$WV+[GM>T-J-QP3RZG-G
MS%U9^DW\7),K.:1Y4X2)BEK@<)-W#EDH]XW,<9*-K7X^,_RKL"-.*^NT#<\%
M<K$):VIV%N.).XD&))6WY=A-1AWL1(.(J69$D(QRZ9F>14JR6:ND@/YC=RBH
MDH!5"&*%Q TX@*O@G7G*N66/[\6;N%45D+%O-P@HB<Z:B*Z%MRJR*J2I! R:
MB:I ,!@$! 0US20/#S08+9KV@4.:_.3L\0LC V%_H@9,V^W/(Q.X;<;B2V'>
MZ&PF&1;DN.-S3AHNRS(.2LG9@ROCZ0N61C5)C'^7X.V7+:ZC-VK]"0E?VSYD
MR<B9L? M(SXJ^H+WEMCWL[GY2WOI<7=N/O?!+B.^H'9-\9.NM*T;"F<?P6-H
MJ.VM1F9;2L2"N&Y<AW ><FADVSY\^?N4V_G-R+I(M4TFX+:A*@KP[*_5CWOY
M;Q]@J)V^R&)F^9<M;?WV7;*2AL#W-F"V\N7E<&[3)F";)M!S+-LL6E:^$K#2
MQWCQ6;_J:5>O&4DN"PE40!L1J_*5]7-\<W.6WG_Z2#)>Z734LIOBN.&NQTQ=
M+V]&7*FCL9W;/%$9..1?&;*1KB<8(NDV:QUTDUTTA#J.0IM$7 ]Q_P!1+)V-
M=ZF/\78NN6WKZQ6ANEVO;5\PVL;!CIK$V;<.Y.+@)5JDYW#2N<HAS+Y*96]=
MC&X6$;;]CR\4G%"#607375.X:D7DN:^M?G#$\X:*RK9^,I)I@&W=Q^#MV\A!
M,9J+69[X8Z>S639G8MH,E)J0&+@=Q%K[>G+A%HJ+M95>_K<*DN0%0\PB]\XR
MW0;I;>WC8IP1NAN/'-L6Q?MEVO9-D?Y=8P;W3;V8MP4)MRC\L9RMV5R1&YHE
M+CP1>MJ7*PG7\3;\U:)XJ2L]BV.C+N9!T8C<B^N>B):(EHBCN$"K@'8<*T/W
M5YU[]$4'^^;F#S/B* 4 X"-*?I"I0[]6:0#4Y(C%,"O\HB/=0?X'6FMJ@XJN
M7:4^)/CQXARX4[JCIK:N3HR* 8>@1 P" AX</M[==3/,P$9*AC<"F#\=.GC3
MGJU**I!&:!4Y#"/&@"/;ZO'10CIGZ@$1H'&G,.X/1HB)J$054_,+TT 0$0KR
MY=OLUJ'-H 5DYCB:A:V_C3)B90@<ZTH/CX4ISUO&]N*H01FJ$XB4:&Z@[^=/
M=K4.!- JH!A 1 0[M61,H <@^[1;]1J(4#<!XTKW^/'A718O(+JC)&H(\@$=
M%5+I'N'1$[H./(HZ(C= AR*'LT1(0IP'1%C1$[I-W>T-$2Z#=WM#WZ(G^2?P
M^W1$T2& :4]H:(L=!N[VA[]$2$HAQ$/NT1-T1&24\L:@- [@U"RTN5RW4\P.
MJHC4 I6O9P[?1J5JW!M.*DT >85T10C%$IN/:(Z%0[TK("-0XCS#M\=5.2Q4
M]+JZR@%: /8--8G)=*F\>H*\ZAHB<IV>O\-$0]$1B?I#U_>.B(.B):(EHB6B
M):(EHB6B):(L@%>&E0!4H!7)6C1+X0,;AS\?QUYUPX.?09U7HV["UM3R1%3@
M0!  "M*\O#5M#E*KR 992E?$>-.'+AJ0X-P.:R<QU5:))E3)0 "HB CP[0'A
MZ=9O-9&T4=-U-7 +5W?6=\4A>H3$,)C<^7541KVZ[J$Q4"R!!=3BK,Q3#4_2
M( 4*B80I3MJ'?PUSL<)':6YJQP%>2UR6D@ ID&X@7IH59<!X %*])1_F'MIK
MTH8VL/F7FRW&OTJA81@R[Q.B?0U1 O54?\0P#4?4;OUC=R,:#I)KRX+:VBD<
M 0,2NMHD0;I$22+T%(4H4 .T \->-624DD8!>O&#&*/S0D! Z:@E 1JNK3AQ
M .H!Y<PX:LQI#JG)6<X$4"&L0X\  0&G;P[^?IUJ5FA@'04.JA?30-$6.'5U
M<.FG.H4_BFF-?!$<BB?EK%ZRUZ -2H<@52"OVCJI'G!4CC\E?ZYUT):(EHB6
MB):(EHB0\>&B)G0'C[/=HBP)  .%1'^/#1$R@]P_8.B+&B):(EHBR'#Q].B(
M1DB' 0,%0'LX4[N[1%K<A"(N*B4H)G#B DH #P'A0 '^ UV>ZY56?28M4<1C
MIJ!JEZRE 1Z@ >0<1X>&NN)^N,.YKED :\@9*K$PCSX4_CCK2H.2-0:T,(^(
MZ*RX.\VH[8Y'(XYOD-M&"'N71N9A=YLNNL/V(OD4UY12;)*+ND]]JP!KC/<T
M:E&MRH/1="Z1*W3 IP A:4T,K6@U*:E=;M2S[1L.%);=BVI;5E6ZE(34LE;]
MI047;D(G*W),OKCN.33BH=JS8DD+@N&4=/WJP)^8Z>N55U1,HH<PV  R2I6Q
M' JR2C=5--=!=)1!9!4@*I+HKD,DL@JD<!(JDLF<2F*("!BB(" @.LGCS%35
M<KQ/MLV[8,4G#X7V]X4P^O<##]LN=7%^)K&L)S,Q13A6*G%[7@8Q=]% H(?]
MF7,9 #<>BNJ-B:[&@4D\*X+>)G"N#KXL2V\57KA/%-YXOL@T O:..;EQM:5Q
MV):!K3:BRM=:W+1DX=W 0!K:9_W+ S5NE\HC\"726H:I/"UL9/%68?-FO$6Y
M3Z2FW3<S=:T\$V]Q=;LWAE# =RV!9>*MNUQ6PWQNG<=ZW6Y+BHV3<07S*X#O
M&7EL@R2K^9M!>+<NUOE71P^=9-727#0K:HYKZ$7YM[P9E>R+:QQE[$6.LPV/
M:"D4YMRW,O6?!90CHR1A(E>"C9I!*^F,]6?;Q+I9 7YA%V=-=4#*#YA^J%*U
MZ.VE;58>XK4NZ*VS;?HV[+#B;:@;&NACAO'C2XK,@[+<)O+.A[5FT+=3DK>C
M+3=HD5C$&BJ2;%0H&1 @@ Z(MID\!8*FUKG=3.%,2R[B];VM')5Y.)/'%GOU
MKNR/C\(8MAW_ '.JZAU3S][626W8\(B5=BJ^C08M_EU4_)3Z2*0UP=A5EE)_
MG%EA_%[3-4M%EA)/+[6P+50RA)0Q&K9B6)?W\E$DNIY'%9,T4?)4=&3\E$A*
M=)"@!%U'1$OQT1+EP'1$M$33IE4*('* E'\..B*N5:'2-UMP$P4XI\1&O&HA
MX:(LD4*<!X?%R$![N^G,!KHBBN6P' !IS[N?VTUHV1[109+!_J\%7?+K%,)4
MTCJ=M"D,<0 .%:%"M..MXY*UUD+%[22*"I0A3 :@8! ?[0#P$![0I2H4'6RR
M054SI&H!3EH 5 0$! 1X\0'O"FF>2+)5QK\0!3PK^>I1'*/4 "';HBP<H&+T
MB " ZTCXK.3@M=?1P'ZNDHU$1$!#AVUUNSU+):NJD=(XE,'+D-!Y=FMU"80O
M4-./*O#10I::7 O W/\ 'T:(I)4@+R*/'O"NBE&\LHAQ#L#PT3%.*0I0H =M
M>/'1$*@AS =%"&8H<1XUI]P:(A:(CAR#T!]VB(I2@( (U_@=$1:#W#]@Z(F&
M)S'C7N]7HT1"H(<P$-$3#?I'U??HB#2G/1$M$4YHKTG O'N#N_Y-%/!6Y3":
MO+LY:*%@Y -QXUT*A]=-$ 2T,'/L^_53DLJ%34C"!RT[]8G)="G5J8!\0T1.
M4[/7^&B(>B)P&$ IHB;HB6B):(EHB6B):(EHB6B))B(J=-.WLY\!U5_I5F>I
M7Z90*0H!7E4:]^O+?C+]J]2/^VJ]PH;JX4&O#U4].NQ95%$]DD(F%0>!:='C
M7G7T:P=ZE.:G*?!2G(>(U]/JU0_W K?_ !N6F3+P8Y%PZ  ,J8XI)]E3 (";
MCW= Z]:W;J!!Y%>8XD/P^24I*>6P:?+J^89ZFGY0_P"@8  QA]8CJEO &R.=
MX%9&5WI/R0%8D%V[9N4M*_WJQN0G$1X]1N_6?7-,5'0'!;7%LB-41!),"@
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M=%"D:*$M$2T1,/R]?X#HB"/(?0/W:(@:(CAR#T!]VB(Y/TAZ_O'1%*T1!/\
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M$M$2T1+1$,P@/<.M&@%I)S6D8!S5A'@/QF$!X]O\>&N&8FM."WC: [!2W!A
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M T#CKE=Y/4MUL;@0(3H*(\*!0*@'*GXZQTEWF&111TBCY;DW_P D4*]O_I"
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MC$_2'K^\=$3M$0C%'B/"E?O'1$S1$P_+U_@.B((\A] _=HB!HBP8*@(:(DF
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M<3T[1 P!P#T:ZX?[GV*)_0M/.4W$0"IAITE[1KRUV'TGY+E!Q6X-6Y&;1)(
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M:K8Q3#2H %:\J?CK1A)K50HPT >FO'CZZ=NKHL5 .8AHH2J'>'VAHB>4P\
M>%?#OT1&T1-/^D?5]X:(@Z(F'Y>O\!T1!'D/H'[M$0-$2T1+1%(04,4?U4 *
M?<.BE72*IA 1ZJ]P\.6L7>I2K9(P"',.0=H>.JA$;1$M$2T1+1$M$2T1"/\
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MM2F^%3AR3 /^FF&J$>8%2./R_,)Q%U 'B'9_,/OUSKH4DCGD AV\>8CST12
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MGR2NI26RE<D0O"0RJB",4E(.FL4Z?S"D8@BT8K.#HHZJUQH7?&969:,&_/\
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MS1$$:AWA]H:VBR*RDS"EIKA\)1[  !]0>(ZT6:1B$.% X@/CVCSU(4%5;IF
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ML&G\>D-$1"J&+3CR'Q[Z]^B*21P''JKV4XT[^\1T1'*H4U.//Q#NKWZ(G"<
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MLK5Y#E^5!1,@$$KIN5@7!;W=&V^Z)V/EFL!NWW4XZD9')MXY$:3UJ3^(91U
M15XQ[.--B>'AK_PU>MIABZU4V?G0;=Q'KRL<Y4.H#\_4)=.FY;:VKH^W3!F-
MMKF%; P'B=E*LK#QW&/&$0:>EW=PW!)O9B9DKDN.XKBG'W_:)6XKHN>:>23]
M?I3(H[=*"0B9.DA73<FMJ[>58@\0'E3F Z:#X)K:N$X7VZX]P?"9<MVUE)N9
MB,V9IR_G6]6EV.F$FB>Z\VSBUP7G$QZ;2-CDDK5*Z<'3:MEBKK)H&Z5%E1^+
M4%I JI#@30+Q=$?21P QLD^,I_*.X>_L=6YMUS-M7P99UZWK9TC&;:L-YWM4
M+$O>(Q([CL>1,U*S[:QT4(6*E[Q=75(Q<.W(S15!$[@JU59;_?/TVL*WB>^Y
M1I?&8;)O"\\E[9LOQ=]VC.69_4>/,B[3[,AK#Q;<-EM+FL2Y+65!:WH;RY9I
M,QTNS?"Z7HDD!B 0B#<7TWL1RDXM?=L9,S?C/+Z.X^_MT-NYFL6>L0E\6E?N
M5<76]A[)<!%1UTX[N?'\ICZ]K*MEL1Y%2T)(@1X4KE!1%9%L9$LR'UPR6D2'
MTI<$R&9H;-K_ "=GR0N%ED[;GFN>C9BX\=W"6_<M;7X*U[9QU>EZ7Q/8PD<O
MNB/X6T6A9:&97(PMUV[%5XFP0=*F5'1@U5Y*I)::T7<3[(\1CL_RKLF&5OG_
M "AS!"[A(&Z)3]XB?ZZ:LMRU[7]?E_GAI?\ 8?VAJX8361WY(L56"Y6[=-$J
MP+F*<Y]=(I15J:U71LL[?K)S%"X:@+J?7(@QP;EW$F:[./$/V;9PZNW#+I1W
M:K6=.[CGQ'D&\54'YY)$K=98/\-5(>.HT-R4ZSFO-V3/IS8:RED/)MVR]^YK
MA;!SO?F-<H[A-O%M77;++"&<<@XG8VG%VK<EZ,'UE2>08D)"+L&":SS& N&&
MC;C;Q#<DB@N7SO.U,0K_ "^/C.JIU0H4Y]-_"]P#N#MF8R!G9W@K<O*Y@NK)
MFV1*^H9CA92_<\QZS?*5]P9F5H(90C9><F72\ZU9&N5:%B[D<*2C-DBZ$IB.
MD."H935;.WV=SB>,I_'#[>#NKG'4\_@%#7U/*;<).?:0,#$2T&I9KBUU=NI<
M4W3;MT,)A0TV:<MV4?RCI%!=1R"B!!"=!XD_@JZQR"T&V_IJX3M1WM98QU^9
MH<XSV;FQ]*8/PU+7!8LG94%>>,[=E[:MR^%+D6QR&7&<F^93BZDM&1ERQUNR
MJQ4RKQQFZ8-]!$TX.."GJ4-5]*AD#&:%.E45"%Z#%[:@'9X4UY]RU[26Q@'Y
MKOA>TD.&2UQ.1/YHE.8:B< YB(\1[*Z\6)[V'S+VNFU7INH$P#XBFI6H@(<P
MJ'/GSUZ+7:VAW-<,@!E+&YH1EQ;.$#F.!P$P%$0XT P4'U^[6%PXM(HM6Q/
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MAJIB"ATPY\/2.LM#EIK:K5!T4P !C>CM_CAJJ:VJ8%!X\/334JP-14+.BE9
M*C31%D0IP'B'.FB*&N@ \4Z>/9PIHBKU ,7B(\/ 1[N/#6[?2%"CF-6E!'MK
MS#4J$,1IQ'1$BB' >ROW#HBEIF :@'AHBF)\B^G\=$4G1$M5<*B@4K%-4T.4
MI4X5U+HW-%316T.4]DV546 _30I*4&M*T#GKDDD;Z.(6L<3P=1R6SB(!2O=K
MB:T@FJ[7$$"G)#$IAKQX5[QU=56.@?#V^[1$N@?#V^[1$T0Z:U[-$64@ZS4"
M@T"HU^S4(G" G-0!Y!ZN&GBI K@$X?@)Q\0X>O2JG0[-0# )J!7C7M'155@B
M'2F0.T XZYW^HK=OI")JJLEHB:(@7AR\*:(@UIRT19*7K.4IA'I$>(UY!S'C
MV:V:\4 XK%S34G@M)DW9G<FN)##1)0J1:&$ $B?"O#OUU1QN#2>"RZC:JU:@
M(4KX]M=4>]OIXH' _<K=(HAQ-Q[NW5%9%$0 *CP -2BB+.0*4P /.O3S_@-3
MH<<>"J7@&BK4G B+DU1J5 H]O:Z;>_0M-*>/Y* X5KPI^:G:A72T1+1$M$2T
M1+1$M$2T1(0KP'1%@  .6B)G48.8>P=$6.LW<'M]^BBH1"*"%:T#ES]?CHE0
M<D_S?$O\>O12L@<1Y4'T5'\=0H2\P?#^/7HE0L@<:AP#GX^_1*CFG"<2_IIQ
MY]O+12GIN3@8O4/PA7D'@-.7'57CRE69ZE-([+3B/;V@/AXZPH>2W3P7*IP
M0X<>[P[_ !TH>2+-0[P^W2AY(A*B'P^O\-:Q@BM5E)P0A"O =:K- .0M>79W
MCWCXZ(HQB@ < [=;KGH5%4 ?BX#R[O#4*%&H(<P$-$31"H" ZD9J#DIT<D)U
MC@'Z"EZC%'B _;RUQ3>M=T'H^U21ATE5SJ@8I1 :@7IY4'G7PUYWMAS"]'W/
M@:H[H@%2Z%#%,)2B FH!>H*5 !] #JP&@:>2AA+Y2X@XK6%RB-"$H!0-U5#G
MU!RXUU!C$F9&"]'@%AVNH+7K'C3X#\/Y>%>?#CK&:$-C+@1P5F&CJE49#@/2
M8H\:=_<->6M+4\/!8W&!J5(J(@/: \./'^!U>H6-"G@=4PE* B !0"TK36+L
M7+H8/($8#+$X"81$?PU4^*M0%8,LJ!1^(?X'04YI0!0E%1#M$QQ](\/1J5!(
M')2FYQ*( (_'PJ/A7[];U7G4*N2/!*!2]7*@4#C^.NAI&E8/!U'!&%P)N1A"
MGJ^\=;1G.BH:A"5JNF*1QZ@'B%>(AQKPUT1/TO#E! (H<EKZ\4N6IDR"8.=:
MB/L#75UZG/\ %<%Q .&(5&=(Q.=:CV4X]O9S[-=H(.2XR"$T#"7A3EZ:]^I4
M)Y%BA6O#ESX?AHIP4@CHM0XAP]/=HF"E%<$,%?'LTP3!$\T#<.GQ^+EJ,."P
MH4PQ2FKP"H\.8@'=WZ)0\D R!@I2G;VUTP4(-#%'ER$0\.[1$<IQZ0Y=O\<]
M$12#T_I$>'C7[=84*E3D'(U ##R$._[M*%;-(HK1-0%*T[*=E-%** ]/'N[]
M%*0FZN/#U:(F'&@>GA[!T11%$2G(/#C3AQ'6S3Y0H58LEY0API4!'^..K511
MS_I'U?>&BA,*80H'97[]$4M$0 W&G'AQ]>BE61: ):<JA]^BA2-$2T4I5#OT
M."D U5@T9G7,!_[ '[>%0#QUQ7%QAADNFA6R$("0=)2@'  'AX:XJZO,<UT-
M!TA(2@/,-2I6=$6*@',0T1#ZQ\/;[]$053#X?%P'V!J"B,A\/Q ', ] ]_MU
M*)R?^(;U_?J#DK,]2RO^CUZA:U%"HB85, "'\5#4E84*G@%  -<[_45NWTA9
MU560Q.("(<.?\=NB)@B(C4=$6-$0W2I6S)VZ,- 22H7C0?,. APX\1X\M79Z
MQ14>0&FJYPSZC*]1JB)A :\^?'[::]1N##5>>,3AS6Z-B )0X#Q].N!W]S#)
M:L!JK0   #A\/\5XZLM54OGOEU*40  'OYU]VF** *Q3APXFYA01^[NULWTA
M<[O44D2CTNN U%L7_O374.S'S_(J1D?E^85H8>D*\]9K=(!J%=$6=$2T1+1$
MM$2T1+1$M$2T1,/R]?X#HB8'+4+%WJ6!T"LSBA"6E1KV\J=^BL[TK)3F*% [
MZZ+%/*K0:B'9WZA$_P \/Y1^T-$6?- W(O+QU(6C.*7F>'M_+4K1+S/#V_EH
MBR"HAR#V_EHB(#DP!2GM#_JZC%$X'7>6O=00]VB(X+ ( / *@ _J#MU*+!C@
M8:U /6&B(&NA50C\1$._W:A9.]2C*)\N/?V>CQU"JA&)0!&OL_/4C-0<E811
M@*JJ C03$H4.\>.N*;UKM@_M_:K-TY3;% >(";A4.SA6@\QUPKTX+<DU*UY=
MX"X*!S*!1Z>^M/?K!_J*[].DT5.JL)0 0X5&GIY?=J$*D(U7!1(PAT'()2A_
MITYCX".M8&]24,\#_!87#^G&7\B/Q*UP4U&RQDQX"2H4ISX_=KC:_H7!!78^
M/W%N"IK9<5 , E)\/^C6H_:&H]PL58DZ@3ZP(2A1Y@40'TAQ'4>X1(ZA/+$2
M )E.WLI7T\ZZ%_4^Q0H(*'4'I\L0$>8F$*<./$-68#JJJO\ 2D=!00ZA I"\
MNH@_%7N\ XZV6*<4I2%Z2A7C7J']0^ CRIHB.3@)1[A#[];-R6#_ %*6!NH0
M"E*^O6\7%8R<%*)\(AVT#\*:Z&>I9*40_#EV]_HUJH4"09(N2@8A2$.4!"H!
M6O >' ._73;W&-#FL9X-7S6J+,SI=8&)Q !H:E 'A4.>O2#M0KS7F.;I.E5B
MA#<.'?W>&I5:%! 3%-Q+RKV^K1$3S3!RX?QZM$4Y)80$>KCPX4].B*:4>H '
MOT4)P:@JC^"&<E0$:\Q[O'19H8!0*:(B$Y^K\0T1%T124W DI4>7C36;^"UC
MR*L"+"H'$0]'YZHM$A5$O !+3GV:(D"HF&@B6G/LT1$ :" \]$4==(% ,8?X
M_BFM8\BBJ%BF( @ 5#L[.W5U%$ M:A4*#4.'KT122?J#^.S1!FK(AZ=(4[?Q
MT4*1YGA[?RT1.*8##0>'"M:]H:D.TXK2/U*<S:&<J=1@H0@]H5ZO=KBN+@+>
MF*V8B9$RE*0* 4*?QW:X0*+I1PY!J#FMF^D)INS4A4?FF"- KJ51",/4->7#
M1$W1$PP5IX?C0-0BD)ATD*'K^T:_CH!1%@OZS>O[]2B:J:@ %.?XUU!09K"1
M:G ?Y>/WA^.JKH4JE-8N]14I:JB /,?2/WZ(L:(L@' 1[J>W1%KEUN 1:-69
M1J==0RRM*<"E .@!#G4==%OZB5SW'I5!&)F/TF#M\.[77<X%OR7+;^D_-;NW
M+TD#CV '+P#7,%TH;MQY1*5\:<O;IQ4'):B[6%4_*@!7^.%-="YU'17,0]/$
M0"G#OYZ516Z"PBB\-VE0)3B/(7;4/QU4YCY_D589'Y?F%LXM 'G7V>_7#K=S
M7=I;R2!I3E7V>_36[FFEO)"50$G30!&M>[LIK2-Q-:JCP!D@B0P!40$ UI4+
M--U*):(L5#E4*Z(LZ(L5#O#[=$2J'>'VAHB&(B//4+'45R'/N7HS &%,G9LF
MH61N.*QA:,C=S^!B'#5I)RS>/%(IF+)T^$&:"ZQE@H93X0IQU[7;>R3=R[_:
M;!!(V*:[G;&'N!+6EW$@8D#P7C=P[S%V_LEUOL['2Q6L)D+&D!S@*8 G 'YJ
M!A/)62,F1$M+9#P+<N"OEU8L;>;7'?F/+[-=<?(,U'2\BR<8^EY9O&$CC@FF
MHD[%-4YE0$H"!34VW_:MJVF=D.U[C%N-0[660S0]-S30-(F:TNU8D%M1ACP4
M;!N>Y[I"^;<=OEL*%N@/EAEZ@())!A<X-TX AU#CAQ7:M> O?S7FF/W.V,OG
M'.^%9U$+-# -G8HO*Y\@W1.PD79S]GEI.0&(:H+NUVYXQ:.79%15.Z.4BRJQ
M"I\> _52]H[@WM[;M_MCU_\ )3W$4<,;'NE!MJ:B0 =0<#4!HJ #5?+Q]T;<
M[?MPV.X'0_QT-O(^9[VMC(N*Z0"2-):10EV!)%%#OO>5MGL'%N3<P.<OV3=E
MGXA>IP]\ACZY;>O":C[D7<"V:6DWBX^6*9W=+]5-3Y=D!RJK@BKT=7EGI;;N
MQ.[-RWBTV-MC<0WU\W5%UHWQ,=&!4R%SFX1C#4ZE!45I4+GW#O7M?;]JNMY=
M>0365F[3+T7LD<'DT$8:'8O.-&UJ:&F16TR6Y[;A"6W8MX3^><0P%LY,#_\
MD":FLB6G'Q]VJD5*V=-X-VM*_+2*T<],+9UY1S$;.2F24,4X"&N.+M'NJXN[
MBQMMNOI;NT_O-9!(XQC,%X#:M#AYFU%7-Q (77+W3VS!:P7MQN%G':W7]ISI
MHP).!##JH2TX.H?*[ XJWO/<%@;&]P,[4R%FO%-BW-(QA)IC W=?]L6[)NH=
M4QRH2B;:5DFIP8NA(;R534*OTCY8F !IGMW;/<6ZVSKW;;"\N+1K])?'#(]H
M=Q;5K3B.(S'&BVO>X]@VNX;:;C?6EO=.9J#))6,<6\'4<X8'@>/"JTO+FZC%
M>,+?O%:*NBR,AY"M*(DYD<10V4\;VY>4DV@92!C;D$[B[KBBH: 3MT+B;*NU
M)!9 B8*$)Q.H0H^ELO9V[;M<P-FAN+;;)GM;[EUO.^)I>U[F81L<Y^O0X-#
M:T)R!7%O'=VU[5;S.BF@N=QA8YWMVSPLD<&.8U^,CVM9HUM+B\BE0,R%7--Z
M&VQ3*N1,,RV5;1M6^<66_;EPWBE==SVO"039*X&;AZXC(V>=3H-)68M1%O\
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MX8_!M*J#&6XE0_E #CQ^_P#'36Y532E,4:B @%-;*%*(<0* =0!3T=^B(A5
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M@W)"V39\8I&(R-T70_0AH)DK-2S" B$G,F],DU24DYR5;-$ $U5'#A,@5,8
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M6/MJSK6A)>Y+GN>;<DCH&W[=@(]S+SDY+23D2-6,9#Q;)9PX6.8")(I&,80
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M7@\I\I&D-^HH.7!>VM1 A1X_RA779;C1BY<TLC7MHVM5K#$@^8'  H:O36M
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M]O4CD-_8EPVU(25HWNE)!*02*[CY9ZJ1-4 ,!1*:CFO).FOP2HUQMQ=3#_\
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M)@$1.%1$:"(B( ', YZYW>HJ=1&'!6OE*$XI& ![2F_2/+GPU9@!!JFMQXK
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M0H6=*A%6JI*O'"#<E:^9U#TAR*4P<Z<M9REH%*A:Q5)P714PZ$B$[BEK_K4
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M.Y!9+($ 0 W.H5I2G/T:=)_);,E:6U<0"I'[BGXC]GX4TZ3^2MU&<PB@^2$
MY\0U!8YHJ1@G49S"^%F\Z]W.#=U]Y9.VMYFNBX-X.276TFR)79-,[?C7Y96;
MK6M>[I-BE*1.0PL5E<EB,XC'^3YM](W3&W,$%;R\<4TDD84E6RE%(>TBH."[
M[O<R+MIR2PQC>LONDOS;5<&V7<SDZ$M?)L;@B3O2(;9B@L/WCC:]+*FH;)6(
MKLM&<B7-I937-'O$4P;RKTA4XMXLNF<@$U-YKU+L8R)F;*NTK".0=PEJ)67E
MRY+:D7%RPR=G2N.A>1[*YYZ+LR[7&.IQT]FL=OL@6,QC9YQ .U#.85>2.S4
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M*<E!Y !@'[AUSNADU&AH%LR=FD5&*1P 0 P4$.-1#C]VJZ',]1JH?(U^0I1
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M!N%0\?QUNWU+%_I493CP[*?C^6ME@JG74N9+1$M$2T1+1$+K'P]OOT1$*-0
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M+&$Q! :<Z\/ !U**&T-\2I.P!K7MYB&B(CI(%"  B(4'LIW_ )Z(IC3_ -'
M/Y0 H?: \?'4_HBAJ&'J,% IRKQ[M51" XEX  =^M&,#ABJ.=I6#'$P4H&M
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MW#B/9)"5,IG"1E*F[OIOVAMF\]K>\=MEC?[F_>FVY]S,^'3;F%KW](MECU2
MU+6M#W'$AIIAP_4+NO<=H[F]HW<;VQVUFSNG'MX63:IQ*6MZFJ-^F,B@<XEC
M1@"X572+D^IC=V"+"PG:V7L>VA=FX%]MN@<[9L9JY@L#$ML,(]UYK=*-L=W-
MA)QU\Y$NLK-5RTA(LP(")3="P$,F&O,M/I3:=Q;EN%YLMS-#VRW=7VEJ?;37
M,CB,2Z4-TF*&.H:Z63'$5;4%>E<_4^ZV#;K&TWBWAF[C=MC;JY'N(;=@!P#8
MB[4)9I*%S8F89T=0A= OKZFBD>%[/<4;<+RRM;V.,!XLW-WI<*M]6M8Z4;B;
M)EO.;E &T5*LY&2?WK#L6IP+')E%)SY*QA72 A 5\[;_ *4]7V[-YW2WLKFZ
MW&XL8F"*275<0/#,7-+6B)Q(\YQ;5HTNJ:>A?_5#I=>3:-MGN[:VV^"]D>98
MXM-O.POP:X%QE: ?(,'4<=0H*V^0/J0A%CD&>P_@&Y\SXVPCB['&7<Y7LE?=
MLV0[M.V,FVFG?\/&6E;,JSDG5\71%V.?]Q?MP79(HE#RBJF4X#EMWTMZHMK?
M?-RAL=TO[N:VM(NE)*))().BYTDC2T11NE\C'4<3F0 M=P^I@B-Q/LVWRWNV
M6-I#<74O59$8XYH^JUL;' F5[8O.\5:!D"2MDE-\UW73DG)&-L"[<KFRJCC?
M%]H91G,A.K_LZRK9:V_DS$R^2,=F2C[A*5\\F91YT,U613422(JX,H!0 @\<
M7T^LK3:[7=.XMTBLW75W);LA$,LLA?!<B":KF8!K15P=Q)#0*XKKE[[O+K<[
MG;.W]LENQ;6L<[IC+'$P,GMS-#@_$N<:-+> !=6F"X/@S>5F;)UJ?3TO/*T=
M<UA2V=[@RJB^:6$[QXO86:(6U,12%WM[DN*'>LYJY[(@0D6:J3*-:NVTDF\0
M\Q<QT#D+KW^X>R-AVB\[FL=G=%<P[;%;T,PF$UJ^2Y;$8V.!;'*_207O<US"
MPT: X%>%L'>6^;K:=N7F[-EMYMPDG!$1AZ5RV.W,@>]I#GQ,J"&L:YKPX5<2
MTA=.Q#]2 ^2I7"[RX=NMZX_QON$QIE:_L47DI>UK7?-SCW"L"YN*^X%Y9$&V
M2?QB2[%DN6(<J./-D%"%ZFZ(*!3S-[^EHVJ&_CMMS@N=TVR[MX;B+I21L8+I
MX9"\2O-'4)'4:&T8"?,ZB]+9_J6=SEL7W&VSV^V;C:W$MO)U8Y'/-LPOE88F
M"K:@$1N)J\CTMJMDVL[[7^YC)<;8S;#;.W8N8PI#Y\2O""S':F0FMO6==<LK
M$6;;=[PT1"1KNWLC2CIJM\W%E6< P!,1%10O48O%W?\ 3N/M3:W[B^^,LK+]
MUGTGVTD)?+&T.E?$YSW!\#01ID(&NN0-*]?:G?TG=&YMV]MDV.)]BV[ZC;F.
M8,CD=IC9*UK6EDSB#J94Z*9D+YVY"W=;DV>YS-%CV#GK)B^1HK>_;.%<*8*D
ML>6>OM^N;'CQO;KZY86Z\C2EGL0A+@9Q*[]=!(MPDE3E33,BV5%0#E_4-M[+
M[5D[2L-PW';K0;6_M]]U=7;9I!>1S O$;XX&R'6PN# 3T3'B=3Q2B_-]Q[Q[
MF9W1>V&W[A='<F;ZRVMK5T,?M'PD,+VR3.C&EX:7D#K=3 :6FM5[>N7ZH&/(
M+</(8=1LIB\LV#SQ ;<9V]CY6LQG?B.0[@?,H@TS X-63/>=Q8SM^?D$V#^:
M363 BI5#D2.0@Z_/K7Z2;G<=LMWMUPYM])MS[UD7MY3"86 NTONQ^TR=[&E[
M(B#A0$@E?=77U4VZW[C=LS8&NLH]P99OE]Q$)1,\ANIMJ?W7P,>0Q\H(H:D
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M4A[ MVPW!NMQW&;=+D0-=<ZV1S"*V=JCB88V-:UA->I@7/J235>]S&ZC&-0
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MAC:EQ<78EQ-5[.T]K;3L_;3>U&M=+M0B?&X2$$O$I<9-5 T#47&@: &X!H%
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MR"^WN8SE-6<,]+0SXTPZS\L=:\ NI5O!,U7_ .WG.(L3("V,4>*PJUUR[O\
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M]X)%S+N' B<A1)T4$!^9W'N/<MSVVRVZYZ9%A-/*QX!UODN)1-(9*DM/G%0
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M1V?$_P PA0RR>0)BU1)A>:L99%_/TV5R.;W''3.QXTS>V3C<%_O[M$C=O"L
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MO2Z<N;>KK97]9\?B^)L+;5;>ZBQE6TVJ[RS.;5G@3>-GUN"1D#,8YS*E3;O
M?';J&8($ "F'X0^:L_JIM]ILNYV4EM.[=WW-])M\H+ +9FX#1.'XUU!M7-T
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MRV[=;#:' R7-_</A!8YI$3F1&4]05J*@4  K7&E%(D\Y65&9TMC;L^-.!?\
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M(N:36C5U/[9C=VU<.AM]WTOW2*X9#_C(FPMDCA<VIL.J6R6\E0V6@%)=+@*
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M6\^G))N0JLP,=#"5%J=0QO+;B!2\-=5S?7ES:PVD\LC[6W#A$PN);&'NU/#
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M.%##ZM;L]*YY/4FZLLTM$7YAOJ.1]Y.=WFYIG!05[-8Z\(G8@VD=K!<*9"R
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M1%-T1/ E0K7V?GHB8HGRX]_9Z/'1%"43X&X]O=X^G1% 5"AJ> :(@ZE;I#P
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M?F =*-7/S":9T4U5"1J:#IXE:!CPVIX9KIS-4QZ5$:</;7W:D@%2TG5@MB0
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M>=S8VQT&D"B$)114-V\>WM *:XUV.)=B5;(<25\ _'1563\P]'XCHB8-!X"
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M$>8\_MT1933^!Q\(\42]_P#Y] =0>"D9'Y*$4$S#00)RK_''45\5"<*:78(
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MTN$"O"E H"/0H @ F X>(!K@?ZJ!=[/34YIC8>\>',*]U.>H4JV2$G2'+[/
M/#1%+ Q0 *#3@'(![O1K!WJ*L"4X#5Y"/MU"5/-833,8]>05'C7QY<ZZ*[22
M:$JU(%"@ #7GQ'TZE:(51#D(AHB,'(/0&B(Q ^!8?_DP"O\ ]*EJIS'S_)!Q
M7$6+5R501,B;]0<M=%O,%Q](K;DTC@4M0Z1 .0C^6NB28:^"R<QS31%Z3]P:
MAL@=FHH[DL])^[6@>T&M5%')HIG$:T_C[=6ZP\$HY8Z?3_'JTZH\%30U"4'I
M W@4>?HKIKKEDG3"JCIBJ8 \>/LIWZDR&A64D;:M6Z037RV@FJ-!.8!K3O\
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M%H!040^@?#V^[12AF#F'CI6F*@C4*!-H.K@:AP61!!2%0H"(<Q#Q#WZC2/\
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M4:U$?#7L6UTV4'4X"GBO'GLM#A0''P4<"B',! >T!"@@/</#@.NHD4KP7,Z
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MF*PX#J(<0[2TX^OWZ +EEB<XU%%3'(-.SGX]P^&NE>>LE3-Y0\0YAW^[5P\
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MF#2Z,1OCEMW/(D#Z:RXO!#_2  %Z8L;;Y%Q6WB:V_P"0QL6X(B\(2][>O/\
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MON97"6/I.@9.^-KXX&-KTV$/HZA)-*'SV?2HS6>\07VX1^YW>WCB<;>U9;1
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M$NO"]Q/-OUJ?TG#I6-;TG:RT3DNP).XI=GD]M>L+) 25\YRT3(=NF9NF0?,
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M(82N;MOZA;+W#L;;R&6U.^C;Q<RVK9F:F>346ESJ!H!HUSG !E:OHI^.=_\
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MB\ DMX@8K6(W=MMBN25EX>WMP6)9J4@K+>Y%EV<3>T.\%C8\<R_<Y&YE5T7
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M?3)W6)>/$>SO_'1$T7(!P'[A]^F*)?,E_@!]^F**,HX W4%:<>P!#MT183.
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MI3&ZR'H _F_8G<&T;>-XVS>YGVD.[6#H!<QQEYA?U62^:-A#C%)I+'AE30C
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MONSL?S.3,*YOPA9N))6Q,<9\Q_M^>VXC:CN:!] 7&UNZUYMC+6%/DE"O"!&
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M63\O7^ ZE%$/^H?5]P:(FZ(HYQIU#X_CHBRD<1&G#G7V>GPT13TU#$'A0:E
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M-Y"$G64=,Q$BP?LU4'#9T@DLBLD8IB@(:\C<]LO-GOY=LW!H9>0NHX!S7C$
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M-8RW-W&Q'(.:('-K:Z;[V"8K8QMQRCC-;Q)UN-MF2CF+NW[X59.%V,,9K9*
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M,@((# 28FU:T-;4*W:NPWFT,V<VL5]%K[HNQ.";@M]O&VX;"Z1KB0(R"#K(
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M#UJ( 'I 0X=]!T6#@*GFB_,F[!,;UU^\H:UCR5:4S_%6C)%-PH0'CDK1$Y@
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M:"V8TU+L/FKL U8Y*M5NV:5 >E\FES_PT"\.'(!J(ZOTHAF0M=+>2KCW!*G
M!/*/3#7B!3B4/^;0@4'5*P_[6_<FEO(*$M++K5\U9ZJ/_P HNJ/M >D/5K!T
ML8<0 *)I;X*%\R #7RAKSJ8?,'[35IK-\X!\@!0L8?40F><Y,(@!2\:\B (T
M]05U FU>4 #Y*I;$W$D*25L]5* ^4<0J/(*%KWT&FIJ_@2JZHN",2(D5?[*1
M0#C4X=-?10PCJFJXYN^]-<:EEMQV?I%1=, [2E* B7O HB&H_?\ %3U8^:D$
MMTI 'K64&H\*= ?<.MHPX@]2M5C)+B-!P4@(9N3B(">@4H<>'I&E>.M-+3F
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M?\"[_P!P;_JZ:V<PG3?R*7[5+?\  N_]P;_JZ:V<PG3?R*7[5+?\"[_W!O\
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MY'_@G/\ NC^[3J,YA-#^1^Y#/%20CP8NN7_F3^/AIU&<PFA_(_<HPQ$I4?\
ML#KF/_D3^[36SF%/3?R*&:)EJ\(]W2G_ )@X_P#Q=-;.83IOY%9+$2HUK'N^
MS_R!P_\ BZ:V<PG3?R*=^T2G_ ._]R?W::V<PG3?R*DH14D5)Z L70"=L4I
A%$]3&!XT.(!PXCTD$?0&H+V5&(S_ "*D,?0X'+\PO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g680117g40w01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w01.jpg
M_]C_X08J17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,#DZ,CD 1V5N80     #H $  P    '__P  H ( !     $   "?H ,
M!     $   "U          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !.
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  K "8# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MVY'4NF/=H6U9=;?#:31>[_IXZ\V?:;7.N?\ 2M<YY^+B7+N?\47_ (J7QO\
MZ);.WZ/T\?\ G=W_ 'S_ (-<&[;M$1$F-LQR?HS[DQ<Q#QN<>V@24!M@\<CQ
M20U2_P#_V?_M#K!0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'
M' (   (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"24T$)0
M$(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      /%    !@
M        M0   )\   !( $8 ;P!R &T (  R #  +0!& "  1 !2 $$ 1@!4
M '8 ,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E '( (  R #
M,@ T %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "  1@!/ %( ( !0
M $$ 1P!% "  0@!2 $4 00!+ "T -@ T     0
M   !              "?    M0                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    M0    !29VAT;&]N9P   )\    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   +4     4F=H=&QO;F<   "?     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      3\     0   "8    K
M    =   $WP   3@ !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  K "8# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M<&%C:V5T(&5N9#TB=R(_/O_N "%!9&]B90!D0     $# ! # @,&
M        _]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P@ 1" "U )\# 1$  A$! Q$!_\0 X     8# 0$!
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MI.HQO7;E8LUL.(ZJ4^HS-1U1^Y(X_ ^S""UY%:UV<P[PIPW3#*:ZCG>>'*A
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MPC<>RHUK\;RB-*ACV3+&GD1Q8JTCJ<M364':0^B@N%/@++]-WTX1(@9%'67
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MHF)&4>M?+56JCYE&XV,0NG2$<;T5;B,<H\ M+VJTYYW4H4=1?YFJB(Q18!T
M8?+AWXJS^Y=,<H)C&X!BX=J;7=1TMR7_ %A@,000$!;T-K.0YEF#J.BTE][L
MG8 L -M<'4Q=N'/*4*-]9RM':'SF-*^*P%,:H$#E9.W*R@=@*LSE_C:JZ;<
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M#]/!1#D@8.@XYBHRF.>)H_WJ,.U#67.JPT_7(73+3T&[">V49X-A&A9W*O\
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MQ)%5*)Q$B$(@5938)@BH X.Z$@[2B)'MPIW"HXA. K+R<&57X1D1ZB >X*0
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MM6(M;MG(W&,8@^LU7<G]+LK<MQ!4@^_Q4KRA=&PJ-5@B?2-Y6KSCGE<SO_J
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M\EZ[L#CL?+F;;BC79Z._^'__V@ ( 0$!!C\ \/7$_CK@4DT_BSQ]++(W#N.
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M8$!=:&NY0GK3X^ATZ#1@$J&#*QW:D"K'_,*5]/I%.F/M 5&8!5/U4]I!(!U
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MDD2JAOW"M&.A.W0B-!\: "OIT&0Q@4$0:-=\9!!H1-3WN?12="*5KUWC&$C
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M4K4T)T4@Z?TZ<DZ5T&M!_8](S:J&4L*5T!%=/CIU&A722:V5?:&!'<0G2M%
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&E*K6H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g680117g40w02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w02.jpg
M_]C_X09C17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,3(Z,S@ 1V5N80     #H $  P    '__P  H ( !     $   "?H ,
M!     $   #F          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !1D
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  W "8# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M^F[A]'_._P!J2Y9)3?8Q?:__V?_M#NI0:&]T;W-H;W @,RXP #A"24T$!
M    *AP!6@ #&R5'' (   (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%
M4SA"24T$)0      $(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M     0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    %HX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  /%    !@              Y@   )\   !( $8 ;P!R &T (  R #  +0!&
M "  1 !2 $$ 1@!4 '8 ,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '(
M:0!E '( (  R #  ,@ T %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E
M "  1@!/ %( ( !0 $$ 1P!% "  0@!2 $4 00!+ "T -@ U     0
M                   !              "?    Y@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    Y@    !29VAT;&]N9P
M )\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   .8     4F=H=&QO;F<   "?     W5R;%1%6%0
M   !        ;G5L;%1%6%0    !        37-G951%6%0    !       &
M86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E
M;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO
M<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E
M5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453
M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1"  W "8# 2(  A$! Q$!_]T !  #_\0!/P
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M 0,1 ?_$ .P   $$ P # 0            @%!@<) P0* 0(+  $   <! 0$
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M@)P)6!9P$4!J@9@+,]?DWW+A(9/);2[%L?>C563)XFQ#*M:KF&K=*W756Q=
MSE)O.M*ZR)L@MP!: 00-,#4 P 7'].P15:G.I)&ELNN+B?1QJK9<XRHY<W%9
M7(S9A,S9P*11"PC. Z %,!# 1 ,P'J!^,NECL/+L[K"4@)J)+=Y%T$:*V1-<
MN,6EM7MX'1%!OAD0>=(R@>H&$#1 ]0,X'N L@=$O4.:IH)-:5H('_]H " $"
M  $% '?HD?<E/4?2KTJZ.FD"A2!7%,@=<J5'B@SG:]\]7OGC46X,NF6RGUO1
M%>B*=!XY!*?Q3_;^C/GQU4AGP0T. T*]))J=%4BBH<@$T 34>.IY;S0#OI"O
M2%/J!0/N< (2E:0CJ314"EKP1_)"@H((H)42@>(92ZS*_;6UI=@ )=MX5!=A
M+,Q*A7C74*>2>$GA0ZC] #S_ #;\4J("+A=D0$N7Z<NC<)*JL%_0^[(0ZEEP
M*"_/Z1VW%K6VOCTZ],4_Y)XY3^+;9))3R3TJ:7PB3(#+%R=+=2[LZMUJ6YZ<
M*:?5Q%]=ZL&2,P&9 *2*M,YN.ZN$IYLP7*5 <2)/V@>:.>E"5!)0>I23U-M?
M;<$%46^MH+7['(E%N$&"8[K5:)M=LF8/GV!W"%.##Z >H&PV&7=7[/KOHMRM
M>!-2L)#*I'W!'BII(X0 4J0D!U(-,#AG+9ST&V7V=,2S%O[14JX./S%W!*HV
MH9$B#@EQO#Z(EXN/+XG>%AO3B7L<NQ?@0Y+3M3$LJ>E)"4H_-CQ"$CH7^+M1
MP#'R:(9EE><=;CVJUO2J>AQDHG(<;&L3S@2T!QC(HB&97">;04)<Q-:50;>3
MQ,/#LOR3YQQ]K8'2YYNU&_Z[Q4D2T!T*2_$2P^RZAB-.NTNR6]FTVP <9+%+
MJ)J$H<MJTAW"G0N%;U*J9_>E_BGSB^20.AX#H<J(.6)$H-KR+"8]ZAA+3[<N
MW,,IU-9HOK,@ ) XNL8/0[K"Z78D9X.83_9M]32?5E_BD>,3R3QZ;G 0OH]3
MUU\>FV3C5W>M:\RULN_5<X%QMTG5CO-P8O5QL4JV7ZWSV@&UHN5A]=4/''P_
MC\(PV8E32"]+*>$^<4A(DS&F0]*>77/@#R4(YH)Z3@F8+M\?/\%LF2XGKW!K
MBF+EX4WD33SL=6.9=-8EQ%>NB(PDTUX5%J5^4I*@$^<8'B4>7P":"":2GI/T
MA2%0Y-EO#MN7<Y'%QS6,CU@. H\#%Y:9ELB* +1J)4K\Y?X@^,1:2'5=:TD
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MIV?<D2&)ZOCKV!<MJ?'Q=EI]KM2045?)7&0Y](2A+;RD3ODO<9_?HZTMN=7
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M!+,JC3K.>6JA!0&JA<J'.IQ&@-"&*$>E11@2-8;]+BM#T)&,]2@#40 K TH
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MS@DAE%04 <@.#6A4#Y:FOY8C1E"AB7/JU!N@K1E^9JY^%<! @+*064D@"O\
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M>3[;Q;?Y^(6M]M?%+_D.U6/(+BVV#>Y(;^WV'>GW2WG-YMFWWS-[,<JDQ*2
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M9-FM5(-W#^L$L"",JCSPA(*E-OL]*H,]/T\)6O74U1X9D?AA@0M#<.$CH&9
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M)0,P46ANY&F84!=ZD DXEBD#-;SNLE%(_;DH:2PU]*.E<B.HR/7)26#:XWD
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M'7.F2DD8#5 ",-8SK3(!SYUR&+IJD,+B7,^0=@*_#,8U D =23D:Y'(],P<
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M:\X7 5%I'%#:7)LM@A%S;TK;W&M&9F!.'!!K1JD&E0!7Y34 FF?PQ,'J0%D
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MID52=$A)I2O3_' -S72 /:LX"9"Q7)"6I[<=:9FM*8MDD=8;F+W&C53IC5I
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79>6%K"0=2Z:-'2NKHW[E<STSZ?#'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g680117g40w03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w03.jpg
M_]C_X0:^17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,3@Z-#D 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   #>          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !70
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  U "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M+D?JJ[H]+>H9%E65CX6!:]K[<QK6M:ZMK;KO7]-SK?48W])[ZO0_<]2Y>?\
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MG:LM))3<'+N8WC[]CDE3224__]G_[0]$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "H< 5H  QLE1QP"   "   < E  !$=E;F$< @4 #55.251%1"!35$%4
M15,X0DE-!"4      !"-PQ=Q 8^5RD:CK@_CK4FT.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !
M+     $  0$L     0 !.$))300F       .             #^    X0DE-
M! T       0   !:.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!$0
M     !     "   "0    D      .$))300>       $     #A"24T$&@
M   #Q0    8              -X   ";    2 !& &\ <@!M "  ,@ P "T
M1@ @ $0 4@!! $8 5 !V #$ -@ @ $4 1 !' $$ 4@ @ #D ( !F &4 =@!R
M &D 90!R "  ,@ P #( - !? &8 <@!O &T ( !' &$ 8@!R &D 90!L &P
M90 @ $8 3P!2 "  4 !! $< 10 @ $( 4@!% $$ 2P M #8 -@    $
M                     0              FP   -X
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   -X     4F=H=&QO;F<
M  ";    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #>     %)G:'1L;VYG    FP    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ -0 E P$B  (1 0,1 ?_=  0  __$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_1[+_21*GH<SJ&3T[H&7T.V[U[^H9%=K[YESL;;]I?ZC@[Z;LQ_H?\+3ZO\
M@/1?9SA;+H')Y4M (W.>![:]YEP8W2FLN_X.M-(:"YW)X24O GT]('/SX250
M7/DGOZH'RVE)%3__TN(Z//[,RHCE^I\(J]251Q=_;B'1\--__16>DB>B@[0F
M?]>/)!MW;G1]YYVK+224W!R[F-X^_8Y)4TDE/__9.$))300A      !7
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X
M(4%D;V)E &1      0, $ ," P8               #_VP"$  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @("
M @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __" !$( -X FP,!$0 "
M$0$#$0'_Q #R   !! ,  P$            (!08'"0,$"@$""P !  $$ P$!
M              0! @,%  8'" D0   % P,"!0,#! $%      $" P0%  8'
M$1(($PD0(3$4%2(6"B R,T$C-!<90D-$)1@1  (! P,# P(% @,& P4)  $"
M Q$$!0 2!B$3!S$B%$$(46$R(Q5",W%2%H&AL5,D%Q"1-"#!T6()X8)#8T0F
M)T<8$@ ! P($ @<$" 0$!04    ! !$"(0,Q01($46$0<8&1(A,%H;'1,B#P
MP>%"4B,S8G*2%/&"L@:B0U,D--)C@[,5_]H # ,! 0(1 Q$   "HHCG*K- J
M+#MS9ON12FASS(H.BVR$?EJ+*PTV_3%[36_I(-Y8\:HFG5\868#9JCD^"6/J
M6U<A,"I,[>5%&6/9<[:D(S9+M9(X+*$O7M-BGMG<++LI$I9&I9B(<%7Q;ZV!
MPX^J/.QZ.]?A4#AFE4LGVU(W99-Z(RQ'4-Q+?7MPG8$X\[6M?S%,[8Z11:[Q
M'GAB^K,B2PJN%?>>*0VHP,:OT22CPGP1(YLD5\DEF SH7Y5UBOG3NB.(#<K$
MZJXF,X43'5UP_5>$%Y?T?Z-?S%]6XS9 ^&KI7"!R(!J5T/L<EV DIDM>+U<2
MK>YINY*7).YRES_L=B ACX/A>!^O,T&XDGL/G8E][YM[2BY(DC*<2GO;-'Y]
M-AY\W695MSWM,JF03,4Y].1Y0Y9EJVU6.<9]*IW,^QF.?6S1?ZN[S*A%KS&-
ML>K%9V[SGL'5VTU6NX:KS:=,YQ[_ $1LPL!GGW99B,C<<ZI$*2/,IZ45]>/R
MGT(,O(NY&/(GN0.\+&A<\31 FI3/[%QFR/;-#R.7Q$K<>)QP=,XF(15>,?.^
MJD&8D-*\/6ODDV"QBBVJ;N,=[I;H=X]EL">I=ID @,@QZSH-2NV9]@N6]'>*
M,R2:R(%>QZGR:]&Y1$& (_)>S%\]@H2Y4I)/(-Z$?@-W9?YK]9(FJ=-@:TT^
MTUI"G5;$7$FLY82Y;V:ALC[KY8SX[&K1OV+6^3?KW(!](K5?@O;38EA$=2*+
M(W2)M-.4^XZ]TE>3_9U8/'N\!QNO.ND03<1JJR+'1P-J2O.OLO"2'V_G'MB^
M$5C6M1S&>D_/ ;7NOQ]Y2]%G!+"+XQ-#0Q;SZ!KQ,;YI5UO&^_@9Y)]EU=[E
MK=_U)NRY46!AA5KX.J[Q_4WAQUB&Y&*CG!BKU/FU:GH+A[-+&J0\1^I3=,A'
M>N)HX@+>6[Z_-?2-,MJZ7HHM?*KZRN./9K#QMM-<:B$>K63+:DN\]2^%Y"'L
M-B%R:6''NS:R*G7.71YL5-SD^9>XG&7!! ,]) AKXWS7Y_Z)I5EWH#CL$_.+
MZ"Q1S#M$Y5F\&[7N?-*<7^]\TI;[+YVL4;'?\K=1X[%V+7!@ZOS*-MGUSF\\
MY]I.<P>%AI*/P#T[::_0M&@)JVU_1YU"]Y;N=]A':(^X[4-YMHW+0K6>L<&X
M+72\P2OZ9XX^GI!;4+_61?ZUS*+=IUOG/\Z=G-LD>H2NN^=>LV48UG<)(U_\
MQ?;_ $Q$HF9SQ\L[7<=?:G:SNO*X*<[X^DY#7DCTFM:,.6HO@Z4]TT6S/?M'
MY=^,=:!-MK64)/$\4R0C)^GBZYRR>K*G*JR,;Q9&Z_T LL>TRNDY,E=PR$*N
M3QZ;8XW:F7,D)5DEDL62CR87@_5ZCP/.YTC*R9.U@YW3G7'!9$;PE6FI_1T0
ME)'M/EV0QBM(S4DC29&+68AIDB.Q<DR+Q(\Y37E&X)09I>Q"F+SNW*'Z,@;7
MELIY>:O;]3[I9) -U?9^!HX)&3$Q\621<N(J.QY29F=C7@AQDHZQG!&%),*O
M(PJ#OD)ANSJKWYC$=>%!8_TO;&OX8Z'9*V31]=4TG0I,BYG8ZWXIR9'@^3Z<
M)M.BWQY@=K26]"ICF-[QB1:WM=NZAK[79,D&+FMV'FLD?J(GN_$R2-OJR0GY
MLR8U(\8T6.MT19VP;W9-7/1&#S&IZFC=NC#>+*D)D6^H+X-@JN='5-J:,KDS
M,VU=';AW=.CODS5QD)0K-\CA&%6Q:^K"R5*C*"T&<:<]2!>C (BHTL*I@>>Q
MR:& 9S,BKJQXDNCTW,6YUVG,:KDCF!Y!$Y7I3+:=L56<9#:KJ6R"T D\R@_=
MI9X2 Z([ZA&DE"1)@5$EB-M\*@Y77+B0Y(-:UJCRE,<VO*HRR2]KCK)8&E0?
M6[6DG"6.*4$[]C9:X1#7V\I[2+H-1K-9X5%^3-J?(X:T?8D]H9"7.P!JA+#;
MZN,B9K+#)J@IS"8F@WW3#&%DY2OEHQNTJ(*N4<9@S%-V,B1K*;D918TX%+4U
MM?=9(<=J%9(?"V("*=J,QW.8H2J0-?C>M%7W(@M5VXGERH^-BC$<ZM:"Y'L3
M&-#(9!L=?=:065F+<18AQF')474V+5;D@2Y-#<4)U_/7RQ'&Y$ARL]&H"YAQ
MK!QB2QD>Q$&(:@'UKITL![U;JK!^B+!X.RCAN.Y<ER=7DK,DB*#7)TF28R"!
M,G;KFMK$\Y'OM;!4!)AGY__:  @! @ !!0  \^D 4 :FZ(#14=IBA]0E"B%#
M<D!=Y")&*HR::JM66\C5H(@U:U[-F>@9,RBDT9ZG(0$W!2[MA: HT"0"/2"@
M2T&B@.X1T 0&@^JDC%%,3)(BX=L1-[UB4?D&@5\BT"BRK$M(S<=2+QFN#C7?
MK0:TD4=-HUL-12B @ B*ATP1D+Q:IG<W#.+%;S4QJM./B%3N5N)_)4#%VT(:
MUII1RB:H]T=!<-%B](* X"9(X:> :B+A=%LC/SZLHOUBI*+70)%#R[XRH3+A
M<&LMM5BGADBG 1H2B%&K4 IL43+-4M$.F6DOJ41'R P".NE <PC=CQ9NU>OR
M)#(2:BZO74,1),RQ ;;:=E*5M;KY-W%M05<-S-U! S54:0BG*YHVW3E.= J0
M[!H@[#(G\@\A$VH&'IENU-48NYF238@I !T4_I9E3,F54#E<Z;+)?*&*P>+I
MH?(.:&0=A24R^*:/N-0QEE -74H@ >B% HF'0I53&.;TN0#%AKQ9B9NNV."B
M8G(":B1DS'*4JIME01%Q=04NR  '4:$-E(B(+,P,JVZ-(UZ")C#12?44F@7H
MY:L(ZYQD%#$MZ659EM.-%%1@4C@;=M95@22!FBQ5*9R=(S^<, ZT)!/41#++
M'(S%)/VYZ1UW H<:,8P B)A%KYU=<0#^VUWRL:=2:7 7+@YFSOVR39L+H2-H
M\T:*!!!2T6 DNO77P 1"H>3.W<-3E=M.@6DJT"A]&VHF8)")6;5)RE+P L4$
M&ZYU9!B=T MG2PJMR1RYW1WBJW21JUH/XY+P&HQD==>V[9=_$_;3BD?,!2T
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M_:%V7=1BT0PE$I1*=8NQX4I2C1AT IA$:'P*.E&-NI0P@FCZZ!X17DOZ+*+
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M:)=;@L5R9-ZR<]1)1 M'CE53.$"=7V^Y:XI:*1:73;LLD #KXO2ZH2J8)/\
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M"PQCS!Q,)&L3Q<+8;>Y:TS,#*8_@,Y2'7JC*/M0D3XV8<X\3SZ#TE418LO\
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M]Y^*^>7>?BC^K+^H_%?NR_J/Q1_4EWGXIO,G_4?BF\Z?]1^*\.YN1/*9'M=
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M-R[W(>RS;'V*SI/BO.>;#+D#GQ5RA!$304)+8!LS@_ #B5&SN"]VW$U%!)L
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M<IZNLZM/4%<\T=55HN8Y(\E5.443DW35190Z;$N1^SXJ)EFG&28"I49'!$=
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MW,:5/51_AJ:XNV6:61W:2YECA21P(U*T1!U>E: 4T%"#:"^V15&T44$J*5!
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M7!I%QG.RL% H&1A<Q5<5Z%O0?CJ0M]R/#BSMN 7A656M:';*_P#($R("HHM
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M;+U:(QLHZBH-:'\=1B0 .% [)(J!0#8%7JI"^H'2M::NG*2E8HG)6,EBZ%J
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M#22P-4M>2QH*]V]DH5HO[:+N^NK&!T"=P78[B@N7D>4%GD$IV L O6NXDBI
MUCO:)PDEH[%70RO*3$C(QVJS M&#1"5=1T-?3(KO6.439!EBBK'&\HFD,+(0
M2RF(U!W_ ( =?76"Q$;-) EU+GKX)[HG3'2I'9.R-4&0W4S;AU/L!IUU_8@I
MLK3XZ[>U\"G;I3].[K^.[KK-V&.NWGM\9<RP_-[K21WF1(62_:!"%"P"=F04
M]U%-1KF>/42!L/YDRDH8"-D?^5X[Q]E)#$.6B$9/0]=VKJ.&.CW*K*JUJHF[
M#1P1N6-$E!W 4Z^H(IJ>WJT:+>)?@&,1_(DDE!N>VK$N8XP[;Z^T..E*ZG4%
M)#)-( 0'HVPB52*UWH5%"-<D6/:L]O?P(6W%7AA5X[IEW.3*S2D4%!M50?KK
M_P"J-?X>>$YMO-'C?BWCV*>ZBM%GYKY2\-VF-Q$2W%%6)9,E:1$.PVT0UHH)
M&8^U[R??#COW"^'K?*Y_Q#RCD!DM[VZSN)CEAY#QOD:NK7KV\=RKV.;>ID>S
M>SOZEK5R>6\?Y?AIL!R# 7]_QCE/',LNV]QU[9326F5Q5Y&-R,8G8K5:K+&1
M(OL8$V/VK>6);W-^4_$EQBO^S?.NY)=W^:X-=7,6+; <DNGBD>XO.)816M;N
M29F;(XM;=BZRVX!L42 4N=MQ8RRM$J"*W!2>>)H_=%VWA+1BG4K4#:!I);<A
MKB5 (V?K<NK*P:0$@B24'K'T-7'NZ#27DJRK<7)>:T=D5*/&7CDO)8PBQND*
MMMHM7:4?@"-3X2S5Y(K:U:_S,\K%FFDC>!_AK)0O,ZR/NFZU(.PJ2#H,L<<$
M5FZV[$N(C<%_UJFU/9"&1MZ%J@#I35I''!'"XCO$(9U2.5GN#[T1O=!#)$P3
MW4"D>[U&K86MJ)6N8["X81&58+<O((X;%1O,B/;R)M)!"L2.FKIYT>&YO+F6
M<1S"K(I>)#!:,OL<[HZRLXW*3TJ#K+WT5 MHJ8Q*/"-CP4FG,="\4:]V8[R:
MD4ZZ[O\ ^%_#;=^_K\3M_$[^VGZ?E^S_ "[?=34[7!+O,TD[F0LTDCSL\S-(
MQK^XS.2:4]=>9[>.15FL_*G&[P1,2?V[SCDT8*!5+=UC8$*:@575YOE$B8R6
M:0W1) 1!$_OD:,[8V17*FM6)))IJWG1MZ75K-'L4L>RJ;IG[K$;00'4 ]*K^
M)U9W" @R)&%:IJFWV2!D'5I"/P-!7\-<VQ(C?<(HY2L3A]O;21&C).YD9:J\
MAH5(Z?D<_P"!>"Y<X/+^3_NB\(>:XLAN++W/"O".86"2W5NCQ]['&YR=HDL1
M8+-$[*P(8C7%OO7\#-%Q7RUPB[L;3SMPW%GNY3B/+\#$D,/+[>U3;-E<9'8L
MLD\P#ID<!,KS.]Q;SJ(OO&\6XJ"R\P\#Q1POW*<+PT2S7N9Q>.LT:'E%C;Q@
MRY&YXMCX_D034:6^XX2C.TV/;=D^;9:*>Y2]N/AVY7N1R38^(L8+:&=5K"]Z
M]7J*J(UJ?IIKC)*T5E.Z)^U4,NR-%AQ=B=RQ"&2$A58E50L26( U+-(&6WVR
M*EM;D)-901H\<5I"]6:0)$NP5+1T):II75B+\R6<V1@7^)3L2W$5M#:VSNMX
M(H^ZR6\0@$< -.Y<$$GUTXCL<C-'D+.2XMA';-&T$TL\+7,MT7=2UQ.L1;W5
MJE:"FJBQF>":Z22*:*2TE29Z!U<Q23&4*@K_ $U)'7H*&SVQ/'=.N1^3#$\)
ME3MW:O)/,S2%UE^*H.TDIZ4U##&MO%46S6Y6]MIHQ.(X;H%D(#A))!4@%O=4
M5H#J16)MIYVGN2\LIE9D"R/%+"](S! J#8H*FA'J:C3WLH,C7>2O)G+.57?)
M(\2D1J*;^W&*D_J6H]:ZW]N>O\=M[?>A[F[Y?8[=>W3LT_=W?\OI2NBN]V41
MJQJQ#$! 02M?5C^/TU]R/'II/V$PG!^36\1+=;FSO\[C9I=B=7 2^2HJ-<@Q
M\]RLP@^?(L$:JV\0F'>S]T5""11MVU9E45KJ';$T"VTU?:$/<@E:*V:9R#4E
M10=1T+5]1H54)V+DA.VQ:L+5[BAJ;DHWM8MKEF!</W,AB)Q$T0&^.6:,R*$E
M'O"(T0KN(#"E/IKCMS-5);'(Y&&V9F4[)IH7MVM#N )$O9W4;ZCIJ#G-G%+F
M.'9Q(^-^2>*NBW$?(.+23'_JH[.0FUN\WQ]IFGM1)19T,ELS".=ZX?R9]O\
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MK7Z?EJ0LX*LTJ[C0N6Z'<Y'M&XCH 2->6N/W9';S7B2[G[9(!8XKD>$D)%2
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MKZ,D@.]I4A-Y0=Q06ZD4W;=M?3KJFTT_BO\ E_T_)W[_ -7_ *??]/7_ (:
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MBC4R&7:%-!(3U^BDTZ:O0"5VPHRGT*NLHV'=UZ5]=5[K_P#H=].OZM]-U/\
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(^?\ V]-?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g680117g40w04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w04.jpg
M_]C_X06Y17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,C Z,S8 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   "S          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !&\
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  K "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M=K@P>#2 X)L,@F30(KNOS<O+$ 20;_=3ZI))*1A?_]#CN1'BNZ^KEN'=TG<
MTC:W[0Q@B+MC:+O5V&O;ZSJ_7W_\+O7!NL96S<\AK?$KI?\ %]EXN79EX-3A
M3U&P^MB;S[;:V-VVX[FZ?I*OZ3_4]3_1*++C,X^G>)L-CELPQY/5\LAPD_N^
M+M]1MK;FX,M=9C7!V,X1+6BPL=2YNN]]CK6?NKB>HUMJZEF5L:&-9<Y@:/Y
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! !+     $  0$L     0 !.$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #Q0    8              +,   ";    2 !& &\ <@!M
M "  ,@ P "T 1@ @ $0 4@!! $8 5 !V #$ -@ @ $4 1 !' $$ 4@ @ #D
M( !F &4 =@!R &D 90!R "  ,@ P #( - !? &8 <@!O &T ( !' &$ 8@!R
M &D 90!L &P 90 @ $8 3P!2 "  4 !! $< 10 @ $( 4@!% $$ 2P M #8
M-P    $                          0              FP   +,
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   +,
M4F=H=&QO;F<   ";    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   "S     %)G:'1L;VYG    FP
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M#     (_\        #A"24T$$0       0$ .$))3004       $     CA"
M24T$#      $BP    $    E    *P   '   !+0   $;P 8  '_V/_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ *P E P$B  (1 0,1 ?_=
M  0  __$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ XX<(&1F,H<*P/4LY+08VC^6Y6!V6
MM]4OJ[T7J./DY75&OG[396P^H6-<UH;N.G\I_N?N3)S$19_!DQ8SDEPCM>KS
M3.KUET6UEK3^<TS_ -$AJO AS0YID$2"."%U^?\ 53ZJXN$^ZC&;N>"UCWV.
MM)</S:F[G[G?U&+B,(!M=M8^C7:X,'@T@.";#()DT"*[K\W+RQ $D&_W4^J2
M22D87__0X[D1XKNOJY;AW=)W -(VM^T,8(B[8VB[U=AKV^LZOU]__"[UP;K&
M5LW/(:WQ*Z7_ !?9>+EV9>#4X4]1L/K8F\^VVMC=MN.YNGZ2K^D_U/4_T2BR
MXS./IWB;#8Y;,,>3U?+(<)/[OB[?4;:VYN#+768UP=C.$2UHL+'4N;KO?8ZU
MG[JXGJ-;:NI9E;&AC67.8&C^0&U_]]76_67.SL>O<S']"^LF;]P<*W 2[TV;
M0YEFQ<%DYSL?*LHSJWU7M=-GYTEWOW.^C]+<H\$39/84S\[DB8B(_2/%==D_
M=) ^UXVWU/5;M_'_ #?I)*Q31?_1\ZL<]Y#GNW&01X#Y)J,FW#R&9&-8:KJ7
MBRFQO+'M.YI;_5<HOY/];L@V<GGA/0^IMRZOK-T3'ZCDO#;KGMJRG-:2]C0[
MT[\+%IJW-;OW;L/U&/\ I[[K_IKS_P"M[,X?67-.>ST\BQXL-,[O38]K7T4;
MQ_H:'5U+JO\ %Q/[-ZA.[9ZS/YR/1GTK/H;?TWVG_2_\"L'_ !@S_P [<B9G
MT\>=T;Y]"G^=V^WU/W]B,N'PXM.*O^:LAQZ7?M^KV[_P>)YJ-?FDE^=\TDQD
M?__9 #A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M<&%C:V5T(&5N9#TB=R(_/O_N "%!9&]B90!D0     $# ! # @,&
M        _]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P@ 1" "S )L# 1$  A$! Q$!_\0 ]@    4% 0$
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MWIUGFG<;L[9V+"QC41 =JV(BWY1391*J*2(BUHE,KM4A3LBYOH=BCVFM7%0
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M6%%*4?0:A&(]3NHVYQ))P;+O5DW8/#4';%L\Q5J5HZO=#ZJ->RNL87 QG;N
M>60.66&14ND_NS;&=@R/L[D@TMO0 LV'$JWO>B[@;@2#N#Z3PD"Q?N!6N?39
MZR*EJ/F:U;O0$[)!).&&/V=2W-XBF694+<!$6(N>=%<GJ.0 /QJG)%$9@%E0
M(S.>6:)C CLEIK4IK@("@!Z0*)H!PM6H19"T)ZH2#'ES\%+IMXDV1Z20]<6I
M7B1C6E'"_P#$]=VD;VPD' EYIX.#&> &8JI=3Z9=N;G]K7#JC*'KL'$:R*$#
MX(?YMWW(_P!6FAYDX G-0-J40"31D#[E-)4M,GN&) ^(6F,6A*$)#X,?GV,R
MU1J4;N9R1\N!6&:+<2M)G&1X*-W<>2RSM@K5C;6GEJKQ[^Y3C!]#!N:H/U0H
M3E,1G(U).'/EWJ5BZ?/$AG^XYB1R-1*F$HMO->VC/;W0==N3:&Y0*O?N#]BS
M FYE<V<@T234F(Q &04K>]$K4HR ,9 Q / /\DQK+2MC9N2:),G^"Z?> Q@8
MGO%0/@_;@64AJHG9BL<T3:!^"T[F+W2HVA@ R-S\94;TSW+W,UJD/+FHRAZ3
M&O AJ@C,$4/\U9E<'JSY<^88B5<M5!(!2W&VMQM[1F,IBA%<(T)PQ.D5!!DH
MFWNK%KK$?^.<P(VY'$QHQ,LN2O;/>[:Y9O1>DBX(XP.<2ANIPU1A:F3GR5WW
M[8U7;L/;I4,^ISS%!3C4N.V:D4)KQ4+5HUTCZ*J$^*]H8NZ$&]*=%/P4+^YV
MH>9HXJ#A0Y</@M,+X$<AP73MSNNIRLW;1D7A4EL'71XV[)E".UA"$CC*9-'Y
MLA*]9,>K;CS7!RQ'S_FK)?\ XI_4LA'-7RV2*"-M,^;?>H$CS:1] G$=1^*C
M)F!RR^"%,@I:R0_!:8&1ES3FK(:8,'0TU;#EW<%:WD0!N;'JB,^_CWE&-TB$
MXN0U'?+GP7[>W<IB0LW"3&5068QH>&7R5K<W[X$RXQK0X=RW-N#2\OV*@^-4
M1D4[?B^]4'V9"!Q9>G\3_)0D3Y-(^BHM6JA5IHL<%*-P.)"G+BO<&"*Q3P%4
M;=[T;C]/NE&C^(\**W<W-S]>,P ,*9?%='GL;9&Q$FN<""'9:(.(5:I9GP^*
MOG/25.E!*BO$BHP43$5=1*BO%0AEI'T"T-Y@KEYSJ!XT5L@!P'4[DO4G<NHQ
MR.*!B2Y0@?2O=A2Z)!N 8T/?QXK9[N$(^]%@:5\M*UQXJR(S,6#EJ59OHK-J
M(!]IR_XB#Q.:W\#C"!;P1/\ 5$$]Y*W)!JHQ_"P4>]1*\/FH?E'T6YP]/AX*
MXH?E4T/S**CB@B[8YX?)=1QTZ_\ HQ/IS?\ J?-V0[LD?5AR^?+N6_;3Z)>E
MVP.+_<H?D'U6Y\?HH_E'T4>]!9X+_]H " $# @8_ $*=M%X)UE\NS#MP1+)U
M@L%@GD:K')!%NRF'84#(44I$#250H/!.S%:C)&.GQ1[*G2O,:)P RF\1Z5ZE
MAV<E1%PG3%M/P^: E;D8C*'WDU7Z-N41SE$_!3%P @'(#ZCZK5"57P0-R!!\
M4PP7)$@5"J@"M(-$:K#^!RC5-$A#V@"05^O:+\BWR&2MRMF+2Y!E.[.(_P 8
M8G-^2TPLQ9\2[^-5$RR"<(R3=C=E!18)NP%UIRXJ0CDHDBFH COS0M;;;R$L
MR_S1$]?<]'_U.*GM;>WE"Y9#W#(M&(Y2PER;%6]EL=K>.W$0Y$"TB,QR.*E'
M:[&Y(@\""O>G:%NK-)P?]497+(G;&)B7;O",&89\E*V3@"7[NVH\O%%B]>W%
M!PA.(JZC&<23(+;;.Q$'7<#MP?\ U5K<WX 6IP!D7J/EBO\ N2)]U5MYW[DC
M9@:66 'B0:CO*%JQM1&9%&:@X*<[.V!N2SD!CW_1?I[>V+@/](*O0OV(Z *:
M8X\CR439M"%NX20!]_V-5"_$^4Q;GVQB?2@Y<&JP.#JJJJX)CZ%.3>01)=6C
M<F?>]Z( !JQ/P9;6T)2?VP"YH[9J<?< &51BC*%^)NC$8J/NV#J?[9X(:8-3
M MW_ $6JY+_8JY&,7)P^"V,A!@YK]5'4/(</!5[):A0*41ZUZ3@W:V297B(G
MT%&[8DXB8%\0PQKR=1L[^Z(T%>69 Q/@I0V?580;^H > )96O_#;R!$L?,&4
M_P#+E"9A)B8L<(.33)UTS=[0&-J4I:N0 (<\!P=2L;_>1_R8QCI$9 N&K09@
MJY+::YR +N* 88]Z/4A_RVB[#$ D GD&6W)D,^RB,R0Y4M!#:EC'LKV.NI]&
MV^X-O<6-E.]'^XC %?NK:]5L>WO+!B-/]-,N4EM+=R8C&,9 DX  Y_!0ZCU$
M&&PA0RB#7P%>Y"?2-W*)(_\ <MSA]Y1Z;TK3N-Y=E(/D 0U.7!=#V5S]/=W;
M0UMD^"AU'?[6>\NSPA#U8Y.#\PK4+7[7.UMW8L-7J);/#O77;.G2?8D0.ZJV
M5J?JEM87?&9_U1[-*$6QK_"(+:1NW2+%_;7(RCAKT 2 )X48\02%UK<3 LSW
M.WM3C;@!I:68; !F R5V_?WY]YGC$L-1X/DIVKVPO[G9"6$0+E'KB"KUJS^W
M;EG;?URM@3\ R-W:[34)3)D3B>\9'B NC[Z-O3&,@&X-BK5\68R  'FRIS4[
MIM1 Y+=6V\PME>RV%@!%/Q0;UKSX_=V'LQ6K-=$ZH1^A9NO=?_XCY9MS\P([
MEL8"X97[>RM1,V82@7E C,NY=ZX%"];D=8%.-/MDALA8NS'*KJ&]W6_M]+M7
M#HMB7FNWWS;\'YE[L=X)=1A9UW(B1G*1!.'.2VE^_ V;ERT)"%QA.!/T)9U#
MIPN"Y>8D:BX+4JMQ9W40+H>C4[E<VPN>60-'HV."ZG;C &(M1 Y/PX=E)%5D
M4"3DL,V5.UC8,N:]R>W(A$.2Y?P&?,+I/6MCO1/K-FW"U.$J3(ML XY.6XA^
M"$[US29P$H?VC,?[J75+NDD'OKW9*]U;J=@W(6X$0$JB(X *S<L6F&(\@-,@
M7%1R5FW8W%Z,223  D8UKBQX8# (7Y&8D) $'$AJLIW1<:4IF(!.;.K^\ US
MM1D6XT;_ %6]WVXCYKA84& P54'4R11,#Y5A_ P-%$&+FO@MAU;;[NY&U:W,
M)2B#Y3%Z@@8QXJSN]MO-0(!BYR(\P\":*?2K]H3MS&H$8C/%U:M;JX)3_%J(
M_DO;GTJ(LQ) E1B!F.14[L(VQ$"C,[@5HW%3C:L2GMP[N* Y 4P96[=N&C;V
M[AF6&;,/!;XW+C;J_$QBV !./>R@=1E*$BQ.8/'[D-28J0."../8/X!(!7R0
M-)#DG  5/T7[BZ6-S_\ >](WDY3MZG,]O>8VYQPI%M) <.5#<1&N^'!XQ#?-
M6[L9?HW:!C02X*Y?W]R/^"U#*H)_I'$#B$+D9P][\0!I17]WMKT8RB/-3/*J
MZAN97WC$$D\E?W-VZ?\ 'PA'$4.+]W)",8L!XH21\BB#0A5*]2#T5)A5D#W=
MCK>[&4C$7;4HDX$ AJ<_N=;3]Q=+O 7=KJLW+4B1&_MIG]2-T9SC3V^!&(4/
MW!^RNI"/586P=S8!B)6IM^*()\LC2CTQ5S8_N#IPM[*X7D:M"7]IP;Q5JQ+]
MQREL+8>W#4 7R!K@IF$XF9 \H(/CCGBCLMI;T6R?-P->6;+J%V<0(SMB',RD
M:,HV)Q&J!+%"HJM)F'[!(G%462!-*!:?<\RE#@4'(0)P*$XAR"/'DH=4VUO_
M +@![D>7'FV;<BU"K'[L_:>ZN6-U882M@D6[M:B]#\86SV?4K-C9?O:%G3/;
MW2UB^&]=EZB?").I\D;^S@(71(@#S.XY<.:C+>/[L<0"X R^2<1:W(XK;0<B
MV-S"4OR@$Y+<2FSQO3 ;@[CY-V^;!,#1.,.P>7)&9)U<%[48M(4YH3,9 +S&
MJ)E@WS1C<AY.>#?R4[ED#_%F7;+F.[@>',%;6]LKWMW(S]P2$B)VYC#3<&(6
MR_:O_P"CW9/*0A#> ^<-0:B:%\SFI?XFXA?@8ZA($$RB0X-.2,B&CJIS'+Q7
M4MY(>6W$-S)I][KJNPOW-5V-XW(E\8R84Y _7^%AAV!T?:Q4I3Q=>0T4M93)
MN*.WNQ>C?;[?);C;7;,2(#EW_,>(P.".NSK)D6:)>,J8'-B1@YS9E<V/73?W
M?[9D?-;8ZH EQ*)Q88D+:=5Z%NXWMI/$QR..DC^H9K>[;5IN7KMN,? ZC\@A
MU.S,ZO<N"3YP8,&XB53WBG\?ZNX '9$(T47S0J'92AJ%5[3J[9VTR-Y8\XX7
M(!S3CB6[^91N';R9J/P% / 4Y!=0AM>DV[UBY(>NC>5B?FNO6KEX^]_Y.].7
M#;B0UF8_M.!YJ_M-MN@>B;:7E_- MJ[I&H41;NO[\/<D/[V8_+Z=@_A+\2L5
M$L,$:T98!U@@61(%3\T(2#2 8=W <N2OV+D9'9709P(XDN8CN4-Q;M>YM#$^
M3"0D,2>-<.2_>G3]E*0O[V,(ZJM;JQB3QD')XK=7[$)SMW+A>1=B0< #EFMA
M"5R4;;>ER!Z>&"D6Q1_A.D5<J$Q0DH!\$9'U)G3YHQ=B@'=:OQ*'4-I!]SL[
MGN XF4!6Y3^VO_IYJ<-K&(V[&49X$B5<F75;'5+;]0$Q<@8N0XH\N8. -&6K
M2##2&RQK@&'-UTDM4WH@]QQ"A3%_D:=D&P3#M+<3]4.54\L4V(3U7EQYJI9T
M8FH5%<L7P\)6R !@QQ'CFMWT^3C:L\#RD' [A@!DM[MX :;DV/%OYJ.CTD %
M^2Z3,XB]'ZJ#<2/O['YK4<2CV'O1[D5FL_DL\<^P]_9''[_!;+T:M.3Z_P#J
MR;@W-7<?'!0Q_P"1=-Q_Y8_5#O/:.W__V@ ( 0$!!C\ LY^HW, V*RJ ^I3Q
M1(M40#+U%*4P2+C<J:4@A5RGT(%2>$BN>,KE=?-F2;E.KQY?M/#+%/77%(%*
M$W*X$*]])'$XJ9]RJ>-+E/IE[Y'+!I<+EG6M;E.X$_[QQQ07"YY>-RG>'^\>
MW'^(7'_F,[]#^*FXW$>'[QN!KX\'^6-0N%S\%?O*=P/,?M'/'^(7+_F4[AR_
M\QC_ !"Y?\RG?\1@%5PN0 KD+G.\"/\ U&"!<+G7_P"RG^/^\XH;A<_A<IW_
M !&% W*XZ<O+]2GY\>)]1RP3Z^YT)  %SG>6@I6OJ. IA(^HW(%.H&ESG^:H
MJ"?VC@,45<;K4&F5SGYC_P!Q[<5^H7&NJNKZA-U?+HU:NMJUZ/+7CH\O#+%G
MJ:?N*R)H 0*"TP\O X^8ITJ'$5RKP'PP<Z^'(<>0Y8H>.9'^?WXIX>W'@:<N
M9\,5(IPK3+A3\M<<Q4F@YD^SVX+DEV/%9!HIZ7(9BL BF1>D+;:''QSY8+<6
M^6-]T.%I33-VM[CG42?E#:))6K/A0$?# 4H*3D#Y@0"#P(RS2KQ%1B@'NK05
M]WB,)2/E6"5*.>FG]D>TXJ?YYX/N(X8T@YT*L\JTY?'%"1KXTJ*TS_RXIP5D
M#R/'A7W8/LK_ $#P]^.7"OY^/#%HK7.RV04)/'Z5#R P$I"5 "AJHA23[1P.
M!G4@?GQYSF3QH!1)X9#++'S$DD\13(4IPRP5<:<:G2!D236O@/CB)#MK$>][
MEEK"DVY;Z1%AQ4TZKMS+2Q)8<<"ATD)%2,R:8^J)W)/B1A]ZFW;<>9BP(G44
M4I8?4^S(*5BH\IU5%34<<6X;T_B5^-.C&XL39-P9N#QCN)K$F0F&IKS<A'57
M704ZBGA3#J'FI$64PA<J/U+066Y+#Q+;+X=;<ZC"WLT!1 0"--:UPTUMS>5X
M:Z&E35HE7'UD-UIM-2PU$N:W8RV](-6DBO'3G3'I>X5E82@-'IWC;T9QI?72
MKA-M+KW3Z;J*U6RI*DK .D@FD*\V:X1KA G1VWX[\5U#Q0EQ 469#:?-&D-J
M-%(< 6".&.!Y\00?B.6#J\<O=@$@5K45Q1*14G5J.?'D"?:<:E<5$4"C0U]I
MXYC"N)'B!GPII \,<3PT\.6+203J38K(!D-'^$PS4&F>6!4#5D#3@02,SSKB
MO+/WX]N/,4I_H^.8P]9+&Y%G;R>:!0PH>HCV=MP53*N+:D);#Z4^9MJI430J
M 3F9-QFK:GW&=(<ERY-Q=4AA<AYTN+D.Z D+:2 ?N_*D)'("F+2F6NW7JU&5
M%$J^,EA_;#2[DVIG4;#;Q'##434$*6ZZ'T*25:233!1;'HOTIY2$PFK8T'8"
M6XZ.FM46:^\],#B3502M0^;AAQ-R0Y<[,TL+EQC(=;DJ04$(4R^T5+;Z2B%!
M*JLA692<(=AP(ZDM$A+=R2FX)6V5ZPE]MQ"&EDY5.D9C*F"XXVRWYE*2AE'3
M;;"C7IMIJK2TG[(J:##5PLDI8AN28KUVM"U$P+NQ&6H]&4T3IU!#BM"Q0I40
M<QD8NX+$Z.B^ F3#6XE<FUR0FJX$PC(2&_LD9+3F, T33VJ(/P&=?Y H  B@
M_*17"0<_E->8\O+&7YL?JQ^48M*J#[RS699(&D:E6N(I8"1DE(4K(<AE@C@1
MD1R]Z3]H8XY5 I_7@#^>?]>+O?U+(N/25 L;72ZR'[O*0I,;JI)2@,L4+BR3
MD$Y G#=TW!+E/&ZS7''G@GU4Z4HN!3TQU#[S*51RO4@**T@J!IDDXBV\[.==
MM]]D/SK=(G;C;M3ZFF&BTVMV4E+L2WVLJ/WBU@/+/D00!JQ=MO\ UV8@LNL7
M%G8VW8\YVV3Y:@74B&E?1^M32TVH>H=<<C(IJJ5 8M6T[):KM8+X^Z(MZ=O5
MS3<8[-R:UI,OU*_0-H2ZD:5M%L=/3DI6)';BW28TVUV*:M$Z=:8;:6[U=@EM
M,MX2VT%V;"8?0I#7FT'3J .1P(]LM\R?(4,F8T=U]W(5-4(22*#CX81+;VC=
M&(SE=#DI@L!9 U )2M0<)*<_EX8+5YM$AM 3K+R&W%MI32I+AT^2GMQ#@29"
MQMK<<F- O<<!O0VZO4Q N"2Y3H.17W1U% BK9-:T&*ZM2<RD\4D9E*D>"%)H
M1C2:_)KJ!7X4Q161/#5F:YTIX98!42H<O$5_IXXH*GW@C\V.&+-3(?0[)D<J
M?NJ'R]N.'LX#AX8I44XTY_D\<4!/'B>/+^C%FBRA*=C*N+G42PMH-ZD!+B2X
MRZ4]15!1*\PWF2",6#M_L2(R_<+[=(T!F6M]4BW1!K"416F@G5+3!942XKY=
M1.0 !-JM*=X6'<\)ZT06]R/;D2M=E#RF- M=@VY#;2ER1;F]2URI#Y:!(2E!
M-<,V[=$NW/P(L-%OB"?-FR)[%O4M)-OBWV(F-<XUO 3Y$-E)T>0DC#2$])=O
MA-*<MFWK7;X]@V?$?Z2FTW"[20F9NW<4SS$!"Y#;8U>\E4G>5O1=G E;'3MU
MKC6:!%1DG]C:@$:="1IJM2BH9UJ3B3<K)L.'?Y\AS49%ZB1)(89;2I*!#B-M
M--Z$Y$U)54&I(.)9L^SMOQ5".MMI42TQXA?*6B#J#"2I*Z#CQ!\1BY7%N*P6
MHCCC4L+;0XFBG-"FGT+34QVR:@9E(&)#%L;2Q!FL(GL,(  CJ<-'6$9G[M+B
M=23_ &3[,;-NSBE%R;MVW..%:@HJ=;82RX4J&93K;YY\:X!YDZ:C^8RQ3BHD
M4/$CC3/"4\!2NKB0>'Y,542KV\\<>5?APQ9Z<[#92/A:H8Q4>-.=?R'/ IQ]
MM?CC.M"1X5X^S&X)KS0<, Q'VPHI0=:WTLA(<"T.:%EP!:$$*6FN+#>'EK,Q
MQ268?IF5/2&EN/,EP-L-G[B $@%Y20"H ()H3BU7!\O:5QF7D.2$A+KRGTAU
MUWTZ $,@*- @52D #"%A"EJ4M!<+B,T-\%%M%"5'+@<)4Y#D=!U"4I<4@("*
M$ZB* DE0-:5PX&)(0@H+@2L@>XD4-%>SQQ1QU945*"-"5 5X#3I%17WT.);:
M([Y;Z3E%@-K60H%*W6G4GJI65< H"N=,7R''Z+[4R"]);="/32DRV$+;DQ5(
MR]3K3YT@_,KC3$!HI!2PR\VTY2KBT:RI*5E5%5;X4)-,;55)><=Z;MWBQ@ZV
M&PVRS<GRAIHI)ZK;84:*XFI%,L4335RJ#3XTP%$U7F%:?DKRT YC+%%5K2N=
M1E\:8H>!_P U<<O#GPK6ONQ9QYO\#L@KG6GTF'SP2 I9'"E5&I_1A))&JE3G
MXX!'/]'A[L;F2X7$CJVE:5-H2?,+BPA*%*71"0OJD>-*TQ'A6%@"%8;>FZ;B
MNOJFF&[?:V'T*D)]3I=7U)"?(D(3YE*H2!GBSSKU<XUKM\6.E@*>4IPN*::*
M&A'CI"W9"UM !00"017#DFX[AMEM:8#*WY%\E(MD9GU">I'2^N4M 0IYLA0&
M1 ]N'U2.X&UY*%2942,Y%N*7V7)T$LIDQON4JT*0'TK2#I64$&FDUP!MR[Q)
MR7&BIQIJ2VM3;BG@&VE(2=:7"E6JAY'+&X57M]#;-MB![U#[@0V@%QHC2D54
MI9"Z\ 0!GBY(O6[K=#4/4=5B0EY]2A'2M)<C)B)6L+U I.JE1P%<7";VXE1]
MV+^_$N'$85"D1T-**!T4.K+S3J6%&B5>8*^;+$V_PVG6%VV7U7(LEHM2(Q6Z
ME#L=S5YLVEA1(-"H9<<6+I*/63<+\B0DJU .BY.:10D],EI23I%*\>>$'S"I
MSI4<:#/X8TCA0JK3.M:<?<<:B2HTI4Y_D]N/\F/DYT^88LR1\QL=D-/_ .3#
MP5 $J'@KW#,#"E&N5/ <33,9833E^GC_ $8[K; MFXK1M>5MOM^_O:+<;XN2
MU;)-WM]XM\&P6B0_$:D/1TW6[3&V@L-N444C2:X_$OM7>^W)VW=Q[4^A[6O=
MNNS*X9AW2/-EB3!D-2&&Y&H!H.IJH!39!"<ZX:OTQL3(EE@QX.WH\AIQ^W!^
MX.)=DW%,5I00J0J@2ARH(;!3P-<;@5W@VC;.ZW\/SK9 W,QM7;LZ\HL5RO-R
M:L5K^N7"R2;?"MS;]SE(:ZTB2EF,HDK6$)4H*N_9_9'<'9NR9NY96V+?N!:[
MRSMY[=&WITF&(85<7IJ7)$:1%6&74N.MN-#R%3:@3'W&J[7:!MZRR77(T-TN
M^FN<X!#SLMY)">HZ' //5:2E(0F@!QM[M7M6Y!B[=T[XS8/J,J,MZ+:;=,?#
M4N[34LU48K4=*ZH;HNM,QB^=V=X?A\[E_BM?VA;;@VYN#<+6XI.W+_N.RVX3
MF-O;9V;MICZ9:?K"AZ>VKN/4;F/D(6I JYC9UL1^$JR]GH'<%I<#;$W9*MI(
M>V;<G)*84:!NJVV^V0)T)S[RITN2#TPHJ(IC?PN+*T2DJN5MFK4D])=VL+BE
M1?2*"0E<5^$UJ2I/E<K7&WT*/WMPDW"[E12E)I+?"4MZM)40&F0<\\^. :T
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M<;3>HJ&IK#+*1K30M)5G0(4BF),J\[ONR5NW21<(]NM]LLOH(EM=4E;=O"S
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M;TLQ6[95J65=)D7F(7H1-!K<<:!X#&W'MNFW1(+L2$_<)LYUQ:6RD(UJ<;;
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4ZF-PU5^5/#_1\?;A/_<_2?Y?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g680117g40w05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w05.jpg
M_]C_X0<+17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,C(Z,C$ 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   #V          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !<$
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  [ "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P"M]<,5@ZD-();7^5 ZK0W!-5HVM#VRX'30#Z2V_K;C-?G5^+A6/O="
MYWJA;=>[*R7ZO(%=,3%8W>B/^@QR9*?#0ZE,8\7T1XW5\2\@,#CXG;H-8]RU
M<#+&-ET936AXJ>VP1J" =?\ .:B4#I;NANL<&_I+65XAC:'O8W]:JW6>GZ>_
M<QE>_P#GK?YI970LF3D8EX]]#W2T_2:0_8]COOJ_M^HCCF2:(WV1FQB,;!VW
M?33];N@:/WOX/M])T_F^6U)8GVSH'[ #/0K^WAIK/L]^\G^>]:/W/=]-)3<'
M]66[#[A_>CM;_]#8^L('V^AQ$QLT/Q7(]/OP<OZTTXN357DT-W5U4O\ H66-
MHN=5]/V['6^E_.+K_K$"<AD:G8W\JRNE?53I'4NN7V862UM_3&4VXX89#+B[
M?7ZKO\.VI]/IV_\ 'IAA9L=J3&8 H^;K863G,Q6U8^(S%<6^I30&-8X.<?3]
M];R]OILV_P# OOJ_F_TBY+!8,KZZ=6-4.876%Y$EOJ#97?M/[OVC?L71Y^1]
M8?2R:=[L3)IJL].JO;J?S8?^ZWW;'_\ %JI]6>A.Z-2^J\,.2\-<XLDC80+*
MVAS]N_Z>^QZEY2''D!K2/JE?A_Z$CFYB..NLM!7\OW6]]FO&*<'8W8ZT9 ?W
M!:TT[?\ P1):)>-[?ZKORL26EP0N^ ;\77YOE<^C5<1VX?\ !^9__]&A]:>L
M6WY;G;W!F[;76# %8):V8_?V^HJOU>^L+NB=0_:550R&/I?1=3.V9BREWJ>[
M;Z=S&[_^"]19/5;R[->"8   \H&[_ORKX=VYA:?$[?D5/*KX1L-&M$&N+KN^
MC= ZUE]:P\G(SG-?FX[SZSFC:UM=@+Z/09[OT7L?0QO[]7OL]2U8?6NO]5Q.
MMY5(LVU83_LN'4T!S&LI]OIY.[:_(^T?SGK[_6Q\C^9_066+,Z!UD=%ZM3E/
M&[$M!JR& 3NJ=K;7M_TE6W[3C?\ %>BI_6.P/Z_U*'!X?D6.:\0003['MV^U
M"(J1(TVV72E<0#KJ7H#]:&_L9G4O2;]H-CL;T9.SU 6.W?O[/1_3;$ER#+IZ
M=;5.C<ZJP-_K57U_]56DK/N2X;O]"_KQ\##PBZ_K?]SQ/__2X?J1W76.[S_"
M%3I>X"1H .?"%:S9B[X]X\.W\I4W3]G;SVXB/[:EE\Q\RQ1^4>0;3<D6,+'
M$'F5)M]C1-AE_$^('#O[2J-[*0^:6J-$HO(W/UVNL#BW^KNC_JTD#_ ]TD=:
M^BO3?U?_V?_M#Y)0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'
M' (   (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"24T$)0
M$(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      /%    !@
M        ]@   )L   !( $8 ;P!R &T (  R #  +0!& "  1 !2 $$ 1@!4
M '8 ,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E '( (  R #
M,@ T %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "  1@!/ %( ( !0
M $$ 1P!% "  0@!2 $4 00!+ "T -@ X     0
M   !              ";    ]@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    ]@    !29VAT;&]N9P   )L    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   /8     4F=H=&QO;F<   ";     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    ".$))300,      7=     0   "4    [
M    <   &=    7! !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  [ "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M?U?_V0 X0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
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M>'!A8VME="!E;F0](G<B/S[_[@ A061O8F4 9$     ! P 0 P(#!@
M         /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(!
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,#_\( $0@ ]@"; P$1  (1 0,1 ?_$ 0    (" P$! 0$!
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M3F$MU7C%Y;AYWD*XS:T)#T:QZWH?KA>NFBHD-4^";5,SK9*H+$ U<SJ2/)
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MW\[OCXX>X\D0>-<ZY-^<FYPQ[@[A&(877QI8VMI@[>)63I.84\.H"6N)VO\
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MR>NFO[:X$O,<OI[:T?C;?B_RZY^CY'CE6.7'JXUO%52UZ\Y10,\I5NI?$1G
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M@P>?5SBKX (MNQ($>ZE""!'OJ!G%0BMU 5W/3[S \8 ^<@^ZO_U&XF.0^O\
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M<ZTY$'..HT"6B<ND<ZVUTR2&Q(R X32OMV!G&./7\AF@0,*"@]XU8V2.%=W
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M':3@,@.[P7#@,P<Q3VK8./&DU$S%#E2%<3J Q&$'#$<>JK?I#N?^6L K99L
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M[Z7O^[L+_P 0P\NZ<GXX,<'R'$Q1V6\0KN;0@D8!@<BO-2./.12ZF8;>X"K
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M:_W#\&[^D\#N\7]EJ>/=]A7Q[?3M[;=.VG52E2P;3YGU:?X]6LC1*VZ>3;H
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M_P#$;;__ $OWZ8! 2 #3X  '4$:DG]O5HVP ^>0*-I8)0D#4_,:=75?A-*:
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M>-EH2-M,[RZ\R^$P4F"&/Y!C<AG;B.U#Y? WBY#&K%$9([AS>K'+!']*M)(
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MBB=  X)]\/9X36UIF_:;W;S&5EL;2:20R\4]S;1;ZRY##$[-++##E,)<Q D
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M>IKCE7(8+.>:X9PMM<O+<+'5:K<B!%B;<HVGU[@=10Z]1V SE_/;$JZF1)9
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M9N.<Z]J.68SEG&<BPDGL?N[2Y22]XYR"U!1<CQ7D=B9+.\A-1X96[-0]9_\
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M[1M5B30Z=6=U7R*\3)+.BU9RDS*'AW3/)+)M:A*^D4T'R^[&Y84, C!E.\J
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MKW:]D[Z8O?\ MAS).:<?61BTD?%>?;K?(VL;;G"I:<GQC,4%-OW&E>_7U_\
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M^KR@R([ 4^M8Q4U-.O87/Y5WAQ6!]V.#WF1NC3RI"^<M8O+&68(L?DN 26^
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MF9V"LJL-:U!.XUZI+OJDC_P@T012[!T"NE)*)3L0:FHKT94FW*765OX@1E]
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M#5"L<5/GNZGN(IH91<?S! A)0"BM3;K&1LTT!_'JYR("B6;(2SA3ZI%!GDC
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:?MK6M-VWR2;?O/RK;XZ[J;-OJKWW:5KU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g680117g40w06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w06.jpg
M_]C_X08_17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,C0Z,S0 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   "^          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !/4
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  M "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#J<7%86-]@X'99GUD^L>+T-[,;'JJMS;-/TDEK#QM;2PM??9_;KJK_
M )=GZ-=/@4@"O3]U<9T*VG ]?*ZK?55DVY5M'K7Q4YXQSL_1-N/J;=]C[O\
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M5$5$(%-4051%4SA"24T$)0      $(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$1       $     (   )    "0      X0DE-!!X       0
M.$))300:      /%    !@              O@   )L   !( $8 ;P!R &T
M(  R #  +0!& "  1 !2 $$ 1@!4 '8 ,0 V "  10!$ $< 00!2 "  .0 @
M &8 90!V '( :0!E '( (  R #  ,@ T %\ 9@!R &\ ;0 @ $< 80!B '(
M:0!E &P ; !E "  1@!/ %( ( !0 $$ 1P!% "  0@!2 $4 00!+ "T -@ Y
M     0                         !              ";    O@
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    O@    !2
M9VAT;&]N9P   )L    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   +X     4F=H=&QO;F<   ";
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  M "4# 2(  A$! Q$!_]T
M!  #_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$!
M 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2
M,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D23
M5&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A
M<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C
M%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W
M1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#J<7%86-]@X'99GUD^L>+T-[,;'JJM
MS;-/TDEK#QM;2PM??9_;KJK_ )=GZ-=/@4@"O3]U<9T*VG ]?*ZK?55DVY5M
M'K7Q4YXQSL_1-N/J;=]C[O\ KJ9DD0!3+B@)2HE:KK/UU=BW7,Q:K-C0YK;L
M8,T^E^A;6ZOUO9_*_P#!%L_5SKF)]8<"R]E'V?)QW"O+QC[MCG#=794_\^F[
M:_9N]_LLK1.H]<Z9B&NK(N/JVM]2JNMC['.;^^WT6O\ :L;ZN,?B?7_-HK,8
MG4\$9(K (&YKFECH_-_P_P#GIL)FZ+)EQ 1L#;=Z/[-7ZD;!$)+0]$;TE*UW
M_]#T?%KBMG]4?D7,?6"OI>+U"[[5A#(!:<B7,W@>H6^KV?\ J[K6;W^S^<6E
MU+ZW=#Z/4UEUWVB\ #T,>'N!CBQTBJK^W9O7,'ZR]1^L/4O4Q,5F,[ QW9%8
M#B^Q[7V5TC%M?[*_T[679#:O3]GIU?I4V<3(:;LN&8A*SL=-6UB9M;L?'<.F
MES&L8VG<T/+FMW._5O1;8VFFICMU?VEU/^C6Q]7IRNIY62Z":FAI(,D%\[?^
M@UZP\3/R,YSL7IO3[_5M.VVVX[:V GWS;N=M_P WU/Y"XG.ZKF4=<R,W RGX
M[L8G&QK:7; :ZWF9;]&VO(O:[(]*[U4R&,V"10#/FS"C$&R7V_T_?*2\L_\
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M ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
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M8VME="!E;F0](G<B/S[_[@ A061O8F4 9$     ! P 0 P(#!@
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MW;:_FV //ZJU!&UC:\,=V [*M(? JC'9.T=QH;6BE-Q"+9'+/RG?PHV/-8,
M8G?6E+)\PB-<&#WTNI6*?7[*4'(?;NJ&'+M-7)MDV4TDC\6. '8<:Z:XJXEG
M).\ZC)[*X4?9G]%BO]P##MD5;ZLW5_AII2U S)\7Z>$T\C$,:>]=<*&/+/UP
MIP+@\Q?$#C'$C8-QRH+"BYLQF#LG^E/_ #.N06L<3"C \<<\OA09_2;BVR.5
MV$!AO6?$.(IS:7D81$1![ZN"9)S&ZDM=3;+=,MHNRY:M)&D>\R<<1A2VPJ@
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M $R-P!Q,X1$8BF>RMP]/<15U(LJ5*L&FV6U!FA#@@?#.D(:VI 4?MA_*FZK
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MXKI%M]'U%JSRD2RN,6S 7'$;\=]6>ALV7T'-MK<#OW5U9Z.W83JT)T&XK-!
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MD$<$P4323[BI.TF*:2%X(,K;Q+2X"DQ0W0:&XGE :L[D2;A0;:;1\^N97%_
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MI]%"GUI1OAT304TI45(-==/0?PZ))-'I4'Z1\Z?('HU)/^'PZYAPBP16S]K
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%4_FZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g680117g40w07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w07.jpg
M_]C_X0<(17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,C<Z,3$ 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   #T          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !;X
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  Z "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P"STW!J?]57$C4U.)67TOH]UF'392PVNL<002  /WG/=]%JZ3H[&_\
M-IS"/\$X?E3]#?C8W1ZGWEK*JVOLL+C AIVR7?FL201>GBTST(5M(]6IUHT]
M($M)/[C'V!M;EH]$P?JZ^JVKJ[6U9-3S'K6.J&P@;=OOK;]+<H7]8PC7C^H)
M;G,]6@$-:'-G9L;[O?<_<[8VKU%8^K.4'YES+&B[(PF^BXZ;BPGV.U_/;'_@
MB,)\6ATL(GBX=1KYMS]F?4;</TF/P=/M)CM_PR2WY.V?0U_=]L_E23K\3_C(
MKP'^*__0WNE".A.'C65EXEGV?K?3VM>&69/2K,;'#Q-;K77G,>Q\^UMGHM_0
M^Q_J/1,?ZR=$Q.G?9KKG/MC:65,+A,\>K[:O^DL]V1B]3ZST>CIN_(9AVMNR
MK;&%A;738'ML#)_PV_T:]WTWJ2?+9A RE"4(5?%(<,40F.,5J;V=W+OZK3:]
M]H#*ZX#3<&%M8C:YC-M+/7N?N_GJK&5K+^I=K?\ G-U#(I>]]&2YU1+A'Z2M
ML6[.=]>]C=CT'ZVU/Z:UV;Z]EEEUA9@T.+G,80-;R+/9N9^8Q970/K(WHC:J
MVX_VAM)WO!=L=+]WJ?I#ZGO?N]7Z/_!I<ORF7(!DA"XD\(K^K\R_F,L1Z"?%
M]D]0_9]_?:DN.'^,SH!Z8;/2R/M (9]CAN^"'.]46[O1]'V_\9_P22E^Z9O\
MW+YN'9A]R/[PV?_1Y$W65@>QI:&ZDD[H'[HC:O4.@?5U_1NGU^HT#+R*VY&;
M:XP!8-UGI.>?973AU^Q>98H9=U#%HY;D7TU.'D;&-_ZA=S_C3^LUN.VGZOXC
MMC\MOK9EAX]+<64T#][UGL<^S_@]GTZ[5M?$Q[LL6#BJ,I<4_IPB/_28.7EP
M<4ZV%!Y?ZW]>=U;J3'XKV?9*&FO&=:"2XDS=DLJ_=L]OTO\ !UUK!<7M:Y[[
M-[W&"Z(GMV3%S 29W/(U>=24!]@<\,F.\B>W]53@0PP$(Z"(X8CB_&7Z''^\
MPRE+)(D]=3HD]1TS!_CX))MK^9'Q[))7+QWM%!__TN'Z=D!N9BW@_1MJ>#_5
M>UW\%L_XPKB[ZSVEVKO0H GD>U<UB_0;S]/OSS^:M_\ QC?^*E_'\Q1_Y[[+
M7R\?NX]N/@E?^-!K1KAEVMYTV.!2:XM(>]A+7CVQ.L*!5G'_ )@?2Y/T/H_V
M?Y*:.+BUOP^6K\>-)JF&[(C='_6X[))?G_G?Q23O5VR?^A?R_P"HK=/ZO\OY
M?WW_V?_M#XY0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"24T$)0      $(W#
M%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$1       $     (   )    "
M0      X0DE-!!X       0     .$))300:      /%    !@
M    ]    )L   !( $8 ;P!R &T (  R #  +0!& "  1 !2 $$ 1@!4 '8
M,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E '( (  R #  ,@ T
M %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "  1@!/ %( ( !0 $$
M1P!% "  0@!2 $4 00!+ "T -P P     0                         !
M              ";    ]                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    ]     !29VAT;&]N9P   )L    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M /0     4F=H=&QO;F<   ";     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M      EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A
M=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E
M9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO
M;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T
M;&]N9P      .$))300H       ,     C_P        .$))3001       !
M 0 X0DE-!!0       0    ".$))300,      7:     0   "4    Z
M<   &6    6^ !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1"  Z "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
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M &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #
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M(&5N9#TB=R(_/O_N "%!9&]B90!D0     $# ! # @,&
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M51I&G;PE3=#.W-@H[';48]BV<"NHL+*8>MY855%%*8Q8%6CMD"ZHZZL3+/\
M5_*MQ!>@LBWFL(10KU=A&9.XL=9(<NPZMOJ\UX[.KK8B6) 43& 87BF=B!K<
MLJH=LTI<(:+R4&8'/K:XYWH\5(2N)3U6KZA1IY,V^A18JJBFR=13ZR8X-1D%
M+E8!"3JYE3=R09H&8\GXQX_&0A]CT\)%--K<L8?E#-*[FLLE%Y(X^("O90H&
M)6ANADR!"%E@JHPK)Z'VA@HEAU22[1(BE9%Z"G%]TP10VPV ,"6/Z4K:N/\
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M_P"B/T(/HSWO@"NI'S:JG@YHH<,N^_"SLHV^*.H5W)8]UDR037M#:"OWN^=
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MV_H:>@O24]0F2RR2*A"%BLF-AZ^_FZ03 (#S*BPGH2KW\:P>T%JY.WBB;PQ
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M4HI=S9;/18]XVXE;0995S:'*JK<W;-V(Y3Q2X!UF\>/-]JOBZY&>U7Q=8O\
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MVA"&-SYR205 &)4["!XB-UZT+ND?$C]#J=*H;$6!\<Q :0)GKG:Q'.7E^/Q
M *VNKQ?$46E&NETKXGC3/D?"]K"V0/<Z1)I' @6D0VLM%[DSFY3>=PV5_<C7
M/:'2>XZ6!OX _4%[RNT/#0,H[TK3=<Z%K8]+K7M:V82 EC[D^(B[-J ($!W5
MJ^J]8UL<G5]5*TG(TB,-C!$9 N2 MP;O\U&(Q.8T!&ECVN&7$EVT.+E_$ @%
MB:<'ZZ5W:&M1;(@L<QL1@EF[:<1J#G&!<5:-GBWBR#=E:-AJ!SY07@DEP/A(
M3_5M=OL1:D+VECC:^ZP[\F4IQI_@:2F^M5)[N''EN :N)-D[2MAM-JZ:USO^
M0W20V<G@\ !:&-\D@)12J;4I3!(61GPD8J[?B7?Q@CLH3ZDAG:=N[>2=SO!N
M-*V91PO2YFJB^M/2E:E@>YNJ8";W:U-K=G8<#9%6A$'>$@%S?W]JC@T^48EJ
MM<%04=$X[0$^[F*VS>;R@'A@;VK6Y3F]G-ZV@#'>;4^^TU_<"1K5>[4:9O\
M#D>[N4XC[^W*E,A,&:(@>%%SVNFRP !:MVYFE+$MTL4HRM8+$*T*,%;E<2-M
MR ,+"G.6,?D5.]0"NW;:ZD8%'N"[@OS46.T"XO1<KW.XA&_Q?0. !Q)K,6>W
M) 0>5-J<4IA>U9&)F&XX+_+D;_"M-,0\3MO %#6AZ5J&YX3*'9=YC(>/0X-/
MK0X5-K)G&[P7/4 9W>)Z;E*-+FM#7_>9MK,]S2&A1L]"YBSB02#M:EJ$2-+$
MV6MN3[O%KB6NQRMK+ S*WM6L/]I=N.:NC]<T(32ZV!@R'S1)BR4?=Y4C<F_*
M&DXT\.8731N5@&QQ-W'\!=<?AIFD:,_M#E=L12Z1Q.XHYK>(2NIEMWMB?;:/
M%9:>Q?&IMMKXW)O_ ,C2I@?]N2U\.P+OJ%KM=DE#4(N4X$[LP:0!>Q7PU+*9
MS("<3CZK6Q46<WP40YCLW#MW>M-@]GMHA7L79O\ G^S93@)'.WM(L>TU&UMG
M-)):WR@)BOJJ:,NRO+D3;<)ZE!KER/ @#D#B;6&4\?Q=E'712AT;(WN:Y?"I
M#0 N!VHFZM+T7KD8//1L;A8"0V:#QIPA<&S-:207 );;PK5<ITK="X@O<5\9
M)Q;^;RNW- -<Z-SF#>ZDYA_9BO96O^&NL:HLTW47NEA.QNI 25HV-.I:%W L
MWN%2ND*:<L !'F*8IQ'JVT[WES6FQ=EP!L&=C7!K"=TK7' U\5P-!!9$,=YN
MY>+<7?N[:<N*5\<:D//,]^THLO\ TG8$?2+CR^6]/?-J(HX,R+(YK+FZ$.(:
M3M0D(+"R4UXD#GD*,I4$?=(2U[AR>')8%:+6.*;%W"PQV)@,0+&X->TD!W7I
MY)-L$P[ZE#LN7(4WT^21JQ$N:NP9FAN8'>%M6G=IX\O1]/&U^NE%L@:<ICB&
M'.DLB>)K2YZ)6DZKHOA?0]1^$F-$;XSI(G.A<B,<T%N=T2> O4/#FEQLY:CZ
MIT?X T>GZY$_,QXDERB4>4F,.$80[""*YFIAE;T\%7ES06DG , N0.&%:0R,
M1[1X%VA$.?9F3SKBU +US>9[+=\^WUUES.3/DV[LR=JV1<R7S)X:AUN@^*>G
M#J>AU8DCDS2Q@EA#VJ'8A0%&ZU=/Z[TX0Y]3"UK7L)+&N-GV.!8X.+]I"5/(
M&IRUD:/^HYF!=^!/&F^OBS/IM1&7:1T3]//&89&6YT<I:_SQS#!P*N0-=:I&
MR$F0 @DA"2,;8#L%AA7Q9"RSSU"!W_\ .ZM%%,P>ZB%6*XY#*,72-P5$ .ZU
M:H3S.="_4O=&KE 9R\L@:#<-+T38X>$7O5HP>Y/I^8P-P:_0;5FAH^F@TM\9
M!V<*C9,/^'?-P&\#>"E2?"O6.H,TL74)&B*9UVF9>6T/V O4-#BB4SW_ $Q<
MQ['B1EO$04#F+:_K (IW41T/1NUN92]S?"?PAHMGXD)1U&CET[8VV# U WLI
M&S1)W5J3!J""1\UWI<G.EG,&RLRN_579AER^GU<:DS+YJZU_6,W](_J,GNN;
M#R^T1-G,3O6G(J^SKJJKY9.WRUK$PYC_ /4:^+EP]XT_^EU1_P!6Y7/R;<5S
M-1>Y*;[AE]VRA,N"W6HORBN%/7A6FY'G0IZ*C_\ =O?D5WD7(J%,^7QY,5R^
M+=47]*3WG+;DKGYN3P)]_P R9N;?=>O@S_VI?ZM[I#FYR9N7D]EF_AW?[G,H
M_P!.S^]+]S!?LK4+S\OC7^8+6U*.%=_K2O_:  @! P(&/P ?)B?37=2BDS'T
MFESN])^VOU'>D_;0]H[^8_;7ZCK_ (C]M'VC_P"8_;0]H_']X_;0/-?C^\[[
M:"32#^)WVTTNG?C^\[[:8.>Z_P"(_;7Z[OYC]M#V[OYS]M:B\G\[OMK]:3#]
M]V_#'Y+U<58?([MHA36-7QK&A02L:.9B[.-03E@?(XKX@"GIK_Q(D_(W[*_\
M2+^1OV5_X<7\C?LHN&EB#OR-^RO*,O-S8</].;_"Y<;T=]&D:RB0T)QH\QP4
MT<KKTH<2*RN:AHMC?E>F/SWTZ"4-#X\=YI0!_@3*$P_9]?RXTCC3N^C0Y90[
M:Y8*A :1,K::QLI<'/N3LMA3X'E'!Q"[Z+O>,:+@Y7$TZ)[3DQS#8E,U6G:9
M&N-^--;J-/E?M2EY+TKPYQW47MB>#2^[VSKW94K"K?):K;:1N%#)MJ,LNXDJ
MM\!:H-(]P:F;-;[HV_P[=ZBH]+HB&,8YF?>K@B+^$^HUII7O#F3A[A;]U^4U
M'JRWPB5S7=FSU[:<S[V-2Q:B(.A=8VNG [*U/3RO+B>IXM==J'AMIVKU.I+8
MB<!YDX<:'_)U7I_95Y]0.P_LK*[53Y?S&O\ R)4S?OGR)AVK==U"K$UC5S0%
M%25./[*C:O@!MOJ34.:C!&Y.T"M3K>6"A?FX-4!P'=XNXUJI=2R[HS?M:>6>
MTA"[N1*^'8)6I,W3N=;>YP/U+Z:,36^.0YCPNMO1MV5"UQROE: >T-&';4T;
MG O:XA.RH>JZ<.)C81)Q"V/:,.RH(VM;F:%.\)6-;?2:\QK 8_(6# 5=OKH,
MV4]JV H1)8B_"F,8<P& .T[J:XMRM= +?B</%Z*> 6^)Q4&Q((((["'$5/"?
M$)%ONO9-^4!!73]2YP)C8YM]HM38CD:]K<%Q%1:DMS<J9IR[" $N<:U436Y'
ME'#L.(K4Z=P!#V$9=AMM]%%S7YH;Y@;)P"4DS2*L7>BO UU+XDS?51-.KS4'
M9J>?PU*XNM?NX5"QK521>U-GHIWMXVZ:%'2$E,H=@"-Y^[OX4V33>8A6^( E
MN\MNE^-%G+&=MO,OU4P2SHP%1PIJ.(+&BV;$[_V4_3QA0Z_8E0:P$!8_2@KG
M21E<$7&M8QJ_J CAP2D<X!#NH/*7X5X&@=U?HBG=E&L*PIQV9:D;D/,?*0NS
M[4KI6J+_  "5PD14NU G[:ETH(RA5M=RDJ#O!V+=NRFZB"![9 "<I>7!H&XF
MY!V#%:T^IY>6%S5"6S+M0X)A>E(*/%@M[<-O=39W.<V,'>A/:,0.-:<M:>7E
MQ'T&NCF-_M@9,PW@BWHJ-JV:Y3QX5,I"/;G'8-G;3@13;_*[<E'Y"*=^7ZJA
M<1C,:_I[G!HD <";88H>RM9HXH"8B[PG:GU4^>>0.U90,8ZP:=KR4[DX5,Z>
M<.U+'$DL4MRXC98ILJ-T^GD?&TD7:0X;\IV+MI=+(C76(*EX'$D"W"F1QO<7
M ;0@6FZI]].&@-&U3C:I&,1+UIGM\ZN8>T!?0F!WT,A\5#,1Z?E>>!HWK&]9
M0?%3U.#/JK3NV"1>ZM)*81)]P$E$)N,>W'"FS-":N3PX8'8/VX5J8W];T,,#
M69EU6I9 J$AP8UQ!DR8NRJ@(6F!O]RNA>]O87.;%*YUAM)P-L-XPJ0:'^X/1
MY9FJ0WFD&P4W-@>W&FM9-[0DW#\S7 %% W+MPV4YKYB0W8FVF^\O#(,A\1M<
M"P[S8;ZCE+@2]Q0B_K%(_P#5# _U^+_Z?37A-<MQ\-6/R/ *E#]%'Y 0;5+E
MVLIL@%FW/ "H-5&Y'96W[+@]XM6AU<9"(TN_"X!' ]AQKJ$/7/AG2=6Z1,2T
MPSAP<QP<HDBF8YKX2;9BT^,  X5INHMZ$>F=0D:>:QCW27  !$DXD\*6 (+A
ML(IS=!\!0:[6L(<R:621S"YH'ZD:@2E?*T@1JN8$5J-7+"QNJ<T%K6M#6L9@
M&-8U&1@?NL &W&G\MP#R/7NK6])F+7P1M:K3@' CUM-,C #8V[L-PIFE7VCH
MW-3BBIZ+TW*;$I]M9B4;7A*_))8HAHV^0C;1_)]5/B.#C(#V;/3LHL?9S B'
M&UJ_IVK/_"E"-(/E.TG<*EA4$95:FT+36 . 8$3?MIC=2W*+XVIYCL&E%X;*
MUW59G!T4,3W\"6#-E[21EXD@4=>^\LI<]QWYSF'HP[J<TD5#*[9.X>EEO33$
M_?-6-(H^1Q&XT1M^0&GH/N_51CWUK&9@C2-HW5I( ;G*G'-:@9(\VU<;'CVK
MWUFC&4#8*<QSE)IOA<950 6*NL1?ABN PJ'X%Z#.UX8YHU,[+-+Q_M,W!BI(
M3YG7L$6(-D)RL#>!3:#MHA$)M4T4KDB9,UU[ ^S.&_NIICL ]U#?1K&G$8@&
MC-M-)7"I(P<6T_<AJ?5$KJ04;'L?QJ#JFH*RO\89L8V,%Q]/U5J=+S2[3R>7
M\+3XLOI)/;0U<<0<76/\-JS<H-D51W8UJ-5 S-UK6C)#^$D*^3_XV*[M2CS9
M.9'.0"_:YSKEQ_,<:U3'.2'2L)] /UUTV#J^K+>>UY#MSB?!W)8G8+UJ?>-$
MWFL86<XWCY;MD0^\[\>(-*)K_71G3"C7?3Y9-6&-0JN")MIP&J#OR7% Z> N
M'X[5!"PQ1J[::D.IU U$P/E3)AL!VIOVU-JM7(W3:,-(+'$<O)]USG89A=N.
M)J-H!$7,\(.(:MAW!$X5KM*X^V$41](6FM%G.  J*%\X9"V,V.UVS[*EZEK'
M(YP3\PQ0=H6M4V*;/TK2.,4)WY!ED=_&[U-J&=C2Y[' @<1A4T@TI+'M/-X-
MVUH),X;J S#\(\GJH:F746;;&CRYP6 7[-M:>?2ZOEVM?YX5IH>K-S0DA)HK
MM/\ WH_N+M+5-JS?U2++RN=B/T\V5?RK;>ML:G=[X1I XLA:+(,#G3%>-).W
M,>%>R*BFZJ=Q:\X'_J<"W!NY;4QSFV %L0+87W4W0QL!#W(FP\$PQOVU%U+J
M$*O+@5(XVO6H?%"5=IP7)^[$[*,.VI)'PDM:2&K>RJ#>F!VG/+;==F-=3U^E
MF8-;*T:?2C=++8RI_P#B9F["0:ED3P )VH;'ON5VXTV1N^H-&2@F>UAV6<;T
M_5AWB:7-"?N H/0E-#0@W"B:'LQ7-:H[+"D4Y$WG?_ISW3#OJ65Y4.<">-\*
M+X&N<YULO;847.',U;<6?<C_ .X/O4XN*N./']F[A3FM/B^BFNU3G\J%YD=M
M!:Q"B;G#TE:9I8R&Q-'E#LH!VA!@APX4SW=Y#)M*^.Q52'"1U^+;'A4K4<@=
M9, -@K4RQO+7M +EL!&#XGE; --BOF!RB]2=)T!/].T!=$!='3$^U>!]T*.6
M ?%X"38BF1EH#2T*NZN4R0YCN"J?W1N)V&H-2= Z/2-C<Y7W>7)X"W<AIX&\
MCN52.PXUB>%-N<<*+<O@'UT<H04F08[N_P!'UU$WE-Y;02X;SB#]E<QKVM<>
M(6_T4V70Z!\C1AE\?I+%7O6I-,YN36QA7QN8[,!M0%"WM=:H^7.Y'/PM@3A_
ME6LEB:!(86M&]!(C3W*3]-333(=J(++474].QK&Z)[))$!+GPR$1SHT8$,(#
M3O6N1[L_4=2+R!#&A=(!;FY@2(HOQO0 "V8VKK/Q+U&1D>I;&(]' U#&=5(H
MB+B1FF$060N>T,.50PV-330:5^H<]V8DM+0Y?OEYQ<\J\DJ4(HCJ?58M-8>S
M)#B+WRN&WM6U//-$NL L9""O8/KJ:24AH:TAK1@AK,@S$XUX@HVBI=5(VPP[
MOGQKFD6->,4JC!/6GSVU,\.(S/3&V7#Z=M,U&=G(D=E 7 C:>%<O1ZB!A&%G
M&HQU1S9BPJTN:,P*_O"Y' K:FPQ. C8,Y*=Z+4$5RV;3RL%R!F 6)HWOD>,J
M;,:&D$F260J0?%E.T%>.S9A6HZ!TC31OSZ,F:21SLK \>$AC44;7%Y+0;I6L
MZG\6=;TNCZ;%RS%*69I)@%=*YH 74, +1$B-#E:J@BF:B$NBZ)!F;IH3CES$
M&>1N#9)@ X-!/+;X;7J+IVAUSV01+8("CBJ$XE"J;A; 463:N7?=WT;C3LTL
MCRECF*KVXIPIXF#EWDDT<V#<*#B%8MZT&@+UED&8H, <!2N0,[J1@2L"B[S\
M^ZAIVGP%@[<Q==>"46$1*@")@FT!;'C65C?%Q6HB)&YSC4>HDC;S)%OM390U
M4,SF3,>"W*4+' J'C\8-UJ-O5V/CUH:%>UF?.19<?"3B[&ZFF:IF@,;BP,E)
M(RN8P'*]P(0918A4*WVU[I!JR.G0 ,9E\(<&V" (UL8*EK6AHN3]XT_F^,W(
M 0$#:0T($'=QKE]*)?*OB/E:UNTN[-@6],A9J^;$YJ%PVN%R@V 85(UKB@-'
MQ$T8V_>K1Z5K 2^1H"]NWA6LUDK&EC7%C;;!8=]<D6;PQKQU@,:DED;X6DIW
M_9LK.X*2=M>\,: -VRH'!HSJ+;+E*TC"XHQH &^VVB&L1Y*D\:#5)>0GF+0N
MP%-B4?A_1.:7NM/F)#2"+L#A>VT]V^G1NC=G5!@<VX,:WQ.W "^TTW6?%$GN
M\2 M@:YOO#QN<GD:3]WS4_0=)T0T>A:1[,*'6P<7^8DXD$I1G+RZ0-7@5M\T
MH #SW_92D6H73LJ*=S3[-KG'@6@Y?31U#@&QL0(?O(<3QVVM7B<$KV2D5Y>-
M1:<'Q&Y/U4H")34"FM#&2H>YH[PX)]O=38&BS++O2B<M3ZUC<^I><K&C8XXO
M<=@:+[=E2Z]L@9H0XNEGE4-=O,8^]VV%&'X;BS=1<%,T@S2$X$QDJ&-*; N-
M.FUDN:1QS650>U2>)XTYLCBN_>E%0@+0%I@ N E-==:;A?Y^GZ:UO4=0VSLK
M&-WEOF .\% [<M$MBY6E)5%.&[#S;V[KTFJ 7@:]G#:OT]GUUG:#E;;]M'Q;
M*C@!1S\#L%:$/87%FJ8O9F:/63ZZ7?1]J F/"Q=?N!)-2]2UROZ3 /81$^>W
MF<!BUX\64^)JHZZ@-@TTP;&UH 8T(UK=C,O#!<33I&D9SBJV[-W9A3B Y5OA
M\TICRQ#36H4JY4"LR(EJ8TW!3#8ME[16ET!9G@C:N'WW7>_AG*9EW6H1N?D:
MN\+^;\R6XCC2#49NWY_/"D<+5^H/0:DD)MFI<&[ZA#' AN!"H[\JX]U0.N(Y
M)6. N"+9CFMP-MZ&K&M;%"P'4S%L>**UY5UQ<$1AP'$T)]3F,30C0T>-P(7O
M0XG[*CGT!S:>4%+DN#AY@Y1L*  6HG(0F^W:>R@T(MJ8U+BF.0*OU4'Y5!'?
M\]G;0:YAOZ*B@D"^-N':*?!JG1OF1,IN20+COV4[W73ACD.!W8(F/<J;:\!)
M^WY]U9W"PKR\?5A08QO@RJ:4"U:F'6=/$T<PN?*8_P H^]WI3WP2R!C'QN:J
M#PJ6FQP3=2*IKI\0D1Y+W]H :W'L>ZU#0:]KSI6$%AC.5[-I'XK^JF:311.9
M!&,7D%Q)Q)(M?TC;4>:0N>ER1@5P&_MIH#::6@41EP^?IHY')M]))_U*.ZFC
MF*Y19/F*C:=^_=>M9J(WAT;I'>8$%"4QQ7LN!?"@W*,_;?U6'\-SMQK+IG!W
M;:VT_;MX4G*.3L^JO)M]25&T#@>^G$A&BR[J# %>02AW#']F_96K+O#((F##
M%) 3P""]^SY-#FQY4G?=E/<N/S^?^=.>]I1<?G\]E7WTU!3?#1!6^';L)[#1
MR@AF'=B!Z<WIH!Q0;.W94L[0DI1J_F_8IH,:X AR[<<$MPOCV&BV-2W;A^P'
MO!/&LQ#CQ5;]N)/XL6X(:S/<,R\*_7"9]W##L6M7H]02#"Y [#./,'-WAPPI
MHC<D9%U^?S-.F<+\MH*8DI[,#L^]ZZU#-0 6&($IN5JIW_70='>+8:T;'%"(
MWF^[.P+Z;4WV9R>J@W+:A>L:M0)"-IK@,P^=Z]X:RPOW#'T4Z"0'(7L7N:?V
M>FIM7I)AEB5SAM08XU9A/SM2DLYN[;0:QI+%K]&Z;MJX_76GZKI=*DVF9RY.
M,)P?^9CD7:&KLH1)<?,=Q_;0,=RI VJOG[Q]W;NK3OD*YF$$;D.W<@"E:\(4
M9O56B;E"<AR8?]5M*0XV"Y02,.%96MML7'CC05%X?(*:N^G(%=EMVXCN6A).
M >I$!L306BYL'%5LT$N-ME/TNKZKJ(^I GEN;*]HE&)! (:"TW"B^P4[3=0^
M(9)=#(W+D(85!Q!<6KPL0>(H0L*2#;5I2AQHAK4I>6<%V]GHHZ35=(U'+D:<
MRAB(1=;X)C6LTNJ5K@XX;0?(G\*7V5IU1<."?N_FX[ZT$8>.7S'$.VO\*(>S
M"E(0IANX=U:$;/=W?_M;3FF$$I6D9%&&SAE^S93 ,=O:M. H+7 5D;B17OVF
MC#]3 T(#M'WD[J#VMRR!Q!"IAQQIL,L\YAX%1WG$"@93*7+Q[JNJKNH<X%*[
MD]=.3"NF<K_R.7?L6M-APWUHER_<[$S?/';C1_.?IK3KCR')V\YM#D<SEI9,
M$V^OOK_D+S$'FQ3[**X+3=_S^?S%,H9_)MIW]$R=^/\ #L7=6H_J.;W=!FYG
MFR[<NQ-_"NI^XIR.:<OYD"IPQIV?]-+]GSQJ)<JY6^G*:*;S](^3;C\^^O_:
M  @! 0$&/P"T22XNI49H2D4M[=R* 6&X4EE95J:T!ZM9),;C)2T,3R--C;*:
M4U% C&:W>KT\2U/ >?4S?@>&)5  3@L5NV@;@/\ "%MP'GXGK(36]NEDHBF8
MFS@BMB00P45MEBDJ@/AI^CH6R7V0U-5VY&\]-5K0KWRI!V_;7J/?/>2;S^W=
MW!HQ K5VD;0C7_9/2AF<JRJ'#]R0 G52OA1CI4G3]?0)4';'1:(NTBH7MJ!X
M*5;6NO49>!:-0C[@!7BK3<X--$ U'GTI-NAD52KL88G(HQ-2%4J6VL!IXCI=
MUI$5:FJ0PD$!1JSF)02?%AX5TZ):UM!0L0SVT([8!_9C$+CU$CI0EM:M4.1N
MM(B68BA5/NM4%2=:$=/$UC:EO%C[2UV1 #7:S1'T*1KX^/3#V<#2DBL<6-BE
M8!EJ(_NK?>JZ:T'CT0F)N'7?M)3 3MLH=!1;&CU\*^70_P"270+LVU1QZZ;8
ME-W; -B&!.E*>'09>,Y@C:K>GBN0;:9#0-&RX\[B/$5\#TD\W&\A:0["'FN^
M-W,'T#9ZGFQZ*I)%?+K=V+*ON=U?:6M=NWM?5VJ[MNF[^[Z>K-0 R[HE(*ER
M'!&TT4^L5\" :>?5H7C-6@@[H" "E '#4%&<$:]3_=[@U S!:[E(J*?3K3PK
MUEG5-NR.1F:E&!0DU4"E23^K7J*'9HTD1)73ZHP:*"!X5\*]6\@B9AX-0"FT
MFJU0 ^MV&I!IIU&)(Y(V[>TL\8C0UVU+4!%"U2*])!(SA_ M0 DU&G]Y *5#
M>9'7J=7HNU3ZG%"FZD=2-IH-:^?2;3&@HI 4EF6B^#2;B@*TU\P#KTJLNY4^
MDL"\;+JRQ[M"(E9JUIX^/31M'5!JP900" & 9/ #7R-3TAV+7TD47:GB#4K0
MD[? Z]!.V5B$@0E?O(T&^H9BU-P568DGP '7%<Y;<-X]D<AEL399&?*WV,L[
MZYNKBZMHY))FFN8IF"ONJH!I3H=GB7&(]HH!'@,4E / #;:Z=;CQ3CA;R8X/
M&$@_;7VM>@L>!PT8'E'B[%!^H+ !U+89;B^!O+:975XY\59,IWJ5;_<5-0=>
MO<_Y>X*G\^_SAV_91=ON_P O_A7M=E-OX9O^]['[ON^JE>K9R2NR2WHBJ*L2
MU"01]E?/S!KU9!0"&MXOJ&X$>.T@@:_IZE]&T,@4$^!HE06TH-IT'69^XU-M
M,5W#<35-:!377JW"QJ5$D)K35/30%:UK4?M?9U;QB)-H)=R*"14KLJ 0-)-W
M@:UZ9U@5(^WJ-@ ?6E'.NA.NE->K7'VY+75S<>UMX-P62Y?NTVQ@[I)' U*H
MK-MK0=6%]><6RN#XHT\#7N9SRMQ>VN8)H0\[X1,EW\GD9;.30E;0;UUT!(Z-
MG>_).*OLPTBO9W+7F2@6ZM8D2:[/X<)%MI6DV,OT*NH8#TE3<W]ISSN6B2-=
M6F/Q&-LQ=06P5D%M=WT\]Q;7RL"")8T5T.GJ\.K7-<8S=WEK.QD7&Y:TO;FW
MN+B.=8T6.:SDM8U3(VF\G:5(GK0%17K*8?)P/;38J:2.=95>&5(]HD5FB;:\
M??C931O$D@>'06/[EVW.!."@(-"!O0-Z0IUKX5ZLN*92\C.=X3<MB#$\@,TF
M**][&3"I#-$(FV!O [>@0:BOVU_]BGGNV^(^K;N_^C^SJRU569X=VE5/K6IJ
MP](V^/B"?#SZM*U.Z"$BIJ:* IUU-:> \.I-=U$J!4G793_4>LTZU!]O."%
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M_=BQ.3CCA 7[N.'(V<=SVH6J=T:,A\/2M0/&O7:>B /5 32H\="?/7I60U
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MY,DLC]Z8ESZC7J*TQ31PM(Y>X,;&2\FL'';M+=;<#<+MJ%M=49PQT/7/LO\
MEM^7<Y\;#XZPN.X%/#BTBND;*W&']WRC)*DI3NY"UGO1%!+N"QO%JKBM?C+F
M'-DNX+C*7'*_F?DN^66WR>4Q_P#S/D5Y?9?)1;FESO),_;"XB0)& [E"41NO
MAVYAL9[6ZQ6!^)>5Y"TG0V[Q29G+W$-T653L5O;99^[XC</T]1TJ5]&TZ5((
M!J/,  ](I.TLZ%@?.K:$G7I2#4;:_P!%I(5.NQMVTH!M8;0:^=?$^?5KJ0#
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M>_(+<XP'&++E'&K^[AY+A,/\<6\@N(KG"0-/$DSWS>]GFC=8XX+=A6RL,/\
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M !ZBMG22.8SQQK*88S&8YD6 R!3O#(T8"[2#O)6@!#==I!)$[2 K%%NCN!O
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MI>?(?R3G;Z]R&6G:[;(W%[G\A=RWV5R_(,@S=V;*7^1N)9I9*G>[L"1T,O\
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)_P"NOZZ]?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g680117g40w08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w08.jpg
M_]C_X07L17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,CDZ,#4 1V5N80     #H $  P    '__P  H ( !     $   ";H ,
M!     $   #           8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !*(
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  N "4# 2(  A$! Q$!_]T !  #_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! !+     $  0$L     0 !.$))300F       .
M         #^    X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!$0      !     "   "0    D      .$))300>
M   $     #A"24T$&@     #Q0    8              ,    ";    2 !&
M &\ <@!M "  ,@ P "T 1@ @ $0 4@!! $8 5 !V #$ -@ @ $4 1 !' $$
M4@ @ #D ( !F &4 =@!R &D 90!R "  ,@ P #( - !? &8 <@!O &T ( !'
M &$ 8@!R &D 90!L &P 90 @ $8 3P!2 "  4 !! $< 10 @ $( 4@!% $$
M2P M #< ,0    $                          0              FP
M ,                       0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ,      4F=H=&QO;F<   ";    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0  __$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MDKZ?O-7BEV/S\7U_=?_9.$))300A      !7     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$!@      !P ( 0$  0$
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M(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X (4%D;V)E &1      0,
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M%*&VI+AM33\S(CZ"*F)3<"]I3^NK=0*YFY)TDFBHJ98QAVE(?> =%AVH)%W
M4-M& 1#%K4QW^P*VTM^%S^(H  M "GJ*)08 4$U/.H)T@QD+E<)!'!Y ( (
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M,/I]0T'D'AD184;;,<P^!?RI&T( [0:#_F"7Q?GV,V[<#* 0$P_FC>TG3P(
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M([=EDK@?-4.44;?-]0/_ *U*[[T#_ S>U];!J'S\+MP^3CY,HQL\W#L939E
M^&66K+ 6-GZ&:.<3F\K;L>WLL\B00LVY9=6R\BW&J]:\([$>_IU(D!JP46P+
MQS9L";AH@HGE.+CC1GZ=#O7>4!C<W)#N8H[7^&T@%S8 !^OFT]R63T1TPHW
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M"FJF"Z[7 ECK9IS?*2J;AV=\ G^6.M\N]4K]7#6WG'^;Q59D>XPSS9,S)O\
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MQ(B9#*5"PQ!Q6]_LBQLKY]0MW;^XN[F3:)@SC$ 0B6P,16((;$C"6UOP_<7
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M&BA:$=3U89A"[&T8]>TVS$BQ@XX<:+S_ /'\T1S*)/%'N^R$9& ,AMIR X$
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MU#^Y/5HZ;UZ6FW#$V;%OPV;$C]Z5J-)2#@\40RB!4+5J+,'JG.!4Z?=*\O\
MY'^U2_,?B4$RFAT^782:,AR"M7;?GA.)'<05L YE"Y:MESB=403[,!RQ4;-R
M\!<$GB<QPIAA1/\ 5U'EDR_N&W;W&B_<TVX?BF3*,B.X MR0C<@(R!(HB%;D
M Y4@_B.2BX4R^16)_J/]JE^;YJ*?JI]5$\D6D5,$^(LHTR4AF06ZM3WKT"\1
MJ:Q;<XF@8OG1&X[5QZK<>K>KWHVMK; ;46,Y$4 %27Z-Q*M6;$#:](MR!MVH
MTEK'WY9$&+\U+U/T\1-B3"< !X>8&6;MFI")H^=/BR<8A:=)=Z<U:&IB,5%I
M/2O^*P']1P_84@>)^*;2B63<5$<EBGG0#A51A9ML6QE0*S*_>/\ ,2FVD -B
MS@NYY<<%LS&^X(D1'&D3I;OQ4!?MF_ZKC],>04</(.10\*%#>>J;@RVL7%NT
M#X(!ZAQYG(<$Y*[.</-6/(9,B#$'K^I"5[:B%W\4>/%L%*YM+L;MK(4$AR8+
M_P"SMKD0)%R0P'?P0U3Q4FG72GU_\K_Z692$I%GE\5X@'?W(NR+H 8M\EJU$
M67;4C&,3*9S-0@'HO3;\(.82D\LP6.GGBS<UZAZ)O;CW90!MN:B8+RA'@3'Q
M' $9NK/_ *R,9SC:D+ACD7IKX^]2B8F-BV1T?AWL@&8#+AVZHTEQ4H;NT+ML
MXB0!<=_M6V.R$OY>\)$<'#.!P9ZJ1E,UR6&:D1^(_$J*)=&F"B+<7D6#=:%6
M[,8X"O,H%.K-J1\ K[<D/5?2]\;8A"1(8-J(85Y"JN:B97YAI2)<DXD]Y0U0
MTW)8CX>Y,WV&YK:;C_DC?$!TGB?]*E(1;DO*%(D4U'XJ!/D92K13^H!CGP6K
M2XC7H^"<XH+! "9R0!-"*\T;( _4'Q1 D"&%>*[^PUJBQ*!:JG,BEO<VY$\(
MM)RI::QR/S6"/YOF5$<E[$>BW U?<'P4AP0[#8P8"JB-7)7-W*&DR# =,WYH
M((47>C5,R]7/X1&75CA[T8\ /@_9)I G4?BHN*KO"8Q>2AN3(BY,D$9@##N1
M+=@7U&U$28]'^2$;0TQU"@S#5/1"V/(!0*J!:J"!:G8[57K0D''T?F%(DT8?
M +S!2_,?B5'@C%V4=-9DLWS5NV^%?:CV3E^$.I^'&1^*UQ^[%_\ !/FL>P(=
MOJID?-$0]IQ[FP5RE&^0[)']H_$H,,DW+Y+;C0\1*JD,G6'9N9&3'2IZI2&Y
M)&DCRXY]R!A+Q'$CX+EV$]@[8@83W5N)YAC3H5*-0'-.')=R-/O'XJ-$2V2U
M+4Z'9?H[AE9B94+(6X_=;O[2B.T1)8<5Z3MM7_+*<A^33I]KE%RY6"E^8_%1
MZ(UR1,8G'%2^IQS0;! DH6K+ RN .<<,.BNZP--N@&3BA;O3Y]I5$.QG_3+W
MJ.WC(?N]O 2 .$SYGX2P<8X*3X]A_,?B5%'HIT^\44.*T<59@#*-S4&(+#V*
M1,223C^G'[)[=)F(C%SDU?DR]4W=TZM>XF1R&#%2(#.L5.1QUGXH<61TBJO
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M=M8/0]/V:Q@[Y QKG#=O81V5/\=MF2EQQM*BMV"ZVA",G(45+Q]NO_K#Z_\
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M@'/W^F1I'MI200<X(( &-QCU!TL+;0H)&4Y2/3X^IU(6IA"5]JB2@%.0$[9
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$=-?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g680117g40w09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w09.jpg
M_]C_X08-17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,S Z,S< 1V5N80     #H $  P    '__P  H ( !     $   !UH ,
M!     $   "S          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !,,
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  K !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! !+     $  0$L     0 !.$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #Q0    8              +,   !U    2 !& &\ <@!M "  ,@ P
M "T 1@ @ $0 4@!! $8 5 !V #$ -@ @ $4 1 !' $$ 4@ @ #D ( !F &4
M=@!R &D 90!R "  ,@ P #( - !? &8 <@!O &T ( !' &$ 8@!R &D 90!L
M &P 90 @ $8 3P!2 "  4 !! $< 10 @ $( 4@!% $$ 2P M #< ,@    $
M                         0              =0   +,
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   +,     4F=H=&QO
M;F<   !U    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   "S     %)G:'1L;VYG    =0    -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $     CA"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MJ94W<?YP^^^^[]&]GI_HV5;UL?9Q_P WO6TGUO6_LS]G7-XOYD[N--W,[O\
M!Q_W_P#EKM-/V/\ F;?L_GZ4;?\ MS;_ --'7QW0>FS_ /_9 #A"24T$(0
M    5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ T
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M.-.DEVI9.X*^UCP3.PM>]2G;;@MW R0A.>1'*G-G]<Q&(X9XYYUVWN2$D;@
M-/Z1B[@F0S6CT1J+;6S(<!SP-;#9*K&M.KQ<BJ*D=PH/U6TD_=4A4H744-7]
MC-PUO[C0G(C#WX'B@%;?<",ZVN+76P3CSNAS&%=P>=P!'(T$#$+X\*=N7/#W
MEI1!8<?C76>&!@<< A\Z_D@C2P74XKZ4'$WKMQ9^VQL#&*E]2AQ\;BPK;!L3
MOX.T]<IR4FP=_JQ'*GAGT!Y(Y(GOJ49DVH,7UHE/(P7YT:6E&-2->U6D85)!
M,S5%,$"XA/+'Q]][UO>UNC5NHN:Y<0</NIL>XVG[9:;J#\Z,44)#7N0IBF2
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M,:MA_@?RJ7V+2>QM#_1[,:$8_L9F@!.VD,[5YT-3@AP(./NH2PP/,1S-A3C
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M ]9PK;QLAZDNNS6J27(;(,0E0[_O>Z@@W^ZD&D2.Z?2B!N[2T.U.=](:6GB
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MNOW5W";<3%SXXCTL$+TMB,%QK^<]R[J1W4=PUF]O"],D99QN>>=,=9::\6:
ME <::YI(<WAGSICW8CRJ25[=4I1'*;>6'A1=[4J?_N_?"S;[(PI!%&$1I5!J
M(!>]P"EV:IP%%NVV$O03$N /N_&]1Q3Q@0,/F1XTPQCT_*@@PJP]-(*"^Q:*
MYI3F?F H@F]!QPHE?A7_ %7^]HZ3/I3^/_;&'YEX+FOA['\OMY4WE\J/^$<Z
M;S'WU-R]@Q^%'E7_V@ ( 0$!!C\ VHGW:_#_ +/3KOIJB:(2)]OW?M3I^%$%
MD;;'\CLJ^QT1-YH\:2&7/@OSM.)TG[$_^ Q-!4%;)#0OP[=%UUZS-R&RT+#]
M72.%X41 )U8YB9DJ?O\ P5.ET'MZ:+]GV=NMJ:[5[(FB)V_;IKVZ50!4U3OW
MUU3KT].R]O3[NF=NG>0WKJFG[W[?LZITW#N_EG)!TT#L2?RI\OI\=?[.A_$N
MB:JO?7_Y1.OWB^&NGI\?CZ]EZMJ3*S<##,M<8*4X*D;<&P:U:1]P%3L!M+W7
MX*GV=1K&HY#QI0D-B:-R;6''-%5$[*ANCHJ:](?\]X@@+Z*N0U::_L19:*O0
MM,9WBCKIF+;;3=]6$;CA*@H  ,E3(B5=$1-=5Z<I>:/J'Q.'F8QU>;XZPQJS
MY'SXUU) 9D8Q@T*]FU#KNWY/U#V@*FB[M%35]NKQ?ZJ6W9,>3[2RG\ VL6N^
M52;8DGONUL$BO.)ZHQN >Y#KHBYAR=19U12XIN,RI3%D^Y1S:2K<>6-"*VC7
MH078Y*Y\A>NT^R_#INAK.4\"F7D@U!BK:R&#[Q\T4D)MKR$$<U115=$<[BFY
M-4Z'<"HB@+C9J@JCS9)J+K)BI XVJ?O(JI]_2FJJG;145/3MVTTZ-?* (.Y5
M3>J:IKIZ:>O0I[@=4<;'N6FB[DT7^I.JT_==@K+N-NU7T<''U4M?7:OB_;TB
M;DTVZ[M._P"S[=.D1%1?M[)Z_:J_>B=184<2<?F2&8K >B$](<1D-53T52-.
M_53DW)M2N3W,^.Q-=C3GY"5T8G!WHVS&:= 54$73NFG4^SM.*N.JRHIX,JPM
MK:XBQ(==65E='.3/M+*PG/-QH4&%%:)UYYPQ!L!4B5$37K,/I_\ ^GGA.'\5
M\+5<ZVH;SZB*NHKX7(W+(43ST:YO,+NU5^1QKPV_(!6X,V/K=WX(CP>T9,6S
MG6LVY6O*:C,MV9/E/S;JY&0\9M*L99.]DI9Z*+LETI9EH3BEWT9CU,JUHXC6
MK3=8EDJNS#3>;SK,>(\8M&VXA*9&YL54U1-=%ZK>/*6PN<BF7/N$;HF& R>2
MK3@[9BS:QIE]IF!%;'RO$\B"SIN5?CU><;9=/J*7)">FP*W)$D)^C': J E&
MW;QD=A0I7855E\V6G!%4$M$TZD8OE=[#S3%:U&G9U/%GRAETC#Q@#4B)!MC-
MVE:=#3;,8<<K9:Z"B(J]J[+\3G#:4-HR91GQ1 D1Y+*(,NOLHJJKD"S@.KM>
M9/11U14U$A59"@T>NTQ[Z::)WU]?3H6D5U5]RV'<B3OY$1->R_!>H$K0_,M7
M;/I]NQ&*55[Z_P!Y4Z'5Q$U3[455[_:BZ=^AT74M-%U5!5-?WNR(G57:"6JU
MUC!FBB+JA^VE-.*)(FBJ.U._PZQ*^H9D9^-+I:\T%EQI5!WVX(\T0@2Z$VYJ
MG6$?]+WAJ[D5EYSCCT;D7ZI+VK>="S@\$O6$RLH^+8!Q"24R]R;;USSUJ2(!
M)3Q/"I*W+<1,QE1@VT=/?-8]5@(-L0YUG7-;W@9%I?;N5%$#::B.K8BV&O=%
MZJR"79R9#EFS%@-0VY%A9V$^:01@2' : GYUG8$0LQ0:$EVEIIWZH,O^K^3*
MX(Q"U:C2(?&[42)*YKMJUXO/!=RJ2:?I^!K-9-#]MH[,9;5!< "U1,NQ'Z;>
M*ZG LNL<?<=3/V&TG9G;65>VZ4>1/R26#MM(;D;R1]@"98=W(BAIUR/@F85+
M<#+)1',:J+Z(D:@RZI #.MR"@L1462:<D+HPXGYD-]#9=0A/1<:AR+!N.PY#
MD+B6164.*Y7ULF(GAGXSD40B<9"B2091IL4]6 7QOBFFJ=4N)WBH'$G,DYK%
MVHLB:;I\>\J0Q%F"TX+H;AHKLG1:CN&:F,=]L%U!MM4EB38?)YD423:H$*;5
M%44575"33I]4#:+<\=!1/1!=!?AIZHNG5<UHFJ4ERSIH/XB:HODU]=?ETZ$1
M1571%UT54^"Z=OCT&X>^GP14T_;Z](J@JHBZZ()I^SXKZ=1L+Q6X4,(:.,_=
M19Z..LQ67G]'#B)Z-;&M2+T]/3KZ[OJBS>XC65EEO)')O&/&4D6&)?MJ;CFQ
M# ,!JX#DY5<@5T>EQ-Q6GQUV^Y5?FWJG5'1>SE..Q*>C"VBPR&=99)E^7>UO
M[YJFKF1WSK6\R*Y:B-LLKW;80!1$(NJ'ZG_J+Q)JUY^N(K=MA=!<Q6YU;P93
M632$P[&B.M'&?Y$D1G=K]BHD->*JS&1"WNE !MUEY9KS3AO%HZCHN:KY6STW
M^5Q.ZZKIJB]1Q!7'Q>8-50&U71?$H$@@J(/RH6B?#]O4W-,.9"BY/X]8G9#A
M\QN.ZLT),5ER5.K8KK(. ,6X:T21$D?DO:(0J)IU+?>!*BP&>XQ<PV-0;BWD
M!5B^Z;A/?ED#A(3;XIJKFJH>J:+TD19#\M*MJ.P!R'22><>IDA*H2)XR4&IV
M.RVD!B2*;_;KL/>B=<?\C0M49S_CS%,P3>NKBNWE'$ES=W;X33=3[%1-=._4
ML"!%))ZBJJBJBJA(G9%_\/4%K=V*+;/;>_X0:IE053U_$?3!LB8&YM14!A23
MOZ%I\>WQZ!%U3^\2MHFNFOV]NOQHB?%=H>G].GQZY?1X0D6\GC_+KBA$E05>
MLZG%;F0S&10_,U?=:$405UU].AEL29A/, ^];[R)LI-T[=6EI.?)LT+;)238
MF&\A51T3OIUS1]5/)]5F&#X;]/?#-'C_ !QRC0T-?D61#SQ.\<O-1XNI[.EO
MH]AGU)A2QP6QB0I<B$]:Z1P:<=$@S>GXN^IKZZ,=?Q!UR7E\7ZDN*L>Y$P2'
M!.6$5E<A_0@AYG HW9TMF*^Y$BNS(9.*3D;8!J.6\DOQFN/LKPYNZHDC^QD6
M2P\@QR5*A/R:J#(;8D6<.?(;1V$JB(NM/AJB=T3'H',_./\ U"\TQ.5D$O"I
M^)\.KC7'<*NR>"TDY^"X,N(]DEBH,S@9%]MMJ$KGR"\1B2)&GX1FO,-[Q;8U
M\J)<8/\ 4*KN39#$M&W0:=;K,AM(%3?0FS\;C<AF2,F+($]S)BHIK]3/TQ\!
M\=W/)$J/9YES'A=%3N5\>5,XP5IG))1Q'K.7 CO6%$-JD5(39G)D.^(&0<,P
M$GXLUF5'EQI+\6;$E-NL2XTADSC28<MAX1=9?;,=C@&B$)"J*B+U],$F3*.6
ML?BP*AQQPE<<$Z6^O*OVZD?S*C(1A$47T%$1.W4UT!1!.P5W3OVU<3LO]"_#
MJN7<.GL+II1[_BVT&GWZ>O4)Q4]66E5$'1$U3731!^'W]-(K8J2 FJ[?N[?N
M_=TNK(KKV1-.WWZ_*NO2,@G@6<W(K3?:%05INRC.U[AHB::D#<E5T5=%TZY]
MXER%EJ:_Q;S/R)AM@S_%US%A%Q_*K&,OB)=LR.$^*VBAV4Q0T714Z^G:_IJJ
MAI)D*GSJ^LJ6GA1XM="LW,C-BP!AR&VU(]TS!AQ@*0*B^X0"I*BZ:9-RU"K'
MX\Z=XGY207IUQ;WF0W<D(%;&I*HC=F6F1VD^4++3#2FX\9(*:JJKU;8O @.,
MG&<KH]_#]GXI(WK\%J;/C3HH#Y6; 7']I-'J:&*HJ=.91#Q'&;[(JZ5*KW9W
MA\DZJF,EK-K["&Z6YI0+\;1CL7UTZ6)!JZ^$U$A"T7LV&FO\NWH#".(WN%MD
M41!'T1.OJ(^L+,<"H\IFS>*;_BURWD^1Z[H\?Q3$9_)LI^F@EI"(+)[&&HDN
M1J,AL?!M)!116TRJU)2D9Q:6>8$XV1.@KV03I=N^R1.*AN/-2)?B-5[*8DJ*
MJ=^OIW9<)S2959=8LB?;;&FY?<FT&G?\L3:+;]R].JHIJLA275=/CZ)W[^O5
M<QWV+'N3]2]4&A333;KZKU!'Q*FC3&J*BZ]A3[$TZ#4$+MKW3TU[I]W2IV0?
MC_\ ;1.W6J*@**Z@6GS"0KJ)BOP5%3K,N9:RM=;X\^K_ !>OYOH+%E-T8,SA
M-0\.Y8I#53W,R:_)HD:<N@HALVP+Z)UPG3X-,KKRPQOA"DK,YCT<IJ=!AYWE
MV#UF42'ZB7%1&K"+:Q)(R",$11EMR&U13;+J#@'^HKO$Q\+0?]<,SSE<Q@89
M8<92\3M847%LIA2K!\'7;FNOI(>W!IE\0<7<8*G3LW+O^I-E')EC?D5ID&2W
M?(D/%\B<OVS!XI]E>#2,K9.2(R*"O. ).[RU(DVZ47/G .<U%SCV7'64_)F,
MTN40+NMNT$VJNEY)J/839BO7,!R4W&N114.2RZVZ2>1M=SPVH($PD&(^K9(O
MD>=UWNZC\@DVB>JZ:]?5;FV)9ABLCEW*\AOOIRPVG<O((789+FLMNCOG*ZH"
M0Y-DO8?BSLN5,46Q450/+J&W6+XGD2VAU,6D@PV8[A:'[0Y#,.$P);7IH/O[
M.R*B=TU7K@7C<(P1#Q#BG$:Z8P J(A:2:P+>X-4751-VTLW2-/@2JGPZ>5!T
M3SBNY4]%4OP^GJG5:.TM?9W::[?NQ_\ IZA$G92;:%$]/0>ZK]^J]!K]@KI]
MR(O2Z=OZ5Z1?V?\ 8G_TZG67&&.+E'.OTNW\_FCC_'XK8NW.:86[4G5<P\?T
MX;5<DV5MBS;=E"C J'(G5;0-BKA#U]5'TAY!9NSG,II,-^HGA:)*=E>2S:XW
M?L\>Y#QV!%EJ!1YT'$<D9F.010'&TKWB4-!5>LE^I+-L;"JY2XGI9%IP/EL(
M(CU<7*U.R[8P;#*:F;&F5.88Q--I&I%3,9.)*;4T)-VU4&FN_I0^EB!D$JD?
MK95[ XRP]O%WYZW:7OF>HG(;C34)JV19"M--(ZV)JV*H/9*KF27CV)O\OWU@
M3647F%XW$PK%PIY"QWIN+5N*U(,U46B;D16W5<\2ONO A$?84298 V3CMFZY
M(06DT\41H#D2B1M411%B,T9DOXD'OUS9SE8U\@H/('/'(4N-)>;D.U/NTL1>
M.)6^0RC%:,4[499*-@FXG&Q,NR"E'92JEP^)^*;2OSKE>X5LV:MN#'FG85.)
M@JEL2ZRZRB-, PWJ3<=IYPM 37I'23175>)! 41H$(E+8V""B-M@B[11$T1$
MZ<T'L3JKIIWUU^/;UZK!V]_:7GP3X)CWQ_IZKQ^*-MZ_^5/]G0?^%.E1%_;^
MS3MUH2Z"BI\/CIV]._3+S"D#C)H;3@%L,21=4(275!77[?7K"/KSX[K,KX2Y
M2H<TGYSG^%\<S84+BOE'(;:MG5MI=6&+R(Q/8;=W35@93GJ-^&Q,74GF2<,C
M+DG$LRHG\IPX<MGY-Q_?MLA+*-C]WK/*KNQ=#8DJF>?_ "R[H32EM33J*W:W
M.)Q"?A["\T>N@SHUEM1#9>%QMJ0RP"(FA(2HJ?=U"F86:MX\!@16A&W!:MR;
M[MM5@EH^]6LD.KKR"@O*J(&NNO7+W/')BR*ZAH.(>1<@KHI/-UEC#QBKQ2VD
MSK)E'T5F'+EQ6E2.XYHGG-D5W:+UQ=CC?'<_C?Z=,-PZAL\:Y5RQBJ@X!#PS
MD$4SR/D\"74/O2.5<XOX=L+TYUDWI$BP;1DR8:9[4_#'%462=;7ON6N397:L
ML!DO(6726O'899DQQ][7N'6]&8D8"5F#$$6F_P!Y293;JA:HJ]M$5/7^LDZ<
M1!U53737T_V]^JL-KFGL[U?7OZXXG]6O4$E3OL;_ *D!.AU[+M31%_9KZ=+K
M\4T[=*GWC_8B]:IHHZ?V::=NE!25%UVHFO=/7:J(O;5.G*&PB1)G\U8BY[./
M+8![?8USLEED?$Z)"*/,.;454^8=4373K(YSM[0\>0J^[D1W(?Z*DJQ:C><O
M\L#L:0VV9 NH;43UZB6UI96^>6M.C+C-EEC\F3!COL;4%(E0:Z2);3G9IM&T
M:]- 7MUD'T5\26?ZE+R4(E=]0>35PI*J*Z%'=CRV."XLR&OMY647;B-'D#39
M;*Z(@Q5_--X0Q/Z8?J)OI<SB&"?Z#Q3R01E/C\-"(/2IN)VBM-./V?%D:28B
MPZTA%3FOR[XY:"EWB=Y19;3211UBZQ:WK\@JW@(5)%"952)3/<%1=%5"37NB
M="B]E%2^7]Y#5?3[U7OT2JFA"X7KZJNOHJ:?9U5#VT]K?CKI\-V-%IKI\5Z@
M^G80_P#Q3[_NZ#NGHJZK]_\ 3]G2K]FG]O17V<Y1C6%40H2K<9;>UF.5ZH *
M9JU(M9,89*BVBEM;W%HGIU?YS9\VP>0HE$3\5NHXJKK#*;"XN& %Q*>!8G'B
M4@2"0T4G%?)L!1555TTZR3$_IAX7XZX$Q6"R2TV1YJC_ "OR_<D<L:^,ZD%Y
M8&!8SYG'Q)/X2:XCB((JJ;NOK,X)^IKEG+.0.0Y.:<?9[Q1R+G%J;C5_,X]P
MYRAY6P2C7;&KZ1JLD/-V$&%&!F,Y':>1L=155RF5$>M+!+U]M6H\5R-XPE..
M$JC&1H%+:2)HB*.B#\?CU)<P(XJ\_<FQ;"'@$EW;8/82TXUX+/D5R!(\@%,H
M&G/^7-DFPIJ@1)M;7H[.VG23GY&VMFZX9/R;"0W)<?=NLSGFRX4QW);F:\XH
M/DUN)E\W51"=31^GK!)FVNY\'$\**N:<=FP?>/$[-EP96TBL(S4$7G)8$(F\
M2B2:* ]0X_&F095AUG BLL6#^+7,^LA@3 ,F,N0,)X(4IIV,8FYM1P1<W"JJ
MJZ)6P;;+DY$-YX&V8N7Q8%P[8/2B%EF(%A";BNU<=7'042-Q?&BZFJZ]-0N0
ML EXXKJ-DMAB\QJ]07!-8\Q'ZEYX'=L.4VXAK%??$ #=HNNB5'*G\TPOY *M
MR*0EQX)/N5>!W%V2JTI_'^I?KHNF@>T\?DW+KIM[]0N_;Q NG[$1/[=>FUTT
M7L*)Z_A3U^WX=99]._!+>+Q[SBK#JV_YPY2RJ!^L1L=RC-40<%XMP2M)\*Y[
M*TB*[96DZ0+Z1!!MH&E+>J6=GR%G^49S+M)9C,R/-;Z=:.C/CF4R&-4Q),XM
M82LEXA2*Q':1%3U'5.@C//RH%!4M)'J:""1M,I-%2;]][=O0+"?(0O&XNBZF
MJ=^BLAK)5IR#DMC"=QS&XB,R9=GF%ZVM3@.*QFT\DA;!BS>"0X IHKA(G=41
M.L+.L=F4F:8GDM)D]GFS3KC,Y+FF>FQ\EK;-2!7):3),F8PZ2_F#Y%$D4>W4
M[-YY.MSX;#BL2I\E"5DU;75'VTU\QJ"_EZ)KJJ)HG7(F03+1W(Z/&K(L=IY2
MO2(<$ZZI-R,U7XZ31O-^VDV:$ABOC=>;:<_"JZ]26)(-G9^X"0\P\@C[F2+2
MN-1&HT8G'6&HN_Q 'E54>-1W)L3IF38,SF,?XPX\RW*EB&+CD]J\D.0:MXVV
M11MUTB=E&+"E\Z"HZBAHJ+9Q;46JVDJ2.?1--L@^C$F*;,B,K4.(KLJ0Y81B
M+R$2MF;P(J"*#TN53ZZ/52;.XO;%B*TVC[=3C]'7MVTF.Y(DDKC=<S8RA-\A
M;)XGC\6J@WM5R2]7ML-NN/%)?D.!$D,2W(3%I->K*]D$$*Y3DBH.&V('J@!W
M!4Z;PA)$4\*EY2]G)QR2X6EBW5=41\1:D,.^;]8&+/;M#%U?B<9L].R+U"3_
M -%M/_*@C_LZYG^I6]AQ;2-Q%AKE]74LR046+D&33)T*EQ2C>=;_ #T:L<@L
MF!<1O5Q6A/1/BGU#7V26Q7=]R]SO>YS<7<N2XS3 S65D2%#:C2IZ@D:O:EVL
MDF6$\J>'3354360Y*LCL-[@16(]1%,HQV39'XHD>=-11>!] ,45EI3\:JJ=M
M=(V57%8BV**U)C5J-+.9H8DC18["^8E\UA)>W(BHFUE%73NB=87BV35TFZQ_
MC?![KF+*H\=]]&&+Z=OI< DV]BR#+T%8\R;(M&B11=;)AGQ"3BB0SK6%^J5%
MY<.1K"UO:&7%JIUQ8(;<=FSN*61#D8_/N;%04Y#PMQCDI^8[N<U(KB579CF$
M[D'-[-K <"I /%XP2\FN&W-L]\VU!Y85%5@],?)M10 ;0E).E=CV"//M/RFV
MVWWO</S+=_:-GDDV(K1C)KX\LB!E20M55 $EVDO4R.\PZW(C,[/) )LO<P'V
M@T&O-'/"S'1?(JDV6Y'3/<2*.G7,>3FVP<J!3T5'#%45F9X7)=@^+C2..%[Q
M^K)EM_RJYNVA\_E1.I%G.EPXM9C4IJ!51=KCC1VC#:%8V\U)FC.C:"H(I;FQ
M>=U#<6B]1K9R"U.CRWF*ZNO+1U^K@5UE(9BW-Y7L4D5'7?X6 "-M/F'YVK::
M@JJ*Q6AE#;"T\T$>>$@9 '(BM/6B"P;@MR&FAC,^-\]YEI]Z+U%MTJ0\RP)[
MQT"19OOEL4JZZ6U2E#5K=XTLB,41$\>JJJKKIU$T^ AVU5$7335.WP7JM^C^
MK:DTE9;IA?,^<\A/K)<HPNJFUG3..>.;OV*&[2T-PL)Z9)GOBL8I",-$H-H9
M]5][D%= BRH6"XJN0-S9/GAP,@6GCS+OVL**X$%TI4NQ'4S-S5014%>JO.LR
M13<2+^M8YCTA&F%Q_#X@DDW(YT'QM0(<J5'0@CF:"X(Z"VAF2Z6TFK8AUV <
M>0I<FRFV+FTL@DOM>[DMOB3:N 42C)"0]W^9EH(_,&G4[F?-H33'*GU3VT7D
M6_9>:]O-Q7!840(/'''Z-R68[L2/14CJ2'&$31'Y&G=41>I#JQI#CS#0L16&
MF'#-Z28DC8;$3<IIZ"BIHJKVZ3A*+:E,H/I_HXU+F#K"I(B/<G9.K%MD]8U,
MCH_[6SH(_M:<B14%M >\HD&_HCG Q&B2)#02:^(3<N+7+ 97VL>!/VA,L(R"
M9>5%U9+>1J2*2(B!51T2+.D2'&*Y^2,F11N*VB^.: HBA36!ZHV**JN-;U%"
M<!4+EIZ4PK=G9VH27(XDRV\ 0*B1/<%F43I&$5MAU3 &NYB2(NU%TZI[20RR
MRS"AN6[/N'FT$9SC+ABS*CODK:R5E20)M31?$OX1/OI IA;%YNB!IEUQM^OM
M'W[*5(2YN7(Z&0V$USW3K0J@H*"+7CUTT+J20ON1S=K&:ZF46F%G29MDX+<A
MY(+C)>\CQZ\'W";:*/( #1/4218\Y)+G@\LN$4Q9SWB6+I"A"Z,S_'6.+2*!
M!Y>S2HWNW+KU 8%$0GU;;!5_"BF8@BDNJ(B(I=_NZYGN6D:G8MDV7O\ &%6Q
M*L!-DL$Q'3%E1VN!!!?<M1),AKRJC:BX6OQZQ7'H,)R=6V%L>36=*$1TO,M.
M:)009T1 U8K$C>,E'Y0)!1M$5$W=6L"-(?MLCR&9!_F&<'B,["2\;4:MI8B"
MJ,_I\22ZC;J?@+:J BBVJKQ;]-5+&&ZHZ897-',EQ#8-B"[28A9QTB8[.E"X
M3DV3E?(%C%A['$;1&6WFMBH*]4V*Q&V9S=730JAQLA%Z$01XP-R)!MEN'Q2G
MMQ(/[@J@IHB(B<Q?4WD_M7'>*\"E3<5IU4GV;7-9.VHP:ICQ5,_=3)^23HPH
M" 9FV!(GIUDF4Y;=';Y%DUW>9AF]I/>=88NLIN[-VSOK2;2"3MI(@1[.0;"&
MFW<SO541%5.O(B0G9L-6!.'6/@PPE?J:A(@6C;[D9IE?((/"*J)"3;HDJ(:)
M$,VE  ;-OQ^)P:]&U E=BF:JU)F2E44(I:%K'54\8HBDBWS 0A9BV"EC^,S1
M($U<L'6FK&$XQLCZ/0G45 <7N)-J3>YIQ1&O:?=:;I0929+ 1<<?E0*!A&FF
MU1EM'PFV-N@-M=U4B7=V[IT82FA<,&7&Y4=Y"-H)KJD\[(-Y%$&6VT)4W.DB
MMB:HNJ?AQQAJ4#EG$Q\[1Q]QA[RU4W+1;;K:V9%>+^%FU]&/F-Z,2& /(J:@
MG>(WODK&<CV +J3JR1;9F5D9$1?Q"ID^J*YMVJ H6NJ:]<N<B2;9RDLH^%6>
M-8E-8:)^7_.N6PGZ7'$B,C\WE;D/FZKB*GA;:(U].L0PF!.E7M]:5-\H#XEL
M@<GUF+S9\ISP&927FUD3H[RJ9(VBH::H0KKE@Q;-,QY-C5$.;GMQ7#[B'CDQ
MZ7[6!@57(<; 'IA1G#>DF2B3YJ@#M %576R"3.@X57R,C<81UAZ-+E3H;[5:
MV3[SHH8#7H;;I!\_D=10 T[=9/\ 5'F3!KEOU.9$=UBAS&V//6\/X#*G8OA;
M<18@A&9J\ER@K>W;;1-ZKXC,B+;MD/R'/&+A&XZJ>J @?*VBHFNY=$3MZ=<%
M?2+C\L1_F()/._)45HY".I!K7I&,<6U\A(Q"K,>-9%86A^31"\32ZHJ(O7Y3
MCJ1R1"",[(81V2\]&",V#<M$\K#C8KOT,U%Q.QKI\RQ@< SLF9+<2I)D&W6$
M=)H'Y]'"C CD$X[4=Q5C@BF'D4QW?,B)7-C%E,5UL[9K(CP@5[0&62;ALZ*9
M.PI HYYT(T%DV5$D_,0NL3IX[@.-2K*%(:<4!+RPJEAV2JL$KBNN^21*7>Z:
M(9HJ"FNB)TRW'FLH[9,QG(P1K=V19QX57(;*Q)(K2^WA6-G9/H)-NHI.LIY&
MP144NL?D3[2(&-MNNW-Z,&T<-]8U(2GMOZ:P43=AV3R-0U,7!$A>10#3=I#4
MG6G)%RBYQ(T9A-2(SUFK\>'%D-1'GX+K5-3L"C3;)M@3"HB" [=TO)"-1QV!
M>5V--S_=CYW<BMJJTR1^,D_R>Z2*Q&I6]45?(K;B*GHNO'_ [EZ$.'68U.Y3
MS2LB,^^MITV8V[7XS#;@(\TV?LZ9J2^UYEV>:6&B*J*J<=WX45C2.PJ3DQMB
M=83&UN9<W(<2?F1(0/QMC<0XT2O9!EH/CJG==.OYNNYB.7F=W%WR%;S'GU%U
MF(TX;-##,'35AUJ%$;/R*>\R<)17YETZSJ6D,CGY)D1.+!<)N2,WQV3557P4
M1PC5B/#9BM.J6X1:0>PI^%>$>.*@6XM;@W#_ !MBD-EL&T%H:_$:E978-$3S
MV+KSJ_:3BK\>@$I.C:JB(2J@H"*O<U15T^7^K3KZB,B.<\Q483=5O%N-..#\
MD3&,.J8M0XW!=:1U'&Y\P7S5L#7<3A&0(JZ]--&V!--S@&O/5MEZ1%A,$,X"
M&0A1_<?Q("(FHFCJ*B:B:)TDYF841W61*BJFYPXC RT]@E2VX(*,B,3?D15$
M=V@*.I#TXL@&&&761BVU/'=,+-9C[R.P+:U(E,FHDUPB= ==?(CK(CH0DE1"
MDR4;;IX+,%PHBMO-Q">F'(CC6MM;25&VD$A$U52(D5>ZJB,LP8PU#,)M#G6$
M=1:M7IP J-*RZH..-DT#Q>Y<;#>X2:IIKU ;)AM]<BF';S7'V#F6#='CHNQW
MWBF3&9/@:ES&WT D31PVQ51T%"ZENR:T-LJ1+EV8J* ['ESWVQ:1[04CNHRX
M0L&*(ANIJ@H.U.JN^")(2T>SJ^Y1?':/G<BQLEQO"HC2G_B*36.2WM!5=?GV
MIWU3K.>9@L''I'(MW9U%?%>\J*M8W,<JJ>$+9*3HQ(V/P&T;8;(U;-S]U%T6
MCGC$!F=7YFDR$XT]_P NLXMD;M:H X.TFUC^X0";(4T =%'3K%\&J7 <@4U%
M;8^C_D%Z%8N8Q KA4P?@H(3YSES+=,8WR:HT*FBHNO645L22Z,V/8/6;$U6F
MY,T29LVK(@5%)([F_P B;NW825--!1>N/L]H9D:3-?X<XXSZQAQR1]PJ*VQ*
M$OZW'1A25^N<F09+:."BB+S)MKH0*G5QDBSFVQ*@FS*QYI1<%YPX;B10:457
M>XZZJ((IW)5ZY3R1RRLDE7W(6:G<2'IJN/NNN7$L7I,?W8BK)N.HH(@>B=M/
M55)),R0U%9FNN!(<)W9&MFGO;,SIZ-D7CKWV6A:>1.SB(+FOY?9RXA^.+(CU
MS=:XIB+SM1:..N($F%'=><CI#EOHI @)L:?U%%5"%>H#&+TEAD<O([B'$>QS
M':V?>9=<I(5IM(]95,-./6,I^0)>  $W6R%/PIU?R_J<R;/<#Y&RN509%C>
M<8UJ9=R#Q1@T!\+6XMLQJP"30Q\RN*:,D0(LMXVJ0C(B;DRMC09/4X5:V\RE
M>SC):?#\DR1O],RJXHOYHF5.*6&1P8"MMUUK,@ U[H" 0WD:D AH@VK;;EA$
MK@9B8[ <(V+$#B0VHY7$AY]@8KB)--ALUW+Y5*:A&I%N19FYF6I,UVK$J1J_
M*:?FN*40QT:81SW7B44-/P%J"=E15JN'/-'\_P#H;?T/E_,]NEXM+C=[[K73
MR[UN4\FOKJFW[^BN^3^7OIHX[;II%M^GRX^=YIR+9,6C8^ PE#@M6U45'Z6^
M(J\\W)<;4@39N+3K&8<7Z],CG<KP8R.Y'?6G#%5(P6P>; '&F<?KH&30<P:"
MM>:+67*>-Z6WM,P;+Y.JV@H_K)X#MG:6VR?(&+*RPGDN-/N9F0+!VLSF 2?'
MK :&(I*8&ZZV1Z#JG62</\L_4+@67Y+@L:%$S<N$*^\EPZ>_M8X/QL7M[C,*
MZ!'/)HD"2TLYF.PZ$3>"/.;D5$JJB.^GU'8)1<39IQ=CN'7<UG%B@8IF=Z.5
M)7_S310YSKX8S;'(]G&<C"FK[HCMU%%H^,/Y/RFU=B9_$R@7J^VK_P!*#$85
MTS92\/D29P,S&'2!GP!*-H0;3<1BB)UF%JF38'#9RO*\HR6)4K93I-]"'(;F
M=;,TS,&!%E+/GM,S$;;0'6T(&U+LFG4."UE>!D].1U4@/VUI3S'DE/'XG'FI
M$%UPXD;<H&VX*(WJ6@_%)LW(\UXZB1*>HDRK)B-)LKM5HZR*ZY.E*#41IR2^
M'C\44U(!+Y44D(!+JQYWY2@\A<I<FW#3&&<;P,5D4]'187Q[8 $FXL<I2R="
MVL<LR"0BMN1JQUOR1HRL@_Y'U 8%/],M[*Q?C+,JS*&\]M\6X]C\8R*:,Y.?
MKV\5KXDR[L^07[9R T\];6,D6_:&7B:$'!,^J:UH:QS(WLDBS4I9E;:>!N/!
M-F0#ULRX\ZD&59+O=2$CCB,JRV:.H1D*=1$QRQ8MH=!']JT"*==9M7!/&[=_
MJU7);"3'&7.5/:L."*NQHZ(A[=.N-</E.?P5ED,>YN=@D"%64^M]:QMIDA^T
M-F"R/B)-S1.JB?%%JY/C;V[;YY6=H^)6_)C8I'V?@\*-:AM]-J]9Y1\BY=@4
MOD"OHTR2TI\, '<=XSPLB;JX%0MFXS75&49'?9 ^C)R(S:18Q(C($XHD:N#_
M #([<V]<P"S857LF)$??W;/=&PV ^4W>R+W'X=^FZ_'*:R>Y)M)2R:*#/BH^
M,ER$+LQYU^(&A'# HXH:E\NU57OIIUE689 ]=S,MRB^O,ORF=);ER7;C(LGM
M9=S:V$MQUIL'F73EEXU</1&!0!1%14ZR>9.$W9+KC<86'E2)";89 Y\MQYXW
M/\!\B A%OR&>B(J)IKT+]><J,Q*@'5RW6R104G'7%D1#,'CD(H@XFPB5MR06
MA&*BNWJ5DY0FI&63XRG3L.*S-BXW7,N[ GR&UF.>YFV)J1:*"^$40AT7MT_8
M3[!2LK5_RNR9$N!*EMMJVBE(AB;SNJ[55&U)495"77NG4/('9\(JMIB;57-7
M'GBY+FTMN(U5FR A#&,;>CZF*D:"WIO14TU6.-=DD"PQ6U(9./R(TJ3;6E2>
MYZ1&I[AB(R)M/-O((H>Y&Q(MREW7K(L/FRHRR<EK7.0\=R./)=JW<7RJ@D-,
MY8]6NOO/K82YS QI;0IO%T@-OQ$KA+UF/'UJ4)+_ !Z2<RQ)ZM"IC9%7.25<
MBSPJFA;6L<9>=&2^*F H\2:-KHB(F90DG8UD3#+-=)F0T)ERUENM[8S4I(@>
MQ9DR4V')\YF<6(GF(1)W3K(\\LF8:0L0Q9W&(+T9@?"=KD,H&Y"0B)#<8*/$
MAFJJA*KC3FXNY=536Y-/T^_'75=-WEQI=-====_].G7)GU=_41E4+)^>OJ#Q
MG!.7<ZQ-<B="!QGPK"GOSOI]X!X\67*8:M.0,V=M3R.WDZ +K[K$81!J.1+E
MZ8%Q\[AV-Y"[&D5TV3D+,++XH^!5925&9;G0'WX2FJL[R_"NI(J^EEG7(^2V
M.46%7CTZ+7A:S2<<5^P<C04T3PM1!2.#Y:B@"!$OKT2$@."ZL5YJ,$Z0X,5C
M1PG030$<95'T7Y5W *%\O=5TNW(X-I.)J4U#>8EN ^NV/)+W#;NHL WXB5=%
M;U=_"OVI?T]M75I,7,LW%CJY+C*;S\=L4G@ZP\X+CFX?,JJ6HDJZ(B+TX[#$
M;*%+B/0PF$_8NR732.T^VK0NOM:LP-_Y:H@CJN].^G0.1VH+0L^%Y"-E7Y(
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5[VOPZK?Q?ANOLV_CH/Z=W]FG7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g680117g40w11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w11.jpg
M_]C_X06D17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,S0Z,S8 1V5N80     #H $  P    '__P  H ( !     $   !RH ,
M!     $   "N          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !%H
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  I !L# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M1QP"   "   < E  !$=E;F$< @4 #55.251%1"!35$%415,X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L
M 0 !.$))300F       .             #^    X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!$0      !     "   "
M0    D      .$))300>       $     #A"24T$&@     #Q0    8
M         *X   !R    2 !& &\ <@!M "  ,@ P "T 1@ @ $0 4@!! $8
M5 !V #$ -@ @ $4 1 !' $$ 4@ @ #D ( !F &4 =@!R &D 90!R "  ,@ P
M #( - !? &8 <@!O &T ( !' &$ 8@!R &D 90!L &P 90 @ $8 3P!2 "
M4 !! $< 10 @ $( 4@!% $$ 2P M #< ,P    $
M     0              <@   *X                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "N     %)G:'1L;VYG    <@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     CA"24T$#      $=@    $    ;
M*0   %0   UT   $6@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ *0 ; P$B  (1 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!
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M '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
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M/WAP86-K970@96YD/2)W(C\^_^X (4%D;V)E &1      0, $ ," P8
M          #_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0("
M 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __" !$( *X <@,!$0 "$0$#$0'_Q #O   !! ,! 0$
M   (!@<)"@,$!0L" 0$  @(# 0$!            !08#! ('" $ "1   00!
M P,# P0" P$      P$"! 4&  <($1(3(10)(A46,B,S"C$T)#47&!$  @$#
M P,!!00&!08*"P   0(#$00% !(&(3$'$T%1(C(482,S"'%"4F(5%H&1H30U
M<M)3)"4VL='A@D-%51@).<&B<X.3HV1E5A<W$@ ! P($ @@$ P<$ @,    !
M !$"(0,Q01($46%Q@9&A(C(3!?"QP4+A(Q00T5)B,Q4&\7*R0X*B@R0T_]H
M# ,! 0(1 Q$   "YQL9(4=6S$'M33 CEE\C*9=8QV-+/Q2UYNED0SXR;53'\
M^E^X_?J"1,6();]9;-[N4\3>S-.0-..NI.QK2@5AQC&47PQS *P&#*N@&+*
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M@F.*-*?LP3LG8IB"ZJL5(G%S\U52MG#]RB1Q47#E\%<W&XW<3.'V1D#*1X$
MN&Q1V]WVFX(8ZXR$G!P!?!E<MBW>$AAK9NHCO1AMHVXPR<._-$_J8#H"?]9.
M/*( '>H&[O+A@^>/=11]4DD#$HL%ADR+XN?F5I?%3+5!40I6[)/ZF_$Q@8XC
M^;HQ<Y8'%:8;B-V[A<D[M+-SQ6N #'O0TA@K6W-T#5,.6<1B:.> 6O\ N7@-
M00*,4YWDY#CIIT=2]2YN"6ZNY"%MQ#GBBP\)P6.:B81)DS]M4#IP5^,Y 1)#
M(2@7 [UNK5O<,8P].(&,21J,NRG6A.6I\2_W% PH&PX(/$D*S:,?ZITOT59;
M3<7"/5D*/A2C=RG$2A3(?&*U"]ICR9"<]V6.3+UKDGFS_ 7E.#J#@8-]%X6K
MBORX/%"$C^8<!U+W*P32,P?_ % 47XJW)O"4-%:+;_QQF".DG2H6+U+EL.#E
M\.ZE>GNX@9T1];?2E+^6+CO[UKUW9'J'<HV-MMY FCG-98/U( 8U31P0$L6*
M$Y>4$<\V7OPN2$9V[@!<M5L <\7HB=<I,,HD_(*[:LUE;' CYKT)PN&1-&A*
M0#8N10=:@;,OS@?D-0?A48*7^/2VYE=&QM[B4V($8RR!S.>D55V5N7A=AE13
M>,DQ)$E:UF@ZUYSY7P.'QDHRCA_JI]*#8J4@/$ O=[8B )QMW 2,3H$)$=!@
M.U&[:N6Q9F&EB*8CRXUXT4XS$0).[!G^I^BE?]OW=NV'K&5=7#H97MU?$!*5
M7CF?]%>]UB =Q<,81/&W; 8/P))<(F/ERZ.?6I3M1(+9"G:I2])SQ4=<8@GF
MOMP;%1!QK]5-!L5+^)OCN6W][F?S[)],GC"1H&;*3&IS/!0M:HB()%>2M;FW
MM_5@[%FISRIQ4][Z8A.+F(!J1Q;Y*UM[H(N&8C$9O(B)?J*VGMVW_H68L.)X
MGM= $T1CK.@C!2N0O8J,CYAB>*Q*BV0^BD.84XYA$9A>Y[2W%[I@\?\ =$B7
M63ITCG((QNV3Z43IE'[@36F3C NI7-C[K&S:N&L9#4=)Q;(%7KDO=HW9".D
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M6+2('8HB2G']+ [>C'4'-*EBS5<,^3YJ[*>Y$94(T,2W F8D.[\8;;3IMQ
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MC[K4R"<\..*NQ:I ^2<4=%&!Q=&.6I69W;>IQ@$#[;;E GS.7T_N7]6.'?\
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M'%&W_:XBY&DJU<%-;V%L#@35:!MHQERP0G= -P8H5JO,HZHL=1^91(\JVYA
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M0Y6[NI9[N&'+NQD62?[UV;</A K_ +2X5?XW$7?IXN/.PVI#6&7O4-BEI=O
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M6KVZ:DL[8MZ#AF2-FW,E&(HK>U:#7M[_ -GN[:PCP,R>K@L(VWN S8JT;H*
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M2Y"H-[E+F.!IC\-(H0!6ITDMRHV))M9FZ%"&ZL?<O32(+ZR$H4#:;B/<!M%
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M=>A(+R4*10>L4  ;V=:4KK\"?^[5_O'ZWO[]_MUQL7*-'(N!P8*'N#_"+/\
MKJ#I:=R*?^J3_P"C5N;:&238\I8I7I\)([>ZFKN.&QN)MEQ201PR2,@!K5J
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MITIK/&--DEQ;1P.927<J)%E*H-VU%58R2/?KE&20^DE]ROE5S0TH\-URC+W
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M:EP_ECQ=+R3@N6BX)C<OG+?QMRSA\N1BY%=W4=O@[>SB4Y*ZM[4EFO9.+8G
M7?&6NHEOH,Q+QP>G*L*F.2TDO<E:7OT\D5 PCWQ@4[:Q@Y!P_ADN"FN(8KDV
MN7M(;^TM)%(ENK+TKZ6WF2WZ$QT.[L#[=?W%?PZ?C6_^'_M_B_B?N]OMU__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g680117g40w12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w12.jpg
M_]C_X06F17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,S8Z,C0 1V5N80     #H $  P    '__P  H ( !     $   !UH ,
M!     $   "C          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !%P
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  G !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#L?K76+,.O21)U\-%C]0ZA]CHJQ>G85_4<ZFAEN0RH 5UBP?H1DY+W
M?H[+?YQE+&6V^FM[ZP5,&.SD-,@A9'4&]2J ;A,IVY=E9M%Y=NW-KKHVL]/V
ML_1UMN9;_P">U+/(8XP8GJQX\<9Y3Q;4&'U=^L[KIQLO!^PY[I<W'N.[>UOT
MGXUS0&V[/\+5_.5KH_M'4=N[[/7MYY_\R7!=,KS<WKN%9D^DT5W6.I;1N^DU
MEM6RQUA]U>QV]]C%UGJW[?3W/WS'TC$?1A1C)(XSD]/&#5LIQ1&48_5P2%T_
M_]#N^OB<>L1,GMJLOK%F#EUM]!PRKL.N+VU$.#=PVMW._FG?S;ZWU_\ ;BY;
MZ]]?ZD_KV5TUF2YN'BMK8*F$M:7EGJ7/?M^G[W;%3Z'F>CT?K1AS['58M-#&
M[M7/LR&L]M;Z=^V/97ZGOL^A^D4LH<4 /JC'8R7WT;V!U6KZNW5]9R<9U?3L
MJTX=9V@6D.#KK\RFD>U]-'HU4O:SV;+?T'O77?MSH'V/]K?;\;[%Q]H]01/T
M_3]/^>];_@?3]5><_7_+%_4\?IM=]N31TS':QME[@^PVWQ?:Y]GYUGI?9F/_
M #/]&N9]%L1(F)^7$J,8C[9C>^J\S_6"5;/_T>=^L3K/^='4A:#N=??N.L A
M[O3Y_-?4I](<[U'5[2X/9#?I ;V^JZ'6L_F=V+]LW6M_6/L[,JO#_6+%Q*2L
MA6*^.+NY-KWV66/!]1YW.ANWZ0]@;7_@V^C]!GYC%3]2[?ZFT[ICTX_P<;=W
M[RSDDU;K]7__V?_M#BQ0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #
M&R5'' (   (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"24T$)0
M    $(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M %HX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$1       $     (
M  )    "0      X0DE-!!X       0     .$))300:      /%    !@
M            HP   '4   !( $8 ;P!R &T (  R #  +0!& "  1 !2 $$
M1@!4 '8 ,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E '( (  R
M #  ,@ T %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "  1@!/ %(
M( !0 $$ 1P!% "  0@!2 $4 00!+ "T -P S     0
M       !              !U    HP                     !
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M;&]N9P   *,     4F=H=&QO;F<   !U     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    ".$))300,      1X     0   !P
M   G    5   #,P   1< !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  G !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ',
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M P,# P,# P,# P/_P@ 1" "C '4# 1$  A$! Q$!_\0 [@   @(# 0$  P
M        " D&!P0%"@L#  $" 0 !!0$! 0$            & @,$!0<( 0 )
M$  !! $# @0% @8" P     # 0($!08 !P@1$A,4%0DA,2(R%C,*$$$C)#07
M)1A"0S81  $# P($! ,%! <'!0$   $" P01!08 $B$Q$P=!(A0(414687$R
M(Q>!0C,DD:&Q4C0E"?#!T6*"0S7Q4[,F)Q@2  $# @0#!@,%!P($!P    $
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MC%33&]&]W]:3^LF@?IN^X7VIK%.OJ$7KZKF?3UY=/T#7\_\ TZ__V@ ( 0$
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MG5N:A+9[Z5O= .&I%^8SY*Y?_P#OVF$HN'- Y\:J8A=JRGJODQ>B;7+ABB:
MN$)'!1 ":6+J56:!749RB"QDRTVI54IN:CN7IHFB-)"LS@6E&8PS[5MXQ.F-
MVT00#C)D!;@_E'>5(6[6:_H1UII3JH1<,HS&*=7'X,MY;M3\Q?$.M<(ZY>"D
M)[?RG$C+FIQN M4#MR^:%V%BC5_T"MRW-F4+1D'EC@ND7; ,M)=\C%FP4FXJ
M4H@"00C[F1^\(R:J<G-6_P Q"Q5^=RXUJ$3*1X *[U'I)C>V\"1(GE^7B%IF
M)6=MCK(>7%F&7T5NWMM]=T3A7AWEBR_M;G1A&X+9G#SZ_<,0^#AGYJ\.HRW%
MG0' C#UDY /^'DMS9VMWWMK&V9 RAHD#E&3N#R9FS7]L2;'4+UL"W;9V:ID#
M@'P8]JDX(J<2Y^Q0B.]";4?ZHC)D>U6:JJW6SF6%V$HD\1.) ?L76.E0O"&T
MVXT".<M)(<<'1,9D%OHK,C,F((HH;FU(>Z:E\3', \2*#FAO;5Z<*:A'S2E
MY@M5SQ7]G&+ZI!Y:3$^)J7S73Q*9B-M W Q;4P9CQ=T1SJ.>:!C2F2YZ43DR
M/:K=4SJ$;9QB=79E\ENNJVK(EM)P((AY:?K&).9(6F6&'<C Q,>?!&[K,R :
M'#Q4]P;#0-*(71%HQ+D&C\%>_P @ZC&,978CVHC*@()\4#(C5GVJ#<%JY.I#
M-D1FZM@IPI=BW-F$FF8R [U<MW#IN0+$<#B/'&B-JY&,A*E?5W<T;\X^09=N
M"%C61;U.!]65G;3G6<Q%N+D+9;6W($1M1^[[/PP3 *((9@FU!V^B/8J\4)$4
M+,O*I'\*E.6"V^XG:T[;<VW!S,XL"XRI@<T;ELTB'K12M6XDU^Y:KH6UE8#Z
M;D3SQX+;7#)[DH#4.YG!^1&>(K20G"0,#@1@>:88KN1147Y($8)S1\.:C[6U
M-O:9W)@B(YZ?4?#G5=)AM)SO;BT)F4LB#IK$9 /X*9D"1$L>'[D!;L1%*\48
M[>S*4Y%J,K.ZNA][*0 #&@.+JS;A-M('?FAIN&$LWJ)5Q;%VHX(R=V !G<#
M<*]_9VMV#!/7!$MFG#.H6Q65%+6&B#BHF($S' GCV("8#\J#P"VHE6$H3#<
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M[? MQ4K]W2)3LF()X]ZW,C.6G7Y7P+X]H.3^G *,(,)G'BKDW%(K7+$IFJC
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M \D%]E***3H50?(@ < :;?A\!HBI!;4!7Q\BO$4\::5#JKU!V#9QIP2X*[O
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M02I5Q;:A=HL9S'NICMMB-);6PJ?CTW$\@C3%H4H2$WZ7=&G"M8!VLA"24Z<
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M+M[:[99)45+C#EL:[/B)<;=<XZ]R)+$N(\@.H76I6H&GAETN"U+F=E,GBI5
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M\ELJ/4=9@S63-6VA-%)ZD;>5&FWB=/H;4I;"U]:&36BHLD)>8<*4D':IEP
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2J#?L<I2O\KMI6M/)2E>--?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g680117g40w13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w13.jpg
M_]C_X03X17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,S<Z,S@ 1V5N80     #H $  P    '__P  H ( !     $   !UH ,
M!     $   "&          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0   ZX
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  @ !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MG7;Z/K[H_P",3UIW'F__V?_M#7Y0:&]T;W-H;W @,RXP #A"24T$!
M*AP!6@ #&R5'' (   (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"
M24T$)0      $(W#%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M 0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$1
M$     (   )    "0      X0DE-!!X       0     .$))300:      /%
M    !@              A@   '4   !( $8 ;P!R &T (  R #  +0!& "
M1 !2 $$ 1@!4 '8 ,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E
M '( (  R #  ,@ T %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "
M1@!/ %( ( !0 $$ 1P!% "  0@!2 $4 00!+ "T -P T     0
M               !              !U    A@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    A@    !29VAT;&]N9P   '4
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    ".$))300,      /*
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P"GU6H[,4M$?[E<Z)A59S[1DY3<-E<M8V&FPEI LO<ZX[/2
MW.V[/3_ZXEG5[J\6/]=%=Z/E4C-QVXSS8YC;6O;4 YIL.VQ['/+FLWM_1;_<
MCD,AC)B:HCS5A$3D D+T._=Z#ZGCTL=]C:P'6V64WB=6VX]C\6S83_@GNK]1
MC%TTN\/Q6'TW-PKV[<2^JZVLDWUUN!>U\_IO4K_G/I_G[/>MK>/3W>2>3*A/
M3BX?^=PK (\1AKP\7_-XG__0POK!FW.SAB&QPHKJKBJ?;+F[W&/SO[2V/J!0
M<M^9C"YU>RRE[V-VPZJUMF._:Z/5IN8ZGTZ[JG_]J/\ BMG(_6'(=]OR+V\M
MM8QOP8#7_P!]6S]1>KU8/7:<E[@,>^FRJPDP 6C[55N_Z]C[?[:EH$<)"V-B
MB-%\XL9U3*LJ<X-IOM%-FX[PUCWUU_IOI_S3&^Y==_SAS/\ QO\ [9ZS_M6S
M[)Z^X^IZOJ_9_5]3Z?J>C^D7G67E/&$YYUL<V7'P<[W/_P W=[EO_;&?\S_L
MF]N[]JSLG7;Z/K[H_P",3UIW'F__V3A"24T$(0      5P    $!    #P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  (  R #  ,@ T     0 X0DE-! 8       <
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M P,# P,# P,# P,# P,# P,# P,# P/_P@ 1" "& '4# 1$  A$! Q$!_\0
MZP   @,  @,! 0          !PD&" H$!0(#"P ! 0 !! ,! 0
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MYTT%F @VX2V_T&<J(81=*:.!_'.M<A.P0&*V_+,M4)Z")LK&<I!(E>@6U7E
MS]ASS2Y$N&_M=-6!!173!Q4$N-&"&X&"8'#7:\\E8Z$B40517,S6&3?"7;U
M(*?[M=*YDK&6<.LV4/UJH#,BEXUDRVU9@>0:%=,!FH6WZ8[_V@ ( 0(  04
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M\U6(*@_(:XKQTPO%A?S=7]REHBG3BV+, MKBZ>'0BRE?D+!<0*H#;:"V"$G
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M2D4Q0T6W:+Y6>FANS?)31'8*8]TW=P=T(J+BMJX,9TY51,D'1*9:J9$+5%-
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M1E1O\5&B=2)S499,C;U 1,).3E0JY9![\)2(/$:B_7P4]Y"U)@$-O(?GR&'
M9/TK:W(TW,91DW"M7YLMT 6C<M"0YTE3JU!UXB[*<GI@M-42"FU*(92KDM*B
MO4H;"Z8;K]-<,2,R XCTG *.YLWS($/485(D.G4"MQ;-PBWY>66+CKJIS!'G
M$T)Q#?2BE<F#^HD ')=B/BO0]A"<FL;>Z9@<Q0D\.7LG1\T0(L409/7V1*(1
M!H ?FC;^ZMO*X?R]0?ZCR.!6^O;G;0_M6XNR-B0P$IF4Q"38 DL&R6]O086
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M?J(;XEEK0!5H#[B=ZK1IHC2BM3,::@H;NV'E !FK3ZE!I?ZFF5#Q%0A8;NQ
MEV *$FQN'XHTS*"@07*%LG\LS<\Z$>XG4<<$3H+Z_D@K4<]"UMFW7P1U>%$
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MN0S3&OM[\Y8;=;GBV8QLD,]GQWF<W'[C)LSV7X-D4>+,8@1;R]#+SUKF]I^
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M.X/*3<K:CF=P5CXZRVU?4I97>,,SIP 40M3DQJTXU$W.Y=4F\+XC>I.K)%X
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>X$\UPLEQ=-L^N_6!+;4FTS%2>Q]&5*#?=[PX:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g680117g40w14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w14.jpg
M_]C_X06@17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    %    L8=I  0    !    N    .0 +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z,SDZ,38 1V5N80     #H $  P    '__P  H ( !     $   !TH ,
M!     $   "N          8! P #     0 &   !&@ %     0   3(!&P %
M     0   3H!*  #     0 "   " 0 $     0   4(" @ $     0  !%8
M        2     $   !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  J !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M/T?_V?_M#B90:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"4  $1V5N81P"!0 -54Y)5$5$(%-4051%4SA"24T$)0      $(W#
M%W$!CY7*1J.N#^.M2;0X0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$1       $     (   )    "
M0      X0DE-!!X       0     .$))300:      /%    !@
M    K@   '0   !( $8 ;P!R &T (  R #  +0!& "  1 !2 $$ 1@!4 '8
M,0 V "  10!$ $< 00!2 "  .0 @ &8 90!V '( :0!E '( (  R #  ,@ T
M %\ 9@!R &\ ;0 @ $< 80!B '( :0!E &P ; !E "  1@!/ %( ( !0 $$
M1P!% "  0@!2 $4 00!+ "T -P T     0                         !
M              !T    K@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    K@    !29VAT;&]N9P   '0    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M *X     4F=H=&QO;F<   !T     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0 X0DE-!!0       0    ".$))300,      1R     0   !P    J
M5   #<@   16 !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1"  J !P# 2(  A$! Q$!_]T !  "_\0!/P   04! 0$! 0$
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M &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #
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M(&5N9#TB=R(_/O_N "%!9&]B90!D0     $# ! # @,&
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MH2(3!;'!T3+PD>%"4F+"\:(C,Q0&('*"DF,D4Y,T%?_:  P# 0$"$0,1
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MY8K=D?BZ*JA6'WOT(%Z,A.-1W(&)!"%50T5% @4$@>Y1A=<W[<Y.!B(O0D9
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M5*-X<E=@?FU([7!Y/[OIVJ=N/W8E6)Q^4VP@_0ZU9M[UXBF!J@ I:Z-@JBJ
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M!'%)&R0"!0'X ZOMMND=J1*5VNR=RQ!Y 6VQ/]_9DOR6 FBC*;A\PFA"B%*
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MU%:JN!*0E50D$^5*>'C_ !KX5.O :\!OM_/7U3VL?WG/J=7I)Y=3H=&M>/\
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M24^\4X#'XI2X<XOT6(MO"9?;%J_1I+2GFT+RVZVZ39;R)*4N&*\M<2TLJ<%
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MYT)4/ GP\!H$'\-Q0:;#I((YHH$D[K2HJ!&QXCST[U6D!:TJ(112U)4TBJ2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g680117g40w20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g40w20.jpg
M_]C_X05;17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    /    L8=I  0    !    P    .P +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#(Z,3 @
M,3$Z-3,Z,#D 2F]C96QY;B!,869O;F0   .@ 0 #     ?__  "@ @ $
M 0   -^@ P $     0   #L         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M0DE-!"4      !!ZU/! 1YM84^^LW1FQ^TQ/.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!$0
M !     "   "0    D      .$))300>       $     #A"24T$&@     #
MGP    8              #L   #?    -0 Q #$ +@ R "  20!N ', :0!D
M &4 <@ @ %0 <@!A &0 :0!N &< ( !0 &\ ; !I &, >0 @ &0 80!T &4
M9  @ $X ;P!V &4 ;0!B &4 <@ @ #( .0!? "  ,@ P #( ,0 M #$    !
M                          $              -\    [
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<    [     %)G:'1L
M;VYG    WP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    .P    !29VAT;&]N9P   -\    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MV?HV>QKMF[Z/M=[/M7J?\.DF\<K^7]+_ )Z?H7__V0 X0DE-!"$      %<
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$
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M!P@) !$0(!(*(4$3%#$5%C9 ,C49,"(S-!<8.#D1   & 0," P,'" <)
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MZ! @0($"! @08# ;!@,@@08#((-0C#1PX/-6FP"NL=!@,A__V@ ( 0(  04
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MM #U+%*2)JD0QE^IZN*0PUF09O6-SDDFK&!F3Q+.;>JRBS:0(ZK_ $Y*/9N
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M2Q4? \</#9HW@[?7+G*IQ6RO'M-<*VU6N>P6MWN+=G#8\UIXVN5* XZ*7O\
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M/-,)QQ*PA-)^ZO\ GC4!3"+7!/#"MJ/;AX04I^=?9@M!"X. 05&)-;**4/,
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MXFR\&D$^W$C)=N+WO/O<TJ/L,#<!:]BY!:":DN %#7D*8EO(S[D+P3U8TK]
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M1 >X!!'P =-->O P#X"/@/L =!'Z 'KOMUDUTC%,8BJ)RJI* 41*;:=,3 <
M$H@.@ZZAIUG2'RICZF5+$E=G:JWX]VVNVA69L>1J\]KPNK?)7:#.(EJ[V&L0
M>G:I%T[Z ]P>@;BLD#@4Q5!#N%[XI .@J EKW!( CIKIIKT81.4I2EWF,(@
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M;/%95XKLG4,I^/L_;[S0N15>G(A&+L[/.*,?(C-/YQRJD9U'R:7>7C5U!*D
M% @D@^9/(.=XT,\N8'P_E&G\:,5XH:7TE!>7J_0+IA]X,SY#L+9*ZR5?*X30
M1(QCVVUH@LLJ3<MX*?[,OV?M>WZ!^S_Q=%^S_33[/0_K\OT]>SR#R_3_ &?)
M_5]/M^3V>7Z/+^[H?I_4'G^?Y/\ =]GVOT]+^_\ ^2/W1]](+UO\^'WZ_"[9
M^\:?=3\-?\[_ (A[M/1>[_VG;[GLUZS%]R?_ %C^@]P07J?Y-/Q\_'7O>M3T
B_$W^8+_,GW'\_3>E_8=_MZ^SY0\O,//]7Y^OZOI]O7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g680117g50w10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g680117g50w10.jpg
M_]C_X08#17AI9@  34T *@    @ #0$   ,    ! '4   $!  ,    ! +L
M  $"  ,    #    J@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    L $;  4    !    N $H  ,    !  (   $Q  (
M   ?    P $R  (    4    WP$[  (    %    \X=I  0    !    ^
M 3  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(R+C @
M*%=I;F1O=W,I #(P,C0Z,#(Z,3 @,34Z,C@Z-#, 1V5N80  !)    <    $
M,#(S,: !  ,    !__\  * "  0    !    =: #  0    !    NP
M   & 0,  P    $ !@   1H !0    $   %^ 1L !0    $   && 2@  P
M  $  @   @$ !     $   &. @( !     $   1M         $@    !
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MPD8S;UYR,6P'#;8PYM1_6,;=-K"X"RO<U_Z2W]$]GZ?\]8/V<?:9C\_A9_\
MC,QAC?6IN0UV]V5B4W&QNDO:;,9UC-OT?933]%9'[=ZC]G]'[0_G^<G])$?1
M];^<VHDWCC"OE!'VK0",IG9UEQ?V/__1\\KM!<YI_-/Y4>MQ:37)#+  ]O9S
M0YM@:?WMEC6.6?1O]=WQ,JVV=H^/L^/_ )';]-/"'?\ K'FC*Z3]7K7NFZG!
MMQ['>5%WV:O=_9IW+ ]7VSWGY\*63ZWIU^M/H:[/ZNX^IM_D_:/4]1 U]7M/
MJ?*(_P#(HZ<7A:G_V?_M#;Y0:&]T;W-H;W @,RXP #A"24T$!       ,AP!
M6@ #&R5'' %:  ,;)4<< @   @  ' )0  1'96YA' (%  U53DE4140@4U1!
M5$53.$))300E       0SUJ<X\RR?J&HAWK9C6#X\3A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M 2P    !  $!+     $  3A"24T$)@      #@             _@   .$))
M30/R       *  #_______\  #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T,
M   &              "[    =0    < 9P T #  =P Q #  80    $
M                     0              =0   +L
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   +L     4F=H=&QO;F<
M  !U    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   "[     %)G:'1L;VYG    =0    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ +0 < P$B  (1 0,1 ?_=  0  O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M3ZWIU^M/H:[/ZNX^IM_D_:/4]1 U]7M/J?*(_P#(HZ<7A:G_V0 X0DE-!"$
M     %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0
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M P,# P,# P,# P,# P,#_\  $0@ NP!U P$1  (1 0,1 ?_=  0 #__$ :(
M   & @,!              <(!@4$"0,* @$ "P$   8# 0$!
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MX01ZF!!2-\M)5<VL7B(!Q/KT<)L,S2QQW$FF0M\(KP]?2OR_XKK7\[*_G_\
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M)CZY(QP-+STYD!!(96!!]Y&;"X.SV,C&NJ+_ (Z=/\^L3>8U5=VW%1BDI/\
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M5FNO('/X]A#W"4Q\C\S0:122R:N."JREC^?#H?\ M9(K^XG)3QL5:+=+5B_
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M(][&KR.>M#XSTB.T,=19;JOLG#UHBBI:_9N8@\TEA'3321Z:.J9S= D59HU
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M+/J&HB(WL./JQ_P^EO<3<SFL,Q/I_DZDGEY$8R$CRZ(MNV@O]W8(5:H;ZW
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M"%6DU2"@^7'K:RF+$>5^?4>J@@,L&/F\<;UD<PC\D>N-S#'Y7A(8:?N'B!*
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MF V\LL1))A[*GY^?0A2Z$JP'KYP/\\': VO\^L+E(]"_WFZOR.%JQI*2_?\
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M(-K7-_S^?:ZZF1PJ1DU''JB:: #I 0FTJ?\ !A_M_P ?[S[0]7Z$C;U9) R
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M_)_'?7ZO?K/XY/\ 3#AP\OY_Y*=*)."_8?M_XK_9Z9^X+6Z[U?QK7]OC]/\
M>C7_ !3PZ*#_ (%^+]G^[FN_V6O]_1_M.GV?<S_V-C\7$?X/Q?/TITGVWC/]
MO4WN'5_ ,5_P+T:'OX?#]I>T/_ O_=]_]1;C3[#DW^7JZ?V\_P!G678&C["F
MM_"/\QQ]M]QJ_7_M7-K_ %O^?\/?H?B\O]5.JGX(O]+T(^9OX%^MM']G3H_L
M6UV]6G_?'VL7XG_TO3:_"OV#HO.Z-7]]9K_=_P# 2@MJ\?VVG0/^ ^GGP?\
I!O5KO[+_ "D_U>?2@?V!X<>E$/\ BR-_U$K_ +T_NW^A].?Z!^77_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173741216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERATECHNOLOGIES INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--11-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">45,980,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">THTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2015 Peel Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Montreal<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H3A 1T8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Montreal, Quebec, Canada<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jocelyn Lafond<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2015 Peel Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Montreal<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H3A 1T8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-6607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">(514) 331-9691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174217888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 34,097<span></span>
</td>
<td class="nump">$ 23,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="nump">9,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">12,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceivable', window );">Tax credits and grants receivable</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncomeTaxReceivableCurrent', window );">Income taxes receivable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Inventories</a></td>
<td class="nump">6,066<span></span>
</td>
<td class="nump">19,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses and deposits</a></td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">7,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Derivative financial assets</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">63,297<span></span>
</td>
<td class="nump">73,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use-assets</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">12,496<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">14,472<span></span>
</td>
<td class="nump">19,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">77,769<span></span>
</td>
<td class="nump">93,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">28,471<span></span>
</td>
<td class="nump">41,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Provisions</a></td>
<td class="nump">9,603<span></span>
</td>
<td class="nump">7,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued', window );">Convertible unsecured senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LoanFacilityCurrent', window );">Current portion of Loan Facility</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">37,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion of lease liabilities</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_WarrantsCurrent', window );">Marathon Warrants</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Deferred revenue</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">47,294<span></span>
</td>
<td class="nump">114,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LoanFacilityNoncurrent', window );">Loan Facility</a></td>
<td class="nump">50,688<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">51,345<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">98,639<span></span>
</td>
<td class="nump">115,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital, warrants and subscription receipts</a></td>
<td class="nump">363,927<span></span>
</td>
<td class="nump">338,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments', window );">Equity component of convertible unsecured senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus</a></td>
<td class="nump">23,178<span></span>
</td>
<td class="nump">18,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(408,659)<span></span>
</td>
<td class="num">(382,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">(20,870)<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 77,769<span></span>
</td>
<td class="nump">$ 93,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing components of convertible instruments classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncomeTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncomeTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LoanFacilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan facility current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LoanFacilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LoanFacilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan facility noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LoanFacilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxCreditsAndGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxCreditsAndGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_WarrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_WarrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174183504">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Net Loss and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th" colspan="2"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81,764<span></span>
</td>
<td class="nump">$ 80,057<span></span>
</td>
<td class="nump">$ 69,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,635<span></span>
</td>
<td class="nump">23,838<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AmortizationOfOtherAssets', window );">Amortization of other asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">4,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits', window );">Research and development expenses, net of tax credits of $ 539 (2022 - $ 316; 2021 &#8211; $ 277)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,370<span></span>
</td>
<td class="nump">36,939<span></span>
</td>
<td class="nump">28,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingExpense', window );">Selling expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,769<span></span>
</td>
<td class="nump">39,391<span></span>
</td>
<td class="nump">28,909<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,617<span></span>
</td>
<td class="nump">17,356<span></span>
</td>
<td class="nump">14,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,391<span></span>
</td>
<td class="nump">119,965<span></span>
</td>
<td class="nump">95,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,627)<span></span>
</td>
<td class="num">(39,908)<span></span>
</td>
<td class="num">(25,236)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinanceCostsAndGainsLossesOnForeignCurrency', window );">Finance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,056)<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
<td class="num">(6,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency', window );">Finance income cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,909)<span></span>
</td>
<td class="num">(6,886)<span></span>
</td>
<td class="num">(6,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,536)<span></span>
</td>
<td class="num">(46,794)<span></span>
</td>
<td class="num">(31,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,957)<span></span>
</td>
<td class="num">(47,237)<span></span>
</td>
<td class="num">(31,725)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified to net profit (loss) in the future</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax', window );">Net change in fair value of financial assets at fair value through other comprehensive income ("FVOCI")</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (23,658)<span></span>
</td>
<td class="num">$ (46,808)<span></span>
</td>
<td class="num">$ (31,288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings (loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (91)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="num">$ (137)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings (loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (91)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="num">$ (137)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See note 1 for share consolidation.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on remeasuring available-for-sale financial assets, net of tax, before reclassification adjustments. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_91_a&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AmortizationOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of other assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AmortizationOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinanceCostsAndGainsLossesOnForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance costs and gains losses on foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinanceCostsAndGainsLossesOnForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance income cost and gains losses on foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating expeneses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense net of tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173086992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost', window );">Other Comprehensive Income Net Of Tax Research and Development Cost</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income net of tax research and development cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165672640">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Share capital Subscription receipts and Public Offering Warrants</div></th>
<th class="th"><div>Equity component of convertible unsecured senior notes</div></th>
<th class="th"><div>Contributed surplus</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Nov. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,224<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 287,312<span></span>
</td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">$ 12,065<span></span>
</td>
<td class="num">$ (300,129)<span></span>
</td>
<td class="num">$ (481)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning balance, Shares at Nov. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,253,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Total comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,725)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax', window );">Net change in fair value of FVOCI financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,725)<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousComponentsOfEquityAbstract', window );"><strong>Transactions with owners, recorded directly in equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Public issue of common shares and&#160;warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,002<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 46,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues', window );">Public issue of common shares and&#160;warrants (Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,181,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareIssueCosts', window );">Share issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,394)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares', window );">Exercise of warrants (Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringPeriodValueAcquisitions', window );">Share issue &#8211; Oncology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringPeriodSharesAcquisitions', window );">Share issue &#8211; Oncology (Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">120,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareBasedCompensationPlanAbstract', window );"><strong>Share-based compensation plan</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation for stock option plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExerciseOfStockOptionsAbstract', window );"><strong>Exercise of Options:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue', window );">Monetary consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares', window );">Monetary consideration Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">166,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExerciseOfStockOptionsAttributedValue', window );">Attributed value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by owners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,824<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 48,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="num">(3,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares', window );">Total contributions by owners shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,527,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Nov. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 335,752<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">12,843<span></span>
</td>
<td class="num">(335,248)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, Shares at Nov. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,780,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Total comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,237)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax', window );">Net change in fair value of FVOCI financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(360)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,808)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,237)<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousComponentsOfEquityAbstract', window );"><strong>Transactions with owners, recorded directly in equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareIssueCosts', window );">Share issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(164)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue', window );">Share issue - ATM program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NumberOfSharesIssuedThroughAtmProgram', window );">Share issue - ATM program (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Repurchase of convertible unsecured senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareBasedCompensationPlanAbstract', window );"><strong>Share-based compensation plan</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation for stock option plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,860<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExerciseOfStockOptionsAbstract', window );"><strong>Exercise of Options:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue', window );">Monetary consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares', window );">Monetary consideration Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExerciseOfStockOptionsAttributedValue', window );">Attributed value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by owners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,477<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,999<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="nump">5,967<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares', window );">Total contributions by owners shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">421,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Nov. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,571)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 338,751<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">18,810<span></span>
</td>
<td class="num">(382,649)<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, Shares at Nov. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,201,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Total comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,957)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax', window );">Net change in fair value of FVOCI financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,957)<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousComponentsOfEquityAbstract', window );"><strong>Transactions with owners, recorded directly in equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareIssueCosts', window );">Share issue costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,053)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringThePeriodValueNewIssues', window );">Public issue of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 25,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringThePeriodSharesNewIssues', window );">Public issue of common shares (Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,778,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible unsecured senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible unsecured senior notes (Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Repurchase of convertible unsecured senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,131)<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareBasedCompensationPlanAbstract', window );"><strong>Share-based compensation plan</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation for stock option plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExerciseOfStockOptionsAbstract', window );"><strong>Exercise of Options:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by owners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,359<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 25,176<span></span>
</td>
<td class="num">(2,132)<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="num">(2,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares', window );">Total contributions by owners shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,778,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Nov. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (20,870)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 363,927<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,178<span></span>
</td>
<td class="num">$ (408,659)<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance, Shares at Nov. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45,980,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 1 for share consolidation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on remeasuring available-for-sale financial assets, net of tax, before reclassification adjustments. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_91_a&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousComponentsOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousComponentsOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ExerciseOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>IncreaseDecreaseThroughSharebasedPaymentTransactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ExerciseOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ExerciseOfStockOptionsAttributedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options attributed value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ExerciseOfStockOptionsAttributedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of options number of shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughExerciseOfOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of options value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughExerciseOfOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of warrants equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of warrants equity value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through shares issued atm program value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through transactions with owners number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NumberOfSharesIssuedThroughAtmProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued through atm program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NumberOfSharesIssuedThroughAtmProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ShareBasedCompensationPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ShareBasedCompensationPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period value new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period shares conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringThePeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringThePeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period value conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuedDuringThePeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period value new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuedDuringThePeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173906192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th" colspan="2"><div>Nov. 30, 2022</div></th>
<th class="th" colspan="2"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash&#160;flows&#160;from&#160;(used&#160;in) Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (23,957)<span></span>
</td>
<td class="num">$ (47,237)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (31,725)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property and equipment</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of intangible assets and other asset</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">11,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdjustmentsForAmortizationOfRightofuseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">449<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation for stock option plan&#160;and stock appreciation rights</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">3,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnLeaseTermination', window );">Gain on lease termination</a></td>
<td class="num">(121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets', window );">Change in fair value of derivative financial assets</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Change in fair value of liability related to deferred stock&#160;unit&#160;plan</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan', window );">Interest on convertible unsecured senior notes and Loan Facility</a></td>
<td class="nump">8,263<span></span>
</td>
<td class="nump">4,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,306<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid on convertible unsecured senior notes and Loan Facility</a></td>
<td class="num">(8,812)<span></span>
</td>
<td class="num">(4,634)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestIncome', window );">Interest income</a></td>
<td class="num">(769)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(195)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Income tax expense</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Gain on repurchase of convertible unsecured senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts', window );">Accretion expense and amortization of deferred financing costs</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Change in fair value of Marathon Warrants</a></td>
<td class="num">(1,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnLoanFacilityModifications', window );">Loss on Loan Facility modifications</a></td>
<td class="nump">3,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Write off of deferred financing costs</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows from (used in) operations before changes in working capital</a></td>
<td class="num">(13,811)<span></span>
</td>
<td class="num">(27,709)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,669)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Change in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="num">(902)<span></span>
</td>
<td class="num">(1,669)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,852<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable', window );">Tax credits and grants receivable</a></td>
<td class="num">(215)<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="nump">10,327<span></span>
</td>
<td class="nump">8,991<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,217)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Prepaid expenses and deposits</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,569)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(7,508)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,549<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Provisions</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Increase (decrease) in working capital</a></td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">13,017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Total cash used in operating activities</a></td>
<td class="num">(5,678)<span></span>
</td>
<td class="num">(14,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,501)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Repurchase of convertible unsecured senior notes</a></td>
<td class="num">(27,452)<span></span>
</td>
<td class="num">(28,746)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Costs related to repurchase of convertible unsecured senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from issuance of Loan Facility</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Costs related to issuance of Loan Facility</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RepaymentOfOtherObligations', window );">Repayment of other obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProceedsFromIssuingSharesAndWarrants', window );">Proceeds from issue of common shares, Public Offering Warrants and subscription receipts</a></td>
<td class="nump">25,160<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">46,002<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Costs related to issuance of common shares, Public Offering Warrants and subscription receipts</a></td>
<td class="num">(1,585)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,394)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdjustmentsForDeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(1,527)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liability</a></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(635)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Total cash from financing activities</a></td>
<td class="nump">14,775<span></span>
</td>
<td class="nump">9,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisition of intangible assets</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(39)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment</a></td>
<td class="num">(318)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(127)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from sale of bonds and money market funds</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">9,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisition of bonds and money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,210)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentsToAcquireDerivativeFinancialAssets', window );">Acquisition of derivative financial assets</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total cash from (used in) investing activities</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">8,682<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12,736)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net change in cash</a></td>
<td class="nump">10,205<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">23,856<span></span>
</td>
<td class="nump">20,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of foreign exchange on cash</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">$ 34,097<span></span>
</td>
<td class="nump">$ 23,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 20,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in derivative financial assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest income expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for accretion expense and amortization of deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdjustmentsForAmortizationOfRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdjustmentsForAmortizationOfRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdjustmentsForDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdjustmentsForDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdjustmentsForTaxCreditsAndGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdjustmentsForTaxCreditsAndGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in operating assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnLoanFacilityModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on loan facility modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnLoanFacilityModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on repurchase of convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on convertible unsecured senior notes and long term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for costs related to repurchase of convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentsToAcquireDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Derivative Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentsToAcquireDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProceedsFromIssuingSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuing shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProceedsFromIssuingSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RepaymentOfOtherObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of other obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RepaymentOfOtherObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172056160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Basis of preparation </div></div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Share consolidation </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;19, 2023, the Board of Directors approved a consolidation of the issued and outstanding common shares (the &#8220;Common Shares&#8221;) on the basis of one for four <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(1-for-4)</div></div> common shares (the &#8220;Consolidation&#8221;) effective July&#160;31, 2023. All references in these Financial Statements to the number of common shares, Public Offering Warrants (as defined in Note 20(a)), Marathon Warrants (as defined in Note 20(c)), Options (as defined in Note 20(h)), weighted average number of common shares, basic and diluted loss per share and the exercise prices of the Public Offering Warrants, Marathon Warrants and Options have been retrospectively adjusted and restated to reflect the effect of the Consolidation for all periods presented. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement of compliance </div></div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These Financial Statements were authorized for issue by the Board of Directors on February&#160;20,&#160;2024. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Going concern uncertainty </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the preparation of these Financial Statements, management is responsible for identifying any event or situation that may cast doubt on the Company&#8217;s ability to continue as a going concern. Substantial doubt regarding the Company&#8217;s ability to continue as a going concern exists if events or conditions, considered collectively, indicate that the Company may be unable to honor its obligations as they fall due during a period of at least, but not limited to, 12 months from November&#160;30, 2023. If the Company concludes that events or conditions cast substantial doubt on its ability to continue as a going concern, it must assess whether the plans developed to mitigate these events or conditions will remove any possible substantial doubt. </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">For the year ended November&#160;30, 2023, the Company incurred a net loss of $23,957 (2022-$47,237<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">; 2021-$31,725</div>) and had negative cash <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">flows</div> from operating activities of $5,678 (2022- <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div>14,692<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">; 2021- $17,501</div>). As at November&#160;30, 2023, cash amounted to $34,097 and bonds and money market funds amounted to $6,290.</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Loan Facility contains various covenants, including minimum liquidity covenants whereby the Company needs to maintain significant cash, cash equivalent and eligible short-term investments balances in specified accounts, which restricts the management of the Company&#8217;s liquidity (refer to Note 17). A breach of the liquidity covenant (a &#8220;Liquidity Breach&#8221;) provides the lender with the ability to demand immediate repayment of the Loan Facility and makes available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements, and may trigger an increase of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">300 basis points</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the interest rate on the outstanding loan balance. On July 3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt, which breach was waived on September 21, 2023. During fiscal 2023, the Company entered into several amendments to the Marathon Credit Agreement to amend certain of the terms and conditions therein (see note 17).</div></div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The amendments to the Marathon Credit Agreement resulted in: (i)&#160;revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between</div></div> $<div style="letter-spacing: 0px; top: 0px;;display:inline;">15,000</div> and $<div style="letter-spacing: 0px; top: 0px;;display:inline;">20,000</div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div></div><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">ased on the Marathon adjusted EBITDA (as defined in the Marathon Credit Agreement, the &#8220;Marathon Adjusted EBITDA&#8221;) targets over the most recently ended four fiscal quarters; (ii)&#160;deleting the quarterly minimum revenue targets and replacing them with Marathon Adjusted EBITDA targets, beginning with the quarter ending November&#160;30, 2023; and (iii)&#160;deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies the Company&#8217;s annual report. Notwithstanding these amendments, there is no assurance that the lender will agree to amend or to waive any future potential covenant breaches, if any. The Company does not meet the condition precedents to drawdown additional amounts under the Marathon Credit Agreement and does not currently have other committed sources of financing available to i</div><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">t.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s ability to continue as a going concern for a period of at least, but not limited to, 12 months from November&#160;30, 2023, involves significant judgement and is dependent on the adherence to the conditions of the Marathon Credit Agreement or to obtain the support of the lender (including possible waivers and amendments, if necessary), increase its revenues and the management of its expenses (including the reorganization mainly focused on its R&amp;D activities-see Note 16(a)) in order to meet or exceed the Marathon Adjusted EBITDA target and generate sufficient positive operating cash flows. Some elements of management&#8217;s plans are outside of management&#8217;s control and the outcome cannot be predicted at this time. Should management&#8217;s plans not materialize, the Company may be in default under the Marathon Credit Agreement, be forced to reduce or delay expenditures and capital additions and seek additional alternative financing, or sell or liquidate its assets. As a result, there is material uncertainty related to events or conditions that cast substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 16pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These Financial Statements have been prepared assuming the Company will continue as a going concern, which assumes the Company will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. These Financial Statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that might result from the outcome of this uncertainty and that may be necessary if the going concern basis was not appropriate for these Financial Statements. If the Company was unable to continue as a going concern, material impairment of the carrying values of the Company&#8217;s assets, including intangible assets, could be required. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Financial Statements have been prepared on a going concern and historical cost basis, except for: </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">bonds and money market funds, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">derivative financial assets, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">liabilities related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> arrangements and derivative financial liabilities, which are measured at fair value, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">lease liabilities which are measured at present value of lease payments not paid at commencement date, </div></td></tr></table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-classified</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment arrangements are measured at fair value at the grant date pursuant to IFRS&#160;2, <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-based</div> Payment</div></div></div>. </div></td></tr></table> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The methods used to measure fair value are discussed further in Note 25. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Functional and presentation currency </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company&#8217;s functional currency is the United States dollar (&#8220;USD&#8221;). </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">All financial information presented in USD has been rounded to the nearest thousand. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Use of estimates and judgments </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s Financial Statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting year. </div></div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Judgments in applying accounting policies </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about critical judgments in applying accounting policies and assumptions that have the most significant effect on the amounts recognized in the Financial Statements is noted below. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestones payments </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase consideration for the oncology platform (Note 13) includes additional milestone payments based on the attainment of commercial milestones that will be settled through the issuance of the Company&#8217;s common shares, which represent a transaction in the scope of IFRS 2. Accordingly, the fair value of the oncology platform at the date of acquisition incorporates management&#8217;s judgement as to the probability of attaining the share-based milestones as well as the expected timing of the attainment of the milestones. </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Management uses judgement in determining whether milestone payments are performance-related development milestones which are capitalized as an intangible asset or are milestones related to the activity or usage of an asset which are expensed. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Key sources of estimation uncertainty </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are as follows: </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales allowances </div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Management uses judgment in estimating provisions for sale allowances such as cash discounts, returns, rebates and chargebacks, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation. The product revenue recognized quarter over quarter is net of these estimated allowances. Such estimates require the need to make estimates about matters that are inherently uncertain. These estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends such as competitive pricing and new product introductions, estimated inventory levels, and the shelf life of products. If actual future results vary, these estimates need to be adjusted, with an effect on sales and earnings in the period of the adjustment. (refer to Notes 2 &#8220;Revenue recognition&#8221; and 3 for additional information). </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recoverability of inventories </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company regularly reviews inventory to determine whether the inventory cost exceeds its net realizable value. The determination of the net realizable value requires management to make estimates and use judgement in considering shelf life of a product, the effects of technological changes and new product introductions. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other areas of judgment and uncertainty are related to the estimation of accruals for clinical trial expenses, the recoverability of intangible assets, the measurement of derivative financial assets, the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> arrangements, the Marathon Warrants and gain or loss on amendments to the Marathon Credit Agreement. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company is subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. Management regularly evaluates estimates and assumptions using historical experience and expectations about the future. Management adjusts estimates and assumptions when facts and circumstances indicate the need for change. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172052160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Significant accounting policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Significant accounting policies </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The accounting policies have been applied consistently by the Company, except as otherwise noted for the initial application of new or amended accounting standards. </div>  <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Basis of consolidation </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of the subsidiaries of the Company are included in these Financial Statements from the date on which control commences until the date on which control ceases. Subsidiaries are entities controlled by the Company. Control is present where the Company has the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable are taken into consideration. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany balances and transactions, revenues and expenses resulting from transactions between subsidiaries and with the Company are eliminated in preparing the Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign currencies </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Transactions in foreign currencies are translated to the functional currency at exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate in effect at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the reporting year, adjusted for effective interest and payments during the reporting year, and the amortized cost in foreign currency translated at the exchange rate in effect at the end of the reporting year. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate in effect at the date on which the fair value was determined. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured at historical cost in a foreign currency are translated using the exchange rate in effect at the date of the transaction. Foreign currency differences arising on translation are recognized in net profit, except for differences arising on the translation of FVOCI financial instruments, which are recognized in other comprehensive income (loss). </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign operations </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The assets and liabilities of foreign operations whose functional currency is not the US$ are translated into US$ at the reporting date. The income and expenses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">foreign-currency</div> denominated operations are translated at average rates for each reporting period. Foreign exchange differences arising on the translation of foreign operations are recognized directly in other comprehensive income (loss). When a foreign subsidiary is disposed of, the cumulative amount recognized in the currency translative reserve forms part of the gain or loss on disposal. </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Revenue recognition </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Revenue from contracts with customers &#8211; Net sales </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">The Company derives revenue from the sales of finished goods, which include Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>and <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div>. The Company recognizes revenue at a point in time when it transfers title of the finished goods to a customer, which generally occurs upon delivery of the finished goods to the customer&#8217;s premises. Payment received from customers prior to the transfer of control of the goods is recorded as deferred revenue. </div></div></div> <div style="font-style: normal; font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Some arrangements for the sale of finished goods provide for customer cash discounts for prompt payment, allowances, rights of return, rebates on sales made under governmental and commercial rebate programs, chargebacks on sales made to government agencies and retail pharmacies and distribution fees, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation which gives rise to variable consideration. At the time of sale, estimates are made for items giving rise to variable consideration based on the terms of the arrangement. The variable consideration is estimated at contract inception using the most likely amount method and revenue is only recognized to the extent that a significant reversal of revenue is not expected to occur. The estimate is based on historical experience, current trends, contractual terms with distributors and other known factors. Sales are recorded net of customer discounts, rebates, chargebacks, distribution fees and estimated sales returns, and exclude sales taxes. A refund liability and a right to recover returned goods asset are recognized for expected returns in relation to sales made before the end of the reporting period. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of variable consideration, including expected returns, on a quarterly basis, adjusting for the amounts of the asset and liability accordingly. </div>  <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Cost of sales </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold includes the cost of raw materials, supplies, direct labour and overhead charges allocated to goods sold as well as write-downs of inventories. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Amortization of the other asset </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">The amortization of the other asset related to the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14). </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Employee benefits </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">profit-sharing</div> or cash bonus plans if the Company has a legal or constructive obligation to pay an amount as a result of past services rendered by an employee and the obligation can be estimated reliably. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits include a defined contribution plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense when due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available. The Company&#8217;s defined contribution plan comprises the registered retirement savings plan, the Quebec Pension Plan and employment insurance. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits are recognized as an expense when the Company is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Finance income and finance costs </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Finance income comprises interest income on financial assets and gains on the disposal of financial assets and financial liabilities. Interest income is recognized as it accrues in net loss using the effective interest method. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finance costs comprise bank charges, interest and accretion expense on lease liabilities, convertible unsecured senior notes, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> loans and obligations and deferred financing costs, impairment losses on financial assets recognized in net loss, changes in fair value of liabilities and derivatives, unrealized foreign currency gain or loss on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> obligations, loss on long-term obligations modifications and other foreign currency gains and losses which are reported on a net basis. </div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Inventories </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Inventories are presented at the lower of cost, determined using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> method, and net realizable value. Inventory costs include the purchase price and other costs directly related to the acquisition of materials and other costs incurred in bringing the inventories to their present location and condition. The Company is responsible for coordinating the production and stability testing and for auditing suppliers at different times during the manufacturing process. Inventory costs also include the costs directly related to the conversion of materials into finished goods. Net realizable value is the estimated selling price in the Company&#8217;s ordinary course of business less the estimated costs of completion and selling expenses. In determining whether the inventory cost exceeds its net realizable value for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory, the Company considers whether there is a high probability of regulatory approval for the product. In making that determination, the Company considers prior history with approvals of similar products, estimated timing of obtaining regulatory approval, regulatory agencies correspondence regarding safety and efficacy of the product and current market factors. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Work in progress inventory appears from the moment third party suppliers use the material provided by the Company until the time the Company receives the finished product. The value of work in progress inventory is equal to the value of material provided by the Company plus all conversion work performed by third party suppliers. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Property and equipment </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Recognition and measurement </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Items of property and equipment are recognized at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and the costs of dismantling and removing the item and restoring the site on which it is located, if any. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment and are recognized in net profit or loss. </div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Subsequent costs </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> servicing of items of property and equipment are recognized in net profit or loss as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Depreciation </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The methods of depreciation and depreciation rates and periods are as follows: </div><div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 46%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 20%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 28%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Method</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rate/period</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">50%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20% 5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Office furniture and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Leasehold improvements</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;">Straight-line</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="-sec-ix-hidden:hidden101085993;display:inline;">Lower of lease term</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">and economic life</div></td></tr></table></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The method of depreciation is selected based on the most closely expected pattern of consumption of the future economic benefits embodied in the asset. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Estimates for depreciation methods, useful lives and residual values are reviewed at each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> and adjusted if appropriate. </div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Research and development </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Development activities involve a plan or design for the production of new or substantially improved products and processes. A development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset. These criteria are usually met when a regulatory filing has been made in a major market and approval is considered highly probable. The expenditure capitalized includes the cost of materials, direct labour, and overhead costs that are directly attributable to preparing the asset for its intended use. Other development </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">expenditures are expensed as incurred. Capitalized development expenditures are measured at cost, less accumulated amortization and accumulated impairment losses.</div></div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">During the years ended November&#160;30, 2023, 2022 and 2021, no development expenditures were capitalized. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> advance payments for good and services that will be used in future research and development activities are expenses when the activity has been performed rather than when the payment is made. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Commercialization rights and oncology platform </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights and the oncology platform acquired by the Company have finite useful lives and are measured at cost less accumulated amortization and any accumulated impairment losses. Commercialization rights&#160;&#8211; <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>111<div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">&#160;months on a </div><div style="letter-spacing: 0px; font-size: 11pt; text-wrap: nowrap; top: 0px;;display:inline;"></div><div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis<div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Commercialization rights&#160;&#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> North American Territory &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>142<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis. Commercialization rights &#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>European Territory &#8211; were amortized at fixed rates based on their estimated useful life of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>148<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a straight-line basis. They were fully amortized during the year ended November&#160;30, 2022. Refer to Note 13. Commercialization rights&#160;for the oncology platform will be amortized over the estimated useful life on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis when the asset is available for use. </div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The amortization method and useful life of intangible assets are reviewed every year and adjusted as required. </div>  <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Asset acquisitions </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Asset acquisitions are acquisitions that do not qualify as business combinations. At the date of acquisition, the Company initially recognizes the individual identifiable assets acquired and liabilities assumed. The cost to the Company at the date of the acquisition is allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of the acquisition. Subsequent consideration for performance-related development milestones is recognized as intangible assets when the specific milestones have been achieved and other recognition criteria are met. Subsequent payments related to activity or usage of an asset, including sales royalties, are expensed as incurred. Asset acquisition transactions do not give rise to goodwill. </div>  <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Other asset </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other asset, which comprised the amount disbursed in connection with the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14), was amortized over its estimated useful life of<div style="display:inline;">&#160;</div>48&#160;months. Other asset was fully amortized during the year ended November&#160;30, 2022. </div>  <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The carrying amounts of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows from other assets or groups of assets (&#8220;Cash-Generating Unit&#8221;). The recoverable amount of an asset or a Cash-Generating Unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the Cash-Generating Unit. </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Impairment losses recognized in prior years are determined by the Company at each reporting date for any indications that the loss has decreased or no longer exists. An asset&#8217;s carrying amount, increased through the reversal of an impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company initially recognizes financial assets on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value through profit or loss, then the initial measurement includes transaction costs that are directly attributable to the asset&#8217;s acquisition or issue. On initial recognition, the Company classifies its financial assets as measured at amortized cost, FVOCI or fair value through profit or loss (&#8220;FVPL&#8221;), depending on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">(i) Financial assets measured at amortized cost </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial;text-align:justify">A financial asset is measured at amortized cost, using the effective interest method and net of any impairment loss, if it meets both of the following conditions and is not designated at fair value though profit or loss: </div> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is to hold assets to collect contractual cash flows;</div> </td> </tr> </table> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table> <div style="margin-top:10pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">The Company currently classifies its cash and trade and other receivables as financial assets measured at amortized cost. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">(ii) Financial assets, measured at fair value through other comprehensive income </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">A debt investment is measured at fair value through other comprehensive income if it meets both of the following conditions and is not designated at fair value through profit or loss: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) Financial assets, measured at fair value through other comprehensive income (continued) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in other comprehensive income (loss). When an investment is derecognized, gains or losses accumulated in other comprehensive income (loss) are reclassified to profit or loss. </div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment&#8217;s fair value in other comprehensive income (loss). </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">This election is made on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">investment-by-investment</div></div> basis. These assets are subsequently measured at fair value. Dividends are recognized in profit or loss, unless the dividend clearly represents a repayment of part of the cost of the investment, and other net gains and losses are recognized in other comprehensive income (loss) and are never reclassified in profit or loss. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently classifies its bonds as financial assets measured at FVOCI. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) Financial assets measured at fair value through profit or loss </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">All financial assets not classified as measured at amortized cost or FVOCI as described above are measured at FVPL. These assets are subsequently measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss. The Company currently classifies its money market funds and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hedge</div> derivative financial assets as financial assets measured at FVPL. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are&#160;transferred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) Financial liabilities </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities are classified into the following categories: </div></div><div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit or loss </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;">A financial liability is classified at fair value through profit or loss if it is classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading,</div></div> it is a derivative or it is designated as such on initial recognition. Financial liabilities at fair value are measured at fair value and net gains and losses, including interest expense, are recognized in profit or loss. </div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company issued the Marathon Warrants which are classified as financial liabilities through profit or loss because the exercise can be made on a cashless basis. All transaction costs related to financial instruments designated at fair value through profit or loss are expensed as incurred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently has no other financial liabilities measured at FVPL. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities measured at amortized cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">This category includes all financial liabilities, other than those measured at FVPL. A financial liability is subsequently measured at amortized cost using the effective interest method. The Company currently classifies accounts payable and accrued liabilities, convertible unsecured senior notes and Loan Facility as financial liabilities measured at amortized cost. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) Compound financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments are instruments that contain both a liability component and an equity component, and the liability component can be converted into share capital at the option of the holder and the number of shares to be issued does not vary with changes in their fair value. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversation option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Upon repurchase, the proceeds are allocated based on the same basis that was used for the initial recognition. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) Derivative financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative financial instruments are recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. The changes in the fair value of derivatives are recognized through profit or loss in the year in which they occur.</div> </div><br/> <div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vii) Offsetting of financial instruments </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position when, and only when, the Company has a legal right to set off the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At each reporting date, the Company recognizes loss allowances for expected credit losses (&#8220;ECLs&#8221;) on financial assets carried at amortized cost and debt securities at FVOCI. The Company&#8217;s trade and other receivables are accounts receivable with no financing component and which have maturities of less than 12 months and, as such, the Company has chosen to apply the simplified approach for ECL. As a result, the Company does not track changes in credit risk related to its trade and other receivables, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(viii) Impairment of financial assets </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For other financial assets subject to impairment, the Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECLs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">debt securities that are determined to have low credit risk at the reporting date; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers a debt security to have a low credit risk when its credit risk rating is equivalent or above investment grade credit rating, such as its bonds classified at FVOCI. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s approach to ECLs reflects a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">probability-weighted</div> outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future <div style="letter-spacing: 0px; top: 0px;;display:inline;">economic </div>conditions. </div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>  <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At inception, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability at the commencement date of the lease, i.e. the date the underlying asset is available for use. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost, less any accumulated amortization and accumulated impairment losses, and adjusted for remeasurement of lease liabilities. Cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets comprises: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">the initial measurement amount of the lease liabilities recognized; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any lease payments made at or before the commencement date, less any lease incentives received; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any initial direct costs incurred; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">an estimate of costs to dismantle and remove the underlying asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease contract. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis over the lesser of (i)&#160;the estimated useful life of the underlying assets; and (ii)&#160;the lease term. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are assessed for impairment whenever there is an indication that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets may be impaired. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date over the lease term. The present value of the lease payments is determined using the lessee&#8217;s incremental borrowing rate at the commencement date if the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is a function of the lessee&#8217;s incremental borrowing rate, the nature of the underlying asset, the location of the asset, the length of the lease and the currency of the lease contract. Generally, the Company uses the lessee&#8217;s incremental borrowing rate for the present value. At the commencement date, lease payments generally include fixed payments, less any lease incentives</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">receivable, variable lease payments that depend on an index (e.g. based on inflation index) or a specified rate, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising the option to terminate the lease. Lease payments also include amounts expected to be paid under residual value guarantees and the exercise price of a purchase option if the Company is reasonably certain to exercise that option. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Variable lease payments that do not depend on an index or a specified rate are not included in the measurement of lease liabilities but instead are recognized as expenses in the period in which the event or condition that triggers the payment occurs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">After the commencement date, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced to reflect lease payments made. In addition, the carrying amount of lease liabilities is remeasured when there is a change in future lease payments arising from a change in an index or specified rate, if there is a modification to the lease terms and conditions, a change in the estimate of the amount expected to be payable under residual value guarantee, or if the Company changes its assessment of whether it will exercise a termination, extension or purchase option. The remeasurement amount of the lease liabilities is recognized as an adjustment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, or in the consolidated statement of comprehensive loss when the carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is reduced to zero. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification and presentation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lease-related</div> expenses </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Amortization charge for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, expenses related to variable lease payments not included in the measurement of lease liabilities and loss (gain) related to lease modifications are allocated in the Company&#8217;s consolidated statement of comprehensive loss based on their function within the Company, while interest expense on lease liabilities is presented within finance costs. </div>  <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Deferred Financing Costs </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares or debt securities. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity or debt issuance on a proportionate basis when it occurs. If at such time the Company deems that these costs are no longer recoverable, they will be expensed as a component of finance expenses. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Provisions </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates are estimated based on historical experience, relevant statutes with respect to governmental pricing programs, and contractual sales terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Returns </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for returns are estimated based on historical return levels, taking into account additional available information on contract changes. The Company reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical results and business practices, as necessary. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Contingent liability </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-occurrence</div> of one or more uncertain future events not wholly within the control of the Company, or a present obligation that arises from past events (and therefore exists) but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or because the amount of the obligation cannot be estimated reliably. </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Income taxes </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in net loss except to the extent that they relate to items recognized directly in other comprehensive income (loss) or in&#160;equity. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Current tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Current tax is the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable in respect of previous years. The Company establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Deferred tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes and deferred tax losses that can be used against taxable profit in future years. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse and to fiscal losses when they will be used, based on the laws that have been enacted or substantively enacted by the reporting date. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A deferred tax liability is generally recognized for all taxable temporary differences. A deferred tax asset is recognized for unused tax losses and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred income tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting or taxable profit or loss at the time of the transaction, and, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising from the initial recognition of goodwill. </div> <div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Share option plan </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records share-based compensation related to Options granted using the fair-value-based method estimated using the Black-Scholes model. Under this method, compensation cost is measured at fair value at the date of grant and expensed over the period in which optionees unconditionally become entitled to the Options. The amount recognized as an expense is adjusted to reflect the number of Options for which the related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of Options that do meet the related service conditions at the vesting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> payment arrangements in which the Company receives services as consideration for its own equity instruments are accounted for as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-settled</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment transactions, regardless of how the equity instruments are obtained by the Company. </div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred stock unit plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred stock units (&#8220;DSUs&#8221;) are totally vested on the date of grant and are settled in cash. When DSUs are granted to officers as part of their annual bonuses, a DSU liability is recorded on the date of grant at the market value of the common shares in place of the liability for the bonus payments. When DSUs are granted to directors as part of their annual compensation in lieu of cash, the expense related to DSUs and their liabilities are recognized on the date of grant. The liability is adjusted to reflect any change in the market value of common shares, and such change is recorded in finance costs. </div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights (&#8220;SARs&#8221;) entitle the grantee to a cash payment based on the increase in the share price of the Company&#8217;s common shares from the grant date to the settlement date. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A liability is recognized for the services acquired and is recorded at the fair value of the SARs in other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities, with a corresponding expense recognized in selling expenses over the period that the grantees become unconditionally entitled to the payment. The fair value of the employee benefits expense of the SARs is measured using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">Estimating fair value requires determining the most ap</div>propri<div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">ate inputs to the valuation model including the expected life of the SARs, volatility, </div><div style="letter-spacing: 0px; font-size: 11pt; white-space: nowrap; top: 0px;;display:inline;">risk-free</div><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"> interest rate and dividend yield and making assumptions about them. At the end of each reporting period until the liability is settled, the fair value of the liability is remeasured, with any changes in fair value recognized in the consolidated statement of net earnings (loss) and comprehensive earnings (loss) of the current year.</div></div><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Government assistance </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Government grants are recognized only when the Company has reasonable assurance that it meets the conditions and will receive the grants. Government grants related to assets are recognized in the consolidated statement of financial position as a deduction from the carrying amount of the related asset. They are then recognized in profit or loss over the estimated useful life of the amortization asset that the grants were used to acquire, as a deduction from the amortization expense. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other government grants are recognized in profit or loss as a deduction from the related expenses, such as salaries for the Canadian Emergency Wage Subsidy program. </div><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Research and development tax credits </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company elected to account for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> research and development tax credits under IAS&#160;20, <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Government Grants and Disclosure of Governmental Assistance</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> research and development tax credits are included in earnings against gross research and development expenses or deducted from the related assets, provided there is reasonable assurance that the Company has complied and will comply with the conditions related to the tax credits and that the credits will be received. </div></div><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Share capital </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, subscription receipts and Public Offering Warrants are classified as equity. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs directly attributable to the issue of common shares and equity classified warrants and subscription receipts are recognized in equity, net of any tax effects. </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Earnings per share </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for its common shares. Basic EPS is calculated by dividing the net profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders by taking the weighted average number of common shares outstanding and taking into consideration all dilutive potential common shares, which consist of the outstanding Options, warrants, subscription receipts and convertible unsecured senior notes. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Changes in accounting policies </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2022, the Company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities in the consolidated statement of cash flows. Previously, the Company elected to classify interest paid as cash flow from financing activities and interest received as cash flows from investing activities. This change was applied retrospectively. </div></div></div><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">New standard adopted </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Onerous contracts &#8211; Cost of Fulfilling a Contract (Amendments to IAS 37) </div> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#8217;s annual reporting periods beginning on December&#160;1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Standards issued but not yet effective </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">A number of new standards are effective for annual periods beginning after December&#160;1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing these Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> (Amendments to IAS 1)</div> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">For the purposes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> Covenants with which a company must comply after the reporting date do not affect a liability&#8217;s classification at that date. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#8217;s own equity instruments to the counterparty; and when classifying liabilities as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> a company can ignore only those conversion options that are recognized as equity. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments will be effective for the Company&#8217;s annual reporting period beginning on December&#160;1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173600016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">United States </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2014, the Company entered into a master services agreement with RxC Acquisition Company (&#8220;RxCrossroads&#8221;), along with two statements of work (&#8220;RxCrossroads Agreements&#8221;). Under the terms of the RxCrossroads Agreements, RxCrossroads acts as the Company&#8217;s exclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party</div> logistics service provider for all of the Company&#8217;s products in the United States and, as such, provides warehousing and logistical support services to the Company, including inventory control, account management, customer support, product return management and fulfillment of orders. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">Under the RxCrossroads Agreements, RxCrossroads also acts as the Company&#8217;s exclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party</div> distributor of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in the United States. In such a role, RxCrossroads purchases </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> from the Company and takes title thereto when the goods arrive in their warehouse. RxCrossroads&#8217; purchases of </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> are triggered by its expectations of market demand over a certain period of time. With respect to </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div>, RxCrossroads fulfills orders received from authorized wholesalers and delivers </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> directly to that authorized wholesaler&#8217;s client, namely, a specialty pharmacy forming part of the Company&#8217;s network of specialty pharmacies. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;1, 2017, the Company entered into amended and restated RxCrossroads Agreements to add Trogarzo<div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div> as a new product sold in the United States. These amended and restated RxCrossroads Agreements replaced the RxCrossroads Agreements entered into in May&#160;2014. On November&#160;1, 2019, the RxCrossroads Agreements were amended anew to include <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;SV</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">as an additional product distributed by RxCrossroads in the United States<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Canada </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company commercialized <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>directly in Canada using a distributor until September 2022, after which time the Company withdrew the product from the market in Canada. </div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Europe </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;9, 2020, the Company entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-wholesaling</div> services agreement with Loxxess Pharma GmbH or&#160;(&#8220;Loxxess&#8221;) pursuant to which Loxxess agreed to act as our third-party service logistics provider (the &#8220;Loxxess Agreement&#8221;) in certain key European countries, including Germany, France, Italy, Austria, The Netherlands, Portugal, Switzerland, United Kingdom, Norway, Sweden, Finland and Denmark. Loxxess is also capable of serving other European countries, including Israel and Turkey. Pursuant to the Loxxess Agreement, Loxxess received customers&#8217; ordered, stored, packaged and shipped Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to European hospitals and pharmacies. Loxxess was also responsible, on our behalf, to collect payments of the goods sold to those hospitals and pharmacies. The hospitals and pharmacies dispensed Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to patients. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On April&#160;27, 2022, the Company announced that it would focus its commercial operations on the North American territory only and, as a result, would cease commercial sales of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe. At that time, the Company sent a notice of termination to TaiMed Biologics Inc. (&#8220;TaiMed&#8221;), as per the contractual terms indicating it was returning the European commercialization rights to Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> to TaiMed within the next 180 days. The discontinuation became effective in December 2022. Refer to Note 13.</div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by product <div style="display:inline;">were</div> as follows:<br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 61%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 1%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;SV</div></div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trogarzo<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,059</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">29,603</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">26,814</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;81,764</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;80,057</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;69,823</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by geography were as follows: </div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 90%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 5%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Canada</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">United States</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;78,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;68,099</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Europe</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">286</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,261</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,455</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">81,764</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">80,057</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">69,823</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168715536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Personnel expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel expenses</div></div></div></div> </td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 55%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Salaries and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>employee benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24,934</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">22,049</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,480</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,833</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,346</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">644</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>compensation</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20(f),(h)</td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,109</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,604</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,651</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination benefits</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,006</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">566</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160;30,882</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;27,565</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160; 13,984</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="clear:both;max-height:0pt;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2023, $1,963 was recorded in termination benefits for severance and other expenses. Refer to note 16(a). </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal</div></div><div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">&#160;2022, $</div>457<div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"> was </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">recorded in termination benefits for severance and other expenses associated with the return to TaiMed of the commercial rights to Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> </div></div></div> <div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849167008032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance income and finance costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Finance income and finance costs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Finance income and finance costs </div></div> </td> </tr> </table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on repurchase of convertible unsecured senior notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160; &#160; &#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net gain on financial instruments carried at fair <br/>value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on lease termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense and amortization of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,&#160;18,&#160;19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,098)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,140)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,358)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest on convertible unsecured senior&#160;notes and on long-term loan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,263)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,357)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160;(3,306)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bank charges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net foreign currency loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(159)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;&#160; (1,027</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(926)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Loss on Loan Facility modifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(c)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,540)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Write off of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(d)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(954)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(15,056)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,559)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,621)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net finance cost recognized in net&#160;profit&#160;or&#160;loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(12,909)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,886)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,426)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; text-indent: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849167008032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bonds and money market funds<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract', window );"><strong>Schedule Of Detailed Information About Bonds And Money Market Funds [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Bonds and money market funds</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Bonds and money market <div style="display:inline;">funds</div> </div></div></td></tr></table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;6,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;8,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Guaranteed investment certificates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;6,290</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;9,214</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As at November&#160;30, 2023, bonds were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interest-bearing</div> financial assets with stated interest rates ranging from 0.85% to 3.75% (2022&#160;&#8211; 0.65% to 3.90%) and had an average maturity of 1.40&#160;years (2022&#160;&#8211; 1.78&#160;years). </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174210464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade And Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TradeAndOtherReceivablesExplanatoryAbstract', window );"><strong>Trade And Other Receivables Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and other receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Trade and other receivables </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;12,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;10,659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Sales taxes receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:3.75pt">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;13,023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;12,045</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TradeAndOtherReceivablesExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other receivables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TradeAndOtherReceivablesExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172838352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax credits and grants receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract', window );"><strong>Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfTaxCreditsReceivableExplanatory', window );">Tax credits and grants receivable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Tax credits and grants receivable </div></div></td></tr></table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(442)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(16)</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax Credit and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">524</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Tax credits receivable comprise grants receivable, and research and development investment tax credits receivable which relate to eligible research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded. There are no unfulfilled conditions or contingencies associated with the government assistance received. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company has unused and unrecorded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> federal tax credits which may be used to reduce future federal income tax payable and expire as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2030</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2031</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2032</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2033</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2039</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2040</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2041</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2042</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2043</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfTaxCreditsReceivableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of tax credits receivable explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfTaxCreditsReceivableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173804464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventories </div></div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;2,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;2,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,708</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,815</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,096</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11,290</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,066</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">19,688</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In fiscal 2023, inventories of $18,540 (2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>$19,587) were recognized as an expense and included in cost of goods sold. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2023, inventories for an amount of $3,295 was returned to TaiMed. and accounts payable was reduced by a total amount of <div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>3,179 ($3,399). </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2023, an inventory provision of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>220<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; </div>nil<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was recognized pending marketing approval of the F8 formulation of tesamorelin and recorded in cost of sales. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;">Inventories were written down to net realizable value by an amount of $2,137 in 2022, which was recorded in cost of sales. Included in the 2022 write-down is a provision of $1,477 on the F8 formulation and $339 on material for the pen in development to be used in conjunction with the F8 formulation, and $252 on expired raw material. The 2022 write-down also includes a provision of $69 on excess stock of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> as a result of the Company&#8217;s decision to withdraw the product from the market in Canada. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172588320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAbstract', window );"><strong>Current prepayments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits', window );">Prepaid expenses and deposits</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Prepaid expenses and deposits </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 71%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Deposits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">467</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,345</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160; 3,154</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160;7,665</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Details Of Current Prepaid Expenses And Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173116656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-weight:bold;display:inline;"> </div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 53%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Office</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">furniture&#160;and</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">improvements</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;&#160;373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;1,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;2,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"><br/></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46) </td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;251</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,196</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;359</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;650</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;2,456</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated depreciation</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;227</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;74</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;816</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;132</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;184</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,206</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;167</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 905</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;137</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;285</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,494</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172576896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract', window );"><strong>Disclosure of quantitative information about right-of-use assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; line-height: 10pt;"><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:3%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:75%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(429)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(87)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(352)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(a)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(799)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(<div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">770</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172980560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 41%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">North&#160;American</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">European&#160;Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rights&#160;&#8211;&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA&#160;SV<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">&#174;</div></div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Oncology</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">platform</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;11,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;37,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,832</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,832</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,804</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;39,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,804</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;32,333</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 3,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;&#160;999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;11,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;15,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">1,087</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">6,613</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">1,511</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">9,211</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 4,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;12,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;24,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 1,442</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 1,071</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 2,513</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 5,796</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;19,837</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 9,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;12,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;10,450</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 1,071</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;15,009</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amortization expense of $</div>2,513<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022&#160;&#8211; $ </div>9,211<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">; 2021 &#8211; $ </div>3,180<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) is included in selling expenses.</div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">On March&#160;18, 2016, the Company entered into a distribution and marketing agreement with TaiMed granting the Company the exclusive right to market Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in Canada and in the United&#160;States. On March&#160;6, 2017, the Company entered into an amended and restated distribution and marketing agreement with TaiMed (&#8220;TaiMed Agreement&#8221;) granting the Company the exclusive right to market and distribute Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in Canada and in the United States (collectively, the &#8220;North&#160;American Territory&#8221;) as well as in European Union countries and other countries such as Israel, Norway, Russia and Switzerland (collectively, the &#8220;European Territory&#8221;). The TaiMed Agreement has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> term that will expire on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis calculated from the date of approval of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in each of the countries covered under the TaiMed Agreement. TaiMed is responsible for the manufacture and supply of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> under the TaiMed Agreement. </div> <div></div><div>  </div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the North American Territory </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Under the terms of the TaiMed Agreement, TaiMed was responsible for developing Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> and for seeking its approval from the US Food and Drug Administration (&#8220;FDA&#8221;). The Company is responsible, but has no obligation, to seek the approval of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> from Health Canada and must use its commercially reasonable efforts to commercialize Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>in the United States. The purchase price of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> payable to TaiMed has been determined at 52% of its net selling price. </div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Initial payments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Under the TaiMed Agreement, the Company agreed to make an initial payment of US$5,000 and will make several further milestone payments in exchange for the right to commercialize Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> and the right to use TaiMed&#8217;s trademark in the North American Territory. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The initial payment of $5,000 was made in accordance with the following: </div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">$1,000 was paid in cash at the signature of the TaiMed Agreement entered into in March 2016;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> </div> </td> </tr> </table> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">$4,000 through the issuance of the Company&#8217;s common shares, payable after the first commercial sale of Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the United States. The $4,000 payment was made on May&#160;15, 2018 and resulted in the issuance of 1,463,505 common shares to TaiMed. </div> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2016, the Company recorded as additions to intangible assets an amount </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div>5,207<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">related to the TaiMed Agreement, which comprised the cash payment of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> $</div>1,000<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at the signature of the TaiMed Agreement, the <div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment of</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>4,000<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">,</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>207<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">in</div> acquisition costs.</div></div> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Further development milestone payments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Under the terms of the TaiMed Agreement, a further milestone of $7,000 was payable in two annual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;equal</div> installments of $3,500 after achieving aggregate net sales of $20,000 over four consecutive quarters of the Company&#8217;s financial year. The first payment of $3,500 was made in July 2019, and the second payment was made in June 2020. The Company determined this milestone to be substantially a development milestone and recorded such amount as additions to intangible assets during 2019. The Company also paid TaiMed further development milestones for Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#160;</div>in 2022. A $3,000 milestone (payable in two annual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;equal</div> installments of $1,500) became due upon the date of the first commercial sale of a once every two weeks <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">intravenous (IV) push</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;injection formulation. An amount of $</div>2,832<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> has been capitalized as an intangible asset in fiscal 2022 related to these milestone payments (refer to Note 15).</div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the TaiMed Agreement, TaiMed may also launch a larger Phase III trial using Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>with a once every four weeks intramuscular, subcutaneous or intravenous-push (either fast or slow) injection formulation to address a much broader patient population. If launched, this development milestone will consist of an upfront milestone payment of up </div></div>to $50,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">depending on the size of the newly targeted population, payable quarterly, based on the percentage of net sales generated </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">by Trogarzo</div><div style="font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;">&#174;</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Further commercial milestone payments </div></div>  <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As further consideration under the TaiMed Agreement, the Company shall make the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payments upon the first occurrence of the following commercial events: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 96%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 21%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial milestone</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial&#160;milestone&#160;payment&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(i) Upon first achieving annual net sales of $200,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(ii) Upon first achieving annual net sales of $500,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 4pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(iii) Upon first achieving annual net sales of $1,000,000</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">$100,000</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> </div> <div style="margin-top:36pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> European Territory </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;17, 2022, the Company announced that it would focus its commercial operations on the North American Territory only and, as a result, would cease the commercial sale of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in Europe. Refer to Note 3. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Consequently, during the second quarter of 2022, the remaining balance of the intangible asset amounting</div></div>&#160;to $6,356 was recognized as part of <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>selling <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses to accelerate and fully amortize &#8211; Commercialization rights Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> &#8211; European Territory.</div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Oncology platform </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">On February&#160;25, 2019, the Company acquired Katana Biopharma Inc. (&#8220;Katana&#8221;) through the purchase of all of its issued and outstanding shares. On May&#160;21, 2019, Katana was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wound-up</div> into the Company and then dissolved. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Katana (now the Company) is the worldwide exclusive licensee of a technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to Sortilin receptors, which are overexpressed on cancer cells. The licence was entered into on February&#160;25, 2019 with Transfert Plus, L.P. (&#8220;Transfert Plus&#8221;), an affiliate of Aligo Innovation, a university research company that commercializes the research results of universities and other institutional partners from various areas of innovation, including life sciences (the &#8220;Licence Agreement&#8221;). </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the acquisition agreement, part of the purchase price was to be settled through the issuance of common shares upon achieving two milestones. The first milestone consisted in initiating a Phase 1 clinical trial evaluating Sudocetaxel zendusortide for the treatment of Sortilin positive solid tumors. This milestone was achieved in March 2021 and was satisfied through the issuance </div></div>of 120,482 common shares (Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div>(b)). </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The second milestone payment of CA$2.3&#160;million will occur when the proof of concept will have been demonstrated in human subjects and will be satisfied through the issuance of common shares of the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">This acquisition was accounted for as an asset acquisition. During 2019, the Company recorded additions to intangible assets of $3,073, which comprised the payment at closing of $1,965 in cash, $5 through the issuance of 900 common shares of the Company, the estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> contingent consideration of $1,028, and $75 <div style="letter-spacing: 0px; top: 0px;;display:inline;">in acquisition costs. As the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payments are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-settled,</div> the Company recognized a corresponding increase in equity, and no remeasurement of the fair value will occur regardless of the achievement of the milestones. Since the common shares for the second milestone payment have not been issued yet, the increase in equity is recorded in contributed surplus. Upon the issuance of the common shares, this amount will be reclassified to share capital. The intangible asset is currently not being amortized. Amortization will begin when the asset is available for use</div>. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">In August 2019, the acquisition agreement was amended to provide for an adjustment to the purchase price of CA$1.08&#160;million in the event the Company could indirectly benefit from a CA$1.2&#160;million subsidy in connection with its research and development activities. The subsidy was granted in October 2019. The adjustment will be payable in two installments. The first installment of CA$500&#160;thousand was paid in cash in October 2019, whereas the second installment of CA$580&#160;thousand will be paid&#160;through the issuance of common shares of the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at the same time as the second milestone payment of CA$2.3&#160;million. The cash<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>payment of $376 (CA$500) thousand was recognized as an addition to intangible assets during&#160;2019. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The annual maintenance fees, under the Licence Agreement amount </div></div> to CA$25&#160;thousand for the first five years and CA$100&#160;thousand thereafter, until royalties become payable beginning with the first commercial sale of a product developed using the licensed technology. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The royalties payable under the Licence Agreement vary between 1.0% and 2.5% on net sales of a product based on the licensed technology. If the Company enters into a sublicence agreement, it must then pay amounts varying between 5% and 15% of revenues received fr<div style="letter-spacing: 0px; top: 0px;;display:inline;">om</div> such sublicence agreement. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company must pay Transfert Plus the following milestone payments upon the occurrence of the following development milestones for the first product developed in the field of oncology: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">First milestone payment: $39 (CA$50) thousand<div style="letter-spacing: 0px; top: 0px;;display:inline;">, which was paid in May 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div></div> upon the successful enrollment of the first patient in the first Phase 1 clinical trial; </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Second milestone payment: CA$100&#160;thousand upon <div style="letter-spacing: 0px; top: 0px;;display:inline;">th</div>e successful enrollment of the first patient in the first Phase 2 clinical trial; </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:6%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">Third milestone payment: CA$200&#160;thousand upon the successful enrollment of the first patient in the first Phase 3 clinical trial. </div> </td> </tr> </table> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition,</div></div>&#160;the Company must pay CA$200&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">thousand per product upon receiving the first approval for such product by a regulatory authority. The approval shall entitle the sponsor to commercialize the product in the territory in which the approval was obtained</div></div>. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172620512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other asset</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td colspan="4" style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021, 2022 and 2023</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">19,530</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;17,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,441</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);;text-align:right;">19,530</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;November&#160;30, 2023 and November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">-</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> May&#160;29, 2018, the Company entered into an agreement with EMD Serono, Inc. (the &#8220;Renegotiated Agreement&#8221;) to settle all outstanding cash payment obligations stemming from a termination and transfer agreement dated December&#160;13, 2013, as amended (the &#8220;2013&#160;Termination Agreement&#8221;). The remaining contractual obligations under the 2013 Termination Agreement totalled approxima</div></div>tely $28,200, which was comprised of a $4,000 payment due in May 2019 and $24,200 in estimated royalties on future sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> payable over the subsequent four to five years. The Renegotiated Agreement allowed the Company to make one lump sum payment of $23,850 in settlement of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> obligation of $4,000 and to eliminate all of the royalty payments due on sales of </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> in the United States. The payment made in connection with the settlement of the future royalty obligation has been accounted for as &#8220;Other asset&#8221; on the consolidated statement of financial position and was amortized through &#8220;Cost of sales&#8221; on the consolidated statement of net loss. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168705968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accured liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TradeAndAccruedPayablesAbstract', window );"><strong>Trade and Accrued Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock', window );">Accounts payable and accured liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts payable and accrued liabilities</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto;">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div>&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Trade payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Accrued liabilities and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Salaries and benefits due to key management personnel</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Employee salaries and benefits payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Liability related to deferred stock unit plan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20(e)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align: top;"> <div style="text-indent: -2em; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.2em; line-height: normal;">Accrued interest payable on convertible unsecured senior notes and Loan Facility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17&#160;and&#160;18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">TaiMed milestone (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,846</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,471</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">41,065</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;">On October&#160;3, 2022, the Company announced that the United States Food and Drug Administration approved Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> (ibalizumab-uiyk) for administration by intravenous (IV)&#160;push, a method by which the undiluted medication is &#8220;pushed&#8221; by syringe for faster administration into the body&#8217;s circulation. Under the TaiMed <div style="letter-spacing: 0px; top: 0px;;display:inline;">A</div>greement, the Company ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#160;additional contingent cash-based milestones based on the attainment of the above milestones. Accordingly<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> a $3,000 cash payment, payable in two annual <div style="letter-spacing: 0px; top: 0px;;display:inline;">equal </div>installments of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">1,500</div> has been accrued. The second payment has been discounted to reflect the effective interest rate of the liability due in year<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">two</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>. The first installment of $ 1,500 was paid in 2023 and the second will be paid in 2024. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and accrued payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TradeAndAccruedPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and accrued payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TradeAndAccruedPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173038544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsAbstract', window );"><strong>Disclosure of other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provisions</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 88%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and&#160;rebates</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restructuring</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">(a)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,358)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,287)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(233)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(233)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;6,032</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;1,485</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160; 7,517</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,506)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(309)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,721)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,536)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">168</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7,101</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,262</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">240</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">9,603</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:justify">In July 2023, the Company initiated a reorganization mainly focused on its R&amp;D activities. On October&#160;24, 2023, the Company announced changes to its operations that saw a tapering of its research and development activities. As such, for the year ended November&#160;30, 2023, $1,963 was recorded in charges related to severance and other expenses, of which an amount of $1,384 was recorded in research and development expenses, $220 in selling expenses and $359 in general and administrative expenses. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173713808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Loan Facility</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loan Facility</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;20, 2022, the Company entered into a credit agreement with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, &#8220;Marathon&#8221;) providing for up to $</div></div>100,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(the &#8220;Loan Facility&#8221; or &#8220;Marathon Credit Agreement&#8221;) in loan. The disbursement of the loan was to be made available to the Company over time in four various tranches with each bearing specific conditions to be met by the Company. </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 27, 2022, a principal amount of $40,000 (&#8220;Tranche 1 Loan&#8221;) was funded while on June 21, 2023, a second $20,000 (&#8216;Tranche 2 Loan&#8221;) was funded as a result of the lender removing during the first quarter of 2023 the condition related to the submission to the FDA of the results from the human factor study the Company was then conducting. Refer to Note 20(c) for a discussion on the cost of the amendment. The Company does not meet the conditions precedents to draw down the additional tranches of capital of $15,000 and $25,000, respectively. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt and in making available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements. On July&#160;10, 2023, the Company and the lender amended the terms of the Marathon Credit Agreement to reduce the minimum liquidity covenant for the period of July&#160;10 to July&#160;28, 2023 as follows: </div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">From $20,000 to $14,000 between July&#160;10, 2023 up to and including July&#160;21, 2023; and </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;">From $14,000 to $16,000 between July&#160;22, 2023 up to and including July&#160;28, 2023. </div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On July 28, 2023, the Company and the lender entered into an additional amendment to the terms of the Marathon Credit Agreement to provide, amongst other things, for the minimum liquidity covenant to be</div> $</div></div>15,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">from July 29, 2023, up to and including October 31, 2023. After such date, the minimum liquidity covenant was set at</div> $</div></div>20,000<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">; <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">provided, however, that if the F8 formulation of tesamorelin was not approved by the United States Food and Drug Administration by March 31, 2024, the minimum liquidity covenant was set at</div> $</div></div>30,000<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. <div style="letter-spacing: 0px; top: 0px;;display:inline;">On September 21, 2023, the Company obtained a waiver from the lender relating to the Liquidity Breach for the period between July 3, 2023 up to end and including July 9, 2023. On October 13, 2023, the Company and the lender entered into an additional amendment to the Marathon Credit Agreement (the &#8220;Fifth Amendment&#8221;) providing for, amongst other things, the following amendments:&#160;</div></div></div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">revising the minimum liquidity requirements for all times following October 31, 2023 to be between $15,000 and $20,000, based on thresholds for Marathon Adjusted EBITDA over the most recently ended four fiscal quarters; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">revising the minimum revenue requirements to be based on Marathon Adjusted EBITDA-based targets instead of quarterly revenue-based targets, beginning with the quarter ending November 30, 2023; </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies to the Company&#8217;s annual report. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the Fifth Amendment, the Company agreed to (i) pay an amount equal to</div> $540 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">amortized value ($600), or</div> 100 </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">($60,000),<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;</div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">which amount was added to the outstanding principal amount of the funded debt as payment in kind; and (ii) reset the exercise price of the Marathon Warrants, which are now exercisable into <div style="letter-spacing: 0px; top: 0px;;display:inline;">1,250,000</div> common shares at $<div style="letter-spacing: 0px; top: 0px;;display:inline;">2.30</div> per common share, down from the previous $<div style="letter-spacing: 0px; top: 0px;;display:inline;">5.80</div> per common share. </div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The salient conditions of the amounts drawn under the Loan Facility are as follows: </div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Loan Facility has an initial term of five years, provides for an interest-only period of 24 months, and bears interest at the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) plus 9.5%. The Tranche 1 Loan and Tranche 2 Loan are repayable in equal monthly installments on an amortization schedule of 36 months starting in July 2024. The Company is entitled to prepay the outstanding Loan Facility at any time subject to certain prepayment premium amount: for Tranche 1 Loan until July 27, 2024, an amount equal to the make whole amount, and after this date, a maximum amount of 3% of the principal amount being prepaid. For Tranche 2 Loan, until June 21, 2025, an amount equal to the make whole amount, and after this date, a maximum amount of 3% of the principal amount being prepaid; </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Loan Facility provides Marathon Adjusted EBITDA-based targets and minimum liquidity requirements (both as defined in the Marathon Credit Agreement) for all times to be between</div>&#160;$</div>15,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">and&#160;</div>$20,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on thresholds for Marathon Adjusted EBITDA over the most recently ended four financial quarters;&#160;</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Loan Facility restricts the ability to incur additional debt and to make acquisitions, dispositions, in-licensing and out-licensing of products or assets, except in very limited circumstances. A breach of the terms and conditions of the Marathon Credit Agreement will create an event of default resulting in an increase of</div> </div>300 basis points <div style="letter-spacing: 0px; top: 0px;;display:inline;">on the outstanding loan and provide the lender with the ability to demand immediate repayment of the debt;&#160;</div> </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The lender has a first ranking security interest on all of the Company&#8217;s assets, subject to certain credit card arrangements restrictions. </div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the Loan Facility is as follows: </div></div></div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 87%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:28.5pt">&#160;</td>
<td colspan="4" style="height:28.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Loan Facility on July&#160;27, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,285)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Tranche 2 Loan on June&#160;21, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Costs related to issuance of Tranche 2 Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Costs related to Marathon Warrants (note 20(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Consideration f<div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> the Fifth Amendment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">57,974</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7,286)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">50,688</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;">On June&#160;21, 2023, the Company drew down on the Tranche 2 Loan, for net proceeds of $19,300. An amount of $482 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was reclassed from deferred financing costs assets and applied against the loan balance.</div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Deferred financing costs in the amount of $347 <div style="letter-spacing: 0px; top: 0px;;display:inline;">were written off in the statement of net loss of November 30, 2023 in relation to the additional tranches of the Loan Facility.&#160;</div> </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173122528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible unsecured senior notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesAbstract', window );"><strong>Convertible Unsecured Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock', window );">Convertible unsecured senior notes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible unsecured senior notes</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the convertible unsecured senior notes is as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2021 </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54,227</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,546) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs incurred </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(73) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(357)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,644</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26,895</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(27,452)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">572</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2023, the Company reimbursed all of the issued and outstanding convertible unsecured senior notes for proceeds of $</div></div>27,452 and 253 shares were issued on conversion of $15 convertible unsecured senior notes. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleUnsecuredSeniorNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleUnsecuredSeniorNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of convertible senior notes explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173775584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases liabilities</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="vertical-align: top;;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 86%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">Carrying</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">value</div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;2,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(605)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(148)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30,&#160;2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(452)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(920)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease (b)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;">Balance as at November 30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(421)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">573</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;;text-indent: 0px;">On February&#160;17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The gain is presented in finance income (Note 5).&#160;</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability of $326. </div></div> </td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173000240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share capital warrants and subscription receipts</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share capital, warrants and subscription receipts</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Authorized in unlimited number and without par value </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Common shares; </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Preferred shares, issuable in one or more series. </div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">All issued shares were fully paid on November&#160;30, 2023 and 2022. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shareholders are entitled to receive dividends as declared by the Company at its discretion and are entitled to one vote per share at the Company&#8217;s annual meeting of shareholders. </div></div></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">No preferred shares are outstanding. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Public offering </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">On January&#160;19, 2021, the Company completed a public offering for the sale and issuance of units. Each unit was comprised of one common share of the Company and o<div style="letter-spacing: 0px; top: 0px;;display:inline;">ne half of one</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">common share purchase warrant of the Company (each whole warrant, a &#8220;Public Offering Warrant&#8221;) and is classified in Share Capital and Public Offering Warrants within equity. During the year ended November 30, 2023, no Public Offering Warrant were exercised (November 30, 2022 nil and November 30, 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> 233,400 Public Offering Warrants were exercised for proceeds of $742). At November 30, 2023, there were </div></div>8,130,550 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Public Offering Warrants outstanding. Four (4)&#160;Public Offering Warrants entitles the holder thereof to purchase one (1)&#160;common share at an exercise price of $</div></div>12.72 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time until January&#160;19, 2024<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The 8,130,550 Public Offering Warrants expired on January <div style="letter-spacing: 0px; top: 0px;;display:inline;">19, 2024</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;31, 2023, the Company completed a public offering for the sale and issuance of </div>12,500,000 common shares at a price of $1.00 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per common share for gross proceeds o</div></div>f $12,500. On November&#160;14, 2023, the Company issued 160,000 common shares at a price of $1.00 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per common share for gross proceeds of $</div>160 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">in relation to the partial exercise of the over-allotment option. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ompany has also completed a concurrent private placement (the &#8220;Concurrent Private Placement&#8221;) with Investissement Qu&#233;bec of</div></div>&#160;9,118,184 common shares and 3,381,816 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">fully-funded, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> subscription receipts, exchangeable at all times into common shares on a one-for-one basis in, in each case, at $</div>1.00 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for gross proceeds of $</div></div>12,500<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. The subscription receipts were issued to limit the share ownership of the investor to not more than 19.9% of the issued and outstanding common shares and the subscription receipts are exchangeable at any time, provided ownership limitations are respected. The Company has also entered into an investor rights agreement pursuant to which Investissement Qu&#233;bec will be entitled to nominate one director to the Company&#8217;s board of directors for as long as it holds 50% of the Common Shares purchased pursuant to the Concurrent Private Placement. The cost of the offering amounted to $</div></div>2,053<div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Milestone oncology </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">In March 2021, the Company issued 120,482 common shares under the terms of the acquisition agreement entered into with all of the shareholders of Katana for Katana&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> oncology platform. The purchase price for the oncology platform provided for share-based consideration to be issued upon attainment of two milestones. The first milestone was achieved in March 2021. The estimated fair value of the share-based consideration of $668 initially recorded in &#8220;Contributed surplus&#8221; on the date of the acquisition was reclassified to &#8220;Share capital&#8221; (Note 13). </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Marathon warrants </div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On February 27, 2023, the Company issued to Marathon an aggregate of</div></div></div> 5,000,000 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">common share purchase warrants (the &#8220;Marathon Warrants exercisable into 1,250,000 common shares, at an exercise price of</div></div></div> $5.80<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">, post Consolidation. The Marathon Warrants are exercisable for a period of</div> seven years. <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants are not traded on any stock exchange, are transferable only to affiliates of Marathon or to other potential lenders under the terms of the Loan Facility and their affiliates and may be exercised on a cashless basis. Accordingly, the Marathon Warrants are derivative financial liabilities measured at fair value through profit or loss.&#160;</div> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants were issued as consideration for various amendments made to the Marathon Credit Agreement, including: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">An amendment to remove a condition precedent to the disbursement of the Tranche 2 Loan requiring the Company to have filed with the FDA the results of a human factor study before June&#160;30, 2023; and </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#9679;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">An amendment to allow for the inclusion of a going concern explanatory paragraph in the annual report of the independent registered public accounting firm for the fiscal year ended November&#160;30, 2022. </div></div></div></td></tr></table><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the Fifth Amendment, the Company has agreed to reset the exercise price of the</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">5,000,000</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Marathon Warrants, which are now exercisable into<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">1,250,000<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">common shares at</div></div>&#160;</div><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">$</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2.30 </div><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">per common share. (Refer to Note 17) </div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The fair value of the Marathon Warrants was treated as a cash outflow in testing whether the debt modification was a substantial modification and it was concluded that the modification was not substantial. At the issuance</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, $</div>2,650<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">were recorded as loss on debt modification using the Black-Sholes model and the assumptions set forth in the table below. An amount </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div>350 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">was recorded reflecting the increase of fair value of Marathon Warrants for the repricing upon entering into the Fifth Amendment. The derivative financial liability relating to the Marathon Warrants is recorded as a liability on the consolidated statement of financial position and resulted in a gain on fair value remeasurement o</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">f $</div>1,525<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> for the year ended November&#160;</div>30<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div> <div> <div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 94%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">measurement</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.326%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88.568%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61.985%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;6.25&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Share price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em;">Exercise price </div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5.80</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate is based on the implied yield on a Canadian government zero-coupon issue, with a remaining term equal to the term of the Marathon warrant life. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of the Marathon warrant is based upon the contractual term. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">With the issuance of the Marathon Warrants, the Company incurred transaction costs totalling $</div>196<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which $</div>78<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> was allocated to the Loan Facility and $</div>118<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">was recorded as deferred financing costs relating to the available tranches under the Loan Facility<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> Deferred financing costs were written off on November 30, 2023 (Note 17).</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">ATM program </div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of a sales agreement dated July&#160;23, 2021, the Company was able to issue and sell from time to time its common shares, having an aggregate offering price of up </div></div>to $50,000, <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">through or to the Agent, as agent or principal, in the United States for a period ending in December 2023. Sales of the common shares were to be made in transactions that were deemed to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market</div></div> distributions&#8220; (&#8220;ATM&#8220;). In the fourth quarter of 202</div>2, 400,000 common shares (2021 &#8211; no common shares) were sold for proceed<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> of $2,960 under the ATM program. Commission, legal and other costs related to this equity <div style="letter-spacing: 0px; top: 0px;;display:inline;">offering</div> were charged directly to equity in the amount of $126 (2021 - nil). The <div style="letter-spacing: 0px; top: 0px;;display:inline;">common </div>shares were sold at the prevailing market prices, which resulted in a price of $1.85 per share. Deferred financing costs in the amount of $607 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">were written off in the statement of net loss of November&#160;30, 2023, in relation to the end of the program in December of 2023 without additional usage.</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(e)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">DSU plan </div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;10, 2010, the Board of Directors adopted the DSU Plan for the benefit of its directors and officers (the &#8220;Beneficiaries&#8221;). The goal of the DSU Plan is to increase the Company&#8217;s ability to attract and retain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">high-quality</div> individuals to act as directors or officers and to better align their interests with those of the shareholders of the Company in the creation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> value. Under the terms of the DSU Plan, Beneficiaries who are directors are entitled to elect to receive all or part of their annual retainer to act as directors in DSUs. Beneficiaries who act as officers are entitled to elect to receive all or part of their annual bonus, if any, in DSUs. The value of a DSU is used to determine the number of DSUs a Beneficiary may be granted or the value to be paid to a Beneficiary upon redemption. This value is equal to the average closing price of the common shares on the Toronto Stock Exchange on the date on which the Company is entitled to grant DSUs, or on the date on which a Beneficiary redeems them, and during the four previous trading days. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">DSUs may only be redeemed when a Beneficiary ceases to act as a director or an officer of the Company. Upon redemption, the Company must provide a Beneficiary with an amount in cash equal to the DSU value on the redemption date. Beneficiaries may not sell, transfer or otherwise assign their DSUs or any rights associated therewith other than by will or in accordance with legislation regarding the vesting and partition of successions. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">DSUs are totally vested on the grant date. When DSUs are granted to officers as part of their annual bonus, a DSU liability is recorded on the grant date in lieu of a liability for a cash bonus payment. In the case of directors, the expenses related to DSUs and their liabilities are recognized on the grant date. During the year ended </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">November&#160;30, 2023, nil (2022 -<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>126<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">; 2021&#160;&#8211;</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>78<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was recorded as an expense and is included in general and administrative expenses. The liability related to DSUs is adjusted periodically to reflect any change in the market value of the common shares. As at November&#160;30, 2023, a gain of</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>224<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(2022 - $221; 2021&#160;&#8211; loss of</div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>209)<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> was recognized within finance costs (Note </div>5)<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">. As at November&#160;</div>30<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had a total </div>24,878<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;DSUs outstanding </div>(202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211;<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>67,536<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> DSUs) and a liability related to the DSUs of $</div>39<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>(202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211;<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> liability of $</div>589<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">).</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Cash-settled</div> forward stock contracts</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">To protect against fluctuations in the value of DSUs, the Company entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts. They were not designated as hedging instruments for accounting purposes. As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts outstanding correspond to a total of 67,535 (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> &#8211; 67,535) common shares at a price of $19.47 per share (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $19.68 per share) expiring on December&#160;1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; December&#160;1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>). As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled</div> forward stock contracts was $110 (202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $603) and is recorded in derivative financial assets. During the year ended November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, a loss of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">$492 (2022 -</div></div>$217<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">;2021&#160;&#8211;</div></div> gain of $212) related to the change in fair value of derivative financial assets was recognized within finance costs. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(f)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">S<div style="letter-spacing: 0px; top: 0px;;display:inline;">tock</div>&#160;Appreciation Rights&#160;</div> </td> </tr> </table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;4, 2018, the Board of Directors approved a stock appreciation rights plan (the &#8220;SARs Plan&#8221;) for its consultants that entitles the grantee to receive a cash payment based on the increase in the stock price of the Company&#8217;s common shares from the grant date to the settlement date. The term of a SAR may not exceed </div></div>10<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">years from the grant date. Generally, SARs vest over a period of three years. </div></div></div> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">For the year ended November&#160;30, 2023, ($22) (2022 - $12, 2021 &#8211; $53) was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> compensation expense for the SARs <div style="letter-spacing: 0px; top: 0px;;display:inline;">P</div>lan. Since these awards will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-settled,</div> the fair value of SARs granted is estimated at each reporting period using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. The liability is recorded in other liabilities on the statement of financial position.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 96%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted in 2019 and 2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2023</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2022</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.55%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.50%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.51%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58.4%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">$</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#8195;&#8199;&#8199;1.58&#160;(CA$2.15)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;<div style="font-size: 13pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8199;</div>8.72&#160;(CA$11.72)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top;text-indent: 0px;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>16.99&#160;(CA$23.07)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: -webkit-right; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;">$&#8195;</div>17.16&#160;(CA$23.07)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk-free</div> interest rate is based on the implied yield on a Canadian government <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> issue, with a remaining term equal to the expected term of a SAR. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of a SAR is estimated taking into consideration the vesting period on the grant date, the life of a SAR and the average length of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">No SARs w<div style="letter-spacing: 0px; top: 0px;;display:inline;">ere</div> granted during the years ended November&#160;30, 2023 and 2022. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(g)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Shareholder rights plan </div> </td> </tr> </table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;3, 2022, the Board of Directors approved certain amendments and the renewal of the Company&#8217;s shareholder rights plan and, on April&#160;6, 2022, the Company and Computershare Trust Services of Canada entered into an amended and restated shareholder rights plan agreement (the &#8220;Rights Plan&#8221;). The Rights Plan was approved by the shareholders on May&#160;10, 2022. The Rights Plan <div style="letter-spacing: 0px; top: 0px;;display:inline;">is</div> designed to provide adequate time for the Board and the shareholders to assess an unsolicited takeover bid for the Company. In addition, Rights the Plan provides the Board with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, as well as provide shareholders with an equal opportunity to participate in a takeover bid to receive full and fair value for their common shares. The Rights Plan will expire at the close of the Company&#8217;s annual meeting of shareholders in 2025 unless the Rights Plan is reconfirmed and approved by shareholders at such meeting. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The rights issued under the Rights Plan are initially attached to and traded with the common shares, and no separate certificate is issued unless a triggering event occurs. The rights become exercisable only when an acquiring person, including any party related to it, acquires or attempts to acquire <div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>% or more of the outstanding common shares without complying with the &#8220;Permitted Bid&#8221; provisions of the Rights Plan or without approval of the Board of Directors. Subject to the terms and conditions set out in the Rights Plan, each right (other than those held by the acquiring person) will permit the holder to purchase for the exercise price that number of common shares determined as follows: a value of twice the exercise price divided by the &#8220;Market Price&#8221; (defined under the Rights Plan as being the average weighted trading price per common share for the 20 consecutive&#160;trading days through and including the trading day immediately preceding the relevant date) on the common share acquisition date (defined as &#8220;Stock Acquisition Date&#8221; under the Rights Plan). The exercise price under the Rights Plan has been set to three (3) times the Market Price. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Rights Plan, a Permitted Bid is a bid made to all holders of common shares and which is open for acceptance for no less than <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days. If, at the end of <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days, more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div>% of the outstanding common shares, other than those owned by the offeror and certain related parties, have been tendered, the offeror may take up and pay for the common shares. If more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div>% of the outstanding common shares, other than those owed by the offeror and certain related parties, have been tendered within the above mentioned <div style="letter-spacing: 0px; top: 0px;;display:inline;">105</div> days period, the offeror must make a public announcement of that fact and the bid must remain open for an additional ten business days from the date of the announcement. </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(h)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Stock option plan </div> </td> </tr> </table> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company has established a stock option plan (the &#8220;Option Plan&#8221;) under which it can grant its directors, officers, employees, researchers and consultants non-transferable options (the &#8220;Option&#8221;) for the purchase of common shares. The exercise date of an Option may not be later than</div> 10&#160;years after the grant date. On March&#160;28, 2023, the Company&#8217;s Board of Directors <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">amended the Option Plan </div></div> to provide, among other things, that the <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum number </div></div> of common shares that may be issued under the <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Option Plan </div></div> (together with any other security-based compensation arrangements) shall not exceed 17% of the issued and outstanding common shares, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-diluted</div> basis<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">.</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The Option Plan has </div></div>a &#8220;reloading&#8221; or &#8220;evergreen&#8221; feature, so that whe<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">shares issuable under the Option Plan will be replenished and such exercised </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions will be available to be regranted in the future. Shareholders ratified this amendment on May&#160;9, 2023.&#160;Generally, the Options vest on the grant date or over a period of up to three years.<div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-indent: 0px;">As at November&#160;30, 2023, 5,762,675 <div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions could still be granted <div style="letter-spacing: 0px; top: 0px;;display:inline;">by</div> the Company (2022<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8211;&#160;</div>1,091,358,</div> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;">2021<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;&#8211;&#160;</div></div>1, 062,851<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">) </div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">under the Option Plan.</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">All Options are to be settled by the physical delivery of common shares. </div></div></div>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in the number of Options outstanding during the past two years were as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0px; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">per&#160;option</div></div></div></div> </td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="5" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of&#160;Options</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom:10pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">O</div></div></div><div style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -12px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">ptions outstanding in CA<div style="display:inline;">$</div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">797,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;15.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.00</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">547,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.00</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144,213)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.52</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Exercised (share price: CA$11.12 (US$8.24))</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,165)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.92</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,180,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;11,84</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">792,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(197,686)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.10</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,774,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.19</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; line-height: normal;">Options exercisable as at November 30, 2022 &#8211; CA$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">554,354</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">16.32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">12.12</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding in US$</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options as at November&#160;30,&#160;2021&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">20,183</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">12.36</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">96,668</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">12.08</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(10,208)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">12.52</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">106,643</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">10.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">203,935</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">3.80</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(31,209)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">279,369</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">6.02</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">65,692</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">9.48</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7,769</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">11.96</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"> </div><div></div><div>  </div> <div style="margin: 0pt 24% 0pt 8%; text-align: justify; font-family: arial; font-size: 11pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides Option information as at November&#160;30, 2023 (Options outstanding in&#160;CA$). </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">1.00&#160;&#8211; 4.76</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.74&#160;&#8211;&#8201;3.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">4.77 &#8211; 8.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.51 &#8211;&#8201;5.89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;707,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;9.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">8.01 &#8211; 15.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.90&#160;&#8211;&#8201;11.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">308,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">15.01 &#8211; 24.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.05&#160;&#8211;&#8201;17.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">621,167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">24.01 &#8211; 36.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.68&#160;&#8211;&#8201;26.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33.27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">36.01 &#8211; 40.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">26.51 &#8211;&#8201;29.45</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,426</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4.35</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">38.24</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28.16</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,774,559</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7.49</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11.51</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td colspan="24" style="padding-bottom:6pt ;vertical-align:top"> <div style="margin: 6pt 10em 0pt 3.5em; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">The following table provides Option information as at November 30, 2023 (Options outstanding in US$).</div> </td>
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00 &#8211; 4.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179,185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4.77 &#8211; 15.00</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">100,184</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.03</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">10.00</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">279,369</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.81</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6.02</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial">For the year ended November&#160;30, 2023, $2,237 (2022 - $3,860, 2021&#160;&#8211; $1,879) was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> compensation expense for the Option Plan. The fair value of Options granted in 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>&#160;and 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was estimated on </div></div> the grant date using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. </div> <div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:bottom">&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;&#8194;Options granted in CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.33%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.62%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64.3%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65.5%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;&#8194;3.80&#160;(CA$5.16)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.00&#160;(CA$16.68)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>3.80&#160;(CA$5.16)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13.00&#160;(CA$16.68)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:20pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#8195;&#8195;&#8195;&#8195;&#8194;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:5pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">12.08</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate is based on the implied yield on a Canadian or U.S. government <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> issue, with a remaining term equal to the expected term of an Option. The volatility is based on the weighted average historical volatility adjusted for changes expected due to publicly available information. The life of an Option is estimated taking into consideration the vesting period on the grant date, the life of the Option and the average period of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since Company policy is to retain all earnings to finance operations and future growth. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the measurement date weighted average fair value of Options granted during the years ended November&#160;30, 2023 and 2022. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">792,193</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.77&#160;(CA$3.76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">547,847</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;8.64&#160;(CA$11.64</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 18pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">203,935</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.72</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">96,668</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.36</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model used by the Company to calculate the option values was developed to estimate the fair value of freely tradable, fully transferable Options without vesting restrictions, which significantly differs from the Company&#8217;s Option grants. This model also requires four highly subjective assumptions, including future stock price volatility and the average Option life, which greatly affect the calculated values. </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Loss per share </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">The calculation of basic loss per<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common</div></div> share was based on the net loss attributable to common shareholders of the Company of $23,957 (2022 &#8211; 47,237, 2021&#160;&#8211; $31,725) and a weighted average number of common shares outstanding calculated as follows. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 58%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Issued common shares as at December&#160;1</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,201,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,780,417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,253,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share options exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of public issue common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,843,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,704,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Impact on conversion of convertible<br/> &#160;&#160;&#160;&#160;unsecured senior notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share issue - ATM program</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Effect of subscription receipts issue</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">287,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">-</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">-</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of broker warrants exercised</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">36,564</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="padding-bottom: 6pt; vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Weighted average number of common shares, <br/> &#160;&#160;&#160;&#160;basic&#160;and&#160;diluted</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">26,332,429</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">23,813,344</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">23,087,557</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial">For the year ended November&#160;30, 2023, 2,053,928 (2022 &#8211; 1,286,695, 2021 &#8211; 817,766) <div style="letter-spacing: 0px; top: 0px;;display:inline;">O</div>ptions, 8,130,550 (2022 &#8211; 8,130,550, 2021 &#8211; 8,130,550) Public Offering Warrants, and 5,000,000 Marathon Warrants were excluded from the weighted average number of diluted common shares calculation as their effect would have been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-dilutive.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The convertible unsecured senior notes were also excluded from the weighted average number of diluted common share calculation for the periods they were outstanding. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The average market value of the Company&#8217;s common shares for purposes of calculating the dilutive effect of Options was based on quoted market prices for the period during which the options were outstanding. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(j)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Accumulated other comprehensive income (loss) </div> </td> </tr> </table>  <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Unrealized losses on FVOCI financial assets, net of tax</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(256)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;(555)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;(195)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; line-height: normal;">Cumulative exchange difference on translation of foreign <br/>operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">940</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">940</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;684</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;385</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173860368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>  <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the components of the current and deferred tax expenses (recovery). </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;450</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">443</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">63</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Origination and reversal of temporary differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,972)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(11,705)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(7,796)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible <br/>temporary<div style="display:inline;">&#160;</div>differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,943</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">11,705</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">7,796</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(29)</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current and deferred tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">421</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">443</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">63</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>  <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation between effective and applicable tax amounts. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at domestic tax statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6,237)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(12,400)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(8,390)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible temporary&#160;differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,943</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">11,705</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">7,796</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of differences in statutory tax rates</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(130)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">102</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">64</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses and other</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">845</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">1,036</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">593</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">421</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">443</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">63</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The applicable statutory tax rate was </div>26.5<div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">in 2023, 2022 and 2021. The Company&#8217;s applicable tax rate is the Canadian combined rates applicable in the jurisdictions in which the Company operates.&#160;</div></div></div> <div></div><div>  </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Unrecognized deferred tax assets </div>  <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As at November&#160;30, 2023 and 2022, the amounts and expiry dates of Canadian tax attributes for which no deferred tax asset was recognized were as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses,<br/> &#8195;without&#160;time&#160;limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">87,151</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">105,549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">86,768</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">105,174</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses carried forward 2027</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,512</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,504</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,569</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">33,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,110</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,426</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,345</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,124</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,494</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,250</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2030</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,420</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,507</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2031</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,346</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,397</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,525</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2032</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,752</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,791</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,874</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,902</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2033</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,444</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,365</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,532</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,451</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2034</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,733</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,665</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,813</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,744</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2037</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,901</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,818</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,972</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,889</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2038</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,013</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,938</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,958</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2039</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,326</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,289</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,340</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2040</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,242</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,218</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,317</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,292</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2041</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,078</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,350</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,276</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2042</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,042</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,885</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,181</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,190</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2043</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,284</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other temporary differences,<br/> &#8195;without time limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of property and<br/> &#8195;equipment over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">435</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">420</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">454</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of intellectual<br/> &#8195;property and patent fees over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,660</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,656</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,765</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,765</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 3pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Available deductions and other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,522</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">32,536</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">69,448</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,034</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the Company&#8217;s past losses, management does not believe that it is probable that the Company can realize its deferred tax assets and, therefore, no amount has been recognized in the consolidated statements of financial position. The generation of future taxable profit is dependent on the successful commercialization of the Company&#8217;s products and technologies. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the above attributes, as at November&#160;30, 2023, the Company had available $8,816 (2022 &#8211; $8,883) of losses carried forward in Ireland without expiry dates for which no deferred tax assets were recognized. As at November&#160;30, 2023, deferred tax liabilities had not been recognized for taxable temporary differences arising from investments in a subsidiary because the Company controls the decisions affecting the realization of such liabilities and it is probable that the temporary differences will not reverse in the foreseeable future. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173517520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental cash flow disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_SupplementalCashFlowDisclosuresAbstract', window );"><strong>Supplemental cash flow disclosures [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory', window );">Supplemental cash flow disclosures</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supplemental cash flow disclosures</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>  <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into the following transactions, which had no impact on its cash flows. </div></div>&#160; <br/></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin: 0px auto; border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;">
<tr>
<td style="width: 660.312px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs included in accounts<br/> &#8195;payable and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to property and equipment included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">156</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of derivative financial assets included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to intangible assets included in accounts payable and accrued<br/> &#8195;liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,832</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of other Deferred financing costs to deficit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue cost included in accounts payable<br/> &#8195;and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">505</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Supplemental Information On Cash Flow [Explanatory]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_SupplementalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_SupplementalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173000400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial instruments</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overview</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">This note provides disclosures relating to the nature and extent of the Company&#8217;s exposure to risks arising from financial instruments, including credit risk, liquidity risk, currency risk and interest rate risk, and how the Company manages those risks. In addition to currency risk, the Company has exposure to risks from disputed accounts receivables. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Credit risk refers to the risk of a loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">The Company&#8217;s exposure to credit risk currently relates to accounts receivable with one major customer (refer to Note&#160;27), other receivable and derivative financial assets which it manages by dealing only with highly rated Canadian</div> financial institutions. Included in the consolidated statements of financial position are trade receivables of $12,798 (2022&#160;&#8211; $10,659), all of which were aged under 60 days or received after year end. There was no amount recorded as bad debt expense for the years ended November&#160;30, 2023 and 2022. Financial instruments other than cash and trade and other receivables that potentially subject the Company to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>significant credit risk consists principally of bonds and money market funds. The Company invests its available cash in highly liquid fixed income instruments from governmental, paragovernmental, municipal and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">high-grade</div> corporate bodies and money market funds (2023&#160;&#8211; $6,290; 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;&#8211; $9,214). As at November&#160;30, 2023, the Company believes it was not exposed to any significant credit risk. The Company&#8217;s maximum credit exposure corresponded to the carrying amount of these financial assets. </div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 15pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Liquidity risk refers to the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in Note 24, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company&#8217;s operating and capital budgets, as well as any material transactions out of the ordinary course of business.</div></div></div><div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">The Company has adopted an investment policy in respect of the safety and preservation of its capital designed to ensure that the Company&#8217;s liquidity needs are met. The instruments are selected with regards to the expected timing of expenditures and prevailing interest rates. <br/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">&#160;</div> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Marathon Credit Agreement, the Company is required to maintain cash, cash equivalents and eligible short-term investments overtime between</div></div></div> $15,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">to $20,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on the last twelve months adjusted EBITDA-based targets, which restricts the management of the Company&#8217;s liquidity. Refer to notes 1 and 17.</div></div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are amounts due on the contractual maturities of financial liabilities as at November&#160;30, 2023 and 2022. </div></div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 85%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;  -</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Facility loan, including interest (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">994</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">1,108</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">487</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">516</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">87,439</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">109,720</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">46,374</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">50,864</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">12,482</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan, including interest (2)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37,894</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,667</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,649</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,421</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">23,597</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes, including interest</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26,895</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,922</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,196</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">595</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,145</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">456</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;107,776</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;130,009</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;76,390</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;29,566</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;24,053</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. The maturities above reflect the fact that the Marathon Credit Agreement has been amended in the subsequent event period and, as such, the contractual maturities are used. </div></div></div></td></tr></table><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is exposed to financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company&#8217;s business transactions denominated in currencies other than US$, primarily cash, sale of goods and expenses incurred in CA$ and euros. </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate fluctuations for foreign currency transactions can cause cash flows, as well as amounts recorded in the consolidated statements of net loss, to vary from period to period and not necessarily correspond to those forecasted in operating budgets and projections. Additional earnings variability arises from the translation of monetary assets and liabilities denominated in currencies other than the US$ at the rates of exchange at each consolidated statement of financial position date, the impact of which is reported as foreign exchange gain or loss in the consolidated statements of net loss. </div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the significant items in the original currencies exposed to currency risk as at November&#160;30, 2023 and 2022. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 67%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,547</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bonds and money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accounts payables and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,395)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(224)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,784)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,849)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(925)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(288)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,362)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(873)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(326)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,192)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,486)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Total exposure</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3,048</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,434)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,587</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,592)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The following exchange rates are those applicable as at November&#160;30, 2023 and 2022.<br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">CA$ &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Euro &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0792</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0903</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0600</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0406</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Based on the Company&#8217;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the CA$ or the euro would have an impact on net earnings for CA$ and in the accumulated other comprehensive loss for euro as follows, assuming that all other variables remained constant.</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Positive (negative) impact</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(172)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">(380)</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">An assumed 5% <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">weakening of the CA$ or of the euro would have had an equal but opposite effect on the above currencies in the amounts shown above, assuming that all other variables remained constant.</div></div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest rate risk</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Interest rate risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div> bonds held by the Company are invested at fixed interest rates and/or mature in the short term. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div> bonds are also instruments that bear interest at fixed rates. The risk that the Company will realize a loss as a result of a decline in the fair value of its bonds is limited because these investments, although they are classified as fair value through OCI, are generally held until close to maturity. The unrealized gains or losses on bonds are recorded in accumulated other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Based on the value of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> bonds as at November&#160;30, 2023, an assumed 0.5% decrease in market interest rates would have increased the fair value of these bonds and the accumulated other comprehensive income (loss) by approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">42</div> </div></div> (2022&#160;&#8211; $79); an assumed increase in market interest rates of 0.5% would have an equal but opposite effect, assuming that all other variables remained constant. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and money market funds bear interest at variable rates. Trade and other receivables, accounts payable and accrued liabilities and provisions bear no interest.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172922208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract', window );"><strong>Disclosure of objectives, policies and processes for managing capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Captital management</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital management</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s objective in managing its capital is to ensure a liquidity position sufficient to finance its business activities. The Company depends primarily on revenue generated by sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>as well as sales of Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> in the United States, and, from time to time, on public offerings of securities in North America to finance its activities. In order to maintain or adjust its capital structure, the Company, upon approval by its Board of Directors, may issue or repay long-term debt, issue shares, repurchase shares, pay dividends or undertake other activities as deemed appropriate under the specific circumstances. The Company has also announced that it will evaluate its options in funding late stage development programs, which may include seeking a potential partner. </div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The capital management objectives remain the same as of the previous year, including that the Company&#8217;s cash deposit and brokerage accounts are subject to control agreements relating to the Loan Facility and certain credit card arrangements allowing creditors to collateralized outstanding loaned values. Furthermore, the Company is required to maintain cash, cash equivalents and eligible short-term investments over time to range of $15,000 to $20,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">based on targeted Marathon Adjusted EBITDA.&#160;</div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">As at November&#160;30, 2023, cash, bonds and money market funds amounted to $40,387 (2022-$33,070). </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Currently, the Company&#8217;s general policy on dividends is to retain cash to keep funds available to finance its growth. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company defines capital to include total equity and, prior to June&#160;30, 2023, convertible unsecured senior notes. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not subject to any externally imposed capital requirements, except those disclosed in Note 17 in relation to the Marathon Credit Agreement. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173715872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Determination of fair values<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfFairValueMeasurementAbstract', window );"><strong>Disclosure of Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Determination of fair values</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Determination of fair values</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial assets and financial liabilities measured at fair value</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;1:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as observable inputs such as quoted prices in active markets. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;2:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 7%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#8201;3:</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other financial assets and financial liabilities</div></div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company has determined that the carrying values of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> financial assets and financial liabilities, including cash, trade and other receivables, and accounts payable and accrued liabilities approximate their fair value because of their relatively short period to maturity.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div> <div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonds and money market funds and derivative financial assets and financial liabilities are stated at fair value, determined by inputs that are primarily based on broker quotes at the reporting date (Level&#160;2). </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that the carrying value of its Loan Facility approximates its fair value because the terms were&#160;modified near the end of the 2023 fiscal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> payment transactions</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Share Options is measured based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> valuation model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk-free</div> interest rate (based on government bonds). Service and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-market</div> performance conditions attached to the transactions, if any, are not taken into account in determining fair value. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the DSUs is determined using the quoted price of the common shares of the&#160;Company and considered Level&#160;2 in the fair value hierarchy. </div></div></div> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Marathon Warrants </div></div></div></div>  <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. Reasonably possible changes at November&#160;30, 2023, to one of the significant unobservable input, holding other inputs consistent, would have the following effects: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;Increase</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Decrease</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility (10% movement (100 bps))</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;125</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfFairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfFairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173006912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfCommitmentsAbstract', window );"><strong>Disclosure of commitments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div> procurement agreements and research agreements </div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;">The Company has <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">long-term</div> procurement agreements with third party suppliers in connection with the commercialization of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div> and Trogarzo<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div>. As at November&#160;30, 2023, the Company had outstanding purchase orders and minimum payments required under these agreements amounting to $14,682 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(2022 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8211; </div></div>$1,644) for the manufacture of Trogarzo<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px">&#174;</div>, </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div> </div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">and for other various services.</div></div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;">As at November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">3</div>, the Company also ha<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">d</div>&#160;research commitments and outstanding clinical material purchase orders amounting to $807 (2022 &#8211; $<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">1,310</div>) in connection with the oncology platform and nil <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(2022 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8211;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>$868) in connection with a new formulation of tesamorelin and of a multi-dose pen injector developed for this new formulation. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"> </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">Licence agreement </div> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;<div style="display:inline;">3</div>, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (&#8220;MGH&#8221;), as amended on April&#160;15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Alcoholic</div> Steatohepatitis (&#8220;NASH&#8221;) in the general population. Under the terms of the amended agreement, the MGH, through Dr.&#160;Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Alcoholic</div> Fatty Liver Disease or NASH in the general population. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of commitments abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168330432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Operating segments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating segments</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The Company has a single operating segment. As described in Note 3, almost all of the Company&#8217;s revenues are generated from one customer, RxCrossroads, which is domiciled in the United States.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 61%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">RxCrossroads</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;81,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;78,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">372</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">906</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">81,764</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">80,057</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">69,823</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are located in Canada, the United States and Ireland. <div style="letter-spacing: 0px; top: 0px;;display:inline;">Of the Company&#8217;s total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets of $14,472 (2022 &#8211; $19,890), $14,138 (2022 &#8211; $18,980) are located in Canada, $32 (2022 &#8211; $69) are located in the United States and $302 (2022 &#8211; $841) are located in&#160;Ireland. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174104976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28.</div></div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Related parties</div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The key management personnel of the Company are the directors, the President and Chief Executive Officer, the Senior Vice President and Chief Financial Officer, the Global Commercial Officer and the Senior Vice President and Chief Medical Officer.&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>  <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel compensation comprises: </div></div><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 91%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div> employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,355</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,078</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,243</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,709</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,355</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,005</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>  <div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As at November&#160;30, 2023, the key management personnel controlled 1.1% (2022&#160;&#8211; 0.8%) of the voting shares of the Company. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165644464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Basis of consolidation </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of the subsidiaries of the Company are included in these Financial Statements from the date on which control commences until the date on which control ceases. Subsidiaries are entities controlled by the Company. Control is present where the Company has the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable are taken into consideration. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany balances and transactions, revenues and expenses resulting from transactions between subsidiaries and with the Company are eliminated in preparing the Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currencies</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign currencies </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Transactions in foreign currencies are translated to the functional currency at exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate in effect at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the reporting year, adjusted for effective interest and payments during the reporting year, and the amortized cost in foreign currency translated at the exchange rate in effect at the end of the reporting year. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate in effect at the date on which the fair value was determined. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured at historical cost in a foreign currency are translated using the exchange rate in effect at the date of the transaction. Foreign currency differences arising on translation are recognized in net profit, except for differences arising on the translation of FVOCI financial instruments, which are recognized in other comprehensive income (loss). </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Foreign operations </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The assets and liabilities of foreign operations whose functional currency is not the US$ are translated into US$ at the reporting date. The income and expenses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">foreign-currency</div> denominated operations are translated at average rates for each reporting period. Foreign exchange differences arising on the translation of foreign operations are recognized directly in other comprehensive income (loss). When a foreign subsidiary is disposed of, the cumulative amount recognized in the currency translative reserve forms part of the gain or loss on disposal. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Revenue recognition </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Revenue from contracts with customers &#8211; Net sales </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">The Company derives revenue from the sales of finished goods, which include Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>and <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div>. The Company recognizes revenue at a point in time when it transfers title of the finished goods to a customer, which generally occurs upon delivery of the finished goods to the customer&#8217;s premises. Payment received from customers prior to the transfer of control of the goods is recorded as deferred revenue. </div></div></div> <div style="font-style: normal; font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Some arrangements for the sale of finished goods provide for customer cash discounts for prompt payment, allowances, rights of return, rebates on sales made under governmental and commercial rebate programs, chargebacks on sales made to government agencies and retail pharmacies and distribution fees, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation which gives rise to variable consideration. At the time of sale, estimates are made for items giving rise to variable consideration based on the terms of the arrangement. The variable consideration is estimated at contract inception using the most likely amount method and revenue is only recognized to the extent that a significant reversal of revenue is not expected to occur. The estimate is based on historical experience, current trends, contractual terms with distributors and other known factors. Sales are recorded net of customer discounts, rebates, chargebacks, distribution fees and estimated sales returns, and exclude sales taxes. A refund liability and a right to recover returned goods asset are recognized for expected returns in relation to sales made before the end of the reporting period. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of variable consideration, including expected returns, on a quarterly basis, adjusting for the amounts of the asset and liability accordingly. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCostOfSalesExplanatory', window );">Cost of sales</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Cost of sales </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Cost of goods sold includes the cost of raw materials, supplies, direct labour and overhead charges allocated to goods sold as well as write-downs of inventories. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">Amortization of the other asset </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;">The amortization of the other asset related to the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14). </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Employee benefits </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Salaries and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">profit-sharing</div> or cash bonus plans if the Company has a legal or constructive obligation to pay an amount as a result of past services rendered by an employee and the obligation can be estimated reliably. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits include a defined contribution plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense when due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available. The Company&#8217;s defined contribution plan comprises the registered retirement savings plan, the Quebec Pension Plan and employment insurance. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Termination benefits are recognized as an expense when the Company is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and finance costs</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Finance income and finance costs </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Finance income comprises interest income on financial assets and gains on the disposal of financial assets and financial liabilities. Interest income is recognized as it accrues in net loss using the effective interest method. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finance costs comprise bank charges, interest and accretion expense on lease liabilities, convertible unsecured senior notes, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> loans and obligations and deferred financing costs, impairment losses on financial assets recognized in net loss, changes in fair value of liabilities and derivatives, unrealized foreign currency gain or loss on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term</div> obligations, loss on long-term obligations modifications and other foreign currency gains and losses which are reported on a net basis. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Inventories </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Inventories are presented at the lower of cost, determined using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> method, and net realizable value. Inventory costs include the purchase price and other costs directly related to the acquisition of materials and other costs incurred in bringing the inventories to their present location and condition. The Company is responsible for coordinating the production and stability testing and for auditing suppliers at different times during the manufacturing process. Inventory costs also include the costs directly related to the conversion of materials into finished goods. Net realizable value is the estimated selling price in the Company&#8217;s ordinary course of business less the estimated costs of completion and selling expenses. In determining whether the inventory cost exceeds its net realizable value for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory, the Company considers whether there is a high probability of regulatory approval for the product. In making that determination, the Company considers prior history with approvals of similar products, estimated timing of obtaining regulatory approval, regulatory agencies correspondence regarding safety and efficacy of the product and current market factors. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Work in progress inventory appears from the moment third party suppliers use the material provided by the Company until the time the Company receives the finished product. The value of work in progress inventory is equal to the value of material provided by the Company plus all conversion work performed by third party suppliers. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Property and equipment </div></div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Recognition and measurement </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Items of property and equipment are recognized at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and the costs of dismantling and removing the item and restoring the site on which it is located, if any. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment and are recognized in net profit or loss. </div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Subsequent costs </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> servicing of items of property and equipment are recognized in net profit or loss as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Depreciation </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The methods of depreciation and depreciation rates and periods are as follows: </div><div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 46%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 20%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 28%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Method</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rate/period</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">50%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20% 5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Office furniture and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Leasehold improvements</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;">Straight-line</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="-sec-ix-hidden:hidden101085993;display:inline;">Lower of lease term</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">and economic life</div></td></tr></table></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The method of depreciation is selected based on the most closely expected pattern of consumption of the future economic benefits embodied in the asset. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Estimates for depreciation methods, useful lives and residual values are reviewed at each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> and adjusted if appropriate. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Intangible assets </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Research and development </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Development activities involve a plan or design for the production of new or substantially improved products and processes. A development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset. These criteria are usually met when a regulatory filing has been made in a major market and approval is considered highly probable. The expenditure capitalized includes the cost of materials, direct labour, and overhead costs that are directly attributable to preparing the asset for its intended use. Other development </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">expenditures are expensed as incurred. Capitalized development expenditures are measured at cost, less accumulated amortization and accumulated impairment losses.</div></div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">During the years ended November&#160;30, 2023, 2022 and 2021, no development expenditures were capitalized. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> advance payments for good and services that will be used in future research and development activities are expenses when the activity has been performed rather than when the payment is made. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Commercialization rights and oncology platform </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercialization rights and the oncology platform acquired by the Company have finite useful lives and are measured at cost less accumulated amortization and any accumulated impairment losses. Commercialization rights&#160;&#8211; <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA SV</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>111<div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">&#160;months on a </div><div style="letter-spacing: 0px; font-size: 11pt; text-wrap: nowrap; top: 0px;;display:inline;"></div><div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis<div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;">. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Commercialization rights&#160;&#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div> North American Territory &#8211; are amortized at fixed rates based on their estimated useful life of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>142<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis. Commercialization rights &#8211; Trogarzo<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#174;</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">&#160;</div>European Territory &#8211; were amortized at fixed rates based on their estimated useful life of </div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>148<div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">months on a straight-line basis. They were fully amortized during the year ended November&#160;30, 2022. Refer to Note 13. Commercialization rights&#160;for the oncology platform will be amortized over the estimated useful life on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis when the asset is available for use. </div></div></div><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">The amortization method and useful life of intangible assets are reviewed every year and adjusted as required. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory', window );">Asset acquisitions</a></td>
<td class="text"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Asset acquisitions </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Asset acquisitions are acquisitions that do not qualify as business combinations. At the date of acquisition, the Company initially recognizes the individual identifiable assets acquired and liabilities assumed. The cost to the Company at the date of the acquisition is allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of the acquisition. Subsequent consideration for performance-related development milestones is recognized as intangible assets when the specific milestones have been achieved and other recognition criteria are met. Subsequent payments related to activity or usage of an asset, including sales royalties, are expensed as incurred. Asset acquisition transactions do not give rise to goodwill. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock', window );">Other asset</a></td>
<td class="text"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Other asset </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other asset, which comprised the amount disbursed in connection with the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14), was amortized over its estimated useful life of<div style="display:inline;">&#160;</div>48&#160;months. Other asset was fully amortized during the year ended November&#160;30, 2022. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"> <div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The carrying amounts of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;">For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows from other assets or groups of assets (&#8220;Cash-Generating Unit&#8221;). The recoverable amount of an asset or a Cash-Generating Unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the Cash-Generating Unit. </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Impairment losses recognized in prior years are determined by the Company at each reporting date for any indications that the loss has decreased or no longer exists. An asset&#8217;s carrying amount, increased through the reversal of an impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Financial instruments </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company initially recognizes financial assets on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value through profit or loss, then the initial measurement includes transaction costs that are directly attributable to the asset&#8217;s acquisition or issue. On initial recognition, the Company classifies its financial assets as measured at amortized cost, FVOCI or fair value through profit or loss (&#8220;FVPL&#8221;), depending on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">(i) Financial assets measured at amortized cost </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial;text-align:justify">A financial asset is measured at amortized cost, using the effective interest method and net of any impairment loss, if it meets both of the following conditions and is not designated at fair value though profit or loss: </div> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is to hold assets to collect contractual cash flows;</div> </td> </tr> </table> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table> <div style="margin-top:10pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">The Company currently classifies its cash and trade and other receivables as financial assets measured at amortized cost. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">(ii) Financial assets, measured at fair value through other comprehensive income </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial">A debt investment is measured at fair value through other comprehensive income if it meets both of the following conditions and is not designated at fair value through profit or loss: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:7%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;">its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. </div> </td> </tr> </table>  <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) Financial assets, measured at fair value through other comprehensive income (continued) </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in other comprehensive income (loss). When an investment is derecognized, gains or losses accumulated in other comprehensive income (loss) are reclassified to profit or loss. </div></div><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment&#8217;s fair value in other comprehensive income (loss). </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">This election is made on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">investment-by-investment</div></div> basis. These assets are subsequently measured at fair value. Dividends are recognized in profit or loss, unless the dividend clearly represents a repayment of part of the cost of the investment, and other net gains and losses are recognized in other comprehensive income (loss) and are never reclassified in profit or loss. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently classifies its bonds as financial assets measured at FVOCI. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) Financial assets measured at fair value through profit or loss </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;">All financial assets not classified as measured at amortized cost or FVOCI as described above are measured at FVPL. These assets are subsequently measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss. The Company currently classifies its money market funds and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hedge</div> derivative financial assets as financial assets measured at FVPL. </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are&#160;transferred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) Financial liabilities </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities are classified into the following categories: </div></div><div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities at fair value through profit or loss </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;">A financial liability is classified at fair value through profit or loss if it is classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-for-trading,</div></div> it is a derivative or it is designated as such on initial recognition. Financial liabilities at fair value are measured at fair value and net gains and losses, including interest expense, are recognized in profit or loss. </div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company issued the Marathon Warrants which are classified as financial liabilities through profit or loss because the exercise can be made on a cashless basis. All transaction costs related to financial instruments designated at fair value through profit or loss are expensed as incurred. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently has no other financial liabilities measured at FVPL. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial liabilities measured at amortized cost </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">This category includes all financial liabilities, other than those measured at FVPL. A financial liability is subsequently measured at amortized cost using the effective interest method. The Company currently classifies accounts payable and accrued liabilities, convertible unsecured senior notes and Loan Facility as financial liabilities measured at amortized cost. </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) Compound financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Compound financial instruments are instruments that contain both a liability component and an equity component, and the liability component can be converted into share capital at the option of the holder and the number of shares to be issued does not vary with changes in their fair value. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversation option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Upon repurchase, the proceeds are allocated based on the same basis that was used for the initial recognition. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) Derivative financial instruments </div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative financial instruments are recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. The changes in the fair value of derivatives are recognized through profit or loss in the year in which they occur.</div> </div><br/> <div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(vii) Offsetting of financial instruments </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position when, and only when, the Company has a legal right to set off the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At each reporting date, the Company recognizes loss allowances for expected credit losses (&#8220;ECLs&#8221;) on financial assets carried at amortized cost and debt securities at FVOCI. The Company&#8217;s trade and other receivables are accounts receivable with no financing component and which have maturities of less than 12 months and, as such, the Company has chosen to apply the simplified approach for ECL. As a result, the Company does not track changes in credit risk related to its trade and other receivables, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(viii) Impairment of financial assets </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For other financial assets subject to impairment, the Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> ECLs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">debt securities that are determined to have low credit risk at the reporting date; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 1%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers a debt security to have a low credit risk when its credit risk rating is equivalent or above investment grade credit rating, such as its bonds classified at FVOCI. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s approach to ECLs reflects a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">probability-weighted</div> outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future <div style="letter-spacing: 0px; top: 0px;;display:inline;">economic </div>conditions. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"> <div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">At inception, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability at the commencement date of the lease, i.e. the date the underlying asset is available for use. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets </div></div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are measured at cost, less any accumulated amortization and accumulated impairment losses, and adjusted for remeasurement of lease liabilities. Cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets comprises: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">the initial measurement amount of the lease liabilities recognized; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any lease payments made at or before the commencement date, less any lease incentives received; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">any initial direct costs incurred; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#183;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">an estimate of costs to dismantle and remove the underlying asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease contract. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are amortized on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div> basis over the lesser of (i)&#160;the estimated useful life of the underlying assets; and (ii)&#160;the lease term. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets are assessed for impairment whenever there is an indication that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets may be impaired. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date over the lease term. The present value of the lease payments is determined using the lessee&#8217;s incremental borrowing rate at the commencement date if the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is a function of the lessee&#8217;s incremental borrowing rate, the nature of the underlying asset, the location of the asset, the length of the lease and the currency of the lease contract. Generally, the Company uses the lessee&#8217;s incremental borrowing rate for the present value. At the commencement date, lease payments generally include fixed payments, less any lease incentives</div></div></div>   <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">receivable, variable lease payments that depend on an index (e.g. based on inflation index) or a specified rate, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising the option to terminate the lease. Lease payments also include amounts expected to be paid under residual value guarantees and the exercise price of a purchase option if the Company is reasonably certain to exercise that option. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Variable lease payments that do not depend on an index or a specified rate are not included in the measurement of lease liabilities but instead are recognized as expenses in the period in which the event or condition that triggers the payment occurs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">After the commencement date, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced to reflect lease payments made. In addition, the carrying amount of lease liabilities is remeasured when there is a change in future lease payments arising from a change in an index or specified rate, if there is a modification to the lease terms and conditions, a change in the estimate of the amount expected to be payable under residual value guarantee, or if the Company changes its assessment of whether it will exercise a termination, extension or purchase option. The remeasurement amount of the lease liabilities is recognized as an adjustment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, or in the consolidated statement of comprehensive loss when the carrying amount of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset is reduced to zero. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification and presentation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lease-related</div> expenses </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Amortization charge for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, expenses related to variable lease payments not included in the measurement of lease liabilities and loss (gain) related to lease modifications are allocated in the Company&#8217;s consolidated statement of comprehensive loss based on their function within the Company, while interest expense on lease liabilities is presented within finance costs. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory', window );">Deferred Financing Costs</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Deferred Financing Costs </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares or debt securities. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity or debt issuance on a proportionate basis when it occurs. If at such time the Company deems that these costs are no longer recoverable, they will be expensed as a component of finance expenses. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Provisions </div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Chargebacks and rebates are estimated based on historical experience, relevant statutes with respect to governmental pricing programs, and contractual sales terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Returns </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for returns are estimated based on historical return levels, taking into account additional available information on contract changes. The Company reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical results and business practices, as necessary. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Contingent liability </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-occurrence</div> of one or more uncertain future events not wholly within the control of the Company, or a present obligation that arises from past events (and therefore exists) but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or because the amount of the obligation cannot be estimated reliably. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Income taxes </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in net loss except to the extent that they relate to items recognized directly in other comprehensive income (loss) or in&#160;equity. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Current tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Current tax is the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable in respect of previous years. The Company establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Deferred tax </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes and deferred tax losses that can be used against taxable profit in future years. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse and to fiscal losses when they will be used, based on the laws that have been enacted or substantively enacted by the reporting date. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">A deferred tax liability is generally recognized for all taxable temporary differences. A deferred tax asset is recognized for unused tax losses and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Deferred income tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting or taxable profit or loss at the time of the transaction, and, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising from the initial recognition of goodwill. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Share option plan </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records share-based compensation related to Options granted using the fair-value-based method estimated using the Black-Scholes model. Under this method, compensation cost is measured at fair value at the date of grant and expensed over the period in which optionees unconditionally become entitled to the Options. The amount recognized as an expense is adjusted to reflect the number of Options for which the related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of Options that do meet the related service conditions at the vesting date. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> payment arrangements in which the Company receives services as consideration for its own equity instruments are accounted for as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">equity-settled</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-based</div> payment transactions, regardless of how the equity instruments are obtained by the Company. </div></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred stock unit plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred stock units (&#8220;DSUs&#8221;) are totally vested on the date of grant and are settled in cash. When DSUs are granted to officers as part of their annual bonuses, a DSU liability is recorded on the date of grant at the market value of the common shares in place of the liability for the bonus payments. When DSUs are granted to directors as part of their annual compensation in lieu of cash, the expense related to DSUs and their liabilities are recognized on the date of grant. The liability is adjusted to reflect any change in the market value of common shares, and such change is recorded in finance costs. </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock', window );">Stock appreciation rights plan</a></td>
<td class="text"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">plan </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock appreciation rights (&#8220;SARs&#8221;) entitle the grantee to a cash payment based on the increase in the share price of the Company&#8217;s common shares from the grant date to the settlement date. </div></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A liability is recognized for the services acquired and is recorded at the fair value of the SARs in other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities, with a corresponding expense recognized in selling expenses over the period that the grantees become unconditionally entitled to the payment. The fair value of the employee benefits expense of the SARs is measured using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model. </div></div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">Estimating fair value requires determining the most ap</div>propri<div style="letter-spacing: 0px; font-size: 11pt;;display:inline;">ate inputs to the valuation model including the expected life of the SARs, volatility, </div><div style="letter-spacing: 0px; font-size: 11pt; white-space: nowrap; top: 0px;;display:inline;">risk-free</div><div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"> interest rate and dividend yield and making assumptions about them. At the end of each reporting period until the liability is settled, the fair value of the liability is remeasured, with any changes in fair value recognized in the consolidated statement of net earnings (loss) and comprehensive earnings (loss) of the current year.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government assistance</a></td>
<td class="text"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Government assistance </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Government grants are recognized only when the Company has reasonable assurance that it meets the conditions and will receive the grants. Government grants related to assets are recognized in the consolidated statement of financial position as a deduction from the carrying amount of the related asset. They are then recognized in profit or loss over the estimated useful life of the amortization asset that the grants were used to acquire, as a deduction from the amortization expense. </div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">Other government grants are recognized in profit or loss as a deduction from the related expenses, such as salaries for the Canadian Emergency Wage Subsidy program. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development tax credits</a></td>
<td class="text"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Research and development tax credits </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The Company elected to account for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> research and development tax credits under IAS&#160;20, <div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Government Grants and Disclosure of Governmental Assistance</div></div></div><div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;">. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> research and development tax credits are included in earnings against gross research and development expenses or deducted from the related assets, provided there is reasonable assurance that the Company has complied and will comply with the conditions related to the tax credits and that the credits will be received. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Share capital </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, subscription receipts and Public Offering Warrants are classified as equity. </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs </div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs directly attributable to the issue of common shares and equity classified warrants and subscription receipts are recognized in equity, net of any tax effects. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Earnings per share </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company presents basic and diluted earnings per share (&#8220;EPS&#8221;) data for its common shares. Basic EPS is calculated by dividing the net profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders by taking the weighted average number of common shares outstanding and taking into consideration all dilutive potential common shares, which consist of the outstanding Options, warrants, subscription receipts and convertible unsecured senior notes. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory', window );">Changes in accounting policies</a></td>
<td class="text"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Changes in accounting policies </div></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2022, the Company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities in the consolidated statement of cash flows. Previously, the Company elected to classify interest paid as cash flow from financing activities and interest received as cash flows from investing activities. This change was applied retrospectively. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory', window );">New standard adopted</a></td>
<td class="text"><div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">New standard adopted </div></div><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Onerous contracts &#8211; Cost of Fulfilling a Contract (Amendments to IAS 37) </div> </div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#8217;s annual reporting periods beginning on December&#160;1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock', window );">Standards issued but not yet effective</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"><div style="font-weight:bold;display:inline;">Standards issued but not yet effective </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">A number of new standards are effective for annual periods beginning after December&#160;1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing these Financial Statements. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Classification of Liabilities as Current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> (Amendments to IAS 1)</div> </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">For the purposes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. </div> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> Covenants with which a company must comply after the reporting date do not affect a liability&#8217;s classification at that date. </div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#8217;s own equity instruments to the counterparty; and when classifying liabilities as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> a company can ignore only those conversion options that are recognized as equity. </div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The amendments will be effective for the Company&#8217;s annual reporting period beginning on December&#160;1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCostOfSalesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the cost of sales. [Refer: Cost of sales]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCostOfSalesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for adopted the new or amended standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for asset acquisiitons explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for deferred financing costs explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for inventories explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for new accounting standards adopted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for other assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for stock appreciation rights plan explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes in accounting policies explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173738752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock', window );">Summary of estimated useful lives, methods of depreciation and depreciation rates</a></td>
<td class="text"><div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The methods of depreciation and depreciation rates and periods are as follows: </div><div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 46%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 20%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 28%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td>
<td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Method</div></div></div></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rate/period</div></div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">50%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">straight-line</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20% 5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Office furniture and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">Declining balance</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:right;">20%</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Leasehold improvements</div></td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;">Straight-line</td>
<td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="-sec-ix-hidden:hidden101085993;display:inline;">Lower of lease term</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">and economic life</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of estimated useful lives methods of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173122528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of net sales by product</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by product <div style="display:inline;">were</div> as follows:<br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 61%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 1%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA</div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;SV</div></div></div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 1%;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 61%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trogarzo<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px">&#174;</div></div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,059</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">29,603</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">26,814</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;81,764</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;80,057</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8194;69,823</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock', window );">Summary of revenue by geographical area</a></td>
<td class="text"> <div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">Net sales by geography were as follows: </div> <div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 90%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt; width: 5%;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Canada</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">United States</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;78,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;68,099</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="2" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: top; width: 90%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Europe</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">286</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,261</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,455</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: top; width: 90%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;">81,764</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">80,057</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">69,823</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="14" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disaggregation of revenue by geographical area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174085008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock', window );">Summary of detailed information about personnel expenses</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 55%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Salaries and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>employee benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24,934</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">22,049</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,480</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>benefits</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,833</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,346</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">644</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>compensation</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20(f),(h)</td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,109</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,604</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,651</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 4.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination benefits</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,006</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">566</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209</div></td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 7.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160;30,882</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;27,565</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160; &#160;&#160; 13,984</div></td>
<td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="18" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about personnel expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166920192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance income and finance costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock', window );">Summary of detailed information about finance income and cost</a></td>
<td class="text"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 14.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on repurchase of convertible unsecured senior notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160; &#160; &#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Net gain on financial instruments carried at fair <br/>value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Gain on lease termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense and amortization of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,&#160;18,&#160;19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,098)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,140)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,358)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Interest on convertible unsecured senior&#160;notes and on long-term loan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,263)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,357)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> &#160; &#160;(3,306)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bank charges</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net foreign currency loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(159)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;&#160; (1,027</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(926)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Loss on Loan Facility modifications</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(c)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,540)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Write off of deferred financing costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">17,&#160;20(d)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(954)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(15,056)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,559)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,621)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Net finance cost recognized in net&#160;profit&#160;or&#160;loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(12,909)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,886)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(6,426)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; text-indent: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about finance income and cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849167039664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bonds and money market funds (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock', window );">Detailed Information About Bonds And Money Market Funds</a></td>
<td class="text"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td>
<td colspan="4" style="height:1.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family:Calibri;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td>
<td colspan="4" style="height:7.5pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;6,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;8,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial">Guaranteed investment certificates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td>
<td colspan="4" style="height:9.75pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;6,290</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;">$&#8195;&#8194;9,214</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000">&#160;</div></td>
<td>&#160;</td></tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about bonds and money market funds explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173790368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock', window );">Summary of detailed information about trade and other receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;12,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;10,659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Sales taxes receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td>
<td colspan="4" style="height:3.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:3.75pt">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;13,023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;">$&#160;&#160;&#160;&#160;&#160;&#160;12,045</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about trade and other receivables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172984352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax credits and grants receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract', window );"><strong>Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock', window );">Disclosure Details Of Tax Credits Roll Forward</a></td>
<td class="text"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(442)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(16)</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax Credit and grants recognized in net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants received</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:3pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:4pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">524</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock', window );">Summary of information about unused and unrecorded non refundable federal tax credit</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2030</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2031</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2032</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2033</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2039</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2040</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2041</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2042</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">2043</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Details Of Tax Credits Roll Forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about unused and unrecorded non refundable federal tax credit explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849167010448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock', window );">Summary of detailed information about inventories</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;2,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;&#8195;2,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,708</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,815</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td>
<td colspan="4" style="height:4.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,096</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11,290</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6,066</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">19,688</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about inventories explanatory text.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172585552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Deposits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAbstract', window );"><strong>Current prepayments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory', window );">Summary of prepaid expenses and deposits</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 71%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Deposits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">467</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,345</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160; 3,154</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160;&#160;7,665</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173116816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of information about property and equipment</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 3%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 53%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Office</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">furniture&#160;and</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">equipment</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold</div></div></div></div> <div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">improvements</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="22" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;&#160;373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;1,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;2,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"><br/></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46) </td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;251</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,196</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;359</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;650</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;2,456</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated depreciation</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(263)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposals</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-  </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(46)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8201;227</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;74</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;816</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;132</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;184</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,206</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:7.5pt">&#160;</td>
<td colspan="2" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td>
<td colspan="4" style="height:7.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;167</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 905</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;137</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;285</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;1,494</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172585552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfRightOfUseAssetAbstract', window );"><strong>Disclosure of right of use Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RightOfUseAssetsTableTextBlock', window );">Summary of right-of-use assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:3%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:75%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(429)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(87)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 1,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(352)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(a)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(799)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">19(<div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>)</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">770</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="10" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of right Of use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use&#160;assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174105136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 41%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 12pt; font-size: 12pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">North&#160;American</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">rights &#8211; Trogarzo<div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px">&#174;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">European&#160;Territory</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Commercialization</div></div> <div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rights&#160;&#8211;&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EGRIFTA&#160;SV<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px">&#174;</div></div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">Oncology</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"><div style="font-weight:bold;display:inline;">platform</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at</div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;11,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;37,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Additions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,832</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,832</td>
<td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,804</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;39,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,804</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;32,333</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 3,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;&#160;999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;11,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;15,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">1,087</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">6,613</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">1,511</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">- </td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">9,211</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 4,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;12,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;24,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Disposal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,612)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 1,442</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;$&#160; 1,071</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 2,513</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Balance as at<br/> November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 5,796</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;14,041</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;19,837</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="2" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 9,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;12,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;10,450</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;-</td>
<td style="padding: 0px; white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160; 1,071</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;3,488</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;">$&#160;15,009</td>
<td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="22" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock', window );">Schedule of Commercial Milestone Payment</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial">As further consideration under the TaiMed Agreement, the Company shall make the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payments upon the first occurrence of the following commercial events: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 96%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 21%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial milestone</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commercial&#160;milestone&#160;payment&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(i) Upon first achieving annual net sales of $200,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(ii) Upon first achieving annual net sales of $500,000</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 4pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">(iii) Upon first achieving annual net sales of $1,000,000</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">$100,000</td>
<td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About In Commercial Milestone Payment Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173172624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock', window );">Summary of other asset</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 85%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1pt">
<td style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td>
<td colspan="4" style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021, 2022 and 2023</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">19,530</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;17,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,441</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);;text-align:right;">19,530</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amounts</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;November&#160;30, 2023 and November&#160;30, 2022</div> </td>
<td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">$</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;">-</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other asset explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165890208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and accured liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and other payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto;">
<tr>
<td style="width:90%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></div>&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Trade payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Accrued liabilities and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Salaries and benefits due to key management personnel</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Employee salaries and benefits payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">Liability related to deferred stock unit plan</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20(e)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align: top;"> <div style="text-indent: -2em; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.2em; line-height: normal;">Accrued interest payable on convertible unsecured senior notes and Loan Facility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17&#160;and&#160;18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#8195;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;">TaiMed milestone (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,846</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="break-inside: avoid; font-size: 11pt;">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,471</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">41,065</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173172624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsAbstract', window );"><strong>Disclosure of other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock', window );">Summary of provision</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 88%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and&#160;rebates</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restructuring</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px">(a)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,358)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,287)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(233)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(233)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2022</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;6,032</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;1,485</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160; 7,517</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td>
<td colspan="4" style="height:15.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions made</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions used</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,506)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(309)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,721)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,536)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rate</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">168</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(2)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2023</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7,101</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,262</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">240</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">9,603</td>
<td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:justify">In July 2023, the Company initiated a reorganization mainly focused on its R&amp;D activities. On October&#160;24, 2023, the Company announced changes to its operations that saw a tapering of its research and development activities. As such, for the year ended November&#160;30, 2023, $1,963 was recorded in charges related to severance and other expenses, of which an amount of $1,384 was recorded in research and development expenses, $220 in selling expenses and $359 in general and administrative expenses. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about provisions explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173824816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Summary of movement in the carrying value of the term loan</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the Loan Facility is as follows: </div></div></div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 87%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:28.5pt">&#160;</td>
<td colspan="4" style="height:28.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Loan Facility on July&#160;27, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,285)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Proceeds from Tranche 2 Loan on June&#160;21, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Costs related to issuance of Tranche 2 Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Costs related to Marathon Warrants (note 20(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Consideration f<div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div> the Fifth Amendment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Term loan as at November&#160;30,&#160;2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">57,974</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7,286)</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">50,688</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173790240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible unsecured senior notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesAbstract', window );"><strong>Convertible Unsecured Senior Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock', window );">Summary of deferred tax related to equity component of convertible unsecured senior notes</a></td>
<td class="text"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The movement in the carrying value of the convertible unsecured senior notes is as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2021 </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54,227</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,546) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs incurred </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(73) </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 26.25pt;">&#160;</td>
<td colspan="4" style="height: 26.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes: </div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(357)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,644</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2022</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26,895</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes from financing cash flows:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid on repurchase</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(27,452)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Other changes:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15)</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 14.25pt;">&#160;</td>
<td colspan="4" style="height: 14.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">572</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 8pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes as at November&#160;30,&#160;2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap; width: 1%;"><br/></td> </tr>
<tr style="font-size: 1px;">
<td colspan="4" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleUnsecuredSeniorNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleUnsecuredSeniorNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred tax related to equity component of convertible notes explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173067104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfLeaseLiabilitiesAbstract', window );"><strong>Disclosure of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock', window );">Summary of lease liabilities</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 86%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">Carrying</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">value</div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;&#160;2,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(605)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(148)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:20.25pt">&#160;</td>
<td colspan="4" style="height:20.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Balance as at November&#160;30,&#160;2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accretion expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(452)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of change in exchange rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Termination (a)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(920)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">New lease (b)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:25.5pt">&#160;</td>
<td colspan="4" style="height:25.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;">Balance as at November 30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(421)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">573</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;;text-indent: 0px;">On February&#160;17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The gain is presented in finance income (Note 5).&#160;</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability of $326. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173688544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareCapitalLineItems', window );"><strong>Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities', window );">Summary of measurement of fair value of warrant liabilities</a></td>
<td class="text"> <div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 94%; border: 0px; margin-left: auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:top;text-align:right;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuance&#160;date</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">measurement</div></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.326%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88.568%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61.985%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160;6.25&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Share price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em;">Exercise price </div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2.30</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5.80</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock', window );">Summary of changes in the number of options outstanding</a></td>
<td class="text"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in the number of Options outstanding during the past two years were as follows: </div></div></div> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width: 71%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0px; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">per&#160;option</div></div></div></div> </td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="4" style="height:1.5pt">&#160;</td>
<td colspan="5" style="height:1.5pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of&#160;Options</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom:10pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">O</div></div></div><div style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -12px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">ptions outstanding in CA<div style="display:inline;">$</div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">797,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;15.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.00</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">547,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.00</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(144,213)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.52</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Exercised (share price: CA$11.12 (US$8.24))</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,165)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.92</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,180,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8194;11,84</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">792,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited and expired &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(197,686)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.10</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="4" style="height:14.25pt">&#160;</td>
<td colspan="5" style="height:14.25pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,774,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30, 2023 &#8211; CA$</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.19</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; line-height: normal;">Options exercisable as at November 30, 2022 &#8211; CA$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">554,354</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">16.32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);">12.12</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options outstanding in US$</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options as at November&#160;30,&#160;2021&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">20,183</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">12.36</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">96,668</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">12.08</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(10,208)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">12.52</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">106,643</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">10.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Granted&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">203,935</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">3.80</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Forfeited &#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(31,209)</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options outstanding as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">279,369</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">6.02</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2023&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">65,692</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">9.48</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Options exercisable as at November&#160;30,&#160;2022&#160;&#8211; US$</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7,769</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">11.96</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock', window );">Summary of the model used to determine fiar value of stock appreciation rights</a></td>
<td class="text">the fair value of SARs granted is estimated at each reporting period using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. The liability is recorded in other liabilities on the statement of financial position.<div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"> </div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 96%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted in 2019 and 2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2023</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;date</div></div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as&#160;at&#160;November&#160;30,&#160;2022</div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.55%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.50%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.51%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58.4%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">$</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>&#8195;&#8199;&#8199;1.58&#160;(CA$2.15)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;<div style="font-size: 13pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8199;</div>8.72&#160;(CA$11.72)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top;text-indent: 0px;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>16.99&#160;(CA$23.07)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"><div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: -webkit-right; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;">$&#8195;</div>17.16&#160;(CA$23.07)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of the following table provides stock option information</a></td>
<td class="text"> <div style="margin: 0pt 24% 0pt 8%; text-align: justify; font-family: arial; font-size: 11pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides Option information as at November&#160;30, 2023 (Options outstanding in&#160;CA$). </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;white-space:nowrap;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">1.00&#160;&#8211; 4.76</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.74&#160;&#8211;&#8201;3.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">4.77 &#8211; 8.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.51 &#8211;&#8201;5.89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right;">&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;707,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;9.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8195;&#8195;&#8195;&#8195;&#8195;3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">8.01 &#8211; 15.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.90&#160;&#8211;&#8201;11.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">308,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">15.01 &#8211; 24.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.05&#160;&#8211;&#8201;17.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">621,167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">24.01 &#8211; 36.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.68&#160;&#8211;&#8201;26.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33.27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;">36.01 &#8211; 40.00</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">26.51 &#8211;&#8201;29.45</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28,426</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4.35</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">38.24</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">28.16</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="2" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td>
<td colspan="4" style="height:9.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,774,559</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">7.49</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">11.51</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td colspan="24" style="padding-bottom:6pt ;vertical-align:top"> <div style="margin: 6pt 10em 0pt 3.5em; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;">The following table provides Option information as at November 30, 2023 (Options outstanding in US$).</div> </td>
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 11pt; font-family: arial; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price range</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></div> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">outstanding</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average<br/></div></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">remaining</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">life</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div></div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(years)</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00 &#8211; 4.76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179,185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4.77 &#8211; 15.00</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">100,184</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.03</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">10.00</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">279,369</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">8.81</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">6.02</td>
<td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="24" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock', window );">Summary of Accumulated other comprehensive income (loss) (Detail)</a></td>
<td class="text">Accumulated other comprehensive income (loss) <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Unrealized losses on FVOCI financial assets, net of tax</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(256)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;(555)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;(195)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td>
<td colspan="4" style="height:3pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 6pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; line-height: normal;">Cumulative exchange difference on translation of foreign <br/>operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">940</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">940</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;684</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;385</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44)</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock', window );">Summary of the measurement date weighted average fair value of stock options granted</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the measurement date weighted average fair value of Options granted during the years ended November&#160;30, 2023 and 2022. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">792,193</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.77&#160;(CA$3.76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">547,847</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;8.64&#160;(CA$11.64</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 18pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: bottom;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options&#160;granted</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div></div><br/> <div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">grant date</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fair value</div></div></div></div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;<br/> <div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div><div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">203,935</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.72</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 6pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">96,668</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.36</div></td>
<td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock', window );">Summary of earnings per share calculation</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify">The calculation of basic loss per<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common</div></div> share was based on the net loss attributable to common shareholders of the Company of $23,957 (2022 &#8211; 47,237, 2021&#160;&#8211; $31,725) and a weighted average number of common shares outstanding calculated as follows. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 58%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Issued common shares as at December&#160;1</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,201,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,780,417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,253,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share options exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of public issue common shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,843,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,704,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Impact on conversion of convertible<br/> &#160;&#160;&#160;&#160;unsecured senior notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of share issue - ATM program</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Effect of subscription receipts issue</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">287,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">-</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">-</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="4" style="line-height: 4pt; font-size: 4pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom: 8pt; vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Effect of broker warrants exercised</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">-</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">36,564</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 11pt;">
<td style="padding-bottom: 6pt; vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Weighted average number of common shares, <br/> &#160;&#160;&#160;&#160;basic&#160;and&#160;diluted</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">26,332,429</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">23,813,344</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">23,087,557</td>
<td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock', window );">Summary of the share-based compensation expense for the stock option plan</a></td>
<td class="text">The fair value of Options granted in 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>&#160;and 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">was estimated on </div></div> the grant date using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes</div> model and the following weighted average assumptions. <div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width: 95%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:bottom">&#8195;&#8195;&#8195;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;&#8194;Options granted in CA$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.33%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.62%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64.3%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65.5%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$&#8195;&#8194;3.80&#160;(CA$5.16)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.00&#160;(CA$16.68)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">$</div>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>3.80&#160;(CA$5.16)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">13.00&#160;(CA$16.68)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:20pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:bottom">&#8195;&#8195;&#8195;&#8195;&#8194;&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options granted in US$</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8194;2022</div></div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:5pt">
<td style="vertical-align:bottom;text-align:center;">&#8195;&#8195;&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Average option life in years</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-date</div> share price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Option exercise price</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3.80</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">12.08</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="8" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about in accumulated other comprehensive income loss explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information for changes in the number of options outstanding explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information for share based compensation expense stock option plan explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the model used to determine fiar value of stock appreciation rights explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of weighted average fair value of options granted and number of options [Explanatory].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of weighted average number of shares outstanding [Explanatory].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166929104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock', window );">Summary of major component of income tax and deferred tax explanatory</a></td>
<td class="text"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the components of the current and deferred tax expenses (recovery). </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Current tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;450</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">443</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">63</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Origination and reversal of temporary differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,972)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(11,705)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(7,796)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible <br/>temporary<div style="display:inline;">&#160;</div>differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,943</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">11,705</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">7,796</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax expense (recovery)</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(29)</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current and deferred tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">421</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">443</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">63</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock', window );">Summary of reconciliation between effective and income tax amounts explanatory</a></td>
<td class="text"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation between effective and applicable tax amounts. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td>
<td colspan="4" style="height: 20.25pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at domestic tax statutory rate</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6,237)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(12,400)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">(8,390)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in unrecognized deductible temporary&#160;differences</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,943</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">11,705</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">7,796</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of differences in statutory tax rates</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(130)</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">102</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">64</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-deductible</div> expenses and other</div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">845</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">1,036</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">593</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">421</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">443</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">63</div></div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of temporary difference, unused tax losses and unused tax credits</a></td>
<td class="text"> <div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">As at November&#160;30, 2023 and 2022, the amounts and expiry dates of Canadian tax attributes for which no deferred tax asset was recognized were as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Federal</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Provincial</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses,<br/> &#8195;without&#160;time&#160;limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">87,151</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">105,549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">86,768</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">105,174</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses carried forward 2027</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,512</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,504</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,569</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">33,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34,110</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,426</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2029</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,345</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,124</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,494</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,250</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2030</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,420</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,507</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2031</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,346</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,397</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,525</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2032</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,752</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,791</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,874</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,902</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2033</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,444</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,365</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,532</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,451</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2034</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,733</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,665</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,813</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,744</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2037</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,901</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,818</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,972</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,889</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2038</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,013</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,938</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,958</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2039</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,326</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,289</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,340</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2040</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,242</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,218</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,317</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,292</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2041</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,078</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,350</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,276</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2042</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,042</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,885</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,181</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">31,190</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">2043</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,284</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other temporary differences,<br/> &#8195;without time limitation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of property and<br/> &#8195;equipment over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">435</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">420</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">454</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess of tax value of intellectual<br/> &#8195;property and patent fees over carrying value</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,660</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,656</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,765</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,765</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td>
<td colspan="4" style="height: 3pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 3pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Available deductions and other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,522</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">32,536</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">69,448</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,034</div></td>
<td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock', window );">Summary of amounts and expiry dates of tax attributes carry forward explanatory</a></td>
<td class="text"> <div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into the following transactions, which had no impact on its cash flows. </div></div>&#160; <br/></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin: 0px auto; border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;">
<tr>
<td style="width: 660.312px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8194;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td>
<td colspan="4" style="height: 15.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs included in accounts<br/> &#8195;payable and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">174</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to property and equipment included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">156</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of derivative financial assets included in accounts payable and<br/> &#8195;accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions to intangible assets included in accounts payable and accrued<br/> &#8195;liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,832</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td>
<td colspan="4" style="height: 9.75pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of other Deferred financing costs to deficit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">38</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Share issue cost included in accounts payable<br/> &#8195;and accrued liabilities</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">505</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of amounts and expiry dates of tax attributes carry forward explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of major component of income tax and deferred tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation between effective and income tax amounts explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166932064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Summary of maturity analysis for non-derivative financial liabilities</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 85%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160;&#160;28,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;  -</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;">Facility loan, including interest (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td>
<td colspan="4" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff">
<td style="padding-bottom: 8pt; vertical-align: top;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">994</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">1,108</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">487</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">516</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="vertical-align: top; padding: 0pt;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;">&#160;</td>
<td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: arial; font-size: 9pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">87,439</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">109,720</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">46,374</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">50,864</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">12,482</td>
<td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> contractual<br/> amount</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less<br/> than<br/> 1 year</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">From<br/> 1 to<br/> 2 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More<br/> than<br/> 3 years</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,065</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan, including interest (2)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37,894</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,667</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,649</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,421</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">23,597</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible unsecured senior notes, including interest</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26,895</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;">
<td style="padding-bottom: 8pt; vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,922</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,196</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">595</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,145</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">456</div></td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td>
<td colspan="4" style="height: 18pt;">&#160;</td></tr>
<tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;107,776</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;130,009</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;76,390</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;29,566</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;24,053</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="20" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on SOFR forward rates. The maturities above reflect the fact that the Marathon Credit Agreement has been amended in the subsequent event period and, as such, the contractual maturities are used. </div></div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock', window );">Summary of currency risk exposure explanatory</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 67%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;EURO</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 20.25pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,547</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Bonds and money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Tax credits and grants receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Accounts payables and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,395)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(224)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,784)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,849)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(925)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(288)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,362)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(873)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Provisions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(326)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,192)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">-</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,486)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Total exposure</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">3,048</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(3,434)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,587</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(7,592)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock', window );">Summary of applicable exchange rates explanatory</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify">The following exchange rates are those applicable as at November&#160;30, 2023 and 2022.<br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Average</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Reporting</div></div></div></div></div><div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">date&#160;rate</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">CA$ &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0,7439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:7pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Euro &#8211; US$</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0792</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0903</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0600</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,0406</td>
<td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-size: 1px;">
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Disclosure of effect of changes in foreign exchange rates</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td colspan="16" style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;CA$</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;&#8195;&#8195;Euro</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 30pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:8pt ;vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Positive (negative) impact</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">152</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">(172)</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;">(380)</td></tr>
<tr style="font-size:1px">
<td colspan="16" style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Applicable Exchange Rates [Explanatory]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Currency Risk Exposure [Explanatory].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172842272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Determination of fair values (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfFairValueMeasurementAbstract', window );"><strong>Disclosure of Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Summary of marathon warrants recognized at fair value and considered level 3</a></td>
<td class="text"> <div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. Reasonably possible changes at November&#160;30, 2023, to one of the significant unobservable input, holding other inputs consistent, would have the following effects: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net loss</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;Increase</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;Decrease</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="padding-bottom: 7pt; vertical-align: top;"> <div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility (10% movement (100 bps))</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;125</div></td>
<td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="8" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfFairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfFairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174043920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock', window );">Summary of operating segments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 61%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">RxCrossroads</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;81,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160; &#160;78,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160; &#160; &#160; &#160; &#160;&#160;68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="padding-bottom:8pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;">Others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">372</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">906</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">81,764</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">80,057</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">69,823</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about operating segments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849171933424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of key management personnel compensation comprises</a></td>
<td class="text"> <div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Key management personnel compensation comprises: </div></div><br/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 91%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;&#8195;2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8195;&#8195;&#8195;&#8195;<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="12" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 18pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Short-term</div> employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Post-employment</div> benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff">
<td style="padding-bottom:6pt ;vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-based</div> compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,355</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">2,078</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">1,243</td>
<td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td>
<td colspan="4" style="height:18pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,709</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">5,355</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">$</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;">4,005</td>
<td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td colspan="12" style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165964416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRateBasis', window );">Borrowings, interest rate basis</a></td>
<td class="text">300 basis points<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Negative operating cash flows</a></td>
<td class="num">$ (5,678)<span></span>
</td>
<td class="num">$ (14,692)<span></span>
</td>
<td colspan="2" class="num">$ (17,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(23,957)<span></span>
</td>
<td class="num">(47,237)<span></span>
</td>
<td colspan="2" class="num">$ (31,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">34,097<span></span>
</td>
<td class="nump">23,856<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="nump">$ 9,214<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumLiquidityRequirementAmount', window );">Minimum liquidity requirement amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumLiquidityRequirementAmount', window );">Minimum liquidity requirement amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MinimumLiquidityRequirementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity requirement amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MinimumLiquidityRequirementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173927504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Summary of methods of depreciation (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationMethodPropertyPlantAndEquipment', window );">Depreciation method, property, plant and equipment</a></td>
<td class="text">Declining balance<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Depreciation rate, property, plant and equipment</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationMethodPropertyPlantAndEquipment', window );">Depreciation method, property, plant and equipment</a></td>
<td class="text">Declining balance and straight-line<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Depreciation rate, property, plant and equipment</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life measured as period of time, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationMethodPropertyPlantAndEquipment', window );">Depreciation method, property, plant and equipment</a></td>
<td class="text">Declining balance<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Depreciation rate, property, plant and equipment</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationMethodPropertyPlantAndEquipment', window );">Depreciation method, property, plant and equipment</a></td>
<td class="text">Straight-line<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Description of useful life, property, plant and equipment</a></td>
<td class="text">Lower of lease term and economic life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationMethodPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The depreciation method used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationMethodPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRatePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165989920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill', window );">Intangible assets amortization method</a></td>
<td class="text">straight-line basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets', window );">Amortization of other assets</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsEgriftaMember', window );">Commercialization Rights EGRIFTA SV&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets finite useful lives</a></td>
<td class="text">111 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoMember', window );">Commercialization Rights Trogarzo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets finite useful lives</a></td>
<td class="text">142 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember', window );">Capitalised development expenditure [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Development expenditures capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember', window );">THTX Commercialization Rights Trogarzo&#174; North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Intangible assets finite useful lives</a></td>
<td class="text">148 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amortisation method used for intangible assets other than goodwill with finite useful lives. [Refer: Intangible assets other than goodwill; Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life measured as period of time other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsEgriftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsEgriftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165497536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of net sale by product (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 81,764<span></span>
</td>
<td class="nump">$ 80,057<span></span>
</td>
<td class="nump">$ 69,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=thtx_EgriftaMember', window );">EGRIFTA&#174; net sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">53,705<span></span>
</td>
<td class="nump">50,454<span></span>
</td>
<td class="nump">43,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoNetSalesMember', window );">Trogarzo&#174; net sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 28,059<span></span>
</td>
<td class="nump">$ 29,603<span></span>
</td>
<td class="nump">$ 26,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=thtx_EgriftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=thtx_EgriftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166380944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of net revenue by geographical area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems', window );"><strong>Disaggregation Of Revenue By Geographical Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 81,764<span></span>
</td>
<td class="nump">$ 80,057<span></span>
</td>
<td class="nump">$ 69,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems', window );"><strong>Disaggregation Of Revenue By Geographical Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems', window );"><strong>Disaggregation Of Revenue By Geographical Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">81,392<span></span>
</td>
<td class="nump">78,744<span></span>
</td>
<td class="nump">68,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems', window );"><strong>Disaggregation Of Revenue By Geographical Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 1,261<span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisaggregationOfRevenueByGeographicalAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disaggregation of revenue by geographical area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisaggregationOfRevenueByGeographicalAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166151936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Summary of detailed information about personnel expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract', window );"><strong>Disclosure Of Personnel Expenses Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salaries and short-term employee benefits</a></td>
<td class="nump">$ 24,934<span></span>
</td>
<td class="nump">$ 22,049<span></span>
</td>
<td class="nump">$ 11,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Post-employment benefits</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">3,604<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TerminationBenefitsExpense', window );">Termination benefits</a></td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee benefits expense</a></td>
<td class="nump">$ 30,882<span></span>
</td>
<td class="nump">$ 27,565<span></span>
</td>
<td class="nump">$ 13,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TerminationBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 171<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_171&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TerminationBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of personnel expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849199287360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel expenses - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract', window );"><strong>Disclosure Of Personnel Expenses Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses', window );">Amount of charges related to severance and other expenses</a></td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of charges related to severance and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of personnel expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174144224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance income and finance costs - Summary of detailed information about finance income and cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th" colspan="2"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract', window );"><strong>Schedule Of Detail Information About Finance Income And Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Gain on repurchase of convertible unsecured senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue', window );">Net gain on financial instruments carried at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnLeaseTermination', window );">Gain on lease termination</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts', window );">Accretion expense and amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,098)<span></span>
</td>
<td class="num">(2,140)<span></span>
</td>
<td class="num">(2,358)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued', window );">Interest on convertible unsecured senior notes and on long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,263)<span></span>
</td>
<td class="num">(4,357)<span></span>
</td>
<td class="num">(3,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankAndSimilarCharges', window );">Bank charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign currency loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="num">(926)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnLoanFacilityModifications', window );">Loss on Loan Facility modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,540)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Write off of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(954)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinanceCostsAndGainsLossesOnForeignCurrency', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,056)<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
<td class="num">(6,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency', window );">Finance income cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,909)<span></span>
</td>
<td class="num">$ (6,886)<span></span>
</td>
<td class="num">$ (6,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankAndSimilarCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bank and similar charges recognised by the entity as an expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankAndSimilarCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion expense and amortization of deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinanceCostsAndGainsLossesOnForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance costs and gains losses on foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinanceCostsAndGainsLossesOnForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance income cost and gains losses on foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnLoanFacilityModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on loan facility modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnLoanFacilityModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on repurchase of convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gain loss on financial instruments carried at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of detail information about finance income and costs abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173827104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract', window );"><strong>Schedule Of Detailed Information About Bonds And Money Market Funds [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentDebtInstrumentsHeld', window );">Bonds</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 8,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GuaranteedInvestmentCertificates', window );">Guaranteed investment certificates</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="nump">$ 6,290<span></span>
</td>
<td class="nump">$ 9,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentDebtInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt instruments held by the entity that were issued by a government. [Refer: Debt instruments held; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentDebtInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GuaranteedInvestmentCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed investment certificates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GuaranteedInvestmentCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165974592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bonds and money market funds - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of detailed information about Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinancialAssetsAverageMaturityTerm', window );">Average maturity period</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of detailed information about Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinancialAssetsStatedInterestPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.85%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of detailed information about Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FinancialAssetsStatedInterestPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinancialAssetsAverageMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets average maturity term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinancialAssetsAverageMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FinancialAssetsStatedInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets, stated interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FinancialAssetsStatedInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173611712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables -Summary of detailed information about trade and other receivables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract', window );"><strong>Schedule of Detailed Information About Trade and Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">$ 12,798<span></span>
</td>
<td class="nump">$ 10,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Sales taxes receivable</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Total</a></td>
<td class="nump">$ 13,023<span></span>
</td>
<td class="nump">$ 12,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166064624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems', window );"><strong>Disclosure of Tax Credits and Grants Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss', window );">Tax credits and grants recognized in net loss</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceived', window );">Tax credits and grants received</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable', window );">Effect of change in exchange rate</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxCreditsAndGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxCreditsAndGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxCreditsAndGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits and grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxCreditsAndGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits and grants recognized in net profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165778320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=thtx_UnusedAndUnrecordedTaxCreditsMember', window );">Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">13,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFourMember', window );">Income tax expire 2024 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFiveMember', window );">Income tax expire 2025 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySixMember', window );">Income tax expire 2026 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySevenMember', window );">Income tax expire 2027 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">2,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyEightMember', window );">Income tax expire 2028 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyNineMember', window );">Income tax expire 2029 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyMember', window );">Income tax expire 2030 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyOneMember', window );">Income tax expire 2031 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyTwoMember', window );">Income tax expire 2032 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyThreeMember', window );">Income tax expire 2033 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyNineMember', window );">Income tax expire 2039 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyMember', window );">Income tax expire 2040 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyOneMember', window );">Income tax expire 2041 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyTwoMember', window );">Income tax expire 2042 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyThreeMember', window );">Income tax expire 2043 | Unused tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=thtx_UnusedAndUnrecordedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=thtx_UnusedAndUnrecordedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_IncomeTaxExpireTwoThousandFortyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168328976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of detailed information about inventories (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,262<span></span>
</td>
<td class="nump">$ 2,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in progress</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="nump">5,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">11,290<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Total Inventories</a></td>
<td class="nump">$ 6,066<span></span>
</td>
<td class="nump">$ 19,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165921440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Additional Information (Detail)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Cost of inventories recognised as expense during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory writedown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProvisionForFormulation', window );">Provision for formulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProvisionForTheInventoryInDevelopment', window );">Provision for the inventory in development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProvisionForTheExpiredRawMaterial', window );">Provision for the expired raw material</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProvisionForExcessStock', window );">Provision of inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=thtx_TaiMedBiologicsInc.Member', window );">TaiMed Biologics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InventoriesReturned', window );">Inventories returned</a></td>
<td class="nump">$ 3,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Reduction in accounts payable</a></td>
<td class="nump">$ 3,399<span></span>
</td>
<td class="nump">&#8364; 3,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LocationInIncomeStatementAxis=thtx_CostOfGoodsSoldMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory writedown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,540<span></span>
</td>
<td class="nump">$ 19,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InventoriesReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories returned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InventoriesReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProvisionForExcessStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for excess stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProvisionForExcessStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProvisionForFormulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for formulation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProvisionForFormulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProvisionForTheExpiredRawMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for the expired raw material.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProvisionForTheExpiredRawMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProvisionForTheInventoryInDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for the inventory in development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProvisionForTheInventoryInDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=thtx_TaiMedBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=thtx_TaiMedBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LocationInIncomeStatementAxis=thtx_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LocationInIncomeStatementAxis=thtx_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168705808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAbstract', window );"><strong>Current prepayments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,687<span></span>
</td>
<td class="nump">$ 6,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Deposits</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid Expenses and Deposits</a></td>
<td class="nump">$ 3,154<span></span>
</td>
<td class="nump">$ 7,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164666464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment - Summary of information about property plant equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">$ 1,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">2,340<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Beginning Balance</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Ending Balance</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Beginning Balance</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Ending Balance</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember', window );">Laboratory equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember', window );">Laboratory equipment | Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Beginning Balance</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Ending Balance</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment | Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Beginning Balance</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Ending Balance</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning Balance</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Beginning Balance</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Ending Balance</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation disposals property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation on property plant and equipment [abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NetCarryingAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>xxx_Net Carrying Amount Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NetCarryingAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PropertyPlantAndEquipmentAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proprety Plant And Equipment Accumulated Depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PropertyPlantAndEquipmentAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=thtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165980288">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets - Disclosure of right of use asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfRightOfUseAssetAbstract', window );"><strong>Disclosure of right of use Asset [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AmortizationOfRightOfUseAsset', window );">Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset', window );">Effect of change in exchange rates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TerminationOfRightOfUseAssets', window );">Termination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">New lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On March 1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a right-of-use asset and a lease liability of $326.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AmortizationOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AmortizationOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of right Of use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Through Net Exchange Differences of Right to use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TerminationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TerminationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164901984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible asset - Summary of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">$ 15,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">12,496<span></span>
</td>
<td class="nump">$ 15,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal</a></td>
<td class="num">(7,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">12,496<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">39,945<span></span>
</td>
<td class="nump">37,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal</a></td>
<td class="num">(7,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">32,333<span></span>
</td>
<td class="nump">39,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">32,333<span></span>
</td>
<td class="nump">39,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Commercialization rights- Trogarzo&#174; North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">14,804<span></span>
</td>
<td class="nump">11,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">14,804<span></span>
</td>
<td class="nump">14,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,804<span></span>
</td>
<td class="nump">14,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Commercialization rights- Trogarzo&#174; European Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">7,612<span></span>
</td>
<td class="nump">7,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal</a></td>
<td class="num">(7,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Commercialization rights &#8211; EGRIFTA SV&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Oncology Platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">24,936<span></span>
</td>
<td class="nump">15,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">9,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">19,837<span></span>
</td>
<td class="nump">24,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization | Commercialization rights- Trogarzo&#174; North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">4,354<span></span>
</td>
<td class="nump">3,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">4,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization | Commercialization rights- Trogarzo&#174; European Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">7,612<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal</a></td>
<td class="num">(7,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization | Commercialization rights &#8211; EGRIFTA SV&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">12,970<span></span>
</td>
<td class="nump">11,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="nump">12,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember', window );">Net Carrying Amount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">15,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">12,496<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">12,496<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember', window );">Net Carrying Amount [Member] | Commercialization rights- Trogarzo&#174; North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">10,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">9,008<span></span>
</td>
<td class="nump">10,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">9,008<span></span>
</td>
<td class="nump">10,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember', window );">Net Carrying Amount [Member] | Commercialization rights- Trogarzo&#174; European Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember', window );">Net Carrying Amount [Member] | Commercialization rights &#8211; EGRIFTA SV&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember', window );">Net Carrying Amount [Member] | Oncology Platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning Balance</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending Balance</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmountAbstract', window );"><strong>Net carrying amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 3,488<span></span>
</td>
<td class="nump">$ 3,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization disposals, intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Amortization Of Intangible Assets Other Than Goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NetCarryingAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>xxx_Net Carrying Amount Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NetCarryingAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsEgriftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsEgriftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_OncologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_OncologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=thtx_NetCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172511168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets - Summary of Commercial Milestone Payment (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAxis=thtx_MilestoneFourMember', window );">Upon first achieving annual net sales of US$ 200,000</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InitialMilestonePaymentsPayable', window );">Initial Milestone Payments Payable</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAxis=thtx_MilestoneFiveMember', window );">Upon first achieving annual net sales of US$ 500,000</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InitialMilestonePaymentsPayable', window );">Initial Milestone Payments Payable</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAxis=thtx_MilestoneSixMember', window );">Upon first achieving annual net sales of US$ 1,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InitialMilestonePaymentsPayable', window );">Initial Milestone Payments Payable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InitialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Milestone Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InitialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_MilestoneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_MilestoneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_MilestoneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_MilestoneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_MilestoneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_MilestoneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849157825984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Additional Information (Detail)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2017</div></th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortisation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,211<span></span>
</td>
<td class="nump">$ 3,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,057<span></span>
</td>
<td class="nump">69,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment', window );">Additions to intangibles Through cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoMember', window );">Trogarzo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember', window );">Katana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of intangible assets during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Business combination cash consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Business combination shares value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Business combination number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Business combination acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BusinessCombinationContingentConsiderationFairValue', window );">Business combination contingent consideration fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued and fully paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Business combination contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of intangible assets during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration', window );">Business combination adjustment to the purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities', window );">Subsidy or grants received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RegulatoryMilestonePaymentPayable', window );">Regulatory payable milestone related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Business Combination Adjustment To Consideration Installment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Business combination cash consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Business Combination Adjustment To Consideration Installment Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Business combination contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Royalty Related License Peptides | First Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Annual maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Royalty Related License Peptides | After Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Annual maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Development Milestone Phase One Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAmountPayable', window );">Milestone amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Development Milestone Phase Two Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAmountPayable', window );">Milestone amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Development Milestone Phase Three Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MilestoneAmountPayable', window );">Milestone amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Top of range | Net Sales Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RoyaltyFeesAsAPercentageOfRevenue', window );">Royalty fees in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Top of range | Royalty Revenue Sublicense Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RoyaltyFeesAsAPercentageOfRevenue', window );">Royalty fees in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Bottom of range | Net Sales Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RoyaltyFeesAsAPercentageOfRevenue', window );">Royalty fees in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember', window );">Katana Amendment Agreement | Bottom of range | Royalty Revenue Sublicense Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RoyaltyFeesAsAPercentageOfRevenue', window );">Royalty fees in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentOfUpfrontMilestones', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_FirstMilestoneInstallmentPaymentsPayable', window );">First milestone installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_SecondMilestoneInstallmentPaymentsPayable', window );">Second milestone installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AcquisitionCostsForIntangibleAssets', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DevelopmentMilestonePayableAnnualInstallment', window );">Milestone Payments annual installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment', window );">Additions to intangibles Through cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment', window );">Additions to intangibles Through share based payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments.', window );">Initial Milestone Payments Payable Aggregate Annual Installments.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LaunchMilestonePayable', window );">Launch milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Milestone One | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Commercialization rights- Trogarzo&#174; North American Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets', window );">Intangible Asset Purchase Consideration</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InitialMilestonePaymentsPayable', window );">Initial payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Commercialization rights- Trogarzo&#174; North American Territory | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember', window );">Taimed Agreement | Commercialization Rights Trogarzo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IntangibleAssetsAgreementTermOfContract', window );">Intangible Assets Agreement Term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_LicenseAgreementTransferPlusLPMember', window );">License Agreement Transfer Plus L P | Katana | Milestone Phase Two Live Demonstration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Business combination contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants, classified as investing activities. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AcquisitionCostsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition costs for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AcquisitionCostsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions other than through business combinations intangible assets other than goodwill cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions other than through business combinations intangible assets other than goodwill share based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BusinessCombinationContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BusinessCombinationContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination increase decrease in purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DevelopmentMilestonePayableAnnualInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payable annual installment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DevelopmentMilestonePayableAnnualInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FirstMilestoneInstallmentPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First milestone installment payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FirstMilestoneInstallmentPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InitialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Milestone Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InitialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial milestone payments payable aggregate annual installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IntangibleAssetsAgreementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Agreement Term Of Contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IntangibleAssetsAgreementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LaunchMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Launch milestone payable
..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LaunchMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone amount payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentOfUpfrontMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Upfront Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentOfUpfrontMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Purchase Price Consideration Of Intangible Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RegulatoryMilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory payable milestone related.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RegulatoryMilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RoyaltyFeesAsAPercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fees as a percentage of revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RoyaltyFeesAsAPercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_SecondMilestoneInstallmentPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second milestone installment payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_SecondMilestoneInstallmentPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=thtx_TrogarzoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=thtx_KatanaAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis=thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis=thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis=thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis=thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NatureOfFeesAxis=thtx_RoyaltyRelatedLicensePeptidesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NatureOfFeesAxis=thtx_RoyaltyRelatedLicensePeptidesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FeesPeriodAxis=thtx_FirstFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FeesPeriodAxis=thtx_FirstFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_FeesPeriodAxis=thtx_AfterFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_FeesPeriodAxis=thtx_AfterFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BasisOfRoyaltyPaymentAxis=thtx_NetSalesBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BasisOfRoyaltyPaymentAxis=thtx_NetSalesBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BasisOfRoyaltyPaymentAxis=thtx_RoyaltyRevenueSublicenseBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BasisOfRoyaltyPaymentAxis=thtx_RoyaltyRevenueSublicenseBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TypeOfArrangementsAxis=thtx_TaimedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=thtx_CommercializationRightsTrogarzoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TypeOfArrangementsAxis=thtx_LicenseAgreementTransferPlusLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TypeOfArrangementsAxis=thtx_LicenseAgreementTransferPlusLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MilestoneAxis=thtx_MilestonePhaseTwoLiveDemonstrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MilestoneAxis=thtx_MilestonePhaseTwoLiveDemonstrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173887360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other asset - Summary of detailed information about other asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ReconciliationOfChangesInOtherAssetsAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_OtherAssetsNonCurrentAtCost', window );">Ending balance</a></td>
<td class="nump">$ 19,530<span></span>
</td>
<td class="nump">$ 19,530<span></span>
</td>
<td class="nump">$ 19,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract', window );"><strong>Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets', window );">Beginning balance</a></td>
<td class="nump">17,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AmortizationOfOtherNonCurrentAssets', window );">Amortization</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets', window );">Ending balance</a></td>
<td class="nump">19,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NetCarryingAmount', window );">Net carrying amounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccumulatedAmortizationOnOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Amortization On Other Non Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccumulatedAmortizationOnOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AmortizationOfOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Other Non Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AmortizationOfOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_OtherAssetsNonCurrentAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets non current at cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_OtherAssetsNonCurrentAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ReconciliationOfChangesInOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ReconciliationOfChangesInOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172404304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other asset - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 29, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=thtx_DueWithOneYearMember', window );">Due with one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInformationAboutOtherAssetsLineItems', window );"><strong>Other asset [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ContractualObligations', window );">Contractual obligations</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=thtx_SeronoIncMember', window );">Serono Inc | 2013 Termination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInformationAboutOtherAssetsLineItems', window );"><strong>Other asset [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ContractualObligations', window );">Contractual obligations</a></td>
<td class="nump">28,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PerformanceObligationFinalSettlementAmount', window );">Performance obligation final settlement amount</a></td>
<td class="nump">23,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=thtx_SeronoIncMember', window );">Serono Inc | 2013 Termination agreement | Due with one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInformationAboutOtherAssetsLineItems', window );"><strong>Other asset [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ContractualObligations', window );">Contractual obligations</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=thtx_SeronoIncMember', window );">Serono Inc | 2013 Termination agreement | Due in next four to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInformationAboutOtherAssetsLineItems', window );"><strong>Other asset [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ContractualObligations', window );">Contractual obligations</a></td>
<td class="nump">$ 24,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureInformationAboutOtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Information About Other Assets [Line item].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureInformationAboutOtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PerformanceObligationFinalSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance obligation final settlement amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PerformanceObligationFinalSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_DueWithOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_DueWithOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=thtx_SeronoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=thtx_SeronoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TypeOfArrangementAxis=thtx_TwoThousandThirteenTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TypeOfArrangementAxis=thtx_TwoThousandThirteenTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=thtx_DueInNextFourToFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=thtx_DueInNextFourToFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173541552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities - Summary of 	accounts payable and accrued liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TradeAndOtherPayablesLineItems', window );"><strong>Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 6,990<span></span>
</td>
<td class="nump">$ 12,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">18,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Salaries and benefits due to key management personnel</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employee salaries and benefits payable</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liability related to deferred stock unit plan</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestPayable', window );">Accrued interest payable on convertible unsecured senior notes and Loan Facility</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">TaiMed milestone</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total</a></td>
<td class="nump">$ 28,471<span></span>
</td>
<td class="nump">$ 41,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest payable. [Refer: Interest payable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TradeAndOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TradeAndOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172337600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and other payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentForContingentLiabilities', window );">payment for Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentOfMilestones', window );">Payment of milestones</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EqualAnnualInstallments', window );">Equal annual installments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EqualAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equal annual installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EqualAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentForContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentForContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849155415392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Summary of provision (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Beginning Balance</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 4,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">18,456<span></span>
</td>
<td class="nump">14,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions used</a></td>
<td class="num">(16,536)<span></span>
</td>
<td class="num">(11,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Effect of change in exchange rate</a></td>
<td class="nump">166<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Ending Balance</a></td>
<td class="nump">9,603<span></span>
</td>
<td class="nump">7,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=thtx_ChargebacksAndRebatesMember', window );">Chargebacks and rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Beginning Balance</a></td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">15,407<span></span>
</td>
<td class="nump">12,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions used</a></td>
<td class="num">(14,506)<span></span>
</td>
<td class="num">(10,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Effect of change in exchange rate</a></td>
<td class="nump">168<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Ending Balance</a></td>
<td class="nump">7,101<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RefundsProvisionMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Beginning Balance</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions used</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Ending Balance</a></td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=thtx_OtherAdditionalProvisionMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions used</a></td>
<td class="num">(1,721)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Effect of change in exchange rate</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Ending Balance</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=thtx_ChargebacksAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=thtx_ChargebacksAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RefundsProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RefundsProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=thtx_OtherAdditionalProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=thtx_OtherAdditionalProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849157814896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Summary of provision (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">$ 18,456<span></span>
</td>
<td class="nump">$ 14,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SeveranceAndOtherExpensesMember', window );">Severance And Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions made</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SeveranceAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SeveranceAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=thtx_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849156897824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRateBasis', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">300 basis points<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmount', window );">Debt instrument collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from issuance of long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementAxis=thtx_FifthAmendmentMember', window );">Fifth Amendment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConsiderationPayable', window );">Consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentAmortizedValue', window );">Debt instrument amortized value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRateBasis', window );">Borrowings, interest rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementAxis=thtx_FifthAmendmentMember', window );">Fifth Amendment [member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember', window );">Cash, Cash Equivalents and Eligible Short-term Investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmount', window );">Debt instrument collateral amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember', window );">Cash, Cash Equivalents and Eligible Short-term Investments [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember', window );">Cash, Cash Equivalents and Eligible Short-term Investments [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained', window );">Debt instrument collateral amount if FDA approval not obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember', window );">Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from issuance of long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember', window );">Loan Facility [Member] | Secured Overnight Financing Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1LoanMember', window );">Loan Facility Tranche 1 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance', window );">Date of commencement of principal repayment in advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 27,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent', window );">Ceiling limit for prepayment of principal amount outstanding, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from issuance of long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche2LoanMember', window );">Loan Facility Tranche 2 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance', window );">Date of commencement of principal repayment in advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent', window );">Ceiling limit for prepayment of principal amount outstanding, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AmountReclassifiedFromDeferredFinancingCosts', window );">Amount reclassified from deferred financing costs.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from issuance of long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3LoanMember', window );">Loan Facility Tranche 3 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche4LoanMember', window );">Loan Facility Tranche 4 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1And2LoanMember', window );">Loan Facility Tranche 1 and 2 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Tranche 1 Loan and Tranche 2 Loan are repayable in equal monthly installments on an amortization schedule of 36 months starting in July 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BorrowingsInterestPeriod', window );">Borrowings interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3And4LoanMember', window );">Loan Facility Tranche 3 and 4 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DeferredFinanceCostsWriteOff', window );">Deferred Finance costs Write Off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AmountReclassifiedFromDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount reclassified from deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AmountReclassifiedFromDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BorrowingsInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings interest period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BorrowingsInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ceiling limit for prepayment of principal amount outstanding percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DateOfCommencementOfPrincipalRepaymentInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of commencement of principal repayment in advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DateOfCommencementOfPrincipalRepaymentInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DebtInstrumentAmortizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amortized value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DebtInstrumentAmortizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument if FDA approval not obtained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DeferredFinanceCostsWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred finance costs write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DeferredFinanceCostsWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line o cCredit facility maximum borrowing capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TypeOfArrangementAxis=thtx_FifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TypeOfArrangementAxis=thtx_FifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=thtx_SecuredOvernightFinancingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=thtx_SecuredOvernightFinancingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche4LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche4LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1And2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche1And2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3And4LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTranche3And4LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172410128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility - Summary of movement in the carrying value of the long term loan (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from Loan Facility on July&#160;27,&#160;2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProceedsFromConsiderationOfTheFifthAmendment', window );">Consideration for the Fifth Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,286)<span></span>
</td>
<td class="num">(7,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,688<span></span>
</td>
<td class="nump">50,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember', window );">Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from Loan Facility on July&#160;27,&#160;2022</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsRecognisedAsExpense', window );">Transaction costs</a></td>
<td class="num">(2,285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BorrowingsAccretionExpense', window );">Accretion expense</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="nump">$ 37,894<span></span>
</td>
<td class="nump">57,974<span></span>
</td>
<td class="nump">$ 57,974<span></span>
</td>
<td class="nump">$ 37,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTrancheTwoLoanMember', window );">Loan Facility Tranche 2 Loan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceeds from Loan Facility on July&#160;27,&#160;2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsRecognisedAsExpense', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=thtx_MarathonWarrantsMember', window );">Marathon Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsRecognisedAsExpense', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsRecognisedAsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are recognised as an expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsRecognisedAsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current loans received and the current portion of non-current loans received. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current loans received. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BorrowingsAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings accretion expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BorrowingsAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProceedsFromConsiderationOfTheFifthAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from consideration of the fifth amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProceedsFromConsiderationOfTheFifthAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTrancheTwoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_LoanFacilityTrancheTwoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=thtx_MarathonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=thtx_MarathonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174170528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible unsecured senior notes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesLineItems', window );"><strong>Convertible unsecured senior notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Increase Decrease Through Conversion Of Convertible Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember', window );">Convertible Unsecured Senior Notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesLineItems', window );"><strong>Convertible unsecured senior notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleInstrumentsNumberOfSharesIssued', window );">Convertible instruments number of shares issued</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Increase Decrease Through Conversion Of Convertible Instruments</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of convertible unsecured senior notes</a></td>
<td class="nump">$ 27,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleInstrumentsNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible instruments number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleInstrumentsNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleUnsecuredSeniorNotesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleUnsecuredSeniorNotesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166370032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ChangesFromFinancingCashFlowsAbstract', window );"><strong>Changes from financing cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Cash paid on repurchase</a></td>
<td class="num">$ (27,452)<span></span>
</td>
<td class="num">$ (28,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Transaction costs incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract', window );"><strong>Other changes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Gain on repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=thtx_LiabilityComponentMember', window );">Liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesLineItems', window );"><strong>Convertible unsecured senior notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued', window );">Convertible unsecured senior notes, Beginning balance</a></td>
<td class="nump">26,895<span></span>
</td>
<td class="nump">54,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccretionExpense', window );">Accretion expense</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ChangesFromFinancingCashFlowsAbstract', window );"><strong>Changes from financing cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Cash paid on repurchase</a></td>
<td class="num">(27,452)<span></span>
</td>
<td class="num">(28,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Transaction costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract', window );"><strong>Other changes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes', window );">Gain on repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued', window );">Convertible unsecured senior notes, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,895<span></span>
</td>
<td class="nump">$ 54,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ChangesFromFinancingCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes from financing cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ChangesFromFinancingCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleUnsecuredSeniorNotesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleUnsecuredSeniorNotesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on repurchase of convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for costs related to repurchase of convertible unsecured senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=thtx_LiabilityComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=thtx_LiabilityComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172596928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Leases liabilities - Summary of lease liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfLeaseLiabilitiesAbstract', window );"><strong>Disclosure of Lease Liabilities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AccretionExpenseOfLeasesLiabilities', window );">Accretion expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates', window );">Effect of change in exchange rates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions', window );">Termination (a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">New lease (b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On February 17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its right-of-use assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. The gain is presented in finance costs (Note 5)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On March 1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a right-of-use asset and a lease liability of $326.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) arising from sale and leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AccretionExpenseOfLeasesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion expense of Leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AccretionExpenseOfLeasesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases liabilities Effect of change in exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173927264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfLeaseLiabilitiesAbstract', window );"><strong>Disclosure of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability', window );">Termination Of Leases Operating Lease Right Of Use Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets', window );">Termination Of Leases Operating Lease Right Of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnLeaseTermination', window );">Gain on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right Of Use Asset Obtained In Exchange For Operating Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of leases operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of leases operating lease right of use liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849160896208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Additional information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 19, 2021</div></th>
<th class="th"><div>Oct. 04, 2018</div></th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>yr </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>yr </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 3,394<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,927<span></span>
</td>
<td class="nump">338,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">3,604<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Deferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockAppreciationRightsContractualLife', window );">SAR Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,957)<span></span>
</td>
<td class="num">$ (47,237)<span></span>
</td>
<td class="num">$ (31,725)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effect of share options number of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,053,928<span></span>
</td>
<td class="nump">1,286,695<span></span>
</td>
<td class="nump">817,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares', window );">Effect of share options number of Warrants shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,130,550<span></span>
</td>
<td class="nump">8,130,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IssuedCapitalAxis=thtx_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CommonStockConversionBasis', window );">Common stock, Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one half of one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,130,550<span></span>
</td>
<td class="nump">8,130,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of each warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued and fully paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PercentageOfOwnershipHoldingCommonShares', window );">Percentage Of Ownership Holding Common Shares</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PercentageOfOwnershipOfTheInvestor', window );">Percentage Of Ownership Of The Investor</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantOrRightExpirationDate', window );">Class Of Warrant Or Right Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised', window );">Class Of Warrant Or Right Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">233,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IssuedCapitalAxis=thtx_OverallotmentMember', window );">Over-allotment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued and fully paid | shares</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_InvesteeAxis=thtx_InvestmentQuebecMember', window );">Investment Quebec [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod', window );">Class of number warrants or rights issued during the period | shares</a></td>
<td class="nump">9,118,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="nump">$ 2,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantsOrRightsAxis=thtx_NonVotingSubscriptionReceiptsMember', window );">Non-voting Subscription Receipts [Member] | Investment Quebec [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod', window );">Class of number warrants or rights issued during the period | shares</a></td>
<td class="nump">3,381,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants', window );">Proceeds from the issuance of common shares and warrants</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantsOrRightsAxis=thtx_MarathonWarrantsMember', window );">Marathon Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants', window );">Potential share issue in the future on exercise of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember', window );">Katana [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued and fully paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member] | Marathon Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category [member] | Marathon Warrants [member] | Affiliates of Marathon Asset Management [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod', window );">Class of number warrants or rights issued during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AgreementAxis=thtx_FifthAmendmentOfTheLoanFacilityMember', window );">Fifth Amendment of the Loan facility [member] | Financial liabilities at fair value through profit or loss, category [member] | Marathon Warrants [member] | Affiliates of Marathon Asset Management [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ClassOfWarrantsOrRightsOutstanding', window );">Class of warrants or rights outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_GainLossOnDebtModification', window );">Gain (loss) on debt modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseInTheFairValueOfLiabilityRecorded', window );">Increase in the fair value of liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently', window );">Gain (loss) due to changes in fair value of financial liabilities at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TransactionCostsOfWarrantsIssued', window );">Transaction cost of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TransactionCostsAllocatedToTheLoanFacility', window );">Transaction costs allocated to the loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DeferredFinancingCostsOnTheLoanFacility', window );">Deferred financing costs on the loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProgramNameAxis=thtx_AtmProgramMember', window );">ATM program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DeferredFinancingCostsWrittenDown', window );">Deferred financing costs written down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_SaleOfStockConsiderationReceivedOnTransaction', window );">Potential aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding', window );">Stock issuable as a percentage of total shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effect of share options number of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=thtx_DeferredStockUnitsMember', window );">Deferred Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Deferred stock units outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,878<span></span>
</td>
<td class="nump">67,536<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Deferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=thtx_CashSettledForwardContractsMember', window );">Cash Settled Forward Contracts [Member] | Deferred Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(492)<span></span>
</td>
<td class="num">$ (217)<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NumberOfCashSettledForwardStockContractsOutstanding', window );">Shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,535<span></span>
</td>
<td class="nump">67,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging', window );">Fair value of cash settled forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PlanAxis=thtx_TwoThousandAndSixteenShareholdersPlanMember', window );">Two Thousand And Sixteen Shareholders Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions', window );">Shareholders rights covenants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> The rights issued under the Rights Plan are initially attached to and traded with the common shares, and no separate certificate is issued unless a triggering event occurs. The rights become exercisable only when an acquiring person, including any party related to it, acquires or attempts to acquire 20% or more of the outstanding common shares without complying with the &#8220;Permitted Bid&#8221; provisions of the Rights Plan or without approval of the Board of Directors. Subject to the terms and conditions set out in the Rights Plan, each right (other than those held by the acquiring person) will permit the holder to purchase for the exercise price that number of common shares determined as follows: a value of twice the exercise price divided by the &#8220;Market Price&#8221; (defined under the Rights Plan as being the average weighted trading price per common share for the 20 consecutive&#160;trading days through and including the trading day immediately preceding the relevant date) on the common share acquisition date (defined as &#8220;Stock Acquisition Date&#8221; under the Rights Plan). The exercise price under the Rights Plan has been set to three (3) times the Market Price.  Under the Rights Plan, a Permitted Bid is a bid made to all holders of common shares and which is open for acceptance for no less than 105 days. If, at the end of 105 days, more than 50% of the outstanding common shares, other than those owned by the offeror and certain related parties, have been tendered, the offeror may take up and pay for the common shares. If more than 50% of the outstanding common shares, other than those owed by the offeror and certain related parties, have been tendered within the above mentioned 105 days period, the offeror must make a public announcement of that fact and the bid must remain open for an additional ten business days from the date of the announcement. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PlanAxis=thtx_TwoThousandAndSixteenShareholdersPlanMember', window );">Two Thousand And Sixteen Shareholders Plan [Member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts', window );">Price per share for the settlement of cash-settled forward stock contracts | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.47<span></span>
</td>
<td class="nump">$ 19.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PlanAxis=thtx_StockOptionPlanTwoThousandAndNineteenMember', window );">Stock Option Plan Two Thousand And Nineteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,237<span></span>
</td>
<td class="nump">$ 3,860<span></span>
</td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Exercise period of options | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Period of vesting of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Generally, the Options vest on the grant date or over a period of up to three years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares', window );">Remaining options available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,762,675<span></span>
</td>
<td class="nump">1,091,358<span></span>
</td>
<td class="nump">1,062,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PlanAxis=thtx_StockAppreciationRightsMember', window );">Stock Appreciation Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Exercise period of options | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TypeOfArrangementsAxis=thtx_FifthAmendmentMember', window );">Fifth Amendment [member] | Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in profit or loss on financial liabilities at fair value through profit or loss that were designated as such upon initial recognition or subsequently. [Refer: Gains (losses) on financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of number warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, Outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantsOrRightsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantsOrRightsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, Conversion basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DeferredFinancingCostsOnTheLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs on the loan facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DeferredFinancingCostsOnTheLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DeferredFinancingCostsWrittenDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs written down.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DeferredFinancingCostsWrittenDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial assets at fair value not designated as hedging.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of covenants under shareholder rights on bidding options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of share options on number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfShareOptionsOnNumberOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of share options on number of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfShareOptionsOnNumberOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_GainLossOnDebtModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on debt modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_GainLossOnDebtModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseInTheFairValueOfLiabilityRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in the fair value of liability recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseInTheFairValueOfLiabilityRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NumberOfCashSettledForwardStockContractsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cash settled forward stock contracts outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NumberOfCashSettledForwardStockContractsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PercentageOfOwnershipHoldingCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership holding common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PercentageOfOwnershipHoldingCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PercentageOfOwnershipOfTheInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership of the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PercentageOfOwnershipOfTheInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential share issue in the future on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share for the settlement of cash-settled forward stock contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of common shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining shares reserved for issue under options and contract for sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received on transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockAppreciationRightsContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock appreciation rights contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockAppreciationRightsContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuable as a percentage of total shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TransactionCostsAllocatedToTheLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to the loan facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TransactionCostsAllocatedToTheLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TransactionCostsOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TransactionCostsOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IssuedCapitalAxis=thtx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IssuedCapitalAxis=thtx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IssuedCapitalAxis=thtx_OverallotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IssuedCapitalAxis=thtx_OverallotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InvesteeAxis=thtx_InvestmentQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InvesteeAxis=thtx_InvestmentQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IssuedCapitalAxis=thtx_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IssuedCapitalAxis=thtx_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantsOrRightsAxis=thtx_NonVotingSubscriptionReceiptsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantsOrRightsAxis=thtx_NonVotingSubscriptionReceiptsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantsOrRightsAxis=thtx_MarathonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantsOrRightsAxis=thtx_MarathonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=thtx_KatanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_InvesteeAxis=thtx_AffiliatesOfMarathonAssetManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_InvesteeAxis=thtx_AffiliatesOfMarathonAssetManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AgreementAxis=thtx_FifthAmendmentOfTheLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AgreementAxis=thtx_FifthAmendmentOfTheLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProgramNameAxis=thtx_AtmProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProgramNameAxis=thtx_AtmProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=thtx_DeferredStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=thtx_DeferredStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=thtx_CashSettledForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=thtx_CashSettledForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PlanAxis=thtx_TwoThousandAndSixteenShareholdersPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PlanAxis=thtx_TwoThousandAndSixteenShareholdersPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PlanAxis=thtx_StockOptionPlanTwoThousandAndNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PlanAxis=thtx_StockOptionPlanTwoThousandAndNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PlanAxis=thtx_StockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PlanAxis=thtx_StockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TypeOfArrangementsAxis=thtx_FifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TypeOfArrangementsAxis=thtx_FifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172267456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail) - Financial liabilities at fair value through profit or loss, category [member] - Marathon Warrants [member]<br></strong></div></th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>yr</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>yr</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free&#160;interest rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems', window );"><strong>Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Measurement&#160;date</a></td>
<td class="nump">0.04326<span></span>
</td>
<td class="nump">0.0392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Expected volatility [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems', window );"><strong>Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Measurement&#160;date</a></td>
<td class="nump">0.88568<span></span>
</td>
<td class="nump">0.61985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=thtx_AverageOptionLifeMember', window );">Average option life in years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems', window );"><strong>Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Measurement&#160;date</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=thtx_SharePriceMember', window );">Share price [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems', window );"><strong>Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Measurement&#160;date</a></td>
<td class="nump">1.63<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=thtx_ExercisePriceToAcquireOneCommonShareMember', window );">Exercise price to acquire one common share with four Marathon Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems', window );"><strong>Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Measurement&#160;date</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ClassOfWarrantsOrRightsAxis=thtx_MarathonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ClassOfWarrantsOrRightsAxis=thtx_MarathonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=thtx_AverageOptionLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=thtx_AverageOptionLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=thtx_SharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=thtx_SharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=thtx_ExercisePriceToAcquireOneCommonShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=thtx_ExercisePriceToAcquireOneCommonShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168432608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail) - Stock Appreciation Rights [Member]<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems', window );"><strong>Disclosure Of The Model Used To Determine Fair Value Of Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">89.51%<span></span>
</td>
<td class="nump">89.51%<span></span>
</td>
<td class="nump">58.40%<span></span>
</td>
<td class="nump">58.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Average option life in years</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Grant-date share price | (per share)</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
<td class="nump">$ 11.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Option exercise price | (per share)</a></td>
<td class="nump">$ 16.99<span></span>
</td>
<td class="nump">$ 23.07<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="nump">$ 23.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of The Model Used To Determine Fair Value Of Options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PlanAxis=thtx_StockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PlanAxis=thtx_StockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164548624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares </div>
<div>$ / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares </div>
<div>$ / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options beginning balance</a></td>
<td class="nump">1,180,052<span></span>
</td>
<td class="nump">1,180,052<span></span>
</td>
<td class="nump">797,583<span></span>
</td>
<td class="nump">797,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options, granted</a></td>
<td class="nump">792,193<span></span>
</td>
<td class="nump">792,193<span></span>
</td>
<td class="nump">547,847<span></span>
</td>
<td class="nump">547,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement', window );">Number of options,Forfeited&#160;and expired &#8211; CAD</a></td>
<td class="num">(197,686)<span></span>
</td>
<td class="num">(197,686)<span></span>
</td>
<td class="num">(144,213)<span></span>
</td>
<td class="num">(144,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,165)<span></span>
</td>
<td class="num">(21,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options ending balance</a></td>
<td class="nump">1,774,559<span></span>
</td>
<td class="nump">1,774,559<span></span>
</td>
<td class="nump">1,180,052<span></span>
</td>
<td class="nump">1,180,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable outstanding</a></td>
<td class="nump">926,539<span></span>
</td>
<td class="nump">926,539<span></span>
</td>
<td class="nump">554,354<span></span>
</td>
<td class="nump">554,354<span></span>
</td>
<td class="nump">926,539<span></span>
</td>
<td class="nump">554,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average beginning balance | (per share)</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 15.32<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average, granted | (per share)</a></td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">16.68<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement', window );">Weighted average,Forfeited and expired | (per share)</a></td>
<td class="nump">12.34<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">13.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average, exercised | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average options exercisable | (per share)</a></td>
<td class="nump">15.19<span></span>
</td>
<td class="nump">$ 15.19<span></span>
</td>
<td class="nump">16.32<span></span>
</td>
<td class="nump">$ 16.32<span></span>
</td>
<td class="nump">$ 11.19<span></span>
</td>
<td class="nump">$ 12.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average ending balance | (per share)</a></td>
<td class="nump">$ 11.51<span></span>
</td>
<td class="nump">$ 8.48<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=country_US', window );">US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options beginning balance</a></td>
<td class="nump">106,643<span></span>
</td>
<td class="nump">106,643<span></span>
</td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">20,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options, granted</a></td>
<td class="nump">203,935<span></span>
</td>
<td class="nump">203,935<span></span>
</td>
<td class="nump">96,668<span></span>
</td>
<td class="nump">96,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options, Forfeited &#8211; USD</a></td>
<td class="num">(31,209)<span></span>
</td>
<td class="num">(31,209)<span></span>
</td>
<td class="num">(10,208)<span></span>
</td>
<td class="num">(10,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options ending balance</a></td>
<td class="nump">279,369<span></span>
</td>
<td class="nump">279,369<span></span>
</td>
<td class="nump">106,643<span></span>
</td>
<td class="nump">106,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable outstanding</a></td>
<td class="nump">65,692<span></span>
</td>
<td class="nump">65,692<span></span>
</td>
<td class="nump">7,769<span></span>
</td>
<td class="nump">7,769<span></span>
</td>
<td class="nump">65,692<span></span>
</td>
<td class="nump">7,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average beginning balance | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average, Forfeited | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average options exercisable | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="nump">$ 11.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average ending balance | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Forfeited and Expired In Share based Payment Arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Options Forfeited and Expired In Share based Payment Arrangement .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165890208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail) - 12 months ended Nov. 30, 2022<br></strong></div></th>
<th class="th"><div>$ / shares</div></th>
<th class="th"><div>$ / shares</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price of options excercised on the exercise date | (per share)</a></td>
<td class="nump">$ 11.12<span></span>
</td>
<td class="nump">$ 8.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164195456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">279,369<span></span>
</td>
<td class="nump">279,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">1,774,559<span></span>
</td>
<td class="nump">1,774,559<span></span>
</td>
<td class="nump">1,180,052<span></span>
</td>
<td class="nump">1,180,052<span></span>
</td>
<td class="nump">797,583<span></span>
</td>
<td class="nump">797,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 11.51<span></span>
</td>
<td class="nump">$ 8.48<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 15.32<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">179,185<span></span>
</td>
<td class="nump">179,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">57,500<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | Top of range [member] | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">4.76<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | Bottom of range [member] | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember', window );">Exercise Price 1 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">100,184<span></span>
</td>
<td class="nump">100,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">8 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">707,695<span></span>
</td>
<td class="nump">707,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | Top of range [member] | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | Bottom of range [member] | US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember', window );">Exercise Price 2 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceThreeMember', window );">Exercise Price 3 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">308,196<span></span>
</td>
<td class="nump">308,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 8.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceThreeMember', window );">Exercise Price 3 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceThreeMember', window );">Exercise Price 3 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFourMember', window );">Exercise Price 4 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">621,167<span></span>
</td>
<td class="nump">621,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 16.85<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFourMember', window );">Exercise Price 4 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFourMember', window );">Exercise Price 4 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 15.01<span></span>
</td>
<td class="nump">$ 11.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFiveMember', window );">Exercise Price 5 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">51,575<span></span>
</td>
<td class="nump">51,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 33.27<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFiveMember', window );">Exercise Price 5 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">26.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFiveMember', window );">Exercise Price 5 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 24.01<span></span>
</td>
<td class="nump">$ 17.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceSixMember', window );">Exercise Price 6 | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options outstanding</a></td>
<td class="nump">28,426<span></span>
</td>
<td class="nump">28,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">4 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 38.24<span></span>
</td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceSixMember', window );">Exercise Price 6 | Top of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">29.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceSixMember', window );">Exercise Price 6 | Bottom of range [member] | CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 36.01<span></span>
</td>
<td class="nump">$ 26.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=thtx_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165532080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Average option life in years | yr</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Grant-date share price | $ / shares</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Option exercise price | $ / shares</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.33%<span></span>
</td>
<td class="nump">3.33%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">64.30%<span></span>
</td>
<td class="nump">64.30%<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Average option life in years | yr</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Grant-date share price | (per share)</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 16.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Option exercise price | (per share)</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 16.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166803616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of Options granted</a></td>
<td class="nump">203,935<span></span>
</td>
<td class="nump">96,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average grant date fair value | $</a></td>
<td class="nump">$ 2,720<span></span>
</td>
<td class="nump">$ 8,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of Options granted</a></td>
<td class="nump">792,193<span></span>
</td>
<td class="nump">547,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">$ 8,640<span></span>
</td>
<td class="nump">$ 3,760<span></span>
</td>
<td class="nump">$ 11,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849157731392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Issued common shares as at December 1</a></td>
<td class="nump">24,201,582<span></span>
</td>
<td class="nump">23,780,417<span></span>
</td>
<td class="nump">19,253,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effect of share issue</a></td>
<td class="nump">2,053,928<span></span>
</td>
<td class="nump">1,286,695<span></span>
</td>
<td class="nump">817,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of common shares, basic&#160;and&#160;diluted</a></td>
<td class="nump">26,332,429<span></span>
</td>
<td class="nump">23,813,344<span></span>
</td>
<td class="nump">23,087,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ProgramNameAxis=thtx_AtmProgramMember', window );">ATM program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effect of share issue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ShareOptionMember', window );">Share options [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfShareOptionsExercised', window );">Effect of share options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">93,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_PublicIssueOfSharesMember', window );">public issue common shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfIssueCommonShares', window );">Effect of issue common shares</a></td>
<td class="nump">1,843,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,704,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_BrokersWarrantsMember', window );">Brokers warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfBrokerWarrantsExercised', window );">Effect of broker warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_SubscriptionReceiptsIssueMember', window );">Subscription Receipts Issue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_EffectOfSubscriptionReceiptsIssue', window );">Effect of subscription receipts issue</a></td>
<td class="nump">287,223<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember', window );">Convertible Unsecured Senior Notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares', window );">Impact on conversion of convertible unsecured senior notes</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfBrokerWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of broker warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfBrokerWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfIssueCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of issue common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfIssueCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfShareOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of share options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfShareOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of share options on number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_EffectOfSubscriptionReceiptsIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of subscription receipts issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_EffectOfSubscriptionReceiptsIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ProgramNameAxis=thtx_AtmProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ProgramNameAxis=thtx_AtmProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ShareOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ShareOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_PublicIssueOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=thtx_PublicIssueOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_BrokersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=thtx_BrokersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_SubscriptionReceiptsIssueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=thtx_SubscriptionReceiptsIssueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=thtx_ConvertibleUnsecuredSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172607440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember', window );">Unrealized losses on FVOCI financial assets, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember', window );">Cumulative exchange difference on translation of foreign operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164791792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of components of the current and deferred tax expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (recovery)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences', window );">Origination and reversal of temporary differences</a></td>
<td class="num">(5,972)<span></span>
</td>
<td class="num">(11,705)<span></span>
</td>
<td class="num">(7,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences', window );">Change in unrecognized deductible temporary differences</a></td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">11,705<span></span>
</td>
<td class="nump">7,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Total deferred tax expense (recovery)</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total current and deferred tax expense</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unrecognized deductable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849174117072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of reconciliation between effective and applicable tax (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Income taxes at domestic tax statutory rate</a></td>
<td class="num">$ (6,237)<span></span>
</td>
<td class="num">$ (12,400)<span></span>
</td>
<td class="num">$ (8,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences', window );">Change in unrecognized deductible temporary differences</a></td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">11,705<span></span>
</td>
<td class="nump">7,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of differences in statutory tax rates</a></td>
<td class="num">(130)<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible&#160;expenses and other</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total current and deferred tax expense</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unrecognized deductible temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173110048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems', window );"><strong>Disclosure of Detailed Information About Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Effective applicable income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems', window );"><strong>Disclosure of Detailed Information About Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset recognised</a></td>
<td class="nump">$ 8,816<span></span>
</td>
<td class="nump">$ 8,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Detailed Information About Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165829024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncomeTaxJurisdictionAxis=thtx_FederalMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation', window );">Research and development expenses, without&#160;time&#160;limitation</a></td>
<td class="nump">$ 87,151<span></span>
</td>
<td class="nump">$ 86,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue', window );">Excess of tax value of property and equipment over carrying value</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue', window );">Excess of tax value of intellectual property and patent fees over carrying value</a></td>
<td class="nump">10,660<span></span>
</td>
<td class="nump">10,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AvailableDeductionsAndOthers', window );">Available deductions and other</a></td>
<td class="nump">73,522<span></span>
</td>
<td class="nump">69,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncomeTaxJurisdictionAxis=thtx_ProvincialMember', window );">Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation', window );">Research and development expenses, without&#160;time&#160;limitation</a></td>
<td class="nump">105,549<span></span>
</td>
<td class="nump">105,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue', window );">Excess of tax value of property and equipment over carrying value</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue', window );">Excess of tax value of intellectual property and patent fees over carrying value</a></td>
<td class="nump">10,656<span></span>
</td>
<td class="nump">10,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AvailableDeductionsAndOthers', window );">Available deductions and other</a></td>
<td class="nump">32,536<span></span>
</td>
<td class="nump">28,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentySevenMember', window );">2027 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">5,512<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentySevenMember', window );">2027 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">5,504<span></span>
</td>
<td class="nump">5,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyEightMember', window );">2028 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">33,761<span></span>
</td>
<td class="nump">34,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyEightMember', window );">2028 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">16,258<span></span>
</td>
<td class="nump">16,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyNineMember', window );">2029 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">14,345<span></span>
</td>
<td class="nump">14,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyNineMember', window );">2029 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">12,124<span></span>
</td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyMember', window );">2030 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">8,423<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyMember', window );">2030 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">8,420<span></span>
</td>
<td class="nump">8,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyOneMember', window );">2031 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">17,346<span></span>
</td>
<td class="nump">17,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyOneMember', window );">2031 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">15,397<span></span>
</td>
<td class="nump">15,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyTwoMember', window );">2032 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">11,752<span></span>
</td>
<td class="nump">11,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyTwoMember', window );">2032 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">10,791<span></span>
</td>
<td class="nump">10,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyThreeMember', window );">2033 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">8,444<span></span>
</td>
<td class="nump">8,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyThreeMember', window );">2033 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">8,365<span></span>
</td>
<td class="nump">8,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyFourMember', window );">2034 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="nump">7,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyFourMember', window );">2034 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">7,665<span></span>
</td>
<td class="nump">7,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtySevenMember', window );">2037 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">6,901<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtySevenMember', window );">2037 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">6,818<span></span>
</td>
<td class="nump">6,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyEightMember', window );">2038 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyEightMember', window );">2038 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyNineMember', window );">2039 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyNineMember', window );">2039 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyMember', window );">2040 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">7,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyMember', window );">2040 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">7,218<span></span>
</td>
<td class="nump">7,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyOneMember', window );">2041 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">19,152<span></span>
</td>
<td class="nump">19,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyOneMember', window );">2041 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">19,078<span></span>
</td>
<td class="nump">19,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyTwoMember', window );">2042 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">29,042<span></span>
</td>
<td class="nump">31,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyTwoMember', window );">2042 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">28,885<span></span>
</td>
<td class="nump">31,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyThreeMember', window );">2043 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">19,298<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyThreeMember', window );">2043 | Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Losses carried forward</a></td>
<td class="nump">$ 19,284<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AvailableDeductionsAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available deductions and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AvailableDeductionsAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess of tax value of intellectual, Property,and fees over carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess of tax value of property,plant and equipment over carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unutilised Research And Development Expenses With No Time Limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncomeTaxJurisdictionAxis=thtx_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncomeTaxJurisdictionAxis=thtx_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncomeTaxJurisdictionAxis=thtx_ProvincialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncomeTaxJurisdictionAxis=thtx_ProvincialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxBenefitCarryForwardYearAxis=thtx_YearTwoThousandAndFortyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165478352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_SupplementalCashFlowDisclosuresAbstract', window );"><strong>Supplemental cash flow disclosures [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities', window );">Deferred financing costs&#160;included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities', window );">Additions to property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities', window );">Acquisition of derivative financial assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities', window );">Additions to intangible assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit', window );">Reclassification of other Deferred financing costs to deficit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities', window );">Share issue cost included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition of derivative financial assets included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions To intangibles included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to property and equipment included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs&#160;included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of other deferred financing costs to deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share issue cost included in accounts payable and accrued liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_SupplementalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_SupplementalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165782080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">$ 12,798<span></span>
</td>
<td class="nump">$ 10,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CurrentTradeReceivablesAgingPeriod', window );">Current trade receivables aging period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BadDebtExpenses', window );">Bad debt expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="nump">9,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_VariableInterestbearingCashAndMoneyMarketFunds', window );">Cash and money market funds</a></td>
<td class="nump">20,231<span></span>
</td>
<td class="nump">23,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained', window );">Minimum cash cash equivalents and short term investments to be maintained</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained', window );">Minimum cash cash equivalents and short term investments to be maintained</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Interest rate, measurement | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Positive impact of market interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows', window );">Increase (decrease) in cash flows</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets', window );">Increase (decrease) in profit or loss</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Interest rate, measurement | Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Positive impact of market interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets', window );">Increase (decrease) in accumulated other comprehensive</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Increase (decrease) in fair value of assets</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets', window );">Negative impact of market interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Interest rate, measurement | Cash and market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets', window );">Positive impact of market interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows', window );">Increase (decrease) in cash flows</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets', window );">Increase (decrease) in profit or loss</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets', window );">Negative impact of market interest rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PositivePercentageImpactOnForeignCurrencyExposures', window );">Positive percentage impact on foreign currency exposures</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NegativePercentageImpactOnForeignCurrencyExposures', window );">Negative percentage impact on foreign currency exposures</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of assets, recognised in profit or loss after tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BadDebtExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BadDebtExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CurrentTradeReceivablesAgingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current trade receivables aging period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CurrentTradeReceivablesAgingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in cash flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in accumulated other comprehensive income after tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash cash equivalents and short term investments to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NegativePercentageImpactOnForeignCurrencyExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Negative percentage impact on foreign currency exposures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NegativePercentageImpactOnForeignCurrencyExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PositivePercentageImpactOnForeignCurrencyExposures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Positive percentage impact on foreign currency exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PositivePercentageImpactOnForeignCurrencyExposures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_VariableInterestbearingCashAndMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest-Bearing Cash And Money Market Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_VariableInterestbearingCashAndMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=thtx_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=thtx_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=thtx_VariableInterestRateCashAndMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=thtx_VariableInterestRateCashAndMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168403808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of the contractual maturities of financial liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 28,471<span></span>
</td>
<td class="nump">$ 41,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermLoanUndiscountedCashFlows', window );">Facility loan / Term loan, including interest</a></td>
<td class="nump">80,141<span></span>
</td>
<td class="nump">57,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows', window );">Convertible unsecured senior notes including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LeaseLiabilitiesUndiscountedCashFlows', window );">Lease Liabilities</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities</a></td>
<td class="nump">109,720<span></span>
</td>
<td class="nump">130,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities carrying amount</a></td>
<td class="nump">28,471<span></span>
</td>
<td class="nump">41,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilitites</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities carrying amount</a></td>
<td class="nump">28,471<span></span>
</td>
<td class="nump">41,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CurrentPositionOfTermLoanIncludingInterest', window );">Term loan, including interest, Carrying amount</a></td>
<td class="nump">57,974<span></span>
</td>
<td class="nump">37,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued', window );">Convertible unsecured senior notes including interest carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilitites</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_NonderivativeFinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">87,439<span></span>
</td>
<td class="nump">107,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">28,471<span></span>
</td>
<td class="nump">41,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermLoanUndiscountedCashFlows', window );">Facility loan / Term loan, including interest</a></td>
<td class="nump">17,416<span></span>
</td>
<td class="nump">5,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows', window );">Convertible unsecured senior notes including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LeaseLiabilitiesUndiscountedCashFlows', window );">Lease Liabilities</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities</a></td>
<td class="nump">46,374<span></span>
</td>
<td class="nump">76,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">From 1 to 2 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermLoanUndiscountedCashFlows', window );">Facility loan / Term loan, including interest</a></td>
<td class="nump">50,348<span></span>
</td>
<td class="nump">28,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows', window );">Convertible unsecured senior notes including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LeaseLiabilitiesUndiscountedCashFlows', window );">Lease Liabilities</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities</a></td>
<td class="nump">50,864<span></span>
</td>
<td class="nump">29,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsMember', window );">More than 3 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermLoanUndiscountedCashFlows', window );">Facility loan / Term loan, including interest</a></td>
<td class="nump">12,377<span></span>
</td>
<td class="nump">23,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows', window );">Convertible unsecured senior notes including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LeaseLiabilitiesUndiscountedCashFlows', window );">Lease Liabilities</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Financial liabilities</a></td>
<td class="nump">$ 12,482<span></span>
</td>
<td class="nump">$ 24,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible unsecured senior notes including interest undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CurrentPositionOfTermLoanIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current position of term loan, including interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CurrentPositionOfTermLoanIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LeaseLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LeaseLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LongTermLoanUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term loan undiscounted cash flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LongTermLoanUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_NonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonderivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_NonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165712288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)<br> &#8364; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 34,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="nump">6,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceivable', window );">Tax credits and grants receivable</a></td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">$ (28,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">&#8364; 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,547<span></span>
</td>
<td class="nump">&#8364; 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Bonds and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TaxCreditsAndGrantsReceivable', window );">Tax credits and grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,395)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,784)<span></span>
</td>
<td class="num">(5,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_TotalLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(925)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(3,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsLiabilities', window );">Total exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">&#8364; 3,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,587<span></span>
</td>
<td class="num">&#8364; (7,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets less the amount of current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TaxCreditsAndGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits and grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TaxCreditsAndGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_TotalLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_TotalLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172272336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Summary of exchange rates (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CA$ &#8211; US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">7,404<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Reporting date rate</a></td>
<td class="nump">7,363<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro &#8211; US$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">10,792<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Reporting date rate</a></td>
<td class="nump">10,903<span></span>
</td>
<td class="nump">10,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173061376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Summary of Company's foreign currency exposures (Detail)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis', window );">Positive (negative) impact</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="num">&#8364; (172)<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="num">&#8364; (380)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Positive negative impact of foreign exchange gain loss sensitivity analysis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173104688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital management - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems', window );"><strong>Disclosure of objectives, policies and processes for managing capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained', window );">Minimum cash cash equivalents and short term investments to be maintained</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems', window );"><strong>Disclosure of objectives, policies and processes for managing capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained', window );">Minimum cash cash equivalents and short term investments to be maintained</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashbondAndMoneyMarketFundsMember', window );">Cash bond and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems', window );"><strong>Disclosure of objectives, policies and processes for managing capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CashBondAndMoneyMarketFunds', window );">Cash,bond and money market funds</a></td>
<td class="nump">$ 40,387<span></span>
</td>
<td class="nump">$ 33,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CashBondAndMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash bond and money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CashBondAndMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash cash equivalents and short term investments to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=thtx_CashbondAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=thtx_CashbondAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849164730752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail) - Revenue multiple, measurement input [member] - Warrant reserve [member] - At fair value [member]<br></strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_RevenueMultipleMeasurementInputMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_RevenueMultipleMeasurementInputMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_RevenueMultipleMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_RevenueMultipleMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849173749616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail) - Historical volatility for shares, measurement input [member] - Warrant reserve [member] - At fair value [member]<br></strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Expected volatility unobservable input, liabilities</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_SignificantUnobservableInputLiabilitiesBasisPoints', window );">Expected volatility unobservable input, liabilities, basis points</a></td>
<td class="nump">0.0100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_SignificantUnobservableInputLiabilitiesBasisPoints">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant unobservable input liabilities basis points.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_SignificantUnobservableInputLiabilitiesBasisPoints</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172349536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=thtx_OncologyPlatformMember', window );">Oncology Platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfCommitmentsLineItems', window );"><strong>Disclosure of Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired', window );">Long term purchase commitments</a></td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CommitmentsAxis=thtx_TrogarzoMember', window );">Trogarzo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfCommitmentsLineItems', window );"><strong>Disclosure of Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired', window );">Long term purchase commitments</a></td>
<td class="nump">14,682<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_CommitmentsAxis=thtx_MultidosePassInjectorDevelopedMember', window );">Multidose pass injector developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_DisclosureOfCommitmentsLineItems', window );"><strong>Disclosure of Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_BorrowingsOutstanding', window );">Line of credit facility outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_BorrowingsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_BorrowingsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_DisclosureOfCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_DisclosureOfCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term purchase commitments minimum payments required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=thtx_OncologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=thtx_OncologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CommitmentsAxis=thtx_TrogarzoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CommitmentsAxis=thtx_TrogarzoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_CommitmentsAxis=thtx_MultidosePassInjectorDevelopedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_CommitmentsAxis=thtx_MultidosePassInjectorDevelopedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849172088528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating segments - Summary of single operating segment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 81,764<span></span>
</td>
<td class="nump">$ 80,057<span></span>
</td>
<td class="nump">$ 69,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=thtx_RxCrossRoadsMember', window );">RxCrossroads</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">81,392<span></span>
</td>
<td class="nump">78,744<span></span>
</td>
<td class="nump">68,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=thtx_RxCrossRoadsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=thtx_RxCrossRoadsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849166286912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating segments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">$ 14,472<span></span>
</td>
<td class="nump">$ 19,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">14,138<span></span>
</td>
<td class="nump">18,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849168677136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Summary of key management personnel compensation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">$ 3,259<span></span>
</td>
<td class="nump">$ 3,191<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 5,355<span></span>
</td>
<td class="nump">$ 4,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849165609152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related parties - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_thtx_RelatedPartyPercentageOfVotingRightsHeld', window );">Related party percentage of voting shares held</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_thtx_RelatedPartyPercentageOfVotingRightsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party percentage of voting shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">thtx_RelatedPartyPercentageOfVotingRightsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>thtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>187
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD5Y2/16JS]7;J<N:8= /L1NA:FLA'[M(IS\:5K65E-5M$TTJXT\7ILTJS!P
M@YI@T(^PKE"_X)N+IJ87GJDQJ90D1HA;T!5EKM6HT07][/I02E+>,X4 7^R8
M(((HS(Q1M)A%0> @%M3(@GYFC508\D5Y#W)>.Z3ZF#3(-$U@DB&'2HTNZ&=7
MGRW*\Q:CB2<8A@F:*K6896GFRA@:9=#/LEZJ1YX)JB1)XBEC+6891K%#'M(\
M0\%9&X2"D3M6J-V0';G(2\4G;Q.>J;=3GS45D9^*;_*<-VW56)%'TJU&E=E(
MGHM&Q?W<0)CT0VF8P,ET6<Q"&+B CHZV<WY,JF2\9^U1@UV<2;WLF,V#-@L;
M(Y@XI&DTHIG]%U=5FY!=>FM4::16IAK.FI:,"[54I6,\\6P.L9B@.'6E8Z3!
MAOQ@^QGZ%1?=(0#?@(^<E. ]R=L >+3*->&5H'2:G"U6.$E=C$.:<<C/.(OB
M@I*:S@:MR;,0&2%K,4H<&V"DF8?\S/N;""*W2NLW(KJMFE6?!69A$DT%FE:N
M]*=QAYZP11O2@57A/.HL)M@YY9ITZ,Q=FJ!J3]38Q9GHPNE4G=?F5)QF&SJ'
M;?F9"#$)IBB<37="%C,(0Y0X*ANL28?]I#LNW6>DXF>EW7/U=NJWIAWVTVXV
MIV&355%PO%4>W##-',L/:YQA/\X^GI.]L,FK*)E"S6*DJCQ'^L)'9XI^J/W3
M'8?-"30!E4[#VF(# Y<\C3#L1YA9!\])-<D401Q.4ZW%#$:1HVS'FE]XYIBQ
MDSLGT>10EL9X6A!;S"",4@P=(C6Q<.S-$W^J+:YCH7A1]^2T\$R]G;JIR8?]
MY+O=$D%!3BJFYN0E. QX[FKANKFK<\$JV=]IY51]M<^5A7EJJI!QNFZQPZFJ
M.AV3I?&(_7CL)TMM47<5+]OX5R51_K\*4>P[Q1R\L)R%0NQ:%9JBV$]153A+
MP>Z:]J:J;D15-':!)A@1AHF1IBW\3%/H2-6AQF?H/_A4A0C+F?7<)S0/+R_"
M((VCZ9JU&>(4Q:$#[J&&7#B[I6MV3='=]O57&&U("+IM+V;W%+"NSK.*MQQG
M&MG;8H13QP8DU/0+SSGSI,Y\$YI,NT!!:AQ76>U0E#A65ZCI%_KI9^3K\0S0
M(=B\1;.=95C,;&<9RZ/;W_;J76TE[EE9JRW/1K4+7B7*8='?9O</DE?=A? =
MEY+ONJ];2M94M ;J[QNN%O_PT-XQC_^G8/4?4$L#!!0    ( !Q 55CU&<BQ
M"@<  "L=   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK5E1;]LV$/XK
MA%<,+=#$(B514IH8:!UG"["U1=-M#T4?&(NVA<JB)]).LE^_(RU;MG124L O
MMB5]=[[OCCQ^%"\?5/E#+Z0TY'&9%_IJL#!F=3$<ZNE"+H4^5RM9P).9*I?"
MP&4Y'^I5*47JC);YD'D>'RY%5@Q&E^[>YW)TJ=8FSPKYN21ZO5R*\NF#S-7#
MU8 .=C>^9/.%L3>&H\N5F,L[:?Y:?2[A:KCWDF9+6>A,%:24LZO!>WIQPV)K
MX!!_9_)!'_PFELJ]4C_LQ6UZ-?!L1#*74V-="/C:R+',<^L)XOBW<CK8_Z<U
M//R]\W[CR .9>Z'E6.7_9*E97 WB 4GE3*QS\T4]_"XK0J'U-U6Y=I_DH<)Z
M S)=:Z.6E3%$L,R*[;=XK!)Q8$#]#@-6&;"F >\P\"L#OVD0=!@$E4'P4H.P
M,@A?RH%7!MSE?ILLE^EK8<3HLE0/I+1H\&9_N'(Y:TAP5MB1=6=*>)J!G1F-
M5:%5GJ7"R)3<&?B"86,T43/R$<;U'TIK(HJ4C-421N["#JF-W-X^(W_=79/7
MK]Z05R0KR->%6FN ZLNA@<"L^^&T"F*\#8)U!$$9^5,59J')I$AE>NQ@"(SV
MM-B.UICU>ORH-N?$]]X2YC$?">CZY>8,,9^\W)SVL/'W1?*=/[_#W[XNMBS3
MHTID!5Q+\DW<:U/"-/V.97_K/<"]V]YUH5=B*J\&X%C+<B,'HU]_H=Q[AV7N
ME,XF)W)VE-5@G]6@S_OHB]S(8BVQA&T-N3.TO7DSBFG$@\OAYC 3",KSPN@8
M-6FC>!+;0;E!8@_WL8>](^+32I;"9,6<R$=89+1$9UUXRKJ?TMGD1,Z.<L?W
MN>.]=1\K[2;27*E4$^A^*9:[K8_PH&PTX7[8& )M%/-C/VX, <17[$<Q/@2B
M/8VHE\;[I2I-]I]P"S30468A2R*TE@;C$[5B\!I<V@@6!+1!I0T*XICA3.(]
MD_B9B:BE**<+M]"D,"MSM7+=;C>VWY)"NI(9\4BFI4RS[0KUBH1^0E[;)@VK
MT2OB4_[.]5SRZR\QH_0=W&-1] ;+1]PBXGM^U,P)@N*)GS22TD:QF$4!GI5D
MGY6D-RMWH+:>F^!)^X]YQ!OA7;=1/G!H5A;Q%2=>@I.@7JTOO%X:O\D"6E7N
M:BM24#"97:BLG.QE5GD]FC,AIXWF>HW!(C_D#6X8+."4=Y [$$^TE]Q798":
M>E$SKEP=QI"P5AFN$1BE2<+#)B7$7>B%7?5B-2762\E)NUFIE@>TG/S/3-9!
MC+4B.:,>9ZU:(3@_2;QFM\1P+&1^5[5J%45[Y<3H)BM$,=UI)I2*WYX$-&@1
M::-XY#=9M$$T"3LHU)*%]FN6'84IK&%X,0*D&# N>),#@HO"L-G9,!CGC';P
MJ.4+[5WA&Z5P=% V(<*&'7:EB@V"XW'<:@,8+&!= ZL6%+1?4;@Y<R]AG[]G
M!"M5QVQIBX$SYH=^JT (+N!1$C0Y(3A8!WG'FDQK>4'[]<7MGLBNK:%TVH+@
M+&"MIH:A@M:405"\0RC36ES0?G5AM[$Y% B-OKUR0S&2IH:_QG!!Q/RFUL=P
M/HU8HWG?/!/R-_J]1^?26D'0I'>7< N[1DW,0ABR%$\P0DDIISE(Q&R6P7;?
M**>K5J6:98:\MDEZ8W?R("3);&W6)5[Q7MGRL[N*DWJ;G,K;\3N'6NNP?JUC
MA]IT(8JY;0-D)K*2;$2^EE:KSES'RZP2LA)=$RC* <(L2K6>+RH5C^[Q7P]N
M_OXTOAV@<I:U%0Y+FFT2 9WYO*%Y)QB*)A$^#UFME5B_5IH\5JE)L]E,EA+:
M/XAX&&VE*'2^W\;8)IK-BYWZ4 4Z<5E;_32E.P*)XN;ZAH"XWR'<6:VA6+^&
M^M1=1#<9'[(\QV9C-1-5Z1K6X:X'S4%;)R$E;X,"ULH" O*["E[++=8OM[;B
M^#@+78VX<L6/&S$/XR8=!!?PN*4A,9Q/6=RQYV:U &-!;TMU2ST,3:(7 N^/
MK%?!_6Q_/*FWR:F\'2>O5GVL7_5]$#J;$MCK%["KT+L5IR^;'Y[Q^(VA+SPK
MJZ/RMW9:&(@FK9&$H3HG1RT96;]DO,[RM7WE_G/)Z/?9E0S^DF0@("09&*HS
M&59J'M^I11M[5@%]74C7/$3Q1#8J7Q=&E%G^5"VP*;'O@,1TJN"!W:.N5)Y-
MGVP7K7KJ$[1< ^N,!H4CLM2]@("&*Z$-P05,8E&Z[HIM<]\2+27YJ(PD]!S2
M>@=7A;NRZ].V0!#<[N@$5JES;((,#\YEEK*<NQ,T35S,VW>]^[O[4[H/[FRJ
M<7],+VXH<G_"+FXP_'L674P@_]B3&)ZX@\!A'=+V&/%/4<ZS0I-<SB \[SR"
MH5]N3^:V%T:MW$G2O3)&+=W/A12I+"T GL\4Y*BZL'^P/Q\=_0]02P,$%
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M-&=^-!OXD^AFGKFQTM0X0<(2)"P]K0LIR*80 <%K! 3&J>+3Z!I!%Q,!<K)
MPF(D+$'"4B2,@F!"J(2OH1(>G2P6W95$>\FPRO+*>LPV>]8NI./?/]U2:Y47
M?.62\W-/5M=,NTB_#=4QX<RDY=K<V)"IH8&$)4A8BH31(QTKN#QZ=7ED=/G\
MG][AR[R] &-\6<HO* NKX==@-;_(:"_7N/=79<7R!_YRQZKN0ZWG(Z6!@2NO
M^8W-F>IX)"Q!PE(DC)K[5?#[[-7O,Z/?IRP@9[J3'(DBR;-&@U,]BX0E2%BJ
M[0WUE*\6\]R1L>K8@P!DFY?][:C,.NFQMI[R9FV53P6KZK>MI%)62[;DXYB_
M;#;/[0S..D%$J_C8R/,\E!9#:0F4ED)I%$43H^E 3G2,<T"OO.5U_7**Y[/!
MED_W=2]*%,L76T_C@MQM;T$(\\"V)05GWA<+S,5B<WLG>QY)2Z$TBJ*)GA\D
M/<>LZ4WTO/7F1:CZ47,H-T=,C2A3YEJ3)R"BAJ$3\<61+T<8TFP"I:50&D71
MQ @;M$['+$B^J/\O ;8HZY'90Y44SUUW)B\9S:8FGUZ@\B24EI[6(11E5/3M
MH#TZ1L6*7S.P:I'7W<QQVA1AYHU-$5#ALJ<==JT?N;ZL74.-)E!:"J51%$T,
MHD&7=,RZH2Z(M%&@2FRAIZPO?&5]H12*S0V:[%JHC@BE411-=.T@.#I&D4J8
M^W_X+B*.\Y/UJ5B4F_)!?S$"%1U[VF$L!$$DQP)43>QIPK2MV$RA-BF*)OIX
M4 H=LU1H\K'Y7&#FCIT+D$+:W%&5-(?87J3,&%!A$4I+H32*HHG1-(B03F34
M-;IX.6\3H9:=)L6*^D5ZW&VR0AL/2'UM#J7%4%H"I:50&D71Q*@9)$S'K&&.
M1LVJK*RZ*1=?K7)G#B-5I7.B<":O+J#*)I26G'0$*=0F1='$=*1!!"5F$?1P
MY?BI\V]]J4U!@FJ<4%H,I2506@JE411-#)9!XR1FC?/GLF!-5K59@46=+_N[
M5]IP4:5,?^;+&6NJD*D4BLU-FNQ<J(P)I5$4373N06:B65O4.[?/JM,M/H_P
M1A:?YEJ3)Q)5JW2"@"A*!-1J J6E4!I%T<0H&J1*8I8J/S2OV;Q=MH,V!*"9
ME#U-N!WBNK+_H3HET2B+BLT4:I.B:*)?!YF2F&7%?V]Q]\G:W3W3^^?^CJG6
MR:I$Z/F1FK7LJ=Z+/$\9OU E4=.V,)05!DTAG7R,:IGHET'Y(V;ES^B7_AZ4
M=O(^DH@X,GDCE;4Y4=5(SR>A+:>CQU"S"9260FD411.C:1 ;B5ELG!?+-J7^
M1K\WP=&&A"K7.6$HI['/B2HDNJX?^LKV!!6GVY^@,4HB3YF!-5(BMTJ\2![$
MFH+>2%(0&60]8I;?Q-X<VZ"@Z]6;(^2QX0D5]H@J[!$WC&S/4<8G5-J#TE(H
MC:)H8D0-TAXQ2WM3$LT(5-6#TF(H+8'24BB-HFABP RJ'C&K>J8="T23?.>%
MQ)6SB\TF)KL>JMA!:>F)/4)15L6=;X-FYYHUNVF;$%RH<@>EQ5!: J6E4!I%
MT<20&90[UZS<838CN*JJ=Z[L6)R;FS(Y1*#Z'Y260FGT6.^*KA]T/=>LPT$W
M);BJWA9&\BT><X,F!P!4NH/24BB-'NE<T?\'&Z7-BMR4-:.K$[:"R)9W)YA-
M3O8P=H\S=I.SKD<T2P)-.8^,^6Y0W5S/O-Y';5%PH>E_4%H,I2506@JE411-
MC*9!*W3-HMY):<2N9A>N$\BRK=G2Y B ZGM06GI2?U"43=&S@V[GGIXD>&Y]
M^/*SM:O*ARK;:CVLBEUDIJ[B5,%.+16;VS79<]"=Q% :1=%$#P]:HGMZBJ#@
M8>M-/9X?> 0Z]J 3J(SHJC*B9[?_Y%""BHA06@JE411-#*5!1'3-NY1_9;M]
MQ:\):O;-SW2Z==5=M.=$=NG<W)#)9PF=35?>*YIHBA%'+I5"FT91--&C@\KG
MSHS+Q,D9GRY2-IM#:3&4ED!I*91&433QH4>#C.@9-2= QF=OX'"HN9&RDC W
M8VIX0&G)24>00FU2%$UT^R %>HYQLC@UX]-#BEMS*"V&TA(H+872*(HF!LL@
M'GK?DA2H#1=5O"*./!-HGE$HE8G-#9KL6JC<!Z51%$UT[: +>F9=<'*^YQ'>
MR,6$N=;D:425V8CCR$^FC*%&$R@MA=(HBB8&T<&3$\UI@:>D>YH1DR- 31AT
MY V)4(N)ITD$E$VF4),411.].@B%WG](*M2Z6!7) B^4$PD\=6,QF<UFLO,T
M@IOF,D]3S)\%H>R6D]0[<W=\:W</ZIUG5N^^-8?S"'9L0H9N$/8T^7K:&1DJ
M%$)I*91&430QF :AT)N2="@G&Q)M1&B>A4>('RK+MU 9OZX;A;ZRA-,D#CHN
MD0>P9M]P%#G*M9>F<6Y$ D]^RK2FH!OY^CMPWB"6>4<>Z7=2#J>N6V^.D,>&
M)S1MS].(81ZQ'5_9G@VUFT!I*91&430QH@:QSC.+=9.>-@W5Z:"T&$I+H+04
M2J,HFOC,Z4&G\\TZG?&ITZI^Q1=+,SEA?FXV,=7U4%H"I:4G]@A%616=.JAP
MOEF%FY;#Z4.U."@MAM(2*"V%TBB*)H;,H,7Y9BT.D\/I:W0Z^1IL;F[)Y B!
M2GI06@JET2.=*SI^4.I\L[(&S>#T505-OF%C;LYD[T.U."@MA=(HBB:&R:#%
M^68M;LK"TM=H6L0-?#G1TVQR<BA =3DH+=7WB&;=H)8;'^('/RSBFR\*4(F>
M/G2'+I060VD)E)9":11%$Z-I$!3]T],!1Q,]?<V>5V+[KCP#0']W!$I+H+3T
MM ZA**.B;P=]SS?K>\:G36O]K%'C?$?)TO!5<4]3+#:W;K(#H5EZ4!I%T40_
M#\*C;Y8'S4\5-ST4\@AX1'<TUYI\XM EX85AY$2>'%!0W1%*2Z$TBJ*) 37H
MCKYY*_!ME^A9]Q<+WY;VZ6L>D"<_U:LO(]R@#62G:S;:2G<1$O/A3'8E5!%$
MT<3?(!L4P<"L"$YUI7&Z.&)K9+HPUYHZ702J:$?D$V\,-9E :2F41E$T,;P&
M;3(P;Q9&)(@'ZF96><5A;L74E:7&X#EQ7'E6T1132Z70IE$4373GH!L&Q'AM
M.3D[/( ^H@]*BZ&T!$I+H32*HHE1,XB.P0F_.?*?LL,#3:Z>^G01<S,FAP=4
M;#SI"%*H38JBB6X?1,3 ,TX6IV:'!]"D/B@MAM(2*"V%TBB*)@;+H%H&X#S!
M0$W'X^L\7[[]%&@2!7TGE*\B-+1S3:*1IICG*C\HH86IZH^Y1[ZUQP]^?OC_
MDRIX!#NVR,?^@+%FWW&K"7CRC!I#[2906@JE411-#*=!3 S^2[*@JXT)52?D
MXR0*E=6])EDP<&=$\;5:SI8'L$::=!WE@:VZEGEV%,C3"]44#**1IST&@V 7
M(#(%=7UZ<X0\-CJABEV@*G:>/XMLVY$3M*%V$R@MA=(HBB9&5*O8B;\H/@@_
MX5$QYHZQ[JK;<EY6XMVMGG8+3[G)E]T*_=V?Y*\O:]:MVK/BV7HL-_NBR:I\
M\]SGCRRMO.&1N5B4_(LV:'>\\N+9:DIKL<GJ.E^U=QD;Q@^JL799OFQ_Q;*]
M$\GR1UXYJ_F'5=,N$?M< XYH;UX^YDW.ZK=6S=OX2]?&=[J.N*C7C#4?LR:[
MOMJRZH'=LLVFMKK6M,=^\"DWNFI_N^3RQCF[4#Z_=2X_ZC[_$,PN4][/FF]"
M^S+EG<R_N1A,7U_ML@?V<U8]Y/Q\NF$KW@S[7<C'0I4_K%_?-.7N_1F_EK\O
MFZ;<=B_7+%NRJBW OU^5_)C[-ZV!I[+ZVAWJ]?\ 4$L#!!0    ( !Q 55C^
M&XL%20P   )$   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULM9QM;]NZ
M&8;_"I$=##U 78LODJTL#9"ZTE;@M W:GO7#L ^*3,=:9=&5Y*39KQ\I*:9-
M/B:=Q/O2VLI-FL]MOEQ\1/GB7M0_FB7G+?JU*JOF[=FR;=?GXW&3+_DJ:]Z(
M-:_D7Q:B7F6M?%O?CIMUS;-Y5VA5CDD01.-55E1GEQ?=M>OZ\D)LVK*H^'6-
MFLUJE=4/[W@I[M^>X;/'"U^*VV6K+HPO+];9+?_*VS_7U[5\-][6,B]6O&H*
M4:&:+]Z>7>'S-.H*=(I_%OR^V7F-5"@W0OQ0;S[,WYX%JD6\Y'FKJLCD?W=\
MQLM2U23;\7.H]&S[F:K@[NO'VM,N>!G,3=;PF2B_%_-V^?9L>H;F?)%MRO:+
MN/\''P(*57VY*)ON7W0_:(,SE&^:5JR&PK(%JZ+J_\]^#4;L%,#1@0)D*$#,
M NQ  3H4H&8!>J  &PJP8S\A' J$QWY"-!2(.N][LSJGWV=M=GE1BWM4*[6L
M3;WHOJZNM#2XJ%3/^MK6\J^%+-=>SD35B+*89RV?HZ^M_$]VF[9!8H%F6;-$
MJ>QZ#1JA/[^^1Z]^^QW]AHH*?5N*39-5\^9BW,HVJ)K&^?!Y[_K/(P<^#Q/T
M453MLD%)->?S_0K&LO';",AC!.^(L\9/XNX-HL%K1 )"@0;-CB].@.+)\<6Q
M(QJZ_3YH5Q\]]'U(T__Z%QP%?ULHYX>7M5CUKUYM&C[O7Q;5[^CSFM=96U2W
MT!?1?Q"#/TC-6.?-.LOYVS,Y)36\ON-GEWW-D(FGK"PY465[!K.MP<Q5^^4G
M.5N7H@&[;E\RZDJJ*?GN<D1H'$XNQG>[7@ R-B'4D"6 C.()"?=EJ;NY_\+_
M=@0=;H,.G;WJ:OX?.97T(UNN1E#LX2E[RRDK2TY4V9YQT=:XR&G_>RXKS8NL
M6P7EG+BNY9I>MP](SGZ(_]P4:V4JY&=?;[CS[;,P,#J2K:&QH4ELC=734G<,
M[BXTV3HQ<=9RM1)U6_QWZT11M5EU6]R4'&5-PV7'4I:(=LGK_@)DRL0.)L34
M<,4681R%Q/#%5DV#R!"E[I#<QDRWQDR?9$RM6&8D%B,Y50_60%9,[>_>C'%F
M:QB)#1\ #3,TJ3L MPWQUH;86<O795;SD8*\.<K%2I)OTULBYQLD,2;_@<2Z
MN[ NLZH?H*K']'_*UCOCK',0-"VV^P_!QH0ZLT5T.C&[CRW",36[CSMBMV\X
MT 06..OYN^1_),,NN30/M;R6F-<9 =)58#5\A!5Y[%D J,QYQ2])/>WVQ+]#
MH-A9SVPI)Q*NN'*1%36ZR\H-5P-ISNOB+E,;#[20CE2R>Y2. 35\RMY(B,T1
M!8@(-A=N0#0BV.P<GJ@\[A#M#GF6.V61W11E(9>BFI<=O;=";:EX7?-A5/6#
M;%,5;?]*#3S0.0+$2YAI':C"IG>VB@3F?.0)V6.=1FGL!,G+#Y4<3+QIU>#*
M174G%^YNO=I4#<\WG4V\*N3T5(F6]^O7'R*K4)KEG;.@5]1>=TAD+F& BE&3
M(Q- 16D0F6:Y@_28I;$8NT%S:]8Z*^8G=8S9_68Z-8?3#)*QB#+3,T &F?82
MJL8:J[$3/K5I1277/ Z&']H-GD2Q&3V@HC@R@P=4.#8W%)XV>V+79(S=6+F-
M72[<7$[2<S!Z&U^GD;E@ R(66K$#(#RUYN27D##6*(S=X/BA^[91F_U"_)<B
M'?B;MQ&5V2LU(&+4C-T6F5-.ZFFR)W0-N]@-BSIT.?[55 %&;D/I:,JF9NB
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MS\8E@$I-0-2\H>()RM.;- &';H94SPOFVU,-RB30 !M7<4!,G)L!,AI9J4Q
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MFK1$N^E)^!,M-&9;.73@#Y:X#/<Z>T-T8FES%BOJ+E:T-,@%C[QM^5D=A"A
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MOVA@1&UJQ#7GC\B^#(^S,U4WWN#BZ@DU,V&S2LD,E@\ZR#./;6MH;V\[<B*
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MCPH([9"C(Z(S^GF[)5SVVN@\?PK3"/M2:P+#UO*207B9WD4HPEB%J.C63YN
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M3P'N5VQOP] Y@YU51L*9^0LU?(GME)YYT S(Q'-C"$YX(=,I#$T<G:;K)S2
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MB,Z^5R30XUY5%J-9M=KB^SB\?!6X93(\\"9I ;E.U,!UJ@418"BZZJCF/3'
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M3@/!G>EU]#.'84G<8NJSOMK4OVCRY\9T2!"$WAPW:M2]'N?U4&\KF?F1R[M
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M6^)?7,D+Y</EWWQU)%OHQ[S;8>A/;;9TZ]/U%Y\_DNB3^]"W1WZ]_*;M^_;
M?V+"N^EP ?V^;<GRT ]X -Z_P^!]\S]02P,$%     @ '$!56$WCF%0[!
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M '3]V*@[5I7^@E\IB\\%W\SQ?<:T,\#YM5)VWW$+M"^^Q=]02P,$%     @
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MMW<:1]$!I1(M2".4)!KJ>7"=7"TS9^\-/@K8F:,^<4I62MV[P9MJ'L2.$#3
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MP/*"&[Q-(P0PA6J3^)MN+R71+[*32N@&^7TMXXX77N>9H5G)FF208(V4((Z
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M#RUB.X^P&'!6/0[[ 0YE\%XU=F?@;5.*\B% B$F-F;%#9BMV$O%&W9U#1*;
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MS9@K*TY3+QA#Q!M\M@JN];ULML!KU6$?31ZWBX.;.2DRZB/]*=(L[E%(^B3
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M1]-@/)]Z[:3M&"-KMZ>)-+CUCBSPS(*R"OB>2VEVC'70'^[X%U!+ P04
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M:-([/HK ML6Z'9!I0H&<&^)R&[H5OV]H?0"O+XRA[<!OL'LQ)_\!4$L#!!0
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MK9-S[,^\D?,<R6P$/_,$:Z[U7L@M//*RP6#%2RY3!&Z 6Z"<8[5!?<A[ B^
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MA)+?7"9_F"KS]K#0>'1=97AEZW#WXN%14'G.F;L?53W&5DX9"3G7,0 V#8[
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M 81W87&70,&I7J,K4L[@0@XOF@]5ON,?\J_RJLJW_':CPU@7U #?KW-LJ_E
M$[3_LL/+_P502P,$%     @ '$!56,YZFDP7!P  )Q$  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&ULO5A;<]LV%G[7K\"HV4X\PU@$>%5B>R9QVZUG
M-FTF;;</G7V 2$A"2Q%: )2<_OI^!Z05*DO;?=H'$==S<*X?#G1U-/8/MU7*
ML_M=T[KK^=;[_>O%PE5;M9/NTNQ5BY6UL3OI,;2;A=M;)>M M&L6(H[SQ4[J
M=GYS%>8^V)LKT_E&M^J#9:[;[:3]]$XUYG@]Y_.'B8]ZL_4TL;BYVLN-^DGY
M7_8?+$:+$Y=:[U3KM&F95>OK^5O^^EU*^\.&?VMU=*,^(TU6QOQ!@[OZ>AZ3
M0*I1E2<.$LU!W:JF(480X[\#S_GI2"(<]Q^X?Q=TARXKZ=2M:7[5M=]>S\LY
MJ]5:=HW_:([?JT&?C/A5IG'ARX[]WDS,6=4Y;W8#,238Z;9OY?U@AQ%!&3]"
M( 8"$>3N#PI2?B.]O+FRYL@L[08WZ@15 S6$TRTYY2=OL:I!YV_NVLKL%//R
M7KFKA0='FE]4 _6[GEH\0LT%>V]:OW7LV[96]3F#!40YR2,>Y'DGGN3X@SE<
MLB2.F(A%\@2_Y*1?$O@EC_![+W\WED''O6E5ZQTS:U*6J7N$M5/LI0X&N&"_
MR97S%D'RGRDS](>DTX=0XKQV>UFIZSDRPRE[4/.;K[_B>?SF"172DPKI4]R?
M==&3U-.R"7[)QFS9SUO%UJ9!BNIV@[E5HUC83B;S6/S"@C3368LQDVU-:: P
MJL>F=>RE594Y*/OIXG+V]5<E7V9O)IO@:_;<#O'L#CZ['60:>_C%%W1I%F,N
M31-\\V3VS83H(\EG/UJ]T:WL(02J6H5Y)YM@!@6C6& 9J_4:;%1;0>T7[&46
M+0MQ03W.HR+.0K>(BF5^,;O=RG:CF&Y9U](QFU;_J<B$=0>$(L.#&M+UE"Q0
MS7XV'D=.F7DD*QTBEM2\HM] ])R?R!B"CTWR$0S;2C>ZUWJE_%&IEBFH&# T
ML)+[?:.K$"C$3.Y,A^#X?SGZ+'BE9S5&SNLJR.*\])TW<(N5GO1[F4<B*7I_
MB"B-X] MHV09_QU_3+MYPDMW.R2:I\@8;P3GSQ*1?"05LH,GD(/'@N7I[ ?3
MOAJ=6*89XU&<Y"Q;)H,?]4GEQSU':3QRS/\>RX[2L7^02.2*J#<WN9.L>AE@
MX!:9+MM/,+?@Q1OWI:,#%]V#PJUL9:UE2^BP N[4@VHC$IQ$.W_OK':U#C=Q
ML,AQJZMMSZ0_CZ'."-27[)=S/XQ"5CJG@$!O@\]Q5:C=2MG3=?&@B(@"XR$D
MPRPLILE_03SXYR1YX.J]U:N.EE#E#**U9N+H8+Z1<$?X&"L#=+K7LR &B3"=
M!]^I&DHVTP'^P9H#G*P?6_^;Q$A?IZ2%"GW&'U!X[7>$  _ '"%8RB+B&<4.
MC[,H2Y<TE4=%7@Y3O$AG_S*.8+R2UFHH"]L<I0T6+A#]&2Y_?..4OODR?#D9
MH&1) DZ<<:1=AE$:<1[3*!4Y;5@RGD8)A;B(N$AIE"Y3&HDLQH8D9B7V)N%+
M_8R';US0(O@6H,X9SY# !8TRD=$HRXA](D)29FAB9"6G45FD-%K&@C8$QFF*
M;Y)GQ!@DF,E(^B2E7,:6(LISRNN24[](4UHL6 XF'-^2E]0O!/7+)2V63$0Q
M=O-HV??!"_VLI$7H'"4"0D>B#/TTIF\0"-TB$JF@+]A".UY0?QD6H< 2OA+4
MQ$5)38(K#(TH2%_0":Q04T*4C"4\XB4/S9+,22B%S<M *LH4M\.KV8_($#N-
M;-'LVWLTIU+I()M.T6!O*4?]IQ!8:9(Q\@Y@*HY9FJ6/4>G6H^;&S=$A=N&$
M/(]#D^7!03!RW\S>'J1N F@,2$A004>9(&N1P,^")0+^REF^A M+4AEFGOT3
MMU([1I,3>NVE\ZP)@1RA;F[QT BY4!M$=FL\;K=&(T= #$C1GJ ->JYZO*.Y
M,495DEXBLD'R8Z^;!"=('/ 'KPMC541 TB,1VP(I5G23CA!DP$=<N,XTFO"I
M#K =I S&7*/ZZ%%A;YPFJ_0XO5$M 2;=T+2K\YT-"#W4;F;=*U,K)'U-*IO^
M*-=5Y*=UUQ!L[Y0EWOK/$Z=)*UI#'NG=X56U;4UC-IK ^@YE45T'N9@W/?"N
M#!4))U2-""*G #LZ,^Y6HJHXQ< +!#//4= ,!8'@_$V8+),+$K.9!B?8\\ZJ
MAN0\:K_%,_0<^Y\!>-=#^F<'73YVV43GU"B65JB8/&P2%.E#Z]S7=/:#@Z9K
M"HE;D@KPM34[J') 3=/' =22\-S*:=Q:(%JI2G9.G0<G7F(6S\$P6:M*NSZ#
M^K*-ROJM&J+WY&P$P_9,=C+<8UDP+?-1-TU0MZ^,3U<^1;]3*K#HH_.23;V&
M%J/'*Z)Q$Y[H<"RE3/^./<V>_@5XVS]^/V_O_T)X+RUJ=<<:M09I?%ED<V;[
M9WD_\&8?GL(KX_&P#MVMDKA6:0/6U\;XAP$=</IOY.8O4$L#!!0    ( !Q
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M-V(MW\E&7KZQ9BLLS88TNF%3>364*S4YY5MC\;;$NN;R0ZFESDM9B5*[QK;
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MG\#=_(N5?VC,FG\EFINF,37?KA0,MS0![Q<&A:Q[H UV/QM>_@=02P,$%
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M)!9DR,E E9BMA)<:*48A?/AX<W5Y-Q6W7P12<3 ^WOPQ;OE]U$^% V">>"+
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M&L+D]\[0KB86Z7 A)JDSGLJ.T^O)L+FQX7F#(@+L[E8Q[](C4FM0>3!HT *
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M;5F;.B]-E;G.=!9XL:,K._C-]1M7%J5ID4CDNZOF<#3U*3.MS<HZKWHX=/B
MOSF;O0[0KB.T;=L<Z%YXK,W@N;?[,M\C+ET+O) W![@NAT<@759+5UI@3;?.
MKC5>B @\INSP#[FR IPV)XWO&CXP$-@(VAG@A=N]A9OUJO;&T=_'YM:V6==D
MN^;&MK0ZM5.F+C(0F:U)V4AVB) Y9:[)$%B3-9L.!&>VL;7=EGX[\ ,)*\)[
MG;T!V>5@<0XARBI6 +I#:/#(FX:>U:+\011-1PO/^[:%*ZI39C_9-B^=V526
M?NG,1UO#P0 ">.AE0>@V]9I.?4H* /INN+'YWM0[V$S8J3JK+1R2 [&.JS(5
M"!5<[P&$6;>771-0IFB.W<09O*D[P%+V>F,J0\>.VPE<63M#0MRM0!/<V+J7
MG^PGT$ZP-?"M S&,.#-%J5M@=[M;"SBF*X"[ W*:<&U5@I@U'9,ND,,1;@"X
M>-T4":^S!1;_*K#X5XLL#@K&XI[QF>$^3;'W(HP9]AY#SC[HS8$U;L>7$)7@
M915M!)PI47E?TUVP?KD6MJR#0V!2R("*+$&TVRTH7?S-,VS@ 'TR:U0/MD.J
M00+O^%2JTFS*BGFVL'6C3F,*4WX&'%/3TOF3>/A+^!-CZC4,EP#_(%1FCP$.
MIVR''-RT6=4XAW+IX-=4 H4XE"FT"24 Q!MLH$=S0)3_!/SRQG4B*)>0W-A=
M6=>X2-G,N.J3->T*>.L/L!@ (" I*P"3!SD='@V/P.T]FA.+WJ(/=#V"@UR'
MHF"$X6CU:I?OLY4H HMI]-?9+TU]%G8O^<-3L4A6)%P25=-4 ^"WXQMN]XV;
MWEXXHKIA['Z]_H\A\9"<I.^G2(V) K1=<["I2(I8G/DG+4B*KX.D^'I14KQG
M\0=8Y U8;G.6P"*0&5$Q 3I\1U*5= _PKF/)R=:I;5WVGW_[]N+\_'GV"W@1
MSE263\=+55 O0(7.2^ZH\_E2W*>R+L&$+4"E-@7(>%;M8D* O&IVIOVS@<><
M?_/E\^S5C^_?O/YPF5W_YK^YILUO6R0[L2N  ?PCQD\ L=[<@-JCR_PRLMRX
M/?"I(_7'(."ZP['S/ .,48$70YIIY?4M &]MU[<UJJ8-B[I:EG8P\(P>;-]6
MC 6$(D8"F38M*1.^#Q^V:\T!0 ,#M3OX,O\X!!;,#H24@=LD4A   A8&3*0C
MW'LPX5M83]>6FYY.<VL1<=Y7UN_>AL@K<\O/ X;-;4MFR1\@(5Q1YIY_+.I#
MT.(H-6Q[8#6!+E&!6(*T \9 ;NV!STS?[9NV_%.8CR5*[U )_X'2 !:R[6';
M+)@..S!@V.KD@]\QN92.UGL#^I=,EX&M<LGLV(&/2/8);-(J RE7'N@0$#?:
M,CQ'%L4 EPVE)<!J00B=UBGR2E$8L_T,!) G'@^2BIYO<.?MD2[IG9>]!Y2L
M5?G1@J$&\A9(+SM8V+M"#I5Y!DWT&JX0WOPS*C7P8) 4V.S+G'+G\-X6MH5)
M-,!!48="*A?-V.0@GG@]'FN\+&S#'B@(3C('0'@;6$^PBI4W+T%2@D1'FI5%
M]G =[QH)B4!_3<M4T #2;?:Q;FZ!'N%Z^!ZL=J)P/#)<8(M^ TA^\DH\=P;&
M#'R6\,EJ3.DLCL-!,!<QK[J5R&J6,/Q39SZAN7V)P89>J90376N8X7''$$?8
M6H$5A IIH[ (.272Q'ZWY>'(8ZVMF%@ GN+OC46=,:\H<?^;@D_K?OC 41[
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M !3-ZMOL=W<=]G@5<X\):3/).\7B4N??0.0E[)6I35&";GEUL.V.RH1^Q^F
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MM1N(LW8._(6WT_1*V)4TCB44[)J<OAU&8-L)U6X\5<U46)+G&=,L2Q[J: .
MSPLBO]N$ -W?Q/0/4$L#!!0    ( !Q 55AE."D![@(  ,H&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;(U5VVZ;0!!]]U>,:%6U$@H7 P;?I#A-
MVCPDBFPG?:CZL(:QC0(LW5WLI%_?6;"I4]E67O8V,V?/G&&'X9:+9[E&5/"2
M9X4<&6NERKYER7B-.9,7O,2"+$LN<J9H*U:6+ 6RI [*,\NU[<#*65H8XV%]
M]B#&0UZI+"WP08"L\IR)UPEF?#LR'&-_,$U7:Z4/K/&P9"N<H7HL'P3MK!8E
M27,L9,H+$+@<&9=.?^)K_]KA*<6M/%B#SF3!^;/>W"8CP]:$,,-8:01&TP:O
M,,LT$-'XO<,TVBMUX.%ZCWY3YTZY+)C$*Y[]2!.U'AFA 0DN696I*=]^QUT^
M-<&89[(>8=OX>K8!<245SW?!Q"!/BV9F+SL=#@+"4P'N+L"M>3<7U2R_,L7&
M0\&W(+0WH>E%G6H=3>320A=EI@194XI3XRENL*@0/L_9(D/Y96@I0M4V*]XA
M3!H$]P2"X\(=+]1:PG618/(6P"(Z+2=WSVGBGD6\YYL+Z-HFN+;;/8/7;7/L
MUGC=$WAS?%$PR7C\##\O%U()^A1^'4NT@?&.P^CGT9<EBW%DT/<O46S0&'_Z
MX 3VX Q)KR7IG4,?SYI7 7P)!;U%R:@:L'B%4O"DBM4QNF<!C].%^R/8L$6!
M'2VV5MS5@].Y_C:]O9E?PNP)*,>>-X"/X'?-GNWKA6UZOD<+KVO:=M29"[YB
MX@_?N[JA:?L1N)$9V 0:F*'C=3Z2-70B?[";0L?L!1KD[7$]>8/0)HC>*6L0
MF>'9;\-O9???*[O8/0429H5\)5BY3F.6 :-F=TS^L\#OD7]_RVM= & 2ECRC
M+BG[_Q?CBA4L821&&&CU71K<(.H\%JG"!&:**4(D/;N1"[W0['D>!%2"*.I<
M5X(:.!4D ,=T X=&S_>I%JWZK="G-;4.^DN.8E5W40DQKPK5M)KVM&W4ETU_
M^N?>=/D[)E9I(2'#)87:%SU2432=L]DH7M;=:L$5];YZN::?#0KM0/8EYVJ_
MT1>TOZ_Q7U!+ P04    "  <0%585?H&P:D"  "#!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q]5$UOVS ,O>=7"%XQM(!;?\9-NL1 TVW8#BV"
MIML.PPZ*3<="9<F3E(_^^U%RZF58FHM$2>3CHZ3'R5:J9UT#&+)KN-!3KS:F
MO0D"7=304'TE6Q!X4DG54(-+M0ITJX"6+JCA01R&6=!0)KQ\XO;F*I_(M>%,
MP%P1O6X:JEYFP.5VZD7>Z\8C6]7&;@3YI*4K6(#YULX5KH(>I60-",VD( JJ
MJ7<;W<Q2Z^\<OC/8Z@.;V$J64C[;Q==RZH66$' HC$6@.&W@#CBW0$CC]Q[3
MZU/:P$/[%?VSJQUK65(-=Y+_8*6II][((R54=,W-H]Q^@7T]0XM72*[=2+:=
M[_#:(\5:&]GL@Y%!PT0WT]W^'@X"1N$; ?$^(':\NT2.Y4=J:#Y1<DN4]48T
M:[A273228\(^RL(H/&489_(Y*"V% $Y@AP^M09/S)[KDH"\F@<$$UBTH]F"S
M#BQ^ RR*R;T4IM;DDRBA_!<@0&8]O?B5WBP^B?@@-U<D"7T2AW%R B_IRTT<
M7O(&WA/L#)EQ63R3G[=+;13^BE_'"NU@TN,P5BDWNJ4%3#V4@@:U 2]__R[*
MP@\G2*8]R?04>K[H!$)DA?_+4,:A)$QT G0_>8GJ(NU_+W>LCM.9'J0!=[5V
MB.T0#1:44\7P'U!1$EU+92X-J(:<D3CUQTEJC=@/TS$:4>2GHW PE]I<0M-R
M^8)Z-23R1TF"8Y)F)$O3P:*F"BZM>$K,<5Y=^.?U!8G]*!R3Q,_"%'VS831X
MPCQ,=$4N04#%C$8W["]DF&48.AZ<V=\P&L66Q;4_S(:61>*/1^FQBP\.A-&
M6CGY:U+(M3"=1OK=OL/<=L+ZZ]ZUIWNJ5DQHPJ'"T/#J>N@1U4F^6QC9.IDM
MI4'1.K/&+@G*.N!Y)?&R]PN;H.^[^1]02P,$%     @ '$!56'Z>2OJD P
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MPRU>IJ"= :Y7"DN@G[@ P_6\_!=02P,$%     @ '$!56#7ZX.-X @  4 4
M !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL?511;]HP$'[OK[#2JMHD
MU 03&+00"=IUZT.GJNVVAVD/)KD0"\?.[ NT_WZV$S*V41X2V^?[/G_GN_-T
MJ_3:% !(7DHAS2PH$*O+,#1I 24S%ZH":7=RI4N&=JE7H:DTL,R#2A'2*!J%
M)>,R2*;>]J"3J:I1< D/FIBZ+)E^78!0VUG0#W:&1[XJT!G"9%JQ%3P!?JT>
MM%V%'4O&2Y"&*TDTY+-@WK]<Q,[?.WSCL#5[<^(B62JU=HN[;!9$3A (2-$Q
M,#MLX!J$<$16QJ^6,^B.=,#]^8[]UL=N8UDR ]=*?.<9%K-@') ,<E8+?%3;
MS]#&,W1\J1+&_\FV\1V. I+6!E79@JV"DLMF9"_M/>P!QM$; -H"J-?='.15
MWC!DR52K+='.V[*YB0_5HZTX+EU2GE#;76YQF"R4S QA,B.EDO!JJ?7:ED)>
M._.[9[848-Y/0[1'.4"8MK2+AI:^0=NGY%Y)+ SY*#/(_B8(K<9.*-T)7="C
MC%_4YH(,HAZA$1T<X1MT@0\\W^ -OF=X0;(0*EV3'_.E06WKX^>A0!N:^#"-
MZYE+4[$49H%M"@-Z T%R?MH?15='1,:=R/@8>W(#R+B C-S)IO]<(<^7MKE(
MD[BY3=R]3]Q]D[A;E[A#81P_R%VJNUEZTO">D?/3<7\27_EA>#7J12/ZGW7<
MFTRBDT\UTTPB6)E<;L"@[5DD*6CD.4\9@B&4CNT7GYRUP)9FU*.3B/QCG/1H
M/SYT=^%>E9>@5[Z7#4E5+;$I^,[:/1?SIDO^N#=OC;VL%9>&",@M-+KX, R(
M;OJW6:"J?,\L%=H.]-/"/GF@G8/=SY7"W<(=T#VBR6]02P,$%     @ '$!5
M6/'M=5Q> @  /P4  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL?51+
M;]LP#+[G5Q#:,&Q 4#MRDJ9=8J#I5FR';D73;8=A!\5F8J&RY$G*8_]^>B1N
MAB6Y6"1%?OQ(DQIOE'XV%:*%;2VDF9#*VN8Z24Q18<W,A6I0NIN%TC6S3M7+
MQ#0:61F":I'0-!TF->.2Y.-@>]#Y6*VLX!(?-)A573/]9XI";2:D1_:&1[ZL
MK#<D^;AA2YRA_=8\:*<E+4K):Y2&*PD:%Q-RT[N>]KU_</C.<6,.9/"5S)5Z
M]LKG<D)23P@%%M8C,'>L\1:%\$".QN\=)FE3^L!#>8]^%VIWM<R9P5LE?O#2
M5A,R(E#B@JV$?52;3[BK9^#Q"B5,^,(F^@Z'!(J5L:K>!3L&-9?Q9-M='PX"
M1NF) +H+H(%W3!18?F"6Y6.M-J"]MT/S0B@U1#MR7/J?,K/:W7(79_,GS4H$
M)DM0MD+M^EP@7[.Y0 -OG\+Y;IQ8E\G[)\4.=1I1Z0G4'H5[)6UEX*,LL?P7
M('$46YYTSW-*SR)^4>L+R-(NT)1F9_"RMNXLX&6GZL:MA:E0Q3/\O)D;J]UX
M_#I6:(3I'X?Q*W-M&E;@A+B=,*C72/(WKWK#]/T9DOV69/\<>CZ+FP)JX0;-
M,BZP!"[C)H:1GKLU WOZ%QXKZ'Q*WU[?8]J)DW$X#Z^A1[N75R,OI-WAX*HS
M8]YNV=9]7SR!TA0&V:CS];^1&L"H/^JX^*SK$P7$M#\XUJOD8*AKU,NPN@8*
MM9(VSG=K;5^'F[@4+^[Q:;EG>LFE 8$+%YI>7 X(Z+BN4;&J"2LR5]8M7! K
M]\*A]@[N?J&4W2L^0?MFYG\!4$L#!!0    ( !Q 55C^,$KD2P,  -D'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;(U536_;.!"]^U<,M,&B 8)(
MHB1_I+8!.VFQ/;0;),WN8=$#+8ULHA+I)2D[VU_?(64K7L!1>K$?R9G'-\,G
M<KI7^KO9(%IXKBMI9L'&VNU-&)I\@S4WUVJ+DE9*I6MN::C7H=EJY(5/JJN0
M1=$PK+F0P7SJY^[U?*H:6PF)]QI,4]=<_[?$2NUG01P<)Q[$>F/=1#B?;OD:
M']$^;>\UC<*.I1 U2B.4!(WE+%C$-\O,Q?N OP3NS0D&5\E*J>]N\*F8!9$3
MA!7FUC%P^MOA+5:5(R(9_QXX@VY+EWB*C^P??>U4RXH;O%75WZ*PFUDP#J#
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M1>T":+U4RAX';H/N-9__!%!+ P04    "  <0%58HQ*.TWT"  !9!0  &0
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M9MFQ"D8'[5Z#KKRI#2G41MJV\_O=_MVX;>WR+[Q]=!Z9KK@T1, *4^/+JW%
M=&OD=F%5X\VS5!:MZ*=K?/M NP \7REE]PMW0?^:YG\!4$L#!!0    ( !Q
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MP-3@9#+VNJO:+HQLG!13:5#8SBQQDH*R ;A?2&FV"UN@G\W)'U!+ P04
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M -VV@W9!JO8E.%=D"]I/2]M!43L#>[Y0BC8+%Z#OR=E?4$L#!!0    ( !Q
M55@1]M!F&@,  ,8&   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;(55
MWT_;,!!^[U]Q"M,$4D1^MREK*\$VM$F T&#;P[0'-[FV%HZ=V0ZE__W.21M
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M:-B UE=:NZ<!!]C_F2S^ U!+ P04    "  <0%58QC*%%B@#  #U!@  &0
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MX[A-AF')[Q*2-^#]A>'L;2<^P/ZEFWT'4$L#!!0    ( !Q 55B;.*"B^@(
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M#TB2# C.UEQPRVE\]LC6 LUP%EH*X,S"K =;=F#)"V!Q A^5M)6!MS+'_&>
MD)CMZ24[>LOD).*=>AK!.#J')$K&)_#&>[ECCS=^ >\--YE0IM4(J@ O'CX<
M:/]ZNS96TU7Y=DQ]AYT>QW;E<V,:EN$\H/HPJ)\P6/SQ*KZ,_CS!/-TS3T^A
M+QZZJG&TA:=]<&3'N)Y&6S&MMUR6\,1$BX,E$TQF",P LT!)QWJ->I?X&%Y#
M<CZ)KP:W6:;15Q,^4UL@%O%D.NC2V+ M%:NE^W,938:#MT5!A>?H9A63)0)W
M3OU8,^LN6IQ>#7\1.Z'8\?EUDAR+'<7_BYU.DM^*'4\'CZBIH)B'/&-#.+M.
MHN'@CAI)E^"S]1#&R>4O"(Z)X/5U.EBU6A,%:)3N$-,D)C0E+[)^YS5,IN.!
MB_2WA'>XUJT[SWC:P9R#K1!6JFZ8W(+MN6$.G&1UA$C%>XU$)A\!94/IG$Y0
M;'_VU)BW6>^F74NZ4,5%2]Z/9%12EP9NP-]/Z=$E%!3(Z>,R4S7)OE,683(<
M#5P"B.I'IK.*#N$(3<-+22 ,Y#YKOTG2;7C/0X['RB0\Z&TUZM)W< .9:J7M
MVMQ^=?](W':]\8=Y]\*0D))+E\V"7*/1=!)TX7<3JQK?*=?*4M_UPXH>.M3.
M@/8+1:GI)R[ _NE<_ =02P,$%     @ '$!56 B)YK>:"0  P1X  !D   !X
M;"]W;W)K<VAE971S+W-H965T-30N>&ULO5E;;]LZ$G[WKR!\F@,;4&21$G5I
M+D":]NP6V%[0M.<\+/:!D>E8B"Y>D4[2_?4[0\FR9,N*76#W(9%DD3/#F6]F
M/E*7ST7YJ)92:O*2I;FZ&B^U7KV=S52\E)E0=K&2.;Q9%&4F-#R6#S.U*J68
MFTE9.F..X\\RD>3CZTOSV]?R^K)8ZS3)Y=>2J'66B?+G.YD6SU=C.M[\\"UY
M6&K\879]N1(/\D[J'ZNO)3S-&BGS)).Y2HJ<E')Q-;ZA;]]1,\&,^#.1SZIU
M3W I]T7QB \?YU=C!RV2J8PUBA!P>9*W,DU1$MCQ[UKHN-&)$]OW&^E_F,7#
M8NZ%DK=%^E<RU\NK<3@F<[D0ZU1_*Y[_+NL%<907%ZDR_\ES/=89DWBM=)'5
MD\&"+,FKJWBI'7',!%9/8,;N2I&Q\KW0XOJR+)Y)B:-!&MZ8I9K98%R28U3N
M= EO$YBGK^^6HI0D%JM$"] MRE+D6A&1SR%0]RHNDY6N A!+N%5D\EW<IU)-
M+V<:U*.065RK>E>I8@=4448^%;E>*O(AG\MY5\ ,[&Z,9QOCW[%!B9^+)YNX
MCD68P]P!>6[C#-?(<P>=<5L[XY__@-?DHY:9^E??:BM97K\LS*:W:B5B>36&
M=%&R?)+CZ]]_H[YS,6"IUUCJ#4F_OJN2B!0+DDFAUJ6$3-'XN!!)29Y$NI;X
M5 >4I(FX3])$)U+U+658V:>6AKG0D@@ B";@?9G=R[*) /FHU%KDL:Q&M0P;
M?4O4X_FBE))XMLO\,^+:$3L;?7A907;*.7DJ4J'1P)\D#&WNAV?$IW84\K/1
MS9,LH3Z0H@)BFBPD27+R4XI2$=]FO+X-JNNH"N*J3,".-X3:O@L7UPX=T";+
M.%';E\QV';AP>#D0$][$A!\;DW@I\@>IT$Z]E"1?&S_!BVH1BD!]5!J2+,D?
M^N(QJ*@?6N3VD,XO^SK)?%WB!0>NA-)$/Q>U&Y]E:0*\*%*HV.KMZ"]3V"!&
MH@Z$[+IQA5J,BM'G/9VW-V_(C[LWHR^DQPBP]/:&P,N>=_T0HR2( HN'&-+?
M?PMIQ"_,Q;N@''"%\6:VXXS^AJ 'D^$EH_3"F,&]P J]@%#?]D-"71P'A7TA
M$[,X*'CR9964.[,FU/,L1MTIH0' !.=QUB!I3B9J"[>W.(-2&PK=!!8=VLR;
M3LF$48OZ?-HQF%\ ,IFW^8TXD XG^($1D!DZEL/-FKD5L7V/4%ANKR>"B%DT
M<@'WU*\RXQ@_@./]T)^BAUV/1#9U3C#8[0BC5A!X%N<1&D]M3N$:VE[8"*PA
MAIWF*($1\RWN&G&PJ%HLC4Z0Q[I8X9[E<@_E^ VN:'^$ ,4&X?6K0\#=B(>Q
M\ -$SR7GQI?^7HQP2.1;/L#4#''"5H#:@R;4L9@33JMA_#0$M051!]1YF%7G
MN%:G+X<JPUTK<CF,VH%-QRJ7@E416L5MA_X22HRR(+)</ZJ-\FV'_1(^4)3/
M+=^D"$J*3D-:UU.!%30F <8B?Z!Q^$WC\(]M'%B0LV(N4[+&ZJ(+8)A:EADR
MD44B6IT=F&'\2,0*.D"<B(JC8:'N[>^#^OO["5K2Y1)W-]\4>:A1D8#KE$Z
M%F/1T$2*> DD<564&N,+32$IYK"(39=YEXKX\?PN7A9 'D?=4MAS\9HRN8$A
MI!ES(+6Q0)F$.IJ5'#F0M4@*%'F.'(4[!SA*!$7KC' H6J\2E'##3S9W.PSE
MS6:EYAI=U-#<;;/;@0.("QK$!:<@KNKU)E0F$59E\93,@4M4(*L7EN35)A#N
M^S VJ/$ 9_D^I/S+GMJ#(9X<*,Q0RZ?VZ*MQ8(GTB'S>HV)=]+4%[#&?[E"
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M?=S]),J'!#R<R@5,A;TK'U>G59L'7:S,-\K[0NLB,[=+*>:RQ 'P?E$4>O.
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M93SSHC38.SFFW^!*%"2]8I46C8=Z%557DF?5M!*':ME1,&)QZN5IQ#+?"Z*
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M9F4F(4@+,/L;(?3!L0?TLS7["U!+ P04    "  <0%58>N1O^Y("  #<!0
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MJ)#CJ3Y, <? 5("\OJ%4'!9J@^9/C-G_4$L#!!0    ( !Q 55@;#34+3 ,
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MC8>\?2SPW@;2 /#]3@A]'I@%NIM@^C]02P,$%     @ '$!56.0Q%!V* @
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MGHA:%XS#C22J+DLJ'\^A$-NI-_!V"[=LG6NSX,>3BJYA"?JNNI$X\UN6E)7
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MXMY(OTI%T006$\4SVT<M[2O=#C>Z<09A-NC[*\[586(25*UX^!]02P,$%
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M@L(@.#7P+QBT"X/VM0:=PB#KNIOW/1,NQ!*/AYSM$->U%4U?9.IGUDHO0O5
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MS+D?(HNHFUL=*%Z9_K#@"KN-&6;X/P"A$W!]R;G:![KEM'^8^!]02P,$%
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ME\0\$O-)+""QD,0B$HM)+($P(?.'@Y?0WUXL_T<72.1&WP!'-175-%334<U
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M"CFHZ64L9V]@RD ^GU,J-AMU037-^W\!4$L#!!0    ( !Q 55BS4O$'\0(
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MM?I>H_HI*"DDIEY,_M@<Z9 [4)CT91:RA0+ @F!VT6D$?J/7^C7M?FO1[1^
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M _E^3:EXNE$+-"?I\_\!4$L#!!0    ( !Q 55CV18*FE@,  "D1   9
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M970X-RYX;6R]W5MSXD8:QO&OTN5-;255LS9(@#VS'E?-6.=#,I5)-A>IO=!
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MAK@-X"HU:DG\!TFN?2/BWVQ[C@;>:^1[_J"GH)OCT_V>]/#X=&Q@,ZA?\*#
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MQ>MU5LK1@[7?-R\_#:.6KJY#--*&:A:JV:CFH)J+:AZJ^:@6H%J(:A&EM=N
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MJ.:AFH]J :J%J!916KO-:))HLZ_R2MH9&DU#-1/5+%2S4<U!-1?5/%3S42U
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MC.NT)_I)>Z(>_?67*BQ2M2/U%HT?XW1=)1/EW8#JK2\R2*1Z3O?"0JYO9-#
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M((T!/H^%T/N%.7YICMN6_P%02P,$%     @ '$!56% -_(J; P  , P  !D
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M20A3C+5A8/2SP1M,4T-$:?RL.)UZ2Q.X.WYA_UAJ)RUSIO!&I/_P1*]&3N1
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M#Z*5S=?*%FAE"[6R+72QT;G4.RMPJ+6B](0 "FP.TW5MUHU6Q/D"'#(A]X1
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M /E^DV7ETTD5H'L/:?8?4$L#!!0    ( !Q 55BEA++TA0(  +(%   9
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M$D6C,E(NKGOM+JX+=7&A- :E<2A-0&D21:,R5"ZNJW=QSW5J]'AC$6UISOY
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M+M$=<G*@NUI :0Q*XU":@-(DBD9EI#QA_]IWM?"AKC*4QJ T#J4)*$VB:/2
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MSR^X?N]<:7USC0,/-8:A-(FBT< K8SC6.GY# UK#^05]!<8C#*BQ"Z5Q*$U
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M"Q4J7\-"<R,'?$UAR86J*P1*TFET>*UT7XD&<J2&Y$(VL#\Z##!Z5:[1?E)
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M&5Q-\0!4TU$V R,KUV.MI<&.S3T6V(2#L@&XGDMI]@.[0=?6)S\!4$L#!!0
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MDH@*/0"^GW&NGG?T":IW3\;_ U!+ P04    "  <0%58-9\NHT\&  "(+
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MAS1(HX#G<R'T6C 7-&,_^@=02P,$%     @ '$!56"XI<D\B P  G0P  !H
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M*?X_@+(#L'\JI7FJV!MJ_4<R^@U02P,$%     @ '$!56-IQ_-JQ @  Y <
M !H   !X;"]W;W)K<VAE971S+W-H965T,3$T+GAM;,U5WV_3,!#^5ZP@(9"V
M)4WZ XTTTCJ$X $TK< >)AZ<Y-)8\X]@.^W@K^?LI%$&;1^0)O'2V+Z[[[[[
M[FJG.Z4?3 U@R:/@TBR#VMKF,@Q-48.@YD(U(-%2*2VHQ:W>A*;10$L?)'@8
M1]$\%)3)($O]V8W.4M5:SB3<:&):(:C^N0*N=LM@$NP/;MFFMNX@S-*&;F -
M]FMSHW$7#B@E$R -4Y)HJ);!U>1RM7#^WN$;@YT9K8FK)%?JP6T^ELL@<H2
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MOY*-H('ABP53Y16MJ]@AK!@OE1;Y!@SSG/+JCN\V1FP!W& 'P-L O)<"_ W
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M=J^::%&4'=.-T-!_E<,,6F0B30"\7PBA'R:F":N;[N@_4$L#!!0    ( !Q
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MJI<33E:J>;TG7+3":AB+ZPU0:2#V%X3P[42^H+XP^?\!4$L#!!0    ( !Q
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M;*R+6I2-=#E1/"]ZT7NN=&=;#%/]\0'"!.C[2\[5T\2TM_7G3/0?4$L#!!0
M   ( !Q 55@YT>4B! ,  "@)   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M.2YX;6RM5M]OFS 0_E<L5DVMM)3?T'0)4M-LVC1UBIIU>YCVX, EH(+-;"=I
M_OO9AK $:):'O8!M[OM\WYVY\VA+V3-/ 01Z*7+"QT8J1'EKFCQ.H<#\FI9
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MSE 69RJ+,Y:%F<N2_W4PZ_LX[O]Q_/$:]U4[O.8G2U%W\Q-02P$"% ,4
M"  <0%58!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( !Q 55A5(I<-[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !Q 55B97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ '$!56.7'F,X1!P  1"(  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !Q 55@Y^G_I
MY 8  %\@   8              " @50/  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  <0%58]1G(L0H'   K'0  &
M@(%N%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ '$!5
M6#J:02ZF @  [08  !@              ("!KAT  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( !Q 55A.U''5IPX  ,2-   8
M      " @8H@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  <0%58_AN+!4D,   "1   &               @(%G+P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ '$!56-X]*:@Z$   O2P  !@
M             ("!YCL  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( !Q 55B]+D=&5"8  'N    8              " @59,  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  <0%583>.85#L$  #]
M"0  &               @('@<@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ '$!56""3F",+ P  B 8  !D              ("!47<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  <0%587<GO
MB(L#  "H!P  &0              @(&3>@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( !Q 55C0"*LQF (  - %   9
M  " @55^  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M'$!56.C\0:U. @  3 4  !D              ("!)($  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  <0%58#N;_(>$#   7"0  &0
M            @(&I@P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( !Q 55B;_R/GTP,  %$(   9              " @<&'  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ '$!56-&RZ>E  @
M%@4  !D              ("!RXL  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  <0%58ID<)NW #  #O!P  &0              @(%"
MC@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !Q 55CI
M@9^)C@(  ,0%   9              " @>F1  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ '$!56'I)0(#-"P  O!\  !D
M     ("!KI0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !Q 55BNP1UH#@,  *8'   9              "
M@42W  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ '$!5
M6/X$( 4E P  / <  !D              ("!B;H  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  <0%58BST@R?@6  #E00  &0
M        @('EO0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( !Q 55C.>II,%P<  "<1   9              " @135  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ '$!56.82V$_Z @  $P<
M !D              ("!8MP  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  <0%58W@:$=#0+  !"'   &0              @(&3WP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !Q 55BU&<?G
M@@0  +,)   9              " @?[J  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ '$!56$HR+)X)!0  )@P  !D
M ("!M^\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  <
M0%58+()9G(D"  "A!0  &0              @('W]   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !Q 55AOEOC V@(  &P&   9
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M970S-RYX;6Q02P$"% ,4    "  <0%585?H&P:D"  "#!0  &0
M    @(&=+ $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M !Q 55A^GDKZI ,  *H'   9              " @7TO 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ '$!56#7ZX.-X @  4 4  !D
M             ("!6#,! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  <0%58\>UU7%X"   _!0  &0              @($'-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !Q 55C^,$KD2P,
M -D'   9              " @9PX 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ '$!56*,2CM-] @  604  !D              ("!
M'CP! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  <0%58
M-<],4TX"   (!0  &0              @('2/@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( !Q 55@$F1G0? ,  /H'   9
M      " @5=! 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ '$!56)6VX+V, @  IP4  !D              ("!"D4! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  <0%58*NA"I2@$   \"@
M&0              @('-1P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( !Q 55A@!GSB;@(  )\%   9              " @2Q, 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ '$!56!'VT&8:
M P  Q@8  !D              ("!T4X! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  <0%58FVV6F_8#  "E"   &0
M@($B4@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !Q
M55C&,H46* ,  /4&   9              " @4]6 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ '$!56)LXH*+Z @  50<  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( !Q 55AERTU##P,  *0&   9
M  " @?)V 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M'$!56(+)0-IB @  9P4  !D              ("!.'H! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    "  <0%58>N1O^Y("  #<!0  &0
M            @('1? $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( !Q 55BVJJY1K@0  *X4   9              " @9I_ 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ '$!56 (J_MZD P
M(Q   !D              ("!?X0! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    "  <0%582D!>AFX$   .&P  &0              @(%:
MB $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !Q 55BI
MM2FYG@,  $,1   9              " @?^, 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ '$!56#Y,O-^& P  T!   !D
M     ("!U) ! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !Q 55C/J0^O$P,  )8+   9              "
M@7"C 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ '$!5
M6"8,96^B @  1@<  !D              ("!NJ8! 'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    "  <0%58,@)$=?T"  "6"   &0
M        @(&3J0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0
M   ( !Q 55B="IU%N@4   PR   9              " @<>L 0!X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ '$!56.M]*?R= @  !@<
M !D              ("!N+(! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q0
M2P$"% ,4    "  <0%58YY^_(( $  #(&0  &0              @(&,M0$
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( !Q 55CZ43;.
M9@(  &T&   9              " @4.Z 0!X;"]W;W)K<VAE971S+W-H965T
M-S4N>&UL4$L! A0#%     @ '$!56';\,S,@"0  *4\  !D
M ("!X+P! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    "  <
M0%58L8/B:'D#  #="@  &0              @($WQ@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !Q 55C+QBBBH@D   E2   9
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M970X,BYX;6Q02P$"% ,4    "  <0%58?V%G>&\#   _"@  &0
M    @('\^0$ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    (
M !Q 55CY?:PQN@(  (P'   9              " @:+] 0!X;"]W;W)K<VAE
M971S+W-H965T.#0N>&UL4$L! A0#%     @ '$!56$[W0O&8!   51<  !D
M             ("!DP " 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"
M% ,4    "  <0%58]D6"II8#   I$0  &0              @(%B!0( >&PO
M=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( !Q 55BOGI18BQ
M !H' 0 9              " @2\) @!X;"]W;W)K<VAE971S+W-H965T.#<N
M>&UL4$L! A0#%     @ '$!56.!MRF+T!   "2   !D              ("!
M\1D" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4    "  <0%58
M!1&J3TL#  !G#0  &0              @($<'P( >&PO=V]R:W-H965T<R]S
M:&5E=#@Y+GAM;%!+ 0(4 Q0    ( !Q 55BO12(C:@0  #,7   9
M      " @9XB @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%
M  @ '$!56&=7R+!)!   UPT  !D              ("!/R<" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    "  <0%58E]1^6>@#   8$
M&0              @(&_*P( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+
M 0(4 Q0    ( !Q 55@Z_K'J%2   $NV 0 9              " @=XO @!X
M;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ '$!56!=[M?L=
M!   >A,  !D              ("!*E " 'AL+W=O<FMS:&5E=',O<VAE970Y
M-"YX;6Q02P$"% ,4    "  <0%584 W\BIL#   P#   &0
M@(%^5 ( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( !Q
M55A9_S#4-0<  ),T   9              " @5!8 @!X;"]W;W)K<VAE971S
M+W-H965T.38N>&UL4$L! A0#%     @ '$!56*6$LO2% @  L@4  !D
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M970Q,#$N>&UL4$L! A0#%     @ '$!56 :[M=OP @  >PD  !H
M     ("!KG\" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%
M  @ '$!56"9K9TAG P  C0L  !H              ("!UH(" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ '$!56(DLN#2' P  7@H
M !H              ("!=88" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL
M4$L! A0#%     @ '$!56&HC[#X' P  ?0H  !H              ("!-(H"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ '$!56.C'
M):!#"@  ZF(  !H              ("!<XT" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#8N>&UL4$L! A0#%     @ '$!56*4)'6QR P  X@L  !H
M     ("![I<" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%
M  @ '$!56&\Z<LC;!0  AR(  !H              ("!F)L" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @ '$!56#6?+J-/!@  B"P
M !H              ("!JZ$" 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL
M4$L! A0#%     @ '$!56.4OQYC1!0  UB<  !H              ("!,J@"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%     @ '$!56 M&
MXFW] @  L H  !H              ("!.ZX" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,3$N>&UL4$L! A0#%     @ '$!56!BP+!K0 @   @@  !H
M     ("!<+$" 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%
M  @ '$!56"XI<D\B P  G0P  !H              ("!>+0" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @ '$!56-IQ_-JQ @  Y <
M !H              ("!TK<" 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&UL
M4$L! A0#%     @ '$!56+<[E JE @  [P4  !H              ("!N[H"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%     @ '$!56/MT
MD'0& P  @ L  !H              ("!F+T" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,38N>&UL4$L! A0#%     @ '$!56-;[,^X? P  / T  !H
M     ("!UL " 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&UL4$L! A0#%
M  @ '$!56&B+4SGX @  V@P  !H              ("!+<0" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%     @ '$!56#G1Y2($ P  * D
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M;',O+G)E;'-02P$"% ,4    "  <0%58\*]G1/<'  !L3@  #P
M    @ &%T0( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ '$!56&SRAGM,
M P  :T8  !H              ( !J=D" 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ '$!56(/_L%J7 @  BT,  !,
M ( !+=T" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     (  @ !,(P  ]=\"
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>540</ContextCount>
  <ElementCount>520</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>167</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Net Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BasisOfPreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Personnel expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PersonnelExpenses</Role>
      <ShortName>Personnel expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Finance income and finance costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinanceIncomeAndFinanceCosts</Role>
      <ShortName>Finance income and finance costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Bonds and money market funds</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BondsAndMoneyMarketFunds</Role>
      <ShortName>Bonds and money market funds</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Trade And Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TradeAndOtherReceivables</Role>
      <ShortName>Trade And Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Tax credits and grants receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TaxCreditsAndGrantsReceivable</Role>
      <ShortName>Tax credits and grants receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Prepaid Expenses and Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PrepaidExpensesAndDeposits</Role>
      <ShortName>Prepaid Expenses and Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Right-of-use assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RightOfUseAssets</Role>
      <ShortName>Right-of-use assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IntangibleAssets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Other asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OtherAsset</Role>
      <ShortName>Other asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Accounts payable and accured liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities</Role>
      <ShortName>Accounts payable and accured liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/Provisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LoanFacility</Role>
      <ShortName>Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Convertible unsecured senior notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes</Role>
      <ShortName>Convertible unsecured senior notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Leases liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LeasesLiabilities</Role>
      <ShortName>Leases liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Share capital warrants and subscription receipts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts</Role>
      <ShortName>Share capital warrants and subscription receipts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Supplemental cash flow disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SupplementalCashFlowDisclosures</Role>
      <ShortName>Supplemental cash flow disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Capital management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/CapitalManagement</Role>
      <ShortName>Capital management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Determination of fair values</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/DeterminationOfFairValues</Role>
      <ShortName>Determination of fair values</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Operating segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OperatingSegments</Role>
      <ShortName>Operating segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RelatedParties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/Revenue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Personnel expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PersonnelExpensesTables</Role>
      <ShortName>Personnel expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/PersonnelExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Finance income and finance costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables</Role>
      <ShortName>Finance income and finance costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/FinanceIncomeAndFinanceCosts</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Bonds and money market funds (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BondsAndMoneyMarketFundsTables</Role>
      <ShortName>Bonds and money market funds (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/BondsAndMoneyMarketFunds</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TradeAndOtherReceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Tax credits and grants receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables</Role>
      <ShortName>Tax credits and grants receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/TaxCreditsAndGrantsReceivable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/Inventories</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Prepaid Expenses and Deposits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PrepaidExpensesAndDepositsTables</Role>
      <ShortName>Prepaid Expenses and Deposits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/PrepaidExpensesAndDeposits</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Property and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/PropertyAndEquipment</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Right-of-use assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RightOfUseAssetsTables</Role>
      <ShortName>Right-of-use assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/RightOfUseAssets</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/IntangibleAssets</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Other asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OtherAssetTables</Role>
      <ShortName>Other asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/OtherAsset</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Accounts Payable and accured liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables</Role>
      <ShortName>Accounts Payable and accured liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/Provisions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Loan Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LoanFacilityTables</Role>
      <ShortName>Loan Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/LoanFacility</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Convertible unsecured senior notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables</Role>
      <ShortName>Convertible unsecured senior notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Leases liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LeasesLiabilitiesTables</Role>
      <ShortName>Leases liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/LeasesLiabilities</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Share capital warrants and subscription receipts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables</Role>
      <ShortName>Share capital warrants and subscription receipts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/FinancialInstruments</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Determination of fair values (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/DeterminationOfFairValuesTables</Role>
      <ShortName>Determination of fair values (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/DeterminationOfFairValues</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Operating segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/OperatingSegments</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RelatedPartiesTables</Role>
      <ShortName>Related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.theratech.com/role/RelatedParties</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Basis of preparation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail</Role>
      <ShortName>Basis of preparation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Significant accounting policies - Summary of methods of depreciation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail</Role>
      <ShortName>Significant accounting policies - Summary of methods of depreciation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Significant accounting policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant accounting policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Revenue - Schedule of net sale by product (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail</Role>
      <ShortName>Revenue - Schedule of net sale by product (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Revenue - Schedule of net revenue by geographical area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail</Role>
      <ShortName>Revenue - Schedule of net revenue by geographical area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Personnel expenses - Summary of detailed information about personnel expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail</Role>
      <ShortName>Personnel expenses - Summary of detailed information about personnel expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Personnel expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail</Role>
      <ShortName>Personnel expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Finance income and finance costs - Summary of detailed information about finance income and cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail</Role>
      <ShortName>Finance income and finance costs - Summary of detailed information about finance income and cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail</Role>
      <ShortName>Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Bonds and money market funds - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail</Role>
      <ShortName>Bonds and money market funds - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Trade and other receivables -Summary of detailed information about trade and other receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail</Role>
      <ShortName>Trade and other receivables -Summary of detailed information about trade and other receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail</Role>
      <ShortName>Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail</Role>
      <ShortName>Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Inventories - Summary of detailed information about inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail</Role>
      <ShortName>Inventories - Summary of detailed information about inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Inventories - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/InventoriesAdditionalInformationDetail</Role>
      <ShortName>Inventories - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail</Role>
      <ShortName>Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Property and equipment - Summary of information about property plant equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail</Role>
      <ShortName>Property and equipment - Summary of information about property plant equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Right-of-use assets - Disclosure of right of use asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail</Role>
      <ShortName>Right-of-use assets - Disclosure of right of use asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Intangible asset - Summary of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible asset - Summary of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Intangible assets - Summary of Commercial Milestone Payment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail</Role>
      <ShortName>Intangible assets - Summary of Commercial Milestone Payment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Intangible assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Other asset - Summary of detailed information about other asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail</Role>
      <ShortName>Other asset - Summary of detailed information about other asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Other asset - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OtherAssetAdditionalInformationDetail</Role>
      <ShortName>Other asset - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Accounts payable and accrued liabilities - Summary of 	accounts payable and accrued liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail</Role>
      <ShortName>Accounts payable and accrued liabilities - Summary of 	accounts payable and accrued liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Accounts payable and accrued liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Accounts payable and accrued liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Provisions - Summary of provision (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail</Role>
      <ShortName>Provisions - Summary of provision (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Provisions - Summary of provision (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail</Role>
      <ShortName>Provisions - Summary of provision (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Loan Facility - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail</Role>
      <ShortName>Loan Facility - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Loan Facility - Summary of movement in the carrying value of the long term loan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail</Role>
      <ShortName>Loan Facility - Summary of movement in the carrying value of the long term loan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Convertible unsecured senior notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail</Role>
      <ShortName>Convertible unsecured senior notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail</Role>
      <ShortName>Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Leases liabilities - Summary of lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases liabilities - Summary of lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail</Role>
      <ShortName>Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Share capital warrants and subscription receipts - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Income Taxes - Summary of components of the current and deferred tax expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail</Role>
      <ShortName>Income Taxes - Summary of components of the current and deferred tax expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Income Taxes - Summary of reconciliation between effective and applicable tax (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail</Role>
      <ShortName>Income Taxes - Summary of reconciliation between effective and applicable tax (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail</Role>
      <ShortName>Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail</Role>
      <ShortName>Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>1108 - Disclosure - Financial instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>1109 - Disclosure - Financial instruments - Summary of the contractual maturities of financial liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail</Role>
      <ShortName>Financial instruments - Summary of the contractual maturities of financial liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>1110 - Disclosure - Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail</Role>
      <ShortName>Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>1111 - Disclosure - Financial instruments - Summary of exchange rates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail</Role>
      <ShortName>Financial instruments - Summary of exchange rates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>1112 - Disclosure - Financial instruments - Summary of Company's foreign currency exposures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail</Role>
      <ShortName>Financial instruments - Summary of Company's foreign currency exposures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>1113 - Disclosure - Capital management - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail</Role>
      <ShortName>Capital management - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>1114 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail</Role>
      <ShortName>Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>1115 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail</Role>
      <ShortName>Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>1116 - Disclosure - Commitments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/CommitmentsAdditionalInformationDetail</Role>
      <ShortName>Commitments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>1117 - Disclosure - Operating segments - Summary of single operating segment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail</Role>
      <ShortName>Operating segments - Summary of single operating segment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>1118 - Disclosure - Operating segments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail</Role>
      <ShortName>Operating segments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>1119 - Disclosure - Related parties - Summary of key management personnel compensation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail</Role>
      <ShortName>Related parties - Summary of key management personnel compensation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="d680117d20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>1120 - Disclosure - Related parties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail</Role>
      <ShortName>Related parties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="d680117d20f.htm">d680117d20f.htm</File>
    <File>thtx-20231130.xsd</File>
    <File>thtx-20231130_cal.xml</File>
    <File>thtx-20231130_def.xml</File>
    <File>thtx-20231130_lab.xml</File>
    <File>thtx-20231130_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g680117dsp18.jpg</File>
    <File>g680117g40w01.jpg</File>
    <File>g680117g40w02.jpg</File>
    <File>g680117g40w03.jpg</File>
    <File>g680117g40w04.jpg</File>
    <File>g680117g40w05.jpg</File>
    <File>g680117g40w06.jpg</File>
    <File>g680117g40w07.jpg</File>
    <File>g680117g40w08.jpg</File>
    <File>g680117g40w09.jpg</File>
    <File>g680117g40w11.jpg</File>
    <File>g680117g40w12.jpg</File>
    <File>g680117g40w13.jpg</File>
    <File>g680117g40w14.jpg</File>
    <File>g680117g50w10.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="50">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="1116">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>194
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d680117d20f.htm": {
   "nsprefix": "thtx",
   "nsuri": "http://www.theratech.com/20231130",
   "dts": {
    "inline": {
     "local": [
      "d680117d20f.htm"
     ]
    },
    "schema": {
     "local": [
      "thtx-20231130.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "thtx-20231130_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "thtx-20231130_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "thtx-20231130_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "thtx-20231130_pre.xml"
     ]
    }
   },
   "keyStandard": 302,
   "keyCustom": 218,
   "axisStandard": 32,
   "axisCustom": 17,
   "memberStandard": 39,
   "memberCustom": 121,
   "hidden": {
    "total": 8,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 2,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 540,
   "entityCount": 1,
   "segmentCount": 167,
   "elementCount": 929,
   "unitCount": 11,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1116,
    "http://xbrl.sec.gov/dei/2023": 50
   },
   "report": {
    "R1": {
     "role": "http://www.theratech.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "1002 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:Cash",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "thtx:IncomeTaxReceivableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
     "longName": "1003 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss",
     "shortName": "Consolidated Statements of Net Loss and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical",
     "longName": "1004 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical)",
     "shortName": "Consolidated Statements of Net Loss and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
     "longName": "1005 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2020",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2020",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AdjustmentsForDepreciationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.theratech.com/role/BasisOfPreparation",
     "longName": "1007 - Disclosure - Basis of preparation",
     "shortName": "Basis of preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.theratech.com/role/SignificantAccountingPolicies",
     "longName": "1008 - Disclosure - Significant accounting policies",
     "shortName": "Significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.theratech.com/role/Revenue",
     "longName": "1009 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.theratech.com/role/PersonnelExpenses",
     "longName": "1010 - Disclosure - Personnel expenses",
     "shortName": "Personnel expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.theratech.com/role/FinanceIncomeAndFinanceCosts",
     "longName": "1011 - Disclosure - Finance income and finance costs",
     "shortName": "Finance income and finance costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.theratech.com/role/BondsAndMoneyMarketFunds",
     "longName": "1012 - Disclosure - Bonds and money market funds",
     "shortName": "Bonds and money market funds",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.theratech.com/role/TradeAndOtherReceivables",
     "longName": "1013 - Disclosure - Trade And Other Receivables",
     "shortName": "Trade And Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.theratech.com/role/TaxCreditsAndGrantsReceivable",
     "longName": "1014 - Disclosure - Tax credits and grants receivable",
     "shortName": "Tax credits and grants receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfTaxCreditsReceivableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfTaxCreditsReceivableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.theratech.com/role/Inventories",
     "longName": "1015 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.theratech.com/role/PrepaidExpensesAndDeposits",
     "longName": "1016 - Disclosure - Prepaid Expenses and Deposits",
     "shortName": "Prepaid Expenses and Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.theratech.com/role/PropertyAndEquipment",
     "longName": "1017 - Disclosure - Property and equipment",
     "shortName": "Property and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.theratech.com/role/RightOfUseAssets",
     "longName": "1018 - Disclosure - Right-of-use assets",
     "shortName": "Right-of-use assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.theratech.com/role/IntangibleAssets",
     "longName": "1019 - Disclosure - Intangible assets",
     "shortName": "Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.theratech.com/role/OtherAsset",
     "longName": "1020 - Disclosure - Other asset",
     "shortName": "Other asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities",
     "longName": "1021 - Disclosure - Accounts payable and accured liabilities",
     "shortName": "Accounts payable and accured liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.theratech.com/role/Provisions",
     "longName": "1022 - Disclosure - Provisions",
     "shortName": "Provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.theratech.com/role/LoanFacility",
     "longName": "1023 - Disclosure - Loan Facility",
     "shortName": "Loan Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes",
     "longName": "1024 - Disclosure - Convertible unsecured senior notes",
     "shortName": "Convertible unsecured senior notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.theratech.com/role/LeasesLiabilities",
     "longName": "1025 - Disclosure - Leases liabilities",
     "shortName": "Leases liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts",
     "longName": "1026 - Disclosure - Share capital warrants and subscription receipts",
     "shortName": "Share capital warrants and subscription receipts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.theratech.com/role/IncomeTaxes",
     "longName": "1027 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.theratech.com/role/SupplementalCashFlowDisclosures",
     "longName": "1028 - Disclosure - Supplemental cash flow disclosures",
     "shortName": "Supplemental cash flow disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.theratech.com/role/FinancialInstruments",
     "longName": "1029 - Disclosure - Financial instruments",
     "shortName": "Financial instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.theratech.com/role/CapitalManagement",
     "longName": "1030 - Disclosure - Capital management",
     "shortName": "Capital management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.theratech.com/role/DeterminationOfFairValues",
     "longName": "1031 - Disclosure - Determination of fair values",
     "shortName": "Determination of fair values",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.theratech.com/role/Commitments",
     "longName": "1032 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.theratech.com/role/OperatingSegments",
     "longName": "1033 - Disclosure - Operating segments",
     "shortName": "Operating segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.theratech.com/role/RelatedParties",
     "longName": "1034 - Disclosure - Related parties",
     "shortName": "Related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "1035 - Disclosure - Significant accounting policies (Policies)",
     "shortName": "Significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.theratech.com/role/SignificantAccountingPoliciesTables",
     "longName": "1036 - Disclosure - Significant accounting policies (Tables)",
     "shortName": "Significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.theratech.com/role/RevenueTables",
     "longName": "1037 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.theratech.com/role/PersonnelExpensesTables",
     "longName": "1038 - Disclosure - Personnel expenses (Tables)",
     "shortName": "Personnel expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables",
     "longName": "1039 - Disclosure - Finance income and finance costs (Tables)",
     "shortName": "Finance income and finance costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.theratech.com/role/BondsAndMoneyMarketFundsTables",
     "longName": "1040 - Disclosure - Bonds and money market funds (Tables)",
     "shortName": "Bonds and money market funds (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.theratech.com/role/TradeAndOtherReceivablesTables",
     "longName": "1041 - Disclosure - Trade and other receivables (Tables)",
     "shortName": "Trade and other receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables",
     "longName": "1042 - Disclosure - Tax credits and grants receivable (Tables)",
     "shortName": "Tax credits and grants receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfTaxCreditsReceivableExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfTaxCreditsReceivableExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.theratech.com/role/InventoriesTables",
     "longName": "1043 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.theratech.com/role/PrepaidExpensesAndDepositsTables",
     "longName": "1044 - Disclosure - Prepaid Expenses and Deposits (Tables)",
     "shortName": "Prepaid Expenses and Deposits (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.theratech.com/role/PropertyAndEquipmentTables",
     "longName": "1045 - Disclosure - Property and equipment (Tables)",
     "shortName": "Property and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.theratech.com/role/RightOfUseAssetsTables",
     "longName": "1046 - Disclosure - Right-of-use assets (Tables)",
     "shortName": "Right-of-use assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:RightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:RightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.theratech.com/role/IntangibleAssetsTables",
     "longName": "1047 - Disclosure - Intangible assets (Tables)",
     "shortName": "Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.theratech.com/role/OtherAssetTables",
     "longName": "1048 - Disclosure - Other asset (Tables)",
     "shortName": "Other asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables",
     "longName": "1049 - Disclosure - Accounts Payable and accured liabilities (Tables)",
     "shortName": "Accounts Payable and accured liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.theratech.com/role/ProvisionsTables",
     "longName": "1050 - Disclosure - Provisions (Tables)",
     "shortName": "Provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.theratech.com/role/LoanFacilityTables",
     "longName": "1051 - Disclosure - Loan Facility (Tables)",
     "shortName": "Loan Facility (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables",
     "longName": "1052 - Disclosure - Convertible unsecured senior notes (Tables)",
     "shortName": "Convertible unsecured senior notes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.theratech.com/role/LeasesLiabilitiesTables",
     "longName": "1053 - Disclosure - Leases liabilities (Tables)",
     "shortName": "Leases liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables",
     "longName": "1054 - Disclosure - Share capital warrants and subscription receipts (Tables)",
     "shortName": "Share capital warrants and subscription receipts (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.theratech.com/role/IncomeTaxesTables",
     "longName": "1055 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsTables",
     "longName": "1056 - Disclosure - Financial instruments (Tables)",
     "shortName": "Financial instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.theratech.com/role/DeterminationOfFairValuesTables",
     "longName": "1057 - Disclosure - Determination of fair values (Tables)",
     "shortName": "Determination of fair values (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "57",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.theratech.com/role/OperatingSegmentsTables",
     "longName": "1058 - Disclosure - Operating segments (Tables)",
     "shortName": "Operating segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.theratech.com/role/RelatedPartiesTables",
     "longName": "1059 - Disclosure - Related parties (Tables)",
     "shortName": "Related parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
     "longName": "1060 - Disclosure - Basis of preparation - Additional Information (Detail)",
     "shortName": "Basis of preparation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:BorrowingsInterestRateBasis",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_TopOfRangeMemberifrsfullRangeAxis",
      "name": "thtx:MinimumLiquidityRequirementAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail",
     "longName": "1061 - Disclosure - Significant accounting policies - Summary of methods of depreciation (Detail)",
     "shortName": "Significant accounting policies - Summary of methods of depreciation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "name": "ifrs-full:DepreciationMethodPropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis",
      "name": "ifrs-full:DepreciationMethodPropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "1062 - Disclosure - Significant accounting policies - Additional Information (Detail)",
     "shortName": "Significant accounting policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail",
     "longName": "1063 - Disclosure - Revenue - Schedule of net sale by product (Detail)",
     "shortName": "Revenue - Schedule of net sale by product (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
     "longName": "1064 - Disclosure - Revenue - Schedule of net revenue by geographical area (Detail)",
     "shortName": "Revenue - Schedule of net revenue by geographical area (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_CAifrsfullGeographicalAreasAxis",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisaggregationOfRevenueByGeographicalAreaTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail",
     "longName": "1065 - Disclosure - Personnel expenses - Summary of detailed information about personnel expenses (Detail)",
     "shortName": "Personnel expenses - Summary of detailed information about personnel expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail",
     "longName": "1066 - Disclosure - Personnel expenses - Additional Information (Detail)",
     "shortName": "Personnel expenses - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail",
     "longName": "1067 - Disclosure - Finance income and finance costs - Summary of detailed information about finance income and cost (Detail)",
     "shortName": "Finance income and finance costs - Summary of detailed information about finance income and cost (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail",
     "longName": "1068 - Disclosure - Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail)",
     "shortName": "Bonds and money market funds - Summary of detailed information about bonds and money market funds (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:GovernmentDebtInstrumentsHeld",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:GovernmentDebtInstrumentsHeld",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
     "longName": "1069 - Disclosure - Bonds and money market funds - Additional information (Detail)",
     "shortName": "Bonds and money market funds - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:FinancialAssetsAverageMaturityTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:FinancialAssetsAverageMaturityTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail",
     "longName": "1070 - Disclosure - Trade and other receivables -Summary of detailed information about trade and other receivables (Detail)",
     "shortName": "Trade and other receivables -Summary of detailed information about trade and other receivables (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail",
     "longName": "1071 - Disclosure - Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail)",
     "shortName": "Tax credits and grants receivable - Disclosure Details Of Tax Credits Roll Forward (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "thtx:TaxCreditsAndGrantsReceivable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock",
       "thtx:DisclosureOfTaxCreditsReceivableExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail",
     "longName": "1072 - Disclosure - Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail)",
     "shortName": "Tax credits and grants receivable - Summary of information about unused and unrecorded non refundable federal tax credit (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail",
     "longName": "1073 - Disclosure - Inventories - Summary of detailed information about inventories (Detail)",
     "shortName": "Inventories - Summary of detailed information about inventories (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.theratech.com/role/InventoriesAdditionalInformationDetail",
     "longName": "1074 - Disclosure - Inventories - Additional Information (Detail)",
     "shortName": "Inventories - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail",
     "longName": "1075 - Disclosure - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail)",
     "shortName": "Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "thtx:PrepaidExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "thtx:PrepaidExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
     "longName": "1076 - Disclosure - Property and equipment - Summary of information about property plant equipment (Detail)",
     "shortName": "Property and equipment - Summary of information about property plant equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail",
     "longName": "1077 - Disclosure - Right-of-use assets - Disclosure of right of use asset (Detail)",
     "shortName": "Right-of-use assets - Disclosure of right of use asset (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2021",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:RightOfUseAssetsTableTextBlock",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
     "longName": "1078 - Disclosure - Intangible asset - Summary of Intangible Assets (Detail)",
     "shortName": "Intangible asset - Summary of Intangible Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail",
     "longName": "1079 - Disclosure - Intangible assets - Summary of Commercial Milestone Payment (Detail)",
     "shortName": "Intangible assets - Summary of Commercial Milestone Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis",
      "name": "thtx:InitialMilestonePaymentsPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis",
      "name": "thtx:InitialMilestonePaymentsPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
     "longName": "1080 - Disclosure - Intangible assets - Additional Information (Detail)",
     "shortName": "Intangible assets - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AmortisationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AmortisationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail",
     "longName": "1081 - Disclosure - Other asset - Summary of detailed information about other asset (Detail)",
     "shortName": "Other asset - Summary of detailed information about other asset (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "thtx:OtherAssetsNonCurrentAtCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "thtx:OtherAssetsNonCurrentAtCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail",
     "longName": "1082 - Disclosure - Other asset - Additional Information (Detail)",
     "shortName": "Other asset - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis",
      "name": "thtx:ContractualObligations",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis",
      "name": "thtx:ContractualObligations",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail",
     "longName": "1083 - Disclosure - Accounts payable and accrued liabilities - Summary of \taccounts payable and accrued liabilities (Detail)",
     "shortName": "Accounts payable and accrued liabilities - Summary of \taccounts payable and accrued liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail",
     "longName": "1084 - Disclosure - Accounts payable and accrued liabilities - Additional Information (Detail)",
     "shortName": "Accounts payable and accrued liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:PaymentForContingentLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:PaymentForContingentLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail",
     "longName": "1085 - Disclosure - Provisions - Summary of provision (Detail)",
     "shortName": "Provisions - Summary of provision (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:OtherShorttermProvisions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2021",
      "name": "ifrs-full:OtherShorttermProvisions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail",
     "longName": "1086 - Disclosure - Provisions - Summary of provision (Parenthetical) (Detail)",
     "shortName": "Provisions - Summary of provision (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_SeveranceAndOtherExpensesMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis",
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
     "longName": "1087 - Disclosure - Loan Facility - Additional Information (Detail)",
     "shortName": "Loan Facility - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:BorrowingsInterestRateBasis",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_28_2023To07_28_2023",
      "name": "thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail",
     "longName": "1088 - Disclosure - Loan Facility - Summary of movement in the carrying value of the long term loan (Detail)",
     "shortName": "Loan Facility - Summary of movement in the carrying value of the long term loan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ProceedsFromNoncurrentBorrowings",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_21_2023To11_30_2023",
      "name": "thtx:ProceedsFromConsiderationOfTheFifthAmendment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
     "longName": "1089 - Disclosure - Convertible unsecured senior notes - Additional Information (Detail)",
     "shortName": "Convertible unsecured senior notes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "thtx:ConvertibleInstrumentsNumberOfSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail",
     "longName": "1090 - Disclosure - Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail)",
     "shortName": "Convertible unsecured senior notes - Summary of deferred tax related to equity component of convertible notes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:RepaymentsOfBondsNotesAndDebentures",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "thtx:AccretionExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock",
       "thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail",
     "longName": "1091 - Disclosure - Leases liabilities - Summary of lease liabilities (Detail)",
     "shortName": "Leases liabilities - Summary of lease liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:AccretionExpenseOfLeasesLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail",
     "longName": "1092 - Disclosure - Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail)",
     "shortName": "Leases liabilities- Summary of Leases liabilities (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "P02_17_2023To02_17_2023",
      "name": "thtx:TerminationOfLeasesOperatingLeaseRightOfUseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P02_17_2023To02_17_2023",
      "name": "thtx:TerminationOfLeasesOperatingLeaseRightOfUseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
     "longName": "1093 - Disclosure - Share capital warrants and subscription receipts - Additional information (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:PaymentsForShareIssueCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P10_04_2018To10_04_2018",
      "name": "thtx:StockAppreciationRightsContractualLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail",
     "longName": "1094 - Disclosure - Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary of measurement of fair value of warrant liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail",
     "longName": "1095 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of The Model Used To Determine Fair Value Of Options (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
     "longName": "1096 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022_CADsrtCurrencyAxis",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_CADsrtCurrencyAxis",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
      "unitRef": "Unit_CAD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail",
     "longName": "1097 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of The Number Of Options Outstanding (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "P12_01_2021To11_30_2022",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019",
      "unitRef": "Unit_CAD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2021To11_30_2022",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019",
      "unitRef": "Unit_CAD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail",
     "longName": "1098 - Disclosure - Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of The Stock Option Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
     "longName": "1099 - Disclosure - Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of Fair Value Of Options Used To Determine The Weighted Average Assumptions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
     "longName": "1100 - Disclosure - Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary Of Summarizes The Measurement Date Weighted Average Fair Value Of Stock Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_USDsrtCurrencyAxis",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail",
     "longName": "1101 - Disclosure - Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary of Calculation of Weighted Average Number of Common Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail",
     "longName": "1102 - Disclosure - Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail)",
     "shortName": "Share capital warrants and subscription receipts - Summary of Accumulated other comprehensive income (loss)  (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:AccumulatedOtherComprehensiveIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2021",
      "name": "ifrs-full:AccumulatedOtherComprehensiveIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail",
     "longName": "1103 - Disclosure - Income Taxes - Summary of components of the current and deferred tax expenses (Detail)",
     "shortName": "Income Taxes - Summary of components of the current and deferred tax expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail",
     "longName": "1104 - Disclosure - Income Taxes - Summary of reconciliation between effective and applicable tax (Detail)",
     "shortName": "Income Taxes - Summary of reconciliation between effective and applicable tax (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "1105 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "ifrs-full:ApplicableTaxRate",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "ifrs-full:ApplicableTaxRate",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail",
     "longName": "1106 - Disclosure - Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail)",
     "shortName": "Income Taxes - Summary of the amounts and expiry dates of tax attributes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis",
      "name": "thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis",
      "name": "thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail",
     "longName": "1107 - Disclosure - Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail)",
     "shortName": "Supplemental cash flow disclosures - Summary of supplemental cash flow (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock",
       "thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock",
       "thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "longName": "1108 - Disclosure - Financial instruments - Additional Information (Detail)",
     "shortName": "Financial instruments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:CurrentTradeReceivablesAgingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
     "longName": "1109 - Disclosure - Financial instruments - Summary of the contractual maturities of financial liabilities (Detail)",
     "shortName": "Financial instruments - Summary of the contractual maturities of financial liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail",
     "longName": "1110 - Disclosure - Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)",
     "shortName": "Financial instruments - Summary of presents the significant items in the original currencies exposed to currency risk (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "ifrs-full:Cash",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis",
      "name": "ifrs-full:Cash",
      "unitRef": "Unit_CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail",
     "longName": "1111 - Disclosure - Financial instruments - Summary of exchange rates (Detail)",
     "shortName": "Financial instruments - Summary of exchange rates (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_CADsrtCurrencyAxis",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_CADsrtCurrencyAxis",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail",
     "longName": "1112 - Disclosure - Financial instruments - Summary of Company's foreign currency exposures (Detail)",
     "shortName": "Financial instruments - Summary of Company's foreign currency exposures (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis",
      "unitRef": "Unit_CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis",
      "unitRef": "Unit_CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
     "longName": "1113 - Disclosure - Capital management - Additional Information (Detail)",
     "shortName": "Capital management - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis",
      "name": "thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis",
      "name": "thtx:CashBondAndMoneyMarketFunds",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
     "longName": "1114 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail)",
     "shortName": "Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
     "longName": "1115 - Disclosure - Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail)",
     "shortName": "Determination of fair values - Summary of marathon warrants recognized at fair value and considered level 3 (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
     "longName": "1116 - Disclosure - Commitments - Additional Information (Detail)",
     "shortName": "Commitments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis",
      "name": "thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis",
      "name": "thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail",
     "longName": "1117 - Disclosure - Operating segments - Summary of single operating segment (Detail)",
     "shortName": "Operating segments - Summary of single operating segment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023_RxCrossRoadsMemberifrsfullSegmentsAxis",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
     "longName": "1118 - Disclosure - Operating segments - Additional Information (Detail)",
     "shortName": "Operating segments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2022",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023_CAifrsfullGeographicalAreasAxis",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail",
     "longName": "1119 - Disclosure - Related parties - Summary of key management personnel compensation (Detail)",
     "shortName": "Related parties - Summary of key management personnel compensation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P12_01_2022To11_30_2023",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail",
     "longName": "1120 - Disclosure - Related parties - Additional Information (Detail)",
     "shortName": "Related parties - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "thtx:RelatedPartyPercentageOfVotingRightsHeld",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn11_30_2023",
      "name": "thtx:RelatedPartyPercentageOfVotingRightsHeld",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d680117d20f.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "thtx_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "terseLabel": "Accretion expense",
        "documentation": "Accretion expense."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccretionExpenseAndAmortizationOfDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccretionExpenseAndAmortizationOfDeferredFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense And Amortization Of Deferred Financing Costs",
        "negatedLabel": "Accretion expense and amortization of deferred financing costs",
        "documentation": "Accretion expense and amortization of deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccretionExpenseOfLeasesLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccretionExpenseOfLeasesLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion expense of Leases liabilities",
        "verboseLabel": "Accretion expense",
        "documentation": "Accretion expense of Leases liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedAmortizationAbstract",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization [Abstract]",
        "verboseLabel": "Accumulated amortization",
        "documentation": "Accumulated amortization."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization Disposals Intangible Assets Other Than Goodwill",
        "terseLabel": "Disposal",
        "documentation": "Accumulated amortization disposals, intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization Of Intangible Assets Other Than Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Accumulated Amortization Of Intangible Assets Other Than Goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedAmortizationOnOtherAssetsNonCurrentAbstract",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization On Other Assets Non Current [Abstract]",
        "verboseLabel": "Accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedAmortizationOnOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedAmortizationOnOtherNonCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization On Other Non Current Assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Accumulated Amortization On Other Non Current Assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Accumulated amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59",
      "r93",
      "r102",
      "r105"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Accumulated depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r296",
      "r303",
      "r305",
      "r306"
     ]
    },
    "thtx_AccumulatedDepreciationDisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedDepreciationDisposalsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Disposals Property Plant And Equipment",
        "negatedLabel": "Disposals",
        "documentation": "Accumulated depreciation disposals property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AccumulatedDepreciationOnPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation On Property Plant And Equipment [Abstract]",
        "terseLabel": "Accumulated depreciation",
        "documentation": "Accumulated depreciation on property plant and equipment [abstract]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "thtx_AcquisitionCostsForIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AcquisitionCostsForIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Costs For Intangible Assets",
        "verboseLabel": "Acquisition costs",
        "documentation": "Acquisition costs for intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Derivative Financial Assets Included in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Acquisition of derivative financial assets included in accounts payable and accrued liabilities",
        "documentation": "Acquisition of derivative financial assets included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination",
        "terseLabel": "Business combination acquisition costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, intangible assets other than goodwill",
        "terseLabel": "Acquisition of intangible assets during the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Contributed surplus"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [member]",
        "terseLabel": "Contributed surplus"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail",
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "verboseLabel": "Provisions made"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Development expenditures capitalized",
        "definitionGuidance": "Additions",
        "verboseLabel": "Additions to intangibles"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill Cash Payment",
        "terseLabel": "Additions to intangibles Through cash payment",
        "documentation": "Additions other than through business combinations intangible assets other than goodwill cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill Share Based Payment",
        "terseLabel": "Additions to intangibles Through share based payment",
        "documentation": "Additions other than through business combinations intangible assets other than goodwill share based payment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "verboseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "thtx_AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions To Intangibles Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Additions to intangible assets included in accounts payable and accrued liabilities",
        "documentation": "Additions To intangibles included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions To Property And Equipment Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Additions to property and equipment included in accounts payable and accrued liabilities",
        "documentation": "Additions to property and equipment included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail",
      "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "New lease",
        "verboseLabel": "New lease (b)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "verboseLabel": "Weighted average number of common shares, basic\u00a0and\u00a0diluted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "thtx_AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 44.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Accretion Expense And Amortization Of Deferred Financing Costs",
        "verboseLabel": "Accretion expense and amortization of deferred financing costs",
        "documentation": "Adjustments for accretion expense and amortization of deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for amortisation expense",
        "terseLabel": "Amortization of intangible assets and other asset"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "thtx_AdjustmentsForAmortizationOfRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdjustmentsForAmortizationOfRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 47.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Amortization of rightofuse assets",
        "verboseLabel": "Amortization of right-of-use assets",
        "documentation": "Adjustments For Amortization of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 41.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in derivative financial assets",
        "terseLabel": "Change in fair value of derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in derivative financial assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other current assets",
        "terseLabel": "Prepaid expenses and deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "thtx_AdjustmentsForDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdjustmentsForDeferredFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Deferred Financing Costs",
        "terseLabel": "Deferred financing costs",
        "documentation": "Adjustments for deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation of property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 48.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Write off of deferred financing costs",
        "negatedLabel": "Write off of deferred financing costs"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "verboseLabel": "Income tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in deferred income other than contract liabilities",
        "verboseLabel": "Deferred revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 42.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in employee benefit liabilities",
        "terseLabel": "Change in fair value of liability related to deferred stock\u00a0unit\u00a0plan",
        "definitionGuidance": "Change in fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "terseLabel": "Reduction in accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 46.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for interest income",
        "negatedLabel": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for interest income expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "verboseLabel": "Adjustments for"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation for stock option plan\u00a0and stock appreciation rights"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "thtx_AdjustmentsForTaxCreditsAndGrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AdjustmentsForTaxCreditsAndGrantsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for Tax credits and grants receivable",
        "verboseLabel": "Tax credits and grants receivable",
        "documentation": "Adjustments for Tax credits and grants receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 45.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Foreign exchange"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r310"
     ]
    },
    "thtx_AffiliatesOfMarathonAssetManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AffiliatesOfMarathonAssetManagementMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliates Of Marathon Asset Management [Member]",
        "terseLabel": "Affiliates of Marathon Asset Management [member]",
        "documentation": "Affiliates of Marathon asset management."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AfterFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AfterFiveYearsMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Five Years [Member]",
        "terseLabel": "After Five Years"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r131"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r141",
      "r149",
      "r150",
      "r153",
      "r154",
      "r156",
      "r162",
      "r188",
      "r241",
      "r263",
      "r266"
     ]
    },
    "thtx_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AgreementMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Member]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other segments [member]",
        "terseLabel": "Others"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for business activities and operating segments that are not reportable."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r206"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortisation expense",
        "verboseLabel": "Amortisation Expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationMethodIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortisation method, intangible assets other than goodwill",
        "terseLabel": "Intangible assets amortization method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amortisation method used for intangible assets other than goodwill with finite useful lives. [Refer: Intangible assets other than goodwill; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "thtx_AmortizationOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AmortizationOfOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Other Assets",
        "terseLabel": "Amortization of other asset",
        "documentation": "Amortization of other assets"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AmortizationOfOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AmortizationOfOtherNonCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Other Non Current Assets",
        "verboseLabel": "Amortization",
        "documentation": "Amortization Of Other Non Current Assets."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AmortizationOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AmortizationOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right of use asset",
        "verboseLabel": "Amortization",
        "documentation": "Amortization of Right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AmountOfChargesRelatedToSeveranceAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AmountOfChargesRelatedToSeveranceAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Of Charges Related To Severance And Other Expenses",
        "terseLabel": "Amount of charges related to severance and other expenses",
        "documentation": "Amount of charges related to severance and other expenses."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_AmountReclassifiedFromDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AmountReclassifiedFromDeferredFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Reclassified From Deferred Financing Costs",
        "terseLabel": "Amount reclassified from deferred financing costs.",
        "documentation": "Amount reclassified from deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts payable, related party transactions",
        "verboseLabel": "Salaries and benefits due to key management personnel"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76"
     ]
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Effective applicable income tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r131",
      "r132",
      "r134",
      "r210",
      "r213"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At fair value [member]",
        "terseLabel": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r131"
     ]
    },
    "thtx_AtmProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AtmProgramMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM program [Member]",
        "terseLabel": "ATM program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ]
    },
    "thtx_AvailableDeductionsAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AvailableDeductionsAndOthers",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available Deductions And Others",
        "terseLabel": "Available deductions and other",
        "documentation": "Available deductions and others."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_AverageOptionLifeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "AverageOptionLifeMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Option Life [Member]",
        "terseLabel": "Average option life in years [member]",
        "documentation": "Average option life."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BadDebtExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BadDebtExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bad Debt Expenses",
        "terseLabel": "Bad debt expenses",
        "documentation": "Bad debt expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankAndSimilarCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BankAndSimilarCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank and similar charges",
        "negatedLabel": "Bank charges"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bank and similar charges recognised by the entity as an expense."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "thtx_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BasisOfRoyaltyPaymentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BasisOfRoyaltyPaymentAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Royalty Payment [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BasisOfRoyaltyPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BasisOfRoyaltyPaymentMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Royalty Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BondsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonds [member]",
        "terseLabel": "Bonds",
        "documentation": "Bonds [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingCostsRecognisedAsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingCostsRecognisedAsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing costs recognised as expense",
        "negatedLabel": "Transaction costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are recognised as an expense."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_BorrowingsAccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BorrowingsAccretionExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings Accretion Expense",
        "terseLabel": "Accretion expense",
        "documentation": "Borrowings accretion expense."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "thtx_BorrowingsInterestPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BorrowingsInterestPeriod",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings Interest Period",
        "terseLabel": "Borrowings interest period",
        "documentation": "Borrowings interest period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "definitionGuidance": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_BorrowingsInterestRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRateBasis",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate basis",
        "terseLabel": "Borrowings, interest rate basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, maturity",
        "verboseLabel": "Borrowings, maturity"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "thtx_BorrowingsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BorrowingsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings Outstanding",
        "terseLabel": "Line of credit facility outstanding",
        "documentation": "Borrowings outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range",
        "definitionGuidance": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r156",
      "r172",
      "r254",
      "r255",
      "r319"
     ]
    },
    "thtx_BrokersWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BrokersWarrantsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brokers Warrants [Member]",
        "terseLabel": "Brokers warrants [member]",
        "documentation": "Brokers Warrants [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationAdjustmentToConsiderationInstallmentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationAdjustmentToConsiderationInstallmentOneMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Adjustment To Consideration Installment One [Member]",
        "terseLabel": "Business Combination Adjustment To Consideration Installment One"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Adjustment To Consideration Installment Two [Member]",
        "terseLabel": "Business Combination Adjustment To Consideration Installment Two",
        "documentation": "Business combination adjustment to consideration installment two."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationAdjustmentToPurchaseConsiderationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationAdjustmentToPurchaseConsiderationAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Adjustment To Purchase Consideration [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationAdjustmentToPurchaseConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationAdjustmentToPurchaseConsiderationMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Adjustment To Purchase Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationContingentConsiderationFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Contingent Consideration Fair Value",
        "terseLabel": "Business combination contingent consideration fair value",
        "documentation": "Business combination contingent consideration fair value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_BusinessCombinationIncreaseDecreaseInPurchaseConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "BusinessCombinationIncreaseDecreaseInPurchaseConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Increase Decrease In Purchase Consideration",
        "terseLabel": "Business combination adjustment to the purchase consideration",
        "documentation": "Business combination increase decrease in purchase consideration."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada [Member]",
        "verboseLabel": "Canada"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CAD",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CA$",
        "definitionGuidance": "CA$",
        "verboseLabel": "CA$ \u2013 US$"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalisedDevelopmentExpenditureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalisedDevelopmentExpenditureMember",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalised development expenditure [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets arising from development expenditure capitalised before the start of commercial production or use. An intangible asset shall only be recognised if the entity can demonstrate all of the following: (a) the technical feasibility of completing the intangible asset so that it will be available for use or sale; (b) its intention to complete the intangible asset and use or sell it; (c) its ability to use or sell the intangible asset; (d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset; (e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and (f) its ability to measure reliably the expenditure attributable to the intangible asset during its development."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail",
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r56",
      "r93",
      "r97",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r183",
      "r192",
      "r193"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail",
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r97",
      "r101",
      "r103",
      "r104",
      "r183",
      "r192",
      "r193"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash, beginning of year",
        "periodEndLabel": "Cash, end of year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r112",
      "r127"
     ]
    },
    "thtx_CashBondAndMoneyMarketFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CashBondAndMoneyMarketFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Bond and Money Market Funds",
        "definitionGuidance": "Cash,bond and money market funds",
        "documentation": "Cash bond and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CashCashEquivalentsAndEligibleShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CashCashEquivalentsAndEligibleShortTermInvestmentsMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents And Eligible Short Term Investments [Member]",
        "terseLabel": "Cash, Cash Equivalents and Eligible Short-term Investments [member]",
        "documentation": "Cash, cash equivalents and eligible short-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Total cash from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r113"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Total cash from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r113"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Total cash used in operating activities",
        "terseLabel": "Negative operating cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r106",
      "r113"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash\u00a0flows\u00a0from\u00a0(used\u00a0in) Operating"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations before changes in working capital",
        "totalLabel": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r312"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Lease payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "thtx_CashSettledForwardContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CashSettledForwardContractsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Settled Forward Contracts [Member]",
        "verboseLabel": "Cash Settled Forward Contracts [Member]",
        "documentation": "Cash Settled Forward Contracts Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash transferred",
        "terseLabel": "Business combination cash consideration transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "thtx_CashbondAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CashbondAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Bond And Money Market Funds [Member]",
        "terseLabel": "Cash bond and money market funds",
        "documentation": "Cash,Bond And Money Market Funds."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "thtx_CategoryOfBorrowingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CategoryOfBorrowingsAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of borrowings [axis]",
        "documentation": "Category Of Borrowings Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CategoryOfBorrowingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CategoryOfBorrowingsDomain",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of borrowings [domain]",
        "documentation": "Category Of Borrowings Domain."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceiling Limit for Prepayment of Principal Amount Outstanding Percent",
        "terseLabel": "Ceiling limit for prepayment of principal amount outstanding, Percent",
        "documentation": "Ceiling limit for prepayment of principal amount outstanding percent."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ChangeInOperatingAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ChangeInOperatingAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Operating Assets And Liabilities [Abstract]",
        "terseLabel": "Change in operating assets and liabilities",
        "documentation": "Change in operating assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ChangesFromFinancingCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ChangesFromFinancingCashFlowsAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes From Financing Cash Flows [Abstract]",
        "terseLabel": "Changes from financing cash flows:",
        "documentation": "Changes from financing cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChangesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in net defined benefit liability (asset) resulting from miscellaneous other changes [abstract]",
        "terseLabel": "Other changes:"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ChargebacksAndRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ChargebacksAndRebatesMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chargebacks And Rebates [Member]",
        "verboseLabel": "Chargebacks and rebates"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Number Warrants Or Rights Issued During The Period",
        "terseLabel": "Class of number warrants or rights issued during the period",
        "documentation": "Class of number warrants or rights issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights",
        "terseLabel": "Exercise price of each warrants",
        "documentation": "Class of warrant or right exercise price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantOrRightExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Expiration Date",
        "terseLabel": "Class Of Warrant Or Right Expiration Date",
        "documentation": "Class of warrant or right expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantOrRightNumberOfSecuritiesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercised",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Number Of Securities Exercised",
        "terseLabel": "Class Of Warrant Or Right Exercised",
        "documentation": "Class of warrant or right number of securities exercised."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Class of warrant or right, Outstanding",
        "documentation": "Class of warrant or right, Outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantsOrRightsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantsOrRightsAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights [Axis]",
        "documentation": "Class of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantsOrRightsExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantsOrRightsExercisePricePerShare",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights Exercise Price Per Share",
        "verboseLabel": "Class of warrants or rights exercise price per share",
        "documentation": "Class of warrants or rights exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantsOrRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantsOrRightsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights [Member]",
        "documentation": "Class of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ClassOfWarrantsOrRightsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ClassOfWarrantsOrRightsOutstanding",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights Outstanding",
        "terseLabel": "Class of warrants or rights outstanding",
        "documentation": "Class of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r136",
      "r148"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r136",
      "r148"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r182"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r198",
      "r199",
      "r222",
      "r223"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of current inventories [abstract]",
        "terseLabel": "Classes of current inventories [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Reporting date rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_CommercializationRightsEgriftaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommercializationRightsEgriftaMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialization Rights EGRIFTA [Member]",
        "terseLabel": "Commercialization Rights EGRIFTA SV\u00ae",
        "verboseLabel": "Commercialization rights \u2013 EGRIFTA SV\u00ae",
        "documentation": "Commercialization Rights EGRIFTA [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommercializationRightsTrogarzoEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommercializationRightsTrogarzoEuropeMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialization Rights Trogarzo Europe [Member]",
        "terseLabel": "Commercialization rights- Trogarzo\u00ae European Territory"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommercializationRightsTrogarzoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommercializationRightsTrogarzoMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialization Rights Trogarzo [Member]",
        "terseLabel": "Commercialization Rights Trogarzo",
        "documentation": "Commercialization Rights Trogarzo [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommercializationRightsTrogarzoNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommercializationRightsTrogarzoNorthAmericaMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialization Rights Trogarzo North America [Member]",
        "verboseLabel": "Commercialization rights- Trogarzo\u00ae North America",
        "terseLabel": "Commercialization rights- Trogarzo\u00ae North American Territory"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommitmentsAxis",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Axis]",
        "documentation": "Commitments [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommitmentsDomain",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Domain]",
        "documentation": "Commitments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Conversion Basis",
        "terseLabel": "Common stock, Conversion basis",
        "documentation": "Common stock, Conversion basis."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that may be reclassified to net profit (loss) in the future"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r36",
      "r118",
      "r120",
      "r125",
      "r250"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income [abstract]",
        "terseLabel": "Total comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "thtx_ConsiderationPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConsiderationPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration Payable",
        "terseLabel": "Consideration payable",
        "documentation": "Consideration payable."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date",
        "terseLabel": "Business combination contingent consideration"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesMember",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r182"
     ]
    },
    "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "thtx_ContractualObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ContractualObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligations",
        "verboseLabel": "Contractual obligations",
        "documentation": "Contractual obligations."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleInstrumentsNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleInstrumentsNumberOfSharesIssued",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Instruments Number Of Shares Issued",
        "verboseLabel": "Convertible instruments number of shares issued",
        "documentation": "Convertible instruments number of shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleUnsecuredSeniorNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleUnsecuredSeniorNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Unsecured Senior Notes [Abstract]",
        "terseLabel": "Convertible senior notes [Abstract]",
        "documentation": "Convertible unsecured senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Unsecured Senior Notes Including Interest Undiscounted Cash Flows",
        "terseLabel": "Convertible unsecured senior notes including interest",
        "documentation": "Convertible unsecured senior notes including interest undiscounted cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleUnsecuredSeniorNotesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleUnsecuredSeniorNotesLineItems",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible unsecured senior notes [Line Items]",
        "documentation": "Convertible unsecured senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleUnsecuredSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleUnsecuredSeniorNotesMember",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Unsecured Senior Notes [Member]",
        "terseLabel": "Convertible Unsecured Senior Notes [member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ConvertibleUnsecuredSeniorNotesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ConvertibleUnsecuredSeniorNotesTable",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Unsecured Senior Notes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CostOfGoodsSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CostOfGoodsSoldMember",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Goods Sold [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of inventories recognised as expense during period",
        "terseLabel": "Cost of inventories recognised as expense during period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "terseLabel": "Cost of goods sold"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r204"
     ]
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current accrued expenses and other current liabilities",
        "verboseLabel": "Accrued liabilities and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail": {
       "parentTag": "ifrs-full_CurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r121",
      "r250"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets (liabilities)",
        "totalLabel": "Total exposure"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets less the amount of current liabilities."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current deferred income other than current contract liabilities",
        "terseLabel": "Deferred revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r292"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial assets",
        "terseLabel": "Derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInterestPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current interest payable",
        "terseLabel": "Accrued interest payable on convertible unsecured senior notes and Loan Facility"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current interest payable. [Refer: Interest payable]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "verboseLabel": "Current portion of lease liabilities",
        "negatedLabel": "Current portion"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r123",
      "r250"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current loans received and current portion of non-current loans received",
        "negatedLabel": "Current portion"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current loans received and the current portion of non-current loans received. [Refer: Loans received]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current notes and debentures issued and current portion of non-current notes and debentures issued",
        "terseLabel": "Convertible unsecured senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_CurrentPositionOfTermLoanIncludingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CurrentPositionOfTermLoanIncludingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "thtx_NonderivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Position Of Term Loan, Including Interest",
        "terseLabel": "Term loan, including interest, Carrying amount",
        "documentation": "Current position of term loan, including interest."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses and deposits",
        "totalLabel": "Prepaid Expenses and Deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_CurrentPrepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepayments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current provisions",
        "negatedLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "verboseLabel": "Income taxes payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "verboseLabel": "Trade receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231"
     ]
    },
    "thtx_CurrentTradeReceivablesAgingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "CurrentTradeReceivablesAgingPeriod",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Trade Receivables Aging Period",
        "terseLabel": "Current trade receivables aging period",
        "documentation": "Current trade receivables aging period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "terseLabel": "Sales taxes receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "thtx_DateOfCommencementOfPrincipalRepaymentInAdvance": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DateOfCommencementOfPrincipalRepaymentInAdvance",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of Commencement of Principal Repayment In Advance",
        "terseLabel": "Date of commencement of principal repayment in advance",
        "documentation": "Date of commencement of principal repayment in advance."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DebtInstrumentAmortizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DebtInstrumentAmortizedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Amortized Value",
        "terseLabel": "Debt instrument amortized value",
        "documentation": "Debt instrument amortized value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DebtInstrumentCollateralAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DebtInstrumentCollateralAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Collateral Amount",
        "terseLabel": "Debt instrument collateral amount",
        "documentation": "Amount of assets pledged to secure a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DebtInstrumentCollateralAmountIfFDAApprovalNotObtained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DebtInstrumentCollateralAmountIfFDAApprovalNotObtained",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Collateral Amount If FDA Approval Not Obtained",
        "terseLabel": "Debt instrument collateral amount if FDA approval not obtained",
        "documentation": "Amount of assets pledged to secure a debt instrument if FDA approval not obtained."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredFinanceCostsWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredFinanceCostsWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Finance costs Write Off",
        "terseLabel": "Deferred Finance costs Write Off",
        "documentation": "Deferred finance costs write off."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Financing Costs",
        "negatedLabel": "Deferred financing costs",
        "documentation": "Deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredFinancingCostsOnTheLoanFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredFinancingCostsOnTheLoanFacility",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Financing Costs On The Loan Facility",
        "verboseLabel": "Deferred financing costs on the loan facility",
        "documentation": "Deferred financing costs on the loan facility."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredFinancingCostsWrittenDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredFinancingCostsWrittenDown",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Financing Costs Written Down",
        "terseLabel": "Deferred financing costs written down",
        "documentation": "Deferred financing costs written down."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costsincluded in accounts payable and accrued liabilities",
        "terseLabel": "Deferred financing costs\u00a0included in accounts payable and accrued liabilities",
        "documentation": "Deferred financing costs\u00a0included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DeferredStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DeferredStockUnitsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Stock Units [Member]",
        "verboseLabel": "Deferred Stock Units [Member]",
        "documentation": "Deferred Stock Units Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21",
      "r46"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) [abstract]",
        "verboseLabel": "Deferred tax expense (recovery)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "totalLabel": "Total deferred tax expense (recovery)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail": {
       "parentTag": "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences",
        "terseLabel": "Origination and reversal of temporary differences"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_DepreciationMethodPropertyPlantAndEquipment": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationMethodPropertyPlantAndEquipment",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation method, property, plant and equipment",
        "terseLabel": "Depreciation method, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The depreciation method used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58"
     ]
    },
    "ifrs-full_DepreciationRatePropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRatePropertyPlantAndEquipment",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation rate, property, plant and equipment",
        "terseLabel": "Depreciation rate, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "thtx_DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Assets At Fair Value Not Designated As Hedging",
        "terseLabel": "Fair value of cash settled forward contracts",
        "documentation": "Derivative financial assets at fair value not designated as hedging."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Adopted The New Or Amended Standards [Text Block]",
        "terseLabel": "Standards issued but not yet effective",
        "documentation": "Description of accounting policy for adopted the new or amended standards."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Asset Acquisiitons Explanatory",
        "terseLabel": "Asset acquisitions",
        "documentation": "Description of accounting policy for asset acquisiitons explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Basis Of Consolidation Explanatory [Policy Text Block]",
        "verboseLabel": "Basis of consolidation",
        "documentation": "Description of accounting policy for basis of consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Deferred Financing Costs Explanatory",
        "terseLabel": "Deferred Financing Costs",
        "documentation": "Description of accounting policy for deferred financing costs explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for finance income and costs [text block]",
        "terseLabel": "Finance income and finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "verboseLabel": "Foreign currencies"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Government assistance"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "thtx_DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Inventories Explanatory [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Description of accounting policy for inventories explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "terseLabel": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "thtx_DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For New Accounting Standards Adopted Explanatory",
        "terseLabel": "New standard adopted",
        "documentation": "Description of accounting policy for new accounting standards adopted explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Other Assets Explanatory [Policy Text Block]",
        "terseLabel": "Other asset",
        "documentation": "Description of accounting policy for other assets explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "verboseLabel": "Revenue recognition"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development tax credits"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "thtx_DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Accounting Policy For Stock Appreciation Rights Plan Explanatory [Policy Text Block]",
        "terseLabel": "Stock appreciation rights plan",
        "documentation": "Description of accounting policy for stock appreciation rights plan explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Changes In Accounting Policies Explanatory",
        "terseLabel": "Changes in accounting policies",
        "documentation": "Description of changes in accounting policies explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Covenants Under Shareholder Rights On Bidding Options",
        "terseLabel": "Shareholders rights covenants",
        "documentation": "Description of covenants under shareholder rights on bidding options."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "definitionGuidance": "Exercise period of options",
        "verboseLabel": "Average option life in years"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of useful life, property, plant and equipment",
        "terseLabel": "Description of useful life, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting requirements for share-based payment arrangement",
        "terseLabel": "Period of vesting of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "thtx_DevelopmentMilestonePayableAnnualInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DevelopmentMilestonePayableAnnualInstallment",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Payable Annual Installment",
        "verboseLabel": "Milestone Payments annual installment",
        "documentation": "Development milestone payable annual installment."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DevelopmentMilestonePhaseOneClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DevelopmentMilestonePhaseOneClinicalTrialMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Phase One Clinical Trial [Member]",
        "terseLabel": "Development Milestone Phase One Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DevelopmentMilestonePhaseThreeClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DevelopmentMilestonePhaseThreeClinicalTrialMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Phase Three Clinical Trial [Member]",
        "terseLabel": "Development Milestone Phase Three Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DevelopmentMilestonePhaseTwoClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DevelopmentMilestonePhaseTwoClinicalTrialMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Phase Two Clinical Trial [Member]",
        "terseLabel": "Development Milestone Phase Two Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of convertible instruments on number of ordinary shares",
        "terseLabel": "Impact on conversion of convertible unsecured senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "thtx_DisaggregationOfRevenueByGeographicalAreaLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisaggregationOfRevenueByGeographicalAreaLineItems",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue By Geographical Area [Line Items]",
        "terseLabel": "Disaggregation Of Revenue By Geographical Area [Line Items]",
        "documentation": "Disaggregation of revenue by geographical area."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisaggregationOfRevenueByGeographicalAreaTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisaggregationOfRevenueByGeographicalAreaTable",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue By Geographical Area [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisaggregationOfRevenueByGeographicalAreaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisaggregationOfRevenueByGeographicalAreaTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue By Geographical Area [Table Text Block]",
        "terseLabel": "Summary of revenue by geographical area",
        "documentation": "Disaggregation of revenue by geographical area."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits",
     "presentation": [
      "http://www.theratech.com/role/PrepaidExpensesAndDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Details Of Current Prepaid Expenses And Deposits",
        "terseLabel": "Prepaid expenses and deposits",
        "documentation": "Disclosure Details Of Current Prepaid Expenses And Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureDetailsOfTaxCreditsRollForwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureDetailsOfTaxCreditsRollForwardTextBlock",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Details Of Tax Credits Roll Forward [Text Block]",
        "verboseLabel": "Disclosure Details Of Tax Credits Roll Forward",
        "documentation": "Disclosure Details Of Tax Credits Roll Forward."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities",
        "terseLabel": "Summary of measurement of fair value of warrant liabilities",
        "documentation": "Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Line Items]",
        "documentation": "Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilitiesTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Fair Value Of Warrant Liabilities [Table]",
        "documentation": "Disclosure in tabular form of significant unobservable inputs used in the measurement of fair value of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureInformationAboutOtherAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureInformationAboutOtherAssetsLineItems",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail",
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Information About Other Assets [Line Items]",
        "verboseLabel": "Other asset [line items]",
        "documentation": "Disclosure Information About Other Assets [Line item]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Amounts And Expiry Dates Of Tax Attributes Carry Forward Explanatory [Table Text Block]",
        "terseLabel": "Summary of amounts and expiry dates of tax attributes carry forward explanatory",
        "documentation": "Disclosure of amounts and expiry dates of tax attributes carry forward explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Applicable Exchange Rates Explanatory [Table Text Block]",
        "terseLabel": "Summary of applicable exchange rates explanatory",
        "documentation": "Disclosure Of Applicable Exchange Rates [Explanatory]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/LoanFacility"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of borrowings [text block]",
        "verboseLabel": "Loan Facility"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]",
        "terseLabel": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "verboseLabel": "Options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "thtx_DisclosureOfCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [abstract]",
        "documentation": "Disclosure of commitments abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "thtx_DisclosureOfCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfCommitmentsLineItems",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Commitments [Line Items]",
        "documentation": "Disclosure of Commitments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfCommitmentsTable",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Commitments [Table]",
        "documentation": "Disclosure of Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Convertible Senior Notes Explanatory [Text Block]",
        "terseLabel": "Convertible unsecured senior notes",
        "documentation": "Disclosure of convertible senior notes explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCostOfSalesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCostOfSalesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cost of sales [text block]",
        "terseLabel": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the cost of sales. [Refer: Cost of sales]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "thtx_DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Currency Risk Exposure Explanatory [Table Text Block]",
        "terseLabel": "Summary of currency risk exposure explanatory",
        "documentation": "Disclosure Of Currency Risk Exposure [Explanatory]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Deferred Tax Related To Equity Component Of Convertible Notes Explanatory [Table Text Block]",
        "terseLabel": "Summary of deferred tax related to equity component of convertible unsecured senior notes",
        "documentation": "Disclosure of deferred tax related to equity component of convertible notes explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Bonds And Money Market Funds Explanatory [Table Text Block]",
        "terseLabel": "Detailed Information About Bonds And Money Market Funds",
        "documentation": "Disclosure of detailed information about bonds and money market funds explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Summary of movement in the carrying value of the term loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "thtx_DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Finance Income And Cost Explanatory [Table Text Block]",
        "terseLabel": "Summary of detailed information about finance income and cost",
        "documentation": "Disclosure of detailed information about finance income and cost"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About In Accumulated Other Comprehensive Income Loss Explanatory [Text Block]",
        "terseLabel": "Summary of Accumulated other comprehensive income (loss) (Detail)",
        "documentation": "Disclosure of detailed information about in accumulated other comprehensive income loss explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About In Commercial Milestone Payment Explanatory [Text Block]",
        "verboseLabel": "Schedule of Commercial Milestone Payment",
        "documentation": "Detailed Information About In Commercial Milestone Payment Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutIncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxLineItems",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About Income Tax [Line Items]",
        "documentation": "Disclosure of Detailed Information About Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutIncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxTable",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About Income Tax [Table]",
        "documentation": "Disclosure of Detailed Information About Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "thtx_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Inventories Explanatory Text [Table Text Block]",
        "terseLabel": "Summary of detailed information about inventories",
        "documentation": "Disclosure of detailed information about inventories explanatory text."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Operating Segments Explanatory [Table Text Block]",
        "terseLabel": "Summary of operating segments",
        "documentation": "Disclosure of detailed information about operating segments explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Other Asset Explanatory [Table Text Block]",
        "terseLabel": "Summary of other asset",
        "documentation": "Disclosure of detailed information about other asset explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutOtherAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutOtherAssetTable",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail",
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Detailed Information About Other Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Personnel Expenses Explanatory [Table Text Block]",
        "terseLabel": "Summary of detailed information about personnel expenses",
        "documentation": "Disclosure of detailed information about personnel expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "verboseLabel": "Summary of information about property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "thtx_DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Provisions Explanatory [Table Text Block]",
        "terseLabel": "Summary of provision",
        "documentation": "Disclosure of detailed information about provisions explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/TradeAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Trade And Other Receivables Explanatory [Table Text Block]",
        "terseLabel": "Summary of detailed information about trade and other receivables",
        "documentation": "Disclosure of detailed information about trade and other receivables explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information About Unused And Unrecorded Non Refundable Federal Tax Credit Explanatory [Table Text Block]",
        "terseLabel": "Summary of information about unused and unrecorded non refundable federal tax credit",
        "documentation": "Disclosure of detailed information about unused and unrecorded non refundable federal tax credit explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information For Changes In The Number Of Options Outstanding Explanatory [Table Text Block]",
        "terseLabel": "Summary of changes in the number of options outstanding",
        "documentation": "Disclosure of detailed information for changes in the number of options outstanding explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Detailed Information For Share Based Compensation Expense Stock Option Plan Explanatory [Table Text Block]",
        "terseLabel": "Summary of the share-based compensation expense for the stock option plan",
        "documentation": "Disclosure of detailed information for share based compensation expense stock option plan explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.theratech.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Summary of net sales by product"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]",
        "terseLabel": "Disclosure of effect of changes in foreign exchange rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for the effect of changes in foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of employee benefits [text block]",
        "terseLabel": "Personnel expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Operating segments"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "thtx_DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Estimated Useful Lives Methods Of Depreciation [Text Block]",
        "terseLabel": "Summary of estimated useful lives, methods of depreciation and depreciation rates",
        "documentation": "Disclosure of estimated useful lives methods of depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfFairValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfFairValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Fair Value Measurement [Abstract]",
        "terseLabel": "Disclosure of fair value measurement [abstract]",
        "documentation": "Disclosure of fair value measurement."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement [text block]",
        "terseLabel": "Determination of fair values"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Finance income and finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFunds"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [text block]",
        "terseLabel": "Bonds and money market funds"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]",
        "verboseLabel": "Disclosure of detailed information about Financial Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194",
      "r200"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "thtx_DisclosureOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Lease Liabilities [Abstract]",
        "documentation": "Disclosure of Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Lease Liabilities [Table Text Block]",
        "terseLabel": "Summary of lease liabilities",
        "documentation": "Disclosure of Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152"
     ]
    },
    "thtx_DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Major Component Of Income Tax And Deferred Tax Explanatory [Table Text Block]",
        "terseLabel": "Summary of major component of income tax and deferred tax explanatory",
        "documentation": "Disclosure of major component of income tax and deferred tax explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of material accounting policy information [text block]",
        "terseLabel": "Significant accounting policies"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Summary of the following table provides stock option information"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]",
        "terseLabel": "Captital management"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalLineItems",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalTable",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the objectives, policies and processes for managing capital."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/OtherAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other assets [text block]",
        "verboseLabel": "Other asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [abstract]",
        "verboseLabel": "Provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail",
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsTable",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail",
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "thtx_DisclosureOfPersonnelExpensesExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfPersonnelExpensesExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Personnel Expenses Explanatory [Abstract]",
        "terseLabel": "Disclosure Of Personnel Expenses Explanatory [Abstract]",
        "documentation": "Disclosure of personnel expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of prepayments and other assets [text block]",
        "verboseLabel": "Summary of prepaid expenses and deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "verboseLabel": "Property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/Provisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions [text block]",
        "verboseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [abstract]",
        "verboseLabel": "Right-of-use assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/RightOfUseAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "verboseLabel": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "thtx_DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Reconciliation Between Effective And Income Tax Amounts Explanatory [Table Text Block]",
        "terseLabel": "Summary of reconciliation between effective and income tax amounts explanatory",
        "documentation": "Disclosure of reconciliation between effective and income tax amounts explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.theratech.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.theratech.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "thtx_DisclosureOfRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfRightOfUseAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of right of use Asset [Abstract]",
        "terseLabel": "Right Of use Asset",
        "documentation": "Disclosure of right Of use Asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceipts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Share capital warrants and subscription receipts"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]",
        "terseLabel": "Summary of marathon warrants recognized at fair value and considered level 3"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "thtx_DisclosureOfSupplementalInformationOnCashFlowexplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfSupplementalInformationOnCashFlowexplanatory",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Supplemental Information On Cash Flow Explanatory",
        "terseLabel": "Supplemental cash flow disclosures",
        "documentation": "Disclosure Of Supplemental Information On Cash Flow [Explanatory]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfTaxCreditsAndGrantsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTaxCreditsAndGrantsReceivableLineItems",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Tax Credits And Grants Receivable [Line Items]",
        "terseLabel": "Disclosure of Tax Credits and Grants Receivable",
        "documentation": "Disclosure of tax credits and grants receivable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfTaxCreditsReceivableExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTaxCreditsReceivableExplanatory",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Tax Credits Receivable Explanatory",
        "terseLabel": "Tax credits and grants receivable",
        "documentation": "Disclosure of tax credits receivable explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Summary of temporary difference, unused tax losses and unused tax credits"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTheModelUsedToDetermineFairValueOfOptionsLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of The Model Used To Determine Fair Value Of Options [Line Items]",
        "terseLabel": "Disclosure Of The Model Used To Determine Fair Value Of Options [Line Items]",
        "documentation": "Disclosure Of The Model Used To Determine Fair Value Of Options."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTheModelUsedToDetermineFairValueOfOptionsTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of The Model Used To Determine Fair Value Of Options [Table]",
        "terseLabel": "Disclosure Of The Model Used To Determine Fair Value Of Options [Table]",
        "documentation": "Disclosure of the model used to determine Fair value of options [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of The Model Used To Determine Fiar Value Of Stock Appreciation Rights [Text Block]",
        "terseLabel": "Summary of the model used to determine fiar value of stock appreciation rights",
        "documentation": "Disclosure of the model used to determine fiar value of stock appreciation rights explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccuredLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Trade And Accrued Payables Explanatory [Text Block]",
        "terseLabel": "Accounts payable and accured liabilities",
        "documentation": "Disclosure of trade and accrued payables explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccuredLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "verboseLabel": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/TradeAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block]",
        "terseLabel": "Trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Summary of key management personnel compensation comprises"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "thtx_DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Weighted Average Fair Value Of Options Granted And Number Of Options Explanatory [Text Block]",
        "terseLabel": "Summary of the measurement date weighted average fair value of stock options granted",
        "documentation": "Disclosure of weighted average fair value of options granted and number of options [Explanatory]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Weighted Average Number Of Shares Outstanding Explanatory [Text Block]",
        "terseLabel": "Summary of earnings per share calculation",
        "documentation": "Disclosure of weighted average number of shares outstanding [Explanatory]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedLabel": "Disposal"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r278"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DueInNextFourToFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DueInNextFourToFiveYearsMember",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due In Next Four To Five Years [Member]",
        "terseLabel": "Due in next four to five years"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_DueWithOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "DueWithOneYearMember",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due With One Year [Member]",
        "terseLabel": "Due with one year"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfExchangeRatesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro \u2013 US$"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "thtx_EffectOfBrokerWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfBrokerWarrantsExercised",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect Of Broker Warrants Exercised",
        "verboseLabel": "Effect of broker warrants exercised",
        "documentation": "Effect of broker warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effect of foreign exchange on cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109"
     ]
    },
    "thtx_EffectOfIssueCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfIssueCommonShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Issue Common Shares",
        "terseLabel": "Effect of issue common shares",
        "documentation": "Effect of issue common shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EffectOfShareOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfShareOptionsExercised",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Share Options Exercised",
        "terseLabel": "Effect of share options exercised",
        "documentation": "Effect of share options exercised."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfShareOptionsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Share Options on Number of Ordinary Shares",
        "terseLabel": "Effect of share options number of ordinary shares",
        "verboseLabel": "Effect of share issue",
        "documentation": "Effect of share options on number of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EffectOfShareOptionsOnNumberOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfShareOptionsOnNumberOfWarrantsShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Share Options on Number of Warrants Shares",
        "terseLabel": "Effect of share options number of Warrants shares",
        "documentation": "Effect of share options on number of warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EffectOfSubscriptionReceiptsIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EffectOfSubscriptionReceiptsIssue",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Subscription Receipts Issue",
        "terseLabel": "Effect of subscription receipts issue",
        "documentation": "Effect of subscription receipts issue."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EgriftaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EgriftaMember",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EGRIFTA [Member]",
        "terseLabel": "EGRIFTA\u00ae net sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "totalLabel": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r41",
      "r226"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r184"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]",
        "terseLabel": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r130"
     ]
    },
    "thtx_EqualAnnualInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EqualAnnualInstallments",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equal Annual Installments",
        "terseLabel": "Equal annual installments",
        "documentation": "Equal annual installments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending Balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r29",
      "r117",
      "r119",
      "r131",
      "r132",
      "r134"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityInterestsOfAcquirer",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer",
        "terseLabel": "Business combination shares value of consideration"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EventAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]",
        "documentation": "Event [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_EventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "EventDomain",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]",
        "documentation": "Event [Domain]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess Of Tax Value Of Intellectual Property And Fees Over Carrying Value",
        "terseLabel": "Excess of tax value of intellectual property and patent fees over carrying value",
        "documentation": "Excess of tax value of intellectual, Property,and fees over carrying value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess Of Tax Value Of Property Plant And Equipment Over Carrying Value",
        "terseLabel": "Excess of tax value of property and equipment over carrying value",
        "documentation": "Excess of tax value of property,plant and equipment over carrying value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExerciseOfStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExerciseOfStockOptionsAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Of Stock Options [Abstract]",
        "terseLabel": "Exercise of Options:",
        "documentation": "IncreaseDecreaseThroughSharebasedPaymentTransactions"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExerciseOfStockOptionsAttributedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExerciseOfStockOptionsAttributedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Of Stock Options Attributed Value",
        "terseLabel": "Attributed value",
        "documentation": "Exercise of stock options attributed value"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "terseLabel": "Exercise Price 5",
        "documentation": "Exercise Price Five Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "terseLabel": "Exercise Price 4",
        "documentation": "Exercise Price Four Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "terseLabel": "Exercise Price 1",
        "documentation": "Exercise Price One Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Option exercise price",
        "verboseLabel": "Option exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "thtx_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "terseLabel": "Exercise Price 6",
        "documentation": "Exercise Price Six Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "terseLabel": "Exercise Price 3",
        "documentation": "Exercise Price Three Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceToAcquireOneCommonShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceToAcquireOneCommonShareMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price To Acquire One Common Share [Member]",
        "terseLabel": "Exercise price to acquire one common share with four Marathon Warrants [member]",
        "documentation": "Exercise price to acquire one common share."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "terseLabel": "Exercise Price 2",
        "documentation": "Exercise Price Two Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FederalMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "terseLabel": "Federal",
        "documentation": "Federal Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee and commission expense",
        "terseLabel": "Annual maintenance fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "thtx_FeesPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FeesPeriodAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FeesPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FeesPeriodMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FifthAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FifthAmendmentMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fifth Amendment [Member]",
        "terseLabel": "Fifth Amendment [member]",
        "documentation": "Fifth amendment member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FifthAmendmentOfTheLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FifthAmendmentOfTheLoanFacilityMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fifth Amendment Of The Loan Facility [Member]",
        "terseLabel": "Fifth Amendment of the Loan facility [member]",
        "documentation": "Fifth amendment of the loan facility member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FinanceCostsAndGainsLossesOnForeignCurrency": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FinanceCostsAndGainsLossesOnForeignCurrency",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Costs And Gains Losses On Foreign Currency",
        "negatedLabel": "Finance costs",
        "negatedTotalLabel": "Finance costs",
        "documentation": "Finance costs and gains losses on foreign currency."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income",
        "totalLabel": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "thtx_FinanceIncomeCostAndGainsLossesOnForeignCurrency": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FinanceIncomeCostAndGainsLossesOnForeignCurrency",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income Cost And Gains Losses On Foreign Currency",
        "totalLabel": "Finance income cost",
        "documentation": "Finance income cost and gains losses on foreign currency."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FinancialAssetsAverageMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FinancialAssetsAverageMaturityTerm",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets Average Maturity Term",
        "terseLabel": "Average maturity period",
        "documentation": "Financial assets average maturity term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]",
        "terseLabel": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r198",
      "r199",
      "r222",
      "r223"
     ]
    },
    "thtx_FinancialAssetsStatedInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FinancialAssetsStatedInterestPercentage",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets Stated Interest Percentage",
        "terseLabel": "Stated interest rate",
        "documentation": "Financial assets, stated interest percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "verboseLabel": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r298"
     ]
    },
    "thtx_FirstFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FirstFiveYearsMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Five Years [Member]",
        "terseLabel": "First Five Years"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_FirstMilestoneInstallmentPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "FirstMilestoneInstallmentPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Milestone Installment Payments Payable",
        "verboseLabel": "First milestone installment",
        "documentation": "First milestone installment payments payable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_GainLossOnDebtModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GainLossOnDebtModification",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss On Debt Modification",
        "terseLabel": "Gain (loss) on debt modification",
        "documentation": "Gain loss on debt modification."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_GainLossOnLeaseTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GainLossOnLeaseTermination",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail",
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss On Lease Termination",
        "negatedLabel": "Gain on lease termination",
        "terseLabel": "Gain on lease termination",
        "documentation": "Gain loss on lease termination."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_GainLossOnLoanFacilityModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GainLossOnLoanFacilityModifications",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss On Loan Facility Modifications",
        "negatedLabel": "Loss on Loan Facility modifications",
        "terseLabel": "Loss on Loan Facility modifications",
        "documentation": "Gain loss on loan facility modifications."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail",
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain On Repurchase Of Convertible Unsecured Senior Notes",
        "negatedLabel": "Gain on repurchase of convertible unsecured senior notes",
        "terseLabel": "Gain on repurchase of convertible unsecured senior notes",
        "negatedTerseLabel": "Gain on repurchase",
        "documentation": "Gain on repurchase of convertible unsecured senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesArisingFromSaleAndLeasebackTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) arising from sale and leaseback transactions",
        "terseLabel": "Termination (a)"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) arising from sale and leaseback transactions."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on remeasuring available-for-sale financial assets, net of tax",
        "verboseLabel": "Net change in fair value of financial assets at fair value through other comprehensive income (\"FVOCI\")",
        "terseLabel": "Net change in fair value of FVOCI financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on remeasuring available-for-sale financial assets, net of tax, before reclassification adjustments. [Refer: Financial assets available-for-sale]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) recognised in profit or loss on financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently",
        "terseLabel": "Gain (loss) due to changes in fair value of financial liabilities at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in profit or loss on financial liabilities at fair value through profit or loss that were designated as such upon initial recognition or subsequently. [Refer: Gains (losses) on financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on change in fair value of derivatives",
        "negatedLabel": "Change in fair value of Marathon Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "terseLabel": "General and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r239",
      "r257",
      "r260"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r239",
      "r257",
      "r260"
     ]
    },
    "ifrs-full_GovernmentDebtInstrumentsHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GovernmentDebtInstrumentsHeld",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government debt instruments held",
        "verboseLabel": "Bonds"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of debt instruments held by the entity that were issued by a government. [Refer: Debt instruments held; Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r93",
      "r102",
      "r105",
      "r183",
      "r193",
      "r195",
      "r262"
     ]
    },
    "thtx_GuaranteedInvestmentCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "GuaranteedInvestmentCertificates",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guaranteed Investment Certificates",
        "terseLabel": "Guaranteed investment certificates",
        "documentation": "Guaranteed investment certificates."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]",
        "terseLabel": "Expected volatility [member]",
        "verboseLabel": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IE",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ]
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail",
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total current and deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r42",
      "r43",
      "r44",
      "r78",
      "r129",
      "r209"
     ]
    },
    "thtx_IncomeTaxExpireTwoThousandFortyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandFortyMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Forty [Member]",
        "terseLabel": "Income tax expire 2040",
        "documentation": "Income tax expire two thousand forty member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandFortyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandFortyOneMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Forty One [Member]",
        "terseLabel": "Income tax expire 2041",
        "documentation": "Income Tax Expire Two Thousand Forty One"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandFortyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandFortyThreeMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Forty Three [Member]",
        "terseLabel": "Income tax expire 2043"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandFortyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandFortyTwoMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Forty Two [Member]",
        "terseLabel": "Income tax expire 2042"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandThirtyMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Thirty [Member]",
        "terseLabel": "Income tax expire 2030",
        "documentation": "Income tax expire two thousand thirty member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandThirtyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandThirtyNineMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Thirty Nine [Member]",
        "terseLabel": "Income tax expire 2039",
        "documentation": "Income tax expire two thousand thirty nine member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandThirtyOneMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Thirty One [Member]",
        "terseLabel": "Income tax expire 2031",
        "documentation": "Income tax expire two thousand thirty one member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandThirtyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandThirtyThreeMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Thirty Three [Member]",
        "terseLabel": "Income tax expire 2033",
        "documentation": "Income tax expire two thousand thirty three member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandThirtyTwoMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Thirty Two [Member]",
        "terseLabel": "Income tax expire 2032",
        "documentation": "Income tax expire two thousand thirty two member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentyEightMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Eight [Member]",
        "terseLabel": "Income tax expire 2028",
        "documentation": "Income tax expire two thousand twenty eight member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Five [Member]",
        "verboseLabel": "Income tax expire 2025",
        "documentation": "Income tax expire two thousand twenty five [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Four [Member]",
        "verboseLabel": "Income tax expire 2024",
        "documentation": "Income tax expire two thousand twenty four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentyNineMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Nine [Member]",
        "terseLabel": "Income tax expire 2029",
        "documentation": "Income tax expire two thousand twenty nine member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Seven [Member]",
        "terseLabel": "Income tax expire 2027",
        "documentation": "Income tax expire two thousand twenty seven member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxExpireTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxExpireTwoThousandTwentySixMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expire Two Thousand Twenty Six [Member]",
        "terseLabel": "Income tax expire 2026",
        "documentation": "Income tax expire two thousand twenty six member"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxJurisdictionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxJurisdictionAxis",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "documentation": "Income Tax Jurisdiction Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxJurisdictionMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Member]",
        "terseLabel": "Income Tax Jurisdiction [Member]",
        "documentation": "Income Tax Jurisdiction Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncomeTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncomeTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Receivable Current",
        "terseLabel": "Income taxes receivable",
        "documentation": "Income tax receivable current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "negatedLabel": "Income taxes paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net change in cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets",
        "terseLabel": "Increase (decrease) in fair value of assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Fair Value Measurement Due To Reasonably Possible Increase In Unobservable Input Recognised In Cash Flows",
        "terseLabel": "Increase (decrease) in cash flows",
        "documentation": "Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, after tax, assets",
        "terseLabel": "Increase (decrease) in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of assets, recognised in profit or loss after tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "thtx_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Fair Value Measurement Due To Reasonably Possible Increase In Unobservable Input Recognized In Accumulated Other Comprehensive Income After Tax Assets",
        "terseLabel": "Increase (decrease) in accumulated other comprehensive",
        "documentation": "Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognised in accumulated other comprehensive income after tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail": {
       "parentTag": "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfComponentsOfTheCurrentAndDeferredTaxExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Unrecognized Deductable Temporary Differences",
        "negatedLabel": "Change in unrecognized deductible temporary differences",
        "documentation": "Increase decrease in unrecognized deductable temporary differences."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Unrecognized Deductible Temporary Differences",
        "negatedLabel": "Change in unrecognized deductible temporary differences",
        "documentation": "Increase decrease in unrecognized deductible temporary differences."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTotalLabel": "Increase (decrease) in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through conversion of convertible instruments, equity",
        "terseLabel": "Repurchase of convertible unsecured senior notes",
        "presentationGuidance": "Increase Decrease Through Conversion Of Convertible Instruments",
        "verboseLabel": "Conversion"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "thtx_IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Exercise Of Options Number Of Shares",
        "terseLabel": "Monetary consideration Shares",
        "documentation": "Increase decrease through exercise of options number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseThroughExerciseOfOptionsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughExerciseOfOptionsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Exercise Of Options Value",
        "terseLabel": "Monetary consideration",
        "documentation": "Increase decrease through exercise of options value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquityShares",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Exercise of Warrants Equity Shares",
        "terseLabel": "Exercise of warrants (Shares)",
        "documentation": "Increase decrease through exercise of warrants equity shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseThroughExerciseOfWarrantsEquityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Exercise Of Warrants Equity Value",
        "terseLabel": "Exercise of warrants",
        "documentation": "Increase decrease through exercise of warrants equity value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Net Exchange Differences of Right to use Asset",
        "verboseLabel": "Effect of change in exchange rates",
        "documentation": "Increase Decrease Through Net Exchange Differences of Right to use Asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, other provisions",
        "verboseLabel": "Effect of change in exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "thtx_IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Net Exchange Differences Tax Credits And Grants Receivable",
        "terseLabel": "Effect of change in exchange rate",
        "documentation": "Increase decrease through net exchange differences tax credits and grants receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation for stock option plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "thtx_IncreaseDecreaseThroughSharesIssuedAtmProgramValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughSharesIssuedAtmProgramValue",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Shares Issued ATM Program Value",
        "terseLabel": "Share issue - ATM program",
        "documentation": "Increase decrease through shares issued atm program value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "terseLabel": "Total contributions by owners"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "thtx_IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Transactions With Owners Number Of Shares",
        "terseLabel": "Total contributions by owners shares",
        "documentation": "Increase decrease through transactions with owners number of shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IncreaseInTheFairValueOfLiabilityRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IncreaseInTheFairValueOfLiabilityRecorded",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In The Fair Value Of Liability Recorded",
        "verboseLabel": "Increase in the fair value of liability recorded",
        "documentation": "Increase in the fair value of liability recorded."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_InitialMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InitialMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Milestone Payments Payable",
        "terseLabel": "Initial Milestone Payments Payable",
        "verboseLabel": "Initial payments",
        "documentation": "Initial Milestone Payments Payable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_InitialMilestonePaymentsPayableAggregateAnnualInstallments.": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InitialMilestonePaymentsPayableAggregateAnnualInstallments.",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Milestone Payments Payable Aggregate Annual Installments.",
        "terseLabel": "Initial Milestone Payments Payable Aggregate Annual Installments.",
        "documentation": "Initial milestone payments payable aggregate annual installments."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IntangibleAssetsAgreementTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IntangibleAssetsAgreementTermOfContract",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Agreement Term Of Contract",
        "verboseLabel": "Intangible Assets Agreement Term",
        "documentation": "Intangible Assets Agreement Term Of Contract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r97"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r243",
      "r258"
     ]
    },
    "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnDebtInstrumentsIssued",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense on debt instruments issued",
        "negatedLabel": "Interest on convertible unsecured senior notes and on long-term loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 43.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest On Convertible Unsecured Senior Notes And Long Term Loan",
        "negatedLabel": "Interest on convertible unsecured senior notes and Loan Facility",
        "documentation": "Interest on convertible unsecured senior notes and long term loan."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedLabel": "Interest paid on convertible unsecured senior notes and Loan Facility"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_InterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateMeasurementInputMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate, measurement input [member]",
        "verboseLabel": "Risk-free\u00a0interest rate [member]",
        "terseLabel": "Interest rate, measurement"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ifrs-full_InterestRateTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateTypesMember",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate types [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "thtx_InventoriesReturned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InventoriesReturned",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Returned",
        "terseLabel": "Inventories returned",
        "documentation": "Inventories returned."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InventoriesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoriesTotal",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 12.0
      },
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "terseLabel": "Inventories",
        "totalLabel": "Total Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoryWritedown2011",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Inventory writedown"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r64"
     ]
    },
    "thtx_InvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InvesteeAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Axis]",
        "documentation": "Investee axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_InvesteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InvesteeMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Member]",
        "documentation": "Investee."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_InvestmentQuebecMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "InvestmentQuebecMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Quebec [Member]",
        "verboseLabel": "Investment Quebec [Member]",
        "documentation": "Investment quebec member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital, warrants and subscription receipts",
        "verboseLabel": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "thtx_IssuedCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IssuedCapitalAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital [Axis]",
        "documentation": "Issued capital."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_IssuedCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "IssuedCapitalDomain",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital Subscription receipts and Public Offering Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "thtx_KatanaAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "KatanaAmendmentAgreementMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Katana Amendment Agreement [Member]",
        "terseLabel": "Katana Amendment Agreement",
        "documentation": "Katana amendment agreement."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_KatanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "KatanaMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Katana",
        "terseLabel": "Katana [member]",
        "documentation": "Katana."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesSummaryOfKeyManagementPersonnelCompensationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "thtx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "verboseLabel": "Laboratory equipment",
        "documentation": "Laboratory Equipment [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]",
        "terseLabel": "From 1 to 2 Years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r162",
      "r263",
      "r267",
      "r286"
     ]
    },
    "ifrs-full_LaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than three years [member]",
        "terseLabel": "More than 3 Years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r267"
     ]
    },
    "thtx_LaunchMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LaunchMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Launch Milestone Payable",
        "verboseLabel": "Launch milestone payable",
        "documentation": "Launch milestone payable\n."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "thtx_NonderivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Lease liabilitites"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LeaseLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LeaseLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities Undiscounted Cash Flows",
        "terseLabel": "Lease Liabilities",
        "documentation": "Lease liabilities undiscounted cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold improvements",
        "verboseLabel": "Leasehold improvements"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "thtx_LeasesLiabilitiesEffectOfChangeInExchangeRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LeasesLiabilitiesEffectOfChangeInExchangeRates",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases liabilities Effect of change in exchange rates",
        "terseLabel": "Effect of change in exchange rates",
        "documentation": "Leases liabilities Effect of change in exchange rates."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r131",
      "r132",
      "r134",
      "r210",
      "r214"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesFromSharebasedPaymentTransactions2011",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities from share-based payment transactions",
        "verboseLabel": "Liability related to deferred stock unit plan",
        "terseLabel": "Deferred stock liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "thtx_LiabilityComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LiabilityComponentMember",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Component [Member]",
        "terseLabel": "Liability component"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LicenseAgreementTransferPlusLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LicenseAgreementTransferPlusLPMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Transfer Plus L P [Member]",
        "terseLabel": "License Agreement Transfer Plus L P",
        "documentation": "License agreement transfer plus L P."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "thtx_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line Of Credit Facility Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit facility, maximum borrowing capacity",
        "documentation": "Line o cCredit facility maximum borrowing capacity."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Current",
        "terseLabel": "Current portion of Loan Facility",
        "documentation": "Loan facility current."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility [Member]",
        "documentation": "Loan facility."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Noncurrent",
        "terseLabel": "Loan Facility",
        "documentation": "Loan facility noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche1And2LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche1And2LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 1 and 2 Loan [Member]",
        "documentation": "Loan facility tranche 1 and 2 loan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche1LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche1LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 1 Loan [Member]",
        "terseLabel": "Loan Facility Tranche 1 Loan [Member]",
        "documentation": "Loan facility tranche 1 loan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche2LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche2LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 2 Loan [Member]",
        "documentation": "Loan facility tranche 2 loan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche3And4LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche3And4LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 3 and 4 Loan [Member]",
        "documentation": "Loan facility tranche 3 and 4 loan member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche3LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche3LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 3 Loan [Member]",
        "documentation": "Loan facility tranche 3 loan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTranche4LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTranche4LoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche 4 Loan [Member]",
        "documentation": "Loan facility tranche 4 loan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LoanFacilityTrancheTwoLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LoanFacilityTrancheTwoLoanMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Facility Tranche Two Loan [Member]",
        "terseLabel": "Loan Facility Tranche 2 Loan [member]",
        "documentation": "Loan facility tranche two loan member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans received",
        "terseLabel": "Term loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LocationInIncomeStatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LocationInIncomeStatementAxis",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location In Income Statement [Axis]",
        "documentation": "Location in income statement [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LocationInIncomeStatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LocationInIncomeStatementDomain",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location In Income Statement [Domain]",
        "documentation": "Location in income statement domain."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LongTermLoanUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LongTermLoanUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term loan undiscounted cash flows",
        "terseLabel": "Facility loan / Term loan, including interest",
        "documentation": "Long term loan undiscounted cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_LongTermPurchaseCommitmentsMinimumPaymentsRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "LongTermPurchaseCommitmentsMinimumPaymentsRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Purchase Commitments Minimum Payments Required",
        "terseLabel": "Long term purchase commitments",
        "documentation": "Long term purchase commitments minimum payments required"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]",
        "terseLabel": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MarathonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MarathonWarrantsMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marathon Warrants [Member]",
        "terseLabel": "Marathon Warrants [member]",
        "documentation": "Marathon warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Summary of maturity analysis for non-derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r141",
      "r149",
      "r150",
      "r153",
      "r154",
      "r156",
      "r162",
      "r188",
      "r197",
      "r241",
      "r263"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r131"
     ]
    },
    "thtx_MilestoneAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneAmountPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Amount Payable",
        "terseLabel": "Milestone amount payable",
        "documentation": "Milestone amount payable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneFiveMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Five [Member]",
        "verboseLabel": "Upon first achieving annual net sales of US$ 500,000"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneFourMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Four [Member]",
        "verboseLabel": "Upon first achieving annual net sales of US$ 200,000"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneOneMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestonePhaseTwoLiveDemonstrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestonePhaseTwoLiveDemonstrationMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Phase Two Live Demonstration [Member]",
        "terseLabel": "Milestone Phase Two Live Demonstration",
        "documentation": "Milestone phase two live demonstration."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MilestoneSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MilestoneSixMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Six [Member]",
        "verboseLabel": "Upon first achieving annual net sales of US$ 1,000,000"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Cash Cash Equivalents And Short Term Investments To Be Maintained",
        "terseLabel": "Minimum cash cash equivalents and short term investments to be maintained",
        "documentation": "Minimum cash cash equivalents and short term investments to be maintained."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MinimumLiquidityRequirementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MinimumLiquidityRequirementAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Liquidity Requirement Amount",
        "terseLabel": "Minimum liquidity requirement amount",
        "documentation": "Minimum liquidity requirement amount."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousComponentsOfEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousComponentsOfEquityAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous components of equity [abstract]",
        "terseLabel": "Transactions with owners, recorded directly in equity"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_MultidosePassInjectorDevelopedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "MultidosePassInjectorDevelopedMember",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Multidose pass injector developed [Member]",
        "terseLabel": "Multidose pass injector developed",
        "documentation": "Multi-dose pass injector developed."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NatureOfFeesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NatureOfFeesAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Fees [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NatureOfFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NatureOfFeesMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NegativePercentageImpactOnForeignCurrencyExposures": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NegativePercentageImpactOnForeignCurrencyExposures",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Negative Percentage Impact On Foreign Currency Exposures",
        "terseLabel": "Negative percentage impact on foreign currency exposures",
        "documentation": "Negative percentage impact on foreign currency exposures"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NetCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NetCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Carrying Amount",
        "terseLabel": "Net carrying amounts",
        "documentation": "Net carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NetCarryingAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NetCarryingAmountAbstract",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail",
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Carrying Amount [Abstract]",
        "terseLabel": "Net carrying amounts",
        "verboseLabel": "Net carrying amounts",
        "documentation": "xxx_Net Carrying Amount Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NetCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NetCarryingAmountMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Carrying Amount [Member]",
        "documentation": "Net Carrying Amount [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "thtx_FinanceCostsAndGainsLossesOnForeignCurrency",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "negatedLabel": "Net foreign currency loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r300"
     ]
    },
    "thtx_NetGainLossOnFinancialInstrumentsCarriedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NetGainLossOnFinancialInstrumentsCarriedAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Gain Loss On Financial Instruments Carried At Fair Value",
        "terseLabel": "Net gain on financial instruments carried at fair value",
        "documentation": "Net gain loss on financial instruments carried at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NetSalesBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NetSalesBasisMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Basis [Member]",
        "terseLabel": "Net Sales Basis"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_NonVotingSubscriptionReceiptsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NonVotingSubscriptionReceiptsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Voting Subscription Receipts [Member]",
        "terseLabel": "Non-voting Subscription Receipts [Member]",
        "documentation": "Non voting subscription receipts."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r122",
      "r250"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "verboseLabel": "Lease liabilities",
        "terseLabel": "Non-current portion"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r124",
      "r250"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentLoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current portion of non-current loans received",
        "terseLabel": "Non-current portion"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "thtx_NonderivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current portion of non-current notes and debentures issued",
        "periodEndLabel": "Convertible unsecured senior notes, Ending balance",
        "periodStartLabel": "Convertible unsecured senior notes, Beginning balance",
        "presentationGuidance": "Convertible unsecured senior notes including interest carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_NonderivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NonderivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonderivative Financial Liabilities",
        "totalLabel": "Financial liabilities",
        "documentation": "Nonderivative financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-derivative financial liabilities, undiscounted cash flows",
        "totalLabel": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "verboseLabel": "Less than 1 year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r149",
      "r150",
      "r162",
      "r263",
      "r267"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notional amount",
        "presentationGuidance": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_NumberOfCashSettledForwardStockContractsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NumberOfCashSettledForwardStockContractsOutstanding",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Cash Settled Forward Stock Contracts Outstanding",
        "verboseLabel": "Shares outstanding",
        "documentation": "Number of cash settled forward stock contracts outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "terseLabel": "Business combination number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Warrants exercisable"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "terseLabel": "Deferred stock units outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodStartLabel": "Number of options beginning balance",
        "periodEndLabel": "Number of options ending balance",
        "terseLabel": "Number\u00a0of options outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r172"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedLabel": "Number of options, exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "thtx_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Options Forfeited and Expired In Share based Payment Arrangement",
        "verboseLabel": "Number of options,Forfeited\u00a0and expired \u2013 CAD",
        "documentation": "Number Of Share Options Forfeited and Expired In Share based Payment Arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedLabel": "Number of options, Forfeited \u2013 USD"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of options, granted",
        "verboseLabel": "Number of Options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Shares issued during the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued and fully paid",
        "terseLabel": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "thtx_NumberOfSharesIssuedThroughAtmProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "NumberOfSharesIssuedThroughAtmProgram",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Shares Issued Through ATM Program",
        "terseLabel": "Share issue - ATM program (shares)",
        "documentation": "Number of shares issued through atm program."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodStartLabel": "Beginning balance, Shares",
        "periodEndLabel": "Ending Balance, Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office furniture and equipment",
        "verboseLabel": "Office furniture and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "thtx_OffsettingOfDeferredTaxLiabilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OffsettingOfDeferredTaxLiabilityAxis",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting of Deferred Tax Liability [Axis]",
        "documentation": "Offsetting of Deferred Tax Liability [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_OffsettingOfDeferredTaxLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OffsettingOfDeferredTaxLiabilityMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting of Deferred Tax Liability [Member]",
        "documentation": "Offsetting of Deferred Tax Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_OncologyPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OncologyPlatformMember",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oncology Platform [Member]",
        "terseLabel": "Oncology Platform"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense",
        "totalLabel": "Total operating expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "thtx_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses",
        "documentation": "Operating expeneses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r293"
     ]
    },
    "thtx_OtherAdditionalProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OtherAdditionalProvisionMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Additional Provision [Member]",
        "terseLabel": "Other",
        "documentation": "Other additional provision."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets [member]",
        "terseLabel": "Other Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "thtx_OtherAssetsNonCurrentAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OtherAssetsNonCurrentAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Non Current at Cost",
        "terseLabel": "Ending balance",
        "documentation": "Other Assets non current at cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Exchange differences on translation of foreign operations",
        "verboseLabel": "Exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r39"
     ]
    },
    "thtx_OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Net Of Tax Research And Development Cost",
        "terseLabel": "Other Comprehensive Income Net Of Tax Research and Development Cost",
        "documentation": "Other comprehensive income net of tax research and development cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Bonds and money market funds"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "TaiMed milestone"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_OtherFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsSummaryOfDetailedInformationAboutBondsAndMoneyMarketFundsDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial assets",
        "totalLabel": "Bonds and money market funds",
        "terseLabel": "Bonds and money market funds"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "terseLabel": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_OtherShorttermProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherShorttermProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current provisions",
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "thtx_OverallotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "OverallotmentMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overallotment [Member]",
        "terseLabel": "Over-allotment [member]",
        "documentation": "Over-allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "thtx_PaymentForContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PaymentForContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Contingent liabilities",
        "terseLabel": "payment for Contingent liabilities",
        "documentation": "Payment for Contingent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PaymentOfMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PaymentOfMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Milestones",
        "terseLabel": "Payment of milestones",
        "documentation": "Payment of milestones."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PaymentOfUpfrontMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PaymentOfUpfrontMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Upfront Milestones",
        "verboseLabel": "Upfront payment",
        "documentation": "Payment Of Upfront Milestones."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments For Costs Related To Repurchase Of Convertible Unsecured Senior Notes",
        "negatedLabel": "Costs related to repurchase of convertible unsecured senior notes",
        "negatedTerseLabel": "Transaction costs incurred",
        "documentation": "Payments for costs related to repurchase of convertible unsecured senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForDebtIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForDebtIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for debt issue costs",
        "negatedLabel": "Costs related to issuance of Loan Facility"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for debt issue costs."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedLabel": "Costs related to issuance of common shares, Public Offering Warrants and subscription receipts",
        "terseLabel": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Payment of lease liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "thtx_PaymentsToAcquireDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PaymentsToAcquireDerivativeFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments To Acquire Derivative Financial Assets",
        "negatedLabel": "Acquisition of derivative financial assets",
        "documentation": "Payments To Acquire Derivative Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PercentageOfOwnershipHoldingCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PercentageOfOwnershipHoldingCommonShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Ownership Holding Common Shares",
        "terseLabel": "Percentage Of Ownership Holding Common Shares",
        "documentation": "Percentage of ownership holding common shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PercentageOfOwnershipOfTheInvestor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PercentageOfOwnershipOfTheInvestor",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Ownership Of The Investor",
        "terseLabel": "Percentage Of Ownership Of The Investor",
        "documentation": "Percentage of ownership of the investor."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PercentageOfPurchasePriceConsiderationOfIntangibleAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PercentageOfPurchasePriceConsiderationOfIntangibleAssets",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Purchase Price Consideration Of Intangible Assets",
        "verboseLabel": "Intangible Asset Purchase Consideration",
        "documentation": "Percentage Of Purchase Price Consideration Of Intangible Assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible decrease in unobservable input, assets",
        "terseLabel": "Negative impact of market interest rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of reasonably possible increase in unobservable input, assets",
        "terseLabel": "Positive impact of market interest rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "thtx_PerformanceObligationFinalSettlementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PerformanceObligationFinalSettlementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Obligation Final Settlement Amount",
        "verboseLabel": "Performance obligation final settlement amount",
        "documentation": "Performance obligation final settlement amount."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PlanAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan [Axis]",
        "terseLabel": "Plan [Axis]",
        "documentation": "Plan Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PlanDomain",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan [Domain]",
        "terseLabel": "Plan [Domain]",
        "documentation": "Plan Domain."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfCompanySForeignCurrencyExposuresDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Positive Negative Impact of Foreign Exchange Gain loss Sensitivity Analysis",
        "terseLabel": "Positive (negative) impact",
        "documentation": "Positive negative impact of foreign exchange gain loss sensitivity analysis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PositivePercentageImpactOnForeignCurrencyExposures": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PositivePercentageImpactOnForeignCurrencyExposures",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Positive Percentage Impact On Foreign Currency Exposures",
        "terseLabel": "Positive percentage impact on foreign currency exposures",
        "documentation": "Positive percentage impact on foreign currency exposures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined contribution plans",
        "terseLabel": "Post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "thtx_PotentialShareIssueInTheFutureOnExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PotentialShareIssueInTheFutureOnExerciseOfWarrants",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Share Issue In The Future On Exercise Of Warrants",
        "terseLabel": "Potential share issue in the future on exercise of warrants",
        "documentation": "Potential share issue in the future on exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail": {
       "parentTag": "ifrs-full_CurrentPrepaidExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PrepaidExpensesAndDepositsSummaryOfPrepaidExpensesAndDepositsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "Prepaid Expenses."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PricePerShareForTheSettlementOfCashsettledForwardStockContracts": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PricePerShareForTheSettlementOfCashsettledForwardStockContracts",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Per Share For The Settlement Of Cashsettled Forward Stock Contracts",
        "terseLabel": "Price per share for the settlement of cash-settled forward stock contracts",
        "documentation": "Price per share for the settlement of cash-settled forward stock contracts."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "verboseLabel": "Private Placement [Member]",
        "documentation": "Private Placement."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProceedsFromConsiderationOfTheFifthAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProceedsFromConsiderationOfTheFifthAmendment",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Consideration Of The Fifth Amendment",
        "terseLabel": "Consideration for the Fifth Amendment",
        "documentation": "Proceeds from consideration of the fifth amendment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of Options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from government grants, classified as investing activities",
        "terseLabel": "Subsidy or grants received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from government grants, classified as investing activities. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issue of bonds, notes and debentures",
        "terseLabel": "Proceeds from issue of convertible unsecured senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "verboseLabel": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "thtx_ProceedsFromIssuingSharesAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProceedsFromIssuingSharesAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuing Shares And Warrants",
        "terseLabel": "Proceeds from issue of common shares, Public Offering Warrants and subscription receipts",
        "documentation": "Proceeds from issuing shares and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilitySummaryOfMovementInTheCarryingValueOfTheLongTermLoanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from non-current borrowings",
        "definitionGuidance": "Proceeds from issuance of Loan Facility",
        "terseLabel": "Proceeds from issuance of long-term loan",
        "verboseLabel": "Proceeds from Loan Facility on July\u00a027,\u00a02022"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities",
        "terseLabel": "Proceeds from sale of bonds and money market funds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "thtx_ProceedsFromTheIssuanceOfCommonSharesAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProceedsFromTheIssuanceOfCommonSharesAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From The Issuance Of Common Shares And Warrants",
        "verboseLabel": "Proceeds from the issuance of common shares and warrants",
        "documentation": "Proceeds from the issuance of common shares and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r256"
     ]
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r256"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r35",
      "r107",
      "r118",
      "r120",
      "r210",
      "r212",
      "r250",
      "r259"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r226",
      "r227",
      "r268",
      "r269"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r294"
     ]
    },
    "thtx_ProgramNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProgramNameAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProgramNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProgramNameMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Name [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property and equipment",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56"
     ]
    },
    "thtx_PropertyPlantAndEquipmentAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PropertyPlantAndEquipmentAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Accumulated Depreciation",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Proprety Plant And Equipment Accumulated Depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r243",
      "r258"
     ]
    },
    "thtx_ProvincialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProvincialMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provincial [Member]",
        "terseLabel": "Provincial",
        "documentation": "Provincial Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProvisionForExcessStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProvisionForExcessStock",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision For Excess Stock",
        "terseLabel": "Provision of inventories",
        "documentation": "Provision for excess stock."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProvisionForFormulation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProvisionForFormulation",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision For Formulation",
        "terseLabel": "Provision for formulation",
        "documentation": "Provision for formulation."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProvisionForTheExpiredRawMaterial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProvisionForTheExpiredRawMaterial",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision For The Expired Raw Material",
        "terseLabel": "Provision for the expired raw material",
        "documentation": "Provision for the expired raw material."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ProvisionForTheInventoryInDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ProvisionForTheInventoryInDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision For The Inventory In Development",
        "terseLabel": "Provision for the inventory in development",
        "documentation": "Provision for the inventory in development."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "Provisions used"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "thtx_PublicIssueOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PublicIssueOfSharesMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Issue Of Shares [Member]",
        "terseLabel": "public issue common shares [member]",
        "documentation": "Public Issue Of Shares [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedLabel": "Acquisition of bonds and money market funds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedLabel": "Acquisition of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Acquisition of property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r156",
      "r172",
      "r254",
      "r255",
      "r319"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r156",
      "r172",
      "r254",
      "r255",
      "r319"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_RawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current raw materials",
        "terseLabel": "Raw materials"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r298"
     ]
    },
    "thtx_ReclassificationOfOtherDeferredFinancingCostsToDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ReclassificationOfOtherDeferredFinancingCostsToDeficit",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of Other Deferred Financing Costs to Deficit",
        "terseLabel": "Reclassification of other Deferred financing costs to deficit",
        "documentation": "Reclassification of other deferred financing costs to deficit."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]",
        "verboseLabel": "Cost"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ReconciliationOfChangesInOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ReconciliationOfChangesInOtherAssetsAbstract",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetSummaryOfDetailedInformationAboutOtherAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation Of Changes In Other Assets [Abstract]",
        "verboseLabel": "Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.theratech.com/role/PropertyAndEquipmentSummaryOfInformationAboutPropertyPlantEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in property, plant and equipment [abstract]",
        "terseLabel": "Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RefundsProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RefundsProvisionMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refunds provision [member]",
        "verboseLabel": "Returns"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a provision for refunds to be made by the entity to its customers. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245"
     ]
    },
    "thtx_RegulatoryMilestonePaymentPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RegulatoryMilestonePaymentPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Milestone Payment Payable",
        "terseLabel": "Regulatory payable milestone related",
        "documentation": "Regulatory payable milestone related."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RelatedPartyPercentageOfVotingRightsHeld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RelatedPartyPercentageOfVotingRightsHeld",
     "presentation": [
      "http://www.theratech.com/role/RelatedPartiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Percentage Of Voting Rights Held",
        "terseLabel": "Related party percentage of voting shares held",
        "documentation": "Related party percentage of voting shares held."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Shares Reserved For Issue Under Options And Contract For Sale Of Shares",
        "terseLabel": "Remaining options available for issuance",
        "documentation": "Remaining shares reserved for issue under options and contract for sale of shares."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RepaymentOfOtherObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RepaymentOfOtherObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment Of Other Obligations",
        "negatedLabel": "Repayment of other obligations",
        "documentation": "Repayment of other obligations."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.theratech.com/role/ConvertibleUnsecuredSeniorNotesSummaryOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "negatedLabel": "Repurchase of convertible unsecured senior notes",
        "negatedTerseLabel": "Cash paid on repurchase"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "thtx_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Research and Development Expense."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ResearchAndDevelopmentExpenseNetOfTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ResearchAndDevelopmentExpenseNetOfTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense Net of Tax Credits",
        "verboseLabel": "Research and development expenses, net of tax credits of $ 539 (2022 - $ 316; 2021 \u2013 $ 277)",
        "documentation": "Research and development expense net of tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfEquityComponentOfConvertibleInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of equity component of convertible instruments",
        "terseLabel": "Equity component of convertible unsecured senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing components of convertible instruments classified as equity."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfEquityComponentOfConvertibleInstrumentsMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of equity component of convertible instruments [member]",
        "verboseLabel": "Equity component of convertible unsecured senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing components of convertible instruments classified as equity."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Cumulative exchange difference on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r228"
     ]
    },
    "ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]",
        "terseLabel": "Unrealized losses on FVOCI financial assets, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the accumulated gains and losses on financial assets measured at fair value through other comprehensive income. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r114",
      "r115",
      "r116",
      "r155",
      "r288"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r228"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r114",
      "r115",
      "r116"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenue",
        "verboseLabel": "Net sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r126",
      "r185",
      "r207",
      "r211",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r250"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeAndCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "verboseLabel": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r208",
      "r215",
      "r286"
     ]
    },
    "ifrs-full_RevenueMultipleMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueMultipleMeasurementInputMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue multiple, measurement input [member]",
        "terseLabel": "Revenue multiple, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a revenue multiple used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r255"
     ]
    },
    "thtx_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "documentation": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RightOfUseAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RightOfUseAssetsTableTextBlock",
     "presentation": [
      "http://www.theratech.com/role/RightOfUseAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use Assets [Table Text Block]",
        "terseLabel": "Summary of right-of-use assets",
        "documentation": "Right-of-use\u00a0assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "presentationGuidance": "Right-of-use-assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147"
     ]
    },
    "thtx_RoyaltyFeesAsAPercentageOfRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RoyaltyFeesAsAPercentageOfRevenue",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Fees As A Percentage Of Revenue",
        "terseLabel": "Royalty fees in percentage",
        "documentation": "Royalty fees as a percentage of revenue."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RoyaltyRelatedLicensePeptidesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RoyaltyRelatedLicensePeptidesMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Related License Peptides [Member]",
        "terseLabel": "Royalty Related License Peptides"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RoyaltyRevenueSublicenseBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RoyaltyRevenueSublicenseBasisMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Revenue Sublicense Basis [Member]",
        "terseLabel": "Royalty Revenue Sublicense Basis"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_RxCrossRoadsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "RxCrossRoadsMember",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rx Cross Roads [Member]",
        "terseLabel": "RxCrossroads",
        "documentation": "Rx Cross Roads."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Potential aggregate offering price",
        "documentation": "Sale of stock consideration received on transaction."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SaleOfStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SaleOfStockMember",
     "presentation": [
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScenariosAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScenariosAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenarios [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScenariosDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScenariosDomain",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenarios [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfDetailInformationAboutFinanceIncomeAndCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Detail Information About Finance Income And Costs [Abstract]",
        "verboseLabel": "Scheduled of Detailed Information About Finance Costs [Abstract]",
        "documentation": "Schedule of detail information about finance income and costs abstract."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFunds1Abstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Detailed Information About Bonds And Money Market Funds1 [Abstract]",
        "verboseLabel": "Schedule of Detailed Information About Bonds and Money Market Funds",
        "documentation": "Schedule of detailed information about bonds and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfDetailedInformationAboutBondsAndMoneyMarketFundsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Detailed Information About Bonds And Money Market Funds [Abstract]",
        "verboseLabel": "Schedule of Detailed Information About Bonds and Money Market Funds"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfDetailedInformationAboutTradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Detailed Information About Trade and Other Receivables [Abstract]",
        "documentation": "Disclosure of detailed information about trade and other receivables."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfInformationAboutOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfInformationAboutOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About Other Assets [Abstract]",
        "verboseLabel": "Other asset [Abstract]",
        "documentation": "Schedule of information about other assets."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ScheduleOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]",
        "terseLabel": "Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit [Abstract]",
        "documentation": "Schedule Of Information About Unused And Unrecorded Non Refundable Federal Tax Credit."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SchemeOfShareIssueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SchemeOfShareIssueAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scheme Of Share Issue [Axis]",
        "terseLabel": "Scheme Of Share Issue [Axis]",
        "documentation": "Scheme Of Share Issue Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SchemeOfShareIssueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SchemeOfShareIssueDomain",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scheme Of Share Issue [Domain]",
        "terseLabel": "Scheme Of Share Issue [Domain]",
        "documentation": "Scheme Of Share Issue Domain."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SecondMilestoneInstallmentPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SecondMilestoneInstallmentPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Milestone Installment Payments Payable",
        "verboseLabel": "Second milestone installment",
        "documentation": "Second milestone installment payments payable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SecuredOvernightFinancingRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SecuredOvernightFinancingRateMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate [Member]",
        "documentation": "Secured overnight financing rate."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR",
        "documentation": "Secured overnight financing rate sofr overnight index Swap rate."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r140",
      "r210",
      "r240",
      "r261"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsSummaryOfSingleOperatingSegmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r140",
      "r216",
      "r240",
      "r261"
     ]
    },
    "thtx_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Selling and Marketing Expense."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling expense",
        "terseLabel": "Selling expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "thtx_SeronoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SeronoIncMember",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serono Inc [Member]",
        "terseLabel": "Serono Inc"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SeveranceAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SeveranceAndOtherExpensesMember",
     "presentation": [
      "http://www.theratech.com/role/ProvisionsSummaryOfProvisionParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance And Other Expenses [Member]",
        "terseLabel": "Severance And Other Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareBasedCompensationPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareBasedCompensationPlanAbstract",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Plan [Abstract]",
        "terseLabel": "Share-based compensation plan",
        "documentation": "Share based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareCapitalLineItems",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital [Line Items]",
        "documentation": "Share capital [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareCapitalTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital [Table]",
        "documentation": "Share capital [table]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/SupplementalCashFlowDisclosuresSummaryOfSupplementalCashFlowDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Issue Cost Included in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Share issue cost included in accounts payable and accrued liabilities",
        "documentation": "Share issue cost included in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareIssueCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Issue Costs",
        "terseLabel": "Share issue costs",
        "documentation": "Share issue costs."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ShareOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ShareOptionMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Option [Member]",
        "terseLabel": "Share options [member]",
        "documentation": "Share Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SharePriceMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Member]",
        "terseLabel": "Share price [member]",
        "documentation": "Share price."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits accruals",
        "terseLabel": "Employee salaries and benefits payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Salaries and short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]",
        "terseLabel": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r130"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant unobservable input, liabilities",
        "terseLabel": "Measurement\u00a0date",
        "verboseLabel": "Expected volatility unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "thtx_SignificantUnobservableInputLiabilitiesBasisPoints": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SignificantUnobservableInputLiabilitiesBasisPoints",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Input Liabilities Basis Points",
        "terseLabel": "Expected volatility unobservable input, liabilities, basis points",
        "documentation": "Significant unobservable input liabilities basis points."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StatementTable",
     "presentation": [
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail",
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [table]",
        "verboseLabel": "Statement [Table]",
        "documentation": "Statement Table."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockAndWarrantsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock And Warrants Issued During Period Shares New Issues",
        "terseLabel": "Public issue of common shares and\u00a0warrants (Shares)",
        "documentation": "Stock and warrants issued during period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "terseLabel": "Public issue of common shares and\u00a0warrants",
        "documentation": "Stock and warrants issued during period value new issues."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockAppreciationRightsContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockAppreciationRightsContractualLife",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights Contractual Life",
        "verboseLabel": "SAR Contractual Life",
        "documentation": "Stock appreciation rights contractual life."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockAppreciationRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockAppreciationRightsMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights [Member]",
        "presentationGuidance": "Stock Appreciation Rights [Member]",
        "definitionGuidance": "Stock Appreciation Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issuable As A Percentage Of Total Shares Issued And Outstanding",
        "terseLabel": "Stock issuable as a percentage of total shares issued and outstanding",
        "documentation": "Stock issuable as a percentage of total shares issued and outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Share issue \u2013 Oncology (Shares)",
        "documentation": "Stock Issued During Period Shares Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Acquisitions",
        "terseLabel": "Share issue \u2013 Oncology",
        "documentation": "Stock Issued During Period Value Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During the Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible unsecured senior notes (Shares)",
        "documentation": "Stock issued during the period shares conversion of convertible securities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringThePeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringThePeriodSharesNewIssues",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During the Period Shares New Issues",
        "terseLabel": "Public issue of common shares (Shares)",
        "documentation": "Stock issued during the period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During the Period Value Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible unsecured senior notes",
        "documentation": "Stock issued during the period value conversion of convertible securities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockIssuedDuringThePeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockIssuedDuringThePeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During the Period Value New Issues",
        "terseLabel": "Public issue of common shares",
        "documentation": "Stock issued during the period value new issues."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_StockOptionPlanTwoThousandAndNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "StockOptionPlanTwoThousandAndNineteenMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan Two Thousand And Nineteen [Member]",
        "verboseLabel": "Stock Option Plan Two Thousand And Nineteen [Member]",
        "documentation": "Stock Option Plan Two Thousand And Nineteen Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SubscriptionReceiptsIssueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SubscriptionReceiptsIssueMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receipts Issue [Member]",
        "terseLabel": "Subscription Receipts Issue [Member]",
        "documentation": "Subscription receipts issue."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_SupplementalCashFlowDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "SupplementalCashFlowDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures [abstract]",
        "documentation": "Supplemental Cash Flow Disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaiMedBiologicsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaiMedBiologicsInc.Member",
     "presentation": [
      "http://www.theratech.com/role/InventoriesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TaiMed Biologics Inc [Member]",
        "terseLabel": "TaiMed Biologics Inc. [Member]",
        "documentation": "TaiMed Biologics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaimedAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaimedAgreementMember",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taimed Agreement [Member]",
        "terseLabel": "Taimed Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaxBenefitCarryForwardYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaxBenefitCarryForwardYearAxis",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Benefit Carry Forward Year [Axis]",
        "terseLabel": "Tax Benefit Carry Forward Year [Axis]",
        "documentation": "Tax Benefit Carry Forward Year Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaxBenefitCarryForwardYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaxBenefitCarryForwardYearMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Benefit Carry Forward Year [Member]",
        "terseLabel": "Tax Benefit Carry Forward Year [Member]",
        "documentation": "Tax Benefit Carry Forward Year Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaxCreditsAndGrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaxCreditsAndGrantsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail",
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits and grants receivable",
        "verboseLabel": "Tax credits and grants receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Tax credits and grants receivable",
        "documentation": "Tax credits and grants receivable."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaxCreditsAndGrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaxCreditsAndGrantsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credits And Grants Received",
        "terseLabel": "Tax credits and grants received",
        "documentation": "Tax credits and grants received."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TaxCreditsAndGrantsRecognizedInNetProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TaxCreditsAndGrantsRecognizedInNetProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableDisclosureDetailsOfTaxCreditsRollForwardDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credits and Grants Recognized in Net Profit or Loss",
        "verboseLabel": "Tax credits and grants recognized in net loss",
        "documentation": "Tax credits and grants recognized in net profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectFromChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect from change in tax rate",
        "terseLabel": "Impact of differences in statutory tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "terseLabel": "Non-deductible\u00a0expenses and other"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfReconciliationBetweenEffectiveAndApplicableTaxDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Income taxes at domestic tax statutory rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "thtx_TermOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TermOfWarrants",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Of Warrants",
        "verboseLabel": "Term of warrants",
        "documentation": "Term of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TerminationBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TerminationBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/PersonnelExpensesSummaryOfDetailedInformationAboutPersonnelExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination benefits expense",
        "terseLabel": "Termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "thtx_TerminationOfLeasesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TerminationOfLeasesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Of Leases Operating Lease Right Of Use Assets",
        "terseLabel": "Termination Of Leases Operating Lease Right Of Use Assets",
        "documentation": "Termination of leases operating lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TerminationOfLeasesOperatingLeaseRightOfUseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TerminationOfLeasesOperatingLeaseRightOfUseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/LeasesLiabilitiesSummaryOfLeasesLiabilitiesParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Of Leases Operating Lease Right Of Use Liability",
        "documentation": "Termination of leases operating lease right of use liability."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TerminationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TerminationOfRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/RightOfUseAssetsDisclosureOfRightOfUseAssetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Of Right Of Use Assets",
        "terseLabel": "Termination",
        "documentation": "Termination of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_ThtxCommercializationRightsTrogarzoNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "ThtxCommercializationRightsTrogarzoNorthAmericaMember",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "THTX Commercialization Rights Trogarzo North America [Member]",
        "terseLabel": "THTX Commercialization Rights Trogarzo\u00ae North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.theratech.com/role/BasisOfPreparationAdditionalInformationDetail",
      "http://www.theratech.com/role/BondsAndMoneyMarketFundsAdditionalInformationDetail",
      "http://www.theratech.com/role/CapitalManagementAdditionalInformationDetail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range",
        "definitionGuidance": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r156",
      "r172",
      "r254",
      "r255",
      "r319"
     ]
    },
    "thtx_TotalLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TotalLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Lease Liabilities",
        "negatedLabel": "Lease liabilities",
        "documentation": "Total lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TradeAndAccruedPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TradeAndAccruedPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Accrued Payables [Abstract]",
        "terseLabel": "Trade and other payables (Abstract)",
        "documentation": "Trade and accrued payables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "thtx_NonderivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 35.0
      },
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail",
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total",
        "verboseLabel": "Accounts payable and accrued liabilities carrying amount",
        "negatedLabel": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "verboseLabel": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r292"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail": {
       "parentTag": "ifrs-full_CurrentAssetsLiabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 13.0
      },
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail",
      "http://www.theratech.com/role/TradeAndOtherReceivablesSummaryOfDetailedInformationAboutTradeAndOtherReceivablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade and other receivables",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables [abstract]",
        "terseLabel": "Trade and other payables (Abstract)",
        "disclosureGuidance": "Trade and other payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TradeAndOtherPayablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TradeAndOtherPayablesLineItems",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TradeAndOtherPayablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TradeAndOtherPayablesTable",
     "presentation": [
      "http://www.theratech.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfTheContractualMaturitiesOfFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables, undiscounted cash flows",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r267"
     ]
    },
    "thtx_TradeAndOtherReceivablesExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TradeAndOtherReceivablesExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Receivables Explanatory [Abstract]",
        "terseLabel": "Trade And Other Receivables Explanatory [Abstract]",
        "documentation": "Trade and other receivables explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.theratech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TrancheAxis",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TrancheDomain",
     "presentation": [
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TransactionCostsAllocatedToTheLoanFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TransactionCostsAllocatedToTheLoanFacility",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs Allocated To The Loan Facility",
        "verboseLabel": "Transaction costs allocated to the loan facility",
        "documentation": "Transaction costs allocated to the loan facility."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TransactionCostsOfWarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TransactionCostsOfWarrantsIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs Of Warrants Issued",
        "verboseLabel": "Transaction cost of warrants issued",
        "documentation": "Transaction costs of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TrogarzoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TrogarzoMember",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trogarzo [Member]",
        "verboseLabel": "Trogarzo\u00ae",
        "documentation": "Trogarzo"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TrogarzoNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TrogarzoNetSalesMember",
     "presentation": [
      "http://www.theratech.com/role/RevenueScheduleOfNetSaleByProductDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trogarzo Net Sales [Member]",
        "terseLabel": "Trogarzo\u00ae net sales"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TwoThousandAndSixteenShareholdersPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TwoThousandAndSixteenShareholdersPlanMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Sixteen Shareholders Plan [Member]",
        "terseLabel": "Two Thousand And Sixteen Shareholders Plan [Member]",
        "documentation": "Two Thousand And Sixteen Shareholders Plan Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TwoThousandThirteenTerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TwoThousandThirteenTerminationAgreementMember",
     "presentation": [
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Thirteen Termination agreement [Member]",
        "terseLabel": "2013 Termination agreement",
        "documentation": "Two thousand thirteen termination agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of arrangement [Axis]",
        "documentation": "Type of Arrangement Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfArrangementMember",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/OtherAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of arrangement [Member]",
        "documentation": "Type of arrangement Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfArrangementsAxis",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of arrangements [axis]",
        "terseLabel": "Type of arrangements [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfArrangementsMemberDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfArrangementsMemberDomain",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsAdditionalInformationDetail",
      "http://www.theratech.com/role/IntangibleAssetsSummaryOfCommercialMilestonePaymentDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of arrangements Member [Domain]",
        "terseLabel": "Type of arrangements [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfReversalOfDeferredTaxLiabilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfReversalOfDeferredTaxLiabilityAxis",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Reversal Of Deferred Tax Liability [Axis]",
        "terseLabel": "Type Of Reversal Of Deferred Tax Liability [Axis]",
        "documentation": "Type Of Reversal Of Deferred Tax Liability Axis."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_TypeOfReversalOfDeferredTaxLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "TypeOfReversalOfDeferredTaxLiabilityMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Reversal Of Deferred Tax Liability [Member]",
        "terseLabel": "Type Of Reversal Of Deferred Tax Liability [Member]",
        "documentation": "Type Of Reversal Of Deferred Tax Liability Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInstrumentMember",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of instrument [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.theratech.com/role/CommitmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r187",
      "r190",
      "r191"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsSummaryOfPresentsTheSignificantItemsInTheOriginalCurrenciesExposedToCurrencyRiskDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r187",
      "r190",
      "r191"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.theratech.com/role/OperatingSegmentsAdditionalInformationDetail",
      "http://www.theratech.com/role/RevenueScheduleOfNetRevenueByGeographicalAreaDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]",
        "verboseLabel": "US$",
        "presentationGuidance": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "US$"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r316"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail",
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfMeasurementOfFairValueOfWarrantLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r316"
     ]
    },
    "thtx_UnusedAndUnrecordedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "UnusedAndUnrecordedTaxCreditsMember",
     "presentation": [
      "http://www.theratech.com/role/TaxCreditsAndGrantsReceivableSummaryOfInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused And Unrecorded Tax Credits [Member]",
        "terseLabel": "Unused tax credits",
        "documentation": "Unused and unrecorded tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses for which no deferred tax asset recognised",
        "verboseLabel": "Losses carried forward"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "thtx_UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unutilised Research And Development Expenses With No Time Limitation",
        "terseLabel": "Research and development expenses, without\u00a0time\u00a0limitation",
        "documentation": "Unutilised Research And Development Expenses With No Time Limitation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, intangible assets other than goodwill",
        "terseLabel": "Intangible assets finite useful lives"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "thtx_UsefulLifeMeasuredAsPeriodOfTimeOtherAssets": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeOtherAssets",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful Life Measured As Period Of Time Other Assets",
        "terseLabel": "Amortization of other assets",
        "documentation": "Useful life measured as period of time other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.theratech.com/role/SignificantAccountingPoliciesSummaryOfMethodsOfDepreciationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment",
        "verboseLabel": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "thtx_VariableInterestRateCashAndMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "VariableInterestRateCashAndMarketFundsMember",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Rate Cash And Market Funds [Member]",
        "terseLabel": "Cash and market funds"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_VariableInterestbearingCashAndMoneyMarketFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "VariableInterestbearingCashAndMoneyMarketFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.theratech.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable InterestBearing Cash And Money Market Funds",
        "terseLabel": "Cash and money market funds",
        "documentation": "Variable Interest-Bearing Cash And Money Market Funds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantReserveMember",
     "presentation": [
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3Detail",
      "http://www.theratech.com/role/DeterminationOfFairValuesSummaryOfMarathonWarrantsRecognizedAtFairValueAndConsideredLevel3ParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant reserve [member]",
        "terseLabel": "Warrant reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "thtx_WarrantsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "WarrantsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Current",
        "terseLabel": "Marathon Warrants",
        "documentation": "Warrants current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/LoanFacilityAdditionalInformationDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Warrants exercisable price per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "Weighted average options exercisable"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "verboseLabel": "Weighted average, exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "verboseLabel": "Weighted average, Forfeited"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Weighted average, granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise",
        "terseLabel": "Weighted average share price of options excercised on the exercise date"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average ending balance",
        "periodStartLabel": "Weighted average beginning balance",
        "terseLabel": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, share options granted",
        "terseLabel": "Weighted average grant date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "thtx_WeightedAverageFairValueOfStockOptionsGrantedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "WeightedAverageFairValueOfStockOptionsGrantedTable",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfSummarizesTheMeasurementDateWeightedAverageFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Fair Value Of Stock Options Granted [Table]",
        "verboseLabel": "Weighted Average Fair Value Of Stock Options Granted",
        "documentation": "weighted average fair value of stock options granted."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheStockOptionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining life"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "thtx_WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheNumberOfOptionsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Share Options Forfeited and Expired In Share based Payment Arrangement",
        "terseLabel": "Weighted average,Forfeited and expired",
        "documentation": "Weighted Average Share Options Forfeited and Expired In Share based Payment Arrangement ."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfFairValueOfOptionsUsedToDetermineTheWeightedAverageAssumptionsDetail",
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfTheModelUsedToDetermineFairValueOfOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Grant-date share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.theratech.com/role/ShareCapitalWarrantsAndSubscriptionReceiptsSummaryOfCalculationOfWeightedAverageNumberOfCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Issued common shares as at December 1"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.theratech.com/role/InventoriesSummaryOfDetailedInformationAboutInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current work in progress",
        "terseLabel": "Work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r298"
     ]
    },
    "thtx_YearTwoThousandAndFortyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndFortyMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Forty [Member]",
        "terseLabel": "2040",
        "documentation": "Year two thousand and forty."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndFortyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndFortyOneMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Forty One [Member]",
        "terseLabel": "2041",
        "documentation": "Year Two Thousand And Forty [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndFortyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndFortyThreeMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Forty Three [Member]",
        "terseLabel": "2043",
        "documentation": "Year two thousand and forty three."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndFortyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndFortyTwoMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Forty Two [Member]",
        "terseLabel": "2042",
        "documentation": "2042 [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyEightMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Eight [Member]",
        "terseLabel": "2038",
        "documentation": "Year Two Thousand And Thirty Eight Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyFourMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Four [Member]",
        "terseLabel": "2034",
        "documentation": "Year Two Thousand And Thirty Four Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty [Member]",
        "terseLabel": "2030",
        "documentation": "Year Two Thousand And Thirty Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyNineMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Nine [Member]",
        "terseLabel": "2039",
        "documentation": "Year two thousand and thirty nine"
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyOneMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty One [Member]",
        "terseLabel": "2031",
        "documentation": "Year Two Thousand And Thirty One Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtySevenMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Seven [Member]",
        "terseLabel": "2037",
        "documentation": "Year Two Thousand And Thirty Seven Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyThreeMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Three [Member]",
        "terseLabel": "2033",
        "documentation": "Year Two Thousand And Thirty Three Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndThirtyTwoMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Two [Member]",
        "terseLabel": "2032",
        "documentation": "Year Two Thousand And Thirty Two Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndTwentyEightMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Twenty Eight [Member]",
        "terseLabel": "2028",
        "documentation": "Year Two Thousand And Twenty Eight [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndTwentyNineMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Twenty Nine [Member]",
        "terseLabel": "2029",
        "documentation": "Year Two Thousand And Twenty Nine Member."
       }
      }
     },
     "auth_ref": []
    },
    "thtx_YearTwoThousandAndTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.theratech.com/20231130",
     "localname": "YearTwoThousandAndTwentySevenMember",
     "presentation": [
      "http://www.theratech.com/role/IncomeTaxesSummaryOfTheAmountsAndExpiryDatesOfTaxAttributesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Twenty Seven [Member]",
        "terseLabel": "2027",
        "documentation": "Year Two Thousand And Twenty Seven Member."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "136",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_136&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_91_a&doctype=Standard&forcepdf=true",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B33&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "171",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_171&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>195
<FILENAME>0001193125-24-040745-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-040745-xbrl.zip
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MM8,ETZ#4^D[]9"[.3CR[?%!J30>-9SW/[NW4:YD>Z![S"(-_\+_HF7\FMEQ
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M'>.+]VK;[W?L2HX% T.OX(J[N#U]6-^2I\VG92KY]WP+X[RR7D\:>9\T.H)
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MEPCXOVT.^+CKS!QJM$F/@LDT/ARBH:^AOP;H7V\.^D>)HIE@"\$*&NV>*RZ
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M E\)>/0N$TF^%-Y6GJ#BAB3)0M!40J9NEPY1N[>@QT&DSQ0;_4V0$PET5\P
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M;U>U(%G))-_(? ^J%T3&;Y#2<9A:)8H,%^'*[B88'T!W*9;AC'_L&3!9I'T
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M@!!DQ)00YO)!V0HM<LPOAF'R.7R?:]TP4QX$.:%DPM=VH/Y@"WBM1*SJBR0
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MD>HI7]0]=  8GR=HY#2?_!T=<J=5Q];]DX>%/$^+(CAXOYC\_NN'_)4PQ)6
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MP[]R.Z/[ 2EI88]BL#U*23/:>6Z<===S8'_^G ,[BQS8*V09RHB_R!'N21Y
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MAJ'+3ZQP<R<!\YU7K%IG7,Y2#HOQ[7/Q@T8'9^^Y*;113*D'N.8%MG8'W*!
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M NKE?HNHH2>99D5[K;> "S<^\-Y_2*R1KC!H,3*SSP] %Y?)N N9\_V<?]1
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MW>Z_;,-<-&60^:%"HS)8<X."ZF7Z;>\0\H'"D)3J)RBX#8](>10B*F6$Y&Q
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MPA/L2[L\C%2N=0%_GH?T-I]P3K9"ZL\&U=@JQF2T ()9:ANK"O.+#@*DR B
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M-8O10W"XQ\FC?E9FI \4;6H>;VIO(S$LO\W;<O+?9I;Z>+SQT/?N=!.S&S4
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MEH[E/7P6:&R"4R^EZ- W+))5&6*:?4G@>*[=P2Z-'B_.I05)2S=TKBL4\SP
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MH5>8D* 7M)3*B@0LJFRVF[QKP]XZAIFF<RPX:9J^9JDO,.'Z7GC*M[5MWIH
M\69,0^JJ+;)P2"E<%B1!:11NFA360(X^QI<\XI<<=?WQ_2O&_:YX2R6PHM5Z
M'(Z:KA7_"&Q;1?N*F A]:9>_R=X_22U=_728EXAA:9!122S;QC*XJZ+M"LX<
M-C3ZMF(QERN7BW9L8&*X: RWZ07=@BA6,)Q8?P1T+]?$T&C\<1@,Q=$(.Z(D
MCF-##70@1YTTIBJ+HVHM6#2NL =M="Y=<S1JRE.+&O_-JW)65]-U"Z@M*8^\
MF@"O0S\LU_;K>4[*RWZ0H@,:LO[<,XCFRBJC*732Y27O@8Y_-SDEW2G,QERQ
M"M@Y$]#H!U)6,JNZ(,$D 4NTEFHF$Z=7,9;V0VX+K(%X7N,;%<KK'U_M[*?N
MTF$3VNM;Y@DW4Q \+:LY!QC5#MP*S0$=;Z+ '#*DZR<%\RZ/92Q<7J*>__A3
M1% 1'D7O8"IYP6^*H1+&G(4/)[? H$:YQD%<;=.5[RF%;/U[GNX/04U!D_??
MF6J2]1P"33L'*)$L <UL,",QM16OSNSO,[N(Y9YT,7]WJ(=!:*Z6N%#N6/AA
MH&B8,=&CN[D9MYZ7KEH3^#3OFHU']L&#L-1"L4OM:L63<SJ(J6*]<R?=]$3C
MV<#K^;J=+Y,'IH?H.0_M0;&5X3,'(W%V#6H/ ME<C#^<+6Y?>A+JK28TU=WD
M5_MP_M$T7QP6LBU*-SQ23)^&!M3N,/ ?T0M3EV@!V\!"X:2.F@W,/#^R7]HL
M%8K>3DB?QHIEQ4R$$H5YI.:Z9KK@WK2_<;?W%2UUFC3H!LL549WT_%YT!6^$
M+$#R "U<LX?H^5<#W]1V99FS.)$VA8)#O2JGQ5@T$753%#G\7Z- Y[363$PP
MMIFR2=YJ:_"F/Q>H12Y8)HD$0=,Y2GD8."#<X5Q1*PB.7DTR3QM10K:C$[;H
M+A;K:;XL,E=OAG+D0C" =>8+XQ@6$GF>-LI;53[ A),O%%-?VN7;LFV!2KW)
M&+L+H/F#8H+8"&GHR4Y7K#\\W"+S[/>9'UMA-XK'\8N=1R864F$+2!)(0Z73
MLG!AW>9ZV7<1WY()U2NR].]B9IMR'14Z #DFQ2>I-6I$UL-R. PD]C%;1*W"
M/HK#:"UJZ,CT6;@B#?]4/M*#;Z1W4P;1)/&!EQ)Y\[9N>\,'6^!<\Q+4@9<P
MY-SS=AB'5^3,%,81<&L3]^+]9[_H7&O'!)A@0'/XIXC]T6M'TA.C9#QW)3-\
MVS'C)(TX6$PG2SQE25,N0S<N<RL7$,3L23V17''^886_;;D$7_J#(^B+!C8-
MAX'Y((8PC-!I%]@WO6&12^N93'+/+2TKBZGWM*47&AN;GI-*PJOTQ.:VZRNU
M53"5C$/D;F08:ZXWNS/H_4)=T.W-B+(FX"+'1P0%;VBZHQ(6&69\2G8#69H[
M\?FTBH%;/)C9N5_DN+'M$/V49XM6<'\_L:U^RI'F_-9KMPVWY9WI5(V(1XKU
MY5M.(O=;]5C2F%F.6)9)Z"2CP&65@OGIFK">2VDMM2-[6-!EG:/SL'N]J]C:
M@ '>4.A5J,+F8CJEMZ$Y(/4BF3><$NDNRQ7-B(\)!#H@T+G32C9RL'/'U_6:
MEC%Y] /_N+__/!D4$B0[N,4^ 'AMG[F#T1C?%+LCM%I'TA/D/5>5\ 7#JBTL
M&-& C.Y&5!L[W(*HMNY?XSAHK%>.@DJBA)E"/KCQQE0S.%O%I-,F,E8,'O&R
M],T5)'6_3Q[0FZ,>;/GLH0L9Z"B&Y"L.F<Q8K$7'J4.I;\Z'=9HWYZB9#!5$
M9-E0>/?WCEE&M?KUF+V3:2BNXZ/<('NR;EK.)>T6#OF7^X?F/!]U,Q[<*U>D
M=NK*G11H-!#;_B"^6#3O!-1[-Y9A9&!(]+&FW6=7GY:B:USEKV)+8"RPYZQU
M\P=,$[F\T!I;BZ4P"A,=PTA+VD>?R@=[9DS"- (DYHO.3*.#Q_3!-_C*'JCS
M3JM9T2V3X_FBJN$SOS8L6)K\<GHB>ODNEB.:&LPFOL7 EQTNDC#_T/V$ <L!
M="OF*([^'G 9-7,AO7AF/6P;U_9QN$R*]KGVC61Q^J<>NJ=^XMU@?]D(S[_+
M.\,]ZTUQGB?'](B;;Y&1D[C MZ?KJ=1BW$FMQQ;<,O]>^:)?2@[P.]\"R3S.
M#=^%F$G:R><7K'I'NN/2:.AZR1<+Q-CHO.'TN6+B%X]<@H7.)^B=N<QMF?U&
MLD@2VE96=<;A6*U-^YB\?DWVSB*?=B24>#TT"(INQ3]S &NFB^-@LGB/\!O)
M&0'<%Z]17Q=4H"\>_2=8YCHZ@9*K$EP[I[1K+MT2P)!\R 6"+:9\-X$17 U2
M(Y)-F:P7J1Q9"XQ\NLAF>K<7M99EX\-83+)3209WZ0+F,KP=KL5S62VF0!0N
M&G[P3@#MCYS.LX29<]'F:8:TM-6;][,5)0HUZMS1V-QKI,OWWY N6X%TN3MX
M(E]WN+"V3Q,/N/]#UAA$04,@[:VXQ47/VDQ)3YS 3M&*H &FV 4CQXS%NU!B
MF; LO2"UOASI]3HZ31OT,,\E,+S8^KV;<E-])<?R=+'088!3-PQ[<J:?5)(;
MVYO:>C &\YD95/3-9@UM*6VXSK.&N>'CZ;#7R!1(U<R36G"&;N%!3ST2;F21
M[F9?XL&@Z$Y3\QPYX+9_96%TBEJV;/7*9CN#.EA";E/!%*#C+O/%!1V%I*$O
MWPP2#947\!42],-1WC!K#,1A6Y<6TY4R)Y?]=GD9"9<T;741PZVP)_OG.I9X
MUTK ]?.P*C(V1% TV<W61M]FMRY[.4BFLNGD_)RWSL_9>,COZI1PR9Z,[>:&
M<A;D>/O#SN'>@0KX0X<-T8)MB24CB&LL[BQDXN^G25[6%;=Z/-@WV 2Y>-_?
M+HLA7'67KLB9PQ"/;O?=$NTRZ;L/'3:N8@*%IE$ @(!O/A0&@.,BQ6RJB&^%
M4:C*>OWV]]D1D:U,,,U9[6D-Z8A:Y& W>9O3=/W;?N^*$!E4*RTVHX*71LS)
M"YQ4QJHC\?*85.C^T_WG%W]>ODFM1-(1@]/*^<I&KO/M7#$H=USWA:8,Z(2=
M._9J05-(:B&HO62D@P0Y#H-Q*-(SYV:$&^<AB\Z*RZA#@W67K@_A\&];P](7
M6Y/[@(1.E"$\+*;MY$;,&&\C-GJ6/-OCUJWG@)M.<S'] S9YG@=^B 9(PA-.
MX,'>[I-G:;*_N_?T83(K9D+=9/WI'2_\-+>:9?K"4WS^X/'#W>3OG.4!Q3 3
ML7"!0_(A7ZLCB)$[-\*FD&I25S955 .<GB]:MD3;O0*%HX=QQ:12%@"J&(*U
M$,6VF[P$B;0H.0-J*;TY[V??4)*0)9OL&DQC!\QE([F'6UNULOC[CP^B-5=1
M"F--KJH=?P!(AK[-!'_PJ]Z5>3 JQ&EXE?1I.\PTM:K1: *AL**=HM/]0Z:?
MM>@A.&@376['2*I+M?&1\-*OYGEY=UJ+4U1AB"VZWA;KK;C&ST99(Z]Z/6!%
M6/1H*3Y>)>UWOI+-O-925<WF&=]LKX4MTN6&D2)I^.'-D4>BP09O2'K[F;.;
MIL&IIL&)N"M[0QFC?'UA=I45DMU+3DBMN 8"+Z#W?VGH4GF5YXB[.?/HY,4O
MKXZ<A10TAMU"EI;W(7'->-/0+<I3_[X,/;XN,V<FB +^%;=ZJY;"DG)KTAY'
MV -XH]*!@08L1&F/</F\%LKD DD%X9KU>3DD)4!!+G!:;D7B^),1('?Q\0@R
M"W<N1G$IO--(%749R?UC5F=Z7;$,_.+KE F#W@?N\<8<!WFH0EC1/_!9>7/,
M("1/TMX UZ@3QC'WWG"]8AP;\59<!W<9DIK2AY*W69E=Y 9?B:',252WNGVA
MJYL6X]73Y%7 #K$] W\WQ+\\OMX[O_W=V1=V_GNT$-P*-[ZO#^W"#M_N;,XL
M.7[_QO/]T=O$/?EG!Y7'!.E=NS!SF1]!GX?&7: DA<EU!&$/Y, \7^*LK=%9
MN>Q0V]&YSAK:TZP1;Z=V7I65Y$%!@FJER=8H<5FNK*&9U!AEFI6!3>#5T9JD
M5_F?PO"-+*DTJ$4G=_!?<Y8!-[E^L-_X2=>:4=G,A6C(BC!-"9P23AIW!1!'
MR1/LT-)Z[EIZBQ0"1R0FI>9T+O*2B8H8.VZ-?F5K.&:E#),V*A? \]LB$'1<
M#8V2V:)D^#82<J:-G')M0A<1Z/KI9\G9>D7FCFMY$XEDW++/ P(SJ9+B0V$H
M2?N.A.F,8V@+SNK98'6X70)[6]),P\*5ZIY+IYGR*[*=L)A=5=</A[-FBIE]
M]2B2N*9:S.+&62B=0$>NKTDY$TOX:I&5++2&KONJ8_G$KR;R+:<A!0.(KF-L
MJ,RUZFHH1B.H<UF&WD>W@_[ED^3Z#F6BMQASA5[/F&H6VGQVF96M4F-(\QOQ
MT'0I OW.S'/:)[XD9VPMA<Q9(=0Q $S?Z]3QTV^IXZU(';^#UV"G.QT[_5-N
M9F@-HY0PTAD$)QP?/)C\^; '=9!03Y_7;[2@ TZD&6363FQ5K=P=OP67ZWTB
M8;V+^;ZJPE:SPIKV":QU7Y=6:P,I':#Z&QT%W\*3 Y1PH36EZ#*I8>,7P8-'
MVGD[5X,= 497PU':[[6%ATF+P#]=(JA"T-Z"33=9%BZDPAB#Y/B'EV'30TN6
MO?IE4-BRA8O@W*=%-LD7ZK.E?)^R\J$#(&4R@TYP6F,MKD6P<H4QNXN+"^@K
M-UUU/1+=J@3 >%HM"<PB!J9)^%F_@!7EU-P,M';).<FC<>T'=_KA>R=-SGYZ
M^?XH.9&O)Z<=]^#Z@L5*0V^7K6Z9DMHR[#XVJ\HZ4&(\/:G0LC%VHAMVZCMI
MCI35]1J^-OWQIU>G??\J.&'>G]U&.;KC-R31PSUWVHJ[#Y<E"&'.A!)WZ,O&
M>12IY@N;C-(Z:UF[^/>7FFS9%0L/6TIN=#&SKBG(P]3Y4FKY&3?N8086#C"H
M1:L-D.7S^G$-9R)I-P40=<0Y",<OO?YZT:1]B28]"K60S,6_NQI_9A N0 ]Y
MB:5D&F%N7'B404'9#,=]=PONU9LDZBW<G&3G!0+/)\B2<W(1Q>U;8QIHZ6_8
MU4UNFBMN44?3TS2%N#;T0S%U)<803@D,KG)O#8[$M;W-J%@:?%[J*GU3W, H
M)>']S6@J?)QF&"R2PR5]U7PRI9!F2^Z,I5'@?@YVK1FGUX.^"-SA:9&%29T>
M299*'^9_+XS8V\;D^X3:H?W^H]KO)\Y^__)P?.A([?WI:T2Y]Z4EX5XO,5QU
M0K,M!I'HT#'OQH=1/\'/,1;T$;E]'7$9Z[!,_UJW<9?1PV0YRWM$>M'PEPX#
M]_,+7SL7QC-9?:H[-_#E0GC=K;PY/3Z!P:WO/^5% P?LB;0W-2 HG3L@G?!(
M9D3>,)(PN(^U-+0LKXO<$/HD;2#&+V=J(EAE+CS41A>L!HH%T9J;T3\C%==I
MW#J.5<O3VB9XB3$YZ]MQ+6G8VUK?9IRY; 8Q=9F80%<#4XF%U)M9K"<OP#?F
MXN=A"%H^Q&LOE0;Q;>G*W<A@T>JD,!+?6Q^I3/2Q\T'07 ;R64KM]S[,9Y8M
MX3Q*M+:X11:PLV8J[4O<MF9>US3K:HEOI<FLZB:+?&="L@>_ :S@DVI'DSZ+
M/D/X&,RJO:IV8)XYB!7+?8A/MH[#"@=@$*1KX9!-U_V<./T?DX+MH"=8LQ;,
M6KT<>!0D TDS16P=]VP+-@4R%1]9YNDB3P[ EG-(JS2IJZ8@23F!';GOJ)]X
MJ)RY<0R&'I;%L:*/!7K DM&UG^[O[?D!/-C_RW[$K/<77;N'(8(@?L3WC[$:
M_)C1CD^[R9%51 DIFL[?X-!D/<.J@*">M^KAB7D\/E38Y07M2:L=2KQAO?\T
M6=(6SV-<FF%YYQP'8P.&H>@9B+H8LR[ISI%<9Z__A0BCI,3@$OK5/>^$-8M[
MN*R;0EL47EGH+3#-KYWCHW S;C4[C;Q?1KIZ9+EE*L-Q\FP,8)[Q9L ,JVHH
M5:[<M%X<"-XSI"%GQB@_ NTT(0L7,<$U0@1735!*ILZ&]J06XH0<C_0RJWND
MC;-1B:KG?3?Q :TLN)YYQSSW!Y^# SL'P7;AY!=EI^U<H /8S]=\*_(7/5%[
M&IV*PTVG0BK4_;,%EQJ(#/G0DC'AZEE>WT*P(.?P\)2(Y6C3\3Q(GX4#"0O/
MU'XVU/A6ZG*R>] <7OT+$7T5:/43F$]#KFE_"[J,.H>R2&9 @W$U0 _AE-7<
M@:B'_E/C0'+N&^P0O5+DA&J;:<BL9:\:=ILS0$%QD.%$S/S:6R.6J/!#X*T,
MG+?&2]5*+G?>*SKM^<=\VK6>Q^"BSI:A9G6XQ$#&M6!@6S>XJF=B+MUXI<[R
M'0 ,7)4!;9%MCNXC;<"K?%)K*Q+?45QL( DPM'&,#JV;JFFU"*.?4;;1?BDZ
M3F-<&OA:%,(ONL$X9$,+R=/>NSQ@#PE,=(LL@H L'%%N]<VQ-QD7P@$;7E($
M2Q@ +1HM0>*P;U\6(&U@LR8)E] >2""%'R-7R4ZA66=@D)@QJ2P2EW('#%9.
MK['&N0^<#6KR;+F0?IW>\D&*N<Z#Z^OP\1Z,$<1'54FI30I'/?,E3[ANK .!
M_(GN,A"K,6\LK04V-N]5GFRRI*HPATQ2@2@P6&)U!!NF*4<]PS6B84[QX5KL
M93WSQ04\/'J'-\28W=Y96T>> 4B>V2+O/LF%HHU6J%6R('\SN!M.HFB\?ATM
MC<]B!"98NO?LT</;VS80%9ZLR),,B:,A' Z6JY"OEY&W21);TPBD?#@6J!#\
M&+MS&[=1J'@+,WP$JR2A:5D*%Q^2:TN\(ZTWM^.9E4'[+\9[TC:=2W[#;_$]
M3IT_^Y8Z_ZS4^>]]F1T;]IYO\]"L4SR;U\/LIULEG]TR L9ATY!OB,@PU$*?
MP#I10%\_YABBJ*&KFN@.I$=]R/,5!T"E"J@27#-N*U>-<4[S--,#AS7L3\S]
MTRL@_X0,&TP1=JO(K3AU$7I_,VD&.;HA>!%BL^I?*DSZSH#R]P^0?/KN_=G^
M?R9G^73.E!WK3\QTG;W57-?)(FM9B6_/W+]\;IYT!(>%\8=TX"]PX3(VQN8L
MR4[QC7T'K]Z!Y>+MNEJ!'9_;AEO[5'Q^"E!_/>P/+@SZ.+@\&\^UOZN_*,2W
MD-_J0!8 D651[PVZ1#DUHPU,I?BQ=#1W*1EFM>N2WM89#"HX&$;F"7>'% #Y
M-; [-1,C8Q8RF+#:5NK?U]80:)E]$*)R-L=;IE+CSO32'>":Z:.;D95*^BC!
M+%\BF2RF!VBSC=:?2RYY""FYT61L9T!(UP591JYV65LPI=PU89FK/X&<=BJ6
M(L^'E^%&/Z5$*2"^X^JW\54R]"\ ?Z2+%$%;[9::,>\VZFMEKDTT-Q(/OYT]
M^O#LXJ+63EG:WB0EC5XQ-.NBK*PUQ"PW8N^FJR]1AKJ+>C"L20EQ$W-YZ0-&
MT3*ZVR86,P86AWO^:.]/V&&4T@)1DVEE6[28;NG]&FS:AHUKLP7J0Z+JKL[1
MA=!/7AP[AV#F0!QN[>Y"X01;XS&E_=X6O'1QR;UB##AKR3OJ^@\4&G]>:EZE
MSEQ$"^4/E4.:OBZ5C+V1X,F&#Z8.'&CJC)9%XDY1Z+OD4O"&/ 4Y\Z"M99X]
M2(^E2VAX.X$&$*_;V'31H$RJ+?+RLJ@KSI2DGI6C6 (=DXDY)FS>"V[:@3BE
M2'.HJ'9A(8U18V,4X2#0%.H#ZJRF-+^/^0*Y@H]5W4U01)<FIS\?/H5#VZ[A
M[)%%15L @\<1@3=6X/=;=V'8&UXS:PM3N0XJ/!+5A@,USS%I@6:&I%U:!!>[
MOWV6!2YWNPC\H#\<4$"JQ!F"<)\M<#,\9LP-W:]A)"$#'X+;E.2_2?-T?'?-
M2"V21<:!;99Q+/9=G4CIH=S,JZM2;&)9?)9<D5#75D-2:NBY03=^QWTURB*3
MK5DW;8ZCVU8?I8XFXJC8>":/7/AYP1VMHE5<5G2FFLVK$H]\LEYE&C3AG!C?
MN '5F=D'^\F#MR_>[S^7_,6'$E^GY]QX)9[LH,5#I8]Q1"%2]L,G(X0NR<UW
MF:&^78J+Z*3CK*^3':X? 3=",+J@?X?6;=DBA9&.TTTK(43BN+%ZNLO.I,&A
MINNVXCUB59!Z); 5QPA PZE%8^[RVG'V['D$"N:7B0?)B8>%J]%2\G$NN.]:
MKB[CX#3=2F(7_(V.>)DE/Q35"=]4=+U,=QU$0?[J4 J5#^J&)8C[SWI?&)(#
M[]J+$'MGC>@8@J^J>C&[PN8*DW/J;FPRFZLU&:KKG4F><7C1:+TWL!D+"4^=
ME0W=J6UR0F](DS<GGKHX^I.-+>58)0F![8Y?9L&!.#^ TP27^;R8+H;7@UZ<
M@6B*8N</0KX7#%/2:\/ JKB"D%#R-ES5L]O'!Y^\46+EZY;:V,;9*+_BQJ@D
M=[Q49W,VCW3*5@[)N+$IO*B,0PF.!]->ON'=XP3-1MUZ#4WS!GFYAJ89[,S&
M3O59W,PU&;BUJWOO#X#?\1D3N>7N?+V)W32@K5&43-5I[/VWH5L A0%.R=E/
M^\_V'J46+>,D72N%M0.;)*0ABB*"<Y?1ET*P&RD>\&9YC3SV_D:O'^U]BUYO
M1>'7C2' P%SZ_T)S22*X^\FQF9IGK)VV)\#7*X !-8@R)<Y< 'K_&H3C1I-Y
M-&^EL8D@LSFX=Z-PB607-XS"@&JNF$0@*4?"1)(#<1WB]\=19.D(Y=XR^U@L
MNZ7GQY(GVC7_]LRC0H4Q,H@0C7@S:!VW:94BIBI4\1J%_IPN >7]*OH=Q+DR
M%NB+IEH4,^L_7N?G=29@(EA+D5.^8P:+F/K,@\.+]8/=8^-KG/9\%WS2&J=G
M#:JA^6-V=8KHP-1"J4K1* LC;6W=&;_2!O#-]WL1*Z=N60SVD_U0-HCK5M7A
MY\T$1S0-?#O!@B7M>I5''55_>O^?%E*3U;*(6]*/N-F?-4KG?@Y">.YWRWR1
ME73\8#2OZXI>;W\)0J6(=[K?*PLI]PC17S+QJ55DR=I8JEV\?Y))/C@!IQ%+
M4QS!)L&AT\<R)CA^!Q;#BI&O: U>>JG?/U9%Z:F^5E"YVL$G\ MKB(HP%;>R
MX"X_O^8"'W!T=-)7.*#1>^JZGMVJ02(KM[%FZ%?S*L (TMD!%Z"4L@O)!/G-
M/F;O="1S0=4>:.8:BO<T&H8?D!HIPV!<AVI!+-YBQ3W3;!\=H%/'GY<'@>1?
M,#?$(8(MY-%G)*BI_NY1&(!)W0<KX8K5&KCDP671=-P7M>.&X1^XO7JK477]
M<-/5YQE8E^HUNE6([I0''DAO30WIP(1[4&?-/%7*P<(X3WQ_]H>I7Y?K-(%T
MZ+&H/BF6PSV;OEU0)8F</$A8.ZT'(%U"F=7.!"+2%!^#XP$B?/XJTB:"A->P
ME-T6+]Z<!?UWX$O:F0N([P7?P^Q>J120P4B+Y^A'SGRE' Y6<'8?\*&06Z>?
MM^(81YP[7.X0'D*;W2?&70Z,+(7;!CN@9L8$ESN]"YSWE[6 X0&",>3A29&-
MOB@E,6.A83Z,N)=-1Y *4 VP71J3ECI&Y[+25->UKSD?J*2PO#?^;-&.B+B)
M\8..OJ5:)X=BF3QD2;2UI.\C536S,(7383'XEU2L7ZO7<4W*@<>MEH8JE,81
M7>@S5LJ9%U1EA]C %??*Y1"6!SZ%."P)+U\B'A=<J&I.JI^ZB9_A.IO#K RV
M++RY*T:LDR*KU71ZP'IA,#DZ*66\!CV'D!&+Z)W<2F^85JM%=+$N,X;=JFNY
M-Z$6$0:6 +1)SC433;7<LLL_OM-LFW638\BJ%38DI\SC#*,G.9K1-L,D/@YA
MC_-\L0I@\:PN@1@.X@F,_T27^JJ^ F!12JTVW3(<*%SXXO" U&T$/1M7/6S!
M(H,YKBOSD.;U<(3F-2R"\O%=S<G9+,T^DW/CYGSM^L6Q<H8>NYP^UXD-0<'C
MX-JXJ4&8WVL#=FYZTZRZNMXODY9".<P.E+]V$8NDI)1NPO<J)-2<$6GZ+0#;
M/@.3]$M#B+IJ#$&2)>11UK(L5@6G= 9!'20ZG).!I?CIRI#,P)KLB'%%6@9*
MJ>^K>.LO^"PJ)MJJS&'JH+_$ I7)H!GK)KGW>NKP*\[G\:Y-LL.8>C=&YGC&
M"0D]9:</AY4K[1RMD[+:$5V)_\DTJY+;S1WL8]=Q/&B"7%$NVM^-C?WS0@6B
MOU)DI#.?(3#0PSL]E:4LJZ"?+R*9)"X9_0>-BSO%*V<N9G"#@6]-C;=#N6XZ
M1 ",STA_TJ^?_.<3!T=GM755>42$B:M-2OVI.@_1![K1?#/6F?4NV73R_I+L
M[W[_&*;@![#G"IG7?IIH<^[]QU(0?Z-W=O!TA[[J0$7,F_N@(>&#*T*B<+#_
M1?9FSP["T YV@V&+ T:7:3,E7[SKO?P+C=WXY<#(0YNH](7^B2L)\+:86#S!
M&K.U$#5X+$-+&#K<E5&)]:O0>%\^0"X.F7*N @*.9_* 2Q7V\3>U)X,*L=&J
ML&C@.DZ_IL+5&Q:F:=T=CVF'QS0Z[I0FU_7"&AO712N2\+)4RUY];.")_WZA
M!K9+ ZF;-7J@PO)%;O<H:&%]?M_ZUK)3*6F4<CJZQHHF[P4!S0%,;SX+-Q<+
M%3BC9)62^I&8A@M0:_F0CYAY;7X+M(3%0+=#VQFA!3=E"*4-EB.GD0.*&'7)
MJWE5QV9VZR([UZW I>9TOZAD\,Y!]QJ5#<ODU7IVAEW%+1NTX9]B]'AMM T&
MF=1X'@GXRQ]>G[TX&I+O]*H#\>N22UOAO[DZ+'SK-LF\E2#<E&4 QMB78C5H
MJH^>'CA>)V\(]5*->->F:*/5&O-AW1%PFB%?HK4@?3759,JDFUU(\50<^O[N
MT>Y3,;UI(Q=JU'E6J-LLDMF81;Y@1>UHYRW(U2.@>=2C0!YB#0"8<^T12"-P
MPP\>#WQ229FP-9TMM(:! 9.1O]H#;V\\+1RIOBZV"S7HCY0+\V[%F3IE_(;*
MO)6BAEWK/RDTH8R1&Q;B2Z(0:=0,*RP#IN_\J*V3CFF7LQY,(1(Y*Z:,^KM?
MM[=^VWCN7&>.V-R]3LOO?TO+?^VT_">T2N;*L"8H)/K#=<2_&R'J5K(3?@[[
M8,$IXYP3VE[K^;Q<3*/*D8#%LD)-A@=X]@TL[A3=Y8)M]T40@K=&8VA:Q6H)
MA?UV^C=RK\!'Q5DL"6-,2!E?/00]6\M-#O1A_D'**QA$1=4;E<XQ7Y/H>\,R
M+>FJ5#3_=X\/=[^/C)^4?K>W^R@VB+"RWSTZW-V+?\T=TC(AV^U9.4TB7IA1
M@6D;W#T+;FJV 7X[ U]\HVNT"#OAX V-+V 2,WY<^!!P\<4)^JK+J<C/Z7CU
MQ=ABIU^Q8<&5A=UN>U:.LS*;90'N[^N-E3D,#=)8<3A+8_S9AI5T0%T)>''E
M,1^VK51VU[_!K@J=)]C@PK/C>7AA)BH0<_8Y6N1N5(C("?ZEO6\5SK$%-UV/
M;/! FA*'B'<$N5RNA+UN&'J(IZ(JK2XF'1<Z>4H&KC!S[KE'X=?2G*3RW]M*
M&F!M.8)"WYE/6 C[#F+O7%CFG)0IKH(:KN,D:[RN0$"YDNS[&X0?DB-2*/1R
MNA.+V8Q$\"77G_[,;-1'Y_@3:Y2SKD:Y"RN7' !P28&^Y$;99?(2\)9<Z\'\
MKD@O#7!$[;"#C+R@)FW=ZD>;Q4X-\@(:=B6?=\H>6S59**BYX8I:_B @"=U:
MRS2W4E]@V7_9/=TE(Z.LD)\1R,1B@7N4$5*L"#K/;6X]9YC49U4'I+6QTD2(
M<^S[\I6L]9W0UT*X1<JF71A%"DCU6NEB(H*R#AK:C$J8RQCJYP=[K1R4,,.P
MH1+IFM(1+C.A: E=7]-VB#CDK82_K/_@@(5I.[;RIC?LFNX/Z,(TUPN%?X/J
MRL:45Z"[BO9?5G-=K[1^S4,-PYII5DR3]ZS'7&10S\;?:*EFU7(K+K";EO4N
MFLENCV,JP3ILQ0(XWL#F2>^D;>XG^8M(9PVBL^:W5.6XZW(0^"QW,>)KC':K
M+1>9SDHO]Y_@?1H#L:G2.UGE&[W*@Z<]5Y&\RH-GNT]&O,J#)_WH^Q=ZE1N=
MRO?#U?J]EF?SUHUE!*Z=E9]/O,3[NX<CJ[F_^[BW[O$:;($.>&T.A>L@+.R!
M33$!^A9FFUX$56#/I8ZTC>%S 5G;76P9R\%/3/GBO.*?*X.1;6H">A=O=N@;
MYM/SSI;46[@. -!L70DV!VZIQC;=5QB='X]E[#',K1 C%R(R &O4I$/9-,^R
MXBV=%U^[ZAK;&"_FB*4DA?FA.KY+K>E4 JG/*E0, K'WC"(>F3&B10S=[OYT
MEM> CM5K7^1\5]<3EVQ<'_,:#B,).P.Y/X._DBS5#'UJASE/^5CR1BB04N6/
MO&Y_A8V9_<,H*JCA7P82#])E?I/O9(5RUF!M5RO(367..TI](=Q-Q SJ)RKE
M(<$CXN'?\;@W[IQOASZ5JHU>*Y%^'Z:Q=*11_G(J7]]DUON(- >0%FR>?Y<4
M;)07%=-X(2( =F1?MF]M3$-.PG[G\SM:+(M=?%W5=_NTVREM%K1%T08]Q?]P
M+7W$)&X@@5"[%@3M8^B%=8QC 1D[0L12N%YP\PIW$*1^X&94!L2D8SB-& ^R
M0"R(?TPKY$])H@9-O+=H/\^J6;9VAAO*&K*K3+HW+(WZH2&]Q4@,IE;A&!3"
M35P'6@&2;/6CZ#]LWVK29![0#_CD &NBC'_:06!06KJM@\@(+.K37U_S?[<P
MK''KB%"?(.3PA5QY2J A/[POF@_)*ZXS]M0:^&5#_DVDF(_'%/.[3N_1$PVC
MJ;EPK^$@!]_@(/>"I>%?#6;Q*XI#I;;K"O3!2;42BO5EJ+T3^A=47NC\JVFT
MO9U9Q?_T],PI31.X;&<;ND[R>O<*N<Q5V9N[K(C!W(04 %=WSM[#>8<^Z\(?
M'8 =Z7^D&T$]VQ&.)<#*BZD1I^>H/RQVZ8L_9"!0X\'^M9N03R(9#C\&*0^Q
M*\-[!8X*OG<',9<<O!0A:V/C K\R6]92U,W7AG+P(K$3;NOSYO3GETZ@PAEK
MV*S7&9O;V<S _%&Z%MI;X<C?%8/UD3B")[%U^;HD.V&&5,+V$5N_TQ30X?XG
M"D;3&GC:98^TZB[KG;]0^N-4DAX="R3HCP.NM$%CZ0UG2X5.:9%[)G[A-J'/
M^FZO/SIY[=YX7^TX$S!=RD(X&CGC;@<N7+W:'5Z:O,7Z_F"/Y N.WRL45(+W
M1"W+[3MNUL=FF%9U=X?/I(XIUJ&XG]NDK57L/91;VR$ALG!.]F8@%C>(P?+$
M_?ZF55GF04_;&#OO0Y9NL4=X&7]Q0;/AIU+_NQL7[99K*Q];=IR*I*OUD@?:
M[^V6)HMUM9H7' DN:!S<J%WQ)-,/4BV&*C[YN@0DA.F2L43H*%%-O1643>G\
MS#*+7RFY0M/68A%N1VGJYL,"NR.]]J38Q1-*4W1L>J:)]GX:1'//T7I5P[[[
MJ39-W8*U.9M'=,^2OW6M$^(R02%[B*K-)]5'A#8YX&E=%84(9YHW#6JS>;6T
MGL<SE(6>@^N%-/9H(>V6JL69T-VBCHYVX2J;@&9YC2T".+7,\]G"F$TS:VE;
M<!]O:4+-5>\0<E\&O^FU^.K=N'A,HL'$$))#."5S8I6<N'&<BCL ZMHWQTZQ
M\*<B9CA+6D4/.UJ09:)FHGM2]"#^1&2._"O9T_]:B!)-E:BQ!?"'G9[ZCH+_
MNY:.F56Y=EYWOFK/[T?D^A-]_[O8#:-I(+]5^AY,C5*IYQ;>P<L^KXZ#]-BO
MW3\*SB>CQ"VU_/9IMFRXUPC]Y;3J2&'^C2[=[(O[/]ZY&;R1871[CL*_KR-]
M5X&XC5647RWXM<'F.J4KM;<?/U7TAK_A?S1?[N_!LR-W>5WOT&@PS%H'/ !?
M],G>_D,[G;(ZF^OLOWFKOZM,6Z3OI*BSI73W99NE6G0L56G<BD _YO:^%P@=
M]5<W$S UZL[@0PB/XF+5%X\9B>K[U,KPB2+GE>2BQ'AS!,R1[:84/U?S:ND.
M5R3])K7L<BW,L>A;I/IV]F!CK_->Y[4.O^6UMK?,^85AZ7$@CN?HW+YHMBA3
M_Y62<;=<K>W3KZ^'$:N-<";MM2-U)^-EGJ:]H@(.@SPY?>:" M>DMGJ%&M&[
MHZ[ 4+NS4 JW,_[(K2=QFH66O'6LI.*UE1&>T)QT0T$ZFEW-*##X_0>48 M/
M&ABF,VG%QB2(?J'S0=L;?.#ZE1_C(=+(U72.X6SG"M\Z,[$%Q^ZN#+@WU06:
M"DX;,RA@R?$VLF2]\.51VZ=ZWO5K2SBXN?_]>/&JTIDIZ*UEB,^2"RI-@IN^
MN_#^XW%R%'2\.C:('9M<,Z IDPDZ-X$]CBP]^GQ=-4U=9;,&%22.^$ R'I.&
MJ3-Q@+/&TWNZ3YT*OH^.U#$,P.AF#.-J]@4?HP.JR_,:CDZU\>U\Z/1Q9YL'
M4Z@0K6E(D][3K\\K $+6V-D>?B4@?>#F19G$E3Q"/%0@"R>#?54BW'(>;G#M
MY2&\%0V#7U,?1S:$.O!U\ZISO*3V5HVJ@QZM<3:U)],"W5?)2&Q5NBDG'E #
M2G))%J%,U]@N&GM8ZK .BD?VGY;,3[= KL28D[AI]G:D+/PF7[^OB-;?O+EA
M@>5M=I$9O1B_C#[%P?NL.+GQW^=RDTXVOLT^(-"/JENFMLW;:C<)3PJ3EOB'
M],?"+A=9RQ>L->CP BR;?T3-C\8>&)L)9#1ZLG)# *2F,G?'!OR2M,K^Y;;5
MC6ZR;ZC XR?3?%[5#.HE_VV1(V%8RYQ<#8/_2.-TA+_)\5GU +5*Z1.*>C\M
MQW?3QT0/?\4[.[4<88/J'M?SE4$6J.X96UPG#>3DLDRC5!9*>;BZZX$M Z$I
M\U9:@YV/[@=3"\=#X>ZKU^_B_0T"_>K%=@N-!*0SOMSVO.,JSZ+I919=P_*R
M8Q(.W-&!-C![7LL[QI2 JS;QJ0O!#X"I%8KG7IO<DJ:-%.04C;8"S@I1KEJ*
MB@,W?C;=%[ZJ%/"P[$9(7>D%F391C8^ PS:,?1>P\V@--%H_I\?)M4>?7C?2
M43GHKGW/-UZBH&:W;?G$O+X?/:5%H[LU"QV$K;#[[NHZ\&[,B9OW]MT+OXX%
MFOH!)M=O;=3JFL+9&U'NFSB0''_(UJICWRW]&JMTR]E/@MC>^-UK=RG]I7"V
M')OW@)<M(H4;L0N/7=+7''5X%,$R"J?P9U\]?[1"MJ/K[-KH1K,$4R'Y6_*^
MLF(Q9DZ3EUQ_?5OW&\#G6\"0UN!38Q?7!*:DL<Y- 0^<BM^-*::[)DX#6[&V
M6/S=@*-J(:WPCBUZ;(QHQ$T1BN /$0E=WZ:[(_ZB>*S7&V77C.[?R4CK'^#[
M:K6-^WWC&YQ:2\Y.Z".D*5:81408R8JG:8*Y, Q:"&B:K3CA1H++=CVLOK#2
M#0#E:HCT-0$MX*M?HDM>LU@;&/E39538&9%TI<%PTTZ&5 ET_BZ.4V!2I>IA
M%D!N,7Q%5TX0"Z1W7CK*J<\Y;\Y$^L,PEK%=$U8A%&R\]V?<7Y&P&TLRKY;Y
MCGUC-\CPW&XUEMF:'?S!JGA#/;#.70\QM3W#GMQW<@6T(Y.G7_KY:V053,2<
M3Q/:3"Q"@.)OT+N%RS9(2LJN;O+[#2]Z] U>M+WPHK?&9;-%N7M$\0*.'1Q_
M+H4>-L*)#;XM+>@4QN([,C&U;Y%K)$!+-<^SF6H4K,M;Q+?S;)$F_]7]Q_\\
M.#Q\/LFGJ:.;<P57,/'9#RV-\]NR_*1V3M=E7C5&5><0O_Q;2W?#X6?#/AG'
MN:3:.@[4P99DU@0A8M.-->@MEA,HN0V]CGK)SS/'O[3Y(6T.(E='P48FJDX'
M"ZB\G?2'8FHT)F&B<]<^S+@?,H^KBY+C$\ZU@0WO !%UU2GIZ\6BFN1^?>N\
MS*^47*N/LM;16/_D$2#&6,?5:Y 9P1MXV8K&93I]L5O&.]NC.4N%\C'>X9'R
M;&[WI+0'DF31CVKO.B&/#T)[MN,>8:5+-E+"N1$0]Z]\FC?XK*"B&R7H?+05
M_M6O&[)H1W3V)D465\KI+P<E;BPEKO&O"882OJ7@'RTO2&E4\#8@S?23*!.R
MX"%M?&1$%P2_2).SGUZ^/W*-8D\%:/(%>Y0F%YW46GH+5G#AUB/0ATHQ*=9'
MX!&C/2V4S<!UA)5P1*2IE+5<OYGJP4)"<I)K^[./ MZ@G=GA9NG(M:?TYPMP
MFRM7=YV?Y[5QX-.GM .E.UKG1<DDOJ&.-$+ W3M?-+E9T'H[J%'-9K25GMVA
M"%OE,BRI;*[D __LT/T=>))L@C9TL6[>5AZUUR2 C!7K4#\!!K]ZJ_CQN,I#
MKS*Y[.G/Z)QN?@::N5YTRHF/-7>XO9Z,M[DK8Z+=E<V%A&H/ZBF9%)J(I0\W
MW&AZ+>E\7!$7C"<!&"@#!*R2-GBA7TZ/0!5)74U0+J^O2&F-"B;TU[NB/"^P
M-K@MA.,M>K\$+:PX"^< DG195$8Q(E-9U47.3>:5\1+H%:@<-3.:;FH'.D!D
MM?F%=LIDG&_(*PIO%,HJ%Q)A>'7<6]Q/-)L(*9V?I[^>9:K!$F^%OG_'I &!
M<*]4N.D?,-9@<S)>_$.>KQB*2"YP1:Z[4* &I"[A@D.WP7!B)"'P@U)FI(W<
ME[+EO2V]L;LMNH?OS*NK\*)6PX2'X+9*J&+*2CH(1]*D4#'@XVR"&=-%GZ,P
M2;?(R3L,411E+XJI$3V^%M%&EUV0S6=-!(S:M)+N5-FB J+[E_[^]QSQFR(
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M\PNU);:IS= 9]U3XB(@6FK*0<E]D*(%NG&9'K(GN"[()Z31E#.G,T)",54J
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M#R&U>>.V!T\VG_CF*,8*4N;/=]EH ,8Z:6@!Z&7N5= L:[,P=J<1)OQZ$'R
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M(FK?,;7C-5Y<$#J%FEKX%-I-A\F)RHO<-9B2V7+RJCD08LLX8^=G!K_E[<8
M+0KF!@XA0M[S4J:P4C\&WI&.,YJ"DQD3[' =4- P[31V92M7%BK=9TFGW$W-
M PHQG78RGS(^P(;W_K;A5^+&,X5<)=?\^RIK7T9?\,$7:W'8:5\XUB(U A*B
MM( &59,&PY!X5#*KR_88)9)$,YT(GDY +&0S+:2?P(UYA;0!HFG-F00IXI:!
MTLUZ4Z?A+&Z29*U.[F4Q+Y$.+@!F2"*"MMB*A#?+"/R\F\![:(CNJOQW #*>
M+8=-\B)7.<(::[>3F?0K<LC115FNA9WSJ*-%6DDL2_B3N2-?D?LIQ_K$(_?*
M7Z3V!'P,6\G$Z[WHK9.K215E 4*"9$,SQ#3>M-]?%GV1HAY_B3:P&A46F^97
M*\7 <AYIR&K'I7&ZDQFWIVK37 ?4]X_^L&T8@_\UAF571.ZY$3 &(_GEVW<X
M5L,8]2[S?U1>OLG]>-WUDR]*GA,977I>>6FW[B7;W0-:LUJ-+L%P]TQF:;GB
M[Z0V _9K %JUIS[I*UAM:@E+.Y"-/2:8&4,9AZ+G'F//F&5W'5'R2%)\>1W*
M>GWR[18XE3)027&RM.]BNLI"M.1;6D0ZP]9D0A=26/2F2.T%8WF=E9ZSRE_\
MS&]:B:5^^?+M_8=O%^^^?/Y\]?7ZPQOYE]4P+R)H3'G--VW5] 6V][PY)M_]
MVW^\;/-_HZ 7_Z:MI,:T8G>[=#OP#<W=X4\Y>?-X\#H[4>R4/=%Y?5ER%4VC
MO_[C)5K0N,*H/QA5+F&4+K'\7G5-N4+9#Q7T:7F$:=72:D/P5SB9)<2I$W7J
M2GM M;L[DNO[7]]];E60-O\U7IRBZ\C+#]'7?(P-%6]EM3E91ZNR3/LE43A!
M%?X3XG^02!N:;VA^/YK_D. \7^TSG[ZYBN[7*<%WZ248- [-MM&5!NK9)W00
M?.>\C&WR&VA8IV&=4V&=3QB=XA4^O"YGG>;X[U_>796Q0,5"U/8/W;7E7_S^
M03Q#A?>\1P65QY$K$H2><T^3+WF#?^%&<7:!0VYZU3ZU:O=H^<M^V(RN0B\S
MIBYX7]>^)<#UE@Y.>0+L_7\#(%LP0BWWWO+1&,4& SZ/A*2>$L.X@J==12XU
M24L[\5 5D.C,MB&D^>T3F8' ,9:\["NS1!L1THB08VK?705'[N>IN!@9@_Y%
MK]T;Y(:<5,N+1Y<2*!T.+@K6P&L3IL>W-(S?,/[>C,_;WUW\NB&CKXW_RO6D
M@;T90;?6$_,FH2@UR]8Y4+(W"RO94ZP1<#TOX:VS(MXXB*>1E%'B:27%4J0S
MVT^GORU#;I[8+<NQOGCQXF=W=JM%H?V/E[<\#NI$<V/8^FM^BQ0?_^/EYR^_
M?GGY$R8ACR$ 1B?*_V?&^4.Q<0JG'?OA\>O&*9\5F"SMPEG"9J=9-V T=0.R
M;N!)J.NUS%A(XXS6IG'>MPZ3L2ED9AY2'ARJ ]I6Y_V*QF@8+W0JB!.5=^FT
ME'5YJITR4!LODR6J]K87#CXV+*&;,8X882EO"XM)#72E!G-;:=L3L(MH1@^_
MDV.VC9[VE3'*"#(6ZYIA;.FZQ%/AMGST@B#4M=_1EV(X@*9D4*SV6^=*,VZ&
M=&/'2UM988X<%(G1WO7=>.K==S[!G6<UN(GKI3<IL55_S*]C&%U]-#*UZ#\)
M*KT)0$LYA7)I5$'$M_]CS>:7[S6R5[',%XO6Z;:*# &)-H9X3^4H:;N"J%P2
MI0<3WKBE3&9G<IQO\TU;J@W2&R%7'P5IW#->DRVH?E/ &S\MJ;MEM\C<\.>7
MTA*K6&>PW3K&RG5(5N04E (T1%KNEP(/GS]\O'G3;@UZ>-D\\%Q'^Z\V_>]2
M$T_<?/E:\8# +M??8"M)BV%$3Y>8IV!?H'C[QTNS2 [[;$,\\.W3K[]5K+'[
MOI[26Y?IH\* T;;BQ9=Y8T'8@)OC=XF*"APP<QW'8R_??A;SWI;='6WM2\IY
M6P"G*II1?I(5H"_=^&59'.%/7B1VC1\NGZ=NN[WF>NAC$& KJ<?:;THHW#DP
MJRBE] @WBSE!_)/H+)$QA% 3C<BLM_!J1.;RD7[Y<G/SY?<=Q:KDTFU]-]5G
M-UIM"C&HGL:%_+!@L6T;_QB81EO[&&*5L6M_O_C%XL6MUPDP-YCO;7U]M/8Z
MOOAL)1B_U&7 MM11Z%YKYI61^EQ;ZI9-L/% $G+7G92*S"^VG<Q=QHO@A7M1
M#9^G=OJ1WAEU3_VXZU7F"@A\1F\3+]552,+]-.6#*L*C:)SZ+%I3+77J&@@4
MD*']D^&$NXO?>9][BCAQ#5(9=C+_GV;^L]_:59T\BO&_MQJHVZY-O=LWZNNI
M/)K8;1R4I_76FHK^Y^"@;)L#P*"#FKTP3.U]\IUIGRV?:7_.Y]B:ZENPL#SM
M-W?,0A^+JOYM+71X"GL+::8FJKFU]VWXZ?]K#W;6,:=EQ>ZHJRP'!^!1,0N-
M,AX:HVY)K<13A86A]WOFJ1^WQIJT<6">O /S++08^#B_)4X4^&E>WMQ7L_T3
M>_XNM'<NEEC@V\4'[4&G;38ZJ]%9E3K+&)WZ80^ML5[L6/RS3;%/L5QI?8\!
ML_WR[:>8S?!&>-NX[%[A/)Z0 2CN^"VCR41[AW<:L+JJ!K?NL6OTL1LS[ !%
M(P?%7DO[DLYS0CO_H^M;/MVT_$:#6GA#\3 0O<7VA.OHX"7DLG>,FY^91VWD
M11\0[+93["%FV3'61%%##FI#QQL"BP[A_';K(NWK-DF!@ATMW72@IAP;@4.9
M.!1ERUU<90I"-0AYES$6NH&CSN^(Q>P]OFS:+21MKV?QF63I%K##313)=O)R
M_W0>'"L@IQ/Q,8? ^NZ<BN!B,4C,RGHNB!9P8J3DMD<%IW"2T+ [?B8YOU#B
M(9I2]Y<QASQO!)7V<Z<;O3H?>)HX_ HPGZV'S5!0IM&F*^%"H_H"WH$& (DM
M?"*L\TL'$,BN%EFK*O&:C*ROTR7%F<_3I6D*BO)VM>N1&.(*2S$O8O?4EYR*
MW.#L3F GO&7<-4N'(B*3:<:0_FD8EY4[,(W+%;<:GNDUHRWKEDUS;7WN5>O9
ME!IG ETP;:O0].L@E;Z'5E-O/^)HA^G%?R=6&(NI$!_="*4G<32H(X;#%7Z#
M53Q^B?&Y%Y0.MZOD---*SN(?S1J'7^,(\87A4LAH<S-_6QG&"5)^A([_LMOA
MN-'<LQ9OB'4ND%4*NUUYLO5R[B"W',Y 2\-NR4C[\_K5^4XMP4KC!]LY@&GX
MJO^RPAG< .05KUQSBAL<8'$Q@\^G/X_#G]X*RXUOD4QF>4[\=LUBJJVUK%(W
M <W!(&D^."1?\\WPOH /<OIZ4-#_X)0%C9,*TDA#! <@@K)2X(/&H+=,!N\0
M["H1OKB)'Q<1#M[*3EL!HXUS\H>+PQT0)LMJ=D>"RGU-IK'#[("'$]Y0Y +G
M_:3:: U0'_1H!=X[U$G1XJ^\(?H$4'A8C#=LU+!1%1N9#1L]#S8ZCH9N=E9'
MJ^9I<?'S$,2-/?-,!''#1HT]<QP4GC9?/#<SH%8[VZX2->W"%1=[?RC?9"&X
M[LD_=:1BT,NQ97^_#0/@] O1Y\RV&9M,5J=Q=DHZ'Z-X<WUV1;2%U:[_=8#.
ML#X#^K<\%FW</&S_M(S,J.XA\<OWME%B:>_M2$5+E7^'VIS1UT>]8:5@JQFL
M'AS?CX/(LK<:7;V+B'JLTQT9](<&JC%H=?;9S^M],WA/@_AZ'7W0[AU%/-2(
M^&H)>O'67AOXOJ13Q!,!_:&!VF_M!2N5[1L[^C'LZ/*$]A:.4XTLZILPN+7"
MOX/#&,HK+S8=*PSP,*&3U2+H&-&JS61P7^^.NNN\_CJ J"&#8Y*!V!BX2OT2
MH[)&(#H-,G@$!)_U6X,CG^KU^=&P4FN:>SRV-(=ZNS=JQ',]SOCHXMD<Z?UV
M(Y]/4S[W6B7-1(XGGQO?KLXYDCS>C59OXW+N>OA]:X2$N-YV@&LIVNZ0VD:>
ME*Z[GO/(F3W(Q9]7&RKY/3:ZD\I99Z!T]&[///[>#W2[:BO=53-:VTX_OSKN
M+G8S7PR]:Y;TE'P$\)PF"6S!"4??QW84,&I5IU@>##2OCXW\QR7M(ZN0G3A_
M:.B#_J;QQ8;SG[#P'[;U=F]MA*HA@0/YK@?%L-DZMM9>RDKNVK5KC[Y7FQ>X
MBDX>>(^8M_-0^TSQSD(T)CGD/8L*CYO+CZN]3!ZYT=>Z*B?9N43QVAYYQ^_4
M;DNAV)YL6S7AL%\@['D_K>KV2DJ#%M'+Z%R[MR+M%==B.I!T#J^ON$RCS^7[
M(FLFFTEIGA7%]&8=MC4/6<1\T9E,<WT[I%F$P40#[GJ]U#3I,0#Y$<Z@P$#G
M65G<X@Z%DVMJY7;/%TM> ?C94T#$*U[!LXP=7E>R'CMYY-R&P7T\Q4/W6]W7
MV ^,9=AR_2Q;75>X(,7.@BCV%J)E'$H8W*RE34&< ^'["=$_?)3X+L@JX!XG
M!SK\'8#DS@V22! P+'K//(]:E*7K("C@0P3;/'1MUM*^P"XM>"R#8@U!=. W
M:+G%,_I 1$RMV9R:Y&'[<90UXX7FA-:]Y@3W/O6?<WT06'$0+K#U&S99Q/9[
M20CD&=X"P<X9ZHEXH<VG5CBS;!<6=I(004X$S;"QG?8?WF:J%E+DDY\7(@<M
M$0$B#)GVBN?%EEF>)TCH<S&S%>@2>%_0L ;J/!6[O98)[/V'RLZ'V"IMT&>W
M%DY7!QY,6S&*#>4Q1O)?T$5\'\A6B&^T,TL$\Y%:]B$6SO\T(C<,9OQ)%(86
MBC*;19$%J\V3T)X"7"*Y2\^*<7< 61(=<&!0GA8')-DPE]32[&PL=CG!;F?P
M@VR#V;YAJY;/NQ$N[7!!311%N\=[E%8 NB!V29=CE\(0  (D&L[4D\ F+<T+
M -3X+SX*V 58"N&3;<(#:\"+CH5ERXL"S07R(_P"!F^!N&()7;5Q9<C&%C5Z
M#+1;W*5/K2_GUH*%$5<QA^62E,[=B.\2T!FZXX2WA<-.DP":*(*M.@PV31\A
M'<'OW @;1,*_(W@!<M>,A8@S]V\I<^9AX"2 %<#"AP0'@4NB*=A:^'S1V#)+
MC"U3&EMZ$<6O1@.NU[/SY(2+D'<ORB5>:9\\;:D%F=(WKW*9-2T#S1W:AO=,
ML7GP=!SW[BW_[PLX#'Q2*L Q25/8!WZDY*W&# P=]L;R[JU%])*[$R]^GJ8I
M+I&1&M'_+M/<V ^U$>9/M"782\X/RN]=_9K_=-CJN;EC8K[I4LT]40M ^0EO
M[2R[ FX']X=V>-Z!+46C9HFSZN/V+%GKMMAH9GV\,D ?=DI,8[.OFX.1JB?Y
MUR0>A'T,*RD\VM+>Y98'D]A+'!+2_./;('"$*4E]B*U9D/BB::^ZCSP'%[;5
MT8>=X?)C)I>1JA0H>2T9OI;K@])U$B'E,E-7-AD.;#L)0R%BE%?P73NN@SUY
M01#1<X7=ZIH/#@3@1SLSA.*S-%"<J'RM$"2GU+((T;7#-?W OQ"RE(8R<_,=
M(8Q^3>*A3K%B^/LVKL:F)NYFC_$S'N0Z'(&7U*:-D^ \/)Y $RD5#Z?$8?]G
MRX]XHV;QS<>A!J0^2SS>NEC0*R<O!,PK<,Z'1#3")C%3U !T[[@^X\]U!]Q9
MQRE <>;JW(<X$16-%2+Z_/O0=5R+2G"6+C)5*5&9-JGFYHU-O:39C[D;2KM4
M;,"S$M^>"D.FL %=<\%UF^-1F)-QH4+WD[P@$&:)Y$]N>*600!L$D$L^VRO0
MPP@/O0B0N=#>_+6P;NG.M#-L$/U' + ;R2=6=:@^KY][8A:E9@HV-.!F =#T
MWZ)C-N=RI"-3[W8-*:3 1O59U@Y<F/AQ[#'9W9PL(]YD/,3A5&#\!F/8$U^7
MDP;8WMJ8,7BG;0NQ"9\(2^D+81!;IL?"4I+MSG-]QM/NXNE+4QS, \Y27(PJ
MZY',G"0>^BG\M,25J7LY<<,(6\I[DX(ZT$6;\23B3<,%>'"Y/UROW$RK>5R3
M#V;4/OP ZH]JI>GEUIC<&G>"P:3N#-II?*M2JW;Z^J@S*GG.++K$QJ U?*W+
MZ)&0SN1GH>?&90(*4U",=Z#O,#H$ N(VM&;@Q2SM,O4*D(:07/*N;Y0GJ8[B
M4RGNL^I>I2LC%W;T0:==E.91X@0VBZT?S-/^A@TG$1*UPS)1C/O(K=,#\)3H
MA$PQXU-CW ,<&'G,M8',T<M#8+K^7X+[I5_SR[\_?I(.30NH">6)8"< LGRU
MO@PN''9 .B@"Y+L34*8^8F&%O:3$EP7**#J71?S*41?XZ ?<+B3N2E"75R&@
M.3O#KI1X$4,W&U0XP9*KE_2'!2B"&17>6KX4HJ#B0;K9/!CRSP0V?#+BX5K$
M.6LH'N364B04I8&(F?7U0;\D9M;!0=U&F7A8MKJCXJO<U.16,"_"PXH@0).;
M8UVUN O$@FH3%P<;4X2U< 9*Z,/C$Y=Q0\=.@PU_^F1HD'D1J>'IC#Y1M2MO
MS\:LY$(=/#)KXB[8#S>FQ7E< P@"T/<=U*3,'ZCA$$L*AP.$;HJ0%AR($ABV
MQZ-[%(LCIT:Q1?IZIU<JO\"08!Y.3D!30C%D].HX9$XQ"!OB$&&I9:"%?.*!
MA&H*[1L&GAD&[G#V2)'2\G(P$T["B'VZHNF&NSN9+2IP ]QA^;<NNNS<F -+
M7<E\/FBS$X3W46G%+2HE2L<O":26=@42(+&G.H\FV]@V.\\!>?5OZCVC4V9#
MZ7DI.=)-PRB)3&AGW()/]T5B@C.H0G%5[/@X?!9+/JN'2[:.4G]E/@;VB<BN
ME/E^=ZR.ZEC=K97?[1H-;?3TOC%8UM#PF93R98GL=:&RVPTV!.Q%6B8S^XOI
M ,S!@$,)SGZY(@0+V;T#+_-P.98LOU"9\"P&*7G@9Q<,%"S>3F_TM)7*.I[#
MC!D/XC"*.=6)PW!O$[$W;N-5\).IC]HE%F]?'P[[E5'F8K%'_DT%,P1((P(O
M6%4(2OV%$M\4-C%9M S<-D%!58/K/@> G8^6[7INO-#.P-L=M6G+Y[E2C()'
MW.LN><0\5@H.()\[)S[YW0)^F,*[WP%,P.:]PB0@'_KV)2[8[F5FUV8!;HJK
M7@23B0R(.FS"N"G.0U/ TQRJ9Z]&O%+GG' 0I?#B7Z-K#,N@C8-95G XT@@8
MC:W@\7TW%!:0T*GI(?]MA<# 8NJ>2!PCR3"@*CBI6,,+HNBD$XJ=)J%X$@G%
M*P<?!2[X\,NGF_=7-1*LQ9U1#O$,I2A9)>>KXXQGX#>V>2:F^"2(UN+:6T<'
M82]E934E<<'NZ*'B@ACL:VE_!.1R%.*SJ?,A3AI/W="A]TQH-F#52?G<S;7"
M580;_PC\BT\?OUU+$8OKK_WMV@=PU3^O+WZ]NOJ:[U"L_0ZJ,0F93$18X^".
M"?2EPT*_(291=:4N3@'Y\M=C!K*8C^TF<"D_ G"CFO\,0CDU>@$5[,["PADY
MK+4&/+.)(46GJ ^;WUC?>?Z;.Z:42.7PY;73"B]0G%], G989(?N&#U8Q'K!
MPR9;"74H=ZO!8.&5T;H&V'O5;HT,1)L6@6O,])55 -V!;G:4WQJMT;#RM^9#
M$\$6MP3R(T#5\S87 ![L D",XP(U&A<8%6X <$--7@/0\R4K_&9S2>D,76+=
MM^9_U.K5I^:?]'!.)Q54TJG<!."M?DL"*-195BUW6CYNL5AX%?:P]2J@[SH.
M QS:7F?8D"E2>AU 'LBA6P#\%#RM'P4S=H_E.IG/)=RQ576LO.KU<85S5<7'
M!A1^B(@5IX2<&*'^>F4AB%&_LRQ$JK(Q>6+,Y>S[K<'K0LQON1".N[P9GB4;
MR/=947EBN06F2_DOUT SR^6K^>@T""+KL\>)ZSD ;[=0E&-ID1LGQ0H96"CP
M[M"BCB/F34ZQRJ3.Q:2IMN3#=:5&6ZTS2XI.>WJ[WR^YCI4&XS8N.>7$EW_%
M9!.%A?%LL& ]8 +N(JJU@.75HYNL:VJ%9,_3*#%$\>%&>?F!V698%T1(I@14
M+4AEKH*?:ZD )7.A0E.*E83S?B'Q0P'&DQ =IU2@EH8\MI0F.=79TTVS)'H_
M ENNMYT<R6E'M;QQI0Q!-B@DQ0H%598=HL.+=XXL7%P7DD&N_Q7O5&F&9H-#
MB+2JQ<2KR.]5$2F=?OC;Q^M4(!7+@97P?TSGNF->,%<+/S_]KLU8/.6 4!-@
MAZU7B1@W%("KL @NRMF:B!2/*??>5L)Z?0G:<-!_W@FY4RI .PC[]_5!M\27
M&^C#;<V(&H!HDT(Z*6NL* IL5Z5B&TX_23S8J&_=IC7>Z6\IC#=U@2TH:T^%
MX [8-KQPGW_%'0=>" [/%:/Q<7!OA0Z7*,QWEMAS"<4%]AP</5U^FCFY;I.3
M.XF<W-,K,=I$[>8%+E;4CWC8/5\@K(_2&M,Y6"G*778E\%D4NIOMD5<3O#*'
M3;G-B97;[*3@>5U.3^^41M;U]B 7I"V-JV]4I!.5E-Z,+8\>"9(8-"0WX'D1
MZ<J*&%VZUE888G&;M53*0W%/7L3CD^&,I@A>BR-UZN=>6 R/+L-V [XU,\6;
M;B*HV )NGR&H^#TM<6V2DNG\GM8&MOE-2?U2VEA FP#+2=>B^%1(T>*U-5.R
MZDAB=5/I%;*B1!#U0ID%E5[*2XN@Y*/%$JOAJ"T*K'8K;H+-;5#?)"_.I:5+
M<-)-2I=@?V9/5$C50"8\F1H7C#5O=%-;J84 [YJ*('0>[^SJHWXO%\M?$QPO
M5,WH7:YVSTL3BD6]VA2'-,4AIUX<H@]X!$_6AK2+]1WK9;_*0X7E!_K('.66
M'VVY?)V+2M;VDES5>M)H*D\.&_A6BDV*->!J=\A\[G>D#\VT25GV,V--T4&7
M,KTU.'6^\XRIYWLB*DF>/;(W67?'K(MCODH,(5AVJ]VHZN>8K]HXPIZK:RT.
MU7JQNO'B)W!_'<?E*8)W7_[UZ?V%,=*FEI.U^N)7Z=%3\ &]""*0V',NO@N7
MVDI$"$*V%M17;.!QE/Z"61_!8M^DH=$M9=TBM[:I>^AO:H:4%T4LUT,HU17\
MAD(5FLOO/H\3T5@GR]1&'L;>@ QYPDKJ[O1&54M[S[-@N2,<%I+9]2W:G-K(
M04V;Q]9WYE<H9<6YJVRM9WO6/0[=B9"P%:9"_/ X4IH'1Z],O;@=,G<V3L*(
M1]2IR:".K1"CQ!)N(IO-00>'"RT!K%H)N&2A^'V4-GRXNODS-7@!>_+3JZ]9
M%X@:<,TI%Z:LZ-=#BE;I9E9L)V;VVR7<NE\SL\HN986BPZ'>&90\9BQ'L#9J
M9G9FG$O!(#LPBIJ],Q.#%DIG@*5>9/E68Y4]Q@ZC!A^@TQ>/HIQUS@]8@9,O
ML#E49<W:?EUF:;^N;+>YAEU]0<ZGWWG+V*7S5E<?#LVF\U95YRVN[(NUE,ML
ME#8PJP59/*6Z)]&8J[+A5D$_#4%O=<M<F&45L?RJY>JDDG*@?+\G$$KPHMEF
M94KZVEJBXO-JHZF*TJ09MO>]<(*(F@R*]EE!6%WLA,'#PK*R..H@VJJ50T]6
MV963R4M9!0'L?UW]_N6:]O@5-*T+AXIB &N6O\@9ZCE/+JN^!_%GA>YR<E/H
M>FIAS>LXJ,'"0M9>\4T5#/_ECE_"H<02&;7AR!]7U[\5Z]*X\R'+5)SE5ZL.
M1 W8[RF53"U%D+@DR7IS%26'4DR]0G 4C4C2!").@)B=LS!"/2J0[^=D#EA6
MLP"?1-K(VGLH=(KB1;&9A(E93O[T!I1:16KE3=JKZ*QX'N+,#9M=/7)WG1+5
MVU<ZN91V(X,3V734E1U6:&$K7G[5ZO8HIUQ)U6LJJ9I*JAHT:Y*B66G*5+QK
MV#=*NLN4V'2;-&92X@#%J@9 0S;Q(EMUG(#OS[ L/9,7F;!!(1$@3*W0$<,S
M4/ZL:[!8%H6F?-K%F$P%! %L.-=@[21LA-,KO%HFQ:R?4>&.8=?<C!#7M#DR
METMVC)(V1WNU.,HUR:BH>D(^6:ZQ(K,B;P4O%2N!!S1CPKY5VP>!72PFW^"[
MEM=6Z@CK44?^9.IN9&^9ZI8QA3(9D*L]3N7%)XW2YC+%=*S:,$;0AY2>TETB
M(>>PV'(]6<>PS"LYR;Q$<EGZ XGMEJX'<>!&O'2G4)E#CRD%-4T)35-"LTD)
MS78]4@KUW(8^,'OJ;SN#RM_6(^>[:76,Z+4"$CL+@W_R,>9EJ3-6:G"B&\IV
MIE8975]"[U:+DMD,,X[",$M\2P3V<R%G\#3Q]/#34%3]2":F0NEA91LMI+U]
M"YVV.3M]IPQAWHG'S\@Z")((=D\G<@!R5@A6*?MALWF<4:_PM:/S"G%0\$+7
MN;\Y=_?%SQQ-F-+"BDB _C]>ME_2O^<85!'_%J\2\Y'???G\^>KK]8<W\B^K
MX54$;N9J7HY1$H1OVF*;;]K2(7R!6PO?OLB-9^8_[!KHHN:_*1W!+%_$/5IX
MNOA'L\;378,F;A,1R764* F8+J[#WEAW@>MH6Q'OR[?K]U8]SWR[2>MV@#SI
M_^.ET4VGEXOXBUR0\X_D;J/5WGBZ^YJQ\BA84W&SU3%V?_R!S\MQ2A)Q/3#,
M?%GX+H=\2A1I/CA!_G?WT<CQ00Z[.37^=V=_6GQ: #D <SXM@!@-0*J$1P.0
M1H8T,N1A9 A9/,*5.ZC-<XG5T;<AN,7.A<AHVC9CD\EJ8X@RX(KGK.5]9:TT
M,J!F,!'XF'!5(R<7\L/=[T8M0U]<PJEL*99[6 D+[&O@24=[Z8KDCE;;5@?8
M>S>2@2BW?*"]\9ZYE4Q0+TAM*:,.O?G'0:#9UH>]WN.=[FA /S0XC8'>ZXZ.
ML:/3 <%('[6'SQH$O-GW\P8!2 SC>8, &,'L/V]&,(9ZKS<XT(X>);A7&WMV
M*27V\NV7-)LGJPL.:)^6_^BGAWUH2PYH=M?LKMG=\]W=D33$8X5"S..ICMQ%
MYD9K-+MK=M?L[IGN[C3]BL[QE4/6?*")>Q\C[DT3;YJP=WWQARTZ]XI>U!3F
MAX9F%Z\5/^M 5U?OCSK/&@*]9T\#/=T<F<\: @-]T'O>--#5AX-#A?R?6#3C
MB ;K5:%Y0Y U3&HLUV-8KA>-U5I?W%TT%NM:2.X%H^;TS>F;TY_DZ0W=--O/
M'@*'JLLYS<CI$=-JHMUB8W0>)UQJFJ/&\*PO_GIZ9]1OC,_U(KBM=X;/.TXR
MPBYHSQP"W?TJZD\> D.]:SYO"!B&WG[F;(!-O Z5.'EB =,CVJFRCW!CJ![#
M4*41](VA6E_\ 8+,O;(T-87YH:'9U[N#YVVGTN"N9PV!@3Y\YGE]L%/;SYL&
M#/#L!\_[,A^RP?.^R'9$<[2ZG7ICH![#0.WH@TX32:TQ_@!!QEYIJIK"_-#0
M1#@][_A)E[=.><80Z.BC9QY#Z^KF,S?1NS@:_9E#H'.P7A-/+(YZQ X,-SAC
M5>FJ?H0^#/6RQA[5;*4N5(/&;JTO A%#[;T"!34%^J'!:?;T[C._, 0@Z!C/
M._]K#G3#?-Z6F]G7.YWG79'9;?/"MF<, J "<]"$5X]DI2X-!&S,TV.8IV<X
M'*M7%_/TO+%/E]]ZUA_LE<G;["WG)R^/SPQ]U-W+/'T",.@"#/:R3)X #$R]
MO=]]YB<  T,?[E<%\R1@T._N)3F?! S,X5[^ZOGQC=0G6*OZB4]ACJT?- *^
ML5R/8+D.J@?1-6;KXZ/OS# ?X%[54Q#1^\'I"4!@OPMX3P  QK/W6XS>7AF8
MIP !<Z^2F"<  7.O8.H#&*JGF_/_@\4</%X0-0;ID0Q24Q_TFE!JG3%X-N@V
M-NE&RJBMMXUG;Y.T]>ZS-\P&^FB_/.^3@,&>\_&>  Q,T&Z',]!.% @CO=TY
MF)7^Q**I#S8#]Q<K<FVZ=N6X7A(S1R.C=LX CE,KW'0X;I3,<]_2[@:]UY=:
M&63.##2HDGDS5/>H)G2[U:Y-$X+&@BZSH %#>YE$S\:$;K>>?2(>0/#<\Z_M
M5N>Y![<!!,\]LMEN/?L4QR$9@2SG%_!?:^PQU6C-#+DN6)EY"_9RR7[-3CFG
M7>%J<J5?OGQ[_^';Q;LOGS]??;W^\$;^96-3?(26>! Z+'S3OKQWG7CZQFBW
M7[_4;.9Y<\MQ7/_V'R_;_-\( /'OC3R"@BG/E^^^7H$V>@*,VQ+;5F(*K7AA
MZ*8_5[\ZI..0A]-*F)(_P5_U5Q+%[F1!LQ,2/XZT21C,M/\V+LRV:6IQH/VW
MB7_M:%/KCFECQGPM9%%LH8\ WX9LXC$[UN(ITPQX9ZAUN<>@V8$?!9[K\&$,
M=C";>PQ_!/_X9^(MM(ZA:[1P:O83"990H')XPU1<)/7PJH<T>+U=:+\,&CF3
MBAYPF!V$=)@WX :RT'-]]O+M1\N.@S#2KB83  ->_4-(_,L*76OL>FZ\P#$4
M'ZGFVK4\[1N+$@_KKLDBHZ,_\D%OI@R0A0C[3V*%,0LO B#&"_$/[0Y/@H>.
M--?7?!;S2:& ]SOF)TS7YJ$+1YM;'J#421C2A#VU_%M&/W"P@8<[3@!&\$_X
M"?QEH7GP8R_2[MUXJD58TX.LBR\!"+DSX-N84V'LSFA!^C-DGB0ZH,00F)AO
M1W2P@WW8L!T0?O94<R/-(H3 \^.%NB'$SLS]@5B!7]S!BMK<6B &8<THB;1;
M/+X_@YUJ3IC<PFO=V3@)(T8?S3W+CUIUP-MOH , /_*B*9[MHQN!"-&(<>\)
MJU$4 -DA% C6>'@'81_,Z30X(24) 1"!DP#,Y^Z<(553' "_ ))W(^1>@'D$
MIT,NGK$0*5D.60%<N7> .]@!,O]-&-Q:X=_!EI$ $+&#[B4/!D@L?4C"8,Z
M"6]8&+I(-RWM<P#GTD1S[=S9\1<1<"CL?&IY$\YU$AP=HF]\)"3^PV\]6@J1
M#:2K'D,0,3XMA)88)N.Y0%$+&_09X 3(CQ,$'#BT9OST'W[]]NGCS95V_:]]
MSH_0/P <=5H(CV&-(X97/N ,P DA<@)^!5N_(_1&6FQ]![DNP#AQPRBF)P1
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M VKH6>"S!;[K._8, <NE\;MWU '=MMX9-J'P^B-*9K0[>GNP5[_5)X2H0Z,
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MB<RR%N0,I=%-Y?7%G =GU/RO:X&6LB"ELGGR<]#C*,O9$/RRK(V>%VQ9[J:
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M'LP3C]BJI?V9MF/C$X5$QZ 4:EEK?0+.K[_I:9.-]V%+B((832+MUQ!T]SS
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M9QZ\B-W#0Q@IAP?=2+OR_01<D&]L#@Z'#LZ[9L&W?@!*[![_AKSG+\!1 8"
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MQW'<'< <:4TPC2T:EV)P5&CZ,-;Q0*Y+/OS8TXL+\0K#2TMC((E0&A%\HU!
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MR!-IARK="BCZ$*%'$M?J!RDO);I24LO7UHA2:DLKI=",&0#IYA<@<7*0<#O
M9#@2_PF-KHKT4@PK%A@G1"V^&?6.2!3KGQ[%<U,4-XB!=S'V\N(>?H\:Z[(O
MP13"R?[@8$IO#RU?!PTUM3+VN@+$%5Z%8\D+09W)4%@E73FT@J0.6JQU>G*:
MT7K:0.0S")2 ZTQH>.P;[S]PH$^$XP_4^R.2@ZW3TR,E %48KX]INWY:5*?,
MD/R$!S^55(SY\+A]JKR#'*A2G?!F<>_MHL3+TNH_"I7B'Q-!4+X=EMLIQFKE
M. "94NO]>8#ERT+D!E2! RD'JP@$6">P)^@<I+DO HB.,(P1%.?X-/SIXG^E
MXJ2B -]:(@2#2T@D"J3#B\9M _%THVS1D9)AMU&#_>'WO72G@4_)^*,H4?9_
M,>CP4-'<?_S@1P.V"@-^>QCSLG>@6QZJ;$5*)2?;4&OOOA^J.K(8NXJU$91A
M$44J*T1+BV0VDC=:#:O>.<0@ ?V2T;P65'IA');3N,JO2PMQ%:^#N3TCQ0_1
MON/C\1,)7E#1&"1'G:AYTQ^!#4P2]PI-:%6S1@>=%V'\YL,!(*0B'UZ&EHUX
M3"K@+]FLQ_P4__\1WICG]P?"5L]84"FE'"PD:Y['FUXJ;&Z%'0?J!/Q1ATU=
MIF%34QEB@64:AG@B0W32>%_MXWW>VZ6%F6&#5)PYOW/1@6N]JEP(G+U?7M?C
M,G,V)1KJ6VR[KV[_-#2W#32W0HO@&<CPJPJ%KA8I;K^&7^:F.Z$OC?TCS'AY
M-GFZ^:O*I:FMA+A:'>OXL%D]43<OU,)L_9.W_HMTS;ZO6IW5DQ1.K-/CXQU2
M,COO5ZE2 ,U"?I7+!9+DC+]Q_<97-<F_^E3^\NVU2)(ODY((P@O5K6)*W*L.
MQ54QA6G2=#V+1G5,T:CQ%G$FP=4DN)H$5YW@VC8)KC-S/MX'W/O!SAOL(UY"
MC<>QKUK-J037XS7/<AMC#RB7>X[%+AJ7#978>LD][HQG\*XJ<VSQVBH+RM4=
MS&Y=-0ZQZ9XGU$K;)L'UL5F76;*+JC@Z;H>N?MO2J;%E/+M584D;2ZLU6::K
M$<(B\/Q[3B5T&E0>CT#XR(-[$4;LJP?''.YYO"M#"E+=2*)A5=Q))K'UN5U&
M:\AUG>LB,KFO)O>UMNF+R4DK30M08<'OOEKLQL>B=7X(PEYUN5R%0#<IL=M/
M4UE![N(I5*6R#(>^]&;GQ4J/H8V_93FP'T6Q@BW%6R=LIZF*#X9GR'V(CW+^
MPT2#(?;+\>,0!@E%<*_2TR[[7&+[VI*1+B[9N7//O0B;R[Z/L?G@WC\O+U^S
MSY'3L!AGE+B0M;/%^HD#:M06)LU,P7)&A-QE#<]&6;5!?. "(V##/AB&;CSH
M2KY5^T8EKS-43PA+1/*_A>>GP?<ZP579P"K!H'5Z>JJ2I)H=72V\S^\1I5U,
M#RP=\],5NY#^0%?FR96M3(=LX9#P[PFEP"0-$+/$,4Q0\"AS)%\$\]R[DS[N
MY#B\V[-K:4K=@Q_\T$3<58O.Y;1E[;\LEN:,Y*45)<WM9YN#FT)\08D1%R#?
MJ!$.IO%<8\%QUV6?1QX@5OFE:))_^;[#/L VC'3>GN<_L,M/P)64ZXFMVGZ(
M*-RB/-QQ5&*VD2Z#FER&=1.Q[^3+(40/?KZ+YWA9TS>L</[$/?T*4@VVVM((
M5X5/IQY'RR15\NKVHK\/QR4J:WM]<4[X@7_VWMF^YP^D';Y6PF0RPV>E(MU<
MMIL@E(J9K&M,[C$,89)[*A37;I)[MB[1HD;49Y)[MH3F3'+/RDEQ^S6\2>[9
M:%C_X:E)[MG1K6]9G?:AV?E5*[1Z$H-)[S&>E4H%.FX@FV<'_2=UI>XZ$'$^
M?X?:LT]-VEEUE!W=Y>*TNAN\=Y>;.HQ+$'=\^.J,E:%YKP6'#7AE>L^U#L(S
M+SY^;CQ\I_D$%LW2E:81Q5+PK;I[Z>FP@LU+U<YNL'/HZ1)6B((0BV^64##=
MK-J "(P"\3W@K;LXU!$0K4/5(%+=XSDR!-ERKQY+F@,7'VQ,ZQ9:S\2W Y/X
M9A+?8)RC9TU\6W1VD_BVZ<2WCDE\FYDD\>$?O[0[G;. NPX&'G[FMA]&ZS;7
M*/_MI+GF60H-IA_Z,A+[*!;%&\]_"#C0W"U\<^X@ MIGKK#FMI1>"53_%RN,
M=X6=!-*89+QG9(#-MII\+[I!S /=;_+$TFEYS>917?$W/R5OC9EQN6 3S*S:
M6&H<QA\F9<B7OB-[PLQ9$N('[+2RX3S$:Q'<B2!D%"N]J26?VW_'4A6EG^[N
MJCB/5"(3,>EW:;(+37;AAF(!37:AR2XTV86/<&M-=M8$;=@Z/9Q^RC39A":;
M<$SZEA_M56Y)("(@+&Q]]S#"U!W,QX$A!.SOO8!/8,I3N8FDSTE/"DR) #,_
MS$SN(#6 +7@@<5M34\*4?N]2.Y4R\="3G<O&2W+PDAO.W.&8Y6Q[\H13LT&5
M"_0#_N-A8AF^<QYCIZ-(O<@<>'R 79#4WV$"&-BMKPDTRE+"]+2Q!+*^%'B&
M@4FIU>'77D_:6?;--8:P"^SV_M/N<^\.5G,%T,%RLTY-N8RH!-=I+SQ7W''L
M@!A[H7"33$XZ_4M8_6W$5<[9K? 0:9GG'U:L<Z8L]CW@CM =S;"RCZW:U]F(
M0]T5)X^_<^=>AM@CJ3":OEZ@Y$B@DXCZ0896AIJQM"/LBPF4%V0-,'7.H^ZH
MA\^Y6)\$1$,<4*/,0IIC#J+&)'[Z,"-E\XU/^\4/@"+/897 C0 UX%>O__P.
M/JLN.T%7)CW'8$*A^F$64D9YCA*3O"F3E6-B1TQ6CLG*J0A#F*P<DY6SNQD2
M-:(^DY6S)31GLG)63HK;K^%-5LY&H_';Q];!Z6GU1%V%<S.V9>L/K8.3 [/S
MJU9H]22&]I%U<'RR0WK&N%8J'O)DTG),6D[=TG+2])@O_D!Z/$JN:<K"B7*)
M,QBA\EP9/=F\FTCI.4* GIS2LYI1VBL9Y?@)DL9D%YGL(I-=A-E%AR:[R&07
M;4]VT3H#>W8TO^A@F?RBDP54Y]+Y1<VGV)IK#WV^X;'+/JL8D'L1_AUO)+?H
M:-VY1?_"BL9PIHVL?(2+M>XT]W6F"RT ;%Y7M!I-4FU$KI)2@-[L)U\^C6;F
M)FY]\3V:,DT]*DO<VCZ\/#E5:1UP L<- ^DJU!V1%3C.?+7)TUA)>['U('F?
M H /SB@KIGU6+$///GD.V.S!J#+0I@E:W%6Y6;IH.^CIS65I36E@MK89/\88
MROI-A'X<3'9JJPT7E&4K,9.I9#*53*:2R51ZXI35"-"HS U"'?-+IG1 FYT_
MD6O%L\E,I@K<F9D\IJ?F,4VZ$%3>2"Q=I#TFO'M)KLE #.-(Y8/HM*5AT4R6
MVDQF %Z?@96CTFEX-_"Y0_E)$K.:;/_. W =S'NA_)XH /5'/P3P=,0<X6+?
M%W2C@U)\B/K;TPJ'D(WHQ390@ *-2.!U@5E5^UT>PK?3\$H'4]8Z/3DD;(81
M#_!6@=++_AS^Y?>]?)\G&-AC?_G2@T=N>@!SD/P*L[9.3]LJ98S:2'F8-.6C
M;A[!KWA= 7/=44,W#QM7#7U=(X FTU#[P1WWDD0E>,N-*<L*5H==JEBA2U5Z
M/L')<T!*S#["BU$+A%CLX2K5R2(@\DBZ*"GYEPV2R#]\ACH%-6ZIF1(8&K!K
M(W@O(;X0"TFH]DT90/#D>2CY_@VW)0R4#B,][.9$$M:1]S+4&5@*>]M#A4D+
M.1Z&\4#GM@4^L#BL]8/K=PNX0BQ^$)X(X-O\UN!+WQ#-5W"0![+%;DT1@RV4
M+N;-:<+[#F* IUW.,$$&[\ F7!K;@UOB<)L' 55- =VA$BL18UT4:=2TT&=H
M P-V*<<RX$.=SL<3#TGL#43$DDY[GA"..N8_8$<W$,,XA(T91K)+*88D1UV0
M(1Z,'ZH.6OA5YY"-X-MPCL3>,O3K!F/LXM;6??;LOAA(DJ&$FL_\'E:?:R]&
MH@(H>>C"R/A.YMY0;US;'Q#UV2LFS]$$XVUSGN-ZDQH-M9LDQI6ZFDP2X]8F
ME-6(^DP2XY;0G$EB7#DI;K^&-TF,&TU>.FY;)TW36FP7M_Z+=,V^KUJ=U9,4
M#CL=Z^BDO4-JQKA-GD*1)H>QIF1?5^JN Q&#1FV<3_=HKR9G;C6CM)I/8) L
M]:Z>"5-')F'*)$R9A"F3,#4U8>IPZQ.F-I4-PD&X_$NH@^;:$ZI.UCS+!9>"
M.1A(WSH^^S/HJ7"O=2=4;:X9T]HO0RO1BFE3I+_1GDW77+=K:E$L4.MXZ_&[
MDCRH1^;0"- ,?2RH7KVDIF(*EB["+@NET(>![\1VM/:&4!I;N2B@RF I3?W"
MVNSB3MKLQN6>-YGY51O1NN*$J-;ZD)]D3E7+[VQ2GDS*DTEY,BE/M4U%F=Z6
M:5=B;$T6TU/COJ]#W?N&SNW7W(;CIN/*L$]G>$JY&?A@]49][F51\6!23C9C
MLL<M3PL!5HDG%@NYRI.P?0^3)X+4)J48\HOV!0M%<"]M$3;8>XH<YR,\UIQ@
MR/X?W,/VM)3R8+$4YA1$:M9#1B>F":3GL/$N24EO(4%I!3?<=:5*6J&TESW.
MNIA2TT_>^RX"$7)V)5R73S[^325ZV((:.%F(A2*8(0P!)W@^$+D$Q''8%IR#
MD+34<AKL%IX-AQB)3QD, >8CM4X4YM)M1!-2]8G"!0RRZ/TL<RD0+A5A@WWH
MTS&(7DBWBX4QH PVP<%$ 9U788UG3"#\@8@X;)C^993;< 159W914M:U_;\B
M#/TTXRF7IVEA/'7RNZ53NU1Q.$S..F4/E$"'R*>\+*GS=)+UX*+'TJP0MEN5
MKS7V"^+UG@?8%BQ-;"*T)0 HT%4_+<Q#@?\E_:TH,4BWU,J-J$E;;0/0]R$^
M4^R_C%3?P)0LS!;RBT\KLDH;>)6#_4TA.I>+<9ML5A&]!,T?L9M-<# QHZ)N
M>O*+?Y\KK@<_MH@Y8T]D[R\"H 6D"V>P@,A*':T5O=_Z;M+Y2Y_35(K)10S[
M#" #G]P+UQ_2F@I+:8Q)!3G9,ZR;7"8G+;=H)[\+F(C-K>US(?U]5=U$E_6!
M)=B4.O?5BY!"Q@%(<FFN>1@AQLB#2/E$W60QW!E(#YE&G=/+\V5H_2CC_"YL
M*J:&$<NB"NH!9]&;U"!-?R6<='V,]V!JY$_8^; 7N^Z(NJ"Y*A<0<?+I\BH[
M,K)W()#5B#>!#]LS,,DZ)NIDFY-U3%.R6C&$R><Q^3R[FUM1(^HS^3Q;0G,F
MGV?EI+C]&M[D\VPTDO_@P&H=F7R>7=SZEM4YZ9B=7[5"JR<QM-O6<=LT)3.N
M%9/0L]5D7U?JKKY_,->2#..IA!<J;_CFNXLMUQ%M YV_=C5SZ-AD#IG,H>W)
M'#)Y0RO.&SI:)F]H$7&\=-[02<6-P'//">#Q:S!.)B(YUY(4='CT3%V6L#&I
MR=9YYB7,3L)9?0+X5YALO-_D%G<:6CT"T\P,M&=C3\>TK#U5)9DU,ZCKNFEE
M>2 DBS;9'$>)=Y@>XX@N!. 4C LE$15$ZSZY7<4@M@H='4RO'I.X8A)7:IZX
M8M)7MC8'87KZRB9[\:RSEH;)8]E8'DOAE$F9!=A&(F0V.G2Q_R$8M>?_?/?E
MTS?VX?/7B_//V#N^V(D%;$]RN(9@O6 L>)(G;!?L4M:#\6!H._##,.VSDO12
ML=B[./"'(FDDPZZEX[B"O>-AE'3RH18B>;A*;:<THU>U6%@DE/T#:%>8^DJ$
M=A^/I0=G'B !X]0M-FD>I2!>?E1OLL]R(#$B_X8'D2?(;+28_^"I>=\!5G[X
MV<*2+!1"@11>N#W-,#YBNHRXQ[0/5Z6IJ&0&GH768^8 8$$A[@_!<?OB*&8W
M?URJS "*YD\2*C"CP\(1TON%PIXG22$L2:G0GSM)*QX9Z=Y ZOW<\\W3W/.M
M!KL.=!)"D1/HTSWUHIF;ZN#YWOXP\'LRZ6"LR"VT<KV**'>@D'Z4NYC SC^!
MO$>)CO#KD\G7'*^%V+7(P[Y5DN=S'=ZC>:C3?'"*G'N%7;@QK!^Y3OVFZ;&7
MOD)@B($(* DLXBYEFA1H->G'\]$/AQ*>R$V8(VQ"7!X4SA3QY"=SJ,>,SHLB
MGA01J+.![MNDN (1[=M2/+'M2:688YS"TJ8QW.X+5['&9_X03ND8L_=_L<#M
MO(0_7I-()'E8-LIY$.E1R+86$<PVT7M&Y=?@X[=VFHYHIR;%74:6^+R(^M+6
M@^:&0I!]SX'Q]RYD\ /@^P$$ZKKB3KPV.3 F4,/DP)@<F(HPA,F!,3DPNYN/
M4"/J,SDP6T)S)@=FY:2X_1K>Y,!L-A&B<VP=FJ8V.[GW;>NPTS([OVJ-5D]B
M:+6M]JGI:F-\*Y6)?UPT"69'Z+6N9%D'ZLMGD&Q% DL'IWQR LM.M[XY,0DL
M)H%E>Q)83.N;E:>P'-<[A67]&07\P6.W]W[@>_ZZP](I@>5X/']@U;-\C!TL
MGFJZV)B\F'71\3"0KEKH"76GZ=05;RMI.I.W4-;6^>6F6'&YCGUJKH+X#FO/
MEC6KJ0W%K+@OR_+,]V_A80G? CFH.- SMFZ^=\!RB0?L0OJ1L/L>G 3NI BQ
MX+-]1B?!<["V1X'TZ*NGQE:9'!V3HV-R=)X[1\=DYVQA9L7T[!S*G&VUSK)@
M]H)3FU(*5I:%69M@09/"\^3 \JP53>[ G?0%F6@RPW!KTX28I*<"Y@#@%X/8
MC<@![7O<'6]&8FNC[!I&^J%WB ^&0-%^0^?+X#CM3JY9BH7M2V2 #FT 125;
MO%<Y'BH' [_*]:;)X(?C0]::0\.KLH1^T^U- G&7Y"\02&0HZ022YI$:'":9
M&$D]+),V*=@S),U:Z6/8;M;$137+T,]C%H>@A)+]PGCGH>3LAMO868)@F'SD
M@^MW.;86T8U]4H2?!U$?(X8!4>> \CMXQU:]?;Z&D?!!'  L&'F/'7;@%-4H
M0=7"33M@*@%[3X;V4!G::D_!UGS#IMN_B*L+@K*/\?WQH"MYXILX8[.,5WKU
MFW >?-^AW 5\S96P>D_R,LL6GS^_\^. LX_2=</\\R:EP%Q[FY0"DU)0$88P
M*04FI6!WP[MK1'TFI6!+:,ZD%*R<%+=?PYN4@LU&$K>:UJE)*=C)O6^W#LR^
MKUJ?U904CJR#8]-5PWA6JNM9V4";#>-@,8D+E<\;6!]4[R7.C$!E<X=Q"5:/
M#U^=L;(]V&O!405>>3L[JNG)N0ZK:?FQPE&>GG<QC7J7@B^)_5]5;/\IS)C&
M\^?R&B:2"<:2#1:2D6-23PU__*J,N1,_AA+*1&7C+@[Z:4K4_;A\6#PC*<7"
MH@:5@A"+YI5P$]UMVH (+*CF>^P\O@/M5BBJWK%((C@R!"%XKQZ[$C;Q:/'!
M!BN24LTS>$Y-!H_)X(%Q#E<S3F?#X$QYO6-ZTJPKH>?DV1-Z%E#\SQG2[W+I
ML>]![ @>3V][5ITUZ+R@HX.U-W'PHD E[7!WT\UM-I"*O_5I/*M/*-^Q]C:K
MYJBTS<RY;6/'*- )FVNHH^SL=9^232>=U>+SB^_-Z.CYN!-U99QH:T^+,3DO
M.Y3S,I>:JA+OL2STA1K]DW)*]T?1"96Z2K_)PMG"Y C3(\<DV*PLP>:<]83K
M^@_)+6'2B:'/ R R;/P2^#T1ABIG1ENLW(O85_1Z6:QP;F9],*7[W*&F*"$:
MMK$,^S"(S0,!5A2/V+O 2WRX*KWF/S#@G4IL:9V>M'76S"E[ +-+L+Y022L(
M6I*X0EDN<.J\0V^Q[DL#@(1A'-!5T*T([J6-.1J8A_+N/_!\#_].TH5@1?=2
M]R31RTWR:DZ2Z:D)!?J?J1%%(,*A#U2-;L8DMX7'CJ3LEP%F#:F$$W>T'P7<
MP04GF2?;T^,#$&+'00#")^E_0RUDIB?DS&TJ\]F/_/V"0T'WEH$QU2J3=C+,
M$6R@GG.DJ@P@X$M*.CP^XT%71M0?R8GS#@HUQMZGZ_/_>TWW!-0NYB*0#CP*
M)!M&:2K^4_/.*[53[\>IV<I: "6<2K3-7-BM.%"<J7(T71?1USY#9&*W+&<@
M/:GZ7L6PK; /V+Q&H3A2_]"WKMZ+M(&*^DWW>@'.R[5XV1Y,3Z!U:LL:S/Q*
MC_M*WGQ\=\D*WC63 F8"E78N4,FD@%6,(:IT**YRQD/=TKY63SI3/7(KV^'9
M_C_#-?7CFJO;/_.>J@EGQ?-PSB1(U7>15Y@>32K;RD7Z]ELJ%4YEJ4( ]2KR
M5@ZLD_;ABJV$%1L#SZ?S#?VMG?Y.K(/.0=5U;87IH**Y':9'C_%4[6Z/GE7&
MY&P_V=>5NNM Q$"S2?7-<[J=S!+3,&!MLZEK)M'+)'I5*M&K/"^J7<JPQ=KV
M@/P\I[666'=ZS8$1G,AZ?ASD;LG[_%XPSM0X+! NW6UC1*DJSBFXW=<E+7'Y
MN>_42.*GL.-(W@L=XQ"$#?;=IY]^>/Z#*YP[83%OQMQ!P+T[,8!EZGJ@^-"
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MPA$7%W1+3_J((:LB/!<5C+/OLI^;K6>R\B.F7)_\+A'7ZCR:]S(?+*=$6BL
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MZ^QU@WWQ<3SVP,-D..G16"X/HWSCQP:[%8(EXR03$=#L3YPH-ZYN2XGM(SD
M%=J!'";]-''L!(S&S"ZP![.:P!K^6"5_M&O '^^XW4_;E;*'OD]$Z_D1$X.A
MZX^013R@MU[LNOL1#,B EV3(NJ.)OJ;PORMAYQJ8MJA;<=MB,+J0]S!4NV4=
M=TZ93W0;LKU#ZZ!SJ"8 =HS@).B1$E #TDRO69_?J[[VC-_=!>(.6R6K)JA
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MK;N[QH5IP+!EQH5IP&",B_HI1@.A,2ZV5>ONLG%AVA]LDW%AVA\8XZ*&BM%
M:(R+;=6ZNVM<F.8#6V9<F!HFQKBHGV(T$!KC8ENU[BX;%Z;^R%89%Z;^B#$N
MZJ<8#83;;UR8PB2F,,FZS!A3F,04)GFLO6$*DYC")#4H[5"9W3 K-2NMB'%J
MBNHO6U3?Y=)CWX/8$3S>@?HCIJB^N9#:(H*NO\]H_:10]Z+T=8>_U;$.-!NN
M5^D_/WO7^JB_-<LTMUKF5JOZ2S"W6C6Q4';JSJCZ$%;$AC"75^;RREQ>/3?R
MS.65N;PREU<U=/]79C?,2LU**V*#+EY5_]C<:LVIJN\*]B\AW1VXT:+ZN_4^
M86_ V6+*VM:$H.OO+S(W0ML.?]L"9JQ%B+6YZ=JUFRY3,W>[;KI,S5QCN=3P
MEL9 6-6;+F-<&./"U,PUQH6IF6N,BYHJ1@.A,2ZV5>ONLG%A:N9NDW%A:N8:
MXZ*&BM% :(R+;=6ZNVM<F)JY6V9<F!1E8US43S$:"(UQL:U:=Y>-"Y-=O%7&
MA<DN-L9%_12C@7#[C0N3=FS2CM=EQIBT8Y-V;-*.3=JQ23O>@A15L]+M6RD9
MIR_@O[SKBNDZ<DROS=:0L X<;6PIEU\_?SZ_N7WW)OFPG+7K!XX(WH#"ET[4
M?]-J-E^]9+9P79U$_#\OF^IOE)SZ[X6,[C%S60W?>37C7$E/G+P:1R[@)CU*
M8NKQR[=[K=>3JH1^2L8J&6+I;.?'V6=_Q6$D>Z.7;[_W!;OG;BR8WV.Q)WZ*
MP):A<-COF!<^_3#]\NW<!Q#ROM@?^)X8_?X;/OU6_\/\821]+V0\8CT9 @;F
M3S<2/-@7GI,,(4,&HS-']GHB$)XM6%=$#T)X]+7M^B&0 1L&TJ:EX9>7_@"
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MS%RM$W(?=-F4\YV^5DU#2/!559!4%:%.&#4+(JD "N;>\^<64*V-RT.&83C
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MV,E(TL8:>T3'FA* *7CBD9BAG2?C4=5I'XAK&'=AZ7@_'W 4&)= /!36A+1
M/:O24"9+D2/'4!&,&^SY=JP#V-$>UC^F SC^ *Q;5^ AWE6>AK&YLA"P.-2=
M^7+$/O3![%;]+4.AE\U[$5IT4R-:E><[L;;!>J5(@S=5H+U]9/!FZZPKP1RT
M^QXHXKL1=NN3]^0>L%CHHTGFV?3+?B!4;ST5Q$M.5Q5[H=N61KEWSV8L<%-*
M-%F?IDR;#XFK_JLO"G6,S*]@8>B@4>FZV@/S:T=]U55?56DU 7I_8F&QH1P*
MS!8 F'@4AWB@#$'-@OU/4=@8 ^@/R8^&[GR/+FPRX9F>-2UUIT..?OR ]=G!
M3!=>-03D]P+_I*R<,2JQ8\*M2@^23W%,0R4J]5OZPS7]D&C3"8X<2RQ^5 K7
MQCI%(6J?V"FJ<[*:SDQ'K;0STUBU]:>GQ$\6-%A%"EB>9-N-X\Y86OFCR!;(
MJG5Z>$;_')SIO_;9_WIXR$ ;*>!#"DX.T:W9.%MO48Y*H&0?[5?TC\]8_7+5
M+'+%&'Z;^DNQVL0Z"C74C"I3<DRI\N/GV\*F[ 8UO@M#SFXH3\ 0X/,2X/\[
M&H@'/_BQ2\+P'*_K9$*!2::*$8A54-,78*?!0?*CX"Z<('>()H<1GILOI']K
M4RC0KA'BDN>Z-8O%?PL/KXBF"8C2PTHG!_:,98QYQ1]UX]#:,%=^14?$B*S&
M"^6RV"'6O):N"",?COME]##6Y:HBU1"*9_=QUQUF".7O\L9/YE;N:(_W;RJ:
M&AT:Z"26'H7WJ'M+#P RYW=S?E^/"$HET3[[,_#O1"*2V>?(V1'I\_7;I\MQ
MP6,94[4"INI7$(GS#A';3)DWHY\R5*:!?S<R-%D%FORG"'B(*?F[0X:76&>G
MUS.$^/R$F%/7<$PXCUP^OAG;3(A @)$(,!X_[]$E#!AJ?%YJ_-#:02_[M[@K
MX] 0XW-ZEB9)\5:Z "]6%Y^R,SOA6\HAY'_C@*?*NTB?V\R=YU%?>.)GQ7U(
M.L@QBYGLCG)1D9/956.1IBP+,M7AA#+0:9OY2,O.U$C+I"J74UJG)XM3=768
MX92?=5HAI;HE(Z6%?#"!!$-XI2Y\H=, HREI1:5!=655LA3^:*V /\PB$+HL
M0%9/@="2E94M5!W(U698K#PE9<-$TG7'EJ3R.):>M#Q0, O_02\@%;2=X4FL
M1"#3NY^V .9./)GIYJ7QS)-$EBMMF)$FI@N2ZS1Y7&4_I\-,OHV8MI+O"X7J
M)J:AO(E14GAD?@VV"N 50SD7P2$*C:GIV0,8#;.Z=3$,9UX9D2!CWDH@ ;E<
MN:P5FSD8,>^J>#A^=Q>(.XQ5[V&:%X8TEB,HJ5T2/?ALX -"8/=50EMI(9,P
M0=(4K&9A^TY20P>K$6*5 =]1&;UA*&$:+<"+)4=*B^JFJ3VC6;EN!;+%@@&3
ME#OKMJ!=^=N"Y@IN"YK+W18<3KDM:)^N:)Q'P[,>^S[7,XS/:.7TR)8X ^DX
MKBB+_G]0AYBN[SHOWW[A Y$&_4]K??+]Z\V:.I\LVLYJ+@1/;(!2BKRSA[Z,
MQ#[RFW@#.@W.,'/Q^1[DWUQ\SF\ELSZ,UQ7OCTY2G->RZ6Q\$\NR%M^33E*X
M0\645&<&.V#Y,^>J@=,'S1F5,W\/XQ(U='P(9D'9P9$ZT, KR<BS6UGM"JW.
M;Y)DR'<MY-M>EGS;4\AW/1$'2S31VZVFH+/S^A[A_)I\?#ZZIEAX)2R:F?"E
MI22^Z=0TI>&KVMQSDA9*U_IKZ]CJM%I/=3ZN&\KC0ZO=/JE"^\MJM;J<Q@ZK
MM,<7WLQ'3SI/48Z+FKF*\_'7 $M(->4.^DH>,24+9AE'F^P::79L\3(DO[:M
MSM'IIGJT;MW.Y'=B?*BG[DRK:;5/FO.OBK)Y=K#5Z/'<_H='V])JE$*\19*&
M30Y:Z5$K3:J,)J@7HH> 4H&.R%=AX(X/AF: 51;2+DU8MQ%KH/W4E0JILF+B
MDEZ@?HQJRP,SHS',_H?]"OQYT#Q8<3?/(T/-CZ3F.G3SK @UM\NI^;C=?@(U
MU[,@6<L4)*M>03)ZH+QQZ=7X)=YWJ@%4K$P_-5PA+8:E;AG_@WSR;H;4SWJ=
M/OL-;*VKQW\O;X4QO=)U;_$648EZYF5=8=(0':IT-JV9",A>%2>C6X]4(_"
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MPZ[;QS9ST)^U";GN@3IZ B_!!1QNAP1/:S673@?/??K0?:E#=QO.-J/.SK4
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MAV9OH-7$A08_,(?M)IOF/<OL]G=.^;*O -1@V+'-KMVNEV:_SNB1CJA5K,G
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M#3/Y G5=]_!:U<!'570X801\,@%K*U^8D:L12+/Y8K@I>F @?E$#1:)>"I6
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M*TUA.G97-*OF_#0;9B< H"[* $MU8';42)6C<LA0BGLRBTL73^AXW&EI[2
M&4VA.I*V3<28OMB8X%-C?V9E93!\>$S0(</M4;I-] <8(WK\8P ;XI,5@5PR
MERU/L)X2$SN*((,3-YPD<]Y2@(HLLXXP3P&O59>:(9^3Q#U0B)4^8[[J<:W
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M?G-6CGOV-UL7?+,(G9U7N*J.5"UBCVE<VJ;=[9Y=2J(7^+RTJ]^HWWB2-YY
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M?/849;=+9=U+WH!DX[%HXP6XK#-V.P]\MDS/2+S?!;T?)HBO)50#L4"3($3
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MBAA2)NJUA</?2O+[66+TP+<<\&59ZC:%[;FR,<V-A=)B; 93JYH):O<,%,B
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M,:%??.#^,7Y#+Q73>?U6FO)P=)L%SXQVFTZ,:'ME(^<T3L0$Q( ^)CF[BCG
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M%EL$8JU475H"/,2_/03G*W2KR@ [:47D7#>'3)/XED\;[DW;CH75@PW1]$Y
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MP7'#R*1Z9A83F@$'UL "6\+9(#P-4&'=]BM3PB)&C&/;3:?T0IP(Z!L"!IR
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M XP<"(7P)%.CP>2KNE@$+HD<+O* 6$$Z!]4$363DA*@*.0Q,MI&@SF/7$RB
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M$(K@ OTHW'&78\A57(B+B78Z\U.PUBHM). HTY-KC&BQQL)QZ:X53T8KGA,
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MR5<0!-QL4'?=[Q3RM_L4\DZDD'^E1-&: YYQ@L?)LNES%@\H"XV-Y2M74B@
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MKHR4U&[YO'36W7BOPS#92J=@GJ<?,RJQ6/%)9<D72]4N&69R8 .YX-+Y&GR
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M2/'(P80.1[**WBI#N9Q%.'G/A?&VD#/$>4YTA(45BA1R?T#*&47E<0.OBT5
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M_S,L@"::5,FRG..2@$)+).N].R?[G>4U[QCL04I48QHI-2*::N-8#,*@&;+
MG$7#(+VIG3X:-(-M?KS=:8*I:/*:UBOH6DW*\@/JG(K@(8O882C#OU,9<=U4
MGL26S"^I">O$/.O#(YT715T(LV0"IYWTK/'3Y*8S0T8 ->J""]%.X?1=<GT"
ME[D<<UDT[.>U;O'MPCM0H\I1[J-+B)L9M"2.HI?X=XH*N\6^\1[+9\&LR#'1
MX);9"+L'A[$-LW0'[SA*9]O,8P<.RJ8SORYJ\]ZZ8[MS]D_7(@PH,1FH>U+F
M#OO>5-G%1=IQT9S5B$G&C4]W#TTRAA8HJD,A8R@_75RU@;=Z5Y:I_J;,/#H
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M6QZ4@;[W2ES I<$$OM<_*1=U(H70^I7PGKD7DGS6+J4ZC;?M5#E*=TF$SSL
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M._N'K0'S#!3Q]KI<K[^;T1(:OY7[C;LZ70:"9>T%&ZA/4$]%USX849A(0K"
M!ZJJ84C446?][K@LVIJI'KH:;_\:DQS24!XE*G]KN6LN1XEF&&M#XHJ$$D$>
M?B#=TUT3V8[51)@GWEMZ0OCLWC[S8++%DNH#3=Q(3$*!RXB\,B,M#P97IW(T
MZ@V6!Q):-;PZZ5_\J$E*84Z:CL]!FJ%DS L5D&4XRY4WCZH0I4'%Z$9^10'%
M0-/]**"VGD]$0)S02,'D-0)Q,BX$A?.6K.@Y6HTK[%ZBOV@AF>.X9*U@F!_
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MXB$32HJ""L1UP*5E&&QP9C*NQA5U4H\-FG##VKFERS.0V)E2O\ZR6@VN6I@
MYERQIKT&J:S[$(SH"E>#W,,X-*G9K+,L9<*@JT51QG 5,MVOR&\:GZP2!V=U
M2+#HF\R&KOW&W#3X_IR;KCO):1,"Z.%LG9&^%4U<'_:/?G108'#C",.K0MF^
M\1PF1.SA*^8&65TY?KM6HFE938BB)X<:*D"^Y8$&U-TH@8MA6-81T\R9!K[N
M=[2;8=!@1>UY.1C,H?%]EG3'LJ3/00&2=^' W.\YAX&6%XA2DL'-L#>^/BN
M*BA]QK/J:JV'(Z<8_ YB<S/>5%(H:K.5Q SJK>R0@6?P#5B2YMIS4.&W+09P
M*HT8<F8(?PD@_5:/^'"]#,T9@3)-Q_M+2A2&-H?-=:7M(U/H<+J2!>L>Q(D
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MR+L>&MR,K?;.K?CP"ZG#F8D?8F,C;A#DU+B+'%&^Q?V+-*L'^WO.-]&@P1S
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M"^Y^J+99E^R^[G:W[4:UK?F?K77WFK#X)EG<B8MX6VWPJL"&C#!AX2'?134
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MO0]F*;JCB>/)=]>\8PP?#2I&!^+I<@@A7WD29_K6V7\?QMW&AT:D)"8L6F=
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M<[S,/Y<-JBZ7BY.$4'I1<ON6T%2F5I4N/3-)0Q]MW(#J>=%KC&6J!5:NGH'
M\A=F,K#A<VR<C4N"UTXWJ$$ 3?1@2FV9&:]9H%L'XBTADPNZX:.M*U;3FU6B
MP9PLJ?]M0GBB+)U;;\E 7Z@_9T;I/XH:@E$+,QOPK I2!=H2);,MH'<Q=[0]
M+;:0A].FWV<T6XA:6P3S&LD9I;^U:6'2I$%DNG1]#H5K=JT_@G$U>VX"=X_X
MVB5Z)2E'Z:/#D!D2PA3CS$62K^J,[*-<Z#-"YB67T.O-08'&>G!IU Y+-IM5
MY+_!DP92?MSPG13_Q/10I@:\0TF[>G@-*%R*#W%\U'B?@B.-]1^!GI-&Y6J%
MJR:QT9A:&HKA<*E1FOBY2;UWY&YJ]7VSA=7W'__V],FW3T<?<3+XB/Y[?U=K
M<<OE'U(7" &C6@&']J (L$)MPH9B@Q"U^H>]_[&7Q$^71"FL(<,!&4DHK>2D
M<53([BG8X-$>;/!5-3;:'_ M#CA<'-P%P!YQ ACO+Y&]C-V).5.5'\C-P/ T
M&>058ZRY0Z%MUXKT?^5,&EHJ4'6Z[JK9B^)>%+<71730;&D%"9T"0Y#:L)%V
MS4@C69 -[IQ"\Z' ;FKM'+DQ6P+O?3"3%N^N!:8\! 7=XYKA7Q=@7/TKV9OQ
M>[&_*[$/8A>SDJOT^D%24X;&S;GBD:*\,R:&%+Z9AP]/-,;R"JW1@A@TN-CC
M63FC4.3)T^^8U$S;#[GR#_B"%DWLI7TO[7<H[0YH.%1OB<%"SO-21NFB2@1W
M.?4 9MOJEZA@I(2 *9>H3P(SQ* U,\O3O?SNY?>NM75Y70B--F,7%'^'R:@#
M30#')AE,&2YL3-VX;FZ'# 8-$0]-V5 ?5LP4PW,%#[HLK[D.#LL";;^$X #M
M!7TOZ'<@Z)2E23\N$Y!49#+8B]5>K.Y K,Y JSDP5ATBWV)/O*0.(-WAMLLL
MP;[8(11#P>'F],=<#HNY>?U273]0R)I[,*(JQG*ZBK;8R_Q>YC^+S3M Z9]P
M&(X,!M?3?82HA0Z.I70!VP!;?_1X;?8"O1?H.Q#H3;'B'_"3O:3M)>UNK% #
M(:RQ,+ @-8D.DA8V"P+*(<ZY G='8:3#3!X.656LD%8$(W44R4":CD6[L/"E
MP&R1_"!B3RZR>3. 2:OZ?V-<(KZ*?AU'>3EE&/)6M04X %=4D%S?#FUZ]W7C
M 2HNCM80+#',KTO?U2]!E#K//5!LK[INK+J8LMNC%AOX=L&$N,(\"#]('0JT
MSS^X]T[V<OHYY-1ZY%C?K\%V278&!<*H[0<E-O:W"=<9"[\!?O%Y)C3/I%_S
M=C')DKWP[H7W;I1LZH1.E:2MKC! \!%]RG+/O<JI-AE^CI037!&U=V7VHGI7
M>E:801T-,;% @)0U-I,?V@%HIPJ?3_H1>Z_66%^4D>M0MTOL2\K,>M@I%:76
M\OH)IZRMTJ4SX.)1Q 7,+*=<>":\^5*<.\$$4V,9_)SNIZF0@G><OV0K7W(7
M5YCZ+$ISB6?!S%*FWQ>_PY YHU=C&@18*N2ZA4F^]Q\Z^D:I!Q8&FB[?<@?D
M<(9KA)R1RGS__LQS!R.'*;RI=5<:+H][]_,4X\L$_#FPKH1^P0U(2OI\R#FQ
M"[VC;N@K%+\.=ZUV/2#J#Q,P7VWI,,5^%3>52DE)G@X@.G"OYX*I0TZE>AJ*
M6;I$TAM'L(IJOW4"N>8YRB>2^.:\\B.>VU'T;OS'Y8U6B>N/F :W[OB2G;)%
MY77.JK!ND2\B#1,/59CQ\ZGD%$:IK5"EL(PQ0,&;[S?)X#=[W/].D R&99)A
M]6&'^AAA8['OVRU,>D29&PTI]KA/%5MS56V7I;8JF2V8<H'"#EB;^V6<25E*
M'WUS<&,8,K].K#61*ZT=AJLP83@1/_XH.D4?!XL'79\9/-)PQO!$PS"VTGS,
M.DL<OTPUBU%-SR K19ZO"E,S&0>%P3YH*+^2BDXM5.;1UK[4'JFU*R9_]RH\
M5B8-MS>.S1=I,LP_2*U17QIA*XYEXA,IJ58*([MD&)VK2BJ_QG^"B&2U<CLE
MC3Q@FB G_:"BXSO5KQ41-*SAV?TU97L&EZ7"I]0T4*Y>-22T^&#Y'.__JLV%
M-I*U^D6;S:BLS]$ @\'0*R;'9;,FP\8M=S7>M+N.XZIR9-$!@;3CC.9W"_T2
M3)X:E_%H$ UW"5*=HAR:\2!34=ZRL>9?BZ_*BIVH*%^G2##LI<3$8>?M?/6[
M\0GWK9J.Z&X,$^/(8 /+)2BK4F)\2 R*5-@^H]LA(]C62DI4Y]QXG$B3B!SD
M1\@[[KZV!+<6S'0J[0;Y:ZL+7J603R&P29+ 7%,BX[XUMQ #WTXMCGR"@K(,
MHMF+H*G+UFF'6/,..$ ;C=J^YKYC')E*]#Y!6Y+7I5DB^!-W9*G2JPRD7!C&
M5(+1?4H(L<?G399#?(>M^L?<I!?0D68S=N!4;YK<6[<C.\SSN$XUJ;V G(3@
M9^-5"]?=2@\&I>:Z>MX$3B_3A(SZ+67A':*<X+"^%';[5[[\3WK(1>_QC;)V
M(@@[H=^W(/UTX-<!AMO=D89PH(8XFM2-8Y9UQQ8T4LJ\,Y<I=MC)R+PZ%([6
M[CP[_(IA_,"3XXIXP?"H\(D>U38* M9F$=188=HNI!X\32KT"VLUO8E"EXF<
MN(.LB^F/YI@J;+>P! D[]/VC)JGV8425G;F>"QW*$C0[,: Z39$6"RQ9=*%G
M9C&1TI)IM<T4Z%+8,(=8UF**8=J!94NV*_::@Q&EUPB<X;8J3*])<&,&&$L=
M8Q\N#MFR1,H5WB3H'53I FX E!(99C#QM9O>(81U]*QD6FM!@R/][JE198Y-
M5ACI:)ENN0K*(NCBXFUQT3-#-,42LD&#Q=NJL#,9\5NRJ\^%SNGYFKLX5&:'
MIB5FEVD:2:+0#L2U)KH-IO[+IRZ0*$'\P9.0,3=WQ88^V6:;SP&;+=35R:Z9
M6)W<34;B/\4JW/6N]3?0S,E0JY88_2$OS_$\TWAV0KE[HG8G2#W--EFYC&(:
M*H9AYN047D$:1:F_E0FW_ZX94G13$T@U?0S!+BS]-?>D[3VQRR.^44UH+S\#
M=.FT\-/&LL/$OC*%"L\,$F96\#08D&MI76B(V'3;8K;!N$NZ#LO9;M^ UJV\
M#GO=!@PM/O@M['$[SB2*JX<-&'U5;D=(8PK&X"$AXO2E[H[2XB@$EGE[^5BR
MX]TAW652_ Q=>'OQ\AY;Z0D!X4GT[N6K9P%I(>FQ0^4NQ!FM0"L(][$_I+XU
MDB$0EB_OQ-';I&_55"0Y)9;^';*E7KF[CX$"8ST*J/>S=,UPHN6Z,(<4ZL,]
M\0)S8* Y5"#PW,T@2HCXKPEY%]V5/W8WY%DRR7(,^Q^4%7<='?R]YL%BO+;B
M4<K&F#DB4<%Q? NI?-I&%B9ADPM?#A?C\TY?AJX*'E@,68H'0O2IQY5P@TXK
MF.^+!EN*(S*%OU^4U4I^:%L^\_K(2E,$@U=5<4K4+9R+C3E:6 M1W4?NW9 X
M3R TK,TC%8K'Y)!XYK.%[K&\38U0^#;("RB[3ONF-;&.[;@CUXU+@G@#X[H7
MJN/FIMH.J9:P.4,G:>C,Z-"Z1EI$[ _BDXFR GP7Z7E;VTD(K<A"Q2+%&]$U
M(I2@]10-C^8Z38OMW(F^*<$#0'4X]VE,?N.:CA%'T=_L)-TWL? T)!2_]>1=
M!]*A5=T&O!@';F5>HI8#UW3X@=E\= %#@\)9,9VMJB-/\HQP"+[47W5;O'RR
MA16/S,0OF$D[:;\9-K#0,M4.YZ0PQ=:5*\8XJ-+5(P0W&4UZO_.]C_?YWIW(
M]]Y5A'*';HI7<W40NTZ#6CG>7NP0*OJ6N.A?>"12P6U,1&6B6HDW-^A21EJ*
M&?-!\S>636VQAJ"P#Y[O@O,H*^_.NB0E\Q<EE.,>4[T<G @&QUE8)K#GA_',
MB0FYV%8C6B_98HF%T<;GJMG;2C49'P1HR"768"!=B3MA.IU^VA*X>W+(2YU+
M1P K/J[[!\C1O!&P'+7<5J<A+\L/KIQ9*H*X7<>^3&4/2[TY+%5[TGW+S?/P
M4'+S/%$=6>W4H_SE0/BS?;L'<4SW8.F]5-ZQ5$I+%B^53'X6'9A4EK@Q[$>1
M(0_>6 4?(V@$9@.;<T@ 5F'=T2BF/(JNJ655TEW;$76BG\#<1^Y]"_ZJ^D7A
M#W84ZSO48S<XY!0&\NL+ Z@)0)8.A9($=8K9.\*.552."_<Z=6AR@ Q>7<Z:
M5-O\PI=O$)Y)PL+N,I7LWV^M^$.,Y;M.F89IN/M.'/23.@ /F)KY'!Y%[TP'
MP0WH1%T% H-\B:4P^..[703P@%'%\>IF\XW/D::08 _A$_V3'*#:C2L)![WU
M="V6&]$B ^(7GCC?+]+^S-U,@V%A?0+M"WO;:T4@NN8D'YIBVN 3C;7:F=O]
M!A0XO4N)/9J0KWH8E@4'Q@<*@,6"R>S(\G,P5M0R[<1VKNG7*BAP%O83^S$)
M2F']K# JG!7$GNK_*'$HQ2"]1Q@HC.9S&^,,QE$E[R9.=K,@_REH=IE*J\LY
M)[WC3EPDB8J66ER5V+E'=H&I9:E= P=N@\N$H(8%)]#]3DSSLO;\;)I%@M4B
M*"E%;4[E*.$O^9RZ/BQ<O$"<M22GL0MWARV)-# ^YL.)O3\(8^:P([MN,.IE
ME;J T'DG?^Z<L@GV-+K2%N(-]3,SW@E>NX%WPJ[IS^45-0UD<^+1,2B8XX>/
MZ#7#B%;LS^Y2^?"F@\P5#3'(E1U1Z0>&N F&V7F$:P<!X.)_5B#4GUI6F0 ]
M<<QDE&(K.O_&9UT/;5TN4:]]]4U]!M&^#0EXVJ:M4I,T_-E 0N>"0$5:X3HE
M)*I CP.@,:)W4[XA^C4N=MA^?%AR-<$8<SD1\&'IHPX."=W)AFS70RNL1;%+
MW1_13GCKXQ$>&KR$:VCW!J(AW*,;LY-A39/>_PCOS+"F;*#>BY[?S1N1GV3?
M@ /@OI<(@,*%Y6M$6N".M/T<&598LJI8_^LT&.<B3:7A+UIT!MZ33. 0:SM>
M=Q[QURG&PWF*,B^]8>VH4.P62%!E.A=3?SO,)FAZT)4 >A@1/9#5&+^R=SKM
M6Q;)!\)7@QV?9#GIH;\[[,$+>CJLVTMXO/P+WG7@1O3W%R_=GUW,CK0$MZ]R
M>LWM0'?'QO(,KD>KB!LO%&'=+()ES8IDO'QCX4+?+)"J&FHDA!X=7 =_HN>Y
MW\-2D=>472'%0\\TXQ13I]/0W$]I -6F4S/AS Z*#*Y&;]&8=_G,.!C6E#D!
MH8(5E8*-2<J^B3^\5)1*H/.F$W0=RP]UTU;A >4]I#5P&W.M@FUO!G/6:Y_^
M&S\=8YWA%2D\N$R#92:;U[W[;D%+272XK?6B\IN.YXFLI4[J;U-SNFTND;'"
M :JMXEP6]TL,BQKAH%.MV*!\B&LRHIG"[6.AJ;W"N-_IL"?[=-A.I,,P@D*X
MML <%NW?LP1ND 1R5CV+F-JPFX]]S[APYS[0\D-?8TB$*(ADC1(X6&X?)7$P
MO5AN^Q&4$[C?>3J[X*!!QZ3IFB.]P0_9 ^:2CT-;/^LF^ ,#1FYT#$UTAM'[
MD\7GRL[PO6I!G;97CM-+ X/?G%':^ 5\.8C_ QZ$R[!R_LFIPJ2.>F6EIY.:
MJRE35;FT,'81I:VS7^'/--XX$/.ZLUU.NNGB#4ZA"[I<T#FL.$)U\O"QZ^8M
M46#QZ[=YSTPM0G+#+DL,)SOO_Q*K, .8J+$DQ5V\-5AE*&)5#%43P&VL5C7(
M=T^??+]/!N[3+C=MP>3+:[K@:+I,5#;!?RJG))T(7DJP9IX8:(8!L-N(_9X/
M;"_ =R3  I#T,BHNB G@6;2.&$O!C2(11/[=/*OJ9ABD@08@.!R)\U+CP7R9
M5O1P(/<'>N=>W/?B_KN).WDJ;,ZSG]+W/ZBD#QRLE&6;%+EA4IEK?1/]7D,<
M+JTV!:4-]I2'K87U0>0 N+(-AK;Z&E)?XD'Q$&)/T?J/;HZ>9D*6M"_$V;GT
M^OEEMR*$W+@%MQ ,=H9MQ$"_F'(D'WVI!N_A*1BP'%0JYW/,TR.D&Y17 ?]9
M+HD> -91 ,(X!K=RXI,P&/D 'D?1*?[F80],SA[A0 3(C*!?N1I'R+E&=<\]
M3ZL>*I3KMK3;C1Q"/R?N([R#CKT_!1T7/X.7)I5U[[L1OM 3V82YO39ER^2E
MD ?/.[OIM^#3ZH^-H+E,3MV4TP\1DK8*EPSZP)SXMR  "L!FLRRI,JU](50$
MKA"N3TU]!&'5.*X<S.X:DX,>36!+D6D*?RFK<&C='TR3JB*NH;:AWW0=[!N'
M)\/\5B<5&R8K)#U1TKH$BY 4:F%DE2$>&8Z?[H)\=X^GBZFPZD>Q"F,J@\%M
M22["WM#T.?I#-T@ +"+]S9:69JA@FU&%7%,$(@V%).X6PM?];79^Q;(J\=I*
M/)8$-P=U85A[ 3L4#]AA-WZRPRIGSA\?>^=1%)8E2?4:QW^"8(M7'@>)A*VP
MRDT/^"TH#8(;PV67;?(X))6@L?7.JZ<P<K6 0\7TKJ*YGZ*6:MV*0B576=G6
M!&\G.9F%]!%="4.;NN6@'0TL6#%\^\%$$Y8$S)JA=(]OYX8J*T+:SW-2R=Z@
M&A@I9P[+ZUNS300+O&Z2'6A6<F-AHG794/UVZ_*OH^@9^U*(<_'YNO0C7VM:
MI4WJ5TK Q7STE%Y%B@<(3Z,K%U/%C6EKU R=R?%=[* Z0<6_YE_/+UMLDV3H
MKKB@H?3W04#5$+[!9NVZ^:,OJ[3#4E:\<:<4H@7OR5]47>N\' P;UBZ:4Z4Y
M&XRB#WHT#BXI][DBUD.%MYW8_#(@?%C+ON!#](XN8CC4ZK\HI8:KD,0!LQR5
MT#BD,T/BH"D.IG(@$TH)6K@?76&*T,//Y12G" QUF1+'@7"$=542V?4ED^/!
MXJGP@U&?]'"XBGH!5S4M9HEXA%W$R4H26?@+[9Q.873X]4RZT(#^_ V309+C
MP,DI3/OD,1+/.!B%,$#("P6-S00Y] J9B["K@%Z2.0;4[1Z]DM5J:W"W,P>2
MR&HVX1#?=#XH"CFB%YU?\W-2SY+?8O^.Q%!9N)V9]Y;^B C8&'A '5V'7".F
M_AE\8]\XO^:TZ@2.-*5@Z2!0+*I*>UM(2M9IU\^6D/%8$)\+4AY]U45=!^DH
M>C%"D:-V.-&PA$@SP0DXNM+/-L',X 3H=L?QT#\V:J*=N!;6&)F?:PD7;=U8
MZ[]C9--A<DY ST;,:H_D&*REYPM,R=1BM3/[T*;!:(7<$%WLK@_D4M9B+%W'
M9B5>-6OM1]1KLAZ@^D+/:B67-1)#X!3=ZI !YNB,7$YD9+IK1[?&LG73NZ/U
MBB.,''&G+3?VC$-<UWR(BGS5\2^DB %]I-]9*-G=FY<:P*? %[,AU)^&?-HB
MK.]3"5J@7U#&H4/@-OJ^>EWZ-Y2;'5O?4YFS\8L;H=YVLTD^.EX40V.@(/R
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M9)JH_JN2%G:O$G2H6QNO,F7YT&@KJYH;AA\\VF;%O*QCTT4L^F->:6=L-T)
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MUCIP0]A6N7+C::>S\&[; :WY:I!YKS?SE^!EP211/W1NLNVM@-B0A;K-].)
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M&51@Z"'2))I(3 =(H99?^-V%P8P2\H6G3I-_S[W9(R67V@)0%B6[E-QIZ%<
M,#G=7DK%P-T44ZO)=S^EDJ "]TN?HEHS=2A]@_3I*M%=C&? TAFZVWT5B@/
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ME3KLIMZ[D9F39#$U5&\"L=/I+G(>JPPFV<R5IMF]S:2!0_U1@$<Y1(H\>VK
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MNJ';75NW6X.V9MB&UN]MQA&5A0ZPD3IL]"\V/:!L+CI+@*YK4N;I:KIN N<
MYU27@05  :#(2QP "@ %@ ) D10HRE*AAGI],5JZI926+G<VAI)MJ;FC)O'V
M.D&TZM!5RY5;_Y@02&6XN $H !0 "@ %@ )  :"H")0ME1W"=&3J.+<*KYDR
MKFK]9;?=&EB:U=_L<0GI!\ E($[!!2>C("U8)G:4DHF0X%G3!,]/SR1TO(@G
M=T(6IX)B#[(X 2SG"%/=^ X5TQ'Y2,1_[R=4.#],4ODP'*?Q*V$U?$N2*]7+
MY.R9>FO0L36KHRL1Y@(^JC,?\=BO4JF<O=:@UU8C0@RL(Q_K@"4/0 &@ %
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MHL;*!3E@Z+V6_;/2O/RWGVR*\/>[6%HP7<'\>Q[#TVP-+,O6>IUBFL$ S]:
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M3D,"3P._U) $'B5&67 _6^)S=X(H5M/1#I'/QMW2H+TIMW7 !> "< &X %P
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MZ;0&IJ;W-Y.FE$0#& [-8(P2;(DN8PRCK8*_&6Z)1C-#24/N+)MQA-51X:J
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MI)0 0T'%[<N1I9%QJ'XDH_B&2@#"Y4*%)D*O->C!G%XP$"1!? FF@1CS97<
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M"/W_YV0G1V<OS0[&\7KMZ(1VK*(DT190!!/#\[Z1C;CU[/ULBU:>Z"*T^&(
M8CV"1;3?(#T7Q=]#*.,&,?4WO=[W1O[ NKZOO=+PQ=OSR\'9V?/;+O4;H?WG
M!_?;H2=M"_OM4*\=[219TCK9A;SB*U@@AX.+/LNRWPIU1>EWOPVZ&KUX>WW3
M:WQOV@^GY7O9 %U=G5^^>#L>C&_.CT';^WC1D]DFO1>PY\%B#-.D!*B%T^'X
M-C@]WJNW]_JIUZW]CSB,4K84UO.DTNV._/GZ-;R5CW,.COU-7\FI=^N[- $V
M]^V;3X +VMF.KOHIT-O] ZO]YLY^?;7/>/TW+]Z>GQ^%YO=!CR/PYK^D[$BN
MP-IKKF-.>A+4SMNSX<U1RJ97C0X=:=U-/^.4_RQGO"/"=ZX9AL[4$?9MF*Q_
MM_"4!_KZ@,&,*UCV^N+-_9[G2&;$'B(=UR_>7I[UP;U^7>CN+-A+).3B:@Q[
MHLOQ44R%\CT1N_'#193;Y:@-Q=7I!;KX$S^PX>WP/CWJ<38P\'^O,M\_.G8T
M@U:=7N7OI$>_-D+?I4U5^YH.38,GP-;V_$7?C[X??3^Z'@55O6<SN%)T\I)R
MZ<DO5PAP;V<RP^,\D_GN1Z9K6&8XXV2\-,)J)FOMYL<R^QOG/?IO'>]3WYN^
M-\]S]G1E9[7O+NZ;T. =K!8?7?^1<G7^&@K[D]>ID[OKLQ=OA^>#JZNMJ<=Z
M9>V&C>GM39>Z>%SV9O?GHI@7>#.XO"CBHSH^D$]+5WN7YBB'[0F8F/W [R^'
M"+^_&EQ?CI^YH=GL2/N&&U^$2*\XYCNV>YX) &K?AVWOH,N3P&E^O-9J:QZY
MKQ/?M8M7?_(>1!BM/[@['FQ5GROQU.70R^2H=*.;L:0>@[L!!O?6^F?LA [Y
MPO[4<+S(].Z=B2L,,PQ%GUEWO!:A*SO&;L"+XL":F4BW^RG1\%M2<!U>E+A.
MG3B\'E.FT7'4P#L2;Z$CHNC$24?K4V*G5.Q(3]U3L?<+0F<7A'T=_<$\&!\%
MR<PS.8%Z4N[_(O 7(-HE40D*^&J!H.SCVP,\)U,W'!ZE;'K5Z-0J^$7._"^N
MZ46WGOU!3?[N[H\P"#:\/H:EL-\=]5-CKSB4JQ=O;WKRS7ZE.(;IL*=$O8L1
MN$K'0=O3AU>>S/XJ6^ J!,W%;=;$]VRF:Y_[GEABAW^(R)C"$/4!ES[@<@3K
M19-2A]] Z\.[X'<SB@,G6MY-):#.=#]Y813$E/?=W6W&#5+=GHW[XC;]/N.(
M)\KN-QTW9PA^OSG;&OS>#>WH5Y'G,SGVM 4Y1]J<\V-82/K8S1'L+7*QFWY3
MT6\JGOARD)Q!=6X'48%:N1GUJ)5^X[#K$]GCVB:,7[P='0>"I5\6GO%,V->>
MX/+%V^%X,!H>!<RWCTP\U=V#+0+GP81)(13SE^GV*2#]YN'85PDN*2[)9;_[
MI/6!>)]H>[)B,/CW<'&&&RPL<W84!?7ZW4+GM/_D*$73V\5GJ1F;L78<"]'N
M.K:.OA]]/YYS/_8=6]H?T]B39;W9$<7TRS@4MN%XK^#_]3AK#L]J]12YY9X6
MC5S?FZ?=FZ[UJ2N;B6?(S-@IH.@-GN0/AF?%C+2.#^33TM5.G#SU0_C,S<T>
MXNA7+]Y>#RZOBW4I.SZ03TM7>X_F*(>M&\"%[6S,?LN_7PY'E$$YN!H7$?Y-
M@U1'KKS;'& W8G8^IEMZ;$C/2[V*E_H/$1G6S/3NA>%X= K8LU+W()/C"J:N
M6] _>5: Y8O?"_[WDX=+_*UGXS](E/  2[ 7A;\*6'G%A^E46-'=],-/GA=?
MS4B\H]\.>8QQ@SB4P:BDO/=1ZD4GS@.Z(8KG,45VOO4>G9UA2OCE>9_IVB\<
MQS(K]D-/>GT%4^-J<#DZAJGQ3))<^ZU(X6J<5 -C(D!('H(._*FQ%&;0[T?Z
M_<C36E;*%Y'<&G$;WGF[]IA&F/0WN-Z^,F8W!K??5!R[GK?L RD]Q^36L\'X
MIIC?>I2#V]OP8]3ML]WY]Y>7,@94)-+LW@AW,R+1XY&[@D?F;31Z_[BIA@$R
MA-Q0&WYUA.+P(<ZGB#EX6O""OC=/NS==ZU-7_*5C1^RL\\56'+S>59S8'BR2
M-SJ[>/&V!*O3\2%]6EK;B8."?@@[;WC60@5;M#R;!TCKXP:5"<+MXO7V9%^]
M!G?#"'6G3\]@V)Z:Q[.G$/1E[_8<49+]\+0_TSJNL+GP['8#YGO3G2-8^?;3
MI;XS?6>>W\S9P;K[;]WN7/=#E3LZ^;H&%_!\<':S=93RJ+2Q8_/MJ,^^^@$\
M6INR(PC;35L0MEXENV!3.M.EWBWIG@G9Y?'465L0P:-2R?(3*OAA3ER1>;+E
M"C.@7L[P2.9G<O["K]#/?_"3%TIL#<%"^HG0=<6)T)NRMW48T%1XOGS6Q2]O
MC+)3N_P3WJ0W79Q>+WZ^>#MDX1K?9P*FRWQA>DOCP7=C+X(FNTN9T&T;3A0:
MIF7Y\ 4F5"Q C:PEO,.PN/K&TG!@K@4BC(R%Z=A4IBP0EG >X&8SA \# F)A
M:7$S1P0Y,$(AC#_\2(#J&B7G3/6E.ASFA_ZR>T//C6SZ K!5(D")DZ!&([1*
M1A@O%JY [ON$>-/U'PVXV7+],(;QZ 5:]0)4>51I4GK42 \$"UH>P,<>J?-]
M %)5FAO-1(ASQ",3:D:@UVDAC3""#Z@$02UY<[.OZQY<[URT6GNVL_OE?=;<
M <,2:"?6'NH7]>Y@PFE;[R[*-*1"<IH *%Z1[?\9?J0%=2:4//K:=!_-99BL
MF[,D1L0NQ%]NZ+\W<MD=0R/9<1B>G?WRXM^KM./T&NOAI TRT-&XO$H_XT:E
M'^OQ!H,"#M DTY@%Z'3])?(MF(+H'.#D>H>>FH>E:,P2B1C_D?M9HEBL5R^R
MWW._KD\O'$_W23$ ]"83##+CR%>?!-QB_$@]#GT\F.R7UV?#X=6?%R_JZD?M
M&?ZD8DYU5IHCB(9]_Z\/7V^_?WCW7W_<?;[[[=.';\:G/]Z=-E]-F[:RQ#P8
M6ZW8>U:ZMNSD'[0<@\/S3E]SDWH^QK=DS>TE)D%FGSQP4_PX-+%2,)A5W-J"
MS$A2H6'[KFL&X&['GBM"N !<FN#1 :^&W!?[5>MR'!ZI(/\;=J@A!L)!>'_X
M#V(^ ==[#'MNC&C0SQ'M</ DH9;0N#'G!](S[>UMN7>9+F90%*,ZG1P5#RCJ
MGV^4W-SB&6)[AR#K%>)0_L$._/TJO\SX1QQ&SG39HL??<>,!^\H S*DU\T"C
M[QTPO)\\Z]1P8&MI3!Q_,3.#N6F)F$YKDD.7J6]1M0P?3;@P;/$@7'^!RQM9
M&KAL+@)<]YQ_F:JFH^-YOJSIB*;<7.#+3-N&;7^(&]K8FXO(F N;WN0)89=N
M3W<P=,/SHQV[]5M\XR66V!R=O2GS1>BKX1LL>6*YL4TCHT[.:$VN4 \<9#QD
M>YS!*KT\,?Q'#UX?QI/0L1WH'ESW,O+O!0ZT$>!94 #?@W=DAO0*V:1WK$ZR
M%?Q4#Z3FV+$)S\U=G7D\GW$8V2>\ZA5FK<)(B1DS$*[O">@%/ *U0HYE;BCA
M[?57B.%A?89ANT[#__@/"@<8EG#=!1@J>-I_OCA[07_+I]/?LB&\QM-;#"L&
MA?>B=^@E)*N_,S?O*8 !KS54]./L[)>:"BB?8J%?O CA8_4;[L)T<.T*X*RA
M1W)D$ZY^:3N84O:6<=6A?_ZDHSW-*/71,J+^]M^__WKW.2/KFPU5Z'J<4Z$*
M.0PKY+#+(:@I]STZ13N ,A=7JK^>?CL=T'HU &=&N2[WL$,*T,1-EK2"[/;0
MAZ7#_K[L9EO/<R)HH%6\_+UPS4>,"_PF/($Q@7=^L/ #]L,^FX\EENZEN@<6
MT%5R-!:!#XNSX&4Y%,&#8_%:O!!!Z'N><'&1KW :, 3$D3D52T/J97Q29N>?
M7<,-5F>*SQHJ0)L9-([04H!6B\_*1>;(/(!J;[QUM2T$(CJGR+_&L"_ HQ]-
M@4/CUHI:/]6L(0OCY?^+_]=?1N/QFXFP7K&KBH=4<\=R7*H;:&@7#& 8/-,V
M:3HE+A?<X/H6>>IF9(S.AA?&%R'0'P^$B ;&M]C!J#+X! /C=^A%P,\SW4'V
MV?\UOC6&WZ^3EY0Y: SF^".&?9AC%3 H[Y.0Z]WT5S-TPKOIET L3!;RW339
M*Z1;A0\_02">&?G!LF82N0@M<X$S+H@%W^)XL;!OH_]\\1UN_B9<04@36=%A
M=#5.(6ZC\\OKJY)<FY43-U']3CCO*X_KUT_?K9W]X:E!0TOF.1W<RGA>#9.R
MF5RSF4SGV[J;G1/TMQFNMNE&O+:0-XM5;7G(77N4V@Y5WWG&_XG=);NJPQMU
M/(V+V:^^&5 :UWLG )O@!^ D+-#70$N9DZS<^#MA& M&[OAQ%$;P"QXBX<D3
M7!3BD. 91.:L ;^AP4K//>0!UD1-%-P1HY\R]>,@&YPMP:!MM0"V\L"7PQ-H
M[<GYJXR.K1*")LI$"(*R:O%@+AV@\9 'Z-2X=5T^PA&>E;ALH2B/;8'WAZ_S
M8@I"@$ S;1D87^()K/7&';PQP/'ZNQD$)IU2F;":BJGC\5K*L*&SE^:K5[ 6
MHNF:P5/676WAU7<+=A0JKIGA-6PR4'_ JX+M<G6#43,L4C/;<6.\!=;-$/U=
MOH2^PBZ+GWCB"7)9!,HIQH^K.ES6*WR4:OT,6F9,A/! ]E'@APL>(3P4LW'U
M$PJUQM$P%#P,$JZHW)J$3(Q/R?09A/IMPJ!"'QS?#G%Q"!&/8.<][RTFN]&O
M*=NM*6I*295<N Y,-K'!XMWNHM"M \X:?GN],_+L:;(V^=AQ8@N"Y^*!3</P
MZ$0SV)I!VSR:4_"TU!Q^%;!;(=3H-UR68&E+#^$_??SZ+;&[8*#D,B8W==DG
MWJ8(UO1!O%0FC[O]]FMR]EVF&YEM0%9+LN<T/TO&_V=F1*X7>HFM@M)ICRLY
M]:&/TH?QZ.HJP!I0 I&Z3$Q)]I_R5V^*.S,: \^JSL#WC#P[",)LHR&_+AWR
MSN'!&JT$G4!=M3X-&Z&97B8;^U=KYN86[6D)*U1I-;9HVDZ11T<'%SXT%FE/
MX/-G@T[:I3P/!.:IN?,8'4##=KM8U3H0;'FATE:'X\=8KTF%V'JS6Z5R.S^:
MVY\(*_:U._65BAY*HYWS-F:*XC#R]3S9,,!1&?VHCI'<+A:PJ*;7_CFL]L7;
MV,UUSK'8/5Q^K[-L5_"NJG/91X%'E3'XT &\P.98/)X]J*.'DB-XT-:/8A+$
M9B#/A$=G _7+Z'PMU&YUZ[7Z%1(2M7.!%5_)^=NVL&1TN;(EM?9;#8[1BDTO
M72^:6M???(Z!@$4-/-@,P3^1Z7C1LKK].X9#'/^DN@WUI-J,XY3DV99-N0%T
MW3/O>;$#IRL0X0(VTPZ>Y-#L0PF M"F[W%L:XH%6Q< (G4BN%=',C. I2\R5
MCF"3&T\B%;#2<*_#JS>A84X<UXDXQUTN(GB\:!KWNDJ<&M_B"<;*(FPK/S 0
M]S#S\:+-GVN(GTX(5L:9<C="[ =\9SL4S!C0"2QT& ]2$;6H8AD#@OLB(H+[
MJI_!8K\G I28SK[@_3/?DP B?P+Z*N$@#!%>&E.,:-C0.CNF.(LIPQLX2/!D
M5X (!\8DCC!QVG"=N<-1DP&X7<8<NC8+C6G@SY-=JPR#G:DPV*?L$3'V'!'3
M(;>\K-L\;&%!XN@%1'5%"R("'8")"=^%>+;Q.&-4-2FC:WJA0M]S$ CZA;(1
M4C-+V_7H4$AO#CTEU5OX(>MEH:UKC;Q^B%)B PHF(&O[:AP#2YOTXNU'G_N,
M3)^Y X;L4 TRX^1XA,7%.+(G(@[>@4K\VSJ6EB^!/W6BSW!Y^R43&A.7#X?$
M]G1S4620,UYB4TY:Z,\>B=B'HQ=OSZ\&H[*Z7?FU25\J&AOO-W30U(9T-J>+
M;BZ=\8NWX^'@:E15\Y[A9S/3!I6^YXP:8M-H5W;(S1'**4^6L8P-I=9<0JJC
MC_BTC_"8OX;"_N3=J6?=)H_JPCP[?_'V8G!Y=5TUS5H6L6+&VJG\]CFO+UZ\
M'9X/+F]&^YG7NU:]?4YZK$UQ-;@X&U9-^E,#7%%P-:I6/3(!YAQ#QNP*U!+.
M_NE0AU>5=*ADUR8^QGCP-W#+!#J"P0]8N:<Q?=RD?W?H*+WC5)S$1;\%-^H0
M++##ZQ=O+P>CF[-"KT_[;=EVI[X5I3 O+J@*IBR%N=4;MK=8WTLV5Y]]TS,^
MP@-H'X *"9OUT'@ &?DQ;!]@HGN,%>/T3%QZYX[GS.,Y[&#^&3LVWR<OPZU!
M(.1YCO)_*8^6-@9X$ #_)]/D3&'7!=M-BSCTR7*(A(N0YIX W>,]P<P/HA/H
MZQQ:\2#"B ^4)J9K*CP@@M/@B>ADR]31 7+V63."IP6.%7'"B+8A+J9ODD32
M7KT,,@QBPRNT?P8B.."Q\NZB#(R7IH(Z?DZ^_)5N2E WF1P6%W<2 >-Y*/<U
MW9398DXH_SFF)..."G?^2[WUV?$CBV7^P*3F!]-QU;95>TM$6"37Q8Q+3(TF
MLCFT1DI<*@M7VX<AX,]UY4"M-(W\"(0DPNW_(" @[RP#WS7,^T"H<PEN*/0Q
M<.[OH5G$'V:!D$+$F%0=Q7=O@I;$ W=O%%9".W;TSM6Y'+_Z0> _PI/"3Y+4
M$*OB4*2OIDNMKU(WL#B?G4E ],)W"&R419$=G6YLT]):(:GNK68-L[N:ME>!
M\!6+)B:MJ:-)'8[OHH642\6I(3, C/&:@YJ\Z<9E)'9IYRD3!J5!G9D/ZN"R
MD>&VQ212-E<N*8\F6%"3"$ Q2T L(L:NC!(<_'L^6)PZZ/N5=(  =X04A3:$
MXH%R+V&N>G8&&I_ OM_!Q4YDW"K+3/0(>+DAC^U5:W'M#26O1G*&AZZM@&M>
M(ANIIY;(=0'J?\^%(ZLS^;<(TATCRO2J1YFN1ID6Q/+V/_*6L42L[8)/GSSV
MM X*X@AP,IU Q78,%-M93.S.(+$](K8-1.QS!,3V>-C6Q-?#87LX[('@L#T:
M=G.\U@'QL.L1JR58U";(U5&E(U][@U@VXE4G/KLELNJZ.U(S0[;),04?QM!!
MQVOCI?.*!1^(!R=4AS'%($6 X85 >L<J 3URY@+_<ETZOS3NK,A/ YORX 4;
M-,%LW.A1""]SG/%O6TFZ-'@8S:*?KW_GYB?'4%_3QM]2_+'6N>J?OY*>W$V_
M8E&:W\GQPU-;/+2ECVY_X@GM#D*-HS-8W2X&9V?%6*.4'#J<'9?>=W]Q"-$-
MJ1Y6M>@&G8+)[_B8=[)Z55]/L%C2K?/3R\O+J]2HLW>M*,7H,PR FO OH3RQ
M+%#%]Y:YR'^E3KC.S\Z*PE-7^L%B9GIPZT@BP//+0S'<2Y]$ =R%FJ21>/J/
M_)Q'V#/D! N-F?QP,';Z$_L9^#^$VF;0]SD&&&Y;O=/_'&[]))HYU@_D2GL-
M5MF)2.CY:Z2D*[^7KTN^G[J^&:F>*M4P6#>,_^G,D>0 1F&E ID:272RHB0$
M)A]^_?3]_6V>J&7EZC/0"8&3JVZS3TQ"O1$LV +AKP\R^CKW,5@A\'C27<I-
M.5']R%/]?\9F "H3OH&%3:UL-G@RD5K9Y 5PLUKC H38QB)Y%[.R@!@L><^<
MH\M5C54W#F") ^_"P[N2<+1\';84/R^'_C!Q,C2XM,6+P)\Y$XH:&.8] @RR
M.&L90RDBNA.Z-\2_F_>!N9BIX?$7T'F-BPGDB$X>>P?W3LB!D 53WVB%V*9.
M,,]S;1!\6E6V<F18O@!#]\ ;1<PR*MTI0@)01$F8B;'.J1,SX/ (PNX]Y)P.
MXX!H.Q*0>1+V=V5H/ V^^ 0ZH% 0@:.G,9H@8^'CD;A#'.@2:\"1(R0)<J9X
M:9;LS_9%2%CSN1"1#/W+Z UN-RUA*W?+#LQ'L",X,?A[BALQ!7><  >J'3(B
M)U)OD\S#KB0QH5,_XC1R(M2Y$)1=LA-)(A0<>QVOX/1VOK?S3>U\5(9A>^+.
M49USCQUPL.XML;*'(&X Z:N9+T4[X'8SE! D^."[#V#<=83?/V+[/ETFD+(V
M6:JE7V;:,^;V4UM_#64@U^KJM8=72W]"> 4BA8X7:# 2B!XOM"]3 &.2;$1+
M;, .D[YTPV+JP?(8AF:P?#5(H6F8,R6=K3!AW<M""O$2<%R$%R+O8?I.O#(0
M?G /'H8L2()P2#=3R 1O_OJ_S/GBS7LMP>$DK?9ZB6R$Z )1>( PE;BT@PC$
M3TL(.RNJ<C>/&GY/Q-P1"FL*P^1@ZT$L#F5RI%D62874\-3XYL^%(=R4KBSM
M>*)[G V& $"$X#BVJ+@NP01*&<+5%CX>] 4U;T))CK9C29YB6'-".JJ!5LS\
MV+6KWTWNCJPG 1,KBX^1"7T@/W#VS=B-ZC@WZ!7C;+$4Q:$=@Z*"R,''A>?1
M8,,-Z#PP0L9<()UTXDKQIS"&/S+>E2MYUD#>B1LTH.1+ 1XA_,LG5SA&E*I'
M*$T&X,OS+\W%3"IHZ FW@7 5+V-I#AZYHA4)@N8$AF2K-,^M25)JF?:JXKI/
MPK179=*7< /B!F.>RZ#EO<7*Q$X)V,6;L]N>W+V4\LI6 35'&EJ$%X%>D]LN
M]RBHZG3K!/%P[,Z#[<2IJ*FQ)#,-K1E:)/K"=5BQ'#6+:+_ _96O8[\5OHD#
M@@G#0L7L[+3KJ1*6[9--4+AF[!OO_C-GS989!)0'_6"ZRKC+2MV8'"QWFEKK
M\^WE?2&,1&+\.74:]PAROO+2J9L[6J&<,#-KV23*K&N08K(0X:J$-V>7<4;)
M(G00>TF4Q8N ((=3SE:MD$LAFQ@?D68ZK]2:Q-J 9V["?EJ#->;E6 &R5YCS
M='W$S "/X?[J2XLL_42HDWN[M%3T:CQA8P:(_?O#.^>$Z##F\3J+ZEL-!]I7
M/>?. ![W"6Q\^JR:/;*QY_OL^3Y[=.-:\K5G &_L^3Y[OL\>X'@$JWW/][FU
M"!,%G L3RXVA#W% <&/K9)^)H]$<-3EJA)H<;X^:[.D^G]PA9>%LI^Z1)8)!
M<H=9Q"GEA)$?R%+O8<0'7 .*;RPB/-1:6PWZ>;!^9H .18TKGX^Y^=>PO/2O
M=U_??_AZ\N[N\^?;+]\^O%:_E!WVY/<QLC3UF7[4\G9UR6BJ&$T7Y2H87_V2
M]B.R2RX8__(F5W 8I+*FS'-FG*NJ,I=ZN1LXE5JIYM(.#,LZ4-GIQGVM99QJ
M*7ZI[YO94"25E5<QAPPTZA"Y3%/@;VHZ 1\E#PQ-8%2*M[02;S\K^EEQ5+,"
MAM]YR(2!,3B<H>3I)T4_*9[7I-"#JQJ*(1/Q:*-V*<);3F"J1:ZP2URL5MY!
M)3I/)@A#5YDO6&OS7CK&% DOLP&:#'I#T!N"9VH("':GFX/RF2#KQ_)DP+,>
MOE%R+C$V8F$Z="TB2Q!K2+ %C#+UDZ>?/$]Q\K2^E"$,)UJ>*%S4/M=,Q9Z6
M73LKUT-#)MG<8U5KFN3&(@["V&2.,RZ!2V5D!C6.T+>/X&4S3UIZ'J),':ND
MP!5*;Q,RA"/K9^MJE]&X+ZQQ13F>UELN=E*6@D]<YR*:8=5T@HT3!ISF0$;_
MX4\$6,8A7C.- TK"2FK07YRN@2<<OI#0Q]BS%%8:?&2YPG-D@S/,K!4UA78H
M_?QY]S1M:-(NA\&T99"1I'#V7[^]3^IFKP.+M-B%6]?5=AF.QVGI,B401<PI
ML- Z8V:&?&9/1]>L:P3$%291;BIX3/>5Z:\,&(9&.W,:"U0IS$OAA63#4$*7
M@E)]JE2-4%6Q<E:]Z!7,!\NGF8*9#Y0:C2Z$ B:'>@X0\9S_$#E=(XC]0LN[
M,*=3XL>FM" )'5<9MZN1YFC679\,/A6PI+QF\HTJ[N&WD!,D.UW:296+4]:<
M3-)3@G"7=:[2F_ O+(ZT#Z#V40;MC@26?5,&RY:4JYDO\G[ELX9K%V65%T^/
MXNY1W#V*NT=Q]RCN'L7=H[B[A>+6-;B6^/:H-=R@UKK=, HA(PGX%L7M\P[U
M)!E_V.?<"XVH!O4#G;/:*'CY'"I,M CA8_5;J8!7!S$,BF*\*0MCT %#[NP>
M!?AFS>E]=]V(86FYC=71BCH]UD\3Z.M-\ADJ QWKPQ7=E7BWTAD.EGRP\NC;
M<F$QAV=&,]BD_%0C76DO5]KBZXZ9XNN=+>!MSK"GD[W1X.2V3R3:)I&H>?;(
MN%'VR'EE1'S'5=O_3Z(LCH<$&2[Q4VB4D MP6"T\*>T# "T& /8OFD]:+(OY
MBZS (<]',QCK=*#TL)ZR5Q+R5IW;3/ QON(QDR?F@;!\N.9?*9ML>5B!@$D"
M.4Y<_W$M95+G='%_X5=E8,OF]X%1"+\[+BQ.L/4)4[C9U@G#?:P.\3K6#$%\
ML,;@QDZZVI+5"&8<GE7<+Y'V+<)Y;[QDBKSQ*\7U%.I\:W,U3.DH371J:#-"
M_B5%9408P8#FZSP=7[(%BMU*PH;AP\"/[YDKV0D18F2)JN B/A;>1_ FK4"Q
M0B^:!M&^2CY[Q69H^0MZ($4<1Z?&+5BM /?L[I+9[338AWQO43BY(*!I_3-V
M0D>^!YZWP)A6)I"9-%JC;TSHLA:!/U%$<,0=B<)3L4 -O:5+#ZM;(K6=R=@(
MC"(2OQ\X=GBG;'IV'+B2@WK$6@NY/Z?B]S3@&V,H-!42D0N"ML]9((\S0=";
M$OU#C,Y"!+1H@=*<**2[+1Y@/5C0TS3YI<A7R3 HJS=S\>0L>Q8R_1$Z+KU=
MP]&3G)E><HE7QB'TA<;1D[>G[Y+!WK48CQW+^_^*I4X<+;<#J+XZ=]H1-#'U
M)\R,(Q$XX0^.M&MU9LV4:BWEK"M0UK'7L0(U@( %Q:$'#=?@/QBLIV$V51&4
M\/4^I-CA]?R;Z:*Q0EEP=?E#V)QR Z/LBU(M]%NQDGQ(GBJNC*&)%B!M>Q@3
MO2/SN")PA/S3 6A9% <>_3))=M7,QHBPAPPSGT8[[YJ/]#4!8F2%X'_$H+I(
MU4J- '.'0#*'*P]PU6!0KW2I%4CFC6R&,=+EQ]',#R0?KD*@Q*%>/5[R2GKB
MWH<VX'7,<0\=MV,K2FH?:"ZWJEA )1?4'^AK"[6FA"D\Q];$=6I\0WFE9PT2
MWR-GC@1;YL ]M-& W[%F@X3V(">K1XS&2(*?S'Y%4YG>'.&SJ%ASULG1<N#1
M_@8.YBL,U.$[L^>" 8\E-A)CE3&52=!K' V,$%98M"_&#P^Y_67"K>2")6'#
MXVQ-2\!=$1%S *LQQ,L\\9C(VT'B7OP-1VR@B='Q\+G8"!?7+_A. 8K"F7"G
M8)"F@L]-Z78FH)2=D(/,MB\$7R9@UR8C+#4 R"PJB8T'C,6"92O=AX4\?Q&G
M9 :X!"?\H2G7-7-.*X-Z:KP,Q)3IE#E^/5+E/;YFM0L[+3&;](8QLVBG7J8&
MIWR5>BLK@4]' @D:GO54C3U58P_RZ4$^/<BG!_GT()\>Y-.#?'J03P_RZ4$^
M/<BG!_EL#/+IZ4I[P$O'F',W%%Y=B173RK:10]TDM>U/S9L*>Q-$435&:$]'
M8T\DAO%58(780(O0JM-9IUE H\3>MI ZCQ5Z8]B2N_C;@R,>0^WT&*O1ROBI
M2**G7.)774*\L%SP+J3B47BRSU6FR.6E6#B'"=2C,CF_99<WR.7%R$4FWJL.
M[_&\/'O8;:KC;H[4\RDU5T42ULS#(#TSW<Z0U21<?=J^-@3;QFAU6*OO2!7V
M@ZTYF*/!G32QWB2J21+V(\73RX11O"03TM<BS@3QL(+8=#DN:,'32=$B"B:K
M#.Z!S-TN6HM",2Y"8J0$ZGC52NK*DNLSI^"[I]8;9,LZ_IV^DX$O+$).-19]
M/ _TM.*?2IB_5Y6#/*V'>FO-<I;.1-V8.IEX*>((PIRV.$DU.A.,ITF15PZ\
MJ8@;&EUGBC$PJE&G!4?G,F*<Q BEI9(QM1F8T6AF$5+$>W "W^.2F4DHT?<&
M!L(0[DWY.Q9G=R5(D^KFX5(@[9L6]$Z7"('VF8QO-:4"%@*\+P^;)I0%5J3"
MS$EM2XX[9M[+8<%5[Z(0]]2TI"I93F#%<RR?:9%8;*P7J(6,:?J1T$Z-KT(%
MZ['6>XH^U5X6B!+T*,$TX'>&Y6AS/;D#GHNCY=$M6LWX)9VX,MF$7D!O94AR
MS2E9+:8[]/[ \_PCGL,X6(8',^P_7SC3(#R9QJ[[^GU"8G$W_5UB7&X3@7Q!
M-.Y2P_-^^ DS'Q9Q6/T9= YSXBN&YKX,1W^>#?_$D^/O_G#XY_@,?Q^_  %9
MY@+7@R 6JW#JTON\N+A\00ZJ\_/A9'0QA$?LB*VO9*?;.E_?^09T?+O=((Q.
M"T<+>R+46\LE9!3/P=:?7:WO\3<-W%6=;%#KJ&6_ZTI98]/R#0B>=X3-/F\8
M,<1ELM3AKDFQ!E./M3'27<%W'013H+N CTL+K*+OBXB*.<>(M*:@@;7-P-:\
MX#(+$\VBGZ_?P^0/'#+7=].\5?GH!W2\=S=-HY=9"\/7H97XU?6M'[LR.!<9
M@S,>5P?V&[BC.^+/2@Y$+5UF/6]6^_N%PX#M4_\]3&/W<K>,Q<$=VS'I[" +
M;)=0-T+;*V>EJ@YS4OR8,>C*F5&5X!4K+Q8ACAQWU95([4M8/:U=[(!&C'>5
M5R(Z/VN93@F[@P\!;5:H^T<JHJ[W:B8AZ@O_D5%A][@_DC6OTYT..%NR)K9N
M*J6$J#$("):H>7]":,F)\,344>*@BM@,Q':P2Y\8?QV2-RM[,=  F \^O8O0
M0!K84,;KT%?^B5D+(7DM^ T"#+T2A"$?CI19>FA^F!<LNZ\V>[YI/6KT87'B
M8'_GC,1CJ:E4*MM?1"5C<-1I3KCJP/*&&G^<.+YABN/3ND)_I*MIR=^-3G;U
M1:YFCBA<^^?PQ=L&S[YL\.Q+]>RDPQ7^U:;(Q8(P<]NK9H?AW. FW1OENM<4
M2;FF QNTOWYQ.;QZ_*)Z:AT2V+E&+"6?Y,R:_G,%1#1[.K8U1K3Q>%TTTK<+
MI6\-=:)^RCA>?;Y")WK<:W=#KSWNM<>];FH^F]N4\T8VY6(CV]AD+;M8OY;U
MZ-\>_=NC?WOT;X_^K4#_&C7AO\9SP/_F8R=)Q,#8  !<>?C9(X ;1&_VX<5N
MOY%HN6%=!"D;/!$H=F;T9(0]&>%^\@*JPV"[GW19[6^XO]KD(++)&>[EGY<;
M;;#&U:DI78C*=6XO]0E/#2T9KYJ8+J./F-,AH9 B?H^RPBTIR0Q'Y;1;C(F(
M'C'0GXT"P=U)@$</_@G7(70MA_\X74;Q0)4=C&P9_3GB.C#E9QVK(%)K4 SP
M/[!5WCM9<^P[#J+;"EHJA26,1L,NPQ*D"%3=M3RLYE @&GTZ.419EV\EQ6;E
M@*4 WK)*<B8AW2D :S!%FY.PG6BD;DG<69_+I\;OH)@1QFHKF*' WOG:_"UK
MJ5ZC"F<V!>4;M9_9WK0^Y+M@<HE.#DKGVK L8'7GJD\.V)10E=IC^"H!/I4%
M,^?8Y'\16"F,%)9R12,G D;?T\CHLE6M!@GO#,&8N >(?G;0&&-!/"I4J.C=
M*JMCI<PXQ186>J])N8XH$7A@ES=_+^D#U;.B=?3W'[YWHG1!P;\WU?($2E%5
M3K95?<\C6W(DCH]FF*; (&9W#Y+CN50J!@U5K;34+.II3D(,R*XMB8+M.C4^
MYM^0SG"TGPZ] !G%TG6O!#V-J3Z+P)\Z48)*Q+E;]:R9R#P/VO7Q;W?O/F4*
M9H:P2,H$@Y0F,?M6BK00!CX0,W"YV$C W\)XB69L;<'/[BRM$N&$2UD7EM:9
MJ)KD,%;38IL?9WY8/E&9?)G+M'[[M[S^$F2*/B];_WBEDB.:\:QWD>8BNW6B
MFBY'0+=J6H]S'<$)C<D]B?M 2Y?)O+.R2TR,EDZY9,K6GR8EHL]-"]N!/Q"C
M5F]^_!VQ9JF=278C-' H(I\8!:><Y6/%<\HB>5 <W"5)%(4E%:]&#&#P0%['
M' F<@X1V-N]V\#M-]S2#G\I#IK8-9C;#-%W5 TAT&H\VJL:CE0!K=/!W0]%>
M-1+M];'!Q:X;=>^F<W"QFV9HOK.CQ(MU'05&@FTT#L-Z)JC':'7L*+O':/48
MK7KK[@8VI!ET>3A:9\M[O%2/E^KQ4CU>JL=+]7BI'B_519GW>*FCQDOM('NM
M6?K7, < Z5%;M1?L[5 $7]/*%G=36>YB5XP'XPRTX.9B!;2@-IBL9OACW="N
MGU(EI4 .'Q$IZY9J*$%[5*D8+@(%ODH([\=*-53>;?C&^$-$LF1*\U3LPLNK
M+.MV^=VUC]MU^U'FM:_;I9V?7EY>7J7GXNR\*W8[^NP!;X-_722TB@,15GP/
M,R/_E3I4/#\[*TY_=:4?+&:F![>.LKPT"0BN('/^A&(:&,30?$XJY@7/>017
M,B=N:,SDAP.WX;UA%/@_A-K%T/>YN!6W+05"Z9NBT<4%[$7ECU<%<-1)-'.L
M'YX(H2V2]*5XC91TY??R=<GW4]<W(]53I3 &:XSQ/QTL,17!*-12J_KYYDV2
M5\?U<MG+UL%&RV:.,;5KN,E2LA&%'R3^0$(C:@:+&$?('F%4$48\G G;N/=]
M.XFW2\(1XWO@WYO!O_R*9?;JHFICDVO5F_2FF]/AXB<MME?G;RJ\PC:>GBSE
M>'ZSVV/D,E.V8Z+.#[]]_?3Q^ZWQ[6^[/T_>[>!SH#^EK94QY51G,;P.NQR'
MB6 C9RZ8)<6).,P\I:IP3N0F()>L3A.)2K(L*PV_%YX(3-==&KYEQ?"$>($1
M:.'"? F6U4_B,#<_*ZG?N@C$W"'&G"\,3<-^"'B2+5V$Q"=8!(X?J.>HYDNX
M.['FJ- XO<_A.M>!S55(;2RAAI A*9IRI&^=%.!:RWB_9!_9DEUJV%9-[*:+
MY[@1@\5X0P:+8;-T\^'%>FN\D^!!)>B\$EBQ@2R:988,-TD-X7&JO7UH(T%@
M/_D VQ8@J+'Y.B3@M\PS_$9P.8VB.:&#I+JU!8>/J]O:@CETY3*5JV5+W\%U
M\T6DH-<#K:3K0)&E46EE+'J;UKQ-BH7.37@'C"<\G)G>\"F2X4VK!,_WX<ON
M W,.C]8*YN8>EG#&,:?PO0+3$^%Q9#JN 6L&S/[D4^A/%#B3F.;$5(A.5^!5
M7@I[[QBLALMH&:402I9H[I8!E.0:(;D<"&F0HR\FD>$X,@H9GLLL=ZL>K'4(
MGT[]5)5=4PUC_ZWB"4ZH$UVG9751\H).S#08\QRASZ[S0X!3)B&&<P&RL^6@
MLCN(V8&>N]31AXJ<_6=$%04(89VM_ WW!B 65M'D.0A.9=IJ?@AY@MP?U6J\
M+!'#FIK!7.IWD*D=S%*C@Z%$__R M8 AFEPX&,FNX?-30];&EL!.\OQD4>5D
M=MIZD6F:9X-L8>F"IC. -AD(GD5)@6I&U_*&C[^*S)_HS-["-=-8 P$OF:F;
M)SQ1H3.OO7Q68E2XPGT.G4JH6"5M^7*<8T2QCRV%YVGSFT%]U?D6"E&+HU6O
M/3"4.N@^XDP8MG>%.N_9<A@$',']2=(!Q.F'^BOI3?G-C*R\H9&=X[/+)XMN
MCO)R&A"#OJJTC73 F":KLF4HRU":><DFGTQ4'HGL&%JH6'"3N\PB;1NESFGL
MXN] %G=3TMSV\N+&H[W2]6Y_>HU24.:W TC^L@ZI)O*L"*$;7?-?2EHHSZ(X
M!\V2WP?F(U:$)U)[*IU G-ED^Q #;[A8@2!@,PNS<R9,6]K(D%P72R49:2^"
M'?:C<%WZ-\"='NP5O3!7VN>@*5YE$KOE!+=,]1U>67CN=ZRYW].<O,HFYXJN
M@,V/ QB\,#W@D<7L_:7I@D&3_B>[E_C]Z&PX-KYK58F2TB+&2T0O&L/S5[M-
M,A@V9$Y]"FD&XWVE&0R;Y1D,CR[18-@LTV#8O52#8;-<@]%QYAKD-%D=OE?%
MB]1,.7@&PJA9!L*HST#H3,L:N:2=R$#H6 )"9_,/=I9^L />\8;$Z7GF]#7J
MMIOD@Z/++MAU<L%!L@>..'E@+]D!.T\.. SZ_\C!_S6Q_^U!_[N([=\ VM\E
M9'\/W>^A^VN@^\4B@3OPG9JA]D<MH/9W#=H_""I_2U#^A_G"]9="_"JKA;48
MN-@KZKZI[JM^IV72:NS5=DPY],UT4P[,UKE]PID?(*8KF,MS&E$E@N?8><.?
MN+)R=)CE):/JT7BH+L/-6&:.R'DI!HS$I,S(1($3/J?G8WND^W$LP04 "5UB
M8RPY#4!*6*,6%TXCEYF _$08"].QY<G^[H73^AN8%^T$JZC#]?(MO@383'PO
M!A&!V0D-)UOT$<LCFEC(&S$+ <6)P<PP%6(Z8"BBA8E!>24\NHVI9_$@8F&&
MD1H.E#F*D:L%PBV))BBJ1.W!X*F@\%/( (PMAJS3TH('F2NMC\\7/XQ.6!!X
M7B0'J!-V8=]]59!_$V'&R(K(.!8%(T$UE?-04O)YJ@ GJ&!H3)V?N5M"9G@S
M00$7)C$3RNN9Z=AUN>2QY]?6\VD<<)20,0ZGQIUFNZ9\O_9ZN*NR*P7N-)PY
M7M$Z2AO'D"\;(==?D(#9R7>U]&D<S2Q%)Y$!D.@:K,8,O]NQQ2ZDI^*;"<\I
M&MT'TW'1)<U 3!($>O68$04<@M.EC;['DM(,(H^<@(.BH8EP,+9%S/;V_V(Q
M$9;Q!9GCX$E?\$F$$TKT!VD:XP 1@(>U"7J8MQ,3M[1!Y=JF*Y=N_IV00)%.
MA*;7%G.:%FA^!P0E\V.,D<-KX8T6["+#T)$K*]A\O, .S$?3'7#FPY0VPTAW
M"AH$SR.M@&^$0Y,IDLT5^MAJX"O>2^O:PGRBE,6@T*-1:9^SBY&)L7[,=E#P
M3>&!7T&TB0^^"Q,: 9,X#3P;M$HK8IL+SV])Z4U1 O&)J!!O/1L!)RTZ_^?(
MFM9ARE'NO<ZK.94?,:#M\)N!7!-3\Y500,MO$-N85HI.&4N153)4J%5%*2F1
MS\6KTP\UIE,L$YU]6=9E-1'3AR<Y0<QLX0C1)!9+C92WR%W-:-8R<]FUI,*F
MOL7'C!*I,8/]@O=#P:X&60YO%)X@>Z&L(/SJ8MUQ?2 (3$MGC7AX',-E%NU-
M0N%A'I7G$_BU=5?)];U[?5_@^J9$;F=V2P@J5RE94H^HJ'B(T%P'3+D3D,%$
MS6 P?$$%BU3*>/% U@-G;ON4MAJ46.?CY08$S@,1K5*$D98%N:M:S?&^<Z%I
MHAHD;TTNRDAR[MMT/)K*E>%@I9V0O,0L4YT>&I'!<M]*DJ3=:CY';@=8KU&S
MA.)1S9J[&V*]]@+U.M<7YW7XF/2\KJE@FR6"C2X.B?/:I'_-DKM&EYV#>8V:
MP1Q'JV".AX-Y;<DH>W@X5S,\Y.BZG@'JX5P]G*N'<ST'.%<SN/$H#S=NBJ/J
MX5P]G*N'<_5PKA[.U<.Y>CA7#^<Z:CA7LT2G\5D/YZJW4.ZS,G::B5B(+$6S
MZ.?:H-*G-#]8"R7QUZ@/O[J^]6/;R-+UJ,.P,DT"'8@AZ:W!L^$%UB#SM *?
MKO^H:-?":*"5@M0".*T?D$^=($35&^P*;<0O\&.%[>!X$Q-\>$+&C/]%CAO%
M$S#,I1@N.'*C0"#8_R3I&IENA'8JSY<FQ>9RV=JF]<_8"1V5VYTDZ1<> .^*
M*73B>,8$X5%*\%JVO7RH$Z@A-"AUW_$]R1SDV0YSX'S/AL_AZ@62:V!?&1E"
ME!=FI%ZR"'P%N, GP=Y=AM CP80:%!Q$:$:,KX /),= 0 5[5=F^B%AW,I5H
MYZ87(YT+?P+OL408%D4-(O$S\EXM5HZ#A06I$L8FR^ET2HS#^<%657PU&AAP
MUKF)A-;+0! 28 F+C5H=!YR!/\$Y@D<?=/Z1?29W@B;6?.&*5+[R7:J*(\HC
MF7;XQ>-,,!PAP[M"= ]85%383*-2IL8T3#N [HD3UXP]:R9G4]*J00:KH3A<
M0KT+ 8G;-&9@,E$%)F8*T C$/192Q.Z9"P10F&Z"@91:2=*9FS]8I5#=A(:P
MJ'H_<TLR2=&2.8?4"VA(0@?,IAFHEX0#;=PBK#%/19G]"3)>$3M4L:&#S(>*
M<\OR YYO-A6'ADM,XI<Q0G,J).!+3-%AMA)F3=D(GL:20 F,_P\1I5Q(AUQ"
M_NX'/W!.$!49ZGFJE" ,.@E*R'3G_IRA74Y@4X'+I68LD *,S0)/V003BS!,
M?2#1IW!3(B_]*\DF&F8Y21-E80(N&2!^K&XXLG']DUBIV*8D]ZQMV\*-B3=%
M-T/THH4(B$-)WE$B@!WA>+X$6 <U6B(R+;KU[ ^PZBQP&+;%\JPGV3^_SOAE
M-YU&_"@Y\2140NJ CZ951:"V2=RYWKK#^(Y$D(?@Z7+)Y9%\$2]2S!!FR2JY
M!-N#%<1R4F=%_[( #CDUWG'A;\EU1.LD.!Y(IIO6#$^< S-BE"<M@N6.5Y;]
M*W4PX"M0$G!2(E>Y.2!U_R'QOJ#_\E-BNY,?PX.U<NH.L:E)&J4!HM?!2AS6
M8/^6AX9H!84E_)"ZMGIDM9W 9$E.C!EH+B,[(F3XDV?30DOR+;+(5;U)9E!4
M%5)7.)U*V[G!R85NO>H>6)Q?;\BQ/VY&,#*N23#294C,15U(3)L@&1J@)L.Y
M&2/SN!G?PW@%WT,G@3CC9CF9XW'G@#CC9ABT\2H,6F>!.*OGSK'P+]$L;#)G
MQYO-V6;@N7$]\-S3P03UR)L>>=,R\J850]X,$SK>@/"?3$H3 W1>;1K:P_NT
M/)V?&/AG)U42GPL2J#WA=086M!-]>+88H0,@@@Z ?WXVD*.6$$;==4=[ -+1
M I!J87_6RJ@>**9^\&%OBE^CI%(;\8T69T"=(E!%W<OG'.YZU] L#VM\M=&N
MX7R]G]V".=G[>6]+/$[Q) 3]P^/]3"I]Q6;T?*>-^:Z7RA @<LI,-BDV6R\8
MXN1SDRLB'$G(R)G*J!##'3 N-5-5=IC.!![G^7/'2ADB8!?EVXZP*88BWT%-
M)'J8J>L_JN"6"D1C(QU*,8?.29:BA+$J)2GZ7MU8%H?@.#6V%SF15$?EG2I0
MMA,86.L/M,TEZ-0)_),Y#F7>)XGJ<)I%-4NC441[($%;ZV)]NU7O]WIL-8V<
M5( WM4I%'Q3@Y:^AF,;N9P15_$XHN?!NJC]U.]3F.@S!%56Z3C$$%U<YT[I?
M2\$X00X-YZ/6F0\"KB<''W/U+497FDB^A.4 P]<E6J%[*"7''>7V/;^KS(4_
MZX7*-%DWW8S^>O?U_8>O)^_N/G^^_?+MPVOU2YE4\X+G?>'-Y2]OY);V+!-(
MX* ![C?+=I/C7W([D]P)9<GF/_?EEOOW-;LT'J1T_]VQYJH]^67'VG6<8AR=
M=:Q=1RK&ZPZTBW:A^BF79K464?9D2UJ_[W=?7@]/+^#]?(YJ_.6,_E-A[:O3
M"[Q3O4IUWO+1HGK_^6*4-Z=/\8$%N19/#^GPT*BQ=)2.PJ]WW[_?_?[Z[/3J
MHM"JW'S@Z:":E^^U?*RQ[7,+3]S\@<<<$KY%;%V-<\ZMY=VRU'4OD' ,JZ)G
M1S .[+[W W'P@?@*FX-_YWW!JI/0FFN0-+AXA%G+@!_J^C;M_YNT[KV,?O[%
MLH283E^L\H)@ "M-<S-#7O;@[1(.">*7.4$]H8]68]W566)IA 9/@F)0X^)A
M;Y.^UY; &_V(1I[0E$W<==D,Z2Z:#59E_D*M X<_E122VWXG1 *^$5_XSD7H
M=W@WK7S-[4\G3(\@SJ]'6*3KO;!<SOV9F"X2.A:!QQT0\D<LKHX[_E521FO4
M#1G'GL/O0333GXLX$"\,&YH)ZARRA0%90#].X%?BZHUP3*+77CP_L?WH1%Z;
M':SQB[<79VITE$#>_K)CE_1Y6Y[/YL0/./7M6=N>5 XM69_1Q>7XNL3Z[*@D
M1A28*+D3_+OZ@+'=,__NJ,F^K&=K6K(3^WG^XNVHQ'Z6<T"D,E)A@ZGX70:=
M;L,OY/+>3;\[\\[(3)/#22BLUW8<//J!'0HO*X8+6$:,)4(;2U?ZWKG=\Q)S
MAUG2&# -/,K]*T<U=,"*[&VQ88FTZ.9>]F[N#B2\$R-]56ZD]WKN6GH:O,Z6
M:!;@YTD(_=H &;,RLF T;^0:\RB#HLK<X3F'\:8%473"K'[&N@(SWZ7$ZP#1
M^YQWMAO9[ES"'375B90_:4+>WF##SN!;UF5?8ZR?S@ VG4>UIHB.HN8WU<!"
MHQ=YXOP\F3DVS,G7_ _A*RYN;L9%Z_59$6QQ28^T+,0ZO%^Q9\/V>T9>E4*C
MN>#-K^0++,LX/3!6IP#5<4*D6.+"B1,SY#(8S$V#0#G7AV^7:6W%A8F+D<=$
M35X8SQ<Z;<1ZO)[$ZA&_Q&&A8 K1Q07@,C*1L*8!4O" \8&!?I#HI4" @X!$
M.,2 HZIS/3CBD1D]A&G-VC]XP'W6B?!D=(1)(&SL" ITRAQ+"^AH)#*\#SM
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ML4Q%*9(FQIT:GZ9&&%/FIGZ1 *N!;V<C;*&%9(^,#;>CV<K3LFW8OO,:UYU
M%8;HH^):B8.%S\N+EBX88>^05T;;P6$MJP7Y5/<L8'#QV'VEBB]P!U]"_A7?
M1B[]O? $XZ<M,YS!75/7?P3#&?AS=7:! XFL) E!APO=0P)_[! >1L@Y7'R
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M$S"4NU1K#,:+\-Q<?TYRF@]MG#H4.^&3^TBAM&1+5#N8<S:AX$_A3K6Y]9-
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M#%0?1+O?4;P+0>RAQ-Y-Z-BCDXU"-4PG0X(MF#G(FHFN(BEBX"!<$7DW7?&
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MRB^9410XDYB14')%<W -*23U,DT+,QEH"OR8*#:E_);.A\(&BQ\SH!,BK,<
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MZ768/'/ 8E!LB-CO3GJ\8M!#GW73#%J!['4B>_UEKT,9D%WMRGU>FZQ#G[5
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M8A(<!AA,B%&QY2:=MB&>Y[&\* ^BWP/ 3(N>TWN /?!KNIO2FT_87Q+5&>P
M<WR7@P<#+N!'@S<)\QG>&7_;1<@9?4Z%&=#SJ+^1%@>$[ZTA_:E9LR7C,,H8
MO;O*L"N!!B0!C$#6ODH@$HA%4<0Q)4V"W3F6_N!2J&G&'%?R@S@TH_/1(@2U
M%NE9=Y;2O:;_"?<]6II!OPX_%'\G+X!\MOZ3,.##>7G/VD"_1K@#QE]IAC;7
MZ";@+UP24C&9,VC<.:"EV>=2%$9#"J)1%H@ +  $I"I\LD5L?-"\/.#>(C*J
M\H7WYZ5_$?U8N7BW#63QO<%"R*$!+3$82V]!L5L18'(_R>J5@=;;._5V,\A[
M/F]#NB>6I3NF]1H 0K.E9^!>^!.>S]R$<"&\!$ ]0XW9TN$U^'X3E?O09[8[
M6^)]-[:ED557@A<^:["&;ZYMZVS)=W H?P&GP=_35QJ\-;&\<PFUG_@I2DNL
M=8[0/=<_5SHC.Z)6ALMGXG9.L!18\=/MX@I.$25-3/+)O>_R\#OB_+VY^3W/
M5;N3"PM ]43FP?+8L^[_N/]_]Z]K<KNXM #O'^E7-K.$0J+US":S]W/7>B6:
M%16K(PP4Q[7N,[S.0U0 \Q.<J(94",@$<E"W0$$U:CFEJA_(,/KU[.'US/LU
M(KX?-!O$/9#QC!F?TL(RGRCZSN%/U,*U]=HR?VHK_'U/;(%H0'OP.ES&AB)G
MYD_*3*EXI]_%2>?<_P2V!.QU;1HVHA2B ;W^23/<!6"R"\>'1&N[Z_7J=5\;
MRUJW+^P!"2F/GI,M#-60ZC=>.PGKD_\X3OQ8#O2$HGK#C JZSK3?"W;R6V@K
M<>**:3CP)7(6W7"9RH7$>0\/OR.4HYK&=T56Y/%PHJB,!\&5P :<V%67:]!/
MYYMKORN,G(+JD=A[2BR \^@R"U&]A43.-TVQP[!\[#SPHU":PP,!A";OM14(
M)+L3WMX&=\(O6@;.$R_+84+_77C>BA[@SK,^=Y;O%5E^T_DM^JA4E QAV_FX
M!TO<;$)"1\EPM/F,;63S<;@B2*(E0; -35I:*%E^<<Q99WJ/WA D310_A-8#
M:5,^<N6<;NQ_CBO%1]\H.Z<@&9\/=".,ZJA87T3<))KKF/XG%ML2?L0D;DF\
M*H?@O4[Z\90C\3&7Q-M=5';_Q_6WR_OKJS^^W'Z^_?WF^DZZ^7)USBDK2]NC
MG_]2UC=3Q#[>FNUBY@VJQJ"Z V503R25VY]T0S-0[6*Z,U6"4"OUD.E=CCVY
MPWK>WJ#J;KHVB%0;*3:JP\]!,=8LNPOR;T5LFRG:S[I-)&;_Y*U,V6%IJ<(H
MPBFVH-->*3KM9]!I>>=M6L97GJ]V9VK+6V79%_POJ-BVQ"QB/YU,\NMF6#X9
M5=.HZRY)MVG2J!^'V,$ %EI/V6>%5;?434=B#FJ1;=.+O( &^\S+?(Q%,Z*7
M,%'(NYDNY#T+B-0*SUK@%\;@0N#;(]:P!56V[?_Y.PTO23.R6GGQN7]TY []
MVWLZ_=M;"#ME^A9IYEH6[/4*\20X?_T)]%&T2M'+ZN$'JH^Q:%2@)B28A?<<
M=)MH:QL^]G_C C@GXU>B*;\7L;Q=;UG]I/&&(+Q(:'6'P]9RBHW2XVDQ>2'\
MM#VGQA?I]T6/LU!*,C]&V@Z@;SQ4DD9=5%*=.F1(<4N^H-Z-<B1M)'[-"U>G
MZU;;&-?]4LK5(+K!V0JT"HSV+\$F>_&Q+95Q9PJ%<<-DPK@V3:* )7 L@;MZ
M79?HWJ.Q"2D9EBAD&-8<V/MGX(1$K[;M>UGC'LFN_\FSEG2ESLE/LC+7&&#:
M!U31!,#7VH3\P'?J<*J!4SIP5__S3OIDFBRT]M%R'Z7+^9-N8$2+H8,?-/OT
M\3(:?_'C8U&?<5=Z<%DHQC E\P&63A_31;L;%T+?N6_7.-WL'T1; 7J%0F=/
M<+B2"P8U0F86$,+J%3:DV:9!%3^R !@ZU&\P"]'*7D)]U3\ZX&B\L"$[U[5K
MS>#\X!<@0[*O(UIKKQ3< &:/@A"''@@Q@&R0Y. 9@*1.5L?>KW X0(.@Y=XN
MOGJ[^(J;0(</J+M62G>[2@)TE941E0[615-FX/A(.&=&#5)FSM02.3/CSG20
M'(/S!M$!J<4@3I#?0O'D/,<;52)W+JDD<W7I\HJH[J";#S"-.?GV*U7"(B0I
M-<()!S1Y8<YR#'Y@P WD8V3IU%=X]VL&)7A[_5-?$=L!4_.KM^>OC,HX^;>
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MVACP8?3(@OOA*)[Q1'M55O;64;[#6X.GIW@8J%^#=T=/+='A5#Z XX(GQMT
M'ZW J +69K',X&%P6!]>HD_H[?!@I-PM)G<5;>*+7!V$EV$MC U&2XOG23XY
M]H*0I?O!L9\^VM9BZSA @U#.)"052JD)-WC#GV,2ZYZQB(J?G4IZ@?T\S!!>
M%_Q,\64JJH(+#0X2'A%40J"P0.E@1! I;1%%4WU77%=<@CQ>/7''7S7J30R
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M58XD944TKH%\IU)C#*VKH-C&F&<1L<W-V)PJT>K]P>G9^H,I8D77OG\4>UK
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M,(#KPVN_JLT2#$?/ZMS20G]49$X8:\<(?#R6EX@D8OB/MA]<&&]!UKQ$$,O
MX,'J?#N(DF<[A#?1!W_27U "Y"/1TE4%BV*NWOT_[O_?_<N&W*VN'0?=/?Q3
M;2[?N-^9CP3(LQ7G1S#7X=%27O"&P8Z\*.Y87_M?_2=^L_'TA ,X%OC/;[N*
M[?C"+1_)(.Q!N*4A;=?[K'OD5]TU4CAB_:_J( P>\)_+4B&Z>HWVCJ;1MF*R
M^:\)X177<B(@CEVB9-@;C\>330"FQ? XN*G#/L,V1AW^!;E-(<[<C+\OP.Q-
M_,E'CQKV^VG.]:^TG<U:M^"K6D:15OH0T$^P;\=%[HA8[[3@&N[S#&9YXHS
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MCBS*YL)L-B9LG:(_ZCCSBJ'U8C3Z03>QW&P/G+7\TZX=)'\:M ,%8.??96T
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ML(C!1-!.=Y;R@3PX6]UY8>11)R*\7(]'D,E2,3R71ZH,2[EU"+B#RYYRO5C
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ME*G65C>5)T(PPHV1C>A:>SM<S^-Q\$<;LZJQ(T??.C*=6,2@T0WLISV=(H5
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M+-NT@8;P+W FYLG=TJSV#_@6[$-4%!Z9X;3]&$[KS 4)GC>1"D#D*_9&0<7
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M6!J_IV0Y60XO BH</THAD]Z_;,C=*G*;YB7O1EI>\JZR[:]TRP]85!(P4
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MX2&J/CJEE8.;UH:5 WR5]"RC493IFY*13KXA=:M=MB9FX?+=KNI^J ",Q1&
M;6YT=WWIPI=,LN0[M;*=9VR<=&DSE#^/RVU(:"33X:^&8^YM[,OQ:(D@EO.Y
MGK(RMSB.C"$8\6+!H$J0-7M%2Q)HO)#6,GIV]:V+B\+[1:LD7QCF S;_+ G6
MU=!HD.XJ:[)\9/!.0:*:]5PL%MAW1-OFML[&=G?4/590'L+(=T)*Q4H3%C;X
M,^[&MG@3(JLMP2[4;% 'OP  #],7]L0/[%$^C!E[4*04(#^!G+Y1<(_$W!D<
M'!,;.D/'Y;!Y,XTO&9BIO&1 @+Q14>YX!Y14'=NGOIKMTS*W[VVBSQ;$QV[\
M&+H9=-*OCQL#U ,AQDC)YCHA:=V</2I6C'J'_8>Z\\*PK3+VA/[QACEC=$/N
MG^U['LF^MI9?@#R$L(H>WLN.7>(1/!;XK7[LFMD Q\[UA@),E@"\IJK#%"^$
M/<$NQHM3SVD7AW07Q^ERO' 7WV(#A$&[$>T4\,4ANSOU]?"!7#+D(K<6;JOP
M?6<5O2^W7]X>QT!:Z883VIVG-)>P#CH?X\HQOM.6G:1:"R?K?;2]=X%!>NW^
M@YFC^3AAS5:KE11<S48XF$\ 8WAT"5[/)C;=M*UF$\<(DC80&$6\WRWHA@-O
M<AG0V0>6P^8W^J99S>?UR1D]P#MK4F*X0/?K"=J;XMUP+6;KTNTVLPGH^IF6
MW1$?">.<O._L56W,% 2]FO8$6G:8KW([V?TNVU.T-,;]CQ:S5F&.FB%'I8_Z
MVV2_1=A+';=3<]1;D7ZZGJC\ZQ4@8#8AY;9J;\KMRR$2#\]AU%J^WFR 2PV6
M:F.#N>.9K5V)<(E.M>,!=Y9RM_#LP*0=4A3/:3:*YP:QTS"1P7U3/;I%'+",
MI5PC8)U?KC^[%,C1!^JD"0\VU<1"G&M::T%'5'!0/S=$@R(D!J'(D*DX)I5"
MQ;(/'A6@>P:0PKC"& 9A$O,S'BMEDU?B*%E<RKI!#(VC4]USL$H&GP5O&&"]
MD1\(Y)\:PPQ"_./V"83R(C9S!=<8Y7/&YKXZV^(L^U42Q5OM?^T/O^)&@58,
M?D[C*BVW#CHO4;TR[>, ^L#-Y2MZ?>@,+[3"5;#A/>7O# ?%?.DJE'$1L$T!
MIH],:*'<Y!#F&^X&R:NYV4DDGRI,S'[@4*&[_.!!5[G8:1G6"&66<90*!90/
MMM>F?16!+ 3F6F$<D!IAP$Y,&@UQO@2#F&(39XY+G[@_<6+Z##KSD2AHE<1O
MJCST3/7>)24D%S&@$)'*3)_[8%$^3#<5AX>(]4_L*4#,GO+%0%\#;HMH5.C"
MN0S&M(ZI5-$0>S?22BG6R>\,%P&,MPZY6X&:_]U>$O,/(-&]_<Z'6_Y@\#D;
M?%Y:FG>PS.M7$_Y42'AU% )\L\$5.%N25S'&:L7&LZD6\M!@.,+(4#I703?,
M!Q)%R&00Z4^L$ 7L%)W.&=G8#BLZ8:IMZ_IQS\IWX5=37WR[_+)8VV#@\5UX
M0N+Z$*' :*9I/^,"6+4N+I1#2H/GNF5 NRD4LD1<ET'C1K%&;<&(B= GWM@N
MA;[MI8RBHCVWT3TI5NN'UWY5\XM<S[;HMK4]VWS*U<Z>[<PN;J4P2PF8I0QK
M:?OUN0[+U:J.VM8J#BLN]8+CYK6*C\N]P:25K>**@%;BL$XCFL3YD2MS0 ?[
M'=!RTZ*UJ6Q$EXWHLA']X$;T2B1W.1P6;;:7%"K<;4*O'LKV=]G^+MO?9?M[
MJ_HOZ5-D^[ML?Y?M[[+]7;:_'UO\REJ<\K4X.R1-$?.ZI.!A Q4%%315-<-7
M%)$K!]XXZ._E%0WSSY,\WU&GFIE7-#2F--'@$II3L_&;0S<DP[#P7U1@KS'^
MJ/BYK^1FDKRUW8S)\:CNC)[%X" M\0#" ZS_[$P[&:HMW(/RI:7\"+/84&^T
M\9@WGG#HFV4V9WOGU6Q3_/XYF[5+F!;U-KG4#W9F@E^NY:#]Y:>I.AM=9?\S
M]']KLT_Z=[^8PE*TOCH+PH#[.ZH5$9_U;"2Y*W[,M<X^;!&U;6F2+,^X91?4
M;MV^UI#([T3'NB1,WK#-QMQ.-N^E/-NZMDJ56Y6\6N>]"CK?J53-+/L!4PJ[
M-O"8,D2*+2FVI-AZO5M57&QI315;>?X/N#_%O1^VOES?)Z-B,>;[;'Z4\'P$
M#6[4ZXB&,_-?T$NX /P1V"4BB(H&5!AVJO]">J$945Q%5(V9+.!XT!??'AU[
M:RUY;OBGQ8*0U:JS*SJ[C_<:JQ/#BK=XD.J25C46ZI[<+5\JJ:[^;+C?+E<.
MX7(541")@ZU+3B!K=Q])G^/CBCD5LXFLER\W]S[[WT&DQ'?UB;PC0;[J;H54
M^0!$N>74^ S$H-FN.U9+SOVYFCN,-MLX4M4P:!.YU$KTB8PZ\T%OE,9\>U/'
M%DG.R.6,BAJL*N*,,>6,-'I199RQE\H9EU0@!U]?J;YII5K!)KD%!JB^VR8P
M(O;'O%K9[]/BGP$I6BOY)YWY=-8;I>>D2]%_;,:H2? /]F.,*8X)[0VEX)>.
M1H9&N.8-E#:KX#*-%07(H,@%KU8UL*..T!K'5PG_'3WVZAZ8M=/^K#,?]P2(
MM7Q3I48X"C]4I D.YP>UWYE/:N>'5Z@)R@K\+,E=24HAK2@R*O]H,2^%/3HK
M^1ZALP"%]&#(H6C@-5JV,//_V250_L4A"[C"I=M T=@%(@5K!^I'M:D.)GVJ
MJIVYVANE90PCV\7-]4[\EH;1Y^:Z4OIHG;G64P7S&*0ZIL?WYZSB'RX'!_L5
MOK*3&059JYW_JH-6JI+_!IWYM#=)HRP=_WQ61)^*SR>.>5!%!*KL@+Y"^ZBH
MIYRHVYAN/"6S_2)>8M\\?YH=!(7\(,X"F]3W,+1$+YHONT4$+">-14_;^1S6
MCB!,3V;D\M.E_,WH@3ODNUG6)B=BM>7&C;E;'674NR'^V*$Z'[,9IXJ,>[/9
M 7JY 42I6!>/P58>]/IIN'R!+CZ6Y).">I?3+<1CV!7>&/;&X_%D$X"XX:W"
MF:WTL^_X-?@7'JQ[6X>X&7]?Z)ODGWP JF&_GW8>_"MM9[/6+?BJ%D<RAV\_
M?#.\2UY02/_D(8XH\C%^'409MKG9S^R[S[:S3(A _Q;TNZ[GV-^(CTG!>EQ%
M&Y*RF2A)M3YB;P^F\)_1Z"U?SA)A#>E)O?36QN*;15Q8BP%',L1ECUS#J9OY
M=_ZXX.\KT]8]_TW#@C9?G"M,GBO_RWA"D$C8 ]'\%]^OJUW -]/OFH" G_34
M\8D$?#.=K6E#!'S3*D%+=L$5KP6--VTGNK(S"JD/&(A0S/FJ82#"?1VXM$Y>
MY22BR\:G##QM3 -^?3&(23_4E1O=TI>@HY1'A(FW*,1LY:O\-W%LD.#;C6WY
MZW3=+>G2Z2VP"(<\Z2#9$;P7QQ*0/[>ZZ4\O('Y54&QB </1#0N%8J^: N!=
M&ZYG.W@FHE_1Z:0?N PQHMDH&C=\W')+!RALM@^FL3#AZN^Z8=*.=,-BP@1Q
M=SF<[XJ$LQ1B6,6>_LV@ [/A5C@PPH #Q3K_Z4!PO##$+^:?AH#^;)9%_/8^
MWK#_;B:Q'H&(".MO/!'%-> LZ Z[B:NLX3).7J1-9&0U'S2QT5V/O07L"ZS.
M\KD# ;PY@L(R'#8 )%QL3?H&77@6PF ;'KXRO1=P'O+/!J3$XB4QMX)-PO!P
M#)-NF@K1'=QPBO7G#^^Q-YPX#+UEM463"M[$?O;6\4$%<E)*F0=\M!F:]O,A
MJP2QXH_2XGVDR_B<P23J7'S @M]MJNV<.+$?K')<WXAO5Q^XLEH,7/D@*&4?
M1*04YHC:-ICC06&P:':YUCB8XT%A-%UV^:"5,,<)3D[\5R":&X%V[%.\U ;E
M(8U*)&*)1"R1B#-@Z"0"KT3@E0B\$H&W(1!Q D"X&P8(QW<??/9'$HF>5P82
M)ZP.D "\$H!7 O V H"W!C>VW#BBP2B1KY0PP&*,P+I5WH/SUU8 #.^A48X"
M.?S8XO'?*,?6(.+ 7(].@RX*W2W#T#L><&<IO^O.8LT#P\P5VCVN>P'L0[,&
MX&POF</MYT# A"//X(MG3,AV,W84OM[%9,OUQC%,MIIQ=#5^Q@(?@S]OX37I
MO91[!S96^4*<[\:"4"^<YL]TA0:W*+:B9RLZ7RQFH. 6F(^CP8/,]3PZA UW
MC$X>YY#7GR*SQUFB)O('FJ4)*/7PPF9%AH^A\R-_UU_82ZK,"=72MSF$;PR_
M%7-)7&!^3'K9"JX(A(ZB+S&9A[/(,3GE#V-EV^WO8FR]2#[7Q0@&+&M+(R\+
M@V?2")UD_6 L@QOQG>HIMT!%$-$L+\7?#"^@;\<7XT:>31./[G:U@KLCX>GR
MX-GDQP8\ D+7MB3?B6EO%-T$>EB@^;_CG'5X,JADX\GX-R8_HEO*1I<:F*B+
M+=9PX1M+TL4QN,^@//!?GSZQ=V?94(OG/^T-5JY@K0/-G6UTE*+&AN9UK>0S
M(F/FL2Z#Y<_">:J<7O![;&J\@)]PC"T0P4 :>"SE9]INYA!ZW;)PK4^$T$0F
M7!5[(PHUJHW\H)27>!J??FJM#.>)'Y8H,\=N!:MQMXNU_RAQ&BE[+FZT8_(&
M'F"AC?H'G%$G(O?9VNZL7PVJ[GDI2[$"Q?MG^YZ'YZZMY1?CAT>(%;FWBV\L
MJF8))^'.$"NA22(\76>7:YA)=5BV'H1K 5H-L813@F(D>4A0[_"R-RQ#\#Q]
ML69"E@I01T<]0T4'/:W1\]VEEUBVXA(0'R@Y4)D:(/1X=4CP8'H\0:; @AX)
M3>N"\,-IPXO%UN%R@B_V 4[L$_&;"%@&R8*5/:^)157?XL^MX?"R!A?EL6&A
M:X6?H%9%0?8"Y]YD!1*V8GA=_B54J0Z^(GE"/Q%?D7U^D(+2^HP]W^#-GU"Z
M<V$6+8>(T8V2$_Y*1XJ;+_CW@,!<.W_"8=H>O@$("ZZ?F51W:0$#?T1T(^'I
M_GV9E LME[3]TU.^;!_^!W[VZV"P_(59/B"-F*8#"X=X^!9^,4?D:5T^(QL_
M42[87&EOK=,< HCS-99X<'LAN6%OF1;8T#>D5W %1\MAP(#3(W/5X[TD^ A/
ML;8TY@VO$Z?JTA]!3B?"LX'9+ARH<.BW]\QNDKHO*TX)ELPW <S);T !6GSH
M[\'%DJSH(S).$S*P7[;@U] $!4-XFB@AZ$.! K$W"%Y:Z]-B'K+8HE' C"O_
MJTO]!16=8V\?UW2[0NZGVQA>IAA/H/4,. 9P>K#ND017P>D@W_TJH+=^85!L
M+737V/1O>E7XXO"*G#Y\D$KDRG=PI4\I(8&XC9D@OYB6:TI,./7(AI1-P8Y5
M+@9OJ3G%U'UTBW:6?DB=L>,!?XCV :2G$A-'*-EU:A:BW4G%*)SGP"-('DMD
MTN>U =("OF=O8#^1S_7%@FP\6I>%OX(2X2;<@>Z"VA_Y_@*<%+#<5UW?TL3B
M,UA==7?O,G%_\)I'H0;9H3FZ2DK4VL]6*+CLU8HX2%TK=&Q]54@M?+P%+=JC
M!\M#+Q+\RF[LRT\@.]#Z5[8;>J,-_.Z+IH1]?[MJ!@D.I@!5G5S-Z0]@P"OH
M,(-(@S]5QS"\$C-!;O3YGY#>.B\'1;?'WL+1H$X[)0BP\$H';>T[M?3TX1=9
M\67D7(6>*A:YPJ</6]? [@BV@J#4D@IU3NSH\T12U"]6YYY/9G!4%:13Q15V
M>>7I,CRZ;WATW>+P*+4E.!+7[L!HNF LH^Y$H*Q3NGKZID =2I1J_KN(]/L>
MR9Q1N63..&X)I">$[>,J^D%)-+HPH ARR$4_4(?')'<F&D;D/=_1,"(WY[C.
M!R\'R_]IT;D!)L72=T&Z* '!;,.?P"$S[1>"LAF+O#&,2X,RS!UQMZ9'<WX6
M=GO1/C0PK*EGR$(H@A4%B_$U5^!:) V4A$7JRT58-'\WU(>6[8'"4%"/,-43
M#PD=%UJ-?1%)'H\*?83MQ+!026"MVX\?]FEETOJHWC*:NUC%MK[RN#T9-AWT
ME'B@7IOZI4NB * @<E]"'1<),-5M4_NA>GR[R&&)UQ>&(6VP5H$U'P,C!YL8
MNLP \-:E A5->'D:RMX^^2Y[[)U3C@)]23QL#R0=LFK9BV?N](5G/Q*ZMSP<
M_\*W&MU]Q_!>+EF?$8:&B.4R'4)K'AY9.>A;)!?X6RB1R(\%00-5*(1H8)K*
MBUL@)HK+:_<:'#FLE ;SY&YU;WNZ2261>TO)#2+D+C2[$P+IVKVS(H+HVGOZ
MY-APK)\BTH9]\!$>7P375=L+UU5#N*UT^V3@.'#.0=61YT-@BN/01K0"C(8:
M:VF86Q#PG %@>PVW6F[V2Y':=42J*E2\3PA6M&"B1T[W#0-P VT:'?,C5& 9
M\#\1L)(Q2^J;#<J*T(;[KN+:3"X]KTF^T7EN& "!O9ZV+X^ !\#6EH$',!I1
M*("3X0'DH #D,:UO4()=Q#C3"<U.'A-(A;;W<2?&Y=R)<DG!)D@.;B\87*U%
MK(2H'*!9A@<,=F],8G%OAA8-@EL2T#VS6K"TQF>WX#OL/SQLZP43CR[F,1R3
MB2MF7:@])9K*Q>YJ8V50HQ%CK7YE2JS:8L;,YAX7A:+4=(8;\D_6%OR9T-P7
M-2H^V"Q/36V/3_H+?G@=&ATU^R91[:YUYG\G%KAWIOG2C>RI2[N9TSW,*,1I
MF8(>M#FO,' 9Y NH)])+1K!RFB?W.'&3<B=NVLD*5V3&RY(=J3OC9_7WJ&9%
M/X*N5>UH7:O3<O2?M:YK=5;J!8?]QG6M#LLU%@\3C<4MZ5IM?G/JL%S_\U#+
MV0?9G"J;4V5SJFQ.E<VILCE5-J?*YE39G-H0LT0VI\KFU,+-J=$0MFP+K5/Z
M'JLZ2=8B[:I%8C*K:"&2R,4Y4I_WL!S8UW"0S_]5]"W7$;G<SW'<LX0K_NAK
MVOHE!A7LYF76/_N@HBR#_IFXQ/E.EA]LAR;3:2DU#UU?6TN,)>%-,-"NF^1N
MQ;Z5GV.OJ-C'Y8\*,^_]O>I]AIWYJ#L9:]WQ)#W,Z: JV7CN9&%O3109/(7B
M)TP.><"#/^HYVG][@>[HX1X)K552KV*ZXH1LHS6-;7#.0[<_4[L#P8RT;A7Q
MDX,PES$4T:282H$$:S;?G9S[U*9QWQBY3^F#U)H*9H1GU;'O%?P*C.XJ;UKI
MS82)<H&O*+NFRCS@&O144-GA^)E^%^YBAGTIF_6+2Q'"E\0TP Y^$=0AEVLY
M-UQLG=\Z<"[?(? U/.PVA Z',WO#,,=OK?LU^4@+2_P29#=2YO?^!QJYNF<[
M+S3SA1;FKR:<X4))_XY"X%!N<%'.ED2ZS4=]%/R2D<H\@&^87QH2%@/YW!4M
M:(S 8R/(NN(]VQPG^YE@_V:D [9XS/1D_3N_WGU^]_[SY<W=;[]=?_KR_A?_
MAQV3]F:PWC!S?<7]Y#[/EO[29[G3K BD,+XX4=\D7,.DCXF_9PKF_N%QAET1
M.G],D1\(:-IZY6):L1C)5G(QDJV:13RY&,E6<C&2K=I!O$8MACL9_#:-6MK)
M%U-VV)_6;\6TOUV'.,82Z<1F/</?9ZEY]ADD+#5N-V^RO;9KLPY]TMDM3-W!
MWZ)YOP>EI6=%LM)\VN[N>IBVU2/]B^.?L0WAJ&A9%4J2SGO3V6]J8W2FT&J5
M4%F55(Y<O?'+!%B-2#:%]]-3(MES@."3JG\/U1\E45*;\Q72]\C3,</.>7QC
M5. ;YV@\^:RTTQ80"+T=V:%9X0*&\Y.>+!%92"W51%CU/ EKKQB3\USA_FKI
M];@!.Q8F.OEMYI";ZY_W: B0['"F[/#'EWW8X74:K9L?33=9]S>XKE(H.S\M
M%H2L5@E+C*_/IQ(VK2J"7H!](B6QRIU);X0P"[&BC4L*QE#$!3T_Q7Z7WT^^
M&W<J>,=H@9(6EN;C?:H'G9KL SKE>KKCI?:>KO74H%/]85?1!M.V@4X)*L<,
M2[FYCK)0ZDL"Q7 \NU%>+B^7EY>\O*@5(8VP9AIA^5&OIII5HKID/;NA3JU*
ME43U-L=JK>D.0J=O!^9W4&L?4B6*]YW?/G-S_<YUO!L*T;!XJ;,S9M*93V:3
M[F@Z2+?%U$#Q5W1Y<6+]7"UG_N6GJ3H;7=%_AE>[^-1/RUZSA.Q[GCVDLY1X
MKU>Z7>36R@.*U/KJ[%#^ABN^;HCSE3Y'C!==ALVGG;DZZ@TTR>1GPN0M9>L_
MOE3*UC-@:ZW73\]?R"=V &U>>5AOO\.S7^YUV--*YSG;_9UT%E;TG5.$!5MB
MJO(I*PKOFE:"9,AKL48%(V?RA5Y6_Z<:Z?_4CF>O#OJ=^6@XZ4Z'Z>$/4I6?
M,0,7U^>%V%J@R_=F[6I-U0%.-AGWQFF4#,G?DK]/P=_5VJP##?A[<(XVZVN+
M^WVPG16A",P(=$A^; SG'$VKBQPD'9%9%9#EVEJ^9T3A9_77DYI8+KS4?W8N
M2YS4 9S4X;"KJ>G8H #63RJCUK!T#D<G]% C&+MB VN(H^-ZT[(*2/*TY.GJ
M>+IBHVI$C:I1V?CV.1M59Q:Z>A_,*KN@BEZAG5V_4#NK,M\BWZD(EO".HDY]
MHI.VKKUWN@>W\?]8V/.H6<HCY)_:4],G0KG FM>S(%G%0F32F4][VC!M[+T]
M:TL^/TH:[&"[XJ33SEQ3N^HXC=';!-/]M'P039"/:EE=J\A1G2PL>%8:''S%
MA*I(!+YZ)I&'Y0P.2[7V @Z8[/=FY^=SR I7&>D^I,)5.P]SN<8*UR-:PCA$
M%@SA:;_;+QT>D2$_6?Y7N/SO(&MU/];&5.JH6UH#2[9N*ELWOG3[("MS/R;'
M+*3:G9;UR=IE9LH:5UGC*FM<&U;C&IMQ<D2+=8@]65I7G<F>+!D[JJ<&L"QK
M5QMF'8XZ\U%/'4OVENS="/:N.# Z[LP'Y0N,FF^QOK:XGZQPK;?"M6(#JW2%
MZW "ON5LTAU/TZJH"6GR-E_>1%UTM&K $YM74]H6/&AD&KO-ETN>/IU-->O,
M9SWU_&PJF6R685(9)FU\3G]P?F9_C?G](T9+1WW,[T\FP^YH-),&SYDD0AN8
M^CR^'3]2:0_#2)5L+=GZE&Q=K2D_TK#/9%@6X$*:\JTWY5];_-BW,?E(-OW!
M)-+&W)FS?Q]2JU3>_F06Z* SGVGC[F@@[4^IJ#/:/'9S<P/MSR%%354E6TNV
M/BE;5VQ_CEAK>%FVE@9H:PW0_'O#ZHL.?.'O&]"@-PD'F3Z8<(NK=)A4<!_1
M\$B!T5G%\$B1D;NOM:KX#4[[&*K!%AZ9T@5E=K \X9%_U6M.2;*";W$RX_^(
M[66C<6<^&@V[@U&1;/LY\9Q<GER>7%YCC[/ <S@O[7$"7^7X@"2C"46#+C2X
MI,G<>&8'7"Y/+D\JEP8L]Y4IEXH#8:Q.6("1>)3M38R2AOT=X :?]E@?N*A8
M6$<49A%&T9*A-F%T+!WNBV52%9I*+10XRD^FYH3#] MX3?JN_#_]MV+"B"ZL
M:,?D&N0:Y!KD&N0:Y!KD&N0:Y!K.:PV)+'H#5K3G&JI+S]>ZY!;D_$_'.\?G
MD;I*9$L4.9S2_Y;/EL^6SY;/EL^6SY;/EL^6SRZ>L\BQ>IM+!>DE22^IO)?4
MMLQ7 WL3HRN*?>L&B/'@&/ ]XGG P9C;#;A%"9C^:FFX&U-_^<6P\ &).Q[R
M7;J:9[;>!]M<IJ\687<8EH)S_>BI2?^WCG/4XMB47(-<@UR#7(-<@UR#7(-<
MPZM?PRO).F;@)RH<//!(F[;(!#Z4"Y$+22PD!71YO(6T.3O;P(B#[[5G(""Q
M'W"J+?O);S$/O/JJ6\P/C)26@H9HZ8+J[OS> UI4_?K'ER.U=L\Z<ZW?5:=E
MQS U@AODL^6S6RQY&K>@?47A90O()9\MG]WBH]FX!9V^*[4R>. "YE:U3:GC
M/AM>4W8X8#5;MPO#K7F\5G7)A0P1R86T;"&-"A')TI2J)EC7% :J*05QN&AO
MU\**J4;Q4H\^R5N-S"[3CA9 &JN=^6S<'8\K'W70JMR:7(-<0SMD6F,7=HBP
MK24 =<:\)=<@U]"*P]) 65-= *N0N2<(7NUK\E4<Q-)H$*M_.L-OKT!6(_A/
MUFHTP 4/ID8KL@SC] O:-PQ]L8^C'6Q]JUSM 0C<?E<32-RW+> 9^6SY[!;+
MI\8M2!9KR&?+9S?R:#9N0:<OUBAH<377VQU2;W=4!$=<EFQ(E R)DB%+$4JR
MSZE[5J)($[OZ5S19N-#DA1VC<&&/OI8CQDIP_FU_W!T/C]/8<L:Y(;D&N89&
M'98=\\(;(D9E28)<@UR#%#.MJ4:HK)WF^+&9,1I[O7Y?5B)(!)8&]W#(A31V
M(8UJKY%5/8UMK&E^JJ=Q"ZH;7Z6R!AHMDE\:'"]2-4$$ED%W-AA)"!;Y;/EL
M*2UE58]\MGQVXXYFXQ9T^JJ>@SM82MI<%<>-IIWYH#<]3MA(EO3(<HVFMZV<
M:RB_1=47IVAG.9'C.P/IJW:U_NPX[2QGG"N3:Y!K:,5A::# E74:<@UR#8T[
MTHU=6#.*-2IHISFIZSWI=^:C7E^5%1N-J-B0W36RNT96]<B%G-E"9%7/N53U
M[-.C-I U0$U94 -G+!TOT#E1.W-M,NL.QNE(9PO803Y;/KO%HJ?8@FII]I#%
M/?+9\ME23#3%6CI!+]CQ XM:9S[N]25,S_%J>F0@40829=W7T4(@A(EM_<$D
M)PN!M"MEU]B%'7N^T/N0=4I5BITJ<#( 73[JCF?'T>9GG*27:Y!K:-1A:0>X
MAJP-DVN0:Y!BIC5E884-O.;%;8:=^:PWE,.$9$%8;,DRCM.H.(XL8CER!*<N
MH.5SR<B<41%+Y9&:X\$M3T:=^:0[D04N\MGRV8V4D\W.7,L"%_EL^>P&,'^S
MQ40# R5'!SN>(-BQVIN-986+K'"1D9&31D;@ORA!\ =V%L&5(R!L]MB;2%1A
MNO'XR?(##WA%<A/$#Q $-_I!D()QL)H,6K"81>0H+^"AQ!$M 04P^;$PMTLR
M'[/).OZO"EL8_0S%I6%M=2J6E(!MV#^)OU/9=@^/^D),0@79]69#K.57M:_V
MIY.^.O@Z'# )#%\!V>[MO'P("V5KV;&B/98R++>4$5^*$J5<QM[1Z%)B[_"C
M2,SM@8":(+_HYK/^XG:B+QAN0_1!ZT"$,=[^:4;_=\4/^  V]=E8>NM?U'[_
M3>>O\5O]+7;;R)HCO-J;#F")X4LH(%EZXTGX&7N1\&/ZW6<N7QYL<XE<I2MK
M!]7E3YZ]Z,SO:6#,7BDWJ'4MS_W;7_5YP$31!>[:W\1__?6G6#TA3!E)IKV1
M846/!08&KV)!0GWKV?XG#GLE_(B=D[*<-2K'6>-.]@:5$PA3H4#HS%-;[@<Y
M;X >#XX!RH)X0#VJKP/AK01R[FIIN!M3?_G%L%"K7,7O>,AWHTQ$>2AU]?T_
MWG^^OG]_\X^/=[_=_?WV_1?E]N--SV>8R'^SWM$/Y)9<I1*]>>5"NC/_:'O$
MA07@V:#J6T<@N ^&I5L+N$#YXL$':+>ZRD7 36^5VM9S<6LIWMK>NKJU=/',
MHL4+*Z+K<)6E;9JZXW;!(C:)"Q=X:^(\@TD.J\"5[UJ9>L#2Q!(C*2OV.:GC
M<B=UDG-2=Y3 LI>+&A BBM#TA5!=5WG>=JVR[ /^FP!G*$ K8!<__Z$,P S%
M]#/]KZ8 5^$/JI(^N5D::9BDV,D(%EE/V7M%3;W,EXZ9ZEJ1UZ87<2^ ?1;U
MG$(G('X)4X>B+].%_,+\B%KI60O]$B9WDYAF6BG3@&-$3:H%,4WN:-&0 _[.
M[\[R/MQWHGM,GZ(L:%S#HUQRI7!.0&-Q9_4^$PJ<7Q:H!S8N?.S_E$BM1OW3
MV MW=N6?>3-!(KW,5SI\DPX?8*8Y9=;5)"M;8"EI?9%9Q/^[R]'/H&66M:W0
MORMB$A7*T8O#$Z<2,^4H3>-_RD+?&)YN=I5G':.,8*BADG.W#^[",6AP4G'(
M@L"/KE*GI9HV#^."4ACFB*QA88+^AC?UUN !_?#W)%-&2O%;3OP*168)D<O7
M&Y/8>\E7*EZ%TG7X)B>0RZ^X2D@,%!AI>7&Q%B#^%OIF^2J?%+U$1$W+++'@
M^>+9BV^*S8XML(,E]+IV':5] H2IF&SE7LZDG)<S#=(S/ B:RLZ\,]R%:;M;
MA]RM6,W+M;5,I&P^DR?=L( [,?:#B8VM;OYFK$@FQ,O['TAVW;.=ET) AQV%
MN"""42\Y6Q)F5@:CZ70JY"?*-XHV?$/_G;Z)<\?_;%W/6+T4.YNM\]'NUP1N
M8IKV,P(N,3&V<>SO(!A<A>V 8E@L=84_9U2S49=.N1"!.!D6N^KF^N>WO;@B
M>G#^>B(1*I":L9/);&,:_<L3JB*1.)WF2,V$R.-I%!ZA%7QOCP\J>U0;URS)
M<\"C2J=%AUEI4;:R@S.8O1'(XX-SF/44/*MIO$PNM_P7FL#BD]81W[)45KW=
M'B8MOV!4IF45>SB:/L?XQ=!9@(_:+I8K=78:>7F1ES^(U8Y@4K-'%7#FV\;J
MS*QE6V2OLN(JDL+[4YCY6FXEI%4E:>,!C*DZ&UWQ?R)&>C:QI:1[K<SB^^U2
MQE5/6YW%0B1IZY9QCA]MDNJD>E*;QBJ'A9MD4I]4+T5+GGG%LT!5Q?E6^,\Q
M7EHJYL8?.ZF8I6)N(6EY3WPUM)6:.';U!@-PU:KBLL'@NF/!572S'&P\!&\[
ME6_;Y+>M,\K_*B+Z-]<_GRZ(?V[$#"!=#B!FHRYO>'I&,IY? ?B"%?AO)?.=
MY>Y6(:-KCA&\BGVH3KSGV]P9XSG'^(?LS4B-:MQQO5;R^K+W;]]Z*C4FT]WH
M/RT6A*Q6^59FHC9V_S!:K+M5W0V 5X5CW<2A-;]2HMRM/N-7?J?%C+@B7!#]
M"&$^OMY<OTL@?WR-K\X2?=6]6\6NPE'>&;6M(C 1>&B58"+3SESM]?LI+)$X
MZF C]^@HY/]Z;V_RV:#F#9IUYL/>1 3VLD_PI@CN"D]"E#0,BMY!J-Z;R%[-
M%0'5X@E-^YUYOS<9YHL _*>O7C5RIQHJ""K>)K4S'_1&:4E=QV%NDO_6"@EU
MT!SBDPB1BH!?IUIG/IIT1P(3XNB,V6C6R6J*.K3_22 >Q8U/QV*S".=<NF3Q
MRW+K8)PISC4#U#G]01(VJZFRK$R1QO"LV/85:OIZ#?KI$#VN4=F)9K6)2\F#
M;>#!BFW)$?*@6A\/RDAE$]=SQ+2W#$@V,1IQ_VPW7CV.:;QKDA)-2JMCD950
M_M2QR.FD,Y^*@L4R%OEJ3W_%ALF4!KG4S-/?YC#DB61 Q3LTZ\Q'O6G9.3_2
M=3^B"!-WAYPR@EF+Z*DH@CGK=^:3_J0[GHU.S]0M8B@A>S4_RED1*Q:)<LY4
M'&FJC=H2Y3PKGGV])D*]3L ,$SX]M>STF5<9ORPN-R6;5FRGS@;H24SKRTK*
M$&<3UR.+,67L,T-FK1W2^.3@;$@C;-GQCY9&/ZNA_:GCGS-,FXUD %2*@#H-
MES':U[,=%=FMCH.>2AI4O%$3.H>SGRZ<E?Y] \14O?',>B1)51%-S*+TIUVU
M](S85Q/1;$^XLBI.*Q2PI,F=86O*,L^1)5^E+J_5;I_U^U13JXTI49=LV XV
MK-1@G/55=.[5=&F3#$F>\WIDU>4KCSQ^L+=.XU6DQD);YQ9YK(;V)PX\SOJ#
MSEP;RL"CE  U6B=#%LY*%T&=3>#Q5,*@XHW"+,2D-Z[/CI1N>E/CCO4(DFK"
MCK/^N#,?:VI7;0)K-IIYFA]VK(K1"D0=9_U)9S[IC6299!/%V1DK\IIM=D36
M&O>FC2DJEUS8"BZLV%B< 1=JO:&L@Y1!1UD'*:.1(+6,[XU/V*E]%N\ZNVAD
M);0_=312122ZL8Q&2@E0G]VB:BS(-3WC:.2)A$'%&X6IB;&H95^Z[PV04O5&
M(VL1)!5%(]5A9SY2NZ-)8QSPAO)."X*1%?%9D6"D.D+\H>E8!B,;*,W.6(_7
M;+*/P60?]+3&)&8D%[:""RNV%2?4K:\1PUP&(YNXGCHK(!-CIJ>",=,R#MG$
M*,07XT?CM>:4!;K.+0Q9">E/'H7$P3C]^J.0(@%SN'URR%U;8[,T5TY4:]=H
M_:P8V#G 5IY(6E2\12ILT:PW+!(,JN?$-]#9/P_15FN(LQ;I4U&$4]. IZ?=
MH5:DR_L$3'T6;-?\Z&A%+%HD.*H-,#@Z*%"I*65H$YGY%1H>]3HAVA \Q&E/
M*X(!<S()+!GXG!BX8KMXA#9$,3C7ZC@E/TS[HY,*888QQHR[YP3S?@B">?#9
M@^TLB<,N@F<JKFT:2\5Y?+CH=Q7\O[=9,3G_31)1AL,#T;/>9%0RUKK[*ZGP
M;RU/:??"&E(M6[%ITA[C2IINC7%_Z_)5QYVYVIU,AMW1J,CL$.FNGH^[6M"W
MI%V PYGT+=O)>4TWS6MV!*<4/:%0&:QT!%\?MU7LM<T026R8+HX_G=/F'=]I
MZX$=7[O;5D&EBH@BB6T9B\M6A"3Z1<&KU3YYPJH49= ;[55V\C];US-6+UG4
MNE\3N(5IVL^P3,73'TRB;!S[.U# 5=@)4@R+,2S^K+N*[BD?[>\TX*$,8"OP
M:"@7_+0I=GC<X(O*'U]^?MO+S-0?0)X='!2KX>FG:GCZA6E9F,D:%^QHR[D1
M\\)$P LYZB)"J=@NWL!U#XX!+TT\#TB#TA">PND54/-J:;@;4W_YQ;"0.HD[
M'O)=NIIG1NP'VURFKZ8Z2Z%JB%$__M_#3$Q!&*8]!G,-+Y_@,F6"YSYQ5X7S
MV<YJ0D%YGTB$I.1,H2K$C$+!%C,Z"V&P7;+_/WO?^MPFDCWZ??^*OIK)WJ1*
M\0C0 \5S5>4XSHQO9>*IV+._NY]26&I93"30 O)C__I[3C=((!H)))YR3^TZ
M-D+0??J\GU,1KG/>(R%\*(1](5PI:)73!&U(KTD&;]W86S8AFCU3.N<DZ :C
M1V"/_GKO_") C29OS> F]@GNS G<HZD89BK&)RDBN'MN3H7Z; F<LGH^7/GR
MI,BH/8&L148>S$?"5BBS)&AS!RWU7>U29N8/VR6Z@O(5FEG=DHU+P3I$CJYW
MJ\O=UGFW1?J;:Z$2GIHO^Z_;GX_V8=?J]D8H^Q+Q1F\QT<A])Y&OQI;FJT#$
M_#C@0;GE)]=4I&[K.<T<<MF)Z;"N!M&E6'DT^OSKMMPD,PVGIHKZ:]2[^4D!
MD-_;NZ#\LU&P$'=0@_'>U61&UYLM'56240GGR*G*0V-=FX=MI3Y33VJ*.]77
M:92$9VE*/S2M-1J>J:]U %33=M  \CIYE:1TA0,;'9SILG.G-&J+FUTNR^?J
MPK&RV[AW3W83V1KK]CZ(M\5ND(V;#^1K:./V^4CZ-#)'E@0WBJ?E9R"7Q7;R
M,I '@-.=#AC(M>X8U7"\JYEQ71R.IC*N=:P5[FBRKT(=EE2 P=THTCQY/:IT
M+0D'_":T0:^J%\!I-G [A7!N<SA?+=3K;B&\---32U>O2].%N]@U?S!L:_T#
M&H+E=#*GCR35Z\*'*JY=!1577<FLN):!&U)QS5UQK3<=U4MQ+5O+[*JM4?^L
MHY;*J&NG9!;6. =^8H,E_"7*Z[(O.%0S!?I];!7BQPDJL+:*V^+U5US1#1',
M&#"7.IQ@Z/-XOIK049^[N8(_29#U"M<0O4UK97!W^QI*_)^MSQDJWL&K;NF<
M,L2[6"ZI-?FN=)2./N@HVO>NSBD&O@*TZ.V]?1A=: )@V$2W+<#@I9 M<$^!
MB, 6F#\9+VYK%-KA^MF"[1ZPP6&F#?8Z6QN<K:G(MT"&[+]S'VTU0)XG<^+-
M/BB=SIO6+_NV<, .8$F9=J!$=T!B^=8<S<]T#8YD<V@$*;4_V%SC![>Y',[5
M)BQ9&UYDD)F#S/,GSQZW1G>LWYD]):@. 5Z[O_YB;*KM]IRMN)=*0!Z1SSG$
M];.>:85)";N3!:OGG<J,E6<'5QR^<KS4.N@<E&SGH.XXAVQ,1!<RD6;G]=_]
M?O7MXN[J\O>O-U]N?KN^NB777R_/,O3#"/K)95PE25-;>S!C;XV^VAYU80%(
M DSF&:#DD,^F95ACN('<>G !M167O%UCTSM2V'K>7EO$F]DK%S0H%TD3U1Q8
M$5N'2R;V?&XX;AO4H#EUX09O1ITG4,1@%;CR?2M3CEA:.L9P"*6JV2A5V\<Q
ML_1P$D&$U6J?1SLF G;F3&_[5IGU!?_&$C "L )TB76H9#]5 EB%ORA$5%\M
M%CS=M W%"@=8:#U9GQ56#Q,W'=%OU33;9C?YRC._YCL^MS3GZ"U<'(J^S!;R
M@2O?A<*S$/AM*>5U0AH]5Z0!^X9I3F,ZG_N&(+,S\6__Z=Q;R-?!SYB]A8R9
M,>LQ+#DG/B:@+IJR_9R/+V.4 TL7+@>_;7=X#9EUD0VW]KG["?/WGV_Y[/V5
M=M_$VT7BX.F86E<0KVR IJ1V1&I1NCK()%@F=BYDGQ,QB')J EE?2#.G#QD;
M2],SYFWR9*!O"10U%'+NZMX=.R;OX.S0,85?75*DIAI7#P7=2[8=(:$UC.<@
MO]&',P,+Z#DXDT0>*=EO-O8K9)D96*Z_W@C'/HB_,O8JY*[=-SNJ!?P[!/W!
M!?SB[>S=7EXC_F8)K:$XSQ(SGEO/'O\@-B=;0 =+:'7M(Z4\7(CYN[; ;LED
MYG1;2?ZZ)",N[$O1WZ0RZC[;#MB;E&!<:LMVX/#8&! _[XL17#W#%ESZV;$7
M,;__';!FEW_/_1_3FUTMEG/[A=+M,&U"=(WA!0\P_ E8<?=DW_E&\H4U^0JH
MY%%J\;R6N]_O_A_>DQ N" <)WFOK*(&6(4H !Z.V54V03OV6&5GO2P:5$@*5
M6B]0]5HCK:WWXVD[#*F4('+&D]#+A5HG!#6E7E!C4\3T03QAX!TH.2ZJ,RAX
M)CB-(N)F#<6?B!^ RBQU6=K#>P99GQ6.[06"G;,YRH\ ]\+XAC\C ^%Q1H3!
M>&_F/7_X9+KCN>VN''HS_40]PYS3R?5FK@9P(7:@'_&UEZ'W^2>^=3IP%7X:
MGNV\,!<V,M*/<[@E%3-I$0IGLL2E.2NZBR=S;MP?#O3-^6C]GC[P!X<8ID,>
MC?F*^="#"2 /J(3"X9@6HO@QRI3&#X 3B>^Y.>9Y:OAYM79E(993UP/*0$@"
M?D7T/\0[!F6"WEJR<MGL%KB8.S%\G!OC'^]OQS-[3OVV\F1A3^B<V1A>9'C,
MDQ\A)W[S3:!.=[7@2'$6"WFF#@&&<#!)NU8[<75?K/1L*3DE*]("W3FR5.XA
M83&@7:JUT#$Q[+W9TBFWE=/.4MA;:?/AD0;*/M/>S[U80Z%NZY6+:<1B)%K)
MQ>2TF*R91T7W3VWVQ"X]L7,\+E57AKUSP3_=\R;[NM%RZRA;&Q(HPI<7QW<%
M3-- (/61G%K;1;1KRF[^*0]D]X&HI33"+)]-EU"$E*(I"F999>KZD<,7:E,M
ME=U+'TFSZ_-AJI'8SWOER)F@N1O?WTSWQ_NI0_V) "!'X.O4]8@#5O]A,P&:
MV<WI$UV',F^F")7/ )1K'QK? !CA]/O?N-0]?(I]U*&Y7$7SZKMKA^9[-8-'
M<X!]E30MYM!\(_OEE8X"T7!!:2B H^//^O':BMQ0H Z]M>K7:ZJ.H@*]^F,T
M#1[MN>&9<]-[>;7\/(#%O]:@*)&;:X>1\K UZG?/)#>O'@&.Y>6'(0!6W?1[
M9_'NMY*72WL@8/)^I6B0S(/S,-$5Q :5O%INSZD:2\X+Y/+_#E.X<D@A+!:E
M#07T'9R>Y/*E''Q6[O[OH[M58!5</.TDWV-_A;R]H2P\=Y<.P_?WDXW_AF4;
MD=#<Q].0"3]OA7BR-5=@'()U5A#PBO0=2?;SBWR[)V!=GK!Y-H?P6PP"U100
M<$>>@.BV1KTS)3ZV1)"4+25G@6B057[F3 ^]UDC11#WKRB>(K)#(F2 PH;5_
MUM>+HXA7J%2D-1A3Q&!KJX'XZ<7!T.TB-(52&HOR"BBA#I60T)5?L#KVX<^1
M/.!8,=Q1B46G^IR]E0FA?EC-TMH&1VMM96X^9\&DI]?49)ORG+6\8]"F8LUN
M>+QF5^;N\R6:?B>#-E==,^;7G*V*%2&[?4YQLN6=N\YW):NN_RD@4[#R+IYE
M+T_B<YX^U/V9UFMOW GD70M2K/,8O'XP(9Q@]FXMTZE?!?!3D'"AV=4'\JB>
M%+EU7U[=1*[,I)>9,S*3OJ%IU/O'/Q211MU7T%TW+#"-6J+ @?DYI:& BIGT
M0YE]*3-T9"9],9GTV4E9/8R4M=:HR)(8>?PE<?(#C[_;"F:'2#XN;0&915]>
M%OU^$C\^B[[?DUGT-3CXK+S]^"SZ?E]FT4L=_55ET?_<S SAK$(AWSR2?E+N
ME90-%>:)EXX%V!E!/>O$\VFDK)#)T4U.CA8(A28E&58L'(:IA8-,3:T1UE0K
M3 :=],)$YF8>.<(X>2)J$X<8]\H:8MSK9AN$TFO:$&-8<:8-]NLWQ+B?;0>#
M1@XQWL+DH& H@F$BJ@D;])6,-AYD.QU=CC:N^VCCFDTVKNU@X\+F&A? 0_5L
M5#J48XT+&&O\&J<:RZ'&N8%O2T>O$\KD.E3S'T>/-+[D(XW]LP?#](&%.."M
MN8XY%@%WM\]P/= XXDB5\XQ3JD?[YAGO<!FE :6<9MS :<;LX)E')'"('#O)
M6/+<VLTQ3A&)$?'4K2G&HANR#3'>'?/?PU[J.<)X-_T<[SPLPJ<US&3-8).
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MW\ S;7C#?U8FO 9P8>60&: >/-1=W?]-X:V/E!BNNUHL_068UGB^0N8'>_"
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M_^EZ;H6^^@?3FI!-()>XG!NN2]V;Z8T#)I?AO' V<62]_]1\II/W_Z6.'64
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MQ2?7XWBZ35DJ$7<>X(<,:&4??]*1@Y[ZJM@2:-">L%-_X2\+#<(ZVS.3NW9
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M"T SAZ]."'H6, /,(I__=7-Y3:;K,"^V0<%L7HNR["_/>([A:@)-)_8>WPO
M](VP?\[W@7G,=W^[MT1MOTMJ=Z;S-^I2YY'>3'\S *TOK,D7=GHWUCHX?\$.
M[0]JH'ML<N%]-DSG7Y@5>#<#E'Z8);UWJP<.W&!;;%[+].H_*]-[$:5,_W7[
M*9PO_5Y;ITOC;P!)N)8A;QJ+Y'J"XHN\,2<)'U\C$A>-LNI)HZS::8UZO7A]
M5)U0]D31MVC$54X;<;&\3U#85RCB[M)$65,JD1ZJ;0V)V*<>EGY_KKKG;A4S
MN8O2EI99WD0,7SL5:YF7G !9$<'S>&98#UA6@.5BU!I35#D]Q[!<OY(%5$Q,
MLH8]\29(]I+R#'JW3FIG$4\]9-I>?JKDE7\TG]8G S?>;0XF=VZ5FDFIK=&P
M&R^AJY%PE=BU3^NK+W9IM<<NB6E9U+3Z8EH7E*U>PN3S2G2MYPS^V>#IV5/(
M\NF<&O:,'JU-8C5H)G6OBB]4XLT4>2YK)!@K=Y0(.'+!&EHQO*C7&O7UA,9O
M]9!Z$G6.5K^*01WL4:['?08U0IU7@T:%>[\*=C\-6B-!]\D*O4\5:$1'-)K;
MK1/M2 $67LJY-"#G\D]1ZX&^ODE]COR34.!Y8($_R5Q07Y/Z]5(+T45YTK)0
M7!:*GTBAN"R>EL73LGA:%D^+UI/?ID6U;AMM/ESPQI7W.^,Y5+A62+W: )O
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M;P A/Y[QA_#W$9LI-]0]2V9/ &+Z/)ZO)G277'P6L*'G"//2(P[2&.L+/4[
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MQ$\WI>Z%-5E?N83WF9&A@T>.&>SIRM%C!M.E@35QS. %:_4?:( <V0(U,%
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M)\ >(T"M)P/RD@";1X"G(03[C ;503-R0V4\_E1,?#F37C+70DW\BL> *LH
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M6*;-'"-M_))#@=O0-KR$& M[!>^<&2Z\CN(C6"WW?^&+)E\VL$-&%89'D:/
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MQ':6,U@<2'L?9]E:4>Z&9!BLA]WP!,)I"SA UO<_3/@:?M<%!>T'#;S@&SH
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M1 +2[UF-1\P*$N;U"(U)[)"?CL;YLK;Y\'9@*M3FS^\SO_,Q!S] R,?WC [
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M-:*=*D[UJ$[H_>1DX+3!ME?6!#UBS_X: ":) F1K]!*"FK5HC7[$F132&[V
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M$?]OIM]P)5$#FETJSLW1QV;<[8[ TX&0J0P@=_:R"F@,6%:2$!K'\*#[=1
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MS62QC7BGUNW$[&82:)6\QS_[.Y@V^NBVK(V[F6@339OLO8T_B$K>Z8OS'2Q
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M[9 OAO?//9[E0Y]E7IM,/X%V^C1NRQ\*F-M"!D*1$WYKVA]=F39?&0$ U0$
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M'L@H.@=;$C3DTI0EZ#2\R,TDKZLH\<X&3@T_EBPB4T53>V;3?*FW7YPO%K;
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M;>6\(:/P?Q,[-^D,Q^1%8[/9^)75/HRJ0!<Y!2UC4('HF0:ER!<42>]P,-6
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M+LEJ-FBY#KI=?=A\I>>:"E_I3[OR^<@N!_F("ZFLJ#K"G7"L8$-K"\\B-<#
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MW!I([UKZ54^VUP<E[TA0\H<^*-D'):\1E.S4REI@ZQE^5Z3CG3F45"V+I**
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MV^Q'5_KR9EXN.VTO6%.7@7PFLQ6IX\8%OQ3B#6&N0A;Q24YM_5AXSJ0RE,*
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MWF@^QGE!C;<Q9!+S>/8:3&NM/WNKCYSM<S7FS+KGP.Y[4KI&,+S,W'@%5Z+
MB,/)G-M1RJ4LT9/FL,NYX9=2,Y.4GX-0M<2W.0+/(6'F2I#6G'G5(J44:3SN
MIJD4.PVJ)V.0V,",WXMOC6+V@*I/N2BUU9T&?PK.)&6\9S/Y=-!_-3:9E*O2
MJ:;#U!*<D>OT6F&EES;1[O)ED''T"LY,X#HQZ<@:)R .+T5&#_05&,\)4S:I
MX_HK06[D( L&L<GBZB"<*:RY16(9=-#C(N&&MG!>2M*#1#@(?P2-K/1EE>_4
M5]AD,<%:-:Y0PU(W7^&.S..K7'G'68/"6]5,]8LM[9P\")\Y;X-'X7A."[,
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MTA:2-D @ULA7'H7U58*J\90\ 1AA<QW2**BP<?!=W[Y+JG]>7@O(= 7L1T?
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M0_Z.59P X?<C@I/&(EEPB_6UH0)L.I=SD_0I<ZN!!'A=/!C^DA;0W QB9 N
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MQUQ#G0^#)1=DN[NU(+O'L?S]OL=ROSZ6]SZ69Q1-\-@'\X&%WL2YW-MY_5
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M/ =I-<?+#T:>G3^>A:/'<W \P,*[6?"3ZFK<\N_&UY-WE^=GD^N;1RG+CQ^
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M&U[)GK0U0\W*]:#-ZMA&9WT"L312QF?<J[S1_01)P0&#?"_""=WK [72[M@
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MU>[9/+.'25!^]$[A%[2/IZ4&^<%@T:ZF2.18K\OHR9=?,-(7Y@)V&G&V&UC
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MHUV\?E3;K9VD4 1ES,;VG>ZTXPJB1A*VD ;4).W0%>3CL.P36*'9^-5QQ#+
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M:!K4:B8S]$)"$0#$'.QX;%!.M'0DCR2AEZG(&W$+:)5$D_":ZM)&I4WU*RT
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M(')[-/Y"7G1SJ,G0A-LU4!UBJ;-<!;^? *,J4,\UL+27M>Z2@:>W H4)-91
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MWB1S:G*9^#XBPNK&,"WC0HA4BFMYKN:$.W(>#UPS>72U(NF!8HF?,2\(927
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MD=$"UX4DQ!EI HU%EH>EP_%%C-[/W\=97FG*-S9.ID_SOP!02P,$%     @
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M-]T=N:@+&J2#P0$K6C!F@FW8F=VC]Y(N_-/K2>^BM=D7F(SEL_T54$L#!!0
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M4(*\*K&'WI$L9)V"!47& $16AG,8=>CY813FNKZ(:ULH%:K0Z7$G;MV-Q<N
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MQ9G;J7AU5>JCX_1E3#%R-%=UX$P@NT)U75:7^K[I68Q'<29ZR325*[=N=%.
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MX>%?OGND?U[\X$6@:O!E$36X&9[?"),=N&E0>350^3J^?"-,/O+""(U2W2#
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M6\-AGNS_!1<_]X\.=_\74$L#!!0    ( !U 55B9<?CXPQX  ,6(   0
M9#8X,#$Q-V1E>#(S+FAT;>U=ZV\;-[;_+D#_ ^%N"AN0GVFZC>,:4&RU,>#8
M7EO9[MYOU PEL9F'=AY6M'_]/0^2PQF-;-E)[%Y<%VAK23.<0_(\?N?%.?HP
M_'A^?/1AT#\][G:.AF?#\\'QX%_;!SNOCW;Y$WR]:WX71^\O3_\MWO]^<GE^
M>?WKQA\?SH:##7$S_/?YX->-2"=J>ZKT9%H<7J19+*.-8]'MP/TG*BE4=GQT
M>O9/>_%<A\7T\)>=-SK9$#+2DP0&4.-B@QYS92^+93;1R7:1S@[W9L4[83Z/
MTJ)(8_YJG";%=J[_JP[W]]WGL8QUM#@<ZECEXD+-Q74:2WA2__SL]XM?-S(D
M<N/XZ/WQT:?CP9>I'NE"P)S%T>ZGXZ-=^'KW"B?>1L?K-0@Y6)>0@%;&4G(Z
MN#FY/KL:GEU>B,O?Q,W@Y-/UV?!L<".N![^?W0P'UX-3\>GB='"-O]%E^P=X
MY?##8!W2OQ_E'JF#?YU\Z%_\/A#]DR'2MO_V]4]B\\<?]G_Z^[O!EV JDXD2
M_:# ;WYYM[4.W0<_W4_XWKJ$_UGFA1XO-H[[N4C'HI@J$<I"V;_[25+*2%RK
M69H5(DW$;\#*XNBWRXNAX]VI+M1V/I.!.DS2>29G&\<'>]N_'>WB5<<X$EP2
M3&$\G0N?O>"C%#.9%;UN9SA5&3PWF"9IE$XTT'J6!#MVI4[2>":3!2]23]@O
M,Z!*%CI-ZC_,%7\6:6:^*7.[OE,9TL3&:12E<YU,1*Z",M,%/C)3$YW#/JI0
MS,HL+V52B"(5-RJ@AR2C?/9N_V!SM&67Q]_!0]'<LVH_#G _&JRWM($;Q_P$
M'$:@^NF_/Q^(D\'Y^<U5_^3LXO=?-_8VZ/-5__34?O[C['3XX=>-_;V]5QOB
M_>4UB -];VC@;[9!19WWKVX&A_:/.[FCR4I+;(YZC$B\/C9_G%I"7K]Y!6*P
M.SRM?OFGN9NG6I%L+VP,</"U [COX3_7_..U78^9G*CM4:;DYVV=Y#I4A_(V
MU:%XV'H<-PB#/6VN46,#AI=7A_NS+R)/(WC:#WOTSSNS8=OO+X?#RX_+%UB%
M,M1%1#*I) A2$,D\KQ1%M0#-=3(DB*^D@=G2,N?RX[[[[#,9HJ3>+.)1&FWF
M6_^/YGXAXVKCE54WH(A)IQZ]OSZFQ?AT7.FNVNJ0"%3B^MQBL'JZH.)CF-;-
M5&8J?\#&?L^M6SWV\,/P7W]Y(B_Z-Z?]?X@3.=,%&/&/,ONL"I\KX']H8X[;
M(2:CGZ_$&<C&M:U%,WDGO/DFCUV"-T=GQ\.:V0]5'F1ZAH8=Y2LM,Q$PG3G1
MZ4&/BGB+(@BYY&4,5"Z$3$(1IG!'DA:(&P@J 6P8*1QQ%JE"[8BS F_*R]&?
M ":Z'?@9;_L/@"L]UH W=")TD0O889VI8B%&"T C8Q#G)% X&-('2$D'D2*@
M!FHA">'?PM)YM'M&*N/LN&\NHV]VZ2M#=\\@,9B*&.L('BLK1+:_LX\/^IZH
MK]NIP;X=P21>?4\&7 %T+]);%8]4QI+W>J\G#O8.7O=P^K X<_S/3V]Z;W_9
MZ^WMOP62\Q)7"[8L+8N\@#^0AVJ\0;_.%2VN+(MIF@&! #;3;H=NA]]%F40Z
MAH4+15+BTY&2VB"P0QIN+0M<('$KHU+MB*=>(124(I-)#OPGP% D!4^.34PF
MLQS&RX@E&RL 4T>H7H*:(BD"7)_!J,+@=YJN3&0HA2R(WV>93@(] V9+QV,=
MP!@@"!^!6#!-44_\H_P1#!\,]VZD@AX1,4PS^#GMB<NDD)E.^=O:4T7MH3UQ
ML=/?6?5 ?!Z05*1)#Q1DGH.9+7-5%/G.$IS_'JH19/,:O6_8^"LG[SG/Z5K!
M8FMR/7+AA/FI%><-JRRK&F#]@+%!05'0@$1IFD8AK#S^.:,YH/^4&W;V?ESF
M%=1V141"(I ]0GT+4 35J0*,B\. &L2GOD]E!J(W[G9.03T&19HY;]7S GND
M*!,E;E/P8&? O,P.L/6Q4@5(;&Y5/?U@:8/%[B$?X'#J%G6JN2K2_REU*-E&
M9$!>#A:V=(^:D4(&9BJ4O3U$ =&CTIH5_ ZX2CT%/[7*<7W1C1[+%&Q4CA-%
M^HH4T0&L&:HTLZVP>(74"7YCC$_E)C_#3"Z7M@RV%<UMI.4H(@,9&)03R"C*
M+=]XS$$BQ=I=?8%=0G,-_)K>ZAQ_A8T#.!#K1-(RR G,'G0(<B5=CE^F6;<#
M=^0SC ?<*L/;EED:[(U&#OXH(^(FZ9,OTCFM+$*($1J30@/AE458&NV[FP"C
MBD[(N\AQ.5DKB7Y1@$94(2&6RZ59^EKI*2W4&<HCKB1N/+M$N-V&>:4AVK)N
MG6:\D!0$;@MPD)*PSS__+ YV7[^R(EMIK6ZG?G>,E@61'=X%M\LZ7QH]0UP(
M!*"9)*1&@K0FA4]F>>X%=&"2ME4\0V:WN,[PQ;.9HV4>#%/2! &, C)+$GOO
MQ&;+$P/@#IR4NRTR)LG:BV7MMWMZ]D^8OXGFDX.-OMM,Y,4B4O6E4/'22N!7
MGA<^4L KX(5'<[G(P;$^VIWA0SZ QW[V/S"+UQMV7,HV'/[PEOYIQ/_,:IT,
M+H:#ZZ?.-ZS+=N<(@27#&MC&:[?>E_,$8ZTV&OML/':A-!H*AJH:8'LDY\!C
MC'C[S@G+[N>S]XMMN#>W/$;@O](#I(%@9O>-DJ3)-G Z0J/"#@7+A3H'J6!E
MUI2+GDAI$@6H1[1&9.I"]C21@K/D%O E>9 &DO<#YTQZ/U:YB6=",'5:P*8"
M)F-W:X$P)4]Q/K)@M_+>M>3YX8K:W>79V77=A*4*U5@G;J6ZG3H%6^#8@FX(
M#!D\(&J?+(U,WF%Y$-$< [<^J:"%8[51F<-M.<D#NNC"\.(:4T.E%D0IW#^Q
MLY&S6:0#QC]HBS)UJV&UT2J)69H7]GK4H'ILKT07%&>=I+<&5]\$F@(1B*$&
M,-<TUH$X!:P<I3./A9[>56UDK1#>I>,>P]HI; _)B#]SA&(A^1"\A;FV4-UL
M8;=#UZPEE &@NS*3D5WNY5T$'"K%'VD&5& 46XG+;"(3_5]>Z)A"$/#D$AZ]
M %9!'DDSQ\]HUP!@@+)4VX 9@9M(E8,/!G8*^3WQOZ!H <V0' X>17T)E IS
M<=+_V_[.ZX.?.=XQTE$$!.Q@8*?;818NB#XYR92B+;74F* 7#V=Q=SM-^1J<
M_U6;([[EWNB\VWGH"K[]Y6UC!5%%+0UA)N1FR0$3X/KIFLR@33QIY:;03N@D
M5%^L^TPAN]]/K\0D2^?P(+R=O-\0I06C5T$ H!FD/5IT.Y1/6"B9$0]PV#(W
MH47X- *U$2WX\2&%,2F2@EO'W-*<LLVX^BZO<]%;EEXHC'W:J$),H6GKP]D5
M,;=3E  >/HO*G&(XZ/3IB$'")FQ/5!*^QI_2&::1\9-W$? <.'9\<[<#R)T7
MA_Y :P(3P!C7LVBOO RF/5$FY,PL20NO^&I9*'$!M+'S65I.IFTW #9HNC%H
M :((_^>YH+#A]"6&FFD#MUA_K25O=I.MO*&1))/\8.U'UFD5XV.@QFZX%)]V
M;G:\G^9I"8\:6?G#T "H\P3FI1TK+<EZ-5TGZG@I>OD<FF_354_/*W]0Z.(.
M=M <<:@F3B%<&9APU3*2FJ@$A 5W'; AQ>=YYAIS%GA530JKD84W,$:T0:![
M0HYA9<U%/7-#I&ZQ@N*C3B@S20D0&#.G5<5X&NYM:%(EU2^D=9L3U2CVGQ7J
M)+H<J$H4>N()6!N*3AH(@I[9TX?+&WLBX2%_<IS4+)\)KVED0)6S;F3C@Q?I
MO+X8C>':,":-B^:)1B [!.:L?E]$0)(<@(J@45G<+]%IHK:+J<Y"E\_)1 P.
MJIT.QPRKD!7Z(/6P!FF2VMQ-7HV6)_ "<VEF%\/I8E2(FMT5Q!A9/M4SMW86
M6/@T$&I[&!'XI4^&1A])Y:6W"\D=JI<6W[^?)0%L#!B6!&\'4D%<=#XU/-T3
M:=+DZUX;&3:< 4^*&$>-0=IL3),]C]1I?!!T^+9:)EZ(:JX,459RQB-8X=NS
M0,7_./=6&6@L/=AQ[_Z\2E($'+GF@*["7S%':X(ZH),DA6[A0NVT(2:=;M/H
MEBAL![8[XK+RIF%TH";AJC#REF ZQK$D>F!=3,#(E*PYQ8A4E6!LT$I%*7QA
MR?5T*N7 F%)D&#]"V.T8^^TL'>"_>%:(<9;&;3K>&<O#IL%J5#D^KCCMVQ:9
M>=5KS2JW9A6<'_6R%5X4'Q._BE7%+1N-.C$L5%LNO+!%9*\V6FLP.$KVXP]O
M?_[[V[;[]AOWM3S!'ZE^+6Y/P[JX2I+Z!HG59FS=VIUVH-@(KA+^,U$6HW;)
MAT"9 N"6Y<KI0KX*^?WG=WD%]3$10EB$$A]H]$'#9SA8%5-]1\Q95::TU*6\
ML.L+N];9-6LX0BU:F6%HS:&T>AF\9,"F-D4CHE0R$$$MW^V,@<.3 +-RX!EH
M](],\ O-$]V!P4?VF5E5L\7C#+G)*3J4T?3IC#/2@+>>#9,S' 2>7OF%[V7R
MN?((3U+CZ((I.\E4"*"CG^<I4,P&Q%UXEN1E1M1S-02ZS&@74AZ5"R5P8N>P
M .0D5A>]HQ]>)/-%,K]2,JF63>;&-0)0'<MH O]A !RK;*+ >8=[J'Y15H,P
MP ._)E.I'SFHJOALC9D2953H&&/ )H"8HHTQ?SL7V2!I(JM7"YG4\#/:P:;#
MUH,YQ%@4 $+)*>=P9X5PO"0'OX5;_<GIOB50395HL6J/,/=<.#FA<++O!HQD
MCE'?6&*D*R<W@U1L(3^KQ#I88Q5B7$1,TEN5)2;ZA+4<,Q688HZX!*X;92F!
MFHQ+LL<UC^+Q@3/0_^Q+F!03E2;-IRDV !!NHHX9TN!IY6-ZP81 9MF"ZE42
M&^0C<P6WD9OLQ4F-L\&A$W95V%UTP9N"'&YP.*:*'"",5PKR@=R:/WZJ@?5B
M>,(Z^1.V-RTI^;7"DV+R7$@)IG-?GJK;\1-54\"CM'$>9^#C0@7#Q0!9W4S=
M)--LS=QBVQ1=U1%*L$#&PUA79>K;>)L#C->.BY>OF8#B2D**HYM8F3<;1AT
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MM <R>'GZ;_CRP_#C^?'_ E!+ P04    "  =0%58QNN:ZYP2  !Y6P  $0
M &0V.# Q,3=D97@T,C8N:'1M[5QM4]O(LO[N*O^'*;;V%%09$TA@$R!4&>R
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M$^Y8[#QFIBA)0U+R<*H!J91WT%!&H/]JIH^?I=/?Q/K]YBF:U?O]#X<G]@_
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M3(/7RT$M(:<3<@NV+S^K5+"Z2$I&.RJX-6>2S+F<(+V:"?T$R,0;P0SYUW<
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M<YGUS6&P$IA4M)^.%LB]O-Z+#1.<V4 T@0P#+X3<$==[Q>GV="H99C,F/@N
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M=#JS#7TQ8F)Y:VU7\!&I<$?N0%+CBM2$+^A+VO]3Y?:=M?LJE$TF#T@#F$0
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M_@E$TLGY5:>?6H,QC]F6B@ ;1Z&XDQ3V\. -H0"9$'(KDF+(@6_P_E/[8PX
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M!>9#I*UF;*.B..BW 4/+#SZCX5U'L<Q.+O!Z&3%^Q^!9XS(6"UHZN+.E;3J
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M]U C5>-8*L1*-+)BD2)1BM%=O7?1-4#8CK+"EAHGH F@5\"M6FGC[L\O=+^
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M,(7>2$2%9;;$NH3;'&U2$:@B!>A>@!LKF^BP$/44\$ILZTA J8QNKXS6.M&
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M(.]&>VN1^V@7&MWQH#N\<M3:@ 0?Z!:K/SC#+2274;@%]8O[4'%:I._<O2(
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MQL8BH"(Z*#Y6)\4';\;H$RS?<++GGT-L@>NI-LRY9?NL(&?48!6/SP6=/6-
M^:@ HBMH8:FNR>6/?BJ@3B9)NZK_2WP04"?N< .:._5_^4"?\LDK[2-L98+M
MA'\9M-S,:7WXN3:\7E/S/SYZ7R5W3*C/CR@H-E:4>8PN:R5XHTX&[='UH#<D
M_:MNI_EE[:<M)39^\HU'"-OF4=*,GH+[[;9"HRF&QJJDM3N9>ST;;7Y/&^V<
MPKV_KB\;IZMV]6$D^)2*K_P;[13_'/&@JFWUUYUUO@'KA*=7K2]P4WU:W_\
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M/*WZ:UX[*V<IL74:EB[[WJ0@NBDP&QG/$"E&O*GX@=.S*[%?)WI'5GC;&LY
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M-7I3,),U+ERQ@'6!K10R\S4^C$XJ&?-":M"4A:"LW AA5LB"4JNEAW_ETE%
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MG*/.!D*HBD6:'3!B00HVM^5'S@$9X/$0F#Z$' FD7YWKP&%K#&>T#!B^S?#
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MCXF;11-W'))GQZNF'ZPP'#E$9B+]>71,#"O&O,08=WV\)?VA'3E8F9)LK=^
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M.PB^/=S['3[\</KIXYO_!U!+ P04    "  =0%58F3SCY -!   DK $ $0
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ME':6&J>T?_+EM'=\WNT?GARWH*/'5U$["#KZ,524!/5P+B.9SCSU9'6.<:7
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M6L'UV"2[S,JTH<L75V82%8X*V)$(\\!$:-HBH]WP@XK/B<%?YXQ2_XI.O5^
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MLI%A!WXS)9L3DQ#'-LW-"ZM,>R(+R"_*'7HC$=N2W">@SB5%/:(X'.H(V[K
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MS0/4&N[Y_>BSQG]XY0:4]NB+?_GNM'MQ!,*SQ\+S]][Y;Q>]^AHJ)B6[N@O
M@PLM2Q\A]^(!L(-]L#"[_=[^YV-P@#\=]L[%X?'^9A-^S^/M%]\=RKJE5?=R
MZY&LNJT;K+K[VE3;._>\P)M?:T;94\@=\AOOQB5-UEQYF4>1F#L/L_(Y9_G)
MI.NI2G>_7Y@^_7K1)CR05[$XOTS2)$ZR)S<&[_MZ[[G3/XUEM/36T$+>?BJ"
MW_)\(6=!W(M5GX+V[A]LFN/OVU=_;-_[YOMCJ5WOA@^)3,,JD6,^P,3?VM3
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M@O.E85>QTD3F<B#-(H"C0WX(H#8P^>$//4$ASL]&\AKX+$JFYED)]>7$D%]
MMF@:*7E?CCJ8Z*1.L[G"&*-.C';97"PL23Q8%JF.Y.9+YK,IPF]=X9T<)*C"
M"=I6N:5I&YG99J4>(%^LJ<W1IJ_KIDEN%F.^+%];MEY=;H6ORTFJ9LUSW&MY
M#VX"0G%8(/?Q[+;,%%4)5Z=L.PY:L1^695?U.>16 @\ED,-#HL?^4PSHG:4V
MH)N]J"6QGIVZPX(]JO_!<,NIM2O/$'-8*KQ=,5$RSKP&Q5YE/G6[&J4@SU38
M 3ZZ$F7__6&! Q/KM;]DK]B6R)):Q>3&SC;7F3]_OO D)A/%VET$;TUGOF3#
M3K.T6A2E,F>1 "(W5!NH!>P'[-.?*A(7](>M=T()K..PP-[.L#=. %N5S8:>
MW]U9\H*HUQ@HR6E$-DY (QAICM5D @?",3@;KS0(O YAW-+ ^T+[K\>:_>],
M[.":=U<S5+PWAP<9K6/,4;Z=J:LR]3QVH"6Y'""OJ/+(FKBQLR99<O,F;WY7
MRZ='I.(&^D5WI!3F@<09?<*0GPO/XC->L[6;[RE4<['W],][37<,4OR+Z@2-
M[S@$M0XFTU7,CNH-SVG)H_$0Q%W3/G(A,):'&;9'_<Q5^0GUQ,,#T!/ O[A4
M,>S8&AO3(I5JCMD HF8 X&[)>*0']IKVT[JURUCF@"44D1TTUS!:E>5ZV.84
MQ4X$5-L1?R5P-3>Q$2L?@8)36;KXN!;/8>Z(-;G.BI4E$AO&(,"(LV6:SFRC
MU-K0QK6!K;GCT^L> %G(292,X!ZXQDN=ET9_D_TUY]L[XX:MOK7 %?D5F2WM
MLR>[T1]@%T\GMN^"#'#6C^MUW ;('S) _JH-D-]=OE7B&2AAT*#(D3-I)H<E
M:R2K44)3J>Q0R7I@""12F%5DU^I*5;ZY[A[-,I"\S91+@:TUTG1;HS.:;!%_
M('1SX$K#'2X3+)^=F5'6'(BZ1BQG]1B"B6911[]RW+:I\)%?0629;ES2R920
M&A_$MIKHQCO*-,$G,,W\KY(T"J^PS)DOW''Q)II_H7(*/.G$58O?_C:^,L8H
MK:T7QXMA&VH^SE5-F8%)[!T"<='6X+^L55!8TYM8IRVRH1'3A-AOVSTKISDE
M/)1WOFL-3XORY3C%\L:SC (=["[:  ,-?TI21P*5Z_,L-C<8&>S4,M9:OL)_
M@SU5M2],D:Y/HS13A*W)"38",3;E6#W/QM28A_@.M]\.7S84U_S>29<"R4A/
MA3LFPPI^;V)L; JZ;*-<\,*MH)ABG#CWKN%5HM=X\ND#B\W-$)+&M@V)L3'J
M:AN,)1PZG3E7@2,_IC+/"U(0 \[8E#&^"P;]T< (N(D!<N(U5V&QX;V7:]Z>
M>>N4>K'VG@U465N/ ]ED[#6:>B 62U,/Y]G;CQWV/F1>N<T$@\[H8!5FW+!]
M-HI4$WNBE[CPP5R$!_[.D@*[[R.2@+V!!!VE,H@.5X>51XG.KQ%=_W8F]6U^
MLU-E8L.#8O!V-=F$V0QH85+&/,T@=I5B![S,AJ>1]19H4]B[9@(AE]A//UD)
M7'8OFPN(LY0% @PUYQ)8O]ZH0HQ.H/8A978G&1!?\7@%74Z-M]WCYUN-G8\I
MP555UMX^KJ[@3H /M6 =;IOGMY6:@IM=K0=7[<XP Y/2M-B6^N!-[..RR.J9
MMRJHQ3EF)N<W>A%?^V:&S#%6VG"4E27N^J7!(6ZP-S@E9'>49%>2?!4TR,T3
M]";71),0:]E#LD"<U8$QW;1,*9H]LQ$E4+:(0 [M!F12A]<_N#4\P,?%2][6
MVK J9MUNS;4WJ4SNNK,MXAV1U2(Z3KRB?YBD9<[#F"19HTV258V2U96J56+?
M\K];??KM$9L3RG,]0H3TT]"+.]_8!#.\]41PC)^S3L"1&#)P>=PZ(RT.HS29
M-QPQ*RV;6K?!(6HY:EB&,HP4:2V88\4VYKC@_7%VKVQ]0HK D&RIR[ A4*;@
MJ? >(]Q)=6D2Y81V<#Z">;BJS+&#3'?<!MMIICY-JCBS#8KJ\2<6PRP+D2\S
MD]^FL7<4F\IN$$95%FOC%0\?KWC]T\0K_D.R7R^6.OO5C!3LGIX>'>[3R^E_
M/CNY^/3YY*(/?\+'WMD7@AAV/\*?]/'PF %G)Q]%[\OIT<F?7X"ED.D79=#:
M[.G#]-1YL;F\@]F.DW@#"\@"@VXA%!$'Q5U.9NEFY2PR5:X?SNT\ +\W*5F]
MTL7$AF+GI9C 8M"2X"G@I4U#S7'0J!%K-AU2G_"-J2$P'7/MVRA>)^:T%FJD
M-26EOV(1@ P$6V_V1_RH!(=XK!$&]@#5 Z"E4>9L:LY79I,X"7>Q1.=KH.#*
M0Z_QK/UBR+;MZ@J#[%SK5IOTL9]V6[Q%76)L;]]/9,CUI10:_0:*1+_+2!$"
M:<H<#74R?^W7:&YR?IG%B\FH-V"'F97+J%T)O_3:EV9@VYJ>QPS"->X:XTX9
MMF;&1<]'"S(,JKHSY^?C6A^!O%$+LJIV];Q!V+S#R[>C'!^?208_%I. BY@4
MX*N"XVJIM!ZZPE@V2'_L%(<T[4,)"=R"^7K*75\F$3BIB)0O#YK3<1WB1Q-,
MJNHBFTKSN95&<B L=/Y*I:/,F0!S,X_A;C.\].FMA<.X%N030#<=40*4:>T>
M&KG$9AGX*STGCEZHYT1E:+0AA28D3^@I-6=5BN%53.PTOU(1G+^VO;/.QH:U
M/SBHZB -=Y$X+>#Q84WV)1T2N\!DMT =3C;8>%V2MD9\:\2W1OR_S3[9^5&-
M>!D;!6D%"Q)**5;J1LMB8S[&8#C7\GE<3.QJS'%A2V,X72-N=\=K#.R6?A^0
M?G]<^_JVE$3FEA'^BF5I*DA:UM1.QYC@;)V77J=S*_.D\V^PO9N?\L>QQ7<\
M6_QV;ZS!5J^JYZ \E8$<,L.&WBJVI6.,?E.816OP_ILM=6:BFKF.!64+YG[<
MREYO<VX/F7-[T^;<EDKYW,L!>[&T#MC-O>[!0\,&/"K77.EL&K,NK2O6C GI
MU$$A"\<DW<XKVW[KR5"0R&Z"8S2K 4D(X%1,*Q"G<H6D@ G>@3@B*]'K4GQH
M"LO8"ZL ?^JC0)N](5ONCXLJJ_HK12I>I8E1&'6-[5"CC!9"@ ?61<_@.E,>
M8=<\%I ::&38/@H1P+AHA/S%^$=9\.Q*H=.R*+ICJ^5H:,6(*M'A4>, 7AG^
M:O].>-9GGNI!00LSHS:I*A>16=@706^J37ZY%G^,]@_.VDNQ:'TCR]'4&NAD
MBBTK@ 5@FQ"\[>U+^4P\6Z(L&.?B;7LM_2^G.<T,4>Z:90/XZ[# $'&O>&H1
M3U0ND'H"FHBHPHS>]U0E6"48Z4L'^?M\^'O'U)!GBH9+>(L;)@$A'!'0"H]'
MRZ!)%PKX& ^XX9[PTN'Z8@T?S!DQ'Y-TH,-0P8ONNEN5-LOZ'%N!'DDUO -"
M>.[+6(:2#<F+F#H@G.?4L@ ?HE<@D*=VPVXY,ZQO+^7=[_LPM0\K8HZOJSH!
M.JN92Z;<!(0'XO<),7JILMS,CJ*AKC'1$-K\DX1'7@$#7B7(M*B:Q=K.+V4J
M26=988"L.%+.KH+XB\%0%(^A&EB$<A-%2$(_CV(B"?4M@#N,S&PM(QD65^LU
MR9..<)0A2L+H^.A,?!QO>(P40ZDC[.V!0$2EF%R2 1A:Q@W ;C9)8::Q>$B]
M^7?>NL(W(H!>+C4"J+O_W\<G?QSU#C[U$+CS'97OCS)#J :?GY\PCP[U-11K
MH8\UV&U]5K.1X(ROO>16C[&,N<H)Z[]=XQPW9EJG7 NT*<#M!$&NN7M(?L."
MR:GV5XQE5)4R!H.Z;-3W6"J3ZXFI$%"XY,Q'=38H4VLF6JRVG=T7)B0/_,X_
MY;K1;EE= 85&&R:MRAM4K!9RM=-DB!K,U)]CA?[<1%%L,-+\YI"K>%(6@TK]
M?4%4+#6N<@%O%'=I2MTX\4TTM;$RE6,<$4G)616&E@R0G86?+36:8I%^2I.%
MJ8\ N=OHS5>MO4I+A!)NBS80O88(%#UKV)3*FV2,6ZKCOXHX*!LD-7OCP&@G
M!W_"EY_[7X[V_C]02P,$%     @ '4!56,V=&ZGA'0  Y:4  !$   !D-C@P
M,3$W9&5X-#,X+FAT;>T]:U/;.+O?F>$_:-BS.W3&4*"TVP66&2YIR;P4>"'=
MGCUGS@?%48BVCIV5;6CVUY_G(LERX@1ZVV;[IA]*XMCR(^FYWW1PUGES?GAP
MUCHZ/5Q=.>BT.^>MP]9_;^QN/GMY\)2_PO6G]@9Q<'QY^KLX?GUR>7YY_>O:
MN[-VI[4F;CJ_G[=^74MTJC8&2M\.BKV+S QELG8H5E?@^1.5%LH<'IRV?W,W
MW^M>,=A[N?E<IVM")OHVA0%4OUBCUURYVX;2W.ITH\A&>UNC8E_8[]VL*+(A
M7^IG:;&1Z[_4WO:._]Z70YV,]SIZJ')QH>[%=3:4\*:C\_;KBU_7# *Y=GAP
M?'CP]K#U8:"[NA \Z;>'XN I7']ZA3-O F1G]PM"$M/2>%#>7)U?_OZF==$1
M)Y<7G>NCD\[?#M$?95[H_IA  D!:UZU3T;[H7!(0LA#%0(E1(F,E9-H3/5DH
MD?7I:B+S0N2PE;(H#?P\&BEI='HKLK3Z?21OU::8G$P%*,UE8MNG9K9V^%/:
MS4?[.(Q Q#TZ/F^)D];Y^<W5T4G[XO6O:UMK]/WJZ/34?7_7/NV<_;JVO;7U
MXYHXOKP^;5W3=0L#7]D W#X_NKII[;D/<Y=M<HVG-A8)@$"\/K0?3AT@SW[^
M$5;Y:>>T^N4W^S1/M0+9W5@?X,6.NP[_70>O<E/"Q=[H&B7?;^@TUSVU)^\R
MW1,?-Z7#">!@6P@[CEN==ZW6Q1YC9P7=Q"3L7KD=F[Z/QD.BG\! -PM11P<Q
M&]4?.R$ OG-P\^;H_/SPK'5]U&F=G%T 2WO=;MT</.7KHFUON#AQES9QHI&0
M(L[,*#.RT(#8M]F=,JGJB>Z8D/R@?7A<YL *\UR<5/?EXB@N#IZV89/6_UW^
MI&1<%FJ_J^(GD1C(.Z027>1BH&0/R*FO+7F-@'YB/9*))3F@M*X;'6AQ9VO[
MN;A2*A$WA5&JB,3S8L +_2K),A.)-S!SXUXGDTA<F0S>QD/5 (G$V;,CL=UY
M2515854=HX*5###CK-5^?=8!/'U1Q]/@.C T)$[8WIVUF:-_37S]1R'H^D 9
MI5/9!QXB?OIA>_?G_0Y<DOCQY?Z33]^A9SO-.P37O_D.'1\>79S^,[G)E>,F
M[?/VU57+,Y%3>_WM\5O/1FB"[B/_C811L)C(!4BH9D,=ZP28"M#XP2O0!&".
M%ORNC-_?FJQ,>QMQEF1F[X<M^@<+\\/+[5^>[W_JGX.G^*+#)?5_>X2J43\*
M%>8 K>$HR<9*-3(!5--)#3IL5I^W7WXE'?$=2-#6T0VIA\2CQ+W.!_!8D8F!
M!CT0)^! QXLR+H3,Q8U*=6;$;RCJK@C]06,B]#\9:-47KV !0/:!Z+LD>6A6
M5W0*#X/P[4D48/>Z&-#@L$K#G)Z,L[2G6=S"QT)J%,R\F/MT RF,S>NS\S>L
M#T +5^BC7Y%JM>XS\QZ&-X*74:>K*Y\\W<UO,=6+RW>1Z.!\7UU>MTA;<M,E
MJT&:0L,@\A9T%42!?I8DV7V^-\<<($ ^S1SXLFI]8"],VA63=D=H9S@6EQ?C
M1(E?Q2PFMS:AVC\'$R5D0&ZYV4;>W@P95?C3--?Z:"[U. 38%XTH@$9LOZ_B
M0M\I<0K&(=JOB ";#A,Z YT+1=@_1(I'S#7($_"R?Q2P([0JR<PL\$EW.W #
MN/^#0O65E&\F&B2+D.$P'51LLH%)!I/>6B+;-++M+#*R=721-.%8('+N=9)\
MLM#91+Q:7?&#Y0,)HQD%=EV!/!MQK6F@%F$F8K(=2,!K\S(>B P>,6*D3 [6
MHT23#Q9GC-Z23,,0#3(N'LCT%I8#?O)&P(M](!!S*U/]%]F7 '%>F#)&SPO!
M+"9 AA>":!D2P+V2^3! VR_3F"6(!ED22R0F$MQ#H*G5%:2XO(1G-1J3]P,-
M$^#Q>FJDX'GKVAEE.0DBF$WB36$/@:QNQ/U&RJ:)?!QQ+B5! W$^6V3B] AP
M HI*B?X/2Z=U!!W"4T2@A.TC4P(M.?>B3O0M?=.,/UV5(XV #@0?4$:LKEA4
M:@/A]%@=BNKH![:2,H5\SUI6G,'U,;^K1DXG68]0LP5R)LXCI$U=$&UV 1B0
M53V@C;[)@(9@ 8CXX2_==Z^0Q>0\J$S'!#M179: )6=I;62R6/6 0 &.@?1#
M:X!'H2@,Y-C$"H'-EV;W8!#>NF?EZ@JB#O*3_KQIT$M 9L*^%" I@7-)Y#NH
M9?9T/M1Y+I-99(@FQ6G[-_AN'?CD7D14&S$6U[5*-9S")+P4H'E7P7L!S9-[
M.<X1)Y^.\"5G8 &V_P<P\]F:&Y<"#'L__$+_)CRW%M=.R#G]J2&&_P3>L+O(
MO.$$R%"E.0FO1\AOHV*%TA0)F\T&=);$P2![B*Y+:?(PQAQ.NSI</.$!=-I>
M3'QZ>W@L<R5N9"+-&'&I40%R&"1!3J1I"0I3%Y_*Z2EDF/^U\_/S:&MK2R3D
M71^-@'7++JQN(3^LK@#S+UE3JNM!7;1K=:]);YMIK(=C9W7NK2S0.<^A 5(B
M!WAK7G;_ &.)/"I^2D;=:76_*<ZR>W6G0&5#8>3T1ZNN/F[, M5> -1D=W"S
MM<5"HL4O0UT4K-\]S=A3=9Q)@Q$,<:IAP8O,Y$MM[V^CSYV%I<\L+?,&RG1X
MIT Z:TL.Y"7"F%>AIBP>4%EBH\C> :SMXJBH5=T:.=P41_GJ"CZ,"(=V2S40
M8BOIC]K?'CF[R[,%.QP\7(X0CMVM']U(#12C) ;]HB9>(2I6 4"E%D[2$Y%"
M8AR%5;^HXB$RSV$D]/BCUJN0;9 WKX&MU%8$E&/XEL#,4=,<HYG5N$B2G"T,
M18[\RM[_D'K;R$K3K C8J7N'[N.:PG+ASY:/A9X93AV@P<D0YJ?BK$2+D;GH
M'$UTR2.^#(]XMJ@\XJ;(XO?B<D34>I7(] OPBYS&S'C,$8RY2>;B/,,*<108
M1$IL)'P^1]2V-U0D-F5^-0A ZY,TECB0UDM#].S?.#5# @'(IPX!6;(/3%&
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MFT</ICK-#*-;-V4SG!/FCBPF[*7*A;^,2W]MFEO8F-.U&AF5 \4P"T;\:GU
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M5,WP-YBRGW-M-P>@?*088Q!]ZN& K+@KT_>F'!68H0GLZT[2+P,]S%72=VN
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M6M$2*<DZ4CX[5AJ,S9,.-03K9(.G)N/<%;F_'YOP'2=H%J/S:ET89CR ZOQ
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M^_O>QJ#;IO :(RH0#R=M-CCIRH$-[;SX?U6XG/?.12Y^XUQLG,<6#N50PUF
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MCA>EO/6:YC; TXE]]1E8R"-QIMV34:(>A34/ZY.S6R CNCF^2)PTBVI% *,
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MOJRV/-\,5#OI?<%%_D;@_P%02P,$%     @ '4!56$,KP[!((@  R=\  !$
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M$/W8XE3#AL=!&#VHF-;X^53XV5E;_ S\)*K 3 MW"B0#;="!+.@8^1"3>EK
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M)&T\@I&MS3><-^RX#6.A. X*MG%@0V&-5*)8^\R$ 1NN^89-LE 3>M@_#P4
MF5OA.EOMG3V;EV\2^:AZ J+HE:%2S%[[&(#!WTF_K\)1BYSBJW'3)-[#SO!.
M &7C0 S#P .OF!>*FG1Z<TJ[(S+!P<8V>RH#:T7$UL0TY0"D]9!LEE46*\A:
MU3):E20$3_RTUED^4H^N!BPK(X78UP7U7FXQR)U#45)K15JJ2:$*HQV557!!
MH14PUI/W60&7]COQL*!E"Z#A,94F._62J&IZR.RS^\RYH@S?&Y.[P="*CGO;
M'5/6%;./I>>8RJ^I^=M<4)[-#/,0LNEEF:^9;FIO7L(;>(8P7.)C4=OT%IHZ
MP*$.<*@#'.H ASK 81T"'+[YZKY'BV-S1:AL_+', F79BN%B#!W'RJ)9W<@D
M;DXF,:9_8?PK5H[CD'W^%E6*=<)*=9D-P4B$]W3=!.:XQ6(OXZ@F,#;*I*V@
M=&N>R?1@:9ORXVR)C)S,DP5WYTK;6/YKDR/\!.^OPE_F1QTK#P,-6?<T<][,
MM(75UYP3]U!"Q&)XV2CP)@!13/>B\)7&(=I^*#&$!!T4;!9,+@CM 7D<$YD;
M*:L?:"I@4:UY/CUTGJ =2?EV>"XZ8<?ERY6;C;EALY)B+'UBV\AH6K:QN6J/
MBH?D M-S*EBT+;I^7M/"FD.I+F7K=7'N"I;0M3VW"%94X76;FY>_]$4*#T1#
MMG3EJW;0.9J&A4O;\@C0;"Q4R\0BK0QWA47>?/IA;!2\R-R65E(O35E':I:8
MK".+#9W7&39(+TEO<Z8X[8ADP=A@@IN:172$=<.P]!065'4406E)#Z7]*B5*
M-AM\HT&<U3U=L:_2= M>O@<U,^AW*Y9?,J7L3M'M=@A*DFK;?8L-LTK/J;!C
M4I;#2H9,D;=CUE;+U:V6ZWJ##5DM;Z@XCB1E^Y-QGB'$59::2G(O5&AX54"S
M0@V>JCCYM!@;I1CE?1&4.J3K4MI/ )AK76"T!UP,F$+79C5DJ6J#A;?Q<A(&
MTC<N&VEOY\IR+ L-F@T2G@V71PM$=QIJC\&@O8N7>.Z\;:6<E5(N.#7>Y*^1
M8<<5%W+&;3J[YHY1;/*OQ#./VV_Y<0M9X5"1A95#+=*J\Z;0%K;++AB#[Z&.
M<F(=!:A$,=^7@XFJ)@ED\6:@?YL%61_%1)"0B-T!V3>6.6*#]"KYO.W3U+"F
MOH#,L_I]Q':OZC+ 3X>F:UVG\ -J?N3".9?W*R5)D2 .: =BCX7C6^J$I:Z*
MZQR:#2I';=.:%M712('/OFVK5F1W"T/_I=(;@RQ1"J6GB4Z%IS] U(\P*"YG
M5,;TPOCAF1@:-;]P#,X",#"%]?&AD<JCM/P+MT ULY1,OS@4#\17+PW[_'=B
M/ )V/N8K3 L_935%Z?Y&]06O'(@PD!1K_]6)XD^ K^M:I8GP]9S2HD^"Q(^4
M5R7DV8]+KDD9\^UMJ#I'R8A+XL36O4/.*W+^$?IR&K;#X\V5K,RR'4L7KB B
M2.OV6L1VML7QS#(H,F,LKB-<N0@29X&=^FZ4%@Z9FTD:8VH)!2=N6PVQV?#5
M;1!KP[#CY<$>M4NB=DG4+HG:)5&[)'Y&E\2C7! 8(78)NS>X[-W<B,]GO>O>
MU6_(:%N6X^9R]EEG8]9&:N("O8NUQV:#U5QD5>GEJ=IG8RN::>"HX_&<X2ZW
MXMTWS['D&SAG\NS#(3]D!'WPA4Y[J]W90C4ZK5W#]M+%JWJ6<S0!>8[F\*<+
M/ HK:F.9K9Q2T&P4M(*654B>^1PHDQ7@JSOHG9Q= O9^Z/=N1/_R9%NPP+?
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M;5IY(M,*D)FKT__ P[/!Q?G1_P-02P,$%     @ '4!56/Y!!.V.$   (5,
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ML: &('*C7ELN-)0Y3%7LJ%C10L/:/6/Y<YL>^!(  "ASV8>H8.#@< X(&"6
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M.MN*XV .:2OEVG8+E& "KPKW77#>+"0*106@)K'".0J/T$6&.26!Z$SZ742
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MU$D[I%CMV38>(;!N:%E+AR7T@\4IJ6HZ+2SH*;D<8)CZEM'HHK+9'<)WA*/
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MGE>OPC!'%,0+^'(1;.T;<%*T0I ?S0U9L;TOV!$U=<%&PXT[=P0\3F#!!_*
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MP?<V,M[OWN*IB*;0@ZM@C*3*2=$S91YU1M"FBU$_AP0K-YX],CP!.7X\CY/
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MV:$\B^>TNCQZ>1_N>+4=O#;I/F\(D\( 9D?B_\,YD NQH\P_+]<?;K!<_T@
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M6M)QQQOAC@<;S!W7]9P0_4ZZ_B"O#!%TBU +2+6[O"F%BR8:\'^Z7G 1"*>
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M_T4HZRJD"[ _F\K#B63BN Q'>@>R9Z,8>V?#G*QUF2+<:YA-4/H#<]*JS"9
MU7@D:;N<=9>E899DXT7 A$"-2+*\C!-*'0_UK,27SSV@*,.-@XXF'HJMYG:H
MX5U."]D-WF<EOB<+U,T] $" C#/: S@W$SHSW)Z) %BQ%1XNRAXQ4DZH62V>
M#E44J'T0-36660;3C($08687&9XDE(C!UOY/VS9FFRC.= /E)3SG=Q=F0 :Y
M40H4=4!0@>%;&?6E]4[O\OL>2 N[QN!(4=40=CT!&@<-,6+-R^UW?<HC7)>=
M\T';G'4(5$0-RND'4B-)DT/(\O4S)[6)6ME0"]XB@\/&"F[#DB^P/Y=B'8\
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MY0]%46CD="J&$HQ6H"'4$F5-F1!=KCL6*.8KF"L8-+:QEG0^BFTM6JZ%NH$
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M5T.BH#AO+O^"D_05Q/\#4$L#!!0    ( !U 55B2ML;,4Q8  /*@   1
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M#T_H10F+.0K2@[4FH,ORO[-?!0_@W?VV"-[66(_?(;W*U+">X"$0=D<Z0D^
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MDZ(<Q%&<AI0K3]7*J$*!VE)/B@[[ /IVC!HENR(/CV;PH<F"'E.H6+)$: -
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MF>#9 4*Z.OT#'IZW/EX<_C]02P,$%     @ '4!56,R,[+*C"@  GBL  !$
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M@MOS*!(Q  3!"2Y'HH\ $%%4CZE@.QR"T9LJI^63A4041P')Z G(XF.&?*J
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M   /    9#8X,#$Q-V1E>#@N:'1MK53;;MI $'U'XA]&6R5/W)-6J6,L&>R
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M5MG[=:L6J?;IE:V<Y9K_ U!+ P04    "  =0%58!P=?>L08   2EP  $0
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MN?Y\_F[_P'\.H<'].6,0B9_$2H ]8*DZ!NQ=&1V[&P_]PR^_;P9U<=CY\@E
M[C>'.9B4&G\,);D>/A)^U7HHG&_1GF'Q3\T*.Z+;IPF0 O!O:!-M'Z!0V2L
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M8/IRB](M6LA-B<": IZF)L%UL*JL;#9"/%KUP=92!G:S:L-!*J$-^*$C,G'
M3Q1IZ&ZVIT%;M5E%9R0*A=I^0/1+/>QKU\,"N*5500Z)&KFRL2$I].?K%+<2
M1Y>*?!O^4VCQ<<Z0/MP/!_/ %U5.S%A';.M90$_7$B,3V)JP%(:^30TP%& (
MK:G460G_1&RB*F5#KG<YJK9/D2_*LA?3Y%ZPY@HFDO:6X:#5(-G]O;A$EFPV
M0W\IF<@%S]B._T=EEP +WARCD':<LT2"'#,BOY-%38-MX.3A15LYR'Y1A(Q
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M*L: FG<H\D/-QSK'1,,8,/$=CG_*6<%SANN W%A$P\XI[U\\]R^I.=A%0#"
M4.@%!B@;F9P<\P(,>/[Z&@:@<W+/SJ@ \IO6.V3/W<'S\U"@-,7U76F1_Q$&
M(%4!R_^2ZT#W,N:*3Z$^6B$+89Q.$0$DD>]0//\UC?^75S"^]G,UP7MG+<@X
M!%X.H ((")RB:UO=B:.>YBW?Q\O,:Y61,G1K<,:VPV\V=ZQK^BQ*BZ4CK/NX
MNC;#W_MK\)$1/A!-_8:2M-J2"H:9W[_[@SR^P(V5[G8X2[/KN<4 BDXX]+&^
MD85)FN]B(!5E;?FWK2B3-A0G5L-QJB,<I-JC(;/;;\F3I$WF)C+ G<(MCU<2
ME,4_.NZZULO!MS196\PX6(]C]39YH8]R*9?R#.7SC!M=A(<Z&W0Y4%:(#!1^
MI@;=L1N</*S!T*@A1W 4T3I+F"+EAS"]>.3(\F8/C<?S8M<;II$8D1]XH5(Z
M(8C6H<:32=K25XT7.I>98^9W(K ^G5Q""-2Z]%#*9^H+<+H*S]#/CA8OA*U+
M"ZM>#=V=Z!IOP.<E5ZZS8G59@M.7&$:DO(O<]R04:QK13^LB$S\-01-+_%(:
M+J""O$K;[4>N[)M@OUCTY[Y_U,K* -G2^ D#RLFW[<"/?S(Q"=N4US4H&])#
M:EQRT6ELP<<RYD T//_@ $T4XT6C'=0_TNC^./2::1X%#1<4Y4G5?<TX,J4?
M(GYXI75/-O=\R(/[54,P21(%JTO7Z"1%3UPS\TNP8D(P]/,(KW=^&@^5*ABM
M1O21]O*!GUE?7%SM/(H=:UBAG\:<];>_DL1ZHZT%''=NU(R>;Z'Q&B=]%?E-
M"HDKF\*<QJQU:O*:6-;/UCXP)\'">V!"IY<<[3F#AJ>M?6LJ#9(]LB\1=1 8
M!_$IU/*P(J!&AT*7!:=/?#LR;?K,G_,NUU3M2%,B'!WJ8]5E9?%S@)W^X9-!
MG?Z4<SJKG0=L%+1W;N')?LO"V51,SH?3S=1)H<!PQ$XN'4YS%]<.LOQLHQ<E
M)3$F?"(VS&"S(<091)%/>?,#$1YTEE>&N=I7$TV\^_]/>^9D=4M^>>WIXL22
M((&H;$H=-R6$[:#).09V;VK=*2^,6J7Q+&BVHI3/A%+/VR;?Z)R?F24*J\,/
MGT3@*[OD'C:O77DN->S>X**Z4%P5:U"(1[2<GZFFPRKG6'?2OF@#)1Y3;[HP
M9G)_:=C8?R;:4$OQ@<QD"PC8N<@_:;J+AQ+2^>S5.57MM79#V($VDO=KRZHC
MRQQ7'8PX-0E(0V*2+*))J[EW3,JJ?]Q:%F./Y)3*F-JN<ZT*6%8AF:44J4\*
M@#/.OR+=?SME)%>?/M8]C5AV<OSP+*%77<[2;%P5861C_ 4LP0E]OWAU=35T
MNG'>=268>L'A8[HFL2T.:/"3/R'RZ&9%J"".3"9--78E0490#A(N6\7N@RDQ
M116W0!?ZW#99@9D\"0AT>5SV65&+H\/0\*2*0"YI_%-T!TQM=/(2HB%%UFJ5
M%-PN[']J6*CJXY(YUBYWK:8JMGVAE+*E\16\R>,=:]TY-\XF*; =LO.3<7BH
M[;_]_=90"NUZ@FD+?OO#Z* NZ.R[A11/BPR@E7M_Q3.%K2>S**_RO#-H:>C[
MG1_O1QC"R_B_K?.7\DPPH\C[-IYJ(;-LD#:/WK"F^C8.ARD)FG_[PL8Y.^/&
M[-4U#-:R_DC";3W'=DI[)\*[:%+#?V#J_[42^UPS:_X#.1I\) GL>O[P/Q0N
M%H\Q CD$%+N#-/9:J%3,3SY6@09L6."3G2LDSLL%Y96$2@3K.-Q\7\Y#B*^H
M;ZKT8C\NLKY_"T[OH7BE5TB0U:?4Y_*XA#?[*S)V;A89_Y_-Q/UG"C8P :_>
M@0W]OEOS#-X"0ES1[W,<C\(H":9E.4"AX\('1GHP$M!4P=6# :J)C_PM1=%!
M8Z-? ==KV"M(D+ZS.)S8;-K+29+82"']\88[+1\RE(8("4L$$_^VHO&K+&5A
MP.!J32]*TN8?JDTB4'O_.A9\)2:./Q@9$5<GU!7X]#Q<^D8BJ,06?NI?A3^,
M_)109^L7*!"\>!Y S7)(F3KS"RX8\ISA"2AM<BDU89&$1I'.,8D^<O(Z,@(+
M,F)L4G=I\S"@]B4&T&,1"#L6@8B:8<"SR^<26'"BB@4GYO48 +U]:@.5W>N$
M3H]K</U8)7&]K,9BJZU,J[ (>_GU^ZF2F[N5A")'7XQIJ98M.B9FNOS:267_
ME07\F%CU![)H8D]Z8=2&$'=Y965!XK3S^:.WV]+41+23BG@>PMIOT(3AS'CE
ME0;O^^V%N/4;O.(0XR(P"]820H:1E'0)D.TPQ6^S]K4Q>WBD\Q%=**'?N/Z[
MY"K&F@[%.Y.S+G"R7HO-KS&N<:HY!G(J%$%,@Y>W+SMT/=GN&,W?: 0.&/!O
M[N$7^@K[A;X:@\]Q/ASV0/Z'5 <A#[8.G29>0L=PO=C@XENLS2:)?([ :_S'
MY?C?*P(]9C0]D!(^4)^#XS6>+YYF@9\U8RRO  /-2?HV&F:. 8_]]("]R7I4
M&^JBW;-8M!\5Y"UW^0>!('X/Z3BR_.$/;]3[(_&G5<&]BNI^ZK&%>/[[0D-/
M6EW'+;!8E,\E]9#B&('G:E-Z91%OVR?-&KF0_W/;EX.60&D<]VNR#;2*F;AG
MX6L_.JA)[EYQO!*[/A5_\YO^%)^%KT_.;* =R&%#O8].+KYSLVN16H$[IM'[
M# 5T#$,O]CO!(Z2M\?!6EJTKMNIW&SE-\,P"K&Z?]N"VRZTP[ K:RM^&]+/A
MY/:[LT0 @__XIDC#SKX?(2#YR HEOC\5080GP_B/K;?_LH)24E%J '=NE#B+
M2;Z01;&8R769$;L44Y:[)^E;[*B+?L6>!QRE?3,*LXJ/4Z._177T  D&;^VU
MJ[:Y([T>1TH;SP+/>$'<K5 Z[=0,(\'&AJ=B/.V,2AMYD[YX.L5 <4*3Q=:H
M_<COAT>-<\SSL+/&M3U9Q5U(!IS.T.DTJ#CU>(7E/-00],;S+KQX%R\9*TUK
M91:MGH9%(_M&G2QO+PQZJ.1D2W?38D"F_9.H?9U)]>O *T!C,)T&RAE[34X+
M=4N_956'Y,,PBCS/[F[2D)V:'A-[U7T,B L7.?5$0,YR%7+I(Y,E@'L\RX0Z
M!D1&U&_IPFD<A'.<TG<$A3@2Y-[\9/3UY87^HR/A7ZW"5^AI/(C0EK'.N,":
MR:]+771(H'2=3-3^[4M?DT"69,!SJKW>#9W0B9HXZ$6JLASN =X>!TZVW$2C
M WRE)>%R)-8*6'>S91>PH:#BRZH%ID0@='M_^-MHM[M8(ZT,SAY/'NRCXC>4
M^/[$\LK.4:)OS/D%%_F 40P QT\GKH/OQ46E!:5&/C:W>%^_RZI%$V)K-4F.
M]+F*8?>9>Q2V0 G^KI=T!Q6WC&_N9WO3#^R2$,ZP>#T16:S_N;L6"B(G[GA]
MT+IY2[*DW"UDE+%1% ,L]Y564WS%!U"2O-"(@2@S;^%DP;*+D7%JUS64)K4"
MX!=\H^X484#4365'!+*=OW%AT[WNM X-.['**>O_S%/,-*L[WXP!OL(<6U"4
M\,C]D?%K7,4ILNGGN_:T?B\ADO]@0Y'&:DQ%O'_U@T)-2[06FY/.JATN\YLQ
M#J[U22UA\^W7+IH]- YQSOVSA5_1$G?0Z_>02(D#3I2(&R<3NZKIRSHKV;<!
M6ZQY[ <0>(E9JD1HW']"'71Q=DT&*8,WPN\;LPVO:[.'8$#16/<)1^H'0^">
M&1MC3-Q>?G-L7X3+!9724DWE]Z%< I+^AUQX=]]B %O.P_,*K*K>Q?\) =C+
M2H.6\?VGN>)Y:"U=HFU@XNU?O]?T'[T>@)T;Q%78!)]PGFVM^CFY]:(D'(0%
M-W(:]@L^Y\>%1S:XXW@H-OVFY;S&BR4TMQ+"F>\TG^X'AKLB)[3\D?0@>+6B
M.O749[S9&QN2\9Y:Q34;Q2R=-P'+B/E$Q/4N'^%[5A,L9_OES3.AX+O_-$/6
M\Y(=SOR4R'!:E@8$SLM_A*U@7(G\7N%Q&C%-U08_@=)%.-V'^T&.$B?>&U'6
M@2Y8X7Z:M"0"^1R[C3/+37WULY_J;WG.=FMYL4:\":XH0&ME8J>8MW6_KR>U
M1J'ER6N)0!^ H$3^Q#RYWKX.9A=BI^&HY$]HJZ1C7L:X55Z8_,B$'09L[3YH
M:\& =AQ[+58,< @>8V[OKK$#_:6E00,X_N.<H9RT>LHH_%X4YS]3UK\,LC_L
MZC#^DGDJ5\#JA&MI>=**L_FAR?3QIKH%'/=+]MO PIJPU=?!ZQ]E-7V_5Y[)
M<&#-^">X[DI5R4N\F\PN=8#_>6#5PFV/(W<F$42U#-AC0/]HO2_M.?&SN59L
M5&7586\7:T^E4C/46K_#0K[2^"NW7X;3/8R!T^MJ,6Y]CFXI4!NC(U,^M8'L
M_L\93%VA@3J?SI%;PX+)X"<ORPLTR<9:8]*,=F%9M=+$G:%?YL+?[ 3,:OF>
MYQ7K_%3G<P5'6&7YYC6?R\')@Y7[9EY9QW.XRRP)MM/I^TH_/A6%T^O]\Q7P
M]"K>O[XE^36.OFO9HVKC/%-\(N8@*N]4 TUH__C-FK7T;8V#>Y]%^MK[R569
MJ'S(FR4@:?]*1,BK3 QH>62  5_R,6 QXU]3%BA#MI;/B(?_/%<\QZF W#Y'
MSTD/GN/*&D/PCO J_M;9TC3SS&%SS?AQ#UYR<0>-QY)"4;: MMCG#ZP]./_$
MKR$)0@'FO71H]<*DO=BA<,M49QFG!GK@]#K'X*S5M)^#*8-9+_6@IRVU!0$D
M5VQ"C XS^T8R'6D(L0H(SUV!T]LLL>.KD3RWO"2+AV+Z[S:-BINGTT.:MV[R
MSLUG2[2\6'R$&HCHIG>/:)QX'_@4RSHV,IN0P :<".5Z('N%TPO#L;XOIS<Z
M<3!"/OL.Q5G:LWO(=?'-TY-GO8^"Q,J.J;N42!!X$?_J*KA&8U?'ZZ@Z%GR2
MU.DCNA:^Z[G:0)\55/V(7+OV]I'B0$QI!P;L?0\^]Y?9XT9)O@N58==_IQHI
M07M'%X6?A\;O@?R=QOK-_M8?9VH%5_5Q40_><%U6,W][-K>' 39N>TMP2H/E
MCQ+8DE4>,CS^+)6KRY-<SS%<,2ER$H$7^"_B/H<2<&!C39Q%N>">F*%WO%B*
MEF%)K5_V@<XT*>"6S%;<M*.(,AEM/=/#@)DBD)UKD!ZR@5-">3'<^$NM3N%9
MWR$]Z+M+DO;2GYPU<A<4_>?L0:"!T)PD ATZ%+9BAB/&&=-O'-WF1.[6@37.
MK5J<9W'/6O;0Q%(5R<FK.RI.(MYL2B)U3"TMW;K1:NIT. C<BG]/X:#58WLY
MX0^LQCH0/)_#\6R@K_<;2AEMAQ\?P(IBR;F5.LN54!( 6Z0K698,0T?8L.G>
MP[;[;'_H#* )<XJ,B#6?SI:2*YWN)X3'(B=NQL%I%@&:B#S']GOUM&3+A/4=
M:\3GZ_$G:"#+DT>'Q@DS[K-.(>"HN!OK3H*Z7-?E3-@$.3(*Z,9F0XD_1;J"
MP+N6F-QX\D;B\3W=^G$-<4HL2 X_DSE8@U/;/RZS3\X4V!DKJQ^][KJVMHB?
M5XLF[O^W:H+@O([_?K_^$5?#(Q<1;IDPT(5_"_\I E?BQV.;V$<-525WO*]J
MLKKX3YK"#LG;4!*+_UXC<Q'%I\PW.Y3[&3]VT>ED<43[-H*'9^\.U(^<B,?U
M(U\3E<>*G@]'52D-LX1LP.GS.B\U7)80$XB1::M(\E=0_M,AQ6S32_TU,QSR
MFS+>'$,&4+R9E9E*0T1C4*'OEL_79/@F'L=%O58H#$_AA3YBTNZ^=>^19E7M
M<]AV3+\E10HZ\KFSSR]SJ:FZ\RW3Z>!08.NW:!&#_L_JL';3H^YC<8?;>RJO
ME%X![C6[[@UUO#3:]>#6N&W9VT<YV.KUI+U#_XO!:J8\3H6)L-)5O]N'%^'T
MIK.6C_^"OO,KIELQ]GT[</Y<LLCYBCB\Z8,,IP<C2QN*XZ:)MIL]]3ZEH]ML
MQ,Q"<P:X_]=; #BR=<V&8,9L,S[M[#5N4<'(YR"ZG ]\J_!(3=CZ SQ]"UJ9
ME<%0T/]=@JZHO5Z@(%V=A'N<]'TLHOQIB<\VOM_S@]I_V\W(\<S"UH!'V6_2
M\#/W02IZ TZ% <5?A+SZ=H<R6'9ZD:,\R])^6G#"?5+ME7,E26$NI857B0ZG
M8P5( 01NV'WF;UTF4OQ6XIZO6KVQ]+D :0BJ_\D]&'\,!" 5/V:-91L]XRSI
M,PK@</W../7U 62/#DT@\)3'S=:36++!@3!9*),U>=Q\_4C/8OVT?B+*#UQI
M^R4?D>?PJVJ4,O<2=US(5+BCIV+]\2Y3)[A]7W%#3V[/FM#I5$JWY-[YL/26
M+S[+@R+(ET]9:7>N9M$"$L +^8O&#(G"0^V*ZH''Y6;*LU>Y*5MK2-[VV=1N
M= +3*.+E-&J':.^/C@(-#QZVZ5V[W=&EH*-S':P)LIX()E&?M!]I?"S;DZ'M
M!#?_(E%8:66TVXJ/V0KEM30_CE\[S[R]\NS Z"SM, !^\>=RS/V6@6T.HW'6
M]I'6 ]0>4P+6NQ]@)>(HN_?(]BYKYM7WO!;/DESBX(Q)S)15Y]WYA8DV5XF-
M'OG$AC=$L85!D]PJY1=H#]"D)N2+!_0/WQS<4NNE?5=J(I!D'WZ!=B%-EC-R
M/!,E]6=4V<>H2S@P9GT)%[D3I'S*"Q-9%+GJ:;O3:3HQ]JS&$\N<&7-G<0&S
M8^'#\Y)QAD,,J(9LO\>"$OU)+)&_BF(AJS3C?$=G^<B@6^.+7E/S4@KY5"+H
M_==ZG-MSH#[' /U^KE"9 3K[J4AIX8,468/]F$A(E_@>FBC?RTF7QO7Z-Y'2
M0G6)FJK6TB'9US8S\UTN(XE@->MOM[>R/3\:Z$/VL]],\ZQ_=$KX&O#QE!?Z
M83]CKK4Q*(%?^'2O7/&ZWS5J#&BV ?0>Z>Z=^YDM-3MMWY_F'^:W^UU#X+Z]
MR?VML2-^OZ4@I8 EH?M'%,\.FOBO8&""#@HM40B\E0>-)@G(&K,+;N^]='?B
M,-?2^,-9H<F,(@9XKO2BA/27\O0=+<<XMY&?4U3*)Y9]%8*A**&_7B]P&>3*
M'_:[T[(P",ZJWB!S1EQ,;>C!7?YK-\HW83LP_/QZ7-IH\&-7MN&MU#MF+1(0
M];72)YI#'U,5^XJGA:0P8%"526F<\<DT2C)FX-H]-9)P,0)9' 3L+]1(,._/
M'Q)^NR&VZ4EV%NLY'DJ\)J]W(EEJV>?B$$4IEH$_E8)C,1K^L&28HI @>W4X
MDJG0'GDR%:G$C29TV*LDG+] 5_4V  ,$'MYF.(?DI];_6TCV?UI!M'?T\O/8
M'!UU&7>C9#V.>6?/L7D.:6LRYF*149%KZSC29G*R$']:BP:VI8/R$\NN#AB0
M<C>]U:0[_DP5&!;VKCX^?6ND/V-]TH5G\/6SMU($,/KK_D$D??Q>2B OT'O]
M/5WD.-MK)Z39NC,OM,"VE#Z T#WH[HTY^QG9".2X4I-?E8\GFM098#F$W'\L
MNY5MS3;] '+E,_+XL@WL[G_DDBT.8KZR'<.R=ZZZ[CNZ,/CD'I#W1>F.HP3U
MEYU-:,+Q0N>5]J*OBRP=>C+/L![WX [_M=.PEQ675H8TNN&XJ3WY'$KKIX82
MQX#\FZ57'';WWRS1*5J:'+0_9EF/P1II[Y'2X7&>UGN6[=[O>1.ATKO<*)[B
M 0&AN>U;SG$8T$VG'*ES,I=G ]W[*[:X79P7SYNY<R,VR%(?[:U)')[$*\,B
M<KH()5];43J:06* _Q$&'(9B2<AG#%B(P(!SX@4,F.8%Y^.%6,-(8P\*IV)
M"!IV\J3[W&L" R:_(L_947_K]Q"R&LMT;OY-I546)0R@@--%3)<OF)<\4=BU
MD]EQ7)U7/N1+X]EJ!&SE1JF_$L\/)N3"JZ^I\I>/ @4Q( J!VZXUQERG49Q7
M$:QP?:EP[NL':YT9.#7R_U+,\H>>N'N?1HWR;=Y$$][ZP!JMC(_C2FX(4G[3
M2A^\5'M'(;IXA;8:/O%8?10@(I2/@5_Z[];-W_J]N*.\JN"/>B-#(Q/#VBJ%
M_L2G'3H%0MT_RO8E(.9M!UI]/ZK>^L);%L2N[].0;+/<Y9)%$YN,#"!WFC
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M-K6125M2JD$8C%B/$;C\W1<K=#Y*Y@ZIIKRYH"/1]=/#BD2TB!$0+.#GEMA
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M MN6) JE9QB-#ANP%;W2G9D@O'HU5F\JZ$FLFJ\-],>7J,PA];D1 Q5*!_Y
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ME]?,==G?!>+X^RU'*<-9,$/_'U!+ P04    "  =0%58>6CZ@J9S   MC0
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MC!!S\T8X<W%@QU+.$.7EZ M'H'[-8:P/."ZZPE .J "L&T1E1"&2T!^<NH@
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M;B,D$O-NSAGGF;E@\(V)H$<<K*5W[L=DO2>+3HW"H^M#7B?*@JO!B:%9.\?
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M]O7S:[*'\B<R")Z[G\+ KC)9XD;.9F>^(OII/]:/MH7@/"V/CLL9[YTKW)"
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M,R"ZG:K07N/FAB$\D1D,<UM*DE$<4CC8KN.M>K3R"N&MX,CC>(<8M[;(8?\
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MH]IEC!H *#Y]-L7:Y;=-(SG>&KKW&/J0?4? $=4+;14,2".X0%VE:ZC85/\
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M)W5,J*@IZ%O6E>E0AA,])Y6TK&9B6E<$5C,B*1NK44I_84&XT)H*[@VT&KJ
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M-WT?K^E>EW9&YW_</Z86(+WM=]:9XBG]/CT?]PO-NG_\>"E-=OIG*TI7I_\
M79#ZC].+MP/[ Y@D#I-U]?A=ZU+8JW*TJ*[@,P"1_?J/NY"9HNR@MPV(1%U:
M(,VX9MVWHM2HI[J4JM:C_]E02P,$%     @ '4!56#0.1%.G=@  :)   !$
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M]83"$?^"W/@7^._D^-9V"J[.KO"_&)?D!X.\RF_$N1K:KK#S7UR$JQMJR_2
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MW&C+/5A:C%9GR2S\MEC9><Q>D-0Y*N 2:KTC3GZ18_G15SD?-H^D93N 8HW
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M!1B*B@!)3.AH<\=N+1=SLAR+9=@L-HWBU$R1S+?[; EM(LT;497D]L$>=<5
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MIZLLLL$-I >F@T-&SSJA&8KYX(]Z(Z6T!&D02F5E5O;ES!5R"3F.F%8*I5"
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M)[']Y^&=WN9I8W45SQB2;MSO,>ZVO:V?>$/TFY[AO-TK-?>V9+6U,<*NS-J
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M&I( KAP:L0S!<B#2GR5'S5J?CBY4&E ZUSJ =0-/.H.-M%% _DK$$DYE1=Q
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MG9.0[9)<;=>QM57M+N08^W'[I^UL<5CP7[P>PV];<_'8KRWDW3B'=SL=N/\
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MJ"1G0C++H0<50"G4L3Y>2CIA9$+Z%)R9FTL10@!EZ9C&T]VK^>\7LYW0X1W
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M:>YF5]V.C5^49C\<7Q+(VJYNU(H0Q8SR"I)H*4&?CC(,%$JMJ/S:BP72P3U
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M)!U+IHT=*ZNC?N5S/3/I\,?_V5!+ P04    "  =0%58?RP@92N(  !'H@
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M9"\ZJ;MDCNO2#9IQFB&8LGWR5'8[06KLT858V*6[>SVS20[W-QX.GG/AY:Y
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M,1+BM_:,I&<+H$R23J>$91(X 1(! Q(?%7+MR+W9%H\@I$R<F3H,A^EK?L9
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M(G'+V*V\?\@S=EA_(-@[Y)I\79Y7M6..SMM;W=U<6-Q\>_DA2JI&T:.=[NM
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M=E;F 6G\W?XRWNKR2UMR1':/<$;BMFTCH%)]IJ-;_P#L_P ()H!UPUL>B@
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MO<+'##=W5OLN5NA( RJ[ \NYEXL\0^/&Y9:XV>+!2Y;CAY->C-FVE2R2QCY
MV7MK*_4LI7M[4;::D4UQ#Q-S;Q-RWQKYD&3RW.?*7DO+H<UPWSOS+D-]>277
M,<1=8RV-[89?%V#06<F(F17AL8X_AET1D%[;\:XQPS%^',DA&4Y#E+G(7_,,
M[;7UOMDQ^$P$EG#80V=PKT,ES*S".FY.M-<;AXQ<\AS_ -JOE>]:RL..9"ZN
M<K=>"/(2R-)>8*SO[UI?_P"/^4[C/8(SE[&Z$EM&#$8PD]S:9E,@R21IEEO(
MS9W6-NBJ]VTR-E)MNL=<Q$@[90M5((Z$:9K=T99H1#'(6W%1$K+#(B-0;@3[
M2I]1U%-1<DSDXDSF5PF.MX+)03#B+$V\+NA)_;DO;I@.X4 6-1M6O4D!0 /P
M  '_ )#_ ,!_MU<S3R1*L<4A.Y@*4'X$BNLKE,7;HUM;0"R+I3=(8WD+D/0@
M[0:@&M1^6J?'BI393M_UTW4KN_1N]V[T^E?IJ56].^9*]M:[* *2XW(VVG2H
MK]:5KI'W!J6]11@D:@ D=*BI<M]1^!.KD_K2.$J"Q):,;2S%UH %:7I6HK0?
M0:OY2#(?E5"D$02  >UG?;(6!_4H'3_#0VQJ'5B.XJNHD0@"CKT/<:1S4U_3
M2G4:MH)96=%17*RHP=@&HE0 P&TBE=P+4!]=-@,?EI+5>,<RY3899 0YQ^$Y
M7'996%A:.DJ2V]TZ2]N)AM[RFA#&IY=<^.>67G)#9086'$X_DC0M'8W.2M'N
M;7_JU"0V@N\FDT;R;>Y H >@8ZM/&?)?MDXMQ?D6%25?]3Y*^ESG"!?XPFV$
M=K/QO'9+.XZ\RMU&IMED12H9GJ8QKR%QH^9X[>_P,]N+ >%_!W,^87_*+J^P
MT4MUF<;G^?YC$X:QQ)S-X;>8P*T_[)F]H.T7$Z>7.-'C\G*K6WX]XYYUX[M<
ME/R3Q_;VL[M=>4+FUSL^.PW+KR];MV?\5&L=I422.S4&O'/,K6TVY;+<*QG'
M,UDYI3-?9&_P,UQB?@Y*28"XR5QA[FU:TCG*=R1(1UI33\<DE6[GM@97[2E$
MM'$(DGNI8F.ZWA5B$4$@!R=8Q# ZE<=8*0PZK2UAJ"1ZG55CZ?F-I_WG1/;]
M/QI_\1INVK@FG6@!Z?AJZM[2[FMT<,@" KN5JDT(]*:N6R48>[DDD<F15?N;
MNA<EJG=2M:>M=5^(O]_;_86O9[>WM?X5^GI34X-'1YZ?MJ4+JE2KQ@U3T%.I
M%::6M36, [*HNW]1&W] 4+4[J$$UU=%8F8-'+O\ VVV%!TWL>H%$/M(^@_#6
M2D  7Y 9 E4"!7V=T 5(4LPK4>H_,Z5$<;B(1W%,@5R"7()V5( K[J@FG0>F
MK,[6#RO25XP2I";7!E Z/^V:@ [J"GKK-<>@EBA')<1)8/W>Y\"25D=L?)>0
MJ02([HC:U08PQ_#7DK[>\Y'?\=YM;2X;(6L=[+*D]WC[7-PQ3W-E%$NP15N*
MSNF^-49).B/TN9?AV<^4S^9PV8Y#<RV"3WK06$2X^-81%M-J(T=)UJ=A +="
MW7_4V+Q,F-R4UX\U_)86%K$\EI:LQM>S+*2EPEYM0550QC)WD>FNWD+6WM+J
MZ26X<[C(EK'#(DTRSS-OGD"QA44C=1S4D]-?QG$;(08CCW),U_%V4#RE)\ED
M+B:5I;:(MN_CH;B[D?>IV[W+'KZ9MTDBNLWE>[DLGF)F[EU>7Y9F2--Z#;91
M.2%12(U4#I4UU80075E-D;;!\>NLE807=O-?V(R6+@FM'O+..1[JVCNT1FB:
M10LBJ2I(&A3J>A'IZ?ETIJGK_P"[1!J/\?\ W=/3IIR I )'H"/<*:<LJ!QZ
MD4! JPJ>A^NOZ/[^[T;_ "4K2OI3_P".IC5:R7!$JT9H5E*G?&R]6B,;*.HJ
M#6A_'48D #A0.R2*@4 V!5ZJ0OJ!TK6FKIRDI6*)R5C)8NA:@)12%,; _7U(
M^FLA[&*B3?3H)*M*Z@;V+#M * :BA]/STH*+10I"R%U=]U4A69DW4H"2I/Z1
MU]*:Q[N:IM 4@L@,3R;:**M293NJ: $4/UUG?*WEKF&!\=^-N(8YLER'EF?G
M%OC;*WC4%+6U2/=<Y+,7CKV[>SMDENIY&557J2)OO?\ M6X-S+QGY9\*>7/)
M/'O"O*>7X_\ ACYGXYXLCQ\EW%,ZQO:9/$\QP^6"-;;I4L+[?:7#N%;9C_*D
M/'7LLKF>/6&/Y39"!(<CP7DL<T%MGL3=0S;TM&L[B)^Q([&*)/8&=.VVL;;W
MV=Q]I-=8VQML98M<)+%D[5E6&=XI(6^39WD,B#>FU@'*LPI4:MHN-<=OL3QW
M( '_ %+=I-97%W:0C:(,38R]J_N_EL:R3=N.)0M5K0:O,B%WO=EOBB-F,%I-
M0=Q(8RX*@QD5?W D59MQU:Y_*V9/C+B-Y\G.7<J,(.7YRTD2:RXO9A6[,]I8
M7*)+D9$W( BP5K(VW[?_ /ZJW@SSGR[[?_N%X;F./?;=E<3P/,9#C.0\FX/(
MMRC-<*SUED,3?6T9RWC);Z_-Y:9"SR6/R6)=89$00J)+#P;YUS.'XS]ZG L#
MNSMHL%GA./?<!Q_%(8Y?*'C*RCD%NF7BMU5N18&*DV.N-US;QFQ=3#_]A'_'
M1)/T-/\ $>FI!&01ZFM1Z?G_ +=%I -X:A(J:]23U]3K]0_OT_5_5LKM]?PU
M,AC95:7IM<5>-ZE>V:A-R&IDK6E:5]-(68$*F_=[5>8 %(R*BFV-/H*DZNT*
M TAWN$H !U/1F!B!?H:'Z=!K)+$&D=YB5!4M(BK(:R&C&-1TI7^E?\-,W-.;
MXFRN8PK#&69ES.=FH31FQV)[\K/N/;42M'6M1TJ-2WV(X7DIDAA6XQL7*;Z#
M&9#(.R!A/)Q_&M=Y'%6Q;^VMS.LKA@>V!U/AW[8LAR"ZL<'R++W.;R?'./;L
M;P_QQX]Q %SGLA98I):3\AN\<%A>]NC/<R2RJBTW :\0>&?&-A8X# \#Q.4L
M^.=A MS@N1V&1OK:X_E4BVGY.0)(O(Z 2"6M.FN6X/#X6\XKF<J][>7V 7#6
M^:X5RS'322R2&XLBC6_Q9)97_9="A20E33H,%88/Q_Q'AG),E/:0W&(&)LY\
M6IDD:.XR'&LK>VOR;?#2N"7LRPFCD)VDK0:N$N[M;RWQ,D-K-=6L@6RC>!:2
MVT$TC=VXB*5VJ"H$8.ZFL=ROFD-WQGA$L??^/4VF>Y?;N=\=GCXDV_PW'?3?
M= "6Y4TAH#W!C\'@L;98G$XVUBLL=C<?"EO9VENG58H(8PJ(*]6/JS$DDDDZ
M\6?9WP;,Q7&+^U[#7W-_*EQ:E7M9/+_E+&6$7'N+FZBF>-YN(^/D:XN/1XKG
M+K$0"CC7'>2<8Y!FN,\KXOF;;/<7Y1QO+76!Y+QK-V,G?L,YA,O8SVV0QF7L
MW&Z&6)T92:'VL0>+<>^Y3QSQ#[J>"1XYK"\Y5CI(_$GFR*3%110B:ZR5K!D/
M'7+KZ2U=9).[C\1+<2(Q:<,^[6*P/%/-5KXA\H9/;$GB/[@(K;QARV:],4;/
M:X'*Y.^GX3RYI)6*0C%Y6[EEVU[:UIJJJVV6,M&_0QR*5#*\<@)1U(-:@D$:
M<L!0-T)Z#<2?6GY#I^>OU#_U?^_MTIZ>M=3*M5HY[CAF>JAP6*[B"@3\C2OI
MTU-G,[E<=@L'CD,U_F<W?VF(P]E%""QEN,C?2Q6T%!U[>XLQJ*=-9+ ^-FF\
MFY6VAG%]R)I)L-P2Q1*QHMM>RQ#)\CFG>G:,$<,+$4[A!UDKZZR387%W$KDX
MO Q?Q4-YN=W,+2QR_*,*"BL&D8R-45!T,L4M4R5TTK8J"4"693'(8VR,T11E
M$BL2D&ZO4%J=!J._O[JYO[ZXFC2WBWGO9#(2 ]N*,D B-')9VK^E22*#7W%>
M8>3VHS][XQX1C^&<*R$ZRR8K&\@Y N9SW+[VW5U$,UQC>/<:BCA#U;?,)* [
M=9K"6-P1QC+2QYJ:V:NR'*R1A+B6(!MH^0J@OTJ6ZZ5O(W#K?(YC'6T=IQ[E
MN'N[O!<QP0$IEW8C.XV2.8GNM7M3)/"_Z2A!(/'+K/<W\5<PP4L4US9-?YO!
M6G.(\C:R53'\CXAC#&^%Y);121[;F-8L=>Q*966"170<5\N^15Q6=OLIB(LY
MQ7A>+R5AG^$6AR\BY<<JR^1QSS8GEN9O#*K6XB:2RM8 H#3,0R@-0D+0G:%I
M]     %IT'TUYD^XOGMS;VW%?#7CWDG.LDES<"U2_FPV.EEQ>'2=NB7.<RY@
MLX>A)FG4 $G7EGR[Y&RS7G.?,G..1^5.1760DW1SYSE62FR=[C$[_<CC@QEH
MT5O A(*10!1]!J)EM5B>;:\C15<Q(X 8JL;2 Q[XQ^H K3J*:QMR#,OQ,G;*
MP<.3)!=));3=IRB*\5&"M4=:]-3V\T<4T6[M]FX5)K:0+62-BLH9'D5HP0:
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M5T,KRDQ(R,=JLP+1@T0E74=#7TR*[UCE$V098HJQQO*)I#"R$$LIB-0=_P"
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M6J:IM]D@9!U:0C\#05_#7-L2(WW"*.4K$X?;VTD1HR3N9&6JO(:%2.GY'/\
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M7ZMU]0-7(;<L>U3,R5/LW^D@7KMW4H>O4:](=W\3Z;8O3=3_ )E.]V^O^?\
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M_K -0^;/MF%B_)*!H8+Y6S:VYT]Y6C_EGS]/IT^W .)S2ZZHZJ/;VP#)>0N
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MWY0B3V)J?:_H#(TWP\R;"E.\%SH5T_I-%[3\RI2(T4[@"4M+OTH*8UFR<=@
ME0!_2J*!4HXD:HYB50Y18^N]?C/8]+V. (Z\\+C"/H\ILE6+D$^+%_<NQQ+X
MZ>:Z7<,;F*+,/,AO&3'^-<NA8,S-S]AX4S?X4<FWI4FL 04U,MQ'=O6GP)0C
MZY,/M#1^$O,)TK.P(U><\4B7*YH?3'3U2ZY%V")%>,J*E" 3M9OIY74WOQP7
M@-_/3@Q)TFW.94VF"(Y7C4C<:DXJ\J#IN6R@8\[AMS3/)39K%^TZ*N/[D-$%
M<>!'X"&R0#&K[.?.Q:*2.)6M/%:"E=2>X-XPF,>FR@75]#U$4HNK4&C=7UZ\
MI>OI/$\7NXJ2YKG9;H5E2* SSL11K)AQA\@B6^W.".6CIW?F;%ST>74C+B??
MFU.]P:72/3.'A"JU]F"T7FANU5-JY&@R"$^Z@O*EPB^'3=;2559H#S[8U:9/
M+67&-W;6$,LZR=K ":'JHDZ2$W=TR^593,<PXF5ZJAY:',_-&_PV82B>KL:$
M[9,LER9OR$;$P&P\\TNLB#L\1@9BZT=RWDJ7F2\E"+[KRN+/YYGN;VP:UR5R
MEBS%$.!H'"B25S<TXAN4O,L::RD;6@T2^=9QC(K#N.L6; P>Q7V<JNYR/]=X
M#">-8NF9G=H*@#U3P;- <W&8X(,:S2'[;!*?7:K<0S$BNW"$J@</4KVI5=>V
ME#3]!AN/LO@+B:U1@;D3_,>CGI&7AK)!030'8([9I3<0+O&7XD^QC\A>:X^N
M<,2*W?J4X7GK54Z]QP>[9_+A3IVA#QZ.>;5H$]QM\:<:%L8@2IR%6CQ-TUXP
M_V270V!S4=:W4CP+VQ26-ST3II%+P.!:QUWB9)T2)<G']2(B-(]M2$-]@T.;
M[8Z-3O(-$G8/L85;*_K:9LJEK$M6-9M;;=0J,K,N1F#A)=I^:]8-8HY2OOO+
MG2SD,6E=C8]H"J26C3MF5:,*<D8>YJF,F5Q\XHH+9X6HTG2_ZJ1_! HB9@78
M2U]H6FHX;;]:\N4X!6#'PC6(ESSJ?2U^<\NW70EY?>LI!F[STJ=^\+QWW2TL
M,.5AX5%LM0$OA^$N>YQHATF[<7-C8D"(GIE:^>PP4Z#%X@N::SZ/7VM]L<Z/
M-0T8RPUE&\;,":[[LBPSDK1HKS"((*@28Q(BUIPEY%&>;'C5J^4%)G&V\L+)
MQ^9QJ>27C$BO$>[BS RYFR;/5M2XS]D^>R&O,8P"(U ;* %N.AN +? &9BSH
M,Q)7;MUJWLO3\IT*E@%46;E'6,UX &(V!T+KU%I:HLBA"SM&'E2<F@)X!":)
M*ZB+*L895&%AT90ET9C:AN)%7F\A6BJ$1#?X6(.BJ,0L:GJHO"?2J+G954QQ
M B[(J*L'?Y)*GV%_9O->6CUL9E+EALZ\R_B],G.S=F["=;TK;#WOGHWW"FI[
MC"3H\XA,J\RF4&L-C'^XG,MZTK^LI^3\@.KQP%#M*N_2Z*-2'BLS:O,OABEZ
M'F;:@3W7$/-+W23UC!>>#/7MW<GBN50VZZ 1O>2J+M)%J6];=D%!K-U(W-[!
M.D1G;X0$RF]D5L&7JW&% 1)QXQ00]QYXD4<X^6S3JB?[A*27+]?E4^;U'2U"
M*R8>,X:\T5O)&F6FZ\MAFHJCB]O=:[JW.^,KBEQ,G+7WB6+P=:B*1@F(-I*6
M=<;(%RTM,:GO+&0_7&K^^C 3\<;-X1.O2K!!AL5X8AY(A7+-N$2+?FE8YL G
MSJVA*SX=\YYQC@#/PV@&\N4'X-=$-DHXV)C*U"^2$?]7 'T<@N,[AMEM:8#*
MWY%\E(MD9GU">I'2^N4M 0IYLA0&1 ]N'U2.X&UY*%2942,Y%N*7V7)T$LID
MQON4JT*0'TK2#I64$&FDUP!MR[Q)R7&BIQIJ2VM3;BG@&VE(2=:7"E6JAY'+
M&X57M]#;-MB![U#[@0V@%QHC2D54I9"Z\ 0!GBY(O6[K=#4/4=5B0EY]2A'2
MM)<C)B)6L+U I.JE1P%<7";VXE1]V+^_$N'$85"D1T-**!T4.K+S3J6%&B5>
M8*^;+$V_PVG6%VV7U7(LEHM2(Q6ZE#L=S5YLVEA1(-"H9<<6+I*/63<+\B0D
MJU .BY.:10D],EI23I%*\>>$'S"ISI4<:#/X8TCA0JK3.M:<?<<:B2HTI4Y_
MD]N/\F/DYT^88LR1\QL=D-/_ .3#P5 $J'@KW#,#"E&N5/ <33,9833E^GC_
M $8[K; MFXK1M>5MOM^_O:+<;XN2U;)-WM]XM\&P6B0_$:D/1TW6[3&V@L-N
M444C2:X_$OM7>^W)VW=Q[4^A[6O=NNS*X9AW2/-EB3!D-2&&Y&H!H.IJH!39
M!"<ZX:OTQL3(EE@QX.WH\AIQ^W!^X.)=DW%,5I00J0J@2ARH(;!3P-<;@5W@
MVC;.ZW\/SK9 W,QM7;LZ\HL5RO-R:L5K^N7"R2;?"MS;]SE(:ZTB2EF,HDK6
M$)4H*N_9_9'<'9NR9NY96V+?N!:[RSMY[=&WITF&(85<7IJ7)$:1%6&74N.M
MN-#R%3:@3'W&J[7:!MZRR77(T-TN^FN<X!#SLMY)">HZ' //5:2E(0F@!QM[
MM7M6Y!B[=T[XS8/J,J,MZ+:;=,?#4N[34LU48K4=*ZH;HNM,QB^=V=X?A\[E
M_BM?VA;;@VYN#<+6XI.W+_N.RVX3F-O;9V;MICZ9:?K"AZ>VKN/4;F/D(6I
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MU$I<)4?#&W(>M;XBV[I%;@HK4A]X"J"2$E( &$C@:^/Z?AC2C(<:T_UO>>&
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M+58GF-N7R<7[I;>@#)VCOF%&3KD,A:='3NL)*:M+!3*""4. J0"7H/<:TSK
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MWP[+;LD;.[O=I-QQMW;%W-'UT8NT<D3;?<HJ5!,W;.X8*W(-QAK"FI$)Y:%
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ME+L=E5S@I/S!(ZB0!RJ?9B6P*$,OOMIRIY4K5I_(G#Q(^5LJ!\""#^C#:"=
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MSNXH=R]G=P]V,4DA<?8+YC $V/V&UT5 3$1,0DY$3$Y4A%U45$Y,3$Y,%-"
M(!PPH@"<;*P?NIR< $ V]N]^TK-Q?M=W@1\%'POGI][X?QX;EM@?8\.2^_/8
ML+%^R<!2QOXM&Z_EISS-G_+/OB<?3]8!DK.1V*OH8MH; -E9"P 'G>''@-L
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MQ?,\SQZQ/=3?^)X;V/%^<2[ 8?LI;')-)\WEV4!Q<T/6V[O'JP%C;"? ^>(
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M2#T'-XB)FH7)[\Y^,!@@W=VAQA 4VD/?T06$ 9, !@ 2<,?\00%VP!B  "@
M#7B<L1!Y_*;^)489CD+\U(C$$0V#HV"(,Y&8]KDS:A5=2^T?-KQ\2H\M^)<1
M4_UIQ/H>*)@[P@L#I3L;EP<*\6L0F$$Z(G\WC)R\=/_ (!$J?S00J#\:.HYP
MK]\-/2>4]^^&FAM<]7<#8\<_1"N#7)U^&N)GAC/24%8Y2X*G=3 [.]@=[7C5
M_1/PJV@@$?\&4X;_.YTR$FQBBD"I<QG!4<"?BC(<S/YW<",O..H,;N #OXI\
M^0M,Y T!H=R1J@XHA]]>8>!DX/7+*T[K/[\J9T: 0%%_)]X$X]U_!S<&P7_
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MKW*:U@\2<57:2+BUS^9?WA)IM'AF1!DBLKF!.-_M3]'I[KA$[O%"^2.%-)_
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M 'I,33EO*U 8L<CA?/7BHQOBQX2/Z02$/47\V!1GRY08X8$C5 0BUZLJOYX
MG'N3<QF+I7IRGXYJ0\!;>$,/G;EEWDM*2I=5&=KCWTQBI9N[(KE90/*\%)11
M01=ZV!82Z" G4\;WL.+%T-S7@X0$Q</%KHAYN7J+Y6;J[HRMV/%7"V_O]*#D
MG[SY=O/VD"#:Y_4@<9PULI1$6&(VLH&Y^HV0MX(ON=!CA"QG15M$=2RUGB%2
MR,VH&YG%4?ZBGF%XZW/'2OY6^;.#$;1+R$ KKY<]4_']XIL;FU --E#]S6GZ
MF_&AUL@-!^N7^C*]##-F E&-3I_ )%.1L@)4_KSESTLO><J,*29VR$99==?
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MG!4L*]O-@_/IXI[Z\LI?UA3C2Y*MS-ZVRYG)5&9V<XU84YA_2]G9?:#&VJ)
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M.$4/DDUJG&LS6)IC;4$\S&'1B1G5J^C $3.F,IQ!@G.@Z"$.0H=5%@V/*H;
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MTUMMLIQ@ 0,2WY<:L6+>AO4-/=PULO,A1))(PP!.(HV/2/Z;WC7C#:BC@C4
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M\>? ]E%V8O>,R3PPB!T4]E<WMX])7'\]"\+PT0"VGQ@'@#\)Y\QA5NZ=!L*
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ME@E"0-3\QIU=5^$TIH 1ZC(2H%-U10_+7J9J*0]P@8::U"*02*LJNNO?JW8
M.-@50M.PC.M3IM'^T_/JY/B"GP2>1$4*"I%3L6A/DU[Z-\/CU<RLC11EI&4J
MK $4JZG8I=BIUV@5^74MQ<W&.QMG;^:YN;_(WT%G8V%N SP-<7L["V$]W"O\
M. OY>Q( ->I[N/*Y;DHL6MWODX]C;C(VHM9D+>:>[$/VUK=QH**92/5\&6I
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M_P!IO;>^6WYIR:T-CE<]9W""[X_;7>Z">VL9%(DCO7M@SLX%%0,H(.O5KPC
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MRIJ".K1;E6A^[L%NK1=[,\L7D>$D"I 1)XF !.@!^'0+./J4$;5I]1!J#\'
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MWQ]T/!)EY/T\>UG$.1<I]M.,V,\0N#CN38WA5N^0R<&'L]K2B9[6.&4*Q 4
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M!_\ HZZ=B3T:5%8U #T6A;=H:=@3U:$J=_F7<H6CD[M66OT54:4^'7MM^H?
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MZPN=Y;S?G7*,E'B.-<.XUAF>3(Y+,WTX'V\5HM(UBVF::5ECC1W95/*^??\
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M=210*;W,2/%81!V6X2"/>9%$ZR!Y'LH4"*JAE)8:'X17<U:27#0W;WN\ O\
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MUB4.*)V%3KUZ3,=(S()-^X%@YC67Y^,Z5^(ZC!C+$QT5@P"!ZM4A21$7(/\
MUJ#K:(PL9DC#/&X+J2OI<"A)VT- !34_CU$8XV5]C[1N4RD"-:T(.ZC ?'4
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M.-\D[/PC;?-S\P(BLBKJZ.B7"8*#%L4(0*-A4:*]2*4 0(NJ!:!?Y&U:5 R
M0%]#14]!'J2K)Z.GH'LIQ7(I11351N&*$I/X7C&W_,IBF4K5)4WLDK9T0?^9
M= $ S\7-SAFNB8"[(. _5QI RQVN:PF#.5YRJ#C#H5!GA-,O^.(MY^AV4;]R
M*:MKYW7!(6L'OY#Y0R?43</"":JG<%OO=V,_!+3<8#!K72@<X:)I:0]!HO$!
M+< -@"'_K $0H M  3B  %PN17!=?G/_4B/K"'?^:1&^)<+.$6[G?*D26<>Y
MY)93OZ/ZPX?B%_RH7'_I,<F?>JSI K>#.;LCL127_7*!.__J!+*3EFZ_*SHV
M[NI_4-R<Y?ZH.,/_J*A9.KK_KFC8P#U^5Q2<'.5_5Y!^_$.U+,3!YJ<C?JX*
M.DJR<I<+QP5L!0)9P1"6TK YX%=1<G/^-YRLX[_SR;I9Z>D[PQ69=!SAP)^*
MK*,5Z._P.NZ.\$N\EI>CM%O++S2N!Q0"A[G)6\ M?D>%EHV6^Z^HN(!_ON4N
MG0"UAO^=>CUD=/\=7A?B^ .OY0:1OO,;301Q@[D8VD*1@XL<+SMGFU\>([P@
MZ"!MDH7!X3 G1YBSS4\1_%^4"Q/^A"?XA=>QL['],P'O%P%IVV_T1>2@;?ZP
M >7&Y;"@_'I?1A7K)8WPCQY(W?LAA4YP6;V8N4:7=:K?=?I+K5\OZSB_Y% N
MI=B(?K@9^+TIN.3]L4%2!GBLK9$41^03\Z?0#\S3U+3?&+[+IQ'R^0LC>/GD
M^@-SJ?/H$D;.I/._+6@K%^3_[VF7OL#^X=%+NP!4Z1^_GS3YWS34?Z/1__;A
MCSKU!836\;MG/\K%]C3]TE^*R#SB!C@A,PD?P(OT@"(2D@=T !DDI =X &!
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MS,6]C)=%)IHEC9F*LV]3(WT;1KUQOPU^X"\YASC]H7(+B+$V/&,O>R<JS/B
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MN<EK>YNYL5!:W-A8X^SBD$<$P4323[BI.TF*:2%X(,K;Q+2X"DQ0W0:&XGE
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M*L+9>W!98^PM$CMK6UA4>U$4#XGY]4 8#X?.AU_SUZ/M('H:FM21HVOHQ/\
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M=Q?VKJ5!YWY7F:]2WSV02/BUA.T@DPO#,8@Q_%L3V68O;-%B8EG="-PFN'W
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MW-F[CN4):\5V/\VW_@ !Q)7X5K3JX9I+281J9!&LETG?<'<((V-F$3<?:&)
M#:^M>K@2WUG^JO=3/ERGZA2*_D[3M#1L<-\$%NT:1E/8R+4$@]+_ ,FW8!W
MJU_[P"G;<E\>""TE*#2G2&2;']W>-H$EZ!4;B2YCQ[-1C4 ,-@^?H>F[<MB8
MN]'M*O=!MU:MW*6)DV@_Z?AKTU)[*NQ=VR2\ KN_+*[<<[5'Q^)'X=?U['^O
M_OO*;?LZ^OZ?_1I\:;JZ4_FZ_]E02P,$%     @ '4!56!*U)";,IP  &<(
M !$   !G-C@P,3$W9S0P=S W+FIP9^R[!U"4R]8 ..0H44!RCI)AR$%RSE&B
M,#/ D)D9,@@J*!(E2A1!!,DY"ZAD$"1G4**2<Q 1=L!P[WWOOG__?;NU55M[
MF_J^K_ND/GWZ]#G=T\7%Q,4\%K:2#]0. -#2 G !  !L #8*"0 -64-!_@%0
MJ  85W4 P!6%^G?="X7C)PTJ\B5P^0;0(Y^[*()7]>O()P-%\JI^R5/^" I
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ME/.;%P-SJ_(2I(^B()"%VT=W:X>GQA_>CA\JZN@D)#4O]OPLL!'PS=P^^^/
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MF)Y3#@K/?Q7BZ<+.T&B5/6- RW%D3;@4.HJ202=1=JS*"Q<UXQX>M5LTNM_
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M2YR%TP?C<_Q.X1C4PPG3:3>E"=! .FB@;?^M14O9R'&:DL%8V2\!A!^<DZL
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M.%K]=+C-6:O]R&7A$RO!QZZ81\,+9?S.3C/-VU33O#)+E8_=9.ERP%'V^A<
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M[A<$+3-+GR1SRMB7!2]XS#@T,\7$VIFDTLRS%I&8!2'$;M^S)YD4K18!8$C
M; #V8H5%B/"W;0]X<STTGB3R]RJO8OW?,E9L0=E%V1%'H_RK4=*G=[:./F-.
MUT0(#G@; TD652"3LKK?49) 1I])J')AY87.#EV+V4=2\^T>2X_Q%3]-'*3Q
MW#A6FZ9J(S_ZGH&C5]0>"@=$" R!J7YFH> P8(P.>""PKIOAOI,<FNZVQ@BT
M?3M'E=*T-C#&1N \,4#&^%S[C*"W,TTWJ7]R=>[3?#X(=#TW3.32Q 7:'N"&
M9[515+&E6G.BUI='H=$W3Z., -#+%J;B+ <$0;J+W',] I/#?QXU.QA2RKCA
M>I'.?X1;T 7]=(P^+N^O#MMP-/,<ZLLJ"Z.-N)!)<2"3E'F M71/A;I<OAAC
M=/,X>1H\H!=@'N:KF#%R)QI@EF]YU("%P"$.Q:&A2K7&['$J4N1A7*Z<QP:C
M;I8H200-Q-F;G*3:B_63GOV+@3P=]W?M2OU'>9,-OI\W&F9L2%H-!N#6GZP^
M,L,<N=X!S.R&SB@NA:3X?+FRG97]P-=&\C3?T6=[';V<I,_>"J<*:A\*>JHM
M&QA,LDC&@-!+G.D($;  I+GD@ ;-M:;^V?P;+'IOC;J+3J>K:QI\<$CPUK8V
MDW+=*/8A@\+I'32W:0:U'5=:3+U"=S>=,\"674':27V:P8LBLTO0%;4UL8E&
MG"- <C2+8)L6Y=L:Y6[J$3'@M<%&Q!A?B?53F*0_?BM/:V57(?73W;57'>!1
M=F0.!OPW)M7 ;*YT4A;F<5!OYK.*[ACO(5=E=3UL>I;&^;5Y6@'Q/B8K6DG]
MYA#BPBUT-2:AS!-,%3'+EVM/ ^91=KAX;5GD#FN*W "X778J)F&#0CA<UDYC
MNW<N)VJNU</NTONXPW[$1.WU\:$C2D30 7;%.SMKF<VV9.^@X-(FD&5SR#Y;
MJ@(2UO$49XAXL4^-5F#\O0IX"XW&7FB.Q"W*HH5O%*4-0;MW"WU6KH1Z@ WI
MO2XI^H3#+FS-TK,T1O973%@ -K7:ZM-TWI B;U*2,:B34/N6YB6MC8T^$E 3
MG+7!N8@-" "?1_$6@:[K6B<UKB/"W4Q/*,DF(\KF!1F:WQ%'Y&HE$1R.,5PC
MBI'X5Q<"@(=YG(J8HY[97%#>V).T(HOZ+8HM/<QX+=YLF/V'T<0LL8P+;.&!
M)PX^JVU*E)D1N'IN/4E-Y<@5I"K@FWOKJ.ICRY1!(0!C9I)[[%*@GZ)%,SIZ
M-+)"2QH#G%Q/B2Z'8M%O6^HN>B7-E7%"Y .]%V+7)ETP)%KA !]( ^Z38&ZN
MPI-$UH[;?Z4K!N.7;\\O#'\5:B2;3B-ID&5N<(Y#YEW[AMH0AC<^<DD%0!B5
M.P@>(C=>M"[I'Q(_0ZG2J&Q%@?',0&D"9ZYVL1SEY?C\0 "MKJ\7Q%%I1KI=
M*^)XTSY'PO:PMD#W.D2:1P(%I$-K+1>Y,YN4WG<-E?W(USVATGN.E@;^ /U!
M>\KM#PT#*.]*TW7.A:V/2ZU[6MF$@)8^Y/B(NS:@"! =U:OJO6-;')U?52M)
MR-(C#8P1&0+D@+<&[_-1B,3F- 1I8]KAEQ)=M#BY?Q (!8FG!^NE=VAK46R(
M+',;$8)9NVG$:@YQ@7%6C9XMXL@W96C8:@<^4%X))<#X2$_U;7;[$6I"]I8X
MVONL._)E*<:?X&DIOK52>[AQY;@&KB39.TK8;3:NFM<[_D-TD-G)X/  6AC?
M)("44JFU*4P2%D9\)&*NWXEW\8([*$^I(9VG;NWDG<[P;C2MF4<+TN9JHOK3
MTI6I8'N;JF F]VM3:W9V' V15H1!WA(!<W]_:HX-/E&):K7!4%'1..T!/NYB
MMLWF\H!X8&]JUN4YO9S>MH QWFU/OM-?W D:U7NU&F;_  Y'N[E.(^_MRI3(
M3!FB('A1<]KILL  6K=N9I2Q+=+%*,K6"Q"M"C!6Y7$C;<@#"PISEC'Y%3O4
M KMVVNI&!1[@NX+\U%CM N+T7*]SN(1O\7T#@ <2:S%GMR0$'E3:G%*87M61
MB9AN."_RY&_PK33$/$[;P!0UH>E:AN>$RAV7>8R'CT.#3ZT.%3:R9QN\%SU
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MX(MZ*C:MFN4\>%3*0CVYQV#9VTX$4V_RNW)1^0BG?E^JH7$8S&OZ>YP:) '
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MH#8--,&QM: &-"-:W8S+PP7$TZ1I&<XJMNS=V84X@.5;X?-*8\L0TUJ%*N5
MK,B):F--P4PV+9>T5I= 69X(VKA]]UWOX9RF9=UJ$;GY&KO"_F_,EN(XT@U&
M;M^?SPI'"U?J#T&I)";9J7!N^H0QP(;@0J._*N/=4#KB.25C@+@BV8YK<#;>
MAJQK6Q0L!U,Q;'BBM>5=<7!$8<!Q-"?4YC$T(T-'C<"%[T.)^RHY] <VGE!2
MY+@X>8.4;"@ %J)R$)OMVGLH-"+:F-2XICD"K]5!^501W_/9VT&N8;^BHH)
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MPL:E1)":TU3TT!6M:U'[7V=6\8B3:"7<B@D5*[*@$#23=X&M>F=8%2/MZC8
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MR7 [L??) JK16R5I,Z: *'4>>M3U_*?#);FXCN,CC89KN^:MS/;13Q3W9$:
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M]8^D];Y"/J9GB[3QA-M*@G;M4HQ'Z#]0TKT -20@JC_6JDC<4(&U=:[=?/\
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M3</Z)QK+[QC^J#.<0M@]OSW[43HP5_99O-0Q>00%N&$R"0P0QD1 '0.I D:
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M;/O&=T>IM)'%'+_X0C%=^-OY 07.GC4BE2?,!_A7I=>1)9[Z-[]C,CH!" O
MK$$4(-[]&T6<($"HM4?T.1[69T4;?,5"KL+'5.RQYHX2JS:OS_Y&>:F:F;$-
M>0#6"NEA;=!"%C"/<PX0?T4N"E%EP!F@;O7FRXIP?@QGS-2OKX<P\(&Y=#Y
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MR=NIZ$C4-1&.WVQ_#ZJZ_P!.H^VQ1C.V<[9]-+&W< <=P!&Z?73JL94HJ)!
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M!S@@@ 8W&/4'2PMM"@D93E(]/CZG4A:F$)7VJ)* 4Y 3MD 8.O\ =_\ U/\
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M\[)M90!/:VI*8J&T^XD*5JFH9:Y#;\NR9NYS$FR0F"IBRF2YLF-[S)<FWU?
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MO@@[@^GC2&W7Q8O_ -]?U0/<UO7(BC(;L*2Q\S.38\N2X6X_NL,<7\4I:W0
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MG#_&O#:L1B@)=:E.4D6RMD.]KCB/?7=6$E2L**>XX3\H&BHYP<XR1MC]FO\
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MUFM:B,.J4DZ4,9!.4D#!3]F_4G0/R>I/=^+;_3K^'K]G3^UTU__94$L#!!0
M   ( !U 55A5/ 1S[&(  %Q\   1    9S8X,#$Q-V<T,'<P.2YJ<&?LN@=4
M5,NV 'B:**#D)" 929)SSD$E1XD*W0TTH1N:)@@(B*#D#$I2<LZ2$44R"$@&
M"0(2)$L25 2FP7#O?>^^/W_>S)JU9LTMUCF]:Z?:M6O7KJI3G$Z<SN-<4O&$
MV0" IB; !0# !> "B!3 1$,@]!\ H@&PSV$ @(-H?\/N((Z?/!CHE\#9&V!
M/[X@P7.8'/VD@:3.X3.9BD<P .NG;!WZ601X.IH!@)WXUZ\"!&$-9=2Q0Z 0
MKG8(9T9!$5XA1@YC&!R"\'#E! 3Y!84E^04E!?@9!00DA?@EA<0 -2C<"JT*
MP$P'_;#E]!0 TC%^M^.6COD;?@[\*#@@S)]VX_RY;R#!/_H&DOQSWS! OW2
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MH8/6I8;6R@@HHNLJZ-I-=-MB/T?FW\N?<6[ 'YOEOV7X5?Y(8@#<S='QA[L
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M/^6?\D_Y_U_YX^,9%([>*WHPR\F>;@%,/R\GY,^^RF$"Q)@8F'^^XP3.[RM
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MI.)Y^V4VDWWA-^X14&'7#?;C@R>3=^OC.K,G'"T+,)J5,^@SN"KT\<@V*>*
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M,"T[<\RD\3PIJR?E?LX4%ZJE.H&3E;A[<R=Y8:.,$+X6PG)TF?(F$6,GVXW
M[\GY@K36*JD2N[1J5ES!826R-)D>RIWIKG+BI\ (GW#;$H1TN^#+,\)2D4[G
MHDI/'M:/<W6"'V1B;^4+B5^FFG+*O_&QBX\DA%GU6:#-BU;O]AJ1W4SS.Z>
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MC2IZ@D:O:EVLDF6$\J>'3354360Y*LCL-[@16(]1%,HQV39'XHD>=-11>!]
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M*J)"3;HDJ(:)$,VE  ;-OQ^)P:]&U E=BF:JU)F2E44(I:%K'54\8HBDBWS
M0A9BV"EC^,S1($U<L'6FK&$XQLCZ/0G45 <7N)-J3>YIQ1&O:?=:;I0929+
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M [=TO)"-1QV!>5V--S_=CYW<BMJJTR1^,D_R>Z2*Q&I6]45?(K;B*GHNO'_
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MMV]]FO[VG4/=IO\ T6B\/ZOL_3-/=#L_DCQ?P_D\.GNO<=_>[]WYNO7'F_\
M2_'_ #;4[?YT_4?T[R>4?'^L>'^)_5_+_E-WY?F\?D_+Z=U\FON2_P 39O\
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M@HJ,C(*,C(J$X*+\?/WK@D:(CT](1$A,1$1,3D1$1'[^0T3^@X7D?R/@[!5
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MKVA  ?40VF;%/C< Y[KPFV&4$7F4-LI&(DC8_&\3_KT%;'],.)L$"# N=)(
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M=KX+!<[FR%SMD4@W"3X^N <O^#R7\4)=7?A\P&Y\ KS\?("4K(\;&.H$0S)
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M[LA84?-PWX,GA[5R(:J9!B[KWZ\G!%'1SIC.6"3,U"CIB.9X5NVJ"3P"245
M\I^*G51]RUVB %T^R?9:+$E0$R\SKX&"VOC$.R,]7LM5RQ++/'^T&/K!R\(]
M18'L#C:KRO1]UCD,-K;EXMB&D2XV*;'YTO;G<D=LY$B]X/:A&/.DU)G:P@XT
MC,V:)?2  6N=+>O1F&MG0/LAWT!$;%AM.>W-5LDS@#C +_&;4:6-](Q\HDY]
MFP7/#4*_3,L3[MGCT,YHD.KQ/0+>*A^Z*'JZ64X6TJUKC2GW]+-8L#\^BFG)
M*\-\39A^HI"%0\4>%"Z=G%<MMM!/Z&59;=I),"!V4(RP_O')ZGSKX!;TX?G#
MZ\4UX I.QM7R;ASVE%QR]H5CL]9<>=-BD-Q7E52>DE><S:"G3]O+37I#Q;AH
M-&G$.T0%,N:5(&+UA(:PZH-T;0PJ#4P!ZA"!(,[90G,!^E?J+.Y0W9[K>]T]
M6\YF<928?2TSTU6=-K;T9)R%JQ,J(.?>QR-*3,RD;DH$5W#*E3 ,U;!27:"9
M1F_<A@WAU@\V7$BX,@2>Z*B_-I^>GDKW(L#,NP+!UA835G"X^VG;9(GP^F(X
M\)BZ:'DFG/H-9LCFLR^T>K4GI4R+#IRCK[5<P<Y$F*/V-/8=EB\4O.5$L=F-
MB_KRGG-[TJ<JQ7)./9)+13,VAV,'YTA=Z5DZ5J"!>HRD)I/=T\3=RY @)JYA
M=GF$]I *$VN0@U5#@%G-!+YB[_AI7I*S>=P5]]'4'LX]"!U#3KZHVF#;Z&=S
MNUNI7UF2$!CVF!UP0Q<+0AS8\M'<]EBUW.A@OP/B.WF+WO5D#17F+9S"Z0,^
MI^FI<% &S7V""*1Z.I;LE?SG(%>\9FKZ;OZ$Q\^]BQI[13&F78DP>X3$=F!4
MBE >4]_PLMZ22Q/[VU2T=+!3,8X.8V?EPP&=:<H2/_<1+HV87,=RJC-@XZX[
MQ](#1L9T417[$/O.19/#[PMH7";<2AU-GJ(JV*F@(1K=J.O(E RE,&F6D.FO
MYG!"_D0M2\K68,[^[?J:9: \0]7=X/[Z+?-A%::"%!)+X_'O;3-5(BG28UL]
M(H,9/=.>&E !$MW#*\LETA#JB+GX&LS<U3CBG@6\I"6Z($8'L?JCTJ>UHZ'Q
MT3KY+"L/^+:7^<2LFAU5#S%M[5R+([K#@*A:"P.>S1K@([ZM#Y?'"VFN.W>V
M"YT/N2PN>T[T* A1*H7S),1F855-F3;LEX1@I+@_:%&#)YW*;G@]F?*_PAKD
MWCLZ?6,][A2,&_H)QAY8SH+1W<NNLO"HODR#I%;L[:U5#*.E,Z#\BS8_JR=]
M_-3<$GMRT;N%G+&5[Z8W@D*_8W^4,>%1:JME=FY1,VA!@$:96Q.*&KDLHD6G
M24A-'PILZ%53=YSD#_&[!7"TQ6CLK8O(3SU"EWVHE-I])&Q2=UPZSPWO?8.M
M&\T\)+=FRU1J"-7M9'WRJC=53TPMYFFX BFO8N()YRO7JFP;6D>K]JWTK#,
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M3%$ZO=I[GY[9IHF77#%/6I5CR8P8N\=A6$+HO^[(%?_B"3(GWLSX25T<<VP
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M#I^-;_X?^W^+^)^[V^W7_]E02P,$%     @ '4!56$*:^.XC4P  +6P  !$
M  !G-C@P,3$W9S0P=S$R+FIP9^RZ=5R46]< ^@P=TBDEW3ET=PO2'<+,T,S
M,)0@*-(@'0**@M(A2J=TBDI**X(B""B@I, =,,XY[WO>[W[WO?'//7M^S_/L
MO6JOO?;::]><3ITN8A>J![@Z 8">'L +   >@ <B!S#1.1#Z!X#H .SS/ #
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MH:?3IQO$_']$1U%!84!*15L/"^M\'/(R@*P 3'H.38:SB 4 #!@& -99>&3
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M1YGN+(?9\[ME/]+9*M#WW%X:Z#B"!#S1D00,"*,MH('.J0%&@#(Z9P+X 2*
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M)@;FG^\>@?-[!-#_/F'\D3!_I[_@07_&_"_3:>?9/<)#P!<31/;K'J$;V 0
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M7&WV.8IL=+^4W-)VWP8OFP4R0TQO!SJ\^PSS$AD^VP);,%B^=X\*.X;AD_5
M'?$-4/2=XQ@NZ/VZ.YVUB[C/<@4O?$Y@&I+%OMYFS;G6HNOF+=\S1[^Q,K>C
MX7J)@Y[IN3B"^7M<[9V%CO;=4^".OS%806? U(WO%=&%/N:J%#ZGDZG@I_$M
MVA\0?/Z9]Q063[J^/WDVG^L4M+/M)6O=N<]*G]EA^(P^X4A/F<+8SO;:4;8S
M_JTO;"F3JYR%)K6^>3/+'CRY?%^J6!]O'-_M;^$;VJ/KRZ ?ZWT^!)$*[%>\
MMJFJ-=^FUAY?^OP1[.ZG4 $,@<LFP5<&'L@*'W?O32;M6^9"PY+XK5P%1.(R
M^/C>7<04I73'66#;] LU[H@;L';=>-_W0GC#SN2X>VZNK0NY)\@&8I+':-./
M_9;.N[8@*![#/D3]SKY!U\]CN']C_F&LGL>37#U;#?,.NQN3HGQE\@T[SWT\
M]W9<)50^I>8\?)F G-D6\BK#_E#P@>0SK/L^AN+=J_3-@<4>W(HD;3;.>U(;
MLZQP8O\DLRE"Q#;UN]EI!6,RZ#'VHSNO)1/V]S\W]@S*KSZ7ILGQ$7*ORA7:
ML%-\_[;C<7VJA[7V;66;Z;XOVZL)&?;ZB*5G#2M%%9M13A6RBE(MG];,[*_3
M?+SU,G0:X69_^12XO#,[H;@>Z?SZ&+5P"K!XS\X'O:[;.P7RK@BL_-H!8N H
M GD&+!B!O!%>^53$.E&+TDE?C>(%[_0*A7'*-F)!?/Q9.&R[8T]:DN4Z<3D0
MC1BF Q<LC0&WXDM/2S7>'WG=H)I@YIG2XIN5AR JIFO#@LDDX/AJL;29H=BB
M]$8[*7/3F$3E0\;8>C4W/Y">F,_=USK@%U5-J;O%,_!Q<&,HQ<5-7!,QRH^G
M>PH('[90#4^> D&RF5?6KI+&PXBD&W!L^Z@0/J-[VV.169-@VCOUB\M!U6:2
MS>9[')QI1%I9?4-IN@8?;C939US@>4?1/RB\4<K\XI8HI^\IT!_%8"S/J/Y.
M=T0%9SKDU4U06-HE4IV,01JQV>^VC17T6O?DS.ME<R_/"M?<8@YHBMY3)KEG
MG1U>%[1J/0\LEM!\$%VNM#\%/L\X<#?X**WTECK2N U>>YQ*D^^)7(SEO-&@
MHHE-BN'JN&;J=--6 QG-#QW2*S'5@;O)9A;&Y(LEE;_ +K@8+[IA'="]>GM6
MC908#,5N4$SS3V>!3[H?DDUF&Y>&VX#C>WDF^MX.!<+'O_=L$==VRKQ_^XBK
M?ONNUE#V73C&!&:]4#:-@^-M^Z\$<_42,$(-Y?<)A(]LJR[49 ;'6U89P7F-
MHC&4\8ZR+K6P<98B?<Q. 1%"JA!_0?%BM4'-&P2?#5<Y)>N^L&OEVF=&6SEQ
M.'LF/&6RL8RT5X<OS%[W5UNT8WP?)[0!1SG0ATW?E3L\[B+=EW+^\)CXH4#/
M/5![O#QT&?.$2=?'V=U_8:9W.@D<&8.9!MTDX70:#O70?C(N9(TQ7^?GEH5Y
M(YAVMT2*M8A\9=T@^K.*I^9A/A@:9)I=6C'Y A8QI<.^11$#.J*Q6#5H8:F9
MO8TA/:3-TH>KU@NE/N0#BW(RQW+#/;6""@NV1)YC=L<2NR \[>[R%&L.\RA]
M(#1]275\U_'P$9/5Y2LQ)<&OKY!G1<\JS5VP-L:!],R3O7B8ZT([FB5XS5 :
M+%\Z;RP3[GG7T=</MFU=6>;6GS'JQ1P=Z'K8R_Y!RPH6R=C?WMUW'PO^2929
MCD'.9 ^G2VDTVI;,I;L1)['#[A1@7A.)A_FQS40/W@@+-@"SF5TO)>IP6UY3
ME5!S6IOBZ<QTG)L.SW8"8[;:U'NM-F)T>TDE,KC<+DN.#R^Q-_<70[Q04,Z$
MXUE,JK?JXTZDWZM9L7RNWM!("*NM9U;SU-P\4KQ  >3C.>'7XB+RY6-;#)(I
M^8<&'X42I+T/F]WD<M>?]?'L>/Z"GS"^Y.8P?<8P*U.-42V<_?6F565$;?J-
M0[C:3E_8K TX*.7&N&Q6QP%9+FM-TEWV"\185P,+:2N7#0U#M,C"?#2[LA-K
M:R5VL^;NL++EWC?\LF(ZZE!S]S-< #]+EY4XNQN*N<^3A:&FRW2I$03O5N?K
MH=U8'S1.=@-7-S5="N(!,.DPX\HD%B5&<4-<7!L<^!?R37N>^#T, _M?!=UK
M;_=Z'.KL[G>!XC66KM-=T6)KJG3*VLAHJ>([-T49\)>F;MPA&;S5+E"<[L!]
M61+X<BC0>^1XN8X]E7G!I9YE7P,61,]8?L-/-!VXN%.I:]+7V"9<_@)3PD/$
ML,&A=+Z>_;B_7^OXJ5DW5-U@C'G9B='ME;BDS[L3<;UAFP5$2S,?+.JB]MK<
MC8.F4V#&,UQ@69]#RTW<*M_E7OJ=^<SMMT2B@E/;5)]A(9)-"J.;MXI,%MG8
M+@UJX8A4(N.<O O79.WN.3W?2NT4(6,M&M-6(XC!_-!Q3\NBJ5>IVD!7P'"1
M2<>@R6XY#(N$VS )"U<):5'6?0V5/N9G[369Y\A.##5)S>+E$L/ XDVS&<G8
M"83+>,9VKV% R-XGB$J[4FT9-CAS6Y,SMZNUDWXE!YZ\FS/A5[F 2\R "YIZ
MB'G#@O?JW=CO$LT6$.2ZXS2I5FAJ&5F-6(V::R=+SI,Q\E(*V)==@:A6KYH@
MVQN,A7&%J ,=GX4-E%V;'M#(K%2GW<F<"?JHM%R?VF0W_F@+>TBVF4'*+RR
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M>24\S<);;!4=KKC830&I,M"I2FH[S;A0M32E!LNBJVY+9 >0\E0HM"O,A6K
M7YI5:<A<EXO/DR7V(<=;5Z;V0A#A"LMY;%R:9\R@ "=(AO-H+J H*!7TR@H
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M-^QRE*_RNVE:T\E*5XTU_]E02P,$%     @ '4!56#<C>:QD00  Q%D  !$
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M\M/R\_.O"PX%&1D%)045)245'24E)=W)BY+NAPCU_T;!\6. FAC@ %CP<+@
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MU].T_$]X,M1)\OT'].F,%O@AAWUP53\!?_#4IR#.CRR)3W=:.QE0W-/Z"3^
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M13-'GG0Q9$'MS*5Z9**$DNPB']P1JC<K"YV%]UQM4<Q0<^D*B)-4'%FB)=O
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M$E#'HMY$J-D#14-BDD)!7I.+C"+%\MU^+IX$U8.S&^<_U3"R!./O<XG2)+/
M)XHAR:\UO?9I!S>2,6R[B6'=B^=8@FXEI4(D:>SJNR3,%VBX*&?N[\!5+9[H
MDZ@AAFKQJM,4UC['P-=R;C)'^WN^):]ZD<O_L+/;=UK[[G B=V\*/T]SCX69
MN:4SB9U-/6WIUF8+^0C3MY#/Z<R8EOG)6]Z)K]Q[+F7/7%[@>['G? UJ-O_"
M%=_A^>#S5_;+>[GA\_VFI?8DIMK'0'=+-_.BE_ M/K66N1;E0H'8=*MFS.+D
M4G\2/5?!PT6.:[5X!B3*LL= [;#V97J>04 1LU9$4Y3;3_\UH&2'_].$Y:?B
MX/C4F@4G<:(+(.3JD;WJYA"BOMS+G((FW+*8M8\$MR@G*C6K1-VM"916WN.0
MXG<KP]Y R-*ZG\5O\1Y%\]:24WDI0D6J25=28W2R#VET@Y.4E%AL&F0)8D@4
MTEBD,3'-T<]-7\QXD50&/D?[J,[KI8[8(_J=0<YG?JYD9,3J_HVI/+YZJA0N
MYY:51:HW(<]!&[:%5; [<GH6(>-9LU7%O+ >IC2O['F&G&$#W2J9A3/M(C0C
MN_L?#:#R;!I7"87H)26,>O>>=Z[Z3>IB?$R:>"E[;<SX5%7?\MO,1 UE*W ]
M7T3;O^^($41V^,2%Q@]J0&7GT(;Q3GJ4"FS%Q?=0 &M8^>%=US7MGIXK7G)>
M1+-G,I\C^5?XOS(Q%4V'2L4;&XQ/DVE?7;7PV="UC[N@*63+P^/URII$HJCN
M"/3>67SA,Y>A=S2W E'O)78&NO&7II+U']7*N!%2*5\^"_?=-TH6CO&K'&<.
M:5Y@),Q>&B"[K)VI9=6KGF>#F*NW]$DILQ93A8S7-(LXY9;"GL^3*YWO-[WM
MC:^8?RF2>8<\62.+Y48.?4-9W"S^!W(/-FM(MP)=]915[-=8L6UHP7:_6@(M
MIQ]*PBO)(!7'',;U$%Z&<C6ZH4C>;9]"B7AD"1_DTPE"^6CI#[$&\S0R*((:
MRE65;9H%NW.T@]&C:!Y3(,WF&-#O,$"7C^UWG969_NK,7E]5B2Y/S[-M7YR@
M)BCWGWO52H0WA'B9/Q_%?+'>\$;%C2KIT9ZB0'H)STL3C#,.U8P4JO&EZ6N1
MCU,T2!;3X#ZFQ5T"IKPZ.;6K%E\^8)X.^64@FQT<PNZ\$J]Y9VBD+=""N$,Q
MM#/"A/-,NYRS>\U2;,26]R"D-T"P=YU&JR?9^IF(D!?K&VV\6 AGYBA?/5=)
MJ>V1Q*V@J*[4L+)9G\9;"2J=W3QO8"';R]S!47?\577ZGZ;[N3DWO#C"8]A[
M5$4I&TUW@0"\UE,3EO-&Y&M7CW &9UMI'.0!T^RB*EO_3<_@Y2RB)+^NQM&;
MMHVM)<FBO0A3YXLH@Q:JN+#I^:3V[VV!,\? 3&?YD?4VI?WC#-Q^G;.W)T+E
MND&.=JKE=ELM-E[V3"@-NE(63998#6N+>]?ZY7JE0':LVXY!7U/DX ,S)?K/
M:\GH<ZF>UTB*D@ #C&O+Y[DN7<)@GGXU?R64HSBMC_A23*'O75<?6269-E ,
M>F<]NY],IT"/GXG(>Y<GS%$2S\1!RFM0*I0R&"H3D%G4^'YD>@F4*B*]0LE@
M.>-CE)A7H6<?%DAD=\2LLL85BF3Z6F=5-T#]U2L1(?LBA;KNC7,<M;!Y!@/Y
MS4ID.S,=0MB^V<*O6GE?6?9MR3=/(;# >P3_=X[\6J=+.!1=:DGL4GZ/M[OH
MAD&<MVN3B?']_4 HLR_LZ1E3I;#M\B$<^U1Z!AAO?9%P(MG"C+EZR9+T*)2-
M;3OL<7B:*0]!&KVW\,3[RDQY_H;+]>W-'Q:KG_J8#4_+X9?=HYFX3#,=F#Y7
M3E1:U6!0F2 S[3]5+8PH&GI<8JGFC"DJUQP3FIB:W0<E,,QOV+R;9N-7A.Y(
M"2XNO;:]<C8]JEA>:.;+\_I:WE@S1#.M!N88V.%^E>B7!64ID'G6=9<Z[!OF
M$9TFM&G*KS;W*V[8P^9U&5W)K,X5LJ!86HV[X5Y]=QSWF5&:M75I;?QW!*AL
M;PK>]K.U[^"Q?7$,4 BRMZ<QY>C;XI=<-LDR,NB;U4]+='0DU9<F53?L4,0K
M98Y_CL@HE9Q)S:/CU+^8D?K.FX?2P%9/26UIK6COCM+3V#.BVD+ZS.:Q8+DW
M.4*$^5.3-D1B-FTR59XX6KR1QEJKI":M[:F=7"GJ]Q4_GXFJWH9)APY=E4B<
M!]WA9.B"75#(/AP.<9/L>-'LN!52^"0-[P5QOSX^:_A&)K()U!JW2Z*3K3&U
M'(9+D]Z?>@6@?&#X^FYQK7\_\G,S7B<#1;>!@ZF5GJ"%/MV7-7K,;J!]CG>+
MPQ1&-^$<0\]1?J,E6)>3U'8^R0"G[&/9-W-U.!EN#"!HQ4QMP'2DJ(_@[;,>
MS,J^H)N<8ZF56QYGFAAD&&L=RP[G")6!IPZWA&GQ07GUI'49 0PG-C^DBLU0
MSNV.!\Y-7]_N>O7L@N4=;J;T:%-W>ZY+?$"?2"##J&<M&Z4%+'F8\0(=NC"_
MY-$[R:2IZ,!7J&RFK93IUQI4B^1/7T4\B%R*:\Y+#/%?7%COT[Z"F9/#NW"Q
M/<."1>*64T$]S:/)(TJ9T!8]/ZTS;_SN6ZFOW0MI];1A<(S&/1P54_E\TT^?
MY/7V>;;4KQ\\Q[HHJOIX26?*R@T*#92^TO$,=T@4%[_,[Q)&92:I68Q9SNL6
MR]R8SO(3,KAR&RD9SIZR@M!1PD1R?\_?I=49^Z#*&E8-W>?-+TMJ?Y8PQ:]8
MS&#.M;ANTDWW;CVG)V C-B*H<J+ZNE#(T;WNDMVEMQ06"_8?,/TV8J6-4^[&
MB3@+UMR/,4OA)IN" ARA)*.)J5LW%?9SX>=#SEEL*#+Q#);&V)J 5TO%B(78
M^^^DE< )#(A6:K86;6%-ZY,"FX)I5S_H%/0*[\=\7[.B*J#1]@QK&#8 6(N*
M.2IGTG@-;'BVA'!C%SJ<5\;5;_5YM<\0W&%XJ9OD.NOK_?"L; --0;KE?*+N
MQM[JO8ZG^_"<&#;T5M5[AH8>^[&I"[ H?6/WV >=8UQ:UY]F3WOQ5Y1_F_H6
M?E^V8$3N!5FGBKZGH)XF2< <:L9U5^'\M7YP_U2\NZ^UBN)SA+-YNDW0,ZE2
M@$YC=+&[2GX4_')IC._3(^[@E$J>"X#<CK"- >YT394@@;3,7F:BX*-L1XR(
M]"J/(%R#)K6^@J/1RH9QUOX&]R %BE)ZY&6Q@9JP+D=]+'^C_A$_5R"K3@V.
MUT9#G(M(X\J"%A]F?I[MDKZ>J?'6?-P-_LNI$PE2@(D[_38#6:H2$W]0@%'=
MB&]RJL!()*3;E!TO/S7PRG ;D<C&P>6TG4*.C?&.;Q1K6Q.)&S,1K&=3GX?:
M[Z)@ _4:MZ8$U)?K]MY&%7;ZP29<[.](T3O[I0ALXX;G#%*^'UWKC\<>E2XG
M>%TJPKD@^JQ=-[2U(C-^3-A9O82KSU27CK?Q@GGLH .):IM3LMYT]93AD_'1
M8KS^V#S2@E$2NAJJ,Z7E8W4[#&DZY.?=VF4V]G7N%MU&Q:;T^MV4_L3SD6:S
MI%UN>9HGH32DY[)AUW;&$R&3X&FF=?;=**L-Y9>[:9,49;0;E*:>/8N5BK99
ML>[LWHW+ZWI6+ DJK _Z[L'&1YO/\/I=87M!I?XFNFS:MD1IR(+]A6JIMA:#
MM1%&2ECD4'V1KX%3N9F"VY.)OV3!S(Y86,+58:$XSY((+3FE1[=O9BR2<T0W
MZ*E9YR18Z2DC =GF&%,Z9T"O+?#=RZQ83T2RWT%M%I18$2Y4;6@_[ECV-FRU
M1M(X43V^+:>5QTT^7O & YZS\7M>*_XWQ<*7\SZL;-,4*W:U6HY>OV8.J6]0
MT&KTM*02 KYX7"+;E14^!N:MH!U5@4.3&U<&%VO65 K35%].-7S_AAGI2ZS'
M+JP#M4O^*L.@K;=I5E<B28'O,HF.3V.S,F3@^B3T1NA[Q4GVJ1%JTW;;U@8V
M?$RV>U7<F=33OI_IEL!K)D[:BY[#";"+=P47G)'-Z/POP6NKH]7SWXH%_3P+
M!B/HU<TN.- 6=X>1.NK79D>#E(?-J58-+.^G J1):O7?AZ69DI/O!/09/\D&
MYJ/98O/NSC\&$BH@-V]\B434U!F]L7JVMFU(R;IT!8"MO7]I4'-7NF'R0J.H
MYP=KEK0$AP*EH6-@ *PW$=GNW3_!V\OH]M[$5;$BW;4[A<NPR\H:>SP7P"OF
M)=O(DR\7%M:G*-H6@'/25PA5/3Z/<))?&YXT>.YE;YK29\GC0YHJ1W#A;FL.
M:(+%T+ON0W)R ]M"#-RX+,GY$DL@/\)]FPY7>ZB-]0E)F;"P1 A,/X\[OI.5
MTZ<LP/H]?'S$/GW1'Q8V%4ME_F"0HG[T[N>.RIK'DDH*NQB;D)6L[1EOJ5S1
MMM>L[RYD7[;W:&P]S].O(927QMLGF  (,M-X,A0=*=[O255PVOC(O+A3MHU2
MLE&3.'_MLU5G1=N: &#6Q&SH*61>4=A'IV1BL:*3I!T26Y'RJ9CB"E..'*%7
M_OT/@ZD@-+%YAY"<2MYJP=03?1N.3-H&172^\5'::HD8D#X_$"#S:,<06N>@
MMS[M(R8H1,#%7?&Q65=GANW:!;]/X)DPC?L?HYD_OV&CN>^DGN'1&C0A'4V:
M=1L%2KG8ZQ]IP!"WI[CM--Z5I?%*8@:'ALMAP_H+#7<3&V:*Q8W?/G>3TAPZ
MN1A(Y:A'PI$3<77TYO4,7)CA_#>SX7!Y21/BWH*T5\DC&_EK]JLVAI61Z82?
M."-)MP@XR=!G/$QQBS8O9/92GTDN(I,964V>JL Y<*=;Z]/#FWJ!+HLKM_=\
M1]^D&K4>00U7RQPK2[I DB=HI>^[N3U,8TDZ3M,Z)$U*H$1Z=5&C/_[;$5,<
ME>-M.9/W=H_X+$WK]Z/<CP$[T'Z1ND -1[&=@A%;<:+5(&O04X)W^PA;Q8W&
MOG.L6WH!6@%X4MDBZD9Z>FG*$[!V.1NH9+(N[]5[L=K#)!'%)8H(<<N/@<DO
ME:;!!:\7D%J75OH-MU)>A#?XF9?ET1&/S10+T3N$AO,CYP$<CD1][XDM)HY[
M@'"7FL#H];AD8%%(Q9XSXOXF=>NESU7:N$$1>06MYED39OF+MZ<WGE$D%+8=
MAMV3+PD'X\?$SS"GIR6-7J</K=]J;8[9&Z+8K#$L$]8H8(A)Q<T4GC>_9AJX
M?WU7>ESDWAGFYL41[OE+A[F"/OC3H<1-9Y@5W,/*SWDMKZ$:NR&KPV64+?3S
M-]STYJ-BFZ\M,];).MU(.9\[2[',E1KM''M]9KD<'N8-ZF:A5"S(]8K-UU.F
M3%[6N@*.C9@";8T;#K2^UE]7W)[GL]!;6J&K=J8NONFAU93J0%D5X0"O_\3;
M52P695GA#8"U@]>D O:V(8+91+S@3,GA#X_J#-.;CHI?+B#:GQNX5&Q1TJ6Q
MA7_@L#0M/ C2-_/+ZR@\X EOB%14GFVE!A]939M.^S"]X'BF;6ZYQH;=A#7P
M%BFR['&U5:?MC(? 4Q+ZV$39+]_E:9VL>R#[!E'Y?&S.1.9IGQ]Z6J5M]RJH
M@6]$PCR$7<<R[VU@N[S7\>3_ 5!+ P04    "  =0%58N<[A*QI3   <;
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MB5'0B%'.YY$=0SWO09%!6HF!<EE^=A -0$%%Q\#$PL;!Q4/Y1R+20VB_B%<
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MI6J@I,B@;R!GH*1_*<5Z*74EION:*TI<RI!R?B71:H5JW25-_)*V?D'_F=4
M ,\%#H$BM-T1+NZ(GZD<T'%#Z%O!8$Z7'*I0!!@,=7?^!5_\*SC!+^I$E[+Z
M$*\+#GD(XD+FCTXP7,O2&6R@9&SPN[$? CIP&,Q6'XQP=]&V<K!&HO$!'0 .
MP) _6X !T ?   )P!UPN17!=?G/_4B/OA(#^M C?RAWBA(! +U4BZSB7W J:
MM]5_^%#B@A\5]+<>D_REQ]HN" @,ZH;$7KOLEPL"^JL3R$Y:P7]7].S<-/]0
MX%"%/Q4HXD]%P\K)[7=%RP[A\;NBY.RD^+N"].,?U?+6CG8_'?$S[>K=E%>X
MS,P7L T#@PW,W4H6M@3\*C?AT'_"R3O],Y\\W,;@%A2AS*SGA #^4N2=;!C^
M%5[/S0EQB=?Q<I*%/_^%QO4 6R-@<$5+A.7OJ-"QTW'[%147\,]_A4LG@&T1
M_TJ] 3*Z_Q5>W]KI!UX';BU[^S?ZBC4<YF)D#T8.+G*\(%"[7QXCO"#H(6V2
MAR$0,&<G&-3NIPC^+\J%"7_!$_S"ZT'L[/]*P/M%0-KV&WT1.6@[/VQ N7$Y
M+"B__B^CZOHEC?!/#V0"?TBA$UQ6+V:NR66=\G>=[E+KY\LZSB\YE$LIMBL_
MW S\7G4O>0\N816 Q]8627%"OC%_"OW /,[(_(WAOWR;(-^_,$*7;] ?S*7.
MXTL8.9/._V5!>W]!_C]/N_0%]@^/7MH%H,K^>'[2%'_34/^)1O?;AS_J5!<0
M6N_OGOTH%_L_Q*6_E)%Y! XX(S,)/\"+]( R$E($]  Y)&0 > !\@# 2HX3$
MW43B])"P&/*Q168=#Z0<!/D/_RG+#P@"%DC*16ZZT'<3L 2L?O(X(7]@)$X9
MT+[4H8/4=1.IE0&01]:5D#5U9-LB2 V_I_7?RE]Q".#/_O5?,OPJ?Y(8 '5W
M<OKA+@#3"N8.M7'[AQQBC>#[Y;:+B?>7H ?^878 \G]FT:49>G\FR85IF&Y.
M$&NPFZ&3QL4T1_E;.QB7-"1 @GRP+BNJBG_1C64'A[F[_ V%"8-#[""_,[B2
M_H60]B4.62>P=$? D.L;&&Z) -M<6N_M\FL!POW!?(&YH*@ZVS'\?]!_-'>X
MT]^6L4OG_QVCZ6;W]Z4.T]()86!I]S<<H348*0?V0JBZJ1AH:OQ*IMB_T']C
MQK&'P7WDG"!VOSQ%]*/S*K_0%]ZU =M:NE]F4QP/,!SQ+]@-?Z'_SHYG9:<
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M\O*!Q(2LK$""0LA,B\RYPB!^/E&DM*"-#:^MP'_8A)SU15J^:,22G\]:P%9
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M3("1A!2+3XZ)3)>?W-*5^2HV15#"M<?R>@(L5Q0$6?>>OH;7Z%N["8F(XI
MEU<56.A8F)B7C:( Q*B,:'QR).BZEE=<@QXSD6(\[7S-OY>P+*]GU?4ICUF
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MKI_]UN0^^2,J3=.OFS2^Z0<7[>(&&?.39./'H4@AYSHV"BHR>P&;CG)*ZCK
M:.F91L[JE5:U>)\7I?KPS?0'S795S;9D=C?ZXOU'U:>T71SS+,S38\CY9L>I
M^#?KF,NC!P.'5-.5OO8&74.U',TWP; GN[N_%3LI&3FK2_8<'8%KH*^22!+3
M,S1W0X??[09-,)>P@9&NHE9F<, 5 L=9S-$#IC>:9>8(3@"_*,Q:-")VQ06=
MIMXI8:#<C=]AX5T*!V-OS8ZP\EA$_P,^[.?ZQ:0JZ5U1>FDZQ"  )6A9S1:6
M1>Y)XC3ER=)+6@26K7KMT:G<5V^$\3A<C@"UG;7*MRC"KS02H9^NF)D^36S6
M\. >4Y8^VHJ8.[?-I"'(FO+;:K+&QHMX-"9=8E: IO]0_<N8J$Z)98&6,S5V
MT&*U[A=4=O(ON-N33I^N[\J5/%Q7DT/':,]D*GAO+XV+$V'^J5^6!*@(>@S@
MXFMP@B@R/%YUBC?2:A9QVU(F/R&!JW3CU0W-2Z **5S7VY0E?SPB<^6H2%IA
M'*!=(:<2;XI&[WWFHDCJQZL?Z5R@^&A)24>.3>MACU+_<]/=H;!ED@<%I;HB
M(_ZH$3L$W?)W'$0&NS%4Y,&E8-NL:AD#L"6M&#GU(&Z#/IS#O6W!JHG478@6
M,6_NQPKA#Q1!I2FT@5]?_U(6E>_8J+K,HR&_(KKFVQSTM0.>*EX_;6.0\B%5
M,8O@K)<6*V"Y4K.,W"J(<%D_V(:=HE=ZEG@L,'\E'D_ 6LEL6*C'B3E%0LF
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M=:HMCK_^3A*5P D'KKC2,.U<;>>V36O'ZK$\AM^MH2+*<!>[*_+J(<O"EXV
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M;[B<-?U[;7;1N5(:F;O7KV]\X3!.+O$4?NUJ]T:ZJZGFDTMA8 IK+T.,W?Q
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MLKL\=P,Z6//<BEEX5EK$MOKJPU@TB/LX)(*8?"FAMV% 4]JY82)UV_59N?_
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MY*2 2>0\*42335'.2P$H2M"VP$K6A(2$ C=XK36OF/'7Y/\ =R_H/[X?S/\
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MW^R6W([#.;<2ZW*M%WALW"&XEYLE#JTM/!+A!/K2=?JCNR"I:9_?;ND^4J)
M#GYLG-N<?/BHB@J3X::4I*@.H'4)VJ@#DJB4I!5R*O*M1XUTEUL$U4'%$I]8
MH07$].G&B0FI\"?AIE[ER;04I1ZJ.4""I3C9(-%>51\->XY)X_O!Z'@JM/VO
M]'E7E\W+S_Q;ZR.[0%ONQVLCR>1*C5*UI0+Y/#TEL@5=9 W4*5XZQJ^,NE3-
MXM8C$H7U$=2"\E#J#QI1LL.@)KN$BAU'="N8"77$H*DAM%$J#8%!S"BDD!/B
M?CI:0H% 4M034JX)4XV$.(XD^MSEX5-!I#$9+8O%N4)UL4ZA72=N3".2&'.
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MB$/,/.QI+;%N*%I,=UPJ( ^S37L'A*6"]S"$O-DND4DA?5;:H\%BJC6E?+2
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M>:VPU+VLL8#M_/!OANU+(QU\>^93]DK2E%R9V7%D3T04GWJ!RD#+0M9:SNO
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M< RTIF=?#,P]'CY>(7GY.W *\O(#HK(JZKBXIPM3@!;+&,"YS*KTZWL2R@"
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M6<!/DF5))@R$UQ;#B1\B)"I@ 1;B$12#"O. A(3 /);"HJ(\4# ,"A8""5E
M(:(_Z;_GRQ8.?TJ%1F.8@*&"0B*B(F(\EE80*Q[,L*(\8E!^08P=!&"B(A!^
MJ)BP"!,C%")NA4 Z6F"<UM;1PAK&9^<$LV9BQ$RNN!82 45#8,B?:QIC%$8U
M6TND!=(#8Q=>45X!(>'OF#=@'FX8 [F<+*\3MQ#7/77.T]FUA6&BB[SXR2Q@
MEKV8@("0 !CT TT.X>AD ?>09-)35M"1T5.04];05--44E'09531D/N-=.J_
MOYBKZZIHF:M96,(<S*U$K(3Y12S%>*#\0E >(2LK01Y141$!'IB5L! $9"$
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M-_%F,96XNE;[ +CRC&J3)OF+C?IX(2M&+[C'E<J'[U#M#Z0'CO)0RZ .%[[
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MMDQ4.SP^$W3A7H&M#/:B$OGBMV#:,F@-GHB3:J$*?;+\GF4 ?9*U9DW:X+7
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M\S.8>+U'C3JN\#"27\_>'.K;43(T'G*K1G8\FP=7'[AOVN5(<3I&1K5M!]S
MV;-@N?S5P3$U4KII1*2F-#QENL.\(YTTK2;FWLK!G@\#M?!K0%% $3"D()^<
M!SCA8F7[W_H-CX%V@:'UQ=<#>1>;[2*J,X>,T5(BQ=4ZT)DFU9WE<!&NJHVO
M=Y\M?C7Q#W&XJ<.@M$BJH,]X0=H<>JNC>N7@;2G\&N5\BB8+PIP)?$=HJ._,
M<Y$/;J'OS<96W*Y25[ZKRX@Z\%<-?[.7W ULX&YJ^7)ZH]HV&3K,=D?T1%67
M$?H#*%+S*==[CN&Y*91;-6'C"F&Q4VYG(V5D;Q\MSN3 <C+O#WTK:^\D-'E*
M6_YY],AXO#KL^6R7O%,SN8 B/4CK(>$K[COD7%KN6]U)<XFNJZZC#F(!]F,W
M/YJ*136FVF0XO%!POU.@82MW"T7M_6!9\E')OC1%I(JEW>;$UE>K*PI:IDB*
MJ]G1*KAAYS/\;8@"%JR<W+=QYR[[7>C6I$2A"FV[NT;S-\[TA,R!\35W/85'
MBS]+&Z]H/"V>J"NJDA\=]<+AU>2BXD;JM6_&.EVBLU .D(A@BE!N&)QH+!6S
MMXFWYM3 '^TOO'8F^5(D!RZ9ZD./+4,_"A'?R5VJ=3FLX<1':,>5IAM*-T+'
MZG!(U,^P;L^:L+&W'@.XA479>4_LD3L%['=I5'0D=85"TGN69[O@->'#G] Y
M0NG>^4O=:!$"OF^7IJT*2@<#AO)GQ_0?VR#!2&B8T$[(5CCMFCD)C >L8/9X
M82'S(06AOQR$+7T>45A?E"Q43580P!,QVOL8K PEOI,ZTY6KMR_GN+(H/?U8
M7)4:MY':+%QTAAR/J5/^^A44[MY]81:*%1L3T>G4R$U-[B"O #*Z"_2#U$3W
M.K[8C7%"U\?=%'0C1\ "\M#[9YZO1W;=OV0,F^;T?@A2SZ*PWTMHFO>).*S]
MO/_29K8P A)FL#5G1' ,!#;:LW]^> Q(I?,YU?KS:G]^:37+]<RPT-%0:3W>
M.8W3H,L(UV.Z7C_)C"B=0?)*E.$["JX.9B0L*J5-*.AC=;0*(<MDM,\FJ<MP
M#SDT?,Q=-A72>AO]CMAGLXWSAE!&9W/AT>.$E+D^WX7\GNN?(W*U2DA:!C]B
M2^?23TW<'GEC+Y1,)Q[M:MK2?"_',V*NAVV%^T[QVW?*U N#J=4#88^E<7V4
M< XC:JP.;-?.2.S1OMF#W"/5"'5_1B^R>0@-0QSUXKXLWMK=-@UC2+EQ-FQT
M*64=?3STH2FMZHSXE!-2B("JU#!+>O;=5D]C\UQHC)_'LP:XM+H#KGECREK/
M(.-*%0EW".H($]HCZ,/K\3K2PJD;0_@)L*X3(;IVXAMJVN>\8]OM/&G?6IQG
MS]8?WKQ',?60=/MQOX]T\]"!E[Q;+MK/P=/;,8I_8(A0&,83B_O0/%S/UUTJ
M"K'TQ?E+]$">75.Q[VJ@G01-BEED?7'P-42!X+7P)R''@-NB\U8G<5ECQ8K6
M[0(!Z5S+X&?VT?@,*;?/>3^_..C:*_*6\GE#G'1'?\S* ^%KG6MOZ>.2A XS
MT'ENL&6:EX.[A"-UG-6\-G-%XQ]HX^E5V.+QU-R+U-2E3"\%DZA+H*.4*&_[
MQXCZ^KY<J_.VI2?NHTW0-=7L,C"R[B ]Z[;O0H^OQ3RD+LYNSGUDM4H:.JP>
MW$T7-W0M@J[T&R[Z_&>1 LIWIA5VG-8Y*70J5796P9R8;" TD\:#W3C69 E/
MX$TDH8,KLQN"IQ_&$J?S7'-TC;3\_EQWD\?XN\)&06/Q#S'7IU1H&C*S[V0B
MG3^_"4]X*>S-N>"S&S_><.6E^,'#^_E>](5KSB2E%=5Q4O2<\W8TR979G8XO
MGG>S]+2IE5U-?",U/JEE[R^9/&I^L_?:Y0_#+@]=9^86UK?F:UV-,I(E^^ O
M2"2>2H@ 1&L#"5^+NPH#G[,7>V*.:/QU&9:+Y?J[IFMG.6H%3++=/@M65,8%
MD[R)M<QG-?%OZ5?/68I^ROY(MK06\.*ITWN1=]U>IKONC6GI_;"K@G&MS-J'
M+\T1LI7T:V.;0KNTCK@Q@Y:,JM#T_">)+51ZKZ)5#8.O)%,:;I%+ETW.+*>]
MGL(/9VL)LAWXLLJ(]K>W4:EASME=J3,P#XKHT-;EX;%037A [F;LF??@W.-%
M6'9)\,@E,"XW(<Z$G\^HF.M@5]SG6<+MUC[TBYI8.1".\?471/12=*\8\M5N
MQBTE-GB8V3UOF)W['.K3KB*<?\TPP49I&ZFQE>/'1SZFV[3QK$7AAJ?#VC?'
M?2P"'Z6[7O/5@TMPGT_J?6^%2#1!@X*CKX1(:1[V4<T__W* N[D91W8/H08U
MI&(P"8"KT-2_D1B5KWIB,)6M<Y\G72*JE&Z<3/US&%MRAH356KN2= YPW>*(
M?JW)Z1A0.@;4CS0R1?%"KL[S4)=G-MA,MH8=C9L/''WP8EGPY5A?.NX>,<E8
M*ZBA)2K.H96B-0VLW2="9._LMQ_=KC4'#':4#E#HAY<E\,1R$^P07Y/#WE$Q
M?DT=: 7H>1%'#%-=-46SICKT0<YR<]G9\EE8AO'<?%N]6!<9EGV3>WP%EWKS
MKJ8R%_E2W]^&7USW?7$,5#%/-!<S)U=("?8R5X#ZC>#YRT\E;4(XC0\3'P>\
M8[V'ZE.A3Q#/<D$14EF%75]7PDFQ*++OK0/W"?:&^$F@.#]-"2*VM>4Y3<O7
MB:-]S:4J^E=?;,$;=PUZZZ:-)FA]=QKA*\%UN:]?I-@^%Z:M&,XC.?\:FF#\
M6+JN60]+<P5S>KJQ[U]-C(Z"SVB1/FCXB%.0-+I*/V&H?_6"F+VYN'2<'V^Y
M=UY:*\*Q4O.EK6L<[WJC937E3F&;C)14J,B-IZ,>D\*:%PT,%,0E7'2XD27D
MV:L%"?>'(BR(K1)>%9*9!CQU%NM*Z5A9M!DI+F)UOLIYVYIH$4FTQA3+>/AX
MW]/DP&G4!ROBS6W7U>'4R20_%2K#C@&']@/>RZY;F3XW+1._<2S@K;^&<R[S
MX#;(J<:1*= ^(V*Z:^D[Y":K=%&&V$.+R/O(E.$6\ALSG!P\V5M9Q_?F9FFA
MYJ960O_,@_E/.@?@!?RFV>IWOI<Y8L?BA+I)2G)3QJ@+;DX$$94:*!QPG0DO
M>C/%TE41G-VU?6]GM:K7)\[4O'/W(9/M!D#Z%:7KM_]\A.]9685RS.%.YW*G
ME$+PD<_EI$J!U2>NS5VCFY78N0O34D;IO8_'?,YJ/]VVYV$J7%')O6T2R9K0
M^DBJT^-:+)]'MG?Y:*%6,%3?MJV]Y5PJ"]+=SLDF&2VZR#Y[Y%WRF2[(9PX5
M'<4-?9W:D_#1X!5UF_$!Y"ZM)X5;!:$2KE[L1QY)VALW"&CIR( 0PS7D=C_B
M7=?+Q/6C24BUH^N^8X)M=5658>S7*34BSSZAF2$!D=']\19TW;B(2-&4EVM?
MFP:P:W"01$4W1&T7R')./?AC2A<-:L-E6<E5\]Y<5YH-6BC$T,U \J+CH6*Q
MBJY[<SK=LD=]I8_*Q=KJFH $%9 :5XA?3"Z.95.')J-X\;O/UR70MZ_@K](F
M\Y(6C.ZMD[[P'6LSOY!<KR)L_%A)&Y,6'0-$(DS-(T,1VRD&%_:,)R.@+Y56
M&#[/-QU2[$GZ'?>,C&9C4=.],,0YFN8?4JBI$5TT+]X9\VH;WRF^*W/ ?(!3
MX#3*:?KA0*9K1U,Q_H%M&!I)+++O=&',+^RPN9Q$TRR0#)2:N_!6(U*.=.&H
M*?[ KWBE7,>Y*5LY%S\C_'"RCB%O6W%Y^67GV$Y]W%#=16+MFNJ@A7=ZF;S7
M2$,R 3P/%MC&D$$_579&EKJNOEYKE&)!)WY%S)@[E&E6M]$OI?L<RYY3;NKB
MU[>LG6WDKG>08W[]WG<.,XB2<PSP#UYY^7W6;-QC2!Z-@6NC+S8[#+4[#MUY
M[>!33"_']Z+$G%:X$L_OMJ/&ZR\23>4J^KJU=="WYC'^"0F)%P.:0TPJCH':
MJP_%)O:=3/CS.AT&Y6:B$A3MSN!'-HJ^1ZI0+3IM3UJ-3HT;MN>Y<5CV(8S#
M]T@L,V9KU_<!7"Q9!BY?M:T)Z3+^S;I]+J6PX;H45#<\++CA(SH_[4/2W<!C
MP'GG1;V^L>"N<-7JFW[)<YHW=H(J7,75&R]P6%JK@^R"[]O[D:=L8/4_\H!;
M:.&Q4IU-_UJV":E2ZE"/*[/?KL+Q[%"YT#]!.1O_B%6=&WT-F?P21/& OM"[
MNTE.%X=[,X+UD'N[EC9V]>;9=9:O\M1.V:E;\T;M3WL0CEC^\[Y%1>P'=*9N
MIDT]M=[@"R9T>!,%=@]L8>%9<5=(9PG*7H'B1<XKS(;%AH:;CYP)4*UA7))0
M*M[UI.MZ*1]H'7Z^A%[HHP^G*.W!<\7MN5:ZN!*0_;VLPH KM?0ZML[NKRO1
M6DT2&>!;:QD1S ::#&E4B/ZG7\\<5G&?'Y+M3JE.K5JH+^RKLV-M94YG7=/$
M,:N[Z/+EQ?(-/(2G?H\V#VM'%1=A<+;G\[,J$,18N/$QP))AJ,)5>D#J(?G-
M;Y0Y9,BS'A12,9\W<9NI3]V'LX7ATQ+YT5<#,YZ)5U4%]ZBGXEK7\R//]_7K
MTFDL7U+(F!DHB-BJM*MO&*)?7V^,(5;TQ;;73"DV3$*F$MI(,:>D*.@ZU]C=
M(>P=[.?U:TIIJ5X=?ZC!%1XC<YAW[B[=9R))[KV@-":1DIG%E@.I^&\4+F(%
M@A0+1QH9R6;RD"O,'6D\=39\WUP)]/,N+SD!0YLS8SBU:]$!7;E,@T+TI(A'
M,E^^#@[Z5@UFKSE*/3L:':8^,'^TZVGZS-N,83';_+AWY%O.SBO'?1S8FRD>
MO]:CRS>Z]IV_L(L\RSN[YQ>)#K^&QJ[3%>_"G/AL..0HPY0&$AJ!&^0.541B
M;-.32_MAF18YD:^3B)X]N!G8<OUBF]\C!IJ7= XOX@]W^<:\F/-!>D("@SVW
MUW>?$[JMSC^Q2+;S5NSZ$*FQ_\C9"HE0Z]%5()$*BKSS/FV9F*5>@2$-G&)&
MO+WX46E8=WV^G>>Y[?4,ZS"NEO5>07/5;L^HH:Z(W?)CX!K]P)&ER09QA2OL
MG%^N%,O6^\\98UX,>6Q)'-\PB>T8=:_O:$E==%J(4E;!>T8W!S@3N[<OFZ#?
M>"Z/2%F+7[]MZ$W=N<_;6)_P5S98D@-O[B-' H,?U?AZ2'\^!K1PTEN. <*7
MNVF[:@C/ ZS)@<W*1#>>P[F5U=HF*XM09AG]JF\\FL/;00/>=,J>#LU$-"$?
M%A<7"O1M.6&W)7'OI:A5![PVQ:]],E!V2?EC4R<IGUS/X=/>4>48V4\:03G>
M_7O%F;9]#1N@(VTQGZ#*RUWY(/0EOX=4E5],8D?FH>U#*#9S/E#8U:24#FV3
M_EHQEBJI%_Z/9V'9^:7=*Q0N>!V\C3%F']ZR)+J6N?>WF*MB*6S2F]6KW2I_
M,?RE3\["A>GM\Y+F D+2)_L^OA.Y#*!>GZ:U;Z3"X@$BCPN7=MC".<?H9>,V
MA#X\="B<"W) 427+Z0>K@"G#!;*8"(,?+2P7#2']IR7M12/C"@TH=\F6-C;F
M^YP^+_! TU^O*;-L2#@A2431+M(41^P',<OU]RM%WK_?)951+]WH=[[^8<1S
M[#-N/THH_].^N-'EKALL.3"6H!(=U.3&RIG!#;H72=MQ#%:>_-4C"/@;!SY;
M8)JP96Z@$/WH+5UA27;Z_HO8Q"9GEF#31VTW!X05L](JKCJS5%;BZ]T6+6-Q
MO;"9N*\D.1)H4A9H:38MU;D)0Y1S5]^@1O;X"YH%OIP]@DCR?;U<(QXQ@]]Z
M(#7=:%'GD@FJW_)?J:]7&]Z3+#Z<&Z^+@?L!DU[&6 <6SIL5B9Y$]XI2C=JY
MEXL)"?T\6%=X9^O.M2$@GHU"ZY=4/N85R!$E,QY64K[%ZC+,_\+6)2W@XO!M
MU&CHK'/!]9OW=< NNX=)U.UA&Z5>YK8]B/?Y$W4F9=N*:A[S(O#F=SUP;NZV
MA><=VC(LT5IZS<:]KW0BWUUV:LV.\("43(["+Y2.&8^EOW'_6OQ95N8@>.F"
MVXT;22^G#?D</X7+&'-A5QYT*1P#HLIYPA<9;Y7CM,Y.FB\LS\XK6OB<R^Z^
M>7]COJI3+,K8!O6L-=T LVERC=NEQ;M:M,KX;07;KVW-C<F\X^Z@;5*FWBK>
M6%3[_%%.GW0A.3C^4V;82,:HUH;T3.^Y]%?X>_MW1-A9,_8]HPI5RQE5/^IF
M:'[MLW0 7\!?. 3S[1U,#FM^/-@SUQPH[C@\N2/]T.5]4+TSN49<6.+5\$G3
M?F6U(5.]/B3Q4M6$^73=OO,+P^<>]#'PY1#\1R(F8L+T*N0T%EY/\%\\F%4?
MG!ADJM1![2;H4A<12D@3V#&$//6\XTI7]L5IC7R$C:O@4\23)4-$BM_7[**Q
MR=AA>.7.M>JL>9],"9>9Q7UK"=#NT72[;@W!@(DW=?;H-0(5:GNA&P:&.'CD
MZ:1.6V\W;K5=M_,1Y5M^YR?@\CI)9=2-3P%!&(_4;']RV+"XNY5_87KE5M'V
M<D)RX\KX?LKXM2;^\G[->B]\P4?C1B_"9<O4*8@*7SV)KYU::WG_"'4/3]Q!
M]-MGP?XG&2N2]&_4SE/SZ#$]_9J[D'@MKCF>5%U?1E=;J)!*0B@ZHU0-JLT8
M+9;;&25$+UQK?^0ST%ZO?[GPCDH^3;5J2D@*DXAYTY<X'XYU$UR6PM8MZ=O3
MU>?,:1(VX>IQ$@U-;A,#N2%LFJS"+C8# [H/C@$YE1F6RUZ9M>?5P(5&I<9]
M=!(J7(4*="[;6UN9'\1\&Y9-$RO<LGKC$Y%;CV .R\(K(V@K4:[4MN6PI?L!
M?.$JD"=LF6TZ^A"NF^()'E$?;:DBB[-'^V0IW@0J=T_(ZWFO;2Q,N3!3KX:X
MA5.*J_9UD@WX>;\_TO.R+J\R,T%Y>[[1\MFTE40K&?+&9J)!I87JT>NU\<F7
M(B];WHH-U[ UFZQ>Y9K<E6&N]VFQTCQG[)9*E^',XDG3ZY^D3IN[>J;^;9G#
M0:]*)7.9+W?8*SF<'9?X(O'<AGN',F,,]/G?+AI\YE@$[9]3"U*LIHU[E>#M
M4*YF=42GHLGI%W53?KE'3W8$<A:K9 _PWE *9E/%;/WA]_=]NY#18R.=TF\_
M8-.=RP2WWW&G&%@[L-F9/_3OL^*R2HZ O3)B@I7'=E[P:=&C&LPFO9?+.BWP
M^J%.6MJU%B7D^2<UNCSW+>K&;YE.Q)HVW!0=*'\== >G$:7T;JS#OKV;=[*Z
MK*T^4IURJ.DH9H^_!9%B_,[O=9ZX@4BEE/:!]BZQ?/.YJ@D?.:.U.F*5HF=#
M5+7/FZ[$3'2#A<K(]>V^UCT.[!_)$"K09-Q/Y"F<(GMEI;R'K(#1JO9W&SR@
M-W]D..GYQ75(I*QT+PCYYJ%^<*YT=2'<LZ/FFGWZMX>7Z[+WB5VW9ITZ(\Q&
M-27U'Z05>R2J;7PJM9DC,WL/]/?)76$.\+.J$A%)O%7:98U:4[U/R:XY^T*<
M^T5YQ5BO_'CAX(S6],<+#"D&%_L:WAM4K>F\"ML]4UI"EQD:T1P##\LFX6V;
M)"0VNIEFK*#BVFRQ>;D4I'N-S%%V;BP1MNHZM><,#Z8-O@[&?28M@:8S\[*H
M5H6FV$6V,,6,J%_?=6ZY&5#B:^-M_27$<'HX*50IN$N3*'=X=)FM?ZRT_0W#
M6:4K(E\+(O+O=.M)I3>:.R!,MD=KFYA'DQC#&>(]%6 EJZ/H5WNASE,1_,X:
MJ:O&A$S1[B,"C^(>V)\ORA@W)12&<?JF?C@2_48,YWW^^=E;SXLC"[S/;P9T
MK2Q<V6YNZ976FIW;8^CJ6U@N-MY!%Z<HTFB&&4.*C_O[A\KWBTN\S%%SU7B;
M8T]\FN);#89DC&(Z/G$*B!$%9A<FLZ@LYLTF6(>1@XDR"U(!H&3;%^96*Q)3
M&_TQXL''KQMBQP"^<CJ9')SG]ET=T"R^\SQ_=KHM9/ &Q=LV;LJ)2=FL8\"\
MN)Y /V. ,777><F>(Y3LLZ^/4IX_#C?U[@OG>J@+P4'44E@G:->,G-IV__X#
M\CMCD23%""\N8O)+*4IFW/=97?IN&1J?]5)B/4-+6=I7UYZ+:Z$57QJMFXK#
M4I:2*V$RS_.E_<I#K/.B6TLP=))"G>?GV+3P I^1(**)_- 8)[&9I2:OBO#.
M8&9OF89'QF8MR&&=BJ7Y,YCTQ&(WZJ+O@?Q$ [';MNZ[$6E2^R"#PL\YL6V1
M[0>ND\/B"4\5N$EFK))Y:R>^&(1;OI<7BHOU;V2 OQ.X'_*1RT940HKS]M'M
M\YJM6 /I["H/T&4(![?[-[VU%TV7QH\!1I$BP=MH)?-N-B5G^,@.EYU5EG6R
MN-U9.#M%L'^Q8'(7E"LCG,98_*I5LI&AD2.2N@[<6TJ1V_)94VY]84!1)X2V
M.Z&$]I+2E#1G]XSHDAI?),/7++PO*G5\'&M+4];:#KFZ@H^;ES4F5QT'GHX;
ME8>^TG=GZD+P%HY2/V3K>X^@>TMI9EBJ;V3T+#O<''= 8#AEM!1)%[_BP%M,
M?>5F\>TS-=,!@:1)ZC8^GJ+5<V$;#C)5*_L/.VP$,W:5%:ZIY*:%7[I$*_[R
M&/A4>O"Q98.@<1M?P=5-][9GQ"=S.<>';"Y<84O&GCF> 3X.WD\[%!22ABDW
M)(U7S@Z0J$4)W\"VR[] 8&TTE2"_SD("OZ969Y]!T*X;=/..09!?Y 9>0"?J
M!LG*V_YJP5N"0B,Y[S6R8F8'6K<VBCRQI:>T#P5U/S!TW'! W%+'G[06%_PT
M^'J2Q^",F-O;CQN);JZ.DNT?0W>F+*("Z6KQIH\6<,A<Z/T(BC%YY\7>NX1)
M+(&VN?7NZ(TMNU;8L^RVR^Y9@5@0IXBSC<A/OI?WCJ0'MZVG[0>*TZ)1-^LE
MIO*MPA6SP0@>_JP-F8+Q@2<502&^-Q25<&]%+*RVA%"ZIJY+?UHHX[@IKZ69
MY+Y9T )-N*1S5$UZR0@['5O//Y5K8D1I;LD/X5Y8F'#'7WQ8EKE/RU-BG'5]
MJ,ISBV.-<GA7A'XDK/%H8;6-I0-R@1&N>]F(Y3Y7<%P-UK-'LB,C!-LF:(*:
M,X985Z86>E!?SS>RF/:O3_4<1<RNMC\J6G(3<*P]MY\Z]N%=DF[I.8W^)?/X
M-Y@@;13;'KO1=M?!ZD*:U>UD:"RW]1;.<LPW-[] ;?.NO"0SFN)[>WD^4J9^
MQP-]G=TE!6WDY',<L0,M$I\X'U2^S)@<WHY?:<E6.)20T]!Y"G#K)89ZWIT9
M*<KO,U.Z?"";-+/A;MT?TWLSSS37GN,+*UC&? 4W)LA\Y0K7[G94NF4+G7&]
MB&43]. +-QM1NVUR!+LRS>OHE^>SKF?[<UCKL-Y]&481X=N]5ZDKZ0["[9[)
MCFMYW!0DD]7X5:94>,#KB&>E]4XABV2]%UO<3,_!D:XTUSH#X3'P6+,E?"X4
MJ5Y5I6ZVU8(N1KQO^T:]N)JY;+?WOP)B&)WG+ [G@S5#KCBJ\9C:EZ2O9BRM
M3?9B9"&C%W$7Q7:U/]BPX^A'#_/U>NAED;X ?\/7U >Y-D8_NOK;MCJW>XQ\
MT.Z-K[FVP*^&G2LH:>ASN/JJ2GRF CJ!)%$[T=4'290'=662_/MF(J1(M"%'
M"O&I\C\_7HTB9K>2&9U_3;%?MZ^5)V?U[5_';Y8]J]4TT=;]O#-!F\54T$YK
M4I5HI9<-NK/UN)J('24245&?)I\7B>Y)=;CV*^6;MG62)C@'A]AI_AI_AZ+=
MY@:*Y:81T8T/EP_U5ZW!O^$SGQ>H<SU#O#Y4[>W?5;5W9M#Y6YW9JT-)'%D,
M%O;K;#=:8K$YW;NY,3+(]5@<QF*C<;5,=0KCQR4\;K&Z,6]M\T.!=> Z#,9S
MBHX4I_AKY4'5=MD+1W#E<,V#UL,?S(^NJ;MOX2_('KV6%*Q*_:"5A@\?E!GI
M:@L!XRK"1BLA_'ZK&_L*PQTG34.XC'Y]&UMB90>)&.ODW;5:5</D<-.Q:IPM
M=7XF2.0W?5CJRIHG#,UM.AH"FFP^GM<!J)IT2SHR-(K?$ISTXXLQ4PG1;J!*
M&2,$Z%5A9D5>1&E^>/S_ $]OC@*\>FAP';Y=*C%3^6I"K(H6]W _('T53^D$
M_P!?>F94&IN'6^WY]"1C*U8BFDE'5E=6_M60\D'_  _I[;)J1(/@ITVXD).A
MJ#J?!NF49C)RBH0))O+!Q.?(;/4P[&W#!$E]-_+'%.XT?3U?U]E^H>-JKCIH
MK-J4^)Z_Y.O_UM1>10:W("RZURN61@P91K3*5",OTMP/]O\ 7V)!G XTZ0T/
M^^_\/4R*G73(02=2L &:^DZ2?Z"P)]N=-]1VIU13<J6TKZOJ8U 7U!0/U #V
MGZWTFJ^)<'DH\_I5*"6&GQ^?TZFTT;.109<A>6EQ4SZ)+_6FD/\ J!;W7NE'
M+"GBDTW(E)!((.D1GFQ(8BX'^\^U'6NDO/#'%.5< Q3 T\H)*F1)@4D4,+LO
M[;6N.1[3EVB96\^G*:CX=<?YNOI]?R4?EC)\N/@%\>M\9;*'+=A]:8^3X^=M
MO.PGKQNWJZDI\=MW,UT;-))&-V[%DQ]5&7YEM(P+<^]RQ 2A0P ;/EQ(I^T$
MZCTICF:6V*D=RM@=:07\^_+=>9;^<)VCL_8L0IGVMFQ@-UU6*JXL=AH]TUF(
MH\SDJ-*N(QRQTV-K<DTU?$!99S]2H(]FG+T,RW*!%;PY""#3^'!_:<]4W&;Q
M'D9B.U /S]/MZVR?^$N^^GR?P([;V'55%.M1U_\ *?=]#CH(:C'5M:F)W%L?
M9V;@J:^MI:>"JR%%E:^*IFQLU2995H;11OXX@H4\U0,-R235CP^/V>7\_P#!
MTGVTCP"M>ZM:>?6PEV?B4RW4O85%*-8J]L5^NX+F00KY[,%%V0^*Q'Y'LEC%
M;J#TIT;1D"XA8GM'[.OD4]E[=_N1\C_D9L+QK$FV^Y>R<?%3O=1#3MN6NR-,
ML8('[;05JD?X'^GMZ&H)4\1T67BDS7E!Q8'H/ZAFBFJ+H%]/[:GTWT$$/_5E
M'/\ A[4=)OEJQT\8:J50)"-5]-W(MJ'Y*C^G]#[JP#:E;@.O?X>EG19",Z;D
MJ%/-V^AX_P!X /M(KGN7R7K72-3*@4<^3UMJ;MJDC$N@7--'B*W'%/Z%09 +
M_7GZ^T^E-6KQ!3JV:CTH?\ Z_]?4)KZE8LK/)8H<C/D)@C,6C^ZAR4\52 ]R
M!I-FN>-)_K[$= B"7U'2!LL?MZ?*:8%&UG6Q6P*  AN+?X$$^Z=5ZCR3B)M1
MU$ZM!L+@K91S_M5_?NO=8)I(ZE:B.>)9*>HCDIYXVL!-$R/%)%(+$,DB7!'U
MM]/?NO=)S;E1-"D^V*R0O4881O0U3/J-=M^4^/'S>KDS497[:>Y)NBM_:YMG
MX?GU[IQR%,LD195+,KW0_I)'Y('UU"U^?Q[\WX?LZ]UL\_\ "7#Y?4W4OS&S
M?Q9WCE8Z78ORNQE <"*F8+247=W5])5Y7;;4JR,#]WO39(R&,X'KD@@') ][
MGB+VTQ4]ZH2. ^W)]!4XXTITZDNEE'J0/Y]4B?.NKS^5_F,_,3.YB>"ER$G>
M_>1QE3/5XR&ER.WH^R<['DZ2K:'[BO&=KWQBPQ+,$F\*1Z%OHN.=@@5A:3J.
MQ;:@_P!,/BZ1;FVB:ZC\S*/\'5W_ /PG%^8E-TQ\QMZ_&/+M28W;GS!V]AYM
MBP3UE3][1=S=7TN3K]FX$15%/%3UD^Z-C2Y+'M/ T2>6*!GC!;W3F.U2:P6]
M9J4/'_5^W\NJ6,I%VR#@5ZWX(LA#NC9>=BI1Y&J<)FZ"6(CU&L3&U*F-EN+A
MI2I'^/L%-^G=0Z>(Z/.OE+?S&=K'9G\QWY)42HT,.Y\EMCL&F70(T6'>>UJ&
MI>-!P&T5M)*#;\W]O0_V]Q]G5+__ '*E^S_)T3FK0B<:F8E7/Z@#SQ87_P!2
M";V]OKP'V=%J? #_ $>I$#I"C,YMI &L^E=0'%E' O\ T]Z?X3U[/\7^'J?1
MUNI'-]-R18?1AS_0?X>T(^)_]*.J]),U4?\ HT6M_=UG-/GK<6\8W!'!Y;?Z
MKQG3[0X\+_;?ZOY]6J/X>O_0TX\M5>>@KIUD+38?/9*K0\ BDJ<E44M0C64*
MP\A0^Q!T7=/F'R2SQ!M?,@!91;4#<W8D<<>U'6NG4F,^OZD@ZM?ZC;Z,!^;6
M]I^M]9@%9%0<@D'4>64L+7%OK9?=]/;7SZ]TQY#'-+X*^@7R97',TM*H8*U5
M2LMJ[%2/_J:V '0OXF"D<^Z=>Z=EDIZZ&"K@)>"HC$L)^C%' 'K47".K*59;
MW5@1^/?NO=+GJ'L7=/3/;?6G;&R*Y\5O#K/L#:'8.U<A$[PBES^S<_0Y_$R-
M*H+QPO4T(AE_#1RLI!!(+JR>&5KP8$?R/3@XC_2G_+T(G?\ V7B.X/E1\C.Z
MH<=D(MM=O=R;P[DR>UY*JDQU8DV^LWE<BF+Q3)35=1'#M[*9@R30D,3&BNEX
MY/2.=H1DM;$^1C_R](+S^T&?,_Y.N>V]^[TZK[$Z[[HV9GJF/L#J/?>T>R*#
M)XG/S.V6W%M?.X_<-)FX<77T/@A%!C:-Z+(I2R&,Q3.U@;H3^9?%A,-/B!'[
M<=(BP2K^F>OJ^]%=E;<[/V?M_M7;,Z3[*[DQVU]\;<J*:17I8\?V!@*#,TL4
M#Q!8VAI:NO:G4@"WC(/(/N*;F V\LL1))A[*GY^?0A2Z$JP'KYP/\\': VO\
M^L+E(]"_WFZOR.%JQI*2_?\ 7'86XMN,LEO4;T57%I8_4+;Z>V[/^VF^SI7N
MIT2F3^,4ZJCJVT5&H^H.66_T(M_0?2UO:X<!]G1,01V^G39D*L(B1HR7=KFY
M'U#6 M_K'WI_A/6_P_GUA^^CCI,FH>TE/3,[:6U%?V786T\%2>2/J+>R[JG4
M;Q'^X/V&OT#;7]#?6W^Y'Q?\&\RW_P!;VYY#M[>K_B_/K__1TW*N"(3[CI S
MI'6-N&)> T7E%95,NKC4C!TX(_/L2?\ 0/1=TEMKYAC$NE"2(U] ;40-(#!>
M..1[8_YN#J^7/SZ%&BFC=4O^J0 ,AYT!A];\^KCV]Y)]O5/7IQ)(2UP$:UK<
M. /]2?[)][\OB[>O=>IW99#H73H7@J07Y/\ M1T\&W^/MOKW4&D Q.0FI&5O
MX?EWJ*S&&XT4F0"!\AC0 !:.I'^50K8#5Y%'%O?NO=.]1&)!R2!'< BP)X^H
MY!X^HM[VP)*:O7JRBIITN<-6LU9@LE%42T^06/\ A6-KVEIZ&GQ&5J:N!:3*
M96H>DG:2EIK%M8N].#JYC1D(QY<NQ(7MG:I446OD.-!Z#I%>_P!J/LZ4?W:1
M(L$%53"GII\AA/%_&JVIQ^(KZN"-<UOV6""C-2FW,K0QR4RU5.P@82*6'[8'
ML6%B!JXD9'2*E:U%:]?0+_D==Z1]B?RB.I"]92MFN@MR;HZ0G@I<O-EGI,;L
M7=]-DMDF>HGIZ2IA:MVCN*E:!'4L:8*^HZN #S#:O'N$P [7*R@_Q\:J?6G^
M7HYVQD:WD0J-:F@]1UK!?\*/<;%COYC.WZ"C 2#['?\ EHQ'I5!%N/*X?.2Q
M&QM:.MDE']/5[#\!*W=Q'Y^$#^9/'HSW50;2 E:M7\^J)<RS1)/-"T8EC5O$
MLK?MF1S90%_M.P/ _K[,VQV^G1/5C7U/2#J"U1)'(TCV53I)]*ZA:[L5]3,M
MK+;C\GVDD9Q7..J]<:IZ>GPM8E.65YTF8R%RSRS2HT19I;W9M3_3\#VQES\^
MM<>E1Z1A33:_0:$&_.KTTS06^E]5GO;W[R_+_+UOK__2TPHLA6+D,HE8IIU?
M+99O7^@$9*JTL26((9?J/9[J/;CCT7]!AMW(QT]7- Y:\=54QZ@Q&H+,X&BW
M^ _WGVR6!DIY=/Z%].AJQ5:L@ %[E0+ZOZ>K2?\ &_M_6W%3V],L "1TJ8YM
M1'J%W/T-OQ]0H-K?[#VZ,HM?BZKTY1*;&91KTH6$0^IY"WU'BW'NG7NFS*S^
M:CJ('B>*<VFHYEN'I:VE834=2C?J5HI1_L5)4_7VXNDNJMZ=>ZS;<S<.X<:M
M<R-'6)//39"F*V-+7TK>&KH[+](XY1=#_:C9?=5:H8D<&ZV:H PZ6>*R551I
MD(*>>6E$E,T%28-)>6@JO374Z@JX FC%B0 ;_GVOVN<V=[$Z&BDY\^/V])I$
M64U<9Z7D<\%2*6^0HHZ+(T-9BX)YMQUT,6UMMT,E9JVMG5H\?Y\+'N9R#1R(
ML\4H<,0HD(249/#I$T7F,^?2&A)84P.ML[_A,_V76Y7H#YO]#YRHR,]9C>Z_
MCQV#AJ?)SRU\F.H^P:>?:CX%:]H8DK*K%KLV!'L2_A:/58< )<PIJFVF4_V<
M>I?R8@Y/Y8^WI;MQT-(J\&.>J>?Y\>\(]X?S )JP21R_;Q]C4Q;RL9(%P^ZZ
M?#01!&)8B62!@6^@"\>P5$->Y2R5J--/R'#HXW5V%O JGMKU2QN77-&M.)A'
M*[B5&"!])C.LG3QRK< GZ>S!Y&9BQ.*]%@\J\.D?4245'$9*F59])9E2<@K&
M?U>188A' 0O^.H_X>T<M  1-0GJO2:7(OD*7(5:*3"ABABO_ )MWDF0,$465
M-*<\?GW1R%TT>M17K990=)&>EA_$X/X<9+OH^X$9?B_Z60-;_4:+^GZW]TJ^
MOXO+JV@TKJQU_]/2TR63CCJ,TK".6!<CES)Y+  +D:HWC-@5?_$<^SUBJ@4.
M:=(D4-6O0 XK) UU2ZM8/62R1@\:4D=G4B_-R/9<7'BTKTJTCH?-L5:30*&]
M$C7L0P*\?DI]-37^I^GM>C%B0W"G2:4!:L.EBLLT.F0-K(_I<:;&Y/T/U'^'
MM12@5?GTR#7/3[B\_#%+'#.- 82*J%@2HX8@G2+D'WN3RZV.E5XH*VG8$)ZM
M<@TA20&4K;^HM?CWX&DJGRZ\20%KPZ#*O!V3N>+,"01;<W,\%!F2"SPXO,I:
M'%Y>6UU2&L_S%0W 7@D_3VS(QA;LS&S9KY'_ %>O5E!E!3S'0J4A1JF=9!<R
MIXYD%K")P5.HWY"FUR/;M"2NDXXU^8R/V]-&BU6O=TKZ*O;+4E8*W]ZLJ"),
MTU3FZRBEW?4X^6G&,PU--24TS4.8IXR6C-O'*A/*Z0&E#:IA=V5K*32330@<
M ?+HLD.EJCSZO2_X3J=I5&W?GCN/9>1JY$H^R^J*K<&Y_O)LK%)EJ_HC(5.^
M$R,M-*JX1JK$8Z5:":>*0R:0I< N?9'OM%M&$N%1J@C_ %4Z6V9T31J/A;JK
M_P#F$=AKVE\QMZ[D#^14P.-K4>ZR()=XY_/[GJDCD4W4Z)(=8/J!_P /8*LS
M^K,WX*<>C&^?Q7-N114S4<3]O1$\[5F&69M5D5 FMC<LQ)+@.USQ_C[5*I5"
M7Z1<:#H#*^MJ,UE(L33,5B>0F>I\@T1QA6U1V'.MQ[2%DF.4!'6NEIG?!C=N
MTM!1,%CBJZ(22  ++(S%M"-]3RGY]ZF 55*H.'5Q0X(SU!%;_N%<ZO7YXQ^D
M?3Q2M>WTN#Q[:H-&K\7^STYX.-7BMPZ__]31SWCFT%-FA' (O-F<RB DI)=<
MC4AB1].2>+>S61B$5SPITEB!_GT#F-E5*E1)^AKW/TTM;AA[*R26U5STJZ&7
M;-?4430M&?-$Q961CZOIR03^FP'LWA-=)/&G2>1,UKQZ%^AKA4HHGC=&,2B/
M4;@7^C< <*/:CI,,"GEUU="->D&74RR,R@:G%P>!PH/'T]^Z]TI</7M"[G4G
MK +*S7!)]/T-](M[N?@=:YZT5K2O2LRN+HL_C)Z"LBCFHZZD>GJ8P%"^-U)+
M(059)(G 92.0P!]U9:Q/&<M_A^75E)0DJ>D?L:MR%'6UFR\M,L^<P4*OC:F=
MM!SNW2WBH\C'(0'DFID_:J!S9@#SS[;MBQ1D?$V* ^8K_FX_\5UZ15IX@'^Q
MT)M-6U5'52T06I:"KUY2@6DK*K'56.RZTT=(N<@EHXY!--1TBC5!.%BGC0AF
M4"_L<<LW=5N+%C1R:J?(?*GSZ+;B(@:_+HWW\OOMZHZ/^:G7>X<9F(L?2[SV
M=W7U9+/2UF4./Q,_8?4>Z<:^]UH<@AIZ%LAEHX8IC Q@U*KGU:;.\P4&U3M-
M\0/[?G_J^72JS4O<Q:<8Z)MG=Q)NW>V^]X+(#%F]V9.:(F[I]EBHJ?"TZEF]
M5O'C_P#!;W(_5[ UJ62U6,CN'$^O2F[DI.[$5U= +O3-^**=VFTR2/("H=+2
M2NI1 JZBP73Q[=>XT@*RU!'ETP!@ \:=)S:.+FK*@5+Q,&F(+E ;Z6L&%OIK
M*BWM.E-1H-(ZUTH>RY8:.GP^.IU9$EJ/.1P'9:>$$W!_H\G^Q]^N7RL=.(X]
M.J*BM.'3*%;^$.WE;09XCIOSI$$WY_IS_3VU7]*E.GM61V^1_P  Z__5T0^Q
M,B:O.Y54 6),SEQ&B\:%7(U((-K7-_S^?:ZZF1PJ1DU''JB:: #I 0FTJ?\
M!A_M_P ?[S[0]7Z$C;U9) R L/U%1J'%_P#@Q^AX]J;1FU%6;'3<OPGH<\#6
M0S(I8E1RAU,;J#ZE('UTZA[./$0G0.DFEM(:N.GQJ4M!Y8Y4<.^M@MB^LD*4
M"B['Z?7_ !][[/GU4&N1U!:.2CE\O(/U?4?2MOH"#]?K[KU[I=8#+!E2-Y5*
M@#@'2P(N#_C;2?;BX-?3KW6#>F%K*R&ASV (AW'@)&K<1);BMBD0_?8:H(L7
MI<G%=3SZ7L01<^]7 \73+'B9>'I\\_9U=&4MX1\^I>/W9'EL3CMX86JJJ"6
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MF%I6Y%5>"W*HQK+GTV&JP:9W4\GBJ;_Q6^4EIW<UC5C5>!(U_E*5(ERL%,K
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M@F7$+HN'B9YXQIXKMFUKV7L=L&1Z.<-O\7D(%YOV1%M#<\ =B;O 7A)BV#&
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M;>VJ=8/@F*%4O@5FX7[2\^&7.0W\&%D52C<H0WQ0:]N=43)']'>R#WW<Q#+
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MZ)#\;;Z(5HSYN,F]>\1]YRV*T [B3_; ,U2YX,-_)/@9VXTOK",^H!MB7KM
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M;,'HO25IQHW0HX*62496B?5ZK&A5?B65R)6I[0P=VQ8J/ IL?K+F&>HH6$I
MC[^WFUECB6/Y'/XF'8T(3R?)U2'>IV10^&F\QJ42 ^_2._<D-"V@!POTO@=T
MW?M)J('W?)T)UP%#CRJ(R^&7M!R0+$MR4LQ+Q>6+S5["L@VID@]P>'/%BQ'&
M<#LI)/_-BX@SULN'RXRA\E[E1BQ<,I*/R!GZE7P7?U'MYENUPUV+SB^. Y/I
M2L0ZH1V!8T0^;,VJM!L@T+K1T )>X/N&G? *(L<(I@@1R[\IOG==E!5,VWHQ
M*5IHXR4&*1 NC'B(@,K9<DS95I[<$/G?YPDMYN/)[0]"!VE)^J-E#Y$P9*^
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MLI-?S4NFG[*\+J:O:2Z@EQW[$.JGA$$IM-$;J7OY44SD$2Q,#C'=.EOGUN4
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MBD9QZ0"^C\I7@3 XW/J_K'W@J5IH]=[+A[?_FJ=BE()!EY:%'[(DKU;%(TW
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M\Y3UJ5[9'S6. S=)I=]+MVE0*&N?MQ-(\(&^$HOMK"%VZ<_2@O01&4@R< H
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M;=-U8Q1J;87U("+7LITQ;:65R.-,NRG.S1_-LKV%NDX./5D.'5S4L.?WKMK
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M>:#%@)!AR:/(?"WRP9SR[$ZU@K2CUU2Y5L2'"\;34@E ;XC%"^=K(24#@[=
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M_/$:T:[ (\&FM?_4R2CED>@^';(%B;[+C,T6#*LJ<-"G1Z$#TEN,.HA0+2B
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M,V'?0@TI\".QMARUA KYAT:RM%VS]7G,IF1N15=&NC,=86T:J ]V?NX!]_I
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M%H2%'6M[]>Q\\;'%N_/%3XV'YXO?O/2R;"%82DHP8("NN,02*K8VJ-EU JP
M8$?4#D=&: LM'BO^XF8[LW/=N]&QP?XL90YRV6?5P0'M-R6/.P[TM[QXY<&-
M$Y%!;39G>SY3-@=U%8'7TQNA':XKUC#CCNV\+;Q%'&^HDL0<*BR;-2/V1&[
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ML;B1=X7E%A^N]1>$TH[]S"@.\>-PB(?F&5Q-11%_#K>SKI1B<KMM%A0*\10
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MM.)A4W/6$T74@^$PE=+<YZ."3A/^0Z2'W_[K?Y(!]ZXM'XHLY5-H+Q\^T&)
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M-TO72$/Y.#BR 5&I1Q;W93P>A_&LV=[(-"W7L=S&+RR;CX3/83:73ZH*->[
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M_:,+Q5GX$__":U*2__[_ U!+ P04    "  =0%58P!9*W]C=  !M!PT %0
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M@!V2Y]=7>?HQR7(2Z<%JG5\6)<QVS2L5&]YM27,2OB81,[FFP&AZ ](=H/Z
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MJ).@-_^PMW]-,#;:C/$.,*WM& = PXO35#!,,>W-Z+DC!W-OE'/N[+G6O<_
M!>==3; <\9J"]D1(+)Z.4#%.M',G6 <3:[/[@ET$\0@W<(_6RNE=T5?D'>5G
M_-SFVMR25)LO.--&-/&ZH>UK8G:D"29QH"%+9FU"&#24P5T!!G6/)_GM'7E
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MKLJI=Q_D0Z1)#=E(?IPB,0Q *["CS$3AXY<Q7:&_C]ANC7V_3_O%:39RB$W
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M >Z;C^#W4[NOO-';WP]U0K:XQC[P]]F0DIH=JG_ -'2E<'^P"9<!Z-$TZF*
M^<!GJLMX3G8V6<9MAIYV#BB<RZK!5:.9<XL-/;\3B)7$C"D,J'3WTN*>!IS(
MS1X')H3N/X::".P/["'-,7I[/$=^,6">G3N@'M5% 1M;T,V2C]HM+*$8UDF0
M6 WVMXH>0P<-SJS#_)J 4P<BV/E4\3!(+A/M=QJ1\+7+:2:7P&!Q=]#V!ZL*
M4 I@O068!I"E"WK8T9PGXVHX'2,75 R2-8-M4%K <;0M&0J+6N<A3C"IF$1&
MPQC318KA%AOZ.=GM2KA+Z"7*&_@(\Q.\1%@X+_*Z3#9U]4M6/YR?JKHX(#LP
M*QQO2S[8=JVU/A1[N2.RY'$S2AA@JP.;EC1X0K3!IB4>7YWY>7B1;_?. \MK
M-BKSHXXYGW@]QF5P6&)K8%&>F\P'D&-+B^WDY2,L=F5R?,@V"1HF- 4K[RT(
M>GBU!1'74V@/VX$$-PS\W)9SQOV:EA0MK*5(H1(;\#7RQ85]PH)?F-;!0U'@
M&VN+,!_8"%2YZ@K8&!O"-JGN"?]561,;^![NZPK_BVR&$*"C?_SUXH1K,@AQ
MS3;Q &,.7\S[9^3/@=*JM/D+@4'1H+:0$XUH^.=[TA,*A%9Y>@O+QVRC\>BG
ML(_OYWH$G'.>Z2$M2168JFD;Q9RMT#[W41Z9ZN,#D]XK4*)>H0$E>_F)!ZDH
MYD#E*&C!RMD=+:W+6(%N7:FN@41PBTJ3Q2;_-X<UJ)) F2_BX1[MF7/'>DXR
M?9O_"^M;++HB6U[0VELZO(A;)N^[RVA'8TJ:!LUF-V4[&D#*X3%.,I=B8P9$
M!5M1[U^FRP]I$353*KX@;2P=9Y=SN*^YWH*&!'C_ D9K34PE> DTN]$<(<UN
M*'T@4+9+;TTI.B0J]MR-T(AI@2ONYKH'QQR;R/%9H?#8( 8X:QWD+S'&@\.C
M^Q>PFV[HS3O*K^#F=[OB$8WC*:]+NJAL_]'O@S6_^.OYBN-KAG_TX#Y&O# 7
M1%=?5A]6?HU;SE"2)^F"MQL5F?T:O(5P"RR>6DMGP;0PI)$BQ)#&?_0(:<(+
MD]WSY>KNX@.XO5O=7=R&03:?+YR.F0)2H77!!8\FP/DLWOZ3<WZ.J%,["TBN
M#>FK+J3]]>"?VE^/_'FA;/]L% ):D>=P3ZH+5;!"_T5*(6^;KNXK<L@O"60-
MZ7@,8TTEE"2.H&BN(P):*F! !GQM"04*8",1UF?H:H7@:> :#KZZ8:O#D44!
MZ[$;6=A0B2CA].)PW!<O$+Z'.=QF==4(*CWZ$/;Q>O AYIS9;&Y:@ONF:3L0
M[OU&42=[D=]8E'6_AS4*U+!'-0K(A#8"R@W.L;M]0.O(^Z2"Z77R0JKQETE>
M(3/'MU!QWETKB?RPV9*B7P.RE)K!**5#LSDK3.F,D )'2@O4 V(TR1.VY$(E
M#;F2_78@[J8X8*)D<@EW:]VI9("5+!('-,=B.>YICKF&3E\HJIK:$^:V<;"-
M0!]P50>8DL3A[/Z$9<"OZ2@29:P(^DUZL).9R8= 9,YZ.NTDVT+\#4@I+9JC
MWA C;S,%<US+2A[X%ND<*'/20V;@.+!-WSX498T0<; )S]6=O=JJABSLW(.Z
MG.$^7:3@(7;7,T ;<9)]4F:P2;N2R!;6^G1!QUJ:+N("6]4=XK I*&-B3[)N
M7BU)RC^3T=(WCL9V9@L0UD#4^&%-0PV>&7O*JP/>H5YOSU',NH/5#=PG-4SO
MBEN(E@MX,WZ5I^2Z=+M])=I4MB#D:U?91D;.)7Y$ ^^R-E1 0P;<%: C!!"E
MIEA!2RO QK)#>8LMV#3REHV\=0&J3EX\'=&+\+R-2:][R]9('FTNAX6QUNYR
MT.%U50CZ=O, T],>WU8EA5"O^BJH*UP$]1)Y/,3!5;XI#EB@<Q2)5ZJ#K9E$
MO;W-.E-V)CALZ&'O1"F" 4E :(*&**!4B:,B=)<\ ]-Z 78A99!"'1_:(KMB
M?:B4X,U_.;&(\7.TT9B#WNNU2YE%5VV94VMYV\ @HV:!'=Z&(")I"+MR>*O-
MIH3XPXU71@(,"P-AH;>P+&%*Q<SR'9%/&&[9DO,6=%G+R\Q5+:4VIB+.:U15
MB3@^2@YT]*AINW-J/U&I<YQ("%-Y!+: \,T,3"":3$I*I:WPVT[X#4]X?\'8
M/+2/0[((H*X7F$4RZC%5HWJ?Y+_BRW79(=LG91.R2O=*!#V\;I.(N)Z.$VY'
MM^1HRS::]NUT+#D7<.MW2T2*$'8W1 J/\*^50C2Z[0G!.O\ [^NK' 42Q'E4
M5U5U@JD4_;HD?+]5JB<7I^PHZ=BY,>2X4M07A5M=9Y"1WN%,9KYT2"H$=[3:
MJ4F%U1.BLB%5 RN89T4)\J)NMNY1RWV1[^CF_;Y(F%-^O[9G!ECNZZP&: UL
MG5]@?5F4,-NA^1EYOGP'/Q65?"X2=?%J?4*^IWC$]V6WM"4R.-H4@:P*.!U9
M\8YLIX3YYH7+NU\#D6.&-0@Y8&8L'Q'ACTF68VKKO(D?D_W U,Z3LLQ@NJHO
MDZS\2[(_"6_36I'RM6RTDY.')DP&8#I@G8..$AB0 @TML*H!I@8(N0 ;]NZ$
MWF&AT22S[>0=SK2;1MX$V1J6]Y$GK[<UX@Q(C]:'H?&LM39T/,38,QJ.<TRK
MPD%%RC:$D,[#W/9>)V$^Q\*(D&XGADOA=,*NWZE6@@EVGI4 (G0)QP(-4H[M
M<!(+_T^XER_]%#W]EG-42,'41>S:L^N[!]0EG"682O*^R-/ 0:<6A#@5'77P
M,R,$_7A*R@09&TROT%JWJC'M<[SFW68;?/-2%&^J^_D*+C4D8(#==0%]'S#L
M%"!>G"='ULNQD<CA+0[4Q=4HZ/,**JT(;Y%!B2EH(SDE7>@J?*I&U<'K/";@
M>3H0-&6K#Z;YC[/,MVR]NWV:3).9BNPJ'HH<OH!#4OZ*=U%.G EL6:>T*.M^
MYUX9R-DI5X9PA\E1V*6,<R&( E=Y^AFK[S/1WB56WEO3%"DKTJ$2I>STH$Z7
MXB8(48SB5 -"'%#J@)*/+6O*L6;DJ5.]];*:B29]:H;-2).H0AN,52J5>WA(
MGJ^_ESCWF.*9896&B0__9/QBCYA L/=X)#+)JTU,XR#I,SK^5O).9)/@MC\C
M6#5B?PI;[<\.JO*W@50XG1&U3$BO<!+Y#GY.ZE.9U2_X%HLH*-'IZ2OFT))B
MBC$&.DTWT/8#N&. G0(K:5KF#RWS].7#8%.[/K!&,[=G5&E-S#/1U3[P/1T@
MG$[B*E%YPB*IJI:VF^S7$&D%R;@3GBYK=P]DT!)YE%9-^X+NV*3O'=ZT#>1J
MQ,A:,4KTSUB,6P4WF85[P9J-F5MACMKZ&U!-1NO8=5_J+A:[6K@KD[2[5G8#
M-S![Q.6YC2]DV5".9[-!0PN6*VI"F2R9Z$[D@'B,5Y/L 6*XM/:*#D<K:PN4
M:"]1Z@XG]%9FV9./:65]3A+XJ"8&&I NIH5]O*Z?Q9PSU9YIRV9(!@,1;H&L
MS_S=XDQKGA<X9-GOBEP!<781KL!W'!9+\LY6:0K3N^39T'+%?4-8L$02D263
M+#F0X#X *34B\S 0AKZ7A-@G5_K;EE'8B@I<0IM1(2N&<_&&55V;$?;Q?SK.
MY9Q_0+YI+"4"RS!E/9J)0X$6P1FS&"H1':+<P<.Q*)/RY4.VW4)\A0/^G)\J
M8K8X\1GB Z?N-^<E3#-I38]%OA+L.&:N=N2+AKJE#M*._!MP(N3(;+8GGR!K
MA\%O-_0SX&L2<I&Y()SDIR%.L/3:+5#T])[[3[PNVY,\VN?0\.I@3_HM!:$%
M3,[A8X ]([U!Y^E'G(=9]=.K+ ' FE*(5U2TI90_+8+(@(8.28FBE ;[E!&\
M!NA4YF(L<\*3.8IG5,Q@+'Q()0"&C9]2<32N0_>+QW5'Q[5?(;@Z5[G*T6<2
M7"F:_O?NH2Q.NX<OL&XO!_<^L)(*)_)"+K_@RSLYU0I[HXT2!2UUT) GCTFW
M'P"#+ZA=6P!OMJB.+E#/35O[$6LC&Y0+"'H6[-Y@1OXN4FO1\H-^K"9MK:9N
MK :_8MYA(QU8C3<G*I2%6TA'W<7;<_=2OIG3#9D3<ED<1__=>V/^A7!@^??F
M4330,W(1OJ"C9?-.AV!9>RQV>?8/?!:.'-)U66RS>ET*JNM840EKM1+I9(8\
M7C0T1/!LBV,12@<4):E1$N02B1-A^9 ;"(NGD%"%?&8@5L,M>('K#$^QQ$@>
M.]CB,8TIZ:1-HET]9_*SMW%#KWN2$QZGH]!EBW]-4(/ FX(\?;);>SQE!@;"
M:K<K:7VRN^P WR,X5_0U;2DJ)+V\0D3&/9.HW[4%-6H,[G%K\/7 ?SO<+WR4
MH\!B23D$\_9BB@-$;N[B^9B5\.ZIN'LH3A7ZQF51UB]"@)AT]KB#HB4+9YF'
M:YQC7T][ M05M'T!Z;S<R_-:NQYSY,)+4DCE>O?#O_P0<A=#'VK3#0K/.-/=
M>W T+C7"6]WB;4OP1IV5NQU7&:?K',XR]$'_2&Q]*)&5N2,"$9N\AGACJW\;
MJ]4ST#,Q_&5PY\+V7>#/C^W?H<[SK']$(1+['TME-0*$1,0^0$O$L1?X,58O
MP &AB1_@('!!@WDJYIE+WS\68QE(9&<JZ%<1&XI:O+&9O(O63*;0,S*2*>X6
M,9&[AVS&LG'<.[QY3*0Q- [:.T[+T)-L9!<_QKATY.%-TRH6 ]O, -)X:$:K
MQYJ"SM/RD?+Z);-?0+(48C'[D51VIH])Q&S_.B*.?<!/T?H %H1&?F A!#KQ
M!8;#Q/,'.4:B5Z<P8U.)(1"+2YBQK&\\0K3[2MH"COU!C!M+ OP9N8,HMY9L
MQHCG# K?OF#6)A.'1"S^8-8V4^,1(MYG,A!R[!5BW&@2(M'(+RP%0R>>P72D
M>+ZA)G#TZQWL=]08 M%X!OL]M=8OQ+JIIBW@V"?$N*LFP)^91U@$?&[\@=$8
M<;T!^ITO7_"$Q'VYR'8/M;4W8$E$X \X<IEZ!$("$!J1^@1](4=>X=T?8_0*
M(B3J^H5%83C7,UB-U-@W4#A" D>OWN$R>[1?1C 48O$-(ZGL7 ,FL9QGT$F:
M=R'DV#7\:[2N@86AD6=8"(-.'(/A,/'\PG:(18=WAN5\(W7-] P#"M%XAJ%4
MEIX!D8C<,V@(.?8,_Q*O9V!@:.89EL&@&\]@-DQ<SR#"XH*.8=;9)$,A%L<P
MZVR2#D;$9Y/:(H[=0I1GDP(0&KF%2,\F;8:)YQ:\GDV23][B9Y+G>841B5C<
MPE@N.[] :,3L&+2$''N&/T3K&3A(-'(-2\'0B6\P'2F><Z@('/UZA^QYIF_H
M"43C&08R6?J%[#EJKZ 6<.P3?A^O3YCBS\PC+ (^-_[ :(RXW@"!T*DO($_0
M8,$^J2H;\EIZ>X.%QR7W^2+R4K;L74)_CZ,(-3M^[$2HUL#7Y>UJX*J*+,R@
MZO6Z_1SIF2(:<VLPAR_Z,!L,[*W^V4AXC?8AC*L<T8W?1H03X%PK.?!#LU=@
M)_Q@QRDB9D0(E##Y B[[4Z9:>-;OZBN&T)-CBDK:B]3>Z_N-:H,&7!/,$FE@
M/,%B) -LC8(FW\#2BOYGC0;U:AW !H,34RVMRRS/J@>8?BR*5![G35IZG9>F
M7(H>=MHV[< .-PSU8HV*VTLIEWZG-^[XLQ,6=_ #0_<F>?J,5EIEENSER!TW
M] K<"8\BW);)$W[BF;8+!5L%KS<R'OV"EC?R+&9YPQX8LK\4Y:]7^759[- X
MRD$[;>H5M@R?(N ^H8:X8.2Q:1H*NTJ&?U$PZA? ?!RP$.:#(/0+DLBH=D69
MP6J]O8%[7,7O.BEK]&_E7I&JJ]_W(U5R,*#O.N"2^B7M HZT3Q2;.GI#PWE^
M46M< N/N(J^S^J6Z*^ID?UF48SXUMF&T^GM%H)Y$S*L.I-<_5Z#&_7!Q/1:+
M46R=& P8"TF#T9I5XSS[#-/W6;$O=MFFNLHWOY-O@$@Z^*M<+N:9K?:,VX*N
M,4"M0^YOS.7]=T+F/1895T!F4D_<!UXT2X?/U+VC \I/N"WB\RJG)Z3=>9D@
M?-#IY,OV5+Q/]=BV1_H#S7GPX%!S%2IBT!^'$9C]#8(6H*T'(\/_(X-1309C
M<8Q_* Y)QDBD')*V6W"<=_R;(9UVBQ#KX_'00_L"@S$/[^I!X2$^);U<(?Z\
MJ.KUENP/WA;[5!Y%"1K[0K>(5V;!A]KA-S%)2X";AHR=C+A&"U2RNPPJU#28
MV4E!,3(V*2)"/S.1_NU4U=AF*K02N9J\SW:5WY5)"E>;37'*Z^OD1?G(LA4]
MOT]36$G,/%K14R&KU*Q]?.[;]O6Y[[!CJC$QD%!J%5K#OOA_B]&UZ#<P/6U:
MSZL2S?-S'?9HYCSD80_ET+N8Q.%<Y8^(=[+SU3RCA ]\JXOG(\R1'*<RRW?7
ML,P*WA.$<XCYW>DTEU4TJ60]D?;-*'+87>$<5TP'I(00.!)*H:PX'HD];P!;
MHIJS)6P)Z5FW& 8?JT]E+G[XD]O4W\T$'I]L^G>/F[99D%L&ILR6 F8]WB80
MXF!R;V!9$&C>$+#5;TQI0"U_+[^460W3XBE_]\/;M](Y3]3%Z\PFY%LT "_@
M";<\PTU#34ZV3/-X]CN]R&'"3B)RC,R8*J[+XC&KD%FBJ//B>0.KZK8N-K^*
MI@MA<U]3AIC?Z9AW+?%+%("V!:1Q@,G#ANUQR!1L$E$@9#21^("'UF1BHV^\
MLH84)A5N[&I#;\@+^M_AM.>RSM/WJ'D($QOS*S>Q0=O %J;+-1[QK9CK(";&
M08C0Q):"A[&)62I\"0N[>X#TBFDZ2%O4L35!QQ!6)Y)!;G^H5W-).P4XQ[3M
M&-@8S87!**F1,+ 19IC4&X6-2C$FM-;E 69LMV['9B%S[F+?J_P#?(3[XHAE
MU#1I4>= 9BV416W:_1KF*@>#SN'-VT*H%D99)U26@U0L5"@SEV-/9NH>@&=C
M[@N,54S;+TTZ_2I]3-!85W?%[>EXW&<(T?)C!TDWOP<,,OY%=P>2IC6H"U"U
M[8,=&)A(\ $>BRK0+4L3T'!V]96(F34!PF.2I<WA@#"5CVGF;U*;\L=Z#]("
MM$W<H?$GRE\.=SB-63%-Z;()!6QZG':X(SZ98)8;;LVIQ'38HYH:DK)\R?+=
MZH#/T%<;)/")I,(C)U3"349$1W\LZZRB/^?IU0&)4Y),R#S]6!95-:&BOJ>S
MU$<]W_!93'?LW2#:""2DU1N<]-%^#44=_>?>X!;=!\DM\:S[)/GG#G\4;,8$
M([E>M"P6>1>3E@5B5,:M<8>)WR&@48FS$*?X%5Q)\A;@6;$=D[VI;DS)L!$Z
M@U)@N'DZM%T-_)L1\ILS:28CDRPIF"_(E#":,D);TD*"!LZ*M$ H)QW2 IZ!
M39,S06K8H:275Z.3<3\%WD=^7!78FDPDP#EY8<U$B1;6)I10F;'C(+"W-2Z9
M<(1E_7*-](?#P(N_GS*RZ[>ZK^HRV0CWX>=0]+6/,4MJF3L>4@/K'+3T "%(
M2J9U),'7EFB(NS"+J2#TC.0(UJ,=F$@PK;59XV5@04$*P5!L'PFV<90%>VPG
M+;9='0X*Y/J05<>B2O:54#Q#1Z5#,+"?TI)9VTUUU*3>*LA&KDOYNTZQ.25]
M!.OX),_PG>.29L-XY)'2#L8RQQ33QO10%R;>RYB"UP6%KE2<(\'!%F\[AF]X
M@QAJI>%"M+"K#R/(L2L1([S-2P02A"I\3R+)"3*DXS$]R%1"3J*&>&TAFNV=
MFPZ]LW>1JTYD9XN+/H$W'=XG>WSPOI <MW52UDM+\A[NLCR7".,SZ<G*SJ;Y
M3^&,3#<5RH6QE=#0V%PM?;[ >G( I]B#D73PY>!D/$^5B]J"[MAHU>PJAMP<
M,65^LB7J/@=+YTU=UTQ[\T)*>(_<C1]L:_D5$XT_/Y/V#,[;+A&M2_ ]]7R3
M[9N-H^WY Q($5E=6>\)NR/HM.3Y'?K:.R9 8OMNWH>2:6LKB5<Y@#RU807.7
MF@A_]C(?V)P:Z;-1'3JS($TSS'JUKA]@>8?8OWLHB]/NX?VIRG)85>?%X3[+
MB7A&FZSN/^&Y@I,CO;!%G1K"H,"408U(H_\CM,%]0QQL!M1];X<HH@V?.@I=
MZ<FE;?"*/[DTC-#;F38G,6;=_6YDSCIE\&:S>L<IKL0*O'UI?%1B@Z]8)N2[
MXB;;/=3%]E3!557!6IYR+NT79NKD2B">#^L"E+C]6;$]0SU 0KJ$JV-H(L47
M^ 3VN&1?!+.Q&</@V_OO(IEFQ8B7S)UBN,_)-B#9AO]H@GKR@?7VY^8#PHP"
M>2=O60,*WAD#'+3'"U32 __0V6"0_:PY8H0[X]?!S?@<WQMH],[JG8/'U2[X
MM#9J$RI_@?7%,]U3Z=^"K1K6[PJ5S<ZEZJ]DXDSIV=)H32WAEB)H2 *\3=D2
M!0.J_?"BB1H/[RJ8;W"NC0O4>E/WVW-X=PZV.BA19!UN>]P-[B=U'Z,!O6:)
MR$C![\JWW<'RT*SS&:<KO :NZ.3M-24%[^RCYEU[_#0 52KZX>=6J9XC_KE"
MA'M'20<TX[>4O"%&[SVE&<C![P>R:\6HTONR:K,OJE,)<17H&@F2W>\;X>Z4
M3QQH]/:]&Z:4AK-KU/3!PY7".LGV,$53*RX%U]S-NR].-?I-2[ 91_"UQC0#
MW];6'D'N;I/>\(7>;#*\$#[CAJF*9!1W395RZ^8CRZL4A+XSMXCX2> %N"M4
MZ]]*U8.TR\PO^:M0PN;!LKZ$P.'F?(5^F5*A;GD>4JA7*=WHW-TK9H<#+)&!
M[!M/0.*ZZJXL=DGYC^+BA$]?5&^;&9#P]^*9B5QL[LND-UWV5*#M#RB!L*^C
MN960A.?562?B;W_S]@__\N=&T"0'*)HO,UQ6,.#C:L98G3RY9@S4Y2SK"YJ+
M'E:H1;9)9MD7CU D5L:5T=S6"!G0T%G.Y'0V,I<16&!Z([GC\S +"OL*O(W8
M?DU\CMAX9WB>=;[!KUCCC(D:+]WE[D74VI</$7([A5+;$+0M0\Z^]EP' [0<
M%B/4RC'AIBK \"32H$@)OUN &_X"_F4K[M'AZX(W9K2.ZV=)$GKOP 1,HFOX
MBR/)]++]S'%8H'+'D*,N(6^Z/]HEP^+'C)^RO? 5#P>$ ]NYD0ZT/4%?T:,G
MVQRM 4(88,J@)1VV^I S=;2=8W,?YCC7<3"!0#['!3D#^]!)]74_WG".D08W
M+'8-[86]&GO<,]>=:5$,[,?TI-9V8.MM(,^E6P7 J1KZ>@#WBQ8W4!5I<"J4
MO%Q#:)]L8*4ZSMBWB<[QPH%,-:;,C.&YG8VWMJ;D]XC;4$I^9F_5G&9KS:W!
MCK.=B!K%R;4--#D'UC:XC+7L@%* >>4'#,C'48; 1!]&Y0BT;'S)L@3:5YT6
MT4W$!0J,3<"@4($Q_L/G5=KO&]F1"7/O>,XFB.YJ.()[R*]MKV<.$B77DIU.
MT\(K5%F=)?O/V1Y6=9'#Z^0%+R,J]%]!0K)>-W^7H%3\LQ<]2 _0=0%M']!T
M"K#[^2K$T+N&92O(L6D9\%:5EBE,KDWYLP/->U'N@>1J?[3[@N"M/%XC7WYD
MRMM42[UVOJY"/1HG5N((DUP-NABV#\4AR825=9EFWH>NXT\R>+1-!,,W5B9_
M ,>:=#&$E]FC(M66V]3[4([X% \G;A8V6T^/XY^/^/'LK*QJD&P>,OA(BFSF
M^0GYW1S6 $5[]#[IS[?_!/[UAQ_>_/###^$ARH*%#U,6*4Z@BL9+%ZJ#IOZA
M.N13 E74+!:HRC@V@NJ[:*#*@$4 508I+J!ZFSUK(G70TCM0AUR*<8I:10)3
M&;]&*'V+,1H'3AFD\&'*P&1.(0'48[U=E27>W"-QO2S\%K7V5CI Q"US\QLU
MQ .<#)H*'G3VL'Y?@FU_50.D"!F7"Y#"PRE*J0'(UQRJ7N%0.^%>"P:TCW"-
M$@3&-G)\30,OLO3 I  V#TDS /X^J3)<B*9X2?;U2[/%(O/$D@Z^8"WCF4E9
MPFU)]1;:NMU%"KU?HM3[" 9*I;M&@#QNE'8)B@)A9";&0>BKW!KZ5V/!Y3W^
M6QRDDJ\H[_"S33W>W^?PR;M'3IH!.OX!KTU9,1RROH (!M/: B(,S !A@^T;
M^ CS$[P]W>^S#<PKJ %*K:Z^0*HG!Y/YTGBHIAOH^X5'\3(2!8.Y =!&L#=
MV9R9F:VMOTK_=JIJ[/'OBFLTO ])!<^+O,I26-(&LM#-FIZW.=U>8F;";]^G
M&- "/3%P5X"6'!C1"QX9SASU<; P<\@]HU<1=LZ@&#."Q4&K/8:#1[6S1W\V
MCGWYX=%'K_*J3O9[_)=UKCC3G$\W$E3K:, "VV-(#^B"=1ZT %&$ZHC5T+6-
MP\3<M2W#O]'?/16+&/V ;N1&/]2 4Y0CPJ_0Z)=4QVLS>L8X7!C],I:AE=6X
M)"0&S^J!I(=$7:"_#"&1#2!1/Q4QW5[DO0TG6)_J=/)ZMT'"N\Z0A3P\U1\
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MSH>9+MMDB!%\GN M&-S1:H#Y)(V1-4H<Z1=6AADBG70&VQ85L@V%M$#K-;G
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M\&O^K0C$LR;5IT$)D\)^5\N!VN]>K*WTI"AK35"?&7&%8??&YP%8W#*?A]Y
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MM+505#8/J+MC]=^Y+AD^D,E2/+UA/$<E.A"4$7]6>R=+G :4\6$*8YH$$%,
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M=)DL+,Z\OX"Q*6M>W7SUT&97W2LNC?01_8H$AV_(6H_7"R3-I7E7B8@T[Z<
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MO/L^:)LUL:#;@LQZHN*%_56Y8+*3X6N!9*F9^JUY5J19X]#)X,<VPK61PLM
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MRC>NVM:ID<6+P&-K:$@INE:PHA6^)JWI"ER;_9ZLI\@RB\SJ/D1%5#WE&7N
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MJ$YLHP7$X/&7[OF#U^=D5S85\;:*9Q)>J\MUQSN5[PV,=+9.^%4ARI5C;M[
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MJ*M,GPK@U1&OCZ@ B'W:Y;J=F&ZG3C="O&>N&YM#E^A)HIN__5U+/ YW?2'
M:+87[*OC^CO(_%\WI#W\)_(/.I?^__Y_4$L#!!0    ( !U 55BX]U^K4*<
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MJ1KE5=J'4^WB#-%(VE:#U< "..N=]68-9Q#'JR 21XB&H?6F7)*/>\Q&*1B
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M0@'8YJG]ALO<+3T:9DFJYMM&2X&VAW%R*BQ \+YW1IHRD+8T4ABY-+:;"T]
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MQIMU% *.;M=OOW+5Z%PEC6ZZ?/<1]R-@B"#7TKU1_"O+3<&H:;G/6P\JN'4
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M$%*7T,9D $Y&K&S$+:7""E_KI,3^)K&L5H?AGL")<M5WU;Y$X2H!L7<[ !1
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M/R=Y.*:(?1#A_;THHBP_.CUWX$_7W>#DX<#,DPR^2&D\HD"%OH%;LD#B=7=
M@JX>)^&NYEMN#<@>X^)9KV^+=G-ZU@M6WETX3J\\.6;A^8Z8P;$A5MZ7 KT^
MPJ_[9,$1Z- U!>IHE48>J6'UNW%!M9^A[OV9K(L@DE=>414K3?Q.$G".WA[Z
M) $"Y5>R>">IDN_UAH(@7GER)-P"[^$R)([>'OK$VHWT8P8<EK1GY#D_1=_D
MI1P#PYL4,%"?*GJ4>LU &IH-*2B-'H!@)3 MD1[N<T@@%9F!\"A["H:@^U&M
M9,0,T*&^F=S.4V:T?<BZ"$KAV^?LM@<EDD-]$&F0D,QD(S =1= 3W1QDMRE8
M@W/UIM(W88'O74]TZ3S2?U-?*@WZ"QIZY0ML<L.T0>KHD:5/=Q*;#'_71\<>
M&Q1VV:6^;Y: 7+VL7)(T3)C!-<U]V@J^K=B.-YQRIU4V7.59'L148YHIF0[V
M$F1#-S6XD ,]QM;/,/T6C:9N,F70Q?G1"7Z.9Q?B88+2V4--WQ2()F^QZ)KQ
M(HI1QS2(X1(PSAYE^L;?KI]D4?)YE;FRZ29@#+7UNTQ_S4Y^/V&Y/L*O0V(L
M)9"8N2*#LR>D?=FO?'F(0LF/?C=J+87.Z.#J<:J'FZ&;.'Q*)G0=N;6XJ* Y
M>\_I6SS]US ;DR@*8I*L,HG#VT1_,AQ#$/,@KMJVB%T]J72:[>HU3\9_#N+)
M'T%*][P\$X[M.WY0/_,;_M^#:$5WRQ_\7\ \MK;CO!V?7%Y>G:(+@BT3-X6A
M)73<-XJ-)4+8EAR(Q-9 !6'0G;9[D0D0N[/7?DZ%@LV6SY2G? -9OME,@,(W
ML+M@*(3,V2,[E^RBBDO*BGG?$?'?T3Q-5K/Y_4^2CL.,#*=KN10$$+((,;71
M8 6!#F%_;XD?]\&=&P'A!Y@C^>!C%>1!-ZWN7SRVX.,^OE.I ( :,QA3&%D(
M9;BSZE\<>H<@!?:0.WM>UP'GQ9[6@O6[ Q2$0 _3ZH[W*LP \_=DTS1E_FA.
MK.^ !OW7KTS1,IYVRWT3U #_]Q3%:<U_FQN?R0 5+0YR[S>"#8C GH(ZFVT!
M(E8]XU6::G'KKV1,&P-E#9R,6U'N("Z3+JD!R)$'9D7%DNA D P'+FEW<9"J
M1RMR **$:X\$[E<"GX ^R!?/:3)+@T63BZIBI((ZIZ<'8<-JB1]XO8AKF-R,
M=Q0@"EP5%D@@C#J7-#@Z!%W%'C+ ]CT9.+O-X2];#L"667N;I_2#-AZU6FOH
M#U3:R9EK6@ "B&M Y>OGAF+B681(G'$N/5.:Z>HKZWMRNIZBGSC-?>2V. $.
M]S\B577BOC/2/ >?C,(\WHA2Q*1LB/6 @LR8=4,M1,%R*S$##L@7KJFU<A!P
M)7[(IZ>MSJ[N)1"C.]U:[AR&& &NXMI0M=Z@ DT[CUI]$$$/S+* AOQJXCN3
M @48CVL\-86RJ8"WE8#-T02%D*XI>Q(% #$@$[C65( :>9Z&[RP%IW(3,.HL
M\&.6CVS.<3N  (/[_ZP=$/RZ(O-'F,^'/V(Z\R;*H7PD3M@S3*VPD>2T10N(
MD9<F3CF45@>(R9",5A=8*?6[.46L8 /YN_9DY_0F+\)9CZ\1("" MPT?O]_'
M7M6:[" KPMD9NM&[\ZP('",@&-9&1JE@(*=(#K+Y0Y3\R+Q+CKR>F'5:Y.V.
M+/WNY>6I)^NPG-X#%>?O&9D\QF5-U0$]A#ZXY]4L*X754((,Z.\GC#@%+=6&
MB+O*;HXM2XWJ!U_BAU4U9",D%1)\CO(D>\?QP>0?JRSG>_=#DKZ0<1*/PXA4
M%##:.(Q'$?1$#\1T+"_V\!WE9O;P=?<F+>X(!30..8>+ M\6@B3IS2F(5;"\
M#<?-9$>%^% S/6]28+!(TCS,&DJ,I+>@'WJN@*XD1H7841YGI]8GV>S_Q6<_
MG+Z$LWF>3.FT17(6R-QD,\;;U?'5U1EZ]&5;]C?'[2B#L_='S8YS7JW#ZCJ+
M181^N^EJVU  1DW_#.P:++L30SN,G[BAE:2+,(;2$FEZ5/'LZ*EWG>P*ADC;
M)FJ^%FR-R8R9?/S=!];&^+5Q_C&^(VGX00GRL9W\RTH5-1Y5+"3TL,KN5%1[
M2CA*^^RYZKKM#GJ,[Q?+*/DDY(;$A%$]#-[#"'IQXF)83O'K@[T>-2*%J^S4
MCIVP=#B2Y<.X%I/\G2KOXQ6=SRN)PR3]EN2$50Y]2N(9V]6?D@ \[IJ.)ZB$
M[GQS<A"VID'K9-7^GI%KVK!:+[=E.?A!)C%[::(^C,=9A]4?G:#;^]SM1TWQ
MMTYS[:]H;6_1@D &B1U5'=\NCH_.\ W%W1UD4K"MDV7[*R5KQ)2&A&J*3C8A
MP[&JA7A 2GD;&KC*M.V_/DX7%\^Z:VM'WNY:DN\<_:%4A[HU#-E55FP/K8@E
M;I*U5XYLAJH(?$#WM18D:)WRVM_#;Y.^WV-Z>8W"C$SH7T@XB]=9P47Z>I[)
MWF*O,AE.7'%Z;^]T0@)GB;5=&[A9W8+E*J4S9\'(FCNLRNYM-5#Y^OFT]]J1
M P*T3IO=<A,R\YJ.QRFI.7P'\633&7A73+6PQ\8S91Y=)X.+Y760?M:6!'&5
M=]M#W8EOK,-81$H_Q@]!F/)W5(PF:Y^ ^B@S&J'R8_5^BVJ#O'6N[F[VIIK_
M,0DHCC$SP']^3294[QL'4)8!TZX5!7KOBV\$N77&[[YHQ6+W!#.^FW2K"-=[
MAX8U7-S$WRCO&^A2N6%EO4CY4N>/)/V3G;^BE'W#MPZZ81G'KHX.R#3M@!3.
M$HLW*E8$'$SKH[4R//"H!.;]J]S$NA0H5H.P IG'^.8<)^'M+=#C)AM'C#0:
MI<&$W0]X83!AF6>E!]L%&D&#\L5W@IE_HYET- TSTM+!RS3GFZA&P<];.HV0
M$^D++]10(3&[GRN'$%&_F*_I7<A$8]2N$IU[>-76K8['^(/^6Y+:Q98IQQ$+
M"S/=RWXW&!ETW+SIB/(D:ENN4L8C!]&RN\-Q$J,F"MRO="DH@)M4'3$^=N-(
M?PX^;94EPQ$%H3&3UG4I:K9$P,V[OC=IHQ?ACS #K(_Z3H)<AWKX27#B)EQ'
MW(36[AL1NL#7S(B2_C:).65=!>V;?^;M_.KLXJ+O2GRGE'&5)MY#17^7/A96
M35UGL=J1;)<=B)8QWM9IW3?=*"/?BJJ;F?P:6L0W0K881?'S=#G.X&&)W5D*
M^1Z(41G5T#Z9E&(H3MIS=+>=ZV12)HAQ\\5W*$PO9%F\+1].;Y)XDJT?7]V1
M=_KK2IY0U*I_&;MUANZ/:\A]2)ALP;?.3]]-<,@ZNP!5_+C/^H5$XOQT$.KH
M8NR2AEYZ[>P%J!O"M,Z![V\0"KT)CPF9<*)_2^*Q,-#=)&F:_*"$UR;"4W:N
MB(A^LCG>GJR0NTJ7/R'3,.;%C;^LP@F+@_%%B*H%1[?GG!<ZTP<R@;TJXJ''
MO+D6&R/(K;/O=W.6E4?R<,J-%,/W*)RI QP57:H7>>A!T^Y.'E.\K1/C]^-
MV:DG8GR:[/3D5+] ?\'3X3$"0S[8'/ER^'\$*0]P:" LZZYOQR>7E]='Z(]5
M]R(NNZ!=)=YW&@E4GSP[^"@)1(9X>JE3L-RX;P'_,#3-!JA=)=7W;Y>HE"8.
MWUZ]W.K&:'9UAN4&V(=R"0(&A&1O&3:,H@3;/-\#'J.Q57*%GQC,W=Y@AQI@
M>_]MK,^ED9 G?ZSYT.I/[R4T-MHZK$=]NSJ].#H[."VU-3D ^=N;=1;=9>3
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M%/P Z:CR)3<=BG/E"OUAG<-K14/\!Q@!5K=!"<,42 ^U1)F/(Q9J/VZINS(
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M)*6>@%DHW/V6HD'JRLR4Y$'DP<7%2?9?W^XFQ2/]L_(U11L4@P6S-0ZGM_2
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MU$,*'J'GIV@D/BT1H]Z%39W"ZMPS0',!T=.GD5*F&J'!*DBVC[1TVTI;^>B
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M=((3'9<,N@K8F(9_!2LDC+.!!.2PP+4H,9C/O!J&:AO<;"40H3\K:K4) H@
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M.: MM#R;,00=,+.)-^2;U#S6 #>0M /Y<55MQM^2^':5,C(.<A;? '%=T46
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M(")ZS1MKGD/"8P,9D)L]1:5!;X&++W/]^7L<ZHX1J+W89-'=0#;\D)PE6G0
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MY_L"\ 2KU2Y'WOW#K#E@@.JCV3XUR1ZO>6LRGX:EG*"ZM,,]Y/+HB9>D)G1
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M$-T#;,PWI#B&J"$#?M_T1IU!MZ%6F72>2Q\]V,1054PTKK9$ 'UTR=>852<
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M).-!69_&O">. C]9D[G4);O3!NBQ JL!C9C2%LSFD/H*"C:\;[[WR@M,JC(
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M?Y6CXWKR^E\R8_3%#^':9T>%<3!_B,(9B6/"+DQQ6+P4'$=I/.;KOH IQ\7
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M-V1E>#$Q,2YH=&U02P$"% ,4    "  =0%58[UA&HNTF  !/)@$ $0
M        @ 'WT 4 9#8X,#$Q-V1E>#$Q,BYH=&U02P$"% ,4    "  =0%58
M.*IE**<I  ",M   $               @ $3^ 4 9#8X,#$Q-V1E>#$R+FAT
M;5!+ 0(4 Q0    ( !U 55CI-*E/F@<    <   1              "  >@A
M!@!D-C@P,3$W9&5X,3(Q+FAT;5!+ 0(4 Q0    ( !U 55B9)0[YF0<  /D;
M   1              "  ;$I!@!D-C@P,3$W9&5X,3(R+FAT;5!+ 0(4 Q0
M   ( !U 55C9%8][)A   #M2   0              "  7DQ!@!D-C@P,3$W
M9&5X,3,N:'1M4$L! A0#%     @ '4!56+H$"$'<!   H@\  !$
M     ( !S4$& &0V.# Q,3=D97@Q,S$N:'1M4$L! A0#%     @ '4!56%#0
M14O9!   H0\  !$              ( !V$8& &0V.# Q,3=D97@Q,S(N:'1M
M4$L! A0#%     @ '4!56"PR 'P  P  O0<  !               ( !X$L&
M &0V.# Q,3=D97@Q-2YH=&U02P$"% ,4    "  =0%58^7:-[$H%  "(/P
M$               @ $.3P8 9#8X,#$Q-V1E>#$W+FAT;5!+ 0(4 Q0    (
M !U 55B_XD]>"3,  +&H 0 0              "  894!@!D-C@P,3$W9&5X
M,C(N:'1M4$L! A0#%     @ '4!56)EQ^/C#'@  Q8@  !
M ( !O8<& &0V.# Q,3=D97@R,RYH=&U02P$"% ,4    "  =0%58QNN:ZYP2
M  !Y6P  $0              @ &NI@8 9#8X,#$Q-V1E>#0R-BYH=&U02P$"
M% ,4    "  =0%58F<[W]0(-   110  $0              @ %YN08 9#8X
M,#$Q-V1E>#0R-RYH=&U02P$"% ,4    "  =0%584^3ZC <3  #<:0  $0
M            @ &JQ@8 9#8X,#$Q-V1E>#0R."YH=&U02P$"% ,4    "  =
M0%58!TJ@T#L-  #=0P  $0              @ '@V08 9#8X,#$Q-V1E>#0R
M.2YH=&U02P$"% ,4    "  =0%58TL54EPP3  #?>   $0
M@ %*YP8 9#8X,#$Q-V1E>#0S,"YH=&U02P$"% ,4    "  =0%588=H%Y.,4
M   @L@  $0              @ &%^@8 9#8X,#$Q-V1E>#0S,2YH=&U02P$"
M% ,4    "  =0%5889255(\8   <@0  $0              @ &7#P< 9#8X
M,#$Q-V1E>#0S,BYH=&U02P$"% ,4    "  =0%58E.%T:3X/  "(=   $0
M            @ %5* < 9#8X,#$Q-V1E>#0S,RYH=&U02P$"% ,4    "  =
M0%58K ]$!F(*  #3/@  $0              @ '"-P< 9#8X,#$Q-V1E>#0S
M-"YH=&U02P$"% ,4    "  =0%58TU!%C-P,  "T3P  $0
M@ %30@< 9#8X,#$Q-V1E>#0S-2YH=&U02P$"% ,4    "  =0%586!GF2'YB
M  !<' , $0              @ %>3P< 9#8X,#$Q-V1E>#0S-BYH=&U02P$"
M% ,4    "  =0%58F3SCY -!   DK $ $0              @ $+L@< 9#8X
M,#$Q-V1E>#0S-RYH=&U02P$"% ,4    "  =0%58S9T;J>$=  #EI0  $0
M            @ $]\P< 9#8X,#$Q-V1E>#0S."YH=&U02P$"% ,4    "  =
M0%58</429HD0   J4   $0              @ %-$0@ 9#8X,#$Q-V1E>#0S
M.2YH=&U02P$"% ,4    "  =0%580RO#L$@B  #)WP  $0
M@ $%(@@ 9#8X,#$Q-V1E>#0T,"YH=&U02P$"% ,4    "  =0%58_D$$[8X0
M   A4P  $0              @ %\1 @ 9#8X,#$Q-V1E>#0T,2YH=&U02P$"
M% ,4    "  =0%58GJ@TS;96   V70( $0              @ $Y50@ 9#8X
M,#$Q-V1E>#0T,BYH=&U02P$"% ,4    "  =0%58W(H(#((2   ,<0  $0
M            @ $>K @ 9#8X,#$Q-V1E>#0T,RYH=&U02P$"% ,4    "  =
M0%58DK;&S%,6  #RH   $0              @ '/O@@ 9#8X,#$Q-V1E>#0T
M-"YH=&U02P$"% ,4    "  =0%58S(SLLJ,*  ">*P  $0
M@ %1U0@ 9#8X,#$Q-V1E>#0T-2YH=&U02P$"% ,4    "  =0%589E<K0(<0
M   ^40  $0              @ $CX @ 9#8X,#$Q-V1E>#0T-BYH=&U02P$"
M% ,4    "  =0%58JMAI"TL$  " #@  $0              @ '9\ @ 9#8X
M,#$Q-V1E>#0T-RYH=&U02P$"% ,4    "  =0%58FO5!]IX"  #M!0  #P
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M-V<T,'<P,BYJ<&=02P$"% ,4    "  =0%58?RP@92N(  !'H@  $0
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M-V<T,'<P-RYJ<&=02P$"% ,4    "  =0%58OFOENY=L  #VA0  $0
M        @ &4Z0P 9S8X,#$Q-V<T,'<P."YJ<&=02P$"% ,4    "  =0%58
M53P$<^QB  !<?   $0              @ %:5@T 9S8X,#$Q-V<T,'<P.2YJ
M<&=02P$"% ,4    "  =0%58BQBQF055   *;@  $0              @ %U
MN0T 9S8X,#$Q-V<T,'<Q,2YJ<&=02P$"% ,4    "  =0%580IKX[B-3   M
M;   $0              @ &I#@X 9S8X,#$Q-V<T,'<Q,BYJ<&=02P$"% ,4
M    "  =0%58-R-YK&1!  #$60  $0              @ '[80X 9S8X,#$Q
M-V<T,'<Q,RYJ<&=02P$"% ,4    "  =0%58N<[A*QI3   <;   $0
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H>"TR,#(S,3$S,%]P<F4N>&UL4$L%!@     Y #D # X  ,>7$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>d680117d20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:thtx="http://www.theratech.com/20231130"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="thtx-20231130.xsd" xlink:type="simple"/>
    <context id="PAsOn11_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="P10_04_2018To10_04_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="P02_17_2023To02_17_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="P03_01_2023To03_01_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="P06_21_2023To11_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P10_03_2022To10_03_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="PAsOn10_03_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="P07_28_2023To07_28_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="P07_29_2023To10_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <startDate>2023-07-29</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_TrogarzoMemberTHTXCommitmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:TrogarzoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashbondAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_USsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:MultidosePassInjectorDevelopedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_KatanaMemberifrsfullBusinessCombinationsAxis_LicenseAgreementTransferPlusLPMemberTHTXTypeOfArrangementsAxis_MilestonePhaseTwoLiveDemonstrationMemberTHTXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestonePhaseTwoLiveDemonstrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:LicenseAgreementTransferPlusLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CAifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_IEifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_IEsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LoanFacilityTranche3LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche3LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">thtx:NetCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_TrogarzoMemberTHTXCommitmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:TrogarzoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashbondAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:ProvincialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IncomeTaxJurisdictionAxis">thtx:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TaxBenefitCarryForwardYearAxis">thtx:YearTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandFortyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFourMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFiveMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySixMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySevenMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyEightMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:IncomeTaxExpireTwoThousandTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">thtx:UnusedAndUnrecordedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_USsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_MilestoneSixMemberTHTXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_MilestoneFiveMemberTHTXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:CommitmentsAxis">thtx:MultidosePassInjectorDevelopedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BusinessCombinationAdjustmentToPurchaseConsiderationAxis">thtx:BusinessCombinationAdjustmentToConsiderationInstallmentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentOneMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BusinessCombinationAdjustmentToPurchaseConsiderationAxis">thtx:BusinessCombinationAdjustmentToConsiderationInstallmentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CAifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IEifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:RevenueMultipleMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_TopOfRangeMemberifrsfullRangeAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:RevenueMultipleMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LoanFacilityTranche3And4LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche3And4LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:AverageOptionLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:ExercisePriceToAcquireOneCommonShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IEsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AllOtherSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_RxCrossRoadsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_USsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CAifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2021To11_30_2022_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:LocationInIncomeStatementAxis">thtx:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ThtxCommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:ThtxCommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_OtherAssetsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AllOtherSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_RxCrossRoadsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_EURsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_USsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_USDsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">thtx:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:BondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:AgreementAxis">thtx:FifthAmendmentOfTheLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:VariableInterestRateCashAndMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CAifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_FirstFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:FeesPeriodAxis">thtx:FirstFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:NatureOfFeesAxis">thtx:RoyaltyRelatedLicensePeptidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AfterFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:FeesPeriodAxis">thtx:AfterFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:NatureOfFeesAxis">thtx:RoyaltyRelatedLicensePeptidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:NetSalesBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:NetSalesBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:RoyaltyRevenueSublicenseBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:BasisOfRoyaltyPaymentAxis">thtx:RoyaltyRevenueSublicenseBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_SellingAndMarketingExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_GeneralAndAdministrativeExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_SeveranceAndOtherExpensesMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:SeveranceAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_ResearchAndDevelopmentExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">thtx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:LocationInIncomeStatementAxis">thtx:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2022To11_30_2023_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1And2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_AllOtherSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_RxCrossRoadsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">thtx:RxCrossRoadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_StockAppreciationRightsMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ShareOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:PublicIssueOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:TwoThousandAndSixteenShareholdersPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:SubscriptionReceiptsIssueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:EgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_CAifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">thtx:BrokersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-06</startDate>
            <endDate>2017-03-06</endDate>
        </period>
    </context>
    <context id="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-06</startDate>
            <endDate>2017-03-06</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2016_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_01_2017_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-01</instant>
        </period>
    </context>
    <context id="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="P12_01_2016To11_30_2017_EuropeMemberifrsfullGeographicalAreasAxis_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:MilestoneOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2022_TrogarzoMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">thtx:TrogarzoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueWithOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="PAsOn05_29_2018_DueInNextFourToFiveYearsMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:TwoThousandThirteenTerminationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">thtx:SeronoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueInNextFourToFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">thtx:DueWithOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P07_23_2021To07_23_2021_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AtmProgramMemberTHTXProgramNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ProgramNameAxis">thtx:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">thtx:CashSettledForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">thtx:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_DevelopmentMilestonePhaseThreeClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_DevelopmentMilestonePhaseTwoClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:MilestoneAxis">thtx:DevelopmentMilestonePhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">thtx:KatanaAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:PlanAxis">thtx:StockOptionPlanTwoThousandAndNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn05_15_2018_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="PAsOn05_15_2018_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementsAxis">thtx:TaimedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="PAsOn07_20_2022_LoanFacilityTranche4LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche4LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis_SecuredOvernightFinancingRateMemberifrsfullTypesOfInterestRatesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">thtx:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1And2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P01_19_2021To01_19_2021_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-19</startDate>
            <endDate>2021-01-19</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="P10_31_2023To10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="P10_31_2023To10_31_2023_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="P10_31_2023To10_31_2023_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:OverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="PAsOn11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:NonVotingSubscriptionReceiptsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="P11_14_2023To11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:OverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:NonVotingSubscriptionReceiptsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:InvestmentQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:IssuedCapitalAxis">thtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">thtx:TaiMedBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:ConvertibleUnsecuredSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_10_2023To07_21_2023_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-21</endDate>
        </period>
    </context>
    <context id="P07_10_2023To07_21_2023_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-21</endDate>
        </period>
    </context>
    <context id="P07_22_2023To07_28_2023_BottomOfRangeMemberifrsfullRangeAxis_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-22</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="P07_22_2023To07_28_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">thtx:CashCashEquivalentsAndEligibleShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-22</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="P10_13_2023To10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:AgreementAxis">thtx:FifthAmendmentOfTheLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="thtx:InvesteeAxis">thtx:AffiliatesOfMarathonAssetManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="PAsOn02_27_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:AverageOptionLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="PAsOn02_27_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:ExercisePriceToAcquireOneCommonShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:ClassOfWarrantsOrRightsAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">thtx:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="P06_21_2023To06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTrancheTwoLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P06_21_2023To11_30_2023_MarathonWarrantsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:MarathonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P06_21_2023To11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="P07_27_2022To07_27_2022_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">thtx:LoanFacilityTranche1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="PAsOn10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="thtx:TypeOfArrangementAxis">thtx:FifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_USsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:ChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">thtx:OtherAdditionalProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">thtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:OncologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsEgriftaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">thtx:CommercializationRightsTrogarzoNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">thtx:LiabilityComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512717</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_CAD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P12_01_2022To11_30_2023" id="ixv-43393">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P12_01_2022To11_30_2023" id="ixv-43394">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P12_01_2022To11_30_2023" id="ixv-43395">0001512717</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P12_01_2022To11_30_2023" id="ixv-43396">--11-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="P12_01_2022To11_30_2023" id="ixv-47757">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P12_01_2022To11_30_2023" id="ixv-47758">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P12_01_2022To11_30_2023" id="ixv-47759">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P12_01_2022To11_30_2023" id="ixv-47760">2023-11-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P12_01_2022To11_30_2023" id="ixv-47761">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P12_01_2022To11_30_2023" id="ixv-47762">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P12_01_2022To11_30_2023" id="ixv-47763">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P12_01_2022To11_30_2023" id="ixv-47764">001-35203</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P12_01_2022To11_30_2023" id="ixv-47765">THERATECHNOLOGIES INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P12_01_2022To11_30_2023" id="ixv-47766">A8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P12_01_2022To11_30_2023" id="ixv-47767">2015 Peel Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P12_01_2022To11_30_2023" id="ixv-47768">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P12_01_2022To11_30_2023" id="ixv-47769">Montreal</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P12_01_2022To11_30_2023" id="ixv-47770">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="P12_01_2022To11_30_2023" id="ixv-47771">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="P12_01_2022To11_30_2023" id="ixv-47772">H3A 1T8</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47773">Jocelyn Lafond</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47774">438</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47775">315-6607</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47776">(514) 331-9691</dei:ContactPersonnelFaxNumber>
    <dei:EntityAddressAddressLine1
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47777">2015 Peel Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47778">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47779">Montreal</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47780">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47781">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="P12_01_2022To11_30_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47782">H3A 1T8</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="P12_01_2022To11_30_2023" id="ixv-47783">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P12_01_2022To11_30_2023" id="ixv-47784">THTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P12_01_2022To11_30_2023" id="ixv-47785">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn11_30_2023"
      decimals="INF"
      id="ixv-47786"
      unitRef="Unit_shares">45980019</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P12_01_2022To11_30_2023" id="ixv-47787">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P12_01_2022To11_30_2023" id="ixv-47788">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P12_01_2022To11_30_2023" id="ixv-47789">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P12_01_2022To11_30_2023" id="ixv-47790">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P12_01_2022To11_30_2023" id="ixv-47791">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P12_01_2022To11_30_2023" id="ixv-47792">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P12_01_2022To11_30_2023" id="ixv-47793">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="P12_01_2022To11_30_2023" id="ixv-47794">false</dei:IcfrAuditorAttestationFlag>
    <dei:AuditorName contextRef="P12_01_2022To11_30_2023" id="ixv-47795">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P12_01_2022To11_30_2023" id="ixv-47796">Montreal, Quebec, Canada</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="P12_01_2022To11_30_2023" id="ixv-47797">85</dei:AuditorFirmId>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="P12_01_2022To11_30_2023" id="ixv-47798">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="P12_01_2022To11_30_2023" id="ixv-47799">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P12_01_2022To11_30_2023" id="ixv-47800">false</dei:EntityShellCompany>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="hidden101085993">Lower of lease term and economic life</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <dei:AmendmentFlag contextRef="P12_01_2022To11_30_2023" id="ixv-47804">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P12_01_2022To11_30_2023" id="ixv-47805">0001512717</dei:EntityCentralIndexKey>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="hidden101085991"
      unitRef="Unit_USD">14472000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47809"
      unitRef="Unit_USD">34097000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47810"
      unitRef="Unit_USD">23856000</ifrs-full:Cash>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47811"
      unitRef="Unit_USD">6290000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47812"
      unitRef="Unit_USD">9214000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47813"
      unitRef="Unit_USD">13023000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47814"
      unitRef="Unit_USD">12045000</ifrs-full:TradeAndOtherCurrentReceivables>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47815"
      unitRef="Unit_USD">524000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47816"
      unitRef="Unit_USD">299000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:IncomeTaxReceivableCurrent
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47817"
      unitRef="Unit_USD">4000</thtx:IncomeTaxReceivableCurrent>
    <thtx:IncomeTaxReceivableCurrent
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47818"
      unitRef="Unit_USD">0</thtx:IncomeTaxReceivableCurrent>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47819"
      unitRef="Unit_USD">29000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47820"
      unitRef="Unit_USD">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:InventoriesTotal
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47821"
      unitRef="Unit_USD">6066000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47822"
      unitRef="Unit_USD">19688000</ifrs-full:InventoriesTotal>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47823"
      unitRef="Unit_USD">3154000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47824"
      unitRef="Unit_USD">7665000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47825"
      unitRef="Unit_USD">110000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47826"
      unitRef="Unit_USD">603000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47827"
      unitRef="Unit_USD">63297000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47828"
      unitRef="Unit_USD">73370000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47829"
      unitRef="Unit_USD">1206000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47830"
      unitRef="Unit_USD">1494000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47831"
      unitRef="Unit_USD">770000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47832"
      unitRef="Unit_USD">1595000</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47833"
      unitRef="Unit_USD">12496000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47834"
      unitRef="Unit_USD">15009000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <thtx:DeferredFinancingCosts
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47835"
      unitRef="Unit_USD">0</thtx:DeferredFinancingCosts>
    <thtx:DeferredFinancingCosts
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47836"
      unitRef="Unit_USD">-1792000</thtx:DeferredFinancingCosts>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47837"
      unitRef="Unit_USD">19890000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47838"
      unitRef="Unit_USD">77769000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47839"
      unitRef="Unit_USD">93260000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47840"
      unitRef="Unit_USD">28471000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47841"
      unitRef="Unit_USD">41065000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47842"
      unitRef="Unit_USD">9603000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47843"
      unitRef="Unit_USD">7517000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47844"
      unitRef="Unit_USD">0</ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47845"
      unitRef="Unit_USD">26895000</ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <thtx:LoanFacilityCurrent
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47846"
      unitRef="Unit_USD">7286000</thtx:LoanFacilityCurrent>
    <thtx:LoanFacilityCurrent
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47847"
      unitRef="Unit_USD">37894000</thtx:LoanFacilityCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47848"
      unitRef="Unit_USD">421000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47849"
      unitRef="Unit_USD">476000</ifrs-full:CurrentLeaseLiabilities>
    <thtx:WarrantsCurrent
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47850"
      unitRef="Unit_USD">1475000</thtx:WarrantsCurrent>
    <thtx:WarrantsCurrent
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47851"
      unitRef="Unit_USD">0</thtx:WarrantsCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47852"
      unitRef="Unit_USD">0</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47853"
      unitRef="Unit_USD">394000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47854"
      unitRef="Unit_USD">38000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47855"
      unitRef="Unit_USD">38000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47856"
      unitRef="Unit_USD">47294000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47857"
      unitRef="Unit_USD">114279000</ifrs-full:CurrentLiabilities>
    <thtx:LoanFacilityNoncurrent
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47858"
      unitRef="Unit_USD">50688000</thtx:LoanFacilityNoncurrent>
    <thtx:LoanFacilityNoncurrent
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47859"
      unitRef="Unit_USD">0</thtx:LoanFacilityNoncurrent>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47860"
      unitRef="Unit_USD">573000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47861"
      unitRef="Unit_USD">1446000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47862"
      unitRef="Unit_USD">84000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47863"
      unitRef="Unit_USD">106000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47864"
      unitRef="Unit_USD">51345000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47865"
      unitRef="Unit_USD">1552000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47866"
      unitRef="Unit_USD">98639000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47867"
      unitRef="Unit_USD">115831000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47868"
      unitRef="Unit_USD">363927000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47869"
      unitRef="Unit_USD">338751000</ifrs-full:IssuedCapital>
    <ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47870"
      unitRef="Unit_USD">0</ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments>
    <ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47871"
      unitRef="Unit_USD">2132000</ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47872"
      unitRef="Unit_USD">23178000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47873"
      unitRef="Unit_USD">18810000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47874"
      unitRef="Unit_USD">-408659000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47875"
      unitRef="Unit_USD">-382649000</ifrs-full:RetainedEarnings>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47876"
      unitRef="Unit_USD">684000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47877"
      unitRef="Unit_USD">385000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47878"
      unitRef="Unit_USD">-20870000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47879"
      unitRef="Unit_USD">-22571000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-47880"
      unitRef="Unit_USD">77769000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-47881"
      unitRef="Unit_USD">93260000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47882"
      unitRef="Unit_USD">81764000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47883"
      unitRef="Unit_USD">80057000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47884"
      unitRef="Unit_USD">69823000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47885"
      unitRef="Unit_USD">19635000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47886"
      unitRef="Unit_USD">23838000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47887"
      unitRef="Unit_USD">18378000</ifrs-full:CostOfSales>
    <thtx:AmortizationOfOtherAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47888"
      unitRef="Unit_USD">0</thtx:AmortizationOfOtherAssets>
    <thtx:AmortizationOfOtherAssets
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47889"
      unitRef="Unit_USD">2441000</thtx:AmortizationOfOtherAssets>
    <thtx:AmortizationOfOtherAssets
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47890"
      unitRef="Unit_USD">4882000</thtx:AmortizationOfOtherAssets>
    <thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47891"
      unitRef="Unit_USD">539000</thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost>
    <thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47892"
      unitRef="Unit_USD">316000</thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost>
    <thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47893"
      unitRef="Unit_USD">277000</thtx:OtherComprehensiveIncomeNetOfTaxResearchAndDevelopmentCost>
    <thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47894"
      unitRef="Unit_USD">30370000</thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits>
    <thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47895"
      unitRef="Unit_USD">36939000</thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits>
    <thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47896"
      unitRef="Unit_USD">28274000</thtx:ResearchAndDevelopmentExpenseNetOfTaxCredits>
    <ifrs-full:SellingExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47897"
      unitRef="Unit_USD">26769000</ifrs-full:SellingExpense>
    <ifrs-full:SellingExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47898"
      unitRef="Unit_USD">39391000</ifrs-full:SellingExpense>
    <ifrs-full:SellingExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47899"
      unitRef="Unit_USD">28909000</ifrs-full:SellingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47900"
      unitRef="Unit_USD">15617000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47901"
      unitRef="Unit_USD">17356000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47902"
      unitRef="Unit_USD">14616000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47903"
      unitRef="Unit_USD">92391000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47904"
      unitRef="Unit_USD">119965000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47905"
      unitRef="Unit_USD">95059000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47906"
      unitRef="Unit_USD">-10627000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47907"
      unitRef="Unit_USD">-39908000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47908"
      unitRef="Unit_USD">-25236000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47909"
      unitRef="Unit_USD">2147000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47910"
      unitRef="Unit_USD">673000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47911"
      unitRef="Unit_USD">195000</ifrs-full:FinanceIncome>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47912"
      unitRef="Unit_USD">15056000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47913"
      unitRef="Unit_USD">7559000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47914"
      unitRef="Unit_USD">6621000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47915"
      unitRef="Unit_USD">-12909000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47916"
      unitRef="Unit_USD">-6886000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47917"
      unitRef="Unit_USD">-6426000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47918"
      unitRef="Unit_USD">-23536000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47919"
      unitRef="Unit_USD">-46794000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47920"
      unitRef="Unit_USD">-31662000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47921"
      unitRef="Unit_USD">421000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47922"
      unitRef="Unit_USD">443000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47923"
      unitRef="Unit_USD">63000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47924"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47925"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47926"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47927"
      unitRef="Unit_USD">299000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47928"
      unitRef="Unit_USD">-360000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47929"
      unitRef="Unit_USD">-197000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47930"
      unitRef="Unit_USD">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47931"
      unitRef="Unit_USD">789000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47932"
      unitRef="Unit_USD">634000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47933"
      unitRef="Unit_USD">299000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47934"
      unitRef="Unit_USD">429000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47935"
      unitRef="Unit_USD">437000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-47936"
      unitRef="Unit_USD">-23658000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47937"
      unitRef="Unit_USD">-46808000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47938"
      unitRef="Unit_USD">-31288000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P12_01_2022To11_30_2023"
      decimals="0"
      id="Fact_101087740"
      unitRef="Unit_USD_per_Share">-91</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P12_01_2022To11_30_2023"
      decimals="0"
      id="Fact_101087140"
      unitRef="Unit_USD_per_Share">-91</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P12_01_2021To11_30_2022"
      decimals="0"
      id="Fact_101087741"
      unitRef="Unit_USD_per_Share">-198</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P12_01_2021To11_30_2022"
      decimals="0"
      id="Fact_101086714"
      unitRef="Unit_USD_per_Share">-198</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P12_01_2020To11_30_2021"
      decimals="0"
      id="Fact_101087742"
      unitRef="Unit_USD_per_Share">-137</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P12_01_2020To11_30_2021"
      decimals="0"
      id="Fact_101086715"
      unitRef="Unit_USD_per_Share">-137</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086103"
      unitRef="Unit_shares">19253360</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47946"
      unitRef="Unit_USD">287312000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47947"
      unitRef="Unit_USD">4457000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47948"
      unitRef="Unit_USD">12065000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47949"
      unitRef="Unit_USD">-300129000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47950"
      unitRef="Unit_USD">-481000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2020"
      decimals="-3"
      id="ixv-47951"
      unitRef="Unit_USD">3224000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47952"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47953"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47954"
      unitRef="Unit_USD">-197000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47955"
      unitRef="Unit_USD">-197000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47956"
      unitRef="Unit_USD">634000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47957"
      unitRef="Unit_USD">634000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47958"
      unitRef="Unit_USD">-31725000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2020To11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47959"
      unitRef="Unit_USD">437000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47960"
      unitRef="Unit_USD">-31288000</ifrs-full:ComprehensiveIncome>
    <thtx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086808"
      unitRef="Unit_shares">4181975</thtx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47962"
      unitRef="Unit_USD">46002000</thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47963"
      unitRef="Unit_USD">46002000</thtx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47964"
      unitRef="Unit_USD">-3394000</thtx:ShareIssueCosts>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47965"
      unitRef="Unit_USD">-3394000</thtx:ShareIssueCosts>
    <thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086720"
      unitRef="Unit_shares">58350</thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares>
    <thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47967"
      unitRef="Unit_USD">742000</thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue>
    <thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47968"
      unitRef="Unit_USD">742000</thtx:IncreaseDecreaseThroughExerciseOfWarrantsEquityValue>
    <thtx:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086805"
      unitRef="Unit_shares">120482</thtx:StockIssuedDuringPeriodSharesAcquisitions>
    <thtx:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47970"
      unitRef="Unit_USD">668000</thtx:StockIssuedDuringPeriodValueAcquisitions>
    <thtx:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47971"
      unitRef="Unit_USD">-668000</thtx:StockIssuedDuringPeriodValueAcquisitions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47972"
      unitRef="Unit_USD">1879000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47973"
      unitRef="Unit_USD">1879000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086333"
      unitRef="Unit_shares">166250</thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsValue
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47975"
      unitRef="Unit_USD">595000</thtx:IncreaseDecreaseThroughExerciseOfOptionsValue>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsValue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47976"
      unitRef="Unit_USD">595000</thtx:IncreaseDecreaseThroughExerciseOfOptionsValue>
    <thtx:ExerciseOfStockOptionsAttributedValue
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47977"
      unitRef="Unit_USD">433000</thtx:ExerciseOfStockOptionsAttributedValue>
    <thtx:ExerciseOfStockOptionsAttributedValue
      contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47978"
      unitRef="Unit_USD">-433000</thtx:ExerciseOfStockOptionsAttributedValue>
    <thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086182"
      unitRef="Unit_shares">4527057</thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2020To11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47980"
      unitRef="Unit_USD">48440000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2020To11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47981"
      unitRef="Unit_USD">778000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2020To11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47982"
      unitRef="Unit_USD">-3394000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-47983"
      unitRef="Unit_USD">45824000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086183"
      unitRef="Unit_shares">23780417</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47985"
      unitRef="Unit_USD">335752000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47986"
      unitRef="Unit_USD">4457000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47987"
      unitRef="Unit_USD">12843000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47988"
      unitRef="Unit_USD">-335248000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47989"
      unitRef="Unit_USD">-44000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-47990"
      unitRef="Unit_USD">17760000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47991"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47992"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47993"
      unitRef="Unit_USD">-360000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47994"
      unitRef="Unit_USD">-360000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47995"
      unitRef="Unit_USD">789000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47996"
      unitRef="Unit_USD">789000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47997"
      unitRef="Unit_USD">-47237000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2021To11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-47998"
      unitRef="Unit_USD">429000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-47999"
      unitRef="Unit_USD">-46808000</ifrs-full:ComprehensiveIncome>
    <thtx:NumberOfSharesIssuedThroughAtmProgram
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086804"
      unitRef="Unit_shares">400000</thtx:NumberOfSharesIssuedThroughAtmProgram>
    <thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48001"
      unitRef="Unit_USD">2960000</thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue>
    <thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48002"
      unitRef="Unit_USD">2960000</thtx:IncreaseDecreaseThroughSharesIssuedAtmProgramValue>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48003"
      unitRef="Unit_USD">-164000</thtx:ShareIssueCosts>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48004"
      unitRef="Unit_USD">-164000</thtx:ShareIssueCosts>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48005"
      unitRef="Unit_USD">-2325000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48006"
      unitRef="Unit_USD">2125000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48007"
      unitRef="Unit_USD">-200000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48008"
      unitRef="Unit_USD">3860000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48009"
      unitRef="Unit_USD">3860000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086334"
      unitRef="Unit_shares">21165</thtx:IncreaseDecreaseThroughExerciseOfOptionsNumberOfShares>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsValue
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48011"
      unitRef="Unit_USD">21000</thtx:IncreaseDecreaseThroughExerciseOfOptionsValue>
    <thtx:IncreaseDecreaseThroughExerciseOfOptionsValue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48012"
      unitRef="Unit_USD">21000</thtx:IncreaseDecreaseThroughExerciseOfOptionsValue>
    <thtx:ExerciseOfStockOptionsAttributedValue
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48013"
      unitRef="Unit_USD">18000</thtx:ExerciseOfStockOptionsAttributedValue>
    <thtx:ExerciseOfStockOptionsAttributedValue
      contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48014"
      unitRef="Unit_USD">-18000</thtx:ExerciseOfStockOptionsAttributedValue>
    <thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086181"
      unitRef="Unit_shares">421165</thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2021To11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48016"
      unitRef="Unit_USD">2999000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2021To11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48017"
      unitRef="Unit_USD">-2325000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2021To11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48018"
      unitRef="Unit_USD">5967000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2021To11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48019"
      unitRef="Unit_USD">-164000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48020"
      unitRef="Unit_USD">6477000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086184"
      unitRef="Unit_shares">24201582</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48022"
      unitRef="Unit_USD">338751000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48023"
      unitRef="Unit_USD">2132000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48024"
      unitRef="Unit_USD">18810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48025"
      unitRef="Unit_USD">-382649000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48026"
      unitRef="Unit_USD">385000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48027"
      unitRef="Unit_USD">-22571000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086174"
      unitRef="Unit_shares">24201582</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48029"
      unitRef="Unit_USD">338751000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48030"
      unitRef="Unit_USD">2132000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48031"
      unitRef="Unit_USD">18810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48032"
      unitRef="Unit_USD">-382649000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48033"
      unitRef="Unit_USD">385000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48034"
      unitRef="Unit_USD">-22571000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48035"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48036"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48037"
      unitRef="Unit_USD">299000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48038"
      unitRef="Unit_USD">299000</ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48039"
      unitRef="Unit_USD">-23957000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2022To11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48040"
      unitRef="Unit_USD">299000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48041"
      unitRef="Unit_USD">-23658000</ifrs-full:ComprehensiveIncome>
    <thtx:StockIssuedDuringThePeriodSharesNewIssues
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086792"
      unitRef="Unit_shares">21778184</thtx:StockIssuedDuringThePeriodSharesNewIssues>
    <thtx:StockIssuedDuringThePeriodValueNewIssues
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48043"
      unitRef="Unit_USD">25160000</thtx:StockIssuedDuringThePeriodValueNewIssues>
    <thtx:StockIssuedDuringThePeriodValueNewIssues
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48044"
      unitRef="Unit_USD">25160000</thtx:StockIssuedDuringThePeriodValueNewIssues>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48045"
      unitRef="Unit_USD">-2053000</thtx:ShareIssueCosts>
    <thtx:ShareIssueCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48046"
      unitRef="Unit_USD">-2053000</thtx:ShareIssueCosts>
    <thtx:StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086796"
      unitRef="Unit_shares">253</thtx:StockIssuedDuringThePeriodSharesConversionOfConvertibleSecurities>
    <thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48048"
      unitRef="Unit_USD">16000</thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities>
    <thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities
      contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48049"
      unitRef="Unit_USD">-1000</thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities>
    <thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48050"
      unitRef="Unit_USD">15000</thtx:StockIssuedDuringThePeriodValueConversionOfConvertibleSecurities>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48051"
      unitRef="Unit_USD">-2131000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48052"
      unitRef="Unit_USD">2131000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48053"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48054"
      unitRef="Unit_USD">2237000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48055"
      unitRef="Unit_USD">2237000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101085989"
      unitRef="Unit_shares">21778437</thtx:IncreaseDecreaseThroughTransactionsWithOwnersNumberOfShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2022To11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48057"
      unitRef="Unit_USD">25176000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2022To11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48058"
      unitRef="Unit_USD">-2132000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2022To11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48059"
      unitRef="Unit_USD">4368000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2022To11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48060"
      unitRef="Unit_USD">-2053000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48061"
      unitRef="Unit_USD">25359000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="INF"
      id="Fact_101086852"
      unitRef="Unit_shares">45980019</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48063"
      unitRef="Unit_USD">363927000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023_ReserveOfEquityComponentOfConvertibleInstrumentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48064"
      unitRef="Unit_USD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023_AdditionalPaidinCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48065"
      unitRef="Unit_USD">23178000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48066"
      unitRef="Unit_USD">-408659000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023_AccumulatedOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-48067"
      unitRef="Unit_USD">684000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48068"
      unitRef="Unit_USD">-20870000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48069"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48070"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086251"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48072"
      unitRef="Unit_USD">450000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48073"
      unitRef="Unit_USD">390000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086296"
      unitRef="Unit_USD">237000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48075"
      unitRef="Unit_USD">2513000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48076"
      unitRef="Unit_USD">11652000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086292"
      unitRef="Unit_USD">8062000</ifrs-full:AdjustmentsForAmortisationExpense>
    <thtx:AdjustmentsForAmortizationOfRightofuseAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48078"
      unitRef="Unit_USD">352000</thtx:AdjustmentsForAmortizationOfRightofuseAssets>
    <thtx:AdjustmentsForAmortizationOfRightofuseAssets
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48079"
      unitRef="Unit_USD">429000</thtx:AdjustmentsForAmortizationOfRightofuseAssets>
    <thtx:AdjustmentsForAmortizationOfRightofuseAssets
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085733"
      unitRef="Unit_USD">449000</thtx:AdjustmentsForAmortizationOfRightofuseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48081"
      unitRef="Unit_USD">2215000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48082"
      unitRef="Unit_USD">3872000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087549"
      unitRef="Unit_USD">1932000</ifrs-full:AdjustmentsForSharebasedPayments>
    <thtx:GainLossOnLeaseTermination
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48084"
      unitRef="Unit_USD">121000</thtx:GainLossOnLeaseTermination>
    <thtx:GainLossOnLeaseTermination
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086777"
      unitRef="Unit_USD">0</thtx:GainLossOnLeaseTermination>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48086"
      unitRef="Unit_USD">492000</ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48087"
      unitRef="Unit_USD">217000</ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087547"
      unitRef="Unit_USD">-212000</ifrs-full:AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48089"
      unitRef="Unit_USD">-224000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48090"
      unitRef="Unit_USD">-221000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087543"
      unitRef="Unit_USD">209000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48092"
      unitRef="Unit_USD">-8263000</thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan>
    <thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48093"
      unitRef="Unit_USD">-4357000</thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan>
    <thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087540"
      unitRef="Unit_USD">-3306000</thtx:InterestOnConvertibleUnsecuredSeniorNotesAndLongTermLoan>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48095"
      unitRef="Unit_USD">8812000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48096"
      unitRef="Unit_USD">4634000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086768"
      unitRef="Unit_USD">3306000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48098"
      unitRef="Unit_USD">769000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48099"
      unitRef="Unit_USD">316000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:AdjustmentsForInterestIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085731"
      unitRef="Unit_USD">195000</ifrs-full:AdjustmentsForInterestIncome>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48101"
      unitRef="Unit_USD">865000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48102"
      unitRef="Unit_USD">456000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086772"
      unitRef="Unit_USD">282000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48104"
      unitRef="Unit_USD">421000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48105"
      unitRef="Unit_USD">443000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086762"
      unitRef="Unit_USD">63000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48107"
      unitRef="Unit_USD">848000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48108"
      unitRef="Unit_USD">109000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086766"
      unitRef="Unit_USD">19000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48110"
      unitRef="Unit_USD">282000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48111"
      unitRef="Unit_USD">1209000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085290"
      unitRef="Unit_USD">890000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48113"
      unitRef="Unit_USD">0</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48114"
      unitRef="Unit_USD">357000</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48115"
      unitRef="Unit_USD">2098000</thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48116"
      unitRef="Unit_USD">2140000</thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087538"
      unitRef="Unit_USD">2358000</thtx:AdjustmentsForAccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48118"
      unitRef="Unit_USD">1525000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <thtx:GainLossOnLoanFacilityModifications
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48119"
      unitRef="Unit_USD">-3540000</thtx:GainLossOnLoanFacilityModifications>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48120"
      unitRef="Unit_USD">954000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48121"
      unitRef="Unit_USD">-13811000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48122"
      unitRef="Unit_USD">-27709000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085289"
      unitRef="Unit_USD">-17669000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48124"
      unitRef="Unit_USD">-902000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48125"
      unitRef="Unit_USD">-1669000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087880"
      unitRef="Unit_USD">1852000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <thtx:AdjustmentsForTaxCreditsAndGrantsReceivable
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48127"
      unitRef="Unit_USD">-215000</thtx:AdjustmentsForTaxCreditsAndGrantsReceivable>
    <thtx:AdjustmentsForTaxCreditsAndGrantsReceivable
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48128"
      unitRef="Unit_USD">126000</thtx:AdjustmentsForTaxCreditsAndGrantsReceivable>
    <thtx:AdjustmentsForTaxCreditsAndGrantsReceivable
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085737"
      unitRef="Unit_USD">323000</thtx:AdjustmentsForTaxCreditsAndGrantsReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48130"
      unitRef="Unit_USD">10327000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48131"
      unitRef="Unit_USD">8991000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087877"
      unitRef="Unit_USD">-4217000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48133"
      unitRef="Unit_USD">4511000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48134"
      unitRef="Unit_USD">3058000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087873"
      unitRef="Unit_USD">-5569000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48136"
      unitRef="Unit_USD">-7508000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48137"
      unitRef="Unit_USD">-1100000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087871"
      unitRef="Unit_USD">5549000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48139"
      unitRef="Unit_USD">1920000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48140"
      unitRef="Unit_USD">3627000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086288"
      unitRef="Unit_USD">2226000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48142"
      unitRef="Unit_USD">0</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48143"
      unitRef="Unit_USD">-16000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085727"
      unitRef="Unit_USD">4000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48145"
      unitRef="Unit_USD">-8133000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48146"
      unitRef="Unit_USD">-13017000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086287"
      unitRef="Unit_USD">-168000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48148"
      unitRef="Unit_USD">-5678000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48149"
      unitRef="Unit_USD">-14692000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086282"
      unitRef="Unit_USD">-17501000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48151"
      unitRef="Unit_USD">27452000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48152"
      unitRef="Unit_USD">28746000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48153"
      unitRef="Unit_USD">0</thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48154"
      unitRef="Unit_USD">73000</thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48155"
      unitRef="Unit_USD">20000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48156"
      unitRef="Unit_USD">40000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:PaymentsForDebtIssueCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48157"
      unitRef="Unit_USD">700000</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:PaymentsForDebtIssueCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48158"
      unitRef="Unit_USD">2285000</ifrs-full:PaymentsForDebtIssueCosts>
    <thtx:RepaymentOfOtherObligations
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48159"
      unitRef="Unit_USD">0</thtx:RepaymentOfOtherObligations>
    <thtx:RepaymentOfOtherObligations
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48160"
      unitRef="Unit_USD">0</thtx:RepaymentOfOtherObligations>
    <thtx:RepaymentOfOtherObligations
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086774"
      unitRef="Unit_USD">5000000</thtx:RepaymentOfOtherObligations>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48162"
      unitRef="Unit_USD">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48163"
      unitRef="Unit_USD">21000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086281"
      unitRef="Unit_USD">595000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48165"
      unitRef="Unit_USD">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48166"
      unitRef="Unit_USD">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086784"
      unitRef="Unit_USD">742000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <thtx:ProceedsFromIssuingSharesAndWarrants
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48168"
      unitRef="Unit_USD">25160000</thtx:ProceedsFromIssuingSharesAndWarrants>
    <thtx:ProceedsFromIssuingSharesAndWarrants
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48169"
      unitRef="Unit_USD">2960000</thtx:ProceedsFromIssuingSharesAndWarrants>
    <thtx:ProceedsFromIssuingSharesAndWarrants
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086781"
      unitRef="Unit_USD">46002000</thtx:ProceedsFromIssuingSharesAndWarrants>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48171"
      unitRef="Unit_USD">1585000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48172"
      unitRef="Unit_USD">89000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087746"
      unitRef="Unit_USD">3394000</ifrs-full:PaymentsForShareIssueCosts>
    <thtx:AdjustmentsForDeferredFinancingCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48174"
      unitRef="Unit_USD">-196000</thtx:AdjustmentsForDeferredFinancingCosts>
    <thtx:AdjustmentsForDeferredFinancingCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48175"
      unitRef="Unit_USD">-1527000</thtx:AdjustmentsForDeferredFinancingCosts>
    <thtx:AdjustmentsForDeferredFinancingCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087749"
      unitRef="Unit_USD">-447000</thtx:AdjustmentsForDeferredFinancingCosts>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48177"
      unitRef="Unit_USD">452000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48178"
      unitRef="Unit_USD">605000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085739"
      unitRef="Unit_USD">635000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48180"
      unitRef="Unit_USD">14775000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48181"
      unitRef="Unit_USD">9656000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087616"
      unitRef="Unit_USD">37863000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48183"
      unitRef="Unit_USD">1500000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48184"
      unitRef="Unit_USD">0</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087614"
      unitRef="Unit_USD">39000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48186"
      unitRef="Unit_USD">318000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48187"
      unitRef="Unit_USD">985000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085752"
      unitRef="Unit_USD">127000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48189"
      unitRef="Unit_USD">3030000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48190"
      unitRef="Unit_USD">9906000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085748"
      unitRef="Unit_USD">640000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48192"
      unitRef="Unit_USD">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48193"
      unitRef="Unit_USD">239000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101085746"
      unitRef="Unit_USD">13210000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <thtx:PaymentsToAcquireDerivativeFinancialAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48195"
      unitRef="Unit_USD">104000</thtx:PaymentsToAcquireDerivativeFinancialAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48196"
      unitRef="Unit_USD">1108000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48197"
      unitRef="Unit_USD">8682000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101086122"
      unitRef="Unit_USD">-12736000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48199"
      unitRef="Unit_USD">10205000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48200"
      unitRef="Unit_USD">3646000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087870"
      unitRef="Unit_USD">7626000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48202"
      unitRef="Unit_USD">23856000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48203"
      unitRef="Unit_USD">20399000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2020"
      decimals="-3"
      id="Fact_101087866"
      unitRef="Unit_USD">12737000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48205"
      unitRef="Unit_USD">36000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48206"
      unitRef="Unit_USD">-189000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="Fact_101087865"
      unitRef="Unit_USD">36000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48208"
      unitRef="Unit_USD">34097000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48209"
      unitRef="Unit_USD">23856000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="Fact_101087860"
      unitRef="Unit_USD">20399000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-24687">&lt;div style="text-align: justify; font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Basis of preparation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;19, 2023, the Board of Directors approved a consolidation of the issued and outstanding common shares (the &#x201c;Common Shares&#x201d;) on the basis of one for four &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1-for-4)&lt;/div&gt;&lt;/div&gt; common shares (the &#x201c;Consolidation&#x201d;) effective July&#160;31, 2023. All references in these Financial Statements to the number of common shares, Public Offering Warrants (as defined in Note 20(a)), Marathon Warrants (as defined in Note 20(c)), Options (as defined in Note 20(h)), weighted average number of common shares, basic and diluted loss per share and the exercise prices of the Public Offering Warrants, Marathon Warrants and Options have been retrospectively adjusted and restated to reflect the effect of the Consolidation for all periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statement of compliance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These Financial Statements were authorized for issue by the Board of Directors on February&#160;20,&#160;2024. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Going concern uncertainty &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the preparation of these Financial Statements, management is responsible for identifying any event or situation that may cast doubt on the Company&#x2019;s ability to continue as a going concern. Substantial doubt regarding the Company&#x2019;s ability to continue as a going concern exists if events or conditions, considered collectively, indicate that the Company may be unable to honor its obligations as they fall due during a period of at least, but not limited to, 12 months from November&#160;30, 2023. If the Company concludes that events or conditions cast substantial doubt on its ability to continue as a going concern, it must assess whether the plans developed to mitigate these events or conditions will remove any possible substantial doubt. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;For the year ended November&#160;30, 2023, the Company incurred a net loss of $23,957 (2022-$47,237&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;; 2021-$31,725&lt;/div&gt;) and had negative cash &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;flows&lt;/div&gt; from operating activities of $5,678 (2022- &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;14,692&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;; 2021- $17,501&lt;/div&gt;). As at November&#160;30, 2023, cash amounted to $34,097 and bonds and money market funds amounted to $6,290.&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Loan Facility contains various covenants, including minimum liquidity covenants whereby the Company needs to maintain significant cash, cash equivalent and eligible short-term investments balances in specified accounts, which restricts the management of the Company&#x2019;s liquidity (refer to Note 17). A breach of the liquidity covenant (a &#x201c;Liquidity Breach&#x201d;) provides the lender with the ability to demand immediate repayment of the Loan Facility and makes available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements, and may trigger an increase of&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;300 basis points&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the interest rate on the outstanding loan balance. On July 3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt, which breach was waived on September 21, 2023. During fiscal 2023, the Company entered into several amendments to the Marathon Credit Agreement to amend certain of the terms and conditions therein (see note 17).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The amendments to the Marathon Credit Agreement resulted in: (i)&#160;revising the minimum liquidity requirements for all times following October&#160;31, 2023 to be between&lt;/div&gt;&lt;/div&gt; $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,000&lt;/div&gt; and $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,000&lt;/div&gt;, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;ased on the Marathon adjusted EBITDA (as defined in the Marathon Credit Agreement, the &#x201c;Marathon Adjusted EBITDA&#x201d;) targets over the most recently ended four fiscal quarters; (ii)&#160;deleting the quarterly minimum revenue targets and replacing them with Marathon Adjusted EBITDA targets, beginning with the quarter ending November&#160;30, 2023; and (iii)&#160;deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies the Company&#x2019;s annual report. Notwithstanding these amendments, there is no assurance that the lender will agree to amend or to waive any future potential covenant breaches, if any. The Company does not meet the condition precedents to drawdown additional amounts under the Marathon Credit Agreement and does not currently have other committed sources of financing available to i&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;t.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s ability to continue as a going concern for a period of at least, but not limited to, 12 months from November&#160;30, 2023, involves significant judgement and is dependent on the adherence to the conditions of the Marathon Credit Agreement or to obtain the support of the lender (including possible waivers and amendments, if necessary), increase its revenues and the management of its expenses (including the reorganization mainly focused on its R&amp;amp;D activities-see Note 16(a)) in order to meet or exceed the Marathon Adjusted EBITDA target and generate sufficient positive operating cash flows. Some elements of management&#x2019;s plans are outside of management&#x2019;s control and the outcome cannot be predicted at this time. Should management&#x2019;s plans not materialize, the Company may be in default under the Marathon Credit Agreement, be forced to reduce or delay expenditures and capital additions and seek additional alternative financing, or sell or liquidate its assets. As a result, there is material uncertainty related to events or conditions that cast substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 16pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These Financial Statements have been prepared assuming the Company will continue as a going concern, which assumes the Company will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. These Financial Statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that might result from the outcome of this uncertainty and that may be necessary if the going concern basis was not appropriate for these Financial Statements. If the Company was unable to continue as a going concern, material impairment of the carrying values of the Company&#x2019;s assets, including intangible assets, could be required. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Financial Statements have been prepared on a going concern and historical cost basis, except for: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;bonds and money market funds, which are measured at fair value, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;derivative financial assets, which are measured at fair value, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;liabilities related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-settled&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; arrangements and derivative financial liabilities, which are measured at fair value, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;lease liabilities which are measured at present value of lease payments not paid at commencement date, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity-classified&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; payment arrangements are measured at fair value at the grant date pursuant to IFRS&#160;2, &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-based&lt;/div&gt; Payment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The methods used to measure fair value are discussed further in Note 25. &lt;/div&gt; &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Functional and presentation currency &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The Company&#x2019;s functional currency is the United States dollar (&#x201c;USD&#x201d;). &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;All financial information presented in USD has been rounded to the nearest thousand. &lt;/div&gt; &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of estimates and judgments &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the Company&#x2019;s Financial Statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Judgments in applying accounting policies &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information about critical judgments in applying accounting policies and assumptions that have the most significant effect on the amounts recognized in the Financial Statements is noted below. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestones payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The purchase consideration for the oncology platform (Note 13) includes additional milestone payments based on the attainment of commercial milestones that will be settled through the issuance of the Company&#x2019;s common shares, which represent a transaction in the scope of IFRS 2. Accordingly, the fair value of the oncology platform at the date of acquisition incorporates management&#x2019;s judgement as to the probability of attaining the share-based milestones as well as the expected timing of the attainment of the milestones. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Management uses judgement in determining whether milestone payments are performance-related development milestones which are capitalized as an intangible asset or are milestones related to the activity or usage of an asset which are expensed. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Key sources of estimation uncertainty &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are as follows: &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales allowances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Management uses judgment in estimating provisions for sale allowances such as cash discounts, returns, rebates and chargebacks, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation. The product revenue recognized quarter over quarter is net of these estimated allowances. Such estimates require the need to make estimates about matters that are inherently uncertain. These estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends such as competitive pricing and new product introductions, estimated inventory levels, and the shelf life of products. If actual future results vary, these estimates need to be adjusted, with an effect on sales and earnings in the period of the adjustment. (refer to Notes 2 &#x201c;Revenue recognition&#x201d; and 3 for additional information). &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recoverability of inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The Company regularly reviews inventory to determine whether the inventory cost exceeds its net realizable value. The determination of the net realizable value requires management to make estimates and use judgement in considering shelf life of a product, the effects of technological changes and new product introductions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:Calibri;text-align:justify"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other areas of judgment and uncertainty are related to the estimation of accruals for clinical trial expenses, the recoverability of intangible assets, the measurement of derivative financial assets, the measurement of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; arrangements, the Marathon Warrants and gain or loss on amendments to the Marathon Credit Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company is subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. Management regularly evaluates estimates and assumptions using historical experience and expectations about the future. Management adjusts estimates and assumptions when facts and circumstances indicate the need for change. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. &lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48211"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48212"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48213"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48214"
      unitRef="Unit_USD">-5678000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48215"
      unitRef="Unit_USD">-14692000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48216"
      unitRef="Unit_USD">-17501000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48217"
      unitRef="Unit_USD">34097000</ifrs-full:Cash>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48218"
      unitRef="Unit_USD">6290000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P12_01_2022To11_30_2023" id="ixv-48219">300 basis points</ifrs-full:BorrowingsInterestRateBasis>
    <thtx:MinimumLiquidityRequirementAmount
      contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48220"
      unitRef="Unit_USD">15000000</thtx:MinimumLiquidityRequirementAmount>
    <thtx:MinimumLiquidityRequirementAmount
      contextRef="P12_01_2022To11_30_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48221"
      unitRef="Unit_USD">20000000</thtx:MinimumLiquidityRequirementAmount>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25123">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The accounting policies have been applied consistently by the Company, except as otherwise noted for the initial application of new or amended accounting standards. &lt;/div&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of consolidation &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements of the subsidiaries of the Company are included in these Financial Statements from the date on which control commences until the date on which control ceases. Subsidiaries are entities controlled by the Company. Control is present where the Company has the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable are taken into consideration. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany balances and transactions, revenues and expenses resulting from transactions between subsidiaries and with the Company are eliminated in preparing the Financial Statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign currencies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Transactions in foreign currencies are translated to the functional currency at exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate in effect at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the reporting year, adjusted for effective interest and payments during the reporting year, and the amortized cost in foreign currency translated at the exchange rate in effect at the end of the reporting year. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate in effect at the date on which the fair value was determined. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; items that are measured at historical cost in a foreign currency are translated using the exchange rate in effect at the date of the transaction. Foreign currency differences arising on translation are recognized in net profit, except for differences arising on the translation of FVOCI financial instruments, which are recognized in other comprehensive income (loss). &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign operations &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The assets and liabilities of foreign operations whose functional currency is not the US$ are translated into US$ at the reporting date. The income and expenses of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;foreign-currency&lt;/div&gt; denominated operations are translated at average rates for each reporting period. Foreign exchange differences arising on the translation of foreign operations are recognized directly in other comprehensive income (loss). When a foreign subsidiary is disposed of, the cumulative amount recognized in the currency translative reserve forms part of the gain or loss on disposal. &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Revenue from contracts with customers &#x2013; Net sales &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;The Company derives revenue from the sales of finished goods, which include Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;and &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;. The Company recognizes revenue at a point in time when it transfers title of the finished goods to a customer, which generally occurs upon delivery of the finished goods to the customer&#x2019;s premises. Payment received from customers prior to the transfer of control of the goods is recorded as deferred revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Some arrangements for the sale of finished goods provide for customer cash discounts for prompt payment, allowances, rights of return, rebates on sales made under governmental and commercial rebate programs, chargebacks on sales made to government agencies and retail pharmacies and distribution fees, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation which gives rise to variable consideration. At the time of sale, estimates are made for items giving rise to variable consideration based on the terms of the arrangement. The variable consideration is estimated at contract inception using the most likely amount method and revenue is only recognized to the extent that a significant reversal of revenue is not expected to occur. The estimate is based on historical experience, current trends, contractual terms with distributors and other known factors. Sales are recorded net of customer discounts, rebates, chargebacks, distribution fees and estimated sales returns, and exclude sales taxes. A refund liability and a right to recover returned goods asset are recognized for expected returns in relation to sales made before the end of the reporting period. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of variable consideration, including expected returns, on a quarterly basis, adjusting for the amounts of the asset and liability accordingly. &lt;/div&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of sales &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Cost of goods sold &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Cost of goods sold includes the cost of raw materials, supplies, direct labour and overhead charges allocated to goods sold as well as write-downs of inventories. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Amortization of the other asset &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;The amortization of the other asset related to the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14). &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee benefits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Salaries and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; employee benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Salaries and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;profit-sharing&lt;/div&gt; or cash bonus plans if the Company has a legal or constructive obligation to pay an amount as a result of past services rendered by an employee and the obligation can be estimated reliably. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits include a defined contribution plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense when due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available. The Company&#x2019;s defined contribution plan comprises the registered retirement savings plan, the Quebec Pension Plan and employment insurance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Termination benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Termination benefits are recognized as an expense when the Company is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income and finance costs &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Finance income comprises interest income on financial assets and gains on the disposal of financial assets and financial liabilities. Interest income is recognized as it accrues in net loss using the effective interest method. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs comprise bank charges, interest and accretion expense on lease liabilities, convertible unsecured senior notes, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; loans and obligations and deferred financing costs, impairment losses on financial assets recognized in net loss, changes in fair value of liabilities and derivatives, unrealized foreign currency gain or loss on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; obligations, loss on long-term obligations modifications and other foreign currency gains and losses which are reported on a net basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Inventories are presented at the lower of cost, determined using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; method, and net realizable value. Inventory costs include the purchase price and other costs directly related to the acquisition of materials and other costs incurred in bringing the inventories to their present location and condition. The Company is responsible for coordinating the production and stability testing and for auditing suppliers at different times during the manufacturing process. Inventory costs also include the costs directly related to the conversion of materials into finished goods. Net realizable value is the estimated selling price in the Company&#x2019;s ordinary course of business less the estimated costs of completion and selling expenses. In determining whether the inventory cost exceeds its net realizable value for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-launch&lt;/div&gt; inventory, the Company considers whether there is a high probability of regulatory approval for the product. In making that determination, the Company considers prior history with approvals of similar products, estimated timing of obtaining regulatory approval, regulatory agencies correspondence regarding safety and efficacy of the product and current market factors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Work in progress inventory appears from the moment third party suppliers use the material provided by the Company until the time the Company receives the finished product. The value of work in progress inventory is equal to the value of material provided by the Company plus all conversion work performed by third party suppliers. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Recognition and measurement &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Items of property and equipment are recognized at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and the costs of dismantling and removing the item and restoring the site on which it is located, if any. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment and are recognized in net profit or loss. &lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Subsequent costs &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;day-to-day&lt;/div&gt;&lt;/div&gt; servicing of items of property and equipment are recognized in net profit or loss as incurred. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Depreciation &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The methods of depreciation and depreciation rates and periods are as follows: &lt;/div&gt;&lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 46%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 20%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 28%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Method&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate/period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;50%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20% 5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;Straight-line&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden101085993;display:inline;"&gt;Lower of lease term&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;and economic life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The method of depreciation is selected based on the most closely expected pattern of consumption of the future economic benefits embodied in the asset. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Estimates for depreciation methods, useful lives and residual values are reviewed at each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; and adjusted if appropriate. &lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Research and development &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. A development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset. These criteria are usually met when a regulatory filing has been made in a major market and approval is considered highly probable. The expenditure capitalized includes the cost of materials, direct labour, and overhead costs that are directly attributable to preparing the asset for its intended use. Other development &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;expenditures are expensed as incurred. Capitalized development expenditures are measured at cost, less accumulated amortization and accumulated impairment losses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;During the years ended November&#160;30, 2023, 2022 and 2021, no development expenditures were capitalized. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; advance payments for good and services that will be used in future research and development activities are expenses when the activity has been performed rather than when the payment is made. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Commercialization rights and oncology platform &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercialization rights and the oncology platform acquired by the Company have finite useful lives and are measured at cost less accumulated amortization and any accumulated impairment losses. Commercialization rights&#160;&#x2013; &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; &#x2013; are amortized at fixed rates based on their estimated useful life of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;111&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;&#160;months on a &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt; text-wrap: nowrap; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Commercialization rights&#160;&#x2013; Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; North American Territory &#x2013; are amortized at fixed rates based on their estimated useful life of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;142&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;months on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis. Commercialization rights &#x2013; Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;European Territory &#x2013; were amortized at fixed rates based on their estimated useful life of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;148&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;months on a straight-line basis. They were fully amortized during the year ended November&#160;30, 2022. Refer to Note 13. Commercialization rights&#160;for the oncology platform will be amortized over the estimated useful life on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis when the asset is available for use. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The amortization method and useful life of intangible assets are reviewed every year and adjusted as required. &lt;/div&gt;  &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset acquisitions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Asset acquisitions are acquisitions that do not qualify as business combinations. At the date of acquisition, the Company initially recognizes the individual identifiable assets acquired and liabilities assumed. The cost to the Company at the date of the acquisition is allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of the acquisition. Subsequent consideration for performance-related development milestones is recognized as intangible assets when the specific milestones have been achieved and other recognition criteria are met. Subsequent payments related to activity or usage of an asset, including sales royalties, are expensed as incurred. Asset acquisition transactions do not give rise to goodwill. &lt;/div&gt;  &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other asset &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Other asset, which comprised the amount disbursed in connection with the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14), was amortized over its estimated useful life of&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;48&#160;months. Other asset was fully amortized during the year ended November&#160;30, 2022. &lt;/div&gt;  &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The carrying amounts of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated. &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows from other assets or groups of assets (&#x201c;Cash-Generating Unit&#x201d;). The recoverable amount of an asset or a Cash-Generating Unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the Cash-Generating Unit. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Impairment losses recognized in prior years are determined by the Company at each reporting date for any indications that the loss has decreased or no longer exists. An asset&#x2019;s carrying amount, increased through the reversal of an impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company initially recognizes financial assets on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value through profit or loss, then the initial measurement includes transaction costs that are directly attributable to the asset&#x2019;s acquisition or issue. On initial recognition, the Company classifies its financial assets as measured at amortized cost, FVOCI or fair value through profit or loss (&#x201c;FVPL&#x201d;), depending on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;(i) Financial assets measured at amortized cost &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial;text-align:justify"&gt;A financial asset is measured at amortized cost, using the effective interest method and net of any impairment loss, if it meets both of the following conditions and is not designated at fair value though profit or loss: &lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;it is held within a business model whose objective is to hold assets to collect contractual cash flows;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial"&gt;The Company currently classifies its cash and trade and other receivables as financial assets measured at amortized cost. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;(ii) Financial assets, measured at fair value through other comprehensive income &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial"&gt;A debt investment is measured at fair value through other comprehensive income if it meets both of the following conditions and is not designated at fair value through profit or loss: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(ii) Financial assets, measured at fair value through other comprehensive income (continued) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in other comprehensive income (loss). When an investment is derecognized, gains or losses accumulated in other comprehensive income (loss) are reclassified to profit or loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment&#x2019;s fair value in other comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;This election is made on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;investment-by-investment&lt;/div&gt;&lt;/div&gt; basis. These assets are subsequently measured at fair value. Dividends are recognized in profit or loss, unless the dividend clearly represents a repayment of part of the cost of the investment, and other net gains and losses are recognized in other comprehensive income (loss) and are never reclassified in profit or loss. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently classifies its bonds as financial assets measured at FVOCI. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iii) Financial assets measured at fair value through profit or loss &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;All financial assets not classified as measured at amortized cost or FVOCI as described above are measured at FVPL. These assets are subsequently measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss. The Company currently classifies its money market funds and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-hedge&lt;/div&gt; derivative financial assets as financial assets measured at FVPL. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are&#160;transferred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv) Financial liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities are classified into the following categories: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at fair value through profit or loss &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;A financial liability is classified at fair value through profit or loss if it is classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-for-trading,&lt;/div&gt;&lt;/div&gt; it is a derivative or it is designated as such on initial recognition. Financial liabilities at fair value are measured at fair value and net gains and losses, including interest expense, are recognized in profit or loss. &lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company issued the Marathon Warrants which are classified as financial liabilities through profit or loss because the exercise can be made on a cashless basis. All transaction costs related to financial instruments designated at fair value through profit or loss are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently has no other financial liabilities measured at FVPL. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities measured at amortized cost &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This category includes all financial liabilities, other than those measured at FVPL. A financial liability is subsequently measured at amortized cost using the effective interest method. The Company currently classifies accounts payable and accrued liabilities, convertible unsecured senior notes and Loan Facility as financial liabilities measured at amortized cost. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(v) Compound financial instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compound financial instruments are instruments that contain both a liability component and an equity component, and the liability component can be converted into share capital at the option of the holder and the number of shares to be issued does not vary with changes in their fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversation option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Upon repurchase, the proceeds are allocated based on the same basis that was used for the initial recognition. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(vi) Derivative financial instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments are recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. The changes in the fair value of derivatives are recognized through profit or loss in the year in which they occur.&lt;/div&gt; &lt;/div&gt;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(vii) Offsetting of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position when, and only when, the Company has a legal right to set off the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At each reporting date, the Company recognizes loss allowances for expected credit losses (&#x201c;ECLs&#x201d;) on financial assets carried at amortized cost and debt securities at FVOCI. The Company&#x2019;s trade and other receivables are accounts receivable with no financing component and which have maturities of less than 12 months and, as such, the Company has chosen to apply the simplified approach for ECL. As a result, the Company does not track changes in credit risk related to its trade and other receivables, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(viii) Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For other financial assets subject to impairment, the Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECLs: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;debt securities that are determined to have low credit risk at the reporting date; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers a debt security to have a low credit risk when its credit risk rating is equivalent or above investment grade credit rating, such as its bonds classified at FVOCI. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s approach to ECLs reflects a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;probability-weighted&lt;/div&gt; outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;economic &lt;/div&gt;conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At inception, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability at the commencement date of the lease, i.e. the date the underlying asset is available for use. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are measured at cost, less any accumulated amortization and accumulated impairment losses, and adjusted for remeasurement of lease liabilities. Cost of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets comprises: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the initial measurement amount of the lease liabilities recognized; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any lease payments made at or before the commencement date, less any lease incentives received; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any initial direct costs incurred; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;an estimate of costs to dismantle and remove the underlying asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease contract. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are amortized on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis over the lesser of (i)&#160;the estimated useful life of the underlying assets; and (ii)&#160;the lease term. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are assessed for impairment whenever there is an indication that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets may be impaired. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date over the lease term. The present value of the lease payments is determined using the lessee&#x2019;s incremental borrowing rate at the commencement date if the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is a function of the lessee&#x2019;s incremental borrowing rate, the nature of the underlying asset, the location of the asset, the length of the lease and the currency of the lease contract. Generally, the Company uses the lessee&#x2019;s incremental borrowing rate for the present value. At the commencement date, lease payments generally include fixed payments, less any lease incentives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;receivable, variable lease payments that depend on an index (e.g. based on inflation index) or a specified rate, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising the option to terminate the lease. Lease payments also include amounts expected to be paid under residual value guarantees and the exercise price of a purchase option if the Company is reasonably certain to exercise that option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Variable lease payments that do not depend on an index or a specified rate are not included in the measurement of lease liabilities but instead are recognized as expenses in the period in which the event or condition that triggers the payment occurs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;After the commencement date, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced to reflect lease payments made. In addition, the carrying amount of lease liabilities is remeasured when there is a change in future lease payments arising from a change in an index or specified rate, if there is a modification to the lease terms and conditions, a change in the estimate of the amount expected to be payable under residual value guarantee, or if the Company changes its assessment of whether it will exercise a termination, extension or purchase option. The remeasurement amount of the lease liabilities is recognized as an adjustment to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, or in the consolidated statement of comprehensive loss when the carrying amount of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset is reduced to zero. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classification and presentation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lease-related&lt;/div&gt; expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Amortization charge for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, expenses related to variable lease payments not included in the measurement of lease liabilities and loss (gain) related to lease modifications are allocated in the Company&#x2019;s consolidated statement of comprehensive loss based on their function within the Company, while interest expense on lease liabilities is presented within finance costs. &lt;/div&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred Financing Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares or debt securities. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity or debt issuance on a proportionate basis when it occurs. If at such time the Company deems that these costs are no longer recoverable, they will be expensed as a component of finance expenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Chargebacks and rebates &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Chargebacks and rebates are estimated based on historical experience, relevant statutes with respect to governmental pricing programs, and contractual sales terms. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Returns &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for returns are estimated based on historical return levels, taking into account additional available information on contract changes. The Company reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical results and business practices, as necessary. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Contingent liability &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-occurrence&lt;/div&gt; of one or more uncertain future events not wholly within the control of the Company, or a present obligation that arises from past events (and therefore exists) but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or because the amount of the obligation cannot be estimated reliably. &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in net loss except to the extent that they relate to items recognized directly in other comprehensive income (loss) or in&#160;equity. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Current tax &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable in respect of previous years. The Company establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Deferred tax &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes and deferred tax losses that can be used against taxable profit in future years. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse and to fiscal losses when they will be used, based on the laws that have been enacted or substantively enacted by the reporting date. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A deferred tax liability is generally recognized for all taxable temporary differences. A deferred tax asset is recognized for unused tax losses and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Deferred income tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting or taxable profit or loss at the time of the transaction, and, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising from the initial recognition of goodwill. &lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Share option plan &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records share-based compensation related to Options granted using the fair-value-based method estimated using the Black-Scholes model. Under this method, compensation cost is measured at fair value at the date of grant and expensed over the period in which optionees unconditionally become entitled to the Options. The amount recognized as an expense is adjusted to reflect the number of Options for which the related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of Options that do meet the related service conditions at the vesting date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; payment arrangements in which the Company receives services as consideration for its own equity instruments are accounted for as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity-settled&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; payment transactions, regardless of how the equity instruments are obtained by the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred stock unit plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The deferred stock units (&#x201c;DSUs&#x201d;) are totally vested on the date of grant and are settled in cash. When DSUs are granted to officers as part of their annual bonuses, a DSU liability is recorded on the date of grant at the market value of the common shares in place of the liability for the bonus payments. When DSUs are granted to directors as part of their annual compensation in lieu of cash, the expense related to DSUs and their liabilities are recognized on the date of grant. The liability is adjusted to reflect any change in the market value of common shares, and such change is recorded in finance costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock appreciation rights&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock appreciation rights (&#x201c;SARs&#x201d;) entitle the grantee to a cash payment based on the increase in the share price of the Company&#x2019;s common shares from the grant date to the settlement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A liability is recognized for the services acquired and is recorded at the fair value of the SARs in other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities, with a corresponding expense recognized in selling expenses over the period that the grantees become unconditionally entitled to the payment. The fair value of the employee benefits expense of the SARs is measured using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt;Estimating fair value requires determining the most ap&lt;/div&gt;propri&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt;ate inputs to the valuation model including the expected life of the SARs, volatility, &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt; white-space: nowrap; top: 0px;;display:inline;"&gt;risk-free&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt; interest rate and dividend yield and making assumptions about them. At the end of each reporting period until the liability is settled, the fair value of the liability is remeasured, with any changes in fair value recognized in the consolidated statement of net earnings (loss) and comprehensive earnings (loss) of the current year.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government assistance &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Government grants are recognized only when the Company has reasonable assurance that it meets the conditions and will receive the grants. Government grants related to assets are recognized in the consolidated statement of financial position as a deduction from the carrying amount of the related asset. They are then recognized in profit or loss over the estimated useful life of the amortization asset that the grants were used to acquire, as a deduction from the amortization expense. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Other government grants are recognized in profit or loss as a deduction from the related expenses, such as salaries for the Canadian Emergency Wage Subsidy program. &lt;/div&gt;&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development tax credits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company elected to account for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; research and development tax credits under IAS&#160;20, &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Government Grants and Disclosure of Governmental Assistance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; research and development tax credits are included in earnings against gross research and development expenses or deducted from the related assets, provided there is reasonable assurance that the Company has complied and will comply with the conditions related to the tax credits and that the credits will be received. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share capital &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common shares, subscription receipts and Public Offering Warrants are classified as equity. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs directly attributable to the issue of common shares and equity classified warrants and subscription receipts are recognized in equity, net of any tax effects. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its common shares. Basic EPS is calculated by dividing the net profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders by taking the weighted average number of common shares outstanding and taking into consideration all dilutive potential common shares, which consist of the outstanding Options, warrants, subscription receipts and convertible unsecured senior notes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Changes in accounting policies &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In fiscal 2022, the Company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities in the consolidated statement of cash flows. Previously, the Company elected to classify interest paid as cash flow from financing activities and interest received as cash flows from investing activities. This change was applied retrospectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New standard adopted &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Onerous contracts &#x2013; Cost of Fulfilling a Contract (Amendments to IAS 37) &lt;/div&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#x2019;s annual reporting periods beginning on December&#160;1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standards issued but not yet effective &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A number of new standards are effective for annual periods beginning after December&#160;1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing these Financial Statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classification of Liabilities as Current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; (Amendments to IAS 1)&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;For the purposes of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; Covenants with which a company must comply after the reporting date do not affect a liability&#x2019;s classification at that date. &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#x2019;s own equity instruments to the counterparty; and when classifying liabilities as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; a company can ignore only those conversion options that are recognized as equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments will be effective for the Company&#x2019;s annual reporting period beginning on December&#160;1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <thtx:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-25133"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of consolidation &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements of the subsidiaries of the Company are included in these Financial Statements from the date on which control commences until the date on which control ceases. Subsidiaries are entities controlled by the Company. Control is present where the Company has the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable are taken into consideration. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany balances and transactions, revenues and expenses resulting from transactions between subsidiaries and with the Company are eliminated in preparing the Financial Statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</thtx:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25221"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign currencies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Transactions in foreign currencies are translated to the functional currency at exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate in effect at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the reporting year, adjusted for effective interest and payments during the reporting year, and the amortized cost in foreign currency translated at the exchange rate in effect at the end of the reporting year. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate in effect at the date on which the fair value was determined. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; items that are measured at historical cost in a foreign currency are translated using the exchange rate in effect at the date of the transaction. Foreign currency differences arising on translation are recognized in net profit, except for differences arising on the translation of FVOCI financial instruments, which are recognized in other comprehensive income (loss). &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign operations &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The assets and liabilities of foreign operations whose functional currency is not the US$ are translated into US$ at the reporting date. The income and expenses of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;foreign-currency&lt;/div&gt; denominated operations are translated at average rates for each reporting period. Foreign exchange differences arising on the translation of foreign operations are recognized directly in other comprehensive income (loss). When a foreign subsidiary is disposed of, the cumulative amount recognized in the currency translative reserve forms part of the gain or loss on disposal. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="P12_01_2022To11_30_2023" id="ixv-25295"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Revenue from contracts with customers &#x2013; Net sales &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;The Company derives revenue from the sales of finished goods, which include Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;and &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;. The Company recognizes revenue at a point in time when it transfers title of the finished goods to a customer, which generally occurs upon delivery of the finished goods to the customer&#x2019;s premises. Payment received from customers prior to the transfer of control of the goods is recorded as deferred revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Some arrangements for the sale of finished goods provide for customer cash discounts for prompt payment, allowances, rights of return, rebates on sales made under governmental and commercial rebate programs, chargebacks on sales made to government agencies and retail pharmacies and distribution fees, including potential clawbacks in certain jurisdictions when pricing terms are based on temporary use authorizations and thus subject to future negotiation which gives rise to variable consideration. At the time of sale, estimates are made for items giving rise to variable consideration based on the terms of the arrangement. The variable consideration is estimated at contract inception using the most likely amount method and revenue is only recognized to the extent that a significant reversal of revenue is not expected to occur. The estimate is based on historical experience, current trends, contractual terms with distributors and other known factors. Sales are recorded net of customer discounts, rebates, chargebacks, distribution fees and estimated sales returns, and exclude sales taxes. A refund liability and a right to recover returned goods asset are recognized for expected returns in relation to sales made before the end of the reporting period. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of variable consideration, including expected returns, on a quarterly basis, adjusting for the amounts of the asset and liability accordingly. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DisclosureOfCostOfSalesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25323"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of sales &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Cost of goods sold &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Cost of goods sold includes the cost of raw materials, supplies, direct labour and overhead charges allocated to goods sold as well as write-downs of inventories. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Amortization of the other asset &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;The amortization of the other asset related to the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14). &lt;/div&gt; </ifrs-full:DisclosureOfCostOfSalesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25395"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee benefits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Salaries and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; employee benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Salaries and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;profit-sharing&lt;/div&gt; or cash bonus plans if the Company has a legal or constructive obligation to pay an amount as a result of past services rendered by an employee and the obligation can be estimated reliably. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits include a defined contribution plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense when due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available. The Company&#x2019;s defined contribution plan comprises the registered retirement savings plan, the Quebec Pension Plan and employment insurance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Termination benefits &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Termination benefits are recognized as an expense when the Company is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25410"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income and finance costs &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Finance income comprises interest income on financial assets and gains on the disposal of financial assets and financial liabilities. Interest income is recognized as it accrues in net loss using the effective interest method. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance costs comprise bank charges, interest and accretion expense on lease liabilities, convertible unsecured senior notes, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; loans and obligations and deferred financing costs, impairment losses on financial assets recognized in net loss, changes in fair value of liabilities and derivatives, unrealized foreign currency gain or loss on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; obligations, loss on long-term obligations modifications and other foreign currency gains and losses which are reported on a net basis. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <thtx:DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-25482"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Inventories are presented at the lower of cost, determined using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; method, and net realizable value. Inventory costs include the purchase price and other costs directly related to the acquisition of materials and other costs incurred in bringing the inventories to their present location and condition. The Company is responsible for coordinating the production and stability testing and for auditing suppliers at different times during the manufacturing process. Inventory costs also include the costs directly related to the conversion of materials into finished goods. Net realizable value is the estimated selling price in the Company&#x2019;s ordinary course of business less the estimated costs of completion and selling expenses. In determining whether the inventory cost exceeds its net realizable value for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-launch&lt;/div&gt; inventory, the Company considers whether there is a high probability of regulatory approval for the product. In making that determination, the Company considers prior history with approvals of similar products, estimated timing of obtaining regulatory approval, regulatory agencies correspondence regarding safety and efficacy of the product and current market factors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Work in progress inventory appears from the moment third party suppliers use the material provided by the Company until the time the Company receives the finished product. The value of work in progress inventory is equal to the value of material provided by the Company plus all conversion work performed by third party suppliers. &lt;/div&gt;</thtx:DescriptionOfAccountingPolicyForInventoriesExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25490"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Recognition and measurement &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Items of property and equipment are recognized at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and the costs of dismantling and removing the item and restoring the site on which it is located, if any. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Gains and losses on disposal of an item of property and equipment are determined by comparing the proceeds from disposal with the carrying amount of property and equipment and are recognized in net profit or loss. &lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Subsequent costs &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;day-to-day&lt;/div&gt;&lt;/div&gt; servicing of items of property and equipment are recognized in net profit or loss as incurred. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Depreciation &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The methods of depreciation and depreciation rates and periods are as follows: &lt;/div&gt;&lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 46%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 20%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 28%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Method&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate/period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;50%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20% 5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;Straight-line&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden101085993;display:inline;"&gt;Lower of lease term&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;and economic life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The method of depreciation is selected based on the most closely expected pattern of consumption of the future economic benefits embodied in the asset. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Estimates for depreciation methods, useful lives and residual values are reviewed at each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; and adjusted if appropriate. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <thtx:DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-25574">&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The methods of depreciation and depreciation rates and periods are as follows: &lt;/div&gt;&lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:96%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 46%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 20%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 28%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="BORDER-TOP:1.50pt solid #000000;height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Method&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate/period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;50%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20% 5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Office furniture and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;Declining balance&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;white-space:nowrap;text-align:right;"&gt;20%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;Straight-line&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.50pt solid #000000;vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:12pt ;BORDER-BOTTOM:1.50pt solid #000000;vertical-align:top;white-space:nowrap;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden101085993;display:inline;"&gt;Lower of lease term&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;and economic life&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</thtx:DisclosureOfEstimatedUsefulLivesMethodsOfDepreciationTextBlock>
    <ifrs-full:DepreciationMethodPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="ixv-48222">Declining balance</ifrs-full:DepreciationMethodPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="2"
      id="ixv-48223"
      unitRef="Unit_pure">0.50</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationMethodPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="ixv-25638">Declining balance and straight-line</ifrs-full:DepreciationMethodPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="2"
      id="ixv-48224"
      unitRef="Unit_pure">0.20</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="ixv-48225">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DepreciationMethodPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="ixv-48226">Declining balance</ifrs-full:DepreciationMethodPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="2"
      id="ixv-48227"
      unitRef="Unit_pure">0.20</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationMethodPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      id="ixv-48228">Straight-line</ifrs-full:DepreciationMethodPropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25730">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Research and development &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. A development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset. These criteria are usually met when a regulatory filing has been made in a major market and approval is considered highly probable. The expenditure capitalized includes the cost of materials, direct labour, and overhead costs that are directly attributable to preparing the asset for its intended use. Other development &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;expenditures are expensed as incurred. Capitalized development expenditures are measured at cost, less accumulated amortization and accumulated impairment losses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;During the years ended November&#160;30, 2023, 2022 and 2021, no development expenditures were capitalized. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; advance payments for good and services that will be used in future research and development activities are expenses when the activity has been performed rather than when the payment is made. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Commercialization rights and oncology platform &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercialization rights and the oncology platform acquired by the Company have finite useful lives and are measured at cost less accumulated amortization and any accumulated impairment losses. Commercialization rights&#160;&#x2013; &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; &#x2013; are amortized at fixed rates based on their estimated useful life of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;111&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;&#160;months on a &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt; text-wrap: nowrap; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Commercialization rights&#160;&#x2013; Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; North American Territory &#x2013; are amortized at fixed rates based on their estimated useful life of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;142&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;months on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis. Commercialization rights &#x2013; Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;European Territory &#x2013; were amortized at fixed rates based on their estimated useful life of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;148&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;months on a straight-line basis. They were fully amortized during the year ended November&#160;30, 2022. Refer to Note 13. Commercialization rights&#160;for the oncology platform will be amortized over the estimated useful life on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis when the asset is available for use. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The amortization method and useful life of intangible assets are reviewed every year and adjusted as required. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48229"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48230"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2020To11_30_2021_CapitalisedDevelopmentExpenditureMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48231"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      id="ixv-48232">P111M</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill contextRef="P12_01_2022To11_30_2023" id="ixv-25753">straight-line basis</ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      id="ixv-48233">P142M</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_ThtxCommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      id="ixv-48234">P148M</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <thtx:DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25855"> &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset acquisitions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Asset acquisitions are acquisitions that do not qualify as business combinations. At the date of acquisition, the Company initially recognizes the individual identifiable assets acquired and liabilities assumed. The cost to the Company at the date of the acquisition is allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of the acquisition. Subsequent consideration for performance-related development milestones is recognized as intangible assets when the specific milestones have been achieved and other recognition criteria are met. Subsequent payments related to activity or usage of an asset, including sales royalties, are expensed as incurred. Asset acquisition transactions do not give rise to goodwill. &lt;/div&gt; </thtx:DescriptionOfAccountingPolicyForAssetAcquisiitonsExplanatory>
    <thtx:DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-25859"> &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other asset &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Other asset, which comprised the amount disbursed in connection with the repurchase of the future royalty rights under the 2013 Termination Agreement (Note 14), was amortized over its estimated useful life of&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;48&#160;months. Other asset was fully amortized during the year ended November&#160;30, 2022. &lt;/div&gt; </thtx:DescriptionOfAccountingPolicyForOtherAssetsExplanatoryPolicyTextBlock>
    <thtx:UsefulLifeMeasuredAsPeriodOfTimeOtherAssets
      contextRef="P12_01_2022To11_30_2023_OtherAssetsMemberifrsfullClassesOfAssetsAxis"
      id="ixv-48235">P48M</thtx:UsefulLifeMeasuredAsPeriodOfTimeOtherAssets>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25864"> &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The carrying amounts of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If such an indication exists, the recoverable amount is estimated. &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of cash inflows from other assets or groups of assets (&#x201c;Cash-Generating Unit&#x201d;). The recoverable amount of an asset or a Cash-Generating Unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the Cash-Generating Unit. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Impairment losses recognized in prior years are determined by the Company at each reporting date for any indications that the loss has decreased or no longer exists. An asset&#x2019;s carrying amount, increased through the reversal of an impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-25935"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company initially recognizes financial assets on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value through profit or loss, then the initial measurement includes transaction costs that are directly attributable to the asset&#x2019;s acquisition or issue. On initial recognition, the Company classifies its financial assets as measured at amortized cost, FVOCI or fair value through profit or loss (&#x201c;FVPL&#x201d;), depending on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;(i) Financial assets measured at amortized cost &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial;text-align:justify"&gt;A financial asset is measured at amortized cost, using the effective interest method and net of any impairment loss, if it meets both of the following conditions and is not designated at fair value though profit or loss: &lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;it is held within a business model whose objective is to hold assets to collect contractual cash flows;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial"&gt;The Company currently classifies its cash and trade and other receivables as financial assets measured at amortized cost. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;(ii) Financial assets, measured at fair value through other comprehensive income &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:arial"&gt;A debt investment is measured at fair value through other comprehensive income if it meets both of the following conditions and is not designated at fair value through profit or loss: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:7%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: SYMBOL; font-size: 9pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: left; line-height: normal;"&gt;its contractual terms give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(ii) Financial assets, measured at fair value through other comprehensive income (continued) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in other comprehensive income (loss). When an investment is derecognized, gains or losses accumulated in other comprehensive income (loss) are reclassified to profit or loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment&#x2019;s fair value in other comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;This election is made on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;investment-by-investment&lt;/div&gt;&lt;/div&gt; basis. These assets are subsequently measured at fair value. Dividends are recognized in profit or loss, unless the dividend clearly represents a repayment of part of the cost of the investment, and other net gains and losses are recognized in other comprehensive income (loss) and are never reclassified in profit or loss. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently classifies its bonds as financial assets measured at FVOCI. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iii) Financial assets measured at fair value through profit or loss &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;All financial assets not classified as measured at amortized cost or FVOCI as described above are measured at FVPL. These assets are subsequently measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss. The Company currently classifies its money market funds and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-hedge&lt;/div&gt; derivative financial assets as financial assets measured at FVPL. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are&#160;transferred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv) Financial liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 6%;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities are classified into the following categories: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at fair value through profit or loss &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;A financial liability is classified at fair value through profit or loss if it is classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-for-trading,&lt;/div&gt;&lt;/div&gt; it is a derivative or it is designated as such on initial recognition. Financial liabilities at fair value are measured at fair value and net gains and losses, including interest expense, are recognized in profit or loss. &lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company issued the Marathon Warrants which are classified as financial liabilities through profit or loss because the exercise can be made on a cashless basis. All transaction costs related to financial instruments designated at fair value through profit or loss are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently has no other financial liabilities measured at FVPL. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities measured at amortized cost &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This category includes all financial liabilities, other than those measured at FVPL. A financial liability is subsequently measured at amortized cost using the effective interest method. The Company currently classifies accounts payable and accrued liabilities, convertible unsecured senior notes and Loan Facility as financial liabilities measured at amortized cost. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 11%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expired. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(v) Compound financial instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compound financial instruments are instruments that contain both a liability component and an equity component, and the liability component can be converted into share capital at the option of the holder and the number of shares to be issued does not vary with changes in their fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversation option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Upon repurchase, the proceeds are allocated based on the same basis that was used for the initial recognition. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(vi) Derivative financial instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments are recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. The changes in the fair value of derivatives are recognized through profit or loss in the year in which they occur.&lt;/div&gt; &lt;/div&gt;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(vii) Offsetting of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position when, and only when, the Company has a legal right to set off the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At each reporting date, the Company recognizes loss allowances for expected credit losses (&#x201c;ECLs&#x201d;) on financial assets carried at amortized cost and debt securities at FVOCI. The Company&#x2019;s trade and other receivables are accounts receivable with no financing component and which have maturities of less than 12 months and, as such, the Company has chosen to apply the simplified approach for ECL. As a result, the Company does not track changes in credit risk related to its trade and other receivables, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(viii) Impairment of financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For other financial assets subject to impairment, the Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; ECLs: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;debt securities that are determined to have low credit risk at the reporting date; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers a debt security to have a low credit risk when its credit risk rating is equivalent or above investment grade credit rating, such as its bonds classified at FVOCI. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 6%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s approach to ECLs reflects a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;probability-weighted&lt;/div&gt; outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;economic &lt;/div&gt;conditions. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26389"> &lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At inception, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability at the commencement date of the lease, i.e. the date the underlying asset is available for use. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are measured at cost, less any accumulated amortization and accumulated impairment losses, and adjusted for remeasurement of lease liabilities. Cost of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets comprises: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the initial measurement amount of the lease liabilities recognized; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any lease payments made at or before the commencement date, less any lease incentives received; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any initial direct costs incurred; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: SYMBOL; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;an estimate of costs to dismantle and remove the underlying asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease contract. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are amortized on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;straight-line&lt;/div&gt; basis over the lesser of (i)&#160;the estimated useful life of the underlying assets; and (ii)&#160;the lease term. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets are assessed for impairment whenever there is an indication that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets may be impaired. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date over the lease term. The present value of the lease payments is determined using the lessee&#x2019;s incremental borrowing rate at the commencement date if the interest rate implicit in the lease is not readily determinable. The incremental borrowing rate is a function of the lessee&#x2019;s incremental borrowing rate, the nature of the underlying asset, the location of the asset, the length of the lease and the currency of the lease contract. Generally, the Company uses the lessee&#x2019;s incremental borrowing rate for the present value. At the commencement date, lease payments generally include fixed payments, less any lease incentives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;receivable, variable lease payments that depend on an index (e.g. based on inflation index) or a specified rate, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising the option to terminate the lease. Lease payments also include amounts expected to be paid under residual value guarantees and the exercise price of a purchase option if the Company is reasonably certain to exercise that option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Variable lease payments that do not depend on an index or a specified rate are not included in the measurement of lease liabilities but instead are recognized as expenses in the period in which the event or condition that triggers the payment occurs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;After the commencement date, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced to reflect lease payments made. In addition, the carrying amount of lease liabilities is remeasured when there is a change in future lease payments arising from a change in an index or specified rate, if there is a modification to the lease terms and conditions, a change in the estimate of the amount expected to be payable under residual value guarantee, or if the Company changes its assessment of whether it will exercise a termination, extension or purchase option. The remeasurement amount of the lease liabilities is recognized as an adjustment to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, or in the consolidated statement of comprehensive loss when the carrying amount of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset is reduced to zero. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classification and presentation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lease-related&lt;/div&gt; expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Amortization charge for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, expenses related to variable lease payments not included in the measurement of lease liabilities and loss (gain) related to lease modifications are allocated in the Company&#x2019;s consolidated statement of comprehensive loss based on their function within the Company, while interest expense on lease liabilities is presented within finance costs. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <thtx:DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26596"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred Financing Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares or debt securities. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity or debt issuance on a proportionate basis when it occurs. If at such time the Company deems that these costs are no longer recoverable, they will be expensed as a component of finance expenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</thtx:DescriptionOfAccountingPolicyForDeferredFinancingCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26669"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Provisions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are assessed by discounting the expected future cash flows at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount on provisions is recognized in finance costs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Chargebacks and rebates &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Chargebacks and rebates are estimated based on historical experience, relevant statutes with respect to governmental pricing programs, and contractual sales terms. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Returns &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for returns are estimated based on historical return levels, taking into account additional available information on contract changes. The Company reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical results and business practices, as necessary. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Contingent liability &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-occurrence&lt;/div&gt; of one or more uncertain future events not wholly within the control of the Company, or a present obligation that arises from past events (and therefore exists) but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or because the amount of the obligation cannot be estimated reliably. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26748"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in net loss except to the extent that they relate to items recognized directly in other comprehensive income (loss) or in&#160;equity. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Current tax &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable in respect of previous years. The Company establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Deferred tax &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes and deferred tax losses that can be used against taxable profit in future years. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse and to fiscal losses when they will be used, based on the laws that have been enacted or substantively enacted by the reporting date. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;A deferred tax liability is generally recognized for all taxable temporary differences. A deferred tax asset is recognized for unused tax losses and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Deferred income tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting or taxable profit or loss at the time of the transaction, and, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising from the initial recognition of goodwill. &lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26824"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Share option plan &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records share-based compensation related to Options granted using the fair-value-based method estimated using the Black-Scholes model. Under this method, compensation cost is measured at fair value at the date of grant and expensed over the period in which optionees unconditionally become entitled to the Options. The amount recognized as an expense is adjusted to reflect the number of Options for which the related service conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of Options that do meet the related service conditions at the vesting date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; payment arrangements in which the Company receives services as consideration for its own equity instruments are accounted for as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity-settled&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; payment transactions, regardless of how the equity instruments are obtained by the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred stock unit plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The deferred stock units (&#x201c;DSUs&#x201d;) are totally vested on the date of grant and are settled in cash. When DSUs are granted to officers as part of their annual bonuses, a DSU liability is recorded on the date of grant at the market value of the common shares in place of the liability for the bonus payments. When DSUs are granted to directors as part of their annual compensation in lieu of cash, the expense related to DSUs and their liabilities are recognized on the date of grant. The liability is adjusted to reflect any change in the market value of common shares, and such change is recorded in finance costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <thtx:DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-26846">&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock appreciation rights&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock appreciation rights (&#x201c;SARs&#x201d;) entitle the grantee to a cash payment based on the increase in the share price of the Company&#x2019;s common shares from the grant date to the settlement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A liability is recognized for the services acquired and is recorded at the fair value of the SARs in other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities, with a corresponding expense recognized in selling expenses over the period that the grantees become unconditionally entitled to the payment. The fair value of the employee benefits expense of the SARs is measured using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt;Estimating fair value requires determining the most ap&lt;/div&gt;propri&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt;ate inputs to the valuation model including the expected life of the SARs, volatility, &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt; white-space: nowrap; top: 0px;;display:inline;"&gt;risk-free&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt;;display:inline;"&gt; interest rate and dividend yield and making assumptions about them. At the end of each reporting period until the liability is settled, the fair value of the liability is remeasured, with any changes in fair value recognized in the consolidated statement of net earnings (loss) and comprehensive earnings (loss) of the current year.&lt;/div&gt;&lt;/div&gt;</thtx:DescriptionOfAccountingPolicyForStockAppreciationRightsPlanExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="P12_01_2022To11_30_2023" id="ixv-26961">&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government assistance &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Government grants are recognized only when the Company has reasonable assurance that it meets the conditions and will receive the grants. Government grants related to assets are recognized in the consolidated statement of financial position as a deduction from the carrying amount of the related asset. They are then recognized in profit or loss over the estimated useful life of the amortization asset that the grants were used to acquire, as a deduction from the amortization expense. &lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Other government grants are recognized in profit or loss as a deduction from the related expenses, such as salaries for the Canadian Emergency Wage Subsidy program. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26966">&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and development tax credits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company elected to account for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; research and development tax credits under IAS&#160;20, &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Government Grants and Disclosure of Governmental Assistance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-refundable&lt;/div&gt; research and development tax credits are included in earnings against gross research and development expenses or deducted from the related assets, provided there is reasonable assurance that the Company has complied and will comply with the conditions related to the tax credits and that the credits will be received. &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-26976">&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share capital &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common shares, subscription receipts and Public Offering Warrants are classified as equity. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs directly attributable to the issue of common shares and equity classified warrants and subscription receipts are recognized in equity, net of any tax effects. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27052">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its common shares. Basic EPS is calculated by dividing the net profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders by taking the weighted average number of common shares outstanding and taking into consideration all dilutive potential common shares, which consist of the outstanding Options, warrants, subscription receipts and convertible unsecured senior notes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <thtx:DescriptionOfChangesInAccountingPoliciesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27062">&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Changes in accounting policies &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In fiscal 2022, the Company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities in the consolidated statement of cash flows. Previously, the Company elected to classify interest paid as cash flow from financing activities and interest received as cash flows from investing activities. This change was applied retrospectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</thtx:DescriptionOfChangesInAccountingPoliciesExplanatory>
    <thtx:DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27068">&lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New standard adopted &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Onerous contracts &#x2013; Cost of Fulfilling a Contract (Amendments to IAS 37) &lt;/div&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments specify which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. The amendments applied to the Company&#x2019;s annual reporting periods beginning on December&#160;1, 2022, to contracts existing at the date the amendments were first applied. The adoption of the standard did not have an impact on the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</thtx:DescriptionOfAccountingPolicyForNewAccountingStandardsAdoptedExplanatory>
    <thtx:DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-27141"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Standards issued but not yet effective &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A number of new standards are effective for annual periods beginning after December&#160;1, 2023 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing these Financial Statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Classification of Liabilities as Current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; (Amendments to IAS 1)&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;For the purposes of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must exist at the end of the reporting period and have substance. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The amendments reconfirmed that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; Covenants with which a company must comply after the reporting date do not affect a liability&#x2019;s classification at that date. &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments also clarify how a company classifies a liability that includes a counterparty conversion option. The amendments provide that: settlement of a liability includes transferring a company&#x2019;s own equity instruments to the counterparty; and when classifying liabilities as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; a company can ignore only those conversion options that are recognized as equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amendments will be effective for the Company&#x2019;s annual reporting period beginning on December&#160;1, 2025. The Company is currently evaluating the impact of the amendments on its financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </thtx:DescriptionOfAccountingPolicyForAdoptedTheNewOrAmendedStandardsTextBlock>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27193">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;12, 2014, the Company entered into a master services agreement with RxC Acquisition Company (&#x201c;RxCrossroads&#x201d;), along with two statements of work (&#x201c;RxCrossroads Agreements&#x201d;). Under the terms of the RxCrossroads Agreements, RxCrossroads acts as the Company&#x2019;s exclusive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;third-party&lt;/div&gt; logistics service provider for all of the Company&#x2019;s products in the United States and, as such, provides warehousing and logistical support services to the Company, including inventory control, account management, customer support, product return management and fulfillment of orders. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;Under the RxCrossroads Agreements, RxCrossroads also acts as the Company&#x2019;s exclusive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;third-party&lt;/div&gt; distributor of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in the United States. In such a role, RxCrossroads purchases &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; from the Company and takes title thereto when the goods arrive in their warehouse. RxCrossroads&#x2019; purchases of &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; are triggered by its expectations of market demand over a certain period of time. With respect to &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;, RxCrossroads fulfills orders received from authorized wholesalers and delivers &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; directly to that authorized wholesaler&#x2019;s client, namely, a specialty pharmacy forming part of the Company&#x2019;s network of specialty pharmacies. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;1, 2017, the Company entered into amended and restated RxCrossroads Agreements to add Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;text-indent: 0px;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; as a new product sold in the United States. These amended and restated RxCrossroads Agreements replaced the RxCrossroads Agreements entered into in May&#160;2014. On November&#160;1, 2019, the RxCrossroads Agreements were amended anew to include &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;as an additional product distributed by RxCrossroads in the United States&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Canada &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company commercialized &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;directly in Canada using a distributor until September 2022, after which time the Company withdrew the product from the market in Canada. &lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;9, 2020, the Company entered into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-wholesaling&lt;/div&gt; services agreement with Loxxess Pharma GmbH or&#160;(&#x201c;Loxxess&#x201d;) pursuant to which Loxxess agreed to act as our third-party service logistics provider (the &#x201c;Loxxess Agreement&#x201d;) in certain key European countries, including Germany, France, Italy, Austria, The Netherlands, Portugal, Switzerland, United Kingdom, Norway, Sweden, Finland and Denmark. Loxxess is also capable of serving other European countries, including Israel and Turkey. Pursuant to the Loxxess Agreement, Loxxess received customers&#x2019; ordered, stored, packaged and shipped Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; to European hospitals and pharmacies. Loxxess was also responsible, on our behalf, to collect payments of the goods sold to those hospitals and pharmacies. The hospitals and pharmacies dispensed Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; to patients. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On April&#160;27, 2022, the Company announced that it would focus its commercial operations on the North American territory only and, as a result, would cease commercial sales of Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in Europe. At that time, the Company sent a notice of termination to TaiMed Biologics Inc. (&#x201c;TaiMed&#x201d;), as per the contractual terms indicating it was returning the European commercialization rights to Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; to TaiMed within the next 180 days. The discontinuation became effective in December 2022. Refer to Note 13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Net sales by product &lt;div style="display:inline;"&gt;were&lt;/div&gt; as follows:&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 61%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; width: 1%;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,454&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,009&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: top; width: 61%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trogarzo&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,059&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,603&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,814&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;81,764&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2002;80,057&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2002;69,823&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Net sales by geography were as follows: &lt;/div&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 90%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; width: 5%;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Canada&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;78,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;68,099&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Europe&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,261&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,455&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;81,764&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,057&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69,823&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27409"> &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Net sales by product &lt;div style="display:inline;"&gt;were&lt;/div&gt; as follows:&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 61%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; width: 1%;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,454&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,009&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: top; width: 61%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trogarzo&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,059&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,603&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,814&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;81,764&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2002;80,057&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2002;69,823&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48238"
      unitRef="Unit_USD">53705000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48239"
      unitRef="Unit_USD">50454000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_EgriftaMemberifrsfullProductsAndServicesAxis_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48240"
      unitRef="Unit_USD">43009000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      id="ixv-48241"
      unitRef="Unit_USD">28059000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      id="ixv-48242"
      unitRef="Unit_USD">29603000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis_TrogarzoNetSalesMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      id="ixv-48243"
      unitRef="Unit_USD">26814000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48244"
      unitRef="Unit_USD">81764000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48245"
      unitRef="Unit_USD">80057000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48246"
      unitRef="Unit_USD">69823000</ifrs-full:Revenue>
    <thtx:DisaggregationOfRevenueByGeographicalAreaTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-27572"> &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Net sales by geography were as follows: &lt;/div&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 90%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; width: 5%;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Canada&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;78,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;68,099&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: top; width: 90%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Europe&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,261&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,455&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 90%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom; width: 5%;;text-align:right;"&gt;81,764&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,057&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69,823&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="14" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </thtx:DisaggregationOfRevenueByGeographicalAreaTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_CAifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48247"
      unitRef="Unit_USD">86000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_CAifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48248"
      unitRef="Unit_USD">52000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_CAifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48249"
      unitRef="Unit_USD">269000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48250"
      unitRef="Unit_USD">81392000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48251"
      unitRef="Unit_USD">78744000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48252"
      unitRef="Unit_USD">68099000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48253"
      unitRef="Unit_USD">286000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48254"
      unitRef="Unit_USD">1261000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_EuropeMemberifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-48255"
      unitRef="Unit_USD">1455000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48256"
      unitRef="Unit_USD">81764000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48257"
      unitRef="Unit_USD">80057000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48258"
      unitRef="Unit_USD">69823000</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-27782">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;"&gt;
&lt;tr style="break-inside: avoid;"&gt;
&lt;td style="width: 32.625px; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Personnel expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 55%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Salaries and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,934&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;22,049&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,480&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,833&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,346&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;644&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20(f),(h)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,651&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,006&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;566&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &#160; &#160;&#160;30,882&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;27,565&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &#160; &#160;&#160; 13,984&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In fiscal 2023, $1,963 was recorded in termination benefits for severance and other expenses. Refer to note 16(a). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In fiscal&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;&#160;2022, $&lt;/div&gt;457&lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt; was &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recorded in termination benefits for severance and other expenses associated with the return to TaiMed of the commercial rights to Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in Europe&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 11pt; top: 0px;;display:inline;"&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-27794"> &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 55%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 1.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 6pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Salaries and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;employee benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,934&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;22,049&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,480&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,833&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,346&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;644&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20(f),(h)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,651&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,006&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;566&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 7.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &#160; &#160;&#160;30,882&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;27,565&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &#160; &#160;&#160; 13,984&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="18" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48259"
      unitRef="Unit_USD">24934000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48260"
      unitRef="Unit_USD">22049000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48261"
      unitRef="Unit_USD">11480000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48262"
      unitRef="Unit_USD">1833000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48263"
      unitRef="Unit_USD">1346000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48264"
      unitRef="Unit_USD">644000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48265"
      unitRef="Unit_USD">2109000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48266"
      unitRef="Unit_USD">3604000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48267"
      unitRef="Unit_USD">1651000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48268"
      unitRef="Unit_USD">2006000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48269"
      unitRef="Unit_USD">566000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:TerminationBenefitsExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48270"
      unitRef="Unit_USD">209000</ifrs-full:TerminationBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48271"
      unitRef="Unit_USD">30882000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48272"
      unitRef="Unit_USD">27565000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48273"
      unitRef="Unit_USD">13984000</ifrs-full:EmployeeBenefitsExpense>
    <thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48274"
      unitRef="Unit_USD">1963000</thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses>
    <thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48275"
      unitRef="Unit_USD">457000</thtx:AmountOfChargesRelatedToSeveranceAndOtherExpenses>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-28241">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income and finance costs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Gain on repurchase of convertible unsecured senior notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &#160; &#160; &#160; &#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Net gain on financial instruments carried at fair &lt;br/&gt;value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Gain on lease termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finance income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense and amortization of deferred financing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,&#160;18,&#160;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,098)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,140)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,358)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Interest on convertible unsecured senior&#160;notes and on long-term loan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,263)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,357)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &#160; &#160;(3,306)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Bank charges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Net foreign currency loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(159)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160;&#160; (1,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Loss on Loan Facility modifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,&#160;20(c)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,540)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Write off of deferred financing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,&#160;20(d)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(954)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,056)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,559)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,621)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Net finance cost recognized in net&#160;profit&#160;or&#160;loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,909)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,886)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,426)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; text-indent: 0px;"&gt;&#160;&lt;/div&gt; </ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-28250"> &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Gain on repurchase of convertible unsecured senior notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &#160; &#160; &#160; &#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Net gain on financial instruments carried at fair &lt;br/&gt;value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Gain on lease termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finance income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense and amortization of deferred financing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,&#160;18,&#160;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,098)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,140)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,358)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Interest on convertible unsecured senior&#160;notes and on long-term loan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,263)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,357)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &#160; &#160;(3,306)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Bank charges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Net foreign currency loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(159)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160;&#160; (1,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(926)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Loss on Loan Facility modifications&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,&#160;20(c)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,540)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Write off of deferred financing costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,&#160;20(d)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(954)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,056)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,559)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,621)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Net finance cost recognized in net&#160;profit&#160;or&#160;loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,909)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,886)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,426)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; text-indent: 0px;"&gt;&#160;&lt;/div&gt; </thtx:DisclosureOfDetailedInformationAboutFinanceIncomeAndCostExplanatoryTableTextBlock>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48276"
      unitRef="Unit_USD">0</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48277"
      unitRef="Unit_USD">357000</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48278"
      unitRef="Unit_USD">0</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48279"
      unitRef="Unit_USD">1257000</thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue>
    <thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48280"
      unitRef="Unit_USD">0</thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue>
    <thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48281"
      unitRef="Unit_USD">0</thtx:NetGainLossOnFinancialInstrumentsCarriedAtFairValue>
    <ifrs-full:RevenueFromInterest
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48282"
      unitRef="Unit_USD">769000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48283"
      unitRef="Unit_USD">316000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48284"
      unitRef="Unit_USD">195000</ifrs-full:RevenueFromInterest>
    <thtx:GainLossOnLeaseTermination
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48285"
      unitRef="Unit_USD">121000</thtx:GainLossOnLeaseTermination>
    <thtx:GainLossOnLeaseTermination
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48286"
      unitRef="Unit_USD">0</thtx:GainLossOnLeaseTermination>
    <thtx:GainLossOnLeaseTermination
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48287"
      unitRef="Unit_USD">0</thtx:GainLossOnLeaseTermination>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48288"
      unitRef="Unit_USD">2147000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48289"
      unitRef="Unit_USD">673000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48290"
      unitRef="Unit_USD">195000</ifrs-full:FinanceIncome>
    <thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48291"
      unitRef="Unit_USD">2098000</thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48292"
      unitRef="Unit_USD">2140000</thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48293"
      unitRef="Unit_USD">2358000</thtx:AccretionExpenseAndAmortizationOfDeferredFinancingCosts>
    <ifrs-full:InterestExpenseOnDebtInstrumentsIssued
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48294"
      unitRef="Unit_USD">8263000</ifrs-full:InterestExpenseOnDebtInstrumentsIssued>
    <ifrs-full:InterestExpenseOnDebtInstrumentsIssued
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48295"
      unitRef="Unit_USD">4357000</ifrs-full:InterestExpenseOnDebtInstrumentsIssued>
    <ifrs-full:InterestExpenseOnDebtInstrumentsIssued
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48296"
      unitRef="Unit_USD">3306000</ifrs-full:InterestExpenseOnDebtInstrumentsIssued>
    <ifrs-full:BankAndSimilarCharges
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48297"
      unitRef="Unit_USD">42000</ifrs-full:BankAndSimilarCharges>
    <ifrs-full:BankAndSimilarCharges
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48298"
      unitRef="Unit_USD">35000</ifrs-full:BankAndSimilarCharges>
    <ifrs-full:BankAndSimilarCharges
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48299"
      unitRef="Unit_USD">31000</ifrs-full:BankAndSimilarCharges>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48300"
      unitRef="Unit_USD">159000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48301"
      unitRef="Unit_USD">1027000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48302"
      unitRef="Unit_USD">926000</ifrs-full:NetForeignExchangeLoss>
    <thtx:GainLossOnLoanFacilityModifications
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48303"
      unitRef="Unit_USD">-3540000</thtx:GainLossOnLoanFacilityModifications>
    <thtx:GainLossOnLoanFacilityModifications
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48304"
      unitRef="Unit_USD">0</thtx:GainLossOnLoanFacilityModifications>
    <thtx:GainLossOnLoanFacilityModifications
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48305"
      unitRef="Unit_USD">0</thtx:GainLossOnLoanFacilityModifications>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48306"
      unitRef="Unit_USD">954000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48307"
      unitRef="Unit_USD">0</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48308"
      unitRef="Unit_USD">0</ifrs-full:AdjustmentsForFinanceCosts>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48309"
      unitRef="Unit_USD">15056000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48310"
      unitRef="Unit_USD">7559000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceCostsAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48311"
      unitRef="Unit_USD">6621000</thtx:FinanceCostsAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48312"
      unitRef="Unit_USD">-12909000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48313"
      unitRef="Unit_USD">-6886000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48314"
      unitRef="Unit_USD">-6426000</thtx:FinanceIncomeCostAndGainsLossesOnForeignCurrency>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-28762">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Bonds and money market &lt;div style="display:inline;"&gt;funds&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family:Calibri;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family:Calibri;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial"&gt;Bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;6,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;8,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial"&gt;Guaranteed investment certificates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;"&gt;$&#x2003;&#x2002;6,290&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;"&gt;$&#x2003;&#x2002;9,214&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;As at November&#160;30, 2023, bonds were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest-bearing&lt;/div&gt; financial assets with stated interest rates ranging from 0.85% to 3.75% (2022&#160;&#x2013; 0.65% to 3.90%) and had an average maturity of 1.40&#160;years (2022&#160;&#x2013; 1.78&#160;years). &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; </ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-28772"> &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family:Calibri;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family:Calibri;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial"&gt;Bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;6,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;8,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:11pt; font-family:arial"&gt;Guaranteed investment certificates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;"&gt;$&#x2003;&#x2002;6,290&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:center;"&gt;$&#x2003;&#x2002;9,214&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.50pt solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutBondsAndMoneyMarketFundsExplanatoryTableTextBlock>
    <ifrs-full:GovernmentDebtInstrumentsHeld
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48315"
      unitRef="Unit_USD">6062000</ifrs-full:GovernmentDebtInstrumentsHeld>
    <ifrs-full:GovernmentDebtInstrumentsHeld
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48316"
      unitRef="Unit_USD">8990000</ifrs-full:GovernmentDebtInstrumentsHeld>
    <thtx:GuaranteedInvestmentCertificates
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48317"
      unitRef="Unit_USD">228000</thtx:GuaranteedInvestmentCertificates>
    <thtx:GuaranteedInvestmentCertificates
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48318"
      unitRef="Unit_USD">224000</thtx:GuaranteedInvestmentCertificates>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48319"
      unitRef="Unit_USD">6290000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48320"
      unitRef="Unit_USD">9214000</ifrs-full:OtherFinancialAssets>
    <thtx:FinancialAssetsStatedInterestPercentage
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      id="ixv-48321"
      unitRef="Unit_pure">0.0085</thtx:FinancialAssetsStatedInterestPercentage>
    <thtx:FinancialAssetsStatedInterestPercentage
      contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      id="ixv-48322"
      unitRef="Unit_pure">0.0375</thtx:FinancialAssetsStatedInterestPercentage>
    <thtx:FinancialAssetsStatedInterestPercentage
      contextRef="PAsOn11_30_2022_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      id="ixv-48323"
      unitRef="Unit_pure">0.0065</thtx:FinancialAssetsStatedInterestPercentage>
    <thtx:FinancialAssetsStatedInterestPercentage
      contextRef="PAsOn11_30_2022_TopOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      id="ixv-48324"
      unitRef="Unit_pure">0.039</thtx:FinancialAssetsStatedInterestPercentage>
    <thtx:FinancialAssetsAverageMaturityTerm contextRef="P12_01_2022To11_30_2023" id="ixv-48325">P1Y4M24D</thtx:FinancialAssetsAverageMaturityTerm>
    <thtx:FinancialAssetsAverageMaturityTerm contextRef="P12_01_2021To11_30_2022" id="ixv-48326">P1Y9M10D</thtx:FinancialAssetsAverageMaturityTerm>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-28862">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade and other receivables &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trade receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;12,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;10,659&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Sales taxes receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="9" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;"&gt;$&#160;&#160;&#160;&#160;&#160;&#160;13,023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;"&gt;$&#160;&#160;&#160;&#160;&#160;&#160;12,045&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-28871">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:98%;border:0"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trade receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;12,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;10,659&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Sales taxes receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="9" style="height:3.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;"&gt;$&#160;&#160;&#160;&#160;&#160;&#160;13,023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:4pt ;vertical-align:bottom;text-align:center;"&gt;$&#160;&#160;&#160;&#160;&#160;&#160;12,045&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48327"
      unitRef="Unit_USD">12798000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48328"
      unitRef="Unit_USD">10659000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48329"
      unitRef="Unit_USD">220000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48330"
      unitRef="Unit_USD">538000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48331"
      unitRef="Unit_USD">5000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48332"
      unitRef="Unit_USD">848000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48333"
      unitRef="Unit_USD">13023000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48334"
      unitRef="Unit_USD">12045000</ifrs-full:TradeAndOtherCurrentReceivables>
    <thtx:DisclosureOfTaxCreditsReceivableExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-28997">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax credits and grants receivable &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:90%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants recognized in net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(442)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:3pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16)&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:4pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax Credit and grants recognized in net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:3pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:4pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;524&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Tax credits receivable comprise grants receivable, and research and development investment tax credits receivable which relate to eligible research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded. There are no unfulfilled conditions or contingencies associated with the government assistance received. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company has unused and unrecorded &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; federal tax credits which may be used to reduce future federal income tax payable and expire as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,209&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2028&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2029&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2030&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;818&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2031&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2032&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2033&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2039&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2040&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2041&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2042&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2043&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfTaxCreditsReceivableExplanatory>
    <thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-29006"> &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:90%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants recognized in net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(442)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:3pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16)&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:4pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax Credit and grants recognized in net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:3pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="padding-bottom:3pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:4pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;524&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </thtx:DisclosureDetailsOfTaxCreditsRollForwardTextBlock>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48335"
      unitRef="Unit_USD">441000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48336"
      unitRef="Unit_USD">316000</thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss>
    <thtx:TaxCreditsAndGrantsReceived
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48337"
      unitRef="Unit_USD">-442000</thtx:TaxCreditsAndGrantsReceived>
    <thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48338"
      unitRef="Unit_USD">-16000</thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48339"
      unitRef="Unit_USD">299000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48340"
      unitRef="Unit_USD">539000</thtx:TaxCreditsAndGrantsRecognizedInNetProfitOrLoss>
    <thtx:TaxCreditsAndGrantsReceived
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48341"
      unitRef="Unit_USD">-324000</thtx:TaxCreditsAndGrantsReceived>
    <thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48342"
      unitRef="Unit_USD">10000</thtx:IncreaseDecreaseThroughNetExchangeDifferencesTaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48343"
      unitRef="Unit_USD">524000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-29190">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,209&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2028&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2029&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2030&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;818&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2031&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2032&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2033&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2039&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2040&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2041&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2042&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;657&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;2043&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutUnusedAndUnrecordedNonRefundableFederalTaxCreditExplanatoryTableTextBlock>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFourMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48344"
      unitRef="Unit_USD">438000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyFiveMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48345"
      unitRef="Unit_USD">1306000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySixMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48346"
      unitRef="Unit_USD">1604000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentySevenMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48347"
      unitRef="Unit_USD">2209000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyEightMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48348"
      unitRef="Unit_USD">2451000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandTwentyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48349"
      unitRef="Unit_USD">1652000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48350"
      unitRef="Unit_USD">818000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48351"
      unitRef="Unit_USD">572000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48352"
      unitRef="Unit_USD">299000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48353"
      unitRef="Unit_USD">198000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandThirtyNineMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48354"
      unitRef="Unit_USD">185000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48355"
      unitRef="Unit_USD">315000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyOneMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48356"
      unitRef="Unit_USD">383000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyTwoMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48357"
      unitRef="Unit_USD">657000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_IncomeTaxExpireTwoThousandFortyThreeMemberifrsfullMaturityAxis_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48358"
      unitRef="Unit_USD">728000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn11_30_2023_UnusedAndUnrecordedTaxCreditsMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-3"
      id="ixv-48359"
      unitRef="Unit_USD">13815000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-29398">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:77%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;2,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;2,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,708&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,815&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,096&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,290&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,066&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,688&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In fiscal 2023, inventories of $18,540 (2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;$19,587) were recognized as an expense and included in cost of goods sold. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the second quarter of 2023, inventories for an amount of $3,295 was returned to TaiMed. and accounts payable was reduced by a total amount of &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x20ac;&lt;/div&gt;3,179 ($3,399). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In fiscal 2023, an inventory provision of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;220&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022 &#x2013; &lt;/div&gt;nil&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was recognized pending marketing approval of the F8 formulation of tesamorelin and recorded in cost of sales. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;Inventories were written down to net realizable value by an amount of $2,137 in 2022, which was recorded in cost of sales. Included in the 2022 write-down is a provision of $1,477 on the F8 formulation and $339 on material for the pen in development to be used in conjunction with the F8 formulation, and $252 on expired raw material. The 2022 write-down also includes a provision of $69 on excess stock of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; as a result of the Company&#x2019;s decision to withdraw the product from the market in Canada. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfInventoriesExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-48360">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:77%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;2,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2002;&#x2003;2,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,708&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,815&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:4.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,096&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,290&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,066&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,688&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTextTableTextBlock>
    <ifrs-full:RawMaterials
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48361"
      unitRef="Unit_USD">2262000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48362"
      unitRef="Unit_USD">2583000</ifrs-full:RawMaterials>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48363"
      unitRef="Unit_USD">1708000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48364"
      unitRef="Unit_USD">5815000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48365"
      unitRef="Unit_USD">2096000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48366"
      unitRef="Unit_USD">11290000</ifrs-full:FinishedGoods>
    <ifrs-full:InventoriesTotal
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48367"
      unitRef="Unit_USD">6066000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48368"
      unitRef="Unit_USD">19688000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoryWritedown2011
      contextRef="P12_01_2022To11_30_2023_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis"
      decimals="-3"
      id="ixv-48369"
      unitRef="Unit_USD">18540000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="P12_01_2021To11_30_2022_CostOfGoodsSoldMemberTHTXLocationInIncomeStatementAxis"
      decimals="-3"
      id="ixv-48370"
      unitRef="Unit_USD">19587000</ifrs-full:InventoryWritedown2011>
    <thtx:InventoriesReturned
      contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      id="ixv-48371"
      unitRef="Unit_USD">3295000</thtx:InventoriesReturned>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      id="ixv-48372"
      unitRef="Unit_EUR">3179000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="P03_01_2023To05_31_2023_TaiMedBiologicsIncMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-3"
      id="ixv-48373"
      unitRef="Unit_USD">3399000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48374"
      unitRef="Unit_USD">220000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48375"
      unitRef="Unit_USD">0</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:InventoryWritedown2011
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48376"
      unitRef="Unit_USD">2137000</ifrs-full:InventoryWritedown2011>
    <thtx:ProvisionForFormulation
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48377"
      unitRef="Unit_USD">1477000</thtx:ProvisionForFormulation>
    <thtx:ProvisionForTheInventoryInDevelopment
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48378"
      unitRef="Unit_USD">339000</thtx:ProvisionForTheInventoryInDevelopment>
    <thtx:ProvisionForTheExpiredRawMaterial
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48379"
      unitRef="Unit_USD">252000</thtx:ProvisionForTheExpiredRawMaterial>
    <thtx:ProvisionForExcessStock
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48380"
      unitRef="Unit_USD">69000</thtx:ProvisionForExcessStock>
    <thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits contextRef="P12_01_2022To11_30_2023" id="ixv-29583">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: Calibri; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Prepaid expenses and deposits &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 71%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Deposits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;467&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,345&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&#160; 3,154&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&#160;7,665&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureDetailsOfCurrentPrepaidExpensesAndDeposits>
    <ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-29592">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 71%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:6pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Deposits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;467&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,345&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&#160; 3,154&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160;&#160;7,665&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory>
    <thtx:PrepaidExpenses
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48381"
      unitRef="Unit_USD">-2687000</thtx:PrepaidExpenses>
    <thtx:PrepaidExpenses
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48382"
      unitRef="Unit_USD">-6320000</thtx:PrepaidExpenses>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48383"
      unitRef="Unit_USD">467000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48384"
      unitRef="Unit_USD">1345000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48385"
      unitRef="Unit_USD">3154000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48386"
      unitRef="Unit_USD">7665000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-29741"> &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 53%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="22" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;furniture&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="22" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;&#160;373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;1,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;961&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;1,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;2,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46) &lt;/td&gt;
&lt;td style="padding: 0px; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;251&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,196&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;359&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;650&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;2,456&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;229&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2009;380&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2009;227&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;74&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;816&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;132&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;184&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,206&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;167&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 905&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;137&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;285&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,494&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-29761"> &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 53%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="22" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;furniture&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="22" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;&#160;373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;1,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;961&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;1,068&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;2,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46) &lt;/td&gt;
&lt;td style="padding: 0px; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;251&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,196&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;359&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;650&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;2,456&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;229&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(263)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposals&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-  &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2009;380&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2009;227&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;74&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;816&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;132&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;184&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,206&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:7.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;167&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 905&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;137&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;285&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;1,494&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2021_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48387"
      unitRef="Unit_USD">373000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48388"
      unitRef="Unit_USD">107000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48389"
      unitRef="Unit_USD">332000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48390"
      unitRef="Unit_USD">650000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48391"
      unitRef="Unit_USD">1462000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48392"
      unitRef="Unit_USD">180000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48393"
      unitRef="Unit_USD">961000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48394"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48395"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48396"
      unitRef="Unit_USD">1141000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48397"
      unitRef="Unit_USD">263000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48398"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48399"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48400"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48401"
      unitRef="Unit_USD">263000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48402"
      unitRef="Unit_USD">290000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48403"
      unitRef="Unit_USD">1068000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48404"
      unitRef="Unit_USD">332000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48405"
      unitRef="Unit_USD">650000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48406"
      unitRef="Unit_USD">2340000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48407"
      unitRef="Unit_USD">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48408"
      unitRef="Unit_USD">128000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48409"
      unitRef="Unit_USD">27000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48410"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48411"
      unitRef="Unit_USD">162000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48412"
      unitRef="Unit_USD">46000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48413"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48414"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48415"
      unitRef="Unit_USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48416"
      unitRef="Unit_USD">46000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48417"
      unitRef="Unit_USD">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48418"
      unitRef="Unit_USD">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48419"
      unitRef="Unit_USD">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48420"
      unitRef="Unit_USD">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48421"
      unitRef="Unit_USD">0</ifrs-full:PropertyPlantAndEquipment>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48422"
      unitRef="Unit_USD">229000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48423"
      unitRef="Unit_USD">69000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48424"
      unitRef="Unit_USD">157000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48425"
      unitRef="Unit_USD">264000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48426"
      unitRef="Unit_USD">719000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48427"
      unitRef="Unit_USD">157000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48428"
      unitRef="Unit_USD">94000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48429"
      unitRef="Unit_USD">38000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48430"
      unitRef="Unit_USD">101000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48431"
      unitRef="Unit_USD">390000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48432"
      unitRef="Unit_USD">263000</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48433"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48434"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48435"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48436"
      unitRef="Unit_USD">263000</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48437"
      unitRef="Unit_USD">123000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48438"
      unitRef="Unit_USD">163000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48439"
      unitRef="Unit_USD">195000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48440"
      unitRef="Unit_USD">365000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48441"
      unitRef="Unit_USD">846000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48442"
      unitRef="Unit_USD">100000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48443"
      unitRef="Unit_USD">217000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48444"
      unitRef="Unit_USD">32000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48445"
      unitRef="Unit_USD">101000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48446"
      unitRef="Unit_USD">450000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48447"
      unitRef="Unit_USD">46000</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48448"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48449"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48450"
      unitRef="Unit_USD">0</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48451"
      unitRef="Unit_USD">46000</thtx:AccumulatedDepreciationDisposalsPropertyPlantAndEquipment>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48452"
      unitRef="Unit_USD">177000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48453"
      unitRef="Unit_USD">380000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48454"
      unitRef="Unit_USD">227000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48455"
      unitRef="Unit_USD">466000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <thtx:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAndAmortisationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48456"
      unitRef="Unit_USD">1250000</thtx:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48457"
      unitRef="Unit_USD">74000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48458"
      unitRef="Unit_USD">816000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48459"
      unitRef="Unit_USD">132000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48460"
      unitRef="Unit_USD">184000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48461"
      unitRef="Unit_USD">1206000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_ComputerEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48462"
      unitRef="Unit_USD">167000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_LaboratoryEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48463"
      unitRef="Unit_USD">905000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48464"
      unitRef="Unit_USD">137000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022_LeaseholdImprovementsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-3"
      id="ixv-48465"
      unitRef="Unit_USD">285000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48466"
      unitRef="Unit_USD">1494000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-30584"> &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:3%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:75%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(429)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 1,595&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(352)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19(a)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(799)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;New lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;770&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <thtx:RightOfUseAssetsTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-30597">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:3%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:75%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(429)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 1,595&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(352)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19(a)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(799)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;New lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;)&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;770&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="10" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:RightOfUseAssetsTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48467"
      unitRef="Unit_USD">2111000</ifrs-full:RightofuseAssets>
    <thtx:AmortizationOfRightOfUseAsset
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48468"
      unitRef="Unit_USD">-429000</thtx:AmortizationOfRightOfUseAsset>
    <thtx:IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48469"
      unitRef="Unit_USD">-87000</thtx:IncreaseDecreaseThroughNetExchangeDifferencesOfRightToUseAsset>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48470"
      unitRef="Unit_USD">1595000</ifrs-full:RightofuseAssets>
    <thtx:AmortizationOfRightOfUseAsset
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48471"
      unitRef="Unit_USD">-352000</thtx:AmortizationOfRightOfUseAsset>
    <thtx:TerminationOfRightOfUseAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48472"
      unitRef="Unit_USD">-799000</thtx:TerminationOfRightOfUseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48473"
      unitRef="Unit_USD">326000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48474"
      unitRef="Unit_USD">770000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-30767">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Calibri; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangible assets &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 41%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;American&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Territory&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;European&#160;Territory&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights&#160;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&#160;SV&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Oncology&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;platform&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;11,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;37,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,804&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;39,945&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,804&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;32,333&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 3,267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&#160;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;11,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;15,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,087&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,613&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,511&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,211&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 4,354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;12,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;24,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 1,442&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 1,071&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 2,513&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 5,796&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;19,837&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 9,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;12,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;10,450&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding: 0px; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 1,071&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;15,009&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amortization expense of $&lt;/div&gt;2,513&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022&#160;&#x2013; $ &lt;/div&gt;9,211&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;; 2021 &#x2013; $ &lt;/div&gt;3,180&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) is included in selling expenses.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercialization rights &#x2013; Trogarzo&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;On March&#160;18, 2016, the Company entered into a distribution and marketing agreement with TaiMed granting the Company the exclusive right to market Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in Canada and in the United&#160;States. On March&#160;6, 2017, the Company entered into an amended and restated distribution and marketing agreement with TaiMed (&#x201c;TaiMed Agreement&#x201d;) granting the Company the exclusive right to market and distribute Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in Canada and in the United States (collectively, the &#x201c;North&#160;American Territory&#x201d;) as well as in European Union countries and other countries such as Israel, Norway, Russia and Switzerland (collectively, the &#x201c;European Territory&#x201d;). The TaiMed Agreement has a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-year&lt;/div&gt; term that will expire on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt;&lt;/div&gt; basis calculated from the date of approval of Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in each of the countries covered under the TaiMed Agreement. TaiMed is responsible for the manufacture and supply of Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; under the TaiMed Agreement. &lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;div&gt;  &lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercialization rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in the North American Territory &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Under the terms of the TaiMed Agreement, TaiMed was responsible for developing Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; and for seeking its approval from the US Food and Drug Administration (&#x201c;FDA&#x201d;). The Company is responsible, but has no obligation, to seek the approval of Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; from Health Canada and must use its commercially reasonable efforts to commercialize Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;in the United States. The purchase price of Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; payable to TaiMed has been determined at 52% of its net selling price. &lt;/div&gt; &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial payments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Under the TaiMed Agreement, the Company agreed to make an initial payment of US$5,000 and will make several further milestone payments in exchange for the right to commercialize Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; and the right to use TaiMed&#x2019;s trademark in the North American Territory. &lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The initial payment of $5,000 was made in accordance with the following: &lt;/div&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;$1,000 was paid in cash at the signature of the TaiMed Agreement entered into in March 2016;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 14pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;$4,000 through the issuance of the Company&#x2019;s common shares, payable after the first commercial sale of Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in the United States. The $4,000 payment was made on May&#160;15, 2018 and resulted in the issuance of 1,463,505 common shares to TaiMed. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2016, the Company recorded as additions to intangible assets an amount &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of $&lt;/div&gt;5,207&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;related to the TaiMed Agreement, which comprised the cash payment of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $&lt;/div&gt;1,000&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at the signature of the TaiMed Agreement, the &lt;div style="text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; payment of&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;4,000&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;207&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in&lt;/div&gt; acquisition costs.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Further development milestone payments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Under the terms of the TaiMed Agreement, a further milestone of $7,000 was payable in two annual&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;equal&lt;/div&gt; installments of $3,500 after achieving aggregate net sales of $20,000 over four consecutive quarters of the Company&#x2019;s financial year. The first payment of $3,500 was made in July 2019, and the second payment was made in June 2020. The Company determined this milestone to be substantially a development milestone and recorded such amount as additions to intangible assets during 2019. The Company also paid TaiMed further development milestones for Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;in 2022. A $3,000 milestone (payable in two annual&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;equal&lt;/div&gt; installments of $1,500) became due upon the date of the first commercial sale of a once every two weeks &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;intravenous (IV) push&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;injection formulation. An amount of $&lt;/div&gt;2,832&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; has been capitalized as an intangible asset in fiscal 2022 related to these milestone payments (refer to Note 15).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the TaiMed Agreement, TaiMed may also launch a larger Phase III trial using Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;with a once every four weeks intramuscular, subcutaneous or intravenous-push (either fast or slow) injection formulation to address a much broader patient population. If launched, this development milestone will consist of an upfront milestone payment of up &lt;/div&gt;&lt;/div&gt;to $50,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;depending on the size of the newly targeted population, payable quarterly, based on the percentage of net sales generated &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by Trogarzo&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Further commercial milestone payments &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;As further consideration under the TaiMed Agreement, the Company shall make the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; payments upon the first occurrence of the following commercial events: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 96%; border: 0px; margin-left: auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 21%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial milestone&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial&#160;milestone&#160;payment&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(i) Upon first achieving annual net sales of $200,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$10,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(ii) Upon first achieving annual net sales of $500,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 4pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(iii) Upon first achieving annual net sales of $1,000,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;$100,000&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="margin-top:36pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercialization rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; European Territory &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;17, 2022, the Company announced that it would focus its commercial operations on the North American Territory only and, as a result, would cease the commercial sale of Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in Europe. Refer to Note 3. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consequently, during the second quarter of 2022, the remaining balance of the intangible asset amounting&lt;/div&gt;&lt;/div&gt;&#160;to $6,356 was recognized as part of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;selling &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses to accelerate and fully amortize &#x2013; Commercialization rights Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; &#x2013; European Territory.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 11pt; font-family: Calibri;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Oncology platform &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;On February&#160;25, 2019, the Company acquired Katana Biopharma Inc. (&#x201c;Katana&#x201d;) through the purchase of all of its issued and outstanding shares. On May&#160;21, 2019, Katana was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;wound-up&lt;/div&gt; into the Company and then dissolved. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Katana (now the Company) is the worldwide exclusive licensee of a technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to Sortilin receptors, which are overexpressed on cancer cells. The licence was entered into on February&#160;25, 2019 with Transfert Plus, L.P. (&#x201c;Transfert Plus&#x201d;), an affiliate of Aligo Innovation, a university research company that commercializes the research results of universities and other institutional partners from various areas of innovation, including life sciences (the &#x201c;Licence Agreement&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the acquisition agreement, part of the purchase price was to be settled through the issuance of common shares upon achieving two milestones. The first milestone consisted in initiating a Phase 1 clinical trial evaluating Sudocetaxel zendusortide for the treatment of Sortilin positive solid tumors. This milestone was achieved in March 2021 and was satisfied through the issuance &lt;/div&gt;&lt;/div&gt;of 120,482 common shares (Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;(b)). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The second milestone payment of CA$2.3&#160;million will occur when the proof of concept will have been demonstrated in human subjects and will be satisfied through the issuance of common shares of the Company. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;This acquisition was accounted for as an asset acquisition. During 2019, the Company recorded additions to intangible assets of $3,073, which comprised the payment at closing of $1,965 in cash, $5 through the issuance of 900 common shares of the Company, the estimated fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; contingent consideration of $1,028, and $75 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in acquisition costs. As the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; payments are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity-settled,&lt;/div&gt; the Company recognized a corresponding increase in equity, and no remeasurement of the fair value will occur regardless of the achievement of the milestones. Since the common shares for the second milestone payment have not been issued yet, the increase in equity is recorded in contributed surplus. Upon the issuance of the common shares, this amount will be reclassified to share capital. The intangible asset is currently not being amortized. Amortization will begin when the asset is available for use&lt;/div&gt;. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;In August 2019, the acquisition agreement was amended to provide for an adjustment to the purchase price of CA$1.08&#160;million in the event the Company could indirectly benefit from a CA$1.2&#160;million subsidy in connection with its research and development activities. The subsidy was granted in October 2019. The adjustment will be payable in two installments. The first installment of CA$500&#160;thousand was paid in cash in October 2019, whereas the second installment of CA$580&#160;thousand will be paid&#160;through the issuance of common shares of the Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at the same time as the second milestone payment of CA$2.3&#160;million. The cash&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;payment of $376 (CA$500) thousand was recognized as an addition to intangible assets during&#160;2019. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The annual maintenance fees, under the Licence Agreement amount &lt;/div&gt;&lt;/div&gt; to CA$25&#160;thousand for the first five years and CA$100&#160;thousand thereafter, until royalties become payable beginning with the first commercial sale of a product developed using the licensed technology. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The royalties payable under the Licence Agreement vary between 1.0% and 2.5% on net sales of a product based on the licensed technology. If the Company enters into a sublicence agreement, it must then pay amounts varying between 5% and 15% of revenues received fr&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;om&lt;/div&gt; such sublicence agreement. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt; &lt;div style="font-family: Calibri; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company must pay Transfert Plus the following milestone payments upon the occurrence of the following development milestones for the first product developed in the field of oncology: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:6%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;First milestone payment: $39 (CA$50) thousand&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, which was paid in May 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;/div&gt; upon the successful enrollment of the first patient in the first Phase 1 clinical trial; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:6%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;Second milestone payment: CA$100&#160;thousand upon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;th&lt;/div&gt;e successful enrollment of the first patient in the first Phase 2 clinical trial; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:6%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(iii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;Third milestone payment: CA$200&#160;thousand upon the successful enrollment of the first patient in the first Phase 3 clinical trial. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition,&lt;/div&gt;&lt;/div&gt;&#160;the Company must pay CA$200&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thousand per product upon receiving the first approval for such product by a regulatory authority. The approval shall entitle the sponsor to commercialize the product in the territory in which the approval was obtained&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; </ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-30776">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 41%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 12pt; font-size: 12pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;American&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Territory&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights &#x2013; Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;European&#160;Territory&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 2pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercialization&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: Calibri; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rights&#160;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&#160;SV&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:7.5px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Oncology&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: Calibri; text-align: right; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;platform&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:2pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 3.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;11,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;37,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Additions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom:2pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,804&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;39,945&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,804&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;32,333&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 3,267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&#160;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;11,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;15,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,087&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,613&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,511&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;- &lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,211&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 4,354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;7,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;12,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;24,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Disposal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,612)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 1,442&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;$&#160; 1,071&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 2,513&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Balance as at&lt;br/&gt; November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 5,796&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;14,041&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;19,837&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 9,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;12,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;10,450&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;-&lt;/td&gt;
&lt;td style="padding: 0px; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160; 1,071&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;3,488&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#160;15,009&lt;/td&gt;
&lt;td style="padding-bottom:2.5pt;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="22" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48475"
      unitRef="Unit_USD">11972000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48476"
      unitRef="Unit_USD">7612000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48477"
      unitRef="Unit_USD">14041000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48478"
      unitRef="Unit_USD">3488000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48479"
      unitRef="Unit_USD">37113000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48480"
      unitRef="Unit_USD">2832000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48481"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48482"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48483"
      unitRef="Unit_USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48484"
      unitRef="Unit_USD">2832000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48485"
      unitRef="Unit_USD">14804000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48486"
      unitRef="Unit_USD">7612000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48487"
      unitRef="Unit_USD">14041000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48488"
      unitRef="Unit_USD">3488000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48489"
      unitRef="Unit_USD">39945000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48490"
      unitRef="Unit_USD">7612000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48491"
      unitRef="Unit_USD">7612000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48492"
      unitRef="Unit_USD">14804000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48493"
      unitRef="Unit_USD">14041000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48494"
      unitRef="Unit_USD">3488000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48495"
      unitRef="Unit_USD">32333000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48496"
      unitRef="Unit_USD">3267000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48497"
      unitRef="Unit_USD">999000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48498"
      unitRef="Unit_USD">11459000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48499"
      unitRef="Unit_USD">15725000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48500"
      unitRef="Unit_USD">1087000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48501"
      unitRef="Unit_USD">6613000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48502"
      unitRef="Unit_USD">1511000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2021To11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48503"
      unitRef="Unit_USD">9211000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48504"
      unitRef="Unit_USD">4354000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48505"
      unitRef="Unit_USD">7612000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48506"
      unitRef="Unit_USD">12970000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48507"
      unitRef="Unit_USD">24936000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48508"
      unitRef="Unit_USD">-7612000</thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48509"
      unitRef="Unit_USD">-7612000</thtx:AccumulatedAmortizationDisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48510"
      unitRef="Unit_USD">1442000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48511"
      unitRef="Unit_USD">1071000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48512"
      unitRef="Unit_USD">2513000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48513"
      unitRef="Unit_USD">5796000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48514"
      unitRef="Unit_USD">14041000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48515"
      unitRef="Unit_USD">19837000</thtx:AccumulatedAmortizationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48516"
      unitRef="Unit_USD">9008000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48517"
      unitRef="Unit_USD">3488000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2023_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48518"
      unitRef="Unit_USD">12496000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48519"
      unitRef="Unit_USD">10450000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsTrogarzoEuropeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48520"
      unitRef="Unit_USD">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_CommercializationRightsEgriftaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48521"
      unitRef="Unit_USD">1071000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OncologyPlatformMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-3"
      id="ixv-48522"
      unitRef="Unit_USD">3488000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn11_30_2022_NetCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-3"
      id="ixv-48523"
      unitRef="Unit_USD">15009000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationExpense
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48524"
      unitRef="Unit_USD">2513000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48525"
      unitRef="Unit_USD">9211000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48526"
      unitRef="Unit_USD">3180000</ifrs-full:AmortisationExpense>
    <thtx:IntangibleAssetsAgreementTermOfContract
      contextRef="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      id="ixv-48527">P12Y</thtx:IntangibleAssetsAgreementTermOfContract>
    <thtx:PercentageOfPurchasePriceConsiderationOfIntangibleAssets
      contextRef="P03_06_2017To03_06_2017_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="2"
      id="ixv-48528"
      unitRef="Unit_pure">0.52</thtx:PercentageOfPurchasePriceConsiderationOfIntangibleAssets>
    <thtx:InitialMilestonePaymentsPayable
      contextRef="PAsOn03_31_2016_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48529"
      unitRef="Unit_USD">5000000</thtx:InitialMilestonePaymentsPayable>
    <thtx:LaunchMilestonePayable
      contextRef="PAsOn12_01_2017_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48530"
      unitRef="Unit_USD">5000000</thtx:LaunchMilestonePayable>
    <thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48531"
      unitRef="Unit_USD">1000000</thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment>
    <thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment
      contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48532"
      unitRef="Unit_USD">4000000</thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn05_15_2018_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="INF"
      id="ixv-48533"
      unitRef="Unit_shares">1463505</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn05_15_2018_CommercializationRightsTrogarzoNorthAmericaMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="INF"
      id="ixv-48534"
      unitRef="Unit_shares">1463505</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48535"
      unitRef="Unit_USD">5207000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment
      contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48536"
      unitRef="Unit_USD">1000000</thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillCashPayment>
    <thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment
      contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48537"
      unitRef="Unit_USD">4000000</thtx:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwillShareBasedPayment>
    <thtx:AcquisitionCostsForIntangibleAssets
      contextRef="P12_01_2015To11_30_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48538"
      unitRef="Unit_USD">207000</thtx:AcquisitionCostsForIntangibleAssets>
    <thtx:InitialMilestonePaymentsPayableAggregateAnnualInstallments.
      contextRef="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48539"
      unitRef="Unit_USD">7000000</thtx:InitialMilestonePaymentsPayableAggregateAnnualInstallments.>
    <thtx:FirstMilestoneInstallmentPaymentsPayable
      contextRef="PAsOn11_30_2022_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48540"
      unitRef="Unit_USD">3500000</thtx:FirstMilestoneInstallmentPaymentsPayable>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48541"
      unitRef="Unit_USD">20000000</ifrs-full:Revenue>
    <thtx:SecondMilestoneInstallmentPaymentsPayable
      contextRef="PAsOn11_30_2021_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48542"
      unitRef="Unit_USD">3500000</thtx:SecondMilestoneInstallmentPaymentsPayable>
    <thtx:PaymentOfUpfrontMilestones
      contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48543"
      unitRef="Unit_USD">3000000</thtx:PaymentOfUpfrontMilestones>
    <thtx:DevelopmentMilestonePayableAnnualInstallment
      contextRef="PAsOn12_31_2016_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48544"
      unitRef="Unit_USD">1500000</thtx:DevelopmentMilestonePayableAnnualInstallment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48545"
      unitRef="Unit_USD">2832000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:Revenue
      contextRef="P12_01_2016To11_30_2017_EuropeMemberifrsfullGeographicalAreasAxis_MilestoneOneMemberTHTXMilestoneAxis_TaimedAgreementMemberTHTXTypeOfArrangementsAxis"
      decimals="-3"
      id="ixv-48546"
      unitRef="Unit_USD">50000000</ifrs-full:Revenue>
    <thtx:DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-31671"> &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;As further consideration under the TaiMed Agreement, the Company shall make the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; payments upon the first occurrence of the following commercial events: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 96%; border: 0px; margin-left: auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 21%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial milestone&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 10pt; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commercial&#160;milestone&#160;payment&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(i) Upon first achieving annual net sales of $200,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$10,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(ii) Upon first achieving annual net sales of $500,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 4pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;(iii) Upon first achieving annual net sales of $1,000,000&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;$100,000&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutInCommercialMilestonePaymentExplanatoryTextBlock>
    <thtx:InitialMilestonePaymentsPayable
      contextRef="PAsOn11_30_2023_MilestoneFourMemberTHTXMilestoneAxis"
      decimals="-3"
      id="ixv-48547"
      unitRef="Unit_USD">10000000</thtx:InitialMilestonePaymentsPayable>
    <thtx:InitialMilestonePaymentsPayable
      contextRef="PAsOn11_30_2023_MilestoneFiveMemberTHTXMilestoneAxis"
      decimals="-3"
      id="ixv-48548"
      unitRef="Unit_USD">40000000</thtx:InitialMilestonePaymentsPayable>
    <thtx:InitialMilestonePaymentsPayable
      contextRef="PAsOn11_30_2023_MilestoneSixMemberTHTXMilestoneAxis"
      decimals="-3"
      id="ixv-48549"
      unitRef="Unit_USD">100000000</thtx:InitialMilestonePaymentsPayable>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn05_31_2022_TrogarzoMemberifrsfullProductsAndServicesAxis"
      decimals="-3"
      id="ixv-48550"
      unitRef="Unit_USD">6356000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      id="ixv-48551"
      unitRef="Unit_shares">120482</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn11_30_2022_KatanaMemberifrsfullBusinessCombinationsAxis_LicenseAgreementTransferPlusLPMemberTHTXTypeOfArrangementsAxis_MilestonePhaseTwoLiveDemonstrationMemberTHTXMilestoneAxis"
      decimals="-5"
      id="ixv-48552"
      unitRef="Unit_CAD">2300000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48553"
      unitRef="Unit_USD">3073000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:CashTransferred
      contextRef="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48554"
      unitRef="Unit_USD">1965000</ifrs-full:CashTransferred>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48555"
      unitRef="Unit_USD">5000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="PAsOn11_30_2019_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="INF"
      id="ixv-48556"
      unitRef="Unit_shares">900</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <thtx:BusinessCombinationContingentConsiderationFairValue
      contextRef="PAsOn11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48557"
      unitRef="Unit_USD">1028000</thtx:BusinessCombinationContingentConsiderationFairValue>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="P12_01_2022To11_30_2023_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48558"
      unitRef="Unit_USD">75000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <thtx:BusinessCombinationIncreaseDecreaseInPurchaseConsideration
      contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-4"
      id="ixv-48559"
      unitRef="Unit_CAD">1080000.00</thtx:BusinessCombinationIncreaseDecreaseInPurchaseConsideration>
    <ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities
      contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      id="ixv-48560"
      unitRef="Unit_CAD">1200000</ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities>
    <ifrs-full:CashTransferred
      contextRef="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentOneMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48561"
      unitRef="Unit_CAD">500000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn11_30_2023_BusinessCombinationAdjustmentToConsiderationInstallmentTwoMemberTHTXBusinessCombinationAdjustmentToPurchaseConsiderationAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48562"
      unitRef="Unit_USD">580000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-5"
      id="ixv-48563"
      unitRef="Unit_CAD">2300000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48564"
      unitRef="Unit_USD">376000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P12_01_2018To11_30_2019_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48565"
      unitRef="Unit_CAD">500000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="P12_01_2022To11_30_2023_FirstFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis"
      decimals="-3"
      id="ixv-48566"
      unitRef="Unit_CAD">25000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="P12_01_2022To11_30_2023_AfterFiveYearsMemberTHTXFeesPeriodAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRelatedLicensePeptidesMemberTHTXNatureOfFeesAxis"
      decimals="-3"
      id="ixv-48567"
      unitRef="Unit_CAD">100000</ifrs-full:FeeAndCommissionExpense>
    <thtx:RoyaltyFeesAsAPercentageOfRevenue
      contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis"
      decimals="3"
      id="ixv-48568"
      unitRef="Unit_pure">0.01</thtx:RoyaltyFeesAsAPercentageOfRevenue>
    <thtx:RoyaltyFeesAsAPercentageOfRevenue
      contextRef="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_NetSalesBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="3"
      id="ixv-48569"
      unitRef="Unit_pure">0.025</thtx:RoyaltyFeesAsAPercentageOfRevenue>
    <thtx:RoyaltyFeesAsAPercentageOfRevenue
      contextRef="P12_01_2022To11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis"
      decimals="2"
      id="ixv-48570"
      unitRef="Unit_pure">0.05</thtx:RoyaltyFeesAsAPercentageOfRevenue>
    <thtx:RoyaltyFeesAsAPercentageOfRevenue
      contextRef="P12_01_2022To11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis_RoyaltyRevenueSublicenseBasisMemberTHTXBasisOfRoyaltyPaymentAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48571"
      unitRef="Unit_pure">0.15</thtx:RoyaltyFeesAsAPercentageOfRevenue>
    <thtx:MilestoneAmountPayable
      contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48572"
      unitRef="Unit_USD">39000</thtx:MilestoneAmountPayable>
    <thtx:MilestoneAmountPayable
      contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseOneClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48573"
      unitRef="Unit_CAD">50000</thtx:MilestoneAmountPayable>
    <thtx:MilestoneAmountPayable
      contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseTwoClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48574"
      unitRef="Unit_CAD">100000</thtx:MilestoneAmountPayable>
    <thtx:MilestoneAmountPayable
      contextRef="PAsOn11_30_2021_DevelopmentMilestonePhaseThreeClinicalTrialMemberTHTXMilestoneAxis_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48575"
      unitRef="Unit_CAD">200000</thtx:MilestoneAmountPayable>
    <thtx:RegulatoryMilestonePaymentPayable
      contextRef="PAsOn11_30_2023_KatanaAmendmentAgreementMemberifrsfullBusinessCombinationsAxis"
      decimals="-3"
      id="ixv-48576"
      unitRef="Unit_CAD">200000</thtx:RegulatoryMilestonePaymentPayable>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-31966">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other asset &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021, 2022 and 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;19,530&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;17,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,441&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;19,530&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;November&#160;30, 2023 and November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; May&#160;29, 2018, the Company entered into an agreement with EMD Serono, Inc. (the &#x201c;Renegotiated Agreement&#x201d;) to settle all outstanding cash payment obligations stemming from a termination and transfer agreement dated December&#160;13, 2013, as amended (the &#x201c;2013&#160;Termination Agreement&#x201d;). The remaining contractual obligations under the 2013 Termination Agreement totalled approxima&lt;/div&gt;&lt;/div&gt;tely $28,200, which was comprised of a $4,000 payment due in May 2019 and $24,200 in estimated royalties on future sales of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; payable over the subsequent four to five years. The Renegotiated Agreement allowed the Company to make one lump sum payment of $23,850 in settlement of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; obligation of $4,000 and to eliminate all of the royalty payments due on sales of &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in the United States. The payment made in connection with the settlement of the future royalty obligation has been accounted for as &#x201c;Other asset&#x201d; on the consolidated statement of financial position and was amortized through &#x201c;Cost of sales&#x201d; on the consolidated statement of net loss. &lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-31982">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt; border-top: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021, 2022 and 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;19,530&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;17,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,441&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Balance as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);;text-align:right;"&gt;19,530&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0); border-top: 0.75pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;November&#160;30, 2023 and November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; border-bottom: 1.5pt solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutOtherAssetExplanatoryTableTextBlock>
    <thtx:OtherAssetsNonCurrentAtCost
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48577"
      unitRef="Unit_USD">19530000</thtx:OtherAssetsNonCurrentAtCost>
    <thtx:OtherAssetsNonCurrentAtCost
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48578"
      unitRef="Unit_USD">19530000</thtx:OtherAssetsNonCurrentAtCost>
    <thtx:OtherAssetsNonCurrentAtCost
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48579"
      unitRef="Unit_USD">19530000</thtx:OtherAssetsNonCurrentAtCost>
    <thtx:AccumulatedAmortizationOnOtherNonCurrentAssets
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48580"
      unitRef="Unit_USD">17089000</thtx:AccumulatedAmortizationOnOtherNonCurrentAssets>
    <thtx:AmortizationOfOtherNonCurrentAssets
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48581"
      unitRef="Unit_USD">2441000</thtx:AmortizationOfOtherNonCurrentAssets>
    <thtx:AccumulatedAmortizationOnOtherNonCurrentAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48582"
      unitRef="Unit_USD">19530000</thtx:AccumulatedAmortizationOnOtherNonCurrentAssets>
    <thtx:NetCarryingAmount
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48583"
      unitRef="Unit_USD">0</thtx:NetCarryingAmount>
    <thtx:NetCarryingAmount
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48584"
      unitRef="Unit_USD">0</thtx:NetCarryingAmount>
    <thtx:ContractualObligations
      contextRef="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48586"
      unitRef="Unit_USD">28200000</thtx:ContractualObligations>
    <thtx:ContractualObligations
      contextRef="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48587"
      unitRef="Unit_USD">4000000</thtx:ContractualObligations>
    <thtx:ContractualObligations
      contextRef="PAsOn05_29_2018_DueInNextFourToFiveYearsMemberifrsfullMaturityAxis_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48588"
      unitRef="Unit_USD">24200000</thtx:ContractualObligations>
    <thtx:PerformanceObligationFinalSettlementAmount
      contextRef="PAsOn05_29_2018_SeronoIncMemberifrsfullCounterpartiesAxis_TwoThousandThirteenTerminationAgreementMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48589"
      unitRef="Unit_USD">23850000</thtx:PerformanceObligationFinalSettlementAmount>
    <thtx:ContractualObligations
      contextRef="PAsOn05_29_2018_DueWithOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-48590"
      unitRef="Unit_USD">4000000</thtx:ContractualObligations>
    <thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-32190">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto;"&gt;
&lt;tr&gt;
&lt;td style="width:90%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#x2003;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,886&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Accrued liabilities and other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Salaries and benefits due to key management personnel&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,036&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Employee salaries and benefits payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Liability related to deferred stock unit plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20(e)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -2em; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.2em; line-height: normal;"&gt;Accrued interest payable on convertible unsecured senior notes and Loan Facility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&#160;and&#160;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#x2003;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;TaiMed milestone (a)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,846&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,471&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,065&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: left; line-height: normal;"&gt;On October&#160;3, 2022, the Company announced that the United States Food and Drug Administration approved Trogarzo&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; (ibalizumab-uiyk) for administration by intravenous (IV)&#160;push, a method by which the undiluted medication is &#x201c;pushed&#x201d; by syringe for faster administration into the body&#x2019;s circulation. Under the TaiMed &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&lt;/div&gt;greement, the Company ha&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;additional contingent cash-based milestones based on the attainment of the above milestones. Accordingly&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; a $3,000 cash payment, payable in two annual &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;equal &lt;/div&gt;installments of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,500&lt;/div&gt; has been accrued. The second payment has been discounted to reflect the effective interest rate of the liability due in year&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;two&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;. The first installment of $ 1,500 was paid in 2023 and the second will be paid in 2024. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfTradeAndAccruedPayablesExplanatoryTextBlock>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-32202">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto;"&gt;
&lt;tr&gt;
&lt;td style="width:90%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#x2003;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,886&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Accrued liabilities and other payables&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Salaries and benefits due to key management personnel&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,036&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Employee salaries and benefits payable&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;Liability related to deferred stock unit plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20(e)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -2em; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.2em; line-height: normal;"&gt;Accrued interest payable on convertible unsecured senior notes and Loan Facility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&#160;and&#160;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#x2003;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; line-height: normal;"&gt;TaiMed milestone (a)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,846&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 11pt;"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,471&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,065&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48591"
      unitRef="Unit_USD">6990000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48592"
      unitRef="Unit_USD">12886000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48593"
      unitRef="Unit_USD">15016000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48594"
      unitRef="Unit_USD">18951000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48595"
      unitRef="Unit_USD">1036000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48596"
      unitRef="Unit_USD">3387000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48597"
      unitRef="Unit_USD">3053000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48598"
      unitRef="Unit_USD">1298000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48599"
      unitRef="Unit_USD">39000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48600"
      unitRef="Unit_USD">589000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:CurrentInterestPayable
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48601"
      unitRef="Unit_USD">840000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentInterestPayable
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48602"
      unitRef="Unit_USD">1108000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:OtherCurrentPayables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48603"
      unitRef="Unit_USD">1497000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48604"
      unitRef="Unit_USD">2846000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48605"
      unitRef="Unit_USD">28471000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48606"
      unitRef="Unit_USD">41065000</ifrs-full:TradeAndOtherCurrentPayables>
    <thtx:PaymentOfMilestones
      contextRef="P10_03_2022To10_03_2022"
      decimals="-3"
      id="ixv-48607"
      unitRef="Unit_USD">3000000</thtx:PaymentOfMilestones>
    <thtx:EqualAnnualInstallments
      contextRef="PAsOn10_03_2022"
      decimals="-3"
      id="ixv-48608"
      unitRef="Unit_USD">1500000</thtx:EqualAnnualInstallments>
    <thtx:PaymentForContingentLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48609"
      unitRef="Unit_USD">1500000</thtx:PaymentForContingentLiabilities>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-32457">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Provisions&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 88%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and&#160;rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;410&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions made&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions used&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,358)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,287)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(233)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(233)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;6,032&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160;1,485&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160; 7,517&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions made&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions used&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,506)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(309)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,721)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,536)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,101&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,262&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,603&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:justify"&gt;In July 2023, the Company initiated a reorganization mainly focused on its R&amp;amp;D activities. On October&#160;24, 2023, the Company announced changes to its operations that saw a tapering of its research and development activities. As such, for the year ended November&#160;30, 2023, $1,963 was recorded in charges related to severance and other expenses, of which an amount of $1,384 was recorded in research and development expenses, $220 in selling expenses and $359 in general and administrative expenses. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-32469"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 88%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and&#160;rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;410&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions made&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions used&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,358)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,287)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(233)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(233)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;6,032&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160;1,485&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160; 7,517&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:15.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions made&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,407&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions used&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,506)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(309)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,721)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,536)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 10pt; vertical-align: top; width: 50%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.2em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,101&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,262&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;240&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,603&lt;/td&gt;
&lt;td style="padding-bottom:10pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:justify"&gt;In July 2023, the Company initiated a reorganization mainly focused on its R&amp;amp;D activities. On October&#160;24, 2023, the Company announced changes to its operations that saw a tapering of its research and development activities. As such, for the year ended November&#160;30, 2023, $1,963 was recorded in charges related to severance and other expenses, of which an amount of $1,384 was recorded in research and development expenses, $220 in selling expenses and $359 in general and administrative expenses. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</thtx:DisclosureOfDetailedInformationAboutProvisionsExplanatoryTableTextBlock>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2021_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48610"
      unitRef="Unit_USD">3713000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48611"
      unitRef="Unit_USD">410000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2021_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48612"
      unitRef="Unit_USD">0</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48613"
      unitRef="Unit_USD">4123000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48614"
      unitRef="Unit_USD">12910000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48615"
      unitRef="Unit_USD">2004000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48616"
      unitRef="Unit_USD">14914000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48617"
      unitRef="Unit_USD">10358000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2021To11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48618"
      unitRef="Unit_USD">929000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2021To11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48619"
      unitRef="Unit_USD">0</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48620"
      unitRef="Unit_USD">11287000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P12_01_2021To11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48621"
      unitRef="Unit_USD">-233000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48622"
      unitRef="Unit_USD">-233000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2022_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48623"
      unitRef="Unit_USD">6032000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48624"
      unitRef="Unit_USD">1485000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2022_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48625"
      unitRef="Unit_USD">0</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48626"
      unitRef="Unit_USD">7517000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48627"
      unitRef="Unit_USD">15407000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48628"
      unitRef="Unit_USD">1086000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48629"
      unitRef="Unit_USD">1963000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48630"
      unitRef="Unit_USD">18456000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48631"
      unitRef="Unit_USD">14506000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2022To11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48632"
      unitRef="Unit_USD">309000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48633"
      unitRef="Unit_USD">1721000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48634"
      unitRef="Unit_USD">16536000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P12_01_2022To11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48635"
      unitRef="Unit_USD">168000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P12_01_2022To11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48636"
      unitRef="Unit_USD">-2000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48637"
      unitRef="Unit_USD">166000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2023_ChargebacksAndRebatesMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48638"
      unitRef="Unit_USD">7101000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2023_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48639"
      unitRef="Unit_USD">2262000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2023_OtherAdditionalProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-3"
      id="ixv-48640"
      unitRef="Unit_USD">240000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48641"
      unitRef="Unit_USD">9603000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_SeveranceAndOtherExpensesMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"
      decimals="-3"
      id="ixv-48642"
      unitRef="Unit_USD">1963000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_ResearchAndDevelopmentExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"
      decimals="-3"
      id="ixv-48643"
      unitRef="Unit_USD">1384000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_SellingAndMarketingExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"
      decimals="-3"
      id="ixv-48644"
      unitRef="Unit_USD">220000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P12_01_2022To11_30_2023_GeneralAndAdministrativeExpenseMemberifrsfullAttributionOfExpensesByNatureToTheirFunctionAxis"
      decimals="-3"
      id="ixv-48645"
      unitRef="Unit_USD">359000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-32867">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loan Facility&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;20, 2022, the Company entered into a credit agreement with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, &#x201c;Marathon&#x201d;) providing for up to $&lt;/div&gt;&lt;/div&gt;100,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(the &#x201c;Loan Facility&#x201d; or &#x201c;Marathon Credit Agreement&#x201d;) in loan. The disbursement of the loan was to be made available to the Company over time in four various tranches with each bearing specific conditions to be met by the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 27, 2022, a principal amount of $40,000 (&#x201c;Tranche 1 Loan&#x201d;) was funded while on June 21, 2023, a second $20,000 (&#x2018;Tranche 2 Loan&#x201d;) was funded as a result of the lender removing during the first quarter of 2023 the condition related to the submission to the FDA of the results from the human factor study the Company was then conducting. Refer to Note 20(c) for a discussion on the cost of the amendment. The Company does not meet the conditions precedents to draw down the additional tranches of capital of $15,000 and $25,000, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;3, 2023, the Company incurred a Liquidity Breach resulting in the lender having the ability to demand immediate repayment of the debt and in making available to the lender the collateralized assets, which include substantially all cash, bonds and money market funds which are subject to control agreements. On July&#160;10, 2023, the Company and the lender amended the terms of the Marathon Credit Agreement to reduce the minimum liquidity covenant for the period of July&#160;10 to July&#160;28, 2023 as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;From $20,000 to $14,000 between July&#160;10, 2023 up to and including July&#160;21, 2023; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;"&gt;From $14,000 to $16,000 between July&#160;22, 2023 up to and including July&#160;28, 2023. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 28, 2023, the Company and the lender entered into an additional amendment to the terms of the Marathon Credit Agreement to provide, amongst other things, for the minimum liquidity covenant to be&lt;/div&gt; $&lt;/div&gt;&lt;/div&gt;15,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;from July 29, 2023, up to and including October 31, 2023. After such date, the minimum liquidity covenant was set at&lt;/div&gt; $&lt;/div&gt;&lt;/div&gt;20,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;provided, however, that if the F8 formulation of tesamorelin was not approved by the United States Food and Drug Administration by March 31, 2024, the minimum liquidity covenant was set at&lt;/div&gt; $&lt;/div&gt;&lt;/div&gt;30,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 21, 2023, the Company obtained a waiver from the lender relating to the Liquidity Breach for the period between July 3, 2023 up to end and including July 9, 2023. On October 13, 2023, the Company and the lender entered into an additional amendment to the Marathon Credit Agreement (the &#x201c;Fifth Amendment&#x201d;) providing for, amongst other things, the following amendments:&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;revising the minimum liquidity requirements for all times following October 31, 2023 to be between $15,000 and $20,000, based on thresholds for Marathon Adjusted EBITDA over the most recently ended four fiscal quarters; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;revising the minimum revenue requirements to be based on Marathon Adjusted EBITDA-based targets instead of quarterly revenue-based targets, beginning with the quarter ending November 30, 2023; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies to the Company&#x2019;s annual report. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In consideration of the Fifth Amendment, the Company agreed to (i) pay an amount equal to&lt;/div&gt; $540 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amortized value ($600), or&lt;/div&gt; 100 &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;($60,000),&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;which amount was added to the outstanding principal amount of the funded debt as payment in kind; and (ii) reset the exercise price of the Marathon Warrants, which are now exercisable into &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,250,000&lt;/div&gt; common shares at $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.30&lt;/div&gt; per common share, down from the previous $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.80&lt;/div&gt; per common share. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The salient conditions of the amounts drawn under the Loan Facility are as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Loan Facility has an initial term of five years, provides for an interest-only period of 24 months, and bears interest at the Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) plus 9.5%. The Tranche 1 Loan and Tranche 2 Loan are repayable in equal monthly installments on an amortization schedule of 36 months starting in July 2024. The Company is entitled to prepay the outstanding Loan Facility at any time subject to certain prepayment premium amount: for Tranche 1 Loan until July 27, 2024, an amount equal to the make whole amount, and after this date, a maximum amount of 3% of the principal amount being prepaid. For Tranche 2 Loan, until June 21, 2025, an amount equal to the make whole amount, and after this date, a maximum amount of 3% of the principal amount being prepaid; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Loan Facility provides Marathon Adjusted EBITDA-based targets and minimum liquidity requirements (both as defined in the Marathon Credit Agreement) for all times to be between&lt;/div&gt;&#160;$&lt;/div&gt;15,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&#160;&lt;/div&gt;$20,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;based on thresholds for Marathon Adjusted EBITDA over the most recently ended four financial quarters;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: arial; font-size: 11pt; text-align: justify; line-height: normal;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Loan Facility restricts the ability to incur additional debt and to make acquisitions, dispositions, in-licensing and out-licensing of products or assets, except in very limited circumstances. A breach of the terms and conditions of the Marathon Credit Agreement will create an event of default resulting in an increase of&lt;/div&gt; &lt;/div&gt;300 basis points &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;on the outstanding loan and provide the lender with the ability to demand immediate repayment of the debt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The lender has a first ranking security interest on all of the Company&#x2019;s assets, subject to certain credit card arrangements restrictions. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The movement in the carrying value of the Loan Facility is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 87%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:28.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:28.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Proceeds from Loan Facility on July&#160;27, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,285)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Term loan as at November&#160;30,&#160;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Proceeds from Tranche 2 Loan on June&#160;21, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Costs related to issuance of Tranche 2 Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Costs related to Marathon Warrants (note 20(c))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Consideration f&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;or&lt;/div&gt; the Fifth Amendment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Term loan as at November&#160;30,&#160;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,974&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,286)&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current portion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50,688&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;On June&#160;21, 2023, the Company drew down on the Tranche 2 Loan, for net proceeds of $19,300. An amount of $482 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was reclassed from deferred financing costs assets and applied against the loan balance.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Deferred financing costs in the amount of $347 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;were written off in the statement of net loss of November 30, 2023 in relation to the additional tranches of the Loan Facility.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <thtx:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48646"
      unitRef="Unit_USD">100000000</thtx:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P07_27_2022To07_27_2022_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48647"
      unitRef="Unit_USD">40000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P06_21_2023To06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48648"
      unitRef="Unit_USD">20000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn11_30_2022_LoanFacilityTranche3LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48649"
      unitRef="Unit_USD">15000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn07_20_2022_LoanFacilityTranche4LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48650"
      unitRef="Unit_USD">25000000</ifrs-full:NotionalAmount>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_10_2023To07_21_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48651"
      unitRef="Unit_USD">20000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_10_2023To07_21_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48652"
      unitRef="Unit_USD">14000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_22_2023To07_28_2023_BottomOfRangeMemberifrsfullRangeAxis_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      id="ixv-48653"
      unitRef="Unit_USD">14000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_22_2023To07_28_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48654"
      unitRef="Unit_USD">16000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_29_2023To10_31_2023"
      decimals="-3"
      id="ixv-48655"
      unitRef="Unit_USD">15000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmount
      contextRef="PAsOn07_28_2023"
      decimals="-3"
      id="ixv-48656"
      unitRef="Unit_USD">20000000</thtx:DebtInstrumentCollateralAmount>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P07_28_2023To07_28_2023"
      decimals="-3"
      id="ixv-48657"
      unitRef="Unit_USD">30000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P10_31_2023To10_31_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48658"
      unitRef="Unit_USD">15000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P10_31_2023To10_31_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-48659"
      unitRef="Unit_USD">20000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <thtx:ConsiderationPayable
      contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48660"
      unitRef="Unit_USD">540000</thtx:ConsiderationPayable>
    <thtx:DebtInstrumentAmortizedValue
      contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48661"
      unitRef="Unit_USD">600000</thtx:DebtInstrumentAmortizedValue>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P10_13_2023To10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"
      id="ixv-48662">100</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn10_13_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48663"
      unitRef="Unit_USD">60000000</ifrs-full:NotionalAmount>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="INF"
      id="ixv-48664"
      unitRef="Unit_shares">1250000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="2"
      id="ixv-48665"
      unitRef="Unit_USD_per_Share">2.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_FifthAmendmentMemberTHTXTypeOfArrangementAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="2"
      id="ixv-48666"
      unitRef="Unit_USD_per_Share">5.8</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:BorrowingsMaturity
      contextRef="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis"
      id="ixv-48667">five</ifrs-full:BorrowingsMaturity>
    <thtx:BorrowingsInterestPeriod
      contextRef="P07_20_2022To07_20_2022_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis"
      id="ixv-48668">P24M</thtx:BorrowingsInterestPeriod>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn07_20_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis_SecuredOvernightFinancingRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="3"
      id="ixv-48669"
      unitRef="Unit_pure">0.095</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche1And2LoanMemberifrsfullBorrowingsByNameAxis"
      id="ixv-48670">The Tranche 1 Loan and Tranche 2 Loan are repayable in equal monthly installments on an amortization schedule of 36 months starting in July 2024.</ifrs-full:BorrowingsMaturity>
    <thtx:DateOfCommencementOfPrincipalRepaymentInAdvance
      contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"
      id="ixv-48671">2024-07-27</thtx:DateOfCommencementOfPrincipalRepaymentInAdvance>
    <thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent
      contextRef="PAsOn11_30_2023_LoanFacilityTranche1LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="2"
      id="ixv-48672"
      unitRef="Unit_pure">0.03</thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent>
    <thtx:DateOfCommencementOfPrincipalRepaymentInAdvance
      contextRef="P12_01_2022To11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"
      id="ixv-48673">2025-06-21</thtx:DateOfCommencementOfPrincipalRepaymentInAdvance>
    <thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent
      contextRef="PAsOn11_30_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="2"
      id="ixv-48674"
      unitRef="Unit_pure">0.03</thtx:CeilingLimitForPrepaymentOfPrincipalAmountOutstandingPercent>
    <thtx:DebtInstrumentCollateralAmount
      contextRef="PAsOn10_31_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      id="ixv-48675"
      unitRef="Unit_USD">15000000</thtx:DebtInstrumentCollateralAmount>
    <thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained
      contextRef="P12_01_2022To11_30_2023_CashCashEquivalentsAndEligibleShortTermInvestmentsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      id="ixv-48676"
      unitRef="Unit_USD">20000000</thtx:DebtInstrumentCollateralAmountIfFDAApprovalNotObtained>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P12_01_2022To11_30_2023" id="ixv-48677">300 basis points</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-33137">&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The movement in the carrying value of the Loan Facility is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 87%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:28.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:28.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Proceeds from Loan Facility on July&#160;27, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,285)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Term loan as at November&#160;30,&#160;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Proceeds from Tranche 2 Loan on June&#160;21, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Costs related to issuance of Tranche 2 Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Costs related to Marathon Warrants (note 20(c))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Consideration f&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;or&lt;/div&gt; the Fifth Amendment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Term loan as at November&#160;30,&#160;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,974&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,286)&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current portion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50,688&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48678"
      unitRef="Unit_USD">40000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:BorrowingCostsRecognisedAsExpense
      contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48679"
      unitRef="Unit_USD">2285000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <thtx:BorrowingsAccretionExpense
      contextRef="P07_27_2022To11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48680"
      unitRef="Unit_USD">179000</thtx:BorrowingsAccretionExpense>
    <ifrs-full:LoansReceived
      contextRef="PAsOn11_30_2022_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48681"
      unitRef="Unit_USD">37894000</ifrs-full:LoansReceived>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48682"
      unitRef="Unit_USD">20000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:BorrowingCostsRecognisedAsExpense
      contextRef="P06_21_2023To11_30_2023_LoanFacilityTrancheTwoLoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48683"
      unitRef="Unit_USD">1182000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:BorrowingCostsRecognisedAsExpense
      contextRef="P06_21_2023To11_30_2023_MarathonWarrantsMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48684"
      unitRef="Unit_USD">78000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <thtx:ProceedsFromConsiderationOfTheFifthAmendment
      contextRef="P06_21_2023To11_30_2023"
      decimals="-3"
      id="ixv-48685"
      unitRef="Unit_USD">540000</thtx:ProceedsFromConsiderationOfTheFifthAmendment>
    <thtx:BorrowingsAccretionExpense
      contextRef="P06_21_2023To11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48686"
      unitRef="Unit_USD">800000</thtx:BorrowingsAccretionExpense>
    <ifrs-full:LoansReceived
      contextRef="PAsOn11_30_2023_LoanFacilityMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48687"
      unitRef="Unit_USD">57974000</ifrs-full:LoansReceived>
    <ifrs-full:CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48688"
      unitRef="Unit_USD">7286000</ifrs-full:CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48689"
      unitRef="Unit_USD">50688000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48690"
      unitRef="Unit_USD">19300000</ifrs-full:NotionalAmount>
    <thtx:AmountReclassifiedFromDeferredFinancingCosts
      contextRef="PAsOn06_21_2023_LoanFacilityTranche2LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48691"
      unitRef="Unit_USD">482000</thtx:AmountReclassifiedFromDeferredFinancingCosts>
    <thtx:DeferredFinanceCostsWriteOff
      contextRef="PAsOn11_30_2023_LoanFacilityTranche3And4LoanMemberifrsfullBorrowingsByNameAxis"
      decimals="-3"
      id="ixv-48692"
      unitRef="Unit_USD">347000</thtx:DeferredFinanceCostsWriteOff>
    <thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-33360">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Convertible unsecured senior notes&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The movement in the carrying value of the convertible unsecured senior notes is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2021 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,227&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 26.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 26.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes from financing cash flows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid on repurchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,546) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs incurred &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(73) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 26.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 26.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other changes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on repurchase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(357)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,644&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,895&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes from financing cash flows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid on repurchase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27,452)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other changes:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;572&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;30, 2023, the Company reimbursed all of the issued and outstanding convertible unsecured senior notes for proceeds of $&lt;/div&gt;&lt;/div&gt;27,452 and 253 shares were issued on conversion of $15 convertible unsecured senior notes. &lt;/div&gt; </thtx:DisclosureOfConvertibleSeniorNotesExplanatoryTextBlock>
    <thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-33372"> &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The movement in the carrying value of the convertible unsecured senior notes is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2021 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,227&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 26.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 26.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes from financing cash flows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid on repurchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,546) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs incurred &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(73) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 26.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 26.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other changes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on repurchase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(357)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,644&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,895&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes from financing cash flows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid on repurchase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(27,452)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other changes:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 14.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;572&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes as at November&#160;30,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="4" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; </thtx:DisclosureOfDeferredTaxRelatedToEquityComponentOfConvertibleNotesExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2021_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48693"
      unitRef="Unit_USD">54227000</ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48694"
      unitRef="Unit_USD">28546000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48695"
      unitRef="Unit_USD">73000</thtx:PaymentsForCostsRelatedToRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes
      contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48696"
      unitRef="Unit_USD">357000</thtx:GainOnRepurchaseOfConvertibleUnsecuredSeniorNotes>
    <thtx:AccretionExpense
      contextRef="P12_01_2021To11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48697"
      unitRef="Unit_USD">1644000</thtx:AccretionExpense>
    <ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2022_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48698"
      unitRef="Unit_USD">26895000</ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48699"
      unitRef="Unit_USD">27452000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48700"
      unitRef="Unit_USD">-15000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <thtx:AccretionExpense
      contextRef="P12_01_2022To11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48701"
      unitRef="Unit_USD">572000</thtx:AccretionExpense>
    <ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2023_LiabilityComponentMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48702"
      unitRef="Unit_USD">0</ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48703"
      unitRef="Unit_USD">27452000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <thtx:ConvertibleInstrumentsNumberOfSharesIssued
      contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="INF"
      id="ixv-48704"
      unitRef="Unit_shares">253</thtx:ConvertibleInstrumentsNumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="P06_30_2023To06_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="-3"
      id="ixv-48705"
      unitRef="Unit_USD">15000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-33664">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases liabilities&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 816px; border-spacing: 0px;"&gt;
&lt;tr style="break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 86%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;Carrying&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;2,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(605)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(148)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30,&#160;2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(452)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Termination (a)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(920)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;New lease (b)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;Balance as at November 30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(421)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;573&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;;text-indent: 0px;"&gt;On February&#160;17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The gain is presented in finance income (Note 5).&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability of $326. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </ifrs-full:DisclosureOfLeasesExplanatory>
    <thtx:DisclosureOfLeaseLiabilitiesTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-48706"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 86%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;Carrying&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&#160;2,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(605)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(148)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:20.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:20.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Balance as at November&#160;30,&#160;2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accretion expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(452)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of change in exchange rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Termination (a)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(920)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;New lease (b)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:25.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:25.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 5em; line-height: normal;"&gt;Balance as at November 30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(421)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;573&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;;text-indent: 0px;"&gt;On February&#160;17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The gain is presented in finance income (Note 5).&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability of $326. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfLeaseLiabilitiesTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-48707"
      unitRef="Unit_USD">2518000</ifrs-full:LeaseLiabilities>
    <thtx:AccretionExpenseOfLeasesLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48708"
      unitRef="Unit_USD">157000</thtx:AccretionExpenseOfLeasesLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48709"
      unitRef="Unit_USD">605000</ifrs-full:CashOutflowForLeases>
    <thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48710"
      unitRef="Unit_USD">-148000</thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-48711"
      unitRef="Unit_USD">1922000</ifrs-full:LeaseLiabilities>
    <thtx:AccretionExpenseOfLeasesLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48712"
      unitRef="Unit_USD">101000</thtx:AccretionExpenseOfLeasesLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48713"
      unitRef="Unit_USD">452000</ifrs-full:CashOutflowForLeases>
    <thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48714"
      unitRef="Unit_USD">17000</thtx:LeasesLiabilitiesEffectOfChangeInExchangeRates>
    <ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="Fact_101087431"
      unitRef="Unit_USD">-920000</ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="Fact_101087432"
      unitRef="Unit_USD">326000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48717"
      unitRef="Unit_USD">994000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48718"
      unitRef="Unit_USD">421000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-48719"
      unitRef="Unit_USD">573000</ifrs-full:NoncurrentLeaseLiabilities>
    <thtx:TerminationOfLeasesOperatingLeaseRightOfUseLiability
      contextRef="P02_17_2023To02_17_2023"
      decimals="0"
      id="ixv-48720"
      unitRef="Unit_USD">799</thtx:TerminationOfLeasesOperatingLeaseRightOfUseLiability>
    <thtx:TerminationOfLeasesOperatingLeaseRightOfUseAssets
      contextRef="P02_17_2023To02_17_2023"
      decimals="0"
      id="ixv-48721"
      unitRef="Unit_USD">920</thtx:TerminationOfLeasesOperatingLeaseRightOfUseAssets>
    <thtx:GainLossOnLeaseTermination
      contextRef="P02_17_2023To02_17_2023"
      decimals="-3"
      id="ixv-48722"
      unitRef="Unit_USD">121000</thtx:GainLossOnLeaseTermination>
    <thtx:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P03_01_2023To03_01_2023"
      decimals="0"
      id="ixv-48723"
      unitRef="Unit_USD">326</thtx:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-33927">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share capital, warrants and subscription receipts&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Authorized in unlimited number and without par value &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Common shares; &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Preferred shares, issuable in one or more series. &lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;All issued shares were fully paid on November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common shareholders are entitled to receive dividends as declared by the Company at its discretion and are entitled to one vote per share at the Company&#x2019;s annual meeting of shareholders. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;No preferred shares are outstanding. &lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;On January&#160;19, 2021, the Company completed a public offering for the sale and issuance of units. Each unit was comprised of one common share of the Company and o&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ne half of one&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;common share purchase warrant of the Company (each whole warrant, a &#x201c;Public Offering Warrant&#x201d;) and is classified in Share Capital and Public Offering Warrants within equity. During the year ended November 30, 2023, no Public Offering Warrant were exercised (November 30, 2022 nil and November 30, 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; 233,400 Public Offering Warrants were exercised for proceeds of $742). At November 30, 2023, there were &lt;/div&gt;&lt;/div&gt;8,130,550 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Public Offering Warrants outstanding. Four (4)&#160;Public Offering Warrants entitles the holder thereof to purchase one (1)&#160;common share at an exercise price of $&lt;/div&gt;&lt;/div&gt;12.72 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at any time until January&#160;19, 2024&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 8,130,550 Public Offering Warrants expired on January &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19, 2024&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;31, 2023, the Company completed a public offering for the sale and issuance of &lt;/div&gt;12,500,000 common shares at a price of $1.00 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;per common share for gross proceeds o&lt;/div&gt;&lt;/div&gt;f $12,500. On November&#160;14, 2023, the Company issued 160,000 common shares at a price of $1.00 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per common share for gross proceeds of $&lt;/div&gt;160 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;in relation to the partial exercise of the over-allotment option. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ompany has also completed a concurrent private placement (the &#x201c;Concurrent Private Placement&#x201d;) with Investissement Qu&#xe9;bec of&lt;/div&gt;&lt;/div&gt;&#160;9,118,184 common shares and 3,381,816 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fully-funded, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; subscription receipts, exchangeable at all times into common shares on a one-for-one basis in, in each case, at $&lt;/div&gt;1.00 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;for gross proceeds of $&lt;/div&gt;&lt;/div&gt;12,500&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;. The subscription receipts were issued to limit the share ownership of the investor to not more than 19.9% of the issued and outstanding common shares and the subscription receipts are exchangeable at any time, provided ownership limitations are respected. The Company has also entered into an investor rights agreement pursuant to which Investissement Qu&#xe9;bec will be entitled to nominate one director to the Company&#x2019;s board of directors for as long as it holds 50% of the Common Shares purchased pursuant to the Concurrent Private Placement. The cost of the offering amounted to $&lt;/div&gt;&lt;/div&gt;2,053&lt;div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Milestone oncology &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;In March 2021, the Company issued 120,482 common shares under the terms of the acquisition agreement entered into with all of the shareholders of Katana for Katana&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; oncology platform. The purchase price for the oncology platform provided for share-based consideration to be issued upon attainment of two milestones. The first milestone was achieved in March 2021. The estimated fair value of the share-based consideration of $668 initially recorded in &#x201c;Contributed surplus&#x201d; on the date of the acquisition was reclassified to &#x201c;Share capital&#x201d; (Note 13). &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Marathon warrants &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February 27, 2023, the Company issued to Marathon an aggregate of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; 5,000,000 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;common share purchase warrants (the &#x201c;Marathon Warrants exercisable into 1,250,000 common shares, at an exercise price of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; $5.80&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, post Consolidation. The Marathon Warrants are exercisable for a period of&lt;/div&gt; seven years. &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Marathon Warrants are not traded on any stock exchange, are transferable only to affiliates of Marathon or to other potential lenders under the terms of the Loan Facility and their affiliates and may be exercised on a cashless basis. Accordingly, the Marathon Warrants are derivative financial liabilities measured at fair value through profit or loss.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Marathon Warrants were issued as consideration for various amendments made to the Marathon Credit Agreement, including: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An amendment to remove a condition precedent to the disbursement of the Tranche 2 Loan requiring the Company to have filed with the FDA the results of a human factor study before June&#160;30, 2023; and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x25cf;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An amendment to allow for the inclusion of a going concern explanatory paragraph in the annual report of the independent registered public accounting firm for the fiscal year ended November&#160;30, 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In consideration of the Fifth Amendment, the Company has agreed to reset the exercise price of the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,000,000&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marathon Warrants, which are now exercisable into&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,250,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;common shares at&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.30 &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per common share. (Refer to Note 17) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The fair value of the Marathon Warrants was treated as a cash outflow in testing whether the debt modification was a substantial modification and it was concluded that the modification was not substantial. At the issuance&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, $&lt;/div&gt;2,650&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;were recorded as loss on debt modification using the Black-Sholes model and the assumptions set forth in the table below. An amount &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of $&lt;/div&gt;350 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;was recorded reflecting the increase of fair value of Marathon Warrants for the repricing upon entering into the Fifth Amendment. The derivative financial liability relating to the Marathon Warrants is recorded as a liability on the consolidated statement of financial position and resulted in a gain on fair value remeasurement o&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;f $&lt;/div&gt;1,525&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for the year ended November&#160;&lt;/div&gt;30&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div&gt; &lt;div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 94%; border: 0px; margin-left: auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 95%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.326%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88.568%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61.985%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160;6.25&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Share price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em;"&gt;Exercise price &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.80&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The risk-free interest rate is based on the implied yield on a Canadian government zero-coupon issue, with a remaining term equal to the term of the Marathon warrant life. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of the Marathon warrant is based upon the contractual term. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;With the issuance of the Marathon Warrants, the Company incurred transaction costs totalling $&lt;/div&gt;196&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of which $&lt;/div&gt;78&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was allocated to the Loan Facility and $&lt;/div&gt;118&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;was recorded as deferred financing costs relating to the available tranches under the Loan Facility&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Deferred financing costs were written off on November 30, 2023 (Note 17).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(d)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;ATM program &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of a sales agreement dated July&#160;23, 2021, the Company was able to issue and sell from time to time its common shares, having an aggregate offering price of up &lt;/div&gt;&lt;/div&gt;to $50,000, &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;through or to the Agent, as agent or principal, in the United States for a period ending in December 2023. Sales of the common shares were to be made in transactions that were deemed to be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;at-the-market&lt;/div&gt;&lt;/div&gt; distributions&#x201c; (&#x201c;ATM&#x201c;). In the fourth quarter of 202&lt;/div&gt;2, 400,000 common shares (2021 &#x2013; no common shares) were sold for proceed&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; of $2,960 under the ATM program. Commission, legal and other costs related to this equity &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;offering&lt;/div&gt; were charged directly to equity in the amount of $126 (2021 - nil). The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;common &lt;/div&gt;shares were sold at the prevailing market prices, which resulted in a price of $1.85 per share. Deferred financing costs in the amount of $607 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;were written off in the statement of net loss of November&#160;30, 2023, in relation to the end of the program in December of 2023 without additional usage.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(e)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;DSU plan &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;10, 2010, the Board of Directors adopted the DSU Plan for the benefit of its directors and officers (the &#x201c;Beneficiaries&#x201d;). The goal of the DSU Plan is to increase the Company&#x2019;s ability to attract and retain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;high-quality&lt;/div&gt; individuals to act as directors or officers and to better align their interests with those of the shareholders of the Company in the creation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; value. Under the terms of the DSU Plan, Beneficiaries who are directors are entitled to elect to receive all or part of their annual retainer to act as directors in DSUs. Beneficiaries who act as officers are entitled to elect to receive all or part of their annual bonus, if any, in DSUs. The value of a DSU is used to determine the number of DSUs a Beneficiary may be granted or the value to be paid to a Beneficiary upon redemption. This value is equal to the average closing price of the common shares on the Toronto Stock Exchange on the date on which the Company is entitled to grant DSUs, or on the date on which a Beneficiary redeems them, and during the four previous trading days. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DSUs may only be redeemed when a Beneficiary ceases to act as a director or an officer of the Company. Upon redemption, the Company must provide a Beneficiary with an amount in cash equal to the DSU value on the redemption date. Beneficiaries may not sell, transfer or otherwise assign their DSUs or any rights associated therewith other than by will or in accordance with legislation regarding the vesting and partition of successions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DSUs are totally vested on the grant date. When DSUs are granted to officers as part of their annual bonus, a DSU liability is recorded on the grant date in lieu of a liability for a cash bonus payment. In the case of directors, the expenses related to DSUs and their liabilities are recognized on the grant date. During the year ended &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;November&#160;30, 2023, nil (2022 -&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;126&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;; 2021&#160;&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;78&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was recorded as an expense and is included in general and administrative expenses. The liability related to DSUs is adjusted periodically to reflect any change in the market value of the common shares. As at November&#160;30, 2023, a gain of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;224&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2022 - $221; 2021&#160;&#x2013; loss of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;209)&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was recognized within finance costs (Note &lt;/div&gt;5)&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As at November&#160;&lt;/div&gt;30&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had a total &lt;/div&gt;24,878&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;DSUs outstanding &lt;/div&gt;(202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;67,536&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; DSUs) and a liability related to the DSUs of $&lt;/div&gt;39&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;(202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; liability of $&lt;/div&gt;589&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash-settled&lt;/div&gt; forward stock contracts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;To protect against fluctuations in the value of DSUs, the Company entered into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-settled&lt;/div&gt; forward stock contracts. They were not designated as hedging instruments for accounting purposes. As at November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-settled&lt;/div&gt; forward stock contracts outstanding correspond to a total of 67,535 (202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt; &#x2013; 67,535) common shares at a price of $19.47 per share (202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013; $19.68 per share) expiring on December&#160;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt; (202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013; December&#160;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;). As at November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, the fair value of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-settled&lt;/div&gt; forward stock contracts was $110 (202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013; $603) and is recorded in derivative financial assets. During the year ended November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, a loss of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;$492 (2022 -&lt;/div&gt;&lt;/div&gt;$217&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;;2021&#160;&#x2013;&lt;/div&gt;&lt;/div&gt; gain of $212) related to the change in fair value of derivative financial assets was recognized within finance costs. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(f)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;S&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;tock&lt;/div&gt;&#160;Appreciation Rights&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;4, 2018, the Board of Directors approved a stock appreciation rights plan (the &#x201c;SARs Plan&#x201d;) for its consultants that entitles the grantee to receive a cash payment based on the increase in the stock price of the Company&#x2019;s common shares from the grant date to the settlement date. The term of a SAR may not exceed &lt;/div&gt;&lt;/div&gt;10&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;years from the grant date. Generally, SARs vest over a period of three years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;For the year ended November&#160;30, 2023, ($22) (2022 - $12, 2021 &#x2013; $53) was recorded as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; compensation expense for the SARs &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;P&lt;/div&gt;lan. Since these awards will be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-settled,&lt;/div&gt; the fair value of SARs granted is estimated at each reporting period using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model and the following weighted average assumptions. The liability is recorded in other liabilities on the statement of financial position.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 96%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted in 2019 and 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.55%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.50%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89.51%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58.4%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;Share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#x2003;&#x2007;&#x2007;1.58&#160;(CA$2.15)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2003;&lt;div style="font-size: 13pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2007;&lt;/div&gt;8.72&#160;(CA$11.72)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top;text-indent: 0px;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;16.99&#160;(CA$23.07)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: -webkit-right; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;"&gt;$&#x2003;&lt;/div&gt;17.16&#160;(CA$23.07)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;risk-free&lt;/div&gt; interest rate is based on the implied yield on a Canadian government &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;zero-coupon&lt;/div&gt; issue, with a remaining term equal to the expected term of a SAR. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of a SAR is estimated taking into consideration the vesting period on the grant date, the life of a SAR and the average length of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations and future growth. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No SARs w&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ere&lt;/div&gt; granted during the years ended November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(g)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Shareholder rights plan &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;3, 2022, the Board of Directors approved certain amendments and the renewal of the Company&#x2019;s shareholder rights plan and, on April&#160;6, 2022, the Company and Computershare Trust Services of Canada entered into an amended and restated shareholder rights plan agreement (the &#x201c;Rights Plan&#x201d;). The Rights Plan was approved by the shareholders on May&#160;10, 2022. The Rights Plan &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;is&lt;/div&gt; designed to provide adequate time for the Board and the shareholders to assess an unsolicited takeover bid for the Company. In addition, Rights the Plan provides the Board with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, as well as provide shareholders with an equal opportunity to participate in a takeover bid to receive full and fair value for their common shares. The Rights Plan will expire at the close of the Company&#x2019;s annual meeting of shareholders in 2025 unless the Rights Plan is reconfirmed and approved by shareholders at such meeting. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The rights issued under the Rights Plan are initially attached to and traded with the common shares, and no separate certificate is issued unless a triggering event occurs. The rights become exercisable only when an acquiring person, including any party related to it, acquires or attempts to acquire &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;% or more of the outstanding common shares without complying with the &#x201c;Permitted Bid&#x201d; provisions of the Rights Plan or without approval of the Board of Directors. Subject to the terms and conditions set out in the Rights Plan, each right (other than those held by the acquiring person) will permit the holder to purchase for the exercise price that number of common shares determined as follows: a value of twice the exercise price divided by the &#x201c;Market Price&#x201d; (defined under the Rights Plan as being the average weighted trading price per common share for the 20 consecutive&#160;trading days through and including the trading day immediately preceding the relevant date) on the common share acquisition date (defined as &#x201c;Stock Acquisition Date&#x201d; under the Rights Plan). The exercise price under the Rights Plan has been set to three (3) times the Market Price. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Rights Plan, a Permitted Bid is a bid made to all holders of common shares and which is open for acceptance for no less than &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105&lt;/div&gt; days. If, at the end of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105&lt;/div&gt; days, more than &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;% of the outstanding common shares, other than those owned by the offeror and certain related parties, have been tendered, the offeror may take up and pay for the common shares. If more than &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50&lt;/div&gt;% of the outstanding common shares, other than those owed by the offeror and certain related parties, have been tendered within the above mentioned &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105&lt;/div&gt; days period, the offeror must make a public announcement of that fact and the bid must remain open for an additional ten business days from the date of the announcement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(h)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Stock option plan &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has established a stock option plan (the &#x201c;Option Plan&#x201d;) under which it can grant its directors, officers, employees, researchers and consultants non-transferable options (the &#x201c;Option&#x201d;) for the purchase of common shares. The exercise date of an Option may not be later than&lt;/div&gt; 10&#160;years after the grant date. On March&#160;28, 2023, the Company&#x2019;s Board of Directors &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amended the Option Plan &lt;/div&gt;&lt;/div&gt; to provide, among other things, that the &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maximum number &lt;/div&gt;&lt;/div&gt; of common shares that may be issued under the &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option Plan &lt;/div&gt;&lt;/div&gt; (together with any other security-based compensation arrangements) shall not exceed 17% of the issued and outstanding common shares, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-diluted&lt;/div&gt; basis&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The Option Plan has &lt;/div&gt;&lt;/div&gt;a &#x201c;reloading&#x201d; or &#x201c;evergreen&#x201d; feature, so that whe&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares issuable under the Option Plan will be replenished and such exercised &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;O&lt;/div&gt;ptions will be available to be regranted in the future. Shareholders ratified this amendment on May&#160;9, 2023.&#160;Generally, the Options vest on the grant date or over a period of up to three years.&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-indent: 0px;"&gt;As at November&#160;30, 2023, 5,762,675 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;O&lt;/div&gt;ptions could still be granted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;by&lt;/div&gt; the Company (2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2013;&#160;&lt;/div&gt;1,091,358,&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&#x2013;&#160;&lt;/div&gt;&lt;/div&gt;1, 062,851&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;under the Option Plan.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All Options are to be settled by the physical delivery of common shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in the number of Options outstanding during the past two years were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0px; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;per&#160;option&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:10pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;O&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -12px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;ptions outstanding in CA&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;797,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2002;15.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;547,847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited and expired &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144,213)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.52&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Exercised (share price: CA$11.12 (US$8.24))&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,165)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,180,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2002;11,84&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;792,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited and expired &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(197,686)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.10&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2023 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,774,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30, 2023 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.19&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; line-height: normal;"&gt;Options exercisable as at November 30, 2022 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;554,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;16.32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options outstanding in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options as at November&#160;30,&#160;2021&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;20,183&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.36&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;96,668&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;12.08&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited &#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(10,208)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.52&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30,&#160;2022&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;106,643&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;10.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;203,935&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;3.80&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited &#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(31,209)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30,&#160;2023&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;279,369&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;6.02&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30,&#160;2023&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;65,692&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;9.48&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30,&#160;2022&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7,769&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;11.96&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;  &lt;/div&gt; &lt;div style="margin: 0pt 24% 0pt 8%; text-align: justify; font-family: arial; font-size: 11pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides Option information as at November&#160;30, 2023 (Options outstanding in&#160;CA$). &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;1.00&#160;&#x2013; 4.76&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.74&#160;&#x2013;&#x2009;3.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;4.77 &#x2013; 8.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.51 &#x2013;&#x2009;5.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;707,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;9.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;8.01 &#x2013; 15.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.90&#160;&#x2013;&#x2009;11.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;308,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;15.01 &#x2013; 24.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.05&#160;&#x2013;&#x2009;17.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;621,167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;24.01 &#x2013; 36.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.68&#160;&#x2013;&#x2009;26.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33.27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;36.01 &#x2013; 40.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.51 &#x2013;&#x2009;29.45&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,426&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.35&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38.24&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.16&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,774,559&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.49&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.51&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td colspan="24" style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin: 6pt 10em 0pt 3.5em; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;The following table provides Option information as at November 30, 2023 (Options outstanding in US$).&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.00 &#x2013; 4.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179,185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.77 &#x2013; 15.00&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100,184&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.03&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;279,369&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.81&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.02&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial"&gt;For the year ended November&#160;30, 2023, $2,237 (2022 - $3,860, 2021&#160;&#x2013; $1,879) was recorded as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based&lt;/div&gt; compensation expense for the Option Plan. The fair value of Options granted in 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&#160;and 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was estimated on &lt;/div&gt;&lt;/div&gt; the grant date using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model and the following weighted average assumptions. &lt;/div&gt; &lt;div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 95%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:bottom"&gt;&#x2003;&#x2003;&#x2003;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;&#x2002;Options granted in CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.33%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.62%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64.3%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65.5%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-date&lt;/div&gt; share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2003;&#x2002;3.80&#160;(CA$5.16)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&#160;(CA$16.68)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;3.80&#160;(CA$5.16)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&#160;(CA$16.68)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:20pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:5pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-date&lt;/div&gt; share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.08&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The risk-free interest rate is based on the implied yield on a Canadian or U.S. government &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;zero-coupon&lt;/div&gt; issue, with a remaining term equal to the expected term of an Option. The volatility is based on the weighted average historical volatility adjusted for changes expected due to publicly available information. The life of an Option is estimated taking into consideration the vesting period on the grant date, the life of the Option and the average period of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation, since Company policy is to retain all earnings to finance operations and future growth. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the measurement date weighted average fair value of Options granted during the years ended November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&#160;granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;grant date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;792,193&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.77&#160;(CA$3.76&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;547,847&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;8.64&#160;(CA$11.64&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 18pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&#160;granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;grant date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;203,935&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.72&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;96,668&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.36&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model used by the Company to calculate the option values was developed to estimate the fair value of freely tradable, fully transferable Options without vesting restrictions, which significantly differs from the Company&#x2019;s Option grants. This model also requires four highly subjective assumptions, including future stock price volatility and the average Option life, which greatly affect the calculated values. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Loss per share &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;The calculation of basic loss per&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;common&lt;/div&gt;&lt;/div&gt; share was based on the net loss attributable to common shareholders of the Company of $23,957 (2022 &#x2013; 47,237, 2021&#160;&#x2013; $31,725) and a weighted average number of common shares outstanding calculated as follows. &lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Issued common shares as at December&#160;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,201,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,780,417&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,253,360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of share options exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of public issue common shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,843,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,704,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Impact on conversion of convertible&lt;br/&gt; &#160;&#160;&#160;&#160;unsecured senior notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of share issue - ATM program&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;Effect of subscription receipts issue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;287,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of broker warrants exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;36,564&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Weighted average number of common shares, &lt;br/&gt; &#160;&#160;&#160;&#160;basic&#160;and&#160;diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;26,332,429&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;23,813,344&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;23,087,557&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial"&gt;For the year ended November&#160;30, 2023, 2,053,928 (2022 &#x2013; 1,286,695, 2021 &#x2013; 817,766) &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;O&lt;/div&gt;ptions, 8,130,550 (2022 &#x2013; 8,130,550, 2021 &#x2013; 8,130,550) Public Offering Warrants, and 5,000,000 Marathon Warrants were excluded from the weighted average number of diluted common shares calculation as their effect would have been &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-dilutive.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The convertible unsecured senior notes were also excluded from the weighted average number of diluted common share calculation for the periods they were outstanding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The average market value of the Company&#x2019;s common shares for purposes of calculating the dilutive effect of Options was based on quoted market prices for the period during which the options were outstanding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(j)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Accumulated other comprehensive income (loss) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Unrealized losses on FVOCI financial assets, net of tax&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(256)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;(555)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;(195)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; line-height: normal;"&gt;Cumulative exchange difference on translation of foreign &lt;br/&gt;operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;684&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;385&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <thtx:CommonStockConversionBasis
      contextRef="P01_19_2021To01_19_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"
      id="ixv-33963">one half of one</thtx:CommonStockConversionBasis>
    <thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised
      contextRef="PAsOn11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48724"
      unitRef="Unit_shares">0</thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised>
    <thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised
      contextRef="PAsOn11_30_2022_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48725"
      unitRef="Unit_shares">0</thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised>
    <thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised
      contextRef="PAsOn11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48726"
      unitRef="Unit_shares">233400</thtx:ClassOfWarrantOrRightNumberOfSecuritiesExercised>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="P12_01_2020To11_30_2021_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="-3"
      id="ixv-48727"
      unitRef="Unit_USD">742000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <thtx:ClassOfWarrantOrRightOutstanding
      contextRef="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48728"
      unitRef="Unit_shares">8130550</thtx:ClassOfWarrantOrRightOutstanding>
    <thtx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="2"
      id="ixv-48729"
      unitRef="Unit_USD_per_Share">12.72</thtx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <thtx:ClassOfWarrantOrRightOutstanding
      contextRef="P12_01_2022To11_30_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48730"
      unitRef="Unit_shares">8130550</thtx:ClassOfWarrantOrRightOutstanding>
    <thtx:ClassOfWarrantOrRightExpirationDate
      contextRef="P12_01_2022To08_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      id="ixv-33981">2024-01-19</thtx:ClassOfWarrantOrRightExpirationDate>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="0"
      id="ixv-48731"
      unitRef="Unit_shares">12500000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="2"
      id="ixv-48732"
      unitRef="Unit_USD_per_Share">1</ifrs-full:ParValuePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P10_31_2023To10_31_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="-3"
      id="ixv-48733"
      unitRef="Unit_USD">12500000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis"
      decimals="0"
      id="ixv-48734"
      unitRef="Unit_shares">160000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis"
      decimals="2"
      id="ixv-48735"
      unitRef="Unit_USD_per_Share">1</ifrs-full:ParValuePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P11_14_2023To11_14_2023_OverallotmentMemberTHTXIssuedCapitalAxis"
      decimals="-3"
      id="ixv-48736"
      unitRef="Unit_USD">160000</ifrs-full:ProceedsFromIssuingShares>
    <thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48737"
      unitRef="Unit_shares">9118184</thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod>
    <thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"
      decimals="INF"
      id="ixv-48738"
      unitRef="Unit_shares">3381816</thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod>
    <thtx:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="PAsOn11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"
      decimals="2"
      id="ixv-48739"
      unitRef="Unit_USD_per_Share">1</thtx:ClassOfWarrantsOrRightsExercisePricePerShare>
    <thtx:ProceedsFromTheIssuanceOfCommonSharesAndWarrants
      contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_NonVotingSubscriptionReceiptsMemberTHTXClassOfWarrantsOrRightsAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"
      decimals="-3"
      id="ixv-48740"
      unitRef="Unit_USD">12500000</thtx:ProceedsFromTheIssuanceOfCommonSharesAndWarrants>
    <thtx:PercentageOfOwnershipOfTheInvestor
      contextRef="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="3"
      id="ixv-48741"
      unitRef="Unit_pure">0.199</thtx:PercentageOfOwnershipOfTheInvestor>
    <thtx:PercentageOfOwnershipHoldingCommonShares
      contextRef="P11_14_2023To11_14_2023_PublicOfferingMemberTHTXIssuedCapitalAxis"
      decimals="2"
      id="ixv-48742"
      unitRef="Unit_pure">0.50</thtx:PercentageOfOwnershipHoldingCommonShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P11_14_2023To11_14_2023_InvestmentQuebecMemberTHTXInvesteeAxis_PrivatePlacementMemberTHTXIssuedCapitalAxis"
      decimals="-3"
      id="ixv-48743"
      unitRef="Unit_USD">2053000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn03_31_2021_KatanaMemberifrsfullBusinessCombinationsAxis"
      decimals="INF"
      id="ixv-48745"
      unitRef="Unit_shares">120482</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="-3"
      id="ixv-48746"
      unitRef="Unit_USD">668000</ifrs-full:IssuedCapital>
    <thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48747"
      unitRef="Unit_shares">5000000</thtx:ClassOfNumberWarrantsOrRightsIssuedDuringThePeriod>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="0"
      id="ixv-48748"
      unitRef="Unit_shares">1250000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn02_27_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="2"
      id="ixv-48749"
      unitRef="Unit_USD_per_Share">5.8</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <thtx:TermOfWarrants
      contextRef="P02_27_2023To02_27_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      id="ixv-48750">P7Y</thtx:TermOfWarrants>
    <thtx:ClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48751"
      unitRef="Unit_shares">5000000</thtx:ClassOfWarrantsOrRightsOutstanding>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2023_FifthAmendmentMemberTHTXTypeOfArrangementsAxis_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis"
      decimals="0"
      id="ixv-48752"
      unitRef="Unit_shares">1250000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <thtx:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="PAsOn07_31_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48753"
      unitRef="Unit_USD_per_Share">2.3</thtx:ClassOfWarrantsOrRightsExercisePricePerShare>
    <thtx:GainLossOnDebtModification
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48755"
      unitRef="Unit_USD">-2650000</thtx:GainLossOnDebtModification>
    <thtx:IncreaseInTheFairValueOfLiabilityRecorded
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48756"
      unitRef="Unit_USD">350000</thtx:IncreaseInTheFairValueOfLiabilityRecorded>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48757"
      unitRef="Unit_USD">1525000</ifrs-full:GainsLossesRecognisedInProfitOrLossOnFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionOrSubsequently>
    <thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities contextRef="P12_01_2022To11_30_2023" id="ixv-34212"> &lt;div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 94%; border: 0px; margin-left: auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 95%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:top;text-align:right;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.326%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88.568%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61.985%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160;6.25&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Share price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em;"&gt;Exercise price &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.30&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.80&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </thtx:DisclosureInTabularFormOfSignificantUnobservableInputsUsedInTheMeasurementOfFairValueOfWarrantLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48758"
      unitRef="Unit_pure">0.04326</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48759"
      unitRef="Unit_pure">0.0392</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48760"
      unitRef="Unit_pure">0.88568</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-48761"
      unitRef="Unit_pure">0.61985</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="2"
      id="ixv-48762"
      unitRef="Unit_Y">6.25</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn02_27_2023_AverageOptionLifeMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="0"
      id="ixv-48763"
      unitRef="Unit_Y">7</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis"
      decimals="2"
      id="ixv-48764"
      unitRef="Unit_pure">1.63</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn02_27_2023_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis_SharePriceMemberifrsfullUnobservableInputsAxis"
      decimals="2"
      id="ixv-48765"
      unitRef="Unit_pure">3.8</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="2"
      id="ixv-48766"
      unitRef="Unit_pure">2.3</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn02_27_2023_ExercisePriceToAcquireOneCommonShareMemberifrsfullUnobservableInputsAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="2"
      id="ixv-48767"
      unitRef="Unit_pure">5.8</ifrs-full:SignificantUnobservableInputLiabilities>
    <thtx:TransactionCostsOfWarrantsIssued
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48768"
      unitRef="Unit_USD">196000</thtx:TransactionCostsOfWarrantsIssued>
    <thtx:TransactionCostsAllocatedToTheLoanFacility
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48769"
      unitRef="Unit_USD">78000</thtx:TransactionCostsAllocatedToTheLoanFacility>
    <thtx:DeferredFinancingCostsOnTheLoanFacility
      contextRef="P12_01_2022To11_30_2023_AffiliatesOfMarathonAssetManagementMemberTHTXInvesteeAxis_FifthAmendmentOfTheLoanFacilityMemberTHTXAgreementAxis_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrsfullCategoriesOfFinancialLiabilitiesAxis_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="-3"
      id="ixv-48770"
      unitRef="Unit_USD">118000</thtx:DeferredFinancingCostsOnTheLoanFacility>
    <thtx:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P07_23_2021To07_23_2021_AtmProgramMemberTHTXProgramNameAxis"
      decimals="-3"
      id="ixv-48772"
      unitRef="Unit_USD">50000000</thtx:SaleOfStockConsiderationReceivedOnTransaction>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn11_30_2022_AtmProgramMemberTHTXProgramNameAxis"
      decimals="INF"
      id="ixv-48773"
      unitRef="Unit_shares">400000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn11_30_2021_AtmProgramMemberTHTXProgramNameAxis"
      decimals="INF"
      id="ixv-48774"
      unitRef="Unit_shares">0</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="-3"
      id="ixv-48775"
      unitRef="Unit_USD">2960000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="-3"
      id="ixv-48776"
      unitRef="Unit_USD">126000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis"
      decimals="-3"
      id="ixv-48777"
      unitRef="Unit_USD">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="2"
      id="ixv-48778"
      unitRef="Unit_USD_per_Share">1.85</ifrs-full:ParValuePerShare>
    <thtx:DeferredFinancingCostsWrittenDown
      contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="-3"
      id="ixv-48779"
      unitRef="Unit_USD">607000</thtx:DeferredFinancingCostsWrittenDown>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48780"
      unitRef="Unit_USD">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48781"
      unitRef="Unit_USD">126000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48782"
      unitRef="Unit_USD">78000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2022To11_30_2023_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48783"
      unitRef="Unit_USD">224000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2021To11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48784"
      unitRef="Unit_USD">221000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2020To11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48785"
      unitRef="Unit_USD">-209000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      id="ixv-48786"
      unitRef="Unit_shares">24878</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      id="ixv-48787"
      unitRef="Unit_shares">67536</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="PAsOn11_30_2022_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48788"
      unitRef="Unit_USD">39000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="PAsOn11_30_2021_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48789"
      unitRef="Unit_USD">589000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <thtx:NumberOfCashSettledForwardStockContractsOutstanding
      contextRef="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      id="ixv-48791"
      unitRef="Unit_shares">67535</thtx:NumberOfCashSettledForwardStockContractsOutstanding>
    <thtx:NumberOfCashSettledForwardStockContractsOutstanding
      contextRef="PAsOn11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="INF"
      id="ixv-48792"
      unitRef="Unit_shares">67535</thtx:NumberOfCashSettledForwardStockContractsOutstanding>
    <thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts
      contextRef="P12_01_2021To11_30_2022_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48793"
      unitRef="Unit_USD_per_Share">19.47</thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts>
    <thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts
      contextRef="P12_01_2020To11_30_2021_OrdinarySharesMemberifrsfullClassesOfShareCapitalAxis_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48794"
      unitRef="Unit_USD_per_Share">19.68</thtx:PricePerShareForTheSettlementOfCashsettledForwardStockContracts>
    <thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging
      contextRef="PAsOn11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48795"
      unitRef="Unit_USD">110000</thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging>
    <thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging
      contextRef="PAsOn11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48796"
      unitRef="Unit_USD">603000</thtx:DerivativeFinancialAssetsAtFairValueNotDesignatedAsHedging>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2022To11_30_2023_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48797"
      unitRef="Unit_USD">-492000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2021To11_30_2022_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48798"
      unitRef="Unit_USD">-217000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
      contextRef="P12_01_2020To11_30_2021_CashSettledForwardContractsMemberifrsfullClassesOfFinancialAssetsAxis_DeferredStockUnitsMemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-3"
      id="ixv-48799"
      unitRef="Unit_USD">212000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <thtx:StockAppreciationRightsContractualLife contextRef="P10_04_2018To10_04_2018" id="ixv-48800">P10Y</thtx:StockAppreciationRightsContractualLife>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48801"
      unitRef="Unit_USD">22000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48802"
      unitRef="Unit_USD">12000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2020To11_30_2021_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48803"
      unitRef="Unit_USD">53000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <thtx:DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-34597">the fair value of SARs granted is estimated at each reporting period using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model and the following weighted average assumptions. The liability is recorded in other liabilities on the statement of financial position.&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 96%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Granted in 2019 and 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;as&#160;at&#160;November&#160;30,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.55%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.50%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89.51%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58.4%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;Share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#x2003;&#x2007;&#x2007;1.58&#160;(CA$2.15)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2003;&lt;div style="font-size: 13pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2007;&lt;/div&gt;8.72&#160;(CA$11.72)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top;text-indent: 0px;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;16.99&#160;(CA$23.07)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: -webkit-right; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; top: 0px; display: inline !important;;display:inline;"&gt;$&#x2003;&lt;/div&gt;17.16&#160;(CA$23.07)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfTheModelUsedToDetermineFiarValueOfStockAppreciationRightsTextBlock>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="4"
      id="ixv-48805"
      unitRef="Unit_pure">0.0355</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="4"
      id="ixv-48806"
      unitRef="Unit_pure">0.035</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="4"
      id="ixv-48807"
      unitRef="Unit_pure">0.8951</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="3"
      id="ixv-48808"
      unitRef="Unit_pure">0.584</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="1"
      id="ixv-48809"
      unitRef="Unit_Y">6.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="1"
      id="ixv-48810"
      unitRef="Unit_Y">7.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48811"
      unitRef="Unit_USD_per_Share">1.58</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48812"
      unitRef="Unit_CAD_per_Share">2.15</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48813"
      unitRef="Unit_USD_per_Share">8.72</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48814"
      unitRef="Unit_CAD_per_Share">11.72</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48815"
      unitRef="Unit_USD_per_Share">16.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48816"
      unitRef="Unit_CAD_per_Share">23.07</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48817"
      unitRef="Unit_USD_per_Share">17.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_StockAppreciationRightsMemberTHTXPlanAxis"
      decimals="2"
      id="ixv-48818"
      unitRef="Unit_CAD_per_Share">23.07</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <thtx:DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions
      contextRef="P12_01_2022To11_30_2023_TwoThousandAndSixteenShareholdersPlanMemberTHTXPlanAxis"
      id="ixv-34907"> The rights issued under the Rights Plan are initially attached to and traded with the common shares, and no separate certificate is issued unless a triggering event occurs. The rights become exercisable only when an acquiring person, including any party related to it, acquires or attempts to acquire 20% or more of the outstanding common shares without complying with the &#x201c;Permitted Bid&#x201d; provisions of the Rights Plan or without approval of the Board of Directors. Subject to the terms and conditions set out in the Rights Plan, each right (other than those held by the acquiring person) will permit the holder to purchase for the exercise price that number of common shares determined as follows: a value of twice the exercise price divided by the &#x201c;Market Price&#x201d; (defined under the Rights Plan as being the average weighted trading price per common share for the 20 consecutive&#160;trading days through and including the trading day immediately preceding the relevant date) on the common share acquisition date (defined as &#x201c;Stock Acquisition Date&#x201d; under the Rights Plan). The exercise price under the Rights Plan has been set to three (3) times the Market Price.  Under the Rights Plan, a Permitted Bid is a bid made to all holders of common shares and which is open for acceptance for no less than 105 days. If, at the end of 105 days, more than 50% of the outstanding common shares, other than those owned by the offeror and certain related parties, have been tendered, the offeror may take up and pay for the common shares. If more than 50% of the outstanding common shares, other than those owed by the offeror and certain related parties, have been tendered within the above mentioned 105 days period, the offeror must make a public announcement of that fact and the bid must remain open for an additional ten business days from the date of the announcement. </thtx:DescriptionOfCovenantsUnderShareholderRightsOnBiddingOptions>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="INF"
      id="ixv-48820"
      unitRef="Unit_Y">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <thtx:StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding
      contextRef="PAsOn11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="2"
      id="ixv-48821"
      unitRef="Unit_pure">0.17</thtx:StockIssuableAsAPercentageOfTotalSharesIssuedAndOutstanding>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      id="ixv-48822">Generally, the Options vest on the grant date or over a period of up to three years.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares
      contextRef="PAsOn11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="0"
      id="ixv-48824"
      unitRef="Unit_shares">5762675</thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares>
    <thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares
      contextRef="PAsOn11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="0"
      id="ixv-48825"
      unitRef="Unit_shares">1091358</thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares>
    <thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares
      contextRef="PAsOn11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="0"
      id="ixv-48826"
      unitRef="Unit_shares">1062851</thtx:RemainingSharesReservedForIssueUnderOptionsAndContractForSaleOfShares>
    <thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-35025"> &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in the number of Options outstanding during the past two years were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0px; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;per&#160;option&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:1.5pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:1.5pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:10pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;O&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -12px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;ptions outstanding in CA&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;797,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2002;15.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;547,847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited and expired &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(144,213)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.52&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Exercised (share price: CA$11.12 (US$8.24))&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,165)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,180,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2002;11,84&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;792,193&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited and expired &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(197,686)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.10&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:14.25pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height:14.25pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30, 2023 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,774,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30, 2023 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.19&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; line-height: normal;"&gt;Options exercisable as at November 30, 2022 &#x2013; CA$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;554,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;16.32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;background-color:rgb(204, 238, 255);"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options outstanding in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options as at November&#160;30,&#160;2021&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;20,183&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.36&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;96,668&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;12.08&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited &#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(10,208)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;12.52&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30,&#160;2022&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;106,643&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;10.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Granted&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;203,935&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;3.80&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Forfeited &#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(31,209)&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="height: 14.25pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options outstanding as at November&#160;30,&#160;2023&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;279,369&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;6.02&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30,&#160;2023&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;65,692&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;9.48&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Options exercisable as at November&#160;30,&#160;2022&#160;&#x2013; US$&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7,769&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;11.96&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationForChangesInTheNumberOfOptionsOutstandingExplanatoryTableTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48827"
      unitRef="Unit_shares">797583</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48828"
      unitRef="Unit_CAD_per_Share">15.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2021_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48829"
      unitRef="Unit_USD_per_Share">12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48830"
      unitRef="Unit_shares">547847</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48831"
      unitRef="Unit_CAD_per_Share">16.68</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48832"
      unitRef="Unit_USD_per_Share">13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48833"
      unitRef="Unit_shares">-144213</thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48834"
      unitRef="Unit_CAD_per_Share">17.8</thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48835"
      unitRef="Unit_USD_per_Share">13.52</thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P12_01_2021To11_30_2022"
      decimals="2"
      id="ixv-48836"
      unitRef="Unit_CAD_per_Share">11.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P12_01_2021To11_30_2022"
      decimals="2"
      id="ixv-48837"
      unitRef="Unit_USD_per_Share">8.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48838"
      unitRef="Unit_shares">21165</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48839"
      unitRef="Unit_CAD_per_Share">1.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48840"
      unitRef="Unit_USD_per_Share">0.92</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48841"
      unitRef="Unit_shares">1180052</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48842"
      unitRef="Unit_CAD_per_Share">1592</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48843"
      unitRef="Unit_USD_per_Share">1184</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48844"
      unitRef="Unit_shares">792193</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48845"
      unitRef="Unit_CAD_per_Share">5.16</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48846"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48847"
      unitRef="Unit_shares">-197686</thtx:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48848"
      unitRef="Unit_CAD_per_Share">12.34</thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48849"
      unitRef="Unit_USD_per_Share">9.1</thtx:WeightedAverageShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48850"
      unitRef="Unit_shares">1774559</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48851"
      unitRef="Unit_CAD_per_Share">11.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48852"
      unitRef="Unit_USD_per_Share">8.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48853"
      unitRef="Unit_shares">926539</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48854"
      unitRef="Unit_CAD_per_Share">15.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48855"
      unitRef="Unit_USD_per_Share">11.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48856"
      unitRef="Unit_shares">554354</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48857"
      unitRef="Unit_CAD_per_Share">16.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48858"
      unitRef="Unit_USD_per_Share">12.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2021_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48859"
      unitRef="Unit_shares">20183</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2021_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48860"
      unitRef="Unit_USD_per_Share">12.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48861"
      unitRef="Unit_shares">96668</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48862"
      unitRef="Unit_USD_per_Share">12.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48863"
      unitRef="Unit_shares">10208</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2021To11_30_2022_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48864"
      unitRef="Unit_USD_per_Share">12.52</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2022_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48865"
      unitRef="Unit_shares">106643</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48866"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48867"
      unitRef="Unit_shares">203935</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48868"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48869"
      unitRef="Unit_shares">31209</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="P12_01_2022To11_30_2023_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48870"
      unitRef="Unit_USD_per_Share">5.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48871"
      unitRef="Unit_shares">279369</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48872"
      unitRef="Unit_USD_per_Share">6.02</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2023_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48873"
      unitRef="Unit_shares">65692</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48874"
      unitRef="Unit_USD_per_Share">9.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn11_30_2022_USsrtCurrencyAxis"
      decimals="0"
      id="ixv-48875"
      unitRef="Unit_shares">7769</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2022_USsrtCurrencyAxis"
      decimals="2"
      id="ixv-48876"
      unitRef="Unit_USD_per_Share">11.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-35888"> &lt;div style="margin: 0pt 24% 0pt 8%; text-align: justify; font-family: arial; font-size: 11pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides Option information as at November&#160;30, 2023 (Options outstanding in&#160;CA$). &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;1.00&#160;&#x2013; 4.76&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.74&#160;&#x2013;&#x2009;3.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;4.77 &#x2013; 8.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.51 &#x2013;&#x2009;5.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:right;"&gt;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;707,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;9.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;8.01 &#x2013; 15.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.90&#160;&#x2013;&#x2009;11.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;308,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;15.01 &#x2013; 24.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.05&#160;&#x2013;&#x2009;17.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;621,167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;24.01 &#x2013; 36.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.68&#160;&#x2013;&#x2009;26.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33.27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;36.01 &#x2013; 40.00&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26.51 &#x2013;&#x2009;29.45&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,426&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.35&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38.24&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.16&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:9.75pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,774,559&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.49&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.51&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td colspan="24" style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin: 6pt 10em 0pt 3.5em; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;The following table provides Option information as at November 30, 2023 (Options outstanding in US$).&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 11pt; font-family: arial; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="4" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.00 &#x2013; 4.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179,185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.77 &#x2013; 15.00&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100,184&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.03&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;279,369&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.81&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.02&lt;/td&gt;
&lt;td style="padding-bottom:4pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="24" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48878"
      unitRef="Unit_CAD_per_Share">1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48879"
      unitRef="Unit_CAD_per_Share">4.76</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48880"
      unitRef="Unit_USD_per_Share">0.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48881"
      unitRef="Unit_USD_per_Share">3.5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48882"
      unitRef="Unit_shares">57500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48883">P0Y10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48884"
      unitRef="Unit_CAD_per_Share">1.52</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48885"
      unitRef="Unit_USD_per_Share">1.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48886"
      unitRef="Unit_CAD_per_Share">4.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48887"
      unitRef="Unit_CAD_per_Share">8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48888"
      unitRef="Unit_USD_per_Share">3.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48889"
      unitRef="Unit_USD_per_Share">5.89</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48890"
      unitRef="Unit_shares">707695</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48891">P9Y3M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48892"
      unitRef="Unit_CAD_per_Share">5.16</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48893"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48894"
      unitRef="Unit_CAD_per_Share">8.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48895"
      unitRef="Unit_CAD_per_Share">15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48896"
      unitRef="Unit_USD_per_Share">5.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48897"
      unitRef="Unit_USD_per_Share">11.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48898"
      unitRef="Unit_shares">308196</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48899">P5Y5M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48900"
      unitRef="Unit_CAD_per_Share">11.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceThreeMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48901"
      unitRef="Unit_USD_per_Share">8.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48902"
      unitRef="Unit_CAD_per_Share">15.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48903"
      unitRef="Unit_CAD_per_Share">24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48904"
      unitRef="Unit_USD_per_Share">11.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48905"
      unitRef="Unit_USD_per_Share">17.67</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48906"
      unitRef="Unit_shares">621167</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48907">P7Y6M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48908"
      unitRef="Unit_CAD_per_Share">16.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFourMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48909"
      unitRef="Unit_USD_per_Share">12.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48910"
      unitRef="Unit_CAD_per_Share">24.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48911"
      unitRef="Unit_CAD_per_Share">36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48912"
      unitRef="Unit_USD_per_Share">17.68</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48913"
      unitRef="Unit_USD_per_Share">26.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48914"
      unitRef="Unit_shares">51575</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48915">P4Y10M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48916"
      unitRef="Unit_CAD_per_Share">33.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceFiveMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48917"
      unitRef="Unit_USD_per_Share">24.5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48918"
      unitRef="Unit_CAD_per_Share">36.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48919"
      unitRef="Unit_CAD_per_Share">40</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48920"
      unitRef="Unit_USD_per_Share">26.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      id="ixv-48921"
      unitRef="Unit_USD_per_Share">29.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      id="ixv-48922"
      unitRef="Unit_shares">28426</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      id="ixv-48923">P4Y4M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48924"
      unitRef="Unit_CAD_per_Share">38.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis_ExercisePriceSixMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      id="ixv-48925"
      unitRef="Unit_USD_per_Share">28.16</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48926"
      unitRef="Unit_shares">1774559</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      id="ixv-48927">P7Y5M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48928"
      unitRef="Unit_CAD_per_Share">11.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48929"
      unitRef="Unit_USD_per_Share">8.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48930"
      unitRef="Unit_USD_per_Share">1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48931"
      unitRef="Unit_USD_per_Share">4.76</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48932"
      unitRef="Unit_shares">179185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      id="ixv-48933">P9Y3M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_ExercisePriceOneMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48934"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48935"
      unitRef="Unit_USD_per_Share">4.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_TopOfRangeMemberifrsfullRangeAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48936"
      unitRef="Unit_USD_per_Share">15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48937"
      unitRef="Unit_shares">100184</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      id="ixv-48938">P8Y10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_ExercisePriceTwoMemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48939"
      unitRef="Unit_USD_per_Share">10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48940"
      unitRef="Unit_shares">279369</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      id="ixv-48941">P8Y9M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48942"
      unitRef="Unit_USD_per_Share">6.02</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2022To11_30_2023_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48944"
      unitRef="Unit_USD">2237000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2021To11_30_2022_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48945"
      unitRef="Unit_USD">3860000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P12_01_2020To11_30_2021_StockOptionPlanTwoThousandAndNineteenMemberTHTXPlanAxis"
      decimals="-3"
      id="ixv-48946"
      unitRef="Unit_USD">1879000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <thtx:DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-36587">The fair value of Options granted in 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&#160;and 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was estimated on &lt;/div&gt;&lt;/div&gt; the grant date using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; model and the following weighted average assumptions. &lt;div style="font-size: 20pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 95%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:bottom"&gt;&#x2003;&#x2003;&#x2003;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;&#x2002;Options granted in CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:8pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.33%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.62%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64.3%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65.5%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-date&lt;/div&gt; share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;$&#x2003;&#x2002;3.80&#160;(CA$5.16)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&#160;(CA$16.68)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;3.80&#160;(CA$5.16)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.00&#160;(CA$16.68)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:20pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:5pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Average option life in years&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-date&lt;/div&gt; share price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Option exercise price&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.08&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="8" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationForShareBasedCompensationExpenseStockOptionPlanExplanatoryTableTextBlock>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="4"
      id="ixv-48947"
      unitRef="Unit_pure">0.0333</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="4"
      id="ixv-48948"
      unitRef="Unit_pure">0.0162</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="3"
      id="ixv-48949"
      unitRef="Unit_pure">0.643</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="3"
      id="ixv-48950"
      unitRef="Unit_pure">0.655</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="1"
      id="ixv-48951"
      unitRef="Unit_Y">9.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48952"
      unitRef="Unit_Y">9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48953"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48954"
      unitRef="Unit_CAD_per_Share">5.16</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48955"
      unitRef="Unit_USD_per_Share">13</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48956"
      unitRef="Unit_CAD_per_Share">16.68</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48957"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48958"
      unitRef="Unit_CAD_per_Share">5.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48959"
      unitRef="Unit_USD_per_Share">13</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-48960"
      unitRef="Unit_CAD_per_Share">16.68</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="4"
      id="ixv-48961"
      unitRef="Unit_pure">0.0392</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="4"
      id="ixv-48962"
      unitRef="Unit_pure">0.0195</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48963"
      unitRef="Unit_pure">0.62</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48964"
      unitRef="Unit_pure">0.64</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="1"
      id="ixv-48965"
      unitRef="Unit_Y">9.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48966"
      unitRef="Unit_Y">9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48967"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48968"
      unitRef="Unit_USD_per_Share">12.08</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48969"
      unitRef="Unit_USD_per_Share">3.8</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="2"
      id="ixv-48970"
      unitRef="Unit_USD_per_Share">12.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <thtx:DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-36919"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the measurement date weighted average fair value of Options granted during the years ended November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&#160;granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;grant date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;792,193&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.77&#160;(CA$3.76&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;547,847&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;8.64&#160;(CA$11.64&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 18pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted in US$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&#160;granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;grant date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 15pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;203,935&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.72&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;96,668&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.36&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;</thtx:DisclosureOfWeightedAverageFairValueOfOptionsGrantedAndNumberOfOptionsExplanatoryTextBlock>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48972"
      unitRef="Unit_shares">792193</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48973"
      unitRef="Unit_USD">2770</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48974"
      unitRef="Unit_CAD">3760</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-48975"
      unitRef="Unit_shares">547847</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48976"
      unitRef="Unit_USD">8640</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48977"
      unitRef="Unit_CAD">11640</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2022To11_30_2023_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48978"
      unitRef="Unit_shares">203935</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2023_USDsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48979"
      unitRef="Unit_USD">2720</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P12_01_2021To11_30_2022_USDsrtCurrencyAxis"
      decimals="0"
      id="ixv-48980"
      unitRef="Unit_shares">96668</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn11_30_2022_USDsrtCurrencyAxis"
      decimals="-1"
      id="ixv-48981"
      unitRef="Unit_USD">8360</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <thtx:DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-37482"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:arial;text-align:justify"&gt;The calculation of basic loss per&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;common&lt;/div&gt;&lt;/div&gt; share was based on the net loss attributable to common shareholders of the Company of $23,957 (2022 &#x2013; 47,237, 2021&#160;&#x2013; $31,725) and a weighted average number of common shares outstanding calculated as follows. &lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom:7pt ;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Issued common shares as at December&#160;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,201,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,780,417&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,253,360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of share options exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of public issue common shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,843,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,704,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Impact on conversion of convertible&lt;br/&gt; &#160;&#160;&#160;&#160;unsecured senior notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of share issue - ATM program&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;Effect of subscription receipts issue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;287,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="line-height: 4pt; font-size: 4pt;"&gt;&lt;div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Effect of broker warrants exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;36,564&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 11pt;"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Weighted average number of common shares, &lt;br/&gt; &#160;&#160;&#160;&#160;basic&#160;and&#160;diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;26,332,429&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;23,813,344&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;23,087,557&lt;/td&gt;
&lt;td style="padding-bottom: 6pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</thtx:DisclosureOfWeightedAverageNumberOfSharesOutstandingExplanatoryTextBlock>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-48983"
      unitRef="Unit_USD">-23957000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-48984"
      unitRef="Unit_USD">-47237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-48985"
      unitRef="Unit_USD">-31725000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares
      contextRef="P12_01_2022To11_30_2023"
      decimals="0"
      id="ixv-48986"
      unitRef="Unit_shares">24201582</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P12_01_2021To11_30_2022"
      decimals="0"
      id="ixv-48987"
      unitRef="Unit_shares">23780417</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P12_01_2020To11_30_2021"
      decimals="0"
      id="ixv-48988"
      unitRef="Unit_shares">19253360</ifrs-full:WeightedAverageShares>
    <thtx:EffectOfShareOptionsExercised
      contextRef="P12_01_2022To11_30_2023_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48989"
      unitRef="Unit_shares">0</thtx:EffectOfShareOptionsExercised>
    <thtx:EffectOfShareOptionsExercised
      contextRef="P12_01_2021To11_30_2022_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48990"
      unitRef="Unit_shares">3338</thtx:EffectOfShareOptionsExercised>
    <thtx:EffectOfShareOptionsExercised
      contextRef="P12_01_2020To11_30_2021_ShareOptionMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48991"
      unitRef="Unit_shares">93562</thtx:EffectOfShareOptionsExercised>
    <thtx:EffectOfIssueCommonShares
      contextRef="P12_01_2022To11_30_2023_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48992"
      unitRef="Unit_shares">1843517</thtx:EffectOfIssueCommonShares>
    <thtx:EffectOfIssueCommonShares
      contextRef="P12_01_2021To11_30_2022_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48993"
      unitRef="Unit_shares">0</thtx:EffectOfIssueCommonShares>
    <thtx:EffectOfIssueCommonShares
      contextRef="P12_01_2020To11_30_2021_PublicIssueOfSharesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48994"
      unitRef="Unit_shares">3704071</thtx:EffectOfIssueCommonShares>
    <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
      contextRef="P12_01_2022To11_30_2023_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48995"
      unitRef="Unit_shares">107</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
      contextRef="P12_01_2021To11_30_2022_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48996"
      unitRef="Unit_shares">0</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
      contextRef="P12_01_2020To11_30_2021_ConvertibleUnsecuredSeniorNotesMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-48997"
      unitRef="Unit_shares">0</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2022To11_30_2023_AtmProgramMemberTHTXProgramNameAxis"
      decimals="INF"
      id="ixv-48998"
      unitRef="Unit_shares">0</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2021To11_30_2022_AtmProgramMemberTHTXProgramNameAxis"
      decimals="INF"
      id="ixv-48999"
      unitRef="Unit_shares">29589</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2020To11_30_2021_AtmProgramMemberTHTXProgramNameAxis"
      decimals="INF"
      id="ixv-49000"
      unitRef="Unit_shares">0</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfSubscriptionReceiptsIssue
      contextRef="P12_01_2022To11_30_2023_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-49001"
      unitRef="Unit_shares">287223</thtx:EffectOfSubscriptionReceiptsIssue>
    <thtx:EffectOfSubscriptionReceiptsIssue
      contextRef="P12_01_2021To11_30_2022_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-49002"
      unitRef="Unit_shares">0</thtx:EffectOfSubscriptionReceiptsIssue>
    <thtx:EffectOfSubscriptionReceiptsIssue
      contextRef="P12_01_2020To11_30_2021_SubscriptionReceiptsIssueMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="0"
      id="ixv-49003"
      unitRef="Unit_shares">0</thtx:EffectOfSubscriptionReceiptsIssue>
    <thtx:EffectOfBrokerWarrantsExercised
      contextRef="P12_01_2022To11_30_2023_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="INF"
      id="ixv-49004"
      unitRef="Unit_shares">0</thtx:EffectOfBrokerWarrantsExercised>
    <thtx:EffectOfBrokerWarrantsExercised
      contextRef="P12_01_2021To11_30_2022_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="INF"
      id="ixv-49005"
      unitRef="Unit_shares">0</thtx:EffectOfBrokerWarrantsExercised>
    <thtx:EffectOfBrokerWarrantsExercised
      contextRef="P12_01_2020To11_30_2021_BrokersWarrantsMemberifrsfullClassesOfOrdinarySharesAxis"
      decimals="INF"
      id="ixv-49006"
      unitRef="Unit_shares">36564</thtx:EffectOfBrokerWarrantsExercised>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P12_01_2022To11_30_2023"
      decimals="INF"
      id="ixv-49007"
      unitRef="Unit_shares">26332429</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P12_01_2021To11_30_2022"
      decimals="INF"
      id="ixv-49008"
      unitRef="Unit_shares">23813344</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P12_01_2020To11_30_2021"
      decimals="INF"
      id="ixv-49009"
      unitRef="Unit_shares">23087557</ifrs-full:AdjustedWeightedAverageShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2022To11_30_2023"
      decimals="INF"
      id="ixv-49010"
      unitRef="Unit_shares">2053928</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2021To11_30_2022"
      decimals="INF"
      id="ixv-49011"
      unitRef="Unit_shares">1286695</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P12_01_2020To11_30_2021"
      decimals="INF"
      id="ixv-49012"
      unitRef="Unit_shares">817766</thtx:EffectOfShareOptionsOnNumberOfOrdinaryShares>
    <thtx:EffectOfShareOptionsOnNumberOfWarrantsShares
      contextRef="P12_01_2021To11_30_2022"
      decimals="INF"
      id="ixv-49013"
      unitRef="Unit_shares">8130550</thtx:EffectOfShareOptionsOnNumberOfWarrantsShares>
    <thtx:EffectOfShareOptionsOnNumberOfWarrantsShares
      contextRef="P12_01_2021To11_30_2022"
      decimals="INF"
      id="ixv-49014"
      unitRef="Unit_shares">8130550</thtx:EffectOfShareOptionsOnNumberOfWarrantsShares>
    <thtx:EffectOfShareOptionsOnNumberOfWarrantsShares
      contextRef="P12_01_2020To11_30_2021"
      decimals="INF"
      id="ixv-49015"
      unitRef="Unit_shares">8130550</thtx:EffectOfShareOptionsOnNumberOfWarrantsShares>
    <thtx:PotentialShareIssueInTheFutureOnExerciseOfWarrants
      contextRef="PAsOn11_30_2023_MarathonWarrantsMemberTHTXClassOfWarrantsOrRightsAxis"
      decimals="INF"
      id="ixv-49016"
      unitRef="Unit_shares">5000000</thtx:PotentialShareIssueInTheFutureOnExerciseOfWarrants>
    <thtx:DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-49018">Accumulated other comprehensive income (loss) &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Unrealized losses on FVOCI financial assets, net of tax&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(256)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;(555)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;(195)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:3pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom: 6pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6.5em; line-height: normal;"&gt;Cumulative exchange difference on translation of foreign &lt;br/&gt;operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;684&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;385&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(44)&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </thtx:DisclosureOfDetailedInformationAboutInAccumulatedOtherComprehensiveIncomeLossExplanatoryTextBlock>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2023_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49019"
      unitRef="Unit_USD">-256000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2022_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49020"
      unitRef="Unit_USD">-555000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2021_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49021"
      unitRef="Unit_USD">-195000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2023_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49022"
      unitRef="Unit_USD">940000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2022_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49023"
      unitRef="Unit_USD">940000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2021_ReserveOfExchangeDifferencesOnTranslationMemberifrsfullComponentsOfEquityAxis"
      decimals="-3"
      id="ixv-49024"
      unitRef="Unit_USD">151000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49025"
      unitRef="Unit_USD">684000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49026"
      unitRef="Unit_USD">385000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="PAsOn11_30_2021"
      decimals="-3"
      id="ixv-49027"
      unitRef="Unit_USD">-44000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-37937">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Calibri; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: Calibri; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the components of the current and deferred tax expenses (recovery). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;450&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax expense (recovery)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Origination and reversal of temporary differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,972)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,705)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,796)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in unrecognized deductible &lt;br/&gt;temporary&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,943&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,705&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax expense (recovery)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(29)&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current and deferred tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reconciliation between effective and applicable tax amounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes at domestic tax statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,237)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12,400)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,390)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in unrecognized deductible temporary&#160;differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,943&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,705&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impact of differences in statutory tax rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(130)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;845&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,036&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;593&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The applicable statutory tax rate was &lt;/div&gt;26.5&lt;div style="font-size: 11pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in 2023, 2022 and 2021. The Company&#x2019;s applicable tax rate is the Canadian combined rates applicable in the jurisdictions in which the Company operates.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;div&gt;  &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Unrecognized deferred tax assets &lt;/div&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at November&#160;30, 2023 and 2022, the amounts and expiry dates of Canadian tax attributes for which no deferred tax asset was recognized were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Federal&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Provincial&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Federal&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Provincial&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses,&lt;br/&gt; &#x2003;without&#160;time&#160;limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;87,151&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105,549&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,768&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105,174&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses carried forward 2027&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,512&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,504&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,569&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,561&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2028&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,761&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,258&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,110&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,426&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2029&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,345&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,494&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,250&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2030&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,420&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,510&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2031&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,346&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,397&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,525&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2032&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,752&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,791&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,874&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,902&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2033&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,444&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,365&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,532&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2034&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,733&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,665&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,813&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,744&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2037&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,818&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,972&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,889&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2038&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,013&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,938&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,958&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2039&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,326&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,289&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,340&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2040&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,242&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,218&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,317&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,292&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2041&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,152&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,078&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,276&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2042&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,885&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,181&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,190&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2043&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,298&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,284&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other temporary differences,&lt;br/&gt; &#x2003;without time limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess of tax value of property and&lt;br/&gt; &#x2003;equipment over carrying value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;435&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;420&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;454&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess of tax value of intellectual&lt;br/&gt; &#x2003;property and patent fees over carrying value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,660&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,656&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,765&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,765&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available deductions and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,522&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,536&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;69,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Given the Company&#x2019;s past losses, management does not believe that it is probable that the Company can realize its deferred tax assets and, therefore, no amount has been recognized in the consolidated statements of financial position. The generation of future taxable profit is dependent on the successful commercialization of the Company&#x2019;s products and technologies. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to the above attributes, as at November&#160;30, 2023, the Company had available $8,816 (2022 &#x2013; $8,883) of losses carried forward in Ireland without expiry dates for which no deferred tax assets were recognized. As at November&#160;30, 2023, deferred tax liabilities had not been recognized for taxable temporary differences arising from investments in a subsidiary because the Company controls the decisions affecting the realization of such liabilities and it is probable that the temporary differences will not reverse in the foreseeable future. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-37950"> &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the components of the current and deferred tax expenses (recovery). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;450&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax expense (recovery)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Origination and reversal of temporary differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,972)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,705)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,796)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in unrecognized deductible &lt;br/&gt;temporary&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,943&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,705&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax expense (recovery)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(29)&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current and deferred tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfMajorComponentOfIncomeTaxAndDeferredTaxExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49028"
      unitRef="Unit_USD">450000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49029"
      unitRef="Unit_USD">443000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49030"
      unitRef="Unit_USD">63000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49031"
      unitRef="Unit_USD">-5972000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49032"
      unitRef="Unit_USD">-11705000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49033"
      unitRef="Unit_USD">-7796000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
    <thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49034"
      unitRef="Unit_USD">-5943000</thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences>
    <thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49035"
      unitRef="Unit_USD">-11705000</thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences>
    <thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49036"
      unitRef="Unit_USD">-7796000</thtx:IncreaseDecreaseInUnrecognizedDeductableTemporaryDifferences>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49037"
      unitRef="Unit_USD">-29000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49038"
      unitRef="Unit_USD">0</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49039"
      unitRef="Unit_USD">0</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49040"
      unitRef="Unit_USD">421000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49041"
      unitRef="Unit_USD">443000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49042"
      unitRef="Unit_USD">63000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <thtx:DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-38252"> &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reconciliation between effective and applicable tax amounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes at domestic tax statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,237)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(12,400)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,390)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in unrecognized deductible temporary&#160;differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,943&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,705&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,796&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impact of differences in statutory tax rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(130)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;102&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;845&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,036&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;593&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfReconciliationBetweenEffectiveAndIncomeTaxAmountsExplanatoryTableTextBlock>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49043"
      unitRef="Unit_USD">-6237000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49044"
      unitRef="Unit_USD">-12400000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49045"
      unitRef="Unit_USD">-8390000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49046"
      unitRef="Unit_USD">-5943000</thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences>
    <thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49047"
      unitRef="Unit_USD">-11705000</thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences>
    <thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49048"
      unitRef="Unit_USD">-7796000</thtx:IncreaseDecreaseInUnrecognizedDeductibleTemporaryDifferences>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49049"
      unitRef="Unit_USD">-130000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49050"
      unitRef="Unit_USD">102000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49051"
      unitRef="Unit_USD">64000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49052"
      unitRef="Unit_USD">845000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49053"
      unitRef="Unit_USD">1036000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49054"
      unitRef="Unit_USD">593000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49055"
      unitRef="Unit_USD">421000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49056"
      unitRef="Unit_USD">443000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49057"
      unitRef="Unit_USD">63000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ApplicableTaxRate
      contextRef="P12_01_2020To11_30_2021"
      decimals="3"
      id="ixv-49058"
      unitRef="Unit_pure">0.265</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P12_01_2022To11_30_2023"
      decimals="3"
      id="ixv-49059"
      unitRef="Unit_pure">0.265</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P12_01_2021To11_30_2022"
      decimals="3"
      id="ixv-49060"
      unitRef="Unit_pure">0.265</ifrs-full:ApplicableTaxRate>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-38581"> &lt;div style="font-family: arial; font-size: 11pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at November&#160;30, 2023 and 2022, the amounts and expiry dates of Canadian tax attributes for which no deferred tax asset was recognized were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Federal&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Provincial&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Federal&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 4pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Provincial&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses,&lt;br/&gt; &#x2003;without&#160;time&#160;limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;87,151&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105,549&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,768&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;105,174&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Losses carried forward 2027&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,512&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,504&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,569&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,561&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2028&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,761&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,258&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,110&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,426&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2029&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,345&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,494&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,250&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2030&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,420&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,510&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,507&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2031&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,346&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,397&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,525&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2032&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,752&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,791&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,874&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,902&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2033&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,444&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,365&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,532&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,451&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2034&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,733&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,665&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,813&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,744&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2037&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,901&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,818&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,972&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,889&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2038&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,013&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,938&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,958&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2039&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,326&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,289&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,340&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2040&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,242&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,218&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,317&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,292&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2041&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,152&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,078&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,276&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2042&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,885&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,181&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,190&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2043&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,298&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,284&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other temporary differences,&lt;br/&gt; &#x2003;without time limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess of tax value of property and&lt;br/&gt; &#x2003;equipment over carrying value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;435&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;420&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;454&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess of tax value of intellectual&lt;br/&gt; &#x2003;property and patent fees over carrying value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,660&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,656&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,765&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,765&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 3pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available deductions and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,522&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,536&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;69,448&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap; width: 5%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 3pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; </ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49061"
      unitRef="Unit_USD">87151000</thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation>
    <thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49062"
      unitRef="Unit_USD">105549000</thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation>
    <thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49063"
      unitRef="Unit_USD">86768000</thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation>
    <thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49064"
      unitRef="Unit_USD">105174000</thtx:UnutilisedResearchAndDevelopmentExpensesWithNoTimeLimitation>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49065"
      unitRef="Unit_USD">5512000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49066"
      unitRef="Unit_USD">5504000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49067"
      unitRef="Unit_USD">5569000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49068"
      unitRef="Unit_USD">5561000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49069"
      unitRef="Unit_USD">33761000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49070"
      unitRef="Unit_USD">16258000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49071"
      unitRef="Unit_USD">34110000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49072"
      unitRef="Unit_USD">16426000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49073"
      unitRef="Unit_USD">14345000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49074"
      unitRef="Unit_USD">12124000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49075"
      unitRef="Unit_USD">14494000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndTwentyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49076"
      unitRef="Unit_USD">12250000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49077"
      unitRef="Unit_USD">8423000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49078"
      unitRef="Unit_USD">8420000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49079"
      unitRef="Unit_USD">8510000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49080"
      unitRef="Unit_USD">8507000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49081"
      unitRef="Unit_USD">17346000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49082"
      unitRef="Unit_USD">15397000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49083"
      unitRef="Unit_USD">17525000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49084"
      unitRef="Unit_USD">15556000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49085"
      unitRef="Unit_USD">11752000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49086"
      unitRef="Unit_USD">10791000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49087"
      unitRef="Unit_USD">11874000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49088"
      unitRef="Unit_USD">10902000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49089"
      unitRef="Unit_USD">8444000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49090"
      unitRef="Unit_USD">8365000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49091"
      unitRef="Unit_USD">8532000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49092"
      unitRef="Unit_USD">8451000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49093"
      unitRef="Unit_USD">7733000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49094"
      unitRef="Unit_USD">7665000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49095"
      unitRef="Unit_USD">7813000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyFourMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49096"
      unitRef="Unit_USD">7744000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49097"
      unitRef="Unit_USD">6901000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49098"
      unitRef="Unit_USD">6818000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49099"
      unitRef="Unit_USD">6972000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtySevenMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49100"
      unitRef="Unit_USD">6889000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49101"
      unitRef="Unit_USD">2013000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49102"
      unitRef="Unit_USD">1938000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49103"
      unitRef="Unit_USD">2034000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyEightMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49104"
      unitRef="Unit_USD">1958000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49105"
      unitRef="Unit_USD">1326000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49106"
      unitRef="Unit_USD">1289000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49107"
      unitRef="Unit_USD">1340000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndThirtyNineMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49108"
      unitRef="Unit_USD">1302000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49109"
      unitRef="Unit_USD">7242000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49110"
      unitRef="Unit_USD">7218000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49111"
      unitRef="Unit_USD">7317000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49112"
      unitRef="Unit_USD">7292000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49113"
      unitRef="Unit_USD">19152000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49114"
      unitRef="Unit_USD">19078000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49115"
      unitRef="Unit_USD">19350000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyOneMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49116"
      unitRef="Unit_USD">19276000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49117"
      unitRef="Unit_USD">29042000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49118"
      unitRef="Unit_USD">28885000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49119"
      unitRef="Unit_USD">31181000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyTwoMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49120"
      unitRef="Unit_USD">31190000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49121"
      unitRef="Unit_USD">19298000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49122"
      unitRef="Unit_USD">19284000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49123"
      unitRef="Unit_USD">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis_YearTwoThousandAndFortyThreeMemberTHTXTaxBenefitCarryForwardYearAxis"
      decimals="-3"
      id="ixv-49124"
      unitRef="Unit_USD">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49125"
      unitRef="Unit_USD">435000</thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue>
    <thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49126"
      unitRef="Unit_USD">420000</thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue>
    <thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49127"
      unitRef="Unit_USD">1000000</thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue>
    <thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49128"
      unitRef="Unit_USD">454000</thtx:ExcessOfTaxValueOfPropertyPlantAndEquipmentOverCarryingValue>
    <thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49129"
      unitRef="Unit_USD">10660000</thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue>
    <thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49130"
      unitRef="Unit_USD">10656000</thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue>
    <thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49131"
      unitRef="Unit_USD">10765000</thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue>
    <thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49132"
      unitRef="Unit_USD">10765000</thtx:ExcessOfTaxValueOfIntellectualPropertyAndFeesOverCarryingValue>
    <thtx:AvailableDeductionsAndOthers
      contextRef="PAsOn11_30_2023_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49133"
      unitRef="Unit_USD">73522000</thtx:AvailableDeductionsAndOthers>
    <thtx:AvailableDeductionsAndOthers
      contextRef="PAsOn11_30_2023_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49134"
      unitRef="Unit_USD">32536000</thtx:AvailableDeductionsAndOthers>
    <thtx:AvailableDeductionsAndOthers
      contextRef="PAsOn11_30_2022_FederalMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49135"
      unitRef="Unit_USD">69448000</thtx:AvailableDeductionsAndOthers>
    <thtx:AvailableDeductionsAndOthers
      contextRef="PAsOn11_30_2022_ProvincialMemberTHTXIncomeTaxJurisdictionAxis"
      decimals="-3"
      id="ixv-49136"
      unitRef="Unit_USD">28034000</thtx:AvailableDeductionsAndOthers>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2023_IEsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49137"
      unitRef="Unit_USD">8816000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn11_30_2022_IEsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49138"
      unitRef="Unit_USD">8883000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-39523">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: Calibri; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Supplemental cash flow disclosures&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into the following transactions, which had no impact on its cash flows. &lt;/div&gt;&lt;/div&gt;&#160; &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin: 0px auto; border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 660.312px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs included in accounts&lt;br/&gt; &#x2003;payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions to property and equipment included in accounts payable and&lt;br/&gt; &#x2003;accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;156&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition of derivative financial assets included in accounts payable and&lt;br/&gt; &#x2003;accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions to intangible assets included in accounts payable and accrued&lt;br/&gt; &#x2003;liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,832&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of other Deferred financing costs to deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;38&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share issue cost included in accounts payable&lt;br/&gt; &#x2003;and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;505&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </thtx:DisclosureOfSupplementalInformationOnCashFlowexplanatory>
    <thtx:DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-39538"> &lt;div style="font-family: arial; font-size: 11pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into the following transactions, which had no impact on its cash flows. &lt;/div&gt;&lt;/div&gt;&#160; &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin: 0px auto; border: 0px currentcolor; width: 816px; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 660.312px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2002;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 15.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs included in accounts&lt;br/&gt; &#x2003;payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;174&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions to property and equipment included in accounts payable and&lt;br/&gt; &#x2003;accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;156&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition of derivative financial assets included in accounts payable and&lt;br/&gt; &#x2003;accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions to intangible assets included in accounts payable and accrued&lt;br/&gt; &#x2003;liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,832&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 9.75pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of other Deferred financing costs to deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;38&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share issue cost included in accounts payable&lt;br/&gt; &#x2003;and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;505&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfAmountsAndExpiryDatesOfTaxAttributesCarryForwardExplanatoryTableTextBlock>
    <thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49139"
      unitRef="Unit_USD">0</thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities>
    <thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49140"
      unitRef="Unit_USD">0</thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities>
    <thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49141"
      unitRef="Unit_USD">174000</thtx:DeferredFinancingCostsincludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49142"
      unitRef="Unit_USD">0</thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49143"
      unitRef="Unit_USD">156000</thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49144"
      unitRef="Unit_USD">0</thtx:AdditionsToPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49145"
      unitRef="Unit_USD">0</thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49146"
      unitRef="Unit_USD">104000</thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49147"
      unitRef="Unit_USD">0</thtx:AcquisitionOfDerivativeFinancialAssetsIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49148"
      unitRef="Unit_USD">0</thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49149"
      unitRef="Unit_USD">2832000</thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49150"
      unitRef="Unit_USD">0</thtx:AdditionsToIntangiblesIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49151"
      unitRef="Unit_USD">0</thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit>
    <thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49152"
      unitRef="Unit_USD">38000</thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit>
    <thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49153"
      unitRef="Unit_USD">0</thtx:ReclassificationOfOtherDeferredFinancingCostsToDeficit>
    <thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49154"
      unitRef="Unit_USD">505000</thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49155"
      unitRef="Unit_USD">37000</thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities>
    <thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49156"
      unitRef="Unit_USD">0</thtx:ShareIssueCostIncludedInAccountsPayableAndAccruedLiabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-39840">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Overview&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;This note provides disclosures relating to the nature and extent of the Company&#x2019;s exposure to risks arising from financial instruments, including credit risk, liquidity risk, currency risk and interest rate risk, and how the Company manages those risks. In addition to currency risk, the Company has exposure to risks from disputed accounts receivables. &lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Credit risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;Credit risk refers to the risk of a loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. &lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: arial; font-size: 14.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;The Company&#x2019;s exposure to credit risk currently relates to accounts receivable with one major customer (refer to Note&#160;27), other receivable and derivative financial assets which it manages by dealing only with highly rated Canadian&lt;/div&gt; financial institutions. Included in the consolidated statements of financial position are trade receivables of $12,798 (2022&#160;&#x2013; $10,659), all of which were aged under 60 days or received after year end. There was no amount recorded as bad debt expense for the years ended November&#160;30, 2023 and 2022. Financial instruments other than cash and trade and other receivables that potentially subject the Company to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;significant credit risk consists principally of bonds and money market funds. The Company invests its available cash in highly liquid fixed income instruments from governmental, paragovernmental, municipal and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;high-grade&lt;/div&gt; corporate bodies and money market funds (2023&#160;&#x2013; $6,290; 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;&#x2013; $9,214). As at November&#160;30, 2023, the Company believes it was not exposed to any significant credit risk. The Company&#x2019;s maximum credit exposure corresponded to the carrying amount of these financial assets. &lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-indent: 0px;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 15pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Liquidity risk refers to the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in Note 24, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Company&#x2019;s operating and capital budgets, as well as any material transactions out of the ordinary course of business.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:15pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify;text-indent: 0px;"&gt;The Company has adopted an investment policy in respect of the safety and preservation of its capital designed to ensure that the Company&#x2019;s liquidity needs are met. The instruments are selected with regards to the expected timing of expenditures and prevailing interest rates. &lt;br/&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Marathon Credit Agreement, the Company is required to maintain cash, cash equivalents and eligible short-term investments overtime between&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; $15,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;to $20,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;based on the last twelve months adjusted EBITDA-based targets, which restricts the management of the Company&#x2019;s liquidity. Refer to notes 1 and 17.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 24pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following are amounts due on the contractual maturities of financial liabilities as at November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; contractual&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&lt;br/&gt; than&lt;br/&gt; 1 year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;From&lt;br/&gt; 1 to&lt;br/&gt; 2 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&lt;br/&gt; than&lt;br/&gt; 3 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;  -&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Facility loan, including interest (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,416&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;516&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;87,439&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;109,720&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;46,374&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;50,864&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;12,482&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on SOFR forward rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; contractual&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&lt;br/&gt; than&lt;br/&gt; 1 year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;From&lt;br/&gt; 1 to&lt;br/&gt; 2 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&lt;br/&gt; than&lt;br/&gt; 3 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term loan, including interest (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37,894&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,667&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,649&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,421&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes, including interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,895&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,081&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,081&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,922&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,196&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;595&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,145&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;456&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;107,776&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;130,009&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;76,390&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;29,566&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;24,053&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on SOFR forward rates. The maturities above reflect the fact that the Marathon Credit Agreement has been amended in the subsequent event period and, as such, the contractual maturities are used. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Currency risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is exposed to financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company&#x2019;s business transactions denominated in currencies other than US$, primarily cash, sale of goods and expenses incurred in CA$ and euros. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exchange rate fluctuations for foreign currency transactions can cause cash flows, as well as amounts recorded in the consolidated statements of net loss, to vary from period to period and not necessarily correspond to those forecasted in operating budgets and projections. Additional earnings variability arises from the translation of monetary assets and liabilities denominated in currencies other than the US$ at the rates of exchange at each consolidated statement of financial position date, the impact of which is reported as foreign exchange gain or loss in the consolidated statements of net loss. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the significant items in the original currencies exposed to currency risk as at November&#160;30, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 67%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;EURO&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;EURO&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,547&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Bonds and money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accounts payables and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,395)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(224)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,784)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,849)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(925)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(288)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,362)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(326)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,192)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,486)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Total exposure&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,048&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,434)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,587&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,592)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The following exchange rates are those applicable as at November&#160;30, 2023 and 2022.&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;CA$ &#x2013; US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7439&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Euro &#x2013; US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0792&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0903&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0600&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0406&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;Based on the Company&#x2019;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the CA$ or the euro would have an impact on net earnings for CA$ and in the accumulated other comprehensive loss for euro as follows, assuming that all other variables remained constant.&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Euro&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;Euro&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Positive (negative) impact&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(172)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(380)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;An assumed 5% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;weakening of the CA$ or of the euro would have had an equal but opposite effect on the above currencies in the amounts shown above, assuming that all other variables remained constant.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest rate risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Interest rate risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term&lt;/div&gt; bonds held by the Company are invested at fixed interest rates and/or mature in the short term. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt; bonds are also instruments that bear interest at fixed rates. The risk that the Company will realize a loss as a result of a decline in the fair value of its bonds is limited because these investments, although they are classified as fair value through OCI, are generally held until close to maturity. The unrealized gains or losses on bonds are recorded in accumulated other comprehensive income (loss). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Based on the value of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&lt;/div&gt; bonds as at November&#160;30, 2023, an assumed 0.5% decrease in market interest rates would have increased the fair value of these bonds and the accumulated other comprehensive income (loss) by approximately &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;42&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; (2022&#160;&#x2013; $79); an assumed increase in market interest rates of 0.5% would have an equal but opposite effect, assuming that all other variables remained constant. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and money market funds bear interest at variable rates. Trade and other receivables, accounts payable and accrued liabilities and provisions bear no interest.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49157"
      unitRef="Unit_USD">12798000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49158"
      unitRef="Unit_USD">10659000</ifrs-full:CurrentTradeReceivables>
    <thtx:CurrentTradeReceivablesAgingPeriod contextRef="P12_01_2022To11_30_2023" id="ixv-49159">P60D</thtx:CurrentTradeReceivablesAgingPeriod>
    <thtx:CurrentTradeReceivablesAgingPeriod contextRef="P12_01_2021To11_30_2022" id="ixv-49160">P60D</thtx:CurrentTradeReceivablesAgingPeriod>
    <thtx:BadDebtExpenses
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49161"
      unitRef="Unit_USD">0</thtx:BadDebtExpenses>
    <thtx:BadDebtExpenses
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49162"
      unitRef="Unit_USD">0</thtx:BadDebtExpenses>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49163"
      unitRef="Unit_USD">6290000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49164"
      unitRef="Unit_USD">9214000</ifrs-full:OtherFinancialAssets>
    <thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-49165"
      unitRef="Unit_USD">15000000</thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained>
    <thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained
      contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-49166"
      unitRef="Unit_USD">20000000</thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="P12_01_2022To11_30_2023" id="ixv-39940"> &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; contractual&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&lt;br/&gt; than&lt;br/&gt; 1 year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;From&lt;br/&gt; 1 to&lt;br/&gt; 2 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&lt;br/&gt; than&lt;br/&gt; 3 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160;&#160;28,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;  -&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; text-indent: -1em; font-size: 9pt; font-family: arial; line-height: normal;"&gt;Facility loan, including interest (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,416&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;516&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: top; padding: 0pt;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: arial; font-size: 9pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;87,439&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;109,720&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;46,374&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;50,864&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;12,482&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="20" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on SOFR forward rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 9pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; contractual&lt;br/&gt; amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less&lt;br/&gt; than&lt;br/&gt; 1 year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;From&lt;br/&gt; 1 to&lt;br/&gt; 2 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;More&lt;br/&gt; than&lt;br/&gt; 3 years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;41,065&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term loan, including interest (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37,894&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,667&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,649&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,421&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible unsecured senior notes, including interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,895&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,081&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,081&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: top; width: 54%;"&gt;&lt;div style="text-indent: -1em; font-family: arial; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,922&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,196&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;595&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,145&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;456&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;107,776&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;130,009&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;76,390&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;29,566&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;24,053&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="20" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on SOFR forward rates. The maturities above reflect the fact that the Marathon Credit Agreement has been amended in the subsequent event period and, as such, the contractual maturities are used. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49167"
      unitRef="Unit_USD">28471000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49168"
      unitRef="Unit_USD">28471000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49169"
      unitRef="Unit_USD">28471000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49170"
      unitRef="Unit_USD">0</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49171"
      unitRef="Unit_USD">0</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <thtx:CurrentPositionOfTermLoanIncludingInterest
      contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49172"
      unitRef="Unit_USD">57974000</thtx:CurrentPositionOfTermLoanIncludingInterest>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49173"
      unitRef="Unit_USD">80141000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49174"
      unitRef="Unit_USD">17416000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49175"
      unitRef="Unit_USD">50348000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49176"
      unitRef="Unit_USD">12377000</thtx:LongTermLoanUndiscountedCashFlows>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49177"
      unitRef="Unit_USD">994000</ifrs-full:LeaseLiabilities>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49178"
      unitRef="Unit_USD">1108000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49179"
      unitRef="Unit_USD">487000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49180"
      unitRef="Unit_USD">516000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49181"
      unitRef="Unit_USD">105000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:NonderivativeFinancialLiabilities
      contextRef="PAsOn11_30_2023_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49182"
      unitRef="Unit_USD">87439000</thtx:NonderivativeFinancialLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49183"
      unitRef="Unit_USD">109720000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49184"
      unitRef="Unit_USD">46374000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49185"
      unitRef="Unit_USD">50864000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2023_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49186"
      unitRef="Unit_USD">12482000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49187"
      unitRef="Unit_USD">41065000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49188"
      unitRef="Unit_USD">41065000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49189"
      unitRef="Unit_USD">41065000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49190"
      unitRef="Unit_USD">0</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49191"
      unitRef="Unit_USD">0</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <thtx:CurrentPositionOfTermLoanIncludingInterest
      contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49192"
      unitRef="Unit_USD">37894000</thtx:CurrentPositionOfTermLoanIncludingInterest>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49193"
      unitRef="Unit_USD">57667000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49194"
      unitRef="Unit_USD">5649000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49195"
      unitRef="Unit_USD">28421000</thtx:LongTermLoanUndiscountedCashFlows>
    <thtx:LongTermLoanUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49196"
      unitRef="Unit_USD">23597000</thtx:LongTermLoanUndiscountedCashFlows>
    <ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49197"
      unitRef="Unit_USD">26895000</ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49198"
      unitRef="Unit_USD">29081000</thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows>
    <thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49199"
      unitRef="Unit_USD">29081000</thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows>
    <thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49200"
      unitRef="Unit_USD">0</thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows>
    <thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49201"
      unitRef="Unit_USD">0</thtx:ConvertibleUnsecuredSeniorNotesIncludingInterestUndiscountedCashFlows>
    <ifrs-full:LeaseLiabilities
      contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49202"
      unitRef="Unit_USD">1922000</ifrs-full:LeaseLiabilities>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49203"
      unitRef="Unit_USD">2196000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49204"
      unitRef="Unit_USD">595000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49205"
      unitRef="Unit_USD">1145000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:LeaseLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49206"
      unitRef="Unit_USD">456000</thtx:LeaseLiabilitiesUndiscountedCashFlows>
    <thtx:NonderivativeFinancialLiabilities
      contextRef="PAsOn11_30_2022_CarryingAmountMemberifrsfullMeasurementAxis"
      decimals="-3"
      id="ixv-49207"
      unitRef="Unit_USD">107776000</thtx:NonderivativeFinancialLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49208"
      unitRef="Unit_USD">130009000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49209"
      unitRef="Unit_USD">76390000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49210"
      unitRef="Unit_USD">29566000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="PAsOn11_30_2022_LaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-3"
      id="ixv-49211"
      unitRef="Unit_USD">24053000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <thtx:DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-40769">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 67%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;EURO&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;EURO&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 20.25pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,547&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Bonds and money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Trade and other receivables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Tax credits and grants receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;239&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Accounts payables and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,395)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(224)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,784)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,849)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(925)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(288)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,362)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(873)&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Provisions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(326)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,192)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,486)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Total exposure&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,048&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,434)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,587&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,592)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;</thtx:DisclosureOfCurrencyRiskExposureexplanatoryTableTextBlock>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49213"
      unitRef="Unit_CAD">358000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49214"
      unitRef="Unit_EUR">123000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49215"
      unitRef="Unit_CAD">1547000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49216"
      unitRef="Unit_EUR">236000</ifrs-full:Cash>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49217"
      unitRef="Unit_CAD">8543000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49218"
      unitRef="Unit_EUR">0</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49219"
      unitRef="Unit_CAD">12387000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49220"
      unitRef="Unit_EUR">0</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49221"
      unitRef="Unit_CAD">296000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49222"
      unitRef="Unit_EUR">2000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49223"
      unitRef="Unit_CAD">733000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49224"
      unitRef="Unit_EUR">2141000</ifrs-full:TradeAndOtherCurrentReceivables>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49225"
      unitRef="Unit_CAD">497000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49226"
      unitRef="Unit_EUR">145000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49227"
      unitRef="Unit_CAD">66000</thtx:TaxCreditsAndGrantsReceivable>
    <thtx:TaxCreditsAndGrantsReceivable
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49228"
      unitRef="Unit_EUR">239000</thtx:TaxCreditsAndGrantsReceivable>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49229"
      unitRef="Unit_CAD">5395000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49230"
      unitRef="Unit_EUR">224000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49231"
      unitRef="Unit_CAD">10784000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49232"
      unitRef="Unit_EUR">5849000</ifrs-full:TradeAndOtherCurrentPayables>
    <thtx:TotalLeaseLiabilities
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49233"
      unitRef="Unit_CAD">925000</thtx:TotalLeaseLiabilities>
    <thtx:TotalLeaseLiabilities
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49234"
      unitRef="Unit_EUR">288000</thtx:TotalLeaseLiabilities>
    <thtx:TotalLeaseLiabilities
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49235"
      unitRef="Unit_CAD">1362000</thtx:TotalLeaseLiabilities>
    <thtx:TotalLeaseLiabilities
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49236"
      unitRef="Unit_EUR">873000</thtx:TotalLeaseLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49237"
      unitRef="Unit_CAD">326000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49238"
      unitRef="Unit_EUR">3192000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49239"
      unitRef="Unit_EUR">3486000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49240"
      unitRef="Unit_CAD">3048000</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn11_30_2023_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49241"
      unitRef="Unit_EUR">3434000</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49242"
      unitRef="Unit_CAD">2587000</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="PAsOn11_30_2022_CurrencyRiskMemberifrsfullTypesOfRisksAxis"
      decimals="-3"
      id="ixv-49243"
      unitRef="Unit_EUR">-7592000</ifrs-full:CurrentAssetsLiabilities>
    <thtx:DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-41109">&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The following exchange rates are those applicable as at November&#160;30, 2023 and 2022.&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: right; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;date&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;CA$ &#x2013; US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0,7439&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:7pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Euro &#x2013; US$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0792&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0903&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0600&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,0406&lt;/td&gt;
&lt;td style="padding-bottom:7pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</thtx:DisclosureOfApplicableExchangeRatesexplanatoryTableTextBlock>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-49244"
      unitRef="Unit_pure">7404</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn11_30_2023_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-49245"
      unitRef="Unit_pure">7363</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P12_01_2021To11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-49246"
      unitRef="Unit_pure">7722</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn11_30_2022_CADsrtCurrencyAxis"
      decimals="0"
      id="ixv-49247"
      unitRef="Unit_pure">7439</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P12_01_2022To11_30_2023_EURsrtCurrencyAxis"
      decimals="0"
      id="ixv-49248"
      unitRef="Unit_pure">10792</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn11_30_2023_EURsrtCurrencyAxis"
      decimals="0"
      id="ixv-49249"
      unitRef="Unit_pure">10903</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="P12_01_2021To11_30_2022_EURsrtCurrencyAxis"
      decimals="0"
      id="ixv-49250"
      unitRef="Unit_pure">10600</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="PAsOn11_30_2022_EURsrtCurrencyAxis"
      decimals="0"
      id="ixv-49251"
      unitRef="Unit_pure">10406</ifrs-full:ClosingForeignExchangeRate>
    <thtx:PositivePercentageImpactOnForeignCurrencyExposures
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-49252"
      unitRef="Unit_pure">0.05</thtx:PositivePercentageImpactOnForeignCurrencyExposures>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-41391">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="16" style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;Euro&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;CA$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&#x2003;Euro&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 30pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Positive (negative) impact&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;152&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(172)&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 8pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(380)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="16" style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49253"
      unitRef="Unit_CAD">152000</thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis>
    <thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49254"
      unitRef="Unit_EUR">-172000</thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis>
    <thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49255"
      unitRef="Unit_CAD">129000</thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis>
    <thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49256"
      unitRef="Unit_EUR">-380000</thtx:PositiveNegativeImpactOfForeignExchangeGainLossSensitivityAnalysis>
    <thtx:NegativePercentageImpactOnForeignCurrencyExposures
      contextRef="P12_01_2022To11_30_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-49257"
      unitRef="Unit_pure">0.05</thtx:NegativePercentageImpactOnForeignCurrencyExposures>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="3"
      id="ixv-49258"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="-3"
      id="ixv-49259"
      unitRef="Unit_USD">42000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets>
    <thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets
      contextRef="P12_01_2022To11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="-3"
      id="ixv-49260"
      unitRef="Unit_USD">42000</thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="-3"
      id="ixv-49261"
      unitRef="Unit_USD">79000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets>
    <thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets
      contextRef="P12_01_2021To11_30_2022_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="-3"
      id="ixv-49262"
      unitRef="Unit_USD">79000</thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognizedInAccumulatedOtherComprehensiveIncomeAfterTaxAssets>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_BondsMemberifrsfullClassesOfFinancialAssetsAxis_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis"
      decimals="3"
      id="ixv-49263"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets>
    <thtx:VariableInterestbearingCashAndMoneyMarketFunds
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49264"
      unitRef="Unit_USD">20231000</thtx:VariableInterestbearingCashAndMoneyMarketFunds>
    <thtx:VariableInterestbearingCashAndMoneyMarketFunds
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49265"
      unitRef="Unit_USD">23505000</thtx:VariableInterestbearingCashAndMoneyMarketFunds>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="3"
      id="ixv-49266"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets
      contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      id="ixv-49267"
      unitRef="Unit_USD">101000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets>
    <thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows
      contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      id="ixv-49268"
      unitRef="Unit_USD">101000</thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets
      contextRef="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      id="ixv-49269"
      unitRef="Unit_USD">118000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets>
    <thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows
      contextRef="P12_01_2021To11_30_2022_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-3"
      id="ixv-49270"
      unitRef="Unit_USD">118000</thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_VariableInterestRateCashAndMarketFundsMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="3"
      id="ixv-49271"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputAssets>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="3"
      id="ixv-49272"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets
      contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-3"
      id="ixv-49273"
      unitRef="Unit_USD">300000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossAfterTaxAssets>
    <thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows
      contextRef="P12_01_2022To11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="-3"
      id="ixv-49274"
      unitRef="Unit_USD">300000</thtx:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInCashFlows>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets
      contextRef="PAsOn11_30_2023_InterestRateMeasurementInputMemberifrsfullUnobservableInputsAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberifrsfullTypesOfInterestRatesAxis"
      decimals="3"
      id="ixv-49275"
      unitRef="Unit_pure">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-41646">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Capital management&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s objective in managing its capital is to ensure a liquidity position sufficient to finance its business activities. The Company depends primarily on revenue generated by sales of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#160;&lt;/div&gt;as well as sales of Trogarzo&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; in the United States, and, from time to time, on public offerings of securities in North America to finance its activities. In order to maintain or adjust its capital structure, the Company, upon approval by its Board of Directors, may issue or repay long-term debt, issue shares, repurchase shares, pay dividends or undertake other activities as deemed appropriate under the specific circumstances. The Company has also announced that it will evaluate its options in funding late stage development programs, which may include seeking a potential partner. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The capital management objectives remain the same as of the previous year, including that the Company&#x2019;s cash deposit and brokerage accounts are subject to control agreements relating to the Loan Facility and certain credit card arrangements allowing creditors to collateralized outstanding loaned values. Furthermore, the Company is required to maintain cash, cash equivalents and eligible short-term investments over time to range of $15,000 to $20,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;based on targeted Marathon Adjusted EBITDA.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;As at November&#160;30, 2023, cash, bonds and money market funds amounted to $40,387 (2022-$33,070). &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currently, the Company&#x2019;s general policy on dividends is to retain cash to keep funds available to finance its growth. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company defines capital to include total equity and, prior to June&#160;30, 2023, convertible unsecured senior notes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not subject to any externally imposed capital requirements, except those disclosed in Note 17 in relation to the Marathon Credit Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained
      contextRef="PAsOn11_30_2023_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-49276"
      unitRef="Unit_USD">15000000</thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained>
    <thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained
      contextRef="PAsOn11_30_2023_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-3"
      id="ixv-49277"
      unitRef="Unit_USD">20000000</thtx:MinimumCashCashEquivalentsAndShortTermInvestmentsToBeMaintained>
    <thtx:CashBondAndMoneyMarketFunds
      contextRef="PAsOn11_30_2023_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      id="ixv-49278"
      unitRef="Unit_USD">40387000</thtx:CashBondAndMoneyMarketFunds>
    <thtx:CashBondAndMoneyMarketFunds
      contextRef="PAsOn11_30_2022_CashbondAndMoneyMarketFundsMemberifrsfullClassesOfAssetsAxis"
      decimals="-3"
      id="ixv-49279"
      unitRef="Unit_USD">33070000</thtx:CashBondAndMoneyMarketFunds>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-41736">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Determination of fair values&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;Certain of the Company&#x2019;s accounting policies and disclosures require the determination of fair value, for both financial and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets and financial liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#x2009;1:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined as observable inputs such as quoted prices in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#x2009;2:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#x2009;3:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other financial assets and financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial;text-align:justify"&gt;The Company has determined that the carrying values of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; financial assets and financial liabilities, including cash, trade and other receivables, and accounts payable and accrued liabilities approximate their fair value because of their relatively short period to maturity.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonds and money market funds and derivative financial assets and financial liabilities are stated at fair value, determined by inputs that are primarily based on broker quotes at the reporting date (Level&#160;2). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that the carrying value of its Loan Facility approximates its fair value because the terms were&#160;modified near the end of the 2023 fiscal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; payment transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Share Options is measured based on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Black-Scholes&lt;/div&gt; valuation model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;risk-free&lt;/div&gt; interest rate (based on government bonds). Service and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-market&lt;/div&gt; performance conditions attached to the transactions, if any, are not taken into account in determining fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the DSUs is determined using the quoted price of the common shares of the&#160;Company and considered Level&#160;2 in the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Calibri; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: Calibri; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marathon Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. Reasonably possible changes at November&#160;30, 2023, to one of the significant unobservable input, holding other inputs consistent, would have the following effects: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;Increase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Decrease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility (10% movement (100 bps))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;125&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-41898"> &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Marathon Warrants are recognized at fair value and considered Level&#160;3 in the fair value hierarchy. Reasonably possible changes at November&#160;30, 2023, to one of the significant unobservable input, holding other inputs consistent, would have the following effects: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-bottom: 8pt; vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;Increase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;Decrease&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 6em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility (10% movement (100 bps))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;125&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="8" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="0"
      id="ixv-49280"
      unitRef="Unit_pure">10</ifrs-full:SignificantUnobservableInputLiabilities>
    <thtx:SignificantUnobservableInputLiabilitiesBasisPoints
      contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_HistoricalVolatilityForSharesMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="4"
      id="ixv-49281"
      unitRef="Unit_pure">0.0100</thtx:SignificantUnobservableInputLiabilitiesBasisPoints>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_BottomOfRangeMemberifrsfullRangeAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="0"
      id="ixv-49282"
      unitRef="Unit_pure">-100</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="PAsOn11_30_2023_AtFairValueMemberifrsfullMeasurementAxis_RevenueMultipleMeasurementInputMemberifrsfullUnobservableInputsAxis_TopOfRangeMemberifrsfullRangeAxis_WarrantReserveMemberifrsfullClassesOfLiabilitiesAxis"
      decimals="0"
      id="ixv-49283"
      unitRef="Unit_pure">125</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-42017">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt; procurement agreements and research agreements &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;"&gt;The Company has &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;long-term&lt;/div&gt; procurement agreements with third party suppliers in connection with the commercialization of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; and Trogarzo&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;. As at November&#160;30, 2023, the Company had outstanding purchase orders and minimum payments required under these agreements amounting to $14,682 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2022 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013; &lt;/div&gt;&lt;/div&gt;$1,644) for the manufacture of Trogarzo&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt;, &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;and for other various services.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%; font-size: 11pt; font-family: arial; text-indent: 0px; text-align: justify;"&gt;As at November&#160;30, 202&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;3&lt;/div&gt;, the Company also ha&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;research commitments and outstanding clinical material purchase orders amounting to $807 (2022 &#x2013; $&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;1,310&lt;/div&gt;) in connection with the oncology platform and nil &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2022 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2013;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;$868) in connection with a new formulation of tesamorelin and of a multi-dose pen injector developed for this new formulation. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: arial; text-align: justify; line-height: normal;"&gt;Licence agreement &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;&lt;div style="display:inline;"&gt;3&lt;/div&gt;, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (&#x201c;MGH&#x201d;), as amended on April&#160;15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Alcoholic&lt;/div&gt; Steatohepatitis (&#x201c;NASH&#x201d;) in the general population. Under the terms of the amended agreement, the MGH, through Dr.&#160;Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of &lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EGRIFTA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SV&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:9.1px"&gt;&#xae;&lt;/div&gt; above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Alcoholic&lt;/div&gt; Fatty Liver Disease or NASH in the general population. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired
      contextRef="PAsOn11_30_2023_TrogarzoMemberTHTXCommitmentsAxis"
      decimals="-3"
      id="ixv-49284"
      unitRef="Unit_USD">14682000</thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired>
    <thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired
      contextRef="PAsOn11_30_2022_TrogarzoMemberTHTXCommitmentsAxis"
      decimals="-3"
      id="ixv-49285"
      unitRef="Unit_USD">1644000</thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired>
    <thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired
      contextRef="PAsOn11_30_2023_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      id="ixv-49286"
      unitRef="Unit_USD">807000</thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired>
    <thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired
      contextRef="PAsOn11_30_2022_OncologyPlatformMemberifrsfullClassesOfContingentLiabilitiesAxis"
      decimals="-3"
      id="ixv-49287"
      unitRef="Unit_USD">1310000</thtx:LongTermPurchaseCommitmentsMinimumPaymentsRequired>
    <thtx:BorrowingsOutstanding
      contextRef="PAsOn11_30_2023_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis"
      id="ixv-49288"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <thtx:BorrowingsOutstanding
      contextRef="PAsOn11_30_2022_MultidosePassInjectorDevelopedMemberTHTXCommitmentsAxis"
      decimals="-3"
      id="ixv-49289"
      unitRef="Unit_USD">868000</thtx:BorrowingsOutstanding>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-42175">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating segments&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The Company has a single operating segment. As described in Note 3, almost all of the Company&#x2019;s revenues are generated from one customer, RxCrossroads, which is domiciled in the United States.&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;RxCrossroads&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;81,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;78,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Others&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;372&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,313&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81,764&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,057&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69,823&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;All of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are located in Canada, the United States and Ireland. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Of the Company&#x2019;s total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets of $14,472 (2022 &#x2013; $19,890), $14,138 (2022 &#x2013; $18,980) are located in Canada, $32 (2022 &#x2013; $69) are located in the United States and $302 (2022 &#x2013; $841) are located in&#160;Ireland. &lt;/div&gt; </ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock contextRef="P12_01_2022To11_30_2023" id="ixv-42191">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;RxCrossroads&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;81,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;78,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160; &#160; &#160; &#160; &#160;&#160;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="padding-bottom:8pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;Others&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;372&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,313&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81,764&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,057&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69,823&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </thtx:DisclosureOfDetailedInformationAboutOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_RxCrossRoadsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49291"
      unitRef="Unit_USD">81392000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_RxCrossRoadsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49292"
      unitRef="Unit_USD">78744000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_RxCrossRoadsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49293"
      unitRef="Unit_USD">68917000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023_AllOtherSegmentsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49294"
      unitRef="Unit_USD">372000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022_AllOtherSegmentsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49295"
      unitRef="Unit_USD">1313000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021_AllOtherSegmentsMemberifrsfullSegmentsAxis"
      decimals="-3"
      id="ixv-49296"
      unitRef="Unit_USD">906000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49297"
      unitRef="Unit_USD">81764000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49298"
      unitRef="Unit_USD">80057000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49299"
      unitRef="Unit_USD">69823000</ifrs-full:Revenue>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2023"
      decimals="-3"
      id="ixv-49300"
      unitRef="Unit_USD">14472000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2022"
      decimals="-3"
      id="ixv-49301"
      unitRef="Unit_USD">19890000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2023_CAifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49302"
      unitRef="Unit_USD">14138000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2022_CAifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49303"
      unitRef="Unit_USD">18980000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2023_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49304"
      unitRef="Unit_USD">32000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2022_USifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49305"
      unitRef="Unit_USD">69000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2023_IEifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49306"
      unitRef="Unit_USD">302000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn11_30_2022_IEifrsfullGeographicalAreasAxis"
      decimals="-3"
      id="ixv-49307"
      unitRef="Unit_USD">841000</ifrs-full:NoncurrentAssets>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-42336">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: arial; font-size: 11pt; border: 0px; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Calibri; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Related parties&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: arial; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;The key management personnel of the Company are the directors, the President and Chief Executive Officer, the Senior Vice President and Chief Financial Officer, the Global Commercial Officer and the Senior Vice President and Chief Medical Officer.&#160;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Key management personnel compensation comprises: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 91%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term&lt;/div&gt; employee benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,355&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,078&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,243&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,709&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,355&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,005&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: center; font-family: arial; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:11pt; font-family:arial"&gt;As at November&#160;30, 2023, the key management personnel controlled 1.1% (2022&#160;&#x2013; 0.8%) of the voting shares of the Company. &lt;/div&gt; </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="P12_01_2022To11_30_2023" id="ixv-42351"> &lt;div style="font-family: arial; font-size: 11pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: arial; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Key management personnel compensation comprises: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: arial; font-size: 11pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 91%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: arial; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2003;&#x2003;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-bottom: 7pt; vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2003;&#x2003;&#x2003;&#x2003;&lt;div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="12" style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 18pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term&lt;/div&gt; employee benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Post-employment&lt;/div&gt; benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="padding-bottom:6pt ;vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 11pt; font-family: arial; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based&lt;/div&gt; compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,355&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,078&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,243&lt;/td&gt;
&lt;td style="padding-bottom:6pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:18pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:arial; font-size:11pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,709&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,355&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,005&lt;/td&gt;
&lt;td style="padding-bottom:8pt ;white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td colspan="12" style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1.5pt solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49308"
      unitRef="Unit_USD">3259000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49309"
      unitRef="Unit_USD">3191000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49310"
      unitRef="Unit_USD">2690000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49311"
      unitRef="Unit_USD">95000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49312"
      unitRef="Unit_USD">86000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49313"
      unitRef="Unit_USD">72000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49314"
      unitRef="Unit_USD">1355000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49315"
      unitRef="Unit_USD">2078000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49316"
      unitRef="Unit_USD">1243000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P12_01_2022To11_30_2023"
      decimals="-3"
      id="ixv-49317"
      unitRef="Unit_USD">4709000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P12_01_2021To11_30_2022"
      decimals="-3"
      id="ixv-49318"
      unitRef="Unit_USD">5355000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P12_01_2020To11_30_2021"
      decimals="-3"
      id="ixv-49319"
      unitRef="Unit_USD">4005000</ifrs-full:KeyManagementPersonnelCompensation>
    <thtx:RelatedPartyPercentageOfVotingRightsHeld
      contextRef="PAsOn11_30_2023"
      decimals="3"
      id="ixv-49320"
      unitRef="Unit_pure">0.011</thtx:RelatedPartyPercentageOfVotingRightsHeld>
    <thtx:RelatedPartyPercentageOfVotingRightsHeld
      contextRef="PAsOn11_30_2022"
      decimals="3"
      id="ixv-49321"
      unitRef="Unit_pure">0.008</thtx:RelatedPartyPercentageOfVotingRightsHeld>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_101085289"
          xlink:label="Fact_101085289"
          xlink:type="locator"/>
        <link:footnote id="FN_350225" xlink:label="FN_350225" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The company voluntarily changed its accounting policy to classify interest paid and received as part of operating activities, see Note 1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085289"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085290"
          xlink:label="Fact_101085290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085290"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085727"
          xlink:label="Fact_101085727"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085727"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085731"
          xlink:label="Fact_101085731"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085731"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085733"
          xlink:label="Fact_101085733"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085733"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085737"
          xlink:label="Fact_101085737"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085737"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085739"
          xlink:label="Fact_101085739"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085739"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085746"
          xlink:label="Fact_101085746"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085746"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085748"
          xlink:label="Fact_101085748"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085748"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085752"
          xlink:label="Fact_101085752"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085752"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101085989"
          xlink:label="Fact_101085989"
          xlink:type="locator"/>
        <link:footnote id="FN_350223" xlink:label="FN_350223" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See note 1 for share consolidation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101085989"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086103"
          xlink:label="Fact_101086103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086103"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086122"
          xlink:label="Fact_101086122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086122"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086174"
          xlink:label="Fact_101086174"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086174"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086181"
          xlink:label="Fact_101086181"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086181"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086182"
          xlink:label="Fact_101086182"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086182"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086183"
          xlink:label="Fact_101086183"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086183"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086184"
          xlink:label="Fact_101086184"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086184"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086251"
          xlink:label="Fact_101086251"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086251"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086281"
          xlink:label="Fact_101086281"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086281"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086282"
          xlink:label="Fact_101086282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086282"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086287"
          xlink:label="Fact_101086287"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086287"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086288"
          xlink:label="Fact_101086288"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086288"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086292"
          xlink:label="Fact_101086292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086292"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086296"
          xlink:label="Fact_101086296"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086296"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086333"
          xlink:label="Fact_101086333"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086333"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086334"
          xlink:label="Fact_101086334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086334"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086714"
          xlink:label="Fact_101086714"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086714"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086715"
          xlink:label="Fact_101086715"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086715"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086720"
          xlink:label="Fact_101086720"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086720"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086762"
          xlink:label="Fact_101086762"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086762"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086766"
          xlink:label="Fact_101086766"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086766"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086768"
          xlink:label="Fact_101086768"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086768"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086772"
          xlink:label="Fact_101086772"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086772"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086774"
          xlink:label="Fact_101086774"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086774"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086777"
          xlink:label="Fact_101086777"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086777"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086781"
          xlink:label="Fact_101086781"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086781"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086784"
          xlink:label="Fact_101086784"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086784"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086792"
          xlink:label="Fact_101086792"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086792"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086796"
          xlink:label="Fact_101086796"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086796"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086804"
          xlink:label="Fact_101086804"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086804"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086805"
          xlink:label="Fact_101086805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086805"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086808"
          xlink:label="Fact_101086808"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086808"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101086852"
          xlink:label="Fact_101086852"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101086852"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087140"
          xlink:label="Fact_101087140"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087140"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087431"
          xlink:label="Fact_101087431"
          xlink:type="locator"/>
        <link:footnote id="FN_350226" xlink:label="FN_350226" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On February 17, 2023, the Company terminated its lease in Ireland. Accordingly, the Company reduced its right-of-use assets by $799, the lease liabilities by $920 and recorded a gain on lease termination of $121. The gain is presented in finance costs (Note 5)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087431"
          xlink:to="FN_350226"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087432"
          xlink:label="Fact_101087432"
          xlink:type="locator"/>
        <link:footnote id="FN_350227" xlink:label="FN_350227" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On March 1, 2023, the Company signed a new lease in Ireland. Accordingly, the Company recorded a right-of-use asset and a lease liability of $326.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087432"
          xlink:to="FN_350227"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087538"
          xlink:label="Fact_101087538"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087538"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087540"
          xlink:label="Fact_101087540"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087540"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087543"
          xlink:label="Fact_101087543"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087543"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087547"
          xlink:label="Fact_101087547"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087547"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087549"
          xlink:label="Fact_101087549"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087549"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087614"
          xlink:label="Fact_101087614"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087614"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087616"
          xlink:label="Fact_101087616"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087616"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087740"
          xlink:label="Fact_101087740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087740"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087741"
          xlink:label="Fact_101087741"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087741"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087742"
          xlink:label="Fact_101087742"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087742"
          xlink:to="FN_350223"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087746"
          xlink:label="Fact_101087746"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087746"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087749"
          xlink:label="Fact_101087749"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087749"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087860"
          xlink:label="Fact_101087860"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087860"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087865"
          xlink:label="Fact_101087865"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087865"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087866"
          xlink:label="Fact_101087866"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087866"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087870"
          xlink:label="Fact_101087870"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087870"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087871"
          xlink:label="Fact_101087871"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087871"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087873"
          xlink:label="Fact_101087873"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087873"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087877"
          xlink:label="Fact_101087877"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087877"
          xlink:to="FN_350225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_101087880"
          xlink:label="Fact_101087880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_101087880"
          xlink:to="FN_350225"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
